

Table of Contents

Actemra (tocilizumab).....15

Acthar Gel, Cortrophin Gel.....24

Actimmune .....27

Adacel TDAP vaccine .....32

Adakveo .....34

Adalimumab.....36

Adbry (tralokinumab-ldrm)..... 144

ADHD Agents ..... 149

Aduhelm (aducanumab-avwa) ..... 169

Aemcolo ..... 179

Afinitor, Torpenz (everolimus) ..... 181

Afrezza .....206

Agamree (vamorolone).....210

Airsupra (albuterol-budesonide).....214

Aldurazyme .....217

Alinia.....219

Alkeran.....221

Alpha Interferons .....225

Alzheimer's Agents .....229

Amondys 45 .....234

Amtagvi (lifileucel) .....238

Anthelmintics .....241

Anticonvulsants .....245

Antidepressants .....265

Antiemetics .....281

Antiglaucoma Agents .....284

Antipsoriatic Agents.....286

Antipsychotics.....289

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Anxiolytics.....	325
Apomorphine products (Apokyn, Kynmobi) .....	334
Aquadeks .....	338
Arcalyst (rilonacept).....	340
Arikayce .....	345
Atorvaliq (atorvastatin oral suspension) .....	349
Austedo (deutetrabenazine) .....	352
Azole Antifungals .....	360
Baxdela .....	375
Belbuca, Butrans .....	380
Benefit Determination Mifeprex .....	392
Benlysta .....	394
Benznidazole.....	398
Besremi.....	400
Biltricide .....	403
Bimzelx (bimekizumab-bkzx) .....	405
Blood Glucose Monitors.....	409
Bonjesta and Diclegis .....	419
Breast Cancer .....	421
Breo Ellipta.....	425
Brexafemme.....	428
Breztri, Trelegy Ellipta.....	430
Brilinta and Effient .....	434
Bronchitol .....	437
Buprenorphine Sublingual Tablet.....	439
Bylvay (odevixibat) .....	442
Cablivi.....	447
Cabotegravir Containing Agents .....	450
Camzyos (mavacamten) .....	455

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Carbaglu (carglumic acid) .....	458
Cayston .....	463
Ceprozin.....	465
CGRP Inhibitors .....	468
Cholbam .....	490
Cialis for BPH .....	493
Cibinqo (abrocitinib) .....	495
Cimzia .....	501
Colony Stimulating Factors .....	518
Combination Basal Insulin-GLP-1 Receptor Agonist .....	537
Compounds and Bulk Powders.....	540
Constipation Agents .....	551
Continuous Blood Glucose Monitoring Devices (CGM) .....	561
Copper Chelating Agents .....	569
Corlanor.....	574
Cosentyx (secukinumab) .....	578
Cough and Cold Products .....	594
Coverage of Off-Label Non-FDA Approved Indications .....	601
Cuvrior (trientine hydrochloride).....	610
Cystaran, Cystadrops .....	613
Daliresp (roflumilast) .....	615
Daraprim.....	618
Daybue (trofinetide) .....	622
DDAVP (desmopressin) tablets.....	625
Declomycin .....	627
Dificid .....	630
Dofetilide .....	632
Dojolvi (triheptanoin) .....	635
DPP-4 Inhibitors.....	638

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Dry Eye Disease .....	643
Duexis and Vimovo .....	648
Duopa .....	653
Dupixent (dupilumab) .....	656
Durezol .....	674
Duvyzat (givinostat) .....	676
Ecoza (econazole).....	679
Egrifta .....	681
Elaprase .....	683
Elevidys.....	685
Elidel-Protopic.....	692
Elmiron .....	695
Emflaza (deflazacort) .....	697
Enbrel .....	700
Endari .....	710
Enspryng.....	713
Entocort EC .....	716
Entresto .....	718
Entyvio (vedolizumab).....	722
Eohilia (budesonide) .....	725
Epaned .....	728
Epinephrine Products .....	730
Eplerenone .....	733
Epsolay (benzoyl peroxide) cream.....	735
Erythropoietic Agents .....	737
Esbriet, Ofev.....	759
Estrogens .....	766
Eucrisa.....	768
Evrysdi (risdiplam) .....	770

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Exkivity .....	776
Exondys .....	779
Ezallor Sprinkle (rosuvastatin) .....	783
Fabry Disease Agents .....	786
Fasenra (benralizumab) .....	789
Fecal Microbiota Agents.....	796
Fentanyl IR .....	799
Fexmid (cyclobenzaprine 7.5mg) .....	805
Filspari (sparsentan) .....	807
Filsuvez (birch triterpenes) .....	811
Firdapse .....	815
Flucytosine .....	818
Forteo, Prolia, Teriparatide, Tymlos .....	821
Fotivda .....	831
Furoscix (furosemide injection) .....	834
Galafold .....	836
Gattex (teduglutide) .....	839
Gaucher's Disease Agents .....	842
Generic fluticasone-salmeterol diskus, Wixela Inhub (authorized generic of Advair Diskus), Airduo, fluticasone/salmeterol (authorized generic of Airduo) .....	846
Global Quantity Limits .....	849
GLP-1 Agonists .....	853
Glycopyrrolate Products .....	860
Gonadotropin-Releasing Hormone Agonists .....	862
Gralise, Horizant.....	885
Growth Hormone, Growth Stimulating Agents .....	888
HCG.....	958
Hemangeol .....	960
Hemophilia Clotting Factors.....	962
Hepatitis C .....	992

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Hereditary Angioedema (HAE) Agents .....	1004
Hetlioz, Hetlioz LQ (tasimelteon) .....	1010
High Cost Oral Atypical Antipsychotics (Caplyta, Fanapt, Lybalvi, Rexulti, Vraylar) ....	1017
HIV (Fuzeon, Selzentry) .....	1030
Hydroxychloroquine.....	1033
Hyftor (sirolimus) topical gel .....	1035
Igalmi (dexmedetomidine).....	1037
Ilaris (canakinumab) .....	1039
Ilumya (tildrakizumab-asmn).....	1047
Imcivree .....	1052
Immune Globulins .....	1056
Impavido .....	1301
Inbrija .....	1303
Infliximab Products.....	1306
Ingrezza (valbenazine).....	1310
Inhaled Corticosteroids .....	1316
Injectable Oncology Agents.....	1318
Inqovi .....	1320
Insulin Pen Needles and Syringes .....	1323
Insulins, Concentrated.....	1426
Iqirvo (elafibranor) .....	1428
Iron Chelators .....	1431
Irritable Bowel Syndrome-Diarrhea .....	1438
Isotretinoin.....	1442
Isturisa .....	1451
Jesduvroq (daprodustat) .....	1455
Joenja (leniolisib).....	1459
Juxtapid.....	1462
Jynarque.....	1466

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Kalydeco (ivacaftor) .....	1468
Katerzia, Norliqva (amlodipine oral solution) .....	1472
Kerendia (finerenone).....	1475
Keveyis.....	1478
Kevzara (sarilumab) .....	1480
Kineret .....	1488
Korlym .....	1494
Kuvan.....	1497
LAMA-LABA .....	1499
Lampit .....	1501
Lantidra (donislecel-jujn) .....	1503
Leqvio (inclisiran) .....	1507
Leucovorin .....	1513
Libervant, Nayzilam, Valtoco .....	1515
Lidoderm (lidocaine) 5% patches .....	1519
Likmez .....	1521
Livdelzi (seladelpar) .....	1524
Livmarli (maralixibat) .....	1527
Livtency .....	1532
Lodoco (colchicine) .....	1535
Long-Acting Opioid Products.....	1538
Lonhala and Yupelri .....	1602
Lucemyra (lofexidine).....	1605
Lumizyme -Arizona .....	1608
Lupkynis (voclosporin) .....	1610
Luxturna.....	1614
Lyrica .....	1617
Lysteda .....	1625
Lyvispah (baclofen granules), Ozobax-Ozobax DS (baclofen oral solution) .....	1627

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Makena .....	1629
Marinol, Syndros.....	1631
Mepron .....	1637
Metformin Products .....	1639
Migranal .....	1644
Monurol .....	1646
Mozobil .....	1648
MS Agents .....	1650
Multaq .....	1657
Myalept.....	1659
Myfembree, Oriahnn .....	1662
Mytesi .....	1667
Nadolol.....	1669
Namzaric .....	1671
Natpara.....	1673
Nexiclon XR (clonidine ER) .....	1677
Nexletol (bempedoic acid) and Nexlizet (bempedoic acid-ezetimibe).....	1679
Nityr .....	1684
Nocdurna.....	1686
Non-Preferred Drugs .....	1689
Non-Preferred Prenatal Vitamins .....	1693
Northera.....	1708
Nourianz .....	1712
Nucala (mepolizumab) .....	1715
Nuedexta .....	1727
Nuplazid .....	1729
Nuzyra .....	1731
OAB - Overactive Bladder Agents.....	1736
Ocaliva.....	1739



## UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Octreotide Products .....	1742
Ohtuvayre (ensifentrine).....	1750
Ojjaara (momelotinib) .....	1755
Olumiant.....	1758
Omnipod 5 .....	1763
OmvoH (mirikizumab-mrkz).....	1767
Onureg.....	1770
Opfolda.....	1773
Ophthalmic Antihistamine .....	1776
Opzelura (ruxolitinib).....	1779
Oral Oncology Agents .....	1785
Orencia (abatacept).....	1798
Orfadin (nitisinone) .....	1804
Orgovyx.....	1806
Orilissa .....	1809
Orkambi.....	1813
Osphena .....	1816
Otezla (apremilast) .....	1818
Oxervate .....	1824
Palforzia [Peanut (Arachis hypogaea)] .....	1826
Palynziq .....	1831
Panretin .....	1835
Pediculicides.....	1838
Phexxi .....	1840
Pombiliti.....	1843
Pradaxa Pellet Packs .....	1846
Praluent .....	1849
Preferred Drugs .....	1859
Preferred Non-Solid Dosage Forms.....	1862

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Pretomanid .....	1865
Prevymis .....	1867
Primary Hyperoxaluria (PH1) Agents [Oxlumo (lumasiran), Rivfloza (nedosiran)] .....	1870
Procysbi .....	1875
Progesterone - Non-Oral .....	1878
Progesterone - Oral .....	1880
Provigil, Nuvigil .....	1882
Pulmonary Arterial Hypertension (PAH) Agents.....	1888
Pulmozyme .....	1899
Pyrukynd (mitapivat) .....	1901
Qbrexza.....	1905
Qlosi, Vuity.....	1907
Qutenza (capsaicin).....	1911
Radicava (edaravone) .....	1915
Ranolazine products.....	1918
Rayos .....	1921
Recorlev (levoketoconazole) .....	1924
Rectiv.....	1927
Regranex .....	1929
Relyvrio (sodium phenylbutyrate and taurursodiol).....	1931
Repatha .....	1934
Respiratory Syncytial Virus (RSV) Vaccines .....	1944
Revcovi .....	1947
Reyvow .....	1950
Rezdiffra (resmetirom) .....	1955
Rezurock (belumosudil) .....	1959
Rhofade .....	1962
Rinvoq (upadacitinib) .....	1965
Ryaltris.....	1988

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Samsca.....	1990
Sedative Hypnotics.....	1992
Sensipar.....	2000
Serevent Diskus.....	2004
SGLT-2 Inhibitors.....	2007
Shingrix (zoster vaccine recombinant, adjuvanted).....	2016
Short-Acting Opioid Products.....	2018
Signifor.....	2098
Siliq.....	2101
Simponi (golimumab).....	2106
Sivextro.....	2115
Skyclarys.....	2119
Skyrizi (risankizumab-rzaa).....	2122
Sodium Oxybate Products (Lumryz, Xyrem, Xywav).....	2131
Sofdra (sofipironium).....	2140
Sohonos (palovarotene).....	2143
Soliris.....	2146
Somavert.....	2157
Soriatane.....	2160
Sotyktu (deucravacitinib).....	2163
Spevigo (spesolimab-sbzo).....	2167
Spinraza.....	2170
Spravato, ketamine.....	2178
Stelara.....	2186
Strensiq.....	2199
Sublingual Immunotherapy (SLIT).....	2204
Sublocade, Brixadi.....	2214
Suboxone.....	2219
Sucraid.....	2226

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Sunlenca.....	2229
Sunosi.....	2232
Sutent .....	2238
Symdeko .....	2248
Symlin.....	2251
Synagis .....	2253
Systane, Refresh, Gonak, Genteal, Tears Naturale .....	2268
Talicia and Mycobutin .....	2275
Taltz (ixekizumab) .....	2283
Targretin .....	2298
Tarpeyo (budesonide).....	2301
Tasmar .....	2304
Tavneos.....	2307
Tecelra (afamitresgene autoleucel) .....	2310
Tegsedi.....	2313
Test Strips .....	2317
Testosterone.....	2342
Thalomid .....	2352
Therapeutic Duplication (Subtype A).....	2364
Therapeutic Duplication (Subtype B).....	2394
Thrombopoiesis Stimulating Agents .....	2408
Tobramycin Inhalation .....	2418
Topical Capsaicin Products .....	2421
Topical NSAIDs .....	2424
Tremfya (guselkumab).....	2430
Tretinoin Capsules .....	2440
Tretinoin Topical .....	2443
Trikafta (elexacaftor/tezacaftor/ivacaftor) .....	2445
Triptans.....	2449

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Tryvio (aprocitentan) .....	2464
Twynéo (tretinoin-benzoyl peroxide 0.1-3% cream).....	2468
Uloric .....	2470
Ultomiris (ravulizumab-cwvz) .....	2472
Upneeq .....	2479
Urea Cycle Disorder Agents.....	2482
Vafseo (vadadustat) .....	2487
Valchlor .....	2491
Valsartan oral solution .....	2494
Vecamyl .....	2496
Velphoro (sucroferric oxyhydroxide), Auryxia (ferric citrate) .....	2498
Velsipity .....	2500
Veltassa .....	2503
Vemlidy.....	2506
Veozah (fezolinetant) .....	2509
Verkazia (cyclosporine ophthalmic emulsion 0.1%).....	2511
Verquvo.....	2514
Vijoice (alpelisib) .....	2518
Viltepro.....	2521
Vivjoa (oteseconazole) .....	2525
Vonjo (pacritinib) .....	2527
Vonoprazan Containing Agents.....	2530
Voxzogo (vosoritide) .....	2536
Vtama (tapinarof).....	2540
Vyjuvek (beremagene geperpavec-svdt) .....	2543
Vyndaqel and Vyndamax .....	2546
Vyondys 53.....	2551
Wainua (eplontersen).....	2555
Wakix (pitolisant) .....	2558

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Wegovy (semaglutide).....	2563
Xdemvy (lotilaner).....	2569
Xeljanz, Xeljanz XR (tofacitinib).....	2571
Xenazine .....	2584
Xenleta.....	2589
Xermelo .....	2592
Xhance (fluticasone nasal spray) .....	2594
Xolair (omalizumab).....	2596
Xolremdi (mavoxixafor).....	2611
Xopenex Respules .....	2614
Xphozah (tenapanor).....	2616
Xuriden .....	2619
Zeposia (ozanimod) .....	2621
Zilbrysq.....	2626
Zimhi (naloxone) .....	2630
Zokinvy .....	2632
Zolgensma (onasemnogene abeparvovec-xioi).....	2634
Zontivity .....	2639
Zortress .....	2641
Zoryve (roflumilast).....	2643
Ztalmy (ganaxolone).....	2648
Zurzuvae (zuranolone).....	2651
Zyvox.....	2654

Actemra (tocilizumab)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-148437
<b>Guideline Name</b>	Actemra (tocilizumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Actemra Actpen, Actemra SQ			
Diagnosis	Rheumatoid Arthritis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTEMRA ACTPEN	TOCILIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 162 MG/0.9ML	6650007000D520	Brand
ACTEMRA	TOCILIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 162 MG/0.9ML	6650007000E520	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:

1.1 Diagnosis of moderately to severely active Rheumatoid Arthritis (RA)

**AND**

1.2 History of failure to a 3 month trial of ONE non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

1.3 History of failure, contraindication, or intolerance to TWO of the following:\*

- Enbrel (etanercept)\*\*
- Humira (adalimumab)\*\*
- Xeljanz (tofacitinib) tablet\*\*

**AND**

2 - Prescribed by, or in consultation with, a rheumatologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial. **Drug may require PA.
-------	---

Product Name: Actemra Actpen, Actemra SQ			
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (PJIA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic



ACTEMRA ACTPEN	TOCILIZUMAB SUBCUTANEOUS SOLN AUTO- INJECTOR 162 MG/0.9ML	6650007000D520	Brand
ACTEMRA	TOCILIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 162 MG/0.9ML	6650007000E520	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:

1.1 Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis

**AND**

1.2 Paid claims or submission of medical records (e.g., chart notes) confirming a minimum duration of a 6-week trial and failure, contraindication, or intolerance to ONE of the following conventional therapies at maximally tolerated doses:

- leflunomide
- methotrexate

**AND**

1.3 History of failure, contraindication, or intolerance to TWO of the following:\*

- Enbrel (etanercept)\*\*
- Humira (adalimumab)\*\*
- Xeljanz (tofacitinib) tablet\*\*

**AND**

2 - Prescribed by, or in consultation with, a rheumatologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial. **Drug may require PA.
-------	---

Product Name: Actemra Actpen, Actemra SQ	
Diagnosis	Systemic Juvenile Idiopathic Arthritis (SJIA)

Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTEMRA ACTPEN	TOCILIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 162 MG/0.9ML	6650007000D520	Brand
ACTEMRA	TOCILIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 162 MG/0.9ML	6650007000E520	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:</p> <p>1.1 Diagnosis of active systemic juvenile idiopathic arthritis</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure, contraindication, or intolerance to ONE of the following conventional therapies at maximally tolerated doses:*</p> <ul style="list-style-type: none"> <li>• Minimum duration of a 3-month trial and failure of methotrexate</li> <li>• Minimum duration of a 1-month trial of nonsteroidal anti-inflammatory drug (NSAID) (e.g., ibuprofen, naproxen)</li> <li>• Minimum duration of a 2-week trial of systemic glucocorticoid (e.g., prednisone)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by, or in consultation with, a rheumatologist</p>			
Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.		

Product Name: Actemra Actpen, Actemra SQ	
Diagnosis	Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Systemic Juvenile Idiopathic Arthritis (SJIA)
Approval Length	12 month(s)

Therapy Stage		Reauthorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
ACTEMRA ACTPEN	TOCILIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 162 MG/0.9ML	6650007000D520	Brand
ACTEMRA	TOCILIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 162 MG/0.9ML	6650007000E520	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by, or in consultation with, a rheumatologist</p>			

Product Name: Actemra Actpen, Actemra SQ			
Diagnosis		Giant Cell Arteritis	
Approval Length		12 month(s)	
Therapy Stage		Initial Authorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
ACTEMRA ACTPEN	TOCILIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 162 MG/0.9ML	6650007000D520	Brand
ACTEMRA	TOCILIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 162 MG/0.9ML	6650007000E520	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:</p> <p>1.1 Diagnosis of giant cell arteritis</p>			

**AND**

**1.2** Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure, contraindication, or intolerance to a glucocorticoid (e.g., prednisone)\*

**AND**

**2** - Prescribed by, or in consultation with, a rheumatologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.
-------	---

Product Name: Actemra Actpen, Actemra SQ			
Diagnosis	Giant Cell Arteritis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTEMRA ACTPEN	TOCILIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 162 MG/0.9ML	6650007000D520	Brand
ACTEMRA	TOCILIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 162 MG/0.9ML	6650007000E520	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy

**AND**

**2** - Prescribed by, or in consultation with, a rheumatologist

Product Name: Actemra Actpen, Actemra SQ
--

Diagnosis	Systemic Sclerosis-Associated Interstitial Lung Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ACTEMRA ACTPEN	TOCILIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 162 MG/0.9ML	6650007000D520	Brand
ACTEMRA	TOCILIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 162 MG/0.9ML	6650007000E520	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting a diagnosis of active systemic sclerosis-associated interstitial lung disease (SSc-ILD) as documented by ALL of the following:

1.1 ONE of the following:

1.1.1 Skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints

**OR**

1.1.2 TWO of the following:

- Skin thickening of the fingers (e.g., puffy fingers, sclerodactyly of the fingers)
- Fingertip lesions (e.g., digital tip ulcers, fingertip pitting scars)
- Telangiectasia
- Abnormal nailfold capillaries
- Pulmonary arterial hypertension
- Raynaud’s phenomenon
- SSc-related autoantibodies (e.g., anticentromere, anti-topoisomerase I, anti-RNA polymerase III)

**AND**

1.2 Presence of interstitial lung disease as determined by finding evidence of pulmonary fibrosis on HRCT (high-resolution computed tomography), involving at least 10% of the lungs

**AND**

**2** - Prescribed by, or in consultation with, a pulmonologist

Product Name: Actemra Actpen, Actemra SQ			
Diagnosis	Systemic Sclerosis-Associated Interstitial Lung Disease		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTEMRA ACTPEN	TOCILIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 162 MG/0.9ML	6650007000D520	Brand
ACTEMRA	TOCILIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 162 MG/0.9ML	6650007000E520	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy			
<b>AND</b>			
2 - Prescribed by, or in consultation with, a pulmonologist			

## 2 . Revision History

Date	Notes
6/12/2024	Updated GL name. Removed COT allowance, removed concomitant use criterion, and updated submission of medical records language, where applicable. Updated t/f requirements for RA, PJIA, and SJIA. Updates notes section, where applicable.



Acthar Gel, Cortrophin Gel



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140884
<b>Guideline Name</b>	Acthar Gel, Cortrophin Gel
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Acthar Gel			
Diagnosis	Infantile spasm (i.e., West Syndrome)*		
Approval Length	4 Week(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTHAR	CORTICOTROPIN INJ GEL 80 UNIT/ML	30300010004010	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of infantile spasms (i.e., West Syndrome)*			



**AND**

**2** - Patient is less than 2 years old

**AND**

**3** - Both of following:

**3.1** Initial dose: 75 units per meters squared intramuscular (IM) twice daily for 2 weeks

**AND**

**3.2** After 2 weeks, dose should be tapered according to the following schedule: 30 units per meters squared IM in the morning for 3 days; 15 units per meters squared IM in the morning for 3 days; 10 units per meters squared IM in the morning for 3 days; 10 units per meters squared IM every other morning for 6 days (3 doses)

Notes	*Note: Acthar Gel is not medically necessary for treatment of acute exacerbations of multiple sclerosis.
-------	--

Product Name: Acthar Gel, Cortrophin			
Diagnosis	Opsoclonus-myoclonus syndrome (i.e., OMS, Kinsbourne Syndrome)*		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTHAR	CORTICOTROPIN INJ GEL 80 UNIT/ML	30300010004010	Brand
CORTROPHIN	CORTICOTROPIN INJ GEL 80 UNIT/ML	30300010004010	Brand
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of Opsoclonus-myoclonus syndrome (i.e., OMS, Kinsbourne Syndrome)*</p>			

**AND**

**2** - For Cortrophin requests ONLY: Trial and failure or intolerance to Acthar Gel (verified via paid pharmacy claims or submission of medical records/chart notes)

Notes	*Note: Acthar Gel is not medically necessary for treatment of acute exacerbations of multiple sclerosis.
-------	--

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Actimmune



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140909
<b>Guideline Name</b>	Actimmune
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Actimmune			
Diagnosis	Chronic Granulomatous Disease (CGD)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTIMMUNE	INTERFERON GAMMA-1B INJ 100 MCG/0.5ML (2000000 UNIT/0.5ML)	21700060702020	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of chronic granulomatous disease

Product Name: Actimmune			
Diagnosis	Chronic Granulomatous Disease (CGD)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTIMMUNE	INTERFERON GAMMA-1B INJ 100 MCG/0.5ML (2000000 UNIT/0.5ML)	21700060702020	Brand
<b>Approval Criteria</b>			
1 - Patient does not show evidence of progressive disease while on Actimmune			

Product Name: Actimmune			
Diagnosis	Severe, Malignant Osteopetrosis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTIMMUNE	INTERFERON GAMMA-1B INJ 100 MCG/0.5ML (2000000 UNIT/0.5ML)	21700060702020	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of severe, malignant osteopetrosis			

Product Name: Actimmune	
Diagnosis	Severe, Malignant Osteopetrosis

Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTIMMUNE	INTERFERON GAMMA-1B INJ 100 MCG/0.5ML (2000000 UNIT/0.5ML)	21700060702020	Brand
<b>Approval Criteria</b>			
1 - Patient does not show evidence of progressive disease while on Actimmune			

Product Name: Actimmune			
Diagnosis	Primary Cutaneous Lymphomas		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTIMMUNE	INTERFERON GAMMA-1B INJ 100 MCG/0.5ML (2000000 UNIT/0.5ML)	21700060702020	Brand
<b>Approval Criteria</b>			
1 - Patient has ONE of the following diagnoses:			
<ul style="list-style-type: none"> <li>• Mycosis fungoides (MF)</li> <li>• Sézary syndrome (SS)</li> </ul>			

Product Name: Actimmune	
Diagnosis	Primary Cutaneous Lymphomas
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
ACTIMMUNE	INTERFERON GAMMA-1B INJ 100 MCG/0.5ML (2000000 UNIT/0.5ML)	21700060702020	Brand
<b>Approval Criteria</b>			
1 - Patient does not show evidence of progressive disease while on Actimmune			

Product Name: Actimmune			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACTIMMUNE	INTERFERON GAMMA-1B INJ 100 MCG/0.5ML (2000000 UNIT/0.5ML)	21700060702020	Brand
<b>Approval Criteria</b>			
1 - Actimmune will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.			

Product Name: Actimmune			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

ACTIMMUNE	INTERFERON GAMMA-1B INJ 100 MCG/0.5ML (2000000 UNIT/0.5ML)	21700060702020	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Actimmune therapy</p>			

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Adacel TDAP vaccine



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140794
<b>Guideline Name</b>	Adacel TDAP vaccine
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Adacel			
Diagnosis	Pregnant Patients 19 years of age and older*		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ADACEL	TET TOX-DIPH-ACELL PERTUSS AD INJ 5-2-15.5 LF-LF-MCG/0.5ML	18990003221815	Brand
<b>Approval Criteria</b>			



1 - Vaccine is being used to prevent pertussis in infants younger than 2 months of age

**AND**

2 - Patient is 19 years of age or older

**AND**

3 - Both of the following:

- Patient is pregnant
- Vaccine is being administered during 3rd trimester of pregnancy

Notes	*Patients under 19 years of age must get immunization from PCP or pediatrician through the VFC (Vaccines For Children) Program
-------	--

## 2 . Revision History

Date	Notes
5/11/2023	Matching FFS

Adakveo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140910
<b>Guideline Name</b>	Adakveo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Adakveo			
Diagnosis	Sickle cell disease		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ADAKVEO	CRIZANLIZUMAB-TMCA IV SOLN 100 MG/10ML	82807020702020	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of sickle cell disease, identified by any genotype			

**AND**

**2** - ONE of the following:

**2.1** BOTH of the following:

- Age 16 to 20 years
- Prescriber attests the service is medically necessary to correct or ameliorate a defect, a condition, or a physical or mental illness in an eligible patient

**OR**

**2.2** Age greater than or equal to 21 years

**AND**

**3** - Patient has experienced at least two vaso-occlusive crises within the past 12 months

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Adalimumab



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-157591
<b>Guideline Name</b>	Adalimumab
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHN'S DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBIM STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBIM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBIM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBIM PSORIASIS/UVEITIS STARTER	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand



ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UVEITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UVEITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Diagnosis of moderately to severely active rheumatoid arthritis

**AND**

2 - Paid claims or submission of medical records (e.g., chart notes) documenting history of failure to a 3 month trial of ONE non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced

**AND**

**3** - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic DMARD [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**4** - Prescribed by or in consultation with a rheumatologist

**AND**

**5** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHN'S DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M CROHNS/UC/HS STARTER	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M PSORIASIS/UVEITIS STARTER	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand

ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UVEITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UVEITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to the requested therapy

**AND**

2 - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**3 - Prescribed by or in consultation with a rheumatologist**

**AND**

**4 - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars**

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry

Diagnosis	Polyarticular Juvenile Idiopathic Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-ADBM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM PSORIASIS/UVEITIS STARTER	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand

ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UVEITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UVEITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis

**AND**

2 - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a rheumatologist

**AND**

4 - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP</a>
-------	--

	<p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
--	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM PSORIASIS/UEVITIS STARTER	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UEVITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UEVITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to the requested therapy

**AND**

2 - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a rheumatologist

**AND**

4 - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry	
Diagnosis	Psoriatic Arthritis

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'SDISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO- INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM PSORIASIS/UEVITIS STARTER	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand

SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/VEITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/VEITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Diagnosis of active psoriatic arthritis

**AND**

2 - Paid claims or submission of medical records (e.g., chart notes) documenting history of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced



**AND**

**3** - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**AND**

**5** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry	
Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Guideline Type		Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic	
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand	
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand	
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand	
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand	
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand	
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand	
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand	
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand	
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand	
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand	
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand	
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand	
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand	
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand	
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand	
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand	
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand	
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand	
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand	

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'SDISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO- INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO- INJECTOR 40 MG/0.4ML	6627001520D510	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M CROHNS/UC/HS STARTER	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M PSORIASIS/UVEITIS STARTER	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand

ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UEVITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UEVITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to the requested therapy

**AND**

2 - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]

- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**AND**

**4** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CYLTEZO STARTER PACKAGE FOR PSORIASIS/UEVEITIS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBIM STARTER PACKAGE FOR PSORIASIS/UEVEITIS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBIM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBIM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBIM PSORIASIS/UEVEITIS STARTER	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand

ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UEVITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UEVITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Diagnosis of moderate to severe chronic plaque psoriasis

**AND**

2 - Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

3 - BOTH of the following:

3.1 Paid claims or submission of medical records (e.g., chart notes) documenting history of failure to ONE of the following topical therapies, unless contraindicated or clinically significant adverse effects are experienced:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)

- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**3.2** Paid claims or submission of medical records (e.g., chart notes) documenting history of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced

**AND**

**4** - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**5** - Prescribed by or in consultation with a dermatologist

**AND**

**6** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes

\*PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP>

^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.

The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM PSORIASIS/UEVITIS STARTER	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UVEITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UVEITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to the requested therapy

**AND**

**2** - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**3** - Prescribed by or in consultation with a dermatologist

**AND**

**4** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Ankylosing Spondylitis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO- INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO- INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO- INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO- INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO- INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M CROHNS/UC/HS STARTER	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M PSORIASIS/UVEITIS STARTER	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand

ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UEVITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UEVITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

**1 -** Diagnosis of active ankylosing spondylitis

**AND**

**2 -** Paid claims or submission of medical records (e.g., chart notes) documenting history of failure to TWO NSAIDs (non-steroidal anti-inflammatory drugs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced

**AND**

**3 -** Patient is NOT receiving the requested medication in combination with ANY of the following:



- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**4** - Prescribed by or in consultation with a rheumatologist

**AND**

**5** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Ankylosing Spondylitis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CYLTEZO STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBIM STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBIM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBIM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBIM PSORIASIS/UEVITIS STARTER	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand

ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UEVITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UEVITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to the requested therapy

**AND**

2 - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a rheumatologist

**AND**

**4** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Adult Crohn's Disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO- INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO- INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO- INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBМ CROHNS/UC/HS STARTER	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBМ PSORIASIS/UVEITIS STARTER	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand

ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UVEITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UVEITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Diagnosis of moderately to severely active Crohn's disease

**AND**

2 - ONE of the following:

2.1 Paid claims or submission of medical records (e.g., chart notes) documenting history of failure to ONE of the following conventional therapies at maximally indicated doses within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced:

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- Azathioprine (Imuran)
- 6-mercaptopurine (Purinethol)
- Methotrexate (Rheumatrex, Trexall)

**OR**

2.2 Patient has lost response or intolerant to infliximab (e.g., Remicade, Inflectra, Renflexis)

**AND**

3 - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]

- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**4** - Prescribed by or in consultation with a gastroenterologist

**AND**

**5** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Pediatric Crohn's Disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBМ STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBМ STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBМ CROHNS/UC/HS STARTER	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBМ PSORIASIS/UVEITIS STARTER	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand

ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UVEITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UVEITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Diagnosis of moderately to severely active Crohn's disease

**AND**

2 - Paid claims or submission of medical records (e.g., chart notes) documenting history of failure to ONE of the following conventional therapies at maximally indicated doses within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced:

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- Azathioprine (Imuran)
- 6-mercaptopurine (Purinethol)
- Methotrexate (Rheumatrex, Trexall)

**AND**

3 - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]

- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**4** - Prescribed by or in consultation with a gastroenterologist

**AND**

**5** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Ulcerative Colitis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBМ STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBМ STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBМ CROHNS/UC/HS STARTER	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBМ PSORIASIS/UVEITIS STARTER	ADALIMUMAB-ADBМ AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand

ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UVEITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UVEITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Diagnosis of moderately to severely active ulcerative colitis

**AND**

2 - Paid claims or submission of medical records (e.g., chart notes) documenting history of failure to ONE of the following conventional therapies at maximally indicated doses within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced:

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- 6-mercaptopurine (Purinethol)
- Azathioprine (Imuran)
- Aminosalicylates (e.g., mesalamine, sulfasalazine)

**AND**

3 - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]



- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**4** - Prescribed by or in consultation with a gastroenterologist

**AND**

**5** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC%20CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry

Diagnosis	Adult Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-ADB M	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M STARTER PACKAGE FOR PSORIASIS/ UVEITIS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M CROHNS/UC/HS STARTER	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M PSORIASIS/ UVEITIS STARTER	ADALIMUMAB-ADB M AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADB M	ADALIMUMAB-ADB M PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand

ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UVEITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UVEITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to the requested therapy

**AND**

2 - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a gastroenterologist

**AND**

**4** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry

Diagnosis	Hidradenitis Suppurativa
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO- INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO- INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO- INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-ADBM PSORIASIS/UEVEITIS STARTER	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UEVEITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand

HYRIMOZ PLAQUE PSORIASIS/UVEITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage II or III)

**AND**

2 - Paid claims or submission of medical records (e.g., chart notes) documenting history of failure to at least ONE oral antibiotic (e.g., doxycycline, clindamycin, rifampin) at maximally indicated doses within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced

**AND**

3 - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

4 - Prescribed by or in consultation with a dermatologist

**AND**

5 - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

	<p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
--	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Hidradenitis Suppurativa		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM PSORIASIS/UEVITIS STARTER	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UEVITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UEVITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to the requested therapy

**AND**

2 - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a dermatologist

**AND**

4 - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars

Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry	
Diagnosis	Uveitis (UV)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO- INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM PSORIASIS/UEVITIS STARTER	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand

SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UVEITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UVEITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand

**Approval Criteria**

1 - Diagnosis of non-infectious uveitis

**AND**

2 - Uveitis is classified as ONE of the following:

- intermediate
- posterior

- panuveitis

**AND**

**3** - Paid claims or submission of medical records (e.g., chart notes) documenting history of failure to at least ONE corticosteroid (e.g., prednisolone, prednisone) at maximally indicated dose within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced

**AND**

**4** - Paid claims or submission of medical records (e.g., chart notes) documenting history of failure to at least ONE systemic non-biologic immunosuppressant (e.g., methotrexate, cyclosporine, azathioprine, mycophenolate) at a maximally indicated dose within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced

**AND**

**5** - Patient is NOT receiving the requested medication in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**6** - Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Ophthalmologist

**AND**

**7** - If the request is non-preferred\*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred\* adalimumab biosimilars



Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>
-------	--

Product Name: Humira, Abrilada, Amjevita, Cyltezo, Brand Adalimumab-adbm^, Hadlima, Hulio, Brand Adalimumab-fkjp, Hyrimoz, Brand Adalimumab-adaz, Idacio, Brand Adalimumab-aacf, Simlandi, Brand Adalimumab-ryvk, Yuflyma, Brand Adalimumab-aaty, Yusimry			
Diagnosis	Uveitis (UV)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO- INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO- INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO- INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO- INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM STARTER PACKAGE FOR PSORIASIS/UEVITIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBM PSORIASIS/UEVITIS STARTER	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
ADALIMUMAB-ADBМ	ADALIMUMAB-ADBМ PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
ADALIMUMAB-AATY 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UEVITIS (4 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-AACF (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
HYRIMOZ PLAQUE PSORIASIS/UEVITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand

YUSIMRY	ADALIMUMAB-AQVH SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001509D520	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to the requested therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving the requested medication in combination with ANY of the following:</p> <ul style="list-style-type: none"> <li>• Biologic disease-modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab)]</li> <li>• Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]</li> <li>• Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Rheumatologist</li> <li>• Ophthalmologist</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>4 - If the request is non-preferred*, submission of medical records (e.g., chart notes) or paid claims demonstrating history of failure to ALL preferred* adalimumab biosimilars</p>			
Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>^The following NDCs for Brand Adalimumab-adbm products are preferred: 00597054522, 00597054544, 00597054566, 00597058589, 00597055580, 00597059520, 00597057540, 00597057550, 00597057560, 00597056520.</p> <p>The following NDCs for Brand Adalimumab-adbm products are non-preferred: 82009014422, 82009014822, 82009014622, 82009015022.</p>		

**2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
10/23/2024	Added new GPIs for Brand Adalimumab-aacf and Hyrimoz products; Updated list of preferred vs non-preferred NDCs of Brand Adalimumab-adbm products in Notes section.

Adbry (tralokinumab-ldrm)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-152441
<b>Guideline Name</b>	Adbry (tralokinumab-ldrm)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Adbry			
Diagnosis	Atopic Dermatitis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ADBRY	TRALOKINUMAB-LDRM SUBCUTANEOUS SOLN PREFILLED SYR 150 MG/ML	9027308045E520	Brand
ADBRY	TRALOKINUMAB-LDRM SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9027308045D530	Brand



**Approval Criteria**

1 - Diagnosis of moderate to severe atopic dermatitis

**AND**

2 - Submission of documentation (e.g., chart notes) demonstrating ONE of the following:

- Involvement of at least 10% body surface area (BSA)
- SCORing Atopic Dermatitis (SCORAD) index value of at least 25

**AND**

3 - Patient is 12 years of age or older

**AND**

4 - Prescribed by or in consultation with ONE of the following:

- Dermatologist
- Allergist/Immunologist

**AND**

5 - History of failure, contraindication, or intolerance to BOTH of the following topical therapies: (document drug, date of trial, and/or contraindication to medication)\*

- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
- Eucrisa (crisaborole) ointment

Notes

\*Note: Claims history may be used in conjunction as documentation of drug, date, and/or contraindication to medication

Product Name: Adbry

Diagnosis

Atopic Dermatitis

Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ADBRY	TRALOKINUMAB-LDRM SUBCUTANEOUS SOLN PREFILLED SYR 150 MG/ML	9027308045E520	Brand
ADBRY	TRALOKINUMAB-LDRM SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9027308045D530	Brand

**Approval Criteria**

1 - Submission of documentation (e.g., chart notes) demonstrating positive clinical response to therapy as evidenced by at least ONE of the following:

- Reduction in body surface area involvement from baseline
- Reduction in SCORing Atopic Dermatitis (SCORAD) index value from baseline

**2 . Background**

Clinical Practice Guidelines			
Table 1. Relative potencies of topical corticosteroids			
Class	Drug	Dosage Form	Strength (%)
Very high potency	Augmented betamethasone dipropionate	Ointment, gel	0.05
	Clobetasol propionate	Cream, foam, ointment	0.05
	Diflorasone diacetate	Ointment	0.05
	Halobetasol propionate	Cream, ointment	0.05
	Amcinonide	Cream, lotion, ointment	0.1

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

High Potency	Augmented betamethasone dipropionate	Cream, lotion	0.05
	Betamethasone dipropionate	Cream, foam, ointment, solution	0.05
	Desoximetasone	Cream, ointment	0.25
	Desoximetasone	Gel	0.05
	Diflorasone diacetate	Cream	0.05
	Fluocinonide	Cream, gel, ointment, solution	0.05
	Halcinonide	Cream, ointment	0.1
	Mometasone furoate	Ointment	0.1
	Triamcinolone acetonide	Cream, ointment	0.5
Medium potency	Betamethasone valerate	Cream, foam, lotion, ointment	0.1
	Clocortolone pivalate	Cream	0.1
	Desoximetasone	Cream	0.05
	Fluocinolone acetonide	Cream, ointment	0.025
	Flurandrenolide	Cream, ointment, lotion	0.05
	Fluticasone propionate	Cream	0.05
	Fluticasone propionate	Ointment	0.005
	Mometasone furoate	Cream, lotion	0.1
Triamcinolone acetonide	Cream, ointment, lotion	0.1	
Lower-medium potency	Hydrocortisone butyrate	Cream, ointment, solution	0.1
	Hydrocortisone probutate	Cream	0.1
	Hydrocortisone valerate	Cream, ointment	0.2
	Prednicarbate	Cream	0.1
Low potency	Alclometasone dipropionate	Cream, ointment	0.05
	Desonide	Cream, gel, foam, ointment	0.05

	Fluocinolone acetonide	Cream, solution	0.01
Lowest potency	Dexamethasone	Cream	0.1
	Hydrocortisone	Cream, lotion, ointment, solution	0.25, 0.5, 1
	Hydrocortisone acetate	Cream, ointment	0.5-1

### 3 . Revision History

Date	Notes
8/20/2024	Added new GPI for Adbry to the guideline. No changes to criteria.

ADHD Agents



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160425
<b>Guideline Name</b>	ADHD Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

## 1 . Criteria

<p>Product Name: Brand Adderall, generic amphetamine/dextroamphetamine, Brand Adderall XR, Brand Concerta, Brand Daytrana, generic dexamethylphenidate tabs, Brand Focalin XR, Brand Methylin, generic methylphenidate tabs, Brand Ritalin LA, methylphenidate CD/ER caps, Vyvanse caps, generic atomoxetine, generic dextroamphetamine tabs, Adhansia XR, Adzenys XR-ODT, generic amphetamine tabs, generic amphetamine/dextroamphetamine ER, Brand Aptensio XR, Azstarys, Cotempla XR-ODT, Brand Desoxyn, Brand Dexedrine, generic dexamethylphenidate ER, generic dextroamphetamine ER, Dyanavel XR, Evekeo ODT, Brand Focalin, Jornay PM, generic methamphetamine, methylphenidate ER tabs, generic methylphenidate ER (OSM), Methylphenidate ER (OSM), generic methylphenidate ER (LA) caps, generic methylphenidate ER (XR) caps, Mydayis, Brand Procentra, Qelbree, Quillichew ER, Quilivant XR, Relexxii, Brand Ritalin, Brand Strattera, Vyvanse chew, Zenzedi, generic dextroamphetamine oral soln, Brand Evekeo, generic methylphenidate patches/soln, methylphenidate chew tabs, amphetamine ER, Adzenys ER, lisdexamfetamine</p>	
Approval Length	12 month(s)
Guideline Type	Prior Authorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name	Generic Name	GPI	Brand/Generi c
ADDERALL	AMPHETAMINE- DEXTROAMPHETAMINE TAB 5 MG	61109902100305	Brand
AMPHETAMINE/DEXTROAMPHETAMI NE	AMPHETAMINE- DEXTROAMPHETAMINE TAB 5 MG	61109902100305	Generic
ADDERALL	AMPHETAMINE- DEXTROAMPHETAMINE TAB 7.5 MG	61109902100307	Brand
AMPHETAMINE/DEXTROAMPHETAMI NE	AMPHETAMINE- DEXTROAMPHETAMINE TAB 7.5 MG	61109902100307	Generic
ADDERALL	AMPHETAMINE- DEXTROAMPHETAMINE TAB 10 MG	61109902100310	Brand
AMPHETAMINE/DEXTROAMPHETAMI NE	AMPHETAMINE- DEXTROAMPHETAMINE TAB 10 MG	61109902100310	Generic
ADDERALL	AMPHETAMINE- DEXTROAMPHETAMINE TAB 12.5 MG	61109902100312	Brand
AMPHETAMINE/DEXTROAMPHETAMI NE	AMPHETAMINE- DEXTROAMPHETAMINE TAB 12.5 MG	61109902100312	Generic
ADDERALL	AMPHETAMINE- DEXTROAMPHETAMINE TAB 15 MG	61109902100315	Brand
AMPHETAMINE/DEXTROAMPHETAMI NE	AMPHETAMINE- DEXTROAMPHETAMINE TAB 15 MG	61109902100315	Generic
ADDERALL	AMPHETAMINE- DEXTROAMPHETAMINE TAB 20 MG	61109902100320	Brand
AMPHETAMINE/DEXTROAMPHETAMI NE	AMPHETAMINE- DEXTROAMPHETAMINE TAB 20 MG	61109902100320	Generic
ADDERALL	AMPHETAMINE- DEXTROAMPHETAMINE TAB 30 MG	61109902100330	Brand
AMPHETAMINE/DEXTROAMPHETAMI NE	AMPHETAMINE- DEXTROAMPHETAMINE TAB 30 MG	61109902100330	Generic
ADDERALL XR	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 5 MG	61109902107005	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADDERALL XR	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 10 MG	61109902107010	Brand
ADDERALL XR	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 15 MG	61109902107015	Brand
ADDERALL XR	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 20 MG	61109902107020	Brand
ADDERALL XR	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 25 MG	61109902107025	Brand
ADDERALL XR	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 30 MG	61109902107030	Brand
CONCERTA	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 18 MG	61400020100460	Brand
CONCERTA	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 27 MG	61400020100465	Brand
CONCERTA	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 36 MG	61400020100470	Brand
CONCERTA	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 54 MG	61400020100480	Brand
DAYTRANA	METHYLPHENIDATE TD PATCH 10 MG/9HR	61400020005910	Brand
DAYTRANA	METHYLPHENIDATE TD PATCH 15 MG/9HR	61400020005915	Brand
DAYTRANA	METHYLPHENIDATE TD PATCH 20 MG/9HR	61400020005920	Brand
DAYTRANA	METHYLPHENIDATE TD PATCH 30 MG/9HR	61400020005930	Brand
DEXMETHYLPHENIDATE HYDROCHLORIDE	DEXMETHYLPHENIDATE HCL TAB 2.5 MG	61400016100320	Generic
DEXMETHYLPHENIDATE HYDROCHLORIDE	DEXMETHYLPHENIDATE HCL TAB 5 MG	61400016100330	Generic
DEXMETHYLPHENIDATE HCL	DEXMETHYLPHENIDATE HCL TAB 5 MG	61400016100330	Generic
DEXMETHYLPHENIDATE HYDROCHLORIDE	DEXMETHYLPHENIDATE HCL TAB 10 MG	61400016100340	Generic
DEXMETHYLPHENIDATE HCL	DEXMETHYLPHENIDATE HCL TAB 10 MG	61400016100340	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FOCALIN XR	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 5 MG	61400016107020	Brand
FOCALIN XR	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 10 MG	61400016107030	Brand
FOCALIN XR	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 15 MG	61400016107035	Brand
FOCALIN XR	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 20 MG	61400016107040	Brand
FOCALIN XR	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 25 MG	61400016107045	Brand
FOCALIN XR	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 30 MG	61400016107050	Brand
FOCALIN XR	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 35 MG	61400016107055	Brand
FOCALIN XR	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 40 MG	61400016107060	Brand
METHYLIN	METHYLPHENIDATE HCL SOLN 5 MG/5ML	61400020102020	Brand
METHYLIN	METHYLPHENIDATE HCL SOLN 10 MG/5ML	61400020102030	Brand
METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HCL TAB 5 MG	61400020100305	Generic
METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HCL TAB 10 MG	61400020100310	Generic
METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HCL TAB 20 MG	61400020100315	Generic
RITALIN LA	METHYLPHENIDATE HCL CAP ER 24HR 10 MG (LA)	61400020107010	Brand
RITALIN LA	METHYLPHENIDATE HCL CAP ER 24HR 20 MG (LA)	61400020107020	Brand
RITALIN LA	METHYLPHENIDATE HCL CAP ER 24HR 30 MG (LA)	61400020107030	Brand
RITALIN LA	METHYLPHENIDATE HCL CAP ER 24HR 40 MG (LA)	61400020107040	Brand
METHYLPHENIDATE HYDROCHLORIDE CD	METHYLPHENIDATE HCL CAP ER 10 MG (CD)	61400020100210	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 10 MG (CD)	61400020100210	Generic
METHYLPHENIDATE HYDROCHLORIDE CD	METHYLPHENIDATE HCL CAP ER 20 MG (CD)	61400020100220	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 20 MG (CD)	61400020100220	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

METHYLPHENIDATE HYDROCHLORIDE CD	METHYLPHENIDATE HCL CAP ER 30 MG (CD)	61400020100230	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 30 MG (CD)	61400020100230	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 40 MG (CD)	61400020100240	Generic
METHYLPHENIDATE HYDROCHLORIDE CD	METHYLPHENIDATE HCL CAP ER 50 MG (CD)	61400020100250	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 50 MG (CD)	61400020100250	Generic
METHYLPHENIDATE HYDROCHLORIDE CD	METHYLPHENIDATE HCL CAP ER 60 MG (CD)	61400020100260	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 60 MG (CD)	61400020100260	Generic
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CAP 10 MG	61100025100110	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CAP 20 MG	61100025100120	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CAP 30 MG	61100025100130	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CAP 40 MG	61100025100140	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CAP 50 MG	61100025100150	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CAP 60 MG	61100025100160	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CAP 70 MG	61100025100170	Brand
ATOMOXETINE HYDROCHLORIDE	ATOMOXETINE HCL CAP 10 MG (BASE EQUIV)	61354015100110	Generic
ATOMOXETINE	ATOMOXETINE HCL CAP 10 MG (BASE EQUIV)	61354015100110	Generic
ATOMOXETINE HYDROCHLORIDE	ATOMOXETINE HCL CAP 18 MG (BASE EQUIV)	61354015100118	Generic
ATOMOXETINE	ATOMOXETINE HCL CAP 18 MG (BASE EQUIV)	61354015100118	Generic
ATOMOXETINE HYDROCHLORIDE	ATOMOXETINE HCL CAP 25 MG (BASE EQUIV)	61354015100125	Generic
ATOMOXETINE	ATOMOXETINE HCL CAP 25 MG (BASE EQUIV)	61354015100125	Generic
ATOMOXETINE HYDROCHLORIDE	ATOMOXETINE HCL CAP 40 MG (BASE EQUIV)	61354015100140	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ATOMOXETINE	ATOMOXETINE HCL CAP 40 MG (BASE EQUIV)	61354015100140	Generic
ATOMOXETINE HYDROCHLORIDE	ATOMOXETINE HCL CAP 60 MG (BASE EQUIV)	61354015100160	Generic
ATOMOXETINE	ATOMOXETINE HCL CAP 60 MG (BASE EQUIV)	61354015100160	Generic
ATOMOXETINE HYDROCHLORIDE	ATOMOXETINE HCL CAP 80 MG (BASE EQUIV)	61354015100170	Generic
ATOMOXETINE	ATOMOXETINE HCL CAP 80 MG (BASE EQUIV)	61354015100170	Generic
ATOMOXETINE HYDROCHLORIDE	ATOMOXETINE HCL CAP 100 MG (BASE EQUIV)	61354015100180	Generic
ATOMOXETINE	ATOMOXETINE HCL CAP 100 MG (BASE EQUIV)	61354015100180	Generic
DEXTROAMPHETAMINE SULFATE	DEXTROAMPHETAMINE SULFATE TAB 5 MG	61100020100305	Generic
DEXTROAMPHETAMINE SULFATE	DEXTROAMPHETAMINE SULFATE TAB 10 MG	61100020100310	Generic
DEXTROAMPHETAMINE SULFATE	DEXTROAMPHETAMINE SULFATE TAB 15 MG	61100020100315	Generic
DEXTROAMPHETAMINE SULFATE	DEXTROAMPHETAMINE SULFATE TAB 20 MG	61100020100330	Generic
DEXTROAMPHETAMINE SULFATE	DEXTROAMPHETAMINE SULFATE TAB 30 MG	61100020100350	Generic
ADHANSIA XR	METHYLPHENIDATE HCL CAP ER 24HR 25 MG	61400020107068	Brand
ADHANSIA XR	METHYLPHENIDATE HCL CAP ER 24HR 35 MG	61400020107073	Brand
ADHANSIA XR	METHYLPHENIDATE HCL CAP ER 24HR 45 MG	61400020107078	Brand
ADHANSIA XR	METHYLPHENIDATE HCL CAP ER 24HR 55 MG	61400020107083	Brand
ADHANSIA XR	METHYLPHENIDATE HCL CAP ER 24HR 70 MG	61400020107088	Brand
ADHANSIA XR	METHYLPHENIDATE HCL CAP ER 24HR 85 MG	61400020107091	Brand
ADZENYS XR-ODT	AMPHETAMINE TAB EXTENDED RELEASE DISINTEGRATING 3.1 MG	6110001000H410	Brand
ADZENYS XR-ODT	AMPHETAMINE TAB EXTENDED RELEASE DISINTEGRATING 6.3 MG	6110001000H420	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADZENYS XR-ODT	AMPHETAMINE TAB EXTENDED RELEASE DISINTEGRATING 9.4 MG	6110001000H430	Brand
ADZENYS XR-ODT	AMPHETAMINE TAB EXTENDED RELEASE DISINTEGRATING 12.5 MG	6110001000H440	Brand
ADZENYS XR-ODT	AMPHETAMINE TAB EXTENDED RELEASE DISINTEGRATING 15.7 MG	6110001000H450	Brand
ADZENYS XR-ODT	AMPHETAMINE TAB EXTENDED RELEASE DISINTEGRATING 18.8 MG	6110001000H460	Brand
AMPHETAMINE SULFATE	AMPHETAMINE SULFATE TAB 5 MG	61100010100310	Generic
AMPHETAMINE SULFATE	AMPHETAMINE SULFATE TAB 10 MG	61100010100320	Generic
AMPHETAMINE/DEXTROAMPHETAMINE	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 5 MG	61109902107005	Generic
AMPHETAMINE/DEXTROAMPHETAMINE	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 10 MG	61109902107010	Generic
AMPHETAMINE/DEXTROAMPHETAMINE	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 15 MG	61109902107015	Generic
AMPHETAMINE/DEXTROAMPHETAMINE	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 20 MG	61109902107020	Generic
AMPHETAMINE/DEXTROAMPHETAMINE	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 25 MG	61109902107025	Generic
AMPHETAMINE/DEXTROAMPHETAMINE	AMPHETAMINE- DEXTROAMPHETAMINE CAP ER 24HR 30 MG	61109902107030	Generic
APTENSIO XR	METHYLPHENIDATE HCL CAP ER 24HR 10 MG (XR)	61400020107055	Brand
APTENSIO XR	METHYLPHENIDATE HCL CAP ER 24HR 15 MG (XR)	61400020107060	Brand
APTENSIO XR	METHYLPHENIDATE HCL CAP ER 24HR 20 MG (XR)	61400020107065	Brand
APTENSIO XR	METHYLPHENIDATE HCL CAP ER 24HR 30 MG (XR)	61400020107070	Brand
APTENSIO XR	METHYLPHENIDATE HCL CAP ER 24HR 40 MG (XR)	61400020107075	Brand
APTENSIO XR	METHYLPHENIDATE HCL CAP ER 24HR 50 MG (XR)	61400020107080	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

APTENSIO XR	METHYLPHENIDATE HCL CAP ER 24HR 60 MG (XR)	61400020107085	Brand
AZSTARYS	SERDEXMETHYLPHENIDAT E-DEXMETHYLPHENIDATE CAP 26.1-5.2 MG	61409802800120	Brand
AZSTARYS	SERDEXMETHYLPHENIDAT E-DEXMETHYLPHENIDATE CAP 39.2-7.8 MG	61409802800130	Brand
AZSTARYS	SERDEXMETHYLPHENIDAT E-DEXMETHYLPHENIDATE CAP 52.3-10.4 MG	61409802800140	Brand
COTEMPLA XR-ODT	METHYLPHENIDATE TAB EXTENDED RELEASE DISINTEGRATING 8.6 MG	6140002000H410	Brand
COTEMPLA XR-ODT	METHYLPHENIDATE TAB EXTENDED RELEASE DISINTEGRATING 17.3 MG	6140002000H420	Brand
COTEMPLA XR-ODT	METHYLPHENIDATE TAB EXTENDED RELEASE DISINTEGRATING 25.9 MG	6140002000H430	Brand
DESOXYN	METHAMPHETAMINE HCL TAB 5 MG	61100030100305	Brand
DEXEDRINE	DEXTROAMPHETAMINE SULFATE CAP ER 24HR 10 MG	61100020107010	Brand
DEXEDRINE	DEXTROAMPHETAMINE SULFATE CAP ER 24HR 15 MG	61100020107015	Brand
DEXMETHYLPHENIDATE HYDROCHLORIDE ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 5 MG	61400016107020	Generic
DEXMETHYLPHENIDATE HCL ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 5 MG	61400016107020	Generic
DEXMETHYLPHENIDATE HYDROCHLORIDE ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 10 MG	61400016107030	Generic
DEXMETHYLPHENIDATE HCL ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 10 MG	61400016107030	Generic
DEXMETHYLPHENIDATE HYDROCHLORIDE ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 15 MG	61400016107035	Generic
DEXMETHYLPHENIDATE HCL ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 15 MG	61400016107035	Generic
DEXMETHYLPHENIDATE HYDROCHLORIDE ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 20 MG	61400016107040	Generic
DEXMETHYLPHENIDATE HCL ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 20 MG	61400016107040	Generic
DEXMETHYLPHENIDATE HYDROCHLORIDE ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 25 MG	61400016107045	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DEXMETHYLPHENIDATE HYDROCHLORIDE	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 25 MG	61400016107045	Generic
DEXMETHYLPHENIDATE HCL ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 25 MG	61400016107045	Generic
DEXMETHYLPHENIDATE HYDROCHLORIDE ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 30 MG	61400016107050	Generic
DEXMETHYLPHENIDATE HCL ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 30 MG	61400016107050	Generic
DEXMETHYLPHENIDATE HYDROCHLORIDE ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 35 MG	61400016107055	Generic
DEXMETHYLPHENIDATE HCL ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 35 MG	61400016107055	Generic
DEXMETHYLPHENIDATE HYDROCHLORIDE ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 40 MG	61400016107060	Generic
DEXMETHYLPHENIDATE HCL ER	DEXMETHYLPHENIDATE HCL CAP ER 24 HR 40 MG	61400016107060	Generic
DEXTROAMPHETAMINE SULFATE ER	DEXTROAMPHETAMINE SULFATE CAP ER 24HR 5 MG	61100020107005	Generic
DEXTROAMPHETAMINE SULFATE ER	DEXTROAMPHETAMINE SULFATE CAP ER 24HR 10 MG	61100020107010	Generic
DEXTROAMPHETAMINE SULFATE ER	DEXTROAMPHETAMINE SULFATE CAP ER 24HR 15 MG	61100020107015	Generic
DYANA VEL XR	AMPHETAMINE EXTENDED RELEASE SUSP 2.5 MG/ML	6110001000G120	Brand
DYANA VEL XR	AMPHETAMINE CHEW TAB EXTENDED RELEASE 5 MG	61100010000410	Brand
DYANA VEL XR	AMPHETAMINE CHEW TAB EXTENDED RELEASE 10 MG	61100010000420	Brand
DYANA VEL XR	AMPHETAMINE CHEW TAB EXTENDED RELEASE 15 MG	61100010000430	Brand
DYANA VEL XR	AMPHETAMINE CHEW TAB EXTENDED RELEASE 20 MG	61100010000440	Brand
EVEKEO ODT	AMPHETAMINE SULFATE ORALLY DISINTEGRATING TAB 5 MG	61100010107210	Brand
EVEKEO ODT	AMPHETAMINE SULFATE ORALLY DISINTEGRATING TAB 10 MG	61100010107220	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EVEKEO ODT	AMPHETAMINE SULFATE ORALLY DISINTEGRATING TAB 15 MG	61100010107230	Brand
EVEKEO ODT	AMPHETAMINE SULFATE ORALLY DISINTEGRATING TAB 20 MG	61100010107240	Brand
FOCALIN	DEXMETHYLPHENIDATE HCL TAB 2.5 MG	61400016100320	Brand
FOCALIN	DEXMETHYLPHENIDATE HCL TAB 5 MG	61400016100330	Brand
FOCALIN	DEXMETHYLPHENIDATE HCL TAB 10 MG	61400016100340	Brand
JORNAY PM	METHYLPHENIDATE HCL CAP DELAYED ER 24HR 20 MG (PM)	61400020107067	Brand
JORNAY PM	METHYLPHENIDATE HCL CAP DELAYED ER 24HR 40 MG (PM)	61400020107077	Brand
JORNAY PM	METHYLPHENIDATE HCL CAP DELAYED ER 24HR 60 MG (PM)	61400020107087	Brand
JORNAY PM	METHYLPHENIDATE HCL CAP DELAYED ER 24HR 80 MG (PM)	61400020107090	Brand
JORNAY PM	METHYLPHENIDATE HCL CAP DELAYED ER 24HR 100 MG (PM)	61400020107094	Brand
METHAMPHETAMINE HCL	METHAMPHETAMINE HCL TAB 5 MG	61100030100305	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER 10 MG	61400020100403	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER 20 MG	61400020100405	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 18 MG	61400020100460	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 27 MG	61400020100465	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 36 MG	61400020100470	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 45 MG	61400020100475	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 54 MG	61400020100480	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 63 MG	61400020100485	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 72 MG	61400020100490	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 24HR 10 MG (LA)	61400020107010	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 24HR 20 MG (LA)	61400020107020	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 24HR 30 MG (LA)	61400020107030	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 24HR 40 MG (LA)	61400020107040	Generic
METHYLPHENIDATE HYDROCHLORIDE ER (LA)	METHYLPHENIDATE HCL CAP ER 24HR 60 MG (LA)	61400020107048	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 24HR 10 MG (XR)	61400020107055	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 24HR 15 MG (XR)	61400020107060	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 24HR 20 MG (XR)	61400020107065	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 24HR 30 MG (XR)	61400020107070	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 24HR 40 MG (XR)	61400020107075	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 24HR 50 MG (XR)	61400020107080	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL CAP ER 24HR 60 MG (XR)	61400020107085	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER 24HR 18 MG	61400020107518	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER 24HR 27 MG	61400020107527	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER 24HR 36 MG	61400020107536	Generic
METHYLPHENIDATE HYDROCHLORIDE ER	METHYLPHENIDATE HCL TAB ER 24HR 54 MG	61400020107554	Generic
MYDAYIS	AMPHETAMINE- DEXTROAMPHETAMINE 3- BEAD CAP ER 24HR 12.5 MG	61109902107060	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MYDAYIS	AMPHETAMINE- DEXTROAMPHETAMINE 3- BEAD CAP ER 24HR 25 MG	61109902107065	Brand
MYDAYIS	AMPHETAMINE- DEXTROAMPHETAMINE 3- BEAD CAP ER 24HR 37.5 MG	61109902107070	Brand
MYDAYIS	AMPHETAMINE- DEXTROAMPHETAMINE 3- BEAD CAP ER 24HR 50 MG	61109902107075	Brand
PROCENTRA	DEXTROAMPHETAMINE SULFATE ORAL SOLUTION 5 MG/5ML	61100020102020	Brand
QELBREE	VILOXAZINE HCL CAP ER 24HR 100 MG	61354080207020	Brand
QELBREE	VILOXAZINE HCL CAP ER 24HR 150 MG	61354080207030	Brand
QELBREE	VILOXAZINE HCL CAP ER 24HR 200 MG	61354080207040	Brand
QUILLICHEW ER	METHYLPHENIDATE HCL CHEW TAB EXTENDED RELEASE 20 MG	6140002010H220	Brand
QUILLICHEW ER	METHYLPHENIDATE HCL CHEW TAB EXTENDED RELEASE 30 MG	6140002010H230	Brand
QUILLICHEW ER	METHYLPHENIDATE HCL CHEW TAB EXTENDED RELEASE 40 MG	6140002010H240	Brand
QUILLIVANT XR	METHYLPHENIDATE HCL FOR ER SUSP 25 MG/5ML (5 MG/ML)	6140002010G220	Brand
RELEXXII	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 45 MG	61400020100475	Generic
RELEXXII	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 63 MG	61400020100485	Generic
RELEXXII	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 72 MG	61400020100490	Brand
RITALIN	METHYLPHENIDATE HCL TAB 5 MG	61400020100305	Brand
RITALIN	METHYLPHENIDATE HCL TAB 10 MG	61400020100310	Brand
RITALIN	METHYLPHENIDATE HCL TAB 20 MG	61400020100315	Brand
STRATTERA	ATOMOXETINE HCL CAP 10 MG (BASE EQUIV)	61354015100110	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

STRATTERA	ATOMOXETINE HCL CAP 18 MG (BASE EQUIV)	61354015100118	Brand
STRATTERA	ATOMOXETINE HCL CAP 25 MG (BASE EQUIV)	61354015100125	Brand
STRATTERA	ATOMOXETINE HCL CAP 40 MG (BASE EQUIV)	61354015100140	Brand
STRATTERA	ATOMOXETINE HCL CAP 60 MG (BASE EQUIV)	61354015100160	Brand
STRATTERA	ATOMOXETINE HCL CAP 80 MG (BASE EQUIV)	61354015100170	Brand
STRATTERA	ATOMOXETINE HCL CAP 100 MG (BASE EQUIV)	61354015100180	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 10 MG	61100025100510	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 20 MG	61100025100520	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 30 MG	61100025100530	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 40 MG	61100025100540	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 50 MG	61100025100550	Brand
VYVANSE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 60 MG	61100025100560	Brand
ZENZEDI	DEXTROAMPHETAMINE SULFATE TAB 2.5 MG	61100020100303	Brand
ZENZEDI	DEXTROAMPHETAMINE SULFATE TAB 5 MG	61100020100305	Brand
ZENZEDI	DEXTROAMPHETAMINE SULFATE TAB 7.5 MG	61100020100308	Brand
ZENZEDI	DEXTROAMPHETAMINE SULFATE TAB 10 MG	61100020100310	Brand
ZENZEDI	DEXTROAMPHETAMINE SULFATE TAB 15 MG	61100020100315	Brand
ZENZEDI	DEXTROAMPHETAMINE SULFATE TAB 20 MG	61100020100330	Brand
ZENZEDI	DEXTROAMPHETAMINE SULFATE TAB 30 MG	61100020100350	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DEXTROAMPHETAMINE SULFATE	DEXTROAMPHETAMINE SULFATE ORAL SOLUTION 5 MG/5ML	61100020102020	Generic
EVEKEO	AMPHETAMINE SULFATE TAB 5 MG	61100010100310	Brand
EVEKEO	AMPHETAMINE SULFATE TAB 10 MG	61100010100320	Brand
METHYLPHENIDATE	METHYLPHENIDATE TD PATCH 10 MG/9HR	61400020005910	Generic
METHYLPHENIDATE	METHYLPHENIDATE TD PATCH 15 MG/9HR	61400020005915	Generic
METHYLPHENIDATE	METHYLPHENIDATE TD PATCH 20 MG/9HR	61400020005920	Generic
METHYLPHENIDATE	METHYLPHENIDATE TD PATCH 30 MG/9HR	61400020005930	Generic
METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HCL SOLN 5 MG/5ML	61400020102020	Generic
METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HCL SOLN 10 MG/5ML	61400020102030	Generic
METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HCL CHEW TAB 2.5 MG	61400020100510	Generic
METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HCL CHEW TAB 5 MG	61400020100520	Generic
METHYLPHENIDATE HYDROCHLORIDE	METHYLPHENIDATE HCL CHEW TAB 10 MG	61400020100530	Generic
AMPHETAMINE ER	AMPHETAMINE EXTENDED RELEASE SUSP 1.25 MG/ML	6110001000G110	Generic
ADZENYS ER	AMPHETAMINE EXTENDED RELEASE SUSP 1.25 MG/ML	6110001000G110	Brand
DEXEDRINE	DEXTROAMPHETAMINE SULFATE CAP ER 24HR 5 MG	61100020107005	Brand
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CAP 10 MG	61100025100110	Generic
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CAP 20 MG	61100025100120	Generic
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CAP 30 MG	61100025100130	Generic
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CAP 40 MG	61100025100140	Generic
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CAP 50 MG	61100025100150	Generic

LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CAP 60 MG	61100025100160	Generic
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CAP 70 MG	61100025100170	Generic
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 10 MG	61100025100510	Generic
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 20 MG	61100025100520	Generic
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 30 MG	61100025100530	Generic
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 40 MG	61100025100540	Generic
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 50 MG	61100025100550	Generic
LISDEXAMFETAMINE DIMESYLATE	LISDEXAMFETAMINE DIMESYLATE CHEW TAB 60 MG	61100025100560	Generic
RELEXXII	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 18 MG	61400020100460	Brand
RELEXXII	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 27 MG	61400020100465	Brand
RELEXXII	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 36 MG	61400020100470	Brand
RELEXXII	METHYLPHENIDATE HCL TAB ER OSMOTIC RELEASE (OSM) 54 MG	61400020100480	Brand

**Approval Criteria**

1 - If the patient is under 6 years old, ALL of the following:

1.1 The requesting clinician has documented that the child has a diagnosis of attention deficit hyperactivity disorder (ADHD)

**AND**

**1.2** The requesting clinician has documented that psychosocial issues have been evaluated before request for ADHD medications

**AND**

**1.3** The requesting clinician has documented non-medication alternatives that have been attempted before request for ADHD medications

**AND**

**1.4** The requested dose does NOT exceed the Food and Drug Administration (FDA) recommended maximum daily dosage unless the provider has submitted clinical justification for the dose exceeding the FDA maximum

**AND**

**2** - If the request is non-preferred\*, the patient has a history of failure, contraindication, or intolerance to a trial of FOUR preferred products\*\*

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a> **Alternatives may require prior authorization.
-------	---

Product Name: clonidine tabs, generic clonidine ER 12 hr, guanfacine, generic guanfacine ER, Brand Intuniv, Brand Kapvay			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CLONIDINE HYDROCHLORIDE	CLONIDINE HCL TAB 0.1 MG	36201010100305	Generic
CLONIDINE HYDROCHLORIDE	CLONIDINE HCL TAB 0.2 MG	36201010100310	Generic
CLONIDINE HYDROCHLORIDE	CLONIDINE HCL TAB 0.3 MG	36201010100315	Generic
CLONIDINE HYDROCHLORIDE	CLONIDINE HCL TAB ER 12HR 0.1 MG	61353020107420	Generic

CLONIDINE HYDROCHLORIDE ER	CLONIDINE HCL TAB ER 12HR 0.1 MG	61353020107420	Generic
CLONIDINE HCL ER	CLONIDINE HCL TAB ER 12HR 0.1 MG	61353020107420	Generic
GUANFACINE HYDROCHLORIDE	GUANFACINE HCL TAB 1 MG	36201025100320	Generic
GUANFACINE HYDROCHLORIDE	GUANFACINE HCL TAB 2 MG	36201025100330	Generic
INTUNIV	GUANFACINE HCL TAB ER 24HR 1 MG (BASE EQUIV)	61353030107520	Brand
INTUNIV	GUANFACINE HCL TAB ER 24HR 2 MG (BASE EQUIV)	61353030107530	Brand
INTUNIV	GUANFACINE HCL TAB ER 24HR 3 MG (BASE EQUIV)	61353030107540	Brand
INTUNIV	GUANFACINE HCL TAB ER 24HR 4 MG (BASE EQUIV)	61353030107550	Brand
KAPVAY	CLONIDINE HCL TAB ER 12HR 0.1 MG	61353020107420	Brand
GUANFACINE HYDROCHLORIDE ER	GUANFACINE HCL TAB ER 24HR 1 MG (BASE EQUIV)	61353030107520	Generic
GUANFACINE HYDROCHLORIDE ER	GUANFACINE HCL TAB ER 24HR 2 MG (BASE EQUIV)	61353030107530	Generic
GUANFACINE HYDROCHLORIDE ER	GUANFACINE HCL TAB ER 24HR 3 MG (BASE EQUIV)	61353030107540	Generic
GUANFACINE HYDROCHLORIDE ER	GUANFACINE HCL TAB ER 24HR 4 MG (BASE EQUIV)	61353030107550	Generic

**Approval Criteria**

**1** - If the patient is under 6 years old, ONE of the following:

**1.1** ALL of the following:

**1.1.1** The requesting clinician has documented that the child has a diagnosis of attention deficit hyperactivity disorder (ADHD)

**AND**

**1.1.2** The requesting clinician has documented that psychosocial issues have been evaluated before request for ADHD medications

**AND**

**1.1.3** The requesting clinician has documented non-medication alternatives that have been attempted before request for ADHD medications

**AND**

**1.1.4** The requested dose does NOT exceed the Food and Drug Administration (FDA) recommended maximum daily dosage unless the provider has submitted clinical justification for the dose exceeding the FDA maximum

**OR**

**1.2** BOTH of the following:

**1.2.1** Diagnosis of insomnia

**AND**

**1.2.2** Trial and failure, contraindication, or intolerance to melatonin

**AND**

**2** - If the request is non-preferred\*, the patient has a history of failure, contraindication, or intolerance to a trial of FOUR preferred products\*\*

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC%20CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP</a> **Alternatives may require prior authorization.
-------	---

Product Name: Xelstrym	
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
XELSTRYM	DEXTROAMPHETAMINE TD PATCH 4.5 MG/9HR	61100020005910	Brand
XELSTRYM	DEXTROAMPHETAMINE TD PATCH 9 MG/9HR	61100020005920	Brand
XELSTRYM	DEXTROAMPHETAMINE TD PATCH 13.5 MG/9HR	61100020005930	Brand
XELSTRYM	DEXTROAMPHETAMINE TD PATCH 18 MG/9HR	61100020005940	Brand

**Approval Criteria**

1 - If the request is non-preferred\*, the patient has a history of failure, contraindication, or intolerance to a trial of THREE preferred products\*\*

**AND**

2 - The patient has a history of failure, contraindication, or intolerance to Daytrana

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a> **Alternatives may require prior authorization.
-------	---

Product Name: Onyda XR			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ONYDA XR	CLONIDINE HCL EXTENDED RELEASE SUSP 0.1 MG/ML	6135302010G110	Brand

**Approval Criteria**

1 - If the request is non-preferred\*, the patient has a history of failure, contraindication, or intolerance to a trial of THREE preferred products\*\*

**AND**

<p><b>2</b> - The patient has a history of failure, contraindication, or intolerance to generic clonidine patch</p>	
Notes	<p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>                  **Alternatives may require prior authorization.</p>

## 2 . Revision History

Date	Notes
11/11/2024	Added criteria for new target Onyda XR; Updated GPI table, where applicable.



Aduhelm (aducanumab-avwa)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140936
<b>Guideline Name</b>	Aduhelm (aducanumab-avwa)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Aduhelm			
Diagnosis	Alzheimer's Disease		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ADUHELM	ADUCANUMAB-AVWA IV SOLN 170 MG/1.7ML (100 MG/ML)	62050510102020	Brand
ADUHELM	ADUCANUMAB-AVWA IV SOLN 300 MG/3ML (100 MG/ML)	62050510102030	Brand

**Approval Criteria**

**1** - Diagnosis of one of the following:

- Mild cognitive impairment (MCI) due to Alzheimer's Disease (AD)
- Mild dementia due to Alzheimer's Disease (AD)

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values, examination histories) documenting the basis for diagnosis, including all of the following:

**2.1** Documentation of a comprehensive history and neurological examination, inclusive of a description of the nature and duration of cognitive symptoms within the previous 3 months

**AND**

**2.2** Medical records documenting baseline (within the previous three months) cognitive function based on ONE of the following objective assessments:

- Mini-Mental State Examination (MMSE) score greater than or equal to 24
- Montreal Cognitive Assessment (MoCA) score greater than or equal to 15

**AND**

**2.3** Medical records documenting confirmed evidence of clinically significant AD neuropathology based on ONE of the following:

- Cerebral Spinal Fluid (CSF) biomarkers
- Amyloid positron emission tomography (PET)

**AND**

**3** - Patient has received recent (within the previous 3 months) baseline brain magnetic resonance imaging (MRI) prior to initiating treatment

**AND**

**4** - Patient does NOT have significant cerebrovascular disease as established by brain MRI showing any of the following:

- Acute or sub-acute hemorrhage
- Prior macro-hemorrhage or prior subarachnoid hemorrhage (unless finding is not due to an underlying structural or vascular hemorrhage)
- 4 or more brain microhemorrhages
- Cortical infarct
- More than 1 lacunar infarct
- Superficial siderosis
- History of diffuse white matter disease

**AND**

**5** - Patient does not have any of the following non-AD neurodegenerative disorders:

- Probable dementia with Lewy bodies by consensus criteria
- Suspected frontotemporal degeneration
- Dementia in down syndrome

**AND**

**6** - Patient does not have any of the following exclusionary neurological or psychiatric conditions:

- Uncontrolled seizure disorder
- Uncontrolled mood disorder, anxiety disorder, or psychosis
- Substance use disorder active in the past 2 years

**AND**

**7** - Patient does not have any of the following cardiovascular conditions:

- Uncontrolled hypertension
- Coronary artery disease (including unstable angina and myocardial infarction)
- Heart failure
- Arrhythmia

- Clinically significant carotid atherosclerosis and/or peripheral arterial disease

**AND**

**8** - Both of the following:

- Patient is not currently taking an anticoagulant or antiplatelet agent (unless aspirin 325 milligrams/day or less)
- Patient has no history of transient ischemic attack (TIA), stroke, or unexplained loss of consciousness within the previous year prior to initiating treatment

**AND**

**9** - Patient does not have any uncontrolled clinically significant chronic medical condition [e.g., liver disease, kidney disease, pulmonary disease, autoimmune disease requiring chronic immunosuppression, malignant neoplasm, active chronic infection (HIV, HCV), poorly controlled diabetes mellitus]

**AND**

**10** - Prescribed dosing is in accordance with the United States Food and Drug Administration approved labeling

**AND**

**11** - Prescribed by or in consultation with one of the following:

- Neurologist
- Geriatrics specialist

**AND**

**12** - Prescriber attests that the patient and/or authorized representative (e.g., power of attorney, invoked health care proxy) has shared in decision-making and has been informed on the known and potential risks and lack of established clinical benefit associated with Aduhelm (aducanumab-avwa) treatment

**AND**

**13** - Therapy should be discontinued permanently and the request should be denied if one or more of the following apply:

- If the patient has had greater than or equal to 10 new incident microhemorrhages, regardless of clinical severity (including asymptomatic)
- If the patient had a serious event [Serious events include concern for immediate risk of death (a life-threatening event); inpatient hospitalization or prolongation of existing hospitalization due to symptoms; new persistent or significant disability/incapacity]
- If the patient has had greater than or equal to 3 new incident areas of superficial siderosis, regardless of clinical severity (including asymptomatic) therapy should be discontinued permanently and the request should be denied

Product Name: Aduhelm			
Diagnosis	Alzheimer's Disease		
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ADUHELM	ADUCANUMAB-AVWA IV SOLN 170 MG/1.7ML (100 MG/ML)	62050510102020	Brand
ADUHELM	ADUCANUMAB-AVWA IV SOLN 300 MG/3ML (100 MG/ML)	62050510102030	Brand

**Approval Criteria**

**1** - Prescribed dosing is in accordance with the United States Food and Drug Administration approved labeling

**AND**

**2** - Follow-up MRIs (magnetic resonance imaging) have been conducted at the following timeframes:

- Week 14 [after 4th infusion, prior to first 6 mg/kg (milligrams/kilogram) dose]
- Week 22 (after 6th infusion, prior to first 10 mg/kg dose)
- Week 30 (after 8th infusion, prior to third 10 mg/kg dose)
- Week 42 (after 11th infusion, prior to sixth 10 mg/kg dose)
- Every 6 months thereafter

**AND**

**3** - Patient's diagnosis continues to be mild cognitive impairment or mild dementia stage due to Alzheimer's disease as established by one of the following examination scales:

**3.1** One of the following:

- Mini Mental State Exam (MMSE) score greater than or equal to 24
- Montreal Cognitive Assessment (MoCA) score greater than or equal to 15

**OR**

**3.2** Both of the following:

- MMSE < 24 or MoCA < 15
- Rate of decline was slower than expected (less than 2 points/year)

**AND**

**4** - ONE of the following [ARIA-H (amyloid related imaging abnormalities - haemosiderin), microhemorrhages]:

- Patient has had no new incident microhemorrhage
- Patient has had 1 to 4 new incident microhemorrhage(s) AND microhemorrhages are asymptomatic (no clinical symptoms)
- Patient has had 5 to 9 new incident microhemorrhages AND microhemorrhages are asymptomatic (no clinical symptoms) AND the microhemorrhages have been stabilized
- Patient has had 1 to 9 new incident microhemorrhages AND microhemorrhages resulted in mild, moderate, or severe clinical symptoms AND the microhemorrhages have been stabilized

**AND**

**5 - ONE of the following (ARIA-H, superficial siderosis):**

- Patient has had no new incident areas of superficial siderosis
- Patient has had 1 new incident area of superficial siderosis AND superficial siderosis is asymptomatic (no clinical symptoms)
- Patient has had 2 new incident areas of superficial siderosis AND superficial siderosis is asymptomatic (no clinical symptoms) AND the superficial siderosis has been stabilized
- Patient has had 1 to 2 new incident areas of superficial siderosis AND superficial siderosis resulted in mild, moderate, or severe clinical symptoms AND the superficial siderosis has been stabilized

**AND**

**6 - ONE of the following [ARIA-E (amyloid related imaging abnormalities - edema)]:**

- Patient has had no new ARIA-E
- Patient has mild ARIA-E on MRI AND ARIA-E is asymptomatic (no clinical symptoms)
- Patient has had moderate or severe ARIA-E on MRI AND ARIA-E is asymptomatic (no clinical symptoms) AND the ARIA-E is stable
- Patient has had mild, moderate or severe ARIA-E on MRI AND ARIA-E resulted in mild, moderate, or severe clinical symptoms AND the ARIA-E is stable

**AND**

**7 - One of the following:**

**7.1 Patient does NOT meet any of the following:**

- Initiation of anticoagulation
- Development of active immune-mediated/autoimmune conditions (e.g., Crohn's disease, SLE, aplastic anemia, myasthenia gravis, meningitis/encephalitis)
- Initiation of immunomodulatory medications (e.g., cancer immunotherapies, rituximab, azathioprine)
- Development of other neurologic conditions (e.g., intracerebral bleeds, TBI, stroke)

**OR**

**7.2 BOTH of the following:**

- Patient does meet one of the above

- Prescriber documents clinical rationale for continued use of aducanumab (Aduhelm)

**AND**

**8** - Prescribed by or in consultation with one of the following:

- Neurologist
- Geriatric specialist

**AND**

**9** - Therapy should be discontinued permanently and the request should be denied if one or more of the following apply:

- If the patient has had greater than or equal to 10 new incident microhemorrhages, regardless of clinical severity (including asymptomatic)
- If the patient had a serious event [Serious events include concern for immediate risk of death (a life-threatening event); inpatient hospitalization or prolongation of existing hospitalization due to symptoms; new persistent or significant disability/incapacity]
- If the patient has had greater than or equal to 3 new incident areas of superficial siderosis, regardless of clinical severity (including asymptomatic) therapy should be discontinued permanently and the request should be denied

## 2 . Background

Clinical Practice Guidelines				
Appendix				
<u>ARIA - H (Microhemorrhages)</u>				
		New Incident Microhemorrhages		
		Radiographic Severity		
		Mild (1 to 4)	Moderate (5 to 9)	Severe (≥10)
Clinical Sympto	Asymptomatic	Continue treatment; MRI q4w until stable	Suspend treatment; MRI q4w until stable; Restart once stable	Stop Permanently



<b>m Severity</b>	Mild	Suspend treatment; MRI q4w until stable Restart once stable and clinical symptoms resolved	Stop Permanently
	Moderate		
	Severe		
	Serious	Stop Permanently	

**ARIA - H (Superficial Siderosis)**

		<b>New Incident Areas of Superficial Siderosis (Central Read)</b>		
		<b>Radiographic Severity</b>		
		Mild (1)	Moderate (2)	Severe (≥3)
<b>Clinical Sympto m Severity</b>	Asymptomatic	Continue treatment; MRI q4w until stable	Suspend treatment; MRI q4w until stable; Restart once stable	Stop Permanently
	Mild	Suspend treatment; MRI q4w until stable Restart once stable and clinical symptoms resolved		Stop Permanently
	Moderate			
	Severe			
Serious	Stop Permanently			

**ARIA - E**

		<b>ARIA-E Severity on MRI (Central Read)</b>		
		<b>Radiographic Severity</b>		
		Mild	Moderate	Severe
<b>Clinical Sympto m Severity</b>	Asymptomatic	Continue treatment; MRI q4w until stable	Suspend treatment; MRI q4w until stable; Restart once stable	
	Mild	Suspend treatment; MRI q4w until stable Restart once stable and clinical symptoms resolved		
	Moderate			
	Severe			
Serious	Stop Permanently			

### 3 . Revision History

Date	Notes
8/25/2022	C&S to match FFS 10.1.22 except removed duplicate and unnecessary notes and removal of all Medicare sections.

Aemcolo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140679
<b>Guideline Name</b>	Aemcolo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Aemcolo			
Approval Length	1 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AEMCOLO	RIFAMYCIN SODIUM TAB DELAYED RELEASE 194 MG (BASE EQUIV)	16000048200620	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of travelers' diarrhea			

**AND**

**2** - History of failure, contraindication, or intolerance to ONE of the following:

- Azithromycin (generic Zithromax)
- Ciprofloxacin (generic Cipro)
- Levofloxacin (generic Levaquin)
- Ofloxacin (generic Floxin)

## **2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Afinitor, Torpenz (everolimus)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151825
<b>Guideline Name</b>	Afinitor, Torpenz (everolimus)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz			
Diagnosis	Neuroendocrine tumors		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand

AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

**1 -** Diagnosis of ONE of the following:

- Neuroendocrine tumors of pancreatic origin
- Neuroendocrine tumors of gastrointestinal origin
- Neuroendocrine tumors of lung origin
- Neuroendocrine tumors of thymic origin

**AND**

**2 -** Disease is progressive

**AND**

**3 -** ONE of the following:

- Disease is unresectable
- Disease is locally advanced
- Disease is metastatic

**AND**

**4** - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz			
Diagnosis	Renal cell cancer		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic

TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

**1 - Diagnosis of renal cell cancer**

**AND**

**2 - ONE of the following:**

**2.1 Disease has relapsed**

**OR**

**2.2 BOTH of the following:**

- Medically or surgically unresectable tumor
- Diagnosis of Stage IV disease

**AND**

**3 - ONE of the following:**

**3.1 Patient with non-clear cell histology**

**OR**

**3.2 BOTH of the following:**

**3.2.1 Patient with predominantly clear cell histology**



**AND**

**3.2.2** History of failure, contraindication, or intolerance to at least one prior systemic therapy [e.g., Nexavar (sorafenib), Sutent (sunitinib), Opdivo (nivolumab), Cabometyx (cabozantinib)]

**AND**

**4** - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz

Diagnosis	Renal Angiomyolipoma with Tuberous Sclerosis Complex
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic

EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

1 - Diagnosis of renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery

**AND**

2 - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz			
Diagnosis	Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand

AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

**1** - Diagnosis of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS)

**AND**

**2** - Patient is NOT a candidate for curative surgical resection

**AND**

**3** - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz	
Diagnosis	Waldenströms Macroglobulinemia or Lymphoplasmacytic Lymphoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

1 - Diagnosis of ONE of the following:

- Waldenströms macroglobulinemia
- Lymphoplasmacytic lymphoma

**AND**

2 - ONE of the following:

- Disease is non-responsive to primary treatment
- Disease is progressive
- Disease has relapsed

**AND**

**3** - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz			
Diagnosis	Breast Cancer		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic

TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

**1** - Diagnosis of breast cancer

**AND**

**2** - ONE of the following:

**2.1** Disease is recurrent

**OR**

**2.2** Disease is metastatic

**AND**

**3** - ONE of the following:

**3.1** Disease is hormone receptor positive (HR+) [i.e., estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+)]

**OR**

**3.2** BOTH of the following:

- Disease is hormone receptor negative (HR-)
- Disease has clinical characteristics that predict a HR+ tumor

**AND**

**4** - Disease is human epidermal growth factor receptor 2 (HER2)-negative

**AND**

**5** - ONE of the following:

**5.1** Patient is a postmenopausal woman

**OR**

**5.2** BOTH of the following:

- Patient is a premenopausal woman
- Patient is being treated with ovarian ablation/suppression

**OR**

**5.3** Patient is male

**AND**

**6** - ONE of the following:

**6.1** BOTH of the following:

**6.1.1** Used in combination with Aromasin (exemestane)

**AND**

**6.1.2** ONE of the following:

**6.1.2.1** Disease progressed while on or within 12 months of non-steroidal aromatase inhibitor [e.g., Arimidex (anastrozole), Femara (letrozole)] therapy

**OR**

**6.1.2.2** Patient was treated with tamoxifen at any time

**OR**

**6.2** Used in combination with ONE of the following:

- fulvestrant
- tamoxifen

**AND**

**7** - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz			
Diagnosis	Hodgkin Lymphoma		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic



EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

1 - Diagnosis of classical Hodgkin lymphoma

**AND**

2 - ONE of the following:

- Disease is refractory
- Disease has relapsed

**AND**

3 - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz	
Diagnosis	PEComa (perivascular epithelioid cell tumor), recurrent angiomyolipoma, lymphangiomyomatosis, or gastrointestinal stromal tumor (GIST)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type		Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic	
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand	
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand	
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand	
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand	
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand	
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand	
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand	
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic	
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic	
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic	
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic	
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic	
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic	
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic	
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic	
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic	
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic	
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic	

**Approval Criteria**

1 - ONE of the following:

1.1 ONE of the following diagnoses:

- PEComa (perivascular epithelioid cell tumor)
- Recurrent angiomyolipoma
- Lymphangiomyomatosis

**OR**

**1.2** ALL of the following:

**1.2.1** Diagnosis of Gastrointestinal Stromal Tumor (GIST)

**AND**

**1.2.2** Disease has progressed after single agent therapy with ONE of the following:

- Gleevec (imatinib)
- Sutent (sunitinib)
- Stivarga (regorafenib)

**AND**

**1.2.3** Used in combination with ONE of the following:

- Gleevec (imatinib)
- Sutent (sunitinib)
- Stivarga (regorafenib)

**AND**

**2** - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz			
Diagnosis	Thymic Carcinoma or Thymoma		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

1 - ONE of the following:

- Diagnosis of thymic carcinoma
- Diagnosis of thymoma

**AND**

2 - ONE of the following:

**2.1** History of failure, contraindication, or intolerance to at least one prior first-line chemotherapy regimen

**OR**

**2.2** Patient has extrathoracic metastatic disease

**AND**

**3** - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz

Diagnosis	Follicular carcinoma, Hürthle cell carcinoma, or papillary carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic

EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

1 - Diagnosis of ONE of the following:

- Follicular carcinoma
- Hürthle cell carcinoma
- Papillary carcinoma

**AND**

2 - ONE of the following:

- Unresectable locoregional recurrent disease
- Persistent disease
- Metastatic disease

**AND**

3 - ONE of the following:

- Patient has symptomatic disease
- Patient has progressive disease

**AND**

4 - Disease is refractory to radioactive iodine treatment

**AND**

5 - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure,

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz

Diagnosis	Meningioma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

1 - Diagnosis of meningioma

**AND**

2 - Disease is recurrent or progressive

**AND**

3 - Surgery and/or radiation is not possible

**AND**

4 - Used in combination with bevacizumab (e.g., Avastin, Mvasi, Zirabev)

**AND**

5 - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz			
Diagnosis	Endometrial Carcinoma		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand



AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

1 - Diagnosis of endometrial carcinoma

**AND**

2 - Used in combination with letrozole

**AND**

3 - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz

Diagnosis | Tuberos Sclerosis Complex associated Partial-Onset Seizures

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

1 - Diagnosis of tuberous sclerosis complex associated partial-onset seizures

**AND**

2 - Used as adjunctive therapy

**AND**

**3** - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic

TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic
<p><b>Approval Criteria</b></p> <p><b>1</b> - Use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - If the request is for Brand Afinitor, Brand Afinitor Disperz, or Torpenz, history of failure, intolerance, or contraindication to generic everolimus tablet or generic everolimus tablet for oral suspension</p>			

Product Name: Brand Afinitor, generic everolimus tablet, Brand Afinitor Disperz, generic everolimus tablet for oral suspension, Torpenz			
Diagnosis	All indications		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AFINITOR	EVEROLIMUS TAB 2.5 MG	21532530000310	Brand
AFINITOR	EVEROLIMUS TAB 5 MG	21532530000320	Brand
AFINITOR	EVEROLIMUS TAB 7.5 MG	21532530000325	Brand
AFINITOR	EVEROLIMUS TAB 10 MG	21532530000330	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Brand
AFINITOR DISPERZ	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Brand
EVEROLIMUS	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
EVEROLIMUS	EVEROLIMUS TAB 5 MG	21532530000320	Generic
EVEROLIMUS	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
EVEROLIMUS	EVEROLIMUS TAB 10 MG	21532530000330	Generic

EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 2 MG	21532530007310	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 3 MG	21532530007320	Generic
EVEROLIMUS	EVEROLIMUS TAB FOR ORAL SUSP 5 MG	21532530007340	Generic
TORPENZ	EVEROLIMUS TAB 2.5 MG	21532530000310	Generic
TORPENZ	EVEROLIMUS TAB 5 MG	21532530000320	Generic
TORPENZ	EVEROLIMUS TAB 7.5 MG	21532530000325	Generic
TORPENZ	EVEROLIMUS TAB 10 MG	21532530000330	Generic

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on therapy

**2 . Revision History**

Date	Notes
8/21/2024	Update to guideline name. Added Torpenz and new generics for Afinitor/Afinitor Disperz as targets to the guideline. Added embedded step in initial auth sections for all indications. Consolidated all reauth sections into one section. Updated initial auth sections for meningioma and PEComa etc. Cosmetic/formatting updates.

Afrezza



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140631
<b>Guideline Name</b>	Afrezza
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

## 1 . Criteria

Product Name: Afrezza			
Diagnosis	Type 1 or Type 2 diabetes mellitus		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AFREZZA	INSULIN REGULAR (HUMAN) INHALATION POWDER 4 UNIT/CARTRIDGE	27104010002940	Brand
AFREZZA	INSULIN REGULAR (HUMAN) INHALATION POWDER 8 UNIT/CARTRIDGE	27104010002950	Brand
AFREZZA	INSULIN REGULAR (HUMAN) INHALATION POWDER 12 UNIT/CARTRIDGE	27104010002955	Brand

AFREZZA	INSULIN REGULAR (HUMAN) INHAL POWD 4 (90) & 8 (90) UNIT/CART	27104010002978	Brand
AFREZZA	INSULIN REGULAR (HUMAN) INH POWD 8 (90) & 12 (90) UNIT/CART	27104010002988	Brand
AFREZZA	INSULIN REGULAR (HUMAN) INH POWD 4 & 8 & 12 UNIT/CART (60)	27104010002990	Brand

**Approval Criteria**

**1 - One of the following:**

**1.1** Diagnosis of type 1 diabetes mellitus and used in combination with a basal insulin or continuous insulin pump

**OR**

**1.2** Diagnosis of type 2 diabetes mellitus

**AND**

**2 - Patient is unable to self-inject medications (e.g. Humalog, Lantus, Levemir) due to ONE of the following:**

- Physical impairment
- Visual impairment
- Lipohypertrophy
- Documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-5 for specific phobia diagnostic criteria)

**AND**

**3 - Forced Expiratory Volume (FEV1) within the last 60 days is greater than or equal to 70% of expected normal as determined by the physician**

**AND**

**4 - Afrezza will not be approved in patients with ONE of the following:**

- Who smoke cigarettes
- Who recently quit smoking (within the past 6 months)
- With chronic lung disease (e.g. asthma, chronic obstructive pulmonary disease)

Product Name: Afrezza	
Diagnosis	Type 1 or Type 2 diabetes mellitus
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
AFREZZA	INSULIN REGULAR (HUMAN) INHALATION POWDER 4 UNIT/CARTRIDGE	27104010002940	Brand
AFREZZA	INSULIN REGULAR (HUMAN) INHALATION POWDER 8 UNIT/CARTRIDGE	27104010002950	Brand
AFREZZA	INSULIN REGULAR (HUMAN) INHALATION POWDER 12 UNIT/CARTRIDGE	27104010002955	Brand
AFREZZA	INSULIN REGULAR (HUMAN) INHAL POWD 4 (90) & 8 (90) UNIT/CART	27104010002978	Brand
AFREZZA	INSULIN REGULAR (HUMAN) INH POWD 8 (90) & 12 (90) UNIT/CART	27104010002988	Brand
AFREZZA	INSULIN REGULAR (HUMAN) INH POWD 4 & 8 & 12 UNIT/CART (60)	27104010002990	Brand

**Approval Criteria**

1 - Repeat pulmonary function test confirms that patient has NOT experienced a decline of 20% or more in Forced Expiratory Volume (FEV1)

**AND**

2 - Patient continues to be unable to self-inject short-acting insulin due to ONE of the following:

- Physical impairment
- Visual impairment
- Lipohypertrophy



- Documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-5 for specific phobia diagnostic criteria)

**AND**

**3** - Patient continues to not smoke cigarettes

## 2 . Revision History

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Agamree (vamorolone)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-145522
<b>Guideline Name</b>	Agamree (vamorolone)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	5/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Agamree			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AGAMREE	VAMOROLONE ORAL SUSP 40 MG/ML	22100075001820	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) documenting a diagnosis of Duchenne muscular dystrophy (DMD)

**AND**

**2** - Patient is 2 years of age or older

**AND**

**3** - Patient has received genetic testing for a mutation of the dystrophin gene

**AND**

**4** - Submission of medical records (e.g., chart notes) documenting one of the following:

**4.1** Patient has a confirmed mutation of the dystrophin gene

**OR**

**4.2** Muscle biopsy confirmed an absence of dystrophin protein

**AND**

**5** - Submission of medical records (e.g., chart notes) or paid claims confirming patient has had a trial and failure or intolerance to prednisone or prednisolone given at a dose of 0.75 mg/kg/day (milligrams per kilogram per day) or 10 mg/kg/weekend

**AND**

**6** - Prescribed by or in consultation with a neurologist who has experience treating children

**AND**

**7** - One of the following:

**7.1** For patients less than or equal to 50kg, dose will not exceed 6mg/kg of body weight once daily

**OR**

**7.2** For patients greater than 50kg, dose will not exceed 300mg/day

Product Name: Agamree

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
AGAMREE	VAMOROLONE ORAL SUSP 40 MG/ML	22100075001820	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting patient has experienced a benefit from therapy (e.g., improvement in preservation of muscle strength)

**AND**

**2** - One of the following:

**2.1** For patients less than or equal to 50kg (kilograms), dose will not exceed 6mg/kg (milligrams per kilogram) of body weight once daily

**OR**

**2.2** For patients greater than 50kg, dose will not exceed 300mg/day

**AND**

**3** - Submission of medical records (e.g., chart notes) or paid claims confirming patient has had a trial and failure or intolerance to prednisone or prednisolone given at a dose of 0.75 mg/kg/day or 10 mg/kg/weekend

## 2 . Revision History

Date	Notes
4/9/2024	New guideline

Airsupra (albuterol-budesonide)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140820
<b>Guideline Name</b>	Airsupra (albuterol-budesonide)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2023
-----------------	-----------

### 1 . Criteria

Product Name: Airsupra			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AIRSUPRA	ALBUTEROL-BUDESONIDE INHALATION AEROSOL 90-80 MCG/ACT	44209902783220	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of asthma

**AND**

2 - Patient is 18 years of age or older

**AND**

3 - Trial and failure, contraindication, or intolerance to treatment with ALL of the following preferred products:

- Advair Diskus (brand) or Advair HFA
- Dulera
- Brand Symbicort

**AND**

4 - Trial, failure, contraindication, or intolerance to BOTH of the following:

- Generic albuterol inhaler
- A preferred inhaled corticosteroid (e.g., Pulmicort, Brand Flovent, Asmanex)

**AND**

5 - Physician has provided rationale for needing to use fixed-dose combination therapy with Airsupra instead of taking individual products in combination (i.e., albuterol inhaler and Pulmicort)

Product Name: Airsupra			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

AIRSUPRA	ALBUTEROL-BUDESONIDE INHALATION AEROSOL 90-80 MCG/ACT	44209902783220	Brand
<p><b>Approval Criteria</b></p> <p>1 - Patient demonstrates positive clinical response to therapy</p>			

## 2 . Revision History

Date	Notes
10/3/2023	New guideline.



Aldurazyme



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140628
<b>Guideline Name</b>	Aldurazyme
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Aldurazyme			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ALDURAZYME	LARONIDASE SOLN FOR IV INFUSION 2.9 MG/5ML (500 UNIT/5ML)	30906550002020	Brand
<b>Approval Criteria</b>			
1 - One of the following:			

**1.1** Confirmed diagnosis of Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I)

**OR**

**1.2** Both the following:

**1.2.1** Confirmed diagnosis of Scheie form of Mucopolysaccharidosis I (MPS I)

**AND**

**1.2.2** Have moderate to severe symptoms

## 2 . Revision History

Date	Notes
3/15/2020	C&S Implementation

Alinia



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140658
<b>Guideline Name</b>	Alinia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	2/1/2021
-----------------	----------

## 1 . Criteria

Product Name: Brand Alinia, generic nitazoxanide			
Diagnosis	Diarrhea caused by Giardia lamblia		
Approval Length	3 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ALINIA	NITAZOXANIDE FOR SUSP 100 MG/5ML	16400060001920	Brand
ALINIA	NITAZOXANIDE TAB 500 MG	16400060000330	Brand
NITAZOXANIDE	NITAZOXANIDE TAB 500 MG	16400060000330	Generic

**Approval Criteria**

1 - Diagnosis of giardiasis

**AND**

2 - History of failure, contraindication, or intolerance to metronidazole

Product Name: Brand Alinia, generic nitazoxanide

Diagnosis	Diarrhea caused by Cryptosporidium parvum
-----------	---

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
ALINIA	NITAZOXANIDE FOR SUSP 100 MG/5ML	16400060001920	Brand
ALINIA	NITAZOXANIDE TAB 500 MG	16400060000330	Brand
NITAZOXANIDE	NITAZOXANIDE TAB 500 MG	16400060000330	Generic

**Approval Criteria**

1 - Diagnosis of cryptosporidiosis

**2 . Revision History**

Date	Notes
12/15/2020	Added generic tablet GPI

Alkeran



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140662
<b>Guideline Name</b>	Alkeran
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	4/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Brand Alkeran tabs, generic melphalan tabs			
Diagnosis	Multiple Myeloma		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ALKERAN	MELPHALAN TAB 2 MG	21101040000305	Brand
MELPHALAN	MELPHALAN TAB 2 MG	21101040000305	Generic

**Approval Criteria**

1 - Diagnosis of palliative treatment of multiple myeloma

**AND**

2 - If the request is for generic melphalan, there is a reason or special circumstance the patient cannot use brand Alkeran

Product Name: Brand Alkeran tabs, generic melphalan tabs

Diagnosis	Ovarian Cancer
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ALKERAN	MELPHALAN TAB 2 MG	21101040000305	Brand
MELPHALAN	MELPHALAN TAB 2 MG	21101040000305	Generic

**Approval Criteria**

1 - Diagnosis of palliative treatment of nonresectable epithelial ovarian

**AND**

2 - If the request is for generic melphalan, there is a reason or special circumstance the patient cannot use brand Alkeran

Product Name: Brand Alkeran tabs, generic melphalan tabs

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ALKERAN	MELPHALAN TAB 2 MG	21101040000305	Brand
MELPHALAN	MELPHALAN TAB 2 MG	21101040000305	Generic

**Approval Criteria**

1 - The use for Alkeran is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

**AND**

2 - If the request is for generic melphalan, there is a reason or special circumstance the patient cannot use brand Alkeran

Product Name: Brand Alkeran tabs, generic melphalan tabs

Diagnosis	Multiple Myeloma, Ovarian Cancer, NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ALKERAN	MELPHALAN TAB 2 MG	21101040000305	Brand
MELPHALAN	MELPHALAN TAB 2 MG	21101040000305	Generic

**Approval Criteria**

1 - There is documentation of positive clinical response to Alkeran therapy

**2 . Revision History**

Date	Notes
------	-------

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

2/23/2021	New policy specific to Arizona.
-----------	---------------------------------



Alpha Interferons



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140933
<b>Guideline Name</b>	Alpha Interferons
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Intron A			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
INTRON A	INTERFERON ALFA-2B FOR INJ 10000000 UNIT	21700060202130	Brand
INTRON A	INTERFERON ALFA-2B FOR INJ 18000000 UNIT	21700060202135	Brand
INTRON A	INTERFERON ALFA-2B FOR INJ 50000000 UNIT	21700060202160	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of hairy cell leukemia

**OR**

**2** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of condylomata acuminata (genital or perianal)

**OR**

**3** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of AIDS (acquired immunodeficiency syndrome)-related Kaposi's sarcoma

**OR**

**4** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of leptomeningeal metastases

**OR**

**5** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of meningiomas

**OR**

**6** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of kidney cancer

**OR**

**7** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting treatment of myeloproliferative neoplasms (MPNs) such as essential thrombocythemia (ET), polycythemia vera (PV), or primary myelofibrosis (PM)

**OR**

**8** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of follicular lymphoma

**OR**

**9** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of adult T-cell leukemia, lymphoma

**OR**

**10** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of mycosis fungoides, Sézary syndrome

**OR**

**11** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of desmoid tumors/aggressive fibromatosis

**OR**

**12** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of giant cell tumor of the bone

**OR**

**13** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of malignant melanoma

Product Name: Alferon N	
Approval Length	8 Week(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ALFERON N	INTERFERON ALFA-N3 INJ 5000000 UNIT/ML	21700060302020	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting treatment of refractory or recurring external condylomata acuminata (genital or venereal warts) due to human papillomavirus (HPV) infection

**2 . Revision History**

Date	Notes
8/8/2022	C&S to match AZM 10.1.22

Alzheimer's Agents



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140666
<b>Guideline Name</b>	Alzheimer's Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Brand Aricept, generic donepezil, Brand Namenda/Namenda XR, generic memantine/memantine XR, Brand Razadyne, generic galantamine hydrobromide, Brand Razadyne ER, generic galantamine ER			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DONEPEZIL HYDROCHLORIDE	DONEPEZIL HYDROCHLORIDE TAB 5 MG	62051025100310	Generic
ARICEPT	DONEPEZIL HYDROCHLORIDE TAB 5 MG	62051025100310	Brand
DONEPEZIL HYDROCHLORIDE	DONEPEZIL HYDROCHLORIDE TAB 10 MG	62051025100320	Generic
DONEPEZIL HCL	DONEPEZIL HYDROCHLORIDE TAB 10 MG	62051025100320	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ARICEPT	DONEPEZIL HYDROCHLORIDE TAB 10 MG	62051025100320	Brand
DONEPEZIL HYDROCHLORIDE	DONEPEZIL HYDROCHLORIDE TAB 23 MG	62051025100330	Generic
DONEPEZIL HCL	DONEPEZIL HYDROCHLORIDE TAB 23 MG	62051025100330	Generic
ARICEPT	DONEPEZIL HYDROCHLORIDE TAB 23 MG	62051025100330	Brand
DONEPEZIL HYDROCHLORIDE ODT	DONEPEZIL HYDROCHLORIDE ORALLY DISINTEGRATING TAB 5 MG	62051025107210	Generic
DONEPEZIL HCL	DONEPEZIL HYDROCHLORIDE ORALLY DISINTEGRATING TAB 5 MG	62051025107210	Generic
DONEPEZIL HYDROCHLORIDE ODT	DONEPEZIL HYDROCHLORIDE ORALLY DISINTEGRATING TAB 10 MG	62051025107220	Generic
DONEPEZIL HCL	DONEPEZIL HYDROCHLORIDE ORALLY DISINTEGRATING TAB 10 MG	62051025107220	Generic
RAZADYNE ER	GALANTAMINE HYDROBROMIDE CAP ER 24HR 8 MG	62051030107020	Brand
GALANTAMINE HYDROBROMIDE ER	GALANTAMINE HYDROBROMIDE CAP ER 24HR 8 MG	62051030107020	Generic
RAZADYNE ER	GALANTAMINE HYDROBROMIDE CAP ER 24HR 16 MG	62051030107030	Brand
GALANTAMINE HYDROBROMIDE	GALANTAMINE HYDROBROMIDE CAP ER 24HR 16 MG	62051030107030	Generic
GALANTAMINE HYDROBROMIDE ER	GALANTAMINE HYDROBROMIDE CAP ER 24HR 16 MG	62051030107030	Generic
RAZADYNE ER	GALANTAMINE HYDROBROMIDE CAP ER 24HR 24 MG	62051030107040	Brand
GALANTAMINE HYDROBROMIDE ER	GALANTAMINE HYDROBROMIDE CAP ER 24HR 24 MG	62051030107040	Generic
GALANTAMINE HYDROBROMIDE	GALANTAMINE HYDROBROMIDE TAB 4 MG	62051030100320	Generic
GALANTAMINE HYDROBROMIDE	GALANTAMINE HYDROBROMIDE TAB 8 MG	62051030100330	Generic
GALANTAMINE HYDROBROMIDE	GALANTAMINE HYDROBROMIDE TAB 12 MG	62051030100340	Generic
GALANTAMINE HYDROBROMIDE	GALANTAMINE HYDROBROMIDE ORAL SOLN 4 MG/ML	62051030102020	Generic
MEMANTINE HYDROCHLORIDE	MEMANTINE HCL TAB 5 MG	62053550100320	Generic
NAMENDA	MEMANTINE HCL TAB 5 MG	62053550100320	Brand
MEMANTINE HYDROCHLORIDE	MEMANTINE HCL TAB 10 MG	62053550100330	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NAMENDA	MEMANTINE HCL TAB 10 MG	62053550100330	Brand
MEMANTINE HCL TITRATION PAK	MEMANTINE HCL TAB 28 X 5 MG & 21 X 10 MG TITRATION PAK	62053550100350	Generic
NAMENDA TITRATION PAK	MEMANTINE HCL TAB 28 X 5 MG & 21 X 10 MG TITRATION PAK	62053550100350	Brand
NAMENDA XR	MEMANTINE HCL CAP ER 24HR 7 MG	62053550107020	Brand
MEMANTINE HYDROCHLORIDE ER	MEMANTINE HCL CAP ER 24HR 7 MG	62053550107020	Generic
NAMENDA XR	MEMANTINE HCL CAP ER 24HR 14 MG	62053550107030	Brand
MEMANTINE HYDROCHLORIDE ER	MEMANTINE HCL CAP ER 24HR 14 MG	62053550107030	Generic
NAMENDA XR	MEMANTINE HCL CAP ER 24HR 21 MG	62053550107040	Brand
MEMANTINE HYDROCHLORIDE ER	MEMANTINE HCL CAP ER 24HR 21 MG	62053550107040	Generic
NAMENDA XR	MEMANTINE HCL CAP ER 24HR 28 MG	62053550107050	Brand
MEMANTINE HYDROCHLORIDE ER	MEMANTINE HCL CAP ER 24HR 28 MG	62053550107050	Generic
MEMANTINE HYDROCHLORIDE	MEMANTINE HCL ORAL SOLUTION 2 MG/ML	62053550102020	Generic

**Approval Criteria**

1 - Diagnosis of dementia of the Alzheimer's type

Product Name: Brand Exelon, generic rivastigmine			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EXELON	RIVASTIGMINE TD PATCH 24HR 4.6 MG/24HR	62051040008520	Brand
RIVASTIGMINE TRANSDERMAL SYSTEM	RIVASTIGMINE TD PATCH 24HR 4.6 MG/24HR	62051040008520	Generic
EXELON	RIVASTIGMINE TD PATCH 24HR 9.5 MG/24HR	62051040008530	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

RIVASTIGMINE TRANSDERMAL SYSTEM	RIVASTIGMINE TD PATCH 24HR 9.5 MG/24HR	62051040008530	Generic
EXELON	RIVASTIGMINE TD PATCH 24HR 13.3 MG/24HR	62051040008540	Brand
RIVASTIGMINE TRANSDERMAL SYSTEM	RIVASTIGMINE TD PATCH 24HR 13.3 MG/24HR	62051040008540	Generic
RIVASTIGMINE TARTRATE	RIVASTIGMINE TARTRATE CAP 1.5 MG (BASE EQUIVALENT)	62051040200110	Generic
RIVASTIGMINE TARTRATE	RIVASTIGMINE TARTRATE CAP 3 MG (BASE EQUIVALENT)	62051040200120	Generic
RIVASTIGMINE TARTRATE	RIVASTIGMINE TARTRATE CAP 4.5 MG (BASE EQUIVALENT)	62051040200130	Generic
RIVASTIGMINE TARTRATE	RIVASTIGMINE TARTRATE CAP 6 MG (BASE EQUIVALENT)	62051040200140	Generic

**Approval Criteria**

1 - Diagnosis of dementia of the Alzheimer's type

**OR**

2 - Diagnosis of dementia associated with Parkinson's disease

Product Name: Adlarity

Approval Length | 12 month(s)

Guideline Type | Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ADLARITY	DONEPEZIL HYDROCHLORIDE TD PATCH WEEKLY 5 MG/DAY	62051025108820	Brand
ADLARITY	DONEPEZIL HYDROCHLORIDE TD PATCH WEEKLY 10 MG/DAY	62051025108830	Brand

**Approval Criteria**

1 - Diagnosis of dementia of the Alzheimer's type



**AND**

**2** - One of the following:

**2.1** History of failure, contraindication, or intolerance to ALL of the following preferred drugs\* (verified via paid pharmacy claims):

- generic donepezil
- generic galantamine IR/ER
- generic memantine
- generic oral rivastigmine

**OR**

**2.2** Both of the following:

**2.2.1** History of failure, contraindication, or intolerance to generic rivastigmine patch\* (verified via paid pharmacy claims)

**AND**

**2.2.2** Patient is unable to swallow oral formulations or has documented swallowing difficulties

Notes	*PA may be required.
-------	----------------------

## 2 . Revision History

Date	Notes
8/8/2022	C&S to match AZM 10.1.22

Amondys 45



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-147023
<b>Guideline Name</b>	Amondys 45
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	
-----------------	--

### 1 . Criteria

Product Name: Amondys 45			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
<b>Product Name</b>	<b>Generic Name</b>	<b>GPI</b>	<b>Brand/Generic</b>
AMONDYS 45	CASIMERSEN IV SOLN 100 MG/2ML (50 MG/ML)	74600025002020	Brand
<b>Approval Criteria</b>			

**1** - Diagnosis of Duchenne muscular dystrophy (DMD) by, or in consultation with, a neurologist with expertise in the diagnosis of DMD

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) confirming the mutation of the DMD gene is amenable to exon 45 skipping

**AND**

**3** - ONE of the following:

**3.1** Submission of medical records (e.g., chart notes, laboratory values) confirming that the patient has a 6-Minute Walk Test (6MWT) greater than or equal to 300 meters while walking independently (e.g., without side-by-side assist, cane, walker, wheelchair, etc.) prior to beginning Amondys 45 therapy

**OR**

**3.2** BOTH of the following:

**3.2.1** Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)

**AND**

**3.2.2** ONE of the following:

**3.2.2.1** Patient has achieved a score of greater than 17 on the North Star Ambulatory Assessment (NSAA)

**OR**

**3.2.2.2** Patient has achieved a time to rise from the floor (Gower's test) of less than 7 seconds

**AND**

**4** - Amondys 45 is prescribed by, or in consultation with, a neurologist with expertise in the treatment of DMD

**AND**

**5** - Dosing is in accordance with the United States Food and Drug Administration approved labeling

**AND**

**6** - Amondys 45 is not used concomitantly with other exon skipping therapies for DMD

Product Name: Amondys 45			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AMONDYS 45	CASIMERSEN IV SOLN 100 MG/2ML (50 MG/ML)	74600025002020	Brand

**Approval Criteria**

**1** - Amondys 45 is prescribed by, or in consultation with, a neurologist with expertise in the treatment of Duchenne muscular dystrophy (DMD)

**AND**

**2** - Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)

**AND**

**3** - Dosing is in accordance with the United States Food and Drug Administration approved labeling

**AND**

**4** - Amondys 45 is not used concomitantly with other exon skipping therapies for DMD

## 2 . Revision History

Date	Notes
5/2/2024	Updated guideline name and formulary to SP. Updated initial authorization length to 12 months. Updated "6-Minute Walk Time" with "6-Minute Walk Test"

Amtagvi (lifileucel)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-152664
<b>Guideline Name</b>	Amtagvi (lifileucel)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Amtagvi			
Approval Length	1 Time Authorization in Lifetime*		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AMTAGVI	LIFILEUCEL IV SUSP 72,000,000,000 CELLS	21651047001820	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes) confirming a diagnosis of melanoma			

**AND**

**2** - Disease is ONE of the following:

- Unresectable
- Metastatic

**AND**

**3** - Paid claims or submission of medical records (e.g., chart notes) confirming previous treatment with a programmed cell death protein-1 (PD-1) blocking antibody (e.g., Opdivo, Keytruda)

**AND**

**4** - If cancer is BRAF V600 mutation positive, ONE of the following:

**4.1** Paid claims or submission of medical records (e.g., chart notes) confirming previous treatment with a BRAF inhibitor alone (e.g., Zelboraf, Tafinlar)

**OR**

**4.2** Paid claims or submission of medical records (e.g., chart notes) confirming previous treatment with combination of a BRAF inhibitor and MEK inhibitor (e.g., Zelboraf/Cotellic, Tafinlar/Mekinist, Braftovi/Mektovi)

**AND**

**5** - Prescribed by an oncologist at an authorized treatment center

**AND**

**6** - Patient has never received Amtagvi treatment in their lifetime

Notes

\*Per prescribing information, Amtagvi is for one-time, single dose intra venous use only.

## 2 . Revision History

Date	Notes
8/26/2024	New program.



Anthelmintics



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140680
<b>Guideline Name</b>	Anthelmintics
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Albenza, generic albendazole			
Diagnosis	See Note section*		
Approval Length	1 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ALBENDAZOLE	ALBENDAZOLE TAB 200 MG	15000002000320	Generic
ALBENZA	ALBENDAZOLE TAB 200 MG	15000002000320	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of *Enterobius vermicularis* (pinworm)

**OR**

2 - Diagnosis of Hydatid Disease [*Echinococcus* (Tapeworm)]

**OR**

3 - Diagnosis of *Ancylostoma/Necatoriasis* (Hookworm)

**OR**

4 - Diagnosis of *Ascariasis* (Roundworm)

**OR**

5 - Diagnosis of *Mansonella perstans* (Filariasis)

**OR**

6 - Diagnosis of *Toxocariasis* (Roundworm)

**OR**

7 - Diagnosis of *Trichinellosis*

**OR**

8 - Diagnosis of *Trichuriasis* (Whipworm)

**OR**

**9 - Diagnosis of Capillariasis**

Notes	* Enterobius vermicularis (pinworm), Hydatid Disease [Echinococcosis (Tapeworm)] Ancylostoma/Necatoriasis (Hookworm), Ascariasis (Roundworm), Mansonella perstans (Filariasis), Toxocariasis (Roundworm), Trichinellosis, Trichuriasis (Whipworm), Capillariasis
-------	---

Product Name: Brand Albenza, generic albendazole			
Diagnosis	Neurocysticercosis		
Approval Length	6 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ALBENDAZOLE	ALBENDAZOLE TAB 200 MG	15000002000320	Generic
ALBENZA	ALBENDAZOLE TAB 200 MG	15000002000320	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of neurocysticercosis			

Product Name: Brand Stromectol, generic ivermectin			
Approval Length	1 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
IVERMECTIN	IVERMECTIN TAB 3 MG	15000007000310	Generic
STROMECTOL	IVERMECTIN TAB 3 MG	15000007000310	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of intestinal strongyloidiasis due to the nematode parasite Strongyloides stercoralis			

**OR**

**2** - Diagnosis of onchocerciasis due to the nematode parasite *Onchocerca volvulus*

## **2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Anticonvulsants



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-155094
<b>Guideline Name</b>	Anticonvulsants
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Aptiom, Briviact tabs/oral soln, generic lacosamide tabs/oral soln, Brand Vimpat tabs/oral soln, Xcopri			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
APTIOM	ESLICARBAZEPINE ACETATE TAB 200 MG	72600024100320	Brand
APTIOM	ESLICARBAZEPINE ACETATE TAB 400 MG	72600024100330	Brand
APTIOM	ESLICARBAZEPINE ACETATE TAB 600 MG	72600024100340	Brand
APTIOM	ESLICARBAZEPINE ACETATE TAB 800 MG	72600024100360	Brand
BRIVIACT	BRIVARACETAM TAB 10 MG	72600015000310	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BRIVIACT	BRIVARACETAM TAB 25 MG	72600015000320	Brand
BRIVIACT	BRIVARACETAM TAB 50 MG	72600015000330	Brand
BRIVIACT	BRIVARACETAM TAB 75 MG	72600015000340	Brand
BRIVIACT	BRIVARACETAM TAB 100 MG	72600015000350	Brand
BRIVIACT	BRIVARACETAM ORAL SOLN 10 MG/ML	72600015002020	Brand
LACOSAMIDE	LACOSAMIDE TAB 50 MG	72600036000320	Generic
VIMPAT	LACOSAMIDE TAB 50 MG	72600036000320	Brand
LACOSAMIDE	LACOSAMIDE TAB 100 MG	72600036000330	Generic
VIMPAT	LACOSAMIDE TAB 100 MG	72600036000330	Brand
LACOSAMIDE	LACOSAMIDE TAB 150 MG	72600036000340	Generic
VIMPAT	LACOSAMIDE TAB 150 MG	72600036000340	Brand
LACOSAMIDE	LACOSAMIDE TAB 200 MG	72600036000350	Generic
VIMPAT	LACOSAMIDE TAB 200 MG	72600036000350	Brand
LACOSAMIDE	LACOSAMIDE ORAL SOLUTION 10 MG/ML	72600036002060	Generic
VIMPAT	LACOSAMIDE ORAL SOLUTION 10 MG/ML	72600036002060	Brand
XCOPRI	CENOBAMATE TAB TITRATION PACK 14 X 12.5 MG & 14 X 25 MG	7212001000B720	Brand
XCOPRI	CENOBAMATE TAB TITRATION PACK 14 X 50 MG & 14 X 100 MG	7212001000B725	Brand
XCOPRI	CENOBAMATE TAB TITRATION PACK 14 X 150 MG & 14 X 200 MG	7212001000B730	Brand
XCOPRI	CENOBAMATE TAB PACK 100 MG & 150 MG TABS (250 MG DAILY DOSE)	7212001000B738	Brand
XCOPRI	CENOBAMATE TAB PACK 150 MG & 200 MG TABS (350 MG DAILY DOSE)	7212001000B740	Brand
XCOPRI	CENOBAMATE TAB 50 MG	72120010000320	Brand
XCOPRI	CENOBAMATE TAB 100 MG	72120010000325	Brand
XCOPRI	CENOBAMATE TAB 150 MG	72120010000330	Brand
XCOPRI	CENOBAMATE TAB 200 MG	72120010000335	Brand
XCOPRI	CENOBAMATE TAB 25 MG	72120010000310	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ONE of the following:

**1.1** ALL of the following:

**1.1.1** Diagnosis of partial-onset seizures

**AND**

**1.1.2** If the request is for a non-preferred product, history of greater than or equal to 8 week trial of at least TWO of the following\* (any release formulation qualifies):

- Carbamazepine
- Divalproex
- Gabapentin
- Lamotrigine
- Levetiracetam
- Oxcarbazepine
- Phenytoin
- Pregabalin
- Topiramate
- Valproic acid
- Zonisamide
- Fycompa
- Generic lacosamide
- Xcopri

**AND**

**1.1.3** If the request is for a non-preferred product, ONE of the following:

**1.1.3.1** BOTH of the following:

- Documented history of persisting seizures after titration to the highest tolerated dose with each medication trial of preferred formulary alternatives
- Lack of compliance as a reason for treatment failure has been ruled out

**OR**

**1.1.3.2** BOTH of the following:

- Documentation of failure of preferred formulary alternatives due to intolerable side effects

- Reasonable efforts were made to minimize the side effect (e.g., change timing of dosing, divide dose out for more frequent but smaller doses, etc.)

**AND**

**1.1.4** If the request is for Brand Vimpat, trial and failure, contraindication, or intolerance to generic lacosamide

**OR**

**1.2** For continuation of prior therapy for a seizure disorder

Notes	*Drug may require PA
-------	----------------------

**Product Name: Motpoly XR**

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
MOTPOLY XR	LACOSAMIDE CAP ER 24HR 100 MG	72600036007020	Brand
MOTPOLY XR	LACOSAMIDE CAP ER 24HR 150 MG	72600036007025	Brand
MOTPOLY XR	LACOSAMIDE CAP ER 24HR 200 MG	72600036007030	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ONE of the following:

**1.1** BOTH of the following:

**1.1.1** Diagnosis of ONE of the following:

- partial-onset seizures
- primary generalized tonic-clonic seizures



**AND**

**1.1.2** Patient weighs at least 50 kg (kilograms)

**OR**

**1.2** For continuation of prior therapy for a seizure disorder

**Product Name: Fycompa**

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
FYCOMPA	PERAMPANEL TAB 2 MG	72550060000310	Brand
FYCOMPA	PERAMPANEL TAB 4 MG	72550060000320	Brand
FYCOMPA	PERAMPANEL TAB 6 MG	72550060000330	Brand
FYCOMPA	PERAMPANEL TAB 8 MG	72550060000340	Brand
FYCOMPA	PERAMPANEL TAB 10 MG	72550060000350	Brand
FYCOMPA	PERAMPANEL TAB 12 MG	72550060000360	Brand
FYCOMPA	PERAMPANEL SUSP 0.5 MG/ML	72550060001820	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ONE of the following:

**1.1** Diagnosis of partial-onset or primary generalized tonic-clonic seizures

**OR**

**1.2** For continuation of prior therapy for a seizure disorder

Product Name: Epidiolex			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EPIDIOLEX	CANNABIDIOL SOLN 100 MG/ML	72600017002020	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ONE of the following:</p> <p>1.1 Diagnosis of seizures associated with Dravet syndrome</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 Diagnosis of seizures associated with Lennox-Gastaut syndrome</p> <p style="text-align: center;"><b>OR</b></p> <p>1.3 Diagnosis of seizures associated with tuberous sclerosis complex (TSC)</p> <p style="text-align: center;"><b>OR</b></p> <p>1.4 For continuation of prior therapy for a seizure disorder</p>			

Product Name: Diacomit			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DIACOMIT	STIRIPENTOL CAP 250 MG	72600070000120	Brand
DIACOMIT	STIRIPENTOL CAP 500 MG	72600070000130	Brand

DIACOMIT	STIRIPENTOL PACKET 250 MG	72600070003020	Brand
DIACOMIT	STIRIPENTOL PACKET 500 MG	72600070003030	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of Dravet syndrome and currently taking clobazam

**OR**

2 - For continuation of prior therapy for a seizure disorder

Product Name: Fintepla			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FINTEPLA	FENFLURAMINE HCL ORAL SOLN 2.2 MG/ML	72600028102020	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ALL of the following:

1.1 Diagnosis of seizures associated with Dravet syndrome

**AND**

1.2 History of greater than or equal to 8-week trial of at least TWO of the following\* (any release formulation qualifies):

- Divalproex (e.g., generic Depakote)
- Epidiolex
- Levetiracetam (e.g., generic Keppra)
- Topiramate (e.g., generic Topamax)

- Valproic acid (e.g., generic Depakene)
- Zonisamide (generic Zonegran)

**AND**

**1.3** ONE of the following:

**1.3.1** BOTH of the following:

**1.3.1.1** Documented history of persisting seizures after titration to the highest tolerated dose with each medication trial of preferred formulary alternatives

**AND**

**1.3.1.2** Lack of compliance as a reason for treatment failure has been ruled out

**OR**

**1.3.2** BOTH of the following:

**1.3.2.1** Documentation of failure of preferred formulary alternatives due to intolerable side effects

**AND**

**1.3.2.2** Reasonable efforts were made to minimize the side effect (e.g., change timing of dosing, divide dose out for more frequent but smaller doses, etc.)

**OR**

**2** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ALL of the following:

**2.1** Diagnosis of seizures associated with Lennox-Gastaut syndrome

**AND**

**2.2** History of greater than or equal to 8 week trial, contraindication, or intolerance of at least TWO of the following\* (any release formulation qualifies):

- Banzel (rufinamide)
- Clobazam
- Divalproex
- Felbamate
- Lamotrigine
- Topiramate
- Valproic Acid
- Epidiolex

**AND**

**2.3** ONE of the following:

**2.3.1** BOTH of the following:

- Documented history of persisting seizures after titration to the highest tolerated dose with each medication trial of preferred formulary alternatives
- Lack of compliance as a reason for treatment failure has been ruled out

**OR**

**2.3.2** BOTH of the following:

- Documentation of failure of preferred formulary alternatives due to intolerable side effects
- Lack of compliance as a reason for treatment failure has been ruled out

**OR**

**3** - For continuation of prior therapy for a seizure disorder

Notes	*Drug may require PA
-------	----------------------

Product Name: Brand Banzel, generic rufinamide	
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
RUFINAMIDE	RUFINAMIDE TAB 200 MG	72600065000320	Generic
BANZEL	RUFINAMIDE TAB 200 MG	72600065000320	Brand
RUFINAMIDE	RUFINAMIDE TAB 400 MG	72600065000330	Generic
BANZEL	RUFINAMIDE TAB 400 MG	72600065000330	Brand
RUFINAMIDE	RUFINAMIDE SUSP 40 MG/ML	72600065001820	Generic
BANZEL	RUFINAMIDE SUSP 40 MG/ML	72600065001820	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting BOTH of the following:

**1.1** Diagnosis of seizures associated with Lennox-Gastaut syndrome

**AND**

**1.2** If the request is for generic rufinamide suspension, trial and failure, contraindication, or intolerance to Brand Banzel suspension

**OR**

**2** - For continuation of prior therapy for a seizure disorder

Product Name: Brand Onfi, generic clobazam			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CLOBAZAM	CLOBAZAM TAB 10 MG	72100007000310	Generic
ONFI	CLOBAZAM TAB 10 MG	72100007000310	Brand
CLOBAZAM	CLOBAZAM TAB 20 MG	72100007000320	Generic

ONFI	CLOBAZAM TAB 20 MG	72100007000320	Brand
CLOBAZAM	CLOBAZAM SUSPENSION 2.5 MG/ML	72100007001830	Generic
ONFI	CLOBAZAM SUSPENSION 2.5 MG/ML	72100007001830	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting **ONE** of the following:

**1.1** BOTH of the following:

- Diagnosis of seizures associated with Lennox-Gastaut syndrome
- If the request is for Brand Onfi, trial and failure, contraindication, or intolerance to generic clobazam

**OR**

**1.2** ALL of the following:

- Diagnosis of Dravet syndrome
- Patient is currently taking Diacomit
- If the request is for Brand Onfi, trial and failure, contraindication, or intolerance to generic clobazam

**OR**

**2** - For continuation of prior therapy for a seizure disorder

Product Name: Sympazan			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYMPAZAN	CLOBAZAM ORAL FILM 5 MG	72100007008205	Brand
SYMPAZAN	CLOBAZAM ORAL FILM 10 MG	72100007008210	Brand
SYMPAZAN	CLOBAZAM ORAL FILM 20 MG	72100007008220	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting **ONE** of the following:

**1.1** ALL of the following:

**1.1.1** Diagnosis of seizures associated with Lennox-Gastaut syndrome (LGS)

**AND**

**1.1.2** BOTH of the following:

- Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)
- Not used as primary treatment

**AND**

**1.1.3** History of greater than or equal to 8 week trial, contraindication, or intolerance of at least **TWO** of the following\* (any release formulation qualifies):

- Brand Banzel suspension/tablets or rufinamide tablets
- Divalproex
- Felbamate
- Lamotrigine
- Topiramate
- Valproic acid

**AND**

**1.1.4** Prescriber provides a reason or special circumstance the patient cannot use generic clobazam tablets or suspension

**OR**

**1.2** ALL of the following:



**1.2.1** Diagnosis of refractory partial onset seizures (four or more uncontrolled seizures per month after an adequate trial of at least two antiepileptic drugs)

**AND**

**1.2.2** BOTH of the following:

- Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)
- Not used as primary treatment

**AND**

**1.2.3** History of greater than or equal to 8 week trial of at least TWO of the following\* (any release formulation qualifies):

- Carbamazepine
- Divalproex
- Fycompa
- Gabapentin
- Lacosamide
- Lamotrigine
- Levetiracetam
- Oxcarbazepine
- Phenytoin
- Pregabalin
- Topiramate
- Valproic acid
- Xcopri
- Zonisamide

**AND**

**1.2.4** Prescriber provides a reason or special circumstance the patient cannot use generic clobazam tablets or suspension

**OR**

**1.3** ALL of the following:

**1.3.1** Diagnosis of Dravet syndrome

**AND**

**1.3.2** Patient is currently taking Diacomit

**AND**

**1.3.3** Prescriber provides a reason or special circumstance the patient cannot use generic clobazam tablets or suspension

**OR**

**1.4** For continuation of prior therapy for a seizure disorder

Notes	*Drug may require PA
-------	----------------------

Product Name: Brand Gabitril, generic tiagabine			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GABITRIL	TIAGABINE HCL TAB 2 MG	72170070100302	Brand
TIAGABINE HYDROCHLORIDE	TIAGABINE HCL TAB 2 MG	72170070100302	Generic
GABITRIL	TIAGABINE HCL TAB 4 MG	72170070100305	Brand
TIAGABINE HYDROCHLORIDE	TIAGABINE HCL TAB 4 MG	72170070100305	Generic
GABITRIL	TIAGABINE HCL TAB 12 MG	72170070100315	Brand
TIAGABINE HYDROCHLORIDE	TIAGABINE HCL TAB 12 MG	72170070100315	Generic
GABITRIL	TIAGABINE HCL TAB 16 MG	72170070100320	Brand
TIAGABINE HYDROCHLORIDE	TIAGABINE HCL TAB 16 MG	72170070100320	Generic

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ONE of the following:

**1.1** ALL of the following:

**1.1.1** Diagnosis of partial-onset seizures

**AND**

**1.1.2** Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)

**AND**

**1.1.3** Not used as primary treatment

**AND**

**1.1.4** If the request is for Brand Gabitril, trial and failure, contraindication, or intolerance to generic tiagabine

**OR**

**1.2** For continuation of prior therapy for a seizure disorder

Product Name: Brand Sabril powd pack, generic vigabatrin powd pack, Vigadrone powd pack, Vigpoder powd pack, Vigafyde

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
SABRIL	VIGABATRIN POWD PACK 500 MG	72170085003020	Brand
VIGABATRIN	VIGABATRIN POWD PACK 500 MG	72170085003020	Generic
VIGADRONE	VIGABATRIN POWD PACK 500 MG	72170085003020	Generic

VIGPODER	VIGABATRIN POWD PACK 500 MG	72170085003020	Generic
VIGAFYDE	VIGABATRIN ORAL SOLN 100 MG/ML	72170085002020	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of infantile spasms

**OR**

2 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ALL of the following:

2.1 Diagnosis of complex partial seizures

**AND**

2.2 Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)

**AND**

2.3 Not used as primary treatment

**AND**

2.4 History of greater than or equal to 8 week trial of at least TWO of the following\* (any release formulation qualifies):

- Carbamazepine
- Divalproex
- Fycompa
- Gabapentin
- Lacosamide
- Lamotrigine
- Levetiracetam
- Oxcarbazepine
- Phenytoin

- Pregabalin
- Topiramate
- Valproic acid
- Xcopri
- Zonisamide

**OR**

**3** - For continuation of prior therapy for a seizure disorder

Notes

\*Drug may require PA

Product Name: Brand Sabril tabs, generic vigabatrin tabs

Approval Length | 12 month(s)

Guideline Type | Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SABRIL	VIGABATRIN TAB 500 MG	72170085000320	Brand
VIGABATRIN	VIGABATRIN TAB 500 MG	72170085000320	Generic

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ONE of the following:

**1.1** ALL of the following:

**1.1.1** Diagnosis of complex partial seizures

**AND**

**1.1.2** Used as adjunctive therapy (defined as accessory treatment used in combination to enhance primary treatment)

**AND**

**1.1.3** Not used as primary treatment

**AND**

**1.1.4** History of greater than or equal to 8 week trial of at least TWO of the following\* (any release formulation qualifies):

- Carbamazepine
- Divalproex
- Fycompa
- Gabapentin
- Lacosamide
- Lamotrigine
- Levetiracetam
- Oxcarbazepine
- Phenytoin
- Pregabalin
- Topiramate
- Valproic acid
- Xcopri
- Zonisamide

**OR**

**1.2** For continuation of prior therapy for a seizure disorder

Notes	*Drug may require PA
-------	----------------------

Product Name: Brand Trokendi XR, generic topiramate ER, Brand Qudexy XR, generic topiramate ER sprinkle			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TOPIRAMATE ER	TOPIRAMATE CAP ER 24HR 25 MG	72600075007020	Generic
TROKENDI XR	TOPIRAMATE CAP ER 24HR 25 MG	72600075007020	Brand
TOPIRAMATE ER	TOPIRAMATE CAP ER 24HR 50 MG	72600075007030	Generic
TROKENDI XR	TOPIRAMATE CAP ER 24HR 50 MG	72600075007030	Brand

TOPIRAMATE ER	TOPIRAMATE CAP ER 24HR 100 MG	72600075007040	Generic
TROKENDI XR	TOPIRAMATE CAP ER 24HR 100 MG	72600075007040	Brand
TOPIRAMATE ER	TOPIRAMATE CAP ER 24HR 200 MG	72600075007050	Generic
TROKENDI XR	TOPIRAMATE CAP ER 24HR 200 MG	72600075007050	Brand
QUDEXY XR	TOPIRAMATE CAP ER 24HR SPRINKLE 25 MG	7260007500F310	Brand
TOPIRAMATE ER	TOPIRAMATE CAP ER 24HR SPRINKLE 25 MG	7260007500F310	Generic
QUDEXY XR	TOPIRAMATE CAP ER 24HR SPRINKLE 50 MG	7260007500F320	Brand
TOPIRAMATE ER	TOPIRAMATE CAP ER 24HR SPRINKLE 50 MG	7260007500F320	Generic
QUDEXY XR	TOPIRAMATE CAP ER 24HR SPRINKLE 100 MG	7260007500F330	Brand
TOPIRAMATE ER	TOPIRAMATE CAP ER 24HR SPRINKLE 100 MG	7260007500F330	Generic
QUDEXY XR	TOPIRAMATE CAP ER 24HR SPRINKLE 150 MG	7260007500F340	Brand
TOPIRAMATE ER	TOPIRAMATE CAP ER 24HR SPRINKLE 150 MG	7260007500F340	Generic
QUDEXY XR	TOPIRAMATE CAP ER 24HR SPRINKLE 200 MG	7260007500F350	Brand
TOPIRAMATE ER	TOPIRAMATE CAP ER 24HR SPRINKLE 200 MG	7260007500F350	Generic

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ONE of the following:

1.1 ALL of the following:

1.1.1 Diagnosis of partial-onset seizures

**AND**

1.1.2 If the request is for a non-preferred product, trial and failure, contraindication, or intolerance to BOTH of the following:

- Generic topiramate immediate-release (IR) tablet or topiramate IR sprinkle capsule
- Brand Trokendi XR

**OR**

**1.2** For continuation of prior therapy for a seizure disorder

## **2 . Revision History**

Date	Notes
9/24/2024	Added Vigfafyde as a target to the guideline. Updated product name list and GPI table accordingly. No changes to criteria.



Antidepressants



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140823
<b>Guideline Name</b>	Antidepressants
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/18/2023
-----------------	------------

## 1 . Criteria

Product Name: citalopram oral soln, fluoxetine soln, generic sertraline oral soln			
Diagnosis	Requests for Patients greater than 12 years of age		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CITALOPRAM HYDROBROMIDE	CITALOPRAM HYDROBROMIDE ORAL SOLN 10 MG/5ML	58160020102020	Generic
FLUOXETINE HYDROCHLORIDE	FLUOXETINE HCL SOLUTION 20 MG/5ML	58160040002020	Generic
FLUOXETINE HCL	FLUOXETINE HCL SOLUTION 20 MG/5ML	58160040002020	Generic
SERTRALINE HCL	SERTRALINE HCL ORAL CONCENTRATE FOR SOLUTION 20 MG/ML	58160070101320	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SERTRALINE HYDROCHLORIDE	SERTRALINE HCL ORAL CONCENTRATE FOR SOLUTION 20 MG/ML	58160070101320	Generic
<b>Approval Criteria</b>			
1 - The patient is unable to swallow the oral tablet/capsule			
Notes	For group code ACUAZPH, antidepressant medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.		

Product Name: generic mirtazapine, generic mirtazapine ODT, trazodone, generic citalopram tabs, citalopram oral soln, generic escitalopram, generic fluoxetine caps, fluoxetine soln, fluvoxamine IR, generic paroxetine IR tabs, generic sertraline tabs/oral soln, generic duloxetine 20 mg and 30 mg and 60 mg, venlafaxine tabs, generic venlafaxine ER caps, amitriptyline, amoxapine, generic clomipramine, generic desipramine, doxepin caps/conc, imipramine, generic nortriptyline, nortriptyline soln, protriptyline, trimipramine, bupropion tabs, generic bupropion ER (SR), generic bupropion ER (XL) 150 mg and 300 mg			
Diagnosis	PREFERRED DRUG Requests for patient 6 years of age or younger		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MIRTAZAPINE	MIRTAZAPINE TAB 7.5 MG	58030050000308	Generic
MIRTAZAPINE	MIRTAZAPINE TAB 15 MG	58030050000315	Generic
MIRTAZAPINE	MIRTAZAPINE TAB 30 MG	58030050000330	Generic
MIRTAZAPINE	MIRTAZAPINE TAB 45 MG	58030050000345	Generic
MIRTAZAPINE ODT	MIRTAZAPINE ORALLY DISINTEGRATING TAB 15 MG	58030050007215	Generic
MIRTAZAPINE ODT	MIRTAZAPINE ORALLY DISINTEGRATING TAB 30 MG	58030050007230	Generic
MIRTAZAPINE ODT	MIRTAZAPINE ORALLY DISINTEGRATING TAB 45 MG	58030050007245	Generic
TRAZODONE HYDROCHLORIDE	TRAZODONE HCL TAB 50 MG	58120080100305	Generic
TRAZODONE HYDROCHLORIDE	TRAZODONE HCL TAB 100 MG	58120080100310	Generic
TRAZODONE HYDROCHLORIDE	TRAZODONE HCL TAB 150 MG	58120080100315	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TRAZODONE HYDROCHLORIDE	TRAZODONE HCL TAB 300 MG	58120080100325	Generic
CITALOPRAM HYDROBROMIDE	CITALOPRAM HYDROBROMIDE TAB 10 MG (BASE EQUIV)	58160020100310	Generic
CITALOPRAM HYDROBROMIDE	CITALOPRAM HYDROBROMIDE TAB 20 MG (BASE EQUIV)	58160020100320	Generic
CITALOPRAM	CITALOPRAM HYDROBROMIDE TAB 20 MG (BASE EQUIV)	58160020100320	Generic
CITALOPRAM HYDROBROMIDE	CITALOPRAM HYDROBROMIDE TAB 40 MG (BASE EQUIV)	58160020100340	Generic
CITALOPRAM	CITALOPRAM HYDROBROMIDE TAB 40 MG (BASE EQUIV)	58160020100340	Generic
CITALOPRAM HYDROBROMIDE	CITALOPRAM HYDROBROMIDE ORAL SOLN 10 MG/5ML	58160020102020	Generic
ESCITALOPRAM OXALATE	ESCITALOPRAM OXALATE TAB 5 MG (BASE EQUIV)	58160034100310	Generic
ESCITALOPRAM OXALATE	ESCITALOPRAM OXALATE TAB 10 MG (BASE EQUIV)	58160034100320	Generic
ESCITALOPRAM OXALATE	ESCITALOPRAM OXALATE TAB 20 MG (BASE EQUIV)	58160034100330	Generic
ESCITALOPRAM OXALATE	ESCITALOPRAM OXALATE SOLN 5 MG/5ML (BASE EQUIV)	58160034102020	Generic
FLUOXETINE HYDROCHLORIDE	FLUOXETINE HCL CAP 10 MG	58160040000110	Generic
FLUOXETINE HYDROCHLORIDE	FLUOXETINE HCL CAP 20 MG	58160040000120	Generic
FLUOXETINE HCL	FLUOXETINE HCL CAP 20 MG	58160040000120	Generic
FLUOXETINE HYDROCHLORIDE	FLUOXETINE HCL CAP 40 MG	58160040000140	Generic
FLUOXETINE HYDROCHLORIDE	FLUOXETINE HCL SOLUTION 20 MG/5ML	58160040002020	Generic
FLUOXETINE HCL	FLUOXETINE HCL SOLUTION 20 MG/5ML	58160040002020	Generic
FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE TAB 25 MG	58160045100310	Generic
FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE TAB 50 MG	58160045100320	Generic
FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE TAB 100 MG	58160045100330	Generic
PAROXETINE HYDROCHLORIDE	PAROXETINE HCL TAB 10 MG	58160060000310	Generic
PAROXETINE HYDROCHLORIDE	PAROXETINE HCL TAB 20 MG	58160060000320	Generic
PAROXETINE HCL	PAROXETINE HCL TAB 30 MG	58160060000330	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PAROXETINE HYDROCHLORIDE	PAROXETINE HCL TAB 30 MG	58160060000330	Generic
PAROXETINE HCL	PAROXETINE HCL TAB 40 MG	58160060000340	Generic
PAROXETINE HYDROCHLORIDE	PAROXETINE HCL TAB 40 MG	58160060000340	Generic
SERTRALINE HCL	SERTRALINE HCL TAB 25 MG	58160070100305	Generic
SERTRALINE HYDROCHLORIDE	SERTRALINE HCL TAB 25 MG	58160070100305	Generic
SERTRALINE HCL	SERTRALINE HCL TAB 50 MG	58160070100310	Generic
SERTRALINE HYDROCHLORIDE	SERTRALINE HCL TAB 50 MG	58160070100310	Generic
SERTRALINE HYDROCHLORIDE	SERTRALINE HCL TAB 100 MG	58160070100320	Generic
SERTRALINE HCL	SERTRALINE HCL ORAL CONCENTRATE FOR SOLUTION 20 MG/ML	58160070101320	Generic
SERTRALINE HYDROCHLORIDE	SERTRALINE HCL ORAL CONCENTRATE FOR SOLUTION 20 MG/ML	58160070101320	Generic
DULOXETINE HYDROCHLORIDE	DULOXETINE HCL ENTERIC COATED PELLETS CAP 20 MG (BASE EQ)	58180025106720	Generic
DULOXETINE HCL	DULOXETINE HCL ENTERIC COATED PELLETS CAP 30 MG (BASE EQ)	58180025106730	Generic
DULOXETINE HYDROCHLORIDE	DULOXETINE HCL ENTERIC COATED PELLETS CAP 30 MG (BASE EQ)	58180025106730	Generic
DULOXETINE HYDROCHLORIDE	DULOXETINE HCL ENTERIC COATED PELLETS CAP 60 MG (BASE EQ)	58180025106750	Generic
VENLAFAXINE HYDROCHLORIDE	VENLAFAXINE HCL TAB 25 MG (BASE EQUIVALENT)	58180090100320	Generic
VENLAFAXINE HCL	VENLAFAXINE HCL TAB 25 MG (BASE EQUIVALENT)	58180090100320	Generic
VENLAFAXINE HYDROCHLORIDE	VENLAFAXINE HCL TAB 37.5 MG (BASE EQUIVALENT)	58180090100340	Generic
VENLAFAXINE HCL	VENLAFAXINE HCL TAB 37.5 MG (BASE EQUIVALENT)	58180090100340	Generic
VENLAFAXINE HYDROCHLORIDE	VENLAFAXINE HCL TAB 50 MG (BASE EQUIVALENT)	58180090100350	Generic
VENLAFAXINE HCL	VENLAFAXINE HCL TAB 50 MG (BASE EQUIVALENT)	58180090100350	Generic
VENLAFAXINE HYDROCHLORIDE	VENLAFAXINE HCL TAB 75 MG (BASE EQUIVALENT)	58180090100360	Generic
VENLAFAXINE HCL	VENLAFAXINE HCL TAB 75 MG (BASE EQUIVALENT)	58180090100360	Generic
VENLAFAXINE HYDROCHLORIDE	VENLAFAXINE HCL TAB 100 MG (BASE EQUIVALENT)	58180090100370	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

VENLAFAXINE HCL	VENLAFAXINE HCL TAB 100 MG (BASE EQUIVALENT)	58180090100370	Generic
VENLAFAXINE HCL ER	VENLAFAXINE HCL CAP ER 24HR 37.5 MG (BASE EQUIVALENT)	58180090107020	Generic
VENLAFAXINE HYDROCHLORIDE ER	VENLAFAXINE HCL CAP ER 24HR 37.5 MG (BASE EQUIVALENT)	58180090107020	Generic
VENLAFAXINE HYDROCHLORIDE ER	VENLAFAXINE HCL CAP ER 24HR 75 MG (BASE EQUIVALENT)	58180090107030	Generic
VENLAFAXINE HCL ER	VENLAFAXINE HCL CAP ER 24HR 150 MG (BASE EQUIVALENT)	58180090107050	Generic
VENLAFAXINE HYDROCHLORIDE ER	VENLAFAXINE HCL CAP ER 24HR 150 MG (BASE EQUIVALENT)	58180090107050	Generic
VENLAFAXINE HYDROCHLORIDEER	VENLAFAXINE HCL CAP ER 24HR 150 MG (BASE EQUIVALENT)	58180090107050	Generic
AMITRIPTYLINE HYDROCHLORIDE	AMITRIPTYLINE HCL TAB 10 MG	58200010100305	Generic
AMITRIPTYLINE HYDROCHLORIDE	AMITRIPTYLINE HCL TAB 25 MG	58200010100310	Generic
AMITRIPTYLINE HCL	AMITRIPTYLINE HCL TAB 25 MG	58200010100310	Generic
AMITRIPTYLINE HYDROCHLORIDE	AMITRIPTYLINE HCL TAB 50 MG	58200010100315	Generic
AMITRIPTYLINE HYDROCHLORIDE	AMITRIPTYLINE HCL TAB 75 MG	58200010100320	Generic
AMITRIPTYLINE HCL	AMITRIPTYLINE HCL TAB 75 MG	58200010100320	Generic
AMITRIPTYLINE HYDROCHLORIDE	AMITRIPTYLINE HCL TAB 100 MG	58200010100325	Generic
AMITRIPTYLINE HCL	AMITRIPTYLINE HCL TAB 100 MG	58200010100325	Generic
AMITRIPTYLINE HYDROCHLORIDE	AMITRIPTYLINE HCL TAB 150 MG	58200010100330	Generic
AMITRIPTYLINE HCL	AMITRIPTYLINE HCL TAB 150 MG	58200010100330	Generic
AMOXAPINE	AMOXAPINE TAB 25 MG	58200020000305	Generic
AMOXAPINE	AMOXAPINE TAB 50 MG	58200020000310	Generic
AMOXAPINE	AMOXAPINE TAB 100 MG	58200020000315	Generic
AMOXAPINE	AMOXAPINE TAB 150 MG	58200020000320	Generic
CLOMIPRAMINE HCL	CLOMIPRAMINE HCL CAP 25 MG	58200025100120	Generic
CLOMIPRAMINE HYDROCHLORIDE	CLOMIPRAMINE HCL CAP 25 MG	58200025100120	Generic
CLOMIPRAMINE HCL	CLOMIPRAMINE HCL CAP 50 MG	58200025100130	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CLOMIPRAMINE HYDROCHLORIDE	CLOMIPRAMINE HCL CAP 50 MG	58200025100130	Generic
CLOMIPRAMINE HCL	CLOMIPRAMINE HCL CAP 75 MG	58200025100140	Generic
CLOMIPRAMINE HYDROCHLORIDE	CLOMIPRAMINE HCL CAP 75 MG	58200025100140	Generic
DESIPRAMINE HCL	DESIPRAMINE HCL TAB 10 MG	58200030100305	Generic
DESIPRAMINE HYDROCHLORIDE	DESIPRAMINE HCL TAB 10 MG	58200030100305	Generic
DESIPRAMINE HCL	DESIPRAMINE HCL TAB 25 MG	58200030100310	Generic
DESIPRAMINE HYDROCHLORIDE	DESIPRAMINE HCL TAB 25 MG	58200030100310	Generic
DESIPRAMINE HCL	DESIPRAMINE HCL TAB 50 MG	58200030100315	Generic
DESIPRAMINE HYDROCHLORIDE	DESIPRAMINE HCL TAB 50 MG	58200030100315	Generic
DESIPRAMINE HCL	DESIPRAMINE HCL TAB 75 MG	58200030100320	Generic
DESIPRAMINE HYDROCHLORIDE	DESIPRAMINE HCL TAB 75 MG	58200030100320	Generic
DESIPRAMINE HCL	DESIPRAMINE HCL TAB 100 MG	58200030100325	Generic
DESIPRAMINE HYDROCHLORIDE	DESIPRAMINE HCL TAB 100 MG	58200030100325	Generic
DESIPRAMINE HCL	DESIPRAMINE HCL TAB 150 MG	58200030100330	Generic
DESIPRAMINE HYDROCHLORIDE	DESIPRAMINE HCL TAB 150 MG	58200030100330	Generic
DOXEPIN HYDROCHLORIDE	DOXEPIN HCL CAP 10 MG	58200040100105	Generic
DOXEPIN HCL	DOXEPIN HCL CAP 10 MG	58200040100105	Generic
DOXEPIN HYDROCHLORIDE	DOXEPIN HCL CAP 25 MG	58200040100110	Generic
DOXEPIN HYDROCHLORIDE	DOXEPIN HCL CAP 50 MG	58200040100115	Generic
DOXEPIN HCL	DOXEPIN HCL CAP 50 MG	58200040100115	Generic
DOXEPIN HYDROCHLORIDE	DOXEPIN HCL CAP 75 MG	58200040100120	Generic
DOXEPIN HCL	DOXEPIN HCL CAP 75 MG	58200040100120	Generic
DOXEPIN HYDROCHLORIDE	DOXEPIN HCL CAP 100 MG	58200040100125	Generic
DOXEPIN HCL	DOXEPIN HCL CAP 100 MG	58200040100125	Generic
DOXEPIN HYDROCHLORIDE	DOXEPIN HCL CAP 150 MG	58200040100130	Generic
DOXEPIN HCL	DOXEPIN HCL CONC 10 MG/ML	58200040101305	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

IMIPRAMINE HYDROCHLORIDE	IMIPRAMINE HCL TAB 10 MG	58200050100305	Generic
IMIPRAMINE HCL	IMIPRAMINE HCL TAB 10 MG	58200050100305	Generic
IMIPRAMINE HYDROCHLORIDE	IMIPRAMINE HCL TAB 25 MG	58200050100310	Generic
IMIPRAMINE HCL	IMIPRAMINE HCL TAB 25 MG	58200050100310	Generic
IMIPRAMINE HYDROCHLORIDE	IMIPRAMINE HCL TAB 50 MG	58200050100315	Generic
IMIPRAMINE HCL	IMIPRAMINE HCL TAB 50 MG	58200050100315	Generic
IMIPRAMINE PAMOATE	IMIPRAMINE PAMOATE CAP 75 MG	58200050200105	Generic
IMIPRAMINE PAMOATE	IMIPRAMINE PAMOATE CAP 100 MG	58200050200110	Generic
IMIPRAMINE PAMOATE	IMIPRAMINE PAMOATE CAP 125 MG	58200050200115	Generic
IMIPRAMINE PAMOATE	IMIPRAMINE PAMOATE CAP 150 MG	58200050200120	Generic
NORTRIPTYLINE HYDROCHLORIDE	NORTRIPTYLINE HCL CAP 10 MG	58200060100105	Generic
NORTRIPTYLINE HYDROCHLORIDE	NORTRIPTYLINE HCL CAP 25 MG	58200060100110	Generic
NORTRIPTYLINE HCL	NORTRIPTYLINE HCL CAP 25 MG	58200060100110	Generic
NORTRIPTYLINE HYDROCHLORIDE	NORTRIPTYLINE HCL CAP 50 MG	58200060100115	Generic
NORTRIPTYLINE HYDROCHLORIDE	NORTRIPTYLINE HCL CAP 75 MG	58200060100120	Generic
NORTRIPTYLINE HCL	NORTRIPTYLINE HCL CAP 75 MG	58200060100120	Generic
NORTRIPTYLINE HCL	NORTRIPTYLINE HCL SOLN 10 MG/5ML	58200060102005	Generic
PROTRIPTYLINE HCL	PROTRIPTYLINE HCL TAB 5 MG	58200070100305	Generic
PROTRIPTYLINE HCL	PROTRIPTYLINE HCL TAB 10 MG	58200070100310	Generic
TRIMIPRAMINE MALEATE	TRIMIPRAMINE MALEATE CAP 25 MG	58200080100105	Generic
TRIMIPRAMINE MALEATE	TRIMIPRAMINE MALEATE CAP 50 MG	58200080100110	Generic
TRIMIPRAMINE MALEATE	TRIMIPRAMINE MALEATE CAP 100 MG	58200080100115	Generic
BUPROPION HYDROCHLORIDE	BUPROPION HCL TAB 75 MG	58300040100305	Generic
BUPROPION HCL	BUPROPION HCL TAB 75 MG	58300040100305	Generic

BUPROPION HYDROCHLORIDE	BUPROPION HCL TAB 100 MG	58300040100310	Generic
BUPROPION HCL	BUPROPION HCL TAB 100 MG	58300040100310	Generic
BUPROPION HYDROCHLORIDE ER (SR)	BUPROPION HCL TAB ER 12HR 100 MG	58300040107420	Generic
BUPROPION HYDROCHLORIDE ER (SR)	BUPROPION HCL TAB ER 12HR 150 MG	58300040107430	Generic
BUPROPION HYDROCHLORIDE ER (SR)	BUPROPION HCL TAB ER 12HR 200 MG	58300040107440	Generic
BUPROPION HYDROCHLORIDE ER (XL)	BUPROPION HCL TAB ER 24HR 150 MG	58300040107520	Generic
BUPROPION HYDROCHLORIDE ER (XL)	BUPROPION HCL TAB ER 24HR 300 MG	58300040107530	Generic

**Approval Criteria**

1 - The patient is unresponsive to other treatment modalities, unless contraindicated (i.e., other medications or behavioral modification attempted)

**AND**

2 - The physician attests that the requested medication is medically necessary (Document rationale for use)

**Notes**

For group code ACUAZPH, antidepressant medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.

Product Name: Brand Remeron, Brand Remeron Soltab, Marplan, Brand Nardil, generic phenelzine, Emsam, generic tranylcypromine, Brand Parnate, nefazodone, Brand Viibryd, Trintellix, Brand Celexa, Citalopram caps, Brand Lexapro, Brand Prozac, fluoxetine tabs, fluvoxamine ER, Brand Paxil, generic paroxetine ER, Brand Paxil CR, Brand Zoloft, Sertraline caps, paroxetine caps, generic paroxetine susp, Brand Pristiq, generic desvenlafaxine ER, Desvenlafaxine ER, Brand Cymbalta, duloxetine 40 mg, Fetzima Titration, Fetzima, Brand Effexor XR, venlafaxine ER tabs, Brand Anafranil, Brand Norpramin, Brand Pamelor, Brand Wellbutrin SR, Brand Wellbutrin XL, bupropion ER (XL) 450 mg, Forfivo XL, Aplenzin, Pexeva, Drizalma Sprinkle, generic vilazodone, Auvelity



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Diagnosis	Non-Preferred Drugs		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REMERON	MIRTAZAPINE TAB 15 MG	58030050000315	Brand
REMERON	MIRTAZAPINE TAB 30 MG	58030050000330	Brand
REMERON SOLTAB	MIRTAZAPINE ORALLY DISINTEGRATING TAB 15 MG	58030050007215	Brand
REMERON SOLTAB	MIRTAZAPINE ORALLY DISINTEGRATING TAB 30 MG	58030050007230	Brand
REMERON SOLTAB	MIRTAZAPINE ORALLY DISINTEGRATING TAB 45 MG	58030050007245	Brand
MARPLAN	ISOCARBOXAZID TAB 10 MG	58100010000305	Brand
NARDIL	PHENELZINE SULFATE TAB 15 MG	58100020100305	Brand
PHENELZINE SULFATE	PHENELZINE SULFATE TAB 15 MG	58100020100305	Generic
EMSAM	SELEGILINE TD PATCH 24HR 6 MG/24HR	58100027008520	Brand
EMSAM	SELEGILINE TD PATCH 24HR 9 MG/24HR	58100027008530	Brand
EMSAM	SELEGILINE TD PATCH 24HR 12 MG/24HR	58100027008540	Brand
TRANLYCYPROMINE SULFATE	TRANLYCYPROMINE SULFATE TAB 10 MG	58100030100305	Generic
PARNATE	TRANLYCYPROMINE SULFATE TAB 10 MG	58100030100305	Brand
NEFAZODONE HYDROCHLORIDE	NEFAZODONE HCL TAB 50 MG	58120050100305	Generic
NEFAZODONE HYDROCHLORIDE	NEFAZODONE HCL TAB 100 MG	58120050100310	Generic
NEFAZODONE HCL	NEFAZODONE HCL TAB 100 MG	58120050100310	Generic
NEFAZODONE HYDROCHLORIDE	NEFAZODONE HCL TAB 150 MG	58120050100320	Generic
NEFAZODONE HCL	NEFAZODONE HCL TAB 150 MG	58120050100320	Generic
NEFAZODONE HYDROCHLORIDE	NEFAZODONE HCL TAB 200 MG	58120050100330	Generic
NEFAZODONE HCL	NEFAZODONE HCL TAB 200 MG	58120050100330	Generic
NEFAZODONE HYDROCHLORIDE	NEFAZODONE HCL TAB 250 MG	58120050100340	Generic
VIIBRYD	VILAZODONE HCL TAB 10 MG	58120088100310	Brand
VIIBRYD	VILAZODONE HCL TAB 20 MG	58120088100320	Brand
VIIBRYD	VILAZODONE HCL TAB 40 MG	58120088100340	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

VIIBRYD STARTER PACK	VILAZODONE HCL TAB STARTER KIT 10 (7) & 20 (23) MG	58120088106410	Brand
TRINTELLIX	VORTIOXETINE HBR TAB 5 MG (BASE EQUIV)	58120093100310	Brand
TRINTELLIX	VORTIOXETINE HBR TAB 10 MG (BASE EQUIV)	58120093100320	Brand
TRINTELLIX	VORTIOXETINE HBR TAB 20 MG (BASE EQUIV)	58120093100340	Brand
CELEXA	CITALOPRAM HYDROBROMIDE TAB 10 MG (BASE EQUIV)	58160020100310	Brand
CELEXA	CITALOPRAM HYDROBROMIDE TAB 20 MG (BASE EQUIV)	58160020100320	Brand
CELEXA	CITALOPRAM HYDROBROMIDE TAB 40 MG (BASE EQUIV)	58160020100340	Brand
CITALOPRAM HYDROBROMIDE	CITALOPRAM HYDROBROMIDE CAP 30 MG	58160020100120	Brand
LEXAPRO	ESCITALOPRAM OXALATE TAB 5 MG (BASE EQUIV)	58160034100310	Brand
LEXAPRO	ESCITALOPRAM OXALATE TAB 10 MG (BASE EQUIV)	58160034100320	Brand
LEXAPRO	ESCITALOPRAM OXALATE TAB 20 MG (BASE EQUIV)	58160034100330	Brand
PROZAC	FLUOXETINE HCL CAP 10 MG	58160040000110	Brand
PROZAC	FLUOXETINE HCL CAP 20 MG	58160040000120	Brand
PROZAC	FLUOXETINE HCL CAP 40 MG	58160040000140	Brand
FLUOXETINE HYDROCHLORIDE	FLUOXETINE HCL TAB 10 MG	58160040000310	Generic
FLUOXETINE HYDROCHLORIDE	FLUOXETINE HCL TAB 20 MG	58160040000320	Generic
FLUOXETINE HYDROCHLORIDE	FLUOXETINE HCL TAB 60 MG	58160040000360	Generic
FLUVOXAMINE MALEATE ER	FLUVOXAMINE MALEATE CAP ER 24HR 100 MG	58160045107020	Generic
FLUVOXAMINE MALEATE ER	FLUVOXAMINE MALEATE CAP ER 24HR 150 MG	58160045107030	Generic
PAXIL	PAROXETINE HCL TAB 10 MG	58160060000310	Brand
PAXIL	PAROXETINE HCL TAB 20 MG	58160060000320	Brand
PAXIL	PAROXETINE HCL TAB 30 MG	58160060000330	Brand
PAXIL	PAROXETINE HCL TAB 40 MG	58160060000340	Brand
PAXIL	PAROXETINE HCL ORAL SUSP 10 MG/5ML (BASE EQUIV)	58160060001820	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PAROXETINE HYDROCHLORIDE ER	PAROXETINE HCL TAB ER 24HR 12.5 MG	58160060007520	Generic
PAXIL CR	PAROXETINE HCL TAB ER 24HR 12.5 MG	58160060007520	Brand
PAROXETINE HCL ER	PAROXETINE HCL TAB ER 24HR 12.5 MG	58160060007520	Generic
PAROXETINE HYDROCHLORIDE ER	PAROXETINE HCL TAB ER 24HR 25 MG	58160060007530	Generic
PAXIL CR	PAROXETINE HCL TAB ER 24HR 25 MG	58160060007530	Brand
PAROXETINE HCL ER	PAROXETINE HCL TAB ER 24HR 25 MG	58160060007530	Generic
PAROXETINE HYDROCHLORIDE ER	PAROXETINE HCL TAB ER 24HR 37.5 MG	58160060007540	Generic
PAXIL CR	PAROXETINE HCL TAB ER 24HR 37.5 MG	58160060007540	Brand
PAROXETINE HCL ER	PAROXETINE HCL TAB ER 24HR 37.5 MG	58160060007540	Generic
ZOLOFT	SERTRALINE HCL TAB 25 MG	58160070100305	Brand
ZOLOFT	SERTRALINE HCL TAB 50 MG	58160070100310	Brand
ZOLOFT	SERTRALINE HCL TAB 100 MG	58160070100320	Brand
ZOLOFT	SERTRALINE HCL ORAL CONCENTRATE FOR SOLUTION 20 MG/ML	58160070101320	Brand
PAROXETINE	PAROXETINE MESYLATE CAP 7.5 MG (BASE EQUIV)	62226060300110	Generic
PRISTIQ	DESVENLAFAXINE SUCCINATE TAB ER 24HR 25 MG (BASE EQUIV)	58180020207510	Brand
DESVENLAFAXINE ER	DESVENLAFAXINE SUCCINATE TAB ER 24HR 25 MG (BASE EQUIV)	58180020207510	Generic
PRISTIQ	DESVENLAFAXINE SUCCINATE TAB ER 24HR 50 MG (BASE EQUIV)	58180020207520	Brand
DESVENLAFAXINE ER	DESVENLAFAXINE SUCCINATE TAB ER 24HR 50 MG (BASE EQUIV)	58180020207520	Generic
PRISTIQ	DESVENLAFAXINE SUCCINATE TAB ER 24HR 100 MG (BASE EQUIV)	58180020207540	Brand
DESVENLAFAXINE ER	DESVENLAFAXINE SUCCINATE TAB ER 24HR 100 MG (BASE EQUIV)	58180020207540	Generic
DESVENLAFAXINE ER	DESVENLAFAXINE TAB ER 24HR 50 MG	58180020007520	Brand
DESVENLAFAXINE ER	DESVENLAFAXINE TAB ER 24HR 100 MG	58180020007540	Brand
CYMBALTA	DULOXETINE HCL ENTERIC COATED PELLETS CAP 20 MG (BASE EQ)	58180025106720	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CYMBALTA	DULOXETINE HCL ENTERIC COATED PELLETS CAP 30 MG (BASE EQ)	58180025106730	Brand
CYMBALTA	DULOXETINE HCL ENTERIC COATED PELLETS CAP 60 MG (BASE EQ)	58180025106750	Brand
DULOXETINE HCL	DULOXETINE HCL ENTERIC COATED PELLETS CAP 40 MG (BASE EQ)	58180025106740	Generic
DULOXETINE HYDROCHLORIDE	DULOXETINE HCL ENTERIC COATED PELLETS CAP 40 MG (BASE EQ)	58180025106740	Generic
FETZIMA TITRATION PACK	LEVOMILNACIPRAN HCL CAP ER 24HR 20 & 40 MG THERAPY PACK	5818005010B620	Brand
FETZIMA	LEVOMILNACIPRAN HCL CAP ER 24HR 20 MG (BASE EQUIVALENT)	58180050107020	Brand
FETZIMA	LEVOMILNACIPRAN HCL CAP ER 24HR 40 MG (BASE EQUIVALENT)	58180050107040	Brand
FETZIMA	LEVOMILNACIPRAN HCL CAP ER 24HR 80 MG (BASE EQUIVALENT)	58180050107060	Brand
FETZIMA	LEVOMILNACIPRAN HCL CAP ER 24HR 120 MG (BASE EQUIVALENT)	58180050107080	Brand
EFFEXOR XR	VENLAFAXINE HCL CAP ER 24HR 37.5 MG (BASE EQUIVALENT)	58180090107020	Brand
EFFEXOR XR	VENLAFAXINE HCL CAP ER 24HR 75 MG (BASE EQUIVALENT)	58180090107030	Brand
EFFEXOR XR	VENLAFAXINE HCL CAP ER 24HR 150 MG (BASE EQUIVALENT)	58180090107050	Brand
VENLAFAXINE HCL ER	VENLAFAXINE HCL TAB ER 24HR 37.5 MG (BASE EQUIVALENT)	58180090107510	Generic
VENLAFAXINE HYDROCHLORIDE ER	VENLAFAXINE HCL TAB ER 24HR 37.5 MG (BASE EQUIVALENT)	58180090107510	Generic
VENLAFAXINE HYDROCHLORIDE ER	VENLAFAXINE HCL TAB ER 24HR 75 MG (BASE EQUIVALENT)	58180090107520	Generic
VENLAFAXINE HYDROCHLORIDE ER	VENLAFAXINE HCL TAB ER 24HR 150 MG (BASE EQUIVALENT)	58180090107530	Generic
VENLAFAXINE HYDROCHLORIDE ER	VENLAFAXINE HCL TAB ER 24HR 225 MG (BASE EQUIVALENT)	58180090107540	Generic
ANAFRANIL	CLOMIPRAMINE HCL CAP 25 MG	58200025100120	Brand
ANAFRANIL	CLOMIPRAMINE HCL CAP 50 MG	58200025100130	Brand
ANAFRANIL	CLOMIPRAMINE HCL CAP 75 MG	58200025100140	Brand
NORPRAMIN	DESIPRAMINE HCL TAB 10 MG	58200030100305	Brand
NORPRAMIN	DESIPRAMINE HCL TAB 25 MG	58200030100310	Brand
PAMELOR	NORTRIPTYLINE HCL CAP 10 MG	58200060100105	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PAMELOR	NORTRIPTYLINE HCL CAP 25 MG	58200060100110	Brand
PAMELOR	NORTRIPTYLINE HCL CAP 50 MG	58200060100115	Brand
PAMELOR	NORTRIPTYLINE HCL CAP 75 MG	58200060100120	Brand
WELLBUTRIN SR	BUPROPION HCL TAB ER 12HR 100 MG	58300040107420	Brand
WELLBUTRIN SR	BUPROPION HCL TAB ER 12HR 150 MG	58300040107430	Brand
WELLBUTRIN SR	BUPROPION HCL TAB ER 12HR 200 MG	58300040107440	Brand
WELLBUTRIN XL	BUPROPION HCL TAB ER 24HR 150 MG	58300040107520	Brand
WELLBUTRIN XL	BUPROPION HCL TAB ER 24HR 300 MG	58300040107530	Brand
BUPROPION HYDROCHLORIDE ER (XL)	BUPROPION HCL TAB ER 24HR 450 MG	58300040107545	Generic
FORFIVO XL	BUPROPION HCL TAB ER 24HR 450 MG	58300040107545	Generic
APLENZIN	BUPROPION HBR TAB ER 24HR 174 MG	58300040207520	Brand
APLENZIN	BUPROPION HBR TAB ER 24HR 348 MG	58300040207530	Brand
APLENZIN	BUPROPION HBR TAB ER 24HR 522 MG	58300040207540	Brand
PEXEVA	PAROXETINE MESYLATE TAB 10 MG (BASE EQUIV)	58160060300310	Brand
PEXEVA	PAROXETINE MESYLATE TAB 20 MG (BASE EQUIV)	58160060300320	Brand
PEXEVA	PAROXETINE MESYLATE TAB 30 MG (BASE EQUIV)	58160060300330	Brand
DRIZALMA SPRINKLE	DULOXETINE HCL CAP DELAYED RELEASE SPRINKLE 20 MG (BASE EQ)	5818002510H120	Brand
DRIZALMA SPRINKLE	DULOXETINE HCL CAP DELAYED RELEASE SPRINKLE 30 MG (BASE EQ)	5818002510H130	Brand
DRIZALMA SPRINKLE	DULOXETINE HCL CAP DELAYED RELEASE SPRINKLE 40 MG (BASE EQ)	5818002510H140	Brand
DRIZALMA SPRINKLE	DULOXETINE HCL CAP DELAYED RELEASE SPRINKLE 60 MG (BASE EQ)	5818002510H160	Brand
VILAZODONE HYDROCHLORIDE	VILAZODONE HCL TAB 10 MG	58120088100310	Generic
VILAZODONE HYDROCHLORIDE	VILAZODONE HCL TAB 20 MG	58120088100320	Generic
VILAZODONE HYDROCHLORIDE	VILAZODONE HCL TAB 40 MG	58120088100340	Generic
PEXEVA	PAROXETINE MESYLATE TAB 40 MG (BASE EQUIV)	58160060300340	Brand
AUVELITY	DEXTROMETHORPHAN HBR-BUPROPION HCL TAB ER 45-105 MG	58999902300420	Brand
SERTRALINE HYDROCHLORIDE	SERTRALINE HCL CAP 150 MG	58160070100130	Brand

SERTRALINE HYDROCHLORIDE	SERTRALINE HCL CAP 200 MG	58160070100140	Brand
PAROXETINE HYDROCHLORIDE	PAROXETINE HCL ORAL SUSP 10 MG/5ML (BASE EQUIV)	58160060001820	Generic

**Approval Criteria**

**1** - The patient is unresponsive to other treatment modalities, unless contraindicated (i.e., other medications or behavioral modification attempted)

**AND**

**2** - The physician attests that the requested medication is medically necessary (Document rationale for use)

**AND**

**3** - Patient has a history of failure, contraindication, or intolerance to at least 3 of the following preferred alternatives\*:

- Bupropion (Generic Wellbutrin)
- Bupropion SR (Generic Wellbutrin SR)
- Bupropion XL (Generic Wellbutrin XL) 150 mg and 300 mg
- Citalopram (Generic Celexa)
- Duloxetine 20mg, 30mg, or 60 mg capsules
- Escitalopram Tablets (Generic Lexapro)
- Esketamine (Spravato)
- Fluoxetine Capsules (Generic Prozac)
- Fluoxetine Solution (Generic Prozac)
- Fluvoxamine Tablets (Generic Luvox)
- Mirtazapine (Generic Remeron)
- Paroxetine tablets (Generic Paxil)
- Sertraline tablets (Generic Zoloft)
- Trazodone (Generic Desyrel)
- Venlafaxine (Generic Effexor)
- Venlafaxine ER Capsules (Generic Effexor ER)

**Notes**

For group code ACUAZPH, antidepressant medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression

	on, obsessive-compulsive disorder, and panic disorder. *Drug may require PA.
--	---

Product Name: venlafaxine besylate ER			
Diagnosis	Non-Preferred Drugs		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VENLAFAXINE BESYLATE ER	VENLAFAXINE BESYLATE TAB ER 24HR 112.5 MG	58180090057520	Brand

**Approval Criteria**

1 - The patient is unresponsive to other treatment modalities, unless contraindicated (i.e., other medications or behavioral modification attempted)

**AND**

2 - The physician attests that the requested medication is medically necessary (Document rationale for use)

**AND**

3 - Patient has history of failure or intolerance to preferred generic venlafaxine or venlafaxine ER capsules

**AND**

4 - Patient has a history of failure, contraindication, or intolerance to at least 2 of the following preferred alternatives\*:

- Bupropion (Generic Wellbutrin)
- Bupropion SR (Generic Wellbutrin SR)
- Bupropion XL (Generic Wellbutrin XL) 150 mg and 300 mg
- Citalopram (Generic Celexa)

<ul style="list-style-type: none"> <li>• Duloxetine 20mg, 30mg, or 60 mg capsules</li> <li>• Escitalopram Tablets (Generic Lexapro)</li> <li>• Esketamine (Spravato)</li> <li>• Fluoxetine Capsules (Generic Prozac)</li> <li>• Fluoxetine Solution (Generic Prozac)</li> <li>• Fluvoxamine Tablets (Generic Luvox)</li> <li>• Mirtazapine (Generic Remeron)</li> <li>• Paroxetine tablets (Generic Paxil)</li> <li>• Sertraline tablets (Generic Zoloft)</li> <li>• Trazodone (Generic Desyrel)</li> </ul>	
Notes	<p>For group code ACUAZPH, antidepressant medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.</p> <p>*Drug may require PA.</p>

## 2 . Revision History

Date	Notes
10/18/2023	Moved Sertraline capsule and paroxetine suspension from preferred to non-preferred. Removed citalopram capsule GPI from preferred section. Updated product names of both preferred and non-preferred sections. Updated T/F list to specify sertraline tablets are the preferred prerequisite.



Antiemetics



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150390
<b>Guideline Name</b>	Antiemetics
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Anzemet, granisetron tablet			
Diagnosis	Nausea and vomiting associated with cancer chemotherapy		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ANZEMET	DOLASETRON MESYLATE TAB 50 MG	50250025200320	Brand
GRANISETRON HYDROCHLORIDE	GRANISETRON HCL TAB 1 MG	50250035100310	Generic
<b>Approval Criteria</b>			

1 - Prevention or treatment of nausea and vomiting associated with cancer chemotherapy

Product Name: Anzemet, granisetron tablet

Diagnosis Nausea and vomiting associated with radiotherapy

Approval Length 3 month(s)

Guideline Type Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ANZEMET	DOLASETRON MESYLATE TAB 50 MG	50250025200320	Brand
GRANISETRON HYDROCHLORIDE	GRANISETRON HCL TAB 1 MG	50250035100310	Generic

**Approval Criteria**

1 - Prevention or treatment of nausea and vomiting associated with radiotherapy (total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen)

Product Name: Anzemet, granisetron tablet

Diagnosis Postoperative nausea and/or vomiting

Approval Length 1 month(s)

Guideline Type Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ANZEMET	DOLASETRON MESYLATE TAB 50 MG	50250025200320	Brand
GRANISETRON HYDROCHLORIDE	GRANISETRON HCL TAB 1 MG	50250035100310	Generic

**Approval Criteria**

1 - Prevention of postoperative nausea and/or vomiting (administration prior to induction of anesthesia)

**2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
7/24/2024	Update to guideline name. Removed ondansetron 24mg tab as a target. Removed GPI for obsolete Anzemet 100mg strength. Updated product name lists and GPI tables accordingly. No changes to criteria.

Antiglaucoma Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140722
<b>Guideline Name</b>	Antiglaucoma Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Zioptan			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AZOPT	BRINZOLAMIDE OPHTH SUSP 1%	86802320001820	Brand
TRAVATAN Z	TRAVOPROST OPHTH SOLN 0.004% (BENZALKONIUM FREE) (BAK FREE)	86330070002025	Brand
TRAVOPROST (BAK FREE)	TRAVOPROST OPHTH SOLN 0.004% (BENZALKONIUM FREE) (BAK FREE)	86330070002025	Generic
ZIOPTAN	TAFLUPROST PRESERVATIVE FREE (PF) OPHTH SOLN 0.0015%	86330065002025	Brand

**Approval Criteria**

1 - Diagnosis of elevated intraocular pressure due to ocular hypertension or open angle glaucoma

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Antipsoriatic Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140713
<b>Guideline Name</b>	Antipsoriatic Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Dovonex cream, generic calcipotriene cream, Brand Calcitrene ointment, generic calcipotriene ointment, Brand Vectical, generic calcitriol ointment			
Diagnosis	Psoriasis		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CALCIPOTRIENE	CALCIPOTRIENE CREAM 0.005%	90250025003710	Generic
CALCIPOTRIENE	CALCIPOTRIENE OINT 0.005%	90250025004210	Generic
CALCITRIOL	CALCITRIOL OINT 3 MCG/GM	90250028004220	Generic
DOVONEX	CALCIPOTRIENE CREAM 0.005%	90250025003710	Brand
CALCITRENE	CALCIPOTRIENE OINT 0.005%	90250025004210	Brand

VECTICAL	CALCITRIOL OINT 3 MCG/GM	90250028004220	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of psoriasis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - History of failure, contraindication, or intolerance to TWO medium to Very high potency corticosteroid topical treatments (see Table 1 in Background section)</p>			

## 2 . Background

Benefit/Coverage/Program Information		
<b>Table 1. Relative Potency of Selected Topical Corticosteroid Products</b>		
Drug	Dosage Form	Strength
<b>Super High Potency</b>		
Augmented betamethasone dipropionate (Diprolene)	Gel, Ointment	0.05%
Clobetasol propionate (Temovate, Temovate E)	Cream, Solution	0.05%
Halobetasol propionate (Ultravate)	Cream	0.05%
<b>High Potency</b>		
Augmented betamethasone dipropionate (Diprolene, Diprolene AF)	Cream, Lotion	0.05%
Betamethasone dipropionate	Lotion, Ointment	0.05%

Fluocinonide (Lidex, Lidex E)	Cream, Solution	0.05%
Triamcinolone acetonide (Kenalog)	Cream, Ointment	0.5%
<b>Medium Potency</b>		
Betamethasone valerate (Beta-Val)	Cream	0.1%
Fluocinolone acetonide (Synalar)	Cream, Ointment	0.025%
Fluticasone propionate (Cutivate)	Cream, Lotion	0.05%
	Ointment	0.005%
Hydrocortisone butyrate (Locoid)	Ointment, Solution	0.1%
Mometasone furoate (Elocon)	Cream, Ointment, Solution	0.1%
Prednicarbate (Dermatop)	Cream	0.1%
Triamcinolone acetonide (Kenalog)	Cream, Lotion, Ointment	0.1%
	Ointment	0.025%

### 3 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22



Antipsychotics



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-155838
<b>Guideline Name</b>	Antipsychotics
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Brand Abilify tabs, generic aripiprazole tabs, generic ziprasidone caps, Brand Geodon caps, Brand Latuda, lithium carbonate, generic lithium carbonate ER, Brand Lithobid, generic risperidone tabs/soln, Brand Risperdal tabs/soln, risperidone ODT, generic quetiapine, Brand Seroquel, Brand Zyprexa, generic olanzapine, generic olanzapine ODT, Brand Zyprexa Zydis, generic lurasidone			
Diagnosis	Patients Under 6 Years Old		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ABILIFY	ARIPIPRAZOLE TAB 2 MG	59250015000305	Brand
ARIPIPRAZOLE	ARIPIPRAZOLE TAB 2 MG	59250015000305	Generic
ABILIFY	ARIPIPRAZOLE TAB 5 MG	59250015000310	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ARIPIRAZOLE	ARIPIRAZOLE TAB 5 MG	59250015000310	Generic
ABILIFY	ARIPIRAZOLE TAB 10 MG	59250015000320	Brand
ARIPIRAZOLE	ARIPIRAZOLE TAB 10 MG	59250015000320	Generic
ABILIFY	ARIPIRAZOLE TAB 15 MG	59250015000330	Brand
ARIPIRAZOLE	ARIPIRAZOLE TAB 15 MG	59250015000330	Generic
ABILIFY	ARIPIRAZOLE TAB 20 MG	59250015000340	Brand
ARIPIRAZOLE	ARIPIRAZOLE TAB 20 MG	59250015000340	Generic
ABILIFY	ARIPIRAZOLE TAB 30 MG	59250015000350	Brand
ARIPIRAZOLE	ARIPIRAZOLE TAB 30 MG	59250015000350	Generic
ZIPRASIDONE HYDROCHLORIDE	ZIPRASIDONE HCL CAP 20 MG	59400085100120	Generic
GEODON	ZIPRASIDONE HCL CAP 20 MG	59400085100120	Brand
ZIPRASIDONE HCL	ZIPRASIDONE HCL CAP 20 MG	59400085100120	Generic
ZIPRASIDONE HYDROCHLORIDE	ZIPRASIDONE HCL CAP 40 MG	59400085100130	Generic
GEODON	ZIPRASIDONE HCL CAP 40 MG	59400085100130	Brand
ZIPRASIDONE HCL	ZIPRASIDONE HCL CAP 40 MG	59400085100130	Generic
ZIPRASIDONE HYDROCHLORIDE	ZIPRASIDONE HCL CAP 60 MG	59400085100140	Generic
GEODON	ZIPRASIDONE HCL CAP 60 MG	59400085100140	Brand
ZIPRASIDONE HCL	ZIPRASIDONE HCL CAP 60 MG	59400085100140	Generic
ZIPRASIDONE HYDROCHLORIDE	ZIPRASIDONE HCL CAP 80 MG	59400085100150	Generic
GEODON	ZIPRASIDONE HCL CAP 80 MG	59400085100150	Brand
ZIPRASIDONE HCL	ZIPRASIDONE HCL CAP 80 MG	59400085100150	Generic
LATUDA	LURASIDONE HCL TAB 20 MG	59400023100310	Brand
LATUDA	LURASIDONE HCL TAB 40 MG	59400023100320	Brand
LATUDA	LURASIDONE HCL TAB 60 MG	59400023100330	Brand
LATUDA	LURASIDONE HCL TAB 80 MG	59400023100340	Brand
LATUDA	LURASIDONE HCL TAB 120 MG	59400023100350	Brand
LITHIUM CARBONATE	LITHIUM CARBONATE CAP 150 MG	59500010100103	Generic
LITHIUM CARBONATE	LITHIUM CARBONATE CAP 300 MG	59500010100105	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LITHIUM CARBONATE	LITHIUM CARBONATE CAP 600 MG	59500010100110	Generic
LITHIUM CARBONATE	LITHIUM CARBONATE TAB 300 MG	59500010100305	Generic
LITHIUM CARBONATE ER	LITHIUM CARBONATE TAB ER 300 MG	59500010100405	Generic
LITHOBID	LITHIUM CARBONATE TAB ER 300 MG	59500010100405	Brand
LITHIUM CARBONATE ER	LITHIUM CARBONATE TAB ER 450 MG	59500010100410	Generic
RISPERIDONE	RISPERIDONE TAB 0.25 MG	59070070000303	Generic
RISPERIDONE	RISPERIDONE TAB 0.5 MG	59070070000306	Generic
RISPERDAL	RISPERIDONE TAB 0.5 MG	59070070000306	Brand
RISPERIDONE	RISPERIDONE TAB 1 MG	59070070000310	Generic
RISPERDAL	RISPERIDONE TAB 1 MG	59070070000310	Brand
RISPERIDONE	RISPERIDONE TAB 2 MG	59070070000320	Generic
RISPERDAL	RISPERIDONE TAB 2 MG	59070070000320	Brand
RISPERIDONE	RISPERIDONE TAB 3 MG	59070070000330	Generic
RISPERDAL	RISPERIDONE TAB 3 MG	59070070000330	Brand
RISPERIDONE	RISPERIDONE TAB 4 MG	59070070000340	Generic
RISPERDAL	RISPERIDONE TAB 4 MG	59070070000340	Brand
RISPERIDONE	RISPERIDONE SOLN 1 MG/ML	59070070002010	Generic
RISPERDAL	RISPERIDONE SOLN 1 MG/ML	59070070002010	Brand
RISPERIDONE ODT	RISPERIDONE ORALLY DISINTEGRATING TAB 0.25 MG	59070070007210	Generic
RISPERIDONE ODT	RISPERIDONE ORALLY DISINTEGRATING TAB 0.5 MG	59070070007220	Generic
RISPERIDONE ODT	RISPERIDONE ORALLY DISINTEGRATING TAB 1 MG	59070070007230	Generic
RISPERIDONE ODT	RISPERIDONE ORALLY DISINTEGRATING TAB 2 MG	59070070007240	Generic
RISPERIDONE ODT	RISPERIDONE ORALLY DISINTEGRATING TAB 3 MG	59070070007250	Generic
RISPERIDONE ODT	RISPERIDONE ORALLY DISINTEGRATING TAB 4 MG	59070070007260	Generic
QUETIAPINE FUMARATE	QUETIAPINE FUMARATE TAB 25 MG	59153070100310	Generic
SEROQUEL	QUETIAPINE FUMARATE TAB 25 MG	59153070100310	Brand
QUETIAPINE FUMARATE	QUETIAPINE FUMARATE TAB 50 MG	59153070100314	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SEROQUEL	QUETIAPINE FUMARATE TAB 50 MG	59153070100314	Brand
QUETIAPINE FUMARATE	QUETIAPINE FUMARATE TAB 100 MG	59153070100320	Generic
SEROQUEL	QUETIAPINE FUMARATE TAB 100 MG	59153070100320	Brand
QUETIAPINE FUMARATE	QUETIAPINE FUMARATE TAB 150 MG	59153070100325	Generic
QUETIAPINE FUMARATE	QUETIAPINE FUMARATE TAB 200 MG	59153070100330	Generic
SEROQUEL	QUETIAPINE FUMARATE TAB 200 MG	59153070100330	Brand
QUETIAPINE FUMARATE	QUETIAPINE FUMARATE TAB 300 MG	59153070100340	Generic
SEROQUEL	QUETIAPINE FUMARATE TAB 300 MG	59153070100340	Brand
QUETIAPINE FUMARATE	QUETIAPINE FUMARATE TAB 400 MG	59153070100350	Generic
SEROQUEL	QUETIAPINE FUMARATE TAB 400 MG	59153070100350	Brand
ZYPREXA	OLANZAPINE TAB 2.5 MG	59157060000305	Brand
OLANZAPINE	OLANZAPINE TAB 2.5 MG	59157060000305	Generic
ZYPREXA	OLANZAPINE TAB 5 MG	59157060000310	Brand
OLANZAPINE	OLANZAPINE TAB 5 MG	59157060000310	Generic
ZYPREXA	OLANZAPINE TAB 7.5 MG	59157060000315	Brand
OLANZAPINE	OLANZAPINE TAB 7.5 MG	59157060000315	Generic
ZYPREXA	OLANZAPINE TAB 10 MG	59157060000320	Brand
OLANZAPINE	OLANZAPINE TAB 10 MG	59157060000320	Generic
ZYPREXA	OLANZAPINE TAB 15 MG	59157060000330	Brand
OLANZAPINE	OLANZAPINE TAB 15 MG	59157060000330	Generic
ZYPREXA	OLANZAPINE TAB 20 MG	59157060000340	Brand
OLANZAPINE	OLANZAPINE TAB 20 MG	59157060000340	Generic
OLANZAPINE ODT	OLANZAPINE ORALLY DISINTEGRATING TAB 5 MG	59157060007210	Generic
ZYPREXA ZYDIS	OLANZAPINE ORALLY DISINTEGRATING TAB 5 MG	59157060007210	Brand
OLANZAPINE ODT	OLANZAPINE ORALLY DISINTEGRATING TAB 10 MG	59157060007220	Generic
ZYPREXA ZYDIS	OLANZAPINE ORALLY DISINTEGRATING TAB 10 MG	59157060007220	Brand
OLANZAPINE ODT	OLANZAPINE ORALLY DISINTEGRATING TAB 15 MG	59157060007230	Generic
ZYPREXA ZYDIS	OLANZAPINE ORALLY DISINTEGRATING TAB 15 MG	59157060007230	Brand

OLANZAPINE ODT	OLANZAPINE ORALLY DISINTEGRATING TAB 20 MG	59157060007240	Generic
ZYPREXA ZYDIS	OLANZAPINE ORALLY DISINTEGRATING TAB 20 MG	59157060007240	Brand
LURASIDONE HYDROCHLORIDE	LURASIDONE HCL TAB 20 MG	59400023100310	Generic
LURASIDONE HYDROCHLORIDE	LURASIDONE HCL TAB 40 MG	59400023100320	Generic
LURASIDONE HYDROCHLORIDE	LURASIDONE HCL TAB 60 MG	59400023100330	Generic
LURASIDONE HYDROCHLORIDE	LURASIDONE HCL TAB 80 MG	59400023100340	Generic
LURASIDONE HYDROCHLORIDE	LURASIDONE HCL TAB 120 MG	59400023100350	Generic

**Approval Criteria**

**1** - The patient has been diagnosed per current DSM (Diagnostic and Statistical Manual of Mental Disorders) criteria with one of the following disorders:

- Bipolar Spectrum Disorder
- Schizophrenic Spectrum Disorder
- Tourette’s or other tic disorder
- Autism Spectrum Disorder

**AND**

**2** - The requesting clinician has documented that psychosocial issues have been evaluated before request for antipsychotic medications

**AND**

**3** - The requesting clinician has documented non-medication alternatives that have been attempted before request for antipsychotic medications

**AND**

**4** - The above documentation includes information on the expected outcomes and an evaluation of potential adverse events

**AND**

**5** - The patient does not have a known hypersensitivity to the requested agent

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

Product Name: haloperidol tabs/oral conc, loxapine, thioridazine, molindone, thiothixene, pimozide, fluphenazine tabs/elix/oral conc, trifluoperazine, perphenazine, chlorpromazine tabs			
Diagnosis	Patients Under 12 Years Old		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HALOPERIDOL	HALOPERIDOL TAB 0.5 MG	59100010100305	Generic
HALOPERIDOL	HALOPERIDOL TAB 1 MG	59100010100310	Generic
HALOPERIDOL	HALOPERIDOL TAB 2 MG	59100010100315	Generic
HALOPERIDOL	HALOPERIDOL TAB 5 MG	59100010100320	Generic
HALOPERIDOL	HALOPERIDOL TAB 10 MG	59100010100325	Generic
HALOPERIDOL	HALOPERIDOL TAB 20 MG	59100010100330	Generic
HALOPERIDOL	HALOPERIDOL LACTATE ORAL CONC 2 MG/ML	59100010201305	Generic
LOXAPINE	LOXAPINE SUCCINATE CAP 5 MG	59154020200105	Generic
LOXAPINE SUCCINATE	LOXAPINE SUCCINATE CAP 5 MG	59154020200105	Generic
LOXAPINE	LOXAPINE SUCCINATE CAP 10 MG	59154020200110	Generic
LOXAPINE SUCCINATE	LOXAPINE SUCCINATE CAP 10 MG	59154020200110	Generic
LOXAPINE	LOXAPINE SUCCINATE CAP 25 MG	59154020200115	Generic
LOXAPINE SUCCINATE	LOXAPINE SUCCINATE CAP 25 MG	59154020200115	Generic
LOXAPINE	LOXAPINE SUCCINATE CAP 50 MG	59154020200120	Generic
LOXAPINE SUCCINATE	LOXAPINE SUCCINATE CAP 50 MG	59154020200120	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

THIORIDAZINE HCL	THIORIDAZINE HCL TAB 10 MG	59200080100305	Generic
THIORIDAZINE HCL	THIORIDAZINE HCL TAB 25 MG	59200080100315	Generic
THIORIDAZINE HCL	THIORIDAZINE HCL TAB 50 MG	59200080100320	Generic
THIORIDAZINE HCL	THIORIDAZINE HCL TAB 100 MG	59200080100325	Generic
MOLINDONE HYDROCHLORIDE	MOLINDONE HCL TAB 5 MG	59160050100305	Generic
MOLINDONE HYDROCHLORIDE	MOLINDONE HCL TAB 10 MG	59160050100310	Generic
MOLINDONE HYDROCHLORIDE	MOLINDONE HCL TAB 25 MG	59160050100315	Generic
THIOTHIXENE	THIOTHIXENE CAP 1 MG	59300020100105	Generic
THIOTHIXENE	THIOTHIXENE CAP 2 MG	59300020100110	Generic
THIOTHIXENE	THIOTHIXENE CAP 5 MG	59300020100115	Generic
THIOTHIXENE	THIOTHIXENE CAP 10 MG	59300020100120	Generic
PIMOZIDE	PIMOZIDE TAB 1 MG	62000030000303	Generic
PIMOZIDE	PIMOZIDE TAB 2 MG	62000030000305	Generic
FLUPHENAZINE HYDROCHLORIDE	FLUPHENAZINE HCL TAB 1 MG	59200025100305	Generic
FLUPHENAZINE HCL	FLUPHENAZINE HCL TAB 1 MG	59200025100305	Generic
FLUPHENAZINE HYDROCHLORIDE	FLUPHENAZINE HCL TAB 2.5 MG	59200025100310	Generic
FLUPHENAZINE HYDROCHLORIDE	FLUPHENAZINE HCL TAB 5 MG	59200025100315	Generic
FLUPHENAZINE HYDROCHLORIDE	FLUPHENAZINE HCL TAB 10 MG	59200025100320	Generic
FLUPHENAZINE HYDROCHLORIDE	FLUPHENAZINE HCL ELIXIR 2.5 MG/5ML	59200025101005	Generic
FLUPHENAZINE HCL	FLUPHENAZINE HCL ORAL CONC 5 MG/ML	59200025101320	Generic
TRIFLUOPERAZINE HCL	TRIFLUOPERAZINE HCL TAB 1 MG (BASE EQUIVALENT)	59200085100305	Generic
TRIFLUOPERAZINE HYDROCHLORIDE	TRIFLUOPERAZINE HCL TAB 1 MG (BASE EQUIVALENT)	59200085100305	Generic
TRIFLUOPERAZINE HCL	TRIFLUOPERAZINE HCL TAB 2 MG (BASE EQUIVALENT)	59200085100310	Generic
TRIFLUOPERAZINE HYDROCHLORIDE	TRIFLUOPERAZINE HCL TAB 2 MG (BASE EQUIVALENT)	59200085100310	Generic
TRIFLUOPERAZINE HCL	TRIFLUOPERAZINE HCL TAB 5 MG (BASE EQUIVALENT)	59200085100315	Generic

TRIFLUOPERAZINE HYDROCHLORIDE	TRIFLUOPERAZINE HCL TAB 5 MG (BASE EQUIVALENT)	59200085100315	Generic
TRIFLUOPERAZINE HCL	TRIFLUOPERAZINE HCL TAB 10 MG (BASE EQUIVALENT)	59200085100320	Generic
TRIFLUOPERAZINE HYDROCHLORIDE	TRIFLUOPERAZINE HCL TAB 10 MG (BASE EQUIVALENT)	59200085100320	Generic
PERPHENAZINE	PERPHENAZINE TAB 2 MG	59200045000305	Generic
PERPHENAZINE	PERPHENAZINE TAB 4 MG	59200045000310	Generic
PERPHENAZINE	PERPHENAZINE TAB 8 MG	59200045000315	Generic
PERPHENAZINE	PERPHENAZINE TAB 16 MG	59200045000320	Generic
CHLORPROMAZINE HYDROCHLORIDE	CHLORPROMAZINE HCL TAB 10 MG	59200015100305	Generic
CHLORPROMAZINE HCL	CHLORPROMAZINE HCL TAB 25 MG	59200015100310	Generic
CHLORPROMAZINE HYDROCHLORIDE	CHLORPROMAZINE HCL TAB 25 MG	59200015100310	Generic
CHLORPROMAZINE HYDROCHLORIDE	CHLORPROMAZINE HCL TAB 50 MG	59200015100315	Generic
CHLORPROMAZINE HCL	CHLORPROMAZINE HCL TAB 100 MG	59200015100320	Generic
CHLORPROMAZINE HYDROCHLORIDE	CHLORPROMAZINE HCL TAB 100 MG	59200015100320	Generic
CHLORPROMAZINE HYDROCHLORIDE	CHLORPROMAZINE HCL TAB 200 MG	59200015100325	Generic

**Approval Criteria**

1 - The patient has been diagnosed per current DSM (Diagnostic and Statistical Manual of Mental Disorders) criteria with one of the following disorders:

- Bipolar Spectrum Disorder
- Schizophrenic Spectrum Disorder
- Tourette’s or other tic disorder
- Autism Spectrum Disorder

**AND**

2 - The requesting clinician has documented that psychosocial issues have been evaluated before request for antipsychotic medications



**AND**

**3** - The requesting clinician has documented non-medication alternatives that have been attempted before request for antipsychotic medications

**AND**

**4** - The above documentation includes information on the expected outcomes and an evaluation of potential adverse events

**AND**

**5** - The patient does not have a known hypersensitivity to the requested agent

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

Product Name: generic clozapine, Brand Clozaril, clozapine ODT, generic haloperidol decanoate, Brand Haldol Decanoate, fluphenazine decanoate, haloperidol lactate inj			
Diagnosis	Patients Under 18 Years Old		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CLOZAPINE	CLOZAPINE TAB 25 MG	59152020000320	Generic
CLOZARIL	CLOZAPINE TAB 25 MG	59152020000320	Brand
CLOZAPINE	CLOZAPINE TAB 50 MG	59152020000325	Generic
CLOZARIL	CLOZAPINE TAB 50 MG	59152020000325	Brand
CLOZAPINE	CLOZAPINE TAB 100 MG	59152020000330	Generic
CLOZARIL	CLOZAPINE TAB 100 MG	59152020000330	Brand
CLOZAPINE	CLOZAPINE TAB 200 MG	59152020000340	Generic

CLOZARIL	CLOZAPINE TAB 200 MG	59152020000340	Brand
CLOZAPINE ODT	CLOZAPINE ORALLY DISINTEGRATING TAB 12.5 MG	59152020007210	Generic
CLOZAPINE ODT	CLOZAPINE ORALLY DISINTEGRATING TAB 25 MG	59152020007220	Generic
CLOZAPINE ODT	CLOZAPINE ORALLY DISINTEGRATING TAB 100 MG	59152020007230	Generic
CLOZAPINE ODT	CLOZAPINE ORALLY DISINTEGRATING TAB 150 MG	59152020007240	Generic
CLOZAPINE ODT	CLOZAPINE ORALLY DISINTEGRATING TAB 200 MG	59152020007250	Generic
HALOPERIDOL DECANOATE	HALOPERIDOL DECANOATE IM SOLN 50 MG/ML	59100010302010	Generic
HALDOL DECANOATE 50	HALOPERIDOL DECANOATE IM SOLN 50 MG/ML	59100010302010	Brand
HALDOL DECANOATE 100	HALOPERIDOL DECANOATE IM SOLN 100 MG/ML	59100010302020	Brand
HALOPERIDOL DECANOATE	HALOPERIDOL DECANOATE IM SOLN 100 MG/ML	59100010302020	Generic
FLUPHENAZINE DECANOATE	FLUPHENAZINE DECANOATE INJ 25 MG/ML	59200025302005	Generic
HALOPERIDOL LACTATE	HALOPERIDOL LACTATE INJ 5 MG/ML	59100010202005	Generic

**Approval Criteria**

1 - BOTH of the following:

1.1 ONE of the following:

1.1.1 The requested medication must be used for an FDA (Food and Drug Administration) approved indication

**OR**

1.1.2 The use of the drug is supported by information in ONE of the following appropriate compendia of literature:

- Food and Drug Administration (FDA) approved indications and limits
- Published practice guidelines and treatment protocols

- Comparative data evaluating the efficacy, type, and frequency of side effects and potential drug interactions among alternative products as well as the risks, benefits, and potential patient outcomes
- Drug Facts and Comparisons
- American Hospital Formulary Service Drug Information
- United States Pharmacopeia - Drug Information
- DRUGDEX Information System
- UpToDate
- MicroMedex
- Peer-reviewed medical literature, including randomized clinical trials, outcomes, research data, and pharmaco-economic studies
- Other drug reference resources

**AND**

**1.2** The patient meets the FDA minimum age limit or the prescriber attests they are aware of FDA labeling regarding the use of the antipsychotic medication and feels the treatment with the requested medication is medically necessary (document rationale for use)

**OR**

**2** - The patient is currently on the requested medication

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

Product Name: Abilify Asimtufii, Abilify Maintena			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ABILIFY MAINTENA	ARIPIRAZOLE IM FOR ER SUSP PREFILLED SYRINGE 300 MG	5925001500E430	Brand
ABILIFY MAINTENA	ARIPIRAZOLE IM FOR ER SUSP PREFILLED SYRINGE 400 MG	5925001500E440	Brand
ABILIFY MAINTENA	ARIPIRAZOLE IM FOR EXTENDED RELEASE SUSP 300 MG	5925001500G230	Brand
ABILIFY MAINTENA	ARIPIRAZOLE IM FOR EXTENDED RELEASE SUSP 400 MG	5925001500G240	Brand

ABILIFY ASIMTUFII	ARIPIPRAZOLE IM ER SUSP PREFILLED SYRINGE 720 MG/2.4ML	5925001500E455	Brand
ABILIFY ASIMTUFII	ARIPIPRAZOLE IM ER SUSP PREFILLED SYRINGE 960 MG/3.2ML	5925001500E465	Brand

**Approval Criteria**

1 - Patient has ONE of the following diagnoses:

- Schizophrenia or schizoaffective disorder
- Bipolar disorder

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

2.1.1 Patient is non-adherent with oral atypical antipsychotic dosage forms

**AND**

2.1.2 Patient has established tolerability with aripiprazole

**OR**

2.2 Patient is unable to take oral solid alternatives

**AND**

3 - If the patient is less than 18 years of age, the prescriber attests they are aware of FDA (Food and Drug Administration) labeling regarding use of long acting injectable antipsychotic products in patients less than 18 years of age and feels the treatment with the requested product is medically necessary (document rationale for use)

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavi
-------	---

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	oral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
--	---

Product Name: Abilify Mycite			
Approval Length		12 month(s)	
Therapy Stage		Initial Authorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 2 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B705	Brand
ABILIFY MYCITE MAINTENANCE KIT	ARIPIPRAZOLE TAB 2 MG WITH SENSOR&STRIPS (FOR POD) MAINT PAK	5925001503B706	Brand
ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 5 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B710	Brand
ABILIFY MYCITE MAINTENANCE KIT	ARIPIPRAZOLE TAB 5 MG WITH SENSOR&STRIPS (FOR POD) MAINT PAK	5925001503B711	Brand
ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 10 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B720	Brand
ABILIFY MYCITE MAINTENANCE KIT	ARIPIPRAZOLE TAB 10 MG WITH SENSOR&STRIPS(FOR POD) MAINT PAK	5925001503B721	Brand
ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 15 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B730	Brand
ABILIFY MYCITE MAINTENANCE KIT	ARIPIPRAZOLE TAB 15 MG WITH SENSOR&STRIPS(FOR POD) MAINT PAK	5925001503B731	Brand
ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 20 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B740	Brand
ABILIFY MYCITE MAINTENANCE KIT	ARIPIPRAZOLE TAB 20 MG WITH SENSOR&STRIPS(FOR POD) MAINT PAK	5925001503B741	Brand
ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 30 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B750	Brand

ABILIFY MYCITE MAINTENANCE KIT	ARIPIRAZOLE TAB 30 MG WITH SENSOR&STRIPS(FOR POD) MAINT PAK	5925001503B751	Brand
---	--	----------------	-------

**Approval Criteria**

**1** - ALL of the following:

**1.1** Patient is 18 years of age or older

**AND**

**1.2** Patient has ONE of the following:

- Schizophrenia or schizoaffective disorder
- Bipolar disorder
- Autism
- Major depressive disorder
- Tourette's

**AND**

**1.3** Submission of medical records or claims history documenting the patient is currently prescribed aripiprazole and tolerates the medication

**AND**

**1.4** Submission of medical records or claims history documenting the patient's adherence to aripiprazole is less than 80 percent within the past 6 months (medication adherence percentage is defined as the number of pills absent in a given time period divided by the number of pills prescribed during that same time, multiplied by 100)

**AND**

**1.5** ALL of the following strategies (if applicable to the patient) to improve patient adherence have been tried without success:

- Utilization of a pill box

- Utilization of a smart phone reminder (ex. alarm, application, or text reminder)
- Involving family members or friends to assist
- Coordinating timing of dose to coincide with dosing of another daily medication

**AND**

**1.6** Submission of medical records or claims history documenting patient has experienced life-threatening or potentially life-threatening symptoms, or has experienced a severe worsening of symptoms leading to a hospitalization which was attributed to the lack of adherence to aripiprazole

**AND**

**1.7** Prescriber acknowledges that Abilify MyCite has not been shown to improve patient adherence and attests that Abilify MyCite is medically necessary for the patient to maintain compliance, avoid life-threatening worsening of symptoms, and reduce healthcare resources utilized due to lack of adherence

**AND**

**1.8** Prescriber agrees to track and document adherence of Abilify MyCite through software provided by the manufacturer

**AND**

**1.9** The patient has a history of failure, contraindication, or intolerance or reason or special circumstance they cannot use TWO of the following (drug may require PA):

- Abilify Maintena
- Invega Sustenna
- Risperdal Consta
- Aristada
- Perseris

**OR**

**2** - ONE of the following:

**2.1** The patient has been receiving treatment with the requested non-preferred behavioral health medication and is new to the plan (enrollment effective date within the past 90 days)

**OR**

**2.2** The patient is currently receiving treatment with the requested non-preferred behavioral health medication in the hospital and must continue upon discharge

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

Product Name: Abilify Mycite			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 2 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B705	Brand
ABILIFY MYCITE MAINTENANCE KIT	ARIPIPRAZOLE TAB 2 MG WITH SENSOR&STRIPS (FOR POD) MAINT PAK	5925001503B706	Brand
ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 5 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B710	Brand
ABILIFY MYCITE MAINTENANCE KIT	ARIPIPRAZOLE TAB 5 MG WITH SENSOR&STRIPS (FOR POD) MAINT PAK	5925001503B711	Brand
ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 10 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B720	Brand
ABILIFY MYCITE MAINTENANCE KIT	ARIPIPRAZOLE TAB 10 MG WITH SENSOR&STRIPS(FOR POD) MAINT PAK	5925001503B721	Brand



ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 15 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B730	Brand
ABILIFY MYCITE MAINTENANCE KIT	ARIPIPRAZOLE TAB 15 MG WITH SENSOR&STRIPS(FOR POD) MAINT PAK	5925001503B731	Brand
ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 20 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B740	Brand
ABILIFY MYCITE MAINTENANCE KIT	ARIPIPRAZOLE TAB 20 MG WITH SENSOR&STRIPS(FOR POD) MAINT PAK	5925001503B741	Brand
ABILIFY MYCITE STARTER KIT	ARIPIPRAZOLE TAB 30 MG WITH SENSOR, STRIPS & POD STARTER PAK	5925001503B750	Brand
ABILIFY MYCITE MAINTENANCE KIT	ARIPIPRAZOLE TAB 30 MG WITH SENSOR&STRIPS(FOR POD) MAINT PAK	5925001503B751	Brand

**Approval Criteria**

1 - Documentation that patient is clinically stable on Abilify MyCite

**AND**

2 - Submission of medical records or claims history documenting that the use of Abilify MyCite has increased adherence to 80 percent or more

**AND**

3 - Prescriber attests that the patient requires the continued use of Abilify MyCite to remain adherent

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

Product Name: Aristada, Aristada Initio

Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ARISTADA	ARIPRAZOLE LAUROXIL IM ER SUSP PREFILLED SYR 441 MG/1.6ML	5925001520E420	Brand
ARISTADA	ARIPRAZOLE LAUROXIL IM ER SUSP PREFILLED SYR 662 MG/2.4ML	5925001520E430	Brand
ARISTADA INITIO	ARIPRAZOLE LAUROXIL IM ER SUSP PREFILLED SYR 675 MG/2.4ML	5925001520E435	Brand
ARISTADA	ARIPRAZOLE LAUROXIL IM ER SUSP PREFILLED SYR 882 MG/3.2ML	5925001520E440	Brand
ARISTADA	ARIPRAZOLE LAUROXIL IM ER SUSP PREFILLED SYR 1064 MG/3.9ML	5925001520E450	Brand

**Approval Criteria**

1 - Patient has a diagnosis of schizophrenia or schizoaffective disorder

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

2.1.1 Patient is non-adherent with oral atypical antipsychotic dosage forms

**AND**

2.1.2 Patient has established tolerability with oral aripiprazole

**OR**

2.2 Patient is unable to take oral solid alternatives

**AND**

**3** - If the patient is less than 18 years of age, the prescriber attests they are aware of FDA (Food and Drug Administration) labeling regarding use of long acting injectable antipsychotic products in patients less than 18 years of age and feels the treatment with the requested product is medically necessary (document rationale for use)

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

**Product Name: Invega Sustenna**

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
INVEGA SUSTENNA	PALIPERIDONE PALMITATE ER SUSP PREF SYR 39 MG/0.25ML	5907005010E626	Brand
INVEGA SUSTENNA	PALIPERIDONE PALMITATE ER SUSP PREF SYR 78 MG/0.5ML	5907005010E629	Brand
INVEGA SUSTENNA	PALIPERIDONE PALMITATE ER SUSP PREF SYR 117 MG/0.75ML	5907005010E632	Brand
INVEGA SUSTENNA	PALIPERIDONE PALMITATE ER SUSP PREF SYR 156 MG/ML	5907005010E635	Brand
INVEGA SUSTENNA	PALIPERIDONE PALMITATE ER SUSP PREF SYR 234 MG/1.5ML	5907005010E638	Brand

**Approval Criteria**

**1** - Patient has a diagnosis of schizophrenia or schizoaffective disorder

**AND**

**2** - ONE of the following:

**2.1** BOTH of the following:

**2.1.1** Patient is non-adherent with oral atypical antipsychotic dosage forms

**AND**

**2.1.2** Patient has established tolerability with oral paliperidone or oral risperidone

**OR**

**2.2** Patient is unable to take oral solid alternatives

**AND**

**3** - If the patient is less than 18 years of age, the prescriber attests they are aware of FDA (Food and Drug Administration) labeling regarding use of long acting injectable antipsychotic products in patients less than 18 years of age and feels the treatment with the requested product is medically necessary (document rationale for use)

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

Product Name: Invega Trinza			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
INVEGA TRINZA	PALIPERIDONE PALMITATE ER SUSP PEF SYR 273 MG/0.88ML	5907005010E643	Brand
INVEGA TRINZA	PALIPERIDONE PALMITATE ER SUSP PEF SYR 410 MG/1.32ML	5907005010E647	Brand
INVEGA TRINZA	PALIPERIDONE PALMITATE ER SUSP PEF SYR 546 MG/1.75ML	5907005010E651	Brand
INVEGA TRINZA	PALIPERIDONE PALMITATE ER SUSP PEF SYR 819 MG/2.63ML	5907005010E655	Brand
<b>Approval Criteria</b>			

1 - Patient has a diagnosis of schizophrenia or schizoaffective disorder

**AND**

2 - Patient has been treated with Invega Sustenna for at least 4 months

**AND**

3 - If the patient is less than 18 years of age, the prescriber attests they are aware of FDA (Food and Drug Administration) labeling regarding use of long acting injectable antipsychotic products in patients less than 18 years of age and feels the treatment with the requested product is medically necessary (document rationale for use)

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

Product Name: Invega Hafyera

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
INVEGA HAFYERA	PALIPERIDONE PALMITATE ER SUSP PEF SYR 1,092 MG/3.5ML	5907005010E670	Brand
INVEGA HAFYERA	PALIPERIDONE PALMITATE ER SUSP PEF SYR 1,560 MG/5ML	5907005010E675	Brand

**Approval Criteria**

1 - Patient has a diagnosis of schizophrenia or schizoaffective disorder

**AND**

2 - Patient has been treated with Invega Sustenna or Invega Trinza for at least 6 months

**AND**

**3** - If the patient is less than 18 years of age, the prescriber attests they are aware of FDA (Food and Drug Administration) labeling regarding use of long acting injectable antipsychotic products in patients less than 18 years of age and feels the treatment with the requested product is medically necessary (document rationale for use)

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

Product Name: Perseris			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PERSERIS	RISPERIDONE SUBCUTANEOUS FOR ER SUSP PREFILLED SYR 90 MG	5907007000E420	Brand
PERSERIS	RISPERIDONE SUBCUTANEOUS FOR ER SUSP PREFILLED SYR 120 MG	5907007000E430	Brand

**Approval Criteria**

**1** - Patient has a diagnosis of schizophrenia or schizoaffective disorder

**AND**

**2** - ONE of the following:

**2.1** BOTH of the following:

**2.1.1** Patient is non-adherent with oral atypical antipsychotic dosage forms

**AND**

**2.1.2** Patient has established tolerability with oral risperidone

**OR**

**2.2** Patient is unable to take oral solid alternatives

**AND**

**3** - If the patient is less than 18 years of age, the prescriber attests they are aware of FDA (Food and Drug Administration) labeling regarding use of long acting injectable antipsychotic products in patients less than 18 years of age and feels the treatment with the requested product is medically necessary (document rationale for use)

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

Product Name: Brand Risperdal Consta

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
RISPERDAL CONSTA	RISPERIDONE MICROSPHERES FOR IM EXTENDED REL SUSP 12.5 MG	5907007010G210	Brand
RISPERDAL CONSTA	RISPERIDONE MICROSPHERES FOR IM EXTENDED REL SUSP 25 MG	5907007010G220	Brand
RISPERDAL CONSTA	RISPERIDONE MICROSPHERES FOR IM EXTENDED REL SUSP 37.5 MG	5907007010G230	Brand
RISPERDAL CONSTA	RISPERIDONE MICROSPHERES FOR IM EXTENDED REL SUSP 50 MG	5907007010G240	Brand

**Approval Criteria**

**1** - Patient has ONE of the following diagnoses:

- Schizophrenia or schizoaffective disorder

<ul style="list-style-type: none"> <li>• Bipolar disorder</li> </ul>	
<b>AND</b>	
2 - ONE of the following:	
2.1 BOTH of the following:	
2.1.1 Patient is non-adherent with oral atypical antipsychotic dosage forms	
<b>AND</b>	
2.1.2 Patient has established tolerability with oral risperidone	
<b>OR</b>	
2.2 Patient is unable to take oral solid alternatives	
<b>AND</b>	
3 - If the patient is less than 18 years of age, the prescriber attests they are aware of FDA (Food and Drug Administration) labeling regarding use of long acting injectable antipsychotic products in patients less than 18 years of age and feels the treatment with the requested product is medically necessary (document rationale for use)	
Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.

Product Name: Rykindo, generic risperidone ER IM			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RYKINDO	RISPERIDONE FOR IM EXTENDED RELEASE SUSPENSION 25 MG	5907007000G220	Brand



RYKINDO	RISPERIDONE FOR IM EXTENDED RELEASE SUSPENSION 37.5 MG	5907007000G230	Brand
RYKINDO	RISPERIDONE FOR IM EXTENDED RELEASE SUSPENSION 50 MG	5907007000G240	Brand
RISPERIDONE ER	RISPERIDONE MICROSPHERES FOR IM EXTENDED REL SUSP 12.5 MG	5907007010G210	Generic
RISPERIDONE ER	RISPERIDONE MICROSPHERES FOR IM EXTENDED REL SUSP 25 MG	5907007010G220	Generic
RISPERIDONE ER	RISPERIDONE MICROSPHERES FOR IM EXTENDED REL SUSP 37.5 MG	5907007010G230	Generic
RISPERIDONE ER	RISPERIDONE MICROSPHERES FOR IM EXTENDED REL SUSP 50 MG	5907007010G240	Generic

**Approval Criteria**

1 - Patient has ONE of the following diagnoses:

- Schizophrenia or schizoaffective disorder
- Bipolar disorder

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

- Patient is non-adherent with oral atypical antipsychotic dosage forms
- Patient has established tolerability with oral risperidone

**OR**

2.2 Patient is unable to take oral solid alternatives

**AND**

3 - History of failure, contraindication, or intolerance to Risperdal Consta

**AND**

4 - If the patient is less than 18 years of age, the prescriber attests they are aware of FDA (Food and Drug Administration) labeling regarding use of long acting injectable antipsychotic products in patients less than 18 years of age and feels the treatment with the requested product is medically necessary (Document rationale for use)

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

**Product Name: Uzedy**

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
UZEDY	RISPERIDONE SUBCUTANEOUS ER SUSP PREF SYR 50 MG/0.14ML	5907007000E610	Brand
UZEDY	RISPERIDONE SUBCUTANEOUS ER SUSP PREF SYR 75 MG/0.21ML	5907007000E618	Brand
UZEDY	RISPERIDONE SUBCUTANEOUS ER SUSP PREF SYR 100 MG/0.28ML	5907007000E626	Brand
UZEDY	RISPERIDONE SUBCUTANEOUS ER SUSP PREF SYR 125 MG/0.35ML	5907007000E634	Brand
UZEDY	RISPERIDONE SUBCUTANEOUS ER SUSP PREF SYR 150 MG/0.42ML	5907007000E642	Brand
UZEDY	RISPERIDONE SUBCUTANEOUS ER SUSP PREF SYR 200 MG/0.56ML	5907007000E658	Brand
UZEDY	RISPERIDONE SUBCUTANEOUS ER SUSP PREF SYR 250 MG/0.7ML	5907007000E674	Brand

**Approval Criteria**

1 - Patient has a diagnosis of schizophrenia or schizoaffective disorder

**AND**

**2 - ONE of the following:**

**2.1 BOTH of the following:**

- Patient is non-adherent with oral atypical antipsychotic dosage forms
- Patient has established tolerability with oral risperidone

**OR**

**2.2 Patient is unable to take oral solid alternatives**

**AND**

**3 - History of failure, contraindication, or intolerance to BOTH of the following:**

- Perseris
- Risperdal Consta

**AND**

**4 - If the patient is less than 18 years of age, the prescriber attests they are aware of FDA (Food and Drug Administration) labeling regarding use of long acting injectable antipsychotic products in patients less than 18 years of age and feels the treatment with the requested product is medically necessary (Document rationale for use)**

Notes	For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.
-------	--

Product Name: Brand Abilify, aripiprazole oral soln, aripiprazole ODT, Brand Clozaril, generic ziprasidone caps, Brand Geodon caps, Brand Haldol Decanoate, generic paliperidone ER, Brand Invega, Brand Latuda, loxapine, Brand Lithobid, fluphenazine tabs/inj, Brand Risperdal, generic risperidone soln, Brand Saphris, generic asenapine SL, Secuado, generic olanzapine/fluoxetine, Brand Symbyax, Brand Seroquel, generic quetiapine ER, Brand Seroquel XR, chlorpromazine tabs, perphenazine/amitriptyline, Versacloz, Brand Zyprexa, Brand Zyprexa Zydis, generic haloperidol lactate inj

Diagnosis	Non-Preferred Drugs**
Approval Length	12 month(s)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Guideline Type		Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic	
ABILIFY	ARIPIPRAZOLE TAB 2 MG	59250015000305	Brand	
ABILIFY	ARIPIPRAZOLE TAB 5 MG	59250015000310	Brand	
ABILIFY	ARIPIPRAZOLE TAB 10 MG	59250015000320	Brand	
ABILIFY	ARIPIPRAZOLE TAB 15 MG	59250015000330	Brand	
ABILIFY	ARIPIPRAZOLE TAB 20 MG	59250015000340	Brand	
ABILIFY	ARIPIPRAZOLE TAB 30 MG	59250015000350	Brand	
ARIPIPRAZOLE	ARIPIPRAZOLE ORAL SOLUTION 1 MG/ML	59250015002020	Generic	
ARIPIPRAZOLE ODT	ARIPIPRAZOLE ORALLY DISINTEGRATING TAB 10 MG	59250015007220	Generic	
ARIPIPRAZOLE ODT	ARIPIPRAZOLE ORALLY DISINTEGRATING TAB 15 MG	59250015007230	Generic	
CLOZARIL	CLOZAPINE TAB 25 MG	59152020000320	Brand	
CLOZARIL	CLOZAPINE TAB 50 MG	59152020000325	Brand	
CLOZARIL	CLOZAPINE TAB 100 MG	59152020000330	Brand	
CLOZARIL	CLOZAPINE TAB 200 MG	59152020000340	Brand	
ZIPRASIDONE HYDROCHLORIDE	ZIPRASIDONE HCL CAP 20 MG	59400085100120	Generic	
GEODON	ZIPRASIDONE HCL CAP 20 MG	59400085100120	Brand	
ZIPRASIDONE HCL	ZIPRASIDONE HCL CAP 20 MG	59400085100120	Generic	
ZIPRASIDONE HYDROCHLORIDE	ZIPRASIDONE HCL CAP 40 MG	59400085100130	Generic	
GEODON	ZIPRASIDONE HCL CAP 40 MG	59400085100130	Brand	
ZIPRASIDONE HCL	ZIPRASIDONE HCL CAP 40 MG	59400085100130	Generic	
ZIPRASIDONE HYDROCHLORIDE	ZIPRASIDONE HCL CAP 60 MG	59400085100140	Generic	
GEODON	ZIPRASIDONE HCL CAP 60 MG	59400085100140	Brand	
ZIPRASIDONE HCL	ZIPRASIDONE HCL CAP 60 MG	59400085100140	Generic	
ZIPRASIDONE HYDROCHLORIDE	ZIPRASIDONE HCL CAP 80 MG	59400085100150	Generic	
GEODON	ZIPRASIDONE HCL CAP 80 MG	59400085100150	Brand	
ZIPRASIDONE HCL	ZIPRASIDONE HCL CAP 80 MG	59400085100150	Generic	
HALDOL DECANOATE 50	HALOPERIDOL DECANOATE IM SOLN 50 MG/ML	59100010302010	Brand	

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HALDOL DECANOATE 100	HALOPERIDOL DECANOATE IM SOLN 100 MG/ML	59100010302020	Brand
PALIPERIDONE ER	PALIPERIDONE TAB ER 24HR 1.5 MG	59070050007505	Generic
INVEGA	PALIPERIDONE TAB ER 24HR 1.5 MG	59070050007505	Brand
PALIPERIDONE ER	PALIPERIDONE TAB ER 24HR 3 MG	59070050007510	Generic
INVEGA	PALIPERIDONE TAB ER 24HR 3 MG	59070050007510	Brand
PALIPERIDONE ER	PALIPERIDONE TAB ER 24HR 6 MG	59070050007520	Generic
INVEGA	PALIPERIDONE TAB ER 24HR 6 MG	59070050007520	Brand
PALIPERIDONE ER	PALIPERIDONE TAB ER 24HR 9 MG	59070050007530	Generic
INVEGA	PALIPERIDONE TAB ER 24HR 9 MG	59070050007530	Brand
LATUDA	LURASIDONE HCL TAB 20 MG	59400023100310	Brand
LATUDA	LURASIDONE HCL TAB 40 MG	59400023100320	Brand
LATUDA	LURASIDONE HCL TAB 60 MG	59400023100330	Brand
LATUDA	LURASIDONE HCL TAB 80 MG	59400023100340	Brand
LATUDA	LURASIDONE HCL TAB 120 MG	59400023100350	Brand
LOXAPINE	LOXAPINE SUCCINATE CAP 5 MG	59154020200105	Generic
LOXAPINE SUCCINATE	LOXAPINE SUCCINATE CAP 5 MG	59154020200105	Generic
LOXAPINE	LOXAPINE SUCCINATE CAP 10 MG	59154020200110	Generic
LOXAPINE SUCCINATE	LOXAPINE SUCCINATE CAP 10 MG	59154020200110	Generic
LOXAPINE	LOXAPINE SUCCINATE CAP 25 MG	59154020200115	Generic
LOXAPINE SUCCINATE	LOXAPINE SUCCINATE CAP 25 MG	59154020200115	Generic
LOXAPINE	LOXAPINE SUCCINATE CAP 50 MG	59154020200120	Generic
LOXAPINE SUCCINATE	LOXAPINE SUCCINATE CAP 50 MG	59154020200120	Generic
LITHOBID	LITHIUM CARBONATE TAB ER 300 MG	59500010100405	Brand
FLUPHENAZINE HYDROCHLORIDE	FLUPHENAZINE HCL TAB 1 MG	59200025100305	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLUPHENAZINE HCL	FLUPHENAZINE HCL TAB 1 MG	59200025100305	Generic
FLUPHENAZINE HYDROCHLORIDE	FLUPHENAZINE HCL TAB 2.5 MG	59200025100310	Generic
FLUPHENAZINE HYDROCHLORIDE	FLUPHENAZINE HCL TAB 5 MG	59200025100315	Generic
FLUPHENAZINE HYDROCHLORIDE	FLUPHENAZINE HCL TAB 10 MG	59200025100320	Generic
RISPERDAL	RISPERIDONE TAB 0.5 MG	59070070000306	Brand
RISPERDAL	RISPERIDONE TAB 1 MG	59070070000310	Brand
RISPERDAL	RISPERIDONE TAB 2 MG	59070070000320	Brand
RISPERDAL	RISPERIDONE TAB 3 MG	59070070000330	Brand
RISPERDAL	RISPERIDONE TAB 4 MG	59070070000340	Brand
RISPERIDONE	RISPERIDONE SOLN 1 MG/ML	59070070002010	Generic
RISPERDAL	RISPERIDONE SOLN 1 MG/ML	59070070002010	Brand
SAPHRIS	ASENAPINE MALEATE SL TAB 2.5 MG (BASE EQUIV)	59155015100710	Brand
ASENAPINE MALEATE SL	ASENAPINE MALEATE SL TAB 2.5 MG (BASE EQUIV)	59155015100710	Generic
SAPHRIS	ASENAPINE MALEATE SL TAB 5 MG (BASE EQUIV)	59155015100720	Brand
ASENAPINE MALEATE SL	ASENAPINE MALEATE SL TAB 5 MG (BASE EQUIV)	59155015100720	Generic
SAPHRIS	ASENAPINE MALEATE SL TAB 10 MG (BASE EQUIV)	59155015100730	Brand
ASENAPINE MALEATE SL	ASENAPINE MALEATE SL TAB 10 MG (BASE EQUIV)	59155015100730	Generic
SECUADO	ASENAPINE TD PATCH 24 HR 3.8 MG/24HR	59155015008520	Brand
SECUADO	ASENAPINE TD PATCH 24 HR 5.7 MG/24HR	59155015008530	Brand
SECUADO	ASENAPINE TD PATCH 24 HR 7.6 MG/24HR	59155015008540	Brand
OLANZAPINE/FLUOXETINE	OLANZAPINE-FLUOXETINE HCL CAP 3-25 MG	62995002500110	Generic
SYMBYAX	OLANZAPINE-FLUOXETINE HCL CAP 3-25 MG	62995002500110	Brand
OLANZAPINE/FLUOXETINE	OLANZAPINE-FLUOXETINE HCL CAP 6-25 MG	62995002500120	Generic
SYMBYAX	OLANZAPINE-FLUOXETINE HCL CAP 6-25 MG	62995002500120	Brand
OLANZAPINE/FLUOXETINE	OLANZAPINE-FLUOXETINE HCL CAP 6-50 MG	62995002500125	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OLANZAPINE/FLUOXETINE	OLANZAPINE-FLUOXETINE HCL CAP 12-25 MG	62995002500140	Generic
OLANZAPINE/FLUOXETINE	OLANZAPINE-FLUOXETINE HCL CAP 12-50 MG	62995002500145	Generic
SEROQUEL	QUETIAPINE FUMARATE TAB 25 MG	59153070100310	Brand
SEROQUEL	QUETIAPINE FUMARATE TAB 50 MG	59153070100314	Brand
SEROQUEL	QUETIAPINE FUMARATE TAB 100 MG	59153070100320	Brand
SEROQUEL	QUETIAPINE FUMARATE TAB 200 MG	59153070100330	Brand
SEROQUEL	QUETIAPINE FUMARATE TAB 300 MG	59153070100340	Brand
SEROQUEL	QUETIAPINE FUMARATE TAB 400 MG	59153070100350	Brand
QUETIAPINE FUMARATE ER	QUETIAPINE FUMARATE TAB ER 24HR 50 MG	59153070107505	Generic
SEROQUEL XR	QUETIAPINE FUMARATE TAB ER 24HR 50 MG	59153070107505	Brand
QUETIAPINE FUMARATE ER	QUETIAPINE FUMARATE TAB ER 24HR 150 MG	59153070107515	Generic
SEROQUEL XR	QUETIAPINE FUMARATE TAB ER 24HR 150 MG	59153070107515	Brand
QUETIAPINE FUMARATE ER	QUETIAPINE FUMARATE TAB ER 24HR 200 MG	59153070107520	Generic
SEROQUEL XR	QUETIAPINE FUMARATE TAB ER 24HR 200 MG	59153070107520	Brand
QUETIAPINE FUMARATE ER	QUETIAPINE FUMARATE TAB ER 24HR 300 MG	59153070107530	Generic
SEROQUEL XR	QUETIAPINE FUMARATE TAB ER 24HR 300 MG	59153070107530	Brand
QUETIAPINE FUMARATE ER	QUETIAPINE FUMARATE TAB ER 24HR 400 MG	59153070107540	Generic
SEROQUEL XR	QUETIAPINE FUMARATE TAB ER 24HR 400 MG	59153070107540	Brand
CHLORPROMAZINE HCL	CHLORPROMAZINE HCL TAB 10 MG	59200015100305	Generic
CHLORPROMAZINE HYDROCHLORIDE	CHLORPROMAZINE HCL TAB 10 MG	59200015100305	Generic
CHLORPROMAZINE HCL	CHLORPROMAZINE HCL TAB 25 MG	59200015100310	Generic
CHLORPROMAZINE HYDROCHLORIDE	CHLORPROMAZINE HCL TAB 25 MG	59200015100310	Generic
CHLORPROMAZINE HCL	CHLORPROMAZINE HCL TAB 50 MG	59200015100315	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CHLORPROMAZINE HYDROCHLORIDE	CHLORPROMAZINE HCL TAB 50 MG	59200015100315	Generic
CHLORPROMAZINE HCL	CHLORPROMAZINE HCL TAB 100 MG	59200015100320	Generic
CHLORPROMAZINE HYDROCHLORIDE	CHLORPROMAZINE HCL TAB 100 MG	59200015100320	Generic
CHLORPROMAZINE HCL	CHLORPROMAZINE HCL TAB 200 MG	59200015100325	Generic
CHLORPROMAZINE HYDROCHLORIDE	CHLORPROMAZINE HCL TAB 200 MG	59200015100325	Generic
PERPHENAZINE/AMITRIPTYLINE	PERPHENAZINE-AMITRIPTYLINE TAB 2-10 MG	62994002600310	Generic
PERPHENAZINE/AMITRIPTYLINE	PERPHENAZINE-AMITRIPTYLINE TAB 2-25 MG	62994002600315	Generic
PERPHENAZINE/AMITRIPTYLINE	PERPHENAZINE-AMITRIPTYLINE TAB 4-10 MG	62994002600320	Generic
PERPHENAZINE/AMITRIPTYLINE	PERPHENAZINE-AMITRIPTYLINE TAB 4-25 MG	62994002600325	Generic
PERPHENAZINE/AMITRIPTYLINE	PERPHENAZINE-AMITRIPTYLINE TAB 4-50 MG	62994002600330	Generic
VERSACLOZ	CLOZAPINE SUSP 50 MG/ML	59152020001820	Brand
ZYPREXA	OLANZAPINE TAB 2.5 MG	59157060000305	Brand
ZYPREXA	OLANZAPINE TAB 5 MG	59157060000310	Brand
ZYPREXA	OLANZAPINE TAB 7.5 MG	59157060000315	Brand
ZYPREXA	OLANZAPINE TAB 10 MG	59157060000320	Brand
ZYPREXA	OLANZAPINE TAB 15 MG	59157060000330	Brand
ZYPREXA	OLANZAPINE TAB 20 MG	59157060000340	Brand
ZYPREXA ZYDIS	OLANZAPINE ORALLY DISINTEGRATING TAB 5 MG	59157060007210	Brand
ZYPREXA ZYDIS	OLANZAPINE ORALLY DISINTEGRATING TAB 10 MG	59157060007220	Brand
ZYPREXA ZYDIS	OLANZAPINE ORALLY DISINTEGRATING TAB 15 MG	59157060007230	Brand
ZYPREXA ZYDIS	OLANZAPINE ORALLY DISINTEGRATING TAB 20 MG	59157060007240	Brand
FLUPHENAZINE HCL	FLUPHENAZINE HCL INJ 2.5 MG/ML	59200025102005	Generic
HALOPERIDOL LACTATE	HALOPERIDOL LACTATE INJ 5 MG/ML	59100010202005	Generic

**Approval Criteria**



**1** - ALL of the following:

**1.1** ONE of the following:

**1.1.1** Patient has a history of failure, contraindication, or intolerance to at least FOUR of the following:

- Aripiprazole oral (generic Abilify)
- Aripiprazole injectable formulations (Abilify Maintena, Aristada, Aristada Initio)
- Clozapine/clozapine ODT
- Lurasidone
- Olanzapine/olanzapine ODT
- Paliperidone oral (does not apply to requests for paliperidone ER tablets)\*\*\*
- Paliperidone injectable formulations (Invega Sustenna, Invega Trinza, Hafyera)
- Quetiapine
- Risperidone/risperidone ODT
- Risperidone injectable formulations (Perseris, Risperdal Consta)

**OR**

**1.1.2** There are no preferred formulary alternatives for the requested drug

**AND**

**1.2** If the request is for a multi-source brand medication (i.e., MSC O), ONE of the following:

**1.2.1** BOTH of the following:

**1.2.1.1** The brand is being requested because of an adverse reaction, allergy, or sensitivity to the generic, and the prescriber must attest to submitting the FDA (Food and Drug Administration) MedWatch Form for allergic reactions to the medications

**AND**

**1.2.1.2** If there are generic product(s), the patient has tried at least three (if available)

**OR**

**1.2.2** ONE of the following:

**1.2.2.1** The brand is being requested due to a therapeutic failure with the generic (please provide reason for therapeutic failure)

**OR**

**1.2.2.2** The brand is being requested because transition to the generic could result in destabilization of the patient (rationale must be provided)

**OR**

**1.2.2.3** Special clinical circumstances exist that preclude the use of the generic equivalent of the multi-source brand medication for the patient (rationale must be provided)

**AND**

**1.3** ONE of the following:

**1.3.1** The requested drug must be used for an FDA-approved indication

**OR**

**1.3.2** The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- FDA approved indications and limits
- Published practice guidelines and treatment protocols
- Comparative data evaluating the efficacy, type, and frequency of side effects and potential drug interactions among alternative products as well as the risks, benefits, and potential patient outcomes
- Drug Facts and Comparisons
- American Hospital Formulary Service Drug Information
- United States Pharmacopeia - Drug Information
- DRUGDEX Information System
- UpToDate
- MicroMedex
- Peer-reviewed medical literature, including randomized clinical trials, outcomes, research data, and pharmaco-economic studies
- Other drug reference resources

**AND**

**1.4** ONE of the following:

**1.4.1** The drug is being prescribed within the manufacturer's published dosing guidelines

**OR**

**1.4.2** The drug falls within dosing guidelines found in ONE of the following compendia of current literature:

- FDA approved indications and limits
- Published practice guidelines and treatment protocols
- Comparative data evaluating the efficacy, type, and frequency of side effects and potential drug interactions among alternative products as well as the risks, benefits, and potential patient outcomes
- Drug Facts and Comparisons
- American Hospital Formulary Service Drug Information
- United States Pharmacopeia - Drug Information
- DRUGDEX Information System
- UpToDate
- MicroMedex
- Peer-reviewed medical literature, including randomized clinical trials, outcomes, research data, and pharmacoeconomic studies
- Other drug reference resources

**AND**

**1.5** The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plans' program\*

**OR**

**2** - The requested medication is a behavioral health medication and ONE of the following:

**2.1** The patient has been receiving treatment with the requested non-preferred behavioral health medication and is new to the plan (enrollment effective date within the past 90 days)

**OR**

<p><b>2.2</b> The patient is currently receiving treatment with the requested non-preferred behavioral health medication in the hospital and must continue upon discharge</p>	
<p>Notes</p>	<p>For group code ACUAZPH, antipsychotic medications for patients with co-existing behavioral health conditions should be provided through the Regional Behavioral Health Authority (RBHA). Examples of behavioral health conditions include, but are not limited to: anxiety, depression, obsessive-compulsive disorder, and panic disorder.</p> <p>*Medications used solely for anti-obesity/weight loss, cosmetic (e.g., alopecia, actinic keratosis, vitiligo), erectile dysfunction, and sexual dysfunction purposes are NOT medically accepted indications and are NOT recognized as a covered benefit. Erectile dysfunction drugs (Cialis/Tadalafil) are covered for clinical diagnoses other than ED.</p> <p>**PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC</a></p> <p>***If the request is for generic paliperidone ER tablets, please omit "paliperidone oral" as an alternative.</p>

## 2 . Revision History

Date	Notes
9/24/2024	Added age criterion to Abilify Mycite initial criteria section. Cleaned up GPIs for fluphenazine hcl inj. Removed Lybalvi products as targets from this guideline as they will be part of a separate guideline. Removed Zyprexa Relprevv products as targets as these are medical.

Anxiolytics



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140805
<b>Guideline Name</b>	Anxiolytics
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/1/2023
-----------------	----------

## 1 . Criteria

Product Name: buspirone, Brand Xanax tabs, Brand Xanax XR, generic alprazolam tabs, alprazolam ODT, generic alprazolam ER/XR, chlordiazepoxide, generic clorazepate dipotassium, Brand Tranxene T, Brand Valium tabs, generic diazepam tabs, diazepam conc, diazepam intensol, generic lorazepam, Brand Ativan, lorazepam conc, lorazepam intensol, oxazepam, generic clonazepam tabs, Brand Klonopin tabs, clonazepam ODT, alprazolam intensol, Loreev XR			
Diagnosis	Requests for patients less than 6 years of age		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BUSPIRONE HYDROCHLORIDE	BUSPIRONE HCL TAB 5 MG	57200005100310	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BUSPIRONE HYDROCHLORIDE	BUSPIRONE HCL TAB 7.5 MG	57200005100315	Generic
BUSPIRONE HYDROCHLORIDE	BUSPIRONE HCL TAB 10 MG	57200005100320	Generic
BUSPIRONE HYDROCHLORIDE	BUSPIRONE HCL TAB 15 MG	57200005100330	Generic
BUSPIRONE HCL	BUSPIRONE HCL TAB 15 MG	57200005100330	Generic
BUSPIRONE HYDROCHLORIDE	BUSPIRONE HCL TAB 30 MG	57200005100340	Generic
BUSPIRONE HCL	BUSPIRONE HCL TAB 30 MG	57200005100340	Generic
XANAX	ALPRAZOLAM TAB 0.25 MG	57100010000305	Brand
XANAX	ALPRAZOLAM TAB 0.5 MG	57100010000310	Brand
XANAX	ALPRAZOLAM TAB 1 MG	57100010000315	Brand
XANAX	ALPRAZOLAM TAB 2 MG	57100010000320	Brand
XANAX XR	ALPRAZOLAM TAB ER 24HR 0.5 MG	57100010007505	Brand
XANAX XR	ALPRAZOLAM TAB ER 24HR 1 MG	57100010007510	Brand
XANAX XR	ALPRAZOLAM TAB ER 24HR 2 MG	57100010007520	Brand
XANAX XR	ALPRAZOLAM TAB ER 24HR 3 MG	57100010007530	Brand
ALPRAZOLAM	ALPRAZOLAM TAB 0.25 MG	57100010000305	Generic
ALPRAZOLAM	ALPRAZOLAM TAB 0.5 MG	57100010000310	Generic
ALPRAZOLAM	ALPRAZOLAM TAB 1 MG	57100010000315	Generic
ALPRAZOLAM	ALPRAZOLAM TAB 2 MG	57100010000320	Generic
ALPRAZOLAM ODT	ALPRAZOLAM ORALLY DISINTEGRATING TAB 0.25 MG	57100010007205	Generic
ALPRAZOLAM ODT	ALPRAZOLAM ORALLY DISINTEGRATING TAB 0.5 MG	57100010007210	Generic
ALPRAZOLAM ODT	ALPRAZOLAM ORALLY DISINTEGRATING TAB 1 MG	57100010007215	Generic
ALPRAZOLAM ODT	ALPRAZOLAM ORALLY DISINTEGRATING TAB 2 MG	57100010007220	Generic
ALPRAZOLAM ER	ALPRAZOLAM TAB ER 24HR 0.5 MG	57100010007505	Generic
ALPRAZOLAM XR	ALPRAZOLAM TAB ER 24HR 0.5 MG	57100010007505	Generic
ALPRAZOLAM ER	ALPRAZOLAM TAB ER 24HR 1 MG	57100010007510	Generic
ALPRAZOLAM XR	ALPRAZOLAM TAB ER 24HR 1 MG	57100010007510	Generic
ALPRAZOLAM ER	ALPRAZOLAM TAB ER 24HR 2 MG	57100010007520	Generic
ALPRAZOLAM XR	ALPRAZOLAM TAB ER 24HR 2 MG	57100010007520	Generic
ALPRAZOLAM ER	ALPRAZOLAM TAB ER 24HR 3 MG	57100010007530	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ALPRAZOLAM XR	ALPRAZOLAM TAB ER 24HR 3 MG	57100010007530	Generic
CHLORDIAZEPOXIDE HCL	CHLORDIAZEPOXIDE HCL CAP 5 MG	57100020100105	Generic
CHLORDIAZEPOXIDE HYDROCHLORIDE	CHLORDIAZEPOXIDE HCL CAP 5 MG	57100020100105	Generic
CHLORDIAZEPOXIDE HCL	CHLORDIAZEPOXIDE HCL CAP 10 MG	57100020100110	Generic
CHLORDIAZEPOXIDE HYDROCHLORIDE	CHLORDIAZEPOXIDE HCL CAP 10 MG	57100020100110	Generic
CHLORDIAZEPOXIDE HYDROCHLORIDE	CHLORDIAZEPOXIDE HCL CAP 25 MG	57100020100115	Generic
CLORAZEPATE DIPOTASSIUM	CLORAZEPATE DIPOTASSIUM TAB 3.75 MG	57100030100305	Generic
CLORAZEPATE DIPOTASSIUM	CLORAZEPATE DIPOTASSIUM TAB 7.5 MG	57100030100310	Generic
CLORAZEPATE DIPOTASSIUM	CLORAZEPATE DIPOTASSIUM TAB 15 MG	57100030100320	Generic
TRANXENE T	CLORAZEPATE DIPOTASSIUM TAB 7.5 MG	57100030100310	Brand
VALIUM	DIAZEPAM TAB 2 MG	57100040000305	Brand
DIAZEPAM	DIAZEPAM TAB 2 MG	57100040000305	Generic
VALIUM	DIAZEPAM TAB 5 MG	57100040000310	Brand
DIAZEPAM	DIAZEPAM TAB 5 MG	57100040000310	Generic
VALIUM	DIAZEPAM TAB 10 MG	57100040000315	Brand
DIAZEPAM	DIAZEPAM TAB 10 MG	57100040000315	Generic
DIAZEPAM INTENSOL	DIAZEPAM CONC 5 MG/ML	57100040001310	Generic
DIAZEPAM	DIAZEPAM CONC 5 MG/ML	57100040001310	Generic
DIAZEPAM	DIAZEPAM ORAL SOLN 1 MG/ML	57100040002001	Generic
LORAZEPAM	LORAZEPAM TAB 0.5 MG	57100060000305	Generic
ATIVAN	LORAZEPAM TAB 0.5 MG	57100060000305	Brand
LORAZEPAM	LORAZEPAM TAB 1 MG	57100060000310	Generic
ATIVAN	LORAZEPAM TAB 1 MG	57100060000310	Brand
LORAZEPAM	LORAZEPAM TAB 2 MG	57100060000315	Generic
ATIVAN	LORAZEPAM TAB 2 MG	57100060000315	Brand
LORAZEPAM	LORAZEPAM CONC 2 MG/ML	57100060001320	Generic
LORAZEPAM INTENSOL	LORAZEPAM CONC 2 MG/ML	57100060001320	Generic
OXAZEPAM	OXAZEPAM CAP 10 MG	57100070000105	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXAZEPAM	OXAZEPAM CAP 15 MG	57100070000110	Generic
OXAZEPAM	OXAZEPAM CAP 30 MG	57100070000115	Generic
CLONAZEPAM	CLONAZEPAM TAB 0.5 MG	72100010000305	Generic
KLONOPIN	CLONAZEPAM TAB 0.5 MG	72100010000305	Brand
CLONAZEPAM	CLONAZEPAM TAB 1 MG	72100010000310	Generic
KLONOPIN	CLONAZEPAM TAB 1 MG	72100010000310	Brand
CLONAZEPAM	CLONAZEPAM TAB 2 MG	72100010000315	Generic
KLONOPIN	CLONAZEPAM TAB 2 MG	72100010000315	Brand
CLONAZEPAM ODT	CLONAZEPAM ORALLY DISINTEGRATING TAB 0.125 MG	72100010007210	Generic
CLONAZEPAM ODT	CLONAZEPAM ORALLY DISINTEGRATING TAB 0.25 MG	72100010007215	Generic
CLONAZEPAM ODT	CLONAZEPAM ORALLY DISINTEGRATING TAB 0.5 MG	72100010007220	Generic
CLONAZEPAM ODT	CLONAZEPAM ORALLY DISINTEGRATING TAB 1 MG	72100010007230	Generic
CLONAZEPAM ODT	CLONAZEPAM ORALLY DISINTEGRATING TAB 2 MG	72100010007240	Generic
ALPRAZOLAM INTENSOL	ALPRAZOLAM CONC 1 MG/ML	57100010001310	Generic
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 1 MG	5710006000F310	Brand
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 1.5 MG	5710006000F315	Brand
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 2 MG	5710006000F320	Brand
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 3 MG	5710006000F330	Brand

**Approval Criteria**

1 - The patient is unresponsive to other treatment modalities, unless contraindicated (i.e., other medications or behavioral modification attempted)

**AND**

2 - The physician attests that the requested medication is medically necessary (document rationale for use)



Product Name: Loreev XR			
Diagnosis	Requests for Patients 6 years of age and older		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 1 MG	5710006000F310	Brand
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 1.5 MG	5710006000F315	Brand
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 2 MG	5710006000F320	Brand
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 3 MG	5710006000F330	Brand
<p><b>Approval Criteria</b></p> <p>1 - Trial and failure, or contraindication to generic lorazepam</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - The physician attests that the requested medication is medically necessary (document rationale for use)</p>			

Product Name: buspirone, Brand Xanax tabs, Brand Xanax XR, generic alprazolam tabs, alprazolam ODT, generic alprazolam ER/XR, chlordiazepoxide, generic clorazepate dipotassium, Brand Tranxene T, Brand Valium tabs, generic diazepam tabs, diazepam conc, diazepam intensol, generic lorazepam, Brand Ativan, lorazepam conc, lorazepam intensol, oxazepam, generic clonazepam tabs, Brand Klonopin tabs, clonazepam ODT, alprazolam intensol, Loreev XR			
Diagnosis	Greater than 1 Anxiolytic in 30 days		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BUSPIRONE HYDROCHLORIDE	BUSPIRONE HCL TAB 5 MG	57200005100310	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BUSPIRONE HYDROCHLORIDE	BUSPIRONE HCL TAB 7.5 MG	57200005100315	Generic
BUSPIRONE HYDROCHLORIDE	BUSPIRONE HCL TAB 10 MG	57200005100320	Generic
BUSPIRONE HYDROCHLORIDE	BUSPIRONE HCL TAB 15 MG	57200005100330	Generic
BUSPIRONE HCL	BUSPIRONE HCL TAB 15 MG	57200005100330	Generic
BUSPIRONE HYDROCHLORIDE	BUSPIRONE HCL TAB 30 MG	57200005100340	Generic
BUSPIRONE HCL	BUSPIRONE HCL TAB 30 MG	57200005100340	Generic
XANAX	ALPRAZOLAM TAB 0.25 MG	57100010000305	Brand
XANAX	ALPRAZOLAM TAB 0.5 MG	57100010000310	Brand
XANAX	ALPRAZOLAM TAB 1 MG	57100010000315	Brand
XANAX	ALPRAZOLAM TAB 2 MG	57100010000320	Brand
XANAX XR	ALPRAZOLAM TAB ER 24HR 0.5 MG	57100010007505	Brand
XANAX XR	ALPRAZOLAM TAB ER 24HR 1 MG	57100010007510	Brand
XANAX XR	ALPRAZOLAM TAB ER 24HR 2 MG	57100010007520	Brand
XANAX XR	ALPRAZOLAM TAB ER 24HR 3 MG	57100010007530	Brand
ALPRAZOLAM	ALPRAZOLAM TAB 0.25 MG	57100010000305	Generic
ALPRAZOLAM	ALPRAZOLAM TAB 0.5 MG	57100010000310	Generic
ALPRAZOLAM	ALPRAZOLAM TAB 1 MG	57100010000315	Generic
ALPRAZOLAM	ALPRAZOLAM TAB 2 MG	57100010000320	Generic
ALPRAZOLAM ODT	ALPRAZOLAM ORALLY DISINTEGRATING TAB 0.25 MG	57100010007205	Generic
ALPRAZOLAM ODT	ALPRAZOLAM ORALLY DISINTEGRATING TAB 0.5 MG	57100010007210	Generic
ALPRAZOLAM ODT	ALPRAZOLAM ORALLY DISINTEGRATING TAB 1 MG	57100010007215	Generic
ALPRAZOLAM ODT	ALPRAZOLAM ORALLY DISINTEGRATING TAB 2 MG	57100010007220	Generic
ALPRAZOLAM ER	ALPRAZOLAM TAB ER 24HR 0.5 MG	57100010007505	Generic
ALPRAZOLAM XR	ALPRAZOLAM TAB ER 24HR 0.5 MG	57100010007505	Generic
ALPRAZOLAM ER	ALPRAZOLAM TAB ER 24HR 1 MG	57100010007510	Generic
ALPRAZOLAM XR	ALPRAZOLAM TAB ER 24HR 1 MG	57100010007510	Generic
ALPRAZOLAM ER	ALPRAZOLAM TAB ER 24HR 2 MG	57100010007520	Generic
ALPRAZOLAM XR	ALPRAZOLAM TAB ER 24HR 2 MG	57100010007520	Generic
ALPRAZOLAM ER	ALPRAZOLAM TAB ER 24HR 3 MG	57100010007530	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ALPRAZOLAM XR	ALPRAZOLAM TAB ER 24HR 3 MG	57100010007530	Generic
CHLORDIAZEPOXIDE HCL	CHLORDIAZEPOXIDE HCL CAP 5 MG	57100020100105	Generic
CHLORDIAZEPOXIDE HYDROCHLORIDE	CHLORDIAZEPOXIDE HCL CAP 5 MG	57100020100105	Generic
CHLORDIAZEPOXIDE HCL	CHLORDIAZEPOXIDE HCL CAP 10 MG	57100020100110	Generic
CHLORDIAZEPOXIDE HYDROCHLORIDE	CHLORDIAZEPOXIDE HCL CAP 10 MG	57100020100110	Generic
CHLORDIAZEPOXIDE HYDROCHLORIDE	CHLORDIAZEPOXIDE HCL CAP 25 MG	57100020100115	Generic
CLORAZEPATE DIPOTASSIUM	CLORAZEPATE DIPOTASSIUM TAB 3.75 MG	57100030100305	Generic
CLORAZEPATE DIPOTASSIUM	CLORAZEPATE DIPOTASSIUM TAB 7.5 MG	57100030100310	Generic
CLORAZEPATE DIPOTASSIUM	CLORAZEPATE DIPOTASSIUM TAB 15 MG	57100030100320	Generic
TRANXENE T	CLORAZEPATE DIPOTASSIUM TAB 7.5 MG	57100030100310	Brand
VALIUM	DIAZEPAM TAB 2 MG	57100040000305	Brand
DIAZEPAM	DIAZEPAM TAB 2 MG	57100040000305	Generic
VALIUM	DIAZEPAM TAB 5 MG	57100040000310	Brand
DIAZEPAM	DIAZEPAM TAB 5 MG	57100040000310	Generic
VALIUM	DIAZEPAM TAB 10 MG	57100040000315	Brand
DIAZEPAM	DIAZEPAM TAB 10 MG	57100040000315	Generic
DIAZEPAM INTENSOL	DIAZEPAM CONC 5 MG/ML	57100040001310	Generic
DIAZEPAM	DIAZEPAM CONC 5 MG/ML	57100040001310	Generic
DIAZEPAM	DIAZEPAM ORAL SOLN 1 MG/ML	57100040002001	Generic
LORAZEPAM	LORAZEPAM TAB 0.5 MG	57100060000305	Generic
ATIVAN	LORAZEPAM TAB 0.5 MG	57100060000305	Brand
LORAZEPAM	LORAZEPAM TAB 1 MG	57100060000310	Generic
ATIVAN	LORAZEPAM TAB 1 MG	57100060000310	Brand
LORAZEPAM	LORAZEPAM TAB 2 MG	57100060000315	Generic
ATIVAN	LORAZEPAM TAB 2 MG	57100060000315	Brand
LORAZEPAM	LORAZEPAM CONC 2 MG/ML	57100060001320	Generic
LORAZEPAM INTENSOL	LORAZEPAM CONC 2 MG/ML	57100060001320	Generic
OXAZEPAM	OXAZEPAM CAP 10 MG	57100070000105	Generic

OXAZEPAM	OXAZEPAM CAP 15 MG	57100070000110	Generic
OXAZEPAM	OXAZEPAM CAP 30 MG	57100070000115	Generic
CLONAZEPAM	CLONAZEPAM TAB 0.5 MG	72100010000305	Generic
KLONOPIN	CLONAZEPAM TAB 0.5 MG	72100010000305	Brand
CLONAZEPAM	CLONAZEPAM TAB 1 MG	72100010000310	Generic
KLONOPIN	CLONAZEPAM TAB 1 MG	72100010000310	Brand
CLONAZEPAM	CLONAZEPAM TAB 2 MG	72100010000315	Generic
KLONOPIN	CLONAZEPAM TAB 2 MG	72100010000315	Brand
CLONAZEPAM ODT	CLONAZEPAM ORALLY DISINTEGRATING TAB 0.125 MG	72100010007210	Generic
CLONAZEPAM ODT	CLONAZEPAM ORALLY DISINTEGRATING TAB 0.25 MG	72100010007215	Generic
CLONAZEPAM ODT	CLONAZEPAM ORALLY DISINTEGRATING TAB 0.5 MG	72100010007220	Generic
CLONAZEPAM ODT	CLONAZEPAM ORALLY DISINTEGRATING TAB 1 MG	72100010007230	Generic
CLONAZEPAM ODT	CLONAZEPAM ORALLY DISINTEGRATING TAB 2 MG	72100010007240	Generic
ALPRAZOLAM INTENSOL	ALPRAZOLAM CONC 1 MG/ML	57100010001310	Generic
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 1 MG	5710006000F310	Brand
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 1.5 MG	5710006000F315	Brand
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 2 MG	5710006000F320	Brand
LOREEV XR	LORAZEPAM CAP ER 24HR SPRINKLE 3 MG	5710006000F330	Brand

**Approval Criteria**

1 - The medication is being used to adjust the dose of the drug

**OR**

2 - The medication will be used in place of the previously prescribed drug, and not in addition to it

**OR**

**3** - The medication dosage form will be used in place of the previously prescribed medication dosage form, and not in addition to it

**OR**

**4** - The physician attests they are aware of the multiple anxiolytics prescribed to the patient and feels treatment with both medications is medically necessary (document rationale for use)

## 2 . Revision History

Date	Notes
7/13/2023	Updated Indication for Greater than 1 Anxiolytic in 30 days to remove reject number and type.

Apomorphine products (Apokyn, Kynmobi)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140890
<b>Guideline Name</b>	Apomorphine products (Apokyn, Kynmobi)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Brand Apokyn, generic apomorphine injection, Kynmobi			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
APOKYN	A POMORPHINE HCL SOLN CARTRIDGE 30 MG/3ML	7320301010E220	Brand
A POMORPHINE HYDROCHLORIDE	A POMORPHINE HCL SOLN CARTRIDGE 30 MG/3ML	7320301010E220	Generic
KYNMOBI TITRATION KIT	A POMORPHINE HCL FILM 10/15/20/25/30 MG TITRATION KIT	73203010106420	Brand
KYNMOBI	A POMORPHINE HYDROCHLORIDE FILM 10 MG	73203010108210	Brand

KYNMOBI	APOMORPHINE HYDROCHLORIDE FILM 15 MG	73203010108215	Brand
KYNMOBI	APOMORPHINE HYDROCHLORIDE FILM 20 MG	73203010108220	Brand
KYNMOBI	APOMORPHINE HYDROCHLORIDE FILM 25 MG	73203010108225	Brand
KYNMOBI	APOMORPHINE HYDROCHLORIDE FILM 30 MG	73203010108230	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting all of the following:

1.1 Diagnosis of Parkinson’s disease

**AND**

1.2 Medication will be used as intermittent treatment for OFF episodes

**AND**

1.3 Patient is currently on a stable dose of a carbidopa/levodopa-containing medication and will continue receiving treatment with a carbidopa/levodopa-containing medication while on therapy

**AND**

1.4 Patient continues to experience greater than or equal to 2 hours of OFF time per day despite optimal management of carbidopa/levodopa therapy including BOTH of the following:

- Taking carbidopa/levodopa on an empty stomach or at least one half-hour or more before or one hour after a meal or avoidance of high protein diet
- Dose and dosing interval optimization

**AND**

1.5 History of failure, contraindication, or intolerance to TWO anti-Parkinson’s disease

therapies from the following adjunctive pharmacotherapy classes (trial must be from two different classes):

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)

**AND**

**2** - Prescribed by or in consultation with a neurologist or specialist in the treatment of Parkinson's disease

Product Name: Brand Apokyn, generic apomorphine injection, Kynmobi			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
APOKYN	APOMORPHINE HCL SOLN CARTRIDGE 30 MG/3ML	7320301010E220	Brand
APOMORPHINE HYDROCHLORIDE	APOMORPHINE HCL SOLN CARTRIDGE 30 MG/3ML	7320301010E220	Generic
KYNMOBI TITRATION KIT	APOMORPHINE HCL FILM 10/15/20/25/30 MG TITRATION KIT	73203010106420	Brand
KYNMOBI	APOMORPHINE HYDROCHLORIDE FILM 10 MG	73203010108210	Brand
KYNMOBI	APOMORPHINE HYDROCHLORIDE FILM 15 MG	73203010108215	Brand
KYNMOBI	APOMORPHINE HYDROCHLORIDE FILM 20 MG	73203010108220	Brand
KYNMOBI	APOMORPHINE HYDROCHLORIDE FILM 25 MG	73203010108225	Brand
KYNMOBI	APOMORPHINE HYDROCHLORIDE FILM 30 MG	73203010108230	Brand
<b>Approval Criteria</b>			
<b>1</b> - Documentation of positive clinical response to therapy			



**AND**

**2** - Patient will continue to receive treatment with a carbidopa/levodopa-containing medication

## **2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Aquadeks



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140697
<b>Guideline Name</b>	Aquadeks
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Aquadeks			
Diagnosis	Cystic Fibrosis		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AQUADEKS	*MULTIPLE VITAMINS W/ MINERALS CHEW TAB**	78310000000500	Brand
AQUADEKS	*PEDIATRIC MULTIPLE VITAMIN W/ MINERALS & C DROPS 45 MG/ML**	78421000002020	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of cystic fibrosis

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Arcalyst (rilonacept)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-155104
<b>Guideline Name</b>	Arcalyst (rilonacept)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Arcalyst			
Diagnosis	Cryopyrin-Associated Periodic Syndromes (CAPS)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ARCALYST	RILONACEPT FOR INJ 220 MG	66450060002120	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting a diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS) [including Familial Cold Auto-inflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS)]

**AND**

**2** - Prescribed by or in consultation with ONE of the following:

- Immunologist
- Allergist
- Dermatologist
- Rheumatologist
- Neurologist
- Specialist with expertise in the management of CAPS

**AND**

**3** - The medication will NOT be used in combination with another biologic agent

Product Name: Arcalyst			
Diagnosis	Cryopyrin-Associated Periodic Syndromes (CAPS)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ARCALYST	RILONACEPT FOR INJ 220 MG	66450060002120	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting patient has experienced disease stability or improvement in clinical symptoms while on therapy as evidenced by ONE of the following:

- Improvement in rash, fever, joint pain, headache, or conjunctivitis
- Decreased number of disease flare days

- Normalization of inflammatory markers (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], serum amyloid A [SAA])
- Corticosteroid dose reduction
- Improvement in MD global score or active joint count

Product Name: Arcalyst			
Diagnosis	Deficiency of Interleukin-1 Receptor Antagonist (DIRA)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ARCALYST	RILONACEPT FOR INJ 220 MG	66450060002120	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:</p> <p>1.1 Diagnosis of deficiency of interleukin-1 receptor antagonist (DIRA)</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Patient weighs at least 10 kg (kilograms)</p> <p style="text-align: center;"><b>AND</b></p> <p>1.3 Patient is currently in remission (e.g., no fever, skin rash, and bone pain; no radiological evidence of active bone lesions; C-reactive protein [CRP] less than 5 mg/L [milligrams per liter])</p>			

Product Name: Arcalyst	
Diagnosis	Recurrent Pericarditis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ARCALYST	RILONACEPT FOR INJ 220 MG	66450060002120	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) or paid claims documenting BOTH of the following:

**1.1** Diagnosis of recurrent pericarditis as evidenced by at least 2 episodes that occur a minimum of 4 to 6 weeks apart

**AND**

**1.2** History of failure, contraindication, or intolerance to ALL of the following:

- nonsteroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen)
- colchicine
- corticosteroids (e.g., prednisone)

**AND**

**2** - Prescribed by or in consultation with a cardiologist

Product Name: Arcalyst			
Diagnosis	Recurrent Pericarditis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ARCALYST	RILONACEPT FOR INJ 220 MG	66450060002120	Brand
<b>Approval Criteria</b>			

1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy

## 2 . Revision History

Date	Notes
9/17/2024	Updated guideline name. Updated CAPS criteria. Added new criteria for DIRA and recurrent pericarditis.



Arikayce



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140917
<b>Guideline Name</b>	Arikayce
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Arikayce			
Diagnosis	Refractory Mycobacterium avium complex (MAC) lung disease		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ARIKAYCE	AMIKACIN SULFATE LIPOSOME INHAL SUSP 590 MG/8.4ML (BASE EQ)	07000010121830	Brand
<b>Approval Criteria</b>			

**1** - Diagnosis of refractory Mycobacterium avium complex (MAC) lung disease

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) or claims history documenting respiratory cultures positive for MAC within the previous 6 months

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) or claims history documenting the patient has been receiving a multidrug background regimen containing at least TWO of the following agents for a minimum of 6 consecutive months within the past 12 months (prescription claims history may be used in conjunction as documentation of medication use, dose, and duration):

- Macrolide antibiotic\* (e.g., azithromycin, clarithromycin)
- Ethambutol\*
- Rifamycin antibiotic\* (e.g., rifampin, rifabutin)

**AND**

**4** - Patient will continue to receive a multidrug background regimen

**AND**

**5** - Documentation that the patient has not achieved negative sputum cultures after receipt of a multidrug background regimen for a minimum of 6 consecutive months

**AND**

**6** - In vitro susceptibility testing of recent (within 6 months) positive culture documents that the MAC isolate is susceptible to amikacin with a minimum inhibitory concentration (MIC) of less than or equal to 64 micrograms per milliliter (mcg/mL)

**AND**

7 - Prescribed by or in consultation with one of the following:

- Infectious disease specialist
- Pulmonologist

Notes

\*Drug may require PA)

Product Name: Arikayce

Diagnosis Refractory Mycobacterium avium complex (MAC) lung disease

Approval Length 6 month(s)

Therapy Stage Reauthorization

Guideline Type Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ARIKAYCE	AMIKACIN SULFATE LIPOSOME INHAL SUSP 590 MG/8.4ML (BASE EQ)	07000010121830	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 Documentation that the patient has achieved negative respiratory cultures

**OR**

1.2 ALL of the following:

1.2.1 Patient has not achieved negative respiratory cultures while on Arikayce

**AND**

1.2.2 Physician attestation that patient has demonstrated clinical benefit while on Arikayce

**AND**

**1.2.3** In vitro susceptibility testing of most recent (within 6 months) positive culture with available susceptibility testing documents that the Mycobacterium avium complex (MAC) isolate is susceptible to amikacin with an minimum inhibitory concentration (MIC) of less than 64 micrograms per milliliter (mcg/mL)

**AND**

**1.2.4** Patient has NOT received greater than 12 months of Arikayce therapy with continued positive respiratory cultures

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) or claims history documenting that the patient continues to receive a multidrug background regimen containing at least TWO of the following agents (prescription claims history may be used in conjunction as documentation of medication use, dose, and duration):

- Macrolide antibiotic\* (e.g., azithromycin, clarithromycin)
- Ethambutol\*
- Rifamycin antibiotic\* (e.g., rifampin, rifabutin)

**AND**

**3** - Prescribed by or in consultation with one of the following:

- Infectious disease specialist
- Pulmonologist

Notes	*Drug may require PA
-------	----------------------

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Atorvaliq (atorvastatin oral suspension)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140797
<b>Guideline Name</b>	Atorvaliq (atorvastatin oral suspension)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Atorvaliq			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ATORVALIQ	ATORVASTATIN CALCIUM SUSP 20 MG/5ML (4MG/ML) (BASE EQUIV)	39400010101810	Brand
<b>Approval Criteria</b>			
1 - BOTH of the following:			

**1.1** Patient is less than 10 years of age

**AND**

**1.2** Prescribed by or in consultation with a cardiologist

**OR**

**2** - BOTH of the following:

**2.1** Medication is being used for ONE of the following:

**2.1.1** To reduce the risk of ONE of the following:

**2.1.1.1** Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD

**OR**

**2.1.1.2** MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD

**OR**

**2.1.1.3** Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD

**OR**

**2.1.2** As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in ONE of the following:

- Adults with primary hyperlipidemia
- Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH)

**OR**

**2.1.3** As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH)

**OR**

**2.1.4** As an adjunct to diet for the treatment of adults with ONE of the following:

- Primary dysbetalipoproteinemia
- Hypertriglyceridemia

**AND**

**2.2** ONE of the following:

**2.2.1** Trial and failure, contraindication, or intolerance to generic atorvastatin tablets (verified via paid pharmacy claims or submitted chart notes)

**OR**

**2.2.2** Patient is unable to swallow oral tablets

## 2 . Revision History

Date	Notes
5/22/2023	Updated all criteria to allow patients under 10 years old with cardiologist prescriber to bypass PA criteria.

Austedo (deutetrabenazine)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157496
<b>Guideline Name</b>	Austedo (deutetrabenazine)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Austedo*, Austedo XR*			
Diagnosis	Moderate to Severe Tardive Dyskinesia		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AUSTEDO PATIENT TITRATION KIT	DEUTETRABENAZINE TAB TITRATION PACK 6 MG & 9 MG & 12 MG	6238003000B720	Brand
AUSTEDO	DEUTETRABENAZINE TAB 6 MG	62380030000310	Brand



AUSTEDO	DEUTETRABENAZINE TAB 9 MG	62380030000320	Brand
AUSTEDO	DEUTETRABENAZINE TAB 12 MG	62380030000330	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 6 MG	62380030007510	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 12 MG	62380030007520	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 24 MG	62380030007530	Brand
AUSTEDO XR PATIENT TITRATION KIT	DEUTETRABENAZINE TAB ER TITRATION PACK 6 MG & 12 MG & 24 MG	6238003000C120	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 30 MG	62380030007535	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 36 MG	62380030007540	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 42 MG	62380030007545	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 48 MG	62380030007550	Brand
AUSTEDO XR PATIENT TITRATION KIT	DEUTETRABENAZINE TAB ER TITRATION PACK 12 & 18 & 24 & 30 MG	6238003000C140	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 18 MG	62380030007525	Brand

**Approval Criteria**

**1** - Diagnosis of moderate to severe tardive dyskinesia (TD) secondary to treatment with a centrally acting dopamine receptor blocking agent (DRBA)

**AND**

**2** - Prescribed by or in consultation with a psychiatrist or neurologist

**AND**

**3** - Patient is 18 years of age or older

**AND**

**4** - Patient has an Abnormal Involuntary Movement Scale (AIMS) score of 3 or 4 on any one of the AIMS items 1 through 9

**AND**

**5** - Austedo is not prescribed concurrently with tetrabenazine or Ingrezza

**AND**

**6** - Dose does not exceed 48 mg (milligrams) per day

Notes	*Patients will be approved for ONE strength of Austedo/Austedo XR ONLY: Approve ALL requests at GPI-14. Confirm there is only 1 active PA on file for ALL Austedo products. End-date/Retire all other active P A's for Austedo products.
-------	--

Product Name: Austedo*, Austedo XR*			
Diagnosis	Moderate to Severe Tardive Dyskinesia		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AUSTEDO PATIENT TITRATION KIT	DEUTETRABENAZINE TAB TITRATION PACK 6 MG & 9 MG & 12 MG	6238003000B720	Brand
AUSTEDO	DEUTETRABENAZINE TAB 6 MG	62380030000310	Brand
AUSTEDO	DEUTETRABENAZINE TAB 9 MG	62380030000320	Brand
AUSTEDO	DEUTETRABENAZINE TAB 12 MG	62380030000330	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 6 MG	62380030007510	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 12 MG	62380030007520	Brand

AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 24 MG	62380030007530	Brand
AUSTEDO XR PATIENT TITRATION KIT	DEUTETRABENAZINE TAB ER TITRATION PACK 6 MG & 12 MG & 24 MG	6238003000C120	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 30 MG	62380030007535	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 36 MG	62380030007540	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 42 MG	62380030007545	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 48 MG	62380030007550	Brand
AUSTEDO XR PATIENT TITRATION KIT	DEUTETRABENAZINE TAB ER TITRATION PACK 12 & 18 & 24 & 30 MG	6238003000C140	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 18 MG	62380030007525	Brand

**Approval Criteria**

**1** - Patient is responding positively to therapy as evidenced by a reduction in the baseline score of any one of the Abnormal Involuntary Movement Scale (AIMS) items 1 through 9

**AND**

**2** - Austedo is not prescribed concurrently with tetrabenazine or Ingrezza

**AND**

**3** - Dose does not exceed 48 mg per day

Notes	*Patients will be approved for ONE strength of Austedo/Austedo XR ONLY: Approve ALL requests at GPI-14. Confirm there is only 1 active PA on file for ALL Austedo products. End-date/Retire all other active PAs for Austedo products.
-------	--

Product Name: Austedo\*, Austedo XR\*

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Diagnosis	Chorea Associated with Huntington Disease
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
AUSTEDO PATIENT TITRATION KIT	DEUTETRABENAZINE TAB TITRATION PACK 6 MG & 9 MG & 12 MG	6238003000B720	Brand
AUSTEDO	DEUTETRABENAZINE TAB 6 MG	62380030000310	Brand
AUSTEDO	DEUTETRABENAZINE TAB 9 MG	62380030000320	Brand
AUSTEDO	DEUTETRABENAZINE TAB 12 MG	62380030000330	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 6 MG	62380030007510	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 12 MG	62380030007520	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 24 MG	62380030007530	Brand
AUSTEDO XR PATIENT TITRATION KIT	DEUTETRABENAZINE TAB ER TITRATION PACK 6 MG & 12 MG & 24 MG	6238003000C120	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 30 MG	62380030007535	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 36 MG	62380030007540	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 42 MG	62380030007545	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 48 MG	62380030007550	Brand
AUSTEDO XR PATIENT TITRATION KIT	DEUTETRABENAZINE TAB ER TITRATION PACK 12 & 18 & 24 & 30 MG	6238003000C140	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 18 MG	62380030007525	Brand

**Approval Criteria**

1 - Diagnosis of chorea associated with Huntington's Disease

**AND**

**2** - Prescribed by or in consultation with a neurologist

**AND**

**3** - Patient is 18 years of age or older

**AND**

**4** - Targeted mutation analysis demonstrates a cytosine-adenine-guanine (CAG) trinucleotide expansion of greater than or equal to 36 repeats in the huntingtin (HTT) gene

**AND**

**5** - Patient has a Unified Huntington Disease Rating Scale (UHDRS) score ranging from 1 to 4 on any one of UHDRS chorea items 1 through 7

**AND**

**6** - Austedo is not prescribed concurrently with tetrabenazine or Ingrezza

**AND**

**7** - Dose does not exceed 48 mg per day

Notes	*Patients will be approved for ONE strength of Austedo/Austedo XR ONLY: Approve ALL requests at GPI-14. Confirm there is only 1 active PA on file for ALL Austedo products. End-date/Retire all other active P A's for Austedo products.
-------	--

Product Name: Austedo*, Austedo XR*	
Diagnosis	Chorea Associated with Huntington Disease
Approval Length	12 month(s)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Therapy Stage		Reauthorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
AUSTEDO PATIENT TITRATION KIT	DEUTETRABENAZINE TAB TITRATION PACK 6 MG & 9 MG & 12 MG	6238003000B720	Brand
AUSTEDO	DEUTETRABENAZINE TAB 6 MG	62380030000310	Brand
AUSTEDO	DEUTETRABENAZINE TAB 9 MG	62380030000320	Brand
AUSTEDO	DEUTETRABENAZINE TAB 12 MG	62380030000330	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 6 MG	62380030007510	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 12 MG	62380030007520	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 24 MG	62380030007530	Brand
AUSTEDO XR PATIENT TITRATION KIT	DEUTETRABENAZINE TAB ER TITRATION PACK 6 MG & 12 MG & 24 MG	6238003000C120	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 30 MG	62380030007535	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 36 MG	62380030007540	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 42 MG	62380030007545	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 48 MG	62380030007550	Brand
AUSTEDO XR PATIENT TITRATION KIT	DEUTETRABENAZINE TAB ER TITRATION PACK 12 & 18 & 24 & 30 MG	6238003000C140	Brand
AUSTEDO XR	DEUTETRABENAZINE TAB ER 24HR 18 MG	62380030007525	Brand

**Approval Criteria**

1 - Patient is responding positively to therapy as evidenced by a reduction in the baseline score of any one of the Unified Huntington Disease Rating Scale (UHDRS) chorea items 1 through 7

<b>AND</b>	
2 - Austedo is not prescribed concurrently with tetrabenazine or Ingrezza	
<b>AND</b>	
3 - Dose does not exceed 48 mg per day	
Notes	*Patients will be approved for ONE strength of Austedo/Austedo XR ONLY: Approve ALL requests at GPI-14. Confirm there is only 1 active PA on file for ALL Austedo products. End-date/Retire all other active P A's for Austedo products.

## 2 . Revision History

Date	Notes
10/15/2024	Added note regarding only one strength of Austedo/Austedo XR can be approved at a time. No changes to clinical criteria.

Azole Antifungals



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-145506
<b>Guideline Name</b>	Azole Antifungals
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Sporanox capsules, generic itraconazole capsules			
Diagnosis	Systemic Fungal Infections		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ITRACONAZOLE	ITRACONAZOLE CAP 100 MG	11407035000120	Generic
SPORANOX	ITRACONAZOLE CAP 100 MG	11407035000120	Brand
SPORANOX PULSEPAK	ITRACONAZOLE CAP 100 MG	11407035000120	Brand



**Approval Criteria**

1 - ONE of the following

1.1 Diagnosis of ONE of the following:

- Blastomycosis
- Histoplasmosis
- Aspergillosis

**OR**

1.2 Both of the following:

1.2.1 Diagnosis of coccidioidomycosis

**AND**

1.2.2 Patient has a history of failure, contraindication, intolerance, or resistance to fluconazole (generic Diflucan) as evidenced by submission of medical records or claims history

Product Name: Brand Sporanox capsules, generic itraconazole capsules			
Diagnosis	Onychomycosis Fingernails		
Approval Length	2 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ITRACONAZOLE	ITRACONAZOLE CAP 100 MG	11407035000120	Generic
SPORANOX	ITRACONAZOLE CAP 100 MG	11407035000120	Brand
SPORANOX PULSEPAK	ITRACONAZOLE CAP 100 MG	11407035000120	Brand

**Approval Criteria**

1 - Diagnosis of fingernail onychomycosis confirmed by ONE of the following:

- KOH (potassium hydroxide) test
- Fungal culture
- Nail biopsy

**AND**

2 - Patient has a history of at least a 6-week trial resulting in therapeutic failure, contraindication, intolerance, or resistance to Terbinafine as evidenced by submission of medical records or claims history

Product Name: Brand Sporanox capsules, generic itraconazole capsules			
Diagnosis	Onychomycosis Fingernails		
Approval Length	2 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ITRACONAZOLE	ITRACONAZOLE CAP 100 MG	11407035000120	Generic
SPORANOX	ITRACONAZOLE CAP 100 MG	11407035000120	Brand
SPORANOX PULSEPAK	ITRACONAZOLE CAP 100 MG	11407035000120	Brand

**Approval Criteria**

1 - Both of the following:

1.1 Three months have elapsed since completion of initial therapy for fingernail onychomycosis

**AND**

1.2 Documentation of positive clinical response to therapy

Product Name: Brand Sporanox capsules, generic itraconazole capsules			
Diagnosis	Onychomycosis Toenails		
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ITRACONAZOLE	ITRACONAZOLE CAP 100 MG	11407035000120	Generic
SPORANOX	ITRACONAZOLE CAP 100 MG	11407035000120	Brand
SPORANOX PULSEPAK	ITRACONAZOLE CAP 100 MG	11407035000120	Brand
<p><b>Approval Criteria</b></p> <p><b>1</b> - Diagnosis of toenail onychomycosis confirmed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• KOH (potassium hydroxide) test</li> <li>• Fungal culture</li> <li>• Nail biopsy</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient has a history of at least a 12-week trial resulting in therapeutic failure, contraindication, intolerance, or resistance to Terbinafine as evidenced by submission of medical records or claims history</p>			

Product Name: Brand Sporanox capsules, generic itraconazole capsules			
Diagnosis	Onychomycosis Toenails		
Approval Length	3 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ITRACONAZOLE	ITRACONAZOLE CAP 100 MG	11407035000120	Generic
SPORANOX	ITRACONAZOLE CAP 100 MG	11407035000120	Brand

SPORANOX PULSEPAK	ITRACONAZOLE CAP 100 MG	11407035000120	Brand
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 Nine months have elapsed since completion of initial therapy for toenail onychomycosis</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Documentation of positive clinical response to therapy</p>			

Product Name: Brand Sporanox Oral Solution, generic itraconazole oral solution			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ITRACONAZOLE	ITRACONAZOLE ORAL SOLN 10 MG/ML	11407035002020	Generic
SPORANOX	ITRACONAZOLE ORAL SOLN 10 MG/ML	11407035002020	Brand
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following diagnoses:</p> <ul style="list-style-type: none"> <li>• Oropharyngeal candidiasis</li> <li>• Esophageal candidiasis</li> </ul>			

Product Name: Brand Vfend tablets, generic voriconazole tablets			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

VFEND	VORICONAZOLE TAB 50 MG	11407080000320	Brand
VORICONAZOLE	VORICONAZOLE TAB 50 MG	11407080000320	Generic
VFEND	VORICONAZOLE TAB 200 MG	11407080000340	Brand
VORICONAZOLE	VORICONAZOLE TAB 200 MG	11407080000340	Generic

**Approval Criteria**

**1** - One of the following:

**1.1** Diagnosis of invasive aspergillosis including *Aspergillus fumigatus*

**OR**

**1.2** ALL of the following:

- Diagnosis of Candidemia
- Patient is non-neutropenic
- Patient has a history of failure, contraindication, intolerance, or resistance to fluconazole (generic Diflucan) as evidenced by submission of medical records or claims history

**OR**

**1.3** Both of the following:

**1.3.1** ONE of the following diagnoses:

- Candida infection in the abdomen
- Candida infection in the kidney
- Candida infection in the bladder wall
- Candida infection in wounds
- Disseminated Candida infections in skin
- Esophageal candidiasis

**AND**

**1.3.2** Patient has a history of failure, contraindication, intolerance, or resistance to fluconazole (generic Diflucan) as evidenced by submission of medical records or claims history

**OR**

**1.4** Diagnosis of *Scedosporium apiospermum* infection (asexual form of *Pseudallescheria boydii*)

**OR**

**1.5** Diagnosis of *Fusarium* spp. infection including *Fusarium solani*

**OR**

**1.6** Diagnosis of *Exserohilum* species infection

Product Name: Brand Vfend Powder for Oral Suspension, generic voriconazole powder for oral suspension

Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
VFEND	VORICONAZOLE FOR SUSP 40 MG/ML	11407080001920	Brand
VORICONAZOLE	VORICONAZOLE FOR SUSP 40 MG/ML	11407080001920	Generic

**Approval Criteria**

**1** - Both of the following:

**1.1** One of the following:

**1.1.1** Diagnosis of invasive aspergillosis including *Aspergillus fumigatus*

**OR**

**1.1.2** ALL of the following:

- Diagnosis of Candidemia
- Patient is non-neutropenic
- Patient has a history of failure, contraindication, intolerance, or resistance to fluconazole (generic Diflucan) as evidenced by submission of medical records or claims history

**OR**

**1.1.3 ONE of the following diagnoses:**

- Candida infection in the abdomen
- Candida infection in the kidney
- Candida infection in the bladder wall
- Candida infection in wounds
- Disseminated Candida infections in skin
- Esophageal candidiasis

**OR**

**1.1.4** Diagnosis of *Scedosporium apiospermum* infection (asexual form of *Pseudallescheria boydii*)

**OR**

**1.1.5** Diagnosis of *Fusarium* spp. infection including *Fusarium solani*

**OR**

**1.1.6** Diagnosis of *Exserohilum* species infection

**AND**

**1.2** Physician has provided rationale for the patient needing to use voriconazole oral suspension instead of voriconazole tablets

Product Name: Brand Noxafil tablets, generic posaconazole tablets

Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NOXAFIL	POSACONAZOLE TAB DELAYED RELEASE 100 MG	11407060000620	Brand
POSACONAZOLE DR	POSACONAZOLE TAB DELAYED RELEASE 100 MG	11407060000620	Generic
POSACONAZOLE	POSACONAZOLE TAB DELAYED RELEASE 100 MG	11407060000620	Generic

**Approval Criteria**

1 - BOTH of the following:

1.1 Used as prophylaxis of invasive fungal infections caused by ONE of the following:

- Aspergillus
- Candida

**AND**

1.2 One of the following conditions:

1.2.1 Patient is at high risk of infections due to severe immunosuppression from ONE of the following conditions:

- Hematopoietic stem cell transplant (HSCT) with graft-versus-host disease (GVHD)
- Hematologic malignancies with prolonged neutropenia from chemotherapy [eg, acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)]

**OR**

1.2.2 Patient has a prior fungal infection requiring secondary prophylaxis

Product Name: Noxafil Suspension, Noxafil delayed release suspension packets	
Diagnosis	Prophylaxis of Aspergillus or Candida Infections
Approval Length	12 month(s)
Guideline Type	Prior Authorization



Product Name	Generic Name	GPI	Brand/Generic
NOXAFIL	POSACONAZOLE SUSP 40 MG/ML	11407060001820	Brand
NOXAFIL	POSACONAZOLE FOR DELAYED RELEASE SUSP PACKET 300 MG	11407060003020	Brand

**Approval Criteria**

1 - BOTH of the following:

1.1 Used as prophylaxis of invasive fungal infections caused by ONE of the following:

- Aspergillus
- Candida

**AND**

1.2 One of the following conditions:

1.2.1 Patient is at high risk of infections due to severe immunosuppression from ONE of the following conditions:

- Hematopoietic stem cell transplant (HSCT) with graft-versus-host disease (GVHD)
- Hematologic malignancies with prolonged neutropenia from chemotherapy [eg, acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)]

**OR**

1.2.2 Patient has a prior fungal infection requiring secondary prophylaxis

Product Name: Noxafil Suspension			
Diagnosis	Oropharyngeal Candidiasis (OPC)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NOXAFIL	POSACONAZOLE SUSP 40 MG/ML	11407060001820	Brand

**Approval Criteria**

1 - BOTH of the following:

1.1 Diagnosis of oropharyngeal candidiasis (OPC)

**AND**

1.2 The patient has a history of failure, contraindication, intolerance, or resistance to TWO of the following as evidenced by submission of medical records or claims history:

- Fluconazole\* (generic Diflucan)
- Itraconazole\* (generic Sporanox)
- Clotrimazole Lozenges\*

Notes

\*Drug may require PA

Product Name: Cresemba			
Approval Length	3 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CRESEMBA	ISAVUCONAZONIUM SULFATE CAP 74.5 MG (ISAVUCONAZOLE 40 MG)	11407030100105	Brand
CRESEMBA	ISAVUCONAZONIUM SULFATE CAP 186 MG (ISAVUCONAZOLE 100 MG)	11407030100120	Brand
<b>Approval Criteria</b>			
1 - One of the following:			
1.1 Both of the following:			
1.1.1 Diagnosis of invasive aspergillosis			

**AND**

**1.1.2** Patient has a history of failure, contraindication, intolerance, or resistance to voriconazole\* (generic Vfend) as evidenced by submission of medical records or claims history

**OR**

**1.2** Diagnosis of invasive mucormycosis

**AND**

**2** - Both of the following:

- Patient is 6 months of age or older
- Patient weighs 16 kg or greater

Notes

\*Drug may require PA

Product Name: Tolsura

Approval Length 3 month(s)

Guideline Type Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TOLSURA	ITRACONAZOLE CAP 65 MG	11407035000113	Brand

**Approval Criteria**

**1** - Both of the following:

**1.1** Diagnosis of ONE of the following fungal infections:

- Blastomycosis
- Histoplasmosis

<ul style="list-style-type: none"> <li>Aspergillosis</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> Patient has a history of failure, contraindication, intolerance, or resistance to itraconazole* capsules (generic Sporanox) as evidenced by submission of medical records or claims history</p>	
Notes	*Drug may require PA

Product Name: Brand Sporanox capsules, generic itraconazole capsules, Brand Sporanox oral solution, generic itraconazole oral solution, Brand Vfend tablets, generic voriconazole tablets, Brand Vfend powder for oral suspension, generic voriconazole powder for oral suspension, Brand Noxafil tablets, generic posaconazole tablets, Noxafil oral suspension, Noxafil delayed release suspension packets, Cresemba, Tolsura			
Diagnosis	All Other Diagnoses		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ITRACONAZOLE	ITRACONAZOLE CAP 100 MG	11407035000120	Generic
SPORANOX	ITRACONAZOLE CAP 100 MG	11407035000120	Brand
SPORANOX PULSEPAK	ITRACONAZOLE CAP 100 MG	11407035000120	Brand
ITRACONAZOLE	ITRACONAZOLE ORAL SOLN 10 MG/ML	11407035002020	Generic
SPORANOX	ITRACONAZOLE ORAL SOLN 10 MG/ML	11407035002020	Brand
VFEND	VORICONAZOLE TAB 50 MG	11407080000320	Brand
VORICONAZOLE	VORICONAZOLE TAB 50 MG	11407080000320	Generic
VFEND	VORICONAZOLE TAB 200 MG	11407080000340	Brand
VORICONAZOLE	VORICONAZOLE TAB 200 MG	11407080000340	Generic
VFEND	VORICONAZOLE FOR SUSP 40 MG/ML	11407080001920	Brand
VORICONAZOLE	VORICONAZOLE FOR SUSP 40 MG/ML	11407080001920	Generic
NOXAFIL	POSACONAZOLE TAB DELAYED RELEASE 100 MG	11407060000620	Brand
POSACONAZOLE DR	POSACONAZOLE TAB DELAYED RELEASE 100 MG	11407060000620	Generic
NOXAFIL	POSACONAZOLE SUSP 40 MG/ML	11407060001820	Brand
TOLSURA	ITRACONAZOLE CAP 65 MG	11407035000113	Brand

POSACONAZOLE	POSACONAZOLE TAB DELAYED RELEASE 100 MG	11407060000620	Generic
NOXAFIL	POSACONAZOLE FOR DELAYED RELEASE SUSP PACKET 300 MG	11407060003020	Brand
CRESEMBA	ISAVUCONAZONIUM SULFATE CAP 74.5 MG (ISAVUCONAZOLE 40 MG)	11407030100105	Brand
CRESEMBA	ISAVUCONAZONIUM SULFATE CAP 186 MG (ISAVUCONAZOLE 100 MG)	11407030100120	Brand

**Approval Criteria**

1 - The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- Food and Drug Administration (FDA) approved indications and limits
- Published practice guidelines and treatment protocols
- Comparative data evaluating the efficacy, type and frequency of side effects and potential drug interactions among alternative products as well as the risks, benefits and potential member outcomes
- Drug Facts and Comparisons
- American Hospital Formulary Service Drug Information
- United States Pharmacopeia – Drug Information
- DRUGDEX Information System
- UpToDate
- MicroMedex
- Peer-reviewed medical literature, including randomized clinical trials, outcomes, research data and pharmaco-economic studies
- Other drug reference resources

**AND**

2 - The medication is being prescribed by or in consultation with an infectious disease specialist

Notes	*Authorization duration based on provider recommended treatment durations, not to exceed 12 months
-------	--

**2 . Revision History**

Date	Notes
4/8/2024	Removed Likmez from GL.



Baxdela



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140698
<b>Guideline Name</b>	Baxdela
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Baxdela			
Diagnosis	Community-Acquired Bacterial Pneumonia		
Approval Length	10 Days*		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BAXDELA	DELAFLORACIN MEGLUMINE TAB 450 MG (BASE EQUIV)	05000025100320	Brand
<b>Approval Criteria</b>			

1 - For continuation of therapy upon hospital discharge

**OR**

2 - As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

3 - All of the following:

3.1 Diagnosis of community-acquired bacterial pneumonia (CABP)

**AND**

3.2 Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Baxdela

**AND**

3.3 History of failure, contraindication, or intolerance to THREE of the following antibiotics or antibiotic regimens:

- Amoxicillin\*\*
- A macrolide\*\*
- Doxycycline\*\*
- A fluoroquinolone\*\*
- Combination therapy with amoxicillin/clavulanate or cephalosporin AND a macrolide or doxycycline

Notes

\*Note: Authorization will be issued for up to 10 days.  
\*\*Drug may require PA

Product Name: Baxdela

Diagnosis

Acute Bacterial Skin and Skin Structure Infections

Approval Length

14 Days\*



Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
BAXDELA	DELAFLOXACIN MEGLUMINE TAB 450 MG (BASE EQUIV)	05000025100320	Brand

**Approval Criteria**

1 - For continuation of therapy upon hospital discharge

**OR**

2 - As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

3 - All of the following:

3.1 One of the following diagnoses:

3.1.1 Both of the following

3.1.1.1 Acute bacterial skin and skin structure infections

**AND**

3.1.1.2 Infection caused by methicillin-resistant Staphylococcus aureus (MRSA) documented by culture and sensitivity report

**OR**

3.1.2 Both of the following:

3.1.2.1 Empirical treatment of patients with acute bacterial skin and skin structure infections

**AND**

**3.1.2.2** Presence of MRSA infection is likely

**AND**

**3.2** History of failure, contraindication, or intolerance to linezolid (generic Zyvox)

**AND**

**3.3** History of failure, contraindication, or intolerance to ONE of the following antibiotics:

- Sulfamethoxazole-trimethoprim (SMZ-TMP)\*\*
- A tetracycline\*\*
- Clindamycin\*\*

**OR**

**4** - All of the following:

**4.1** Diagnosis of acute bacterial skin and skin structure infections

**AND**

**4.2** Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Baxdela

**AND**

**4.3** History of failure, contraindication, or intolerance to THREE of the following antibiotics:

- A penicillin\*\*
- A cephalosporin\*\*
- A tetracycline\*\*
- Sulfamethoxazole-trimethoprim (SMZ-TMP)\*\*

<ul style="list-style-type: none"> <li>Clindamycin**</li> </ul>	
Notes	<p>*Note: Authorization will be issued for up to 14 days.                  **Drug may require PA</p>

Product Name: Baxdela			
Diagnosis	Off-Label Uses*		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BAXDELA	DELAFLOXACIN MEGLUMINE TAB 450 MG (BASE EQUIV)	05000025100320	Brand
<p><b>Approval Criteria</b></p> <p>1 - For continuation of therapy upon hospital discharge</p> <p style="text-align: center;"><b>OR</b></p> <p>2 - As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication</p>			
Notes	*Note: Authorization duration based on provider recommended treatment durations, up to 6 months.		

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Belbuca, Butrans



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140760
<b>Guideline Name</b>	Belbuca, Butrans
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	1/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Belbuca, Brand Butrans, generic buprenorphine patches*			
Diagnosis	Cancer/Hospice/End of Life related pain		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 75 MCG (BASE EQUIVALENT)	65200010108210	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 150 MCG (BASE EQUIVALENT)	65200010108220	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 300 MCG (BASE EQUIVALENT)	65200010108230	Brand

BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 450 MCG (BASE EQUIVALENT)	65200010108240	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 600 MCG (BASE EQUIVALENT)	65200010108250	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 750 MCG (BASE EQUIVALENT)	65200010108260	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 900 MCG (BASE EQUIVALENT)	65200010108270	Brand
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 5 MCG/HR	65200010008820	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 5 MCG/HR	65200010008820	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 7.5 MCG/HR	65200010008825	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 7.5 MCG/HR	65200010008825	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 10 MCG/HR	65200010008830	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 10 MCG/HR	65200010008830	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 15 MCG/HR	65200010008835	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 15 MCG/HR	65200010008835	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 20 MCG/HR	65200010008840	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 20 MCG/HR	65200010008840	Generic

**Approval Criteria**

1 - The patient is being treated for cancer, hospice, or end of life related pain

**AND**

2 - If the request is for Belbuca or generic buprenorphine patches, BOTH of the following:

**2.1** Prescriber attests the information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed; and medical information necessary to verify the accuracy of the information provided may be requested

**AND**

**2.2** The patient has a history of failure, contraindication, or intolerance to BRAND Butrans

Notes	*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. If the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried brand buprenorphine patches a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additionally, a 12 month authorization should be entered for brand buprenorphine patches.
-------	--

Product Name: Belbuca, Brand Butrans, generic buprenorphine patches			
Diagnosis	Cancer/Hospice/End of Life related pain		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 75 MCG (BASE EQUIVALENT)	65200010108210	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 150 MCG (BASE EQUIVALENT)	65200010108220	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 300 MCG (BASE EQUIVALENT)	65200010108230	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 450 MCG (BASE EQUIVALENT)	65200010108240	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 600 MCG (BASE EQUIVALENT)	65200010108250	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 750 MCG (BASE EQUIVALENT)	65200010108260	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 900 MCG (BASE EQUIVALENT)	65200010108270	Brand
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 5 MCG/HR	65200010008820	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 5 MCG/HR	65200010008820	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 7.5 MCG/HR	65200010008825	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 7.5 MCG/HR	65200010008825	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 10 MCG/HR	65200010008830	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 10 MCG/HR	65200010008830	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 15 MCG/HR	65200010008835	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 15 MCG/HR	65200010008835	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 20 MCG/HR	65200010008840	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 20 MCG/HR	65200010008840	Generic

**Approval Criteria**

1 - The patient is being treated for cancer, hospice, or end of life related pain (Document diagnosis and date of diagnosis)

**AND**

2 - If the request is for Belbuca or generic buprenorphine patches ONLY: Prescriber attests the information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed; and medical information necessary to verify the accuracy of the information provided may be requested

Product Name: Belbuca, Brand Butrans, generic buprenorphine patches*			
Diagnosis	Non-cancer pain/Non-hospice/Non-end of life care pain		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 75 MCG (BASE EQUIVALENT)	65200010108210	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 150 MCG (BASE EQUIVALENT)	65200010108220	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 300 MCG (BASE EQUIVALENT)	65200010108230	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 450 MCG (BASE EQUIVALENT)	65200010108240	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 600 MCG (BASE EQUIVALENT)	65200010108250	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 750 MCG (BASE EQUIVALENT)	65200010108260	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 900 MCG (BASE EQUIVALENT)	65200010108270	Brand
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 5 MCG/HR	65200010008820	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 5 MCG/HR	65200010008820	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 7.5 MCG/HR	65200010008825	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 7.5 MCG/HR	65200010008825	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 10 MCG/HR	65200010008830	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 10 MCG/HR	65200010008830	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 15 MCG/HR	65200010008835	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 15 MCG/HR	65200010008835	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 20 MCG/HR	65200010008840	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 20 MCG/HR	65200010008840	Generic

**Approval Criteria**

1 - Prescriber attests to ALL of the following:

1.1 The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed; and medical information necessary to verify the accuracy of the information provided may be requested

**AND**



**1.2** Treatment goals are defined, including estimated duration of treatment

**AND**

**1.3** Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention

**AND**

**1.4** Patient has been screened for substance abuse/opioid dependence

**AND**

**1.5** If used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression

**AND**

**1.6** Pain is moderate to severe and expected to persist for an extended period of time

**AND**

**1.7** Pain is chronic

**AND**

**1.8** Pain is not postoperative (unless the patient is already receiving chronic opioid therapy prior to surgery, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time)

**AND**

**1.9** Pain management is required around the clock with a long-acting opioid

**AND**

**2** - The patient has a history of failure, contraindication, or intolerance to a trial of tramadol IR (immediate release), unless the patient is already receiving chronic opioid therapy prior to surgery for postoperative pain, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time (Drug may require PA)

**AND**

**3** - If the request is for neuropathic pain (examples of neuropathic pain include neuralgias, neuropathies, fibromyalgia), BOTH of the following must be met:

**3.1** Unless it is contraindicated, the patient has not exhibited an adequate response to 8 weeks of treatment with gabapentin (Neurontin) or pregabalin (Lyrica) titrated to a therapeutic dose (document date of trial)

**AND**

**3.2** Unless it is contraindicated, the patient has not exhibited an adequate response to at least 6 weeks of treatment with a tricyclic antidepressant titrated to the maximum tolerated dose (document drug and date of trial)

**AND**

**4** - If the request is for Belbuca or generic Butrans, the patient has a history of failure, contraindication or intolerance to BRAND Butrans

Notes

\*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. If the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried brand buprenorphine patches a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additi

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	onally, a 6 month authorization should be entered for brand buprenorphine patches.
--	--

Product Name: Belbuca, Brand Butrans, generic buprenorphine patches*			
Diagnosis	Non-cancer pain/Non-hospice/Non-end of life care pain		
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 75 MCG (BASE EQUIVALENT)	65200010108210	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 150 MCG (BASE EQUIVALENT)	65200010108220	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 300 MCG (BASE EQUIVALENT)	65200010108230	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 450 MCG (BASE EQUIVALENT)	65200010108240	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 600 MCG (BASE EQUIVALENT)	65200010108250	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 750 MCG (BASE EQUIVALENT)	65200010108260	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 900 MCG (BASE EQUIVALENT)	65200010108270	Brand
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 5 MCG/HR	65200010008820	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 5 MCG/HR	65200010008820	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 7.5 MCG/HR	65200010008825	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 7.5 MCG/HR	65200010008825	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 10 MCG/HR	65200010008830	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 10 MCG/HR	65200010008830	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 15 MCG/HR	65200010008835	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 15 MCG/HR	65200010008835	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 20 MCG/HR	65200010008840	Brand

BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 20 MCG/HR	65200010008840	Generic
---------------	--	----------------	---------

**Approval Criteria**

**1** - Patient demonstrates meaningful improvement in pain and function (document improvement in function or pain score improvement)

**AND**

**2** - Identify rationale for not tapering and discontinuing opioid (document rationale)

**AND**

**3** - Prescriber attests to ALL of the following:

**3.1** The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed; and medical information necessary to verify the accuracy of the information provided may be requested

**AND**

**3.2** Treatment goals are defined, including estimated duration of treatment

**AND**

**3.3** Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention

**AND**

**3.4** Patient has been screened for substance abuse/opioid dependence

**AND**

**3.5** If used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression

**AND**

**3.6** Pain is moderate to severe and expected to persist for an extended period of time

**AND**

**3.7** Pain is chronic

**AND**

**3.8** Pain is not postoperative (unless the patient is already receiving chronic opioid therapy prior to surgery, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time)

**AND**

**3.9** Pain management is required around the clock with a long-acting opioid

**AND**

**4** - If the request is for Belbuca or generic Butrans, the patient has a history of failure, contraindication, or intolerance to BRAND Butrans

Notes

\*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 60-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. If the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried brand buprenorphine patches a denial should be issued and a maximum 60-day authorization may be

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment. Additionally, a 6 month authorization should be entered for brand buprenorphine patches.
--	---

Product Name: Belbuca, Brand Butrans, generic buprenorphine patches			
Guideline Type		Quantity Limit	
Product Name	Generic Name	GPI	Brand/Generic
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 75 MCG (BASE EQUIVALENT)	65200010108210	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 150 MCG (BASE EQUIVALENT)	65200010108220	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 300 MCG (BASE EQUIVALENT)	65200010108230	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 450 MCG (BASE EQUIVALENT)	65200010108240	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 600 MCG (BASE EQUIVALENT)	65200010108250	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 750 MCG (BASE EQUIVALENT)	65200010108260	Brand
BELBUCA	BUPRENORPHINE HCL BUCCAL FILM 900 MCG (BASE EQUIVALENT)	65200010108270	Brand
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 5 MCG/HR	65200010008820	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 5 MCG/HR	65200010008820	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 7.5 MCG/HR	65200010008825	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 7.5 MCG/HR	65200010008825	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 10 MCG/HR	65200010008830	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 10 MCG/HR	65200010008830	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 15 MCG/HR	65200010008835	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 15 MCG/HR	65200010008835	Generic
BUTRANS	BUPRENORPHINE TD PATCH WEEKLY 20 MCG/HR	65200010008840	Brand
BUPRENORPHINE	BUPRENORPHINE TD PATCH WEEKLY 20 MCG/HR	65200010008840	Generic

**Approval Criteria**

1 - The requested dose cannot be achieved by moving to a higher strength of the product

**AND**

2 - The requested dose is within the FDA (Food and Drug Administration) maximum dose per day, where an FDA maximum dose per day exists

Notes	Approval durations: 12 months for cancer pain/hospice/end of life related pain; 6 months for non-cancer pain/non-hospice/non-end of life related pain
-------	---

**2 . Revision History**

Date	Notes
12/12/2022	Updated prerequisite options for neuropathic/nerve pain in Non-cancer pain/Non-hospice/Non-end of life care pain initial auth section.

Benefit Determination Mifeprex



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140786
<b>Guideline Name</b>	Benefit Determination Mifeprex
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	3/19/2023
-----------------	-----------

### 1 . Criteria

Product Name: Brand Mifeprex, generic mifepristone			
Approval Length	1 month(s)		
Guideline Type	Benefit Determination		
Product Name	Generic Name	GPI	Brand/Generic
MIFEPREX	MIFEPRISTONE TAB 200 MG	30502060000320	Brand
MIFEPRISTONE	MIFEPRISTONE TAB 200 MG	30502060000320	Generic
<b>Approval Criteria</b>			



1 - Provider attests patient requires treatment for purposes identified in the Hyde amendment and any applicable state laws and regulations

**AND**

2 - Submission of all necessary state form(s) and/or certification document(s)

## 2 . Revision History

Date	Notes
3/15/2023	Added KS and changed GL type to " benefit determination

Benlysta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140941
<b>Guideline Name</b>	Benlysta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Benlysta SQ			
Diagnosis	Systemic Lupus Erythematosus		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BENLYSTA	BELIMUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/ML	9942201500D520	Brand
BENLYSTA	BELIMUMAB SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/ML	9942201500E520	Brand

**Approval Criteria**

1 - Diagnosis of systemic lupus erythematosus

**AND**

2 - Patient is 5 years of age or older

**AND**

3 - Laboratory testing has documented the presence of autoantibodies [e.g., ANA, Anti-dsDNA, Anti-Sm, Anti-Ro/SSA, Anti-La/SSB]

**AND**

4 - Patient is currently receiving standard immunosuppressive therapy [e.g., hydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate]

**AND**

5 - Patient does NOT have severe active central nervous system lupus

**AND**

6 - Patient is not receiving Benlysta in combination with a biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Kineret (anakinra)]

Product Name: Benlysta SQ	
Diagnosis	Active Lupus Nephritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
BENLYSTA	BELIMUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/ML	9942201500D520	Brand
BENLYSTA	BELIMUMAB SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/ML	9942201500E520	Brand

**Approval Criteria**

1 - Diagnosis of active lupus nephritis

**AND**

2 - Patient is 5 years of age or older

**AND**

3 - Patient is currently receiving standard immunosuppressive therapy for systemic lupus erythematosus [e.g., hydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate]

**AND**

4 - Patient does NOT have severe active central nervous system lupus

**AND**

5 - Patient is not receiving Benlysta in combination with a biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Kineret (anakinra)]

Product Name: Benlysta SQ	
Diagnosis	Systemic Lupus Erythematosus, Active Lupus Nephritis
Approval Length	12 month(s)

Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BENLYSTA	BELIMUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/ML	9942201500D520	Brand
BENLYSTA	BELIMUMAB SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/ML	9942201500E520	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Benlysta therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is not receiving Benlysta in combination with a biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Kineret (anakinra)]</p>			

## 2 . Revision History

Date	Notes
10/24/2022	Updated age requirement.

Benznidazole



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140632
<b>Guideline Name</b>	Benznidazole
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Benznidazole			
Diagnosis	Chagas disease (American trypanosomiasis)		
Approval Length	60 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BENZNIDAZOLE	BENZNIDAZOLE TAB 12.5 MG	15000003000320	Brand
BENZNIDAZOLE	BENZNIDAZOLE TAB 100 MG	15000003000340	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of Chagas disease (American trypanosomiasis) due to Trypanosoma cruzi

## 2 . Revision History

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Besremi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-159218
<b>Guideline Name</b>	Besremi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Besremi			
Diagnosis	Polycythemia Vera		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BESREMI	ROPEGINTERFERON ALFA-2B-NJFT SOLN PREFILLED SYR 500 MCG/ML	2170007750E520	Brand
<b>Approval Criteria</b>			



1 - Diagnosis of polycythemia vera

Product Name: Besremi			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BESREMI	ROPEGINTERFERON ALFA-2B-NJFT SOLN PREFILLED SYR 500 MCG/ML	2170007750E520	Brand
<b>Approval Criteria</b>			
1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium			

Product Name: Besremi			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BESREMI	ROPEGINTERFERON ALFA-2B-NJFT SOLN PREFILLED SYR 500 MCG/ML	2170007750E520	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Besremi therapy			

## 2 . Revision History

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
11/4/2024	New program

Biltricide



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140633
<b>Guideline Name</b>	Biltricide
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

## 1 . Criteria

Product Name: Brand Biltricide, generic praziquantel			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BILTRICIDE	PRAZICUANTEL TAB 600 MG	15000050000305	Brand
PRAZICUANTEL	PRAZICUANTEL TAB 600 MG	15000050000305	Generic
<b>Approval Criteria</b>			
1 - ONE of the following:			

**1.1** Infections due to schistosoma

**OR**

**1.2** Infections due to the liver trematodes (flukes), Clonorchis sinensis/Opisthorchis viverrini (i.e., clonorchiasis or opisthorchiasis)

## **2 . Revision History**

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Bimzelx (bimekizumab-bkzx)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-143586
<b>Guideline Name</b>	Bimzelx (bimekizumab-bkzx)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/17/2024
-----------------	-----------

## 1 . Criteria

Product Name: Bimzelx			
Diagnosis	Plaque Psoriasis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BIMZELX	BIMEKIZUMAB-BKZX SUBCUTANEOUS SOLN AUTO-INJECTOR 160 MG/ML	9025051800D520	Brand
BIMZELX	BIMEKIZUMAB-BKZX SUBCUTANEOUS SOLN PREFILLED SYR 160 MG/ML	9025051800E520	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g, chart notes) confirming diagnosis of moderate to severe plaque psoriasis

**AND**

**2** - Submission of medical records (e.g., chart notes) confirming ONE of the following:

- At least 3% body surface area (BSA) involvement
- Severe scalp psoriasis
- Palmoplantar (i.e., palms, soles), facial, or genital involvement

**AND**

**3** - Minimum duration of a 4-week trial and failure, contraindication, or intolerance to ONE of the following topical therapies:

- corticosteroids (e.g., betamethasone, clobetasol)
- vitamin D analogs (e.g., calcitriol, calcipotriene)
- tazarotene
- calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- anthralin
- coal tar

**AND**

**4** - Prescribed by or in consultation with a dermatologist

**AND**

**5** - Both of the following (verified via submission of records or paid pharmacy claims):

**5.1** Trial and failure, contraindication, or intolerance to ONE of the following:

- Enbrel (etanercept)
- Humira (adalimumab)

**AND**

**5.2** Trial and failure, contraindication, or intolerance to Otezla (apremilast)

**AND**

**6** - Not used in combination with other potent immunosuppressants (e.g., azathioprine, cyclosporine)

Product Name: Bimzelx			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BIMZELX	BIMEKIZUMAB-BKZX SUBCUTANEOUS SOLN AUTO-INJECTOR 160 MG/ML	9025051800D520	Brand
BIMZELX	BIMEKIZUMAB-BKZX SUBCUTANEOUS SOLN PREFILLED SYR 160 MG/ML	9025051800E520	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming positive clinical response to therapy as evidenced by ONE of the following:

- Reduction the body surface area (BSA) involvement from baseline
- Improvement in symptoms (e.g., pruritus, inflammation) from baseline

**AND**

**2** - Not used in combination with other potent immunosuppressants (e.g., azathioprine, cyclosporine)

## 2 . Revision History

Date	Notes
2/27/2024	New program.



Blood Glucose Monitors



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140734
<b>Guideline Name</b>	Blood Glucose Monitors
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Non-preferred Blood Glucose Monitors*			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACCU-CHEK AVIVA PLUS	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ACCU-CHEK GUIDE	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ACCU-CHEK GUIDE ME	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ADVANCE INTUITION BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADVOCATE BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ADVOCATE REDI-CODE/TALKING	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
AGAMATRIX JAZZ WIRELESS 2	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
AGAMATRIX PRESTO	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
BD LATITUDE DIABETES MANAGEMENT SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
BD LOGIC BLOOD GLUCOSE MONITOR	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
BIOTEL CARE BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
BIOTEL CARE CONNECTED BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
BLOOD GLUCOSE MONITORING SYSTEM PREMIUM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
BLOOD GLUCOSE SYSTEM PAK	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
CARETOUCH BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
CLEVER CHEK BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
CLEVER CHOICE MICRO BLOODGLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
CONTOUR NEXT BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
CONTOUR NEXT EZ BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
CONTOUR NEXT LINK BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CONTOUR NEXT LINK WIRELESS BLOOD GLUCOSE MONITORING SY	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
CONTOUR NEXT LINK 2.4 WIRELESS BLOOD GLUCOSE MONITORING SYST	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCARD EXPRESSION AUDIO-ENABLED BLOOD GLUCOSE MONITORING	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCARD SHINE	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCARD SHINE CONNEX BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCARD SHINE EXPRESS BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCARD VITAL BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCARD VITAL BLOOD GLUCOSE MONITORING SYSTEM BLACK	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCARD VITAL BLOOD GLUCOSE MONITORING SYSTEM BLUE	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCARD VITAL BLOOD GLUCOSE MONITORING SYSTEM PINK	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCARD X-METER	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCARD 01 BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCARD 01-MINI BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCONAVII BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FORA V30A BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
INFINITY BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
INFINITY VOICE	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
KROGER BLOOD GLUCOSE MONITORING KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
KROGER HEALTHPRO BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
KROGER PREMIUM BLOOD GLUCOSE MONITORING KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
MEIJER BLOOD GLUCOSE MONITORING KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
MEIJER ESSENTIAL BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
MEIJER PREMIUM BLOOD GLUCOSE MONITORING KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
MEIJER TRUERESULT BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
MEIJER TRUETRACK BLOOD GLUCOSE MONITORING KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
MEIJER TRUE2GO BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
MICRODOT BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
MYGLUCOHEALTH BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
NOVA MAX BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ONETOUCH VERIO	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ONETOUCH VERIO FLEX BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OPTIUM BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
PRECISION LINK	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
PRECISION XTRA	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
PRODIGY AUTOCODE BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
PRODIGY AUTOCODE BLOOD GLUCOSE MONITORING/TALKING	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
PRODIGY NO CODING BLOOD GLUCOSE	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
PRODIGY POCKET BLOOD GLUCOSE METER KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
PRODIGY VOICE BLOOD GLUCOSE METER KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
QUICKTEK	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
REFUAH PLUS BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
RELION MICRO BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
RELION PREMIER COMPACT BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
RELION TRUE METRIX AIR BLOOD GLUCOSE METER/BLUETOOTH	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
RELION ULTIMA BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
RIGHTEST GM100 BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
RIGHTEST GM300 BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
RIGHTEST GM550 BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SMART SENSE PREMIUM BLOODGLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
SMART SENSE VALUE BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
SMARTEST EJECT STARTER KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
SMARTEST PERSONA STARTER KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
SMARTEST PRONTO STARTER KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
SMARTEST PROTEGE STARTER KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
SOLUS V2 AUDIBLE BLOOD GLUCOSE MANAGEMENT SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
TRUERESULT BLOOD GLUCOSE MONITORING SYSTEM/NO CODING	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
TRUETRACK BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
TRUETRACK SMART SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
VERASENS BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
WAVESENSE AMP	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
EASY TOUCH GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
EASYMAX NG SELF-MONITORING BLOOD GLUCOSE SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
EASYMAX V BLOOD GLUCOSE SYSTEM/TALKING	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
EASYPRO PLUS	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ELEMENT AUTOCODE SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
FORA TN'G VOICE BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ONE DROP BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ONETOUCH ULTRA MINI	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ONETOUCH ULTRA 2	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ONETOUCH ULTRALINK SYSTEM (DEC)	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ONETOUCH ULTRALINK SYSTEM (HEX)	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ONETOUCH VERIO IQ BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ONETOUCH VERIO REFLECT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
ONETOUCH VERIO SYNC BLOODGLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
FREESTYLE FREEDOM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
FREESTYLE FREEDOM LITE	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
FREESTYLE INSULINX BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
FREESTYLE SIDEKICK II VALUEPACK	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
MM EASY TOUCH BLOOD GLUCOSE METER	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
POCKETCHEM EZ BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
COOL BLOOD GLUCOSE MONITORING KIT	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
CVS ADVANCED GLUCOSE METER	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
FIFTY50 GLUCOSE METER 2.0	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
FORTISCARE SELF-MONITORING BLOOD GLUCOSE SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand

GE100 BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
IGLUCOSE BLOOD GLUCOSE MOITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
GLUCOCOM BLOOD GLUCOSE MONITORING SYSTEM	*BLOOD GLUCOSE MONITORING KIT W/ DEVICE***	97202010006410	Brand
<b>Approval Criteria</b>			
1 - Patient is visually impaired			
Notes	*Please reference background table for list of Non-preferred Blood Glucose Monitors. *Approve Glucose Monitor at NDC Level.		

## 2 . Background

Benefit/Coverage/Program Information			
<b>Non-preferred Blood Glucose Monitors</b>			
CONTOUR KIT NEXT LNK	EASY TOUCH KIT MONITOR	EASYMAX V KIT SYSTEM	
CONTOUR NXT KIT LINK 2.4	KROGER BGM KIT SYSTEM	EASYMAX NG KIT SYSTEM	
CONTOUR KIT NEXT EZ	ELEMENT AUTO KIT SYSTEM	MEIJER BGM KIT ESSENTIA	
CONTOUR KIT NEXT	SMARTEST KIT EJECT	MEIJER GLUCO KIT MONITOR	
CONTOUR KIT MONITOR	SMARTEST KIT PROTEGE	MEIJER BGM KIT PREMIUM	
RELION MICRO KIT	SMARTEST KIT PRONTO	FORA V30A KIT	



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

RELION KIT MONITOR	SMARTEST KIT PERSONA	FORA TN'G KIT VOICE
BD LOGIC KIT MONITOR	GLUCOCOM KIT MONITOR	REFUAH PLUS KIT SYSTEM
BD LATITUDE KIT	RIGHTEST SYS KIT GM300	KROGER BGM KIT
BD LATITUDE KIT SYSTEM	RIGHTEST SYS KIT GM100	KROGER BGM KIT PREMIUM
QUICKTEK KIT	RIGHTEST SYS KIT GM550	CONTOUR KIT LINK 2.4
ADVANCE KIT INTUITIO	IGLUCOSE KIT	EASYMAX V KIT SYSTEM
GLUCOCARD KIT SHNE CON	NOVA MAX KIT SYSTEM	EASYMAX NG KIT SYSTEM
GLUCOCARD KIT SHNE EXP	WAVESENSE KIT KEYNOTE	MYGLUCOHEALT KIT SYSTEM
GLUCOCARD KIT EXPRESSI	AGAMA JAZZ KIT WRLSS 2	MICRODOT KIT SYSTEM
POCKETCHEM KIT EZ	AGAMATRIX KIT PRESTO	ONE TOUCH KIT VERIO FL
GLUCOCARD 01 KIT SYSTEM	WAVESENSE KIT AMP	RELION TRUE KIT MET AIR
GLUCOCARD 01 KIT MINI	SOLUS V2 KIT SYSTEM	VERASENS KIT
GLUCOCARD KIT X-METER	COOL MONITOR KIT	INFINITY KIT VOICE
GLUCOCARD KIT VITAL	TRUERESULT KIT MONITOR	OPTIUM KIT BL GLUC
RELION PREMI KIT COMP SYS	TRUERESULT KIT SYSTEM	PRECISION KIT XTRA
SMART SENSE KIT GLUC SYS	MEIJER BGM KIT ESSENTIA	PRECISION KIT LINK
CVS GLUCOSE KIT METER	MEIJER GLUCO KIT MONITOR	BIOTEL CARE KIT SYSTEM

INFINITY KIT SYSTEM	MEIJER BGM KIT PREMIUM	BIOTEL CARE KIT
EASYPRO KIT MONITOR	FORA V30A KIT	FREESTYLE KIT SIDEKICK
EASYPRO PLUS KIT	FORA TN'G KIT VOICE	FREESTYLE KIT FREEDOM
PRODIGY PCKT KIT METER	REFUAH PLUS KIT SYSTEM	KROGER BGM KIT PREMIUM
PRODIGY AUTO KIT MONITOR	KROGER BGM KIT	CONTOUR KIT LINK 2.4
PRODIGY VOIC KIT METER		
PRODIGY KIT NO CODIN		

### 3 . Revision History

Date	Notes
8/26/2022	C&S to match AZM 10.1.22

Bonjesta and Diclegis



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140634
<b>Guideline Name</b>	Bonjesta and Diclegis
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

## 1 . Criteria

Product Name: Bonjesta, Brand Diclegis, generic doxylamine/pyridoxine			
Diagnosis	Nausea and vomiting associated with pregnancy		
Approval Length	9 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DICLEGIS	DOXYLAMINE-PYRIDOXINE TAB DELAYED RELEASE 10-10 MG	50309902100620	Brand
DOXYLAMINE SUCCINATE/PYRIDOXINE HYDROCHLORIDE	DOXYLAMINE-PYRIDOXINE TAB DELAYED RELEASE 10-10 MG	50309902100620	Generic
BONJESTA	DOXYLAMINE-PYRIDOXINE TAB ER 20- 20 MG	50309902100430	Brand

**Approval Criteria**

1 - Diagnosis of nausea and vomiting associated with pregnancy

**AND**

2 - Documented failure or contraindication to lifestyle modifications (e.g., diet, avoidance of triggers)

**AND**

3 - Documented trial and failure or contraindication to a five day trial of over-the-counter doxylamine taken together with pyridoxine (i.e., not a combined dosage form, but separate formulations taken concomitantly)

**2 . Revision History**

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Breast Cancer



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140709
<b>Guideline Name</b>	Breast Cancer
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Arimidex, generic anastrozole			
Diagnosis	Breast Cancer		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ANASTROZOLE	ANASTROZOLE TAB 1 MG	21402810000310	Generic
ARIMIDEX	ANASTROZOLE TAB 1 MG	21402810000310	Brand
<b>Approval Criteria</b>			

1 - ONE of the following:

1.1 Adjuvant treatment of postmenopausal patients with hormone receptor-positive early breast cancer

OR

1.2 First-line treatment of postmenopausal patients with hormone receptor-positive or hormone receptor status unknown locally advanced or metastatic breast cancer

OR

1.3 Postmenopausal patients with disease progression following tamoxifen therapy

Product Name: Brand Aromasin, generic exemestane			
Diagnosis	Breast Cancer		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AROMASIN	EXEMESTANE TAB 25 MG	21402835000320	Brand
EXEMESTANE	EXEMESTANE TAB 25 MG	21402835000320	Generic

**Approval Criteria**

1 - ONE of the following:

1.1 Adjuvant treatment of postmenopausal patients with estrogen receptor-positive early breast cancer who have received 2 to 3 years of tamoxifen and are switched to exemestane for completion of a total of 5 consecutive years of adjuvant hormonal therapy

OR

1.2 Treatment of advanced breast cancer in postmenopausal patients whose disease has progressed following tamoxifen therapy

Product Name: Brand Fareston, generic toremifene			
Diagnosis	Breast Cancer		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FARESTON	TOREMIFENE CITRATE TAB 60 MG (BASE EQUIVALENT)	21402685100320	Brand
TOREMIFENE CITRATE	TOREMIFENE CITRATE TAB 60 MG (BASE EQUIVALENT)	21402685100320	Generic
<b>Approval Criteria</b>			
1 - Treatment of metastatic breast cancer in postmenopausal patients with estrogen receptor positive tumors or with tumors of unknown estrogen receptor status			

Product Name: Brand Arimidex, generic anastrozole, Brand Aromasin, generic exemestane, Brand Fareston, generic toremifene			
Diagnosis	National Comprehensive Cancer Network (NCCN) Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ANASTROZOLE	ANASTROZOLE TAB 1 MG	21402810000310	Generic
ARIMIDEX	ANASTROZOLE TAB 1 MG	21402810000310	Brand
AROMASIN	EXEMESTANE TAB 25 MG	21402835000320	Brand
EXEMESTANE	EXEMESTANE TAB 25 MG	21402835000320	Generic
FARESTON	TOREMIFENE CITRATE TAB 60 MG (BASE EQUIVALENT)	21402685100320	Brand
TOREMIFENE CITRATE	TOREMIFENE CITRATE TAB 60 MG (BASE EQUIVALENT)	21402685100320	Generic

**Approval Criteria**

1 - Use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.

Product Name: Brand Arimidex, generic anastrozole, Brand Aromasin, generic exemestane, Brand Fareston, generic toremifene

Diagnosis	National Comprehensive Cancer Network (NCCN) Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ANASTROZOLE	ANASTROZOLE TAB 1 MG	21402810000310	Generic
ARIMIDEX	ANASTROZOLE TAB 1 MG	21402810000310	Brand
AROMASIN	EXEMESTANE TAB 25 MG	21402835000320	Brand
EXEMESTANE	EXEMESTANE TAB 25 MG	21402835000320	Generic
FARESTON	TOREMIFENE CITRATE TAB 60 MG (BASE EQUIVALENT)	21402685100320	Brand
TOREMIFENE CITRATE	TOREMIFENE CITRATE TAB 60 MG (BASE EQUIVALENT)	21402685100320	Generic

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22



Breo Ellipta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140803
<b>Guideline Name</b>	Breo Ellipta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Breo Ellipta, generic fluticasone-vilanterol			
Diagnosis	Asthma, COPD		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BREO ELLIPTA	FLUTICASONE FUROATE-VILANTEROL AERO POWD BA 100-25 MCG/ACT	44209902758020	Generic
FLUTICASONE FUROATE/VILANTEROL ELLIPTA	FLUTICASONE FUROATE-VILANTEROL AERO POWD BA 100-25 MCG/ACT	44209902758020	Generic
BREO ELLIPTA	FLUTICASONE FUROATE-VILANTEROL AERO POWD BA 200-25 MCG/ACT	44209902758030	Generic

<p>FLUTICASONE FUROATE/VILANTEROL ELLIPTA</p>	<p>FLUTICASONE FUROATE-VILANTEROL AERO POWD BA 200-25 MCG/ACT</p>	<p>44209902758030</p>	<p>Generic</p>
<p><b>Approval Criteria</b></p> <p><b>1 - ALL of the following:</b></p> <p><b>1.1</b> Diagnosis of asthma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> Patient is 5 years of age or older</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.3</b> The patient has a history of failure, contraindication, or intolerance to treatment with ALL of the following preferred products:</p> <ul style="list-style-type: none"> <li>• Advair Diskus (brand) or Advair HFA</li> <li>• Dulera</li> <li>• Symbicort</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>2 - ALL of the following:</b></p> <p><b>2.1</b> Diagnosis of chronic obstructive pulmonary disease (COPD)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2.2</b> Patient is 18 years of age or older</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2.3 ONE</b> of the following:</p>			

**2.3.1** History of failure, contraindication, or intolerance to treatment with at least a 30 day trial of an orally inhaled anticholinergic agent (e.g., Spiriva, Atrovent, Combivent, Tudorza)

**OR**

**2.3.2** History of failure, contraindication, or intolerance to treatment with at least a 30 day trial of an orally inhaled anticholinergic agent/long-acting beta-agonist combination agent (e.g., Anoro Ellipta, Stiolto Respimat)

**AND**

**2.4** The patient has a history of failure, contraindication, or intolerance to treatment with ALL of the following preferred products:

- Advair Diskus (brand) or Advair HFA
- Dulera
- Symbicort

## 2 . Revision History

Date	Notes
7/7/2023	Added generic, added age criteria

Brexafemme



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140768
<b>Guideline Name</b>	Brexafemme
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	3/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Brexafemme			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BREXAFEMME	IBREXAFUNGERP CITRATE TAB 150 MG	11507040100320	Brand
<p><b>Approval Criteria</b></p> <p>1 - Requested drug is being used for a Food and Drug Administration (FDA)-approved indication</p>			

**AND**

**2** - Trial and failure, contraindication, or intolerance to BOTH of the following:

- One intravaginal product (e.g., clotrimazole, miconazole, tioconazole, terconazole, boric acid)
- Oral fluconazole for a minimum of 3 days duration

## **2 . Revision History**

Date	Notes
2/3/2023	Updated all criteria and approval duration.

Breztri, Trelegy Ellipta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-157271
<b>Guideline Name</b>	Breztri, Trelegy Ellipta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Trelegy Ellipta			
Diagnosis	Asthma		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TRELEGY ELLIPTA	FLUTICASONE-UMECLIDINIUM-VILANTEROL AEPB 100-62.5-25 MCG/ACT	44209903408020	Brand
TRELEGY ELLIPTA	FLUTICASONE-UMECLIDINIUM-VILANTEROL AEPB 200-62.5-25 MCG/ACT	44209903408040	Brand

**Approval Criteria**

1 - Diagnosis of asthma

**AND**

2 - History of failure, contraindication, or intolerance to treatment with ALL of the following preferred products:

- Advair Diskus (brand) or Advair HFA
- Dulera
- Brand Symbicort

**Product Name: Trelegy Ellipta**

Diagnosis	Asthma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TRELEGY ELLIPTA	FLUTICASONE-UMECLIDINIUM-VILANTEROL AEPB 100-62.5-25 MCG/ACT	44209903408020	Brand
TRELEGY ELLIPTA	FLUTICASONE-UMECLIDINIUM-VILANTEROL AEPB 200-62.5-25 MCG/ACT	44209903408040	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**Product Name: Breztri, Trelegy Ellipta**

Diagnosis	COPD
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
TRELEGY ELLIPTA	FLUTICASONE-UMECLIDINIUM-VILANTEROL AEPB 100-62.5-25 MCG/ACT	44209903408020	Brand
TRELEGY ELLIPTA	FLUTICASONE-UMECLIDINIUM-VILANTEROL AEPB 200-62.5-25 MCG/ACT	44209903408040	Brand
BREZTRI AEROSPHERE	BUDESONIDE-GLYCOPYRROLATE-FORMOTEROL AERS 160-9-4.8 MCG/ACT	44209903303220	Brand

**Approval Criteria**

1 - Diagnosis of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema

**AND**

2 - History of failure, contraindication, or intolerance to treatment with at least a 30 day trial of BOTH of the following used in combination:

- Stiolto Respimat (tiotropium-olodaterol)
- Flovent HFA (fluticasone propionate)

Product Name: Breztri, Trelegy Ellipta			
Diagnosis	COPD		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TRELEGY ELLIPTA	FLUTICASONE-UMECLIDINIUM-VILANTEROL AEPB 100-62.5-25 MCG/ACT	44209903408020	Brand
TRELEGY ELLIPTA	FLUTICASONE-UMECLIDINIUM-VILANTEROL AEPB 200-62.5-25 MCG/ACT	44209903408040	Brand
BREZTRI AEROSPHERE	BUDESONIDE-GLYCOPYRROLATE-FORMOTEROL AERS 160-9-4.8 MCG/ACT	44209903303220	Brand



**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**2 . Revision History**

Date	Notes
10/14/2024	Updated guideline name. Added Breztri as a target for COPD. Updated product name list and GPI table accordingly. Formatting updates.

Brilinta and Effient



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150031
<b>Guideline Name</b>	Brilinta and Effient
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brilinta			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BRILINTA	TICAGRELOR TAB 60 MG	85158470000315	Brand
BRILINTA	TICAGRELOR TAB 90 MG	85158470000320	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of acute coronary syndrome (ACS) [e.g., unstable angina (UA), non-ST			

elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI)]

**OR**

**2** - The medication is being used to reduce the risk of a first myocardial infarction (MI) or stroke in a patient with coronary artery disease (CAD) at high risk for such events [e.g., type 2 diabetes mellitus, hypertension, dyslipidemia, multi-vessel CAD, obesity, heart failure, current smoker or chronic kidney disease]

**OR**

**3** - The medication is being used to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score less than or equal to 5) or high-risk transient ischemic attack (TIA)

Product Name: Brand Effient, generic prasugrel

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
EFFIENT	PRASUGREL HCL TAB 5 MG (BASE EQUIV)	85158060100320	Brand
PRASUGREL HYDROCHLORIDE	PRASUGREL HCL TAB 5 MG (BASE EQUIV)	85158060100320	Generic
EFFIENT	PRASUGREL HCL TAB 10 MG (BASE EQUIV)	85158060100330	Brand
PRASUGREL HYDROCHLORIDE	PRASUGREL HCL TAB 10 MG (BASE EQUIV)	85158060100330	Generic

**Approval Criteria**

**1** - Diagnosis of acute coronary syndrome (ACS) [e.g., unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) or ST-segment elevation myocardial infarction (STEMI)]

**AND**

**2** - The patient must be managed with percutaneous coronary intervention (PCI)

## 2 . Revision History

Date	Notes
7/19/2024	Created separate criteria sections for Brilinta and Effient/prasugrel. Updated criteria for both targets. Updated product name lists and GPI table, where applicable.

Bronchitol



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140791
<b>Guideline Name</b>	Bronchitol
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Bronchitol			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BRONCHITOL TOLERANCE TEST	MANNITOL INHAL CAP 40 MG	45307060000140	Brand
BRONCHITOL	MANNITOL INHAL CAP 40 MG	45307060000140	Brand

**Approval Criteria**

1 - Diagnosis of cystic fibrosis (CF)

**AND**

2 - Used in conjunction with standard CF therapies [e.g., chest physiotherapy, bronchodilators, antibiotics, anti-inflammatory therapy (e.g., ibuprofen, oral/inhaled corticosteroids)]

**AND**

3 - Patient has passed the Bronchitol Tolerance Test

Product Name: Bronchitol			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BRONCHITOL TOLERANCE TEST	MANNITOL INHAL CAP 40 MG	45307060000140	Brand
BRONCHITOL	MANNITOL INHAL CAP 40 MG	45307060000140	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Bronchitol therapy			

Buprenorphine Sublingual Tablet



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140782
<b>Guideline Name</b>	Buprenorphine Sublingual Tablet
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	3/19/2023
-----------------	-----------

### 1 . Criteria

Product Name: buprenorphine SL tablets			
Approval Length	6 Months*		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BUPRENORPHINE HYDROCHLORIDE	BUPRENORPHINE HCL SL TAB 2 MG (BASE EQUIV)	65200010100760	Generic
BUPRENORPHINE HCL	BUPRENORPHINE HCL SL TAB 2 MG (BASE EQUIV)	65200010100760	Generic
BUPRENORPHINE HYDROCHLORIDE	BUPRENORPHINE HCL SL TAB 8 MG (BASE EQUIV)	65200010100780	Generic
BUPRENORPHINE HCL	BUPRENORPHINE HCL SL TAB 8 MG (BASE EQUIV)	65200010100780	Generic

**Approval Criteria**

1 - Diagnosis of opioid abuse/dependence

**AND**

2 - ONE of the following:

2.1 Patient is pregnant or breastfeeding\*

**OR**

2.2 BOTH of the following:

2.2.1 Patient had an intolerance or side effect to buprenorphine-naloxone sublingual tablet or film

**AND**

2.2.2 Side effects or intolerances to buprenorphine-naloxone sublingual tablet or films were not resolved with a trial of anti-emetics (e.g., ondansetron) or non-opioid analgesics

**OR**

2.3 Patient has a contraindication to naloxone

**OR**

2.4 BOTH of the following:

2.4.1 Patient has a severe allergy to naloxone [e.g., Stevens-Johnson syndrome, DRESS (Drug Rash with Eosinophilia and Systemic Symptoms)]

**AND**



**2.4.2** Provider has submitted a copy of the MedWatch Form 3500 to the Food and Drug Administration documenting the adverse reaction

**AND**

**3** - Patient is not currently on ANY of the following:

- Benzodiazepines (e.g., Alprazolam, Diazepam, Lorazepam)
- Hypnotics (e.g., Temazepam, Rozerem, Zolpidem)
- Opioids (e.g., Oxycodone, Tramadol, Hydrocodone)

**AND**

**4** - Prescriber attests that the Arizona State Board of Pharmacy Controlled Substance Prescription Drug Monitoring Program database has been reviewed and that patient has been warned about the dangers of ingesting concurrent sedating medications

Notes	*Approve for 1 year if pregnant or breastfeeding
-------	--

## 2 . Revision History

Date	Notes
3/6/2023	Removed X waiver DEA criteria, cleaned up criteria and product name list.

Bylvay (odevixibat)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140998
<b>Guideline Name</b>	Bylvay (odevixibat)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2023
-----------------	-----------

### 1 . Criteria

Product Name: Bylvay			
Diagnosis	Progressive Familial Intrahepatic Cholestasis (PFIC)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BYLVAY	ODEVIXIBAT CAP 400 MCG	52350060000120	Brand
BYLVAY	ODEVIXIBAT CAP 1200 MCG	52350060000140	Brand
BYLVAY (PELLETS)	ODEVIXIBAT PELLETS CAP SPRINKLE 200 MCG	52350060006810	Brand

BYLVAY (PELLETS)	ODEVIXIBAT PELLETS CAP SPRINKLE 600 MCG	52350060006830	Brand
<p><b>Approval Criteria</b></p> <p><b>1</b> - Submission of medical records (e.g., chart notes) confirming diagnosis of progressive familial intrahepatic cholestasis (PFIC) type 1, 2, or 3 confirmed by <b>ONE</b> of the following:</p> <ul style="list-style-type: none"> <li>• Diagnostic test (e.g., liver function test, liver ultrasound and biopsy, bile analysis)</li> <li>• Genetic Testing</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Patient is experiencing <b>BOTH</b> of the following:</p> <ul style="list-style-type: none"> <li>• Moderate to severe pruritus</li> <li>• Patient has a serum bile acid concentration above the upper limit of the normal reference for the reporting laboratory</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is 3 months of age or older</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Patient has had an inadequate response to at least <b>TWO</b> of the following treatments used for the relief of pruritus:</p> <ul style="list-style-type: none"> <li>• Ursodeoxycholic acid (e.g., Ursodiol)</li> <li>• Antihistamines (e.g., diphenhydramine, hydroxyzine)</li> <li>• Rifampin</li> <li>• Bile acid sequestrants (e.g., Questran, Colestid, Welchol)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Prescribed dose is consistent with FDA (Food and Drug Administration)-approved package labeling and does not exceed a total daily dose of 6 mg (milligrams)</p>			

**AND**

**6** - Prescribed by or in consultation with a hepatologist or gastroenterologist

Product Name: Bylvay			
Diagnosis	Progressive Familial Intrahepatic Cholestasis (PFIC)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BYLVAY	ODEVIXIBAT CAP 400 MCG	52350060000120	Brand
BYLVAY	ODEVIXIBAT CAP 1200 MCG	52350060000140	Brand
BYLVAY (PELLETS)	ODEVIXIBAT PELLETS CAP SPRINKLE 200 MCG	52350060006810	Brand
BYLVAY (PELLETS)	ODEVIXIBAT PELLETS CAP SPRINKLE 600 MCG	52350060006830	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy (e.g., reduced serum bile acids, improved pruritus)

**AND**

**2** - Prescribed dose is consistent with FDA-approved package labeling and does not exceed a total daily dose of 6 mg

Product Name: Bylvay	
Diagnosis	Alagille Syndrome (ALGS)
Approval Length	6 month(s)
Therapy Stage	Initial Authorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
BYLVAY	ODEVIXIBAT CAP 400 MCG	52350060000120	Brand
BYLVAY	ODEVIXIBAT CAP 1200 MCG	52350060000140	Brand
BYLVAY (PELLETS)	ODEVIXIBAT PELLETS CAP SPRINKLE 200 MCG	52350060006810	Brand
BYLVAY (PELLETS)	ODEVIXIBAT PELLETS CAP SPRINKLE 600 MCG	52350060006830	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming both of the following:

1.1 Diagnosis of Alagille Syndrome (ALGS)

**AND**

1.2 Molecular genetic testing confirms mutations in the JAG1 or NOTCH2 gene

**AND**

2 - Patient is experiencing BOTH of the following:

- Moderate to severe pruritus
- Patient has a serum bile acid concentration above the upper limit of the normal reference for the reporting laboratory

**AND**

3 - Patient is 12 months of age or older

**AND**

4 - Patient has had an inadequate response to at least TWO of the following treatments used for the relief of pruritus:

- Ursodeoxycholic acid (e.g., Ursodiol)
- Antihistamines (e.g., diphenhydramine, hydroxyzine)
- Rifampin
- Bile acid sequestrants (e.g., Questran, Colestid, Welchol)

**AND**

**5** - Prescribed by or in consultation with a hepatologist or gastroenterologist

**Product Name: Bylvay**

Diagnosis	Alagille Syndrome (ALGS)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
BYLVAY	ODEVIXIBAT CAP 400 MCG	52350060000120	Brand
BYLVAY	ODEVIXIBAT CAP 1200 MCG	52350060000140	Brand
BYLVAY (PELLETS)	ODEVIXIBAT PELLETS CAP SPRINKLE 200 MCG	52350060006810	Brand
BYLVAY (PELLETS)	ODEVIXIBAT PELLETS CAP SPRINKLE 600 MCG	52350060006830	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy (e.g., reduced bile acids, reduced pruritus severity score)

**2 . Revision History**

Date	Notes
9/11/2023	Added criteria for new indication Alagille Syndrome

Cablivi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140868
<b>Guideline Name</b>	Cablivi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	7/1/2021
P&T Approval Date:	
P&T Revision Date:	

## 1 . Criteria

Product Name: Cablivi			
Diagnosis	Acquired thrombotic thrombocytopenic purpura (aTTP)		
Approval Length	2 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CABLIVI	CAPLACIZUMAB-YHDP FOR INJ KIT 11 MG	85151020806420	Brand

**Approval Criteria**

1 - Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP)

**AND**

2 - Cablivi was initiated as a bolus intravenous injection administered by a healthcare provider in combination with plasma exchange therapy

**AND**

3 - Cablivi will be used in combination with immunosuppressive therapy (e.g., corticosteroids)

**AND**

4 - Total treatment duration will be limited to 58 days beyond the last therapeutic plasma exchange

Product Name: Cablivi			
Diagnosis	Acquired thrombotic thrombocytopenic purpura (aTTP)		
Approval Length	2 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CABLIVI	CAPLACIZUMAB-YHDP FOR INJ KIT 11 MG	85151020806420	Brand

**Approval Criteria**

1 - Request is for a new (different) episode requiring the re-initiation of plasma exchange for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) (Documentation of date of prior episode and documentation date of new episode required)



## 2 . Revision History

Date	Notes
4/30/2021	Copy of NY

Cabotegravir Containing Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140810
<b>Guideline Name</b>	Cabotegravir Containing Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2023
-----------------	-----------

### 1 . Criteria

Product Name: Vocabria			
Diagnosis	Treatment of HIV-1 Infection		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VOCABRIA	CABOTEGRAVIR SODIUM TAB 30 MG	12103010200320	Brand
<b>Approval Criteria</b>			
1 - All of the following:			

**1.1** Diagnosis of HIV (human immunodeficiency virus)-1 infection

**AND**

**1.2** Patient is 12 years of age or older

**AND**

**1.3** Patient's weight is greater than or equal to 35 kilograms

**AND**

**1.4** Patient is currently virologically suppressed [HIV-1 RNA (ribonucleic acid) less than 50 copies/milliliter] on a stable, uninterrupted antiretroviral regimen for at least 6 months

**AND**

**1.5** Patient has no history of treatment failure or known/suspected resistance to either cabotegravir or rilpivirine

**AND**

**1.6** Provider attests that patient would benefit from long-acting injectable therapy over standard oral regimens

**AND**

**1.7** Prescribed by or in consultation with a clinician with HIV expertise

**OR**

**2** - For continuation of prior therapy

Product Name: Vocabria			
Diagnosis	HIV-1 Pre-Exposure Prophylaxis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VOCABRIA	CABOTEGRAVIR SODIUM TAB 30 MG	12103010200320	Brand

**Approval Criteria**

1 - Requested drug is being used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV (human immunodeficiency virus)-1 infection

**AND**

2 - Patient's weight is greater than or equal to 35 kilograms

**AND**

3 - Documentation of both of the following U.S. Food and Drug (FDA)-approved test prior to use:

- Negative HIV-1 antigen/antibody test
- Negative HIV-1 RNA (ribonucleic acid) assay

**AND**

4 - One of the following:

4.1 Trial and failure, contraindication or intolerance to BOTH of the following:

- Brand Truvada
- Descovy

**OR**

**4.2** Submission of medical records (e.g., chart notes) from provider documenting BOTH of the following:

- Patient would benefit from long-acting injectable therapy over standard oral regimens
- Patient would be adherent to testing and dosing schedule

Product Name: Vocabria			
Diagnosis	HIV-1 Pre-Exposure Prophylaxis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VOCABRIA	CABOTEGRAVIR SODIUM TAB 30 MG	12103010200320	Brand

**Approval Criteria**

**1** - Provider attests that patient is adherent to the testing appointments and scheduled injections of Apretude

**AND**

**2** - Documentation of both of the following U.S. Food and Drug (FDA)-approved test prior to each maintenance injection of Apretude for HIV PrEP:

- Negative HIV-1 antigen/antibody test
- Negative HIV-1 RNA assay

**2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
9/11/2023	Updated T/F criteria verbiage for PrEP indication.

Camzyos (mavacamten)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140937
<b>Guideline Name</b>	Camzyos (mavacamten)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Camzyos			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CAMZYOS	MAVACAMTEN CAP 2.5 MG	40190050000110	Brand
CAMZYOS	MAVACAMTEN CAP 5 MG	40190050000120	Brand
CAMZYOS	MAVACAMTEN CAP 10 MG	40190050000130	Brand
CAMZYOS	MAVACAMTEN CAP 15 MG	40190050000140	Brand

**Approval Criteria**

**1** - Diagnosis of obstructive hypertrophic cardiomyopathy (HCM)

**AND**

**2** - Patient has New York Heart Association (NYHA) Class II or III symptoms (e.g., shortness of breath, chest pain)

**AND**

**3** - Patient has a left ventricular ejection fraction of greater than or equal to 55%

**AND**

**4** - Patient has valsalva left ventricular outflow tract (LVOT) peak gradient greater than or equal to 50 mmHg at rest or with provocation

**AND**

**5** - Trial and failure, contraindication, or intolerance to both of the following at a maximally tolerated dose:

- non-vasodilating beta blocker (e.g., bisoprolol, propranolol)
- calcium channel blocker (e.g., verapamil, diltiazem)

**AND**

**6** - Prescribed by or in consultation with a cardiologist

Product Name: Camzyos	
Approval Length	12 month(s)
Therapy Stage	Reauthorization



Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
CAMZYOS	MAVACAMTEN CAP 2.5 MG	40190050000110	Brand
CAMZYOS	MAVACAMTEN CAP 5 MG	40190050000120	Brand
CAMZYOS	MAVACAMTEN CAP 10 MG	40190050000130	Brand
CAMZYOS	MAVACAMTEN CAP 15 MG	40190050000140	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy (e.g., improved symptom relief)

**AND**

2 - Patient has a left ventricular ejection fraction of greater than or equal to 50%

**AND**

3 - Prescribed by or in consultation with a cardiologist

**2 . Revision History**

Date	Notes
10/21/2022	New GL

Carbaglu (carglumic acid)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140887
<b>Guideline Name</b>	Carbaglu (carglumic acid)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Carbaglu, Generic carglumic acid			
Diagnosis	Acute Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency		
Approval Length	3 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CARGLUMIC ACID	CARGLUMIC ACID TAB 200 MG	30908230000320	Generic
CARBAGLU	CARGLUMIC ACID TAB 200 MG	30908230000320	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency

**AND**

**2** - Medication will be used as adjunctive therapy to other ammonia lowering therapies (e.g., protein restriction, ammonia scavengers, dialysis)

**AND**

**3** - Prescribed by or in consultation with a specialist focused in the treatment of metabolic disorders

Product Name: Brand Carbaglu, Generic carglumic acid			
Diagnosis	Acute Hyperammonemia due to Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)		
Approval Length	1 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CARGLUMIC ACID	CARGLUMIC ACID TAB 200 MG	30908230000320	Generic
CARBAGLU	CARGLUMIC ACID TAB 200 MG	30908230000320	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA)

**AND**

**2** - Medication will be used as adjunctive therapy to other ammonia lowering therapies (e.g. intravenous glucose, insulin, protein restriction, dialysis)

**AND**

**3** - Patient's plasma ammonia level is greater than or equal to 50 micromol/L

**AND**

**4** - Medication will be used for a maximum duration of 7 days

**AND**

**5** - Prescribed by or in consultation with a specialist focused in the treatment of metabolic disorders

Product Name: Brand Carbaglu, Generic carglumic acid

Diagnosis	Chronic Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
CARGLUMIC ACID	CARGLUMIC ACID TAB 200 MG	30908230000320	Generic
CARBAGLU	CARGLUMIC ACID TAB 200 MG	30908230000320	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency

**AND**

2 - NAGS deficiency has been confirmed by genetic/mutational analysis

**AND**

3 - Medication will be used as maintenance therapy

**AND**

4 - Prescribed by or in consultation with a specialist focused in the treatment of metabolic disorders

Product Name: Brand Carbaglu, Generic carglumic acid			
Diagnosis	Chronic Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CARGLUMIC ACID	CARGLUMIC ACID TAB 200 MG	30908230000320	Generic
CARBAGLU	CARGLUMIC ACID TAB 200 MG	30908230000320	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting a positive clinical response to therapy (e.g., plasma ammonia level within the normal range)			

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22



Cayston



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140846
<b>Guideline Name</b>	Cayston
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Cayston			
Diagnosis	Cystic Fibrosis (CF)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CAYSTON	AZTREONAM LYSINE FOR INHAL SOLN 75 MG (BASE EQUIVALENT)	16140010402120	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of cystic fibrosis (CF)

## 2 . Revision History

Date	Notes
3/31/2020	Bulk copy C&S New York SP to C&S Arizona SP for 5/1 effective



Ceprothin



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140875
<b>Guideline Name</b>	Ceprothin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2022
-----------------	----------

### 1 . Criteria

Product Name: Ceprothin			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CEPROTIN	PROTEIN C CONCENTRATE (HUMAN) FOR IV SOLN 500 UNIT	85550060102120	Brand
CEPROTIN	PROTEIN C CONCENTRATE (HUMAN) FOR IV SOLN 1000 UNIT	85550060102140	Brand

**Approval Criteria**

1 - Diagnosis of severe congenital Protein C deficiency

**AND**

2 - Medication is being used for prevention or treatment of venous thrombosis and/or purpura fulminans

**AND**

3 - Medical record documentation of ONE of the following:

- Low protein C activity
- Low protein C antigen
- Genetic testing demonstrating biallelic mutations in the PROC gene

**AND**

4 - Prescribed by, or in consultation with, a hematologist, or other specialist with expertise in the diagnosis and management of Protein C deficiency

**AND**

5 - Dosing is in accordance with the U.S. Food and Drug Administration (FDA) approved labeling and is adjusted based on the patient's weight, severity of deficiency, and whether treatment is for acute episodes or prophylaxis

Product Name: Ceprothin			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CEPROTIN	PROTEIN C CONCENTRATE (HUMAN) FOR IV SOLN 500 UNIT	85550060102120	Brand

CEPROTIN	PROTEIN C CONCENTRATE (HUMAN) FOR IV SOLN 1000 UNIT	85550060102140	Brand
<p><b>Approval Criteria</b></p> <p>1 - Patient has previously received Ceprotin</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of positive clinical response to Ceprotin</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Dosing is in accordance with the FDA approved labeling and is adjusted based on the patient's weight, severity of deficiency, and whether treatment is for acute episodes or prophylaxis</p>			

## 2 . Revision History

Date	Notes
3/31/2022	New Guideline

CGRP Inhibitors



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-160414
<b>Guideline Name</b>	CGRP Inhibitors
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Aimovig, Emgality 120 mg/mL			
Diagnosis	Preventive Treatment of Migraine		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EMGALITY	GALCANEZUMAB-GNLM SUBCUTANEOUS SOLN AUTO-INJECTOR 120 MG/ML	6770203530D520	Brand
EMGALITY	GALCANEZUMAB-GNLM SUBCUTANEOUS SOLN PREFILLED SYR 120 MG/ML	6770203530E520	Brand
AIMOVIG	ERENUMAB-AOOE SUBCUTANEOUS SOLN AUTO-INJECTOR 70 MG/ML	6770202010D520	Brand

AIMOVIG	ERENUMAB-AOOE SUBCUTANEOUS SOLN AUTO-INJECTOR 140 MG/ML	6770202010D540	Brand
<p><b>Approval Criteria</b></p> <p><b>1 - ONE of the following:</b></p> <p><b>1.1 BOTH of the following:</b></p> <p><b>1.1.1</b> Diagnosis of episodic migraines</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.1.2</b> Patient has 4 to 14 migraine days per month, but no more than 14 headache days per month</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2 ALL of the following:</b></p> <p><b>1.2.1</b> Diagnosis of chronic migraines</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2.2</b> Patient has greater than or equal to 15 headache days per month, of which at least 8 must be migraine days for at least 3 months</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2.3</b> Medication overuse headache has been considered and potentially offending medication(s) have been discontinued</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Patient is 18 years of age or older</b></p>			

**AND**

**3** - TWO of the following:

**3.1** ONE of the following:

**3.1.1** History of failure (after at least a two month trial) or intolerance to Elavil (amitriptyline) or Effexor (venlafaxine)

**OR**

**3.1.2** Patient has a contraindication to both Elavil (amitriptyline) and Effexor (venlafaxine)

**OR**

**3.2** ONE of the following:

**3.2.1** History of failure (after at least a two month trial) or intolerance to Depakote/Depakote ER (divalproex sodium) or Topamax (topiramate)

**OR**

**3.2.2** Patient has a contraindication to both Depakote/Depakote ER (divalproex sodium) and Topamax (topiramate)

**OR**

**3.3** ONE of the following:

**3.3.1** History of failure (after at least a two month trial) or intolerance to ONE of the following beta blockers: atenolol, propranolol, nadolol, timolol, or metoprolol

**OR**

**3.3.2** Patient has a contraindication to ALL of the following beta blockers: atenolol, propranolol, nadolol, timolol, metoprolol

**AND**

**4** - Prescribed by or in consultation with **ONE** of the following specialists:

- Neurologist
- Pain specialist
- Headache specialist\*

**AND**

**5** - Medication will not be used in combination with another CGRP inhibitor for the preventive treatment of migraines

Notes	*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).
-------	---

**Product Name: Aimovig, Emgality 120 mg/mL**

Diagnosis	Preventive Treatment of Migraine
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
EMGALITY	GALCANEZUMAB-GNLM SUBCUTANEOUS SOLN AUTO-INJECTOR 120 MG/ML	6770203530D520	Brand
EMGALITY	GALCANEZUMAB-GNLM SUBCUTANEOUS SOLN PREFILLED SYR 120 MG/ML	6770203530E520	Brand
AIMOVIG	ERENUMAB-AOOE SUBCUTANEOUS SOLN AUTO-INJECTOR 70 MG/ML	6770202010D520	Brand
AIMOVIG	ERENUMAB-AOOE SUBCUTANEOUS SOLN AUTO-INJECTOR 140 MG/ML	6770202010D540	Brand

**Approval Criteria**

**1** - Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity

**AND**

**2** - Use of acute migraine medications [e.g., nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen), triptans (e.g., eletriptan, rizatriptan, sumatriptan)] has decreased since the start of CGRP therapy

**AND**

**3** - Prescribed by or in consultation with one of the following specialists:

- Neurologist
- Pain specialist
- Headache specialist\*

**AND**

**4** - For Chronic Migraine only: Patient continues to be monitored for medication overuse headache (MOH)

**AND**

**5** - Medication will not be used in combination with another CGRP inhibitor for the preventive treatment of migraines

Notes	*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).
-------	---

Product Name: Emgality 100 mg/mL			
Diagnosis	Episodic Cluster Headaches		
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic



EMGALITY	GALCANEZUMAB-GNLM SUBCUTANEOUS SOLN PREFILLED SYR 100 MG/ML	6770203530E515	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of episodic cluster headache</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least three months</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is 18 years of age or older</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Prescribed by or in consultation with ONE of the following specialists:</p> <ul style="list-style-type: none"> <li>• Neurologist</li> <li>• Pain specialist</li> <li>• Headache specialist*</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>5 - Medication will not be used in combination with another injectable CGRP inhibitor</p>			
Notes		*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).	

Product Name: Emgality 100 mg/mL	
Diagnosis	Episodic Cluster Headaches
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
EMGALITY	GALCANEZUMAB-GNLM SUBCUTANEOUS SOLN PREFILLED SYR 100 MG/ML	6770203530E515	Brand
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Prescribed by or in consultation with ONE of the following specialists:</p> <ul style="list-style-type: none"> <li>• Neurologist</li> <li>• Pain specialist</li> <li>• Headache specialist*</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Medication will not be used in combination with another injectable CGRP inhibitor</p>			
Notes		*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).	

Product Name: Ajoovy, Qulipta, Vyepti			
Diagnosis	Preventive Treatment of Migraine		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
QULIPTA	ATOGEANT TAB 10 MG	67701010000310	Brand
QULIPTA	ATOGEANT TAB 30 MG	67701010000320	Brand
QULIPTA	ATOGEANT TAB 60 MG	67701010000330	Brand

VYEPTI	EPTINEZUMAB-JJMR IV SOLN 100 MG/ML	67702015202020	Brand
AJOVY	FREMANEZUMAB-VFRM SUBCUTANEOUS SOLN AUTO-INJ 225 MG/1.5ML	6770203020D520	Brand
AJOVY	FREMANEZUMAB-VFRM SUBCUTANEOUS SOLN PREF SYR 225 MG/1.5ML	6770203020E520	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 BOTH of the following:

1.1.1 Diagnosis of episodic migraines

**AND**

1.1.2 Patient has 4 to 14 migraine days per month, but no more than 14 headache days per month

**OR**

1.2 ALL of the following:

1.2.1 Diagnosis of chronic migraines

**AND**

1.2.2 Patient has greater than or equal to 15 headache days per month, of which at least 8 must be migraine days for at least 3 months

**AND**

1.2.3 Medication overuse headache has been considered and potentially offending medication(s) have been discontinued

**AND**

**2** - Patient is 18 years of age or older

**AND**

**3** - TWO of the following:

**3.1** ONE of the following:

**3.1.1** History of failure (after at least a two month trial) or intolerance to Elavil (amitriptyline) or Effexor (venlafaxine)

**OR**

**3.1.2** Patient has a contraindication to both Elavil (amitriptyline) and Effexor (venlafaxine)

**OR**

**3.2** ONE of the following:

**3.2.1** History of failure (after at least a two month trial) or intolerance to Depakote/Depakote ER (divalproex sodium) or Topamax (topiramate)

**OR**

**3.2.2** Patient has a contraindication to both Depakote/Depakote ER (divalproex sodium) and Topamax (topiramate)

**OR**

**3.3** ONE of the following:

**3.3.1** History of failure (after at least a two month trial) or intolerance to ONE of the following beta blockers: atenolol, propranolol, nadolol, timolol, or metoprolol

**OR**

**3.3.2** Patient has a contraindication to ALL of the following beta blockers: atenolol, propranolol, nadolol, timolol, metoprolol

**AND**

**4** - Trial and failure, contraindication, or intolerance to BOTH of the following:

- Aimovig
- Emgality

**AND**

**5** - Prescribed by or in consultation with ONE of the following specialists:

- Neurologist
- Pain specialist
- Headache specialist\*

**AND**

**6** - Medication will not be used in combination with another CGRP inhibitor for the preventive treatment of migraines

Notes	*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).
-------	---

Product Name: Ajoovy, Qulipta, Vyepti			
Diagnosis	Preventive Treatment of Migraine		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
QULIPTA	ATOGEANT TAB 10 MG	67701010000310	Brand
QULIPTA	ATOGEANT TAB 30 MG	67701010000320	Brand
QULIPTA	ATOGEANT TAB 60 MG	67701010000330	Brand

VYEPTI	EPTINEZUMAB-JJMR IV SOLN 100 MG/ML	67702015202020	Brand
AJOVY	FREMANEZUMAB-VFRM SUBCUTANEOUS SOLN AUTO-INJ 225 MG/1.5ML	6770203020D520	Brand
AJOVY	FREMANEZUMAB-VFRM SUBCUTANEOUS SOLN PREF SYR 225 MG/1.5ML	6770203020E520	Brand

**Approval Criteria**

1 - Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity

**AND**

2 - Use of acute migraine medications [e.g., nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen), triptans (e.g., eletriptan, rizatriptan, sumatriptan)] has decreased since the start of CGRP (calcitonin gene-related peptide) therapy

**AND**

3 - Trial and failure, contraindication, or intolerance to BOTH of the following:

- Aimovig
- Emgality

**AND**

4 - Prescribed by or in consultation with ONE of the following specialists:

- Neurologist
- Pain specialist
- Headache specialist\*

**AND**

5 - For Chronic Migraine only: Patient continues to be monitored for medication overuse headache (MOH)

**AND**

**6** - Medication will not be used in combination with another CGRP inhibitor for the preventive treatment of migraines

Notes	*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).
-------	---

Product Name: Nurtec ODT			
Diagnosis	Preventive Treatment of Episodic Migraine		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NURTEC	RIMEGEPANT SULFATE TAB DISINT 75 MG	67701060707220	Brand

**Approval Criteria**

**1** - BOTH of the following:

**1.1** Diagnosis of episodic migraines

**AND**

**1.2** Patient has 4 to 18 migraine days per month, but no more than 18 headache days per month

**AND**

**2** - Patient is 18 years of age or older

**AND**

**3 - TWO of the following:**

**3.1 ONE of the following:**

**3.1.1** History of failure (after at least a two month trial) or intolerance to Elavil (amitriptyline) or Effexor (venlafaxine)

**OR**

**3.1.2** Patient has a contraindication to both Elavil (amitriptyline) and Effexor (venlafaxine)

**OR**

**3.2 ONE of the following:**

**3.2.1** History of failure (after at least a two month trial) or intolerance to Depakote/Depakote ER (divalproex sodium) or Topamax (topiramate)

**OR**

**3.2.2** Patient has a contraindication to both Depakote/Depakote ER (divalproex sodium) and Topamax (topiramate)

**OR**

**3.3 ONE of the following:**

**3.3.1** History of failure (after at least a two month trial) or intolerance to ONE of the following beta blockers: atenolol, propranolol, nadolol, timolol, or metoprolol

**OR**

**3.3.2** Patient has a contraindication to ALL of the following beta blockers: atenolol, propranolol, nadolol, timolol, metoprolol

**AND**



**4** - Trial and failure, contraindication, or intolerance to BOTH of the following:

- Aimovig
- Emgality

**AND**

**5** - Prescribed by or in consultation with ONE of the following specialists:

- Neurologist
- Pain specialist
- Headache specialist\*

**AND**

**6** - Medication will not be used in combination with another CGRP inhibitor for the preventive treatment of migraines

Notes	*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).
-------	---

Product Name: Nurtec ODT			
Diagnosis	Preventive Treatment of Episodic Migraine		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NURTEC	RIMEGEPANT SULFATE TAB DISINT 75 MG	67701060707220	Brand
<b>Approval Criteria</b>			
1 - Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity			

**AND**

**2** - Use of acute migraine medications [e.g., nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen), triptans (e.g., eletriptan, rizatriptan, sumatriptan)] has decreased since the start of CGRP therapy

**AND**

**3** - Prescribed by or in consultation with ONE of the following specialists:

- Neurologist
- Pain specialist
- Headache specialist\*

**AND**

**4** - Medication will not be used in combination with another CGRP inhibitor for the preventive treatment of migraines

Notes	*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).
-------	---

Product Name: Nurtec ODT, Zavzpret			
Diagnosis	Acute Treatment of Migraine		
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NURTEC	RIMEGEPANT SULFATE TAB DISINT 75 MG	67701060707220	Brand
ZAVZPRET	ZAVEGEPANT HCL NASAL SPRAY 10 MG/ACT	67701090202020	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of migraine with or without aura

**AND**

2 - Will be used for the acute treatment of migraine

**AND**

3 - Patient has fewer than 15 headache days per month

**AND**

4 - Patient is 18 years of age or older

**AND**

5 - Patient has a history of a one-month trial resulting in therapeutic failure, contraindication, or intolerance to FOUR of the following as evidenced by submission of medical records or claims history:

- naratriptan tablets
- rizatriptan tablets/ODT (Oral Disintegrating Tablets)
- sumatriptan auto injection/cartridge
- Imitrex nasal spray (Brand only)
- zolmitriptan tablets/ODT
- Zomig nasal spray (Brand only)

**AND**

6 - Patient has a history of a one-month trial resulting in therapeutic failure, contraindication, or intolerance to Ubrelvy as evidenced by submission of medical records or claims history\*\*

**AND**

7 - If patient has 4 or more headache days per month, patient must meet ONE of the following:

**7.1** Currently being treated with Elavil (amitriptyline) or Effexor (venlafaxine) unless there is a contraindication or intolerance to these medications

**OR**

**7.2** Currently being treated with Depakote/Depakote ER (divalproex sodium) or Topamax (topiramate) unless there is a contraindication or intolerance to these medications

**OR**

**7.3** Currently being treated with a beta blocker (i.e., atenolol, propranolol, nadolol, timolol, or metoprolol) unless there is a contraindication or intolerance to these medications

**AND**

**8** - Prescribed by or in consultation with ONE of the following specialists:

- Neurologist
- Pain specialist
- Headache specialist\*

**AND**

**9** - Medication will not be used in combination with another oral CGRP inhibitor

Notes

\*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).  
 \*\*Patients requesting initial authorization who were established on the rapy via the receipt of a manufacturer supplied sample at no cost in th e prescriber’s office or any form of assistance from the manufacturer s ponsored programs shall be required to meet initial authorization criter ia as if patient were new to therapy.

Product Name: Nurtec ODT, Zavzpret

Diagnosis Acute Treatment of Migraine

Approval Length 12 month(s)

Therapy Stage Reauthorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
NURTEC	RIMEGEPANT SULFATE TAB DISINT 75 MG	67701060707220	Brand
ZAVZPRET	ZAVEGEPANT HCL NASAL SPRAY 10 MG/ACT	67701090202020	Brand
<p><b>Approval Criteria</b></p> <p><b>1</b> - Patient has experienced a positive response to therapy (e.g., reduction in pain, photophobia, phonophobia, nausea)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Prescribed by or in consultation with ONE of the following specialists:</p> <ul style="list-style-type: none"> <li>• Neurologist</li> <li>• Pain specialist</li> <li>• Headache specialist*</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Medication will not be used in combination with another oral CGRP inhibitor</p>			
Notes		*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).	

Product Name: Ubrelvy			
Diagnosis		Acute Treatment of Migraine	
Approval Length		3 month(s)	
Therapy Stage		Initial Authorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
UBRELVY	UBROGEPANT TAB 50 MG	67701080000320	Brand
UBRELVY	UBROGEPANT TAB 100 MG	67701080000340	Brand

**Approval Criteria**

1 - Diagnosis of migraine with or without aura

**AND**

2 - Will be used for the acute treatment of migraine

**AND**

3 - Will not be used for preventive treatment of migraine

**AND**

4 - Patient has fewer than 15 headache days per month

**AND**

5 - Patient is 18 years of age or older

**AND**

6 - Patient has a history of a one-month trial resulting in therapeutic failure, contraindication, or intolerance to TWO of the following as evidenced by submission of medical records or claims history:

- naratriptan tablets
- rizatriptan tablets/ODT (Oral Disintegrating Tablets)
- sumatriptan auto injection/cartridge
- zolmitriptan tablets/ODT
- Zomig nasal spray (Brand only)
- Imitrex nasal spray (Brand only)

**AND**

**7** - If patient has 4 or more headache days per month, patient must meet ONE of the following:

**7.1** Currently being treated with Elavil (amitriptyline) or Effexor (venlafaxine) unless there is a contraindication or intolerance to these medications

**OR**

**7.2** Currently being treated with Depakote/Depakote ER (divalproex sodium) or Topamax (topiramate) unless there is a contraindication or intolerance to these medications

**OR**

**7.3** Currently being treated with a beta blocker (i.e., atenolol, propranolol, nadolol, timolol, or metoprolol) unless there is a contraindication or intolerance to these medications

**AND**

**8** - Prescribed by or in consultation with ONE of the following specialists:

- Neurologist
- Pain specialist
- Headache specialist\*

**AND**

**9** - Medication will not be used in combination with another oral CGRP inhibitor

Notes	*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).
-------	---

Product Name: Ubrelvy	
Diagnosis	Acute Treatment of Migraine
Approval Length	12 month(s)

Therapy Stage		Reauthorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
UBRELVY	UBROGEPANT TAB 50 MG	67701080000320	Brand
UBRELVY	UBROGEPANT TAB 100 MG	67701080000340	Brand
<p><b>Approval Criteria</b></p> <p>1 - Patient has experienced a positive response to therapy (e.g., reduction in pain, photophobia, phonophobia, nausea)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Will not be used for preventive treatment of migraine</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with ONE of the following specialists:</p> <ul style="list-style-type: none"> <li>• Neurologist</li> <li>• Pain specialist</li> <li>• Headache specialist*</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>4 - Medication will not be used in combination with another oral CGRP inhibitor</p>			
Notes		*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS).	

## 2 . Revision History

Date	Notes
------	-------



11/11/2024	Updates throughout guideline to reflect Aimovig is now preferred and Ajovy is non-preferred; Minor cosmetic updates.
------------	--

Cholbam



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140913
<b>Guideline Name</b>	Cholbam
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Cholbam			
Diagnosis	Bile Acid Synthesis Disorder		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CHOLBAM	CHOLIC ACID CAP 50 MG	52700025000120	Brand
CHOLBAM	CHOLIC ACID CAP 250 MG	52700025000140	Brand

**Approval Criteria**

1 - Diagnosis of a bile acid synthesis disorder

**AND**

2 - It is due to single enzyme defects

Product Name: Cholbam

Diagnosis	Peroxisomal Disorders Including Zellweger Spectrum Disorders
-----------	--

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Initial Authorization
---------------	-----------------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
CHOLBAM	CHOLIC ACID CAP 50 MG	52700025000120	Brand
CHOLBAM	CHOLIC ACID CAP 250 MG	52700025000140	Brand

**Approval Criteria**

1 - Diagnosis of peroxisomal disorders including Zellweger spectrum disorders

**AND**

2 - Patient exhibits manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption

**AND**

3 - It is being used as adjunctive treatment

Product Name: Cholbam

Diagnosis	All Indications
-----------	-----------------

Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CHOLBAM	CHOLIC ACID CAP 50 MG	52700025000120	Brand
CHOLBAM	CHOLIC ACID CAP 250 MG	52700025000140	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Cholbam therapy			

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Cialis for BPH



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140729
<b>Guideline Name</b>	Cialis for BPH
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Cialis 5mg, generic tadalafil 5mg			
Diagnosis	Benign Prostatic Hyperplasia (BPH)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CIALIS	TADALAFIL TAB 5 MG	40304080000305	Brand
TADALAFIL	TADALAFIL TAB 5 MG	40304080000305	Generic
<b>Approval Criteria</b>			

**1** - All of the following:

**1.1** The patient has a diagnosis of benign prostatic hyperplasia (BPH)

**AND**

**1.2** History of failure, intolerance, or contraindication to BOTH of the following:

- Alpha Blockers (e.g., tamsulosin, alfuzosin ER, doxazosin, or terazosin)
- 5-alpha reductase inhibitors (e.g., finasteride)

**AND**

**1.3** Dose does not exceed 5 milligrams once daily

**AND**

**2** - Provider attests that patient is not using any form of organic nitrate (for example, nitroglycerin, isosorbide dinitrate, isosorbide mononitrate or amyl nitrate) or Adempas

## 2 . Revision History

Date	Notes
8/9/2022	C&S to match AZM 10.1.22

Cibinqo (abrocitinib)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-144105
<b>Guideline Name</b>	Cibinqo (abrocitinib)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	4/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Cibinqo			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CIBINQO	ABROCITINIB TAB 50 MG	90272005000320	Brand
CIBINQO	ABROCITINIB TAB 100 MG	90272005000325	Brand
CIBINQO	ABROCITINIB TAB 200 MG	90272005000330	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of moderate to severe atopic dermatitis

**AND**

**2** - Submission of medical records documenting ONE of the following:

- Involvement of at least 10% body surface area (BSA)
- SCORing Atopic Dermatitis (SCORAD) index value of at least 25

**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Dermatologist
- Allergist/Immunologist

**AND**

**4** - Submission of medical records (e.g., chart notes, lab work, imaging) or paid claims history documenting ALL of the following\*\*:

**4.1** History of failure, contraindication, or intolerance to the following topical therapies: (document drug, date of trial, and/or contraindication to medication)\*

- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
- Eucrisa (crisaborole)

**AND**

**4.2** Trial and failure of a minimum 12-week supply of Dupixent (dupilumab)

**AND**

**4.3** Trial and failure of a minimum 12-week supply of Adbry (tralokinumab-ldrm)



**AND**

**5** - Not used in combination with biologic immunomodulators (e.g., Dupixent, Adbry) or other immunosuppressants (e.g., azathioprine, cyclosporine)

**AND**

**6** - Patient is 12 years of age or older

Notes

\*Note: Claims history may be used in conjunction as documentation of drug, date, and/or contraindication to medication

\*\*PA may be required. PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCPA>

Product Name: Cibinqo

Approval Length 12 month(s)

Therapy Stage Reauthorization

Guideline Type Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
CIBINQO	ABROCITINIB TAB 50 MG	90272005000320	Brand
CIBINQO	ABROCITINIB TAB 100 MG	90272005000325	Brand
CIBINQO	ABROCITINIB TAB 200 MG	90272005000330	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting a positive clinical response to therapy as evidenced by at least ONE of the following:

- Reduction in body surface area involvement from baseline
- Reduction in SCORing Atopic Dermatitis (SCORAD) index value from baseline

**AND**

2 - Not used in combination with biologic immunomodulators (e.g., Dupixent, Adbry) or other immunosuppressants (e.g., azathioprine, cyclosporine)

## 2 . Background

<b>Clinical Practice Guidelines</b>			
<b>Table 1. Relative potencies of topical corticosteroids</b>			
<b>Class</b>	<b>Drug</b>	<b>Dosage Form</b>	<b>Strength (%)</b>
Very high potency	Augmented betamethasone dipropionate	Ointment, gel	0.05
	Clobetasol propionate	Cream, foam, ointment	0.05
	Diflorasone diacetate	Ointment	0.05
	Halobetasol propionate	Cream, ointment	0.05
High Potency	Amcinonide	Cream, lotion, ointment	0.1
	Augmented betamethasone dipropionate	Cream, lotion	0.05
	Betamethasone dipropionate	Cream, foam, ointment, solution	0.05
	Desoximetasone	Cream, ointment	0.25
	Desoximetasone	Gel	0.05
	Diflorasone diacetate	Cream	0.05
	Fluocinonide	Cream, gel, ointment, solution	0.05
	Halcinonide	Cream, ointment	0.1

	Mometasone furoate	Ointment	0.1
	Triamcinolone acetonide	Cream, ointment	0.5
Medium potency	Betamethasone valerate	Cream, foam, lotion, ointment	0.1
	Clocortolone pivalate	Cream	0.1
	Desoximetasone	Cream	0.05
	Fluocinolone acetonide	Cream, ointment	0.025
	Flurandrenolide	Cream, ointment, lotion	0.05
	Fluticasone propionate	Cream	0.05
	Fluticasone propionate	Ointment	0.005
	Mometasone furoate	Cream, lotion	0.1
	Triamcinolone acetonide	Cream, ointment, lotion	0.1
Lower-medium potency	Hydrocortisone butyrate	Cream, ointment, solution	0.1
	Hydrocortisone probutate	Cream	0.1
	Hydrocortisone valerate	Cream, ointment	0.2
	Prednicarbate	Cream	0.1
Low potency	Alclometasone dipropionate	Cream, ointment	0.05
	Desonide	Cream, gel, foam, ointment	0.05
	Fluocinolone acetonide	Cream, solution	0.01
Lowest potency	Dexamethasone	Cream	0.1
	Hydrocortisone	Cream, lotion, ointment, solution	0.25, 0.5, 1
	Hydrocortisone acetate	Cream, ointment	0.5-1

### 3 . Revision History

Date	Notes
------	-------

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

3/8/2024	Updated criteria to include submission of records where applicable and updated notes section. Added embedded step through Adbry in initial auth section.
----------	--

Cimzia



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140986
<b>Guideline Name</b>	Cimzia
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Cimzia, Cimzia Starter Kit			
Diagnosis	Crohn's Disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CIMZIA	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 2 X 200 MG/ML	5250502010F840	Brand
CIMZIA STARTER KIT	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 6 X 200 MG/ML	5250502010F840	Brand
CIMZIA	CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG	52505020106420	Brand

**Approval Criteria**

**1** - ALL of the following:

**1.1** Diagnosis of moderately to severely active Crohn's disease

**AND**

**1.2** History of failure to ONE of the following conventional therapies at maximally indicated doses within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial):\*

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- 6-mercaptopurine (Purinethol)
- Azathioprine (Imuran)
- Methotrexate (Rheumatrex, Trexall)

**AND**

**1.3** Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD (disease modifying antirheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**1.4** History of failure, contraindication, or intolerance to Humira (adalimumab)

**AND**

**1.5** Prescribed by or in consultation with a gastroenterologist

**OR**

**2 - ALL of the following:**

**2.1** Patient is currently on Cimzia therapy as documented by claims history or medical records (document drug, date, and duration of therapy)

**AND**

**2.2** Diagnosis of Crohn's disease

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with a gastroenterologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.
-------	---

Product Name: Cimzia, Cimzia Starter Kit			
Diagnosis	Crohn's Disease		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CIMZIA	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 2 X 200 MG/ML	5250502010F840	Brand
CIMZIA STARTER KIT	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 6 X 200 MG/ML	5250502010F840	Brand

CIMZIA	CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG	52505020106420	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Cimzia therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Cimzia in combination with any of the following:</p> <ul style="list-style-type: none"> <li>• Biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]</li> <li>• Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]</li> <li>• Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with a gastroenterologist</p>			

Product Name: Cimzia, Cimzia Starter Kit			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CIMZIA	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 2 X 200 MG/ML	5250502010F840	Brand
CIMZIA STARTER KIT	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 6 X 200 MG/ML	5250502010F840	Brand
CIMZIA	CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG	52505020106420	Brand
<p><b>Approval Criteria</b></p>			



**1** - ALL of the following:

**1.1** Diagnosis of moderately to severely active rheumatoid arthritis (RA)

**AND**

**1.2** History of failure to a 3 month trial of one non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

**1.3** Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**1.4** History of failure, contraindication, or intolerance to ALL of the following:

- Humira (adalimumab)
- Enbrel (etanercept)
- Xeljanz (tofacitinib)

**AND**

**1.5** Prescribed by or in consultation with a rheumatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Cimzia therapy as documented by claims history or medical records (document drug, date, and duration of therapy)

**AND**

**2.2** Diagnosis of moderately to severely active RA

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.
-------	---

Product Name: Cimzia, Cimzia Starter Kit			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CIMZIA	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 2 X 200 MG/ML	5250502010F840	Brand
CIMZIA STARTER KIT	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 6 X 200 MG/ML	5250502010F840	Brand
CIMZIA	CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG	52505020106420	Brand
<b>Approval Criteria</b>			

**1** - Documentation of positive clinical response to Cimzia therapy

**AND**

**2** - Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

**Product Name: Cimzia, Cimzia Starter Kit**

Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
CIMZIA	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 2 X 200 MG/ML	5250502010F840	Brand
CIMZIA STARTER KIT	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 6 X 200 MG/ML	5250502010F840	Brand
CIMZIA	CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG	52505020106420	Brand

**Approval Criteria**

**1** - ALL of the following:

**1.1** Diagnosis of active psoriatic arthritis

**AND**

**1.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

**1.3** Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**1.4** History of failure, contraindication, or intolerance to THREE of the following:

- Humira (adalimumab)
- Enbrel (etanercept)
- Otezla (apremilast)
- Xeljanz (tofacitinib)

**AND**

**1.5** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Cimzia therapy as documented by claims history or medical records (document drug, date, and duration of therapy)

**AND**

**2.2** Diagnosis of active psoriatic arthritis

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.
-------	---

Product Name: Cimzia, Cimzia Starter Kit			
Diagnosis	Psoriatic Arthritis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CIMZIA	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 2 X 200 MG/ML	5250502010F840	Brand
CIMZIA STARTER KIT	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 6 X 200 MG/ML	5250502010F840	Brand
CIMZIA	CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG	52505020106420	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Cimzia therapy

**AND**

2 - Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Product Name: Cimzia, Cimzia Starter Kit			
Diagnosis	Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CIMZIA	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 2 X 200 MG/ML	5250502010F840	Brand
CIMZIA STARTER KIT	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 6 X 200 MG/ML	5250502010F840	Brand
CIMZIA	CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG	52505020106420	Brand

**Approval Criteria**

**1** - ALL of the following:

**1.1** Diagnosis of active ankylosing spondylitis or non-radiographic axial spondyloarthritis

**AND**

**1.2** History of failure to two NSAIDs [non-steroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen)] at maximally indicated doses, each used for at least 4 weeks within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trials)\*

**AND**

**1.3** Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD (disease modifying antirheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**1.4** History of failure, contraindication, or intolerance to BOTH of the following:

- Humira (adalimumab)
- Enbrel (etanercept)

**AND**

**1.5** Prescribed by or in consultation with a rheumatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Cimzia therapy as documented by claims history or medical records (document drug, date, and duration of therapy)

**AND**

**2.2** Diagnosis of active ankylosing spondylitis or non-radiographic axial spondyloarthritis

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with a rheumatologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trials.
-------	--

Product Name: Cimzia, Cimzia Starter Kit			
Diagnosis	Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CIMZIA	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 2 X 200 MG/ML	5250502010F840	Brand
CIMZIA STARTER KIT	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 6 X 200 MG/ML	5250502010F840	Brand
CIMZIA	CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG	52505020106420	Brand



**Approval Criteria**

1 - Documentation of positive clinical response to Cimzia therapy

**AND**

2 - Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a rheumatologist

Product Name: Cimzia, Cimzia Starter Kit			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CIMZIA	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 2 X 200 MG/ML	5250502010F840	Brand
CIMZIA STARTER KIT	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 6 X 200 MG/ML	5250502010F840	Brand
CIMZIA	CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG	52505020106420	Brand
<b>Approval Criteria</b>			
1 - ALL of the following:			

**1.1** Diagnosis of moderate to severe plaque psoriasis

**AND**

**1.2** Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**1.3** History of failure to one of the following topical therapies, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial):\*

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**1.4** History of failure of a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

**1.5** Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD (disease modifying antirheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**1.6** History of failure, contraindication, or intolerance to ALL of the following:

- Humira (adalimumab)
- Enbrel (etanercept)
- Otezla (apremilsat)

**AND**

**1.7** Prescribed by or in consultation with a dermatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Cimzia therapy as documented by claims history or medical records (document drug, date, and duration of therapy)

**AND**

**2.2** Diagnosis of moderate to severe plaque psoriasis

**AND**

**2.3** Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**2.4** Prescribed by or in consultation with a dermatologist

Notes

\*Claims history may be used in conjunction as documentation of drug, date, and duration of trials.

Product Name: Cimzia, Cimzia Starter Kit

Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
CIMZIA	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 2 X 200 MG/ML	5250502010F840	Brand
CIMZIA STARTER KIT	CERTOLIZUMAB PEGOL PREFILLED SYRINGE KIT 6 X 200 MG/ML	5250502010F840	Brand
CIMZIA	CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG	52505020106420	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Cimzia therapy

**AND**

2 - Patient is NOT receiving Cimzia in combination with any of the following:

- Biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a dermatologist

**2 . Revision History**

Date	Notes
7/7/2023	Updated guideline name, updated GPI and product name lists, cleaned up criteria, numbering, and notes.



Colony Stimulating Factors



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-145894
<b>Guideline Name</b>	Colony Stimulating Factors
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Nivestym, Leukine, Neupogen, Releuko, Zarxio			
Diagnosis	Bone Marrow/Stem Cell Transplant		
Approval Length	3 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152010E520	Brand
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152010E530	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 300 MCG/ML	82401520102020	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 480 MCG/1.6ML (300 MCG/ML)	82401520102030	Brand

LEUKINE	SARGRAMOSTIM LYOPHILIZED FOR INJ 250 MCG	82402050002120	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152000E545	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML (600 MCG/ML)	8240152000E550	Brand
NEUPOGEN	FILGRASTIM INJ 300 MCG/ML	82401520002010	Brand
NEUPOGEN	FILGRASTIM INJ 480 MCG/1.6ML (300 MCG/ML)	82401520002012	Brand
RELEUKO	FILGRASTIM-AYOW SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152015E520	Brand
RELEUKO	FILGRASTIM-AYOW SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152015E530	Brand
RELEUKO	FILGRASTIM-AYOW INJ SOLN 300 MCG/ML	82401520152020	Brand
RELEUKO	FILGRASTIM-AYOW INJ SOLN 480 MCG/1.6ML (300 MCG/ML)	82401520152030	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152060E530	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152060E540	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 Patient has non-myeloid malignancies and is undergoing myeloablative chemotherapy followed by autologous or allogeneic bone marrow transplant (BMT)

**OR**

1.2 Used for mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis

**OR**

1.3 Patient has had a peripheral stem cell transplant (PSCT) and has received myeloablative chemotherapy

**AND**

2 - Prescribed by, or in consultation with, a hematologist or oncologist

**AND**

3 - If the request is non-preferred\*, patient has a history of failure, contraindication, or intolerance to BOTH of the following:

- Neupogen
- Nivestym

Notes

\*PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP>

Product Name: Nivestym, Leukine, Neupogen, Releuko, Zarxio

Diagnosis: AML Induction or Consolidation Therapy

Approval Length: 3 month(s)

Guideline Type: Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152010E520	Brand
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152010E530	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 300 MCG/ML	82401520102020	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 480 MCG/1.6ML (300 MCG/ML)	82401520102030	Brand
LEUKINE	SARGRAMOSTIM LYOPHILIZED FOR INJ 250 MCG	82402050002120	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152000E545	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML (600 MCG/ML)	8240152000E550	Brand
NEUPOGEN	FILGRASTIM INJ 300 MCG/ML	82401520002010	Brand
NEUPOGEN	FILGRASTIM INJ 480 MCG/1.6ML (300 MCG/ML)	82401520002012	Brand
RELEUKO	FILGRASTIM-AYOW SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152015E520	Brand
RELEUKO	FILGRASTIM-AYOW SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152015E530	Brand



RELEUKO	FILGRASTIM-AYOW INJ SOLN 300 MCG/ML	82401520152020	Brand
RELEUKO	FILGRASTIM-AYOW INJ SOLN 480 MCG/1.6ML (300 MCG/ML)	82401520152030	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152060E530	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152060E540	Brand

**Approval Criteria**

1 - Diagnosis of acute myeloid leukemia (AML)

**AND**

2 - Patient has completed either induction or consolidation chemotherapy

**AND**

3 - Prescribed by, or in consultation with, a hematologist or oncologist

**AND**

4 - If the request is non-preferred\*, patient has a history of failure, contraindication, or intolerance to BOTH of the following:

- Neupogen
- Nivestym

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Nivestym, Ziextenzo, Fulphila, Leukine, Neulasta, Neulasta Onpro, Neupogen, Nyvepria, Udenyca, Udenyca Onbody, Zarxio	
Diagnosis	Neutropenia Associated with Cancer Chemotherapy - Dose Dense Chemotherapy
Approval Length	3 month(s)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152010E520	Brand
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152010E530	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 300 MCG/ML	82401520102020	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 480 MCG/1.6ML (300 MCG/ML)	82401520102030	Brand
LEUKINE	SARGRAMOSTIM LYOPHILIZED FOR INJ 250 MCG	82402050002120	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152000E545	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML (600 MCG/ML)	8240152000E550	Brand
NEUPOGEN	FILGRASTIM INJ 300 MCG/ML	82401520002010	Brand
NEUPOGEN	FILGRASTIM INJ 480 MCG/1.6ML (300 MCG/ML)	82401520002012	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152060E530	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152060E540	Brand
ZIEXTENZO	PEGFILGRASTIM-BMEZ SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157005E520	Brand
FULPHILA	PEGFILGRASTIM-JMDB SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157020E520	Brand
NEULASTA	PEGFILGRASTIM SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157000E520	Brand
NEULASTA ONPRO KIT	PEGFILGRASTIM SOLN PREFILLED SYRINGE KIT 6 MG/0.6ML	8240157000F820	Brand
NYVEPRIA	PEGFILGRASTIM-APGF SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157002E520	Brand
UDENYCA	PEGFILGRASTIM-CBQV SOLN AUTO-INJECTOR 6 MG/0.6ML	8240157010D520	Brand
UDENYCA	PEGFILGRASTIM-CBQV SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157010E520	Brand
UDENYCA ONBODY	PEGFILGRASTIM-CBQV SOLN PREFILL SYR/INFUSION DEV 6 MG/0.6ML	8240157010E525	Brand

**Approval Criteria**

1 - ONE of the following:

**1.1** Patient is receiving National Cancer Institute’s Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer

**OR**

**1.2** Patient is receiving a dose-dense chemotherapy regimen for which the incidence of febrile neutropenia (FN) is unknown

**AND**

**2** - Prescribed by, or in consultation with, a hematologist or oncologist

**AND**

**3** - If the request is non-preferred\*, patient has a history of failure, contraindication, or intolerance to ALL of the following:

- Neupogen
- Nivestym
- Nyvepria
- Udenyca or Udenyca Onbody
- Ziextenzo

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Fylmetra, Nivestym, Ziextenzo, Fulphila, Granix, Neulasta, Neulasta Onpro, Neupogen, Nyvepria, Stimufend, Udenyca, Udenyca Onbody, Zarxio			
Diagnosis	Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia (FN)		
Approval Length	3 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152010E520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152010E530	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 300 MCG/ML	82401520102020	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 480 MCG/1.6ML (300 MCG/ML)	82401520102030	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152000E545	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML (600 MCG/ML)	8240152000E550	Brand
NEUPOGEN	FILGRASTIM INJ 300 MCG/ML	82401520002010	Brand
NEUPOGEN	FILGRASTIM INJ 480 MCG/1.6ML (300 MCG/ML)	82401520002012	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152060E530	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152060E540	Brand
ZIEXTENZO	PEGFILGRASTIM-BMEZ SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157005E520	Brand
FULPHILA	PEGFILGRASTIM-JMDB SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157020E520	Brand
NEULASTA	PEGFILGRASTIM SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157000E520	Brand
NEULASTA ONPRO KIT	PEGFILGRASTIM SOLN PREFILLED SYRINGE KIT 6 MG/0.6ML	8240157000F820	Brand
NYVEPRIA	PEGFILGRASTIM-APGF SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157002E520	Brand
FYLNETRA	PEGFILGRASTIM-PBBK SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157060E520	Brand
GRANIX	TBO-FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152070E530	Brand
GRANIX	TBO-FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152070E540	Brand
GRANIX	TBO-FILGRASTIM SUBCUTANEOUS INJ 300 MCG/ML	82401520702020	Brand
GRANIX	TBO-FILGRASTIM SUBCUTANEOUS INJ 480 MCG/1.6ML (300 MCG/ML)	82401520702030	Brand
STIMUFEND	PEGFILGRASTIM-FPGK SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157015E520	Brand
UDENYCA	PEGFILGRASTIM-CBQV SOLN AUTO-INJECTOR 6 MG/0.6ML	8240157010D520	Brand
UDENYCA	PEGFILGRASTIM-CBQV SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157010E520	Brand
UDENYCA ONBODY	PEGFILGRASTIM-CBQV SOLN PREFILL SYR/INFUSION DEV 6 MG/0.6ML	8240157010E525	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 Patient is receiving chemotherapy regimen(s) associated with greater than 20 percent incidence of febrile neutropenia (FN)

**OR**

1.2 BOTH of the following:

- Patient is receiving chemotherapy regimen(s) associated with 10-20 percent incidence of FN
- Patient has one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia

**AND**

2 - Prescribed by, or in consultation with, a hematologist or oncologist

**AND**

3 - If the request is non-preferred\*, patient has a history of failure, contraindication, or intolerance to ALL of the following:

- Fylnetra
- Neupogen
- Nivestym
- Nyvepria
- Udenyca or Udenyca Onbody
- Ziextenzo

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Nivestym, Ziextenzo, Fulphila, Granix, Neulasta, Neulasta Onpro, Neupogen, Nyvepria, Stimufend, Udenyca, Udenyca Onbody, Zarxio

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Diagnosis	Secondary Prophylaxis of Febrile Neutropenia (FN)		
Approval Length	3 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152010E520	Brand
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152010E530	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 300 MCG/ML	82401520102020	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 480 MCG/1.6ML (300 MCG/ML)	82401520102030	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152000E545	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML (600 MCG/ML)	8240152000E550	Brand
NEUPOGEN	FILGRASTIM INJ 300 MCG/ML	82401520002010	Brand
NEUPOGEN	FILGRASTIM INJ 480 MCG/1.6ML (300 MCG/ML)	82401520002012	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152060E530	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152060E540	Brand
ZIEXTENZO	PEGFILGRASTIM-BMEZ SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157005E520	Brand
FULPHILA	PEGFILGRASTIM-JMDB SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157020E520	Brand
NEULASTA	PEGFILGRASTIM SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157000E520	Brand
NEULASTA ONPRO KIT	PEGFILGRASTIM SOLN PREFILLED SYRINGE KIT 6 MG/0.6ML	8240157000F820	Brand
NYVEPRIA	PEGFILGRASTIM-APGF SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157002E520	Brand
GRANIX	TBO-FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152070E530	Brand
GRANIX	TBO-FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152070E540	Brand
GRANIX	TBO-FILGRASTIM SUBCUTANEOUS INJ 300 MCG/ML	82401520702020	Brand
GRANIX	TBO-FILGRASTIM SUBCUTANEOUS INJ 480 MCG/1.6ML (300 MCG/ML)	82401520702030	Brand
STIMUFEND	PEGFILGRASTIM-FPGK SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157015E520	Brand

UDENYCA	PEGFILGRASTIM-CBQV SOLN AUTO-INJECTOR 6 MG/0.6ML	8240157010D520	Brand
UDENYCA	PEGFILGRASTIM-CBQV SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157010E520	Brand
UDENYCA ONBODY	PEGFILGRASTIM-CBQV SOLN PREFILL SYR/INFUSION DEV 6 MG/0.6ML	8240157010E525	Brand

**Approval Criteria**

1 - Patient is receiving myelosuppressive anti-cancer drugs associated with neutropenia [absolute neutrophil count (ANC) less than or equal to 500 cells per mm<sup>3</sup> (cubic millimeter)]

**AND**

2 - Patient has a history of febrile neutropenia (FN) during a previous course of chemotherapy

**AND**

3 - Prescribed by, or in consultation with, a hematologist or oncologist

**AND**

4 - If the request is non-preferred\*, patient has a history of failure, contraindication, or intolerance to ALL of the following:

- Neupogen
- Nivestym
- Nyvepria
- Udenyca or Udenyca Onbody
- Ziextenzo

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP</a>
-------	--

Product Name: Fylnetra, Nivestym, Ziextenzo, Fulphila, Leukine, Neulasta, Neulasta Onpro, Neupogen, Nyvepria, Stimufend, Udenyca, Udenyca Onbody, Zarxio

Diagnosis	Treatment of Febrile Neutropenia (FN) (off-label)
-----------	---

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Approval Length	1 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152010E520	Brand
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152010E530	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 300 MCG/ML	82401520102020	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 480 MCG/1.6ML (300 MCG/ML)	82401520102030	Brand
LEUKINE	SARGRAMOSTIM LYOPHILIZED FOR INJ 250 MCG	82402050002120	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152000E545	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML (600 MCG/ML)	8240152000E550	Brand
NEUPOGEN	FILGRASTIM INJ 300 MCG/ML	82401520002010	Brand
NEUPOGEN	FILGRASTIM INJ 480 MCG/1.6ML (300 MCG/ML)	82401520002012	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152060E530	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152060E540	Brand
ZIEXTENZO	PEGFILGRASTIM-BMEZ SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157005E520	Brand
FULPHILA	PEGFILGRASTIM-JMDB SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157020E520	Brand
NEULASTA	PEGFILGRASTIM SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157000E520	Brand
NEULASTA ONPRO KIT	PEGFILGRASTIM SOLN PREFILLED SYRINGE KIT 6 MG/0.6ML	8240157000F820	Brand
NYVEPRIA	PEGFILGRASTIM-APGF SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157002E520	Brand
FYLNETRA	PEGFILGRASTIM-PBBK SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157060E520	Brand
STIMUFEND	PEGFILGRASTIM-FPGK SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157015E520	Brand
UDENYCA	PEGFILGRASTIM-CBQV SOLN AUTO-INJECTOR 6 MG/0.6ML	8240157010D520	Brand
UDENYCA	PEGFILGRASTIM-CBQV SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157010E520	Brand
UDENYCA ONBODY	PEGFILGRASTIM-CBQV SOLN PREFILL SYR/INFUSION DEV 6 MG/0.6ML	8240157010E525	Brand



**Approval Criteria**

**1** - Patient is receiving myelosuppressive anti-cancer drugs associated with neutropenia [absolute neutrophil count (ANC) less than or equal to 500 cells per mm<sup>3</sup> (cubic millimeter)]

**AND**

**2** - Diagnosis of febrile neutropenia (FN) and patient is considered high risk for infection-associated complications

**AND**

**3** - Prescribed by, or in consultation with, a hematologist or oncologist

**AND**

**4** - If the request is non-preferred\*, patient has a history of failure, contraindication, or intolerance to ALL of the following:

- Fylnetra
- Neupogen
- Nivestym
- Nyvepria
- Udenyca or Udenyca Onbody
- Ziextenzo

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Nivestym, Neupogen, Zarxio	
Diagnosis	Severe Chronic Neutropenia (SCN)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152010E520	Brand
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152010E530	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 300 MCG/ML	82401520102020	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 480 MCG/1.6ML (300 MCG/ML)	82401520102030	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152000E545	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML (600 MCG/ML)	8240152000E550	Brand
NEUPOGEN	FILGRASTIM INJ 300 MCG/ML	82401520002010	Brand
NEUPOGEN	FILGRASTIM INJ 480 MCG/1.6ML (300 MCG/ML)	82401520002012	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152060E530	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152060E540	Brand

**Approval Criteria**

**1** - Diagnosis of severe chronic neutropenia (SCN) [i.e., congenital, cyclic, and idiopathic neutropenias with chronic absolute neutrophil count (ANC) less than or equal to 500 cells per mm<sup>3</sup> (cubic millimeter)]

**AND**

**2** - Prescribed by, or in consultation with, a hematologist or oncologist

**AND**

**3** - If the request is non-preferred\*, patient has a history of failure, contraindication, or intolerance to BOTH of the following:

- Neupogen
- Nivestym

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC%20CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP</a>
-------	--

Product Name: Nivestym, Leukine, Neupogen, Zarxio	
Diagnosis	HIV-Related Neutropenia (off-label)
Approval Length	6 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152010E520	Brand
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152010E530	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 300 MCG/ML	82401520102020	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 480 MCG/1.6ML (300 MCG/ML)	82401520102030	Brand
LEUKINE	SARGRAMOSTIM LYOPHILIZED FOR INJ 250 MCG	82402050002120	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152000E545	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML (600 MCG/ML)	8240152000E550	Brand
NEUPOGEN	FILGRASTIM INJ 300 MCG/ML	82401520002010	Brand
NEUPOGEN	FILGRASTIM INJ 480 MCG/1.6ML (300 MCG/ML)	82401520002012	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152060E530	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152060E540	Brand

**Approval Criteria**

1 - Diagnosis of human immunodeficiency virus (HIV) infection

**AND**

2 - Patient has an absolute neutrophil count (ANC) less than or equal to 1,000 cells per mm<sup>3</sup>

**AND**

**3** - Prescribed by, or in consultation with, ONE of the following:

- Hematologist
- Oncologist
- Infectious disease specialist

**AND**

**4** - If the request is non-preferred\*, patient has a history of failure, contraindication, or intolerance to BOTH of the following:

- Neupogen
- Nivestym

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Nivestym, Neupogen, Zarxio			
Diagnosis	Hepatitis C Treatment Related Neutropenia (off-label)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152010E520	Brand
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152010E530	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 300 MCG/ML	82401520102020	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 480 MCG/1.6ML (300 MCG/ML)	82401520102030	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152000E545	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML (600 MCG/ML)	8240152000E550	Brand
NEUPOGEN	FILGRASTIM INJ 300 MCG/ML	82401520002010	Brand

NEUPOGEN	FILGRASTIM INJ 480 MCG/1.6ML (300 MCG/ML)	82401520002012	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152060E530	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152060E540	Brand

**Approval Criteria**

**1 - ONE** of the following:

**1.1 ALL** of the following:

- Diagnosis of hepatitis C virus
- Patient is undergoing treatment with Peg-Intron (peginterferon alfa-2b) or Pegasys (peginterferon alfa-2a)
- Documentation of neutropenia [absolute neutrophil count (ANC) less than or equal to 500 cells per mm<sup>3</sup>] after dose reduction of Peg-Intron or Pegasys

**OR**

**1.2 BOTH** of the following:

**1.2.1** Documentation of interferon-induced neutropenia (ANC less than or equal to 500 cells per mm<sup>3</sup>) due to treatment with Peg-Intron (peginterferon alfa-2b) or Pegasys (peginterferon alfa-2a)

**AND**

**1.2.2 ONE** of the following:

- Diagnosis of human immunodeficiency virus (HIV) co-infection
- Status post liver transplant
- Diagnosis of established cirrhosis

**AND**

**2 - Prescribed by, or in consultation with, a hematologist, oncologist, gastroenterologist, hepatologist, or infectious disease specialist**

**AND**

**3** - If the request is non-preferred\*, patient has a history of failure, contraindication, or intolerance to BOTH of the following:

- Neupogen
- Nivestym

Notes

\*PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP>

Product Name: Fylnetra, Nivestym, Ziextenzo, Fulphila, Leukine, Neulasta, Neulasta Onpro, Neupogen, Nyvepria, Stimufend, Udenyca, Udenyca Onbody, Zarxio

Diagnosis	Hematopoietic Syndrome of Acute Radiation Syndrome
Approval Length	3 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152010E520	Brand
NIVESTYM	FILGRASTIM-AAFI SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152010E530	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 300 MCG/ML	82401520102020	Brand
NIVESTYM	FILGRASTIM-AAFI INJ 480 MCG/1.6ML (300 MCG/ML)	82401520102030	Brand
LEUKINE	SARGRAMOSTIM LYOPHILIZED FOR INJ 250 MCG	82402050002120	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152000E545	Brand
NEUPOGEN	FILGRASTIM SOLN PREFILLED SYRINGE 480 MCG/0.8ML (600 MCG/ML)	8240152000E550	Brand
NEUPOGEN	FILGRASTIM INJ 300 MCG/ML	82401520002010	Brand
NEUPOGEN	FILGRASTIM INJ 480 MCG/1.6ML (300 MCG/ML)	82401520002012	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 300 MCG/0.5ML	8240152060E530	Brand
ZARXIO	FILGRASTIM-SNDZ SOLN PREFILLED SYRINGE 480 MCG/0.8ML	8240152060E540	Brand
ZIEXTENZO	PEGFILGRASTIM-BMEZ SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157005E520	Brand

FULPHILA	PEGFILGRASTIM-JMDB SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157020E520	Brand
NEULASTA	PEGFILGRASTIM SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157000E520	Brand
NEULASTA ONPRO KIT	PEGFILGRASTIM SOLN PREFILLED SYRINGE KIT 6 MG/0.6ML	8240157000F820	Brand
NYVEPRIA	PEGFILGRASTIM-APGF SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157002E520	Brand
FYLNETRA	PEGFILGRASTIM-PBBK SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157060E520	Brand
STIMUFEND	PEGFILGRASTIM-FPGK SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157015E520	Brand
UDENYCA	PEGFILGRASTIM-CBQV SOLN AUTO-INJECTOR 6 MG/0.6ML	8240157010D520	Brand
UDENYCA	PEGFILGRASTIM-CBQV SOLN PREFILLED SYRINGE 6 MG/0.6ML	8240157010E520	Brand
UDENYCA ONBODY	PEGFILGRASTIM-CBQV SOLN PREFILL SYR/INFUSION DEV 6 MG/0.6ML	8240157010E525	Brand

**Approval Criteria**

1 - Patient has been acutely exposed to myelosuppressive doses of radiation

**AND**

2 - Prescribed by, or in consultation with, a hematologist or oncologist

**AND**

3 - If the request is non-preferred\*, patient has a history of failure, contraindication, or intolerance to ALL of the following:

- Fylnetra
- Neupogen
- Nivestym
- Nyvepria
- Udenyca or Udenyca Onbody
- Ziextenzo

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

## 2 . Revision History

Date	Notes
4/18/2024	Updated prerequisites for embedded steps throughout guideline.



Combination Basal Insulin-GLP-1 Receptor Agonist



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140772
<b>Guideline Name</b>	Combination Basal Insulin-GLP-1 Receptor Agonist
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	3/19/2023
-----------------	-----------

### 1 . Criteria

Product Name: Soliqua			
Approval Length	12 month(s)		
Guideline Type	Step Therapy		
Product Name	Generic Name	GPI	Brand/Generic
SOLIQUA 100/33	INSULIN GLARGINE-LIXISENATIDE SOL PEN-INJ 100-33 UNIT-MCG/ML	2799100235D220	Brand
<b>Approval Criteria</b>			
1 - Inadequately controlled on BOTH of the following			

- GLP-1 (glucagon-like peptide-1) receptor agonist [e.g., Adlyxin (lixisenatide), Trulicity (dulaglutide), Victoza (liraglutide), Bydureon (exenatide extended-release), Byetta (exenatide)]
- Basal insulin (e.g., insulin glargine, insulin degludec, insulin detemir)

**Product Name: Xultophy**

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
XULTOPHY 100/3.6	INSULIN DEGLUDEC-LIRAGLUTIDE SOL PEN-INJ 100-3.6 UNIT-MG/ML	2799100225D220	Brand

**Approval Criteria**

1 - Diagnosis of type 2 diabetes mellitus

**AND**

2 - Inadequately controlled on BOTH of the following:

- GLP-1 (glucagon-like peptide-1) receptor agonist [e.g., Adlyxin (lixisenatide), Trulicity (dulaglutide), Victoza (liraglutide), Bydureon (exenatide extended-release), Byetta (exenatide)]
- Basal insulin (e.g., insulin glargine, insulin degludec, insulin detemir)

**AND**

3 - History of failure, intolerance, or contraindication to Soliqua

**Product Name: Xultophy**

Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
XULTOPHY 100/3.6	INSULIN DEGLUDEC-LIRAGLUTIDE SOL PEN-INJ 100-3.6 UNIT-MG/ML	2799100225D220	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Xultophy therapy</p>			

## 2 . Revision History

Date	Notes
2/9/2023	Removed TD criteria section.

Compounds and Bulk Powders



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-143553
<b>Guideline Name</b>	Compounds and Bulk Powders
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	3/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Requests for Compounds or Bulk Powders			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Administrative		
<b>Product Name</b>	<b>Generic Name</b>	<b>GPI</b>	<b>Brand/Generic</b>
Bulk Powder			
Compound Preparation			
<b>Approval Criteria</b>			

**1** - One of the following:

**1.1** The compound is an antibiotic.

**OR**

**1.2** Each active ingredient in the compounded drug is a covered medication

**AND**

**2** - ONE of the following:

**2.1** Each active ingredient in the compounded drug is to be administered for an FDA (Food and Drug Administration)-approved indication

**OR**

**2.2** The use of each active ingredient in the compounded drug is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

**3** - If a drug included in the compound requires prior authorization and/or step therapy, all drug specific clinical criteria must also be met

**AND**

**4** - The compounded drug must not include any ingredient that has been withdrawn or removed from the market due to safety reasons.

**AND**

**5** - ONE of the following:

**5.1** A unique vehicle is required for topically administered compounds

**OR**

**5.2** A unique dosage form is required for a commercially available product due to patient's age, weight, or inability to take a solid dosage form

**OR**

**5.3** A unique formulation is required for a commercially available product due to an allergy or intolerance to an inactive ingredient in the commercially available product

**OR**

**5.4** There is a shortage of the commercially available product per the FDA Drug Shortage database or the ASHP Current Drug Shortages tracking log

**AND**

**6** - Coverage for compounds and bulk powders will NOT be approved for any of the following:

**6.1** For topical compound preparations (e.g. creams, ointments, lotions, or gels to be applied to the skin for transdermal, transcutaneous, or any other topical route), requested compound contains any FDA approved ingredient that is not FDA approved for TOPICAL use (see Table 1 in Background section)

**OR**

**6.2** If the requested compound contains topical fluticasone, topical fluticasone will NOT be approved unless both of the following are met:

**6.2.1** Topical fluticasone is intended to treat a dermatologic condition (scar treatments are considered cosmetic and will not be covered)

**AND**

**6.2.2** Patient has a contraindication to all commercially available topical fluticasone formulations

**OR**

**6.3** Requested compound contains any ingredients when used for cosmetic purposes (see Table 2 in Background section)

**OR**

**6.4** Requested compound contains any ingredient(s) which are on the FDA's Do Not Compound List (see Table 3 in Background section)

**Product Name: Requests for Compounds or Bulk Powders**

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Administrative

Product Name	Generic Name	GPI	Brand/Generic
Bulk Powder			
Compound Preparation			

**Approval Criteria**

1 - Patient demonstrates positive clinical response to therapy

**2 . Background**

**Benefit/Coverage/Program Information**

**Table 1: Example topical compound preparations that contain any FDA approved ingredient that are not FDA approved for TOPICAL use, including but NOT LIMITED TO the following:**

- (1) Ketamine
- (2) Gabapentin
- (3) Flurbiprofen (topical ophthalmic use not included)
- (4) Ketoprofen
- (5) Morphine
- (6) Nabumetone
- (7) Oxycodone
- (8) Cyclobenzaprine
- (9) Baclofen
- (10) Tramadol
- (11) Hydrocodone
- (12) Meloxicam
- (13) Amitriptyline
- (14) Pentoxifylline
- (15) Orphenadrine
- (16) Piroxicam
- (17) Levocetirizine
- (18) Amantadine



- (19) Oxytocin
- (20) Sumatriptan
- (21) Chorionic gonadotropin (human)
- (22) Clomipramine
- (23) Dexamethasone
- (24) Hydromorphone
- (25) Methadone
- (26) Papaverine
- (27) Mefenamic acid
- (28) Promethazine
- (29) Succimer DMSA
- (30) Tizanidine
- (31) Apomorphine
- (32) Carbamazepine
- (33) Ketorolac
- (34) Dimercaptopropane-sulfonate
- (35) Dimercaptosuccinic acid
- (36) Duloxetine
- (37) Fluoxetine
- (38) Bromfenac (topical ophthalmic use not included)
- (39) Nepafenac (topical ophthalmic use not included)

**Table 2: Example compounds that contain ingredients for cosmetic purposes:**

- (1) Hydroquinone
- (2) Acetyl hexapeptide-8
- (3) Tocopheryl Acid Succinate
- (4) PracaSil TM-Plus
- (5) Chrysaderm Day Cream
- (6) Chrysaderm Night Cream
- (7) PCCA Spira-Wash
- (8) Lipopen Ultra
- (9) Versapro
- (10) Fluticasone
- (11) Mometasone
- (12) Halobetasol
- (13) Betamethasone
- (14) Clobetasol
- (15) Triamcinolone
- (16) Minoxidil
- (17) Tretinoin
- (18) Dexamethasone
- (19) Spironolactone
- (20) Cycloserine
- (21) Tamoxifen
- (22) Sermorelin

- (23) Mederma Cream
- (24) PCCA Cosmetic HRT Base
- (25) Sanare Scar Therapy Cream
- (26) Scarcin Cream
- (27) Apothederm
- (28) Stera Cream
- (29) Copasil
- (30) Collagenase
- (31) Arbutin Alpha
- (32) Nourisil
- (33) Freedom Cepapro
- (34) Freedom Silomac Andydrous
- (35) Retinaldehyde
- (36) Apothederm

**Table 3: Example ingredients on the FDA's Do Not Compound List:**

- (1) 3,3',4',5-tetrachlorosalicylanilide
- (2) Adenosine phosphate
- (3) Adrenal cortex
- (4) Alatrofloxacin mesylate
- (5) Aminopyrine
- (6) Astemizole

- (7) Azaribine
- (8) Benoxaprofen
- (9) Bithionol
- (10) Camphorated oil
- (11) Carbetapentane citrate
- (12) Casein, iodinated
- (13) Cerivastatin sodium
- (14) Chlormadinone acetate
- (15) Chloroform
- (16) Cisapride
- (17) Defenfluramine hydrochloride
- (18) Diamthazole dihydrochloride
- (19) Dibromsalan
- (20) Dihydrostreptomycin sulfate
- (21) Dipyrone
- (22) Encainide hydrochloride
- (23) Etreinate
- (24) Fenfluramine hydrochloride
- (25) Flosequinan
- (26) Glycerol, iodinated
- (27) Grepafloxacin
- (28) Mepazine

- (29) Metabromsalan
- (30) Methapyrilene
- (31) Methopholine
- (32) Methoxyflurane
- (33) Mibefradil dihydrochloride
- (34) Nomifensine maleate
- (35) Novobiocin sodium
- (36) Oxyphenisatin acetate
- (37) Oxyphenisatin
- (38) Pemoline
- (39) Pergolide mesylate
- (40) Phenacetin
- (41) Phenformin hydrochloride
- (42) Phenylpropanolamine
- (43) Pipamazine
- (44) Potassium arsenite
- (45) Propoxyphene
- (46) Rapacuronium bromide
- (47) Rofecoxib
- (48) Sibutramine hydrochloride
- (49) Sparteine sulfate
- (50) Sulfadimethoxine

- (51) Sweet spirits of nitre
- (52) Tegaserod maleate
- (53) Temafloxacin hydrochloride
- (54) Terfenadine
- (55) Ticrynafen
- (56) Tribromsalan
- (57) Trichloroethane
- (58) Troglitazone
- (59) Trovafloxacin mesylate:
- (60) Urethane
- (61) Valdecoxib
- (62) Zomepirac sodium

### 3 . Revision History

Date	Notes
2/26/2024	Changed initial approval duration to 6 months and added reauth with 12 month approval duration.

Constipation Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-148442
<b>Guideline Name</b>	Constipation Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Amitiza, generic lubiprostone			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUBIPROSTONE	LUBIPROSTONE CAP 8 MCG	52450045000110	Generic
LUBIPROSTONE	LUBIPROSTONE CAP 24 MCG	52450045000120	Generic
AMITIZA	LUBIPROSTONE CAP 8 MCG	52450045000110	Brand
AMITIZA	LUBIPROSTONE CAP 24 MCG	52450045000120	Brand

**Approval Criteria**

**1 - ONE** of the following:

**1.1 ONE** of the following diagnoses:

- Opioid-induced constipation in an adult with chronic, non-cancer pain
- Opioid-induced constipation in patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation
- Chronic idiopathic constipation

**OR**

**1.2 BOTH** of the following:

- Diagnosis of irritable bowel syndrome with constipation
- Patient was female at birth

**AND**

**2 - BOTH** of the following:

**2.1** Trial and failure, contraindication, or intolerance to an osmotic laxative (e.g., lactulose, polyethylene glycol, sorbitol)

**AND**

**2.2** Trial and failure, contraindication, or intolerance to **ONE** of the following:

- Bulk Forming Laxatives (e.g., psyllium, fiber)
- Stimulant Laxatives (e.g., bisacodyl, senna)

Product Name: Ibsrela	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization



Product Name	Generic Name	GPI	Brand/Generic
IBSRELA	TENAPANOR HCL TAB 50 MG	52558580100320	Brand

**Approval Criteria**

1 - Diagnosis of irritable bowel syndrome with constipation

**AND**

2 - History of failure, contraindication, or intolerance to BOTH of the following:

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

3 - History of failure, contraindication, or intolerance to ONE of the following:

- Lubiprostone
- Linzess

Product Name: Linzess	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

  

Product Name	Generic Name	GPI	Brand/Generic
LINZESS	LINACLOTIDE CAP 72 MCG	52557050000110	Brand
LINZESS	LINACLOTIDE CAP 145 MCG	52557050000120	Brand
LINZESS	LINACLOTIDE CAP 290 MCG	52557050000140	Brand

**Approval Criteria**

**1** - ONE of the following:

**1.1** BOTH of the following:

**1.1.1** ONE of the following diagnoses:

- Chronic idiopathic constipation
- Irritable bowel syndrome with constipation

**AND**

**1.1.2** Patient is greater than or equal to 18 years of age

**OR**

**1.2** ALL of the following:

- Diagnosis of functional constipation
- Patient is 6-17 years of age
- The request is for Linzess 72 mcg

**AND**

**2** - BOTH of the following:

**2.1** Trial and failure, contraindication, or intolerance to an osmotic laxative (e.g., (lactulose, polyethylene glycol, sorbitol)

**AND**

**2.2** Trial and failure, contraindication, or intolerance to ONE of the following:

- Bulk Forming Laxatives (e.g., psyllium, fiber)
- Stimulant Laxatives (e.g., bisacodyl, senna)

Product Name: Motegrity

Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MOTEGRITY	PRUCALOPRIDE SUCCINATE TAB 1 MG (BASE EQUIVALENT)	52560060200320	Brand
MOTEGRITY	PRUCALOPRIDE SUCCINATE TAB 2 MG (BASE EQUIVALENT)	52560060200330	Brand

**Approval Criteria**

1 - Diagnosis of chronic idiopathic constipation

**AND**

2 - BOTH of the following:

2.1 History of failure, contraindication, or intolerance to BOTH of the following:

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

2.2 History of failure, contraindication, or intolerance to BOTH of the following:

- Linzess
- Lubiprostone

Product Name: Movantik	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
MOVANTIK	NALOXEGOL OXALATE TAB 12.5 MG (BASE EQUIVALENT)	52580060300320	Brand
MOVANTIK	NALOXEGOL OXALATE TAB 25 MG (BASE EQUIVALENT)	52580060300330	Brand

**Approval Criteria**

1 - ONE of the following diagnoses:

- Opioid-induced constipation in patients being treated for chronic, non-cancer pain
- Opioid-induced constipation in patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation

Product Name: Relistor tablet, Relistor injection, Symproic

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SYMPROIC	NALDEMEDINE TOSYLATE TAB 0.2 MG (BASE EQUIVALENT)	52580057200320	Brand
RELISTOR	METHYLNALTREXONE BROMIDE TAB 150 MG	52580050100320	Brand
RELISTOR	METHYLNALTREXONE BROMIDE INJ 8 MG/0.4ML (20 MG/ML)	52580050102015	Brand
RELISTOR	METHYLNALTREXONE BROMIDE INJ 12 MG/0.6ML (20 MG/ML)	52580050102020	Brand

**Approval Criteria**

1 - ONE of the following diagnoses:

- Opioid-induced constipation in patients being treated for chronic, non-cancer pain
- Opioid-induced constipation in patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation

**AND**

**2** - History of failure, contraindication, or intolerance to BOTH of the following:

- Lactulose
- Polyethylene glycol (Miralax)

**AND**

**3** - History of failure, contraindication, or intolerance to Movantik

**AND**

**4** - For Relistor Injection requests ONLY: The patient is not able to swallow oral medications

Product Name: Trulance			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TRULANCE	PLECANATIDE TAB 3 MG	52543060000320	Brand

**Approval Criteria**

**1** - ONE of the following diagnoses:

- Chronic idiopathic constipation
- Irritable bowel syndrome with constipation

**AND**

**2** - Patient is greater than or equal to 18 years of age

Product Name: Zelnorm			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZELNORM	TEGASEROD MALEATE TAB 6 MG (BASE EQUIVALENT)	52555060200320	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of irritable bowel syndrome with constipation</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient was female at birth</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - History of failure, contraindication, or intolerance to BOTH of the following:</p> <ul style="list-style-type: none"> <li>• Lactulose</li> <li>• Polyethylene glycol (Miralax)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>4 - History of failure, contraindication, or intolerance to ONE of the following:</p> <ul style="list-style-type: none"> <li>• Lubiprostone</li> <li>• Linzess</li> </ul>			

Product Name: Brand Amitiza, generic lubiprostone, Ibsrela, Linzess, Motegrity, Movantik, Relistor tablet, Relistor injection, Symproic, Trulance, Zelnorm	
Approval Length	12 month(s)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Therapy Stage		Reauthorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
LINZESS	LINACLOTIDE CAP 72 MCG	52557050000110	Brand
LINZESS	LINACLOTIDE CAP 145 MCG	52557050000120	Brand
LINZESS	LINACLOTIDE CAP 290 MCG	52557050000140	Brand
MOVANTIK	NALOXEGOL OXALATE TAB 12.5 MG (BASE EQUIVALENT)	52580060300320	Brand
MOVANTIK	NALOXEGOL OXALATE TAB 25 MG (BASE EQUIVALENT)	52580060300330	Brand
SYMPROIC	NALDEMEDINE TOSYLATE TAB 0.2 MG (BASE EQUIVALENT)	52580057200320	Brand
MOTEGRITY	PRUCALOPRIDE SUCCINATE TAB 1 MG (BASE EQUIVALENT)	52560060200320	Brand
MOTEGRITY	PRUCALOPRIDE SUCCINATE TAB 2 MG (BASE EQUIVALENT)	52560060200330	Brand
TRULANCE	PLECANATIDE TAB 3 MG	52543060000320	Brand
LUBIPROSTONE	LUBIPROSTONE CAP 8 MCG	52450045000110	Generic
LUBIPROSTONE	LUBIPROSTONE CAP 24 MCG	52450045000120	Generic
IBSRELA	TENAPANOR HCL TAB 50 MG	52558580100320	Brand
RELISTOR	METHYLNALTREXONE BROMIDE TAB 150 MG	52580050100320	Brand
RELISTOR	METHYLNALTREXONE BROMIDE INJ 8 MG/0.4ML (20 MG/ML)	52580050102015	Brand
RELISTOR	METHYLNALTREXONE BROMIDE INJ 12 MG/0.6ML (20 MG/ML)	52580050102020	Brand
AMITIZA	LUBIPROSTONE CAP 8 MCG	52450045000110	Brand
AMITIZA	LUBIPROSTONE CAP 24 MCG	52450045000120	Brand
ZELNORM	TEGASEROD MALEATE TAB 6 MG	52555060200320	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

## 2 . Revision History

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
6/12/2024	Specified strength of Linzess approved for functional constipation is 72 "mcg"; Minor cosmetic updates.



Continuous Blood Glucose Monitoring Devices (CGM)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-160441
<b>Guideline Name</b>	Continuous Blood Glucose Monitoring Devices (CGM)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Continuous Glucose Monitors, sensors, and transmitters (all brands)			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DEXCOM G6 RECEIVER	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
DEXCOM G6 SENSOR	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
DEXCOM G6 TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
FREESTYLE LIBRE 2/READER/FLASH	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GLUCOSE MONITORING SYSTEM			
FREESTYLE LIBRE 2/SENSOR/FLASH GLUCOSE MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
FREESTYLE LIBRE/READER/FLASH MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
FREESTYLE LIBRE 14 DAY/SENSOR/FLASH MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
DEXCOM G7 RECEIVER	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
FREESTYLE LIBRE 14 DAY/READER/FLASH MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
GUARDIAN REAL-TIME REPLACEMENT MONITOR PEDIATRIC	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
DEXCOM G7 SENSOR	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
ENLITE GLUCOSE SENSOR	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
EVERSENSE E3 SENSOR/HOLDER	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
EVERSENSE SENSOR/HOLDER	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
FREESTYLE LIBRE 3/SENSOR/GLUCOSE MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
GUARDIAN SENSOR (3)	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
GUARDIAN SENSOR 3	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
EVERSENSE E3 SMART TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
EVERSENSE SMART TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
GUARDIAN CONNECT TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
GUARDIAN CONNECT TRANSMITTER KIT	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
GUARDIAN LINK 3 TRANSMITTER KIT	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
MINILINK REAL-TIME TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand

MINIMED 630G GUARDIAN PRESS STARTER TRANSMITTER KIT	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
PARADIGM REAL-TIME TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
GUARDIAN 4 GLUCOSE SENSOR	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
GUARDIAN 4 TRANSMITTER KIT	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
FREESTYLE LIBRE 3/READER/GLUCOSE MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
FREESTYLE LIBRE 3 PLUS/SENSOR/GLUCOSE MONITORING SYSTEM	*CONTINUOUS GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
FREESTYLE LIBRE 2 PLUS/SENSOR/FLASH GLUCOSE MONITOR SYSTEM	*CONTINUOUS GLUCOSE SYSTEM SENSOR***	97202012046300	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 Submission of medical records (e.g., chart notes) documenting patient is already established on the requested continuous blood glucose monitoring (CGM) system

**OR**

1.2 Patient is insulin dependent as confirmed by paid claims for insulin within the past 60 days and the request is for a preferred\* product

**OR**

1.3 Submission of medical records (e.g., chart notes, lab results) documenting ALL of the following:

1.3.1 ONE of the following:

1.3.1.1 If the request is preferred\*, ONE of the following:

1.3.1.1.1 BOTH of the following:

- Diagnosis of Type I or II Diabetes Mellitus
- Frequent insulin adjustments are required based on the results of blood glucose monitoring or CGM testing results

**OR**

**1.3.1.1.2** ONE of the following diagnoses:

- Gestational Diabetes
- Hypoglycemia Unawareness (HU) (defined as the onset of neuroglycopenia, low blood glucose in the brain, before the appearance of autonomic warning symptoms, or the failure to sense a significant fall in blood glucose below normal levels)
- Postprandial Hyperglycemia
- Recurrent Diabetic Ketoacidosis

**OR**

**1.3.1.1.3** Patient requires short term use (72 hours) to determine baseline insulin levels prior to insulin pump initiation

**OR**

**1.3.1.2** If the request is non-preferred\*, ONE of the following:

**1.3.1.2.1** ALL of the following:

- Diagnosis of Type I or II Diabetes Mellitus
- Patient is insulin dependent as demonstrated by paid claims within the past 60 days
- Frequent insulin adjustments are required based on the results of blood glucose monitoring or CGM testing results

**OR**

**1.3.1.2.2** ONE of the following diagnoses:

- Gestational Diabetes
- Hypoglycemia Unawareness (HU) (defined as the onset of neuroglycopenia, low blood glucose in the brain, before the appearance of autonomic warning symptoms, or the failure to sense a significant fall in blood glucose below normal levels)
- Postprandial Hyperglycemia

- Recurrent Diabetic Ketoacidosis

**OR**

**1.3.1.2.3** Patient requires short term use (72 hours) to determine baseline insulin levels prior to insulin pump initiation

**AND**

**1.3.2** Patient must meet the FDA approved age for the requested product

**AND**

**1.3.3** ONE of the following:

- Hemoglobin A1c > 7.0%
- Frequent hypoglycemic episodes
- Patient has a diagnosis that is not defined by elevated hemoglobin A1c or frequent hypoglycemia (e.g., Gestational Diabetes)

**AND**

**1.3.4** Provider attests patient is enrolled or has completed a comprehensive diabetes education program

**AND**

**1.3.5** If the request is non-preferred\*, patient has tried and failed ALL preferred\* products

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Continuous Glucose Monitors, sensors, and transmitters (all brands)	
Approval Length	12 month(s)
Therapy Stage	Reauthorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DEXCOM G6 RECEIVER	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
DEXCOM G6 SENSOR	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
DEXCOM G6 TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
FREESTYLE LIBRE 2/READER/FLASH GLUCOSE MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
FREESTYLE LIBRE 2/SENSOR/FLASH GLUCOSE MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
FREESTYLE LIBRE/READER/FLASH MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
FREESTYLE LIBRE 14 DAY/SENSOR/FLASH MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
DEXCOM G7 RECEIVER	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
FREESTYLE LIBRE 14 DAY/READER/FLASH MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
GUARDIAN REAL-TIME REPLACEMENT MONITOR PEDIATRIC	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
DEXCOM G7 SENSOR	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
ENLITE GLUCOSE SENSOR	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
EVERSENSE E3 SENSOR/HOLDER	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
EVERSENSE SENSOR/HOLDER	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
FREESTYLE LIBRE 3/SENSOR/GLUCOSE MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
GUARDIAN SENSOR (3)	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
GUARDIAN SENSOR 3	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
EVERSENSE E3 SMART TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EVERSENSE SMART TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
GUARDIAN CONNECT TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
GUARDIAN CONNECT TRANSMITTER KIT	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
GUARDIAN LINK 3 TRANSMITTER KIT	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
MINILINK REAL-TIME TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
MINIMED 630G GUARDIAN PRESS STARTER TRANSMITTER KIT	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
PARADIGM REAL-TIME TRANSMITTER	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
GUARDIAN 4 GLUCOSE SENSOR	*CONTINUOUS BLOOD GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
GUARDIAN 4 TRANSMITTER KIT	*CONTINUOUS BLOOD GLUCOSE SYSTEM TRANSMITTER***	97202012066300	Brand
FREESTYLE LIBRE 3/READER/GLUCOSE MONITORING SYSTEM	*CONTINUOUS BLOOD GLUCOSE SYSTEM RECEIVER***	97202012026200	Brand
FREESTYLE LIBRE 3 PLUS/SENSOR/GLUCOSE MONITORING SYSTEM	*CONTINUOUS GLUCOSE SYSTEM SENSOR***	97202012046300	Brand
FREESTYLE LIBRE 2 PLUS/SENSOR/FLASH GLUCOSE MONITOR SYSTEM	*CONTINUOUS GLUCOSE SYSTEM SENSOR***	97202012046300	Brand

**Approval Criteria**

**1** - Patient is using the same continuous glucose monitoring device on a regular basis as evidenced through the patient's claims history and the providers chart notes

**AND**

**2** - Patient is adherent to using the device

**AND**

**3** - Patient has shared the device readings with physician or healthcare professional for review as part of overall diabetes management

## 2 . Revision History

Date	Notes
11/11/2024	Added GPI for Freestyle Libre 2 Plus/ system. Updated product name sections. Updated age criterion verbiage.



Copper Chelating Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-141006
<b>Guideline Name</b>	Copper Chelating Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2023
-----------------	-----------

### 1 . Criteria

Product Name: Brand Depen Titratab, generic penicillamine tablets			
Diagnosis	Severe active rheumatoid arthritis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DEPEN TITRATABS	PENICILLAMINE TAB 250 MG	99200030000305	Brand
PENICILLAMINE	PENICILLAMINE TAB 250 MG	99200030000305	Generic

**Approval Criteria**

1 - Diagnosis of severe active rheumatoid arthritis

Product Name: Brand Depen Titratab, generic penicillamine tablets

Diagnosis	Severe active rheumatoid arthritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
DEPEN TITRATABS	PENICILLAMINE TAB 250 MG	99200030000305	Brand
PENICILLAMINE	PENICILLAMINE TAB 250 MG	99200030000305	Generic

**Approval Criteria**

1 - Documentation of positive clinical response to Depen Titratabs therapy

Product Name: Brand Depen Titratab, generic penicillamine tablets

Diagnosis	Wilson's disease (i.e., hepatolenticular degeneration), Cystinuria
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
DEPEN TITRATABS	PENICILLAMINE TAB 250 MG	99200030000305	Brand
PENICILLAMINE	PENICILLAMINE TAB 250 MG	99200030000305	Generic

**Approval Criteria**

1 - Patient has ONE of the following diagnoses:

- Diagnosis of Wilson’s disease (i.e., hepatolenticular degeneration)
- Diagnosis of Cystinuria

Product Name: Brand Cuprimine, generic penicillamine capsules

Diagnosis	Wilson’s disease (i.e., hepatolenticular degeneration), Cystinuria, Severe active rheumatoid arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
CUPRIMINE	PENICILLAMINE CAP 250 MG	99200030000110	Brand
PENICILLAMINE	PENICILLAMINE CAP 250 MG	99200030000110	Generic

**Approval Criteria**

1 - Patient has ONE of the following diagnoses:

- Wilson’s disease (i.e., hepatolenticular degeneration)
- Cystinuria
- Severe active rheumatoid arthritis

**AND**

2 - History of failure or intolerance to Depen (penicillamine)

Product Name: Brand Cuprimine, generic penicillamine capsules

Diagnosis	Wilson’s disease (i.e., hepatolenticular degeneration), Cystinuria, Severe active rheumatoid arthritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
CUPRIMINE	PENICILLAMINE CAP 250 MG	99200030000110	Brand
PENICILLAMINE	PENICILLAMINE CAP 250 MG	99200030000110	Generic
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Cuprimine (penicillamine) therapy			

Product Name: Brand Syprine, generic trientine, generic Clovique			
Diagnosis	Wilson's disease (i.e., hepatolenticular degeneration)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
SYPRINE	TRIENTINE HCL CAP 250 MG	99200020100110	Brand
TRIENTINE HYDROCHLORIDE	TRIENTINE HCL CAP 250 MG	99200020100110	Generic
CLOVIQUE	TRIENTINE HCL CAP 250 MG	99200020100110	Generic
TRIENTINE HYDROCHLORIDE	TRIENTINE HCL CAP 500 MG	99200020100130	Generic
<b>Approval Criteria</b>			
1 - Diagnosis of Wilson's disease (i.e., hepatolenticular degeneration)			
<b>AND</b>			
2 - History of failure, contraindication, or intolerance to Depen (penicillamine) or Cuprimine (penicillamine)			

Product Name: Brand Syprine, generic trientine, generic Clovique

Diagnosis	Wilson's disease (i.e., hepatolenticular degeneration)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYPRINE	TRIENTINE HCL CAP 250 MG	99200020100110	Brand
TRIENTINE HYDROCHLORIDE	TRIENTINE HCL CAP 250 MG	99200020100110	Generic
CLOVIQUE	TRIENTINE HCL CAP 250 MG	99200020100110	Generic
TRIENTINE HYDROCHLORIDE	TRIENTINE HCL CAP 500 MG	99200020100130	Generic
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Syprine (trientine) therapy			

## 2 . Revision History

Date	Notes
11/6/2023	Added new GPI for trientine

Corlanor



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140635
<b>Guideline Name</b>	Corlanor
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Corlanor			
Diagnosis	Chronic Heart Failure		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CORLANOR	IVABRADINE HCL ORAL SOLN 5 MG/5ML (BASE EQUIV)	40700035102020	Brand
CORLANOR	IVABRADINE HCL TAB 5 MG (BASE EQUIV)	40700035100320	Brand
CORLANOR	IVABRADINE HCL TAB 7.5 MG (BASE EQUIV)	40700035100330	Brand

**Approval Criteria**

**1** - Worsening heart failure in a diagnosis of stable, symptomatic chronic (e.g. New York Heart Association (NYHA) class II, III or IV) heart failure

**AND**

**2** - Patient has a left ventricular ejection fraction (EF) less than or equal to 35%

**AND**

**3** - The patient is in sinus rhythm

**AND**

**4** - Patient has a resting heart rate greater than or equal to 70 beats per minute

**AND**

**5** - ONE of the following:

**5.1** Patient is on maximum tolerated doses of beta blockers (e.g., carvedilol, metoprolol succinate, bisoprolol)

**OR**

**5.2** Patient has a contraindication or intolerance to beta-blocker therapy

Product Name: Corlanor	
Diagnosis	Heart Failure due to Dilated Cardiomyopathy (DCM)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
CORLANOR	IVABRADINE HCL ORAL SOLN 5 MG/5ML (BASE EQUIV)	40700035102020	Brand
CORLANOR	IVABRADINE HCL TAB 5 MG (BASE EQUIV)	40700035100320	Brand
CORLANOR	IVABRADINE HCL TAB 7.5 MG (BASE EQUIV)	40700035100330	Brand

**Approval Criteria**

1 - Diagnosis of stable symptomatic heart failure due to dilated cardiomyopathy (DCM)

**AND**

2 - Patient is in sinus rhythm

**AND**

3 - Patient has an elevated heart rate

Product Name: Corlanor	
Diagnosis	Chronic Heart Failure, Heart Failure due to Dilated Cardiomyopathy (DCM)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
CORLANOR	IVABRADINE HCL ORAL SOLN 5 MG/5ML (BASE EQUIV)	40700035102020	Brand
CORLANOR	IVABRADINE HCL TAB 5 MG (BASE EQUIV)	40700035100320	Brand
CORLANOR	IVABRADINE HCL TAB 7.5 MG (BASE EQUIV)	40700035100330	Brand



**Approval Criteria**

1 - Documentation of positive clinical response to Corlanor therapy

**2 . Revision History**

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Cosentyx (secukinumab)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-143606
<b>Guideline Name</b>	Cosentyx (secukinumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/17/2024
-----------------	-----------

## 1 . Criteria

Product Name: Cosentyx SC			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand

COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO- INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO- INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting ALL of the following:

**1.1** Diagnosis of moderate to severe plaque psoriasis

**AND**

**1.2** Greater than or equal to 3 percent body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**1.3** Both of the following:

**1.3.1** History of failure to TWO of the following topical therapies, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial):\*

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**1.3.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose

within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document date, and duration of trial)

**AND**

**1.4** History of failure, contraindication, or intolerance to ALL of the following:

- Enbrel (etanercept) or Humira (adalimumab)
- Infliximab (Janssen manufacturer)
- Otezla (apremilast)

**AND**

**2** - Patient is 6 years of age or older

**AND**

**3** - Prescribed by, or in consultation with, a dermatologist

**AND**

**4** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)

Notes	*Note: Claims history may be used in conjunction as documentation of drug, date, and duration of trials
-------	---

Product Name: Cosentyx SC			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Cosentyx therapy

**AND**

2 - Prescribed by, or in consultation with, a dermatologist

**AND**

3 - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)

Product Name: Cosentyx SC			
Diagnosis	Ankylosing Spondylitis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand

COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO- INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO- INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:

1.1 Diagnosis of active ankylosing spondylitis

**AND**

1.2 History of failure to two NSAIDs (non-steroidal anti-inflammatory drugs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trials)\*

**AND**

1.3 History of failure, contraindication, or intolerance to ALL of the following:\*

- Enbrel (etanercept) or Humira (adalimumab)
- Infliximab (Janssen manufacturer)
- Xeljanz (tofacitinib) oral tablet

**AND**

2 - Prescribed by, or in consultation with, a rheumatologist

**AND**

<b>3</b> - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)	
Notes	*Note: Claims history may be used in conjunction as documentation of drug, date, and duration of trials

**Product Name: Cosentyx SC**

Diagnosis	Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Cosentyx therapy

**AND**

2 - Prescribed by, or in consultation with, a rheumatologist

**AND**

**3** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)

<b>Product Name: Cosentyx SC</b>	
Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting ALL of the following:

**1.1** Diagnosis of active psoriatic arthritis

**AND**

**1.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document date, and duration of trial)\*



**AND**

**1.3** History of failure, contraindication, or intolerance to THREE of the following\*:

- Enbrel (etanercept) or Humira (adalimumab)
- Infliximab (Janssen manufacturer)
- Orenzia (abatacept)
- Otezla (apremilast)
- Xeljanz (tofacitinib) oral tablet

**AND**

**2** - Patient is 2 years of age or older

**AND**

**3** - Prescribed by, or in consultation with, one of the following:

- Rheumatologist
- Dermatologist

**AND**

**4** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)

Notes	*Note: Claims history may be used in conjunction as documentation of drug, date, and duration of trials
-------	---

Product Name: Cosentyx SC			
Diagnosis	Psoriatic Arthritis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Cosentyx therapy

**AND**

2 - Prescribed by, or in consultation with, ONE of the following:

- Rheumatologist
- Dermatologist

**AND**

3 - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)

Product Name: Cosentyx SC	
Diagnosis	Non-radiographic axial spondyloarthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:

1.1 Diagnosis of active non-radiographic axial spondyloarthritis

**AND**

1.2 History of failure to two NSAIDs (non-steroidal anti-inflammatory drugs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trials)\*

**AND**

1.3 History of failure, contraindication, or intolerance to ALL of the following (document drug, date, and duration of trial):\*

- Enbrel (etanercept) or Humira (adalimumab)
- Infliximab (Janssen manufacturer)
- Xeljanz (tofacitinib) oral tablet

**AND**

**2** - Prescribed by, or in consultation with, a rheumatologist

**AND**

**3** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)

Notes	*Note: Claims history may be used in conjunction as documentation of drug, date, and duration of trials
-------	---

Product Name: Cosentyx SC			
Diagnosis	Non-radiographic axial spondyloarthritis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to Cosentyx therapy

**AND**

**2** - Prescribed by, or in consultation with, a rheumatologist

**AND**

**3** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)

**Product Name: Cosentyx SC**

Diagnosis	Enthesitis-Related Arthritis (ERA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

**1.1** Diagnosis of active enthesitis-related arthritis

**AND**

**1.2** Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to TWO preferred non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen)\*

**AND**

**2** - Patient is 4 years of age or older

**AND**

**3** - Prescribed by, or in consultation with, a rheumatologist

**AND**

**4** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)

Notes	*Note: Claims history may be used in conjunction as documentation of drug, date, and duration of trials
-------	---

Product Name: Cosentyx SC			
Diagnosis	Enthesitis-Related Arthritis (ERA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand

COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

**1** - Documentation of a positive clinical response to therapy as evidenced by at least one of the following:

- Reduction in the total active (swollen and tender) joint count from baseline
- Improvement in symptoms (e.g., pain, stiffness, inflammation) from baseline

**AND**

**2** - Prescribed by, or in consultation with, a rheumatologist

**AND**

**3** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)

Product Name: Cosentyx SC			
Diagnosis	Hidradenitis Suppurativa (HS)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	9025057500D520	Brand

COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO- INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

**1** - BOTH of the following:

**1.1** Submission of medical records (e.g., chart notes) confirming a diagnosis of moderate to severe hidradenitis suppurativa

**AND**

**1.2** Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to Humira\*

**AND**

**2** - Prescribed by, or in consultation with, a dermatologist

**AND**

**3** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)

Notes	*Note: Claims history may be used in conjunction as documentation of drug, date, and duration of trials
-------	---

Product Name: Cosentyx SC	
Diagnosis	Hidradenitis Suppurativa (HS)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization



Product Name	Generic Name	GPI	Brand/Generic
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9025057500D550	Brand

**Approval Criteria**

1 - Patient demonstrates positive clinical response to therapy

**AND**

2 - Prescribed by, or in consultation with, a dermatologist

**AND**

3 - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)

**2 . Revision History**

Date	Notes
2/27/2024	Added notes section for PsA and ERA initial authorization sections. Added criteria for HS indication.

Cough and Cold Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140671
<b>Guideline Name</b>	Cough and Cold Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Hydromet, generic Tussionex, Z-Tuss AC, Tuzistra XR, Tussicaps, generic Tussionex, M-END PE, Poly-Tussin AC, Capcof, Pro-Red AC, Histex-AC, Maxi-Tuss, generic promethazine w/codeine, generic promethazine-phenylephrine-codeine, Rydex, Mar-Cof BP/Mar-Cof GG, Ninjacof-XG, Coditussin AC/Coditussin DAC, generic guaifenesin-codeine, generic pseudoephedrine w/codeine-guaifenesin, Tuxarin ER			
Diagnosis	Under the Age of 18 Years for Cough and Cold Products		
Approval Length	30 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYDROCODONE-HOMATROPINE	HYDROCODONE W/ HOMATROPINE SYRUP 5-1.5 MG/5ML	43101010001210	Generic
HYDROMET	HYDROCODONE W/ HOMATROPINE SYRUP 5-1.5 MG/5ML	43101010001210	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROCODONE-HOMATROPINE	HYDROCODONE W/ HOMATROPINE TAB 5-1.5 MG	43101010000310	Generic
Z-TUSS AC	CHLORPHENIRAMINE W/ CODEINE LIQUID 2-9 MG/5ML	43995202320918	Brand
TUZISTRA XR	CODEINE POLIST-CHLORPHEN POLISTER SUSP 14.7-2.8 MG/5ML	4399520231G120	Brand
TUSSICAPS	HYDROCOD POLST-CHLORPHEN POLST CAP ER 12HR 10-8 MG	43995202366930	Brand
HYDROCOD POLST-CPM POLSTER	HYDROCOD POLST-CHLORPHEN POLSTER SUSP 10-8 MG/5ML	4399520236G110	Generic
M-END PE	PHENYLEPHRINE-BROMPHEN W/ CODEINE LIQD 3.33-1.33-6.33 MG/5ML	43995303110916	Brand
POLY-TUSSIN AC	PHENYLEPHRINE-BROMPHEN W/ CODEINE LIQUID 10-4-10 MG/5ML	43995303110935	Generic
CAPCOF	PHENYLEPHRINE-CHLORPHEN W/ CODEINE SYRUP 5-2-10 MG/5ML	43995303141220	Generic
PRO-RED AC	PHENYLEPHRINE-DEXCHLORPHENIR-CODEINE SYRUP 5-1-9 MG/5ML	43995303171220	Brand
HISTEX-AC	PHENYLEPHRINE-TRIPROLIDINE-CODEINE SYRUP 10-2.5-10 MG/5ML	43995303361220	Brand
MAXI-TUSS CD	PHENYLEPHRINE-CHLORPHEN W/ CODEINE LIQUID 10-4-10 MG/5ML	43995303140913	Generic
PROMETHAZINE-CODEINE	PROMETHAZINE W/ CODEINE SYRUP 6.25-10 MG/5ML	43995202341210	Generic
PROMETHAZINE VC/CODEINE	PROMETHAZINE-PHENYLEPHRINE-CODEINE SYRUP 6.25-5-10 MG/5ML	43995303101210	Generic
PROMETHAZINE-PHENYLEPH-CODEINE	PROMETHAZINE-PHENYLEPHRINE-CODEINE SYRUP 6.25-5-10 MG/5ML	43995303101210	Generic
MAR-COF BP	PSEUDOEPHEDRINE-BROMPHEN-CODEINE LIQD 30-2-7.5 MG/5ML	43995303190940	Brand
NINJACOF-XG	GUAIFENESIN-CODEINE LIQUID 200-8 MG/5ML	43997002280942	Brand
CODITUSSIN AC	GUAIFENESIN-CODEINE LIQUID 200-10 MG/5ML	43997002280945	Generic
TRYMINE CG	GUAIFENESIN-CODEINE LIQUID 225-7.5 MG/5ML	43997002280947	Generic
GUAIFENESIN-CODEINE	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
CODITUSSIN DAC	PSEUDOEPHEDRINE W/ COD-GG LIQUID 30-10-200 MG/5ML	43997303300938	Generic
TUXARIN ER	CODEINE PHOS-CHLORPHENIRAMINE MALEATE TAB ER 12HR 54.3-8 MG	43995202327430	Brand
MAR-COF CG EXPECTORANT	GUAIFENESIN-CODEINE LIQUID 225-7.5 MG/5ML	43997002280947	Brand
VIRTUSSIN DAC	PSEUDOEPHEDRINE W/ COD-GG SOLN 30-10-100 MG/5ML	43997303302010	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GUAIFENESIN DAC	PSEUDOEPHEDRINE W/ COD-GG SOLN 30-10-100 MG/5ML	43997303302010	Generic
RYDEX	PSEUDOEPHEDRINE-BROMPHEN-CODEINE LIQ 10-1.33-6.33 MG/5ML	43995303190922	Brand
M-CLEAR WC	GUAIFENESIN-CODEINE SOLN 100-6.3 MG/5ML	43997002282017	Generic
TUSNEL C	PSEUDOEPHEDRINE W/ COD-GG SYRUP 30-10-100 MG/5ML	43997303301225	Brand
CHERATUSSIN AC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
CODEINE/GUAIFENESIN	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
G TUSSIN AC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
GUAIIATUSSIN AC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
GUAIFENESIN AC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
VIRTUSSIN A/C	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
MAXI-TUSS AC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
VIRTUSSIN A/C/ALC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
HYCODAN	HYDROCODONE W/ HOMATROPINE SYRUP 5-1.5 MG/5ML	43101010001210	Brand
GUIIATUSS AC	CODEINE-GUAIFENESIN SYRUP 10-100 MG/5ML	439970022812	Generic

**Approval Criteria**

**1** - Prescriber attests they are aware of Food and Drug Administration (FDA) labeled contraindications regarding use of opioid containing cough and cold products in patients less than 18 years of age and feels the treatment with the requested product is medically necessary (Document rationale for use)

**AND**

**2** - Patient does not have a comorbid condition that may impact respiratory depression (e.g., asthma or other chronic lung disease, sleep apnea, body mass index greater than 30)

**AND**

**3 - Patient has tried and failed at least one non-opioid containing cough and cold remedy**

Product Name: Hydromet, generic Tussionex, Z-Tuss AC, Tuzistra XR, Tussicaps, generic Tussionex, M-END PE, Poly-Tussin AC, Capcof, Pro-Red AC, Histex-AC, Maxi-Tuss, generic promethazine w/codeine, generic promethazine-phenylephrine-codeine, Rydex, Mar-Cof BP/Mar-Cof GG, Ninjacof-XG, Coditussin AC/Coditussin DAC, generic guaifenesin-codeine, generic pseudoephedrine w/codeine-guaifenesin, Tuxarin ER

Diagnosis	Quantity Limit
Approval Length	30 Day(s)
Guideline Type	Quantity Limit*

Product Name	Generic Name	GPI	Brand/Generic
HYDROCODONE-HOMATROPINE	HYDROCODONE W/ HOMATROPINE SYRUP 5-1.5 MG/5ML	43101010001210	Generic
HYDROMET	HYDROCODONE W/ HOMATROPINE SYRUP 5-1.5 MG/5ML	43101010001210	Generic
HYDROCODONE-HOMATROPINE	HYDROCODONE W/ HOMATROPINE TAB 5-1.5 MG	43101010000310	Generic
Z-TUSS AC	CHLORPHENIRAMINE W/ CODEINE LIQUID 2-9 MG/5ML	43995202320918	Brand
TUZISTRA XR	CODEINE POLIST-CHLORPHEN POLIST ER SUSP 14.7-2.8 MG/5ML	4399520231G120	Brand
TUSSICAPS	HYDROCOD POLST-CHLORPHEN POLST CAP ER 12HR 10-8 MG	43995202366930	Brand
HYDROCOD POLST-CPM POLST ER	HYDROCOD POLST-CHLORPHEN POLST ER SUSP 10-8 MG/5ML	4399520236G110	Generic
M-END PE	PHENYLEPHRINE-BROMPHEN W/ CODEINE LIQD 3.33-1.33-6.33 MG/5ML	43995303110916	Brand
POLY-TUSSIN AC	PHENYLEPHRINE-BROMPHEN W/ CODEINE LIQUID 10-4-10 MG/5ML	43995303110935	Generic
CAPCOF	PHENYLEPHRINE-CHLORPHEN W/ CODEINE SYRUP 5-2-10 MG/5ML	43995303141220	Generic
PRO-RED AC	PHENYLEPHRINE-DEXCHLORPHENIR-CODEINE SYRUP 5-1-9 MG/5ML	43995303171220	Brand
HISTEX-AC	PHENYLEPHRINE-TRIPROLIDINE-CODEINE SYRUP 10-2.5-10 MG/5ML	43995303361220	Brand
MAXI-TUSS CD	PHENYLEPHRINE-CHLORPHEN W/ CODEINE LIQUID 10-4-10 MG/5ML	43995303140913	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PROMETHAZINE-CODEINE	PROMETHAZINE W/ CODEINE SYRUP 6.25-10 MG/5ML	43995202341210	Generic
PROMETHAZINE VC/CODEINE	PROMETHAZINE-PHENYLEPHRINE-CODEINE SYRUP 6.25-5-10 MG/5ML	43995303101210	Generic
PROMETHAZINE-PHENYLEPH-CODEINE	PROMETHAZINE-PHENYLEPHRINE-CODEINE SYRUP 6.25-5-10 MG/5ML	43995303101210	Generic
MAR-COF BP	PSEUDOEPHEDRINE-BROMPHEN-CODEINE LIQD 30-2-7.5 MG/5ML	43995303190940	Brand
NINJACOF-XG	GUAIFENESIN-CODEINE LIQUID 200-8 MG/5ML	43997002280942	Brand
CODITUSSIN AC	GUAIFENESIN-CODEINE LIQUID 200-10 MG/5ML	43997002280945	Generic
TRYMINE CG	GUAIFENESIN-CODEINE LIQUID 225-7.5 MG/5ML	43997002280947	Generic
GUAIFENESIN-CODEINE	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
CODITUSSIN DAC	PSEUDOEPHEDRINE W/ COD-GG LIQUID 30-10-200 MG/5ML	43997303300938	Generic
TUXARIN ER	CODEINE PHOS-CHLORPHENIRAMINE MALEATE TAB ER 12HR 54.3-8 MG	43995202327430	Brand
MAR-COF CG EXPECTORANT	GUAIFENESIN-CODEINE LIQUID 225-7.5 MG/5ML	43997002280947	Brand
TUSNEL C	PSEUDOEPHEDRINE W/ COD-GG SYRUP 30-10-100 MG/5ML	43997303301225	Brand
VIRTUSSIN DAC	PSEUDOEPHEDRINE W/ COD-GG SOLN 30-10-100 MG/5ML	43997303302010	Generic
GUAIFENESIN DAC	PSEUDOEPHEDRINE W/ COD-GG SOLN 30-10-100 MG/5ML	43997303302010	Generic
RYDEX	PSEUDOEPHEDRINE-BROMPHEN-CODEINE LIQ 10-1.33-6.33 MG/5ML	43995303190922	Brand
M-CLEAR WC	GUAIFENESIN-CODEINE SOLN 100-6.3 MG/5ML	43997002282017	Generic
CHERATUSSIN AC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
CODEINE/GUAIFENESIN	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
G TUSSIN AC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
GUAIATUSSIN AC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
GUAIFENESIN AC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
VIRTUSSIN A/C	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
MAXI-TUSS AC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic

VIRTUSSIN AC/ALC	GUAIFENESIN-CODEINE SOLN 100-10 MG/5ML	43997002282020	Generic
HYCODAN	HYDROCODONE W/ HOMATROPINE SYRUP 5-1.5 MG/5ML	43101010001210	Brand

**Approval Criteria**

1 - Prescriber attests that a larger quantity is medically necessary

**AND**

2 - The requested dose is within the Food and Drug Administration (FDA) maximum dose per day, where an FDA maximum dose per day exists (See table in background section)

Notes	*Authorization will be issued for up to 30 days. The authorization should be entered for the quantity requested.
-------	--

## 2 . Background

Benefit/Coverage/Program Information	
<b>CDC Recommended Opioid Maximum Morphine Milligram Equivalents per Day*</b>	
Active Ingredient	FDA Label Max Daily Doses
Morphine	None
Hydromorphone	None
Hydrocodone	None
Tapentadol	600mg IR products
Oxymorphone	None
Oxycodone	None
Codeine	360mg
Pentazocine	None

Tramadol	400mg IR products
Meperidine	600mg
Butorphanol nasal	None
Opium	4 suppositories/day Deodorized tincture: 24mg/day Camphorated tincture: 16mg/day
Acetaminophen	4g/day
Aspirin	2080mg/day
Ibuprofen	3200mg/day
Benzhydrocodone**	None

### 3 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22



Coverage of Off-Label Non-FDA Approved Indications



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140707
<b>Guideline Name</b>	Coverage of Off-Label Non-FDA Approved Indications
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: A drug (non-anti-cancer chemotherapeutic regimen) used for an off-label indication or non-FDA approved indication			
Diagnosis	Off-label non-cancer indication		
Approval Length	12 month(s)		
Guideline Type	Administrative		
Product Name	Generic Name	GPI	Brand/Generic
Off-label use			
Non-FDA approved use			
non-fda			
off-label			

off			
<p><b>Approval Criteria</b></p> <p>1 - The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:</p> <ul style="list-style-type: none"> <li>• Food and Drug Administration (FDA) approved indications and limits</li> <li>• Published practice guidelines and treatment protocols</li> <li>• Comparative data evaluating the efficacy, type and frequency of side effects and potential drug interactions among alternative products as well as the risks, benefits and potential member outcomes</li> <li>• Drug Facts and Comparisons</li> <li>• American Hospital Formulary Service Drug Information</li> <li>• United States Pharmacopeia – Drug Information</li> <li>• DRUGDEX Information System</li> <li>• UpToDate</li> <li>• MicroMedex</li> <li>• Peer-reviewed medical literature, including randomized clinical trials, outcomes, research data and pharmaco-economic studies</li> <li>• Other drug reference resources</li> </ul>			
Notes	Off-label use may be reviewed for medical necessity and denied as such if the off-label criteria are not met. Please refer to drug specific PA guideline for off-label criteria if available.		

Product Name: A drug or biological in an anti-cancer chemotherapeutic regimen			
Diagnosis	Off-label cancer indication		
Approval Length	12 month(s)		
Guideline Type	Administrative		
Product Name	Generic Name	GPI	Brand/Generic
Off-label use			
Non-FDA approved use			
non-fda			
off-label			
off			

**Approval Criteria**

1 - One of the following:

1.1 Diagnosis is supported as a use in AHFS DI [2]

**OR**

1.2 Diagnosis is supported as a use in the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B (see NCCN Categories of Evidence and Consensus table in Background section) [2, A]

**OR**

1.3 Diagnosis is supported in the FDA Uses/Non-FDA Uses section in DRUGDEX Evaluation with a Strength of Recommendation rating of Class I, Class IIa, or Class IIb (see DRUGDEX Strength of Recommendation table in Background section) [2]

**OR**

1.4 Diagnosis is supported as an indication in Clinical Pharmacology [2]

**OR**

1.5 Off-label use is supported in one of the published, peer-reviewed medical literature listed below: [2, B]

- American Journal of Medicine
- Annals of Internal Medicine
- Annals of Oncology
- Annals of Surgical Oncology
- Biology of Blood and Marrow Transplantation
- Blood
- Bone Marrow Transplantation
- British Journal of Cancer
- British Journal of Hematology
- British Medical Journal
- Cancer

- Clinical Cancer Research
- Drugs
- European Journal of Cancer (formerly the European Journal of Cancer and Clinical Oncology)
- Gynecologic Oncology
- International Journal of Radiation, Oncology, Biology, and Physics
- The Journal of the American Medical Association
- Journal of Clinical Oncology
- Journal of the National Cancer Institute
- Journal of the National Comprehensive Cancer Network (NCCN)
- Journal of Urology
- Lancet
- Lancet Oncology
- Leukemia
- The New England Journal of Medicine
- Radiation Oncology

**OR**

**1.6** Diagnosis is supported as a use in Wolters Kluwer Lexi-Drugs rated as "Evidence Level A" with a "Strong" recommendation. (see Lexi-Drugs Strength of Recommendation table in Background section) [2, 4, 5]

<b>Notes</b>	Off-label use may be reviewed for medical necessity and denied as such if the off-label criteria are not met. Please refer to drug specific PA guideline for off-label criteria if available.
--------------	---

## 2 . Background

Clinical Practice Guidelines			
<b>DRUGDEX Strength of Recommendation [6]</b>			
	<b>Class</b>	<b>Recommendation</b>	<b>Description</b>
	Class I	Recommended	The given test or treatment has been proven useful, and should be performed or administered.

Class IIa	Recommended, In Most Cases	The given test or treatment is generally considered to be useful, and is indicated in most cases.
Class IIb	Recommended, in Some Cases	The given test or treatment may be useful, and is indicated in some, but not most, cases.
Class III	Not Recommended	The given test or treatment is not useful, and should be avoided
Class Indeterminate	Evidence Inconclusive	

**NCCN Categories of Evidence and Consensus [A]**

Category	Level of Consensus
1	Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
2A	Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
2B	Based upon lower-level evidence, there is NCCN consensus the intervention is appropriate.
3	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

**Lexi-Drugs: Strength of Recommendation for Inclusion in Lexi-Drugs for Oncology Off-Label Use and Level of Evidence Scale for Oncology Off-Label Use [5]**

**Strength of Recommendation for Inclusion**

<b>Strong (for proposed off-label use)</b>	The evidence persuasively supports the
--	--

	off-label use (ie, Level of Evidence A).
<b>Equivocal (for proposed off-label use)</b>	The evidence to support the off-label use is of uncertain clinical significance (ie, Level of Evidence B, C). Additional studies may be necessary to further define the role of this medication for the off-label use.
<b>Against proposed off-label use</b>	The evidence either advocates against the off-label use or suggests a lack of support for the off-label use (independent of Level of Evidence). Additional studies are necessary to define the

	role of this medication for the off-label use.
<b>Level of Evidence Scale for Oncology Off-Label Use</b>	
<b>A</b>	<b>Consistent evidence from well-performed randomized, controlled trials or overwhelming evidence of some other form (eg, results of the introduction of penicillin treatment) to support off-label use. Further research is unlikely to change confidence in the estimate of benefit.</b>
<b>B</b>	<b>Evidence from randomized, controlled trials with important limitations (eg, inconsistent results, methodologic flaws, indirect, imprecise); or very strong evidence of some other research design. Further research (if performed) is likely to have an impact on confidence in the estimate of benefit and risk and may change the estimate.</b>
<b>C</b>	<b>Evidence from observational studies (eg, retrospective case series/reports providing significant impact on patient care); unsystematic clinical experience; or potentially flawed randomized, controlled trials (eg, when limited options exist for condition). Any estimate of effect is uncertain.</b>
<b>G</b>	<b>Use has been substantiated by inclusion in at least one evidence-based or consensus-based clinical practice guideline.</b>

### 3 . Endnotes

- A. NCCN Categories of Evidence and Consensus. Category 1: The recommendation is based on high-level evidence (i.e., high-powered randomized clinical trials or meta-analyses), and the NCCN Guideline Panel has reached uniform consensus that the recommendation is indicated. In this context, uniform means near unanimous positive

support with some possible neutral positions. Category 2A: The recommendation is based on lower level evidence, but despite the absence of higher level studies, there is uniform consensus that the recommendation is appropriate. Lower level evidence is interpreted broadly, and runs the gamut from phase II to large cohort studies to case series to individual practitioner experience. Importantly, in many instances, the retrospective studies are derived from clinical experience of treating large numbers of patients at a member institution, so NCCN Guideline Panel Members have first-hand knowledge of the data. Inevitably, some recommendations must address clinical situations for which limited or no data exist. In these instances the congruence of experience-based judgments provides an informed if not confirmed direction for optimizing patient care. These recommendations carry the implicit recognition that they may be superseded as higher level evidence becomes available or as outcomes-based information becomes more prevalent. Category 2B: The recommendation is based on lower level evidence, and there is nonuniform consensus that the recommendation should be made. In these instances, because the evidence is not conclusive, institutions take different approaches to the management of a particular clinical scenario. This nonuniform consensus does not represent a major disagreement, rather it recognizes that given imperfect information, institutions may adopt different approaches. A Category 2B designation should signal to the user that more than one approach can be inferred from the existing data. Category 3: Including the recommendation has engendered a major disagreement among the NCCN Guideline Panel Members. The level of evidence is not pertinent in this category, because experts can disagree about the significance of high level trials. Several circumstances can cause major disagreements. For example, if substantial data exist about two interventions but they have never been directly compared in a randomized trial, adherents to one set of data may not accept the interpretation of the other side's results. Another situation resulting in a Category 3 designation is when experts disagree about how trial data can be generalized. An example of this is the recommendation for internal mammary node radiation in postmastectomy radiation therapy. One side believed that because the randomized studies included this modality, it must be included in the recommendation. The other side believed, based on the documented additional morbidity and the role of internal mammary radiation therapy in other studies, that this was not necessary. A Category 3 designation alerts users to a major interpretation issue in the data and directs them to the manuscript for an explanation of the controversy. [3]

- B. Abstracts (including meeting abstracts) are excluded from consideration. When evaluating peer-reviewed medical literature, the following (among other things) should be considered: 1) Whether the clinical characteristics of the beneficiary and the cancer are adequately represented in the published evidence 2) Whether the administered chemotherapy regimen is adequately represented in the published evidence. 3) Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. 4) Whether the study is appropriate to address the clinical question. The following should be considered: a) Whether the experimental design, in light of the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover.); b) That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs; and c) That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs. [2]



## 4 . References

1. Center for Medicaid & Medicare Services. Medicare Prescription Drug Benefit Manual. Chapter 6 – Part D Drugs and Formulary Requirements. Section 10.6. Available at: <https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf>. Accessed September 9, 2020.
2. Center for Medicaid & Medicare Services. Medicare Benefit Policy Manual. Chapter 15 - Covered Medical and Other Health Services. Section 50.4.5. Available at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c15.pdf>. Accessed September 9, 2020.
3. National Comprehensive Cancer Network Categories of Evidence and Consensus. Available at: [https://www.nccn.org/professionals/physician\\_gls/categories\\_of\\_consensus.aspx](https://www.nccn.org/professionals/physician_gls/categories_of_consensus.aspx). Accessed September 9, 2020.
4. Center for Medicaid & Medicare Services. Medicare Benefit Policy Manual. Wolters Kluwer Clinical Drug Information Lexi-Drugs Compendium Revision Request - CAG-004430. Available at: <https://www.cms.gov/medicare-coverage-database/details/medicare-coverage-document-details.aspx?MCDId=31#decision>. Accessed September 9, 2020.
5. Wolters Kluwer Clinical Drug Information’s Request for CMS evaluation of Lexi-Drugs as a compendium for use in the determination of medically-accepted indications of drugs/biologicals used off-label in anti-cancer chemotherapeutic regimens. Available at: <https://www.cms.gov/Medicare/Coverage/CoverageGenInfo/downloads/covdoc31.pdf>. Accessed September 9, 2020.
6. Micromedex Healthcare Series. Recommendation, Evidence, and Efficacy Ratings. [https://www.micromedexsolutions.com/micromedex2/librarian/ssl/true/CS/6E0ED9/ND\\_P\\_R/evidencexpert/ND\\_P/evidencexpert/DUPLICATIONSHIELDSYNC/8B9F5B/ND\\_PG/evidencexpert/ND\\_B/evidencexpert/ND\\_AppProduct/evidencexpert/ND\\_T/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink?docId=3198&contentSetId=50](https://www.micromedexsolutions.com/micromedex2/librarian/ssl/true/CS/6E0ED9/ND_P_R/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/8B9F5B/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink?docId=3198&contentSetId=50). Accessed September 9, 2020.

## 5 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Cuvrior (trientine hydrochloride)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140984
<b>Guideline Name</b>	Cuvrior (trientine hydrochloride)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Cuvrior			
Diagnosis	Wilson's disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CUVRIOR	TRIENTINE TETRAHYDROCHLORIDE TAB 300 MG	99200020200330	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of Wilson's disease (i.e., hepatolenticular degeneration)

**AND**

2 - Documentation of ONE of the following:

- Presence of Kayser-Fleisher rings
- Serum ceruloplasmin (CPN) less than 20 mg/dL (milligrams/deciliter)
- 24-hour urinary copper excretion greater than 100 mcg (micrograms)
- Liver biopsy with copper dry weight greater than 250 mcg/g (gram)
- ATP7B mutation via genetic testing

**AND**

3 - Trial and failure, contraindication, or intolerance to generic penicillamine capsules

**AND**

4 - Prescribed by or in consultation with ONE of the following:

- Gastroenterologist
- Hepatologist

Product Name: Cuvrior			
Diagnosis	Wilson's disease		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CUVRIOR	TRIENTINE TETRAHYDROCHLORIDE TAB 300 MG	99200020200330	Brand
<b>Approval Criteria</b>			

1 - Documentation of a positive clinical response to therapy

## 2 . Revision History

Date	Notes
7/7/2023	Updated guideline name and all criteria, indications, and auth durations.

Cystaran, Cystadrops



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140858
<b>Guideline Name</b>	Cystaran, Cystadrops
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Cystaran, Cystadrops			
Diagnosis	Cystinosis		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CYSTARAN	CYSTEAMINE HCL OPHTH SOLN 0.44% (BASE EQUIVALENT)	86805525102020	Brand
CYSTADROPS	CYSTEAMINE HCL OPHTH SOLN 0.37% (BASE EQUIVALENT)	86805525102015	Brand

**Approval Criteria**

1 - Diagnosis of cystinosis

**2 . Revision History**

Date	Notes
11/23/2020	Added Cystadrops

Daliresp (roflumilast)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140761
<b>Guideline Name</b>	Daliresp (roflumilast)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	1/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Brand Daliresp, generic roflumilast			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ROFLUMILAST	ROFLUMILAST TAB 250 MCG	44450065000310	Generic
DALIRESP	ROFLUMILAST TAB 250 MCG	44450065000310	Brand
ROFLUMILAST	ROFLUMILAST TAB 500 MCG	44450065000320	Generic
DALIRESP	ROFLUMILAST TAB 500 MCG	44450065000320	Brand

**Approval Criteria**

1 - Diagnosis of severe to very severe chronic obstructive pulmonary disease (COPD) [i.e., FEV1 (forced expiratory volume over 1 second) less than or equal to 50% of predicted]

**AND**

2 - COPD is associated with chronic bronchitis

**AND**

3 - History of COPD exacerbation(s)

Product Name: Brand Daliresp, generic roflumilast

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ROFLUMILAST	ROFLUMILAST TAB 250 MCG	44450065000310	Generic
DALIRESP	ROFLUMILAST TAB 250 MCG	44450065000310	Brand
ROFLUMILAST	ROFLUMILAST TAB 500 MCG	44450065000320	Generic
DALIRESP	ROFLUMILAST TAB 500 MCG	44450065000320	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to the requested therapy

**2 . Revision History**



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
12/12/2022	Updated guideline name, updated GPI and product name lists, added generic roflumilast, cleaned up criteria.

Daraprim



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140895
<b>Guideline Name</b>	Daraprim
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Brand Daraprim, generic pyrimethamine			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DARAPRIM	PYRIMETHAMINE TAB 25 MG	13000040000310	Brand
PYRIMETHAMINE	PYRIMETHAMINE TAB 25 MG	13000040000310	Generic
<b>Approval Criteria</b>			
1 - Medical record documentation (e.g. chart notes) of one of the following:			

**1.1** Treatment of severe acquired toxoplasmosis, including toxoplasmic encephalitis

**OR**

**1.2** Treatment of congenital toxoplasmosis

**OR**

**1.3** Secondary prophylaxis of toxoplasmic encephalitis

**OR**

**1.4** ALL of the following:

**1.4.1** Primary Pneumocystis pneumonia (PCP) prophylaxis in human immunodeficiency virus (HIV)-infected patients or as secondary prophylaxis in HIV-infected patients who have been treated for an acute episode of Pneumocystis pneumonia

**AND**

**1.4.2** Patient has experienced intolerance to prior prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX)

**AND**

**1.4.3** ONE of the following:

**1.4.3.1** Patient has been re-challenged with trimethoprim-sulfamethoxazole (TMP-SMX) using a desensitization protocol and is still unable to tolerate

**OR**

**1.4.3.2** Evidence of moderately severe or life threatening-reaction to trimethoprim-sulfamethoxazole (TMP-SMX) in the past (e.g. toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome)

**OR**

**1.5** ALL of the following:

**1.5.1** Primary prophylaxis of toxoplasmic encephalitis

**AND**

**1.5.2** Toxoplasma immunoglobulin G (IgG) positive

**AND**

**1.5.3** CD4 (cluster of differentiation 4) less than or equal to 100 cells per mm<sup>3</sup> if initiating prophylaxis or CD4 100-200 cells per mm<sup>3</sup> if reinstating prophylaxis

**AND**

**1.5.4** Will be used in combination with dapsone or atovaquone

**AND**

**1.5.5** Patient has experienced intolerance to prior prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX)

**AND**

**1.5.6** ONE of the following:

**1.5.6.1** Patient has been re-challenged with trimethoprim-sulfamethoxazole (TMP-SMX) using a desensitization protocol and is still unable to tolerate

**OR**

**1.5.6.2** Evidence of moderately severe or life threatening-reaction to trimethoprim-

sulfamethoxazole (TMP-SMX) in the past (e.g. toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome)	
Notes	*Consider discontinuation of primary prophylaxis if CD4 greater than 200 cells/mm <sup>3</sup> for greater than 3 months after institution of combination antiretroviral therapy.

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Daybue (trofinetide)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140976
<b>Guideline Name</b>	Daybue (trofinetide)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	7/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Daybue			
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DAYBUE	TROFINETIDE ORAL SOLN 200 MG/ML	74653075002020	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of Rett syndrome			

**AND**

**2** - ONE of the following:

**2.1** Submission of medical records (e.g., chart notes) confirming presence of ALL of the following clinical signs and symptoms:

**2.1.1** A pattern of development, regression, then recovery or stabilization

**AND**

**2.1.2** Partial or complete loss of purposeful hand skills, such as grasping with fingers, reaching for things, or touching things on purpose

**AND**

**2.1.3** Partial or complete loss of spoken language

**AND**

**2.1.4** Repetitive hand movements, such as wringing the hands, washing, squeezing, clapping, or rubbing

**AND**

**2.1.5** Gait abnormalities, including walking on toes or with an unsteady, wide-based, stiff-legged gait

**OR**

**2.2** Submission of medical records (e.g., chart notes) documenting molecular genetic testing confirms mutations in the MECP2 gene

**AND**

**3** - Patient is 2 years of age or older

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Geneticist
- Neurologist

Product Name: Daybue			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DAYBUE	TROFINETIDE ORAL SOLN 200 MG/ML	74653075002020	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy			

## 2 . Revision History

Date	Notes
6/6/2023	New guideline



DDAVP (desmopressin) tablets



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140730
<b>Guideline Name</b>	DDAVP (desmopressin) tablets
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand DDAVP tablets, generic desmopressin acetate tablets			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DDAVP	DESMOPRESSIN ACETATE TAB 0.1 MG	30201010100310	Brand
DESMOPRESSIN ACETATE	DESMOPRESSIN ACETATE TAB 0.1 MG	30201010100310	Generic
DDAVP	DESMOPRESSIN ACETATE TAB 0.2 MG	30201010100320	Brand
DESMOPRESSIN ACETATE	DESMOPRESSIN ACETATE TAB 0.2 MG	30201010100320	Generic

**Approval Criteria**

1 - ONE of the following:

1.1 Diagnosis of central diabetes insipidus

**OR**

1.2 Diagnosis of polyuria and/or polydipsia following head trauma or surgery in the pituitary region

**OR**

1.3 Diagnosis of primary nocturnal enuresis

**AND**

2 - For Brand DDAVP ONLY: Trial and failure to generic desmopressin tablets (verified via paid pharmacy claims or submission of medical records)

Notes	Plan setup requires use of generic desmopressin tablets before Brand DDAVP
-------	--

**2 . Revision History**

Date	Notes
8/9/2022	C&S to match AZM 10.1.22

Declomycin



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140714
<b>Guideline Name</b>	Declomycin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: demeclocycline*			
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
DEMECLOCYCLINE HCL	DEMECLOCYCLINE HCL TAB 150 MG	04000010100305	Generic
DEMECLOCYCLINE HCL	DEMECLOCYCLINE HCL TAB 300 MG	04000010100310	Generic
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p>			

**1.1** Diagnosis of ONE of the following:

- Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae
- Respiratory tract infections caused by *Mycoplasma pneumoniae*
- Lymphogranuloma venereum due to *Chlamydia trachomatis*
- Psittacosis (Ornithosis) due to *Chlamydia psittaci*
- Trachoma due to *Chlamydia trachomatis*
- Inclusion conjunctivitis caused by *Chlamydia trachomatis*
- Nongonococcal urethritis in adults caused by *Ureaplasma urealyticum* or *Chlamydia trachomatis*
- Relapsing fever due to *Borrelia recurrentis*
- Chancroid caused by *Haemophilus ducreyi*
- Plague due to *Yersinia pestis*
- Tularemia due to *Francisella tularensis*
- Cholera caused by *Vibrio cholerae*
- *Campylobacter fetus* infections caused by *Campylobacter fetus*
- Brucellosis due to *Brucella* species (in conjunction with streptomycin)
- Bartonellosis due to *Bartonella bacilliformis*
- Granuloma inguinale caused by *Calymmatobacterium granulomatis*
- Infection due to *Escherichia coli*
- Infection due to *Enterobacter aerogenes*
- Infection due to *Shigella* species
- Infection due to *Acinetobacter* species
- Respiratory tract infections caused by *Haemophilus influenzae*
- Respiratory tract and urinary tract infections caused by *Klebsiella* species
- Upper respiratory infections caused by *Streptococcus pneumoniae*
- Skin and skin structure infections caused by *Staphylococcus aureus*.
- Uncomplicated urethritis in men due to *Neisseria gonorrhoeae*, and for the treatment of other uncomplicated gonococcal infections
- Infections in women caused by *Neisseria gonorrhoeae*
- Syphilis caused by *Treponema pallidum* subspecies *pallidum*
- Yaws caused by *Treponema pallidum* subspecies *pertenue*
- Listeriosis due to *Listeria monocytogenes*
- Anthrax due to *Bacillus anthracis*
- Vincent's infection caused by *Fusobacterium fusiforme*
- Actinomycosis caused by *Actinomyces israelii*
- Clostridial diseases caused by *Clostridium* species
- Acute intestinal amebiasis, as adjunctive therapy
- Severe acne, as adjunctive therapy

**OR**

**1.2** The medication is being prescribed by or in consultation with an Infectious Disease specialist

Notes

\*Approval duration: 6 months

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Dificid



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140681
<b>Guideline Name</b>	Dificid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Dificid			
Approval Length	10 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DIFICID	FIDAXOMICIN TAB 200 MG	03530025000320	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Clostridioides difficile-associated diarrhea (CDAD) [previously known as Clostridium difficile- associated diarrhea]</p>			

**AND**

**2** - ONE of the following:

**2.1** History of failure, contraindication, or intolerance to Firvanq (vancomycin) oral solution

**OR**

**2.2** History of failure, contraindication, or intolerance to oral Vancocin (vancomycin) capsules or vancomycin oral solution (NOT Firvanq) if the prescriber provides a reason or special circumstance the patient cannot use Firvanq

**OR**

**2.3** For continuation of prior Difucid therapy

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Dofetilide



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140682
<b>Guideline Name</b>	Dofetilide
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: : Brand Tikosyn, generic dofetilide			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DOFETILIDE	DOFETILIDE CAP 125 MCG (0.125 MG)	35400025000110	Generic
TIKOSYN	DOFETILIDE CAP 125 MCG (0.125 MG)	35400025000110	Brand
DOFETILIDE	DOFETILIDE CAP 250 MCG (0.25 MG)	35400025000120	Generic
TIKOSYN	DOFETILIDE CAP 250 MCG (0.25 MG)	35400025000120	Brand
DOFETILIDE	DOFETILIDE CAP 500 MCG (0.5 MG)	35400025000130	Generic
TIKOSYN	DOFETILIDE CAP 500 MCG (0.5 MG)	35400025000130	Brand



**Approval Criteria**

**1** - Diagnosis of ONE of the following:

- Atrial fibrillation
- Atrial flutter

**AND**

**2** - Patient requires ONE of the following:

- Conversion to normal sinus rhythm
- Maintenance of normal sinus rhythm

**AND**

**3** - Verification that the patient has already started on dofetilide while in the hospital for a minimum of 3 days

**AND**

**4** - Patient does NOT have severe renal impairment [Creatinine Clearance (CrCl) less than 20 milliliters per minute]

**AND**

**5** - Patient does NOT have congenital or acquired long QT syndromes

**AND**

**6** - Patient is NOT concurrently using cimetidine, hydrochlorothiazide, ketoconazole, megestrol, prochlorperazine, trimethoprim, dolutegravir or verapamil

**2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Dojolvi (triheptanoin)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140753
<b>Guideline Name</b>	Dojolvi (triheptanoin)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Dojolvi			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
<b>Product Name</b>	<b>Generic Name</b>	<b>GPI</b>	<b>Brand/Generic</b>
DOJOLVI	TRiheptanoin Oral Liquid 100%	80200080000920	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) showing diagnosis of a long-chain fatty acid oxidation disorder (LC-FAOD) has been confirmed by at least TWO of the following:

- Disease specific elevation of acyl-carnitines on a newborn blood spot or in plasma
- Low enzyme activity in cultured fibroblasts
- One or more known pathogenic mutations in CPT2, ACADVL, HADHA, or HADHB

**AND**

**2** - Not used with any other medium-chain triglyceride (MCT) product

**AND**

**3** - Prescribed by or in consultation with a clinical specialist knowledgeable in appropriate disease-related dietary management (e.g., geneticist, cardiologist, gastroenterologist, etc.)

Product Name: Dojolvi			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DOJOLVI	TRIHEPTANOIN ORAL LIQUID 100%	80200080000920	Brand

**Approval Criteria**

**1** - Prescriber attests to continued need of therapy

**AND**

**2** - Not used with any other medium-chain triglyceride (MCT) product

**AND**

**3** - Prescribed by or in consultation with a clinical specialist knowledgeable in appropriate disease-related dietary management (e.g., geneticist, cardiologist, gastroenterologist, etc.)

## 2 . Revision History

Date	Notes
11/7/2022	New guideline following FFS.

DPP-4 Inhibitors



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-160358
<b>Guideline Name</b>	DPP-4 Inhibitors
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: alogliptin, alogliptin/metformin, alogliptin/pioglitazone, Janumet, Janumet XR, Januvia, Jentadueto, Jentadueto XR, Brand Kombiglyze XR, generic saxagliptin/metformin ER, Brand Onglyza, generic saxagliptin, Tradjenta, Zituvio, sitagliptin, sitagliptin/metformin, Zituvimet, Zituvimet XR			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ALOGLIPTIN	ALOGLIPTIN BENZOATE TAB 6.25 MG (BASE EQUIV)	27550010100310	Generic
ALOGLIPTIN	ALOGLIPTIN BENZOATE TAB 12.5 MG (BASE EQUIV)	27550010100320	Generic
ALOGLIPTIN	ALOGLIPTIN BENZOATE TAB 25 MG (BASE EQUIV)	27550010100330	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ALOGLIPTIN/METFORMIN HCL	ALOGLIPTIN-METFORMIN HCL TAB 12.5-500 MG	27992502100320	Generic
ALOGLIPTIN/METFORMIN HYDROCHLORIDE	ALOGLIPTIN-METFORMIN HCL TAB 12.5-1000 MG	27992502100330	Generic
ALOGLIPTIN/METFORMIN HCL	ALOGLIPTIN-METFORMIN HCL TAB 12.5-1000 MG	27992502100330	Generic
ALOGLIPTIN/PIOGLITAZONE	ALOGLIPTIN-PIOGLITAZONE TAB 12.5-30 MG	27994002100325	Generic
ALOGLIPTIN/PIOGLITAZONE	ALOGLIPTIN-PIOGLITAZONE TAB 12.5-45 MG	27994002100330	Generic
ALOGLIPTIN/PIOGLITAZONE	ALOGLIPTIN-PIOGLITAZONE TAB 25-15 MG	27994002100340	Generic
ALOGLIPTIN/PIOGLITAZONE	ALOGLIPTIN-PIOGLITAZONE TAB 25-30 MG	27994002100345	Generic
ALOGLIPTIN/PIOGLITAZONE	ALOGLIPTIN-PIOGLITAZONE TAB 25-45 MG	27994002100350	Generic
KOMBIGLYZE XR	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 2.5-1000 MG	27992502607520	Brand
KOMBIGLYZE XR	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 5-500 MG	27992502607530	Brand
KOMBIGLYZE XR	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 5-1000 MG	27992502607540	Brand
JANUMET	SITAGLIPTIN-METFORMIN HCL TAB 50-500 MG	27992502700320	Brand
JANUMET	SITAGLIPTIN-METFORMIN HCL TAB 50-1000 MG	27992502700340	Brand
JANUMET XR	SITAGLIPTIN-METFORMIN HCL TAB ER 24HR 50-500 MG	27992502707520	Brand
JANUMET XR	SITAGLIPTIN-METFORMIN HCL TAB ER 24HR 50-1000 MG	27992502707530	Brand
JANUMET XR	SITAGLIPTIN-METFORMIN HCL TAB ER 24HR 100-1000 MG	27992502707540	Brand
JANUVIA	SITAGLIPTIN PHOSPHATE TAB 25 MG (BASE EQUIV)	27550070100320	Brand
JANUVIA	SITAGLIPTIN PHOSPHATE TAB 50 MG (BASE EQUIV)	27550070100330	Brand
JANUVIA	SITAGLIPTIN PHOSPHATE TAB 100 MG (BASE EQUIV)	27550070100340	Brand
JENTADUETO	LINAGLIPTIN-METFORMIN HCL TAB 2.5-500 MG	27992502400320	Brand
JENTADUETO	LINAGLIPTIN-METFORMIN HCL TAB 2.5-850 MG	27992502400330	Brand
JENTADUETO	LINAGLIPTIN-METFORMIN HCL TAB 2.5-1000 MG	27992502400340	Brand
JENTADUETO XR	LINAGLIPTIN-METFORMIN HCL TAB ER 24HR 2.5-1000 MG	27992502407520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

JENTADUETO XR	LINAGLIPTIN-METFORMIN HCL TAB ER 24HR 5-1000 MG	27992502407530	Brand
ONGLYZA	SAXAGLIPTIN HCL TAB 2.5 MG (BASE EQUIV)	27550065100320	Brand
ONGLYZA	SAXAGLIPTIN HCL TAB 5 MG (BASE EQUIV)	27550065100330	Brand
TRADJENTA	LINAGLIPTIN TAB 5 MG	27550050000320	Brand
ZITUVIO	SITAGLIPTIN TAB 25 MG	27550070000320	Brand
ZITUVIO	SITAGLIPTIN TAB 50 MG	27550070000330	Brand
ZITUVIO	SITAGLIPTIN TAB 100 MG	27550070000340	Brand
SITAGLIPTIN	SITAGLIPTIN TAB 25 MG	27550070000320	Brand
SITAGLIPTIN	SITAGLIPTIN TAB 50 MG	27550070000330	Brand
SITAGLIPTIN	SITAGLIPTIN TAB 100 MG	27550070000340	Brand
SAXAGLIPTIN HYDROCHLORIDE	SAXAGLIPTIN HCL TAB 2.5 MG (BASE EQUIV)	27550065100320	Generic
SAXAGLIPTIN HYDROCHLORIDE	SAXAGLIPTIN HCL TAB 5 MG (BASE EQUIV)	27550065100330	Generic
SITAGLIPTIN/METFORMIN HYDROCHLORIDE	SITAGLIPTIN FREE BASE- METFORMIN HCL TAB 50-500 MG	27992502690320	Brand
SITAGLIPTIN/METFORMIN HYDROCHLORIDE	SITAGLIPTIN FREE BASE- METFORMIN HCL TAB 50-1000 MG	27992502690330	Brand
ZITUVIMET	SITAGLIPTIN FREE BASE- METFORMIN HCL TAB 50-500 MG	27992502690320	Brand
ZITUVIMET	SITAGLIPTIN FREE BASE- METFORMIN HCL TAB 50-1000 MG	27992502690330	Brand
ZITUVIMET XR	SITAGLIPTIN FREE BASE- METFORMIN HCL TAB ER 24HR 50-500 MG	27992502697520	Brand
ZITUVIMET XR	SITAGLIPTIN FREE BASE- METFORMIN HCL TAB ER 24HR 50-1000 MG	27992502697530	Brand
ZITUVIMET XR	SITAGLIPTIN FREE BASE- METFORMIN HCL TAB ER 24HR 100-1000 MG	27992502697540	Brand
SAXAGLIPTIN HYDROCHLORIDE/METFORMIN HYDROCHLORIDE ER	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 2.5-1000 MG	27992502607520	Generic
SAXAGLIPTIN HYDROCHLORIDE/METFORMIN HYDROCHLORIDE ER	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 5-500 MG	27992502607530	Generic



SAXAGLIPTIN HYDROCHLORIDE/METFORMIN HYDROCHLORIDE ER	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 5-1000 MG	27992502607540	Generic
<p><b>Approval Criteria</b></p> <p>1 - The patient has a diagnosis of type 2 diabetes mellitus</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p style="padding-left: 20px;">2.1 History of failure to metformin at a minimum dose of 1500 milligrams daily for 90 days</p> <p style="text-align: center;"><b>OR</b></p> <p style="padding-left: 20px;">2.2 Contraindication or intolerance to metformin</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - If the request is non-preferred*, ONE of the following:</p> <p style="padding-left: 20px;">3.1 History of failure for 90 days to THREE preferred* alternatives</p> <p style="text-align: center;"><b>OR</b></p> <p style="padding-left: 20px;">3.2 Intolerance or contraindication to THREE preferred* alternatives</p>			
Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>		

## 2 . Revision History

Date	Notes
------	-------

11/7/2024	Removed Oseni/Kazano/Nesina as targets. Added generic saxagliptin/metformin ER and Zituvimet/Zituvimet XR products as targets. Updated product name list and GPI table accordingly. Removed requirement to t/f individual products if request is for a combination product.
-----------	---

Dry Eye Disease



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-145814
<b>Guideline Name</b>	Dry Eye Disease
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Xiidra			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XIIDRA	LIFITEGRAST OPHTH SOLN 5%	86734050002020	Brand
<b>Approval Criteria</b>			
1 - Tear deficiency associated with ocular inflammation due to ONE of the following:			

- Moderate to severe keratoconjunctivitis sicca
- Moderate to severe dry eye disease

**AND**

**2** - Submission of medical records (e.g., chart notes) confirming diagnosis by **ONE** of the following diagnostic tests:

- Schirmer test
- Ocular surface dye staining (e.g., rose bengal, fluorescein, lissamine green)
- Tear function index/fluorescein clearance test
- Tear break up time
- Tear film osmolarity
- Slit lamp lid evaluation
- Lacrimal gland function

**AND**

**3** - Medication is **NOT** being prescribed to manage dry eyes peri-operative elective eye surgery (e.g., LASIK)

**AND**

**4** - Submission of medical records (e.g., chart notes) or paid claims confirming trial and failure, contraindication, or intolerance to at least **ONE** over-the-counter (OTC) ocular lubricant (e.g., artificial tears, lubricating gels/ointments) in the past 60 days

**AND**

**5** - Prescribed by or in consultation with **ONE** of the following:

- Ophthalmologist
- Optometrist
- Rheumatologist

**AND**

**6** - Submission of medical records (e.g., chart notes) or paid claims confirming a minimum trial of 60 days of Brand Restasis single dose vials, unless contraindicated

Product Name: Cequa, generic cyclosporine emulsion, Miebo, Restasis MultiDose, Tyrvaya, Vevye

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
CEQUA	CYCLOSPORINE (OPHTH) SOLN 0.09% (PF)	86720020002040	Brand
VEVYE	CYCLOSPORINE (OPHTH) SOLN 0.1%	86720020002043	Brand
CYCLOSPORINE	CYCLOSPORINE (OPHTH) EMULSION 0.05%	86720020001620	Generic
RESTASIS MULTIDOSE	CYCLOSPORINE (OPHTH) EMULSION 0.05%	86720020001620	Brand
MIEBO	PERFLUOROHEXYLOCTANE OPHTH SOLN 1.338 GM/ML	86807018002020	Brand
TYRVAYA	VARENICLINE TARTRATE NASAL SOLN 0.03 MG/ACT	86280080202020	Brand

**Approval Criteria**

**1** - Tear deficiency associated with ocular inflammation due to ONE of the following:

- Moderate to severe keratoconjunctivitis sicca
- Moderate to severe dry eye disease

**AND**

**2** - Submission of medical records (e.g., chart notes) confirming diagnosis by ONE of the following diagnostic tests:

- Schirmer test
- Ocular surface dye staining (e.g., rose bengal, fluorescein, lissamine green)
- Tear function index/fluorescein clearance test
- Tear break up time
- Tear film osmolarity
- Slit lamp lid evaluation

- Lacrimal gland function

**AND**

**3** - Medication is NOT being prescribed to manage dry eyes peri-operative elective eye surgery (e.g., LASIK)

**AND**

**4** - Submission of medical records (e.g., chart notes) or paid claims confirming trial and failure, contraindication, or intolerance to at least ONE over-the-counter (OTC) ocular lubricant (e.g., artificial tears, lubricating gels/ointments) in the past 60 days

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Ophthalmologist
- Optometrist
- Rheumatologist

**AND**

**6** - Submission of medical records (e.g., chart notes) or paid claims confirming a minimum trial of 60 days of BOTH of the following, unless contraindicated:

- Brand Restasis single dose vials
- Xiidra\*

Notes

\*PA may be required.

Product Name: Cequa, generic cyclosporine emulsion, Miebo, Restasis MultiDose, Tyrvaya, Vevye, Xiidra

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
CEQUA	CYCLOSPORINE (OPHTH) SOLN 0.09% (PF)	86720020002040	Brand
XIIDRA	LIFITEGRAST OPHTH SOLN 5%	86734050002020	Brand
VEVYE	CYCLOSPORINE (OPHTH) SOLN 0.1%	86720020002043	Brand
CYCLOSPORINE	CYCLOSPORINE (OPHTH) EMULSION 0.05%	86720020001620	Generic
RESTASIS MULTIDOSE	CYCLOSPORINE (OPHTH) EMULSION 0.05%	86720020001620	Brand
MIEBO	PERFLUOROHEXYLOCTANE OPHTH SOLN 1.338 GM/ML	86807018002020	Brand
TYRVAYA	VARENICLINE TARTRATE NASAL SOLN 0.03 MG/ACT	86280080202020	Brand

**Approval Criteria**

1 - Patient demonstrates positive clinical response to therapy (e.g., increased tear production or improvement in dry eye symptoms)

**2 . Revision History**

Date	Notes
4/16/2024	Updates to initial and reauth criteria. Created separate initial auth section for Xiidra. Added Miebo, Tyrvaya, and Restasis MultiDose as targets to the guideline. Updated GPI tables and product name lists accordingly. The standalone Restasis and Miebo GLs will be retired.

Duexis and Vimovo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140716
<b>Guideline Name</b>	Duexis and Vimovo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Duexis			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DUEXIS	IBUPROFEN-FAMOTIDINE TAB 800-26.6 MG	66109902320340	Brand
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following risk factors for NSAID (non-steroidal anti-inflammatory drug) induced adverse GI (gastrointestinal) events:</p>			



- Patient is greater than or equal to 65 years of age
- Prior history of peptic, gastric, or duodenal ulcer
- History of NSAID-related ulcer
- History of clinically significant GI bleeding
- Untreated or active H. Pylori gastritis
- Concurrent use of oral corticosteroids (eg, prednisone, prednisolone, dexamethasone)
- Concurrent use of anticoagulants (eg, warfarin, heparin)
- Concurrent use of antiplatelets (eg, aspirin including low-dose, clopidogrel)

**AND**

**2** - Documentation of history of failure, contraindication, or intolerance to THREE combinations of preferred NSAIDS taken with preferred H2 (histamine 2)-receptor antagonists. (Provide name and date preferred products were tried)\*

**AND**

**3** - Physician has provided rationale for needing to use fixed-dose combination therapy with Duexis instead of taking individual products in combination.

Notes	*Please reference background section for preferred products table
-------	---

Product Name: Brand Vimovo, generic naproxen-esomeprazole			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NAPROXEN-ESOMEPRAZOLE	NAPROXEN-ESOMEPRAZOLE MAGNESIUM TAB DR 375-20 MG	66109902440620	Generic
VIMOVO	NAPROXEN-ESOMEPRAZOLE MAGNESIUM TAB DR 375-20 MG	66109902440620	Brand
NAPROXEN-ESOMEPRAZOLE	NAPROXEN-ESOMEPRAZOLE MAGNESIUM TAB DR 500-20 MG	66109902440640	Generic
VIMOVO	NAPROXEN-ESOMEPRAZOLE MAGNESIUM TAB DR 500-20 MG	66109902440640	Brand
<b>Approval Criteria</b>			

**1 - ONE** of the following risk factors for NSAID (non-steroidal anti-inflammatory drug) induced adverse GI (gastrointestinal) events:

- Patient is greater than or equal to 65 years of age
- Prior history of peptic, gastric, or duodenal ulcer
- History of NSAID-related ulcer
- History of clinically significant GI bleeding
- Untreated or active H. Pylori gastritis
- Concurrent use of oral corticosteroids (eg, prednisone, prednisolone, dexamethasone)
- Concurrent use of anticoagulants (eg, warfarin, heparin)
- Concurrent use of antiplatelets (eg, aspirin including low-dose, clopidogrel)

**AND**

**2 - Documentation** of history of failure, contraindication, or intolerance to **THREE** combinations of preferred NSAIDS taken with preferred proton pump inhibitors (PPIs). (Provide name and date preferred products were tried)\*

**AND**

**3 - Physician** has provided rationale for needing to use fixed-dose combination therapy with Vimovo instead of taking individual products in combination.

Notes	*Please reference background section for preferred products table
-------	---

## 2 . Background

Benefit/Coverage/Program Information		
Preferred Table		
NSAIDS	Proton Pump Inhibitors (PPIs)	H2 (histamine 2)-receptor antagonists
Diclofenac DR (Generic Voltaren)	esomeprazole (Generic Nexium)	Famotidine (Generic Pepcid)
Diclofenac ER (Generic Voltaren ER)	lansoprazole (Generic Prevacid)	Nizatidine (Generic Axid)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Etodolac (Generic Lodine)	omeprazole (Generic Prilosec)	Ranitidine (Generic Zantac)
Etodolac ER (Generic Lodine ER)	pantoprazole sodium (Generic Protonix)	
Fenoprofen (Generic Nalfon)		
Flurbiprofen (Generic Ansaid)		
Ibuprofen		
Indomethacin (Generic Indocin)		
Ketorolac (Generic Toradol)		
Mefenamic (Generic Ponstel)		
Meloxicam (Generic Mobic)		
Nabumetone (Generic Relafen)		
Nabumetone DS (Generic Relafen DS)		
Naproxen (Generic Anaprox)		

Naproxen DR (Generic Anaprox DR)		
Naproxen EC (Generic Anaprox EC)		
Oxaprozin (Generic Daypro)		
Piroxicam (Generic Feldene)		
Sulindac (Generic Clinoril)		

### 3 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Duopa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140656
<b>Guideline Name</b>	Duopa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2020
-----------------	-----------

### 1 . Criteria

Product Name: Duopa			
Diagnosis	Parkinson's disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DUOPA	CARBIDOPA-LEVODOPA ENTERAL SUSP 4.63-20 MG/ML	73209902101820	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of advanced Parkinson's disease

**AND**

2 - Patient is levodopa-responsive

**AND**

3 - Patient experiences disabling "off" periods for a minimum of 3 hours per day

**AND**

4 - Disabling "off" periods occur despite therapy with BOTH of the following:

- Oral levodopa-carbidopa
- One drug from a different class of anti-Parkinson's disease therapy (e.g., COMT [catechol-O-methyltransferase] inhibitor [entacapone, tolcapone], MAO-B [monoamine oxidase-B] inhibitor [selegiline, rasagiline], dopamine agonist [pramipexole, ropinirole])

**AND**

5 - Has undergone or has planned placement of a procedurally-placed tube

**AND**

6 - Prescribed by or in consultation with a neurologist

Product Name: Duopa

Diagnosis	Parkinson's disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
DUOPA	CARBIDOPA-LEVODOPA ENTERAL SUSP 4.63-20 MG/ML	73209902101820	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Duopa therapy

**2 . Revision History**

Date	Notes
10/8/2020	Annual review. Added “advanced” to the diagnosis check and the procedurally-placed tube placement question to align with E&I.

Dupixent (dupilumab)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-144076
<b>Guideline Name</b>	Dupixent (dupilumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	4/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Dupixent			
Diagnosis	Atopic Dermatitis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	9027302000E515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	9027302000E520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 300 MG/2ML	9027302000D520	Brand



DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML	9027302000D515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	9027302000E510	Brand

**Approval Criteria**

1 - Patient is 6 months of age or older

**AND**

2 - Submission of documentation (e.g., chart notes) confirming ONE of the following:

**2.1** BOTH of the following:

**2.1.1** Diagnosis of moderate to severe chronic atopic dermatitis

**AND**

**2.1.2** History of failure, contraindication, or intolerance to the following topical therapies: (document drug, date of trial, and/or contraindication to medication)\*

- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
- Eucrisa (crisaborole)

**OR**

**2.2** BOTH of the following:

**2.2.1** Diagnosis of chronic atopic dermatitis that has been determined to be severe based on physician assessment

**AND**

**2.2.2** History of failure, contraindication, or intolerance to one topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)] (document drug, date of trial, and/or contraindication to medication)\*

**OR**

**2.3** Patient is currently on Dupixent therapy

**AND**

**3** - Patient is NOT receiving Dupixent in combination with another biologic medication [e.g., Xolair (omalizumab), Rituxan (rituximab), Enbrel (etanercept), Remicade/Inflectra (infliximab)]

**AND**

**4** - Prescribed by ONE of the following:

- Dermatologist
- Allergist
- Immunologist

Notes

\*Note: Claims history may be used in conjunction as documentation of drug, date, and/or contraindication to medication

Product Name: Dupixent			
Diagnosis	Atopic Dermatitis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	9027302000E515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	9027302000E520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 300 MG/2ML	9027302000D520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML	9027302000D515	Brand

DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	9027302000E510	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of documentation (e.g., chart notes) confirming positive clinical response to Dupixent therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Dupixent in combination with another biologic medication [e.g., Xolair (omalizumab), Rituxan (rituximab), Enbrel (etanercept), Remicade/Inflectra (infliximab)]</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Dermatologist</li> <li>• Allergist</li> <li>• Immunologist</li> </ul>			

Product Name: Dupixent			
Diagnosis	Asthma		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	9027302000E515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	9027302000E520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 300 MG/2ML	9027302000D520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML	9027302000D515	Brand

DUIXENT	DUIPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	9027302000E510	Brand
---------	--	----------------	-------

**Approval Criteria**

1 - Submission of documentation (e.g., chart notes) confirming diagnosis of moderate-to-severe asthma

**AND**

2 - Patient is 6 years of age or older

**AND**

3 - ONE of the following:

**3.1** ALL of the following:

**3.1.1** Classification of asthma as uncontrolled or inadequately controlled as defined by at least ONE of the following

- Poor symptom control (e.g., Asthma Control Questionnaire [ACQ] score consistently greater than 1.5 or Asthma Control Test [ACT] score consistently less than 20)
- Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months
- Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician's office visit for nebulizer or other urgent treatment)
- Airflow limitation (e.g., after appropriate bronchodilator withhold forced expiratory volume in 1 second [FEV1] less than 80% predicted [in the face of reduced FEV1/forced vital capacity [FVC] defined as less than the lower limit of normal])
- Patient is currently dependent on oral corticosteroids for the treatment of asthma

**AND**

**3.1.2** Dupixent will be used in combination with ONE of the following:

**3.1.2.1** ONE high-dose (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) [e.g., Advair/AirDuo Resplick (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone furoate/vilanterol)] (see Table 1 in Background section)

**OR**

**3.1.2.2** Combination therapy including BOTH of the following:

**3.1.2.2.1** ONE high-dose (appropriately adjusted for age) ICS product [e.g., ciclesonide (Alvesco), mometasone furoate (Asmanex), beclomethasone dipropionate (QVAR)] (see Table 1 in Background section)

**AND**

**3.1.2.2.2** ONE additional asthma controller medication [e.g., LABA - olodaterol (Striverdi) or indacaterol (Arcapta); leukotriene receptor antagonist – montelukast (Singulair); theophylline]

**AND**

**3.1.3** ONE of the following:

**3.1.3.1** Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting that asthma is an eosinophilic phenotype as defined by a baseline (pre-dupilumab treatment) peripheral blood eosinophil level greater than or equal to 150 cells/microliter within the past 6 weeks

**OR**

**3.1.3.2** Patient is currently dependent on oral corticosteroids for the treatment of asthma

**OR**

**3.2** Patient is currently on Dupixent therapy

**AND**

**4** - Patient is NOT receiving Dupixent in combination with ONE of the following:

- Anti-interleukin-5 therapy [e.g. Nucala (mepolizumab), Cinqair (reslizumab), Fasentra (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g. Xolair (omalizumab)]

**AND**

**5** - Prescribed by ONE of the following:

- Pulmonologist
- Allergist
- Immunologist

Product Name: Dupixent			
Diagnosis	Asthma		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	9027302000E515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	9027302000E520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 300 MG/2ML	9027302000D520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML	9027302000D515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	9027302000E510	Brand

**Approval Criteria**

**1** - Submission of documentation (e.g., chart notes) confirming positive clinical response to Dupixent therapy as demonstrated by at least ONE of the following:

- Reduction in the frequency of exacerbations
- Decreased utilization of rescue medications

- Increase in percent predicted forced expiratory volume in 1 second (FEV1) from pretreatment baseline
- Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.)
- Reduction in oral corticosteroid requirements

**AND**

**2** - Dupixent is being used in combination with an inhaled corticosteroid (ICS)-containing controller medication (see Table 1 in Background section)

**AND**

**3** - Patient is NOT receiving Dupixent in combination with ONE of the following:

- Anti-interleukin-5 therapy [e.g. Nucala (mepolizumab), Cinqair (reslizumab), Fasenna (benralizumab)]
- Anti-IgE (immunoglobulin E) therapy [e.g. Xolair (omalizumab)]

**AND**

**4** - Prescribed by ONE of the following:

- Pulmonologist
- Allergist
- Immunologist

Product Name: Dupixent			
Diagnosis	Chronic Rhinosinusitis with Nasal Polyposis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	9027302000E515	Brand

DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	9027302000E520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 300 MG/2ML	9027302000D520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML	9027302000D515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	9027302000E510	Brand

**Approval Criteria**

1 - Patient is 18 years of age or older

**AND**

2 - Submission of documentation (e.g., chart notes) confirming ONE of the following:

2.1 ALL of the following:

2.1.1 Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) defined by ALL of the following:

2.1.1.1 TWO or more of the following symptoms for greater than or equal to 12 weeks duration:

- Mucopurulent discharge
- Nasal obstruction and congestion
- Decreased or absent sense of smell
- Facial pressure or pain

**AND**

2.1.1.2 ONE of the following:

- Evidence of inflammation on paranasal sinus examination or computed tomography (CT)
- Evidence of purulence coming from paranasal sinuses or ostiomeatal complex

**AND**



**2.1.1.3** The presence of nasal polyps

**AND**

**2.1.2** ONE of the following:

- Patient has required prior sino-nasal surgery
- Patient has required systemic corticosteroids in the previous 2 years

**AND**

**2.1.3** Patient has been unable to obtain symptom relief after trial of ALL of the following agents/classes of agents:

- Nasal saline irrigations
- Intranasal corticosteroids (e.g. fluticasone, mometasone, triamcinolone, etc.)
- Antileukotriene agents (e.g. montelukast, zafirlukast, zileuton)

**OR**

**2.2** ALL of the following:

**2.2.1** Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP)

**AND**

**2.2.2** Patient is currently on Dupixent therapy

**AND**

**3** - Patient will receive Dupixent as add-on maintenance therapy in combination with intranasal corticosteroids

**AND**

**4** - Patient is NOT receiving Dupixent in combination with another biologic medication [e.g., Xolair (omalizumab), Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]

**AND**

**5** - Prescribed by ONE of the following:

- Otolaryngologist
- Allergist
- Immunologist

**Product Name: Dupixent**

Diagnosis	Chronic Rhinosinusitis with Nasal Polyposis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	9027302000E515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	9027302000E520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 300 MG/2ML	9027302000D520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML	9027302000D515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	9027302000E510	Brand

**Approval Criteria**

**1** - Submission of documentation (e.g., chart notes) confirming positive clinical response to Dupixent therapy

**AND**

**2** - Patient will continue to receive Dupixent as add-on maintenance therapy in combination with intranasal corticosteroids

**AND**

**3** - Patient is NOT receiving Dupixent in combination with another biologic medication [e.g., Xolair (omalizumab), Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]

**AND**

**4** - Prescribed by ONE of the following:

- Otolaryngologist
- Allergist
- Immunologist

Product Name: Dupixent			
Diagnosis	Eosinophilic Esophagitis (EoE)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	9027302000E515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	9027302000E520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 300 MG/2ML	9027302000D520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML	9027302000D515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	9027302000E510	Brand
<b>Approval Criteria</b>			

**1** - Submission of documentation (e.g., chart notes) confirming diagnosis of eosinophilic esophagitis (EoE)

**AND**

**2** - Patient has symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, gastroesophageal reflux disease [GERD]/heartburn symptoms, chest pain, abdominal pain)

**AND**

**3** - Submission of documentation (e.g., chart notes, lab values) confirming patient has at least 15 intraepithelial eosinophils per high power field (HPF)

**AND**

**4** - Other causes of esophageal eosinophilia have been excluded

**AND**

**5** - BOTH of the following:

- Patient is at least 1 year of age
- Patient weighs at least 15 kg (kilograms)

**AND**

**6** - Paid claims or submission of documentation (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to at least an 8-week trial of ONE of the following:

- Proton pump inhibitors (e.g., pantoprazole, omeprazole)
- Topical (esophageal) corticosteroids (e.g., budesonide, fluticasone)

**AND**

**7** - Prescribed by ONE of the following:

- Gastroenterologist
- Allergist
- Immunologist

**Product Name: Dupixent**

Diagnosis	Eosinophilic Esophagitis (EoE)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	9027302000E515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	9027302000E520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 300 MG/2ML	9027302000D520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML	9027302000D515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	9027302000E510	Brand

**Approval Criteria**

**1** - Submission of documentation (e.g., chart notes) confirming positive clinical response to therapy as evidenced by improvement of at least ONE of the following from baseline:

- Symptoms (e.g., dysphagia, food impaction, heartburn, chest pain)
- Histologic measures (e.g., esophageal intraepithelial eosinophil count)
- Endoscopic measures (e.g., edema, furrows, exudates, rings, strictures)

**AND**

**2** - Prescribed by ONE of the following:

- Gastroenterologist
- Allergist

- Immunologist

Product Name: Dupixent	
Diagnosis	Prurigo Nodularis (PN)
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	9027302000E515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	9027302000E520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 300 MG/2ML	9027302000D520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML	9027302000D515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	9027302000E510	Brand

**Approval Criteria**

1 - Submission of documentation (e.g., chart notes) confirming diagnosis of prurigo nodularis (PN)

**AND**

2 - Patient has at least 20 nodular lesions

**AND**

3 - Trial and failure, contraindication, or intolerance to one previous PN treatment (e.g., topical corticosteroids, topical calcineurin inhibitors [pimecrolimus, tacrolimus], topical capsaicin)

**AND**

**4** - Prescribed by one of the following:

- Dermatologist
- Allergist
- Immunologist

**Product Name: Dupixent**

Diagnosis	Prurigo Nodularis (PN)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	9027302000E515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	9027302000E520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 300 MG/2ML	9027302000D520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML	9027302000D515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	9027302000E510	Brand

**Approval Criteria**

**1** - Submission of documentation (e.g., chart notes) confirming positive clinical response to therapy as evidenced by improvement of at least one of the following:

- Reduction in the number of nodular lesions from baseline
- Improvement in symptoms (e.g., pruritus, inflammation) from baseline

**AND**

2 - Prescribed by one of the following:

- Dermatologist
- Allergist
- Immunologist

## 2 . Background

### Benefit/Coverage/Program Information

**Table 1: Low, medium and high daily doses of inhaled corticosteroids Adults and adolescents (12 years of age and older)**

Drug	Daily dose (mcg)		
	Low	Medium	High
Beclomethasone dipropionate (CFC)	200-500	>500-1000	>1000
Beclomethasone dipropionate (HFA)	100-200	>200-400	>400
Budesonide DPI	200-400	>400-800	>800
Ciclesonide (HFA)	80-160	>160-320	>320
Fluticasone furoate (DPI)	100	N/A	200
Fluticasone propionate (DPI)	100-250	>250-500	>500
Fluticasone propionate (HFA)	100-250	>250-500	>500
Mometasone furoate	110-220	>220-440	>440
Triamcinolone acetonide	400-1000	>1000-2000	>2000

## 3 . Revision History

Date	Notes
3/8/2024	Updated age/weight criterion for EoE indication due to expanded approval.





Durezol



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140718
<b>Guideline Name</b>	Durezol
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Durezol			
Approval Length	2 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DUREZOL	DIFLUPREDNATE OPHTH EMULSION 0.05%	86300012001620	Brand
<b>Approval Criteria</b>			
1 - History of failure, contraindication, or intolerance to BOTH of the following:			

- prednisolone 1%
- dexamethasone ophthalmic drops and/or ointment.

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Duvyzat (givinostat)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-159328
<b>Guideline Name</b>	Duvyzat (givinostat)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Duvyzat			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DUVYZAT	GIVINOSTAT HCL ORAL SUSP 8.86 MG/ML	74603025201820	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of Duchenne muscular dystrophy (DMD)

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting ONE of the following:

**2.1** Patient has a confirmed mutation of the dystrophin gene

**OR**

**2.2** Muscle biopsy confirmed an absence of dystrophin protein

**AND**

**3** - Patient is 6 years of age or older

**AND**

**4** - Submission of medical records (e.g., chart notes) confirming patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.) prior to initiating Duvyzat

**AND**

**5** - Submission of medical records (e.g., chart notes) or paid claims confirming requested drug will be used concomitantly with a corticosteroid regimen (e.g., prednisone/prednisolone, Emflaza [deflazacort], Agamree)

**AND**

**6** - Prescribed by or in consultation with a pediatric neurologist with expertise in treating DMD

Product Name: Duvyzat

Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DUVYZAT	GIVINOSTAT HCL ORAL SUSP 8.86 MG/ML	74603025201820	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming patient has experienced a benefit from therapy (e.g., improvement in preservation of muscle strength)

**AND**

2 - Submission of medical records (e.g., chart notes) confirming patient is maintaining ambulatory status without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)

**AND**

3 - Submission of medical records (e.g., chart notes) or paid claims confirming patient continues to receive concomitant corticosteroid regimen (e.g., prednisone/prednisolone, Emflaza [deflazacort], Agamree)

**2 . Revision History**

Date	Notes
11/5/2024	New program.

Ecoza (econazole)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140712
<b>Guideline Name</b>	Ecoza (econazole)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Ecoza, Generic econazole			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ECONAZOLE NITRATE	ECONAZOLE NITRATE CREAM 1%	90154035103705	Generic
ECOZA	ECONAZOLE NITRATE FOAM 1%	90154035103910	Brand
<b>Approval Criteria</b>			

1 - History of failure, contraindication, or intolerance to ALL of the following:

- butenafine
- ciclopirox
- clotrimazole
- clotrimazole w/ betamethasone
- ketoconazole
- miconazole
- nystatin
- terbinafine
- tolnaftate

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22



Egrifta



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140863
<b>Guideline Name</b>	Egrifta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Egrifta SV			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EGRIFTA SV	TESAMORELIN ACETATE FOR INJ 2 MG (BASE EQUIV)	30150085102130	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of human immunodeficiency virus (HIV)-associated lipodystrophy			

## 2 . Revision History

Date	Notes
3/8/2021	Updated GPI's and product name list.

Elaprase



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140845
<b>Guideline Name</b>	Elaprase
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Elaprase			
Diagnosis	Hunter syndrome		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ELAPRASE	IDURSULFASE SOLN FOR IV INFUSION 6 MG/3ML (2 MG/ML)	30906850002020	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of Hunter syndrome (Mucopolysaccharidosis II, MPS II)

## 2 . Revision History

Date	Notes
3/11/2020	C&S Implementation

Elevidys



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151816
<b>Guideline Name</b>	Elevidys
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Elevidys			
Approval Length	45 days or until the patient reaches 6 years of age, whichever is shorter		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ELEVIDYS 10.0-10.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 10 X 10 ML KIT	74600030406410	Brand
ELEVIDYS 10.5-11.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 11 X 10 ML KIT	74600030406411	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ELEVIDYS 11.5-12.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 12 X 10 ML KIT	74600030406412	Brand
ELEVIDYS 12.5-13.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 13 X 10 ML KIT	74600030406413	Brand
ELEVIDYS 13.5-14.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 14 X 10 ML KIT	74600030406414	Brand
ELEVIDYS 14.5-15.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 15 X 10 ML KIT	74600030406415	Brand
ELEVIDYS 15.5-16.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 16 X 10 ML KIT	74600030406416	Brand
ELEVIDYS 16.5-17.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 17 X 10 ML KIT	74600030406417	Brand
ELEVIDYS 17.5-18.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 18 X 10 ML KIT	74600030406418	Brand
ELEVIDYS 18.5-19.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 19 X 10 ML KIT	74600030406419	Brand
ELEVIDYS 19.5-20.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 20 X 10 ML KIT	74600030406420	Brand
ELEVIDYS 20.5-21.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 21 X 10 ML KIT	74600030406421	Brand
ELEVIDYS 21.5-22.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 22 X 10 ML KIT	74600030406422	Brand
ELEVIDYS 22.5-23.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 23 X 10 ML KIT	74600030406423	Brand
ELEVIDYS 23.5-24.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 24 X 10 ML KIT	74600030406424	Brand
ELEVIDYS 24.5-25.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 25 X 10 ML KIT	74600030406425	Brand
ELEVIDYS 25.5-26.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 26 X 10 ML KIT	74600030406426	Brand
ELEVIDYS 26.5-27.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 27 X 10 ML KIT	74600030406427	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ELEVIDYS 27.5-28.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 28 X 10 ML KIT	74600030406428	Brand
ELEVIDYS 28.5-29.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 29 X 10 ML KIT	74600030406429	Brand
ELEVIDYS 29.5-30.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 30 X 10 ML KIT	74600030406430	Brand
ELEVIDYS 30.5-31.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 31 X 10 ML KIT	74600030406431	Brand
ELEVIDYS 31.5-32.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 32 X 10 ML KIT	74600030406432	Brand
ELEVIDYS 32.5-33.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 33 X 10 ML KIT	74600030406433	Brand
ELEVIDYS 33.5-34.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 34 X 10 ML KIT	74600030406434	Brand
ELEVIDYS 34.5-35.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 35 X 10 ML KIT	74600030406435	Brand
ELEVIDYS 35.5-36.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 36 X 10 ML KIT	74600030406436	Brand
ELEVIDYS 36.5-37.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 37 X 10 ML KIT	74600030406437	Brand
ELEVIDYS 37.5-38.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 38 X 10 ML KIT	74600030406438	Brand
ELEVIDYS 38.5-39.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 39 X 10 ML KIT	74600030406439	Brand
ELEVIDYS 39.5-40.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 40 X 10 ML KIT	74600030406440	Brand
ELEVIDYS 40.5-41.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 41 X 10 ML KIT	74600030406441	Brand
ELEVIDYS 41.5-42.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 42 X 10 ML KIT	74600030406442	Brand
ELEVIDYS 42.5-43.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 43 X 10 ML KIT	74600030406443	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ELEVIDYS 43.5-44.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 44 X 10 ML KIT	74600030406444	Brand
ELEVIDYS 44.5-45.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 45 X 10 ML KIT	74600030406445	Brand
ELEVIDYS 45.5-46.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 46 X 10 ML KIT	74600030406446	Brand
ELEVIDYS 46.5-47.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 47 X 10 ML KIT	74600030406447	Brand
ELEVIDYS 47.5-48.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 48 X 10 ML KIT	74600030406448	Brand
ELEVIDYS 48.5-49.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 49 X 10 ML KIT	74600030406449	Brand
ELEVIDYS 49.5-50.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 50 X 10 ML KIT	74600030406450	Brand
ELEVIDYS 50.5-51.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 51 X 10 ML KIT	74600030406451	Brand
ELEVIDYS 51.5-52.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 52 X 10 ML KIT	74600030406452	Brand
ELEVIDYS 52.5-53.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 53 X 10 ML KIT	74600030406453	Brand
ELEVIDYS 53.5-54.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 54 X 10 ML KIT	74600030406454	Brand
ELEVIDYS 54.5-55.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 55 X 10 ML KIT	74600030406455	Brand
ELEVIDYS 55.5-56.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 56 X 10 ML KIT	74600030406456	Brand
ELEVIDYS 56.5-57.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 57 X 10 ML KIT	74600030406457	Brand
ELEVIDYS 57.5-58.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 58 X 10 ML KIT	74600030406458	Brand
ELEVIDYS 58.5-59.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 59 X 10 ML KIT	74600030406459	Brand



ELEVIDYS 59.5-60.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 60 X 10 ML KIT	74600030406460	Brand
ELEVIDYS 60.5-61.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 61 X 10 ML KIT	74600030406461	Brand
ELEVIDYS 61.5-62.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 62 X 10 ML KIT	74600030406462	Brand
ELEVIDYS 62.5-63.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 63 X 10 ML KIT	74600030406463	Brand
ELEVIDYS 63.5-64.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 64 X 10 ML KIT	74600030406464	Brand
ELEVIDYS 64.5-65.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 65 X 10 ML KIT	74600030406465	Brand
ELEVIDYS 65.5-66.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 66 X 10 ML KIT	74600030406466	Brand
ELEVIDYS 66.5-67.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 67 X 10 ML KIT	74600030406467	Brand
ELEVIDYS 67.5-68.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 68 X 10 ML KIT	74600030406468	Brand
ELEVIDYS 68.5-69.4 KG	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 69 X 10 ML KIT	74600030406469	Brand
ELEVIDYS 69.5 KG PLUS	DELANDISTROGENE MOXEPARVOVEC-ROKL IV SUSP 70 X 10 ML KIT	74600030406470	Brand

**Approval Criteria**

1 - Diagnosis of Duchenne muscular dystrophy by, or in consultation with, a pediatric neuromuscular specialist with expertise in the diagnosis of DMD

**AND**

2 - Submission of medical records (e.g., chart notes, laboratory values) confirming both of the following:

- A mutation in the DMD gene

- The mutation is not a deletion in exon 8 or exon 9

**AND**

**3** - Patient is aged 4 or 5 years of age

**AND**

**4** - Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)

**AND**

**5** - Patient does not have an elevated anti-AAVrh74 total binding antibody titer greater than or equal to 1:400

**AND**

**6** - Patient will receive a corticosteroid regimen prior to and following receipt of Elevidys in accordance with the United States Food and Drug Administration (FDA) approved Elevidys labeling

**AND**

**7** - Elevidys is prescribed by, or in consultation with, a pediatric neuromuscular specialist with expertise in the treatment of DMD

**AND**

**8** - Elevidys dosing is in accordance with FDA approved labeling

**AND**

**9** - Patient will not receive exon-skipping therapies for DMD [e.g., Amondys (casimersen),

Exondys 51 (eteplirsen), Viltepso (viltolarsen), Vyondys 53 (golodirsen)] concomitantly or following Elevidys treatment

**AND**

**10** - Patient has never received Elevidys treatment in their lifetime

## 2 . Revision History

Date	Notes
8/15/2024	Updated GPs

Elidel-Protopic



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140636
<b>Guideline Name</b>	Elidel-Protopic
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

## 1 . Criteria

Product Name: Brand Elidel, generic pimecrolimus, Brand Protopic 0.03%, generic tacrolimus 0.03%			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ELIDEL	PIMECROLIMUS CREAM 1%	90784060003720	Brand
PIMECROLIMUS	PIMECROLIMUS CREAM 1%	90784060003720	Generic
PROTOPIC	TACROLIMUS OINT 0.03%	90784075004210	Brand
TACROLIMUS	TACROLIMUS OINT 0.03%	90784075004210	Generic

**Approval Criteria**

1 - The patient is 2 years of age or older

**AND**

2 - ONE of the following:

2.1 History of failure, contraindication, or intolerance to ONE topical corticosteroid in the past 90 days

**OR**

2.2 Drug is being prescribed for the facial or groin area

Product Name: Brand Protopic 0.1%, generic tacrolimus 0.1%

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
PROTOPIC	TACROLIMUS OINT 0.1%	90784075004230	Brand
TACROLIMUS	TACROLIMUS OINT 0.1%	90784075004230	Generic

**Approval Criteria**

1 - The patient is 16 years of age or older

**AND**

2 - ONE of the following:

2.1 History of failure, contraindication, or intolerance to ONE topical corticosteroid in the past 90 days

**OR**

**2.2** Drug is being prescribed for the facial or groin area

## **2 . Revision History**

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Elmiron



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140637
<b>Guideline Name</b>	Elmiron
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Elmiron			
Diagnosis	Bladder pain or discomfort associated with interstitial cystitis		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ELMIRON	PENTOSAN POLYSULFATE SODIUM CAPS 100 MG	56500060100110	Brand
<b>Approval Criteria</b>			

1 - Patient has a documented diagnosis of bladder pain or discomfort associated with interstitial cystitis

## 2 . Revision History

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1



Emflaza (deflazacort)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-145787
<b>Guideline Name</b>	Emflaza (deflazacort)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Emflaza, generic deflazacort			
Diagnosis	Duchenne Muscular Dystrophy		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DEFLAZACORT	DEFLAZACORT TAB 6 MG	22100017000340	Generic
EMFLAZA	DEFLAZACORT TAB 6 MG	22100017000340	Brand
DEFLAZACORT	DEFLAZACORT TAB 18 MG	22100017000350	Generic
EMFLAZA	DEFLAZACORT TAB 18 MG	22100017000350	Brand

DEFLAZACORT	DEFLAZACORT TAB 30 MG	22100017000360	Generic
EMFLAZA	DEFLAZACORT TAB 30 MG	22100017000360	Brand
DEFLAZACORT	DEFLAZACORT TAB 36 MG	22100017000365	Generic
EMFLAZA	DEFLAZACORT TAB 36 MG	22100017000365	Brand
EMFLAZA	DEFLAZACORT SUSP 22.75 MG/ML	22100017001830	Brand

**Approval Criteria**

1 - Diagnosis of Duchenne muscular dystrophy

**AND**

2 - Patient is 2 years of age or older

**AND**

3 - History of failure, contraindication, or intolerance to ONE of the following for the treatment of Duchenne muscular dystrophy:

- Prednisone
- Prednisolone

**AND**

4 - Prescribed by or in consultation with a neurologist

**AND**

5 - If the request is for generic deflazacort, patient must have tried and failed Brand Emflaza

Product Name: Brand Emflaza, generic deflazacort	
Diagnosis	Duchenne Muscular Dystrophy
Approval Length	12 month(s)

Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DEFLAZACORT	DEFLAZACORT TAB 6 MG	22100017000340	Generic
EMFLAZA	DEFLAZACORT TAB 6 MG	22100017000340	Brand
DEFLAZACORT	DEFLAZACORT TAB 18 MG	22100017000350	Generic
EMFLAZA	DEFLAZACORT TAB 18 MG	22100017000350	Brand
DEFLAZACORT	DEFLAZACORT TAB 30 MG	22100017000360	Generic
EMFLAZA	DEFLAZACORT TAB 30 MG	22100017000360	Brand
DEFLAZACORT	DEFLAZACORT TAB 36 MG	22100017000365	Generic
EMFLAZA	DEFLAZACORT TAB 36 MG	22100017000365	Brand
EMFLAZA	DEFLAZACORT SUSP 22.75 MG/ML	22100017001830	Brand

**Approval Criteria**

1 - Physician attestation that the patient has had a positive clinical response to therapy

**AND**

2 - If the request is for generic deflazacort, patient must have tried and failed Brand Emflaza

**2 . Revision History**

Date	Notes
4/16/2024	Updated guideline name, added generic deflazacort and added step through preferred Brand Emflaza for generic deflazacort

Enbrel



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-143527
<b>Guideline Name</b>	Enbrel
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	3/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Enbrel			
Diagnosis	Moderately to Severely Active Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML	6629003000E525	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML	6629003000E530	Brand
ENBREL MINI	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	6629003000E230	Brand

ENBREL SURECLICK	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	6629003000D530	Brand
ENBREL	ETANERCEPT FOR SUBCUTANEOUS INJ 25MG/0.5ML	66290030002015	Brand

**Approval Criteria**

**1** - Diagnosis of moderately to severely active Rheumatoid Arthritis (RA)

**AND**

**2** - History of failure to a 3 month trial of ONE non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

Notes	*Note: Claims history may be used in conjunction as documentation of drug, date, and duration of trial
-------	--

Product Name: Enbrel			
Diagnosis	Moderately to Severely Active Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		

Product Name	Generic Name	GPI	Brand/Generic
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML	6629003000E525	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML	6629003000E530	Brand
ENBREL MINI	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	6629003000E230	Brand
ENBREL SURECLICK	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	6629003000D530	Brand

ENBREL	ETANERCEPT FOR SUBCUTANEOUS INJ 25MG/0.5ML	66290030002015	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Enbrel therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with a rheumatologist</p>			

Product Name: Enbrel			
Diagnosis	Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML	6629003000E525	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML	6629003000E530	Brand
ENBREL MINI	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	6629003000E230	Brand
ENBREL SURECLICK	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	6629003000D530	Brand
ENBREL	ETANERCEPT FOR SUBCUTANEOUS INJ 25MG/0.5ML	66290030002015	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis</p> <p style="text-align: center;"><b>AND</b></p>			

**2** - Patient is 2 years of age or older

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

Product Name: Enbrel

Diagnosis	Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML	6629003000E525	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML	6629003000E530	Brand
ENBREL MINI	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	6629003000E230	Brand
ENBREL SURECLICK	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	6629003000D530	Brand
ENBREL	ETANERCEPT FOR SUBCUTANEOUS INJ 25MG/0.5ML	66290030002015	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to Enbrel therapy

**AND**

**2** - Prescribed by or in consultation with a rheumatologist

Product Name: Enbrel

Diagnosis	Active Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML	6629003000E525	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML	6629003000E530	Brand
ENBREL MINI	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	6629003000E230	Brand
ENBREL SURECLICK	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	6629003000D530	Brand
ENBREL	ETANERCEPT FOR SUBCUTANEOUS INJ 25MG/0.5ML	66290030002015	Brand

**Approval Criteria**

1 - Diagnosis of active psoriatic arthritis

**AND**

2 - History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

3 - Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Notes	*Note: Claims history may be used in conjunction as documentation of drug, date, and duration of trial
-------	--



Product Name: Enbrel	
Diagnosis	Active Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML	6629003000E525	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML	6629003000E530	Brand
ENBREL MINI	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	6629003000E230	Brand
ENBREL SURECLICK	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	6629003000D530	Brand
ENBREL	ETANERCEPT FOR SUBCUTANEOUS INJ 25MG/0.5ML	66290030002015	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Enbrel therapy

**AND**

2 - Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Product Name: Enbrel	
Diagnosis	Moderate to Severe Chronic Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML	6629003000E525	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML	6629003000E530	Brand
ENBREL MINI	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	6629003000E230	Brand
ENBREL SURECLICK	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	6629003000D530	Brand
ENBREL	ETANERCEPT FOR SUBCUTANEOUS INJ 25MG/0.5ML	66290030002015	Brand

**Approval Criteria**

1 - Diagnosis of moderate to severe chronic plaque psoriasis

**AND**

2 - Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

3 - Both of the following:

**3.1** History of failure to one of the following topical therapies, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial):\*

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**3.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

**4** - Prescribed by or in consultation with a dermatologist

Notes	*Note: Claims history may be used in conjunction as documentation of drug, date, and duration of trial
-------	--

Product Name: Enbrel			
Diagnosis	Moderate to Severe Chronic Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML	6629003000E525	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML	6629003000E530	Brand
ENBREL MINI	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	6629003000E230	Brand
ENBREL SURECLICK	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	6629003000D530	Brand
ENBREL	ETANERCEPT FOR SUBCUTANEOUS INJ 25MG/0.5ML	66290030002015	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to Enbrel therapy

**AND**

**2** - Prescribed by or in consultation with a dermatologist

Product Name: Enbrel			
Diagnosis	Ankylosing spondylitis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML	6629003000E525	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML	6629003000E530	Brand
ENBREL MINI	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	6629003000E230	Brand
ENBREL SURECLICK	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	6629003000D530	Brand
ENBREL	ETANERCEPT FOR SUBCUTANEOUS INJ 25MG/0.5ML	66290030002015	Brand
<p><b>Approval Criteria</b></p> <p><b>1 - Diagnosis of active ankylosing spondylitis</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - History of failure to two non-steroidal anti-inflammatory drugs (NSAIDs: e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trials)*</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - Prescribed by or in consultation with a rheumatologist</b></p>			
Notes	*Note: Claims history may be used in conjunction as documentation of drug, date, and duration of trial		

Product Name: Enbrel

Diagnosis	Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML	6629003000E525	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML	6629003000E530	Brand
ENBREL MINI	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	6629003000E230	Brand
ENBREL SURECLICK	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	6629003000D530	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS INJ 25 MG/0.5ML	66290030002015	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Enbrel therapy

**AND**

2 - Prescribed by or in consultation with a rheumatologist

**2 . Revision History**

Date	Notes
2/23/2024	Added age criteria for PJIA . Removed concomitant use criterion from all sections.

Endari



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140638
<b>Guideline Name</b>	Endari
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Endari			
Diagnosis	Sickle cell disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ENDARI	GLUTAMINE (SICKLE CELL) POWD PACK 5 GM	82801020003020	Brand
<b>Approval Criteria</b>			

**1 - BOTH of the following:**

- Diagnosis of sickle cell disease
- Used to reduce acute complications of sickle cell disease

**AND**

**2 - ONE of the following:**

- Patient is using Endari with concurrent hydroxyurea therapy
- Patient is unable to take hydroxyurea due to a contraindication or intolerance

**AND**

**3 - Patient has had 2 or more painful sickle cell crises within the past 12 months**

<b>Product Name: Endari</b>			
Diagnosis	Sickle cell disease		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ENDARI	GLUTAMINE (SICKLE CELL) POWD PACK 5 GM	82801020003020	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Endari therapy			

## 2 . Revision History

Date	Notes
------	-------

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1
-----------	---



Enspryng



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160435
<b>Guideline Name</b>	Enspryng
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Enspryng			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ENSPRYNG	SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE 120 MG/ML	9940507040E520	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of neuromyelitis optica spectrum disorder (NMOSD)

**AND**

2 - Patient has a positive serologic test for anti-aquaporin-4 (AQP4) antibodies

**AND**

3 - History of failure, contraindication, or intolerance to rituximab therapy

**AND**

4 - One of the following:

- History of one or more relapses that required rescue therapy during the previous 12 months
- History of two or more relapses that required rescue therapy during the previous 24 months

**AND**

5 - Prescribed by, or in consultation with, a neurologist

**AND**

6 - Patient is NOT receiving Enspryng in combination with any of the following:

- Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya (fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]
- Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab), etc]
- Anti-IL6 (anti-interleukin-6) therapy [e.g., Actemra (tocilizumab)]
- B-cell depletion therapy [e.g., rituximab, Uplizna (inebilizumab)]

Product Name: Enspryng

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage		Reauthorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
ENSPRYNG	SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE 120 MG/ML	9940507040E520	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Enspryng therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by, or in consultation with, a neurologist</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is NOT receiving Enspryng in combination with any of the following:</p> <ul style="list-style-type: none"> <li>• Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya (fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]</li> <li>• Complement inhibitors [e.g., Soliris (eculizumab), Ultomiris (ravulizumab), etc]</li> <li>• Anti-IL6 (anti-interleukin-6) therapy [e.g., Actemra (tocilizumab)]</li> <li>• B-cell depletion therapy [e.g., rituximab, Uplizna (inebilizumab)]</li> </ul>			

## 2 . Revision History

Date	Notes
11/11/2024	Updated examples of complement inhibitors

Entocort EC



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140639
<b>Guideline Name</b>	Entocort EC
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Brand Entocort EC, generic budesonide			
Diagnosis	Crohn's Disease		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BUDESONIDE	BUDESONIDE DELAYED RELEASE PARTICLES CAP 3 MG	22100012006720	Generic
ENTOCORT EC	BUDESONIDE DELAYED RELEASE PARTICLES CAP 3 MG	22100012006720	Brand

**Approval Criteria**

1 - Entocort EC is being used for the treatment of Crohn's disease

**2 . Revision History**

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Entresto



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-157914
<b>Guideline Name</b>	Entresto
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Entresto tablets, Entresto sprinkle capsules			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ENTRESTO	SACUBITRIL-VALSARTAN TAB 24-26 MG	40992002600320	Brand
ENTRESTO	SACUBITRIL-VALSARTAN TAB 97-103 MG	40992002600340	Brand
ENTRESTO	SACUBITRIL-VALSARTAN TAB 49-51 MG	40992002600330	Brand
ENTRESTO	SACUBITRIL-VALSARTAN SPRINKLE CAP 6-6 MG	40992002606820	Brand
ENTRESTO	SACUBITRIL-VALSARTAN SPRINKLE CAP 15-16 MG	40992002606830	Brand

**Approval Criteria**

1 - As continuation of therapy initiated during an inpatient stay

**OR**

2 - BOTH of the following:

2.1 Diagnosis of pediatric heart failure with systemic left ventricular systolic dysfunction which is symptomatic

**AND**

2.2 Prescribed by, or in consultation with, a cardiologist

**OR**

3 - ALL of the following:

3.1 Diagnosis of heart failure (with or without hypertension)

**AND**

3.2 Ejection fraction is less than or equal to 40 percent

**AND**

3.3 Heart failure is classified as ONE of the following:

- New York Heart Association Class II
- New York Heart Association Class III
- New York Heart Association Class IV

**AND**

**3.4** ONE of the following:

**3.4.1** Patient is on a stabilized dose and receiving concomitant therapy with ONE of the following beta-blockers:

- bisoprolol
- carvedilol
- metoprolol

**OR**

**3.4.2** Patient has a contraindication or intolerance to beta-blocker therapy

**AND**

**3.5** Patient does NOT have a history of angioedema

**AND**

**3.6** Patient will discontinue any use of concomitant ACE (angiotensin converting enzyme) inhibitor or ARB (angiotensin II receptor blocker) before initiating treatment with Entresto

**AND**

**3.7** Patient is NOT concomitantly on aliskiren therapy

**AND**

**3.8** Prescribed by, or in consultation with, a cardiologist

Product Name: Entresto tablets, Entresto sprinkle capsules

Approval Length	12 month(s)
-----------------	-------------



Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ENTRESTO	SACUBITRIL-VALSARTAN TAB 24-26 MG	40992002600320	Brand
ENTRESTO	SACUBITRIL-VALSARTAN TAB 97-103 MG	40992002600340	Brand
ENTRESTO	SACUBITRIL-VALSARTAN TAB 49-51 MG	40992002600330	Brand
ENTRESTO	SACUBITRIL-VALSARTAN SPRINKLE CAP 6-6 MG	40992002606820	Brand
ENTRESTO	SACUBITRIL-VALSARTAN SPRINKLE CAP 15-16 MG	40992002606830	Brand
<p><b>Approval Criteria</b></p> <p>1 - The Entresto dose has been titrated to a dose of 97 mg (milligrams) /103 mg twice daily, or to a maximum dose as tolerated by the patient</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Documentation of positive clinical response to therapy</p>			

## 2 . Revision History

Date	Notes
10/25/2024	Removed operational note regarding ACEI discontinuation.

Entyvio (vedolizumab)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-148507
<b>Guideline Name</b>	Entyvio (vedolizumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Entyvio SC			
Approval Length	14 Week(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ENTYVIO	VEDOLIZUMAB SOLN PEN-INJECTOR 108 MG/0.68ML	5250308000D520	Brand
<b>Approval Criteria</b>			
1 - ONE of the following:			

**1.1 ALL of the following:**

**1.1.1** Submission of medical records (e.g., chart notes) confirming a diagnosis of ONE of the following:

- Moderately to severely active Crohn's disease
- Moderately to severely active ulcerative colitis

**AND**

**1.1.2** Paid claims or submission of medical records (e.g., chart notes) confirming ONE of the following:

**1.1.2.1** Will be used as a maintenance dose following two doses of Entyvio IV for induction

**OR**

**1.1.2.2** Patient is currently established on Entyvio IV

**AND**

**1.1.3** Prescribed by or in consultation with a gastroenterologist

**OR**

**1.2** Patient has received 2 doses of Entyvio IV for induction

Product Name: Entyvio SC			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ENTYVIO	VEDOLIZUMAB SOLN PEN-INJECTOR 108 MG/0.68ML	5250308000D520	Brand

**Approval Criteria**

1 - Patient demonstrates positive clinical response to therapy as evidenced by at least ONE of the following:

- Improvement in intestinal inflammation (e.g., mucosal healing, improvement of lab values [platelet counts, erythrocyte sedimentation rate, C-reactive protein level]) from baseline
- Reversal of high fecal output state

**2 . Revision History**

Date	Notes
6/13/2024	Added allowance for CD diagnosis to SC formulation criteria due to expanded approval; Minor cosmetic updates.

Eohilia (budesonide)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-147109
<b>Guideline Name</b>	Eohilia (budesonide)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Eohilia			
Diagnosis	Eosinophilic Esophagitis (EoE)		
Approval Length	12 Week(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EOHILIA	BUDESONIDE ORAL SUSPENSION 2 MG/10ML	22100012001820	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of eosinophilic esophagitis (EoE)

**AND**

**2** - Patient has symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, heartburn, abdominal pain)

**AND**

**3** - Patient has at least 15 intraepithelial eosinophils per high power field (HPF)

**AND**

**4** - Other causes of esophageal eosinophilia have been excluded

**AND**

**5** - Patient is 11 years of age or older

**AND**

**6** - Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure (of a minimum 8-week duration), contraindication, or intolerance to a proton pump inhibitor (e.g., pantoprazole, omeprazole)

**AND**

**7** - Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure (of a minimum 8-week duration), or intolerance to a topical (esophageal) corticosteroid (e.g., budesonide, fluticasone)

**AND**

**8** - Prescribed by or in consultation with ONE of the following:

- Allergist/Immunologist
- Gastroenterologist

## 2 . Revision History

Date	Notes
5/6/2024	New program.

Epaned



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140683
<b>Guideline Name</b>	Epaned
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Epaned			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EPANED	ENALAPRIL MALEATE ORAL SOLN 1 MG/ML	36100020102020	Brand
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 Patient is less than 8 years of age</p>			



**OR**

**1.2 BOTH** of the following:

**1.2.1 ONE** of the following diagnoses:

- Hypertension
- Heart failure
- Asymptomatic left ventricular dysfunction, defined as left ventricular ejection fraction less than or equal to 35%

**AND**

**1.2.2 ONE** of the following:

**1.2.2.1** History of failure, contraindication, or intolerance to TWO formulary oral anti-hypertensives (e.g., angiotensin-converting enzyme (ACE) inhibitor, ACE inhibitor combination, angiotensin-receptor blockers (ARB), ARB combination, thiazide diuretic)

**OR**

**1.2.2.2** Patient is unable to ingest a solid dosage form (e.g. an oral tablet or capsule) due to ONE of the following:

- Oral/motor difficulties
- Dysphagia

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Epinephrine Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-159404
<b>Guideline Name</b>	Epinephrine Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Epinephrine Pens (Non-Mylan Manufacturer)*, Neffy			
Approval Length	6 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AUVI-Q	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.1 MG/0.1ML	3890004000D510	Brand
AUVI-Q	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.15 MG/0.15ML (1:1000)	3890004000D530	Brand
EPINEPHRINE	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.15 MG/0.15ML (1:1000)	3890004000D530	Generic
EPIPEN 2-PAK	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.3 MG/0.3ML (1:1000)	3890004000D540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AUVI-Q	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.3 MG/0.3ML (1:1000)	3890004000D540	Brand
EPINEPHRINE	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.3 MG/0.3ML (1:1000)	3890004000D540	Generic
NEFFY	EPINEPHRINE NASAL SPRAY 2 MG/0.1ML	38900040002080	Brand
<b>Approval Criteria</b>			
1 - There is a shortage on Epinephrine Pens manufactured by Mylan.			
Notes	*Only approve other rebatable epinephrine autoinjectors if both the branded EpiPen and authorized generic are on the FDA shortage list.		

Product Name: Epinephrine Pens (Mylan Manufacturer)			
Approval Length	6 month(s)		
Guideline Type	Quantity Limit		
Product Name	Generic Name	GPI	Brand/Generic
AUVI-Q	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.1 MG/0.1ML	3890004000D510	Brand
AUVI-Q	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.15 MG/0.15ML (1:1000)	3890004000D530	Brand
EPINEPHRINE	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.15 MG/0.15ML (1:1000)	3890004000D530	Generic
EPIPEN 2-PAK	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.3 MG/0.3ML (1:1000)	3890004000D540	Brand
AUVI-Q	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.3 MG/0.3ML (1:1000)	3890004000D540	Brand
EPINEPHRINE	EPINEPHRINE SOLUTION AUTO-INJECTOR 0.3 MG/0.3ML (1:1000)	3890004000D540	Generic
<b>Approval Criteria</b>			
1 - Medication has been used or lost or the member is going on vacation.*			
Notes	*Only approve other rebatable epinephrine autoinjectors if both the branded EpiPen and authorized generic are on the FDA shortage list.		

**2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
11/6/2024	Added Neffy as a target to the guideline. Updated product name list and GPI table accordingly. Ensured notes were tied to asterisks, where applicable. Updated guideline name.

Eplerenone



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140684
<b>Guideline Name</b>	Eplerenone
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Inspra, generic eplerenone			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
INSpra	EPLERENONE TAB 25 MG	36250030000320	Brand
INSpra	EPLERENONE TAB 50 MG	36250030000330	Brand
EPLERENONE	EPLERENONE TAB 25 MG	36250030000320	Generic
EPLERENONE	EPLERENONE TAB 50 MG	36250030000330	Generic

**Approval Criteria**

1 - Diagnosis of one of the following:

1.1 Symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction

**OR**

1.2 Hypertension

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Epsolay (benzoyl peroxide) cream



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140678
<b>Guideline Name</b>	Epsolay (benzoyl peroxide) cream
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Epsolay			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EPSOLAY	BENZOYL PEROXIDE CREAM 5%	90050010003710	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of rosacea			

**AND**

**2** - Patient has inflammatory lesions

**AND**

**3** - Trial and failure (of a minimum 30-day supply), contraindication or intolerance to one preferred topical product for rosacea (e.g., metronidazole cream/gel/lotion) (verified via paid pharmacy claims)

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22



Erythropoietic Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-145986
<b>Guideline Name</b>	Erythropoietic Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Aranesp, Epogen, Procrit, Retacrit			
Diagnosis	Anemia Due to Chronic Kidney Disease (CKD)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 10 MCG/0.4ML	8240101510E510	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 25 MCG/0.42ML	8240101510E528	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 40 MCG/0.4ML	8240101510E543	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 60 MCG/0.3ML	8240101510E552	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 100 MCG/0.5ML	8240101510E560	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 150 MCG/0.3ML	8240101510E575	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 200 MCG/0.4ML	8240101510E582	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 300 MCG/0.6ML	8240101510E588	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 500 MCG/ML	8240101510E590	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 25 MCG/ML	82401015102010	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 40 MCG/ML	82401015102020	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 60 MCG/ML	82401015102030	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 100 MCG/ML	82401015102040	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 200 MCG/ML	82401015102060	Brand
EPOGEN	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
PROCRIT	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
EPOGEN	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
PROCRIT	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
EPOGEN	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
PROCRIT	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
EPOGEN	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
PROCRIT	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
EPOGEN	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand

PROCRIT	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 40000 UNIT/ML	82401020002060	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 2000 UNIT/ML	82401020042010	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 3000 UNIT/ML	82401020042015	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 4000 UNIT/ML	82401020042020	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 10000 UNIT/ML	82401020042040	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 20000 UNIT/ML	82401020042050	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 40000 UNIT/ML	82401020042060	Brand

**Approval Criteria**

1 - Diagnosis of chronic kidney disease (CKD)

**AND**

2 - Hematocrit is less than 30% at initiation of therapy

**AND**

3 - ONE of the following:

3.1 Patient is on dialysis

**OR**

3.2 ALL of the following:

3.2.1 Patient is NOT on dialysis

**AND**

3.2.2 The rate of hematocrit decline indicates the likelihood of requiring a red blood cell (RBC) transfusion

**AND**

**3.2.3** Reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal

**AND**

**4** - If the request is for a non-preferred\* product, claims history indicates ONE preferred\* agent has been tried at maximum doses as indicated by FDA labeling

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Aranesp, Epogen, Procrit, Retacrit			
Diagnosis	Anemia Due to Chronic Kidney Disease (CKD)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 10 MCG/0.4ML	8240101510E510	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 25 MCG/0.42ML	8240101510E528	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 40 MCG/0.4ML	8240101510E543	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 60 MCG/0.3ML	8240101510E552	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 100 MCG/0.5ML	8240101510E560	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 150 MCG/0.3ML	8240101510E575	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 200 MCG/0.4ML	8240101510E582	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 300 MCG/0.6ML	8240101510E588	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 500 MCG/ML	8240101510E590	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 25 MCG/ML	82401015102010	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 40 MCG/ML	82401015102020	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 60 MCG/ML	82401015102030	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 100 MCG/ML	82401015102040	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 200 MCG/ML	82401015102060	Brand
EPOGEN	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
PROCRIT	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
EPOGEN	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
PROCRIT	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
EPOGEN	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
PROCRIT	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
EPOGEN	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
PROCRIT	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
EPOGEN	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 40000 UNIT/ML	82401020002060	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 2000 UNIT/ML	82401020042010	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 3000 UNIT/ML	82401020042015	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 4000 UNIT/ML	82401020042020	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 10000 UNIT/ML	82401020042040	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 20000 UNIT/ML	82401020042050	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 40000 UNIT/ML	82401020042060	Brand

**Approval Criteria**

1 - Diagnosis of chronic kidney disease (CKD)

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

2.1.1 Patient is on dialysis

**AND**

2.1.2 Most recent or average Hct (hematocrit) over 3 months is 33% or less [Hgb (hemoglobin) 11 g/dL (grams/deciliter) or less]

**OR**

2.2 ALL of the following:

2.2.1 Patient is NOT on dialysis

**AND**

2.2.2 Most recent or average (avg) Hct over 3 months is 30% or less (Hgb 10 g/dL or less)

**AND**

2.2.3 Reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal

**OR**

**2.3** BOTH of the following:

**2.3.1** Request is for a pediatric patient

**AND**

**2.3.2** Most recent or average Hct over 3 months is 36% or less (Hgb 12 g/dL or less)

**AND**

**3** - ONE of the following:

**3.1** Decrease in the need for blood transfusion

**OR**

**3.2** Hgb increased greater than or equal to 1 g/dL from pre-treatment level

**AND**

**4** - If the request is for a non-preferred\* product, claims history indicates ONE preferred\* agent has been tried at maximum doses as indicated by FDA labeling

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Epogen, Procrit, Retacrit			
Diagnosis	Anemia Associated with Zidovudine Treatment in HIV-Infected Patients		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EPOGEN	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand

PROCRIT	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
EPOGEN	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
PROCRIT	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
EPOGEN	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
PROCRIT	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
EPOGEN	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
PROCRIT	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
EPOGEN	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 40000 UNIT/ML	82401020002060	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 2000 UNIT/ML	82401020042010	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 3000 UNIT/ML	82401020042015	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 4000 UNIT/ML	82401020042020	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 10000 UNIT/ML	82401020042040	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 20000 UNIT/ML	82401020042050	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 40000 UNIT/ML	82401020042060	Brand

**Approval Criteria**

1 - Patient is receiving zidovudine administered at less than or equal to 4200 milligrams per week

**AND**

2 - Endogenous serum erythropoietin level is less than or equal to 500 milliunits per milliliter

**AND**

3 - Hematocrit is less than 30% at initiation of therapy

**AND**



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

**4** - If the request is for a non-preferred\* product, claims history indicates ONE preferred\* agent has been tried at maximum doses as indicated by FDA labeling

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Aranesp, Epogen, Procrit, Retacrit			
Diagnosis	Anemia Due to Cancer Chemotherapy		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 10 MCG/0.4ML	8240101510E510	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 25 MCG/0.42ML	8240101510E528	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 40 MCG/0.4ML	8240101510E543	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 60 MCG/0.3ML	8240101510E552	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 100 MCG/0.5ML	8240101510E560	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 150 MCG/0.3ML	8240101510E575	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 200 MCG/0.4ML	8240101510E582	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 300 MCG/0.6ML	8240101510E588	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 500 MCG/ML	8240101510E590	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 25 MCG/ML	82401015102010	Brand

ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 40 MCG/ML	82401015102020	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 60 MCG/ML	82401015102030	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 100 MCG/ML	82401015102040	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 200 MCG/ML	82401015102060	Brand
EPOGEN	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
PROCRIT	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
EPOGEN	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
PROCRIT	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
EPOGEN	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
PROCRIT	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
EPOGEN	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
PROCRIT	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
EPOGEN	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 40000 UNIT/ML	82401020002060	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 2000 UNIT/ML	82401020042010	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 3000 UNIT/ML	82401020042015	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 4000 UNIT/ML	82401020042020	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 10000 UNIT/ML	82401020042040	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 20000 UNIT/ML	82401020042050	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 40000 UNIT/ML	82401020042060	Brand

**Approval Criteria**

1 - Hematocrit less than 30% at initiation of therapy

**AND**

**2** - There is a minimum of two additional months of planned chemotherapy

**AND**

**3** - If the request is for a non-preferred\* product, claims history indicates ONE preferred\* agent has been tried at maximum doses as indicated by FDA labeling

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Epogen, Procrit, Retacrit			
Diagnosis	Preoperative Use for Reduction of Allogeneic Blood Transfusions in Surgery Patients		
Approval Length	1 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EPOGEN	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
PROCRIT	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
EPOGEN	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
PROCRIT	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
EPOGEN	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
PROCRIT	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
EPOGEN	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
PROCRIT	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
EPOGEN	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 40000 UNIT/ML	82401020002060	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 2000 UNIT/ML	82401020042010	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 3000 UNIT/ML	82401020042015	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 4000 UNIT/ML	82401020042020	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 10000 UNIT/ML	82401020042040	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 20000 UNIT/ML	82401020042050	Brand

RETACRIT	EPOETIN ALFA-EPBX INJ 40000 UNIT/ML	82401020042060	Brand
<p><b>Approval Criteria</b></p> <p>1 - Perioperative hematocrit is greater than 30% and less than or equal to 39%</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is at high risk for blood loss during surgery</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is unable or unwilling to donate autologous blood</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Surgery procedure is elective, non-cardiac, and non-vascular</p> <p style="text-align: center;"><b>AND</b></p> <p>5 - If the request is for a non-preferred* product, claims history indicates ONE preferred* agent has been tried at maximum doses as indicated by FDA labeling</p>			
Notes		*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>	

Product Name: Aranesp, Epogen, Procrit, or Retacrit			
Diagnosis	Anemia Associated with Myelodysplastic Disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 10 MCG/0.4ML	8240101510E510	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 25 MCG/0.42ML	8240101510E528	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 40 MCG/0.4ML	8240101510E543	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 60 MCG/0.3ML	8240101510E552	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 100 MCG/0.5ML	8240101510E560	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 150 MCG/0.3ML	8240101510E575	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 200 MCG/0.4ML	8240101510E582	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 300 MCG/0.6ML	8240101510E588	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 500 MCG/ML	8240101510E590	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 25 MCG/ML	82401015102010	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 40 MCG/ML	82401015102020	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 60 MCG/ML	82401015102030	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 100 MCG/ML	82401015102040	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 200 MCG/ML	82401015102060	Brand
EPOGEN	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
PROCRIT	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
EPOGEN	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
PROCRIT	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
EPOGEN	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand

PROCRIT	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
EPOGEN	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
PROCRIT	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
EPOGEN	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 40000 UNIT/ML	82401020002060	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 2000 UNIT/ML	82401020042010	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 3000 UNIT/ML	82401020042015	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 4000 UNIT/ML	82401020042020	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 10000 UNIT/ML	82401020042040	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 20000 UNIT/ML	82401020042050	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 40000 UNIT/ML	82401020042060	Brand

**Approval Criteria**

1 - Diagnosis of myelodysplastic disease (MDS)

**AND**

2 - ONE of the following:

- Serum erythropoietin level less than or equal to 500 milliunits per milliliter
- Hematocrit is less than or equal to 30% at the initiation of therapy

**AND**

3 - If the request is for a non-preferred\* product, claims history indicates ONE preferred\* agent has been tried at maximum doses as indicated by FDA labeling

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Aranesp, Epogen, Procrit, or Retacrit	
Diagnosis	Anemia Associated with Myelodysplastic Disease

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 10 MCG/0.4ML	8240101510E510	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 25 MCG/0.42ML	8240101510E528	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 40 MCG/0.4ML	8240101510E543	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 60 MCG/0.3ML	8240101510E552	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 100 MCG/0.5ML	8240101510E560	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 150 MCG/0.3ML	8240101510E575	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 200 MCG/0.4ML	8240101510E582	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 300 MCG/0.6ML	8240101510E588	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 500 MCG/ML	8240101510E590	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 25 MCG/ML	82401015102010	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 40 MCG/ML	82401015102020	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 60 MCG/ML	82401015102030	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 100 MCG/ML	82401015102040	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 200 MCG/ML	82401015102060	Brand

EPOGEN	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
PROCRIT	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
EPOGEN	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
PROCRIT	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
EPOGEN	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
PROCRIT	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
EPOGEN	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
PROCRIT	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
EPOGEN	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 40000 UNIT/ML	82401020002060	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 2000 UNIT/ML	82401020042010	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 3000 UNIT/ML	82401020042015	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 4000 UNIT/ML	82401020042020	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 10000 UNIT/ML	82401020042040	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 20000 UNIT/ML	82401020042050	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 40000 UNIT/ML	82401020042060	Brand

**Approval Criteria**

1 - One of the following:

1.1 Hematocrit remains less than 36%

**OR**

1.2 Patient has demonstrated a response to therapy

**AND**

2 - If the request is for a non-preferred\* product, claims history indicates ONE preferred\* agent has been tried at maximum doses as indicated by FDA labeling



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Epogen, Procrit, Retacrit	
Diagnosis	Anemia in Patients with Hepatitis C with Ribavirin and Interferon Therapy
Approval Length	3 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
EPOGEN	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
PROCRIT	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
EPOGEN	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
PROCRIT	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
EPOGEN	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
PROCRIT	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
EPOGEN	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
PROCRIT	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
EPOGEN	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 40000 UNIT/ML	82401020002060	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 2000 UNIT/ML	82401020042010	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 3000 UNIT/ML	82401020042015	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 4000 UNIT/ML	82401020042020	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 10000 UNIT/ML	82401020042040	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 20000 UNIT/ML	82401020042050	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 40000 UNIT/ML	82401020042060	Brand

**Approval Criteria**

1 - Diagnosis of hepatitis C virus (HCV) infection

**AND**

**2** - Patient is receiving ribavirin and interferon therapy

**AND**

**3** - Hematocrit is less than or equal to 30% at initiation of therapy

**AND**

**4** - If the request is for a non-preferred\* product, claims history indicates ONE preferred\* agent has been tried at maximum doses as indicated by FDA labeling

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Epogen, Procrit, Retacrit^			
Diagnosis	Anemia in Patients with Hepatitis C with Ribavirin and Interferon Therapy		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EPOGEN	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
PROCRIT	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
EPOGEN	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
PROCRIT	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
EPOGEN	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
PROCRIT	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
EPOGEN	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
PROCRIT	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
EPOGEN	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand

PROCRIT	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 40000 UNIT/ML	82401020002060	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 2000 UNIT/ML	82401020042010	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 3000 UNIT/ML	82401020042015	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 4000 UNIT/ML	82401020042020	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 10000 UNIT/ML	82401020042040	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 20000 UNIT/ML	82401020042050	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 40000 UNIT/ML	82401020042060	Brand

**Approval Criteria**

1 - One of the following:

1.1 Hematocrit remains less than 36%

**OR**

1.2 Patient has demonstrated a response to therapy

**AND**

2 - If the request is for a non-preferred\* product, claims history indicates ONE preferred\* agent has been tried at maximum doses as indicated by FDA labeling

Notes	<p>^Authorization will be issued for 12 months or if patient has demonstrated response to therapy, authorization will be issued for the full course of ribavirin therapy.</p> <p>*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p>
-------	---

Product Name: Aranesp, Epogen, Procrit, Retacrit^	
Diagnosis	Erythropoietin Stimulating Agents - Off-Label Uses
Guideline Type	Prior Authorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name	Generic Name	GPI	Brand/Generic
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 10 MCG/0.4ML	8240101510E510	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 25 MCG/0.42ML	8240101510E528	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 40 MCG/0.4ML	8240101510E543	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 60 MCG/0.3ML	8240101510E552	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 100 MCG/0.5ML	8240101510E560	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 150 MCG/0.3ML	8240101510E575	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 200 MCG/0.4ML	8240101510E582	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 300 MCG/0.6ML	8240101510E588	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 500 MCG/ML	8240101510E590	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 25 MCG/ML	82401015102010	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 40 MCG/ML	82401015102020	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 60 MCG/ML	82401015102030	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 100 MCG/ML	82401015102040	Brand
ARANESP ALBUMIN FREE	DARBEPOETIN ALFA SOLN INJ 200 MCG/ML	82401015102060	Brand
EPOGEN	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
PROCRIT	EPOETIN ALFA INJ 2000 UNIT/ML	82401020002010	Brand
EPOGEN	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand

PROCRIT	EPOETIN ALFA INJ 3000 UNIT/ML	82401020002015	Brand
EPOGEN	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
PROCRIT	EPOETIN ALFA INJ 4000 UNIT/ML	82401020002020	Brand
EPOGEN	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
PROCRIT	EPOETIN ALFA INJ 10000 UNIT/ML	82401020002040	Brand
EPOGEN	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 20000 UNIT/ML	82401020002050	Brand
PROCRIT	EPOETIN ALFA INJ 40000 UNIT/ML	82401020002060	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 2000 UNIT/ML	82401020042010	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 3000 UNIT/ML	82401020042015	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 4000 UNIT/ML	82401020042020	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 10000 UNIT/ML	82401020042040	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 20000 UNIT/ML	82401020042050	Brand
RETACRIT	EPOETIN ALFA-EPBX INJ 40000 UNIT/ML	82401020042060	Brand

**Approval Criteria**

**1** - Off-label requests will be evaluated on a case-by-case basis by a clinical pharmacist

**AND**

**2** - Requests for coverage in patients with hemoglobin (Hgb) greater than 10 grams per deciliter or hematocrit (Hct) greater than 30% will not be approved

**AND**

**3** - If the request is for a non-preferred\* product, claims history indicates ONE preferred\* agent has been tried at maximum doses as indicated by FDA labeling

**Notes**

^If the request is deemed medically necessary, the authorization will be issued for requested length of therapy.

\*PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP>

## 2 . Revision History

Date	Notes
4/22/2024	Removed Mircera as a target from the guideline since it's medical; Updated T/F requirement throughout guideline where if request is non-preferred, one preferred agent is required and provided PDL link in notes sections. Updated GPI table and product name list accordingly.

Esbriet, Ofev



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140951
<b>Guideline Name</b>	Esbriet, Ofev
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Brand Esbriet, generic pirfenidone, Ofev			
Diagnosis	Idiopathic Pulmonary Fibrosis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ESBRIET	PIRFENIDONE CAP 267 MG	45550060000120	Brand
ESBRIET	PIRFENIDONE TAB 267 MG	45550060000325	Brand
ESBRIET	PIRFENIDONE TAB 801 MG	45550060000345	Brand

OFEV	NINTEDANIB ESYLATE CAP 100 MG (BASE EQUIVALENT)	45554050200120	Brand
OFEV	NINTEDANIB ESYLATE CAP 150 MG (BASE EQUIVALENT)	45554050200130	Brand
PIRFENIDONE	PIRFENIDONE TAB 267 MG	45550060000325	Generic
PIRFENIDONE	PIRFENIDONE TAB 534 MG	45550060000333	Generic
PIRFENIDONE	PIRFENIDONE TAB 801 MG	45550060000345	Generic

**Approval Criteria**

**1** - Diagnosis of idiopathic pulmonary fibrosis (IPF) as documented by ALL of the following criteria:

**1.1** Exclusion of other known causes of interstitial lung disease (e.g. domestic and occupational environmental exposures, connective tissue disease, and drug toxicity), as documented by the following:

- ICD-10 Code J84.112 (Idiopathic pulmonary fibrosis)

**AND**

**1.2** ONE of the following:

**1.2.1** In patients NOT subjected to surgical lung biopsy, the presence of a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) revealing IPF or probable IPF

**OR**

**1.2.2** In patients subjected to a lung biopsy, both HRCT and surgical lung biopsy pattern reveal IPF or probable IPF

**AND**

**2** - The agent is not being used in combination with Esbriet or Ofev

**AND**



**3** - The prescriber is a pulmonologist

**AND**

**4** - If requesting generic pirfenidone, patient has tried and failed, or has intolerance to Brand Esbriet

Product Name: Brand Esbriet, generic pirfenidone, Ofev

Diagnosis	Idiopathic Pulmonary Fibrosis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ESBRIET	PIRFENIDONE CAP 267 MG	45550060000120	Brand
ESBRIET	PIRFENIDONE TAB 267 MG	45550060000325	Brand
ESBRIET	PIRFENIDONE TAB 801 MG	45550060000345	Brand
OFEV	NINTEDANIB ESYLATE CAP 100 MG (BASE EQUIVALENT)	45554050200120	Brand
OFEV	NINTEDANIB ESYLATE CAP 150 MG (BASE EQUIVALENT)	45554050200130	Brand
PIRFENIDONE	PIRFENIDONE TAB 267 MG	45550060000325	Generic
PIRFENIDONE	PIRFENIDONE TAB 534 MG	45550060000333	Generic
PIRFENIDONE	PIRFENIDONE TAB 801 MG	45550060000345	Generic

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy

**AND**

**2** - The agent is not being used in combination with Esbriet or Ofev

**AND**

**3** - The prescriber is a pulmonologist

Product Name: Ofev			
Diagnosis	Systemic Sclerosis-Associated Interstitial Lung Disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OFEV	NINTEDANIB ESYLATE CAP 100 MG (BASE EQUIVALENT)	45554050200120	Brand
OFEV	NINTEDANIB ESYLATE CAP 150 MG (BASE EQUIVALENT)	45554050200130	Brand

**Approval Criteria**

**1** - Diagnosis of systemic sclerosis (SSc) - associated interstitial lung disease as documented by ALL of the following:

**1.1** ONE of the following:

**1.1.1** Skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints

**OR**

**1.1.2** TWO of the following:

- Skin thickening of the fingers (e.g., puffy fingers, sclerodactyly of the fingers)
- Fingertip lesions (e.g., digital tip ulcers, fingertip pitting scars)
- Telangiectasia
- Abnormal nailfold capillaries
- Pulmonary arterial hypertension
- Raynaud's phenomenon

- SSc-related autoantibodies (e.g., anticentromere, anti-topoisomerase I, anti-RNA polymerase III)

**AND**

**1.2** Presence of interstitial lung disease as determined by finding evidence of pulmonary fibrosis on high-resolution computed tomography (HRCT), involving at least 10 percent of the lungs

**AND**

**2** - The agent is not being used in combination with Esbriet

**AND**

**3** - The prescriber is a pulmonologist

Product Name: Ofev			
Diagnosis	Chronic fibrosing interstitial lung disease with a progressive phenotype		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OFEV	NINTEDANIB ESYLATE CAP 100 MG (BASE EQUIVALENT)	45554050200120	Brand
OFEV	NINTEDANIB ESYLATE CAP 150 MG (BASE EQUIVALENT)	45554050200130	Brand
<b>Approval Criteria</b>			
<b>1</b> - Diagnosis of chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype as documented by BOTH of the following criteria:			

**1.1** Presence of fibrotic ILD as determined by finding evidence of pulmonary fibrosis on HRCT (high-resolution computed tomography), involving at least 10 percent of the lungs

**AND**

**1.2** Patient is presenting with clinical signs of progression as defined by ONE of the following in the previous 24 months:

**1.2.1** Forced vital capacity (FVC) decline of greater than 10 percent

**OR**

**1.2.2** TWO of the following:

- FVC decline of greater than or equal to 5 percent, but less than 10 percent
- Patient is experiencing worsening respiratory symptoms
- Patient is exhibiting increasing extent of fibrotic changes on chest imaging

**AND**

**2** - The agent is not being used in combination with Esbriet

**AND**

**3** - The prescriber is a pulmonologist

Product Name: Ofev			
Diagnosis	Systemic Sclerosis-Associated Interstitial Lung Disease, Chronic fibrosing interstitial lung disease with a progressive phenotype		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

OFEV	NINTEDANIB ESYLATE CAP 100 MG (BASE EQUIVALENT)	45554050200120	Brand
OFEV	NINTEDANIB ESYLATE CAP 150 MG (BASE EQUIVALENT)	45554050200130	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**AND**

2 - Ofev is not being used in combination with Esbriet

**AND**

3 - The prescriber is a pulmonologist

**2 . Revision History**

Date	Notes
11/7/2022	Added pirfenidone as NP target

Estrogens



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140685
<b>Guideline Name</b>	Estrogens
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Femring			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FEMRING	ESTRADIOL ACETATE VAGINAL RING 0.05 MG/24HR	55350020109020	Brand
FEMRING	ESTRADIOL ACETATE VAGINAL RING 0.1 MG/24HR	55350020109030	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of moderate to severe vasomotor symptoms due to menopause			

**OR**

**2 - Diagnosis of moderate to severe vulvar and vaginal atrophy due to menopause**

<b>Product Name: Premarin</b>			
<b>Approval Length</b>		12 month(s)	
<b>Guideline Type</b>		Prior Authorization	
<b>Product Name</b>	<b>Generic Name</b>	<b>GPI</b>	<b>Brand/Generic</b>
PREMARIN	ESTROGENS, CONJUGATED VAGINAL CREAM 0.625 MG/GM	55350025003710	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of atrophic vaginitis and kraurosis vulvae			

## 2 . Revision History

<b>Date</b>	<b>Notes</b>
8/4/2022	C&S to match AZM as of 10.1.22

Eucrisa



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140765
<b>Guideline Name</b>	Eucrisa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Eucrisa			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EUCRISA	CRISABOROLE OINT 2%	90230025004220	Brand
<b>Approval Criteria</b>			
1 - BOTH of the following:			



**1.1** History of failure, contraindication, or intolerance to ONE topical corticosteroid [e.g., mometasone furoate, fluocinolone acetonide (generic Synalar), fluocinonide]

**AND**

**1.2** ONE of the following:

**1.2.1** Patient is less than 2 years of age

**OR**

**1.2.2** Patient is greater than or equal to 2 years of age and has history of failure, contraindication, or intolerance to ONE topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)]

## 2 . Revision History

Date	Notes
12/13/2022	Updated guideline type.

Evrysdi (risdiplam)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140943
<b>Guideline Name</b>	Evrysdi (risdiplam)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Evrysdi			
Diagnosis	Spinal Muscular Atrophy (SMA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EVRYSDI	RISDIPLAM FOR SOLN 0.75 MG/ML	74706560002120	Brand
<b>Approval Criteria</b>			

**1** - Diagnosis of spinal muscular atrophy (SMA)

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) confirming the mutation or deletion of genes in chromosome 5q resulting in ONE of the following:

**2.1** Homozygous gene deletion or mutation of SMN1 gene (e.g., homozygous deletion of exon 7 at locus 5q13)

**OR**

**2.2** Compound heterozygous mutation of SMN1 gene [e.g., deletion of SMN1 exon 7 (allele 1) and mutation of SMN1 (allele 2)]

**AND**

**3** - Patient is not dependent on invasive ventilation or tracheostomy

**AND**

**4** - Patient is not dependent on the use of non-invasive ventilation beyond use for naps and nighttime sleep

**AND**

**5** - Patient is not receiving concomitant chronic survival motor neuron (SMN)-modifying therapy [e.g., Spinraza (nusinersen)]

**AND**

**6** - Patient has not previously received gene replacement therapy for the treatment of SMA [e.g., Zolgensma (onasemnogene abeparvovec-xioi)]

**AND**

**7** - Submission of medical records (e.g., chart notes, laboratory values) documenting the baseline assessment of at least ONE of the following exams (based on patient age and motor ability) to establish baseline motor ability (baseline motor function analysis could include assessments evaluated prior to receipt of previous chronic SMN-modifying therapy if transitioning therapy)\*:

- Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)
- Hammersmith Infant Neurological Exam Part 2 (HINE-2)
- Hammersmith Functional Motor Scale Expanded (HF MSE)
- Upper Limb Module (ULM) Test
- Motor Function Measure 32 (MFM-32) Scale

**AND**

**8** - Prescribed by a neurologist with expertise in the treatment of SMA

Notes	*Baseline assessments for patients less than 2 months of age requesting Evrysdi are not necessary in order not to delay access to initial therapy in recently diagnosed infants. Initial assessments shortly post-therapy can serve as baseline with respect to efficacy reauthorization assessment.
-------	--

Product Name: Evrysdi			
Diagnosis	Spinal Muscular Atrophy (SMA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EVRYSDI	RISDIPLAM FOR SOLN 0.75 MG/ML	74706560002120	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory values) with the most recent

results documenting a positive clinical response to Evrysdi compared to pretreatment baseline status [inclusive of baseline assessments prior to receipt of previous chronic survival motor neuron (SMN)-modifying therapy] as demonstrated by at least ONE of the following exams:

**1.1** Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) with ONE of the following:

**1.1.1** Improvement or maintenance of previous improvement of at least a 4-point increase in score from pretreatment baseline

**OR**

**1.1.2** Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so

**OR**

**1.2** Hammersmith Infant Neurological Exam Part 2 (HINE-2) with ONE of the following:

**1.2.1** Improvement or maintenance of previous improvement of at least a 2-point (or maximal score) increase in ability to kick

**OR**

**1.2.2** Improvement or maintenance of previous improvement of at least a 1-point increase in any other HINE-2 milestone (e.g., head control, rolling, sitting, crawling, etc.), excluding voluntary grasp

**OR**

**1.2.3** The patient exhibited improvement, or maintenance of previous improvement, in more HINE motor milestones than worsening, from pretreatment baseline (net positive improvement)

**OR**

**1.2.4** Patient has achieved and maintained any new motor milestones when they would otherwise be unexpected to do so

**OR**

**1.3** Hammersmith Functional Motor Scale Expanded (HF MSE) with ONE of the following:

**1.3.1** Improvement or maintenance of previous improvement of at least a 3-point increase in score from pretreatment baseline

**OR**

**1.3.2** Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so

**OR**

**1.4** Upper Limb Module (ULM) with ONE of the following:

**1.4.1** Improvement or maintenance of previous improvement of at least a 2-point increase in score from pretreatment baseline

**OR**

**1.4.2** Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so

**OR**

**1.5** Motor Function Measure 32 (MFM-32) with ONE of the following:

**1.5.1** Improvement or maintenance of previous improvement of at least a 3-point increase in score from pretreatment baseline

**OR**

**1.5.2** Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so

**AND**

**2** - Patient is not dependent on invasive ventilation or tracheostomy

**AND**

**3** - Patient is not dependent on the use of non-invasive ventilation beyond use for naps and nighttime sleep

**AND**

**4** - Patient is not receiving concomitant chronic SMN-modifying therapy [e.g., Spinraza (nusinersen)]

**AND**

**5** - Patient has not previously received gene replacement therapy for the treatment of spinal muscular atrophy (SMA) [e.g., Zolgensma (onasemnogene abeparvovec-xioi)]

**AND**

**6** - Prescribed by a neurologist with expertise in the treatment of SMA

## 2 . Revision History

Date	Notes
10/24/2022	Updated GL name. Removed age requirement and updated note.

Exkivity



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140956
<b>Guideline Name</b>	Exkivity
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	2/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Exkivity			
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EXKIVITY	MOBOCERTINIB SUCCINATE CAP 40 MG	21360050600120	Brand
<b>Approval Criteria</b>			



1 - Diagnosis of non-small cell lung cancer (NSCLC)

**AND**

2 - Disease is locally advanced or metastatic

**AND**

3 - Disease is epidermal growth factor receptor (EGFR) exon 20 insertion mutation positive

**AND**

4 - Subsequent therapy for disease that has progressed on or after platinum-based chemotherapy

Product Name: Exkivity			
Diagnosis	Non-Small Cell Lung Cancer (NSCLC)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EXKIVITY	MOBOCERTINIB SUCCINATE CAP 40 MG	21360050600120	Brand
<b>Approval Criteria</b>			
1 - Patient does not show evidence of progressive disease while on Exkivity therapy			

Product Name: Exkivity	
Diagnosis	NCCN Recommended Regimen
Approval Length	12 month(s)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EXKIVITY	MOBOCERTINIB SUCCINATE CAP 40 MG	21360050600120	Brand
<p><b>Approval Criteria</b></p> <p>1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium</p>			

Product Name: Exkivity			
Diagnosis	NCCN Recommended Regimen		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EXKIVITY	MOBOCERTINIB SUCCINATE CAP 40 MG	21360050600120	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Exkivity therapy</p>			

Exondys



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140758
<b>Guideline Name</b>	Exondys
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Exondys			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EXONDYS 51	ETEPLIRSEN IV SOLN 100 MG/2ML (50 MG/ML)	74600035002020	Brand
EXONDYS 51	ETEPLIRSEN IV SOLN 500 MG/10ML (50 MG/ML)	74600035002040	Brand

**Approval Criteria**

**1** - Diagnosis of Duchenne muscular dystrophy (DMD)

**AND**

**2** - Documentation of a confirmed mutation of the dystrophin gene amenable to exon 51 skipping

**AND**

**3** - Prescribed by or in consultation with a neurologist who has experience treating Duchenne Muscular Dystrophy

**AND**

**4** - Dose will not exceed 30 milligrams per kilogram of body weight once weekly

**AND**

**5** - If ambulatory, patient's condition has been evaluated via the 6-minute walk test (6MWT) or North Star ambulatory assessment (NSAA) [documentation of the patient's most recent results must be provided]

Product Name: Exondys			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EXONDYS 51	ETEPLIRSEN IV SOLN 100 MG/2ML (50 MG/ML)	74600035002020	Brand
EXONDYS 51	ETEPLIRSEN IV SOLN 500 MG/10ML (50 MG/ML)	74600035002040	Brand

**Approval Criteria**

**1** - One of the following:

**1.1** Patient has been on therapy for less than 12 months and all of the following:

**1.1.1** Patient is tolerating therapy

**AND**

**1.1.2** Dose will not exceed 30 milligrams per kilogram of body weight once weekly

**AND**

**1.1.3** Prescribed by or in consultation with a neurologist who has experience treating Duchenne Muscular Dystrophy

**AND**

**1.1.4** If ambulatory, patient's condition has been evaluated via the 6-minute walk test (6MWT) or North Star ambulatory assessment (NSAA) [documentation of the patient's most recent results must be provided]

**OR**

**1.2** Patient has been on therapy for 12 months or more and all of the following:

**1.2.1** Patient has experienced a benefit from therapy (e.g., disease amelioration compared to untreated patients)

**AND**

**1.2.2** Patient is tolerating therapy

**AND**

**1.2.3** Dose will not exceed 30 milligrams per kilogram of body weight once weekly

**AND**

**1.2.4** Prescribed by or in consultation with a neurologist who has experience treating Duchenne Muscular Dystrophy

**AND**

**1.2.5** If ambulatory, patient's condition has been evaluated via the 6-minute walk test (6MWT) or North Star ambulatory assessment (NSAA) [documentation of the patient's most recent results must be provided]

## 2 . Revision History

Date	Notes
11/7/2022	Removed age and ambulatory requirements

Ezallor Sprinkle (rosuvastatin)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140812
<b>Guideline Name</b>	Ezallor Sprinkle (rosuvastatin)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	10/1/2023
-----------------	-----------

### 1 . Criteria

Product Name: Ezallor			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EZALLOR SPRINKLE	ROSUVASTATIN CALCIUM SPRINKLE CAP 5 MG (BASE EQUIVALENT)	39400060106805	Brand
EZALLOR SPRINKLE	ROSUVASTATIN CALCIUM SPRINKLE CAP 10 MG (BASE EQUIVALENT)	39400060106810	Brand
EZALLOR SPRINKLE	ROSUVASTATIN CALCIUM SPRINKLE CAP 20 MG (BASE EQUIVALENT)	39400060106820	Brand
EZALLOR SPRINKLE	ROSUVASTATIN CALCIUM SPRINKLE CAP 40 MG (BASE EQUIVALENT)	39400060106840	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 BOTH of the following:

1.1.1 Patient is less than 10 years of age

**AND**

1.1.2 Prescribed by or in consultation with a cardiologist

**OR**

1.2 BOTH of the following:

1.2.1 Medication is being used for ONE of the following:

1.2.1.1 To reduce the risk of ONE of the following:

- Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD
- MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD
- Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD

**OR**

1.2.1.2 As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in ONE of the following:

- Adults with primary hyperlipidemia
- Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH)

**OR**



**1.2.1.3** As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH)

**OR**

**1.2.1.4** As an adjunct to diet for the treatment of adults with ONE of the following:

- Primary dysbetalipoproteinemia
- Hypertriglyceridemia

**AND**

**1.2.2** ONE of the following:

**1.2.2.1** Trial and failure, contraindication, or intolerance to generic rosuvastatin tablets (verified via paid pharmacy claims or submitted chart notes)

**OR**

**1.2.2.2** Patient is unable to swallow oral tablets

## 2 . Revision History

Date	Notes
9/11/2023	New Program

Fabry Disease Agents



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140996
<b>Guideline Name</b>	Fabry Disease Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	9/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Fabrazyme			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FABRAZYME	AGALSIDASE BETA FOR IV SOLN 5 MG	30903610102110	Brand
FABRAZYME	AGALSIDASE BETA FOR IV SOLN 35 MG	30903610102120	Brand
<b>Approval Criteria</b>			

**1 - Diagnosis of Fabry disease**

**AND**

**2 - Patient is 2 years of age or older**

**AND**

**3 - Submission of medical records (e.g., chart notes) confirming ONE of the following:**

**3.1 Detection of pathogenic mutations in the GLA gene by molecular genetic testing**

**OR**

**3.2 Deficiency in alpha-galactosidase A (alpha-Gal A) enzyme activity in plasma, isolated leukocytes, or dried blood spots (DBS)**

**OR**

**3.3 Significant clinical manifestations (e.g., neuropathic pain, cardiomyopathy, renal insufficiency, angiokeratomas, cornea verticillata)**

**AND**

**4 - Will not be used in combination with Galafold (migalastat)**

**Product Name: Fabrazyme**

Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FABRAZYME	AGALSIDASE BETA FOR IV SOLN 5 MG	30903610102110	Brand

FABRAZYME	AGALSIDASE BETA FOR IV SOLN 35 MG	30903610102120	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>			

## 2 . Revision History

Date	Notes
8/9/2023	Updated guideline name, updated all criteria.

Fasenra (benralizumab)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-150132
<b>Guideline Name</b>	Fasenra (benralizumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	8/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Fasenra			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FASENRA PEN	BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 30 MG/ML	4460402000D520	Brand
FASENRA	BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 10 MG/0.5ML	4460402000E515	Brand
FASENRA	BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 30 MG/ML	4460402000E520	Brand

**Approval Criteria**

**1** - Submission of documentation (e.g., chart notes) confirming diagnosis of severe asthma

**AND**

**2** - Submission of documentation (e.g., chart notes, lab values) confirming asthma is an eosinophilic phenotype as defined by a baseline (pre-treatment) peripheral blood eosinophil level greater than or equal to 150 cells per microliter

**AND**

**3** - ONE of the following:

**3.1** Patient has had at least two or more asthma exacerbations requiring systemic corticosteroids (e.g., prednisone) within the past 12 months

**OR**

**3.2** Prior asthma-related hospitalization within the past 12 months

**AND**

**4** - ONE of the following:

**4.1** BOTH of the following:

**4.1.1** Patient is 6 years of age or older but less than 12 years of age

**AND**

**4.1.2** Paid claims or submission of medical records (e.g., chart notes) confirming patient is currently being treated with ONE of the following unless there is a contraindication or intolerance to these medications:

**4.1.2.1** BOTH of the following:

- Medium-dose inhaled corticosteroid (e.g., greater than 100 – 200 mcg fluticasone propionate equivalent/day)
- Additional asthma controller medication (e.g., leukotriene receptor antagonist [LTRA] [e.g., montelukast], long-acting beta-2 agonist [LABA] [e.g., salmeterol], long-acting muscarinic antagonist [LAMA] [e.g., tiotropium])

**OR**

**4.1.2.2** One medium dosed combination ICS/LABA product (e.g., Advair Diskus [fluticasone propionate 100 mcg/salmeterol 50 mcg], Symbicort [budesonide 80 mcg/formoterol 4.5 mcg] Breo Ellipta [fluticasone furoate 50 mcg/vilanterol 25 mcg])

**OR**

**4.2** BOTH of the following:

**4.2.1** Patient is 12 years of age or older

**AND**

**4.2.2** Paid claims or submission of medical records (e.g., chart notes) confirming patient is currently being treated with ONE of the following unless there is a contraindication or intolerance to these medications:

**4.2.2.1** BOTH of the following:

- High-dose inhaled corticosteroid (ICS) (e.g., greater than 500 mcg fluticasone propionate equivalent/day)
- Additional asthma controller medication (e.g., leukotriene receptor antagonist [LTRA] [e.g., montelukast], long-acting beta-2 agonist [LABA] [e.g., salmeterol], long-acting muscarinic antagonist [LAMA] [e.g., tiotropium])

**OR**

**4.2.2.2** One maximally-dosed combination ICS/LABA product (e.g., Advair [fluticasone propionate 500 mcg/salmeterol 50 mcg], Symbicort [budesonide 160 mcg/formoterol 4.5 mcg], Breo Ellipta [fluticasone 200 mcg/vilanterol 25 mcg])

**AND**

**5** - Prescribed by or in consultation with **ONE** of the following:

- Pulmonologist
- Allergist/Immunologist

Product Name: Fasenra			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FASENRA PEN	BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 30 MG/ML	4460402000D520	Brand
FASENRA	BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 10 MG/0.5ML	4460402000E515	Brand
FASENRA	BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 30 MG/ML	4460402000E520	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming a positive clinical response to therapy as evidenced by **ONE** of the following:

- A reduction in asthma exacerbations
- Improvement in forced expiratory volume in 1 second [FEV1] from baseline

**AND**

**2** - Paid claims or submission of documentation (e.g., chart notes) confirming patient continues to be treated with an inhaled corticosteroid (ICS) (e.g., fluticasone, budesonide) with or without additional asthma controller medication (e.g., leukotriene receptor antagonist [LTRA] [e.g., montelukast], long-acting beta-2 agonist [LABA] [e.g., salmeterol], long-acting muscarinic antagonist [LAMA] [e.g., tiotropium]) unless there is a contraindication or intolerance to these medications



**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Pulmonologist
- Allergist/Immunologist

## 2 . Background

### Clinical Practice Guidelines

**The Global Initiative for Asthma Global Strategy for Asthma Management and Prevention: Table 1. Low, medium and high daily doses of inhaled corticosteroids in adolescents and adults 12 years and older**

Inhaled corticosteroid	Total Daily ICS Dose (mcg)		
	Low	Medium	High
Beclometasone dipropionate (pMDI, standard particle, HFA)	200-500	> 500-1000	> 1000
Beclometasone dipropionate (DPI or pMDI, extrafine particle*, HFA)	100-200	> 200-400	> 400
Budesonide (DPI, or pMDI, standard particle, HFA)	200-400	> 400-800	> 800
Ciclesonide (pMDI, extrafine particle*, HFA)	80-160	> 160-320	> 320
Fluticasone furoate (DPI)	100		200
Fluticasone propionate (DPI)	100-250	> 250-500	> 500
Fluticasone propionate (pMDI, standard particle, HFA)	100-250	> 250-500	> 500
Mometasone furoate (DPI)	Depends on DPI device – see product information		

Mometasone furoate (pMDI, standard particle, HFA)	200-400	> 400
<p>DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; ICS: inhaled corticosteroid; N/A: not applicable; pMDI: pressurized metered dose inhaler (non-chlorofluorocarbon formulations); ICS by pMDI should be preferably used with a spacer *See product information.</p> <p><b><i>This is not a table of equivalence</i></b>, but instead, suggested total daily doses for the 'low', 'medium' and 'high' dose ICS options for adults/adolescents, based on available studies and product information. Data on comparative potency are not readily available and therefore this table does NOT imply potency equivalence. Doses may be country -specific depending on local availability, regulatory labelling and clinical guidelines.</p> <p>For new preparations, including generic ICS, the manufacturer's information should be reviewed carefully; products containing the same molecule may not be clinically equivalent.</p>		

**The Global Initiative for Asthma Global Strategy for Asthma Management and Prevention: Table 2. Low, medium and high daily doses of inhaled corticosteroids in children 6 – 11 years**

Inhaled corticosteroid	Total Daily ICS Dose (mcg)		
	Low	Medium	High
Beclometasone dipropionate (pMDI, standard particle, HFA)	100-200	> 200-400	> 400
Beclometasone dipropionate (pMDI, extrafine particle, HFA)	50-100	> 100-200	> 200
Budesonide (DPI, or pMDI, standard particle, HFA)	100-200	> 200-400	> 400
Budesonide (nebules)	250-500	>500-1000	>1000
Ciclesonide (pMDI, extrafine particle*, HFA)	80	>80-160	>160
Fluticasone furoate (DPI)	50		n.a.
Fluticasone propionate (DPI)	50-100	> 100-200	> 200
Fluticasone propionate (pMDI, standard particle, HFA)	50-100	> 100-200	> 200

Mometasone furoate (pMDI, standard particle, HFA)	100	200
<p>DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; ICS: inhaled corticosteroid; N/A: not applicable; pMDI: pressurized metered dose inhaler (non-chlorofluorocarbon formulations); ICS by pMDI should be preferably used with a spacer *See product information.</p> <p><b><i>This is not a table of equivalence</i></b>, but instead, suggested total daily doses for the 'low', 'medium' and 'high' dose ICS options for adults/adolescents, based on available studies and product information. Data on comparative potency are not readily available and therefore this table does NOT imply potency equivalence. Doses may be country -specific depending on local availability, regulatory labelling and clinical guidelines.</p> <p>For new preparations, including generic ICS, the manufacturer's information should be reviewed carefully; products containing the same molecule may not be clinically equivalent.</p>		

### 3 . Revision History

Date	Notes
7/23/2024	Updated guideline name. Updated criteria and added new GPs.

Fecal Microbiota Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140807
<b>Guideline Name</b>	Fecal Microbiota Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	9/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Vowst			
Approval Length	14 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VOWST	FECAL MICROBIOTA SPORES, LIVE-BRPK CAPS	52522020100120	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of documentation (e.g., chart notes) confirming diagnosis of recurrent clostridioides difficile infection (CDI) as defined by BOTH of the following:</p>			

**1.1** Presence of diarrhea defined as a passage of 3 or more loose bowel movements within a 24-hour period for 2 consecutive days

**AND**

**1.2** A positive stool test for *C. difficile* toxin or toxigenic *C. difficile*

**AND**

**2** - Patient is 18 years of age or older

**AND**

**3** - Patient has a history of two or more recurrent episodes of CDI within 12 months

**AND**

**4** - Submission of medical records (e.g., chart notes) confirming ALL of the following:

**4.1** Patient has completed at least 10 consecutive days of ONE of the following antibiotic therapies 2-4 days prior to initiating Vowst\*:

- Oral vancomycin
- Dificid (fidaxomicin)

**AND**

**4.2** Patient has completed the recommended course of magnesium citrate the day before and at least 8 hours prior to initiating Vowst

**AND**

**4.3** Previous episode of CDI is under control [e.g., less than 3 unformed/loose (i.e., Bristol Stool Scale type 6-7) stools/day for 2 consecutive days]

**AND**

**5** - Prescribed by or in consultation with **ONE** of the following:

- Gastroenterologist
- Infectious disease specialist

Notes

\*Trial requirements may be verified via paid pharmacy claims or submission of medical records/chart notes.

## 2 . Revision History

Date	Notes
8/9/2023	New guideline.

Fentanyl IR



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140699
<b>Guideline Name</b>	Fentanyl IR
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Fentanyl citrate lozenges (generic Actiq)			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FENTANYL CITRATE ORAL TRANSMUCOSAL	FENTANYL CITRATE LOZENGE ON A HANDLE 200 MCG	65100025108450	Generic
FENTANYL CITRATE ORAL TRANSMUCOSAL	FENTANYL CITRATE LOZENGE ON A HANDLE 400 MCG	65100025108455	Generic
FENTANYL CITRATE ORAL TRANSMUCOSAL	FENTANYL CITRATE LOZENGE ON A HANDLE 600 MCG	65100025108460	Generic

FENTANYL CITRATE ORAL TRANSMUCOSAL	FENTANYL CITRATE LOZENGE ON A HANDLE 800 MCG	65100025108465	Generic
FENTANYL CITRATE ORAL TRANSMUCOSAL	FENTANYL CITRATE LOZENGE ON A HANDLE 1200 MCG	65100025108475	Generic
FENTANYL CITRATE ORAL TRANSMUCOSAL	FENTANYL CITRATE LOZENGE ON A HANDLE 1600 MCG	65100025108485	Generic

**Approval Criteria**

**1** - Submission of medical records demonstrating use is for the management of breakthrough pain associated with a cancer diagnosis (cancer diagnosis must be documented)

**AND**

**2** - Patient must have at least a one week history of ONE of the following medications to demonstrate tolerance to opioids (Document drug and date of trial):

- Morphine sulfate at a doses of greater than or equal to 60 milligrams per day
- Fentanyl transdermal patch at a dose of greater than or equal to 25 micrograms per hour
- Oxycodone at a dose of greater than or equal to 30 milligrams per day
- Oral hydromorphone at a dose of greater than or equal to 8 milligrams per day
- Oral oxymorphone at a dose of greater than or equal to 25 milligrams per day
- An alternative opioid at an equianalgesic dose (e.g., oral methadone greater than or equal to 20 milligrams per day)

**AND**

**3** - The patient is currently taking a long-acting opioid around the clock for cancer pain (Document drug)

**AND**

**4** - ONE of the following:

**4.1** The patient is not concurrently receiving an alternative fentanyl transmucosal product



**OR**

**4.2** BOTH of the following:

**4.2.1** The patient is currently receiving an alternative transmucosal fentanyl product

**AND**

**4.2.2** The prescriber is requesting the termination of all current authorizations for alternative transmucosal fentanyl products in order to begin treatment with the requested medication (Only one transmucosal fentanyl product will be approved at a time. If previous authorizations cannot be terminated, the PA request will be denied)

Product Name: Abstral, Brand Actiq, Brand Fentora, generic fentanyl citrate buccal tablet, Lazanda, Subsys			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FENTANYL CITRATE	FENTANYL CITRATE BUCCAL TAB 100 MCG (BASE EQUIV)	65100025100310	Generic
FENTORA	FENTANYL CITRATE BUCCAL TAB 100 MCG (BASE EQUIV)	65100025100310	Generic
FENTANYL CITRATE	FENTANYL CITRATE BUCCAL TAB 200 MCG (BASE EQUIV)	65100025100320	Generic
FENTORA	FENTANYL CITRATE BUCCAL TAB 200 MCG (BASE EQUIV)	65100025100320	Generic
FENTANYL CITRATE	FENTANYL CITRATE BUCCAL TAB 400 MCG (BASE EQUIV)	65100025100330	Generic
FENTORA	FENTANYL CITRATE BUCCAL TAB 400 MCG (BASE EQUIV)	65100025100330	Generic
FENTANYL CITRATE	FENTANYL CITRATE BUCCAL TAB 600 MCG (BASE EQUIV)	65100025100340	Generic
FENTORA	FENTANYL CITRATE BUCCAL TAB 600 MCG (BASE EQUIV)	65100025100340	Generic
FENTANYL CITRATE	FENTANYL CITRATE BUCCAL TAB 800 MCG (BASE EQUIV)	65100025100350	Generic
FENTORA	FENTANYL CITRATE BUCCAL TAB 800 MCG (BASE EQUIV)	65100025100350	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LAZANDA	FENTANYL CITRATE NASAL SPRAY 100 MCG/ACT (BASE EQUIV)	65100025102050	Brand
LAZANDA	FENTANYL CITRATE NASAL SPRAY 300 MCG/ACT (BASE EQUIV)	65100025102057	Brand
LAZANDA	FENTANYL CITRATE NASAL SPRAY 400 MCG/ACT (BASE EQUIV)	65100025102060	Brand
ABSTRAL	FENTANYL CITRATE SL TAB 100 MCG (BASE EQUIV)	65100025100710	Brand
ABSTRAL	FENTANYL CITRATE SL TAB 200 MCG (BASE EQUIV)	65100025100720	Brand
ABSTRAL	FENTANYL CITRATE SL TAB 300 MCG (BASE EQUIV)	65100025100725	Brand
ABSTRAL	FENTANYL CITRATE SL TAB 400 MCG (BASE EQUIV)	65100025100730	Brand
ABSTRAL	FENTANYL CITRATE SL TAB 600 MCG (BASE EQUIV)	65100025100740	Brand
ABSTRAL	FENTANYL CITRATE SL TAB 800 MCG (BASE EQUIV)	65100025100750	Brand
SUBSYS	FENTANYL SUBLINGUAL SPRAY 100 MCG	65100025000910	Brand
SUBSYS	FENTANYL SUBLINGUAL SPRAY 200 MCG	65100025000920	Brand
SUBSYS	FENTANYL SUBLINGUAL SPRAY 400 MCG	65100025000930	Brand
SUBSYS	FENTANYL SUBLINGUAL SPRAY 600 MCG	65100025000940	Brand
SUBSYS	FENTANYL SUBLINGUAL SPRAY 800 MCG	65100025000950	Brand
SUBSYS	FENTANYL SUBLINGUAL SPRAY 1200 MCG (600 MCG X 2)	65100025000960	Brand
SUBSYS	FENTANYL SUBLINGUAL SPRAY 1600 MCG (800 MCG X 2)	65100025000970	Brand
ACTIQ	FENTANYL CITRATE LOZENGE ON A HANDLE 200 MCG	65100025108450	Brand
ACTIQ	FENTANYL CITRATE LOZENGE ON A HANDLE 400 MCG	65100025108455	Brand
ACTIQ	FENTANYL CITRATE LOZENGE ON A HANDLE 600 MCG	65100025108460	Brand
ACTIQ	FENTANYL CITRATE LOZENGE ON A HANDLE 800 MCG	65100025108465	Brand
ACTIQ	FENTANYL CITRATE LOZENGE ON A HANDLE 1200 MCG	65100025108475	Brand
ACTIQ	FENTANYL CITRATE LOZENGE ON A HANDLE 1600 MCG	65100025108485	Brand

**Approval Criteria**

1 - Submission of medical records demonstrating use is for the management of breakthrough pain associated with a cancer diagnosis (cancer diagnosis must be documented)

**AND**

**2** - Patient must have at least a one week history of ONE of the following medications to demonstrate tolerance to opioids (Document drug and date of trial):

- Morphine sulfate at a doses of greater than or equal to 60 milligrams per day
- Fentanyl transdermal patch at a dose of greater than or equal to 25 micrograms per hour
- Oxycodone at a dose of greater than or equal to 30 milligrams per day
- Oral hydromorphone at a dose of greater than or equal to 8 milligrams per day
- Oral oxymorphone at a dose of greater than or equal to 25 milligrams per day
- An alternative opioid at an equianalgesic dose (e.g., oral methadone greater than or equal to 20 milligrams per day)

**AND**

**3** - The patient is currently taking a long-acting opioid around the clock for cancer pain (Document drug)

**AND**

**4** - ONE of the following:

**4.1** The patient is not concurrently receiving an alternative fentanyl transmucosal product

**OR**

**4.2** BOTH of the following:

**4.2.1** The patient is currently receiving an alternative transmucosal fentanyl product

**AND**

**4.2.2** The prescriber is requesting the termination of all current authorizations for alternative transmucosal fentanyl products in order to begin treatment with the requested medication (Only one transmucosal fentanyl product will be approved at a time. If previous authorizations cannot be terminated, the PA request will be denied)

**AND**

**5** - History of failure, contraindication, or intolerance to Fentanyl citrate lozenges (generic Actiq) [Document date of trial]

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Fexmid (cyclobenzaprine 7.5mg)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140686
<b>Guideline Name</b>	Fexmid (cyclobenzaprine 7.5mg)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Fexmid 7.5mg, generic cyclobenzaprine 7.5mg			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CYCLOBENZAPRINE HCL	CYCLOBENZAPRINE HCL TAB 7.5 MG	75100050100304	Generic
FEXMID	CYCLOBENZAPRINE HCL TAB 7.5 MG	75100050100304	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of muscle spasm associated with acute, painful musculoskeletal conditions			

**AND**

**2** - Reason or special circumstance the patient cannot use cyclobenzaprine 5 milligram (mg) or 10mg tablet

## **2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Filspari (sparsentan)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157195
<b>Guideline Name</b>	Filspari (sparsentan)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Filspari			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FILSPARI	SPARSENTAN TAB 200 MG	56483065000320	Brand
FILSPARI	SPARSENTAN TAB 400 MG	56483065000340	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) documenting diagnosis of primary immunoglobulin A nephropathy (IgAN) as confirmed by a kidney biopsy

**AND**

**2** - Patient is at risk of rapid disease progression [e.g., generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g (gram), or by other criteria such as clinical risk scoring using the International IgAN Prediction Tool]

**AND**

**3** - Used to reduce proteinuria

**AND**

**4** - Patient has an estimated glomerular filtration rate (eGFR) of greater than or equal to 30 mL/min/1.73 m<sup>2</sup> (milliliters/minute/1.73 square meters)

**AND**

**5** - Submission of medical records (e.g., chart notes) demonstrating patient has been on a minimum 90-day trial of a maximally tolerated dose of ONE of the following (paid pharmacy claims may be used to confirm appropriate trial):

- An angiotensin-converting enzyme (ACE) inhibitor (e.g., benazepril, lisinopril)
- An angiotensin II receptor blocker (ARB) (e.g., losartan, valsartan)

**AND**

**6** - Medication will NOT be used in combination with any of the following:

- Angiotensin receptor blockers
- Endothelin receptor antagonists (ERAs) (e.g., ambrisentan, bosentan, Opsumit)
- Aliskiren

**AND**



7 - Prescribed by or in consultation with a nephrologist

**AND**

8 - Prescriber is certified/enrolled in the Filspari REMS (Risk Evaluation and Mitigation Strategy) Program

Product Name: Filspari

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
FILSPARI	SPARSENTAN TAB 200 MG	56483065000320	Brand
FILSPARI	SPARSENTAN TAB 400 MG	56483065000340	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting a positive clinical response to therapy as demonstrated by a decrease in urine protein-to-creatinine ratio (UPCR) from baseline

**AND**

2 - Medication is NOT taken in combination with any of the following:

- Angiotensin receptor blockers
- Endothelin receptor antagonists (ERAs) (e.g., ambrisentan, bosentan, Opsumit)
- Aliskiren

**AND**

3 - Prescriber is certified/enrolled in the Filspari REMS (Risk Evaluation and Mitigation Strategy) Program

## 2 . Revision History

Date	Notes
10/9/2024	Added REMS requirement for prescribers in both initial and reauth sections; Minor cosmetic updates.

Filsuvez (birch triterpenes)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147110
<b>Guideline Name</b>	Filsuvez (birch triterpenes)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	6/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Filsuvez			
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FILSUVEZ	BIRCH TRITERPENES GEL 10%	90944020004030	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of ONE of the following:			

- Dystrophic epidermolysis bullosa (DEB)
- Junctional epidermolysis bullosa (JEB)

**AND**

**2** - Disease is confirmed by ONE of the following:

**2.1** Genetic testing confirms mutation in ONE of the following genes:

**2.1.1** For dystrophic epidermolysis bullosa (DEB), collagen type VII (COL7A1)

**OR**

**2.1.2** For junctional epidermolysis bullosa (JEB), ONE of the following:

- ITGA6
- ITGB4
- collagen type XVII (COL17A1)
- LAMA3
- LAMB3
- LAMC2
- ITGA3
- LAMA3A

**OR**

**2.2** Skin biopsy

**AND**

**3** - Patient is 6 months of age or older

**AND**

**4** - Medication is being used for the treatment of wounds

**AND**

**5** - DEB or JEB associated wounds are present for at least 21 days

**AND**

**6** - Patient does not have signs of infection for wound being treated

**AND**

**7** - Patient has no evidence or history of basal or squamous cell carcinoma for wound being treated

**AND**

**8** - Patient does not have history of stem cell transplant

**AND**

**9** - Medication is not being used concurrently with other FDA (Food and Drug Administration) approved therapies (e.g., Vyjuvek) for the treatment of epidermolysis bullosa

**AND**

**10** - Standard wound care management not adequate in healing wounds (e.g., daily wound dressings, pain management, controlling infections)

**AND**

**11** - Prescribed by or in consultation with a specialist with expertise in wound care

Product Name: Filsuvez

Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FILSUVEZ	BIRCH TRITERPENES GEL 10%	90944020004030	Brand

**Approval Criteria**

1 - Patient demonstrates positive clinical response to therapy as evidenced by wound is healing but not completely closed

**AND**

2 - Patient does not have signs of infection for wound being treated

**AND**

3 - Patient has no evidence or history of basal or squamous cell carcinoma for wound being treated

**AND**

4 - Prescribed by or in consultation with a specialist with expertise in wound care

**2 . Revision History**

Date	Notes
5/6/2024	New program.

Firdapse



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140948
<b>Guideline Name</b>	Firdapse
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Firdapse			
Diagnosis	Lambert-Eaton myasthenic syndrome (LEMS)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FIRDAPSE	AMIFAMPRIDINE PHOSPHATE TAB 10 MG (BASE EQUIVALENT)	76000012100320	Brand
<b>Approval Criteria</b>			

1 - Patient has a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS)

**AND**

2 - Patient is not receiving Firdapse in combination with similar potassium channel blockers [e.g., Ampyra (dalfampridine), Ruzurgi (amiframpridine)]

**AND**

3 - Patient is 6 years of age or older

Product Name: Firdapse

Diagnosis	Lambert-Eaton myasthenic syndrome (LEMS)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
FIRDAPSE	AMIFAMPRIDINE PHOSPHATE TAB 10 MG (BASE EQUIVALENT)	76000012100320	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Firdapse therapy

**AND**

2 - Patient is not receiving Firdapse in combination with similar potassium channel blockers [e.g., Ampyra (dalfampridine), Ruzurgi (amifampridine)]

**2 . Revision History**



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
11/7/2022	Added age requirement.

Flucytosine



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140700
<b>Guideline Name</b>	Flucytosine
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Ancobon, generic flucytosine			
Approval Length	2 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ANCOBON	FLUCYTOSINE CAP 250 MG	11000020000105	Brand
FLUCYTOSINE	FLUCYTOSINE CAP 250 MG	11000020000105	Generic
ANCOBON	FLUCYTOSINE CAP 500 MG	11000020000110	Brand
FLUCYTOSINE	FLUCYTOSINE CAP 500 MG	11000020000110	Generic

**Approval Criteria**

1 - One of the following:

1.1 Diagnosis of septicemia, endocarditis or a urinary system infection caused by Candida species

**OR**

1.2 Diagnosis of meningitis or a pulmonary infection caused by Cryptococcus species

**AND**

2 - If the patient is being treated for a systemic infection, flucytosine is being used in combination with amphotericin B

Product Name: Brand Ancobon, generic flucytosine*			
Diagnosis	Infectious Diseases Society of America (IDSA) Recommended Regimens		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ANCOBON	FLUCYTOSINE CAP 250 MG	11000020000105	Brand
FLUCYTOSINE	FLUCYTOSINE CAP 250 MG	11000020000105	Generic
ANCOBON	FLUCYTOSINE CAP 500 MG	11000020000110	Brand
FLUCYTOSINE	FLUCYTOSINE CAP 500 MG	11000020000110	Generic
<b>Approval Criteria</b>			
1 - The medication is being prescribed by or in consultation with an infectious disease specialist.			
Notes	*Approval duration based on provider recommended treatment durations, up to 12 months.		

**2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Forteo, Prolia, Teriparatide, Tymlos



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-145539
<b>Guideline Name</b>	Forteo, Prolia, Teriparatide, Tymlos
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Forteo			
Diagnosis	Patients with osteoporosis at high risk for fracture		
Approval Length	12 Months**		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FORTEO	TERIPARATIDE (RECOMBINANT) SOLN PEN-INJ 600 MCG/2.4ML	3004407000D220	Brand
<b>Approval Criteria</b>			

**1 - Diagnosis of osteoporosis**

**AND**

**2 - ONE of the following:**

**2.1** Bone Mineral Density (BMD) T-score less than or equal to -3.5 based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site). [NOTE: Provider must submit patient specific BMD T-score]

**OR**

**2.2 BOTH of the following:**

**2.2.1** BMD T-score between -2.5 and -3.5 (BMD T-score greater than -3.5 and less than or equal to -2.5) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site). [NOTE: Provider must submit patient specific BMD T-score]

**AND**

**2.2.2 ONE of the following:**

**2.2.2.1** History of ONE of the following resulting from minimal trauma:

- Vertebral compression fracture
- Fracture of the hip
- Fracture of the distal radius
- Fracture of the pelvis
- Fracture of the proximal humerus

**OR**

**2.2.2.2** History of failure, contraindication, or intolerance to ONE conventional osteoporosis therapy [e.g., bisphosphonate or selective estrogen receptor modulator (SERM)] (Document drug, date, and duration of trial)\*

**OR**

**2.3 ALL of the following:**

**2.3.1** BMD T-score between -1 and -2.5 (BMD T-score greater than -2.5 and less than or equal to -1) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site). [NOTE: Provider must submit patient specific BMD T-score]

**AND**

**2.3.2 ONE of the following:**

**2.3.2.1** History of ONE of the following resulting from minimal trauma:

- Vertebral compression fracture
- Fracture of the hip
- Fracture of the distal radius
- Fracture of the pelvis
- Fracture of the proximal humerus

**OR**

**2.3.2.2** ONE of the following Fracture Risk Assessment Tool (FRAX) 10-year fracture probabilities:

- Major osteoporotic fracture at 20 percent or more
- Hip fracture at 3 percent or more

**AND**

**2.3.3** History of failure, contraindication, or intolerance to one conventional osteoporosis therapy [e.g., bisphosphonate or selective estrogen receptor modulator (SERM)] (Document drug, date, and duration of trial)\*

**AND**

**3** - Treatment duration has not exceeded a total of 24 months\*\* of cumulative use of parathyroid hormone analogs (e.g., Teriparatide Injection, Forteo, Tymlos) during the patient's lifetime

Notes	<p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trial</p> <p>**Duration of coverage will be limited to 24 months of cumulative parathyroid hormone analog therapy (e.g., Forteo, Tymlos) in the patient's lifetime</p>
-------	--

Product Name: Brand Teriparatide, generic teriparatide, Tymlos			
Diagnosis	Patients with osteoporosis at high risk for fracture		
Approval Length	12 Months**		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TERIPARATIDE	TERIPARATIDE (RECOMBINANT) SOLN PEN-INJ 620 MCG/2.48ML	3004407000D221	Brand
TYMLOS	ABALOPARATIDE SUBCUTANEOUS SOLN PEN-INJECTOR 3120 MCG/1.56ML	3004400500D230	Brand
TERIPARATIDE	TERIPARATIDE (RECOMBINANT) SOLN PEN-INJ 600 MCG/2.4ML	3004407000D220	Generic

**Approval Criteria**

1 - Diagnosis of osteoporosis

**AND**

2 - ONE of the following:

**2.1** Bone Mineral Density (BMD) T-score less than or equal to -3.5 based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site). [NOTE: Provider must submit patient specific BMD T-score]

**OR**

**2.2** BOTH of the following:

**2.2.1** BMD T-score between -2.5 and -3.5 (BMD T-score greater than -3.5 and less than or equal to -2.5) based on BMD measurements from lumbar spine (at least two vertebral



bodies), hip (femoral neck, total hip), or radius (one-third radius site). [NOTE: Provider must submit patient specific BMD T-score]

**AND**

**2.2.2** ONE of the following:

**2.2.2.1** History of ONE of the following resulting from minimal trauma:

- Vertebral compression fracture
- Fracture of the hip
- Fracture of the distal radius
- Fracture of the pelvis
- Fracture of the proximal humerus

**OR**

**2.2.2.2** History of failure, contraindication, or intolerance to ALL of the following (Document drug, date, and duration of trial)

- bisphosphonate (e.g. alendronate, ibandronate)
- selective estrogen receptor modulator (SERM) (e.g raloxifene)
- Prolia (denosumab)
- Brand Forteo (teriparatide)

**OR**

**2.3** ALL of the following:

**2.3.1** BMD T-score between -1 and -2.5 (BMD T-score greater than -2.5 and less than or equal to -1) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) [NOTE: Provider must submit patient specific BMD T-score]

**AND**

**2.3.2** ONE of the following

**2.3.2.1** History of ONE of the following resulting from minimal trauma:

- Vertebral compression fracture

- Fracture of the hip
- Fracture of the distal radius
- Fracture of the pelvis
- Fracture of the proximal humerus

**OR**

**2.3.2.2** ONE of the following Fracture Risk Assessment Tool (FRAX) 10-year fracture probabilities:

- Major osteoporotic fracture at 20 percent or more
- Hip fracture at 3 percent or more

**AND**

**2.3.3** History of failure, contraindication, or intolerance to ALL of the following (Document drug, date, and duration of trial)

- bisphosphonate (e.g. alendronate, ibandronate)
- selective estrogen receptor modulator (SERM) (e.g raloxifene)
- Prolia (denosumab)
- Brand Forteo (teriparatide)

**AND**

**3** - Treatment duration has not exceeded a total of 24 months\*\* of cumulative use of parathyroid hormone analogs (e.g., Teriparatide Injection, Forteo, Tymlos) during the patient's lifetime

Notes	<p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trial</p> <p>**Duration of coverage will be limited to 24 months of cumulative parathyroid hormone analog therapy (e.g., Forteo, Tymlos) in the patient's lifetime</p>
-------	--

Product Name: Brand Forteo, Brand Teriparatide, generic teriparatide, Tymlos	
Diagnosis	Patients with osteoporosis at high risk for fracture
Approval Length	12 Months*
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TERIPARATIDE	TERIPARATIDE (RECOMBINANT) SOLN PEN-INJ 620 MCG/2.48ML	3004407000D221	Brand
TYMLOS	ABALOPARATIDE SUBCUTANEOUS SOLN PEN-INJECTOR 3120 MCG/1.56ML	3004400500D230	Brand
FORTEO	TERIPARATIDE (RECOMBINANT) SOLN PEN-INJ 600 MCG/2.4ML	3004407000D220	Brand
TERIPARATIDE	TERIPARATIDE (RECOMBINANT) SOLN PEN-INJ 600 MCG/2.4ML	3004407000D220	Generic

**Approval Criteria**

1 - Patient demonstrates positive clinical response to therapy

**AND**

2 - Treatment duration has not exceeded a total of 24 months\* of cumulative use of parathyroid hormone analogs (e.g., Teriparatide Injection, Forteo, Tymlos) during the patient's lifetime)

Notes	*Duration of coverage will be limited to 24 months of cumulative parathyroid hormone analog therapy (e.g., Forteo, Tymlos) in the patient's lifetime
-------	--

Product Name: Prolia			
Diagnosis	Patients with osteoporosis at high risk for fracture		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PROLIA	DENOSUMAB INJ SOLN PREFILLED SYRINGE 60 MG/ML	3004453000E520	Brand
<b>Approval Criteria</b>			

**1 - Diagnosis of osteoporosis**

**AND**

**2 - ONE of the following:**

**2.1** Bone Mineral Density (BMD) T-score less than or equal to -3.5 based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site). [NOTE: Provider must submit patient specific BMD T-score]

**OR**

**2.2** BOTH of the following:

**2.2.1** BMD T-score between -2.5 and -3.5 (BMD T-score greater than -3.5 and less than or equal to -2.5) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site). [NOTE: Provider must submit patient specific BMD T-score]

**AND**

**2.2.2** ONE of the following:

**2.2.2.1** History of ONE of the following resulting from minimal trauma:

- Vertebral compression fracture
- Fracture of the hip
- Fracture of the distal radius
- Fracture of the pelvis
- Fracture of the proximal humerus

**OR**

**2.2.2.2** History of failure, contraindication, or intolerance to ONE conventional osteoporosis therapy [e.g., bisphosphonate or selective estrogen receptor modulator (SERM)] (Document drug, date, and duration of trial)\*

**OR**

**2.3 ALL of the following:**

**2.3.1** BMD T-score between -1 and -2.5 (BMD T-score greater than -2.5 and less than or equal to -1) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site). [NOTE: Provider must submit patient specific BMD T-score]

**AND**

**2.3.2 ONE of the following:**

**2.3.2.1** History of ONE of the following resulting from minimal trauma:

- Vertebral compression fracture
- Fracture of the hip
- Fracture of the distal radius
- Fracture of the pelvis
- Fracture of the proximal humerus

**OR**

**2.3.2.2** ONE of the following Fracture Risk Assessment Tool (FRAX) 10-year fracture probabilities:

- Major osteoporotic fracture at 20 percent or more
- Hip fracture at 3 percent or more

**AND**

**2.3.3** History of failure, contraindication, or intolerance to one conventional osteoporosis therapy [e.g., bisphosphonate or selective estrogen receptor modulator (SERM)] (Document drug, date, and duration of trial)\*

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial
-------	--

Product Name: Prolia	
Diagnosis	Patients with osteoporosis at high risk for fracture
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
PROLIA	DENOSUMAB INJ SOLN PREFILLED SYRINGE 60 MG/ML	3004453000E520	Brand
<p><b>Approval Criteria</b></p> <p>1 - Patient demonstrates positive clinical response to therapy</p>			

## 2 . Revision History

Date	Notes
4/9/2024	Updated criteria to specify 24 month limit on duration does not apply to Prolia. Added reauth criteria. Changed authorization to Initial auth 12 months, Reauth 12 months.

Fotivda



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140983
<b>Guideline Name</b>	Fotivda
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	8/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Fotivda			
Diagnosis	Renal Cell Carcinoma		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FOTIVDA	TIVOZANIB HCL CAP 0.89 MG (BASE EQUIVALENT)	21533076250120	Brand
FOTIVDA	TIVOZANIB HCL CAP 1.34 MG (BASE EQUIVALENT)	21533076250130	Brand

**Approval Criteria**

1 - Diagnosis of advanced renal cell carcinoma (RCC)

**AND**

2 - ONE of the following:

- Disease has relapsed
- Disease is refractory

**AND**

3 - Patient has received two or more prior systemic therapies

Product Name: Fotivda			
Diagnosis	Renal Cell Carcinoma		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FOTIVDA	TIVOZANIB HCL CAP 0.89 MG (BASE EQUIVALENT)	21533076250120	Brand
FOTIVDA	TIVOZANIB HCL CAP 1.34 MG (BASE EQUIVALENT)	21533076250130	Brand
<b>Approval Criteria</b>			
1 - Patient does not show evidence of progressive disease while on Fotivda therapy			

Product Name: Fotivda	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization



Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
FOTIVDA	TIVOZANIB HCL CAP 0.89 MG (BASE EQUIVALENT)	21533076250120	Brand
FOTIVDA	TIVOZANIB HCL CAP 1.34 MG (BASE EQUIVALENT)	21533076250130	Brand
<b>Approval Criteria</b>			
1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium			

Product Name: Fotivda			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FOTIVDA	TIVOZANIB HCL CAP 0.89 MG (BASE EQUIVALENT)	21533076250120	Brand
FOTIVDA	TIVOZANIB HCL CAP 1.34 MG (BASE EQUIVALENT)	21533076250130	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Fotivda therapy			

## 2 . Revision History

Date	Notes
7/3/2023	Updated GPI

Furoscix (furosemide injection)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-159336
<b>Guideline Name</b>	Furoscix (furosemide injection)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Furoscix			
Approval Length	3 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FUROSCIX	FUROSEMIDE SUBCUTANEOUS CARTRIDGE KIT 80 MG/10ML	3720003000F720	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes) documenting diagnosis of chronic heart failure			

**AND**

**2** - Patient is currently on maintenance oral diuretic therapy (e.g., bumetanide, furosemide, torsemide)

**AND**

**3** - Provider attests that patient will be closely monitored for fluid, electrolyte, and metabolic abnormalities throughout therapy (e.g., hypokalemia, hypovolemia, hyponatremia)

**AND**

**4** - Submission of medical records (e.g., chart notes) or paid claims documenting ONE of the following:

**4.1** History of failure to intravenous furosemide (Lasix IV)

**OR**

**4.2** Provider has submitted clinical rationale for why intravenous furosemide is inappropriate

## 2 . Revision History

Date	Notes
11/6/2024	Removed NYHA class requirement. Added step through IV furosemide, unless there is clinical rationale for why IV furosemide is inappropriate.

Galafold



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140847
<b>Guideline Name</b>	Galafold
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Galafold			
Diagnosis	Fabry disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GALAFOLD	MIGALASTAT HCL CAP 123 MG (BASE EQUIVALENT)	30903650100120	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of Fabry disease

**AND**

2 - Patient has an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data

**AND**

3 - Patient is not receiving Galafold in combination with Fabrazyme (agalsidase beta)

Product Name: Galafold			
Diagnosis	Fabry disease		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GALAFOLD	MIGALASTAT HCL CAP 123 MG (BASE EQUIVALENT)	30903650100120	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Galafold therapy

**AND**

2 - Patient is not receiving Galafold in combination with Fabrazyme (agalsidase beta)

**2 . Revision History**

Date	Notes
------	-------

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

3/31/2020	Bulk copy C&S New York SP to C&S Arizona SP for 5/1 effective
-----------	---

Gattex (teduglutide)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-141007
<b>Guideline Name</b>	Gattex (teduglutide)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2023
-----------------	-----------

## 1 . Criteria

Product Name: Gattex			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GATTEX	TEDUGLUTIDE (RDNA) FOR INJ KIT 5 MG	52533070006420	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes) confirming all of the following:			

<p><b>1.1</b> Diagnosis of short bowel syndrome</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2</b> Patient is 1 year of age and older</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.3</b> Documentation that the patient is dependent on parenteral nutrition/intravenous (PN/IV) support for at least 12 consecutive months</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Prescribed by or in consultation with a gastroenterologist</p>
--

Product Name: Gattex			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GATTEX	TEDUGLUTIDE (RDNA) FOR INJ KIT 5 MG	52533070006420	Brand

<p><b>Approval Criteria</b></p> <p><b>1</b> - Submission of medical records (e.g., chart notes) documenting that the patient has had a reduction in weekly parenteral nutrition/intravenous (PN/IV) support from baseline while on Gattex therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Prescribed by or in consultation with a gastroenterologist</p>
--



## 2 . Revision History

Date	Notes
11/7/2023	Updated guideline name and criteria to match AZM

Gaucher's Disease Agents



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140861
<b>Guideline Name</b>	Gaucher's Disease Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	4/1/2021
-----------------	----------

## 1 . Criteria

Product Name: Cerdelga			
Diagnosis	Type 1 Gaucher's disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CERDELGA	ELIGLUSTAT TARTRATE CAP 84 MG (BASE EQUIVALENT)	82700040600120	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of Type 1 Gaucher's disease

**AND**

2 - Patient is one of the following as detected by a Food and Drug Administration (FDA)-cleared test:

- CYP2D6 extensive metabolizer,
- CYP2D6 intermediate metabolizer
- CYP2D6 poor metabolizer

Product Name: Cerezyme

Diagnosis	Type 1 Gaucher's disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
CEREZYME	IMIGLUCERASE FOR INJ 400 UNIT	82700050002120	Brand

**Approval Criteria**

1 - Diagnosis of Type 1 Gaucher's disease that results in one or more of the following conditions:

- Anemia
- Thrombocytopenia
- Bone disease
- Hepatomegaly or splenomegaly

Product Name: Vpriv, Elelyso

Diagnosis	Type 1 Gaucher's disease
Approval Length	12 month(s)

Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ELELYSO	TALIGLUCERASE ALFA FOR INJ 200 UNIT	82700080102120	Brand
VPRIV	VELAGLUCERASE ALFA FOR INJ 400 UNIT	82700085102120	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of Type 1 Gaucher's disease			

Product Name: Brand Zavesca, generic miglustat			
Diagnosis	Type 1 Gaucher's disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MIGLUSTAT	MIGLUSTAT CAP 100 MG	82700070000120	Generic
ZAVESCA	MIGLUSTAT CAP 100 MG	82700070000120	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of mild to moderate Type 1 Gaucher's disease			
<b>AND</b>			
2 - If the request is for generic miglustat, there is a reason or special circumstance why the patient cannot use brand Zavesca			

Product Name: Cerdelga, Cerezyme, Eleyso, Vpriv, Brand Zavesca, generic miglustat	
Diagnosis	Type 1 Gaucher's disease

Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CERDELGA	ELIGLUSTAT TARTRATE CAP 84 MG (BASE EQUIVALENT)	82700040600120	Brand
CEREZYME	IMIGLUCERASE FOR INJ 400 UNIT	82700050002120	Brand
ELELYSO	TALIGLUCERASE ALFA FOR INJ 200 UNIT	82700080102120	Brand
VPRIV	VELAGLUCERASE ALFA FOR INJ 400 UNIT	82700085102120	Brand
MIGLUSTAT	MIGLUSTAT CAP 100 MG	82700070000120	Generic
ZAVESCA	MIGLUSTAT CAP 100 MG	82700070000120	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy			

## 2 . Revision History

Date	Notes
2/23/2021	Added step through brand Zavesca for generic requests to match AZ state PDL.

Generic fluticasone-salmeterol diskus, Wixela Inhub (authorized generic of Advair Diskus), Airduo, fluticasone/salmeterol (authorized generic of Airduo)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147495
<b>Guideline Name</b>	Generic fluticasone-salmeterol diskus, Wixela Inhub (authorized generic of Advair Diskus), Airduo, fluticasone/salmeterol (authorized generic of Airduo)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	6/1/2024
-----------------	----------

## 1 . Criteria

Product Name: generic fluticasone-salmeterol diskus, Wixela Inhub (authorized generic of Advair Diskus), Airduo, fluticasone/salmeterol (authorized generic of Airduo)			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FLUTICASONE PROPRIONATE/SALMETEROL	FLUTICASONE-SALMETEROL AER POWDER BA 55-14 MCG/ACT	44209902708010	Generic
AIRDUO RESPICLICK 55/14	FLUTICASONE-SALMETEROL AER POWDER BA 55-14 MCG/ACT	44209902708010	Generic
FLUTICASONE PROPRIONATE/SALMETEROL	FLUTICASONE-SALMETEROL AER POWDER BA 113-14 MCG/ACT	44209902708015	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AIRDUO RESPICLICK 113/14	FLUTICASONE-SALMETEROL AER POWDER BA 113-14 MCG/ACT	44209902708015	Generic
FLUTICASONE PROPIONATE/SALMETEROL	FLUTICASONE-SALMETEROL AER POWDER BA 232-14 MCG/ACT	44209902708025	Generic
AIRDUO RESPICLICK 232/14	FLUTICASONE-SALMETEROL AER POWDER BA 232-14 MCG/ACT	44209902708025	Generic
FLUTICASONE PROPIONATE/SALMETEROL DISKUS	FLUTICASONE-SALMETEROL AER POWDER BA 100-50 MCG/ACT	44209902708020	Generic
WIXELA INHUB	FLUTICASONE-SALMETEROL AER POWDER BA 100-50 MCG/ACT	44209902708020	Generic
FLUTICASONE PROPIONATE/SALMETEROL	FLUTICASONE-SALMETEROL AER POWDER BA 100-50 MCG/ACT	44209902708020	Generic
FLUTICASONE PROPIONATE/SALMETEROL DISKUS	FLUTICASONE-SALMETEROL AER POWDER BA 250-50 MCG/ACT	44209902708030	Generic
WIXELA INHUB	FLUTICASONE-SALMETEROL AER POWDER BA 250-50 MCG/ACT	44209902708030	Generic
FLUTICASONE PROPIONATE/SALMETEROL	FLUTICASONE-SALMETEROL AER POWDER BA 250-50 MCG/ACT	44209902708030	Generic
FLUTICASONE PROPIONATE/SALMETEROL DISKUS	FLUTICASONE-SALMETEROL AER POWDER BA 500-50 MCG/ACT	44209902708040	Generic
WIXELA INHUB	FLUTICASONE-SALMETEROL AER POWDER BA 500-50 MCG/ACT	44209902708040	Generic
FLUTICASONE PROPIONATE/SALMETEROL	FLUTICASONE-SALMETEROL AER POWDER BA 500-50 MCG/ACT	44209902708040	Generic
AIRDUO DIGIHALER 55/14	FLUTICASONE-SALMETEROL AER POWDER BA 55-14 MCG/ACT W/ SENSOR	44209902718020	Brand
AIRDUO DIGIHALER 113/14	FLUTICASONE-SALMETEROL AER POWDER BA 113-14 MCG/ACT W/SENSOR	44209902718030	Brand
AIRDUO DIGIHALER 232/14	FLUTICASONE-SALMETEROL AER POWDER BA 232-14 MCG/ACT W/SENSOR	44209902718040	Brand

**Approval Criteria**

1 - Trial and failure, contraindication, or intolerance to ALL of the preferred\* agents

Notes

\*PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP>

## 2 . Revision History

Date	Notes
5/17/2024	New program.



Global Quantity Limits



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140667
<b>Guideline Name</b>	Global Quantity Limits
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/15/2020
-----------------	------------

### 1 . Criteria

Product Name: Quantity Limit, Prescription Limit			
Diagnosis	Quantity limit review (General)		
Approval Length	12 month(s)		
Guideline Type	Administrative		
Product Name	Generic Name	GPI	Brand/Generic
Quantity Limit			
Prescription Limit			
<b>Approval Criteria</b>			

**1 - ONE of the following:**

**1.1** The requested drug must be used for an FDA-approved indication

**OR**

**1.2** The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

**2 -** The drug is being prescribed within the manufacturer's published dosing guidelines or falls within dosing guidelines found in ONE of the following compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

**3 -** The requested dosage cannot be achieved using the plan accepted quantity limit of a different dose or formulation.

**AND**

**4 -** The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plans' program.

Product Name: Quantity Limit, Prescription Limit

Diagnosis

Quantity limit review for the treatment of gender dysphoria\*

Approval Length	12 month(s)		
Guideline Type	Administrative		
Product Name	Generic Name	GPI	Brand/Generic
Quantity Limit			
Prescription Limit			
<p><b>Approval Criteria</b></p> <p>1 - The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:</p> <ul style="list-style-type: none"> <li>• American Hospital Formulary Service Drug Information</li> <li>• National Comprehensive Cancer Network Drugs and Biologics Compendium</li> <li>• Thomson Micromedex DrugDex</li> <li>• Clinical pharmacology</li> <li>• United States Pharmacopoeia-National Formulary (USP-NF)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - The drug is being prescribed for an indication that is recognized as a covered benefit by the applicable health plans' program.</p>			
Notes	* If the above criteria are not met, then refer for clinical review by an appropriate trained professional (physician or pharmacist) based on the applicable regulatory requirement.		

Product Name: Quantity Limit, Prescription Limit			
Diagnosis	Monthly prescription limit review for migraine therapy, benzodiazepines, or muscle relaxants		
Approval Length	1 month(s)		
Guideline Type	Administrative		
Product Name	Generic Name	GPI	Brand/Generic
Quantity Limit			
Prescription Limit			

<b>Approval Criteria</b>	
1 - Medical necessity rationale provided for why the member requires 5 or more fills of the same drug or drug class within a month.	
Notes	*If deemed medically necessary, longer authorization duration is permitted

Product Name: Quantity Limit, Prescription Limit			
Diagnosis	Topical products exceeding the allowable package size per fill OR the allowable quantity per month		
Approval Length	12 month(s)		
Guideline Type	Administrative		
Product Name	Generic Name	GPI	Brand/Generic
Quantity Limit			
Prescription Limit			
<b>Approval Criteria</b>			
1 - The physician attests that a larger quantity is needed for treatment of a larger surface area.			

## 2 . Revision History

Date	Notes
1/10/2022	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

GLP-1 Agonists



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-152616
<b>Guideline Name</b>	GLP-1 Agonists
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Byetta, Trulicity, Brand Victoza			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BYETTA	EXENATIDE SOLN PEN-INJECTOR 5 MCG/0.02ML	2717002000D220	Brand
BYETTA	EXENATIDE SOLN PEN-INJECTOR 10 MCG/0.04ML	2717002000D240	Brand
TRULICITY	DULAGLUTIDE SOLN PEN-INJECTOR 0.75 MG/0.5ML	2717001500D520	Brand
TRULICITY	DULAGLUTIDE SOLN PEN-INJECTOR 1.5 MG/0.5ML	2717001500D530	Brand
TRULICITY	DULAGLUTIDE SOLN PEN-INJECTOR 3 MG/0.5ML	2717001500D540	Brand
TRULICITY	DULAGLUTIDE SOLN PEN-INJECTOR 4.5 MG/0.5ML	2717001500D550	Brand

VICTOZA	LIRAGLUTIDE SOLN PEN-INJECTOR 18 MG/3ML (6 MG/ML)	2717005000D220	Brand
<p><b>Approval Criteria</b></p> <p><b>1</b> - Submission of medical records (e.g., chart notes, lab work, imaging) confirming BOTH of the following:</p> <ul style="list-style-type: none"> <li>• Diagnosis of type 2 diabetes mellitus</li> <li>• Baseline A1C greater than or equal to 6.5%</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - ONE of the following:</p> <p><b>2.1</b> History of failure to metformin at a minimum dose of 1500 milligrams (mg) daily for 90 days (verified via paid pharmacy claims or submission of medical records)</p> <p style="text-align: center;"><b>OR</b></p> <p><b>2.2</b> Contraindication or intolerance to metformin (verified via paid pharmacy claims or submission of medical records)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Patient is 10 years of age or older</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Drug is not solely being used for weight loss</p>			

Product Name: Adlyxin, Bydureon BCise, Brand Liraglutide, Mounjaro, Ozempic	
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ADLYXIN	LIXISENATIDE SOLN PEN-INJECTOR 20 MCG/0.2ML (100 MCG/ML)	2717005600D230	Brand
BYDUREON BCISE	EXENATIDE EXTENDED RELEASE SUSP AUTO-INJECTOR 2 MG/0.85ML	2717002000D420	Brand
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 2.5 MG/0.5ML	2717308000D510	Brand
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 5 MG/0.5ML	2717308000D515	Brand
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 7.5 MG/0.5ML	2717308000D520	Brand
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 10 MG/0.5ML	2717308000D525	Brand
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 12.5 MG/0.5ML	2717308000D530	Brand
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 15 MG/0.5ML	2717308000D535	Brand
OZEMPIC	SEMAGLUTIDE SOLN PEN-INJ 0.25 OR 0.5 MG/DOSE (2 MG/1.5ML)	2717007000D210	Brand
OZEMPIC	SEMAGLUTIDE SOLN PEN-INJ 0.25 OR 0.5 MG/DOSE (2 MG/3ML)	2717007000D221	Brand
OZEMPIC	SEMAGLUTIDE SOLN PEN-INJ 1 MG/DOSE (4 MG/3ML)	2717007000D222	Brand
OZEMPIC	SEMAGLUTIDE SOLN PEN-INJ 2 MG/DOSE (8 MG/3ML)	2717007000D225	Brand
LIRAGLUTIDE	LIRAGLUTIDE SOLN PEN-INJECTOR 18 MG/3ML (6 MG/ML)	2717005000D220	Generic

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) confirming BOTH of the following:

- Diagnosis of type 2 diabetes mellitus
- Baseline A1C greater than or equal to 6.5%

**AND**

2 - ONE of the following:

**2.1** History of failure to metformin at a minimum dose of 1500 milligrams (mg) daily for 90 days (verified via paid pharmacy claims or submission of medical records)

**OR**

**2.2** Contraindication or intolerance to metformin (verified via paid pharmacy claims or submission of medical records)

**AND**

**3** - History of a 90 day trial per patient's pharmacy claims resulting in a therapeutic failure, contraindication, or intolerance to ALL of the following (verified via paid pharmacy claims or submission of medical records):

- Byetta
- Brand Victoza
- Trulicity

**AND**

**4** - ONE of the following:

**4.1** If the request is for Bydureon BCise, patient is 10 years of age or older

**OR**

**4.2** If the request is for Adlyxin, Mounjaro, or Ozempic, patient is 18 years of age or older

**AND**

**5** - Drug is not solely being used for weight loss

Product Name: Rybelsus			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic



RYBELSUS	SEMAGLUTIDE TAB 3 MG	27170070000310	Brand
RYBELSUS	SEMAGLUTIDE TAB 7 MG	27170070000320	Brand
RYBELSUS	SEMAGLUTIDE TAB 14 MG	27170070000330	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) confirming BOTH of the following:

- Diagnosis of type 2 diabetes mellitus
- Baseline A1C greater than or equal to 6.5%

**AND**

**2** - ONE of the following:

**2.1** History of failure to metformin at a minimum dose of 1500 milligrams (mg) daily for 90 days (verified via paid pharmacy claims or submission of medical records)

**OR**

**2.2** Contraindication or intolerance to metformin (verified via paid pharmacy claims or submission of medical records)

**AND**

**3** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ONE of the following:

**3.1** History of a 90 day trial per patient's pharmacy claims resulting in a therapeutic failure, contraindication, or intolerance to ALL of the following (verified via paid pharmacy claims or submission of medical records):

- Byetta
- Brand Victoza
- Trulicity

**OR**

**3.2** BOTH of the following:

**3.2.1** The patient is unable to self-inject due to ONE of the following:

- Physical impairment
- Visual impairment
- Lipohypertrophy
- Documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-5 for specific phobia diagnostic criteria)

**AND**

**3.2.2** History of failure, intolerance, or contraindication to ALL of the following:

- Farxiga
- Jardiance
- Invokana
- Invokamet
- Synjardy
- Xigduo XR

**AND**

**4** - Patient is 18 years of age or older

**AND**

**5** - Drug is not solely being used for weight loss

## 2 . Revision History

Date	Notes
------	-------

8/26/2024	Added Brand Liraglutide as a target. Updated GPI table and product name lists accordingly. Minor update to embedded steps, where applicable.
-----------	--

Glycopyrrolate Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140733
<b>Guideline Name</b>	Glycopyrrolate Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Dartisla ODT, Brand Cuvposa, Brand Robinul, Brand Robinul Forte			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DARTISLA ODT	GLYCOPYRROLATE TAB DISINTEGRATING 1.7 MG	49102030007220	Brand
CUVPOSA	GLYCOPYRROLATE ORAL SOLN 1 MG/5ML	49102030002060	Brand
ROBINUL	GLYCOPYRROLATE TAB 1 MG	49102030000310	Brand
ROBINUL FORTE	GLYCOPYRROLATE TAB 2 MG	49102030000315	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting requested drug is being used for a Food and Drug Administration (FDA)-approved indication

**AND**

**2** - Trial and failure or intolerance to generic glycopyrrolate tablets or oral solution (verified via pharmacy paid claims or submission of medical records/chart notes)

Gonadotropin-Releasing Hormone Agonists



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140977
<b>Guideline Name</b>	Gonadotropin-Releasing Hormone Agonists
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2023
-----------------	----------

### 1 . Criteria

Product Name: leuprolide acetate inj kit 5 mg/mL, Lupron Depot Ped, Triptodur, Fensolvi			
Diagnosis	Central Precocious Puberty (CPP)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE INJ KIT 5 MG/ML	21405010106407	Generic
TRIPTODUR	TRIPTORELIN PAMOATE FOR IM ER SUSP 22.5 MG (BASE EQUIV)	3008007040G240	Brand
FENSOLVI	LEUPROLIDE ACET (6 MONTH) FOR INJ PEDIATRIC KIT 45 MG	30080050256450	Brand

LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 7.5 MG	30080050106420	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 11.25 MG	30080050106430	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 15 MG	30080050106440	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 11.25 MG	30080050156420	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 30 MG	30080050156440	Brand
LUPRON DEPOT-PED	LEUPROLIDE ACET (6 MONTH) FOR IM INJ PEDIATRIC KIT 45 MG	30080050256460	Brand

**Approval Criteria**

1 - Diagnosis of central precocious puberty (idiopathic or neurogenic)

**AND**

2 - Onset of secondary sexual characteristics in one of the following:

2.1 Females less than or equal to 8 years of age

**OR**

2.2 Males less than or equal to 9 years of age

**AND**

3 - Confirmation of diagnosis as defined by one of the following:

3.1 Pubertal basal level of luteinizing hormone (based on laboratory reference ranges)

**OR**

**3.2** A pubertal luteinizing hormone response to a gonadotropin releasing hormone (GnRH) stimulation test

**OR**

**3.3** Bone age advanced one year beyond the chronological age

**AND**

**4** - If the request is for Triptodur or Fensolvi, history of failure, contraindication, or intolerance to Lupron-Depot Ped

Product Name: leuprolide acetate inj kit 5 mg/mL, Lupron Depot Ped, Triptodur, Fensolvi			
Diagnosis	Central Precocious Puberty (CPP)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE INJ KIT 5 MG/ML	21405010106407	Generic
TRIPTODUR	TRIPTORELIN PAMOATE FOR IM ER SUSP 22.5 MG (BASE EQUIV)	3008007040G240	Brand
FENSOLVI	LEUPROLIDE ACET (6 MONTH) FOR INJ PEDIATRIC KIT 45 MG	30080050256450	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 7.5 MG	30080050106420	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 11.25 MG	30080050106430	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 15 MG	30080050106440	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 11.25 MG	30080050156420	Brand



LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 30 MG	30080050156440	Brand
LUPRON DEPOT-PED	LEUPROLIDE ACET (6 MONTH) FOR IM INJ PEDIATRIC KIT 45 MG	30080050256460	Brand

**Approval Criteria**

1 - Patient is currently receiving therapy for central precocious puberty

**AND**

2 - Documentation of positive clinical response to therapy

**AND**

3 - Patient is ONE of the following (younger than the appropriate time point for the onset of puberty):

3.1 Female younger than 11 years of age

**OR**

3.2 Male younger than 12 years of age

Product Name: Lupaneta Pack, Lupron Depot 3.75 mg and 3-month 11.25 mg			
Diagnosis	Endometriosis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 3.75 MG	21405010106405	Brand

LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 11.25 MG	21405010156420	Brand
LUPANETA PACK	LEUPROLIDE (1 MON) INJ 3.75 MG & NORETHINDRONE TAB 5 MG KIT	30089902506420	Brand
LUPANETA PACK	LEUPROLIDE (3 MON) INJ 11.25 MG & NORETHINDRONE TAB 5 MG KIT	30089902506440	Brand

**Approval Criteria**

1 - Diagnosis of endometriosis or endometriosis is suspected

**AND**

2 - One of the following:

2.1 History of failure, contraindication, or intolerance to both of the following:

2.1.1 Oral contraceptives or depot medroxyprogesterone (e.g., Depo- Provera)

**AND**

2.1.2 Non-steroidal anti-inflammatory drugs (NSAIDs)

**OR**

2.2 Patient has had surgical ablation to prevent recurrence

**AND**

3 - If the request is for Lupaneta Pack, history of failure, contraindication, or intolerance to Lupron Depot

Product Name: Lupaneta Pack, Lupron Depot 3.75 mg and 3-month 11.25 mg	
Diagnosis	Endometriosis
Approval Length	6 month(s)

Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 3.75 MG	21405010106405	Brand
LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 11.25 MG	21405010156420	Brand
LUPANETA PACK	LEUPROLIDE (1 MON) INJ 3.75 MG & NORETHINDRONE TAB 5 MG KIT	30089902506420	Brand
LUPANETA PACK	LEUPROLIDE (3 MON) INJ 11.25 MG & NORETHINDRONE TAB 5 MG KIT	30089902506440	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of endometriosis or endometriosis is suspected</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Recurrence of symptoms following an initial course of therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Concurrently to be used with add-back therapy (e.g., progestin, estrogen, or bone sparing agents)</p>			

Product Name: Lupron Depot 3.75 mg and 3-month 11.25 mg			
Diagnosis	Uterine Leiomyomata (Fibroids)		
Approval Length	3 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 3.75 MG	21405010106405	Brand

LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 11.25 MG	21405010156420	Brand
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <p>1.1 All of the following:</p> <p>1.1.1 For the treatment of uterine leiomyomata-related anemia</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.2 Patient did not respond to iron therapy of 1 month duration</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.3 For use prior to surgery</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 For use prior to surgery to reduce the size of fibroids to facilitate a surgical procedure (e.g., myomectomy, hysterectomy)</p>			

Product Name: Lupron Depot, Lupron Depot-Ped, Lupaneta Pack, leuprolide acetate inj kit 5 mg/mL, Triptodur, Fensolvi, Leuprolide acetate (3 month) 22.5 mg inj			
Diagnosis	Gender dysphoria in adolescents		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 3.75 MG	21405010106405	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 7.5 MG	21405010106410	Brand
LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 11.25 MG	21405010156420	Brand
LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 22.5 MG	21405010156430	Brand
LUPRON DEPOT (4-MONTH)	LEUPROLIDE ACETATE (4 MONTH) FOR INJ KIT 30 MG	21405010206430	Brand
LUPRON DEPOT (6-MONTH)	LEUPROLIDE ACETATE (6 MONTH) FOR INJ KIT 45 MG	21405010256450	Brand
LUPANETA PACK	LEUPROLIDE (1 MON) INJ 3.75 MG & NORETHINDRONE TAB 5 MG KIT	30089902506420	Brand
LUPANETA PACK	LEUPROLIDE (3 MON) INJ 11.25 MG & NORETHINDRONE TAB 5 MG KIT	30089902506440	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE INJ KIT 5 MG/ML	21405010106407	Generic
TRIPTODUR	TRIPTORELIN PAMOATE FOR IM ER SUSP 22.5 MG (BASE EQUIV)	3008007040G240	Brand
FENSOLVI	LEUPROLIDE ACET (6 MONTH) FOR INJ PEDIATRIC KIT 45 MG	30080050256450	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE (3 MONTH) FOR INJ 22.5 MG	21405010152230	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 7.5 MG	30080050106420	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 11.25 MG	30080050106430	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 15 MG	30080050106440	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 11.25 MG	30080050156420	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 30 MG	30080050156440	Brand
LUPRON DEPOT-PED	LEUPROLIDE ACET (6 MONTH) FOR IM INJ PEDIATRIC KIT 45 MG	30080050256460	Brand

**Approval Criteria**

**1** - Diagnosis of gender dysphoria, according to the current Diagnostic and Statistical Manual of Mental Disorders (i.e., DSM-5) criteria, by a mental health professional with expertise in child and adolescent psychiatry

**AND**

**2** - Medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in gender dysphoria hormone therapy

**AND**

**3** - Patient has experienced puberty development to at least Tanner stage 2

**AND**

**4** - One of the following laboratory tests, based upon the laboratory reference range, confirming:

- Pubertal levels of estradiol in females
- Pubertal levels of testosterone in males
- Pubertal basal level of luteinizing hormone (based on laboratory reference ranges)
- A pubertal luteinizing hormone response to a gonadotropin-releasing hormone (GnRH) stimulation test

**AND**

**5** - A letter from the prescriber and/or formal documentation stating all of the following:

**5.1** Patient has experienced pubertal changes that have resulted in an increase of their gender dysphoria that has significantly impaired psychological or social functioning

**AND**

**5.2** Coexisting psychiatric and medical comorbidities or social problems that may interfere with the diagnostic procedures or treatment have been addressed or removed

**AND**

**5.3** Both of the following:

**5.3.1** Current enrollment, attendance, and active participation in psychological and social support treatment program

**AND**

**5.3.2** Patient will continue enrollment, attendance and active participation in psychological and social support throughout the course of treatment

**AND**

**5.4** Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies

**AND**

**6** - If the request is for Lupaneta Pack, leuprolide acetate, Triptodur, Fensolvi, history of failure, contraindication, or intolerance to Lupron Depot

Product Name: Lupron Depot, Lupron Depot-Ped, Lupaneta Pack, leuprolide acetate inj kit 5 mg/mL, Triptodur, Fensolvi, Leuprolide acetate (3 month) 22.5 mg inj			
Diagnosis	Gender dysphoria in adolescents		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 3.75 MG	21405010106405	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 7.5 MG	21405010106410	Brand
LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 11.25 MG	21405010156420	Brand
LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 22.5 MG	21405010156430	Brand
LUPRON DEPOT (4-MONTH)	LEUPROLIDE ACETATE (4 MONTH) FOR INJ KIT 30 MG	21405010206430	Brand
LUPRON DEPOT (6-MONTH)	LEUPROLIDE ACETATE (6 MONTH) FOR INJ KIT 45 MG	21405010256450	Brand
LUPANETA PACK	LEUPROLIDE (1 MON) INJ 3.75 MG & NORETHINDRONE TAB 5 MG KIT	30089902506420	Brand
LUPANETA PACK	LEUPROLIDE (3 MON) INJ 11.25 MG & NORETHINDRONE TAB 5 MG KIT	30089902506440	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE INJ KIT 5 MG/ML	21405010106407	Generic
TRIPTODUR	TRIPTORELIN PAMOATE FOR IM ER SUSP 22.5 MG (BASE EQUIV)	3008007040G240	Brand
FENSOLVI	LEUPROLIDE ACET (6 MONTH) FOR INJ PEDIATRIC KIT 45 MG	30080050256450	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE (3 MONTH) FOR INJ 22.5 MG	21405010152230	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 7.5 MG	30080050106420	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 11.25 MG	30080050106430	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 15 MG	30080050106440	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 11.25 MG	30080050156420	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 30 MG	30080050156440	Brand
LUPRON DEPOT-PED	LEUPROLIDE ACET (6 MONTH) FOR IM INJ PEDIATRIC KIT 45 MG	30080050256460	Brand

**Approval Criteria**



**1** - One of the following:

- Documentation (within the last 6 months) of appropriate luteinizing hormone (LH) suppression
- Change in dosing

**AND**

**2** - Documented diagnosis of gender dysphoria, according to the current Diagnostic and Statistical Manual of Mental Disorders (i.e., DSM-5) criteria, by a mental health professional with expertise in child and adolescent psychiatry

**AND**

**3** - Medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in gender dysphoria hormone therapy

**AND**

**4** - A letter from the prescriber and/or formal documentation stating all of the following:

**4.1** Patient continues to meet their individual goals of therapy for gender dysphoria

**AND**

**4.2** Patient continues to have a strong affinity for the desired (opposite of natal) gender

**AND**

**4.3** Discontinuation of treatment and subsequent pubertal development would interfere with or impair psychological functioning and well-being

**AND**

**4.4** Coexisting psychiatric and medical comorbidities or social problems that may interfere with treatment continue to be addressed or removed

**AND**

**4.5** Both of the following:

**4.5.1** Current enrollment, attendance, and active participation in psychological and social support treatment program

**AND**

**4.5.2** Patient will continue enrollment, attendance and active participation in psychological and social support throughout the course of treatment

**AND**

**4.6** Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies

Product Name: Lupron Depot, Lupron Depot-Ped, Lupaneta Pack, leuprolide acetate inj kit 5 mg/mL, Triptodur, Fensolvi, Leuprolide acetate (3 month) 22.5 mg inj

Diagnosis	Adjunct for Gender-Affirming Hormonal Therapy for Transgender Adults
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 3.75 MG	21405010106405	Brand
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 7.5 MG	21405010106410	Brand
LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 11.25 MG	21405010156420	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 22.5 MG	21405010156430	Brand
LUPRON DEPOT (4-MONTH)	LEUPROLIDE ACETATE (4 MONTH) FOR INJ KIT 30 MG	21405010206430	Brand
LUPRON DEPOT (6-MONTH)	LEUPROLIDE ACETATE (6 MONTH) FOR INJ KIT 45 MG	21405010256450	Brand
LUPANETA PACK	LEUPROLIDE (1 MON) INJ 3.75 MG & NORETHINDRONE TAB 5 MG KIT	30089902506420	Brand
LUPANETA PACK	LEUPROLIDE (3 MON) INJ 11.25 MG & NORETHINDRONE TAB 5 MG KIT	30089902506440	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE INJ KIT 5 MG/ML	21405010106407	Generic
TRIPTODUR	TRIPTORELIN PAMOATE FOR IM ER SUSP 22.5 MG (BASE EQUIV)	3008007040G240	Brand
FENSOLVI	LEUPROLIDE ACET (6 MONTH) FOR INJ PEDIATRIC KIT 45 MG	30080050256450	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE (3 MONTH) FOR INJ 22.5 MG	21405010152230	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 7.5 MG	30080050106420	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 11.25 MG	30080050106430	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 15 MG	30080050106440	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 11.25 MG	30080050156420	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 30 MG	30080050156440	Brand
LUPRON DEPOT-PED	LEUPROLIDE ACET (6 MONTH) FOR IM INJ PEDIATRIC KIT 45 MG	30080050256460	Brand

**Approval Criteria**

1 - Diagnosis of gender dysphoria, according to the current Diagnostic and Statistical Manual of Mental Disorders (i.e., DSM-5) criteria, by a mental health professional

**AND**

**2** - Medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in transgender hormone therapy

**AND**

**3** - Gonads (i.e., testes, ovaries) have not been removed and are functional (e.g., hormone producing)

**AND**

**4** - Patient is currently receiving hormonal therapy (e.g., testosterone, estrogens, progesterones) to achieve the desired (e.g., non-natal) gender

**AND**

**5** - Inability of cross sex hormone therapy to inhibit natal secondary sex characteristics, luteinizing hormone (LH), or gonadotropins (e.g., menses, testosterone)

**AND**

**6** - A letter from the prescriber and/or formal documentation stating all of the following:

**6.1** Transgender patient has identified goals of gender-affirming hormone therapy

**AND**

**6.2** Coexisting psychiatric and medical comorbidities or social problems that may interfere with the diagnostic procedures or treatment have been addressed or removed

**AND**

**6.3** Both of the following:

**6.3.1** Current enrollment, attendance, and active participation in psychological and social support treatment program

**AND**

**6.3.2** Patient will continue enrollment, attendance and active participation in psychological and social support throughout the course of treatment

**AND**

**6.4** Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies

**AND**

**7** - If the request is for Lupaneta Pack, leuprolide acetate, Triptodur, Fensolvi, history of failure, contraindication, or intolerance to Lupron Depot

Product Name: Lupron Depot, Lupron Depot-Ped, Lupaneta Pack, leuprolide acetate inj kit 5 mg/mL, Triptodur, Fensolvi, Leuprolide acetate (3 month) 22.5 mg inj

Diagnosis	Adjunct for Gender-Affirming Hormonal Therapy for Transgender Adults
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 3.75 MG	21405010106405	Brand
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 7.5 MG	21405010106410	Brand
LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 11.25 MG	21405010156420	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 22.5 MG	21405010156430	Brand
LUPRON DEPOT (4-MONTH)	LEUPROLIDE ACETATE (4 MONTH) FOR INJ KIT 30 MG	21405010206430	Brand
LUPRON DEPOT (6-MONTH)	LEUPROLIDE ACETATE (6 MONTH) FOR INJ KIT 45 MG	21405010256450	Brand
LUPANETA PACK	LEUPROLIDE (1 MON) INJ 3.75 MG & NORETHINDRONE TAB 5 MG KIT	30089902506420	Brand
LUPANETA PACK	LEUPROLIDE (3 MON) INJ 11.25 MG & NORETHINDRONE TAB 5 MG KIT	30089902506440	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE INJ KIT 5 MG/ML	21405010106407	Generic
TRIPTODUR	TRIPTORELIN PAMOATE FOR IM ER SUSP 22.5 MG (BASE EQUIV)	3008007040G240	Brand
FENSOLVI	LEUPROLIDE ACET (6 MONTH) FOR INJ PEDIATRIC KIT 45 MG	30080050256450	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE (3 MONTH) FOR INJ 22.5 MG	21405010152230	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 7.5 MG	30080050106420	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 11.25 MG	30080050106430	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 15 MG	30080050106440	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 11.25 MG	30080050156420	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 30 MG	30080050156440	Brand
LUPRON DEPOT-PED	LEUPROLIDE ACET (6 MONTH) FOR IM INJ PEDIATRIC KIT 45 MG	30080050256460	Brand

**Approval Criteria**

1 - One of the following:

- Documentation (within the last 6 months) of appropriate luteinizing hormone (LH) suppression

- Change in dosing

**AND**

**2** - Documented diagnosis of gender dysphoria, according to the current Diagnostic and Statistical Manual of Mental Disorders (i.e., DSM-5) criteria, by a mental health professional

**AND**

**3** - Medication is prescribed by or in consultation with an endocrinologist or a medical provider experienced in transgender hormone therapy

**AND**

**4** - Gonads (i.e., testes, ovaries) are intact

**AND**

**5** - Patient is currently receiving hormonal therapy (e.g., testosterone, estrogens, progesterones) to achieve the desired (e.g., non-natal) gender

**AND**

**6** - Inability of cross sex hormone therapy to inhibit natal secondary sex characteristics, luteinizing hormone (LH), or gonadotropins (e.g., menses, testosterone)

**AND**

**7** - A letter from the prescriber and/or formal documentation stating all of the following:

**7.1** Transgender patient continues to meet goals of gender-affirming hormone therapy

**AND**

**7.2** Coexisting psychiatric and medical comorbidities or social problems that may interfere with the diagnostic procedures or treatment continue to be addressed or removed

**AND**

**7.3** Both of the following:

**7.3.1** Current enrollment, attendance, and active participation in psychological and social support treatment program

**AND**

**7.3.2** Patient will continue enrollment, attendance and active participation in psychological and social support throughout the course of treatment

**AND**

**7.4** Patient demonstrates knowledge and understanding of the expected outcomes of treatment and related transgender therapies

Product Name: Lupron Depot, Lupron Depot Ped, Lupaneta Pack, Triptodur, leuprolide acetate inj kit 5 mg/mL, Fensolvi, Leuprolide acetate (3 month) 22.5 mg inj			
Diagnosis	Fertility Preservation		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 3.75 MG	21405010106405	Brand
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 7.5 MG	21405010106410	Brand
LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 11.25 MG	21405010156420	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 22.5 MG	21405010156430	Brand
LUPRON DEPOT (4-MONTH)	LEUPROLIDE ACETATE (4 MONTH) FOR INJ KIT 30 MG	21405010206430	Brand
LUPRON DEPOT (6-MONTH)	LEUPROLIDE ACETATE (6 MONTH) FOR INJ KIT 45 MG	21405010256450	Brand
LUPANETA PACK	LEUPROLIDE (1 MON) INJ 3.75 MG & NORETHINDRONE TAB 5 MG KIT	30089902506420	Brand
LUPANETA PACK	LEUPROLIDE (3 MON) INJ 11.25 MG & NORETHINDRONE TAB 5 MG KIT	30089902506440	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE INJ KIT 5 MG/ML	21405010106407	Generic
TRIPTODUR	TRIPTORELIN PAMOATE FOR IM ER SUSP 22.5 MG (BASE EQUIV)	3008007040G240	Brand
FENSOLVI	LEUPROLIDE ACET (6 MONTH) FOR INJ PEDIATRIC KIT 45 MG	30080050256450	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE (3 MONTH) FOR INJ 22.5 MG	21405010152230	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 7.5 MG	30080050106420	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 11.25 MG	30080050106430	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 15 MG	30080050106440	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 11.25 MG	30080050156420	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 30 MG	30080050156440	Brand
LUPRON DEPOT-PED	LEUPROLIDE ACET (6 MONTH) FOR IM INJ PEDIATRIC KIT 45 MG	30080050256460	Brand

**Approval Criteria**

1 - For use in pre-menopausal women

**AND**

**2** - Patient is receiving a cytotoxic agent that is associated with causing primary ovarian insufficiency (premature ovarian failure) [e.g., Cytoxan (cyclophosphamide), procarbazine, vinblastine, cisplatin]

**AND**

**3** - If the request is for Lupaneta Pack, leuprolide acetate, Triptodur, Fensolvi, history of failure, contraindication, or intolerance to Lupron Depot.

Product Name: Lupron Depot, Lupron Depot Ped, Lupaneta Pack, Triptodur, leuprolide acetate inj kit 5 mg/mL, Fensolvi, Leuprolide acetate (3 month) 22.5 mg inj			
Diagnosis	Fertility Preservation		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 3.75 MG	21405010106405	Brand
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 7.5 MG	21405010106410	Brand
LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 11.25 MG	21405010156420	Brand
LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 22.5 MG	21405010156430	Brand
LUPRON DEPOT (4-MONTH)	LEUPROLIDE ACETATE (4 MONTH) FOR INJ KIT 30 MG	21405010206430	Brand
LUPRON DEPOT (6-MONTH)	LEUPROLIDE ACETATE (6 MONTH) FOR INJ KIT 45 MG	21405010256450	Brand
LUPANETA PACK	LEUPROLIDE (1 MON) INJ 3.75 MG & NORETHINDRONE TAB 5 MG KIT	30089902506420	Brand
LUPANETA PACK	LEUPROLIDE (3 MON) INJ 11.25 MG & NORETHINDRONE TAB 5 MG KIT	30089902506440	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE INJ KIT 5 MG/ML	21405010106407	Generic

TRIPTODUR	TRIPTORELIN PAMOATE FOR IM ER SUSP 22.5 MG (BASE EQUIV)	3008007040G240	Brand
FENSOLVI	LEUPROLIDE ACET (6 MONTH) FOR INJ PEDIATRIC KIT 45 MG	30080050256450	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE (3 MONTH) FOR INJ 22.5 MG	21405010152230	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 7.5 MG	30080050106420	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 11.25 MG	30080050106430	Brand
LUPRON DEPOT-PED (1-MONTH)	LEUPROLIDE ACETATE FOR INJ PEDIATRIC KIT 15 MG	30080050106440	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 11.25 MG	30080050156420	Brand
LUPRON DEPOT-PED (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ PEDIATRIC KIT 30 MG	30080050156440	Brand
LUPRON DEPOT-PED	LEUPROLIDE ACET (6 MONTH) FOR IM INJ PEDIATRIC KIT 45 MG	30080050256460	Brand

**Approval Criteria**

1 - Patient is currently receiving gonadotropin-releasing hormone (GnRH) analog therapy for the purpose of fertility preservation

**AND**

2 - Patient continues to receive a cytotoxic agent that is associated with causing primary ovarian insufficiency (premature ovarian failure) [e.g., Cytosan (cyclophosphamide), procarbazine, vinblastine, cisplatin]

Product Name: Lupron Depot 7.5 mg, 22.5 mg, 30 mg and 45 mg, leuprolide acetate inj kit 5 mg/mL, Leuprolide acetate (3 month) 22.5 mg inj	
Diagnosis	Advanced or Metastatic Prostate Cancer
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
LUPRON DEPOT (1-MONTH)	LEUPROLIDE ACETATE FOR INJ KIT 7.5 MG	21405010106410	Brand
LUPRON DEPOT (3-MONTH)	LEUPROLIDE ACETATE (3 MONTH) FOR INJ KIT 22.5 MG	21405010156430	Brand
LUPRON DEPOT (4-MONTH)	LEUPROLIDE ACETATE (4 MONTH) FOR INJ KIT 30 MG	21405010206430	Brand
LUPRON DEPOT (6-MONTH)	LEUPROLIDE ACETATE (6 MONTH) FOR INJ KIT 45 MG	21405010256450	Brand
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE INJ KIT 5 MG/ML	21405010106407	Generic
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE (3 MONTH) FOR INJ 22.5 MG	21405010152230	Brand

**Approval Criteria**

1 - Diagnosis of advanced or metastatic prostate cancer

**2 . Revision History**

Date	Notes
6/6/2023	Added new GPI for Lupron Depot Ped.

Gralise, Horizant



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-144450
<b>Guideline Name</b>	Gralise, Horizant
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	4/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Brand Gralise, generic gabapentin (once-daily)			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GRALISE	GABAPENTIN (ONCE-DAILY) TAB 300 MG	62540030000320	Brand
GRALISE	GABAPENTIN (ONCE-DAILY) TAB 450 MG	62540030000325	Brand
GRALISE	GABAPENTIN (ONCE-DAILY) TAB 600 MG	62540030000330	Brand
GRALISE	GABAPENTIN (ONCE-DAILY) TAB 750 MG	62540030000345	Brand
GRALISE	GABAPENTIN (ONCE-DAILY) TAB 900 MG	62540030000360	Brand

GRALISE	GABAPENTIN (ONCE-DAILY) TAB PACK 300 MG (9) & 600 MG (24)	62540030006330	Brand
GABAPENTIN	GABAPENTIN (ONCE-DAILY) TAB 300 MG	62540030000320	Generic
GABAPENTIN	GABAPENTIN (ONCE-DAILY) TAB 600 MG	62540030000330	Generic

**Approval Criteria**

1 - Diagnosis of postherpetic neuralgia (PHN)

**AND**

2 - Trial and failure or intolerance to generic immediate-release gabapentin (generic for Neurontin)

**Product Name: Horizant**

Approval Length | 12 month(s)

Guideline Type | Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HORIZANT	GABAPENTIN ENACARBIL TAB ER 300 MG	62560030200420	Brand
HORIZANT	GABAPENTIN ENACARBIL TAB ER 600 MG	62560030200430	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 BOTH of the following:

1.1.1 Diagnosis of postherpetic neuralgia (PHN)

**AND**

1.1.2 Trial and failure or intolerance to generic immediate-release gabapentin (generic for Neurontin)

OR

1.2 Diagnosis of restless legs syndrome

## 2 . Revision History

Date	Notes
3/21/2024	Added new GPIs for generic gabapentin (once-daily) tablets (generic for Gralise) as targets to the guideline. Specified trial of preferred generic gabapentin is immediate-release (generic for Neurontin). For Horizant, added step through preferred IR gabapentin for PHN indication.

Growth Hormone, Growth Stimulating Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-147546
<b>Guideline Name</b>	Growth Hormone, Growth Stimulating Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Increlex, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa			
Diagnosis	Idiopathic Short Stature (ISS)		
Approval Length	N/A - Requests for non-approvable diagnoses should not be approved		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
INCRELEX	MECASERMIN INJ 40 MG/4ML (10 MG/ML)	30160045002020	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN- INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN- INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN- INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN- INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN- INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

1 - Requests for coverage for diagnosis of Idiopathic Short Stature (ISS) are not authorized and will not be approved

Notes	Approval Length: N/A - Requests for Idiopathic Short Stature (ISS) should not be approved. Deny as a benefit exclusion.
-------	---

Product Name: Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Sogroya, Ngenla, Skytrofa

Diagnosis	Non-Preferred Review
-----------	----------------------

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand

**Approval Criteria**

1 - Patient has tried and failed at least THREE preferred\* alternatives (NOTE: In instances where there are fewer than three preferred alternatives, the patient must have tried and failed ALL of the preferred products)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa			
Diagnosis	Pediatric Growth Hormone Deficiency (GHD)*		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand

NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 ONE of the following:

1.1.1 All of the following:

- Infant is less than 4 months of age
- Infant has growth deficiency
- Prescribed by an endocrinologist

**OR**

1.1.2 BOTH of the following:

- History of neonatal hypoglycemia associated with pituitary disease
- Prescribed by an endocrinologist

**OR**

**1.1.3 BOTH** of the following:

- Diagnosis of panhypopituitarism
- Prescribed by an endocrinologist

**OR**

**1.2 ALL** of the following:

**1.2.1** Diagnosis of pediatric growth hormone (GH) deficiency as confirmed by **ONE** of the following:

**1.2.1.1** Projected height (as determined by extrapolating pre-treatment growth trajectory along current channel to 18-20 year mark) is greater than 2.0 standard deviations (SD) below midparental height utilizing age and gender growth charts related to height

**OR**

**1.2.1.2** Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender) utilizing age and gender growth charts related to height

**OR**

**1.2.1.3** Growth velocity is greater than 2 SD below mean for age and gender

**OR**

**1.2.1.4** Delayed skeletal maturation of greater than 2 SD below mean for age and gender (e.g., delayed greater than 2 years compared with chronological age)

**AND**

**1.2.2 ONE** of the following:

**1.2.2.1 BOTH** of the following:

- Patient is male



- Bone age less than 16 years

**OR**

**1.2.2.2** BOTH of the following:

- Patient is female
- Bone age less than 14 years

**AND**

**1.2.3** Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following:

**1.2.3.1** BOTH of the following:

**1.2.3.1.1** Patient has undergone TWO of the following provocative GH stimulation tests:

- Arginine
- Clonidine
- Glucagon
- Insulin
- Levodopa
- Growth hormone releasing hormone

**AND**

**1.2.3.1.2** BOTH GH response values are less than 10 micrograms per liter

**OR**

**1.2.3.2** BOTH of the following:

**1.2.3.2.1** Patient is less than 1 year of age

**AND**

**1.2.3.2.2** ONE of the following is below the age and gender adjusted normal range as provided by the physician's lab:

- Insulin-like Growth Factor 1 (IGF-1/Somatomedin-C)
- Insulin Growth Factor Binding Protein-3 (IGFBP-3)

**AND**

**1.2.4 ONE of the following:**

**1.2.4.1** Request does not exceed a maximum supply limit of 0.3 milligrams per kilogram per week

**OR**

**1.2.4.2 BOTH of the following:**

- Tanner Stage 3 or greater
- Request does not exceed a maximum supply limit of 0.7 milligrams per kilogram per week

**AND**

**1.2.5 Prescribed by an endocrinologist**

Notes	*Includes children who have undergone brain radiation. If patient is a Transition Phase Adolescent or Adult who had childhood onset GH deficiency, utilize criteria for Transition Phase Adolescent or Adult GH D deficiency.
-------	---

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa			
Diagnosis	Pediatric Growth Hormone Deficiency (GHD)*		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPOR	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPOR	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPOR	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPOR	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand

SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand
----------	---	----------------	-------

**Approval Criteria**

**1** - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:\*\*

- Previous height and date obtained
- Current height and date obtained

**AND**

**2** - BOTH of the following:\*\*

- Expected adult height not attained
- Documentation of expected adult height goal (e.g., genetic potential)

**AND**

**3** - Calculated height (growth) velocity over the past 12 months

**AND**

**4** - ONE of the following:

**4.1** BOTH of the following:

- Patient is male
- Bone age less than 16 years

**OR**

**4.2** BOTH of the following:

- Patient is female
- Bone age less than 14 years

**AND**

**5** - ONE of the following:

**5.1** Request does not exceed a maximum supply limit of 0.3 milligrams per kilogram per week

**OR**

**5.2** BOTH of the following:

- Tanner Stage 3 or greater
- Request does not exceed a maximum supply limit of 0.7 milligrams per kilogram per week

**AND**

**6** - Prescribed by an endocrinologist

Notes	<p>*Includes children who have undergone brain radiation. If patient is a Transition Phase Adolescent or Adult who had childhood onset GH deficiency, utilize criteria for Transition Phase Adolescent or Adult GH D deficiency.</p> <p>**Documentation of previous height, current height and goal expected adult height will be required for renewal.</p>
-------	---

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa			
Diagnosis	Prader-Willi Syndrome		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXP	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXP	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXP	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXP	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand



**Approval Criteria**

1 - Diagnosis of Prader-Willi Syndrome

**AND**

2 - Prescribed by an endocrinologist

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa

Diagnosis	Prader-Willi Syndrome
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand

SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

1 - ONE of the following criteria:

1.1 BOTH of the following:

1.1.1 Evidence of positive response to therapy (e.g., increase in total lean body mass, decrease in fat mass)

**AND**

1.1.2 Prescribed by an endocrinologist

**OR**

**1.2 ALL of the following:**

**1.2.1** Height increase of at least 2 centimeters per year over the previous year of treatment as documented by BOTH of the following:

- Previous height and date obtained
- Current height and date obtained

**AND**

**1.2.2** BOTH of the following:

- Expected adult height not attained
- Documentation of expected adult height goal

**AND**

**1.2.3** Prescribed by an endocrinologist

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa			
Diagnosis	Growth Failure in Children Small for Gestational Age (SGA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN- INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN- INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN- INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN- INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN- INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

**1** - Diagnosis of small for gestational age (SGA) based on demonstration of catch up growth failure in the first 24 months of life using a 0-36 month growth chart as confirmed by documentation that ONE of the following is below the third percentile for gestational age [more than 2 standard deviations (SD) below population mean]:

- Birth weight
- Birth length

**AND**

**2** - Documentation that height remains less than or equal to the third percentile (more than 2 SD below population mean)

**AND**

**3** - Prescribed by an endocrinologist

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa

Diagnosis	Growth Failure in Children Small for Gestational Age (SGA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN- INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN- INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN- INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN- INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN- INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEGSSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEGSSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEGSSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEGSSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEGSSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEGSSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEGSSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEGSSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

1 - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:\*

- Previous height and date obtained
- Current height and date obtained

**AND**

**2 - Documentation of BOTH of the following:\***

- Expected adult height not attained
- Expected adult height goal

**AND**

**3 - Prescribed by an endocrinologist**

Notes	*Documentation of previous height, current height, and goal expected adult height will be required for renewal.
-------	---

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa

Diagnosis	Turner Syndrome or Noonan Syndrome
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

1 - Diagnosis of pediatric growth failure associated with ONE of the following:

1.1 BOTH of the following:

1.1.1 Turner Syndrome (Gonadal Dysgenesis)

**AND**

**1.1.2** BOTH of the following:

- Patient is female
- Bone age less than 14 years

**OR**

**1.2** BOTH of the following:

**1.2.1** Noonan Syndrome

**AND**

**1.2.2** ONE of the following:

**1.2.2.1** BOTH of the following:

- Patient is male
- Bone age less than 16 years

**OR**

**1.2.2.2** BOTH of the following:

- Patient is female
- Bone age less than 14 years

**AND**

**2** - Height is below the fifth percentile on growth charts for age and gender

**AND**

**3 - Prescribed by an endocrinologist**

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa

Diagnosis	Turner Syndrome or Noonan Syndrome
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand

NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

**1** - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:\*

- Previous height and date obtained
- Current height and date obtained

**AND**

**2** - Documentation of BOTH of the following:\*

- Expected adult height not attained
- Expected adult height goal

**AND**

**3** - Prescribed by an endocrinologist

Notes

\*Documentation of previous height, current height and goal expected adult height will be required for renewal.



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa			
Diagnosis	Short-Stature Homeobox (SHOX) Gene Deficiency		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand

SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

1 - Diagnosis of pediatric growth failure with short-stature homeobox (SHOX) gene deficiency as confirmed by genetic testing

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

- Patient is male
- Bone age less than 16 years

**OR**

2.2 BOTH of the following:

- Patient is female
- Bone age less than 14 years

**AND**

**3 - Prescribed by an endocrinologist**

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa

Diagnosis	Short-Stature Homeobox (SHOX) Gene Deficiency
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand

NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

**1** - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:\*

- Previous height and date obtained
- Current height and date obtained

**AND**

**2** - Documentation of BOTH of the following:\*

- Expected adult height not attained
- Expected adult height goal

**AND**

**3** - Prescribed by an endocrinologist

Notes	*Documentation of previous height, current height, and goal expected adult height will be required for renewal.
-------	---

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa			
Diagnosis	Growth Failure associated with Chronic Renal Insufficiency		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand



SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

1 - Diagnosis of pediatric growth failure associated with chronic renal insufficiency

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

- Patient is male
- Bone age less than 16 years

**OR**

2.2 BOTH of the following:

- Patient is female
- Bone age less than 14 years

**AND**

**3** - Prescribed by ONE of the following:

- Endocrinologist
- Nephrologist

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa

Diagnosis	Growth Failure associated with Chronic Renal Insufficiency
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand

SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

**1 - Height increase of at least 2 centimeters per year over the previous year documented by BOTH of the following:\***

- Previous height and date obtained
- Current height and date obtained

**AND**

**2 - Documentation of BOTH of the following:\***

- Expected adult height not attained
- Expected adult height goal

**AND**

**3** - Prescribed by ONE of the following:

- Endocrinologist
- Nephrologist

Notes	*Documentation of previous height, current height, and goal expected adult height will be required for renewal.
-------	---

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa

Diagnosis	Adult Growth Hormone Deficiency
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand

SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

1 - Diagnosis of adult growth hormone deficiency (GHD) as a result of ONE of the following:

1.1 Clinical records supporting a diagnosis of childhood-onset GHD

**OR**

1.2 BOTH of the following:

1.2.1 Adult-onset GHD

**AND**

**1.2.2** Clinical records documenting that hormone deficiency is a result of hypothalamic-pituitary disease from organic or known causes (e.g., damage from surgery, cranial irradiation, head trauma, or subarachnoid hemorrhage)

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following:

**2.1** BOTH of the following:

**2.1.1** Patient has undergone ONE of the following GH (growth hormone) stimulation tests to confirm adult GH deficiency:

- Insulin tolerance test (ITT)
- ARG (Arginine) and GHRH (growth hormone releasing hormone)
- Glucagon
- ARG

**AND**

**2.1.2** ONE of the following peak GH values:

**2.1.2.1** ITT less than or equal to 5 micrograms per liter

**OR**

**2.1.2.2** GHRH and ARG of ONE of the following:

- Less than or equal to 11 micrograms per liter (mcg/L) if body mass index (BMI) is less than 25 kilograms per square meter ( $\text{kg}/\text{m}^2$ )
- Less than or equal to 8 mcg/L if BMI is greater than or equal to 25 and less than 30  $\text{kg}/\text{m}^2$
- Less than or equal to 4 mcg/L if BMI is greater than or equal to 30  $\text{kg}/\text{m}^2$

**OR**

**2.1.2.3** Glucagon less than or equal to 3 mcg/L



**OR**

**2.1.2.4** ARG less than or equal to 0.4 mcg/L

**OR**

**2.2** BOTH of the following:

**2.2.1** Submission of medical records (e.g., chart notes, laboratory values) documenting deficiency of THREE of the following anterior pituitary hormones:

- Prolactin
- ACTH (adrenocorticotrophic hormone)
- TSH (thyroid stimulating hormone)
- FSH/LH (follicle-stimulating hormone/luteinizing hormone)

**AND**

**2.2.2** Insulin-like Growth Factor 1 (IGF-1)/Somatomedin-C level is below the age and gender adjusted normal range as provided by the physician's lab

**AND**

**3** - ONE of the following:

**3.1** Diagnosis of panhypopituitarism

**OR**

**3.2** Other diagnosis and NOT used in combination with any of the following:

- Aromatase inhibitors [e.g., Arimidex (anastrozole), Femara (letrozole)]
- Androgens [e.g., Delatestryl (testosterone enanthate), Depo-Testosterone (testosterone cypionate)]

**AND**

**4** - Request does not exceed a maximum supply limit of 0.3 milligrams per kilogram per week

**AND**

**5** - Prescribed by an endocrinologist

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa

Diagnosis	Adult Growth Hormone Deficiency
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPPO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand

SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

1 - Documentation of Insulin-like Growth Factor 1 (IGF-1)/Somatomedin C level within the past 12 months

**AND**

2 - ONE of the following:

2.1 Diagnosis of panhypopituitarism

**OR**

2.2 Other diagnosis and NOT used in combination with any of the following:

- Aromatase inhibitors [e.g., Arimidex (anastrozole), Femara (letrozole)]
- Androgens [e.g., Delatestryl (testosterone enanthate), Depo-Testosterone (testosterone cypionate)]

**AND**

**3** - Request does not exceed a maximum supply limit of 0.3 milligrams per kilogram per week

**AND**

**4** - Prescribed by an endocrinologist

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa

Diagnosis	Transition Phase Adolescent Patients
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand

NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEGSOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

1 - Request does not exceed a maximum supply limit of 0.3 milligrams per kilogram per week

**AND**

2 - Documentation of ONE of the following:

- Attained expected adult height

- Closed epiphyses on bone radiograph

**AND**

**3** - Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following:

**3.1** BOTH of the following:

**3.1.1** Documentation of high risk of growth hormone (GH) deficiency due to GH deficiency in childhood from ONE of the following:

**3.1.1.1** Embryopathic/congenital defects

**OR**

**3.1.1.2** Genetic mutations

**OR**

**3.1.1.3** Irreversible structural hypothalamic-pituitary disease

**OR**

**3.1.1.4** Panhypopituitarism

**OR**

**3.1.1.5** Deficiency of THREE of the following anterior pituitary hormones:

- ACTH (adrenocorticotrophic hormone)
- TSH (thyroid stimulating hormone)
- Prolactin
- FSH/LH (follicle-stimulating hormone/luteinizing hormone)

**AND**



**3.1.2 ONE of the following:**

**3.1.2.1** Insulin-like Growth Factor 1 (IGF-1)/Somatomedin-C level is below the age and gender adjusted normal range as provided by the physician's lab

**OR**

**3.1.2.2 ALL of the following:**

**3.1.2.2.1** Patient does not have a low IGF-1/Somatomedin C level

**AND**

**3.1.2.2.2** Discontinued GH therapy for at least 1 month

**AND**

**3.1.2.2.3** Patient has undergone ONE of the following GH stimulation tests after discontinuation of therapy for at least 1 month:

- Insulin tolerance test (ITT)
- ARG (Arginine) and GHRH (growth hormone releasing hormone)
- ARG
- Glucagon

**AND**

**3.1.2.2.4 ONE of the following peak GH values:**

**3.1.2.2.4.1** ITT less than or equal to 5 micrograms per liter (mcg/L)

**OR**

**3.1.2.2.4.2** GHRH and ARG of ONE of the following:

- Less than or equal to 11 mcg/L if body mass index (BMI) is less than 25 kilograms per square meter ( $\text{kg}/\text{m}^2$ )

- Less than or equal to 8 mcg/L if BMI is greater than or equal to 25 and less than 30 kg/m<sup>2</sup>
- Less than or equal to 4 mcg/L if BMI is greater than or equal to 30 kg/m<sup>2</sup>

**OR**

**3.1.2.2.4.3** Glucagon less than or equal to 3 mcg/L

**OR**

**3.1.2.2.4.4** ARG less than or equal to 0.4 mcg/L

**OR**

**3.2** ALL of the following:

**3.2.1** At low risk of severe GH deficiency (e.g., due to isolated and/or idiopathic GH deficiency)

**AND**

**3.2.2** Discontinued GH therapy for at least 1 month

**AND**

**3.2.3** BOTH of the following:

**3.2.3.1** Patient has undergone ONE of the following GH stimulation tests after discontinuation of therapy for at least 1 month:

- ITT
- GHRH and ARG
- ARG

- Glucagon

**AND**

**3.2.3.2** ONE of the following peak GH values:

**3.2.3.2.1** ITT less than or equal to 5 mcg/L

**OR**

**3.2.3.2.2** GHRH and ARG of ONE of the following:

- Less than or equal to 11 mcg/L if BMI is less than 25 kg/m<sup>2</sup>
- Less than or equal to 8 mcg/L if BMI is greater than or equal to 25 and less than 30 kg/m<sup>2</sup>
- Less than or equal to 4 mcg/L if BMI is greater than or equal to 30 kg/m<sup>2</sup>

**OR**

**3.2.3.2.3** Glucagon less than or equal to 3 mcg/L

**OR**

**3.2.3.2.4** ARG less than or equal to 0.4 mcg/L

**AND**

**4** - Prescribed by an endocrinologist

Product Name: Genotropin, Genotropin Miniquick, Humatrope, Omnitrope, Saizen, Saizenprep, Serostim, Zomacton, Zorbtive, Nutropin AQ Nuspin, Norditropin Flexpro, Sogroya, Ngenla, Skytrofa	
Diagnosis	Transition Phase Adolescent Patients
Approval Length	12 month(s)
Therapy Stage	Reauthorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 5 MG	3010002000E159	Brand
GENOTROPIN	SOMATROPIN FOR SUBCUTANEOUS INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E188	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.2 MG	3010002000E404	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.4 MG	3010002000E407	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.6 MG	3010002000E410	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 0.8 MG	3010002000E413	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1 MG	3010002000E416	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.2 MG	3010002000E419	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.4 MG	3010002000E422	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.6 MG	3010002000E425	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 1.8 MG	3010002000E428	Brand
GENOTROPIN MINIQUICK	SOMATROPIN FOR SUBCUTANEOUS INJ PREFILLED SYR 2 MG	3010002000E431	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 6 MG (18 UNIT)	3010002000E120	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 12 MG (36 UNIT)	3010002000E130	Brand
HUMATROPE	SOMATROPIN FOR INJ CARTRIDGE 24 MG	3010002000E140	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 5 MG/1.5ML	3010002000E210	Brand
OMNITROPE	SOMATROPIN SOLUTION CARTRIDGE 10 MG/1.5ML	3010002000E213	Brand
OMNITROPE	SOMATROPIN FOR INJ 5.8 MG	30100020002123	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 5 MG	30100020102120	Brand
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand
SAIZEN	SOMATROPIN (NON-REFRIGERATED) FOR INJ 8.8 MG	30100020102130	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand
ZOMACTON	SOMATROPIN FOR SUBCUTANEOUS INJ 5 MG	30100020002121	Brand
ZOMACTON	SOMATROPIN FOR INJ 10 MG	30100020002140	Brand
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand
NUTROPIN AQ NUSPIN 5	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/2ML	3010002000D207	Brand
NUTROPIN AQ NUSPIN 10	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/2ML	3010002000D220	Brand
NUTROPIN AQ NUSPIN 20	SOMATROPIN SOLUTION PEN-INJECTOR 20 MG/2ML	3010002000D250	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010002000D212	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010002000D230	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010002000D240	Brand
NORDITROPIN FLEXPRO	SOMATROPIN SOLUTION PEN-INJECTOR 30 MG/3ML	3010002000D260	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 5 MG/1.5ML	3010000720D210	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 10 MG/1.5ML	3010000720D220	Brand
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR 15 MG/1.5ML	3010000720D230	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 24 MG/1.2ML (20 MG/ML)	3010001500D220	Brand
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR 60 MG/1.2ML (50 MG/ML)	3010001500D240	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3 MG	3010000380E110	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 3.6 MG	3010000380E115	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 4.3 MG	3010000380E120	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 5.2 MG	3010000380E125	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 6.3 MG	3010000380E130	Brand

SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 7.6 MG	3010000380E135	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 9.1 MG	3010000380E140	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CARTRIDGE 11 MG	3010000380E145	Brand
SKYTROFA	LONAPEG SOMATROPIN-TCGD FOR SUBCUTANEOUS INJ CART 13.3 MG	3010000380E150	Brand

**Approval Criteria**

1 - Documentation of positive response to therapy [e.g., increase in total lean body mass, exercise capacity or IGF-1 (Insulin-like Growth Factor 1) and IGFBP-3 (Insulin-like growth factor binding protein 3) levels]

**AND**

2 - Request does not exceed a maximum supply limit of 0.3 milligrams per kilogram per week

**AND**

3 - Prescribed by an endocrinologist

<b>Product Name: Serostim</b>			
Diagnosis	Human Immunodeficiency Virus (HIV)-associated wasting syndrome or cachexia		
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand

**Approval Criteria**

**1** - Diagnosis of human immunodeficiency virus (HIV)-associated wasting syndrome or cachexia

**AND**

**2** - Documentation of ONE of the following:

**2.1** Unintentional weight loss of greater than 10 percent over the last 12 months

**OR**

**2.2** Unintentional weight loss of greater than 7.5 percent over the last 6 months

**OR**

**2.3** Loss of 5 percent body cell mass (BCM) within 6 months

**OR**

**2.4** Body mass index (BMI) less than 20 kilograms per square meter (kg/m<sup>2</sup>)

**OR**

**2.5** ONE of the following:

**2.5.1** ALL of the following:

- Patient is male
- BCM less than 35 percent of total body weight
- BMI less than 27 kg/m<sup>2</sup>

**OR**

**2.5.2** ALL of the following:

- Patient is female
- BCM less than 23 percent of total body weight
- BMI less than 27 kg/m<sup>2</sup>

**AND**

**3** - A nutritional evaluation has been completed since onset of wasting first occurred

**AND**

**4** - Patient has not had weight loss as a result of other underlying treatable conditions (e.g., depression, mycobacterium avium complex, chronic infectious diarrhea, or malignancy with the exception of Kaposi's sarcoma limited to skin or mucous membranes)

**AND**

**5** - Patient's anti-retroviral therapy has been optimized to decrease the viral load

Product Name: Serostim			
Diagnosis	Human Immunodeficiency Virus (HIV)-associated wasting syndrome or cachexia		
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 4 MG	30100020102118	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 5 MG	30100020102121	Brand
SEROSTIM	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 6 MG	30100020102125	Brand



**Approval Criteria**

1 - Evidence of positive response to therapy [i.e., greater than or equal to 2 percent increase in body weight and/or body cell mass (BCM)]

**AND**

2 - ONE of the following targets or goals has not been achieved:

- Weight
- BCM
- Body Mass Index (BMI)

Product Name: Zorbtive\*

Diagnosis	Short Bowel Syndrome
-----------	----------------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
ZORBTIVE	SOMATROPIN (NON-REFRIGERATED) FOR SUBCUTANEOUS INJ 8.8 MG	30100020102132	Brand

**Approval Criteria**

1 - Diagnosis of Short Bowel Syndrome

**AND**

2 - Patient is currently receiving specialized nutritional support (e.g., intravenous parenteral nutrition, fluid, and micronutrient supplements)

**AND**

3 - Patient has not previously received 4 weeks of treatment with Zorbtive\*

Notes	*Treatment with Zorbtive will not be authorized beyond 4 weeks. Administration for more than 4 weeks has not been adequately studied.
-------	---

Product Name: Increlex	
Diagnosis	Severe Primary IGF-1 Deficiency/Growth Hormone Gene Deletion
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
INCRELEX	MECASERMIN INJ 40 MG/4ML (10 MG/ML)	30160045002020	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 Documentation of ALL of the following:

1.1.1 Diagnosis of severe primary Insulin-like Growth Factor 1 (IGF-1) deficiency

**AND**

1.1.2 Height standard deviation score less than or equal to -3.0

**AND**

1.1.3 Basal IGF-1 standard deviation score less than or equal to -3.0

**AND**

1.1.4 Normal or elevated growth hormone levels

**AND**

**1.1.5** Documentation of open epiphyses on last bone radiograph

**AND**

**1.1.6** The patient will not be treated with concurrent growth hormone therapy

**AND**

**1.1.7** Prescribed by an endocrinologist

**OR**

**1.2** ALL of the following:

**1.2.1** Diagnosis of growth hormone gene deletion and has developed neutralizing antibodies to growth hormone

**AND**

**1.2.2** Documentation of open epiphyses on last bone radiograph

**AND**

**1.2.3** The patient will not be treated with concurrent growth hormone therapy

**AND**

**1.2.4** Prescribed by an endocrinologist

Product Name: Increlex	
Diagnosis	Severe Primary IGF-1 Deficiency/Growth Hormone Gene Deletion
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
INCRELEX	MECASERMIN INJ 40 MG/4ML (10 MG/ML)	30160045002020	Brand
<p><b>Approval Criteria</b></p> <p><b>1 - Height increase of at least 2 centimeters per year over the previous year of treatment as documented by BOTH of the following:*</b></p> <ul style="list-style-type: none"> <li>• Previous height and date obtained</li> <li>• Current height and date obtained</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2 - Documentation of BOTH of the following:*</b></p> <ul style="list-style-type: none"> <li>• Expected adult height not obtained</li> <li>• Expected adult height goal</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>3 - Patient is not treated with concurrent growth hormone therapy</b></p> <p style="text-align: center;"><b>AND</b></p> <p><b>4 - Prescribed by an endocrinologist</b></p>			
Notes		*Documentation of previous height, current height, and goal expected adult height will be required for renewal.	

**2 . Revision History**

Date	Notes
5/20/2024	Specified approval length of 12 months for NP section.



HCG



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140654
<b>Guideline Name</b>	HCG
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	11/1/2020
-----------------	-----------

### 1 . Criteria

Product Name: Novarel, Ovidrel, Brand Pregnyl, generic chorionic gonadotropin			
Diagnosis	Prepubertal Cryptorchidism		
Approval Length	6 Week(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NOVAREL	CHORIONIC GONADOTROPIN FOR IM INJ 5000 UNIT	30062020002130	Brand
OVIDREL	CHORIOGONADOTROPIN ALFA INJ 250 MCG/0.5ML	3006202205E520	Brand
CHORIONIC GONADOTROPIN	CHORIONIC GONADOTROPIN FOR IM INJ 10000 UNIT	30062020002140	Generic
PREGNYL W/DILUENT	CHORIONIC GONADOTROPIN FOR IM INJ 10000 UNIT	30062020002140	Generic

BENZYL ALCOHOL/NACL			
NOVAREL	CHORIONIC GONADOTROPIN FOR IM INJ 10000 UNIT	30062020002140	Generic

**Approval Criteria**

1 - Diagnosis of prepubertal cryptorchidism not due to anatomical obstruction

Hemangeol



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140640
<b>Guideline Name</b>	Hemangeol
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Hemangeol			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HEMANGEOL	PROPRANOLOL HCL ORAL SOLN 4.28 MG/ML (3.75 MG/ML BASE EQUIV)	33100040102080	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of proliferating infantile hemangioma			



**AND**

**2** - Prescriber provides a reason or special circumstance the patient cannot use generic propranolol oral solution

## **2 . Revision History**

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Hemophilia Clotting Factors



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-145464
<b>Guideline Name</b>	Hemophilia Clotting Factors
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Corifact			
Diagnosis	Congenital Factor XIII Deficiency (i.e., Fibrin Stabilizing Factor Deficiency)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CORIFACT	FACTOR XIII CONCENTRATE (HUMAN) FOR INJ KIT 1000-1600 UNIT	85100033006440	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of congenital factor XIII deficiency

**AND**

2 - ONE of the following:

- Routine prophylactic treatment of bleeding
- Peri-operative management of surgical bleeding
- Treatment of bleeding episodes

Product Name: Tretten

Diagnosis	Congenital Factor XIII Deficiency (i.e., Fibrin Stabilizing Factor Deficiency)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TRETTEN	COAGULATION FACTOR XIII A-SUBUNIT FOR INJ 2000-3125 UNIT	85100032102130	Brand

**Approval Criteria**

1 - Diagnosis of congenital factor XIII A-subunit deficiency

**AND**

2 - ONE of the following:

- Routine prophylactic treatment of bleeding
- Peri-operative management of surgical bleeding
- Treatment of bleeding episodes

Product Name: Humate-P

Diagnosis	Von Willebrand Disease (VWD)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMATE-P	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 250-600 UNIT	85100015102122	Brand
HUMATE-P	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 500-1200 UNIT	85100015102132	Brand
HUMATE-P	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 1000-2400 UNIT	85100015102144	Brand

**Approval Criteria**

1 - One of the following:

1.1 Diagnosis of severe von Willebrand disease

**OR**

1.2 BOTH of the following:

- Diagnosis of mild or moderate von Willebrand disease
- History of failure, contraindication or intolerance to treatment with desmopressin

**AND**

2 - ONE of the following:

- Treatment of bleeding episodes
- Peri-operative management of surgical bleeding

Product Name: Alphanate	
Diagnosis	Von Willebrand Disease (VWD)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ALPHANATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 250 UNIT	85100015102160	Brand
ALPHANATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 500 UNIT	85100015102170	Brand
ALPHANATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 1000 UNIT	85100015102180	Brand
ALPHANATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 1500 UNIT	85100015102190	Brand
ALPHANATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 2000 UNIT	85100015102193	Brand

**Approval Criteria**

1 - Diagnosis of mild or moderate von Willebrand disease

**AND**

2 - Used for peri-operative management of surgical bleeding

**AND**

3 - History of failure, contraindication or intolerance to treatment with desmopressin

**Product Name: Wilate or Vonvendi**

Diagnosis	Von Willebrand Disease (VWD)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
WILATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 500-500 UNIT KIT	85100015106430	Brand
WILATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 1000-1000 UNIT KIT	85100015106440	Brand
VONVENDI	VON WILLEBRAND FACTOR (RECOMBINANT) FOR INJ 650 UNIT	85100070202120	Brand

VONVENDI	VON WILLEBRAND FACTOR (RECOMBINANT) FOR INJ 1300 UNIT	85100070202130	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of von Willebrand disease</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Treatment of bleeding episodes</li> <li>• Peri-operative management of surgical bleeding</li> <li>• Routine prophylactic treatment</li> </ul>			

Product Name: NovoSeven RT			
Diagnosis	Congenital Factor VII Deficiency		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 1 MG (1000 MCG)	85100026202117	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 2 MG (2000 MCG)	85100026202126	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 5 MG (5000 MCG)	85100026202145	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 8 MG (8000 MCG)	85100026202160	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of congenital factor VII deficiency</p>			

**AND**

**2 - ONE** of the following:

- Treatment of bleeding episodes
- Routine prophylactic treatment of bleeding

Product Name: Advate, Alphanate, Humate-P, Hemofil M, KoAte, KoAte-DVI, Kogenate FS, Kovaltry, NovoEight, Nuwiq, Recombinate, Xyntha, or Xyntha Solofuse			
Diagnosis	Hemophilia A (i.e., Factor VIII Deficiency, Classical Hemophilia)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ADVATE	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 1500 UNIT	85100010252150	Brand
XYNTHA	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII,MOR) FOR INJ KIT 2000 UNIT	85100010266460	Brand
HUMATE-P	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 250-600 UNIT	85100015102122	Brand
HUMATE-P	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 500-1200 UNIT	85100015102132	Brand
HUMATE-P	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 1000-2400 UNIT	85100015102144	Brand
HEMOFIL M	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ 250 UNIT	85100010002110	Brand
KOATE	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ 250 UNIT	85100010002110	Brand
HEMOFIL M	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ 500 UNIT	85100010002130	Brand
KOATE	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ 500 UNIT	85100010002130	Brand
KOATE-DVI	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ 500 UNIT	85100010002130	Brand
HEMOFIL M	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ 1000 UNIT	85100010002140	Brand
KOATE	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ 1000 UNIT	85100010002140	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

KOATE-DVI	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ 1000 UNIT	85100010002140	Brand
HEMOPIL M	ANTIHEMOPHILIC FACTOR (HUMAN) FOR INJ 1700 UNIT	85100010002146	Brand
NOVOEIGHT	ANTIHEMOPHILIC FACT RCMB (BD TRUNC-RFVIII) FOR INJ 250 UNIT	85100010332120	Brand
NOVOEIGHT	ANTIHEMOPHILIC FACT RCMB (BD TRUNC-RFVIII) FOR INJ 500 UNIT	85100010332130	Brand
NOVOEIGHT	ANTIHEMOPHILIC FACT RCMB (BD TRUNC-RFVIII) FOR INJ 1000 UNIT	85100010332140	Brand
NOVOEIGHT	ANTIHEMOPHILIC FACT RCMB (BD TRUNC-RFVIII) FOR INJ 2000 UNIT	85100010332160	Brand
NOVOEIGHT	ANTIHEMOPHILIC FACT RCMB (BD TRUNC-RFVIII) FOR INJ 3000 UNIT	85100010332170	Brand
KOVALTRY	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 250 UNIT	85100010252120	Brand
KOVALTRY	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 500 UNIT	85100010252130	Brand
KOVALTRY	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 1000 UNIT	85100010252140	Brand
KOVALTRY	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 2000 UNIT	85100010252170	Brand
NUWIQ	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII,SIM) FOR INJ 250 UNIT	85100010222120	Brand
NUWIQ	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII,SIM) FOR INJ 500 UNIT	85100010222130	Brand
NUWIQ	ANTIHEMOPHILIC FACT RCMB (BDD-RFVIII,SIM) FOR INJ 1000 UNIT	85100010222140	Brand
NUWIQ	ANTIHEMOPHILIC FACT RCMB (BDD-RFVIII,SIM) FOR INJ 2000 UNIT	85100010222160	Brand
NUWIQ	ANTIHEMOPHILIC FACT RCMB (BDD-RFVIII,SIM) FOR INJ 2500 UNIT	85100010222165	Brand
NUWIQ	ANTIHEMOPHILIC FACT RCMB (BDD-RFVIII,SIM) FOR INJ 3000 UNIT	85100010222170	Brand
NUWIQ	ANTIHEMOPHILIC FACT RCMB (BDD-RFVIII,SIM) FOR INJ 4000 UNIT	85100010222180	Brand
NUWIQ	ANTIHEMOPHILIC FACT RCMB (BDD-RFVIII,SIM) FOR INJ KIT 250 UNIT	85100010226420	Brand
NUWIQ	ANTIHEMOPHILIC FACT RCMB (BDD-RFVIII,SIM) FOR INJ KIT 500 UNIT	85100010226430	Brand
NUWIQ	ANTIHEMOPHILIC FACT RCMB (BDD-RFVIII,SIM) FOR INJ KIT 1000 UNIT	85100010226440	Brand
NUWIQ	ANTIHEMOPHILIC FACT RCMB (BDD-RFVIII,SIM) FOR INJ KIT 2000 UNIT	85100010226460	Brand
NUWIQ	ANTIHEMOPHILIC FACT RCMB (BDD-RFVIII,SIM) FOR INJ KIT 2500 UNIT	85100010226465	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NUWIQ	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII,SIM) FOR INJ KIT 3000 UNIT	85100010226470	Brand
NUWIQ	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII,SIM) FOR INJ KIT 4000 UNIT	85100010226480	Brand
NOVOEIGHT	ANTIHEMOPHILIC FACT RCMB (BD TRUNC-RFVIII) FOR INJ 1500 UNIT	85100010332150	Brand
KOVALTRY	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 3000 UNIT	85100010252180	Brand
ADVATE	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 250 UNIT	85100010252120	Brand
ADVATE	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 500 UNIT	85100010252130	Brand
ADVATE	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 1000 UNIT	85100010252140	Brand
ADVATE	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 2000 UNIT	85100010252170	Brand
ADVATE	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 3000 UNIT	85100010252180	Brand
ADVATE	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM) FOR INJ 4000 UNIT	85100010252185	Brand
XYNTHA	ANTIHEMOPHIL FACT RCMB (BDD-RFVIII,MOR) FOR INJ KIT 250 UNIT	85100010266420	Brand
XYNTHA SOLOFUSE	ANTIHEMOPHIL FACT RCMB (BDD-RFVIII,MOR) FOR INJ KIT 250 UNIT	85100010266420	Brand
XYNTHA	ANTIHEMOPHIL FACT RCMB (BDD-RFVIII,MOR) FOR INJ KIT 500 UNIT	85100010266430	Brand
XYNTHA SOLOFUSE	ANTIHEMOPHIL FACT RCMB (BDD-RFVIII,MOR) FOR INJ KIT 500 UNIT	85100010266430	Brand
XYNTHA	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII,MOR) FOR INJ KIT 1000 UNIT	85100010266440	Brand
XYNTHA SOLOFUSE	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII,MOR) FOR INJ KIT 1000 UNIT	85100010266440	Brand
XYNTHA SOLOFUSE	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII,MOR) FOR INJ KIT 2000 UNIT	85100010266460	Brand
XYNTHA SOLOFUSE	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII,MOR) FOR INJ KIT 3000 UNIT	85100010266470	Brand
ALPHANATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 250 UNIT	85100015102160	Brand
ALPHANATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 500 UNIT	85100015102170	Brand
ALPHANATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 1000 UNIT	85100015102180	Brand
ALPHANATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 1500 UNIT	85100015102190	Brand
ALPHANATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 2000 UNIT	85100015102193	Brand

NUWIQ	ANTIHEMOPHILIC FACT RCMB (BDD-RFVIII,SIM) FOR INJ 1500 UNIT	85100010222150	Brand
NUWIQ	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII,SIM) FOR INJ KIT 1500 UNIT	85100010226450	Brand
KOGENATE FS	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ KIT 250 UNIT	85100010206420	Brand
KOGENATE FS	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ KIT 500 UNIT	85100010206430	Brand
KOGENATE FS	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ KIT 1000 UNIT	85100010206440	Brand
KOGENATE FS	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ KIT 2000 UNIT	85100010206450	Brand
KOGENATE FS	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ KIT 3000 UNIT	85100010206460	Brand
RECOMBINATE	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ 220-400 UNIT	85100010202115	Brand
RECOMBINATE	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ 401-800 UNIT	85100010202125	Brand
RECOMBINATE	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ 801-1240 UNIT	85100010202135	Brand
RECOMBINATE	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ 1241-1800 UNIT	85100010202145	Brand
RECOMBINATE	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII) FOR INJ 1801-2400 UNIT	85100010202155	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia A

**AND**

2 - ONE of the following:

- Routine prophylactic treatment of bleeding
- Peri-operative management of surgical bleeding
- Treatment of bleeding episodes

Product Name: Eloctate	
Diagnosis	Hemophilia A (i.e., Factor VIII Deficiency, Classical Hemophilia)

Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ELOCTATE	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII FC) FOR INJ 6000 UNIT	85100010302180	Brand
ELOCTATE	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII FC) FOR INJ 250 UNIT	85100010302120	Brand
ELOCTATE	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII FC) FOR INJ 500 UNIT	85100010302125	Brand
ELOCTATE	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII FC) FOR INJ 750 UNIT	85100010302130	Brand
ELOCTATE	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII FC) FOR INJ 1000 UNIT	85100010302135	Brand
ELOCTATE	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII FC) FOR INJ 1500 UNIT	85100010302145	Brand
ELOCTATE	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII FC) FOR INJ 2000 UNIT	85100010302155	Brand
ELOCTATE	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII FC) FOR INJ 3000 UNIT	85100010302165	Brand
ELOCTATE	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII FC) FOR INJ 4000 UNIT	85100010302170	Brand
ELOCTATE	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIII FC) FOR INJ 5000 UNIT	85100010302175	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia A

**AND**

2 - ONE of the following:

- Routine prophylactic treatment of bleeding
- Peri-operative management of surgical bleeding
- Treatment of bleeding episodes

**AND**

3 - Patient is not a suitable candidate for treatment with shorter half-life Factor VIII

(recombinant) products [e.g., Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or Recombinate] as attested by the prescribing physician

**AND**

**4 - ONE of the following:**

**4.1 BOTH of the following:**

- Dose does not exceed 50 IU/kg
- Infusing no more frequently than every 4 days

**OR**

**4.2 Requested dosage regimen does not exceed 12.5 IU/kg/day**

**OR**

**4.3 BOTH of the following:**

**4.3.1 Patient is less than 6 years of age**

**AND**

**4.3.2 ONE of the following:**

- Pharmacokinetic (PK) testing results suggest that dosing more intensive than 50 IU/kg is required
- PK testing results suggest that dosing more frequently than every 3 to 5 days is required
- PK testing results suggest that dosing more intensive than 14.5 IU/kg/day is required

Product Name: Jivi	
Diagnosis	Hemophilia A (i.e., Factor VIII Deficiency, Classical Hemophilia)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
JIVI	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII PEG-AUCL)FOR INJ 3000 UNIT	85100010412160	Brand
JIVI	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII PEG-AUCL)FOR INJ 2000 UNIT	85100010412150	Brand
JIVI	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII PEG-AUCL)FOR INJ 1000 UNIT	85100010412140	Brand
JIVI	ANTIHEMOPHIL FACT RCMB(BDD-RFVIII PEG-AUCL) FOR INJ 500 UNIT	85100010412130	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia A

**AND**

2 - ONE of the following:

- Peri-operative management of surgical bleeding
- Routine prophylactic treatment of bleeding
- Treatment of bleeding episodes

**AND**

3 - Patient has previously received Factor VIII replacement therapy

**AND**

4 - Patient is 12 years of age or older

**AND**

5 - Patient is not a candidate for treatment with shorter acting half-life Factor VIII (recombinant) products [e.g., Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or Recombinate] as attested by the prescribing physician

**AND**

**6** - Patient is not to receive routine infusions more than 2 times per week

**Product Name: Afstyla**

Diagnosis	Hemophilia A (i.e., Factor VIII Deficiency, Classical Hemophilia)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
AFSTYLA	ANTIHEMOPHILIC FACT RCMB SINGLE CHAIN FOR INJ KIT 2500 UNIT	85100010556455	Brand
AFSTYLA	ANTIHEMOPHILIC FACT RCMB SINGLE CHAIN FOR INJ KIT 3000 UNIT	85100010556460	Brand
AFSTYLA	ANTIHEMOPHILIC FACT RCMB SINGLE CHAIN FOR INJ KIT 2000 UNIT	85100010556450	Brand
AFSTYLA	ANTIHEMOPHILIC FACT RCMB SINGLE CHAIN FOR INJ KIT 1500 UNIT	85100010556445	Brand
AFSTYLA	ANTIHEMOPHILIC FACT RCMB SINGLE CHAIN FOR INJ KIT 1000 UNIT	85100010556440	Brand
AFSTYLA	ANTIHEMOPHILIC FACT RCMB SINGLE CHAIN FOR INJ KIT 500 UNIT	85100010556430	Brand
AFSTYLA	ANTIHEMOPHILIC FACT RCMB SINGLE CHAIN FOR INJ KIT 250 UNIT	85100010556420	Brand

**Approval Criteria**

**1** - Diagnosis of hemophilia A

**AND**

**2** - ONE of the following:

- Routine prophylactic treatment of bleeding
- Peri-operative management of surgical bleeding

- Treatment of bleeding episodes

**AND**

**3** - Patient is not a suitable candidate for treatment with shorter acting half-life Factor VIII (recombinant) products [e.g., Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate] as attested by the prescribing physician

**AND**

**4** - ONE of the following:

**4.1** Patient is not to receive routine infusions more frequently than 3 times per week

**OR**

**4.2** BOTH of the following:

- Patient is less than 12 years of age
- Pharmacokinetic (PK) testing results suggest that more frequently than 3 times per week dosing is required

Product Name: Hemlibra			
Diagnosis	Hemophilia A (i.e., Factor VIII Deficiency, Classical Hemophilia)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HEMLIBRA	EMICIZUMAB-KXWH SUBCUTANEOUS SOLN 30 MG/ML	85105030202010	Brand
HEMLIBRA	EMICIZUMAB-KXWH SUBCUTANEOUS SOLN 60 MG/0.4ML (150 MG/ML)	85105030202020	Brand
HEMLIBRA	EMICIZUMAB-KXWH SUBCUTANEOUS SOLN 105 MG/0.7ML (150 MG/ML)	85105030202030	Brand
HEMLIBRA	EMICIZUMAB-KXWH SUBCUTANEOUS SOLN 150 MG/ML	85105030202040	Brand

HEMLIBRA	EMICIZUMAB-KXWH SUBCUTANEOUS SOLN 300 MG/2ML (150 MG/ML)	85105030202060	Brand
HEMLIBRA	EMICIZUMAB-KXWH SUBCUTANEOUS SOLN 12 MG/0.4ML (30 MG/ML)	85105030202007	Brand

**Approval Criteria**

**1 - ONE** of the following:

**1.1 ALL** of the following:

**1.1.1** Diagnosis of severe hemophilia A

**AND**

**1.1.2** Documentation of endogenous factor VIII level less than 1% of normal factor VIII ( < 0.01 IU/mL)

**AND**

**1.1.3** Physician attestation that the patient is not to receive extended half-life factor VIII replacement products (e.g., Eloctate, Adynovate, Afstyla, Jivi) for the treatment of breakthrough bleeding episodes

**OR**

**1.2 ALL** of the following:

**1.2.1 ONE** of the following:

**1.2.1.1 BOTH** of the following:

- Diagnosis of moderate hemophilia A
- Documentation of endogenous factor VIII level greater than or equal to 1% to less than 5% (greater than or equal to 0.01 IU/mL to less than 0.05 IU/mL)

**OR**



**1.2.1.2 BOTH of the following:**

- Diagnosis of mild hemophilia A
- Documentation of endogenous factor VIII level greater than or equal to 5% (greater than 0.05 IU/mL)

**AND**

**1.2.2** Submission of medical records (e.g., chart notes, laboratory values) documenting a failure to meet clinical goals (e.g., continuation of spontaneous bleeds, inability to achieve appropriate trough level, previous history of inhibitors) after a trial of prophylactic factor VIII replacement products

**AND**

**1.2.3** Physician attestation that the patient is not to receive extended half-life factor VIII replacement products (e.g., Eloctate, Adynovate, Afstyla, Jivi) for the treatment of breakthrough bleeding episodes

**OR**

**1.3 BOTH of the following:**

- Diagnosis of hemophilia A
- Patient has developed high-titer factor VIII inhibitors (greater than or equal to 5 Bethesda units [BU])

**AND**

**2** - Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)

Product Name: FEIBA	
Diagnosis	Hemophilia A
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
FEIBA	ANTIINHIBITOR COAGULANT COMPLEX FOR IV SOLN 500 UNIT	85100020002120	Brand
FEIBA	ANTIINHIBITOR COAGULANT COMPLEX FOR IV SOLN 1000 UNIT	85100020002130	Brand
FEIBA	ANTIINHIBITOR COAGULANT COMPLEX FOR IV SOLN 2500 UNIT	85100020002150	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia A

**AND**

2 - Documentation of inhibitors (e.g., Bethesda inhibitor assay)

**AND**

3 - ONE of the following:

- Routine prophylactic treatment of bleeding
- Peri-operative management of surgical bleeding
- Treatment of bleeding episodes

Product Name: NovoSeven RT, Obizur			
Diagnosis	Acquired factor VIII Hemophilia		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 1 MG (1000 MCG)	85100026202117	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 2 MG (2000 MCG)	85100026202126	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 5 MG (5000 MCG)	85100026202145	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 8 MG (8000 MCG)	85100026202160	Brand
OBIZUR	ANTIHEMOPHILIC FACTOR (RECOMB PORC) RPFVIII FOR INJ 500 UNIT	85100010502130	Brand

**Approval Criteria**

1 - Diagnosis of acquired factor VIII hemophilia (e.g., acquired hemophilia A, Factor VIII deficiency)

**AND**

2 - Treatment or prevention of bleeding episodes

**Product Name: Adynovate**

Diagnosis	Hemophilia A (i.e., Factor VIII Deficiency, Classical Hemophilia)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ADYNOVATE	ANTIHEMOPHILIC FACTOR RECOMB PEGYLATED FOR INJ 3000 UNIT	85100010402160	Brand
ADYNOVATE	ANTIHEMOPHILIC FACTOR RECOMB PEGYLATED FOR INJ 2000 UNIT	85100010402150	Brand
ADYNOVATE	ANTIHEMOPHILIC FACTOR RECOMB PEGYLATED FOR INJ 1500 UNIT	85100010402145	Brand
ADYNOVATE	ANTIHEMOPHILIC FACTOR RECOMB PEGYLATED FOR INJ 1000 UNIT	85100010402140	Brand
ADYNOVATE	ANTIHEMOPHILIC FACTOR RECOMB PEGYLATED FOR INJ 750 UNIT	85100010402135	Brand
ADYNOVATE	ANTIHEMOPHILIC FACTOR RECOMB PEGYLATED FOR INJ 500 UNIT	85100010402130	Brand
ADYNOVATE	ANTIHEMOPHILIC FACTOR RECOMB PEGYLATED FOR INJ 250 UNIT	85100010402120	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia A

**AND**

2 - ONE of the following:

- Routine prophylactic treatment of bleeding
- Peri-operative management of surgical bleeding
- Treatment of bleeding episodes

**AND**

3 - Patient is not a suitable candidate for treatment with shorter acting half-life Factor VIII (recombinant) products [Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or Recombinate] as attested by the prescribing physician

**AND**

4 - ONE of the following:

4.1 BOTH of the following:

- Patient is not to receive routine infusions more frequently than 2 times per week
- Patient is not to receive a routine dose greater than 50 IU/kg

**OR**

4.2 ALL of the following:

- Patient is less than 12 years of age
- Patient is not to receive routine infusions more frequently than 2 times per week
- Patient is not to receive a routine dose greater than 70 IU/kg

Product Name: Esperoct	
Diagnosis	Hemophilia A (i.e., Factor VIII Deficiency, Classical Hemophilia)

Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ESPEROCT	ANTIHEMOPHILIC FACTOR RECOMB GLYCOPEG-EXEI FOR INJ 500 UNIT	85100010352130	Brand
ESPEROCT	ANTIHEMOPHILIC FACTOR RECOMB GLYCOPEG-EXEI FOR INJ 1000 UNIT	85100010352140	Brand
ESPEROCT	ANTIHEMOPHILIC FACTOR RECOMB GLYCOPEG-EXEI FOR INJ 1500 UNIT	85100010352145	Brand
ESPEROCT	ANTIHEMOPHILIC FACTOR RECOMB GLYCOPEG-EXEI FOR INJ 2000 UNIT	85100010352150	Brand
ESPEROCT	ANTIHEMOPHILIC FACTOR RECOMB GLYCOPEG-EXEI FOR INJ 3000 UNIT	85100010352160	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia A

**AND**

2 - ONE of the following:

- Routine prophylactic treatment of bleeding
- Peri-operative management of surgical bleeding
- Treatment of bleeding episodes

**AND**

3 - ONE of the following:

3.1 Patient is not to receive routine infusions more frequently than 2 times per week

**OR**

3.2 BOTH of the following:

- Patient is less than 12 years of age

- Pharmacokinetic (PK) testing results suggest that more frequent than 2 times per week dosing is required

**Product Name: Wilate**

Diagnosis	Hemophilia A (i.e., Factor VIII Deficiency, Classical Hemophilia)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
WILATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 500-500 UNIT KIT	85100015106430	Brand
WILATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN) FOR INJ 1000-1000 UNIT KIT	85100015106440	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia A

**AND**

2 - ONE of the following:

2.1 Routine prophylactic treatment of bleeding

**OR**

2.2 Treatment of bleeding episodes

**Product Name: NovoSeven RT**

Diagnosis	Hemophilia A (i.e., Factor VIII Deficiency, Classical Hemophilia)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 1 MG (1000 MCG)	85100026202117	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 2 MG (2000 MCG)	85100026202126	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 5 MG (5000 MCG)	85100026202145	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 8 MG (8000 MCG)	85100026202160	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia A

**AND**

2 - Documentation of inhibitors (e.g., Bethesda inhibitor assay)

**AND**

3 - ONE of the following:

- Peri-operative management of surgical bleeding
- Treatment of bleeding episodes

Product Name: Altuviio	
Diagnosis	Hemophilia A (i.e., Factor VIII Deficiency, Classical Hemophilia)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

  

Product Name	Generic Name	GPI	Brand/Generic
ALTUVIIIO	ANTIHEMOPHILIC FACT RCMB FC-VWF-XTEN-EHTL FOR INJ 250 UNIT	85100010312120	Brand
ALTUVIIIO	ANTIHEMOPHILIC FACT RCMB FC-VWF-XTEN-EHTL FOR INJ 500 UNIT	85100010312125	Brand

ALTUVIII O	ANTIHEMOPHILIC FACT RCMB FC-VWF-XTEN-EHTL FOR INJ 1000 UNIT	85100010312135	Brand
ALTUVIII O	ANTIHEMOPHILIC FACT RCMB FC-VWF-XTEN-EHTL FOR INJ 2000 UNIT	85100010312140	Brand
ALTUVIII O	ANTIHEMOPHILIC FACT RCMB FC-VWF-XTEN-EHTL FOR INJ 3000 UNIT	85100010312145	Brand
ALTUVIII O	ANTIHEMOPHILIC FACT RCMB FC-VWF-XTEN-EHTL FOR INJ 4000 UNIT	85100010312150	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia A

**AND**

2 - ONE of the following:

- Treatment of bleeding episodes
- Prevention of bleeding in surgical interventions or invasive procedures (e.g., surgical prophylaxis)
- Prevention of bleeding episodes (i.e., routine prophylaxis)

**AND**

3 - Patient is not a suitable candidate for treatment with shorter acting half-life Factor VIII (recombinant) products [e.g., Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or Recombinate] as attested by the prescribing physician

**AND**

4 - BOTH of the following:

- Dose does not exceed 50 IU/kg
- Patient is infusing no more frequently than every 7 days

Product Name: AlphaNine SD, Profilnine



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Diagnosis	Hemophilia B (i.e., Congenital Factor IX Deficiency, Christmas Disease)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ALPHANINE SD	COAGULATION FACTOR IX FOR INJ 500 UNIT	85100028002170	Brand
ALPHANINE SD	COAGULATION FACTOR IX FOR INJ 1000 UNIT	85100028002180	Brand
ALPHANINE SD	COAGULATION FACTOR IX FOR INJ 1500 UNIT	85100028002185	Brand
PROFILNINE	FACTOR IX COMPLEX FOR INJ 500 UNIT	85100030002105	Brand
PROFILNINE	FACTOR IX COMPLEX FOR INJ 1000 UNIT	85100030002110	Brand
PROFILNINE	FACTOR IX COMPLEX FOR INJ 1500 UNIT	85100030002115	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia B

**AND**

2 - ONE of the following:

- Routine prophylactic treatment
- Treatment of bleeding episodes

Product Name: BeneFIX, Rixubis, Alprolix, Idelvion, Ixinity, or Rebinyn			
Diagnosis	Hemophilia B (i.e., Congenital Factor IX Deficiency, Christmas Disease)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BENEFIX	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ KIT 250 UNIT	85100028206420	Brand
BENEFIX	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ KIT 500 UNIT	85100028206430	Brand
BENEFIX	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ KIT 1000 UNIT	85100028206440	Brand
BENEFIX	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ KIT 2000 UNIT	85100028206450	Brand
BENEFIX	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ KIT 3000 UNIT	85100028206460	Brand
RIXUBIS	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ 250 UNIT	85100028202120	Brand
RIXUBIS	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ 500 UNIT	85100028202130	Brand
RIXUBIS	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ 1000 UNIT	85100028202140	Brand
RIXUBIS	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ 2000 UNIT	85100028202150	Brand
RIXUBIS	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ 3000 UNIT	85100028202160	Brand
ALPROLIX	COAGULATION FACTOR IX (RECOMB) (RFIXFC) FOR INJ 250 UNIT	85100028402105	Brand
ALPROLIX	COAGULATION FACTOR IX (RECOMB) (RFIXFC) FOR INJ 500 UNIT	85100028402110	Brand
ALPROLIX	COAGULATION FACTOR IX (RECOMB) (RFIXFC) FOR INJ 1000 UNIT	85100028402120	Brand
ALPROLIX	COAGULATION FACTOR IX (RECOMB) (RFIXFC) FOR INJ 2000 UNIT	85100028402130	Brand
ALPROLIX	COAGULATION FACTOR IX (RECOMB) (RFIXFC) FOR INJ 3000 UNIT	85100028402140	Brand
ALPROLIX	COAGULATION FACTOR IX (RECOMB) (RFIXFC) FOR INJ 4000 UNIT	85100028402150	Brand
IDELVION	COAGULATION FACTOR IX (RECOMB) (RIX-FP) FOR INJ 250 UNIT	85100028352110	Brand
IDELVION	COAGULATION FACTOR IX (RECOMB) (RIX-FP) FOR INJ 500 UNIT	85100028352120	Brand
IDELVION	COAGULATION FACTOR IX (RECOMB) (RIX-FP) FOR INJ 1000 UNIT	85100028352130	Brand
IDELVION	COAGULATION FACTOR IX (RECOMB) (RIX-FP) FOR INJ 2000 UNIT	85100028352140	Brand
IDELVION	COAGULATION FACTOR IX (RECOMB) (RIX-FP) FOR INJ 3500 UNIT	85100028352150	Brand
IXINITY	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ 3000 UNIT	85100028202160	Brand
REBINYN	COAGULATION FACTOR IX RECOMB GLYCOPEGYLATED FOR INJ 500 UNT	85100028452120	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

IXINITY	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ 250 UNIT	85100028202120	Brand
IXINITY	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ 500 UNIT	85100028202130	Brand
IXINITY	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ 1000 UNIT	85100028202140	Brand
IXINITY	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ 1500 UNIT	85100028202145	Brand
IXINITY	COAGULATION FACTOR IX (RECOMBINANT) FOR INJ 2000 UNIT	85100028202150	Brand
REBINYN	COAGULATION FACTOR IX RECOMB GLYCOPEGYLATED FOR INJ 1000 UNT	85100028452130	Brand
REBINYN	COAGULATION FACTOR IX RECOMB GLYCOPEGYLATED FOR INJ 2000 UNT	85100028452140	Brand
REBINYN	COAGULATION FACTOR IX RECOMB GLYCOPEGYLATED FOR INJ 3000 UNT	85100028452145	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia B

**AND**

2 - ONE of the following:

- Routine prophylactic treatment
- Peri-operative management of surgical bleeding
- Treatment of bleeding episodes

Product Name: FEIBA			
Diagnosis	Hemophilia B (i.e., Congenital Factor IX Deficiency, Christmas Disease)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FEIBA	ANTIINHIBITOR COAGULANT COMPLEX FOR IV SOLN 500 UNIT	85100020002120	Brand

FEIBA	ANTIINHIBITOR COAGULANT COMPLEX FOR IV SOLN 1000 UNIT	85100020002130	Brand
FEIBA	ANTIINHIBITOR COAGULANT COMPLEX FOR IV SOLN 2500 UNIT	85100020002150	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia B

**AND**

2 - Documentation of inhibitors (e.g., Bethesda inhibitor assay)

**AND**

3 - ONE of the following:

- Routine prophylactic treatment of bleeding
- Peri-operative management of surgical bleeding
- Treatment of bleeding episodes

Product Name: NovoSeven RT			
Diagnosis	Hemophilia B (i.e., Congenital Factor IX Deficiency, Christmas Disease)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 1 MG (1000 MCG)	85100026202117	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 2 MG (2000 MCG)	85100026202126	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 5 MG (5000 MCG)	85100026202145	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 8 MG (8000 MCG)	85100026202160	Brand

**Approval Criteria**

1 - Diagnosis of hemophilia B

**AND**

2 - Documentation of inhibitors (e.g., Bethesda inhibitor assay)

**AND**

3 - ONE of the following:

- Peri-operative management of surgical bleeding
- Treatment of bleeding episodes

Product Name: Fibryga, RiaSTAP			
Diagnosis	Fibrinogen Deficiency (i.e., Factor I deficiency)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FIBRYGA	FIBRINOGEN CONC (HUMAN) INJ APPROXIMATELY 1 GM (900-1300 MG)	85100035002120	Brand
RIASTAP	FIBRINOGEN CONC (HUMAN) INJ APPROXIMATELY 1 GM (900-1300 MG)	85100035002120	Brand

**Approval Criteria**

1 - Diagnosis of congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia

**AND**

**2 - Treatment of bleeding episodes**

<b>Product Name: NovoSeven RT</b>			
Diagnosis	Glanzmann Thrombasthenia		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 1 MG (1000 MCG)	85100026202117	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 2 MG (2000 MCG)	85100026202126	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 5 MG (5000 MCG)	85100026202145	Brand
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB) FOR INJ 8 MG (8000 MCG)	85100026202160	Brand

**Approval Criteria**

**1 - Diagnosis of Glanzmann's thrombasthenia**

**AND**

**2 - Refractory to platelet transfusions**

**AND**

**3 - ONE of the following:**

- Treatment of bleeding episodes
- Peri-operative management of surgical bleeding

<b>Product Name: Coagadex</b>	
Diagnosis	Congenital Factor X Deficiency

Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
COAGADEX	COAGULATION FACTOR X (HUMAN) FOR INJ 250 UNIT	85100031002120	Brand
COAGADEX	COAGULATION FACTOR X (HUMAN) FOR INJ 500 UNIT	85100031002140	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of congenital Factor X deficiency</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <ul style="list-style-type: none"> <li>• Treatment of bleeding episodes</li> <li>• Peri-operative management of surgical bleeding</li> <li>• Routine prophylactic treatment</li> </ul>			

## 2 . Revision History

Date	Notes
4/5/2024	Added new GPI for Hemlibra.

Hepatitis C



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160465
<b>Guideline Name</b>	Hepatitis C
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### Note:

\*Preferred drugs Mavyret and Brand Sofosbuvir-velpatasvir will be approved without requiring prior authorization ONE time per lifetime. Requests for retreatment or non-preferred drugs will require PA\*

## 1 . Criteria

Product Name: Brand Sofosbuvir-velpatasvir*, Mavyret*			
Diagnosis	Hepatitis C Retreatment		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOFOSBUVIR/VELPATASVIR	SOFOSBUVIR-VELPATASVIR TAB 400-100 MG	12359902650330	Generic
MAVYRET	GLECAPREVIR-PIBRENTASVIR TAB 100-40 MG	12359902350320	Brand



MAVYRET	GLECAPREVIR-PIBRENTASVIR PELLET PACK 50-20 MG	12359902353020	Brand
---------	--	----------------	-------

**Approval Criteria**

**1** - Diagnosis of chronic Hepatitis C infection status which has been confirmed by detectable serum hepatitis C virus (HCV) RNA (ribonucleic acid) by quantitative assay completed within the past 90 days from the date of the prior authorization request

**AND**

**2** - Age of the patient is Food and Drug Administration (FDA) approved for the specific HCV DAA (Direct Acting Antiviral) product

**AND**

**3** - The prescribing provider assesses the patient's ability to adhere to the HCV DAA treatment plan and attests the assessment has been documented within the clinical record. For patients that would benefit from adherence aids, the treating provider shall refer the patient to a treatment adherence program

**AND**

**4** - Patient agrees to adhere to the proposed course of treatment, including taking medications as prescribed, attending follow-up appointments, and, if applicable, participating in a treatment adherence program

**AND**

**5** - ONE of the following:

**5.1** Patient has been screened for Hepatitis A and B and has received one Hepatitis A and one Hepatitis B vaccine prior to requesting treatment

**OR**

**5.2** Patient demonstrates laboratory evidence of immunity to Hepatitis A and B

**AND**

**6** - The Prescriber must submit the following information with the request for HCV DAA medications to be considered:

**6.1** HCV treatment history and responses to treatment

**AND**

**6.2** Current medication list

**AND**

**6.3** Laboratory results for ALL of the following:

- HCV screen test results
- Genotype and current baseline HCV viral load
- Total bilirubin
- Albumin level
- International Normalized Ratio (INR)
- Creatinine Clearance (CrCl) or Glomerular Filtration Rate (GFR)
- Liver Function Tests (LFTs)
- Complete Blood Count (CBC)
- Viral resistance status (when applicable)
- Hepatic status (Child Pugh Score)

**AND**

**7** - If the HCV DAA product is being used in combination with ribavirin, the prescribing provider attests to monitoring hemoglobin levels periodically

**AND**

**8** - The prescribing provider attests to monitoring HCV RNA levels obtained at 12- and 24-weeks post therapy completion to demonstrate the Sustained Virologic Response (SVR)

**AND**

**9** - DAA HCV treatment coverage is NOT provided for ANY of the following:

**9.1** DAA dosages greater than the FDA approved maximum dosage

**OR**

**9.2** Patients currently using a potent P-gp inducer drug (St. John's wart, rifampin, carbamazepine, ritonavir, tipranavir, etc.)

**OR**

**9.3** Lost or stolen medication absent of good cause

**OR**

**9.4** Fraud, waste, or misuse of HCV DAA medications

Notes	Approval length: Mavyret = 8-16 Week(s), Brand Sofosbuvir-velpatasvir = 12-24 Week(s). *Preferred drugs Mavyret and Brand Sofosbuvir-velpatasvir will be approved without requiring prior authorization ONE time per lifetime. Requests for retreatment or non-preferred drugs will require PA. Refer to AASLD for specific approval durations AASLD: <a href="https://www.hcvguidelines.org/contents">https://www.hcvguidelines.org/contents</a>
-------	--

Product Name: Brand Eplusa, Brand Harvoni, Brand Ledipasvir-sofosbuvir, Sovaldi, Zepatier			
Diagnosis	Hepatitis C		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOVALDI	SOFOSBUVIR TAB 200 MG	12353080000310	Brand
SOVALDI	SOFOSBUVIR TAB 400 MG	12353080000320	Brand
ZEPATIER	ELBASVIR-GRAZOPREVIR TAB 50-100 MG	12359902300320	Brand

SOVALDI	SOFOSBUVIR PELLETT PACK 150 MG	12353080003015	Brand
SOVALDI	SOFOSBUVIR PELLETT PACK 200 MG	12353080003020	Brand
EPCLUSA	SOFOSBUVIR-VELPATASVIR TAB 200-50 MG	12359902650320	Brand
EPCLUSA	SOFOSBUVIR-VELPATASVIR TAB 400-100 MG	12359902650330	Generic
EPCLUSA	SOFOSBUVIR-VELPATASVIR PELLETT PACK 150-37.5 MG	12359902653020	Brand
EPCLUSA	SOFOSBUVIR-VELPATASVIR PELLETT PACK 200-50 MG	12359902653030	Brand
HARVONI	LEDIPASVIR-SOFOSBUVIR TAB 45- 200 MG	12359902400310	Brand
HARVONI	LEDIPASVIR-SOFOSBUVIR TAB 90- 400 MG	12359902400320	Generic
LEDIPASVIR/SOFOSBUVIR	LEDIPASVIR-SOFOSBUVIR TAB 90- 400 MG	12359902400320	Generic
HARVONI	LEDIPASVIR-SOFOSBUVIR PELLETT PACK 33.75-150 MG	12359902403006	Brand
HARVONI	LEDIPASVIR-SOFOSBUVIR PELLETT PACK 45-200 MG	12359902403010	Brand

**Approval Criteria**

**1** - ONE of the following:

**1.1** Patient was adherent to previous DAA therapy as evidenced by submission of medical records and/or pharmacy prescription claims

**OR**

**1.2** If prior therapy was discontinued due to adverse effects from the DAA, the medical record shall be provided which documents these adverse effects and recommendation of discontinuation by treatment provider

**AND**

**2** - The patient's ability to adhere to the planned course of retreatment has been assessed by the treating provider and documented within the clinical record

**AND**

**3** - Resistance-associated polymorphism testing, when applicable, has been completed and submitted with the prior authorization request when BOTH of the following are true:

- Required for regimens whereby the FDA (Food and Drug Administration) requires such testing prior to treatment to ensure clinical appropriateness
- Deemed medically necessary by the clinical reviewer prior to approval of the requested regimen

**AND**

**4** - HCV retreatment with a DAA shall NOT be approved for ANY of the following:

**4.1** Is considered an experimental service

**OR**

**4.2** Monotherapy of Sofosbuvir (Sovaldi)

**OR**

**4.3** DAA dosages greater than the FDA approved maximum dosage

**OR**

**4.4** Grazoprevir/elbasvir (Zepatier) if the NS5A polymorphism testing has not been completed and submitted with the prior authorization request

**OR**

**4.5** Patients currently using a potent P-gp inducer drug (St. John's wart, rifampin, carbamazepine, ritonavir, tipranavir, etc.)

**OR**

**4.6** Lost or stolen medication absent of good cause

**OR**

**4.7** Fraudulent use of HCV DAA medications

**AND**

**5** - If the request is for brand Epclusa or brand Harvoni, BOTH of the following:

**5.1** The patient has a therapeutic failure, contraindication, or intolerance to the generic as evidenced by submission of medical records or claims history

**AND**

**5.2** The prescriber must submit the FDA MedWatch form

Notes	The approval length should be as recommended per AASLD. Refer to AASLD for specific approval durations. AASLD: <a href="https://www.hcvguidelines.org/contents">https://www.hcvguidelines.org/contents</a>
-------	--

Product Name: Brand Harvoni, Brand Ledipasvir-sofosbuvir			
Diagnosis	Hepatitis C Retreatment		
Approval Length	24 Week(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HARVONI	LEDIPASVIR-SOFOSBUVIR TAB 45-200 MG	12359902400310	Brand
HARVONI	LEDIPASVIR-SOFOSBUVIR TAB 90-400 MG	12359902400320	Generic
LEDIPASVIR/SOFOSBUVIR	LEDIPASVIR-SOFOSBUVIR TAB 90-400 MG	12359902400320	Generic
HARVONI	LEDIPASVIR-SOFOSBUVIR PELLETT PACK 33.75-150 MG	12359902403006	Brand

HARVONI	LEDIPASVIR-SOFOSBUVIR PELLETT PACK 45-200 MG	12359902403010	Brand
---------	---	----------------	-------

**Approval Criteria**

1 - Diagnosis of chronic hepatitis C infection

**AND**

2 - Patient has decompensated cirrhosis (e.g., Child-Pugh Class B or C)

**AND**

3 - ONE of the following:

3.1 Patient is ribavirin ineligible

**OR**

3.2 BOTH of the following:

- Prior failure (defined as viral relapse, breakthrough while on therapy, or non-responder therapy) to Sovaldi or NS5A-based therapy
- Used in combination with ribavirin

**AND**

4 - Not used in combination with another HCV direct acting antiviral agent [e.g., Sovaldi (sofosbuvir)]

Product Name: Vosevi, Viekira Pak	
Diagnosis	Hepatitis C
Approval Length	12 Week(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
VOSEVI	SOFOSBUVIR-VELPATASVIR-VOXILAPREVIR TAB 400-100-100 MG	12359903800330	Brand
VIEKIRA PAK	OMBITAS-PARITAPRE-RITON & DASAB TAB PAK 12.5-75-50 & 250 MG	1235990460B720	Brand

**Approval Criteria**

1 - Diagnosis of chronic hepatitis C infection

**AND**

2 - ONE of the following:

**2.1** Patient is a previous relapser to an NS5A-based regimen [e.g., Daklinza (daclatasvir); Eplusa (sofosbuvir/velpatasvir); Harvoni (ledipasvir/sofosbuvir); Mavyret (glecaprevir/pibrentasvir); Technivie (ombitasvir/paritaprevir/ritonavir); Viekira (ombitasvir/paritaprevir/ritonavir & dasabuvir); Zepatier (elbasvir/grazoprevir)]

**OR**

**2.2** Patient is a previous relapser to a sofosbuvir-based regimen without an NS5A inhibitor

**AND**

3 - Patient is without decompensated liver disease (e.g., Child-Pugh Class B or C)

**AND**

4 - Not used in combination with another HCV direct acting antiviral agent [e.g., Harvoni (ledipasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir)]

Product Name: Vosevi, Viekira Pak	
Diagnosis	Hepatitis C: Prior Failure to Vosevi/Viekira Pak



Approval Length	24 Week(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VOSEVI	SOFOBUVIR-VELPATASVIR-VOXILAPREVIR TAB 400-100-100 MG	12359903800330	Brand
VIEKIRA PAK	OMBITAS-PARITAPRE-RITON & DASAB TAB PAK 12.5-75-50 & 250 MG	1235990460B720	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic hepatitis C infection</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - BOTH of the following:</p> <p style="padding-left: 20px;"><b>2.1</b> Patient had a prior treatment failure with Vosevi or Viekira</p> <p style="text-align: center;"><b>AND</b></p> <p style="padding-left: 20px;"><b>2.2</b> Used in combination with ribavirin</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is without decompensated liver disease (e.g., Child-Pugh Class B or C)</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Not used in combination with another HCV direct acting antiviral agent [e.g., Harvoni (ledipasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir)]</p>			

Product Name: Pegasys	
Diagnosis	Hepatitis C

Approval Length	48 Week(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PEGASYS	PEGINTERFERON ALFA-2A INJ 180 MCG/ML	12353060052020	Brand
PEGASYS	PEGINTERFERON ALFA-2A SOLN PREFILLED SYR 180 MCG/0.5ML	1235306005E540	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic hepatitis C infection</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient without decompensated liver disease (defined as Child-Pugh Class B or C)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Will be used as part of a combination antiviral treatment regimen</p>			

Product Name: Ribavirin tablets and capsules			
Diagnosis	Hepatitis C		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RIBAVIRIN	RIBAVIRIN CAP 200 MG	12353070000120	Generic
RIBAVIRIN	RIBAVIRIN TAB 200 MG	12353070000320	Generic
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of chronic hepatitis C infection</p>			

**AND**

**2** - Used in combination with a direct-acting agent

## **2 . Revision History**

Date	Notes
11/11/2024	Updated approval duration for target drugs Brand Sofosbuvir-velpatasvir and Mavyret.

Hereditary Angioedema (HAE) Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-155259
<b>Guideline Name</b>	Hereditary Angioedema (HAE) Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Cinryze, Haegarda, Orladeyo, Takhzyro			
Diagnosis	Prophylaxis of HAE attacks		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CINRYZE	C1 ESTERASE INHIBITOR (HUMAN) FOR IV INJ 500 UNIT	85802022002120	Brand
HAEGARDA	C1 ESTERASE INHIBITOR (HUMAN) FOR SUBCUTANEOUS INJ 2000 UNIT	85802022002130	Brand
HAEGARDA	C1 ESTERASE INHIBITOR (HUMAN) FOR SUBCUTANEOUS INJ 3000 UNIT	85802022002140	Brand
ORLADEYO	BEROTRALSTAT HCL CAP 110 MG	85840010200120	Brand

ORLADEYO	BEROTRALSTAT HCL CAP 150 MG	85840010200130	Brand
TAKHZYRO	LANADELUMAB-FLYO SOLN PREF SYRINGE 300 MG/2ML (150 MG/ML)	8584204020E520	Brand
TAKHZYRO	LANADELUMAB-FLYO INJ 300 MG/2ML (150 MG/ML)	85842040202020	Brand
TAKHZYRO	LANADELUMAB-FLYO SOLN PREF SYRINGE 150 MG/ML	8584204020E510	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting diagnosis of hereditary angioedema (HAE) confirmed by ONE of the following:

**1.1** C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by ONE of the following (per laboratory standard):

- C1-INH antigenic level below the lower limit of normal
- C1-INH functional level below the lower limit of normal

**OR**

**1.2** HAE with normal C1 inhibitor levels and ONE of the following:

- Confirmed presence of a FXII (factor XII), angiotensin-converting enzyme 1, or plasminogen gene mutation
- Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema

**AND**

**2** - For prophylaxis against HAE attacks

**AND**

**3** - ONE of the following:

- If the request is for Takhzyro, patient is 2 years of age or older
- If the request is for Cinryze or Haegarda, patient is 6 years of age or older
- If the request is for Orladeyo, patient is 12 years of age or older

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Immunologist
- Allergist

**AND**

**5** - If the request is for Orladeyo or Takhzyro, ONE of the following:

**5.1** Submission of medical records documenting a history of failure, contraindication, or intolerance to BOTH of the following:

- Cinryze
- Haegarda

**OR**

**5.2** Submission of medical records documenting that the patient is currently on Orladeyo or Takhzyro therapy

Notes	Please note: Preferred agents are Cinryze and Haegarda.
-------	---

Product Name: Cinryze (off-label), Berinert, Brand Firazyr, generic icatibant, Kalbitor, Ruconest, Sajazir			
Diagnosis	Treatment of acute HAE attacks		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CINRYZE	C1 ESTERASE INHIBITOR (HUMAN) FOR IV INJ 500 UNIT	85802022002120	Brand
BERINERT	C1 ESTERASE INHIBITOR (HUMAN) FOR IV INJ KIT 500 UNIT	85802022006420	Brand
KALBITOR	ECALLANTIDE INJ 10 MG/ML	85840030002020	Brand
RUCONEST	C1 ESTERASE INHIBITOR (RECOMBINANT) FOR IV INJ 2100 UNIT	85802022102130	Brand

SAJAZIR	ICATIBANT ACETATE SUBCUTANEOUS SOLN PREF SYR 30 MG/3ML	8582004010E520	Generic
FIRAZYR	ICATIBANT ACETATE SUBCUTANEOUS SOLN PREF SYR 30 MG/3ML	8582004010E520	Brand
ICATIBANT ACETATE	ICATIBANT ACETATE SUBCUTANEOUS SOLN PREF SYR 30 MG/3ML	8582004010E520	Generic

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting diagnosis of hereditary angioedema (HAE) confirmed by ONE of the following:

**1.1** C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by ONE of the following (per laboratory standard):

- C1-INH antigenic level below the lower limit of normal
- C1-INH functional level below the lower limit of normal

**OR**

**1.2** HAE with normal C1 inhibitor levels and ONE of the following:

- Confirmed presence of a FXII, angiotensin-1, or plasminogen gene mutation
- Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema

**AND**

**2** - For the treatment of acute HAE attacks

**AND**

**3** - NOT used in combination with other approved treatments for acute HAE attacks

**AND**

**4** - ONE of the following:

- If the request is for Cinryze, patient is 6 years of age or older
- If the request is for Kalbitor, patient is 12 years of age or older
- If the request is for Brand Firazyr, generic icatibant, or Sajazir, patient is 18 years of age or older

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Immunologist
- Allergist

**AND**

**6** - If the request is for Brand Firazyr, Ruconest, or Sajazir, ONE of the following:

**6.1** Submission of medical records documenting a history of failure, contraindication, or intolerance to ALL of the following preferred HAE agents:

- Berinert
- Cinryze
- generic icatibant
- Kalbitor

**OR**

**6.2** Submission of medical records or paid claims documenting that the patient is currently on Brand Firazyr, Ruconest, or Sajazir therapy

Notes	Please note: Preferred HAE agents are Berinert, Cinryze, generic icatibant, and Kalbitor.
-------	---

## 2 . Revision History

Date	Notes
9/23/2024	Updated embedded steps to add Cinryze and Kalbitor as preferred alternatives, where applicable; Updated notes sections; Minor cosmetic updates.





Hetlioz, Hetlioz LQ (tasimelteon)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-150117
<b>Guideline Name</b>	Hetlioz, Hetlioz LQ (tasimelteon)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	8/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Hetlioz capsule, generic tasimelteon capsule			
Diagnosis	Non-24-Hour Sleep-Wake Disorder (Non-24)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HETLIOZ	TASIMELTEON CAPSULE 20 MG	60250070000130	Brand
TASIMELTEON	TASIMELTEON CAPSULE 20 MG	60250070000130	Generic

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting diagnosis of non-24-hour sleep-wake disorder (also known as free-running disorder, free-running or non-entrained type circadian rhythm sleep disorder, or hypernycthemeral syndrome) confirmed by meeting ONE of the following conditions:

**1.1** Assessment of at least one physiologic circadian phase marker [e.g., measurement of urinary melatonin levels, dim light melatonin onset (as measured in blood or saliva), assessment of core body temperature]

**OR**

**1.2** If assessment of at least one physiologic circadian phase marker cannot be done, the diagnosis must be confirmed by actigraphy performed for at least 1 week plus evaluation of sleep logs recorded for at least 1 month

**AND**

**2** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting patient is totally blind (has no light perception)\*

**AND**

**3** - Patient is 18 years of age or older

**AND**

**4** - Patient has received at least 3 months of continuous therapy (i.e., 3 consecutive months of daily treatment) under the guidance of a physician who specializes in the treatment of sleep disorders of BOTH of the following:

- Melatonin
- Rozerem (ramelteon)

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Specialist in sleep disorders
- Neurologist

**AND**

**6** - If the request is for Brand Hetlioz capsules, history of failure, intolerance, or contraindication to generic tasimelteon

Notes

\*Requests for patients who are sighted (non-blinded) will be reviewed on a case-by-case basis

Product Name: Brand Hetlioz capsule, generic tasimelteon capsule			
Diagnosis	Non-24-Hour Sleep-Wake Disorder (Non-24)		
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HETLIOZ	TASIMELTEON CAPSULE 20 MG	60250070000130	Brand
TASIMELTEON	TASIMELTEON CAPSULE 20 MG	60250070000130	Generic

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy (e.g., entrainment, clinically meaningful or significant increases in nighttime sleep, clinically meaningful or significant decreases in daytime sleep)

**AND**

**2** - Submission of patient's sleep log demonstrating positive clinical response to therapy

**AND**

**3** - If the request is for Brand Hetlioz capsules, history of failure, intolerance, or contraindication to generic tasimelteon

Product Name: Brand Hetlioz capsule, generic tasimelteon capsule	
Diagnosis	Smith-Magenis Syndrome (SMS)
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HETLIOZ	TASIMELTEON CAPSULE 20 MG	60250070000130	Brand
TASIMELTEON	TASIMELTEON CAPSULE 20 MG	60250070000130	Generic

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of Smith-Magenis Syndrome (SMS)

**AND**

**2** - Submission of test results confirming patient has microdeletion of the chromosome band 17p11.2 by fluorescent in situ hybridization (FISH) analysis

**AND**

**3** - Patient is 16 years of age or older

**AND**

**4** - Patient is experiencing nighttime sleep disturbances (i.e., difficulty falling asleep, frequent nighttime waking and early waking)

**AND**

**5** - Patient has received at least 3 months of continuous therapy (i.e., 3 consecutive months of daily treatment) under the guidance of a physician who specializes in the treatment of sleep disorders of BOTH of the following:

- Melatonin
- Rozerem (ramelteon) (unless contraindicated due to patient age)

**AND**

**6** - Prescribed by or in consultation with ONE of the following:

- Specialist in sleep disorders
- Neurologist

**AND**

**7** - If the request is for Brand Hetlioz capsules, history of failure, intolerance, or contraindication to generic tasimelteon

Product Name: Hetlioz LQ suspension			
Diagnosis	Smith-Magenis Syndrome (SMS)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HETLIOZ LQ	TASIMELTEON ORAL SUSP 4 MG/ML	60250070001820	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of Smith-Magenis Syndrome (SMS)			

**AND**

**2** - Submission of test results confirming patient has microdeletion of the chromosome band 17p11.2 by fluorescent in situ hybridization (FISH) analysis

**AND**

**3** - Patient is 3 through 15 years of age

**AND**

**4** - Patient is experiencing nighttime sleep disturbances (i.e., difficulty falling asleep, frequent nighttime waking and early waking)

**AND**

**5** - Patient has received at least 3 months of continuous therapy (i.e., 3 consecutive months of daily treatment) of melatonin under the guidance of a physician who specializes in the treatment of sleep disorders

**AND**

**6** - Prescribed by or in consultation with ONE of the following:

- Specialist in sleep disorders
- Neurologist

Product Name: Brand Hetlioz capsule, generic tasimelteon capsule, Hetlioz LQ suspension	
Diagnosis	Smith-Magenis Syndrome (SMS)
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HETLIOZ	TASIMELTEON CAPSULE 20 MG	60250070000130	Brand
HETLIOZ LQ	TASIMELTEON ORAL SUSP 4 MG/ML	60250070001820	Brand
TASIMELTEON	TASIMELTEON CAPSULE 20 MG	60250070000130	Generic

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy (i.e., improvement in nighttime total sleep time, improvement in nighttime sleep quality)

**AND**

2 - Submission of patient’s sleep log demonstrating positive clinical response to therapy

**AND**

3 - If the request is for Brand Hetlioz capsules, history of failure, intolerance, or contraindication to generic tasimelteon

**2 . Revision History**

Date	Notes
7/22/2024	Added generic tasimelteon capsules as a target to the guideline. Added embedded step, where applicable, where Brand Hetlioz capsule requests must step through generic tasimelteon. Updated product name lists and GPI tables accordingly.



High Cost Oral Atypical Antipsychotics (Caplyta, Fanapt, Lybalvi, Rexulti, Vraylar)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155862
<b>Guideline Name</b>	High Cost Oral Atypical Antipsychotics (Caplyta, Fanapt, Lybalvi, Rexulti, Vraylar)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Caplyta, Fanapt, Lybalvi, Rexulti, Vraylar			
Diagnosis	Schizophrenia		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CAPLYTA	LUMATEPERONE TOSYLATE CAP 10.5 MG	59400022400110	Brand
CAPLYTA	LUMATEPERONE TOSYLATE CAP 21 MG	59400022400115	Brand
CAPLYTA	LUMATEPERONE TOSYLATE CAP 42 MG	59400022400120	Brand
REXULTI	BREXPIRAZOLE TAB 0.25 MG	59250020000310	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

REXULTI	BREXPIRAZOLE TAB 0.5 MG	59250020000320	Brand
REXULTI	BREXPIRAZOLE TAB 1 MG	59250020000330	Brand
REXULTI	BREXPIRAZOLE TAB 2 MG	59250020000340	Brand
REXULTI	BREXPIRAZOLE TAB 3 MG	59250020000350	Brand
REXULTI	BREXPIRAZOLE TAB 4 MG	59250020000360	Brand
VRAYLAR	CARIPRAZINE HCL CAP THERAPY PACK 1.5 MG (1) & 3 MG (6)	5940001810B220	Brand
VRAYLAR	CARIPRAZINE HCL CAP 1.5 MG (BASE EQUIVALENT)	59400018100120	Brand
VRAYLAR	CARIPRAZINE HCL CAP 3 MG (BASE EQUIVALENT)	59400018100130	Brand
VRAYLAR	CARIPRAZINE HCL CAP 4.5 MG (BASE EQUIVALENT)	59400018100140	Brand
VRAYLAR	CARIPRAZINE HCL CAP 6 MG (BASE EQUIVALENT)	59400018100150	Brand
FANAPT	ILOPERIDONE TAB 1 MG	59070035000310	Brand
FANAPT	ILOPERIDONE TAB 2 MG	59070035000320	Brand
FANAPT	ILOPERIDONE TAB 4 MG	59070035000340	Brand
FANAPT	ILOPERIDONE TAB 6 MG	59070035000360	Brand
FANAPT	ILOPERIDONE TAB 8 MG	59070035000380	Brand
FANAPT	ILOPERIDONE TAB 10 MG	59070035000385	Brand
FANAPT	ILOPERIDONE TAB 12 MG	59070035000390	Brand
FANAPT TITRATION PACK	ILOPERIDONE TAB 1 MG & 2 MG & 4 MG & 6 MG TITRATION PAK	59070035006320	Brand
LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 5-10 MG	62994802500310	Brand
LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 10-10 MG	62994802500320	Brand
LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 15-10 MG	62994802500330	Brand
LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 20-10 MG	62994802500340	Brand

**Approval Criteria**

1 - Diagnosis of schizophrenia

**AND**

**2 - ONE of the following:**

**2.1** Inadequate response (minimum 30 day trial) or adverse reaction to TWO, or contraindication to ALL of the following:

- Aripiprazole
- Clozapine
- Olanzapine
- Quetiapine
- Risperidone
- Ziprasidone

**OR**

**2.2** ONE of the following:

**2.2.1** The patient has been receiving treatment with the requested medication and is new to the plan (enrollment effective date within the past 90 days)

**OR**

**2.2.2** The patient is currently receiving treatment with the requested medication in the hospital and must continue upon discharge

**AND**

**3 - If the request is for Lybalvi, ONE of the following:**

**3.1** Patient has a body mass index (BMI) of 30 kg/m<sup>2</sup> or greater

**OR**

**3.2** Patient has a BMI of 27 kg/m<sup>2</sup> or greater with a weight-related comorbidity (e.g., dyslipidemia, hypertension, type 2 diabetes, sleep apnea)

**OR**

**3.3** Patient has a documented history of weight gain of greater than or equal to 10% of their baseline weight after initiating antipsychotic medication

**OR**

**3.4** Physician has provided clinical rationale for requiring samidorphan in addition to olanzapine therapy

Product Name: Fanapt, Lybalvi, Vraylar			
Diagnosis	Bipolar I Disorder		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VRAYLAR	CARIPRAZINE HCL CAP THERAPY PACK 1.5 MG (1) & 3 MG (6)	5940001810B220	Brand
VRAYLAR	CARIPRAZINE HCL CAP 1.5 MG (BASE EQUIVALENT)	59400018100120	Brand
VRAYLAR	CARIPRAZINE HCL CAP 3 MG (BASE EQUIVALENT)	59400018100130	Brand
VRAYLAR	CARIPRAZINE HCL CAP 4.5 MG (BASE EQUIVALENT)	59400018100140	Brand
VRAYLAR	CARIPRAZINE HCL CAP 6 MG (BASE EQUIVALENT)	59400018100150	Brand
FANAPT	ILOPERIDONE TAB 1 MG	59070035000310	Brand
FANAPT	ILOPERIDONE TAB 2 MG	59070035000320	Brand
FANAPT	ILOPERIDONE TAB 4 MG	59070035000340	Brand
FANAPT	ILOPERIDONE TAB 6 MG	59070035000360	Brand
FANAPT	ILOPERIDONE TAB 8 MG	59070035000380	Brand
FANAPT	ILOPERIDONE TAB 10 MG	59070035000385	Brand
FANAPT	ILOPERIDONE TAB 12 MG	59070035000390	Brand
FANAPT TITRATION PACK	ILOPERIDONE TAB 1 MG & 2 MG & 4 MG & 6 MG TITRATION PAK	59070035006320	Brand
LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 5-10 MG	62994802500310	Brand
LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 10-10 MG	62994802500320	Brand
LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 15-10 MG	62994802500330	Brand

LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 20-10 MG	62994802500340	Brand
---------	---	----------------	-------

**Approval Criteria**

1 - Diagnosis of bipolar I disorder

**AND**

2 - ONE of the following:

**2.1** Inadequate response (minimum 30 day trial) or adverse reaction to THREE, or contraindication to ALL of the following:

- Aripiprazole
- Lamotrigine
- Lithium
- Lurasidone
- Olanzapine
- Risperidone
- Valproate

**OR**

**2.2** ONE of the following:

**2.2.1** The patient has been receiving treatment with the requested medication and is new to the plan (enrollment effective date within the past 90 days)

**OR**

**2.2.2** The patient is currently receiving treatment with the requested medication in the hospital and must continue upon discharge

**AND**

3 - If the request is for Lybalvi, ONE of the following:

**3.1** Patient has a body mass index (BMI) of 30 kg/m<sup>2</sup> or greater

**OR**

**3.2** Patient has a BMI of 27 kg/m<sup>2</sup> or greater with a weight-related comorbidity (e.g., dyslipidemia, hypertension, type 2 diabetes, sleep apnea)

**OR**

**3.3** Patient has a documented history of weight gain of greater than or equal to 10% of their baseline weight after initiating antipsychotic medication

**OR**

**3.4** Physician has provided clinical rationale for requiring samidorphan in addition to olanzapine therapy

**Product Name: Caplyta, Vraylar**

Diagnosis	Bipolar Depression
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
CAPLYTA	LUMATEPERONE TOSYLATE CAP 10.5 MG	59400022400110	Brand
CAPLYTA	LUMATEPERONE TOSYLATE CAP 21 MG	59400022400115	Brand
CAPLYTA	LUMATEPERONE TOSYLATE CAP 42 MG	59400022400120	Brand
VRAYLAR	CARIPRAZINE HCL CAP THERAPY PACK 1.5 MG (1) & 3 MG (6)	5940001810B220	Brand
VRAYLAR	CARIPRAZINE HCL CAP 1.5 MG (BASE EQUIVALENT)	59400018100120	Brand
VRAYLAR	CARIPRAZINE HCL CAP 3 MG (BASE EQUIVALENT)	59400018100130	Brand
VRAYLAR	CARIPRAZINE HCL CAP 4.5 MG (BASE EQUIVALENT)	59400018100140	Brand
VRAYLAR	CARIPRAZINE HCL CAP 6 MG (BASE EQUIVALENT)	59400018100150	Brand

**Approval Criteria**

1 - Diagnosis of bipolar depression

**AND**

2 - ONE of the following:

**2.1** Inadequate response (minimum 30 day trial) or adverse reaction to THREE, or contraindication to ALL of the following:

- Lurasidone
- Quetiapine
- Olanzapine plus fluoxetine
- Valproate monotherapy
- Combination Therapy (i.e., lithium plus lamotrigine/valproate, lurasidone plus lithium/valproate, quetiapine plus lithium/valproate)

**OR**

**2.2** ONE of the following:

**2.2.1** The patient has been receiving treatment with the requested medication and is new to the plan (enrollment effective date within the past 90 days)

**OR**

**2.2.2** The patient is currently receiving treatment with the requested medication in the hospital and must continue upon discharge

Product Name: Rexulti, Vraylar			
Diagnosis	Major Depressive Disorder (MDD)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REXULTI	BREXPIRAZOLE TAB 0.25 MG	59250020000310	Brand
REXULTI	BREXPIRAZOLE TAB 0.5 MG	59250020000320	Brand

REXULTI	BREXPIRAZOLE TAB 1 MG	59250020000330	Brand
REXULTI	BREXPIRAZOLE TAB 2 MG	59250020000340	Brand
REXULTI	BREXPIRAZOLE TAB 3 MG	59250020000350	Brand
REXULTI	BREXPIRAZOLE TAB 4 MG	59250020000360	Brand
VRAYLAR	CARIPRAZINE HCL CAP THERAPY PACK 1.5 MG (1) & 3 MG (6)	5940001810B220	Brand
VRAYLAR	CARIPRAZINE HCL CAP 1.5 MG (BASE EQUIVALENT)	59400018100120	Brand
VRAYLAR	CARIPRAZINE HCL CAP 3 MG (BASE EQUIVALENT)	59400018100130	Brand
VRAYLAR	CARIPRAZINE HCL CAP 4.5 MG (BASE EQUIVALENT)	59400018100140	Brand
VRAYLAR	CARIPRAZINE HCL CAP 6 MG (BASE EQUIVALENT)	59400018100150	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 Diagnosis of major depressive disorder (MDD)

**OR**

1.2 If the request is for Vraylar, diagnosis of treatment resistant depression

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

2.1.1 Inadequate response (minimum 30 day trial) or adverse reaction to TWO different antidepressants from the following classes (antidepressants MUST be from TWO different classes):

- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
- New Generation Antidepressants (e.g., bupropion, mirtazapine, etc)
- Tricyclic Antidepressants (TCAs)



**AND**

**2.1.2** Inadequate response (minimum 30 day trial) or adverse reaction to TWO of the following:

- Aripiprazole
- Quetiapine ER
- Risperidone
- Augmented Therapy (e.g., addition of lithium, another antidepressant from a different class, thyroid hormone to current antidepressant regimen)

**OR**

**2.2** ONE of the following:

**2.2.1** The patient has been receiving treatment with the requested medication and is new to the plan (enrollment effective date within the past 90 days)

**OR**

**2.2.2** The patient is currently receiving treatment with the requested medication in the hospital and must continue upon discharge

Product Name: Rexulti			
Diagnosis	Agitation Associated with Dementia Due to Alzheimer's Disease		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REXULTI	BREXPIRAZOLE TAB 0.25 MG	59250020000310	Brand
REXULTI	BREXPIRAZOLE TAB 0.5 MG	59250020000320	Brand
REXULTI	BREXPIRAZOLE TAB 1 MG	59250020000330	Brand
REXULTI	BREXPIRAZOLE TAB 2 MG	59250020000340	Brand
REXULTI	BREXPIRAZOLE TAB 3 MG	59250020000350	Brand
REXULTI	BREXPIRAZOLE TAB 4 MG	59250020000360	Brand

**Approval Criteria**

1 - The requested medication is being used for treatment of agitation associated with dementia due to Alzheimer's disease

Product Name: Caplyta, Fanapt, Lybalvi, Rexulti, Vraylar			
Approval Length	12 month(s)		
Guideline Type	Quantity Limit		
Product Name	Generic Name	GPI	Brand/Generic
CAPLYTA	LUMATEPERONE TOSYLATE CAP 10.5 MG	59400022400110	Brand
CAPLYTA	LUMATEPERONE TOSYLATE CAP 21 MG	59400022400115	Brand
CAPLYTA	LUMATEPERONE TOSYLATE CAP 42 MG	59400022400120	Brand
REXULTI	BREXPIRAZOLE TAB 0.25 MG	59250020000310	Brand
REXULTI	BREXPIRAZOLE TAB 0.5 MG	59250020000320	Brand
REXULTI	BREXPIRAZOLE TAB 1 MG	59250020000330	Brand
REXULTI	BREXPIRAZOLE TAB 2 MG	59250020000340	Brand
REXULTI	BREXPIRAZOLE TAB 3 MG	59250020000350	Brand
REXULTI	BREXPIRAZOLE TAB 4 MG	59250020000360	Brand
VRAYLAR	CARIPRAZINE HCL CAP THERAPY PACK 1.5 MG (1) & 3 MG (6)	5940001810B220	Brand
VRAYLAR	CARIPRAZINE HCL CAP 1.5 MG (BASE EQUIVALENT)	59400018100120	Brand
VRAYLAR	CARIPRAZINE HCL CAP 3 MG (BASE EQUIVALENT)	59400018100130	Brand
VRAYLAR	CARIPRAZINE HCL CAP 4.5 MG (BASE EQUIVALENT)	59400018100140	Brand
VRAYLAR	CARIPRAZINE HCL CAP 6 MG (BASE EQUIVALENT)	59400018100150	Brand
FANAPT	ILOPERIDONE TAB 1 MG	59070035000310	Brand
FANAPT	ILOPERIDONE TAB 2 MG	59070035000320	Brand
FANAPT	ILOPERIDONE TAB 4 MG	59070035000340	Brand
FANAPT	ILOPERIDONE TAB 6 MG	59070035000360	Brand
FANAPT	ILOPERIDONE TAB 8 MG	59070035000380	Brand
FANAPT	ILOPERIDONE TAB 10 MG	59070035000385	Brand
FANAPT	ILOPERIDONE TAB 12 MG	59070035000390	Brand

FANAPT TITRATION PACK	ILOPERIDONE TAB 1 MG & 2 MG & 4 MG & 6 MG TITRATION PAK	59070035006320	Brand
LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 5-10 MG	62994802500310	Brand
LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 10-10 MG	62994802500320	Brand
LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 15-10 MG	62994802500330	Brand
LYBALVI	OLANZAPINE-SAMIDORPHAN L-MALATE TAB 20-10 MG	62994802500340	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 The requested drug must be used for a Food and Drug Administration (FDA)-approved indication

**OR**

1.2 The use of this drug is supported by information from one of the following appropriate compendia of current literature:

- Food and Drug Administration (FDA) approved indications and limits
- Published practice guidelines and treatment protocols
- Comparative data evaluating the efficacy, type and frequency of side effects and potential drug interactions among alternative products as well as the risks, benefits, and potential patient outcomes
- Drug Facts and Comparisons
- American Hospital Formulary Service Drug Information
- United States Pharmacopeia - Drug Information
- DRUGDEX Information System
- UpToDate
- MicroMedex
- Peer-reviewed medical literature, including randomized clinical trials, outcomes, research data, and pharmaco-economic studies
- Other drug reference resources

**AND**

2 - ONE of the following:

**2.1** The drug is being prescribed within the manufacturer's published dosing guidelines

**OR**

**2.2** The requested dose falls within dosing guidelines found in ONE of the following compendia of current literature:

- Food and Drug Administration (FDA) approved indications and limits
- Published practice guidelines and treatment protocols
- Comparative data evaluating the efficacy, type and frequency of side effects and potential drug interactions among alternative products as well as the risks, benefits, and potential patient outcomes
- Drug Facts and Comparisons
- American Hospital Formulary Service Drug Information
- United States Pharmacopeia - Drug Information
- DRUGDEX Information System
- UpToDate
- MicroMedex
- Peer-reviewed medical literature, including randomized clinical trials, outcomes, research data, and pharmaco-economic studies
- Other drug reference resources

**AND**

**3** - The requested dosage cannot be achieved using the plan accepted quantity limit of a different dose or formulation

**AND**

**4** - The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plans' program

**AND**

**5** - Physician has provided rationale for needing to exceed the quantity limit (QL) of ONE of the following:

- For Caplyta requests, QL of 1 capsule/day
- For Fanapt tablet requests, QL of 2 tablets/day
- For Fanapt titration pack requests, QL of 1 pack/180 days

- For Lybalvi requests, QL of 1 tablet/day
- For Rexulti requests, QL of 1 tablet/day
- For Vraylar 1.5 mg and 3 mg requests, QL of 2 capsules/day
- For Vraylar 4.5 mg and 6 mg requests, QL of 1 capsule/day
- For Vraylar therapy pack requests, 2 packs/365 days

## 2 . Revision History

Date	Notes
9/24/2024	Update to guideline name. Added Lybalvi as a target. Updated prerequisites and t/f verbiage throughout guideline. Added QL criteria for all targets.

HIV (Fuzeon, Selzentry)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140738
<b>Guideline Name</b>	HIV (Fuzeon, Selzentry)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Brand Selzentry tablets, generic maraviroc tablets, Selzentry oral solution			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SELZENTRY	MARAVIROC TAB 150 MG	12102060000320	Brand
SELZENTRY	MARAVIROC TAB 300 MG	12102060000330	Brand
SELZENTRY	MARAVIROC TAB 25 MG	12102060000305	Brand
SELZENTRY	MARAVIROC TAB 75 MG	12102060000310	Brand
SELZENTRY	MARAVIROC ORAL SOLN 20 MG/ML	12102060002020	Brand
MARAVIROC	MARAVIROC TAB 150 MG	12102060000320	Generic

MARAVIROC	MARAVIROC TAB 300 MG	12102060000330	Generic
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <p>1.1 All of the following:</p> <p>1.1.1 Diagnosis of CCR5-tropic HIV-1 infection as confirmed by a highly sensitive tropism assay</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.2 Patient is currently taking or will be prescribed an optimized background antiretroviral therapy regimen</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.3 Prescribed by or in consultation with a clinician with HIV expertise</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 For continuation of prior therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - For generic maraviroc tablets and Selzentry oral solution ONLY; history of failure or intolerance to Brand Selzentry tablets</p>			

Product Name: Fuzeon			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

FUZEON	ENFUVRTIDE FOR INJ 90 MG	12102530002120	Brand
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <p>1.1 All of the following:</p> <p>1.1.1 Patient has been diagnosed with multidrug-resistant HIV-1 infection</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.2 Patient is currently taking or will be prescribed an optimized background antiretroviral therapy regimen</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.3 Prescribed by or in consultation with a clinician with HIV expertise</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 For continuation of prior therapy</p>			

**2 . Revision History**

Date	Notes
10/24/2022	New GL



Hydroxychloroquine



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140651
<b>Guideline Name</b>	Hydroxychloroquine
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Brand Plaquenil, generic hydroxychloroquine			
Guideline Type	Quantity Limit		
Product Name	Generic Name	GPI	Brand/Generic
HYDROXYCHLOROQUINE SULFATE	HYDROXYCHLOROQUINE SULFATE TAB 200 MG	13000020100305	Generic
PLAQUENIL	HYDROXYCHLOROQUINE SULFATE TAB 200 MG	13000020100305	Brand
<b>Approval Criteria</b>			
1 - ONE of the following:			

<p><b>1.1</b> Treatment of chronic discoid lupus erythematosus or systemic lupus erythematosus</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2</b> Treatment of rheumatoid arthritis</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.3</b> Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported</p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.4</b> Treatment of uncomplicated malaria</p>	
Notes	Authorization will be issued for 6 months up to a quantity of 120 tablets per 30 days.

## 2 . Revision History

Date	Notes
4/6/2020	C&S Implementation

Hyftor (sirolimus) topical gel



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140739
<b>Guideline Name</b>	Hyftor (sirolimus) topical gel
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Hyftor			
Approval Length	4 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYFTOR	SIROLIMUS GEL 0.2%	90784070004020	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of facial angiofibroma associated with tuberous sclerosis complex			

<b>AND</b>
<b>2</b> - Patient is 6 years of age or older
<b>AND</b>
<b>3</b> - Patient is not a candidate for laser therapy or surgical treatments
<b>AND</b>
<b>4</b> - Prescribed by or in consultation with a dermatologist

Product Name: Hyftor			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYFTOR	SIROLIMUS GEL 0.2%	90784070004020	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy (e.g., improvement in size or redness of facial angiofibroma)			

## 2 . Revision History

Date	Notes
10/21/2022	new GL

Igalmi (dexmedetomidine)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140740
<b>Guideline Name</b>	Igalmi (dexmedetomidine)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Igalmi			
Approval Length	14 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
IGALMI	DEXMEDETOMIDINE HCL FILM 120 MCG	60206030108220	Brand
IGALMI	DEXMEDETOMIDINE HCL FILM 180 MCG	60206030108230	Brand
<b>Approval Criteria</b>			
1 - One of the following diagnoses:			

- Schizophrenia
- Bipolar I or II disorder

**AND**

**2** - For the treatment of acute agitation

**AND**

**3** - Trial and failure, contraindication or intolerance to at least two preferred products used in acute agitation (e.g., olanzapine, ziprasidone)

**AND**

**4** - Patient is currently being managed with maintenance medication for their underlying disorder (e.g., aripiprazole, olanzapine, quetiapine, lithium, valproic acid)

## 2 . Revision History

Date	Notes
10/24/2022	New

Ilaris (canakinumab)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-141009
<b>Guideline Name</b>	Ilaris (canakinumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2023
-----------------	-----------

## 1 . Criteria

Product Name: Ilaris			
Diagnosis	Periodic Fever Syndromes [Cryopyrin-Associated Periodic Syndromes (CAPS), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency(MKD), Familial Mediterranean Fever(FMF)]		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ILARIS	CANAKINUMAB SUBCUTANEOUS INJ 150 MG/ML	66460020002015	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of one of the following periodic fever syndromes:

- Cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS)
- Tumor necrosis factor (TNF) receptor associated periodic syndrome (TRAPS)
- Hyperimmunoglobulin D (Hyper-IgD) syndrome (HIDS/mevalonate kinase deficiency (MKD))
- Familial Mediterranean Fever (FMF)

**AND**

**2** - Prescribed by or in consultation with one of the following:

- Rheumatologist
- Immunologist

**AND**

**3** - Both of the following:

- Patient is not receiving concomitant treatment with Tumor Necrosis Factor (TNF) inhibitors (e.g., Enbrel [etanercept], Humira [adalimumab], Remicade [infliximab])
- Patient is not receiving concomitant treatment with Interleukin-1 inhibitor (e.g., Arcalyst [rilonacept], Kineret [anakinra])

**AND**

**4** - Patients diagnosed with Familial Mediterranean Fever (FMF) have a history of failure, contraindication, or intolerance to colchicine (applies to diagnosis of FMF ONLY)

Product Name: Ilaris	
Diagnosis	Periodic Fever Syndrome [CAPS, TRAPS, HIDS/MKD, FMF]
Approval Length	12 month(s)
Therapy Stage	Reauthorization



Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
ILARIS	CANAKINUMAB SUBCUTANEOUS INJ 150 MG/ML	66460020002015	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy [defined as a decrease in frequency or severity of attacks, or a decrease in index disease flare or normalization of CRP (C-reactive protein)]</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Both of the following:</p> <ul style="list-style-type: none"> <li>• Patient is not receiving concomitant treatment with Tumor Necrosis Factor (TNF) inhibitors (e.g., Enbrel [etanercept], Humira [adalimumab], Remicade [infliximab])</li> <li>• Patient is not receiving concomitant treatment with Interleukin-1 inhibitor (e.g., Arcalyst [rilonacept], Kineret [anakinra])</li> </ul>			

Product Name: Ilaris			
Diagnosis	Systemic Juvenile Idiopathic Arthritis (SJIA)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ILARIS	CANAKINUMAB SUBCUTANEOUS INJ 150 MG/ML	66460020002015	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) confirming a diagnosis of active systemic juvenile idiopathic arthritis (SJIA)</p>			

**AND**

**2** - Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure, contraindication, or intolerance to one of the following conventional therapies at maximally tolerated doses:

- Minimum duration of a 3-month trial and failure of methotrexate
- Minimum duration of a 1-month trial of a nonsteroidal anti-inflammatory drug (NSAID) (e.g., ibuprofen, naproxen)
- Minimum duration of a 2-week trial of a systemic glucocorticoid (e.g., prednisone)

**AND**

**3** - Both of the following:

- Patient is not receiving concomitant treatment with Tumor Necrosis Factor (TNF) inhibitors (e.g., Enbrel [etanercept], Humira [adalimumab], Remicade [infliximab])
- Patient is not receiving concomitant treatment with Interleukin-1 inhibitor (e.g., Arcalyst [rilonacept], Kineret [anakinra])

**AND**

**4** - Prescribed by or in consultation with one of the following:

- Rheumatologist
- Immunologist

Product Name: Ilaris			
Diagnosis	Systemic Juvenile Idiopathic Arthritis (SJIA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ILARIS	CANAKINUMAB SUBCUTANEOUS INJ 150 MG/ML	66460020002015	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy as evidenced by at least one of the following:

- Reduction in the total active (swollen and tender) joint count from baseline
- Improvement in clinical features or symptoms (e.g., pain, fever, inflammation, rash, lymphadenopathy, serositis) from baseline

**AND**

2 - Both of the following:

- Patient is not receiving concomitant treatment with Tumor Necrosis Factor (TNF) inhibitors (e.g., Enbrel [etanercept], Humira [adalimumab], Remicade [infliximab])
- Patient is not receiving concomitant treatment with Interleukin-1 inhibitor (e.g., Arcalyst [rilonacept], Kineret [anakinra])

Product Name: Ilaris			
Diagnosis	Still's Disease		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ILARIS	CANAKINUMAB SUBCUTANEOUS INJ 150 MG/ML	66460020002015	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming a diagnosis of Still's Disease, including Adult-Onset Still's Disease (AOSD)

**AND**

**2** - Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure, contraindication, or intolerance to one of the following:

- Corticosteroids (e.g., prednisone)
- Methotrexate
- Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen)

**AND**

**3** - Both of the following:

- Patient is not receiving concomitant treatment with Tumor Necrosis Factor (TNF) inhibitors (e.g., Enbrel [etanercept], Humira [adalimumab], Remicade [infliximab])
- Patient is not receiving concomitant treatment with Interleukin-1 inhibitor (e.g., Arcalyst [rilonacept], Kineret [anakinra])

**AND**

**4** - Prescribed by or in consultation with one of the following:

- Rheumatologist
- Immunologist

Product Name: Ilaris			
Diagnosis	Still's Disease		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ILARIS	CANAKINUMAB SUBCUTANEOUS INJ 150 MG/ML	66460020002015	Brand
<b>Approval Criteria</b>			
<b>1</b> - Documentation of positive clinical response to therapy			

**AND**

**2** - Both of the following:

- Patient is not receiving concomitant treatment with Tumor Necrosis Factor (TNF) inhibitors (e.g., Enbrel [etanercept], Humira [adalimumab], Remicade [infliximab])
- Patient is not receiving concomitant treatment with Interleukin-1 inhibitor (e.g., Arcalyst [rilonacept], Kineret [anakinra])

Product Name: Ilaris			
Diagnosis	Gout Flares		
Approval Length	12 Week(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ILARIS	CANAKINUMAB SUBCUTANEOUS INJ 150 MG/ML	66460020002015	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of gout flares

**AND**

**2** - Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure, contraindication, or intolerance to ALL of the following:

- Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen)
- Colchicine
- Corticosteroids (e.g., prednisone)

**AND**

**3** - Patient has not received Ilaris in the last 12 weeks

**AND**

4 - Prescribed by or in consultation with one of the following:

- Rheumatologist
- Nephrologist

## 2 . Revision History

Date	Notes
11/6/2023	Update GL name to Ilaris (canakinumab)

Ilumya (tildrakizumab-asmn)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155408
<b>Guideline Name</b>	Ilumya (tildrakizumab-asmn)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Ilumya			
Diagnosis	Chronic Moderate to Severe Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ILUMYA	TILDRAKIZUMAB-ASMN SUBCUTANEOUS SOLN PREF SYRINGE 100 MG/ML	9025058010E520	Brand
<b>Approval Criteria</b>			

**1** - ONE of the following:

**1.1** ALL of the following:

**1.1.1** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**1.1.2** Greater than or equal to 3 percent body surface area involvement, palmoplantar, facial, genital involvement, or severe scalp psoriasis

**AND**

**1.1.3** Submission of medical records (e.g., chart notes) or paid claims documenting history of failure, to ONE of the following topical therapies, unless contraindicated or clinically significant adverse effects are experienced:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**1.1.4** Submission of medical records (e.g., chart notes) or paid claims documenting history of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced

**AND**

**1.1.5** Submission of medical records (e.g., chart notes) or paid claims documenting history of failure, contraindication, or intolerance to ALL of the following preferred biologic products:

- A preferred\* adalimumab biosimilar
- Enbrel (etanercept)
- Otezla (apremilast)



**AND**

**1.1.6** Patient is NOT receiving Ilumya in combination with ONE of the following:

- Biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.1.7** Prescribed by or in consultation with a dermatologist

**OR**

**1.2** ALL of the following:

**1.2.1** Submission of medical records (e.g., chart notes) or paid claims documenting patient is currently on the requested therapy

**AND**

**1.2.2** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**1.2.3** Patient is NOT receiving Ilumya in combination with ONE of the following:

- Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.2.4** Prescribed by or in consultation with a dermatologist

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Ilumya	
Diagnosis	Chronic Moderate to Severe Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ILUMYA	TILDRAKIZUMAB-ASMN SUBCUTANEOUS SOLN PREF SYRINGE 100 MG/ML	9025058010E520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Ilumya therapy

**AND**

2 - Patient is NOT receiving Ilumya in combination with ONE of the following:

- Biologic DMARD (disease modifying anti-rheumatic drug) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a dermatologist

**2 . Revision History**

Date	Notes
------	-------

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

9/23/2024	Update to guideline name; Added submission of medical records or p aid claims verbiage; Updated embedded steps and notes section.
-----------	--

Imcivree



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-150886
<b>Guideline Name</b>	Imcivree
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	8/8/2024
-----------------	----------

### 1 . Criteria

Product Name: Imcivree			
Diagnosis	POMC, PCSK1, LEPR Deficiency		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
IMCIVREE	SETMELANOTIDE ACETATE SUBCUTANEOUS SOLN 10 MG/ML	61253860102020	Brand
<b>Approval Criteria</b>			
1 - Requests for POMC, PCSK1, LEPR Deficiency is excluded and is to be denied as a benefit exclusion			

Product Name: Imcivree	
Diagnosis	Bardet-Biedl syndrome (BBS)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
IMCIVREE	SETMELANOTIDE ACETATE SUBCUTANEOUS SOLN 10 MG/ML	61253860102020	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:

1.1 Both of the following:

- Diagnosis of Bardet-Biedl syndrome (BBS)
- Molecular genetic testing to confirm homozygous variants in a BBS gene that are interpreted as pathogenic or likely pathogenic (results of genetic testing must be submitted)

**AND**

1.2 One of the following:

1.2.1 Patient has at least three of the following primary features of the disease:

- Rod-cone dystrophy
- Polydactyly
- Learning disabilities
- Hypogonadotropic hypogonadism and/or genitourinary anomalies
- Renal anomalies

**OR**

1.2.2 Both of the following:

1.2.2.1 Patient has at least two of the following primary features of the disease:

- Rod-cone dystrophy
- Polydactyly
- Learning disabilities
- Hypogonadotropic hypogonadism and/or genitourinary anomalies
- Renal anomalies

**AND**

**1.2.2.2** Patient has at least two of the following secondary features of the disease:

- Speech disorder/delay
- Strabismus/cataracts/astigmatism
- Brachydactyly/syndactyly
- Developmental delay
- Ataxia/poor coordination/imbalance
- Mild spasticity (especially lower limbs)
- Diabetes mellitus
- Dental crowding/hypodontia/small roots/high arched palate
- Left ventricular hypertrophy/congenital heart disease
- Hepatic fibrosis

**AND**

**1.3** Patient has been diagnosed with obesity defined by one of the following:

- BMI greater than or equal to 30 kg/m<sup>2</sup> for adults 18 years of age or older
- Weight greater than or equal to 95th percentile using growth chart assessments for pediatric patients

**AND**

**1.4** Patient is 6 years of age or older

**AND**

**1.5** Other causes or types of obesity have been ruled out (e.g., obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign; obesity associated with other genetic syndromes; polygenic obesity)

**AND**

**2** - Prescribed by or in consultation with an endocrinologist

Product Name: Imcivree			
Diagnosis	Bardet-Biedl syndrome (BBS)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
IMCIVREE	SETMELANOTIDE ACETATE SUBCUTANEOUS SOLN 10 MG/ML	61253860102020	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

**1.1** Patient has been on therapy for 12 months or more

**AND**

**1.2** Weight loss of greater than or equal to 5% of baseline body weight or BMI

**2 . Revision History**

Date	Notes
8/7/2024	Update to POMC, PCSK1, LEPR Deficiency section.

Immune Globulins



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-148697
<b>Guideline Name</b>	Immune Globulins
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Asthma (severe, persistent, high-dose steroid-dependent)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - One of the following diagnoses:

- Severe asthma
- Persistent asthma
- High-dose steroid-dependent asthma

**AND**

2 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

3 - Patient is receiving optimal conventional asthma therapy (e.g., high-dose inhaled glucocorticoids, short- and long-acting inhaled  $\beta$  agonists)

**AND**

4 - History of failure, contraindication, or intolerance to at least TWO of the following:

- Anti-IgE therapy [e.g., Xolair (omalizumab)]

- Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
- Anti-interleukin 5 therapy [e.g., Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab)]

**AND**

**5** - Patient has required continuous oral glucocorticoid therapy for a minimum of 2 months prior to the decision to initiate immune globulin therapy

**AND**

**6** - For long term treatment, documentation of titration to the minimum dose and frequency needed to maintain a sustained clinical effect

**AND**

**7** - Prescribed by or in consultation with a pulmonologist or allergist or immunologist

**AND**

**8** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis

Asthma (severe, persistent, high-dose steroid-dependent)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand



HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Diagnosis	Autoimmune Bullous Disease [pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane (cicatricial) pemphigoid, epidermolysis bullosa acquisita, pemphigoid gestationis, linear IgA bullous dermatosis]		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1** - Diagnosis of Autoimmune Bullous Disease [pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane (cicatricial) pemphigoid, epidermolysis bullosa acquisita, pemphigoid gestationis, linear IgA bullous dermatosis]

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable

- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Extensive and debilitating disease

**AND**

**4** - History of failure, contraindication, or intolerance to systemic corticosteroids with concurrent immunosuppressive treatment (e.g., azathioprine, cyclophosphamide, mycophenolate mofetil)

**AND**

**5** - Intravenous immunoglobulin (IVIG) dose does not exceed 1,000 to 2,000 milligrams (mg) per kilogram (kg) per month divided into 3 equal doses, each given over 3 consecutive days or 400 mg per kg per day given over 5 consecutive days per month. IVIG administration may be repeated monthly as needed for patients requiring maintenance therapy. Dosing interval may need to be adjusted in patients with severe comorbidities

**AND**

**6** - For long term treatment, documentation of titration to the minimum dose and frequency needed to maintain a sustained clinical effect

**AND**

**7** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Autoimmune Bullous Disease [pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane (cicatricial) pemphigoid, epidermolysis bullosa acquisita, pemphigoid gestationis, linear IgA bullous dermatosis]
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

**2 - Statement of expected frequency and duration of proposed immune globulin treatment**

**AND**

**3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response**

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Bone Marrow Transplant (BMT)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1** - ONE of the following uses:

- Prevention of acute graft vs. host disease (GVHD)
- Prevention of infection

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Confirmed allogeneic bone marrow transplant within the last 100 days

**AND**

**4** - Documented severe hypogammaglobulinemia [Immunoglobulin (IgG) less than 400 milligrams (mg) per deciliter (dL)]

**AND**

**5** - Intravenous immunoglobulin (IVIG) dose does not exceed 500 mg per kilogram (kg) once weekly for the first 90 days of therapy, then monthly up to 360 days after transplantation

**AND**

**6** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Bone Marrow Transplant (BMT)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

**2 - Statement of expected frequency and duration of proposed immune globulin treatment**

**AND**

**3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response**

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Chronic Inflammatory Demyelinating Polyneuropathy
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1** - Diagnosis of chronic inflammatory demyelinating polyneuropathy as confirmed by ALL of the following:

**1.1** Progressive symptoms present for at least 2 months

**AND**

**1.2** Symptomatic polyradiculoneuropathy as indicated by progressive or relapsing motor or sensory impairment of more than one limb

**AND**

**1.3** Electrodiagnostic findings [consistent with European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) guidelines for definite chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)] indicating at least ONE of the following criteria are present:

- Motor distal latency prolongation in 2 nerves
- Reduction of motor conduction velocity in 2 nerves
- Prolongation of F-wave latency in 2 nerves
- Absence of F-waves in at least 1 nerve
- Partial motor conduction block of at least 1 motor nerve
- Abnormal temporal dispersion in at least 2 nerves
- Distal compound muscle action potential (CMAP) duration increase in at least 1 nerve

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Prescribed by or in consultation with a neurologist



**AND**

**4** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligrams (mg) per kilogram (kg) per month given over 2 to 5 consecutive days administered in up to six monthly infusions. Dosing interval may need to be adjusted in patients with severe comorbidities.

**AND**

**5** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Chronic Inflammatory Demyelinating Polyneuropathy
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy as measured by an objective scale [e.g., Rankin, Modified Rankin, Medical Research Council (MRC) scale]

**AND**

**2** - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

**AND**

**3** - Prescribed by or in consultation with a neurologist

**AND**

**4** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligrams (mg) per kilogram (kg) per month given over 2 to 5 consecutive days. IVIG administration may be repeated monthly as needed to prevent exacerbation. Dosing interval may need to be adjusted in patients with severe comorbidities.

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify	
Diagnosis	Prevention of infection in B-cell Chronic Lymphocytic Leukemia (CLL)
Approval Length	12 month(s)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Therapy Stage		Initial Authorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand



HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Diagnosis of B-cell chronic lymphocytic leukemia (CLL)

**AND**

2 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

3 - ONE of the following:

- Documented hypogammaglobulinemia [Immunoglobulin (IgG) less than 500 milligrams (mg) per deciliter (dL)]
- History of bacterial infection(s) associated with B-cell CLL

**AND**

**4** - Intravenous immunoglobulin (IVIG) dose does not exceed 400 milligrams (mg) per kilogram (kg) every 3 to 4 weeks

**AND**

**5** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Prevention of infection in B-cell Chronic Lymphocytic Leukemia (CLL)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Dermatomyositis or polymyositis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand

GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1** - Diagnosis of dermatomyositis or polymyositis

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - History of failure, contraindication, or intolerance to immunosuppressive therapy (e.g., azathioprine, corticosteroids, cyclophosphamide, methotrexate)

**AND**

**4** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligrams (mg) per kilogram (kg) per month given over 2 to 5 consecutive days administered as monthly infusions. Dosing interval may need to be adjusted in patients with severe comorbidities

**AND**

**5** - For long term treatment, documentation of titration to the minimum dose and frequency needed to maintain a sustained clinical effect

**AND**

**6** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Dermatomyositis or polymyositis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Diabetes Mellitus
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Patient is newly diagnosed with insulin dependent (type 1) diabetes mellitus

**AND**

2 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

3 - Patient is not a candidate for or is refractory to insulin therapy

**AND**

4 - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Diabetes Mellitus
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PEF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PEF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PEF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

**2 - Statement of expected frequency and duration of proposed immune globulin treatment**

**AND**

**3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response**

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Feto-neonatal Alloimmune Thrombocytopenia (AIT)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - One of the following:

**1.1** For pregnant women, ALL of the following:

**1.1.1** Diagnosis of fetoneonatal alloimmune thrombocytopenia (AIT)

**AND**

**1.1.2** ONE of the following:

- Previously affected pregnancy
- Family history of the disease
- Platelet alloantibodies found on screening

**AND**

**1.1.3** ONE of the following:

**1.1.3.1** Intravenous immunoglobulin (IVIG) dose does not exceed 1,000 milligrams (mg) per kilogram (kg) once weekly until delivery

**OR**

**1.1.3.2** BOTH of the following:

- Fetus or newborn is considered to be at high risk for developing intracranial hemorrhage or other severe complication of AIT
- IVIG dose does not exceed 2,000 mg/kg once weekly until delivery

**OR**

**1.2** For newborns BOTH of the following:

**1.2.1** Diagnosis of fetoneonatal alloimmune thrombocytopenia

**AND**

**1.2.2** Thrombocytopenia that persists after transfusion of antigen-negative compatible platelets

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Feto-neonatal Alloimmune Thrombocytopenia (AIT)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Graves' ophthalmopathy Guillain-Barré syndrome (GBS)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand

GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1 - Diagnosis of Guillain-Barré Syndrome**

**AND**

**2 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:**

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3 - Severe disease requiring aid to walk**

**AND**

**4 - Onset of neuropathic symptoms within the last four weeks**

**AND**

**5** - Prescribed by or in consultation with a neurologist

**AND**

**6** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligrams (mg) per kilogram (kg) per month given over 2 to 5 consecutive days. IVIG administration may be repeated in up to three monthly infusions. Dosing interval may need to be adjusted in patients with severe comorbidities

**AND**

**7** - For long term treatment, documentation of titration to the minimum dose and frequency needed to maintain a sustained clinical effect

**AND**

**8** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis

Graves' ophthalmopathy Guillain-Barré syndrome (GBS)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Diagnosis	Prevention of bacterial infection in pediatric HIV		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Diagnosis of HIV disease

**AND**

2 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Patient age less than or equal to 13 years of age

**AND**

**4** - ONE of the following:

- Documented hypogammaglobulinemia [Immunoglobulin (IgG) less than 400 milligrams (mg) per deciliter (dL)]
- Functional antibody deficiency as demonstrated by either poor specific antibody titers or recurrent bacterial infections

**AND**

**5** - Intravenous immunoglobulin (IVIG ) dose does not exceed 400 mg per kilogram (kg) every 28 days

**AND**

**6** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Prevention of bacterial infection in pediatric HIV
Approval Length	12 month(s)
Therapy Stage	Reauthorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Diagnosis	Immune thrombocytopenia [Idiopathic thrombocytopenic purpura (ITP)]		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand

BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - One of the following:

1.1 ALL of the following:

- Diagnosis of acute thrombocytopenic purpura (ITP)
- Documented platelet count less than  $50 \times 10^9$  per Liter (L) (obtained within the past 30 days)
- Intravenous immunoglobulin (IVIG) dose does not exceed 1,000 milligrams (mg) per kilogram(kg) per day for 1 to 2 days

**OR**

1.2 All of the following:

**1.2.1** Diagnosis of chronic thrombocytopenic purpura (ITP)

**AND**

**1.2.2** History of failure, contraindication, or intolerance to at least ONE of the following:

- Corticosteroids
- Splenectomy

**AND**

**1.2.3** IVIG dose does not exceed 2,000 mg per kg per month given over 2 to 5 consecutive days. IVIG administration may be repeated monthly as needed to prevent exacerbation. Dosing interval should be adjusted depending upon response and titrated to the minimum effective dose that can be given at maximum intervals to maintain safe platelet levels.

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen



- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Immune thrombocytopenia [Idiopathic thrombocytopenic purpura (ITP)]
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PEF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PEF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PEF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

**2 - Statement of expected frequency and duration of proposed immune globulin treatment**

**AND**

**3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response**

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Kawasaki Disease
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Diagnosis of Kawasaki disease



**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Intravenous immunoglobulin (IVIG) dose does not exceed 4,000 milligrams (mg) per kilograms (kg) for five consecutive days or a single dose of 2,000 mg per kg

**AND**

**4** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Kawasaki Disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand

GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify	
Diagnosis	Lambert-Eaton Myasthenic Syndrome (LEMS)
Approval Length	12 month(s)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Therapy Stage		Initial Authorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand



HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1** - Diagnosis of Lambert-Eaton myasthenic syndrome (LEMS)

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - History of failure, contraindication, or intolerance to immunomodulator monotherapy (e.g., azathioprine, corticosteroids)

**AND**

**4** - Concomitant immunomodulator therapy (e.g., azathioprine, corticosteroids), unless contraindicated, will be used for long-term management of LEMS

**AND**

**5** - Prescribed by or in consultation with a neurologist

**AND**

**6** - Intravenous Immunoglobulin (IVIG) dose does not exceed 2,000 milligrams (mg) per kilogram (kg) per month given over 2 to 5 consecutive days. IVIG administration may be repeated monthly as needed to prevent exacerbation. Dosing interval may need to be adjusted in patients with severe comorbidities

**AND**

**7** - For long term treatment, documentation of titration to the minimum dose and frequency needed to maintain a sustained clinical effect

**AND**

**8** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Lambert-Eaton Myasthenic Syndrome (LEMS)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

**3** - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Lennox Gastaut Syndrome
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - History of failure, contraindication or intolerance to initial treatment with traditional anti-epileptic pharmacotherapy (e.g., lamotrigine, phenytoin, valproic acid)

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Prescribed by or in consultation with a neurologist

**AND**

**4** - Intravenous immunoglobulin (IVIG) dose does not exceed 400 milligrams (mg) per kilogram (kg) per day given for 4 to 5 consecutive days. IVIG administration may be repeated monthly as needed in patients requiring maintenance therapy. Dosing interval may need to be adjusted in patients with severe comorbidities

**AND**

**5** - For long term treatment, documentation of titration to the minimum dose and frequency needed to maintain a sustained clinical effect

**AND**

**6** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Lennox Gastaut Syndrome		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

**3** - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Multifocal Motor Neuropathy (MMN)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Diagnosis of multifocal motor neuropathy as confirmed by ALL of the following:

- Weakness with slowly progressive or stepwise progressive course over at least one month
- Asymmetric involvement of two or more nerves

- Absence of motor neuron signs and bulbar signs

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Prescribed by or in consultation with a neurologist

**AND**

**4** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,400 milligram (mg) per kilogram (kg) per month given over 2 to 5 consecutive days. IVIG administration may be repeated monthly as needed to prevent exacerbation. Dosing interval may need to be adjusted in patients with severe comorbidities.

**AND**

**5** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Multifocal Motor Neuropathy (MMN)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy as measured by an objective scale [e.g., Rankin, Modified Rankin, Medical Research Council (MRC) scale]

**AND**

**2** - Prescribed by or in consultation with a neurologist

**AND**



**3** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,400 milligram (mg) per kilogram (kg) per month given over 2 to 5 consecutive days. Dosing interval may need to be adjusted in patients with severe comorbidities

**AND**

**4** - For long term treatment, documentation of titration to the minimum dose and frequency needed to maintain a sustained clinical effect

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Prevention of infection in Multiple Myeloma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1 - Diagnosis of multiple myeloma**

**AND**

**2 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:**

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3 - ONE of the following:**

- Documented hypogammaglobulinemia [immunoglobulin (IgG) less than 500 milligrams (mg) per deciliter (dL)]
- History of bacterial infection(s) associated with multiple myeloma

**AND**

**4 - Intravenous immunoglobulin (IVIG) dose does not exceed 400 mg per kilogram (kg) every 3 to 4 weeks**

**AND**

**5 - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:**

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Prevention of infection in Multiple Myeloma		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

**3** - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Relapsing Multiple Sclerosis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Diagnosis of relapsing forms of multiple sclerosis (MS) (e.g., relapsing-remitting MS, secondary- progressive MS with relapses, progressive-relapsing MS with relapses)

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Documentation of an MS exacerbation or progression (worsening) of the patient's clinical status from the visit prior to the one prompting the decision to initiate immune globulin therapy

**AND**

**4** - History of failure, contraindication, or intolerance to at least TWO of the following agents:

- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone/Glatopa (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Lemtrada (alemtuzumab)
- Mavenclad (cladribine)
- Mayzent (siponimod)
- Ocrevus (ocrelizumab)
- Plegridy (peginterferon beta-1a)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)

**AND**

**5** - Prescribed by or in consultation with a neurologist

**AND**

**6** - Induction, when indicated, does not exceed a dose of 400 milligrams (mg) per kilogram (kg) daily for up to five days

**AND**

**7** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Relapsing Multiple Sclerosis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1** - Medical records, including findings of interval examination including neurological deficits incurred and assessment of disability [e.g., Expanded Disability Status Scale (EDSS), Functional Systems Score (FSS), Multiple Sclerosis Functional Composite (MSFC), Disease Steps (DS)]

**AND**

**2** - Stable or improved disability score (e.g., EDSS, FSS, MSFC, DS)

**AND**

**3** - Documentation of decreased number of relapses since starting immune globulin therapy

**AND**

**4** - Diagnosis continues to be the relapsing forms of multiple sclerosis (MS)

**AND**

**5** - Prescribed by or in consultation with a neurologist

**AND**

**6** - Intravenous immunoglobulin (IVIg) dose does not exceed 1,000 milligram (mg) per kilogram (kg) monthly

**AND**

**7** - For long term treatment, documentation of titration to the minimum dose and frequency needed to maintain a sustained clinical effect

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Myasthenia Gravis - Exacerbation		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Diagnosis of generalized myasthenia gravis

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Evidence of myasthenia exacerbation, defined by at least ONE of the following symptoms in the last month

- Difficulty swallowing
- Acute respiratory failure
- Major functional disability responsible for the discontinuation of physical activity
- Recent immunotherapy treatment with a checkpoint inhibitor [e.g., Keytruda (pembrolizumab), Opdivo (nivolumab), Tecentriq (atezolizumab)]

**AND**

**4** - ONE of the following:

- History of failure, contraindication, or intolerance to immunomodulator therapy (e.g., azathioprine, mycophenolate mofetil, cyclosporine) for long-term management of myasthenia gravis
- Currently receiving immunomodulator therapy (e.g., azathioprine, mycophenolate mofetil, cyclosporine) for long-term management of myasthenia gravis

**AND**

**5** - Prescribed by or in consultation with a neurologist

**AND**

**6** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligrams (mg) per



kilogram (kg) per month given over 2 to 5 days administered in up to three monthly infusions. Dosing interval may need to be adjusted in patients with severe comorbidities.

**AND**

**7** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Refractory Myasthenia Gravis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1** - Diagnosis of refractory generalized myasthenia gravis by or in consultation with a physician or center with expertise in management of myasthenia gravis

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Documentation that the disease status is unchanged or worsening (persistent or worsening symptoms that limit functioning) despite failure, contraindication, or intolerance to BOTH of the following (used in adequate doses and duration):

- Corticosteroids
- Two immunomodulator therapies (e.g., azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, tacrolimus)

**AND**

**4** - Currently receiving immunomodulator therapy (e.g., corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, tacrolimus), used in adequate doses, for long-term management of myasthenia gravis

**AND**

**5** - Prescribed by or in consultation with a neurologist

**AND**

**6** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligrams (mg) per kilogram (kg) per month given over 2 to 5 days administered in up to three monthly infusions. Dosing interval may need to be adjusted in patients with severe comorbidities.

**AND**

**7** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Myasthenia Gravis –Exacerbation and Refractory Myasthenia Gravis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Neuromyelitis Optica		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand

GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, laboratory values, etc.) to support the diagnosis of neuromyelitis optica spectrum disorder (NMOSD) by a neurologist confirming ALL of the following:

1.1 Serologic testing for anti-aquaporin-4 immunoglobulin G (AQP4-IgG) or Neuromyelitis optica immunoglobulin G (NMO-IgG) antibodies has been performed

**AND**

1.2 ONE of the following:

1.2.1 If AQP4-IgG/NMO-IgG positive, past medical history of ONE of the following:

- Optic neuritis
- Acute myelitis
- Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting
- Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
- Symptomatic cerebral syndrome with NMOSD-typical brain lesions

**OR**

**1.2.2** If AQP4-IgG/NMO-IgG negative, past medical history of TWO of the following:

- Optic neuritis
- Acute myelitis
- Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting
- Acute brainstem syndrome
- Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
- Symptomatic cerebral syndrome with NMOSD-typical brain lesions

**AND**

**1.3** Diagnosis of multiple sclerosis or other diagnoses have been ruled out

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - History of failure, contraindication, or intolerance to at least TWO of the following:

- Azathioprine
- Corticosteroids
- Mycophenolate mofetil
- Rituximab
- Soliris (eculizumab)

**AND**

**4** - Patient is not receiving immune globulin in combination with either of the following:

- Rituximab

- Soliris (eculizumab)

**AND**

**5** - Prescribed by or in consultation with a neurologist

**AND**

**6** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligram (mg) per kilogram (kg) per month given over 2 to 5 days administered in up to six monthly infusions. Dosing interval may need to be adjusted in patients with severe comorbidities.

**AND**

**7** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Neuromyelitis Optica		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand

THAN 1MCG/ML			
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Patient has previously been treated with immune globulin

**AND**

2 - Submission of medical records (e.g., chart notes, laboratory tests) to demonstrate a positive clinical response from baseline as demonstrated by BOTH of the following:

**2.1** Reduction in the number and or severity of relapses or signs and symptoms of neuromyelitis optica spectrum disorder (NMOSD)

**AND**

**2.2** Maintenance, reduction, or discontinuation of dose(s) of any baseline immunosuppressive therapy (IST) prior to starting immune globulin. (NOTE: Add on, dose escalation of IST, or additional rescue therapy from baseline to treat NMOSD or exacerbation of symptoms while on immune globulin therapy will be considered as treatment failure.)

**AND**

**3** - Patient is not receiving immune globulin in combination with either of the following:

- Rituximab
- Soliris (eculizumab)

**AND**

**4** - Prescribed by or in consultation with a neurologist

**AND**

**5** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligrams (mg) per kilogram (kg) per month given over 2 to 5 days administered in up to six monthly infusions. Dosing interval may need to be adjusted in patients with severe comorbidities

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Posttransfusion Purpura
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand



GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of posttransfusion purpura</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:</p> <ul style="list-style-type: none"><li>• History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable</li><li>• Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested</li></ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Intravenous immunoglobulin (IVIG) dose does not exceed 1,000 milligrams (mg) per kilogram (kg) for 2 days</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:</p> <ul style="list-style-type: none"><li>• Bivigam</li><li>• Flebogamma</li><li>• Gammagard Liquid</li><li>• Gammagard S-D</li><li>• Gammaked</li><li>• Gamunex-C</li><li>• Hizentra</li><li>• Octagam</li><li>• Privigen</li><li>• Xembify</li></ul>			

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Posttransfusion Purpura		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

**3** - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Post B-Cell Targeted Therapies
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation confirming previous treatment of B-cell targeted therapy within the last 100 days [e.g., CAR-T (e.g., Kymriah), Rituxan (rituximab), Besponsa (inotuzumab ozogamicin)]

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - BOTH of the following:

- Documented hypogammaglobulinemia [immunoglobulin (IgG) less than 500 milligrams (mg) per deciliter (dL)]
- History of bacterial infection(s) associated with B-cell depletion

**AND**

**4** - Intravenous immunoglobulin (IVIG) dose does not exceed 400 mg per kilogram (kg) every 4 weeks, up to 360 days after discontinuation of B-cell depleting therapy

**AND**

**5** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Diagnosis	Post B-Cell Targeted Therapies		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Primary Immunodeficiency Syndromes		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Diagnosis of primary immunodeficiency

**AND**

2 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Clinically significant functional deficiency of humoral immunity as evidenced by ONE of the following:

- Documented failure to produce antibodies to specific antigens
- History of significant recurrent infections

**AND**

**4** - Initial intravenous immunoglobulin (IVIG) dose is 200 to 800 milligrams (mg) per kilogram (kg) every 3 to 4 weeks, based on product prescribing information, and titrated based upon patient response (For subcutaneous immune globulin (SCIG) products, FDA-labeled dosing and conversion guidelines will be used to determine benefit coverage.)

**AND**

**5** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Primary Immunodeficiency Syndromes
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand

GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify	
Diagnosis	Rasmussen Syndrome
Approval Length	12 month(s)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Therapy Stage		Initial Authorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of ONE of the following demonstrating that:

- Short term amelioration of encephalitis is needed prior to definitive surgical therapy
- Disease symptoms (e.g., seizures) persist despite surgical treatment
- The patient is not a candidate for surgical treatment

**AND**

2 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligrams (mg) per kilogram (kg) per month given over 2 to 5 days

**AND**

**4** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Rasmussen Syndrome
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

2 - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

3 - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Stiff-Person Syndrome		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Diagnosis of stiff-person syndrome

**AND**

2 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

3 - History of failure, contraindication or intolerance to GABAergic (gamma-aminobutyric acid analogs) medication (e.g., baclofen, benzodiazepines)

**AND**

4 - Prescribed by or in consultation with a neurologist

**AND**

5 - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligrams (mg) per kilogram (kg) per month given over 2 to 5 days. IVIG administration may be repeated monthly

as needed for patients requiring maintenance therapy. Dosing interval may need to be adjusted in patients with severe comorbidities

**AND**

**6** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Stiff-Person Syndrome
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand



GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of a positive clinical improvement from baseline

**AND**

2 - Prescribed by or in consultation with a neurologist

**AND**

3 - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligrams (mg) per kilogram (kg) per month given over 2 to 5 days. IVIG administration may be repeated monthly as needed for patients requiring maintenance therapy. Dosing interval may need to be adjusted in patients with severe comorbidities

**AND**

4 - For long term treatment, documentation of titration to the minimum dose and frequency needed to maintain a sustained clinical effect

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	Thrombocytopenia, secondary to Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), or pregnancy
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand

GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - One of the following:

1.1 Both of the following:

- Diagnosis of thrombocytopenia secondary to Hepatitis C Virus (HCV) infection
- Patient is receiving concurrent antiviral therapy, unless contraindicated

**OR**

1.2 Both of the following:

- Diagnosis of thrombocytopenia secondary Human Immunodeficiency Virus (HIV) infection
- Patient is receiving concurrent antiviral therapy, unless contraindicated

**OR**

1.3 Diagnosis of thrombocytopenia secondary to pregnancy

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - Documented platelet count less than  $50 \times 10^9$  per liter (L) (obtained within the past 30 days)

**AND**

**4** - Intravenous immunoglobulin (IVIG) dose does not exceed 1,000 milligrams (mg) per kilogram (kg) per day for 1 to 2 days

**AND**

**5** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid
- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify			
Diagnosis	Thrombocytopenia, secondary to Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), or pregnancy		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand

XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1** - One of the following:

**1.1** Both of the following:

- Diagnosis of thrombocytopenia secondary to Hepatitis C Virus (HCV) infection
- Patient is receiving concurrent antiviral therapy, unless contraindicated

**OR**

**1.2** Both of the following:

- Diagnosis of thrombocytopenia secondary Human Immunodeficiency Virus (HIV) infection
- Patient is receiving concurrent antiviral therapy, unless contraindicated

**OR**

**1.3** Diagnosis of thrombocytopenia secondary to pregnancy

**AND**

**2** - Intravenous immunoglobulin (IVIG) dose does not exceed 2,000 milligram (mg) per kilogram (kg) per month given over 2 to 5 consecutive days. IVIG administration may be repeated monthly as needed to prevent exacerbation. Dosing interval should be adjusted depending upon response and titrated to the minimum effective dose that can be given at maximum intervals to maintain safe platelet levels.

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	All other indications
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand

GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

**1** - One of the following diagnoses:

- Autoimmune Uveitis
- Cytomegalovirus (CMV) induced pneumonitis in solid organ transplants
- Enteroviral Meningoencephalitis
- IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathy
- Lymphoproliferative disease (treatment of bacterial infections)
- Monoclonal gammopathy
- Paraproteinemic neuropathy
- Renal transplantation (prevention or treatment of acute humoral rejection)
- Severe Rheumatoid arthritis
- Rotaviral enterocolitis
- Staphylococcal toxic shock
- Toxic epidermal necrolysis or Stevens-Johnson syndrome
- Urticaria (delayed pressure)

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- History and physical examination documenting the severity of the condition, including frequency and severity of infections where applicable
- Laboratory results or diagnostic evidence supporting the indication for which immune globulin is requested

**AND**

**3** - If the request is for a non-preferred product, there must be a history of failure, contraindication or intolerance to ALL the following products:

- Bivigam
- Flebogamma
- Gammagard Liquid

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

- Gammagard S-D
- Gammaked
- Gamunex-C
- Hizentra
- Octagam
- Privigen
- Xembify

Product Name: HyQvia, Gammagard S-D, Gammagard liquid, Cuvitru, Gamastan, Gamastan S-D, Gamunex-C, Carimune NF Nanofiltered, Privigen, Hizentra, Bivigam, Flebogamma Dif, Gammaplex, Octagam, Panzyga, Gammaked, Xembify

Diagnosis	All other indications
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
HYQVIA	IMMUN GLOB INJ 2.5 GM/25ML-HYALURON INJ 200 UNT/1.25 ML KIT	19990002356420	Brand
HYQVIA	IMMUN GLOB INJ 5 GM/50ML-HYALURON INJ 400 UNT/2.5 ML KIT	19990002356425	Brand
HYQVIA	IMMUN GLOB INJ 10 GM/100ML-HYALURON INJ 800 UNT/5 ML KIT	19990002356430	Brand
HYQVIA	IMMUN GLOB INJ 20 GM/200ML-HYALURON INJ 1600 UNT/10 ML KIT	19990002356440	Brand
HYQVIA	IMMUN GLOB INJ 30 GM/300ML-HYALURON INJ 2400 UNT/15 ML KIT	19990002356450	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMUNEX-C	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 40 GM/400ML	19100020302084	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 6 GM	19100020102125	Brand
CARIMUNE NF	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 12 GM	19100020102135	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 1 GM/5ML	19100020202050	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 2 GM/10ML	19100020202054	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 4 GM/20ML	19100020202058	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 8 GM/40ML	19100020202062	Brand
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS INJ 10 GM/50ML	19100020202065	Brand
GAMASTAN	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
GAMASTAN S/D	IMMUNE GLOBULIN (HUMAN) IM INJ	19100020002200	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/50ML	19100020102068	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/200ML	19100020102076	Brand
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV SOLN 40 GM/400ML	19100020102090	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2.5 GM/50ML	19100020102034	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 5 GM/100ML	19100020102038	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/200ML	19100020102042	Brand
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV SOLN 20 GM/400ML	19100020102044	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 1 GM/20ML	19100020102030	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 2 GM/20ML	19100020102063	Brand
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 30 GM/300ML	19100020102080	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 1 GM/10ML	19100020602020	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 2.5 GM/25ML	19100020602025	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 5 GM/50ML	19100020602030	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 10 GM/100ML	19100020602035	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 20 GM/200ML	19100020602040	Brand
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV SOLN 30 GM/300ML	19100020602045	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 1 GM/5ML	19100020642020	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 2 GM/10ML	19100020642025	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 4 GM/20ML	19100020642030	Brand
XEMBIFY	IMMUNE GLOBULIN (HUMAN)-KLHW SUBCUTANEOUS INJ 10 GM/50ML	19100020642040	Brand
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV SOLN 10 GM/100ML	19100020102072	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 1 GM/5ML	1910002020E520	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 2 GM/10ML	1910002020E530	Brand
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS SOLN PREF SYR 4 GM/20ML	1910002020E540	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 5 GM	19100020102120	Brand
GAMMAGARD S/D IGA LESS THAN 1MCG/ML	IMMUNE GLOBULIN (HUMAN) IV FOR SOLN 10 GM	19100020102130	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 1 GM/10ML	19100020302060	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 2.5 GM/25ML	19100020302064	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 5 GM/50ML	19100020302068	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 10 GM/100ML	19100020302072	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 20 GM/200ML	19100020302076	Brand
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS SOLN 30 GM/300ML	19100020302080	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to immune globulin therapy

**AND**

**2** - Statement of expected frequency and duration of proposed immune globulin treatment

**AND**

**3** - For long term treatment, documentation of titration to the minimum effective dose and frequency needed to maintain a sustained clinical response

## 2 . Revision History

Date	Notes
6/20/2024	Updates to GPI tables. No changes to criteria.

Impavido



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140789
<b>Guideline Name</b>	Impavido
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	6/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Impavido			
Approval Length	28 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
IMPAVIDO	MILTEFOSINE CAP 50 MG	16000036000120	Brand
<b>Approval Criteria</b>			
1 - Patient has a diagnosis of ONE of the following:			

- Visceral leishmaniasis due to *Leishmania donovani*
- Cutaneous leishmaniasis due to *Leishmania braziliensis*, *Leishmania guyanensis*, or *Leishmania panamensis*
- Mucosal leishmaniasis due to *Leishmania braziliensis*
- Primary Amebic Meningoencephalitis (PAM)
- Keratitis due to *Acanthamoeba*
- Amebic encephalitis due to *Balamuthia mandrillaris*

Inbrija



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140661
<b>Guideline Name</b>	Inbrija
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Inbrija			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
INBRIJA	LEVODOPA INHAL POWDER CAP 42 MG	73200040000160	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of Parkinson's disease			

**AND**

**2** - Inbrija will be used as intermittent treatment for OFF episodes

**AND**

**3** - Prescribed by, or in consultation with, a neurologist or specialist in the treatment of Parkinson's disease

**AND**

**4** - Patient is currently on a stable dose of a carbidopa/levodopa-containing medication and will continue receiving treatment with a carbidopa/levodopa-containing medication while on therapy

**AND**

**5** - Patient continues to experience greater than or equal to 2 hours of OFF time per day despite optimal management of carbidopa/levodopa therapy including BOTH of the following:

- Taking carbidopa/levodopa on an empty stomach or at least one half-hour or more before or one hour after a meal or avoidance of high protein diet
- Dose and dosing interval optimization

**AND**

**6** - History of failure, contraindication, or intolerance to TWO anti-Parkinson's disease therapies from the following adjunctive pharmacotherapy classes (trial must be from two different classes):

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., selegiline)

Product Name: Inbrija



Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
INBRIJA	LEVODOPA INHAL POWDER CAP 42 MG	73200040000160	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Inbrija therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient will continue to receive treatment with a carbidopa/levodopa-containing medication</p>			

## 2 . Revision History

Date	Notes
1/27/2021	Updated criteria for initial authorization. Copied from 79944

Infliximab Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-147862
<b>Guideline Name</b>	Infliximab Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Zymfentra			
Diagnosis	Crohn's Disease (CD)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZYMFENTRA 2-PEN	INFLIXIMAB-DYYB SOLN AUTO-INJECTOR KIT 120 MG/ML	5250504020F530	Brand
ZYMFENTRA 1-PEN	INFLIXIMAB-DYYB SOLN AUTO-INJECTOR KIT 120 MG/ML	5250504020F530	Brand
ZYMFENTRA 2-SYRINGE	INFLIXIMAB-DYYB SOLN PREFILLED SYRINGE KIT 120 MG/ML	5250504020F830	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming a diagnosis of moderately to severely active Crohn's disease

**AND**

2 - Prescribed by or in consultation with a gastroenterologist

**AND**

3 - Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure or intolerance to Infliximab (Janssen manufacturer)

**AND**

4 - Patient has achieved a clinical response following a minimum of 10 weeks of IV Infliximab (Janssen manufacturer)

**AND**

5 - Provider attests that continued IV administration is not appropriate for the patient (e.g., problems with IV access)

Product Name: Zymfentra			
Diagnosis	Ulcerative Colitis (UC)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZYMFENTRA 2-PEN	INFLIXIMAB-DYYB SOLN AUTO-INJECTOR KIT 120 MG/ML	5250504020F530	Brand

ZYMFENTRA 1-PEN	INFLIXIMAB-DYYB SOLN AUTO-INJECTOR KIT 120 MG/ML	5250504020F530	Brand
ZYMFENTRA 2-SYRINGE	INFLIXIMAB-DYYB SOLN PREFILLED SYRINGE KIT 120 MG/ML	5250504020F830	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of moderately to severely active ulcerative colitis

**AND**

**2** - Prescribed by or in consultation with a gastroenterologist

**AND**

**3** - Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure or intolerance to Infliximab (Janssen manufacturer)

**AND**

**4** - Patient has achieved a clinical response following a minimum of 10 weeks of IV Infliximab (Janssen manufacturer)

**AND**

**5** - Provider attests that continued IV administration is not appropriate for the patient (e.g., problems with IV access)

Product Name: Zymfentra	
Diagnosis	Crohn's Disease (CD), Ulcerative Colitis (UC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ZYMFENTRA 2-PEN	INFLIXIMAB-DYYB SOLN AUTO-INJECTOR KIT 120 MG/ML	5250504020F530	Brand
ZYMFENTRA 1-PEN	INFLIXIMAB-DYYB SOLN AUTO-INJECTOR KIT 120 MG/ML	5250504020F530	Brand
ZYMFENTRA 2-SYRINGE	INFLIXIMAB-DYYB SOLN PREFILLED SYRINGE KIT 120 MG/ML	5250504020F830	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy as evidenced by at least ONE of the following:

- Improvement in intestinal inflammation [e.g., mucosal healing, improvement of lab values (platelet counts, erythrocyte sedimentation rate, C-reactive protein level)] from baseline
- Reversal of high fecal output state

**2 . Revision History**

Date	Notes
5/29/2024	Removed criteria for Avsola and Inflectra as these will be medical benefit. Added criteria for new Zymfentra product.

Ingrezza (valbenazine)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157491
<b>Guideline Name</b>	Ingrezza (valbenazine)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Ingrezza*			
Diagnosis	Moderate to Severe Tardive Dyskinesia		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
INGREZZA	VALBENAZINE TOSYLATE CAP 80 MG (BASE EQUIV)	62380080200140	Brand
INGREZZA	VALBENAZINE TOSYLATE CAP 40 MG (BASE EQUIV)	62380080200120	Brand
INGREZZA	VALBENAZINE TOSYLATE CAP THERAPY PACK 40 MG (7) & 80 MG (21)	6238008020B220	Brand

INGREZZA	VALBENAZINE TOSYLATE CAP 60 MG (BASE EQUIV)	62380080200130	Brand
INGREZZA	VALBENAZINE TOSYLATE CAPSULE SPRINKLE 40 MG (BASE EQUIV)	62380080206830	Brand
INGREZZA	VALBENAZINE TOSYLATE CAPSULE SPRINKLE 60 MG (BASE EQUIV)	62380080206850	Brand
INGREZZA	VALBENAZINE TOSYLATE CAPSULE SPRINKLE 80 MG (BASE EQUIV)	62380080206870	Brand

**Approval Criteria**

**1** - Diagnosis of moderate to severe tardive dyskinesia (TD) secondary to a centrally acting dopamine receptor blocking agent (DRBA)

**AND**

**2** - Prescribed by or in consultation with a psychiatrist or neurologist

**AND**

**3** - Patient is 18 years of age or older

**AND**

**4** - Patient has an Abnormal Involuntary Movement Scale (AIMS) score of 3 or 4 on any one of the AIMS items 1 through 9

**AND**

**5** - Ingrezza is not prescribed concurrently with Austedo or tetrabenazine

**AND**

**6** - Dose does not exceed 80 mg per day

Notes

\*Patients will be approved for ONE strength of Ingrezza ONLY: Approve ALL requests at GPI-14. Confirm there is only 1 active PA on file fo

	r ALL Ingrezza products. End-date/Retire all other active PA's for Ingrezza products.
--	---

Product Name: Ingrezza*	
Diagnosis	Moderate to Severe Tardive Dyskinesia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
INGREZZA	VALBENAZINE TOSYLATE CAP 80 MG (BASE EQUIV)	62380080200140	Brand
INGREZZA	VALBENAZINE TOSYLATE CAP 40 MG (BASE EQUIV)	62380080200120	Brand
INGREZZA	VALBENAZINE TOSYLATE CAP THERAPY PACK 40 MG (7) & 80 MG (21)	6238008020B220	Brand
INGREZZA	VALBENAZINE TOSYLATE CAP 60 MG (BASE EQUIV)	62380080200130	Brand
INGREZZA	VALBENAZINE TOSYLATE CAPSULE SPRINKLE 40 MG (BASE EQUIV)	62380080206830	Brand
INGREZZA	VALBENAZINE TOSYLATE CAPSULE SPRINKLE 60 MG (BASE EQUIV)	62380080206850	Brand
INGREZZA	VALBENAZINE TOSYLATE CAPSULE SPRINKLE 80 MG (BASE EQUIV)	62380080206870	Brand

**Approval Criteria**

**1** - Patient is responding positively to therapy as evidenced by a reduction in the baseline AIMS score in any one of the AIMS items 1 through 9

**AND**

**2** - Ingrezza is not prescribed concurrently with Austedo or tetrabenazine

**AND**

**3** - Dose does not exceed 80 mg per day



Notes	*Patients will be approved for ONE strength of Ingrezza ONLY: Approve ALL requests at GPI-14. Confirm there is only 1 active PA on file for ALL Ingrezza products. End-date/Retire all other active PA's for Ingrezza products.
-------	---

Product Name: Ingrezza*	
Diagnosis	Chorea Associated with Huntington's Disease
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
INGREZZA	VALBENZAZINE TOSYLATE CAP 80 MG (BASE EQUIV)	62380080200140	Brand
INGREZZA	VALBENZAZINE TOSYLATE CAP 40 MG (BASE EQUIV)	62380080200120	Brand
INGREZZA	VALBENZAZINE TOSYLATE CAP THERAPY PACK 40 MG (7) & 80 MG (21)	6238008020B220	Brand
INGREZZA	VALBENZAZINE TOSYLATE CAP 60 MG (BASE EQUIV)	62380080200130	Brand
INGREZZA	VALBENZAZINE TOSYLATE CAPSULE SPRINKLE 40 MG (BASE EQUIV)	62380080206830	Brand
INGREZZA	VALBENZAZINE TOSYLATE CAPSULE SPRINKLE 60 MG (BASE EQUIV)	62380080206850	Brand
INGREZZA	VALBENZAZINE TOSYLATE CAPSULE SPRINKLE 80 MG (BASE EQUIV)	62380080206870	Brand

**Approval Criteria**

1 - Diagnosis of chorea in patients with Huntington's disease

**AND**

2 - Prescribed by or in consultation with a neurologist

**AND**

3 - Patient is 18 years of age or older

**AND**

**4** - Dose does not exceed 80 mg per day

Notes	*Patients will be approved for ONE strength of Ingrezza ONLY: Approve ALL requests at GPI-14. Confirm there is only 1 active PA on file for ALL Ingrezza products. End-date/Retire all other active PA's for Ingrezza products.
-------	---

**Product Name: Ingrezza\***

Diagnosis	Chorea Associated with Huntington's Disease
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
INGREZZA	VALBENAZINE TOSYLATE CAP 80 MG (BASE EQUIV)	62380080200140	Brand
INGREZZA	VALBENAZINE TOSYLATE CAP 40 MG (BASE EQUIV)	62380080200120	Brand
INGREZZA	VALBENAZINE TOSYLATE CAP THERAPY PACK 40 MG (7) & 80 MG (21)	6238008020B220	Brand
INGREZZA	VALBENAZINE TOSYLATE CAP 60 MG (BASE EQUIV)	62380080200130	Brand
INGREZZA	VALBENAZINE TOSYLATE CAPSULE SPRINKLE 40 MG (BASE EQUIV)	62380080206830	Brand
INGREZZA	VALBENAZINE TOSYLATE CAPSULE SPRINKLE 60 MG (BASE EQUIV)	62380080206850	Brand
INGREZZA	VALBENAZINE TOSYLATE CAPSULE SPRINKLE 80 MG (BASE EQUIV)	62380080206870	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy

**AND**

**2** - Dose does not exceed 80 mg per day

Notes	*Patients will be approved for ONE strength of Ingrezza ONLY: Approve ALL requests at GPI-14. Confirm there is only 1 active PA on file for ALL Ingrezza products. End-date/Retire all other active PA's for Ingrezza products.
-------	---

## 2 . Revision History

Date	Notes
10/15/2024	Added note regarding only one strength of Ingrezza can be approved at a time. No changes to clinical criteria.

Inhaled Corticosteroids



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140775
<b>Guideline Name</b>	Inhaled Corticosteroids
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	3/19/2023
-----------------	-----------

### 1 . Criteria

Product Name: Alvesco, Arnuity Ellipta, Asmanex HFA, Qvar Redihaler			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ALVESCO	CICLESONIDE INHAL AEROSOL 80 MCG/ACT	44400017003420	Brand
ALVESCO	CICLESONIDE INHAL AEROSOL 160 MCG/ACT	44400017003440	Brand
ARNUIITY ELLIPTA	FLUTICASONE FUROATE AEROSOL POWDER BREATH ACTIV 50 MCG/ACT	44400033108010	Brand
ARNUIITY ELLIPTA	FLUTICASONE FUROATE AEROSOL POWDER BREATH ACTIV 100 MCG/ACT	44400033108020	Brand
ARNUIITY ELLIPTA	FLUTICASONE FUROATE AEROSOL POWDER BREATH ACTIV 200 MCG/ACT	44400033108030	Brand

ASMANEX HFA	MOMETASONE FUROATE INHAL AEROSOL SUSPENSION 50 MCG/ACT	44400036203210	Brand
ASMANEX HFA	MOMETASONE FUROATE INHAL AEROSOL SUSPENSION 100 MCG/ACT	44400036203220	Brand
ASMANEX HFA	MOMETASONE FUROATE INHAL AEROSOL SUSPENSION 200 MCG/ACT	44400036203230	Brand
QVAR REDHALER	BECLOMETHASONE DIPROP HFA BREATH ACT INH AER 40 MCG/ACT	44400010128120	Brand
QVAR REDHALER	BECLOMETHASONE DIPROP HFA BREATH ACT INH AER 80 MCG/ACT	44400010128140	Brand

**Approval Criteria**

1 - Diagnosis of asthma

**AND**

2 - History of failure, contraindication, intolerance to a majority (not more than 3) of the following preferred inhaled corticosteroids:

- Asmanex Twisthaler (mometasone)
- Flovent Diskus (fluticasone)
- Flovent HFA (fluticasone)
- Pulmicort Flexhaler (budesonide)
- budesonide respule (generic)

**2 . Revision History**

Date	Notes
2/9/2023	Removed therapeutic duplication criteria section.

Injectable Oncology Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-160357
<b>Guideline Name</b>	Injectable Oncology Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Synribo, Tecartus			
Diagnosis	Cancer Indications		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYNRIBO	OMACETAXINE MEPESUCCINATE FOR INJ 3.5 MG	21700040102120	Brand
TECARTUS	BREXUCABTAGENE AUTOLEUCEL IV SUSP 100,000,000 CELLS	21651020101810	Brand
TECARTUS	BREXUCABTAGENE AUTOLEUCEL IV SUSP 200,000,000 CELLS	21651020101820	Brand

**Approval Criteria**

1 - The drug is being used as indicated by National Comprehensive Cancer Network (NCCN) guidelines with a Category of Evidence and Consensus of 1, 2A, or 2B

**2 . Revision History**

Date	Notes
11/7/2024	Added Tecartus products as targets to the guideline. Updated product name list and GPI table accordingly. No changes to criteria.

Inqovi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140969
<b>Guideline Name</b>	Inqovi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Inqovi			
Diagnosis	Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
INQOVI	DECITABINE-CEDAZURIDINE TAB 35-100 MG	21990002250320	Brand



**Approval Criteria**

1 - BOTH of the following:

1.1 Diagnosis of myelodysplastic syndrome (MDS)

**AND**

1.2 Patient is intermediate-1, intermediate-2, or high-risk per the International Prognostic Scoring System (IPSS)

**OR**

2 - Diagnosis of chronic myelomonocytic leukemia (CMML)

Product Name: Inqovi			
Diagnosis	Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
INQOVI	DECITABINE-CEDAZURIDINE TAB 35-100 MG	21990002250320	Brand
<b>Approval Criteria</b>			
1 - Patient does not show evidence of progressive disease while on Inqovi therapy			

Product Name: Inqovi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
INQOVI	DECITABINE-CEDAZURIDINE TAB 35-100 MG	21990002250320	Brand

**Approval Criteria**

1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

Product Name: Inqovi	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
INQOVI	DECITABINE-CEDAZURIDINE TAB 35-100 MG	21990002250320	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Inqovi therapy

Insulin Pen Needles and Syringes



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-158139
<b>Guideline Name</b>	Insulin Pen Needles and Syringes
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Non-preferred insulin pen needles and insulin syringes			
Diagnosis	Non-Preferred		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
EASY TOUCH SAFETY PEN NEEDLES/29G X 5MM	INSULIN PEN NEEDLE 29 G X 5 MM (1/5" OR 3/16")	97051050146318	Brand
MAXI-COMFORT SAFETY PEN NEEDLE/29G X 3/16"	INSULIN PEN NEEDLE 29 G X 5 MM (1/5" OR 3/16")	97051050146318	Brand
EASY TOUCH SAFETY PEN NEEDLES/29G X 8MM	INSULIN PEN NEEDLE 29 G X 8 MM (1/3" OR 5/16")	97051050146322	Brand
MAXI-COMFORT SAFETY PEN NEEDLE/29G X 5/16"	INSULIN PEN NEEDLE 29 G X 8 MM (1/3" OR 5/16")	97051050146322	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DROPLET PEN NEEDLES 29GX10MM	INSULIN PEN NEEDLE 29 G X 10 MM	97051050146326	Brand
TECHLITE PEN NEEDLES 29G X 10MM	INSULIN PEN NEEDLE 29 G X 10 MM	97051050146326	Brand
AURORA PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
CAREFINE PEN NEEDLES 29GX1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
CAREONE UNIFINE PENTIPS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
CARETOUCH PEN NEEDLE 29GX1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
DROPLET PEN NEEDLES 29G X1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
DROPLET PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
DRUG MART UNIFINE PENTIPS29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
EASY TOUCH PEN NEEDLES 29GX1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
EXEL COMFORT POINT INSULIN PEN NEEDLES 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
GLOBAL EASE INJECT PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
H-E-B INCONTROL PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
HEALTHWISE PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
HEALTHY ACCENTS UNIFINE PENTIPS PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
INSUPEN 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
KROGER PEN NEEDLES 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
MARATHON MEDICAL PENTIPS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
MEDICINE SHOPPE PEN NEEDLES 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
MEIJER PEN NEEDLES 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PC UNIFINE PENTIPS 29G X 1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PEN NEEDLES/29G X 1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PENTIPS 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PENTIPS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PX PEN NEEDLE 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
QC PEN NEEDLES 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
RAYA SURE PEN NEEDLE 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
RELION PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
SHOPKO UNIFINE PENTIPS PEN NEEDLES/ORIGINAL/29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
SHOPKO UNIFINE PENTIPS PLUS PEN NEEDLES/REMOVER/29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
TECHLITE PEN NEEDLES 29G X 12 MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
TODAYS HEALTH ORIGINAL PEN NEEDLES 29G X 1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
TRUEPLUS PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
ULTRA FLO INSULIN PEN NEEDLES	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
UNIFINE PENTIPS PLUS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
UNIFINE PENTIPS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
VALUMARK PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
VIDA MIA UNIFINE PENTIPS ORIGINAL 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
1ST TIER UNIFINE PENTIPS PLUS/ORIGINAL/29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
1ST TIER UNIFINE PENTIPS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
ADVOCATE INSULIN PEN NEEDLES 29GX12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BD PEN NEEDLE/ORIGINAL/ULTRA-FINE/29G X 12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
LITETOUCH PEN NEEDLES 29GX12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
SURE COMFORT PEN NEEDLES 29GX1/2" 12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
TRUEPLUS 5-BEVEL PEN NEEDLES 29GX12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
ULTICARE ORIGINAL PEN NEEDLES ULTI-FINE	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
ULTICARE PEN NEEDLES/29G X 12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
ULTIGUARD SAFEPACK PEN NEEDLE/29G X 1/2"/SHARPS CONTAINER	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
ULTILET PEN NEEDLE 29GX12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
ULTRA-THIN II PEN NEEDLES 29GX1/2"	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
BD AUTOSHIELD DUO 30G X 5MM	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
EASY TOUCH PEN NEEDLE/30 G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
PEN NEEDLES 30GX5MM	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
SAFETY PEN NEEDLES/30G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
ULTICARE MINI SAFETY PEN NEEDLES 30G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
UNIFINE PENTIPS PLUS/30G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
UNIFINE PENTIPS/30G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
UNIFINE SAFECONTROL PEN NEEDLE/30G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
EASY TOUCH SAFETY PEN NEEDLES/30G X 1/4"	INSULIN PEN NEEDLE 30 G X 6 MM (1/4" OR 15/64")	97051050146341	Brand
ABOUTTIME PEN NEEDLES 30GX 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
ASSURE ID SAFETY PEN NEEDLES 30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
CAREFINE PEN NEEDLES 30GX5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
DROPLET PEN NEEDLES 30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EASY TOUCH PEN NEEDLE 30 G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
EASY TOUCH SAFETY PEN NEEDLES/30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
INSUPEN ULTRAFIN 30GX8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
NOVOFINE AUTOCOVER PEN NEEDLE 30G X 8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
PEN NEEDLES 30GX8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
SAFETY PEN NEEDLES/30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
SECURESAFE SAFETY PEN NEEDLES/30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
SURE COMFORT PEN NEEDLES 30GX5/16" SHORT	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
ULTICARE SHORT SAFETY PEN NEEDLES 30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
UNIFINE SAFECONTROL PEN NEEDLE/30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
AUM SAFETY PEN NEEDLE/31 G X 4MM	INSULIN PEN NEEDLE 31 G X 4 MM (1/6" OR 5/32")	97051050146354	Brand
COMFORT TOUCH PEN NEEDLES/31G X 4MM	INSULIN PEN NEEDLE 31 G X 4 MM (1/6" OR 5/32")	97051050146354	Brand
RAYA SURE PEN NEEDLE 31G X 4MM	INSULIN PEN NEEDLE 31 G X 4 MM (1/6" OR 5/32")	97051050146354	Brand
ABOUTTIME PEN NEEDLES 31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ADVOCATE INSULIN PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
AUM SAFETY PEN NEEDLE/31 G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
AURORA UNIFINE PENTIPS/MINI/31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
BD PEN NEEDLE/MINI/ULTRA-FINE/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
CAREONE UNIFINE PENTIPS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
CARETOUCH PEN NEEDLES 31GX 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
CLICKFINE PEN NEEDLES 31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

COMFORT EZ/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
COMFORT TOUCH PEN NEEDLES/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
DIATHRIVE PEN NEEDLE/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
DROPLET PEN NEEDLES 31G X3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
DROPLET PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
DROPSAFE SAFETY PEN NEEDLE/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
DRUG MART UNIFINE PENTIPS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
EASY COMFORT PEN NEEDLES 31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
EASY TOUCH PEN NEEDLES/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
FIFTY50 PEN NEEDLES 31G X3/16" (5MM)	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
FIFTY50 PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
FREDS PHARMACY UNIFINE PENTIPS PLUS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
GLOBAL EASE INJECT PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
GNP ULTICARE PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
GNP ULTIGUARD SAFEPACK/MINI PEN NEEDLE/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
GOODSENSE CLICKFINE SAFETY PEN NEEDLE/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
GOODSENSE PEN NEEDLE/PENFINE CLASSIC/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
H-E-B IN CONTROL PEN NEEDLE 31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
H-E-B IN CONTROL PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
H-E-B IN CONTROL UNIFINE PENTIPS PLUS 31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
H-E-B IN CONTROL UNIFINE PENTIPS PLUS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
HEALTHWISE SHORT PEN NEEDLES/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HEALTHY ACCENTS UNIFINE PENTIPS PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
HM ULTICARE MINI PEN NEEDLES/31G X 5MM (3/16")	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
INSUPEN 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
KROGER PEN NEEDLES/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
LEADER UNIFINE PENTIPS PLUS/MINI/31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
LEADER UNIFINE PENTIPS/MINI/31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
LITETOUCH PEN NEEDLES/31 G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
LITETOUCH PEN NEEDLES/31G X 5MM/MINI	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
MARATHON MEDICAL PENTIPS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
MM PEN NEEDLES 31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PC UNIFINE PENTIPS 31G X 5MM MINI	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PEN NEEDLES 31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PEN NEEDLES/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PENTIPS 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PENTIPS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PREFERRED PLUS UNIFINE PENTIPS/MINI/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PX MINI PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
RA PEN NEEDLES 31G X 5MM 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
RAYA SURE PEN NEEDLE 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
SHOPKO UNIFINE PENTIPS PEN NEEDLES/MINI/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
SHOPKO UNIFINE PENTIPS PLUS PEN NEEDLES/MINI/REMOVER/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SURE COMFORT PEN NEEDLES 31GX3/16" (5MM)	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TECHLITE PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TECHLITE PEN NEEDLES/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TRUE COMFORT PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TRUE COMFORT PRO PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TRUEPLUS PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TRUEPLUS 5-BEVEL PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTICARE PEN NEEDLES 31G X 5MM/MINI	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTIGUARD SAFEPACK MINI PEN NEEDLE/31G X 3/16"/SHARPS CONTAI	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTIGUARD SAFEPACK/MINI PEN NEEDLE/31G X 3/16"/SHARPS CONTAI	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTILET PEN NEEDLE 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTILET SHORT PEN NEEDLES31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTRA FLO INSULIN PEN NEEDLE 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTRA-THIN II MINI PEN NEEEDLES/31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTRACARE PEN NEEDLES/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
UNIFINE PENTIPS PLUS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
UNIFINE PENTIPS 31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
UNIFINE PENTIPS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
UNIFINE ULTRA PEN NEEDLE/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
WEGMANS UNIFINE PENTIPS PLUS/MINI/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ZEVRX PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
1ST TIER UNIFINE PENTIPS /MINI/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

1ST TIER UNIFINE PENTIPS PLUS/MINI/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
AURORA PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CAREFINE PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CAREONE UNIFINE PENTIPS 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CARETOUCH PEN NEEDLES 31 G X 6 MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CLICKFINE PEN NEEDLE UNIVERSAL/31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CLICKFINE PEN NEEDLES 31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
COMFORT EZ/31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
COMFORT TOUCH PEN NEEDLES/31G X 6 MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
DIATHRIVE PEN NEEDLE/31 G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
DROPLET PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
DROPSAFE SAFTEY PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
DRUG MART UNIFINE PENTIPS31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
EASY COMFORT PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
EASY TOUCH PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
EXEL COMFORT POINT INSULIN PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
GNP CLICKFINE UNIVERSAL PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
H-E-B IN CONTROL PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
H-E-B IN CONTROL UNIFINE PENTIPS PLUS 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
HEALTHWISE MINI PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
HEALTHY ACCENTS UNIFINE PENTIPS PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

INCONTROL ULTICARE MINI PEN NEEDLES/31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
INSUPEN ULTRAFIN 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
KROGER PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
KROGER PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
LITETOUCH PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
LITETOUCH PEN NEEDLES 31G X 6MM/ULTRA SHORT	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
MAXICOMFORT II PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
MEDICINE SHOPPE PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
MEIJER PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
MICRODOT PEN NEEDLE/31G X 6 MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
MM PEN NEEDLES 31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PC UNIFINE PENTIPS 31G X 6MM ULTRA SHORT	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PEN NEEDLES 31GX6MM (1/4")	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
BD INSULIN SYRINGE/U-500/0.5ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-500 0.5 ML 31G X 6MM (15/64")	97051030956330	Brand
ADVOCATE INSULIN SYRINGE/U-100/0.3ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
BD INSULIN SYRINGE ULTRAFINE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
BD INSULIN SYRINGE/0.3ML/29G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
BD SAFETYGLIDE INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
DROPLET INSULIN SYRINGE 0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
EQL INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EXEL COMFORT POINT INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
GNP INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
KROGER INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
LEADER INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
LITETOUCH INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
MONOJECT INSULIN SYRINGE/SAFETY/PERM NEEDLE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
MONOJECT INSULIN SYRINGE/SAFETY/PERM NEEDLE/0.3ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
TECHLITE INSULIN SYRINGE U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
ULTICARE INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
ULTRA FLO INSULIN SYRINGE 0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
VP INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
ADVOCATE INSULIN SYRINGE/U-100/0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DROPLET INSULIN SYRINGE U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
EASY TOUCH INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
EQL INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
EXEL COMFORT POINT INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
GLOBAL INSULIN SYRINGES/U-100/0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
GNP INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
GNP INSULIN SYRINGES/0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
HEALTHWISE INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
INSULIN SYRINGE/NEEDLE 0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
KROGER INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
LEADER INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
LITETOUCH INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
LITETOUCH INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
MEDIC INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
MM INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
MONOJECT INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
PRECISION SURE-DOSE INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PREFERRED PLUS INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
TECHLITE INSULIN SYRINGE U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTICARE INSULIN SYRINGE/SHORT/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTICARE INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTRA COMFORT INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTRA FLO INSULIN SYRINGE 0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTRA FLO INSULIN SYRINGE 1/2 UNIT/0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTRACARE INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
B-D INSULIN SYRINGE ULTRAFINE/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
BD INSULIN SYRINGE ULTRAFINE/0.3ML/30G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
BD INSULIN SYRINGE ULTRAFINE/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
CAREONE INSULIN SYRINGES/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
DROPLET INSULIN SYRINGE U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
EASY TOUCH INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
GLOBAL INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTICARE INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTICARE INSULIN SYRINGE/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE 0.3ML/30G X 1/2"/SHARPS C	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE/0.3ML/30G X 1/2"/SHARPS C	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTRA FLO INSULIN SYRINGE 0.3ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTRA FLO INSULIN SYRINGE 1/2 UNIT/0.3ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
EASY TOUCH INSULIN SYRINGE/U-100/0.5ML/27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 27 X 1/2"	97051030906310	Brand
INSULIN SYRINGES/0.5ML/27GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 27 X 1/2"	97051030906310	Brand
MAXICOMFORT INSULIN SYRINGES 27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 27 X 1/2"	97051030906310	Brand
ADVOCATE INSULIN SYRINGE/U-100/0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
B-D INSULIN SYRINGE ULTRAFINE II/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
BD INSULIN SYRINGE ULTRAFINE/0.5ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
BD INSULIN SYRINGE ULTRAFINE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
CAREONE INSULIN SYRINGES/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
CARETOUCH INSULIN SYRINGE/0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
COMFORT EZ INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
DROPLET INSULIN SYRINGE U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
DROPLET INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
EASY COMFORT INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EASY TOUCH INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
EQL INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
FIFTY50 SUPERIOR COMFORT INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
GNP INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
HEALTHWISE INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
INSULIN SYRINGE/NEEDLE 0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
INSULIN SYRINGES/0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
KINRAY INSULIN SYRINGE PREFERRED PLUS/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
KROGER INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
LEADER INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
LITETOUCH INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
LITETOUCH INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
LONGS INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
MM INSULIN SYRINGE/U-100/1/2ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
MS INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
PRO COMFORT INSULIN SYRINGES/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
PRODIGY INSULIN SYRINGE/1/2ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

RELION INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.5ML/31G X 5/16	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
TECHLITE INSULIN SYRINGE U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
TRUE COMFORT INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
TRUE COMFORT PRO INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTICARE INSULIN SYRINGE ULTRAFINE U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTICARE INSULIN SYRINGE/SHORT/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTICARE INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTIGUARD SAFEPACK/SYRINGE/NEEDLE/31G X 5/16"/SHARPS CONTAIN	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTRA FLO INSULIN SYRINGE 0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTRACARE INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
BD LO-DOSE INSULIN SYRINGE MICROFINE IV/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
BD INSULIN SYRINGE MICROFINE IV/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
EASY TOUCH INSULIN SYRINGE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
EXEL COMFORT POINT INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
GNP INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

INSULIN SYRINGES/0.5ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
LEADER INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
LITETOUCH INSULIN SYRINGE/U- 100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
MAXI-COMFORT INSULIN SYRINGE/U-100/0.5ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
MONOJECT INSULIN SYRINGE/PERM NEEDLE/U- 100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
MONOJECT INSULIN SYRINGE/SOFTPACK/U- 100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
REALITY INSULIN SYRINGE/U- 100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
TRUEPLUS INSULIN SYRINGE/U- 100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
ULTICARE INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
ADVOCATE INSULIN SYRINGE/U- 100/0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
BD INSULIN SYRINGE ULTRAFINE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
BD INSULIN SYRINGE/0.5ML/29G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
BD SAFETY-GLIDE INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
BD SAFETYGLIDE INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
DROPLET INSULIN SYRINGE 0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
EASY TOUCH INSULIN SYRINGE/SAFETY/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
EASY TOUCH INSULIN SYRINGE/U- 100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EASY TOUCH INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
EQL INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
EXEL COMFORT POINT INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
GNP INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
GNP INSULIN SYRINGES/1/2ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
INSULIN SYRINGE/NEEDLE 0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
INSULIN SYRINGES/0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
KINRAY INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
KROGER INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
LEADER INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
LITETOUCH INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
MONOJECT INSULIN SYRINGE/SAFETY/PERM NEEDLE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
RA INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
REALITY INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
RELION INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
SB INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
SECURESAFE SAFETY INSULIN SYRINGES/U-100/0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SURE COMFORT INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
TECHLITE INSULIN SYRINGE U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
ULTICARE INSULIN SAFETY SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
ULTICARE INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
ULTRA FLO INSULIN SYRINGE 0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
ULTRA-THIN II INSULIN SYRINGE/U-100/0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
VALUE HEALTH INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
ADVOCATE INSULIN SYRINGE/U-100/0.5ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
BD SAFETYGLIDE INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
CARETOUCH INSULIN SYRINGE0.5ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
DROPLET INSULIN SYRINGE U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
EASY COMFORT INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
EASY TOUCH INSULIN SYRINGE/SAFETY/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
EASY TOUCH INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
EQL INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
EXEL COMFORT POINT INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
KMART VALU PLUS INSULIN SYRINGE/0.3ML/30G	INSULIN SYRINGE (DISP) U-100 0.3 ML	97051030056305	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

KMART VALU PLUS INSULIN SYRINGE/0.5ML/29G	INSULIN SYRINGE (DISP) U-100 1/2 ML	97051030056310	Brand
KMART VALU PLUS INSULIN SYRINGE/0.5ML/30G	INSULIN SYRINGE (DISP) U-100 1/2 ML	97051030056310	Brand
BD INSULIN SYRINGE LUER-LOK/U-100/1ML	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
BD INSULIN SYRINGE SLIP TIP/U-100/1ML	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
KMART VALU PLUS INSULIN SYRINGE/1ML/29G	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
KMART VALU PLUS INSULIN SYRINGE/1ML/30G	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
MONOJECT INSULIN SYRINGE REGULAR LUER TIP/SOFTPACK/1ML	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
MONOJECT INSULIN SYRINGE/1ML	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX8MM 0.5ML	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
INSULIN SYRINGES/U-100/0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
VERIFINE INSULIN SYRINGE 0.5ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
INSULIN SYRINGES/U-100/0.5ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
INSULIN SYRINGES/U-100/0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
VERIFINE INSULIN SYRINGE 0.5ML/29G X 12MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
AQ INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
GNP INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
HEALTHWISE INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
INSULIN SYRINGE/NEEDLE 0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
INSULIN SYRINGES/U-100/0.5ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
KROGER INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LEADER INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
LITETOUCH INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
LITETOUCH INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
MEDIC INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
MM INSULIN SYRINGE/U-100/1/2ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
MONOJECT INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
PRO COMFORT INSULIN SYRINGES/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
RA INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
SB INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
TECHLITE INSULIN SYRINGE U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
TRUE COMFORT PRO INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
ULTICARE INSULIN SYRINGE/SHORT/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
ULTICARE INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
ULTRA FLO INSULIN SYRINGE 0.5ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/0.5ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
ULTRACARE INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

VANISHPOINT INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
ZEVRX INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
CAREONE INSULIN SYRINGES/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
DROPLET INSULIN SYRINGE U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
DROPLET INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
EASY COMFORT INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
EASY TOUCH INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
PRO COMFORT INSULIN SYRINGES/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
PX INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
TECHLITE INSULIN SYRINGE U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
TRUE COMFORT PRO INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ULTICARE INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ULTICARE INSULIN SYRINGE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE 1/2ML 30G X 1/2"/SHARPS C	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE/0.5ML/30G X 1/2"/SHARPS C	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ULTRA FLO INSULIN SYRINGE 0.5ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ULTRACARE INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
VANISHPOINT INSULIN SYRINGE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZEV RX INSULIN SYRINGE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
MONOJECT INSULIN SYRINGE/DETACH NEEDLE/1ML/25G X 5/8"	INSULIN SYRINGE/NEEDLE U-100 1 ML 25 X 5/8"	97051030906330	Brand
BD SAFETYGLIDE INSULIN SYRINGE/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
BD VEO INSULIN SYRINGE ULTRA-FINE/U-100/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
BD VEO INSULIN SYRINGE ULTRA-FINE/0.3ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
BD VEO INSULIN SYRINGE ULTRA-FINE/1/2 UNIT/0.3ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
DROPLET INSULIN SYRINGE U-100/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
DROPLET INSULIN SYRINGE/U-100/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX6MM 0.3ML	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
GLOBAL EASY GLIDE INSULIN SYRINGE/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
RELION INSULIN SYRINGE/U-100/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
TECHLITE INSULIN SYRINGE U-100/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
INSULIN SYRINGES 0.3ML/31G X 1/4"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/4" (6 MM)	97051030906334	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/31GX1/4"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/4" (6 MM)	97051030906334	Brand
ULTICARE U-100 INSULIN SYRINGES/HALF UNIT/0.3ML/31G X1/4"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/4" (6 MM)	97051030906334	Brand
ULTICARE U-100 INSULIN SYRINGES/0.3ML/31G X 1/4"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/4" (6 MM)	97051030906334	Brand
ULTICARE U-100 INSULIN SYRINGES/0.3ML/31G X1/4"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/4" (6 MM)	97051030906334	Brand
INSULIN SYRINGES 0.5ML/31G X 1/4"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 31 X 1/4" (6 MM)	97051030906336	Brand
SURE COMFORT INSULIN SYRINGES/0.5ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 31 X 1/4" (6 MM)	97051030906336	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ULTICARE U-100 INSULIN SYRINGES/0.5ML/31G X 1/4"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 31 X 1/4" (6 MM)	97051030906336	Brand
INSULIN SYRINGE 1ML/31G X1/4"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 1/4" (6 MM)	97051030906337	Brand
SURE COMFORT INSULIN SYRINGES/U-100/1ML/31GX6MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 1/4" (6 MM)	97051030906337	Brand
ULTICARE U-100 INSULIN SYRINGES/1ML/31G X 1/4"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 1/4" (6 MM)	97051030906337	Brand
VANISHPOINT INSULIN SYRINGE/1ML/30G X 3/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 3/16" (5 MM)	97051030906338	Brand
EASY COMFORT INSULIN SYRINGE/0.3ML/31G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/2"	97051030906341	Brand
EASY COMFORT INSULIN SYRINGES/0.5ML/32GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 32 X 5/16"	97051030906343	Brand
TRUE COMFORT PRO INSULIN SYRINGE/0.5ML/32G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 32 X 5/16"	97051030906343	Brand
EASY COMFORT INSULIN SYRINGE/1ML/32GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 32 X 5/16"	97051030906344	Brand
TRUE COMFORT PRO INSULIN SYRINGE/1ML/32GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 32 X 5/16"	97051030906344	Brand
EASY TOUCH INSULIN SYRINGE/U-100/1ML/27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
INSULIN SYRINGES/U-100/1ML/27GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
MAXICOMFORT INSULIN SYRINGES 27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
MONOJECT INSULIN SYRINGE/DETACH NEEDLE/1ML/27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
MONOJECT INSULIN SYRINGE/SOFTPACK/1ML/27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
VANISHPOINT INSULIN SYRINGE/0.5ML/30G X 3/16"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 30 X 3/16" (5 MM)	97051030906355	Brand
DROPLET INSULIN SYRINGE U-100/0.3ML/30G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 15/64"	97051030906359	Brand
EASY TOUCH INSULIN SYRINGE/U-100/1ML/27G X 5/8"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 5/8"	97051030906360	Brand
DROPLET INSULIN SYRINGE U-100/0.5ML/30G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 30 X 15/64"	97051030906361	Brand
DROPLET INSULIN SYRINGE U-100/1ML/30G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 15/64"	97051030906362	Brand
CARETOUCH INSULIN SYRINGE/U-100/1ML/28G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 5/16"	97051030906368	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BD INSULIN SYRINGE MICROFINE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
EASY TOUCH INSULIN SYRINGE/U- 100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
GNP INSULIN SYRINGES/1ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
GNP ULTRA COMFORT INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
INSULIN SYRINGES/U- 100/1ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
LEADER INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
LITETOUCH INSULIN SYRINGE/U- 100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
MAXI-COMFORT INSULIN SYRINGE/U-100/1ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
MONOJECT INSULIN SYRINGE/PERM NEEDLE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
MONOJECT INSULIN SYRINGE/U- 100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
PRODIGY INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
REALITY INSULIN SYRINGE/U- 100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
SURE COMFORT INSULIN SYRINGE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
TRUEPLUS INSULIN SYRINGE/U- 100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
ULTICARE INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
ADVOCATE INSULIN SYRINGE/U- 100/1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
AQ INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DROPLET INSULIN SYRINGE 1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 29GX12.5MM 1ML	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
EASY TOUCH FLIPLOCK SAFETY INSULIN SYRINGE 1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
EASY TOUCH INSULIN SYRINGE/SAFETY/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
EASY TOUCH INSULIN SYRINGE/U- 100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
EASY TOUCH SHEATHLOCK SAFETY INSULIN SYRINGE 1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
EQL INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
GNP INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
GNP INSULIN SYRINGES/1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
INSULIN SYRINGE/NEEDLE 1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
INSULIN SYRINGES/U- 100/1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
KROGER INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
LEADER INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
LITETOUCH INSULIN SYRINGE/U- 100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
MONOJECT INSULIN SYRINGE/SAFETY/PERM NEEDLE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

RA INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
REALITY INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
SB INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
SECURESAFE SAFETY INSULIN SYRINGES/U-100/1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
SURE COMFORT INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
TECHLITE INSULIN SYRINGE U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
TRUEPLUS INSULIN SYRINGE /U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
ULTICARE INSULIN SAFETY SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
ULTICARE INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
ULTRA FLO INSULIN SYRINGE 1M/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
ULTRA-THIN II INSULIN SYRINGE/U-100/1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
VALUE HEALTH INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
VANISHPOINT INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
VERIFINE INSULIN SYRINGE 1ML/29G X 12MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
CARETOUCH INSULIN SYRINGE/U-100/1ML/29G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 5/16"	97051030906382	Brand
VANISHPOINT INSULIN SYRINGE/1ML/29G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 5/16"	97051030906382	Brand
ADVOCATE INSULIN SYRINGE/U-100/1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
CARETOUCH INSULIN SYRINGE/1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
DROPLET INSULIN SYRINGE U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
EASY COMFORT INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EASY TOUCH FLIPLOCK SAFETY INSULIN SYRINGE 1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
EASY TOUCH INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
EASY TOUCH SHEATHLOCK SAFETY INSULIN SYRINGE 1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
EQL INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
GLUCOPRO INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
GNP INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
GNP INSULIN SYRINGES/1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
HEALTHWISE INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
INSULIN SYRINGE/NEEDLE 1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
KROGER INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
LEADER INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
LITETOUCH INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
LITETOUCH INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
MM INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
MONOJECT INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
PRO COMFORT INSULIN SYRINGES/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
RA INSULIN SYRINGE/U-100/1 ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SB INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
SURE COMFORT INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
TRUE COMFORT PRO INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
TRUEPLUS INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ULTICARE INSULIN SYRINGE/SHORT/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ULTICARE INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ULTRA FLO INSULIN SYRINGE 1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ULTRACARE INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
VANISHPOINT INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ZEVRX INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
BD INSULIN SYRINGE ULTRA FINE/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
BD INSULIN SYRINGE ULTRA-FINE/1ML/30G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
BD INSULIN SYRINGE ULTRAFINE/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
CAREONE INSULIN SYRINGES/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/1.0ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
DROPLET INSULIN SYRINGE U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
DROPLET INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
EASY COMFORT INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
EASY TOUCH FLIPLOCK SAFETY INSULIN SYRINGE 1ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
EASY TOUCH INSULIN SYRINGE/SAFETY/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EASY TOUCH INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
EASY TOUCH SHEATHLOCK SAFETY SYRINGE 1ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
GLUCOPRO INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
HM ULTICARE INSULIN SYRINGE/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
INSULIN SYRINGES/U-100/1ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
PRO COMFORT INSULIN SYRINGES/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
SURE COMFORT INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
TECHLITE INSULIN SYRINGE U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
TRUE COMFORT PRO INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ULTICARE INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ULTICARE INSULIN SYRINGE/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE 1ML 30G X 1/2"/SHARPS CON	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ULTRA FLO INSULIN SYRINGE 1ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ULTRACARE INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ZEVRX INSULIN SYRINGE/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ADVOCATE INSULIN SYRINGE/U-100/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
AQ INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
BD INSULIN SYRINGE ULTRA-FINE/1ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
BD INSULIN SYRINGE ULTRAFINE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
CAREONE INSULIN SYRINGES/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
CARETOUCH INSULIN SYRINGE/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/U-100/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
COMFORT EZ INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
DROPLET INSULIN SYRINGE U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
DROPLET INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX8MM 1ML	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
EASY COMFORT INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
EASY TOUCH FLIPLOCK SAFETY INSULIN SYRINGE 1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
EASY TOUCH INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
EASY TOUCH SHEATHLOCK SAFETY INSULIN SYRINGE 1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
EQL INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
FIFTY50 SUPERIOR COMFORT INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
GLUCOPRO INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
GNP INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
HEALTHWISE INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
INSULIN SYRINGE/NEEDLE 1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
INSULIN SYRINGES/U-100/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
KINRAY INSULIN SYRINGE PREFERRED PLUS/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
KROGER INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
LEADER INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LITETOUCH INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
MM INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
MONOJECT INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
MS INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
PRO COMFORT INSULIN SYRINGES/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
RELION INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
SB INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
SURE COMFORT INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
TECHLITE INSULIN SYRINGE U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
TRUE COMFORT INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
TRUE COMFORT PRO INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
TRUEPLUS INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTICARE INSULIN SYRINGE ULTRAFINE U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTICARE INSULIN SYRINGE/SHORT/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTICARE INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE 1ML 31G X 5/16"/SHARPS CO	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTRA FLO INSULIN SYRINGE 1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTRACARE INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
VERIFINE INSULIN SYRINGE 1ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ADVOCATE INSULIN SYRINGE/U-100/0.3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CAREONE INSULIN SYRINGES/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
CARETOUCH INSULIN SYRINGE/0.3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
COMFORT ASSIST INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
DROPLET INSULIN SYRINGE U-100/0.3/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
DROPLET INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX8MM 0.3ML	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
EASY COMFORT INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
EASY TOUCH INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
EQL INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
FIFTY50 SUPERIOR COMFORT INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
GLOBAL EASY GLIDE INSULINSYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
GNP INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
GNP INSULIN SYRINGES/3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
HEALTHWISE INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
HM ULTICARE INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
INSULIN SYRINGE/NEEDLE 0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

KINRAY INSULIN SYRINGE PREFERRED PLUS/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
KROGER INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
LEADER INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
LITETOUCH INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
LITETOUCH INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
MM INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
MS INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
PRODIGY INSULIN SYRING/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
RELION INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
TECHLITE INSULIN SYRINGE U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTICARE INSULIN SYRINGE ULTRAFINE U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTICARE INSULIN SYRINGE/SHORT/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTICARE INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE/0.3ML/31G X 5/16"/SHARPS	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTRA FLO INSULIN SYRINGE 0.3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTRA FLO INSULIN SYRINGE 1/2 UNIT/0.3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/0.3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTRACARE INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
VERIFINE INSULIN SYRINGE 0.3ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ASSURE ID INSULIN SAFETY SYRINGE U-100/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
DROPLET INSULIN SYRINGE/U-100/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX6MM 0.5ML	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
GLOBAL EASY GLIDE INSULIN SYRINGE/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
RELION INSULIN SYRINGE 0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
TECHLITE INSULIN SYRINGE U-100/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
ASSURE ID INSULIN SAFETY SYRINGE/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
DROPLET INSULIN SYRINGE U-100/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
DROPLET INSULIN SYRINGE/U-100/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX6MM 1ML	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
GLOBAL EASY GLIDE INSULIN SYRINGE/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
RELION INSULIN SYRINGE 1ML/31GX15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
RELION INSULIN SYRINGE/U-100/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
TECHLITE INSULIN SYRINGE U-100/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
EMBRACE PEN NEEDLES/29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
VERIFINE INSULIN PEN NEEDLE 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
EMBRACE PEN NEEDLES/30G X 5MM	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
COMFORT EZ PRO SAFETY PEN NEEDLES 30G X 8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
EMBRACE PEN NEEDLES/30G X 8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PEN NEEDLES	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
AUM INSULIN SAFETY PEN NEEDLE/31GX4MM	INSULIN PEN NEEDLE 31 G X 4 MM (1/6" OR 5/32")	97051050146354	Brand
COMFORT EZ PRO SAFETY PEN NEEDLES 31G X 4MM	INSULIN PEN NEEDLE 31 G X 4 MM (1/6" OR 5/32")	97051050146354	Brand
AQINJECT PEN NEEDLE/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
AUM INSULIN SAFETY PEN NEEDLE/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
COMFORT EZ PRO SAFETY PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
EMBRACE PEN NEEDLES/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PIP PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PURE COMFORT SAFETY PEN NEEDLE 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TRUE COMFORT SAFETY PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
VERIFINE INSULIN PEN NEEDLE 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
VERIFINE PLUS INSULIN PEN NEEDLE 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
EMBRACE PEN NEEDLES/31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PEN NEEDLES/31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PENTIPS 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PREVENT DROPSAFE SAFETY PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PREVENT SAFETY PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PURE COMFORT SAFETY PEN NEEDLE 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PX EXTRA SHORT PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
QC PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
RAYA SURE PEN NEEDLE 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

RELION MINI PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
RELION PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
RELION PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
RELION PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
SURE COMFORT AUTOKEEPER SAFETY PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TECHLITE PEN NEEDLES/31G X 6 MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TOPCARE CLICKFINE UNIVERSAL PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TRUE COMFORT PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TRUE COMFORT PRO PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TRUE COMFORT SAFETY PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TRUEPLUS PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TRUEPLUS 5-BEVEL PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTICARE MICRO PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTICARE MINI PEN NEEDLES ULTI-FINE IV	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTICARE MINI PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTICARE MINI PEN NEEDLES/31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTICARE MINI PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTIGUARD SAFEPACK/MINI PEN NEEDLE/31G X 1/4"/SHARPS CONTAIN	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTIGUARD SAFEPACK/MINI PEN NEEDLE/31G X 6MM/SHARPS CONTAIN	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTRACARE PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
UNIFINE PENTIPS PLUS 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
UNIFINE PENTIPS 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

UNIFINE ULTRA PEN NEEDLE/31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
WEGMANS UNIFINE PENTIPS PLUS/ULTRA SHORT/31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ZEVRX PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
1ST TIER UNIFINE PENTIPS PLUS/ULTRA SHORT/31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
1ST TIER UNIFINE PENTIPS 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ABOUTTIME PEN NEEDLES 31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ADVOCATE INSULIN PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
AURORA PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CAREFINE PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CARETOUCH PEN NEEDLES 31GX 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLEVER CHOICE COMFORT EZ INSULIN PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLICKFINE PEN NEEDLE UNIVERSAL/31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLICKFINE PEN NEEDLES 31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLICKFINE PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLICKFINE UNIVERSAL PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
COMFORT EZ SHORT/31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
COMFORT TOUCH PEN NEEDLES/31G X 8 MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
DIATHRIVE PEN NEEDLE/31 GX 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
DROPLET PEN NEEDLES 31G X5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
DROPLET PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
DROPSAFE SAFETY PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DRUG MART UNIFINE PENTIPS31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
EASY COMFORT PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
EASY TOUCH PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
EMBRACE PEN NEEDLES/31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
FIFTY50 PEN NEEDLES 31G X5/16" (8MM)	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
FIFTY50 PEN NEEDLES/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
GLOBAL EASE INJECT PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
GNP CLICKFINE UNIVERSAL PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
GNP ULTICARE PEN NEEDLES /31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
GNP ULTIGUARD SAFEPACK/SHORT PEN NEEDLE/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
GOODSENSE PEN NEEDLE/PENFINE CLASSIC/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
H-E-B IN CONTROL PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
H-E-B IN CONTROL UNIFINE PENTIPS PLUS 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
HEALTHWISE SHORT PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
HM ULTICARE SHORT PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
INCONTROL ULTICARE MINI PEN NEEDLES/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
INSUPEN ULTRAFIN 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
INSUPEN 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
KROGER PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
KROGER PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
LEADER UNIFINE PENTIPS PLUS/SHORT/31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
LITETOUCH PEN NEEDLES 31GX8MM SHORT	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LITETOUCH PEN NEEDLES/31G X 8MM/SHORT	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
MARATHON MEDICAL PENTIPS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
MEDICINE SHOPPE PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
MEIJER PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
MM PEN NEEDLES 31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PC UNIFINE PENTIPS 31G X 8MM SHORT	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PEN NEEDLES 31GX8MM (5/16")	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PENTIPS 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PENTIPS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PREVENT DROPSAFE SAFETY PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PREVENT SAFETY PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PRO COMFORT PEN NEEDLES/ 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PX PEN NEEDLE 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PX SHORTLENGTH PEN NEEDLES/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
QC PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
RA PEN NEEDLES 31G X 8MM 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
RAYA SURE PEN NEEDLE 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
RELION PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
RELION PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

RELION PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
RELION SHORT PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
SURE COMFORT PEN NEEDLES 31GX5/16" (8MM)	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TECHLITE PEN NEEDLES/31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TODAYS HEALTH SHORT PEN NEEDLES 31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TOPCARE CLICKFINE UNIVERSAL PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TRUE COMFORT PRO PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TRUEPLUS PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TRUEPLUS 5-BEVEL PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTICARE MICRO PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTICARE MICRO PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTICARE SHORT PEN NEEDLES ULTI-FINE IV	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTICARE SHORT PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTICARE SHORT PEN NEEDLES/31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTIGUARD SAFEPACK/SHORT PEN NEEDLE/31G X 5/16"/SHARPS CONTA	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTIGUARD SAFEPACK/SHORT PEN NEEDLE/31G X 8MM/SHARPS CONTAIN	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTILET PEN NEEDLE 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTILET SHORT PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTRA FLO INSULIN PEN NEELE 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTRA-THIN II PEN NEEDLES/SHORT/31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTRACARE PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
UNIFINE PENTIPS PLUS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

UNIFINE PENTIPS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
UNIFINE ULTRA PEN NEEDLE/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
VERIFINE INSULIN PEN NEEDLE 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
VERIFINE PLUS INSULIN PEN NEEDLE 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
WEGMANS UNIFINE PENTIPS PLUS/SHORT/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ZEVRX PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
1ST TIER UNIFINE PENTIPS PLUS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
1ST TIER UNIFINE PENTIPS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ABOUTTIME PEN NEEDLE 32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
AQINJECT PEN NEEDLE/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
AUM MINI INSULIN PEN NEEDLE/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
AUM PEN NEEDLE/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
AUM READYGARD DUO SAFETY PEN NEEDLE/32GX4MM/DUAL AUTO PROTEC	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CAREFINE PEN NEEDLE 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CARETOUCH PEN NEEDLES 32GX 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CLICKFINE PEN NEEDLE 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CLICKFINE PEN NEEDLES 32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
COMFORT EZ MICRO/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
COMFORT TOUCH PEN NEEDLES/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
DIATHRIVE PEN NEEDLE/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DROPLET PEN NEEDLES 32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
DROPLET PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
DRUG MART UNIFINE PENTIPSPLUS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
DRUG MART UNIFINE PENTIPS32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
EASY COMFORT PEN NEEDLES 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
EASY TOUCH PEN NEEDLES 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
EMBRACE PEN NEEDLES/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
FIFTY50 PEN NEEDLES/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
GLOBAL EASE INJECT PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
GLOBAL EASY GLIDE PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
GNP ULTICARE PEN NEEDLES/32GX 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
GNP ULTIGUARD SAFEPACK/MICRO PEN NEEDLE/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
GOODSENSE PEN NEEDLE/PENFINE CLASSIC/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
H-E-B IN CONTROL PEN NEEDLES/NANO/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
H-E-B IN CONTROL UNIFINE PENTIPS PLUS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
H-E-B IN CONTROL UNIFINE PENTIPS PLUS 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
HEALTHWISE MICRON PEN NEEDLES/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
INCONTROL ULTICARE MINI PEN NEEDLES/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
INSUPEN PEN NEEDLES 32G X4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
INSUPEN 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
KROGER PEN NEEDLES/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
LEADER UNIFINE PENTIPS/NANO/32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LEADER UNIFINE PENTIPS/PLUS/32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
LITETOUCH INSULIN PEN NEEDLES/32G X 4MM/MINI	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
MARATHON MEDICAL PENTIPS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
MICRODOT PEN NEEDLE/32G X 4 MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
MM PEN NEEDLES 32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
NOVOFINE PLUS PEN NEEDLE 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PEN NEEDLES/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PENTIPS 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PENTIPS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PIP PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PRO COMFORT PEN NEEDLES/ 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PURE COMFORT PEN NEEDLE/32G X4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PURE COMFORT SAFETY PEN NEEDLE 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
QC UNIFINE PENTIPS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
RELION PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
RELION PEN NEEDLES 32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
RELION PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
SURE COMFORT AUTOKEEPER SAFETY PEN NEEDLES 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
SURE COMFORT PEN NEEDLES 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
SURE COMFORT PEN NEEDLES 32GX5/32" (4MM)	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
TECHLITE PEN NEEDLES/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TRUE COMFORT PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
TRUE COMFORT PRO PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
TRUE COMFORT SAFETY PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
TRUEPLUS PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
TRUEPLUS 5-BEVEL PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTICARE MICRO PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTICARE MICRO PEN NEEDLES/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTICARE MICRO PEN NEEDLES/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTIGUARD SAFEPACK/MICRO PEN NEEDLE/32G X 4 MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTIGUARD SAFEPACK/MICRO PEN NEEDLE/32G X 4MM/SHARPS CONTAIN	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTIGUARD SAFEPACK/MICRO PEN NEEDLE/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTIGUARD SAFEPACK/MICRO PEN NEEDLE/32G X 5/32"/SHARPS CNTR	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTIGUARD SAFEPACK/MICRO PEN NEEDLE/32G X 5/32"/SHARPS CONTA	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTILET PEN NEEDLE 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTILET PEN NEEDLE 32GX4MM/SHORT	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTRA FLO INSULIN PEN NEEDLE 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTRA THIN PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTRACARE PEN NEEDLES/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
UNIFINE PENTIPS PLUS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
UNIFINE PENTIPS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
UNIFINE SAFECONTROL PEN NEEDLE 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
UNIFINE ULTRA PEN NEEDLE/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

VERIFINE INSULIN PEN NEEDLE 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
VERIFINE PLUS INSULIN PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
WEGMANS UNIFINE PENTIPS PLUS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ZEV RX PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
1ST TIER UNIFINE PENTIPS PLUS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
1ST TIER UNIFINE PENTIPS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
AUM MINI INSULIN PEN NEEDLE/32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
AUM PEN NEEDLE/32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
CAREFINE PEN NEEDLES 32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
CARETOUCH PEN NEEDLES 32GX 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
COMFORT TOUCH PEN NEEDLES/32G X 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
DROPLET PEN NEEDLES 32G X 3/16"	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
DROPLET PEN NEEDLES 32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
EASY TOUCH PEN NEEDLES 32GX3/16"	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
EASY TOUCH 32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
PEN NEEDLES 32G X 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
PRO COMFORT PEN NEEDLES/ 32G X 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
PURE COMFORT PEN NEEDLE/32G X 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
TRUE COMFORT PRO PEN NEEDLES 32G X 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
ULTRACARE PEN NEEDLES/32G X 3/16"	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
AUM MINI INSULIN PEN NEEDLE/32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
AUM PEN NEEDLE/32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CAREFINE PEN NEEDLES 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
COMFORT TOUCH PEN NEEDLES/32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
DROPLET PEN NEEDLES 32G X 1/4"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
DROPLET PEN NEEDLES 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
EASY TOUCH PEN NEEDLES 32GX1/4"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
EASY TOUCH 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
FIFTY50 PEN NEEDLES/32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
GNP ULTICARE PEN NEEDLES/32GX1/4"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
GNP ULTIGUARD SAFEPACK/MINI PEN NEEDLE/32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
GOODSENSE PEN NEEDLE/PENFINE CLASSIC/32G X 1/4"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
INSUPEN SENSITIVE 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
NOVOFINE PEN NEEDLE 32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
PEN NEEDLES 32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
PENTIPS 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
PRO COMFORT PEN NEEDLES/ 32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
PURE COMFORT PEN NEEDLE 32G X6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
SURE COMFORT PEN NEEDLES 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
TECHLITE PEN NEEDLES/32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
TRUE COMFORT PRO PEN NEEDLES 32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
ULTICARE MINI PEN NEEDLES/32G X 1/4"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
ULTIGUARD SAFEPACK/MINI PEN NEEDLE/32G X 1/4"/SHARPS CONTAIN	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ULTRACARE PEN NEEDLES/32G X 1/14"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
UNIFINE PENTIPS 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
VERIFINE INSULIN PEN NEEDLE 32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
BD PEN NEEDLE/MICRO/ULTRA-FINE/32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
1ST TIER UNIFINE PENTIPS 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
AUM MINI INSULIN PEN NEEDLE/32GX8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 32GX8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
COMFORT TOUCH PEN NEEDLES/32G X 8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
DROPLET PEN NEEDLES 32G X 5/16"	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
DROPLET PEN NEEDLES 32GX8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
INSUPEN SENSITIVE 32GX8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
PURE COMFORT PEN NEEDLE 32G X8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
TECHLITE PEN NEEDLES/32G X 8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
ADVOCATE INSULIN PEN NEEDLES	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
AUM MINI INSULIN PEN NEEDLE/33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
AUM PEN NEEDLE/33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES/33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
CARETOUCH PEN NEEDLE 33GX5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
CLEVER CHOICE COMFORT EZ INSULIN PEN NEEDLES 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
COMFORT TOUCH PEN NEEDLES/33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
EASY COMFORT PEN NEEDLES 33G X 4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
EASY GLIDE PEN NEEDLES 33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

H-E-B IN CONTROL UNIFINE PENTIPS PLUS 33GX5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
INSUPEN 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
KROGER PEN NEEDLES/33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
MICRODOT PEN NEEDLE/33G X 4 MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
PEN NEEDLES 33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
TRUE COMFORT PRO PEN NEEDLES 33G X 4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
ULTRA FLO INSULIN PEN NEEDLE 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
ULTRACARE PEN NEEDLES/33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
UNIFINE PENTIPS PLUS 33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
UNIFINE PENTIPS PLUS 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
UNIFINE PENTIPS 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
1ST TIER UNIFINE PENTIPS PLUS 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
1ST TIER UNIFINE PENTIPS 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
AUM MINI INSULIN PEN NEEDLE/33GX5MM	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
AUM PEN NEEDLE/33GX5MM	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 33GX5MM	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
COMFORT TOUCH PEN NEEDLES/33GX 3/16"	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
EASY COMFORT PEN NEEDLES 33G X 5MM	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
TRUE COMFORT PRO PEN NEEDLES 33G X 5MM	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
AUM MINI INSULIN PEN NEEDLE/33GX6MM	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand
AUM PEN NEEDLE/33GX6MM	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 33GX6MM	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand
COMFORT TOUCH PEN NEEDLES/33GX1/4"	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EASY COMFORT PEN NEEDLES 33G X 6MM	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand
TRUE COMFORT PRO PEN NEEDLES 33G X 6MM	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 33GX8MM	INSULIN PEN NEEDLE 33 G X 8 MM (1/3" OR 5/16")	97051050146380	Brand
DROPLET MICRON 34G X 9/64"	INSULIN PEN NEEDLE 34 G X 3.5 MM (9/64")	97051050146385	Brand
B-D INSULIN SYRINGE ULTRAFINE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
BD INSULIN SYRINGE ULTRAFINE/0.5ML/30G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
BD INSULIN SYRINGE ULTRAFINE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
BD INSULIN SYRINGE MICROFINE IV/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
B-D INSULIN SYRINGE ULTRAFINE II/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD INSULIN SYRINGE ULTRAFINE/0.3ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD INSULIN SYRINGE ULTRAFINE/1/2 UNIT/0.3ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD INSULIN SYRINGE ULTRAFINE HALF-UNIT/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD INSULIN SYRINGE ULTRAFINE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD SAFETYGLIDE INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD INSULIN SYRINGE/U-100/1ML/27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
BD INSULIN SYRINGE/1ML/27G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
BD INSULIN SYRINGE MICROFINE IV/U-100/1ML/27G X 5/8"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 5/8"	97051030906360	Brand
BD INSULIN SYRINGE MICROFINE/U-100/1ML/27G X 5/8"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 5/8"	97051030906360	Brand
BD INSULIN SYRINGE SAFETYGLIDE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
BD INSULIN SYRINGE/1ML/29G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
BD INSULIN SYRINGE/U-100/2ML/27.5G X 5/8"	INSULIN SYRINGE/NEEDLE U-100 2 ML 27.5 X 5/8"	97051030906390	Brand
BD SAFETYGLIDE INSULIN SYRINGE/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
BD VEO INSULIN SYRINGE ULTRAFINE/U-100/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BD VEO INSULIN SYRINGE ULTRA-FINE/0.5ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
BD SAFETYGLIDE INSULIN SYRINGE/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
BD VEO INSULIN SYRINGE ULTRA-FINE/U-100/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
BD VEO INSULIN SYRINGE ULTRA-FINE/1ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
BD PEN NEEDLE/SHORT/ULTRA-FINE/31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
BD PEN NEEDLE/NANO 2ND GEN/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
BD PEN NEEDLE/NANO 2ND GEN/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
BD PEN NEEDLE/NANO/ULTRA - FINE/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ASSURE ID DUO PRO SAFETY PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
EASY COMFORT SAFETY PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PENTIPS GENERIC PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
UNIFINE SAFECONTROL PEN NEEDLE 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PENTIPS GENERIC PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
EASY COMFORT SAFETY PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PENTIPS GENERIC PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
UNIFINE SAFECONTROL PEN NEEDLE 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PENTIPS GENERIC PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
UNIFINE SAFECONTROL PEN NEEDLE 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ADVOCATE INSULIN PEN NEEDLE/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
EASY COMFORT SAFETY PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PENTIPS GENERIC PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
TECHLITE PLUS PEN NEEDLES32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ULTIGUARD SAFEPAK/TINY PEN NEEDLE/32G X 4MM/SHARPS CONTAINER	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
UNIFINE PROTECT SAFETY PEN NEEDLE 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
VERIFINE PLUS PEN NEEDLE/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PENTIPS GENERIC PEN NEEDLES 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
ULTIGUARD SAFEPAK/TINY PEN NEEDLE/32G X 6MM/SHARPS CONTAINER	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
UNIFINE PROTECT SAFETY PEN NEEDLE 30G X 8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
VERIFINE INSULIN SYRINGE/0.5ML/29G X 12MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
VERIFINE INSULIN SYRINGE/0.3ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand

**Approval Criteria**

1 - If the request is non-preferred\*, history of failure to a preferred\* BD (Becton Dickinson) insulin pen needle or syringe as confirmed by claims history or submission of medical records

**OR**

2 - If the request is non-preferred\*, physician has provided documentation as to why the patient is unable to use a preferred\* BD product (document rationale)

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: All insulin pen needles and insulin syringes			
Diagnosis	Requests exceeding 6 pen needles or syringes per day*		
Approval Length	12 month(s)		
Guideline Type	Quantity Limit		
Product Name	Generic Name	GPI	Brand/Generic
EASY TOUCH SAFETY PEN NEEDLES/29G X 5MM	INSULIN PEN NEEDLE 29 G X 5 MM (1/5" OR 3/16")	97051050146318	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MAXI-COMFORT SAFETY PEN NEEDLE/29G X 3/16"	INSULIN PEN NEEDLE 29 G X 5 MM (1/5" OR 3/16")	97051050146318	Brand
EASY TOUCH SAFETY PEN NEEDLES/29G X 8MM	INSULIN PEN NEEDLE 29 G X 8 MM (1/3" OR 5/16")	97051050146322	Brand
MAXI-COMFORT SAFETY PEN NEEDLE/29G X 5/16"	INSULIN PEN NEEDLE 29 G X 8 MM (1/3" OR 5/16")	97051050146322	Brand
DROPLET PEN NEEDLES 29GX10MM	INSULIN PEN NEEDLE 29 G X 10 MM	97051050146326	Brand
TECHLITE PEN NEEDLES 29G X 10MM	INSULIN PEN NEEDLE 29 G X 10 MM	97051050146326	Brand
AURORA PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
CAREFINE PEN NEEDLES 29GX1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
CAREONE UNIFINE PENTIPS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
CARETOUCH PEN NEEDLE 29GX1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
DROPLET PEN NEEDLES 29G X1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
DROPLET PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
DRUG MART UNIFINE PENTIPS29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
EASY TOUCH PEN NEEDLES 29GX1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
EXEL COMFORT POINT INSULIN PEN NEEDLES 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
GLOBAL EASE INJECT PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
H-E-B INCONTROL PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
HEALTHWISE PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
HEALTHY ACCENTS UNIFINE PENTIPS PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
INSUPEN 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
KROGER PEN NEEDLES 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
MARATHON MEDICAL PENTIPS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MEDICINE SHOPPE PEN NEEDLES 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
MEIJER PEN NEEDLES 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PC UNIFINE PENTIPS 29G X 1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PEN NEEDLES/29G X 1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PENTIPS 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PENTIPS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
PX PEN NEEDLE 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
QC PEN NEEDLES 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
RAYA SURE PEN NEEDLE 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
RELION PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
SHOPKO UNIFINE PENTIPS PEN NEEDLES/ORIGINAL/29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
SHOPKO UNIFINE PENTIPS PLUS PEN NEEDLES/REMOVER/29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
TECHLITE PEN NEEDLES 29G X 12 MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
TODAYS HEALTH ORIGINAL PEN NEEDLES 29G X 1/2"	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
TRUEPLUS PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
ULTRA FLO INSULIN PEN NEEDLES	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
UNIFINE PENTIPS PLUS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
UNIFINE PENTIPS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
VALUMARK PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
VIDA MIA UNIFINE PENTIPS ORIGINAL 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

1ST TIER UNIFINE PENTIPS PLUS/ORIGINAL/29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
1ST TIER UNIFINE PENTIPS 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
ADVOCATE INSULIN PEN NEEDLES 29GX12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
BD PEN NEEDLE/ORIGINAL/ULTRA-FINE/29G X 12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
LITETOUCH PEN NEEDLES 29GX12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
SURE COMFORT PEN NEEDLES 29GX1/2" 12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
TRUEPLUS 5-BEVEL PEN NEEDLES 29GX12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
ULTICARE ORIGINAL PEN NEEDLES ULTI-FINE	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
ULTICARE PEN NEEDLES/29G X 12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
ULTIGUARD SAFEPACK PEN NEEDLE/29G X 1/2"/SHARPS CONTAINER	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
ULTILET PEN NEEDLE 29GX12.7MM	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
ULTRA-THIN II PEN NEEDLES 29GX1/2"	INSULIN PEN NEEDLE 29 G X 12.7 MM (1/2")	97051050146331	Brand
BD AUTOSHIELD DUO 30G X 5MM	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
EASY TOUCH PEN NEEDLE/30 G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
PEN NEEDLES 30GX5MM	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
SAFETY PEN NEEDLES/30G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
ULTICARE MINI SAFETY PEN NEEDLES 30G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
UNIFINE PENTIPS PLUS/30G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
UNIFINE PENTIPS/30G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
UNIFINE SAFECONTROL PEN NEEDLE/30G X 3/16"	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
EASY TOUCH SAFETY PEN NEEDLES/30G X 1/4"	INSULIN PEN NEEDLE 30 G X 6 MM (1/4" OR 15/64")	97051050146341	Brand
ABOUTTIME PEN NEEDLES 30GX 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ASSURE ID SAFETY PEN NEEDLES 30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
CAREFINE PEN NEEDLES 30GX5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
DROPLET PEN NEEDLES 30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
EASY TOUCH PEN NEEDLE 30 G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
EASY TOUCH SAFETY PEN NEEDLES/30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
INSUPEN ULTRAFIN 30GX8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
NOVOFINE AUTOCOVER PEN NEEDLE 30G X 8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
PEN NEEDLES 30GX8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
SAFETY PEN NEEDLES/30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
SECURESAFE SAFETY PEN NEEDLES/30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
SURE COMFORT PEN NEEDLES 30GX5/16" SHORT	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
ULTICARE SHORT SAFETY PEN NEEDLES 30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
UNIFINE SAFECONTROL PEN NEEDLE/30G X 5/16"	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
AUM SAFETY PEN NEEDLE/31 G X 4MM	INSULIN PEN NEEDLE 31 G X 4 MM (1/6" OR 5/32")	97051050146354	Brand
COMFORT TOUCH PEN NEEDLES/31G X 4MM	INSULIN PEN NEEDLE 31 G X 4 MM (1/6" OR 5/32")	97051050146354	Brand
RAYA SURE PEN NEEDLE 31G X 4MM	INSULIN PEN NEEDLE 31 G X 4 MM (1/6" OR 5/32")	97051050146354	Brand
ABOUTTIME PEN NEEDLES 31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ADVOCATE INSULIN PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
AUM SAFETY PEN NEEDLE/31 G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
AURORA UNIFINE PENTIPS/MINI/31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
BD PEN NEEDLE/MINI/ULTRA-FINE/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
CAREONE UNIFINE PENTIPS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CARETOUCH PEN NEEDLES 31GX 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
CLICKFINE PEN NEEDLES 31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
COMFORT EZ/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
COMFORT TOUCH PEN NEEDLES/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
DIATHRIVE PEN NEEDLE/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
DROPLET PEN NEEDLES 31G X3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
DROPLET PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
DROPSAFE SAFETY PEN NEEDLE/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
DRUG MART UNIFINE PENTIPS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
EASY COMFORT PEN NEEDLES 31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
EASY TOUCH PEN NEEDLES/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
FIFTY50 PEN NEEDLES 31G X3/16" (5MM)	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
FIFTY50 PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
FREDS PHARMACY UNIFINE PENTIPS PLUS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
GLOBAL EASE INJECT PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
GNP ULTICARE PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
GNP ULTIGUARD SAFEPAK/MINI PEN NEEDLE/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
GOODSENSE CLICKFINE SAFETY PEN NEEDLE/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
GOODSENSE PEN NEEDLE/PENFINE CLASSIC/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
H-E-B IN CONTROL PEN NEEDLE 31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
H-E-B IN CONTROL PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

H-E-B IN CONTROL UNIFINE PENTIPS PLUS 31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
H-E-B IN CONTROL UNIFINE PENTIPS PLUS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
HEALTHWISE SHORT PEN NEEDLES/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
HEALTHY ACCENTS UNIFINE PENTIPS PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
HM ULTICARE MINI PEN NEEDLES/31G X 5MM (3/16")	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
INSUPEN 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
KROGER PEN NEEDLES/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
LEADER UNIFINE PENTIPS PLUS/MINI/31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
LEADER UNIFINE PENTIPS/MINI/31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
LITETOUCH PEN NEEDLES/31 G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
LITETOUCH PEN NEEDLES/31G X 5MM/MINI	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
MARATHON MEDICAL PENTIPS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
MM PEN NEEDLES 31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PC UNIFINE PENTIPS 31G X 5MM MINI	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PEN NEEDLES 31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PEN NEEDLES/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PENTIPS 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PENTIPS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PREFERRED PLUS UNIFINE PENTIPS/MINI/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PX MINI PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
RA PEN NEEDLES 31G X 5MM 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
RAYA SURE PEN NEEDLE 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SHOPKO UNIFINE PENTIPS PEN NEEDLES/MINI/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
SHOPKO UNIFINE PENTIPS PLUS PEN NEEDLES/MINI/REMOVER/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
SURE COMFORT PEN NEEDLES 31GX3/16" (5MM)	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TECHLITE PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TECHLITE PEN NEEDLES/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TRUE COMFORT PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TRUE COMFORT PRO PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TRUEPLUS PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TRUEPLUS 5-BEVEL PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTICARE PEN NEEDLES 31G X 5MM/MINI	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTIGUARD SAFEPACK MINI PEN NEEDLE/31G X 3/16"/SHARPS CONTAI	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTIGUARD SAFEPACK/MINI PEN NEEDLE/31G X 3/16"/SHARPS CONTAI	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTILET PEN NEEDLE 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTILET SHORT PEN NEEDLES31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTRA FLO INSULIN PEN NEEDLE 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTRA-THIN II MINI PEN NEEEDLES/31GX3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ULTRACARE PEN NEEDLES/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
UNIFINE PENTIPS PLUS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
UNIFINE PENTIPS 31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
UNIFINE PENTIPS 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
UNIFINE ULTRA PEN NEEDLE/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

WEGMANS UNIFINE PENTIPS PLUS/MINI/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
ZEVRX PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
1ST TIER UNIFINE PENTIPS /MINI/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
1ST TIER UNIFINE PENTIPS PLUS/MINI/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
AURORA PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CAREFINE PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CAREONE UNIFINE PENTIPS 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CARETOUCH PEN NEEDLES 31 G X 6 MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CLICKFINE PEN NEEDLE UNIVERSAL/31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
CLICKFINE PEN NEEDLES 31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
COMFORT EZ/31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
COMFORT TOUCH PEN NEEDLES/31G X 6 MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
DIATHRIVE PEN NEEDLE/31 G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
DROPLET PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
DROPSAFE SAFTEY PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
DRUG MART UNIFINE PENTIPS31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
EASY COMFORT PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
EASY TOUCH PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
EXEL COMFORT POINT INSULIN PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
GNP CLICKFINE UNIVERSAL PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
H-E-B IN CONTROL PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

H-E-B IN CONTROL UNIFINE PENTIPS PLUS 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
HEALTHWISE MINI PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
HEALTHY ACCENTS UNIFINE PENTIPS PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
INCONTROL ULTICARE MINI PEN NEEDLES/31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
INSUPEN ULTRAFIN 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
KROGER PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
KROGER PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
LITETOUCH PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
LITETOUCH PEN NEEDLES 31G X 6MM/ULTRA SHORT	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
MAXICOMFORT II PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
MEDICINE SHOPPE PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
MEIJER PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
MICRODOT PEN NEEDLE/31G X 6 MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
MM PEN NEEDLES 31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PC UNIFINE PENTIPS 31G X 6MM ULTRA SHORT	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PEN NEEDLES 31GX6MM (1/4")	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
BD INSULIN SYRINGE/U-500/0.5ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-500 0.5 ML 31G X 6MM (15/64")	97051030956330	Brand
ADVOCATE INSULIN SYRINGE/U-100/0.3ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
BD INSULIN SYRINGE ULTRAFINE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
BD INSULIN SYRINGE/0.3ML/29G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
BD SAFETYGLIDE INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
DROPLET INSULIN SYRINGE 0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
EQL INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
EXEL COMFORT POINT INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
GNP INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
KROGER INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
LEADER INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
LITETOUCH INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
MONOJECT INSULIN SYRINGE/SAFETY/PERM NEEDLE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
MONOJECT INSULIN SYRINGE/SAFETY/PERM NEEDLE/0.3ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
TECHLITE INSULIN SYRINGE U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
ULTICARE INSULIN SYRINGE/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
ULTRA FLO INSULIN SYRINGE 0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

VP INSULIN SYRINGE/U-100/0.3ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 29 X 1/2"	97051030906305	Brand
ADVOCATE INSULIN SYRINGE/U-100/0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
DROPLET INSULIN SYRINGE U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
EASY TOUCH INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
EQL INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
EXEL COMFORT POINT INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
GLOBAL INSULIN SYRINGES/U-100/0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
GNP INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
GNP INSULIN SYRINGES/0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
HEALTHWISE INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
INSULIN SYRINGE/NEEDLE 0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
KROGER INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
LEADER INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
LITETOUCH INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
LITETOUCH INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
MEDIC INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
MM INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MONOJECT INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
PRECISION SURE-DOSE INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
TECHLITE INSULIN SYRINGE U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTICARE INSULIN SYRINGE/SHORT/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTICARE INSULIN SYRINGE/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTRA COMFORT INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTRA FLO INSULIN SYRINGE 0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTRA FLO INSULIN SYRINGE 1/2 UNIT/0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/0.3ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
ULTRACARE INSULIN SYRINGE/U-100/0.3ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 5/16"	97051030906307	Brand
B-D INSULIN SYRINGE ULTRAFINE/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
BD INSULIN SYRINGE ULTRAFINE/0.3ML/30G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
BD INSULIN SYRINGE ULTRAFINE/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
CAREONE INSULIN SYRINGES/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
DROPLET INSULIN SYRINGE U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
EASY TOUCH INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
GLOBAL INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTICARE INSULIN SYRINGE/U-100/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTICARE INSULIN SYRINGE/0.3ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE 0.3ML/30G X 1/2"/SHARPS C	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE/0.3ML/30G X 1/2"/SHARPS C	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTRA FLO INSULIN SYRINGE 0.3ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
ULTRA FLO INSULIN SYRINGE 1/2 UNIT/0.3ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 1/2"	97051030906308	Brand
EASY TOUCH INSULIN SYRINGE/U-100/0.5ML/27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 27 X 1/2"	97051030906310	Brand
INSULIN SYRINGES/0.5ML/27GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 27 X 1/2"	97051030906310	Brand
MAXICOMFORT INSULIN SYRINGES 27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 27 X 1/2"	97051030906310	Brand
ADVOCATE INSULIN SYRINGE/U-100/0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
B-D INSULIN SYRINGE ULTRAFINE II/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
BD INSULIN SYRINGE ULTRAFINE/0.5ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
BD INSULIN SYRINGE ULTRAFINE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
CAREONE INSULIN SYRINGES/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
CARETOUCH INSULIN SYRINGE/0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
COMFORT EZ INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DROPLET INSULIN SYRINGE U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
DROPLET INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
EASY COMFORT INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
EASY TOUCH INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
EQL INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
FIFTY50 SUPERIOR COMFORT INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
GNP INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
HEALTHWISE INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
INSULIN SYRINGE/NEEDLE 0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
INSULIN SYRINGES/0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
KINRAY INSULIN SYRINGE PREFERRED PLUS/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
KROGER INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
LEADER INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
LITETOUCH INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
LITETOUCH INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
LONGS INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
MM INSULIN SYRINGE/U-100/1/2ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MS INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
PRO COMFORT INSULIN SYRINGES/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
PRODIGY INSULIN SYRINGE/1/2ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
RELION INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
TECHLITE INSULIN SYRINGE U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
TRUE COMFORT INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
TRUE COMFORT PRO INSULIN SYRINGE/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTICARE INSULIN SYRINGE ULTRAFINE U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTICARE INSULIN SYRINGE/SHORT/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTICARE INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTIGUARD SAFEPACK/SYRINGE/NEEDLE/31G X 5/16"/SHARPS CONTAIN	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTRA FLO INSULIN SYRINGE 0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
ULTRACARE INSULIN SYRINGE/U-100/0.5ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
BD LO-DOSE INSULIN SYRINGE MICROFINE IV/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
BD INSULIN SYRINGE MICROFINE IV/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
EASY TOUCH INSULIN SYRINGE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
EXEL COMFORT POINT INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
GNP INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
INSULIN SYRINGES/0.5ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
LEADER INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
LITETOUCH INSULIN SYRINGE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
MAXI-COMFORT INSULIN SYRINGE/U-100/0.5ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
MONOJECT INSULIN SYRINGE/PERM NEEDLE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
MONOJECT INSULIN SYRINGE/SOFTPACK/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
REALITY INSULIN SYRINGE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
ULTICARE INSULIN SYRINGE/0.5ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
ADVOCATE INSULIN SYRINGE/U-100/0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
BD INSULIN SYRINGE ULTRAFINE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
BD INSULIN SYRINGE/0.5ML/29G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
BD SAFETY-GLIDE INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
BD SAFETYGLIDE INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
DROPLET INSULIN SYRINGE 0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EASY TOUCH INSULIN SYRINGE/SAFETY/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
EASY TOUCH INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
EASY TOUCH INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
EQL INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
EXEL COMFORT POINT INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
GNP INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
GNP INSULIN SYRINGES/1/2ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
INSULIN SYRINGE/NEEDLE 0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
INSULIN SYRINGES/0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
KINRAY INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
KROGER INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
LEADER INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
LITETOUCH INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
MONOJECT INSULIN SYRINGE/SAFETY/PERM NEEDLE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
RA INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
REALITY INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
RELION INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SB INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
SECURESAFE SAFETY INSULIN SYRINGES/U-100/0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
TECHLITE INSULIN SYRINGE U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
ULTICARE INSULIN SAFETY SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
ULTICARE INSULIN SYRINGE/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
ULTRA FLO INSULIN SYRINGE 0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
ULTRA-THIN II INSULIN SYRINGE/U-100/0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
VALUE HEALTH INSULIN SYRINGE/U-100/0.5ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
ADVOCATE INSULIN SYRINGE/U-100/0.5ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
BD SAFETYGLIDE INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
CARETOUCH INSULIN SYRINGE0.5ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
DROPLET INSULIN SYRINGE U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
EASY COMFORT INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
EASY TOUCH INSULIN SYRINGE/SAFETY/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
EASY TOUCH INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
EQL INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
EXEL COMFORT POINT INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
KMART VALU PLUS INSULIN SYRINGE/0.3ML/30G	INSULIN SYRINGE (DISP) U-100 0.3 ML	97051030056305	Brand
KMART VALU PLUS INSULIN SYRINGE/0.5ML/29G	INSULIN SYRINGE (DISP) U-100 1/2 ML	97051030056310	Brand
KMART VALU PLUS INSULIN SYRINGE/0.5ML/30G	INSULIN SYRINGE (DISP) U-100 1/2 ML	97051030056310	Brand
BD INSULIN SYRINGE LUER-LOK/U-100/1ML	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
BD INSULIN SYRINGE SLIP TIP/U-100/1ML	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
KMART VALU PLUS INSULIN SYRINGE/1ML/29G	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
KMART VALU PLUS INSULIN SYRINGE/1ML/30G	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
MONOJECT INSULIN SYRINGE REGULAR LUER TIP/SOFTPACK/1ML	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
MONOJECT INSULIN SYRINGE/1ML	INSULIN SYRINGE (DISP) U-100 1 ML	97051030056320	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX8MM 0.5ML	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
INSULIN SYRINGES/U-100/0.5ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
VERIFINE INSULIN SYRINGE 0.5ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 5/16"	97051030906318	Brand
INSULIN SYRINGES/U-100/0.5ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 28 X 1/2"	97051030906320	Brand
INSULIN SYRINGES/U-100/0.5ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
VERIFINE INSULIN SYRINGE 0.5ML/29G X 12MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand
AQ INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
GNP INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
HEALTHWISE INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
INSULIN SYRINGE/NEEDLE 0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

INSULIN SYRINGES/U-100/0.5ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
KROGER INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
LEADER INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
LITETOUCH INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
LITETOUCH INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
MEDIC INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
MM INSULIN SYRINGE/U-100/1/2ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
MONOJECT INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
PRO COMFORT INSULIN SYRINGES/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
RA INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
SB INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
TECHLITE INSULIN SYRINGE U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
TRUE COMFORT PRO INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
ULTICARE INSULIN SYRINGE/SHORT/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
ULTICARE INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
ULTRA FLO INSULIN SYRINGE 0.5ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/0.5ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
ULTRACARE INSULIN SYRINGE/U-100/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
VANISHPOINT INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
ZEVRX INSULIN SYRINGE/0.5ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 5/16"	97051030906328	Brand
CAREONE INSULIN SYRINGES/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
DROPLET INSULIN SYRINGE U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
DROPLET INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
EASY COMFORT INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
EASY TOUCH INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
PRO COMFORT INSULIN SYRINGES/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
PX INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
TECHLITE INSULIN SYRINGE U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
TRUE COMFORT PRO INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ULTICARE INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ULTICARE INSULIN SYRINGE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE 1/2ML 30G X 1/2"/SHARPS C	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE/0.5ML/30G X 1/2"/SHARPS C	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ULTRA FLO INSULIN SYRINGE 0.5ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ULTRACARE INSULIN SYRINGE/U-100/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
VANISHPOINT INSULIN SYRINGE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
ZEVRX INSULIN SYRINGE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
MONOJECT INSULIN SYRINGE/DETACH NEEDLE/1ML/25G X 5/8"	INSULIN SYRINGE/NEEDLE U-100 1 ML 25 X 5/8"	97051030906330	Brand
BD SAFETYGLIDE INSULIN SYRINGE/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
BD VEO INSULIN SYRINGE ULTRA-FINE/U-100/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
BD VEO INSULIN SYRINGE ULTRA-FINE/0.3ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
BD VEO INSULIN SYRINGE ULTRA-FINE/1/2 UNIT/0.3ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
DROPLET INSULIN SYRINGE U-100/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
DROPLET INSULIN SYRINGE/U-100/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX6MM 0.3ML	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
GLOBAL EASY GLIDE INSULIN SYRINGE/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
RELION INSULIN SYRINGE/U-100/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
TECHLITE INSULIN SYRINGE U-100/0.3ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 15/64"	97051030906333	Brand
INSULIN SYRINGES 0.3ML/31G X 1/4"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/4" (6 MM)	97051030906334	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/31GX1/4"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/4" (6 MM)	97051030906334	Brand
ULTICARE U-100 INSULIN SYRINGES/HALF UNIT/0.3ML/31G X1/4"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/4" (6 MM)	97051030906334	Brand
ULTICARE U-100 INSULIN SYRINGES/0.3ML/31G X 1/4"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/4" (6 MM)	97051030906334	Brand
ULTICARE U-100 INSULIN SYRINGES/0.3ML/31G X1/4"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/4" (6 MM)	97051030906334	Brand
INSULIN SYRINGES 0.5ML/31G X 1/4"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 31 X 1/4" (6 MM)	97051030906336	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SURE COMFORT INSULIN SYRINGES/0.5ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 31 X 1/4" (6 MM)	97051030906336	Brand
ULTICARE U-100 INSULIN SYRINGES/0.5ML/31G X 1/4"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 31 X 1/4" (6 MM)	97051030906336	Brand
INSULIN SYRINGE 1ML/31G X1/4"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 1/4" (6 MM)	97051030906337	Brand
SURE COMFORT INSULIN SYRINGES/U-100/1ML/31GX6MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 1/4" (6 MM)	97051030906337	Brand
ULTICARE U-100 INSULIN SYRINGES/1ML/31G X 1/4"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 1/4" (6 MM)	97051030906337	Brand
VANISHPOINT INSULIN SYRINGE/1ML/30G X 3/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 3/16" (5 MM)	97051030906338	Brand
EASY COMFORT INSULIN SYRINGE/0.3ML/31G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 1/2"	97051030906341	Brand
EASY COMFORT INSULIN SYRINGES/0.5ML/32GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 32 X 5/16"	97051030906343	Brand
TRUE COMFORT PRO INSULIN SYRINGE/0.5ML/32G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 32 X 5/16"	97051030906343	Brand
EASY COMFORT INSULIN SYRINGE/1ML/32GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 32 X 5/16"	97051030906344	Brand
TRUE COMFORT PRO INSULIN SYRINGE/1ML/32GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 32 X 5/16"	97051030906344	Brand
EASY TOUCH INSULIN SYRINGE/U-100/1ML/27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
INSULIN SYRINGES/U-100/1ML/27GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
MAXICOMFORT INSULIN SYRINGES 27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
MONOJECT INSULIN SYRINGE/DETACH NEEDLE/1ML/27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
MONOJECT INSULIN SYRINGE/SOFTPACK/1ML/27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
VANISHPOINT INSULIN SYRINGE/0.5ML/30G X 3/16"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 30 X 3/16" (5 MM)	97051030906355	Brand
DROPLET INSULIN SYRINGE U-100/0.3ML/30G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 30 X 15/64"	97051030906359	Brand
EASY TOUCH INSULIN SYRINGE/U-100/1ML/27G X 5/8"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 5/8"	97051030906360	Brand
DROPLET INSULIN SYRINGE U-100/0.5ML/30G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 0.5 ML 30 X 15/64"	97051030906361	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DROPLET INSULIN SYRINGE U-100/1ML/30G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 15/64"	97051030906362	Brand
CARETOUCH INSULIN SYRINGE/U-100/1ML/28G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 5/16"	97051030906368	Brand
BD INSULIN SYRINGE MICROFINE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
EASY TOUCH INSULIN SYRINGE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
GNP INSULIN SYRINGES/1ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
GNP ULTRA COMFORT INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
INSULIN SYRINGES/U-100/1ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
LEADER INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
LITETOUCH INSULIN SYRINGE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
MAXI-COMFORT INSULIN SYRINGE/U-100/1ML/28GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
MONOJECT INSULIN SYRINGE/PERM NEEDLE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
MONOJECT INSULIN SYRINGE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
PRODIGY INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
REALITY INSULIN SYRINGE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
SURE COMFORT INSULIN SYRINGE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
TRUEPLUS INSULIN SYRINGE/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
ULTICARE INSULIN SYRINGE/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
ADVOCATE INSULIN SYRINGE/U-100/1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AQ INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
DROPLET INSULIN SYRINGE 1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 29GX12.5MM 1ML	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
EASY TOUCH FLIPLOCK SAFETY INSULIN SYRINGE 1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
EASY TOUCH INSULIN SYRINGE/SAFETY/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
EASY TOUCH INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
EASY TOUCH SHEATHLOCK SAFETY INSULIN SYRINGE 1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
EQL INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
GNP INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
GNP INSULIN SYRINGES/1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
INSULIN SYRINGE/NEEDLE 1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
INSULIN SYRINGES/U-100/1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
KROGER INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
LEADER INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
LITETOUCH INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
MONOJECT INSULIN SYRINGE/SAFETY/PERM NEEDLE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MONOJECT ULTRA COMFORT INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
RA INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
REALITY INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
SB INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
SECURESAFE SAFETY INSULIN SYRINGES/U-100/1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
SURE COMFORT INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
TECHLITE INSULIN SYRINGE U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
TRUEPLUS INSULIN SYRINGE /U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
ULTICARE INSULIN SAFETY SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
ULTICARE INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
ULTRA FLO INSULIN SYRINGE 1M/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
ULTRA-THIN II INSULIN SYRINGE/U-100/1ML/29GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
VALUE HEALTH INSULIN SYRINGE/U-100/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
VANISHPOINT INSULIN SYRINGE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
VERIFINE INSULIN SYRINGE 1ML/29G X 12MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
CARETOUCH INSULIN SYRINGE/U-100/1ML/29G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 5/16"	97051030906382	Brand
VANISHPOINT INSULIN SYRINGE/1ML/29G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 5/16"	97051030906382	Brand
ADVOCATE INSULIN SYRINGE/U-100/1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
CARETOUCH INSULIN SYRINGE/1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DROPLET INSULIN SYRINGE U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
EASY COMFORT INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
EASY TOUCH FLIPLOCK SAFETY INSULIN SYRINGE 1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
EASY TOUCH INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
EASY TOUCH SHEATHLOCK SAFETY INSULIN SYRINGE 1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
EQL INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
GLUCOPRO INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
GNP INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
GNP INSULIN SYRINGES/1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
HEALTHWISE INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
INSULIN SYRINGE/NEEDLE 1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
KROGER INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
LEADER INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
LITETOUCH INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
LITETOUCH INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
MAGELLAN INSULIN SAFETY SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
MM INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
MONOJECT INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
PREFERRED PLUS INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRO COMFORT INSULIN SYRINGES/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
RA INSULIN SYRINGE/U-100/1 ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
SB INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
SURE COMFORT INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
TRUE COMFORT PRO INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
TRUEPLUS INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ULTICARE INSULIN SYRINGE/SHORT/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ULTICARE INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ULTRA FLO INSULIN SYRINGE 1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/1ML/30GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ULTRACARE INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
VANISHPOINT INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
ZEVRX INSULIN SYRINGE/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 5/16"	97051030906384	Brand
BD INSULIN SYRINGE ULTRA FINE/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
BD INSULIN SYRINGE ULTRA-FINE/1ML/30G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
BD INSULIN SYRINGE ULTRAFINE/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
CAREONE INSULIN SYRINGES/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/1.0ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
DROPLET INSULIN SYRINGE U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
DROPLET INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
EASY COMFORT INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
EASY TOUCH FLIPLOCK SAFETY INSULIN SYRINGE 1ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EASY TOUCH INSULIN SYRINGE/SAFETY/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
EASY TOUCH INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
EASY TOUCH SHEATHLOCK SAFETY SYRINGE 1ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
GLUCOPRO INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
HM ULTICARE INSULIN SYRINGE/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
INSULIN SYRINGES/U-100/1ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
PRO COMFORT INSULIN SYRINGES/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
SURE COMFORT INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
TECHLITE INSULIN SYRINGE U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
TRUE COMFORT PRO INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ULTICARE INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ULTICARE INSULIN SYRINGE/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE 1ML 30G X 1/2"/SHARPS CON	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ULTRA FLO INSULIN SYRINGE 1ML/30GX1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ULTRACARE INSULIN SYRINGE/U-100/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ZEVRX INSULIN SYRINGE/1ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 30 X 1/2"	97051030906386	Brand
ADVOCATE INSULIN SYRINGE/U-100/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
AQ INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
BD INSULIN SYRINGE ULTRA-FINE/1ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
BD INSULIN SYRINGE ULTRAFINE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
CAREONE INSULIN SYRINGES/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CARETOUCH INSULIN SYRINGE/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/U-100/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
COMFORT EZ INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
DROPLET INSULIN SYRINGE U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
DROPLET INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX8MM 1ML	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
EASY COMFORT INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
EASY TOUCH FLIPLOCK SAFETY INSULIN SYRINGE 1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
EASY TOUCH INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
EASY TOUCH SHEATHLOCK SAFETY INSULIN SYRINGE 1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
EQL INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
FIFTY50 SUPERIOR COMFORT INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
GLUCOPRO INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
GNP INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
HEALTHWISE INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
INSULIN SYRINGE/NEEDLE 1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
INSULIN SYRINGES/U-100/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
KINRAY INSULIN SYRINGE PREFERRED PLUS/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
KROGER INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LEADER INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
LITETOUCH INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
MM INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
MONOJECT INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
MS INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
PRO COMFORT INSULIN SYRINGES/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
RELION INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
SB INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
SURE COMFORT INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
TECHLITE INSULIN SYRINGE U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
TRUE COMFORT INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
TRUE COMFORT PRO INSULIN SYRINGE/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
TRUEPLUS INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTICARE INSULIN SYRINGE ULTRAFINE U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTICARE INSULIN SYRINGE/SHORT/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTICARE INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE 1ML 31G X 5/16"/SHARPS CO	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTRA FLO INSULIN SYRINGE 1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/1ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
ULTRACARE INSULIN SYRINGE/U-100/1ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand
VERIFINE INSULIN SYRINGE 1ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 5/16"	97051030906387	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADVOCATE INSULIN SYRINGE/U-100/0.3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
CAREONE INSULIN SYRINGES/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
CARETOUCH INSULIN SYRINGE/0.3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
CLEVER CHOICE COMFORT EZ INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
COMFORT ASSIST INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
DROPLET INSULIN SYRINGE U-100/0.3/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
DROPLET INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX8MM 0.3ML	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
EASY COMFORT INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
EASY TOUCH INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
EQL INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
FIFTY50 SUPERIOR COMFORT INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
GLOBAL EASY GLIDE INSULINSYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
GLOBAL INJECT EASE INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
GLUCOPRO INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
GNP INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
GNP INSULIN SYRINGES/3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
HEALTHWISE INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
HM ULTICARE INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
INSULIN SYRINGE/NEEDLE 0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
INSULIN SYRINGE/U-100/1ML/30G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
KINRAY INSULIN SYRINGE PREFERRED PLUS/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
KROGER INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
LEADER INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
LITETOUCH INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
LITETOUCH INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
MM INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
MONOJECT ULTRA COMFORT INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
MS INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
PRODIGY INSULIN SYRING/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
RELION INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/31G X 5/16	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
SURE COMFORT INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
TECHLITE INSULIN SYRINGE U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
TOPCARE ULTRA COMFORT INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
TRUEPLUS INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTICARE INSULIN SYRINGE ULTRAFINE U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTICARE INSULIN SYRINGE/SHORT/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTICARE INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTIGUARD SAFEPACK INSULIN SYRINGE/0.3ML/31G X 5/16"/SHARPS	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTRA FLO INSULIN SYRINGE 0.3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ULTRA FLO INSULIN SYRINGE 1/2 UNIT/0.3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTRA-THIN II INSULIN SYRINGE SHORT/U-100/0.3ML/31GX5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ULTRACARE INSULIN SYRINGE/U-100/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
VERIFINE INSULIN SYRINGE 0.3ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
ASSURE ID INSULIN SAFETY SYRINGE U-100/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
DROPLET INSULIN SYRINGE/U-100/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX6MM 0.5ML	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
GLOBAL EASY GLIDE INSULIN SYRINGE/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
RELION INSULIN SYRINGE 0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
TECHLITE INSULIN SYRINGE U-100/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
ASSURE ID INSULIN SAFETY SYRINGE/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
DROPLET INSULIN SYRINGE U-100/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
DROPLET INSULIN SYRINGE/U-100/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
DROPSAFE INSULIN SAFETY SYRINGE/FIXED NEEDLE 31GX6MM 1ML	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
GLOBAL EASY GLIDE INSULIN SYRINGE/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
RELION INSULIN SYRINGE 1ML/31GX15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
RELION INSULIN SYRINGE/U-100/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
TECHLITE INSULIN SYRINGE U-100/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
EMBRACE PEN NEEDLES/29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
VERIFINE INSULIN PEN NEEDLE 29G X 12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
EMBRACE PEN NEEDLES/30G X 5MM	INSULIN PEN NEEDLE 30 G X 5 MM (1/5" OR 3/16")	97051050146340	Brand
COMFORT EZ PRO SAFETY PEN NEEDLES 30G X 8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EMBRACE PEN NEEDLES/30G X 8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
PEN NEEDLES	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
AUM INSULIN SAFETY PEN NEEDLE/31GX4MM	INSULIN PEN NEEDLE 31 G X 4 MM (1/6" OR 5/32")	97051050146354	Brand
COMFORT EZ PRO SAFETY PEN NEEDLES 31G X 4MM	INSULIN PEN NEEDLE 31 G X 4 MM (1/6" OR 5/32")	97051050146354	Brand
AQINJECT PEN NEEDLE/31G X 3/16"	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
AUM INSULIN SAFETY PEN NEEDLE/31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
COMFORT EZ PRO SAFETY PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
EMBRACE PEN NEEDLES/31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PIP PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PURE COMFORT SAFETY PEN NEEDLE 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
TRUE COMFORT SAFETY PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
VERIFINE INSULIN PEN NEEDLE 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
VERIFINE PLUS INSULIN PEN NEEDLE 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
EMBRACE PEN NEEDLES/31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PEN NEEDLES/31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PENTIPS 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PREVENT DROPSAFE SAFETY PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PREVENT SAFETY PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PURE COMFORT SAFETY PEN NEEDLE 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PX EXTRA SHORT PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
QC PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

RAYA SURE PEN NEEDLE 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
RELION MINI PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
RELION PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
RELION PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
RELION PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
SURE COMFORT AUTOKEEPER SAFETY PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TECHLITE PEN NEEDLES/31G X 6 MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TOPCARE CLICKFINE UNIVERSAL PEN NEEDLES 31GX1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TRUE COMFORT PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TRUE COMFORT PRO PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TRUE COMFORT SAFETY PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TRUEPLUS PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
TRUEPLUS 5-BEVEL PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTICARE MICRO PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTICARE MINI PEN NEEDLES ULTI-FINE IV	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTICARE MINI PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTICARE MINI PEN NEEDLES/31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTICARE MINI PEN NEEDLES/31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTIGUARD SAFEPACK/MINI PEN NEEDLE/31G X 1/4"/SHARPS CONTAIN	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTIGUARD SAFEPACK/MINI PEN NEEDLE/31G X 6MM/SHARPS CONTAIN	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ULTRACARE PEN NEEDLES/31G X 1/4"	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
UNIFINE PENTIPS PLUS 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

UNIFINE PENTIPS 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
UNIFINE ULTRA PEN NEEDLE/31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
WEGMANS UNIFINE PENTIPS PLUS/ULTRA SHORT/31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ZEVRX PEN NEEDLES 31G X 6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
1ST TIER UNIFINE PENTIPS PLUS/ULTRA SHORT/31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
1ST TIER UNIFINE PENTIPS 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
ABOUTIME PEN NEEDLES 31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ADVOCATE INSULIN PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
AURORA PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CAREFINE PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CARETOUCH PEN NEEDLES 31GX 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLEVER CHOICE COMFORT EZ INSULIN PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLICKFINE PEN NEEDLE UNIVERSAL/31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLICKFINE PEN NEEDLES 31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLICKFINE PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
CLICKFINE UNIVERSAL PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
COMFORT EZ SHORT/31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
COMFORT TOUCH PEN NEEDLES/31G X 8 MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
DIATHRIVE PEN NEEDLE/31 GX 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
DROPLET PEN NEEDLES 31G X5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
DROPLET PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DROPSAFE SAFETY PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
DRUG MART UNIFINE PENTIPS31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
EASY COMFORT PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
EASY TOUCH PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
EMBRACE PEN NEEDLES/31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
FIFTY50 PEN NEEDLES 31G X5/16" (8MM)	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
FIFTY50 PEN NEEDLES/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
GLOBAL EASE INJECT PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
GNP CLICKFINE UNIVERSAL PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
GNP ULTICARE PEN NEEDLES /31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
GNP ULTIGUARD SAFEPAK/SHORT PEN NEEDLE/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
GOODSENSE PEN NEEDLE/PENFINE CLASSIC/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
H-E-B IN CONTROL PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
H-E-B IN CONTROL UNIFINE PENTIPS PLUS 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
HEALTHWISE SHORT PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
HM ULTICARE SHORT PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
INCONTROL ULTICARE MINI PEN NEEDLES/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
INSUPEN ULTRAFIN 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
INSUPEN 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
KROGER PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
KROGER PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
LEADER UNIFINE PENTIPS PLUS/SHORT/31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LITETOUCH PEN NEEDLES 31GX8MM SHORT	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
LITETOUCH PEN NEEDLES/31G X 8MM/SHORT	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
MARATHON MEDICAL PENTIPS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
MEDICINE SHOPPE PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
MEIJER PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
MM PEN NEEDLES 31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PC UNIFINE PENTIPS 31G X 8MM SHORT	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PEN NEEDLES 31GX8MM (5/16")	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PENTIPS 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PENTIPS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PREVENT DROPSAFE SAFETY PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PREVENT SAFETY PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PRO COMFORT PEN NEEDLES/ 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PX PEN NEEDLE 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
PX SHORTLENGTH PEN NEEDLES/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
QC PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
RA PEN NEEDLES 31G X 8MM 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
RAYA SURE PEN NEEDLE 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
RELION PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

RELION PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
RELION PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
RELION SHORT PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
SURE COMFORT PEN NEEDLES 31GX5/16" (8MM)	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TECHLITE PEN NEEDLES/31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TODAYS HEALTH SHORT PEN NEEDLES 31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TOPCARE CLICKFINE UNIVERSAL PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TRUE COMFORT PRO PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TRUEPLUS PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
TRUEPLUS 5-BEVEL PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTICARE MICRO PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTICARE MICRO PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTICARE SHORT PEN NEEDLES ULTI-FINE IV	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTICARE SHORT PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTICARE SHORT PEN NEEDLES/31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTIGUARD SAFEPACK/SHORT PEN NEEDLE/31G X 5/16"/SHARPS CONTA	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTIGUARD SAFEPACK/SHORT PEN NEEDLE/31G X 8MM/SHARPS CONTAIN	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTILET PEN NEEDLE 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTILET SHORT PEN NEEDLES 31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTRA FLO INSULIN PEN NEELE 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTRA-THIN II PEN NEEDLES/SHORT/31GX5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ULTRACARE PEN NEEDLES/31G X 5/16"	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

UNIFINE PENTIPS PLUS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
UNIFINE PENTIPS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
UNIFINE ULTRA PEN NEEDLE/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
VERIFINE INSULIN PEN NEEDLE 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
VERIFINE PLUS INSULIN PEN NEEDLE 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
WEGMANS UNIFINE PENTIPS PLUS/SHORT/31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ZEVRX PEN NEEDLES 31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
1ST TIER UNIFINE PENTIPS PLUS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
1ST TIER UNIFINE PENTIPS 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ABOUTIME PEN NEEDLE 32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
AQINJECT PEN NEEDLE/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
AUM MINI INSULIN PEN NEEDLE/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
AUM PEN NEEDLE/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
AUM READYGARD DUO SAFETY PEN NEEDLE/32GX4MM/DUAL AUTO PROTEC	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CAREFINE PEN NEEDLE 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CARETOUCH PEN NEEDLES 32GX 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CLICKFINE PEN NEEDLE 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
CLICKFINE PEN NEEDLES 32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
COMFORT EZ MICRO/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
COMFORT TOUCH PEN NEEDLES/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DIATHRIVE PEN NEEDLE/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
DROPLET PEN NEEDLES 32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
DROPLET PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
DRUG MART UNIFINE PENTIPSPLUS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
DRUG MART UNIFINE PENTIPS32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
EASY COMFORT PEN NEEDLES 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
EASY TOUCH PEN NEEDLES 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
EMBRACE PEN NEEDLES/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
FIFTY50 PEN NEEDLES/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
GLOBAL EASE INJECT PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
GLOBAL EASY GLIDE PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
GNP ULTICARE PEN NEEDLES/32GX 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
GNP ULTIGUARD SAFEPAK/MICRO PEN NEEDLE/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
GOODSENSE PEN NEEDLE/PENFINE CLASSIC/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
H-E-B IN CONTROL PEN NEEDLES/NANO/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
H-E-B IN CONTROL UNIFINE PENTIPS PLUS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
H-E-B IN CONTROL UNIFINE PENTIPS PLUS 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
HEALTHWISE MICRON PEN NEEDLES/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
INCONTROL ULTICARE MINI PEN NEEDLES/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
INSUPEN PEN NEEDLES 32G X4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
INSUPEN 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
KROGER PEN NEEDLES/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LEADER UNIFINE PENTIPS/NANO/32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
LEADER UNIFINE PENTIPS/PLUS/32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
LITETOUCH INSULIN PEN NEEDLES/32G X 4MM/MINI	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
MARATHON MEDICAL PENTIPS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
MICRODOT PEN NEEDLE/32G X 4 MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
MM PEN NEEDLES 32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
NOVOFINE PLUS PEN NEEDLE 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PEN NEEDLES/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PENTIPS 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PENTIPS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PIP PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PRO COMFORT PEN NEEDLES/ 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PURE COMFORT PEN NEEDLE/32G X4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PURE COMFORT SAFETY PEN NEEDLE 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
QC UNIFINE PENTIPS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
RELION PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
RELION PEN NEEDLES 32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
RELION PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
SURE COMFORT AUTOKEEPER SAFETY PEN NEEDLES 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
SURE COMFORT PEN NEEDLES 32GX5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
SURE COMFORT PEN NEEDLES 32GX5/32" (4MM)	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TECHLITE PEN NEEDLES/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
TRUE COMFORT PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
TRUE COMFORT PRO PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
TRUE COMFORT SAFETY PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
TRUEPLUS PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
TRUEPLUS 5-BEVEL PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTICARE MICRO PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTICARE MICRO PEN NEEDLES/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTICARE MICRO PEN NEEDLES/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTIGUARD SAFEPACK/MICRO PEN NEEDLE/32G X 4 MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTIGUARD SAFEPACK/MICRO PEN NEEDLE/32G X 4MM/SHARPS CONTAIN	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTIGUARD SAFEPACK/MICRO PEN NEEDLE/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTIGUARD SAFEPACK/MICRO PEN NEEDLE/32G X 5/32"/SHARPS CNTR	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTIGUARD SAFEPACK/MICRO PEN NEEDLE/32G X 5/32"/SHARPS CONTA	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTILET PEN NEEDLE 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTILET PEN NEEDLE 32GX4MM/SHORT	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTRA FLO INSULIN PEN NEEDLE 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTRA THIN PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTRACARE PEN NEEDLES/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
UNIFINE PENTIPS PLUS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
UNIFINE PENTIPS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
UNIFINE SAFECONTROL PEN NEEDLE 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

UNIFINE ULTRA PEN NEEDLE/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
VERIFINE INSULIN PEN NEEDLE 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
VERIFINE PLUS INSULIN PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
WEGMANS UNIFINE PENTIPS PLUS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ZEVRX PEN NEEDLES 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
1ST TIER UNIFINE PENTIPS PLUS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
1ST TIER UNIFINE PENTIPS 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
AUM MINI INSULIN PEN NEEDLE/32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
AUM PEN NEEDLE/32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
CAREFINE PEN NEEDLES 32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
CARETOUCH PEN NEEDLES 32GX 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
COMFORT TOUCH PEN NEEDLES/32G X 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
DROPLET PEN NEEDLES 32G X 3/16"	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
DROPLET PEN NEEDLES 32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
EASY TOUCH PEN NEEDLES 32GX3/16"	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
EASY TOUCH 32GX5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
PEN NEEDLES 32G X 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
PRO COMFORT PEN NEEDLES/ 32G X 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
PURE COMFORT PEN NEEDLE/32G X 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
TRUE COMFORT PRO PEN NEEDLES 32G X 5MM	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
ULTRACARE PEN NEEDLES/32G X 3/16"	INSULIN PEN NEEDLE 32 G X 5 MM (1/5" OR 3/16")	97051050146367	Brand
AUM MINI INSULIN PEN NEEDLE/32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AUM PEN NEEDLE/32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
CAREFINE PEN NEEDLES 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
COMFORT TOUCH PEN NEEDLES/32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
DROPLET PEN NEEDLES 32G X 1/4"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
DROPLET PEN NEEDLES 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
EASY TOUCH PEN NEEDLES 32GX1/4"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
EASY TOUCH 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
FIFTY50 PEN NEEDLES/32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
GNP ULTICARE PEN NEEDLES/32GX1/4"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
GNP ULTIGUARD SAFEPACK/MINI PEN NEEDLE/32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
GOODSENSE PEN NEEDLE/PENFINE CLASSIC/32G X 1/4"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
INSUPEN SENSITIVE 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
NOVOFINE PEN NEEDLE 32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
PEN NEEDLES 32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
PENTIPS 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
PRO COMFORT PEN NEEDLES/ 32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
PURE COMFORT PEN NEEDLE 32G X6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
SURE COMFORT PEN NEEDLES 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
TECHLITE PEN NEEDLES/32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
TRUE COMFORT PRO PEN NEEDLES 32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
ULTICARE MINI PEN NEEDLES/32G X 1/4"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ULTIGUARD SAFEPAK/MINI PEN NEEDLE/32G X 1/4"/SHARPS CONTAIN	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
ULTRACARE PEN NEEDLES/32G X 1/14"	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
UNIFINE PENTIPS 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
VERIFINE INSULIN PEN NEEDLE 32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
BD PEN NEEDLE/MICRO/ULTRA-FINE/32G X 6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
1ST TIER UNIFINE PENTIPS 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
AUM MINI INSULIN PEN NEEDLE/32GX8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 32GX8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
COMFORT TOUCH PEN NEEDLES/32G X 8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
DROPLET PEN NEEDLES 32G X 5/16"	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
DROPLET PEN NEEDLES 32GX8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
INSUPEN SENSITIVE 32GX8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
PURE COMFORT PEN NEEDLE 32G X8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
TECHLITE PEN NEEDLES/32G X 8MM	INSULIN PEN NEEDLE 32 G X 8 MM (1/3" OR 5/16")	97051050146372	Brand
ADVOCATE INSULIN PEN NEEDLES	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
AUM MINI INSULIN PEN NEEDLE/33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
AUM PEN NEEDLE/33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
CAREONE UNIFINE PENTIPS PLUS PEN NEEDLES/33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
CARETOUCH PEN NEEDLE 33GX5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
CLEVER CHOICE COMFORT EZ INSULIN PEN NEEDLES 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
COMFORT TOUCH PEN NEEDLES/33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EASY COMFORT PEN NEEDLES 33G X 4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
EASY GLIDE PEN NEEDLES 33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
H-E-B IN CONTROL UNIFINE PENTIPS PLUS 33GX5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
INSUPEN 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
KROGER PEN NEEDLES/33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
MICRODOT PEN NEEDLE/33G X 4 MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
PEN NEEDLES 33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
TRUE COMFORT PRO PEN NEEDLES 33G X 4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
ULTRA FLO INSULIN PEN NEEDLE 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
ULTRACARE PEN NEEDLES/33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
UNIFINE PENTIPS PLUS 33G X 5/32"	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
UNIFINE PENTIPS PLUS 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
UNIFINE PENTIPS 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
1ST TIER UNIFINE PENTIPS PLUS 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
1ST TIER UNIFINE PENTIPS 33GX4MM	INSULIN PEN NEEDLE 33 G X 4 MM (1/6" OR 5/32")	97051050146376	Brand
AUM MINI INSULIN PEN NEEDLE/33GX5MM	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
AUM PEN NEEDLE/33GX5MM	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 33GX5MM	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
COMFORT TOUCH PEN NEEDLES/33GX 3/16"	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
EASY COMFORT PEN NEEDLES 33G X 5MM	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
TRUE COMFORT PRO PEN NEEDLES 33G X 5MM	INSULIN PEN NEEDLE 33 G X 5 MM (1/5" OR 3/16")	97051050146377	Brand
AUM MINI INSULIN PEN NEEDLE/33GX6MM	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand
AUM PEN NEEDLE/33GX6MM	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CLEVER CHOICE COMFORT EZ PEN NEEDLES 33GX6MM	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand
COMFORT TOUCH PEN NEEDLES/33GX1/4"	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand
EASY COMFORT PEN NEEDLES 33G X 6MM	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand
TRUE COMFORT PRO PEN NEEDLES 33G X 6MM	INSULIN PEN NEEDLE 33 G X 6 MM (1/4" OR 15/64")	97051050146378	Brand
CLEVER CHOICE COMFORT EZ PEN NEEDLES 33GX8MM	INSULIN PEN NEEDLE 33 G X 8 MM (1/3" OR 5/16")	97051050146380	Brand
DROPLET MICRON 34G X 9/64"	INSULIN PEN NEEDLE 34 G X 3.5 MM (9/64")	97051050146385	Brand
B-D INSULIN SYRINGE ULTRAFINE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
BD INSULIN SYRINGE ULTRAFINE/0.5ML/30G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
BD INSULIN SYRINGE ULTRAFINE/0.5ML/30G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 30 X 1/2"	97051030906329	Brand
BD INSULIN SYRINGE MICROFINE IV/U-100/1ML/28G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 28 X 1/2"	97051030906370	Brand
B-D INSULIN SYRINGE ULTRAFINE II/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD INSULIN SYRINGE ULTRAFINE/0.3ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD INSULIN SYRINGE ULTRAFINE/1/2 UNIT/0.3ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD INSULIN SYRINGE ULTRAFINE HALF-UNIT/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD INSULIN SYRINGE ULTRAFINE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD SAFETYGLIDE INSULIN SYRINGE/0.3ML/31G X 5/16"	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
BD INSULIN SYRINGE/U-100/1ML/27G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
BD INSULIN SYRINGE/1ML/27G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 1/2"	97051030906350	Brand
BD INSULIN SYRINGE MICROFINE IV/U-100/1ML/27G X 5/8"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 5/8"	97051030906360	Brand
BD INSULIN SYRINGE MICROFINE/U-100/1ML/27G X 5/8"	INSULIN SYRINGE/NEEDLE U-100 1 ML 27 X 5/8"	97051030906360	Brand
BD INSULIN SYRINGE SAFETYGLIDE/1ML/29G X 1/2"	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
BD INSULIN SYRINGE/1ML/29G X 12.7MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 29 X 1/2"	97051030906380	Brand
BD INSULIN SYRINGE/U-100/2ML/27.5G X 5/8"	INSULIN SYRINGE/NEEDLE U-100 2 ML 27.5 X 5/8"	97051030906390	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BD SAFETYGLIDE INSULIN SYRINGE/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
BD VEO INSULIN SYRINGE ULTR-FINE/U-100/0.5ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
BD VEO INSULIN SYRINGE ULTRA-FINE/0.5ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 31 X 15/64"	97051030906391	Brand
BD SAFETYGLIDE INSULIN SYRINGE/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
BD VEO INSULIN SYRINGE ULTRA-FINE/U-100/1ML/31G X 15/64"	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
BD VEO INSULIN SYRINGE ULTRA-FINE/1ML/31G X 6MM	INSULIN SYRINGE/NEEDLE U-100 1 ML 31 X 15/64"	97051030906399	Brand
BD PEN NEEDLE/SHORT/ULTRA-FINE/31G X 8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
BD PEN NEEDLE/NANO 2ND GEN/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
BD PEN NEEDLE/NANO 2ND GEN/32G X 5/32"	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
BD PEN NEEDLE/NANO/ULTRA - FINE/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ASSURE ID DUO PRO SAFETY PEN NEEDLES 31G X 5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
EASY COMFORT SAFETY PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PENTIPS GENERIC PEN NEEDLES 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
UNIFINE SAFECONTROL PEN NEEDLE 31GX5MM	INSULIN PEN NEEDLE 31 G X 5 MM (1/5" OR 3/16")	97051050146358	Brand
PENTIPS GENERIC PEN NEEDLES 29GX12MM	INSULIN PEN NEEDLE 29 G X 12 MM (1/2")	97051050146330	Brand
EASY COMFORT SAFETY PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PENTIPS GENERIC PEN NEEDLES 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
UNIFINE SAFECONTROL PEN NEEDLE 31GX6MM	INSULIN PEN NEEDLE 31 G X 6 MM (1/4" OR 15/64")	97051050146361	Brand
PENTIPS GENERIC PEN NEEDLES 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
UNIFINE SAFECONTROL PEN NEEDLE 31GX8MM	INSULIN PEN NEEDLE 31 G X 8 MM (1/3" OR 5/16")	97051050146364	Brand
ADVOCATE INSULIN PEN NEEDLE/32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
EASY COMFORT SAFETY PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PENTIPS GENERIC PEN NEEDLES 32GX4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TECHLITE PLUS PEN NEEDLES32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
ULTIGUARD SAFEPACK/TINY PEN NEEDLE/32G X 4MM/SHARPS CONTAIN	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
UNIFINE PROTECT SAFETY PEN NEEDLE 32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
VERIFINE PLUS PEN NEEDLE/32G X 4MM	INSULIN PEN NEEDLE 32 G X 4 MM (1/6" OR 5/32")	97051050146366	Brand
PENTIPS GENERIC PEN NEEDLES 32GX6MM	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
ULTIGUARD SAFEPACK/TINY PEN NEEDLE/32G X 6MM/SHARPS CONTAIN	INSULIN PEN NEEDLE 32 G X 6 MM (1/4" OR 15/64")	97051050146368	Brand
UNIFINE PROTECT SAFETY PEN NEEDLE 30G X 8MM	INSULIN PEN NEEDLE 30 G X 8 MM (1/3" OR 5/16")	97051050146344	Brand
VERIFINE INSULIN SYRINGE/0.3ML/31G X 8MM	INSULIN SYRINGE/NEEDLE U-100 0.3 ML 31 X 5/16"	97051030906388	Brand
VERIFINE INSULIN SYRINGE/0.5ML/29G X 12MM	INSULIN SYRINGE/NEEDLE U-100 1/2 ML 29 X 1/2"	97051030906327	Brand

**Approval Criteria**

1 - Physician confirmation that the patient requires a greater quantity because of more frequent delivery of insulin

Notes	*The quantity limit for both pen needles and syringes is 6 of each per day.
-------	---

**2 . Revision History**

Date	Notes
10/29/2024	Updated GPIs

Insulins, Concentrated



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140735
<b>Guideline Name</b>	Insulins, Concentrated
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Humulin R U-500 kwikpen and vial			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HUMULIN R U-500 KWIKPEN	INSULIN REGULAR (HUMAN) SOLN PEN-INJECTOR 500 UNIT/ML	2710401000D250	Brand
HUMULIN R U-500 (CONCENTRATED)	INSULIN REGULAR (HUMAN) INJ 500 UNIT/ML	27104010002015	Brand
<b>Approval Criteria</b>			
1 - History of failure, intolerance, or contraindication to ALL of the following:			

- Novolog or Humalog
- Lantus
- Levemir

**OR**

**2** - There is a reason or special circumstance the patient needs to use a concentrated insulin product

## 2 . Revision History

Date	Notes
8/26/2022	C&S to match FFS 10.1.22

Iqirvo (elafibranor)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-155011
<b>Guideline Name</b>	Iqirvo (elafibranor)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Iqirvo			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
IQIRVO	ELAFIBRANOR TAB 80 MG	52780020000320	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) documenting a diagnosis of primary biliary cholangitis (PBC) (also known as primary biliary cirrhosis)

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting ONE of the following:

**2.1** BOTH of the following:

**2.1.1** Patient has failed to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal (ULN) after at least 12 consecutive months of treatment with ursodeoxycholic acid (UDCA) (e.g., Urso, Urso Forte, ursodiol)

**AND**

**2.1.2** Used in combination with ursodeoxycholic acid (UDCA)

**OR**

**2.2** History of contraindication or intolerance to ursodeoxycholic acid (UDCA)

**AND**

**3** - Requested drug will NOT be used in combination with Ocaliva (obeticholic acid)

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Hepatologist
- Gastroenterologist

Product Name: Iqirvo

Approval Length

12 month(s)

Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
IQIRVO	ELAFIBRANOR TAB 80 MG	52780020000320	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy (e.g., ALP level less than 1.67 times ULN, total bilirubin less than or equal to ULN, ALP decrease greater than or equal to 15% from baseline)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Requested drug will NOT be used in combination with Ocaliva (obeticholic acid)</p>			

## 2 . Revision History

Date	Notes
9/16/2024	New program.

Iron Chelators



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140886
<b>Guideline Name</b>	Iron Chelators
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Exjade, Brand Jadenu, generic deferasirox			
Diagnosis	Chronic Iron Overload due to Blood Transfusion		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 125 MG	93100025007320	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 125 MG	93100025007320	Brand
DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 250 MG	93100025007330	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 250 MG	93100025007330	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 500 MG	93100025007340	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 500 MG	93100025007340	Brand
DEFERASIROX	DEFERASIROX TAB 90 MG	93100025000320	Generic
JADENU	DEFERASIROX TAB 90 MG	93100025000320	Brand
DEFERASIROX	DEFERASIROX TAB 180 MG	93100025000330	Generic
JADENU	DEFERASIROX TAB 180 MG	93100025000330	Brand
DEFERASIROX	DEFERASIROX TAB 360 MG	93100025000340	Generic
JADENU	DEFERASIROX TAB 360 MG	93100025000340	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 90 MG	93100025003020	Generic
JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 90 MG	93100025003020	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 180 MG	93100025003030	Generic
JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 180 MG	93100025003030	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 360 MG	93100025003040	Generic
JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 360 MG	93100025003040	Brand

**Approval Criteria**

1 - Diagnosis of chronic iron overload (e.g., sickle cell anemia, thalassemia, etc.) due to blood transfusion

Product Name: Brand Exjade, Brand Jadenu, generic deferasirox			
Diagnosis	Chronic Iron Overload due to Blood Transfusion		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 125 MG	93100025007320	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 125 MG	93100025007320	Brand
DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 250 MG	93100025007330	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 250 MG	93100025007330	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 500 MG	93100025007340	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 500 MG	93100025007340	Brand
DEFERASIROX	DEFERASIROX TAB 90 MG	93100025000320	Generic
JADENU	DEFERASIROX TAB 90 MG	93100025000320	Brand
DEFERASIROX	DEFERASIROX TAB 180 MG	93100025000330	Generic
JADENU	DEFERASIROX TAB 180 MG	93100025000330	Brand
DEFERASIROX	DEFERASIROX TAB 360 MG	93100025000340	Generic
JADENU	DEFERASIROX TAB 360 MG	93100025000340	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 90 MG	93100025003020	Generic
JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 90 MG	93100025003020	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 180 MG	93100025003030	Generic
JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 180 MG	93100025003030	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 360 MG	93100025003040	Generic
JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 360 MG	93100025003040	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

Product Name: Brand Ferriprox, generic deferiprone			
Diagnosis	Chronic Iron Overload due to Blood Transfusion		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DEFERIPRONE	DEFERIPRONE TAB 500 MG	93100028000320	Generic
FERRIPROX	DEFERIPRONE TAB 500 MG	93100028000320	Brand
FERRIPROX	DEFERIPRONE ORAL SOLN 100 MG/ML	93100028002020	Brand
FERRIPROX	DEFERIPRONE TAB 1000 MG	93100028000340	Brand

FERRIPROX TWICE-A-DAY	DEFERIPRONE (TWICE DAILY) TAB 1000 MG	93100028000345	Brand
DEFERIPRONE	DEFERIPRONE TAB 1000 MG	93100028000340	Generic

**Approval Criteria**

1 - BOTH of the following

1.1 Diagnosis of transfusional iron overload due to thalassemia syndromes

**AND**

1.2 Current chelation therapy is inadequate [e.g., Desferal (deferoxamine), Exjade (deferasirox)]

Product Name: Brand Ferriprox, generic deferiprone

Diagnosis	Chronic Iron Overload due to Blood Transfusion
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
DEFERIPRONE	DEFERIPRONE TAB 500 MG	93100028000320	Generic
FERRIPROX	DEFERIPRONE TAB 500 MG	93100028000320	Brand
FERRIPROX	DEFERIPRONE ORAL SOLN 100 MG/ML	93100028002020	Brand
FERRIPROX	DEFERIPRONE TAB 1000 MG	93100028000340	Brand
FERRIPROX TWICE-A-DAY	DEFERIPRONE (TWICE DAILY) TAB 1000 MG	93100028000345	Brand
DEFERIPRONE	DEFERIPRONE TAB 1000 MG	93100028000340	Generic

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: Brand Exjade, Brand Jadenu, generic deferasirox	
Diagnosis	Chronic Iron Overload in Non-Transfusion Dependent Thalassemia Syndrome
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 125 MG	93100025007320	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 125 MG	93100025007320	Brand
DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 250 MG	93100025007330	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 250 MG	93100025007330	Brand
DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 500 MG	93100025007340	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 500 MG	93100025007340	Brand
DEFERASIROX	DEFERASIROX TAB 90 MG	93100025000320	Generic
JADENU	DEFERASIROX TAB 90 MG	93100025000320	Brand
DEFERASIROX	DEFERASIROX TAB 180 MG	93100025000330	Generic
JADENU	DEFERASIROX TAB 180 MG	93100025000330	Brand
DEFERASIROX	DEFERASIROX TAB 360 MG	93100025000340	Generic
JADENU	DEFERASIROX TAB 360 MG	93100025000340	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 90 MG	93100025003020	Generic
JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 90 MG	93100025003020	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 180 MG	93100025003030	Generic
JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 180 MG	93100025003030	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 360 MG	93100025003040	Generic
JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 360 MG	93100025003040	Brand

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of chronic iron overload in non-transfusion dependent thalassemia syndrome

**AND**

**1.2** Patient has liver iron (Fe) concentration (LIC) levels consistently greater than or equal to 5 mg Fe per gram of dry weight prior to initiation of treatment with Exjade or Jadenu

**AND**

**1.3** Patient has serum ferritin levels consistently greater than 300 micrograms per liter prior to initiation of treatment with Exjade or Jadenu

Product Name: Brand Exjade, Brand Jadenu, generic deferasirox			
Diagnosis	Chronic Iron Overload in Non-Transfusion Dependent Thalassemia Syndrome		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 125 MG	93100025007320	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 125 MG	93100025007320	Brand
DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 250 MG	93100025007330	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 250 MG	93100025007330	Brand
DEFERASIROX	DEFERASIROX TAB FOR ORAL SUSP 500 MG	93100025007340	Generic
EXJADE	DEFERASIROX TAB FOR ORAL SUSP 500 MG	93100025007340	Brand
DEFERASIROX	DEFERASIROX TAB 90 MG	93100025000320	Generic
JADENU	DEFERASIROX TAB 90 MG	93100025000320	Brand
DEFERASIROX	DEFERASIROX TAB 180 MG	93100025000330	Generic
JADENU	DEFERASIROX TAB 180 MG	93100025000330	Brand
DEFERASIROX	DEFERASIROX TAB 360 MG	93100025000340	Generic
JADENU	DEFERASIROX TAB 360 MG	93100025000340	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 90 MG	93100025003020	Generic

JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 90 MG	93100025003020	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 180 MG	93100025003030	Generic
JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 180 MG	93100025003030	Brand
DEFERASIROX	DEFERASIROX GRANULES PACKET 360 MG	93100025003040	Generic
JADENU SPRINKLE	DEFERASIROX GRANULES PACKET 360 MG	93100025003040	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Irritable Bowel Syndrome-Diarrhea



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140687
<b>Guideline Name</b>	Irritable Bowel Syndrome-Diarrhea
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Lotronex, generic alosetron			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ALOSETRON HYDROCHLORIDE	ALOSETRON HCL TAB 0.5 MG (BASE EQUIV)	52554015100310	Generic
LOTROXEX	ALOSETRON HCL TAB 0.5 MG (BASE EQUIV)	52554015100310	Brand
ALOSETRON HYDROCHLORIDE	ALOSETRON HCL TAB 1 MG (BASE EQUIV)	52554015100320	Generic
LOTROXEX	ALOSETRON HCL TAB 1 MG (BASE EQUIV)	52554015100320	Brand

**Approval Criteria**

1 - Diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS)

**AND**

2 - Symptoms for at least 6 months

**AND**

3 - Patient was female at birth

**AND**

4 - Age greater than or equal to 18 years

**AND**

5 - History of failure, contraindication, or intolerance to TWO of the following:

- Antispasmodic agent (e.g. dicyclomine)
- Antidiarrheal agents (e.g. loperamide)
- Tricyclic antidepressant (e.g. amitriptyline)

Product Name: Brand Lotronex, generic alosetron			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ALOSETRON HYDROCHLORIDE	ALOSETRON HCL TAB 0.5 MG (BASE EQUIV)	52554015100310	Generic
LOTROXEX	ALOSETRON HCL TAB 0.5 MG (BASE EQUIV)	52554015100310	Brand

ALOSETRON HYDROCHLORIDE	ALOSETRON HCL TAB 1 MG (BASE EQUIV)	52554015100320	Generic
LOTROXEX	ALOSETRON HCL TAB 1 MG (BASE EQUIV)	52554015100320	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Lotronex therapy

**Product Name: Viberzi**

Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
VIBERZI	ELUXADOLINE TAB 75 MG	52558020000330	Brand
VIBERZI	ELUXADOLINE TAB 100 MG	52558020000340	Brand

**Approval Criteria**

1 - Diagnosis of irritable bowel syndrome with diarrhea (IBS-D)

**AND**

2 - History of failure, contraindication, or intolerance to TWO of the following:

- Antispasmodic agent (e.g. dicyclomine)
- Antidiarrheal agents (e.g. loperamide)
- Tricyclic antidepressant (e.g. amitriptyline)

**Product Name: Viberzi**

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization



Product Name	Generic Name	GPI	Brand/Generic
VIBERZI	ELUXADOLINE TAB 75 MG	52558020000330	Brand
VIBERZI	ELUXADOLINE TAB 100 MG	52558020000340	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Viberzi therapy

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Isotretinoin



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140799
<b>Guideline Name</b>	Isotretinoin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	7/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Brand Absorica, Absorica LD, Amnesteem, Claravis, generic isotretinoin caps, Myorisan, Zenatane, Accutane			
Diagnosis	Oncology Uses (Off Label)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYORISAN	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
MYORISAN	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
MYORISAN	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
MYORISAN	ISOTRETINOIN CAP 40 MG	90050013000140	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CLARAVIS	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
CLARAVIS	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
CLARAVIS	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
CLARAVIS	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
AMNESTEEM	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
AMNESTEEM	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
AMNESTEEM	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ZENATANE	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ZENATANE	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ZENATANE	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ZENATANE	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ABSORICA	ISOTRETINOIN CAP 10 MG	90050013000110	Brand
ABSORICA	ISOTRETINOIN CAP 20 MG	90050013000120	Brand
ABSORICA	ISOTRETINOIN CAP 25 MG	90050013000125	Brand
ABSORICA	ISOTRETINOIN CAP 30 MG	90050013000130	Brand
ABSORICA	ISOTRETINOIN CAP 35 MG	90050013000135	Brand
ABSORICA	ISOTRETINOIN CAP 40 MG	90050013000140	Brand
ISOTRETINOIN	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 8 MG	90050013100110	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 16 MG	90050013100115	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 24 MG	90050013100125	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 32 MG	90050013100135	Brand
ACUTANE	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ACUTANE	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ACUTANE	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ACUTANE	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 25 MG	90050013000125	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 35 MG	90050013000135	Generic

**Approval Criteria**

**1** - Used for an oncology indication meeting National Comprehensive Cancer Network (NCCN) with a Category of Evidence and Consensus of 1, 2A, or 2B

**OR**

**2** - Used for an oncology indication from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- Thomson Micromedex DrugDex
- Clinical pharmacology

Product Name: Brand Absorica, Absorica LD, Amnesteem, Claravis, generic isotretinoin caps, Myorisan, Zenatane, Accutane

Approval Length	5 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
MYORISAN	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
MYORISAN	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
MYORISAN	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
MYORISAN	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
CLARAVIS	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
CLARAVIS	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
CLARAVIS	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
CLARAVIS	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
AMNESTEEM	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
AMNESTEEM	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
AMNESTEEM	ISOTRETINOIN CAP 40 MG	90050013000140	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZENATANE	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ZENATANE	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ZENATANE	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ZENATANE	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ABSORICA	ISOTRETINOIN CAP 10 MG	90050013000110	Brand
ABSORICA	ISOTRETINOIN CAP 20 MG	90050013000120	Brand
ABSORICA	ISOTRETINOIN CAP 25 MG	90050013000125	Brand
ABSORICA	ISOTRETINOIN CAP 30 MG	90050013000130	Brand
ABSORICA	ISOTRETINOIN CAP 35 MG	90050013000135	Brand
ABSORICA	ISOTRETINOIN CAP 40 MG	90050013000140	Brand
ISOTRETINOIN	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 8 MG	90050013100110	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 16 MG	90050013100115	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 24 MG	90050013100125	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 32 MG	90050013100135	Brand
ACCUTANE	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ACCUTANE	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ACCUTANE	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ACCUTANE	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 25 MG	90050013000125	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 35 MG	90050013000135	Generic

**Approval Criteria**

1 - ONE of the following:

1.1 Diagnosis of severe recalcitrant nodular acne unresponsive to conventional therapy

**OR**

**1.2** Diagnosis of treatment resistant acne

**AND**

**2** - History of failure, contraindication, or intolerance to an adequate trial on TWO of the following conventional therapy regimens:

- Topical retinoid or retinoid-like agent [e.g., Retin-A/Retin-A Micro (tretinoin)]
- Oral antibiotic [e.g., Ery-Tab (erythromycin), Biaxin (clarithromycin), Minocin (minocycline)]
- Topical antibiotic with or without benzoyl peroxide [e.g., Cleocin-T (clindamycin), erythromycin, BenzaClin (benzoyl peroxide/clindamycin), Benzamycin (benzoyl peroxide/erythromycin)]

**AND**

**3** - If the request is non-preferred\*, there must be a reason or special circumstance that the patient must be treated with a non-preferred medication

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Brand Absorica, Absorica LD, Amnesteem, Claravis, generic isotretinoin caps, Myorisan, Zenatane, Accutane			
Diagnosis	Persistent or Recurring Acne After 2 Months Off Therapy		
Approval Length	5 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYORISAN	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
MYORISAN	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
MYORISAN	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
MYORISAN	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
CLARAVIS	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
CLARAVIS	ISOTRETINOIN CAP 20 MG	90050013000120	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CLARAVIS	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
CLARAVIS	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
AMNESTEEM	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
AMNESTEEM	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
AMNESTEEM	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ZENATANE	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ZENATANE	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ZENATANE	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ZENATANE	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ABSORICA	ISOTRETINOIN CAP 10 MG	90050013000110	Brand
ABSORICA	ISOTRETINOIN CAP 20 MG	90050013000120	Brand
ABSORICA	ISOTRETINOIN CAP 25 MG	90050013000125	Brand
ABSORICA	ISOTRETINOIN CAP 30 MG	90050013000130	Brand
ABSORICA	ISOTRETINOIN CAP 35 MG	90050013000135	Brand
ABSORICA	ISOTRETINOIN CAP 40 MG	90050013000140	Brand
ISOTRETINOIN	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 8 MG	90050013100110	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 16 MG	90050013100115	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 24 MG	90050013100125	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 32 MG	90050013100135	Brand
ACUTANE	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ACUTANE	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ACUTANE	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ACUTANE	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 25 MG	90050013000125	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 35 MG	90050013000135	Generic

**Approval Criteria**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

1 - After greater than or equal to 2 months OFF therapy, persistent or recurring severe recalcitrant nodular acne is still present

Notes	Authorization will be given only by clinical pharmacist review for up to 5 months.
-------	--

Product Name: Brand Absorica, Absorica LD, Amnesteem, Claravis, generic isotretinoin caps, Myorisan, Zenatane, Accutane

Diagnosis	Dose Titration
Approval Length	1 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
MYORISAN	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
MYORISAN	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
MYORISAN	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
MYORISAN	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
CLARAVIS	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
CLARAVIS	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
CLARAVIS	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
CLARAVIS	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
AMNESTEEM	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
AMNESTEEM	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
AMNESTEEM	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ZENATANE	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ZENATANE	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ZENATANE	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ZENATANE	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ABSORICA	ISOTRETINOIN CAP 10 MG	90050013000110	Brand
ABSORICA	ISOTRETINOIN CAP 20 MG	90050013000120	Brand
ABSORICA	ISOTRETINOIN CAP 25 MG	90050013000125	Brand
ABSORICA	ISOTRETINOIN CAP 30 MG	90050013000130	Brand
ABSORICA	ISOTRETINOIN CAP 35 MG	90050013000135	Brand



ABSORICA	ISOTRETINOIN CAP 40 MG	90050013000140	Brand
ISOTRETINOIN	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 8 MG	90050013100110	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 16 MG	90050013100115	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 24 MG	90050013100125	Brand
ABSORICA LD	ISOTRETINOIN MICRONIZED CAP 32 MG	90050013100135	Brand
ACUTANE	ISOTRETINOIN CAP 10 MG	90050013000110	Generic
ACUTANE	ISOTRETINOIN CAP 20 MG	90050013000120	Generic
ACUTANE	ISOTRETINOIN CAP 30 MG	90050013000130	Generic
ACUTANE	ISOTRETINOIN CAP 40 MG	90050013000140	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 25 MG	90050013000125	Generic
ISOTRETINOIN	ISOTRETINOIN CAP 35 MG	90050013000135	Generic

**Approval Criteria**

1 - Confirmation that the cumulative dose is less than 150 mg/kg (milligrams/killogram) (there is little therapeutic benefit to be gained by increasing the cumulative dose beyond 150 mg/kg)\*

Notes	Authorization will be given only by clinical pharmacist review for 1 month to allow for titration up to the target dose. *See Background for dosing regimens.
-------	--

**2 . Background**

Benefit/Coverage/Program Information				
<b>Dosing by Body Weight (based on administration with food):</b>				
Body Weight		Daily Dose		
Kg	Lbs	0.5 mg/kg/day	1 mg/kg/day	2 mg/kg/day

40	88	20	40	80
50	110	25	50	100
60	132	30	60	120
70	154	35	70	140
80	176	40	80	160
90	198	45	90	180
100	220	50	100	200

### 3 . Revision History

Date	Notes
6/6/2023	Updated GPI and product name lists, added Accutane and isotretinoin, removed table in Background, added PDL link in note, cleaned up criteria.

Isturisa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140911
<b>Guideline Name</b>	Isturisa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Isturisa			
Diagnosis	Cushing's Disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ISTURISA	OSILODROSTAT PHOSPHATE TAB 1 MG	30022060600320	Brand
ISTURISA	OSILODROSTAT PHOSPHATE TAB 5 MG	30022060600330	Brand
ISTURISA	OSILODROSTAT PHOSPHATE TAB 10 MG	30022060600340	Brand

**Approval Criteria**

1 - Both of the following:

1.1 Diagnosis of Cushing's disease

**AND**

1.2 ONE of the following:

- Patient is not a candidate for pituitary surgery
- Pituitary surgery has not been curative

Product Name: Isturisa			
Diagnosis	Cushing's Disease		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ISTURISA	OSILODROSTAT PHOSPHATE TAB 1 MG	30022060600320	Brand
ISTURISA	OSILODROSTAT PHOSPHATE TAB 5 MG	30022060600330	Brand
ISTURISA	OSILODROSTAT PHOSPHATE TAB 10 MG	30022060600340	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive response to Isturisa therapy			

Product Name: Isturisa	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)

Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ISTURISA	OSILODROSTAT PHOSPHATE TAB 1 MG	30022060600320	Brand
ISTURISA	OSILODROSTAT PHOSPHATE TAB 5 MG	30022060600330	Brand
ISTURISA	OSILODROSTAT PHOSPHATE TAB 10 MG	30022060600340	Brand
<b>Approval Criteria</b>			
1 - Isturisa will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.			

Product Name: Isturisa			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ISTURISA	OSILODROSTAT PHOSPHATE TAB 1 MG	30022060600320	Brand
ISTURISA	OSILODROSTAT PHOSPHATE TAB 5 MG	30022060600330	Brand
ISTURISA	OSILODROSTAT PHOSPHATE TAB 10 MG	30022060600340	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Isturisa therapy			

## 2 . Revision History

Date	Notes
------	-------

8/4/2022	C&S to match AZM as of 10.1.22
----------	--------------------------------

Jesduvroq (daprodustat)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-144070
<b>Guideline Name</b>	Jesduvroq (daprodustat)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	4/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Jesduvroq			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
JESDUVROQ	DAPRODUSTAT TAB 1 MG	82402520000310	Brand
JESDUVROQ	DAPRODUSTAT TAB 2 MG	82402520000315	Brand
JESDUVROQ	DAPRODUSTAT TAB 4 MG	82402520000320	Brand
JESDUVROQ	DAPRODUSTAT TAB 6 MG	82402520000325	Brand
JESDUVROQ	DAPRODUSTAT TAB 8 MG	82402520000330	Brand

**Approval Criteria**

1 - Diagnosis of chronic kidney disease (CKD)

**AND**

2 - Patient has been on dialysis for at least 4 months

**AND**

3 - Adequate iron stores confirmed by BOTH of the following:

- Patient's ferritin level is greater than 100 mcg/L (micrograms per liter)
- Patient's transferrin saturation (TSAT) is greater than 20%

**AND**

4 - Hemoglobin level is less than 11 g/dL (grams per deciliter)

**AND**

5 - Trial and failure, contraindication, or intolerance to ONE of the following:

- Epogen
- Procrit
- Retacrit

**AND**

6 - Prescribed by or in consultation with ONE of the following:

- Hematologist
- Nephrologist



**AND**

**7 - Patient is NOT on concurrent treatment with an erythropoietin stimulating agent [ESA] (e.g., Aranesp, Epogen, Procrit)**

**Product Name: Jesduvroq**

**Approval Length** 12 month(s)

**Therapy Stage** Reauthorization

**Guideline Type** Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
JESDUVROQ	DAPRODUSTAT TAB 1 MG	82402520000310	Brand
JESDUVROQ	DAPRODUSTAT TAB 2 MG	82402520000315	Brand
JESDUVROQ	DAPRODUSTAT TAB 4 MG	82402520000320	Brand
JESDUVROQ	DAPRODUSTAT TAB 6 MG	82402520000325	Brand
JESDUVROQ	DAPRODUSTAT TAB 8 MG	82402520000330	Brand

**Approval Criteria**

**1 - Patient demonstrates positive clinical response to therapy (e.g., increase in hemoglobin)**

**AND**

**2 - Hemoglobin level does not exceed 12 g/dL (grams per deciliter)**

**AND**

**3 - Adequate iron stores confirmed by BOTH of the following:**

- Patient's ferritin level is greater than 100 mcg/L (micrograms per liter)
- Patient's transferrin saturation (TSAT) is greater than 20%

**AND**

**4** - Patient is NOT on concurrent treatment with an erythropoietin stimulating agent [ESA] (e.g., Aranesp, Epogen, Procrit)

## **2 . Revision History**

Date	Notes
3/7/2024	New program - C&S to align with AZM.

Joenja (leniolisib)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140985
<b>Guideline Name</b>	Joenja (leniolisib)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	8/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Joenja			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
JOENJA	LENIOLISIB PHOSPHATE TAB 70 MG	99391540600320	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes, laboratory values) documenting ALL of the following:

**1.1** Diagnosis of activated phosphoinositide 3-kinase delta syndrome (APDS)

**AND**

**1.2** Molecular genetic testing confirms mutations in the PIK3CD or PIK3R1 gene

**AND**

**1.3** BOTH of the following:

**1.3.1** Presence of nodal and/or extranodal proliferation (e.g., lymphadenopathy, splenomegaly, hepatomegaly)

**AND**

**1.3.2** Presence of other clinical findings and manifestations consistent with APDS (e.g., recurrent sino-pulmonary infections, bronchiectasis, enteropathy)

**AND**

**1.4** Trial and failure, contraindication, or intolerance to at least ONE standard of care treatment for APDS [e.g., immunoglobulin replacement therapy, antimicrobial prophylaxis (e.g., azithromycin, bactrim), rituximab, tacrolimus, etc.]

**AND**

**2** - Patient is 12 years of age or older

**AND**

**3** - Patient weighs greater than or equal to 45 kg (kilograms)

**AND**

**4** - Prescribed by or in consultation with **ONE** of the following:

- Hematologist
- Immunologist

Product Name: Joenja			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
JOENJA	LENIOLISIB PHOSPHATE TAB 70 MG	99391540600320	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy (e.g., reduced lymph node size, increased naive B-cell percentage, decreased severity or frequency of infections/hospitalizations)			

## 2 . Revision History

Date	Notes
7/7/2023	New guideline.

Juxtapid



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140929
<b>Guideline Name</b>	Juxtapid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Juxtapid			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
JUXTAPID	LOMITAPIDE MESYLATE CAP 5 MG (BASE EQUIV)	39480050200120	Brand
JUXTAPID	LOMITAPIDE MESYLATE CAP 10 MG (BASE EQUIV)	39480050200130	Brand
JUXTAPID	LOMITAPIDE MESYLATE CAP 20 MG (BASE EQUIV)	39480050200140	Brand
JUXTAPID	LOMITAPIDE MESYLATE CAP 30 MG (BASE EQUIV)	39480050200150	Brand

**Approval Criteria**

**1** - Diagnosis of homozygous familial hypercholesterolemia (HoFH) as confirmed by BOTH of the following:\*

**1.1** ONE of the following:

- Pre-treatment low density lipoprotein cholesterol (LDL-C) greater than 500 milligrams per deciliter
- Treated LDL-C greater than 300 milligrams per deciliter

**AND**

**1.2** ONE of the following:

- Xanthoma before 10 years of age
- Evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents

**AND**

**2** - Used as an adjunct to a low-fat diet and exercise

**AND**

**3** - Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, LDL apheresis)

**AND**

**4** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**5** - Patient has tried, failed or intolerant to Repatha and Praluent

**AND**

**6** - Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor

Notes	Results of prior genetic testing can be submitted as confirmation of diagnosis of HoFH.
-------	---

Product Name: Juxtapid			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
JUXTAPID	LOMITAPIDE MESYLATE CAP 5 MG (BASE EQUIV)	39480050200120	Brand
JUXTAPID	LOMITAPIDE MESYLATE CAP 10 MG (BASE EQUIV)	39480050200130	Brand
JUXTAPID	LOMITAPIDE MESYLATE CAP 20 MG (BASE EQUIV)	39480050200140	Brand
JUXTAPID	LOMITAPIDE MESYLATE CAP 30 MG (BASE EQUIV)	39480050200150	Brand

**Approval Criteria**

**1** - Patient is continuing a low-fat diet and exercise regimen

**AND**

**2** - Patient continues to receive other lipid-lowering therapy (e.g., statin, low density lipoprotein [LDL] apheresis)

**AND**

**3** - Submission of medical records (e.g. chart notes, laboratory values) documenting low density lipoprotein cholesterol (LDL-C) reduction while on Juxtapid therapy



**AND**

**4** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**5** - Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Jynarque



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-141065
<b>Guideline Name</b>	Jynarque
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	2/2/2024
-----------------	----------

## 1 . Criteria

Product Name: Jynarque, Jynarque Pak			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
JYNARQUE	TOLVAPTAN TAB 15 MG	30454060000320	Brand
JYNARQUE	TOLVAPTAN TAB 30 MG	30454060000330	Brand
JYNARQUE	TOLVAPTAN TAB THERAPY PACK 45 & 15 MG	3045406000B725	Brand
JYNARQUE	TOLVAPTAN TAB THERAPY PACK 60 & 30 MG	3045406000B735	Brand
JYNARQUE	TOLVAPTAN TAB THERAPY PACK 90 & 30 MG	3045406000B745	Brand

JYNARQUE	TOLVAPTAN TAB THERAPY PACK 15 MG	3045406000B710	Brand
JYNARQUE	TOLVAPTAN TAB THERAPY PACK 30 & 15 MG	3045406000B720	Brand

**Approval Criteria**

1 - Diagnosis of autosomal dominant polycystic kidney disease (ADPKD)

Product Name: Jynarque, Jynarque Pak

Approval Length | 12 month(s)

Therapy Stage | Reauthorization

Guideline Type | Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
JYNARQUE	TOLVAPTAN TAB 15 MG	30454060000320	Brand
JYNARQUE	TOLVAPTAN TAB 30 MG	30454060000330	Brand
JYNARQUE	TOLVAPTAN TAB THERAPY PACK 45 & 15 MG	3045406000B725	Brand
JYNARQUE	TOLVAPTAN TAB THERAPY PACK 60 & 30 MG	3045406000B735	Brand
JYNARQUE	TOLVAPTAN TAB THERAPY PACK 90 & 30 MG	3045406000B745	Brand
JYNARQUE	TOLVAPTAN TAB THERAPY PACK 15 MG	3045406000B710	Brand
JYNARQUE	TOLVAPTAN TAB THERAPY PACK 30 & 15 MG	3045406000B720	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Jynarque therapy

**2 . Revision History**

Date	Notes
2/2/2024	COPY OF GL-140881

Kalydeco (ivacaftor)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-141011
<b>Guideline Name</b>	Kalydeco (ivacaftor)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2023
-----------------	-----------

### 1 . Criteria

Product Name: Kalydeco tabs/packet			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KALYDECO	IVACAFITOR TAB 150 MG	45302030000320	Brand
KALYDECO	IVACAFITOR PACKET 13.4 MG	45302030003005	Brand
KALYDECO	IVACAFITOR PACKET 25 MG	45302030003010	Brand
KALYDECO	IVACAFITOR PACKET 50 MG	45302030003020	Brand
KALYDECO	IVACAFITOR PACKET 75 MG	45302030003030	Brand

KALYDECO	IVACAF TOR PACKET 5.8 MG	45302030003002	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystic fibrosis (CF)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Submission of laboratory results confirming that patient has ONE of the mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (see table in Background)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by, or in consultation with, a specialist affiliated with a CF care center</p>			

Product Name: Kalydeco tabs/packet			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KALYDECO	IVACAF TOR TAB 150 MG	45302030000320	Brand
KALYDECO	IVACAF TOR PACKET 13.4 MG	45302030003005	Brand
KALYDECO	IVACAF TOR PACKET 25 MG	45302030003010	Brand
KALYDECO	IVACAF TOR PACKET 50 MG	45302030003020	Brand
KALYDECO	IVACAF TOR PACKET 75 MG	45302030003030	Brand
KALYDECO	IVACAF TOR PACKET 5.8 MG	45302030003002	Brand
<p><b>Approval Criteria</b></p> <p>1 - Provider attests that the patient has achieved a clinically meaningful response while on Kalydeco therapy to ONE of the following:</p>			

- Lung function as demonstrated by percent predicted expiratory volume in 1 second (ppFEV1)
- Body mass index (BMI)
- Pulmonary exacerbations
- Quality of life as demonstrated by Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score

**AND**

**2** - Prescribed by, or in consultation with, a specialist affiliated with a cystic fibrosis (CF) care center

## 2 . Background

Benefit/Coverage/Program Information				
CFTR Gene Mutations that are Responsive to Kalydeco				
List of <i>CFTR</i> Gene Mutations that Produce CFTR Protein and are Responsive to KALYDECO				
<i>711+3A→G *</i>	<i>F311del</i>	<i>I148T</i>	<i>R75Q</i>	<i>S589N</i>
<i>2789+5G→A *</i>	<i>F311L</i>	<i>I175V</i>	<i>R117C *</i>	<i>S737F</i>
<i>3272-26A→G *</i>	<i>F508C</i>	<i>I807M</i>	<i>R117G</i>	<i>S945L *</i>
<i>3849+10kbC→T *</i>	<i>F508C;S1251N †</i>	<i>I1027T</i>	<i>R117H *</i>	<i>S977F *</i>
<i>A120T</i>	<i>F1052V</i>	<i>I1139V</i>	<i>R117L</i>	<i>S1159F</i>
<i>A234D</i>	<i>F1074L</i>	<i>K1060T</i>	<i>R117P</i>	<i>S1159P</i>
<i>A349V</i>	<i>G178E</i>	<i>L206W *</i>	<i>R170H</i>	<i>S1251N *</i>
<i>A455E *</i>	<i>G178R *</i>	<i>L320V</i>	<i>R347H *</i>	<i>S1255P *</i>
<i>A1067T</i>	<i>G194R</i>	<i>L967S</i>	<i>R347L</i>	<i>T338I</i>
<i>D110E</i>	<i>G314E</i>	<i>L997F</i>	<i>R352Q *</i>	<i>T1053I</i>
<i>D110H</i>	<i>G551D *</i>	<i>L1480P</i>	<i>R553Q</i>	<i>V232D</i>

D192G	G551S *	M152V	R668C	V562I
D579G *	G576A	M952I	R792G	V754M
D924N	G970D	M952T	R933G	V1293G
D1152H *	G1069R	P67L *	R1070Q	W1282R
D1270N	G1244E *	Q237E	R1070W *	Y1014C
E56K	G1249R	Q237H	R1162L	Y1032C
E193K	G1349D *	Q359R	R1283M	
E822K	H939R	Q1291R	S549N *	
E831X *	H1375P	R74W	S549R *	
<p>* Clinical data exist for these mutations.</p> <p>† Complex/compound mutations where a single allele of the CFTR gene has multiple mutations these exist independent of the presence of mutations on the other allele.</p>				

### 3 . Revision History

Date	Notes
11/7/2023	Added GPI for 5.8 mg packs

Katerzia, Norliqva (amlodipine oral solution)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-141143
<b>Guideline Name</b>	Katerzia, Norliqva (amlodipine oral solution)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	2/6/2024
-----------------	----------

## 1 . Criteria

Product Name: Katerzia, Norliqva			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KATERZIA	AMLODIPINE BENZOATE ORAL SUSP 1 MG/ML (BASE EQUIVALENT)	34000003081820	Brand
NORLIQVA	AMLODIPINE BESYLATE ORAL SOLN 1 MG/ML (BASE EQUIVALENT)	34000003102020	Brand
<b>Approval Criteria</b>			



**1 - One of the following:**

**1.1 Patient is 8 years of age or younger**

**OR**

**1.2 BOTH of the following:**

**1.2.1 Requested medication is being used for ONE of the following diagnoses:**

- Hypertension
- Chronic stable angina
- Confirmed or suspected vasospastic angina
- Angiographically documented Coronary Artery Disease (CAD)

**AND**

**1.2.2 One of the following:**

**1.2.2.1 Trial and failure, contraindication, or intolerance to generic amlodipine tablets (verified via paid pharmacy claims or submitted chart notes)**

**OR**

**1.2.2.2 Patient is unable to swallow oral tablets/capsules**

**AND**

**2 - For Norliqva requests: trial and failure, contraindication, or intolerance to Katerzia (verified via paid pharmacy claims or submitted chart notes) APPLIES TO NORLIQVA REQUESTS ONLY**

## **2 . Revision History**

Date	Notes
2/6/2024	Updated numbering and Norliqva request wording



Kerendia (finerenone)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140800
<b>Guideline Name</b>	Kerendia (finerenone)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Kerendia			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KERENDIA	FINERENONE TAB 10 MG	30354030000310	Brand
KERENDIA	FINERENONE TAB 20 MG	30354030000320	Brand
<b>Approval Criteria</b>			

**1 - Diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D)**

**AND**

**2 - Urinary albumin-to-creatinine ratio (UACR) greater than or equal to 30 mg/g (milligrams/gram)**

**AND**

**3 - Estimated glomerular filtration rate (eGFR) greater than or equal to 25 mL/min/1.73 m<sup>2</sup> (milliliters/minute/1.73 square meter)**

**AND**

**4 - Serum potassium level less than or equal to 5.0 mEq/L (milliequivalents/liter) prior to initiating treatment**

**AND**

**5 - ONE of the following:**

**5.1** Minimum 30-day supply trial of a maximally tolerated dose and will continue therapy with ONE of the following:

- Generic angiotensin-converting enzyme (ACE) inhibitor (e.g., benazepril, lisinopril)
- Generic angiotensin II receptor blocker (ARB) (e.g., losartan, valsartan)

**OR**

**5.2** Patient has a contraindication or intolerance to ACE inhibitors and ARBs

Product Name: Kerendia	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
KERENDIA	FINERENONE TAB 10 MG	30354030000310	Brand
KERENDIA	FINERENONE TAB 20 MG	30354030000320	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**AND**

2 - ONE of the following:

2.1 Patient continues to be on a maximally tolerated dose of ACE inhibitor or ARB

**OR**

2.2 Patient has a contraindication or intolerance to ACE inhibitors and ARBs

**2 . Revision History**

Date	Notes
6/7/2023	Updated all criteria sections.

Keveyis



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140848
<b>Guideline Name</b>	Keveyis
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Keveyis			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KEVEYIS	DICHLORPHENAMIDE TAB 50 MG	37100020000305	Brand
<b>Approval Criteria</b>			
1 - ONE of the following:			

**1.1** Diagnosis of primary hyperkalemic periodic paralysis or related variant

**OR**

**1.2** Diagnosis of primary hypokalemic periodic paralysis or related variant

<b>Product Name: Keveyis</b>			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KEVEYIS	DICHLORPHENAMIDE TAB 50 MG	37100020000305	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Keveyis therapy			

## 2 . Revision History

Date	Notes
3/31/2020	Bulk copy C&S New York SP to C&S Arizona SP for 5/1 effective

Kevzara (sarilumab)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-155727
<b>Guideline Name</b>	Kevzara (sarilumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Kevzara			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/1.14ML	6650006000D520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/1.14ML	6650006000D530	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/1.14ML	6650006000E520	Brand



KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	6650006000E530	Brand
---------	---	----------------	-------

**Approval Criteria**

1 - ONE of the following:

1.1 Submission of medical records (e.g. chart notes) or paid claims documenting ALL of the following:

1.1.1 Diagnosis of moderately to severely active rheumatoid arthritis (RA)

**AND**

1.1.2 History of failure to a 3 month trial of ONE non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine] at maximally indicated doses within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced

**AND**

1.1.3 History of failure, contraindication, or intolerance to ALL of the following (paid pharmacy claims may be used to confirm trials):

- A preferred\* adalimumab biosimilar
- Enbrel (etanercept)
- Xeljanz (tofacitinib)

**AND**

1.1.4 Prescribed by or in consultation with a rheumatologist

**OR**

1.2 ALL of the following:

1.2.1 Patient is currently on Kevzara therapy as documented by claims history or medical records

**AND**

**1.2.2** Diagnosis of moderately to severely active RA

**AND**

**1.2.3** Prescribed by or in consultation with a rheumatologist

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP</a>
-------	--

Product Name: Kevzara			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/1.14ML	6650006000D520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/1.14ML	6650006000D530	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/1.14ML	6650006000E520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	6650006000E530	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy as evidenced by at least ONE of the following:			
<ul style="list-style-type: none"> <li>• Reduction in the total active (swollen and tender) joint count from baseline</li> <li>• Improvement in symptoms (e.g., pain, stiffness, inflammation) from baseline</li> </ul>			

**AND**

**2** - Prescribed by or in consultation with a rheumatologist

Product Name: Kevzara			
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (PJIA)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/1.14ML	6650006000D520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/1.14ML	6650006000D530	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/1.14ML	6650006000E520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	6650006000E530	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of active polyarticular juvenile idiopathic arthritis (PJIA)

**AND**

**2** - Patient weighs at least 63 kg (kilograms)

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

**AND**

**4** - Paid claims or submission of medical records (e.g., chart notes) confirming a minimum duration of a 6-week trial and failure, contraindication, or intolerance to ONE of the following conventional therapies at maximally tolerated doses:

- leflunomide
- methotrexate

**AND**

**5** - Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure, contraindication, or intolerance to TWO of the following:

- A preferred\* adalimumab biosimilar
- Enbrel (etanercept)
- Orenzia (abatacept) SC
- Xeljanz (tofacitinib)

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Kevzara			
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (PJIA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/1.14ML	6650006000D520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/1.14ML	6650006000D530	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/1.14ML	6650006000E520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	6650006000E530	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy as evidenced by at least ONE of the following:

- Reduction in the total active (swollen and tender) joint count from baseline
- Improvement in symptoms (e.g., pain, stiffness, inflammation) from baseline

**AND**

2 - Prescribed by or in consultation with a rheumatologist

Product Name: Kevzara			
Diagnosis	Polymyalgia Rheumatica (PMR)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/1.14ML	6650006000D520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/1.14ML	6650006000D530	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/1.14ML	6650006000E520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	6650006000E530	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming a diagnosis of polymyalgia rheumatica (PMR)

**AND**

**2** - ONE of the following:

**2.1** Patient has had an inadequate response to corticosteroids (e.g., prednisone)

**OR**

**2.2** Patient cannot tolerate tapering of corticosteroids (e.g., prednisone)

**AND**

**3** - Prescribed by or in consultation with a rheumatologist

Product Name: Kevzara			
Diagnosis	Polymyalgia Rheumatica (PMR)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/1.14ML	6650006000D520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/1.14ML	6650006000D530	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/1.14ML	6650006000E520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	6650006000E530	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy as evidenced by at least ONE of the following:

- Improvement in symptoms (e.g., pain, stiffness) or lab values (e.g., C-reactive protein) from baseline

- Reduced need for corticosteroids (e.g., prednisone)

**AND**

**2** - Prescribed by or in consultation with a rheumatologist

## 2 . Revision History

Date	Notes
9/23/2024	Update to guideline name. Updated RA criteria sections. Added new criteria for PJIA indication. Applied all Kevzara strengths to PMR criteria section. Updated notes sections.

Kineret



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140944
<b>Guideline Name</b>	Kineret
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Kineret			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KINERET	ANAKINRA SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	6626001000E520	Brand
<b>Approval Criteria</b>			



**1** - Submission of medical records (e.g., chart notes) confirming the diagnosis of moderately to severely active rheumatoid arthritis (RA)

**AND**

**2** - Prescribed by or in consultation with a rheumatologist

**AND**

**3** - Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to ONE nonbiologic disease-modifying antirheumatic drug (DMARD) (e.g., Rheumatrex/Trexall [methotrexate], Arava [leflunomide], Azulfidine [sulfasalazine])

**AND**

**4** - One of the following:

**4.1** Both of the following:

**4.1.1** Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to ALL of the following, or attestation demonstrating a trial may be inappropriate\*

- Enbrel (etanercept)
- Humira (adalimumab)
- Xeljanz (tofacitinib)

**AND**

**4.1.2** Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to Orencia (abatacept)

**OR**

**4.2** Paid claims or submission of medical records (e.g., chart notes) confirming continuation of prior Kineret therapy

Notes	*Includes attestation that a total of two TNF inhibitors have already been tried in the past, and the patient should not be made to try a third TNF inhibitor.
-------	--

Product Name: Kineret	
Diagnosis	Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
KINERET	ANAKINRA SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	6626001000E520	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming the diagnosis of neonatal-onset multisystem inflammatory disease (NOMID)

**AND**

2 - Diagnosis of NOMID has been confirmed by one of the following:

**2.1** NLRP-3 (nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3-gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation

**OR**

**2.2** Both of the following:

**2.2.1** Two of the following clinical symptoms:

- Urticaria-like rash
- Cold/stress triggered episodes
- Sensorineural hearing loss
- Musculoskeletal symptoms (e.g., arthralgia, arthritis, myalgia)
- Chronic aseptic meningitis

- Skeletal abnormalities (e.g., epiphyseal overgrowth, frontal bossing)

**AND**

**2.2.2** Elevated acute phase reactants (e.g., erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], serum amyloid A [SAA])

**AND**

**3** - Prescribed by or in consultation with one of the following:

- Allergist/Immunologist
- Rheumatologist
- Pediatrician

<b>Product Name: Kineret</b>			
Diagnosis	Systemic Juvenile Idiopathic Arthritis (SJIA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KINERET	ANAKINRA SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	6626001000E520	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming the diagnosis of active systemic juvenile idiopathic arthritis

**AND**

**2** - Prescribed by or in consultation with a rheumatologist

**AND**

**3** - Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to ONE of the following:

- Nonsteroidal anti-inflammatory drug (NSAID) (e.g., Motrin [ibuprofen], Naprosyn [naproxen])
- Systemic glucocorticoid (e.g., prednisone)

Product Name: Kineret			
Diagnosis	Rheumatoid Arthritis (RA), Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KINERET	ANAKINRA SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	6626001000E520	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Kineret therapy			

Product Name: Kineret			
Diagnosis	Deficiency of Interleukin-1 Receptor Antagonist (DIRA)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KINERET	ANAKINRA SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	6626001000E520	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming the diagnosis of deficiency of interleukin-1 receptor antagonist (DIRA)

**2 . Revision History**

Date	Notes
10/28/2022	Updated criteria, created new criteria for DIRA

Korlym



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140849
<b>Guideline Name</b>	Korlym
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Korlym			
Diagnosis	Endogenous Cushing's Syndrome		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KORLYM	MIFEPRISTONE TAB 300 MG	27304050000330	Brand
<b>Approval Criteria</b>			

**1 - ALL of the following:**

**1.1** Diagnosis of Endogenous Cushing's Syndrome (i.e., hypercortisolism is not a result of chronic administration of high dose glucocorticoids)

**AND**

**1.2** ONE of the following:

- Diagnosis of type 2 diabetes mellitus
- Diagnosis of glucose intolerance

**AND**

**1.3** ONE of the following:

- Patient has failed surgery
- Patient is not a candidate for surgery

Product Name: Korlym			
Diagnosis	Endogenous Cushing's Syndrome		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KORLYM	MIFEPRISTONE TAB 300 MG	27304050000330	Brand

**Approval Criteria**

**1 - Documentation of ONE of the following:**

- Patient has improved glucose tolerance while on Korlym therapy
- Patient has stable glucose tolerance while on Korlym therapy

## 2 . Revision History

Date	Notes
3/31/2020	Bulk copy C&S New York SP to C&S Arizona SP for 5/1 effective



Kuvan



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140896
<b>Guideline Name</b>	Kuvan
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Kuvan			
Diagnosis	Phenylketonuria (PKU)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KUVAN	SAPROPTERIN DIHYDROCHLORIDE SOLUBLE TAB 100 MG	30908565107320	Brand
KUVAN	SAPROPTERIN DIHYDROCHLORIDE POWDER PACKET 100 MG	30908565103020	Brand
KUVAN	SAPROPTERIN DIHYDROCHLORIDE POWDER PACKET 500 MG	30908565103040	Brand

**Approval Criteria**

1 - Diagnosis of phenylketonuria (PKU)

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

LAMA-LABA



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140777
<b>Guideline Name</b>	LAMA-LABA
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/19/2023
-----------------	-----------

## 1 . Criteria

Product Name: Bevespi Aerosphere, Stiolto Respimat, Anoro Ellipta			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BEVESPI AEROSPHERE	GLYCOPYRROLATE-FORMOTEROL FUMARATE AEROSOL 9-4.8 MCG/ACT	44209902543220	Brand
STIOLTO RESPIMAT	TIOTROPIUM BR-OLODATEROL INHAL AERO SOLN 2.5-2.5 MCG/ACT	44209902923420	Brand
ANORO ELLIPTA	UMECLIDINIUM-VILANTEROL AERO POWD BA 62.5-25 MCG/ACT	44209902958020	Brand

**Approval Criteria**

1 - Diagnosis of chronic obstructive pulmonary disease (COPD)

**AND**

2 - One of the following:

**2.1** History of failure, contraindication, or intolerance to treatment with a 30 day trial of a long-acting beta-agonist (e.g., Foradil, Serevent, Striverdi, Arcapta)

**OR**

**2.2** History of failure, contraindication, or intolerance to treatment with a 30 day trial of an orally inhaled anticholinergic agent (e.g., Spiriva, Atrovent, Combivent, Tudorza)

**AND**

3 - If the request is for Bevespi, history of failure, contraindication, or intolerance to treatment with a 30 day trial of both of the following Preferred drugs:

- Anoro Ellipta
- Stiolto Respimat

**2 . Revision History**

Date	Notes
2/9/2023	Removed TD criteria section.

Lampit



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140657
<b>Guideline Name</b>	Lampit
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	2/1/2021
-----------------	----------

## 1 . Criteria

Product Name: Lampit			
Diagnosis	Chagas disease (American trypanosomiasis)		
Approval Length	60 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LAMPIT	NIFURTIMOX TAB 30 MG	16400055000320	Brand
LAMPIT	NIFURTIMOX TAB 120 MG	16400055000340	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi

## 2 . Revision History

Date	Notes
12/15/2020	2021 Implementation

Lantidra (donislecel-jujn)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-141015
<b>Guideline Name</b>	Lantidra (donislecel-jujn)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Lantidra			
Approval Length	30 Day(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LANTIDRA	DONISLECEL-JUJN IV SUSP	27160820301820	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:			

**1.1** Diagnosis of Type 1 diabetes

**AND**

**1.2** Patient is insulin dependent

**AND**

**1.3** Patient is unable to approach target HbA1c (Hemoglobin A1c) because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education

**AND**

**1.4** Patient has reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic symptoms at glucose levels of less than 54 mg/dL (milligrams per deciliter)

**AND**

**1.5** Patient has had at least one episode of severe hypoglycemia in the past 3 years with both of the following:

**1.5.1** Patient required assistance of another person

**AND**

**1.5.2** One of the following:

**1.5.2.1** Symptoms were associated with a blood glucose level less than 50 mg/dL

**OR**

**1.5.2.2** Prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration



**AND**

**1.6** Patient will be on concomitant immunosuppression (e.g., daclizumab, sirolimus, tacrolimus, etanercept, mycophenolate mofetil, etc.)

**AND**

**2** - Prescribed by or in consultation with an endocrinologist

**AND**

**3** - Patient has not had more than three infusions of Lantidra in their lifetime\*

Notes	*There are no data regarding the effectiveness or safety for patients receiving more than three infusions.
-------	--

Product Name: Lantidra			
Approval Length	30 Day(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LANTIDRA	DONISLECEL-JUJN IV SUSP	27160820301820	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting that patient has not achieved independence from exogenous insulin within one year of infusion or within one year after losing independence from exogenous insulin after previous infusion

**AND**

**2** - Patient has not had more than three infusions of Lantidra in their lifetime\*

Notes	*There are no data regarding the effectiveness or safety for patients receiving more than three infusions.
-------	--

## 2 . Revision History

Date	Notes
12/6/2023	New guideline

Leqvio (inclisiran)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140815
<b>Guideline Name</b>	Leqvio (inclisiran)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2023
-----------------	-----------

### 1 . Criteria

Product Name: Leqvio			
Diagnosis	Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LEQVIO	INCLISIRAN SODIUM SUBCUTANEOUS SOLN PREF SYR 284 MG/1.5ML	3935604040E520	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting one of the following diagnoses:

**1.1** Heterozygous familial hypercholesterolemia (HeFH) as confirmed by one of the following:

**1.1.1** Both of the following:

**1.1.1.1** Untreated/pre-treatment LDL-cholesterol (LDL-C) greater than 190 mg/dL

**AND**

**1.1.1.2** One of the following:

- Family history of myocardial infarction in first-degree relative less than 60 years of age
- Family history of myocardial infarction in second-degree relative less than 50 years of age
- Family history of LDL-C greater than 190 mg/dL in first- or second-degree relative
- Family history of familial hypercholesterolemia in first- or second-degree relative
- Family history of tendinous xanthomata and/or arcus cornealis in first- or second-degree relative

**OR**

**1.1.2** Both of the following:

**1.1.2.1** Untreated/pre-treatment LDL-cholesterol (LDL-C) greater than 190 mg/dL

**AND**

**1.1.2.2** Submission of medical records (e.g., chart notes, laboratory values) documenting one of the following:

- Functional mutation in the LDL receptor, ApoB, or PCSK9 gene
- Tendinous xanthomata
- Arcus cornealis before age 45

**OR**

**1.2** Atherosclerotic cardiovascular disease (ASCVD) as confirmed by one of the following:

- Acute coronary syndromes
- History of myocardial infarction
- Stable or unstable angina
- Coronary or other arterial revascularization
- Stroke
- Transient ischemic attack
- Peripheral arterial disease presumed to be of atherosclerotic origin

**AND**

**2** - One of the following:

**2.1** Patient has been receiving at least 12 consecutive weeks of HIGH-INTENSITY statin therapy [i.e., atorvastatin 40-80 mg, rosuvastatin 20-40 mg] and will continue to receive a HIGH-INTENSITY statin at maximally tolerated dose

**OR**

**2.2** Both of the following:

**2.2.1** Patient is unable to tolerate high-intensity statin as evidenced by one of the following intolerable and persistent (i.e., more than 2 weeks) symptoms:

- Myalgia (muscle symptoms without CK elevations)
- Myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN])

**AND**

**2.2.2** One of the following:

- Patient has been receiving at least 12 consecutive weeks of MODERATE-INTENSITY statin therapy [i.e., atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40-80 mg, lovastatin 40 mg, Lescol XL (fluvastatin XL) 80 mg, fluvastatin 40 mg twice daily, or Livalo (pitavastatin) 2-4 mg] and will continue to receive a MODERATE-INTENSITY statin at maximally tolerated dose
- Patient has been receiving at least 12 consecutive weeks of LOW-INTENSITY statin therapy [i.e., simvastatin 10 mg, pravastatin 10-20 mg, lovastatin 20 mg, fluvastatin

20-40 mg, Livalo (pitavastatin) 1 mg] and will continue to receive a LOW-INTENSITY statin at maximally tolerated dose

**OR**

**2.3** Patient is unable to tolerate low- or moderate-, and high-intensity statins as evidenced by one of the following intolerable and persistent (i.e., more than 2 weeks) symptoms for low- or moderate-, and high-intensity statins:

- Myalgia (muscle symptoms without CK elevations)
- Myositis (muscle symptoms with CK elevations less than 10 times ULN)

**OR**

**2.4** Patient has a labeled contraindication to all statins

**OR**

**2.5** Patient has experienced rhabdomyolysis or muscle symptoms with statin treatment with CK elevations greater than 10 times ULN

**AND**

**3** - One of the following:

**3.1** Patient has been receiving at least 12 consecutive weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy

**OR**

**3.2** Patient has a history of contraindication or intolerance to ezetimibe

**AND**

**4** - Patient is unable to maintain adherence to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy

**AND**

**5** - Submission of medical records (e.g., laboratory values) documenting one of the following LDL-C values while on maximally tolerated lipid lowering therapy within the last 120 days:

- LDL-C greater than or equal to 55 mg/dL for diagnosis of ASCVD
- LDL-C greater than or equal to 100 mg/dL for diagnosis of HeFH

**AND**

**6** - Prescribed by or in consultation with one of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**7** - Medication will not be used in combination with PCSK9 inhibitor therapy

Product Name: Leqvio			
Diagnosis	Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LEQVIO	INCLISIRAN SODIUM SUBCUTANEOUS SOLN PREF SYR 284 MG/1.5ML	3935604040E520	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting LDL-C reduction from baseline while on therapy			

**AND**

**2** - One of the following:

**2.1** Patient continues to receive other lipid-lowering therapy (e.g., statins, ezetimibe) at the maximally tolerated dose

**OR**

**2.2** Patient has a documented inability to take other lipid-lowering therapy (e.g., statins, ezetimibe)

**AND**

**3** - Medication will not be used in combination with PCSK9 inhibitor therapy

## 2 . Revision History

Date	Notes
9/11/2023	Update to account for 2022 ACC recommendations of a lower LDL threshold of 55mg/dl for patients with ASCVD at very high risk



Leucovorin



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140688
<b>Guideline Name</b>	Leucovorin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Leucovorin tabs			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LEUCOVORIN CALCIUM	LEUCOVORIN CALCIUM TAB 5 MG	21755040100310	Generic
LEUCOVORIN CALCIUM	LEUCOVORIN CALCIUM TAB 10 MG	21755040100325	Generic
LEUCOVORIN CALCIUM	LEUCOVORIN CALCIUM TAB 15 MG	21755040100335	Generic
LEUCOVORIN CALCIUM	LEUCOVORIN CALCIUM TAB 25 MG	21755040100345	Generic

**Approval Criteria**

1 - ONE of the following:

1.1 Methotrexate toxicity prophylaxis

**OR**

1.2 Treatment of hematologic toxicity from folic acid antagonists (i.e., pyrimethamine toxicity treatment or trimethoprim toxicity treatment)

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Libervant, Nayzilam, Valtoco



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-148393
<b>Guideline Name</b>	Libervant, Nayzilam, Valtoco
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Libervant, Nayzilam, Valtoco			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NAYZILAM	MIDAZOLAM NASAL SPRAY SOLN 5 MG/0.1 ML	72100060002010	Brand
VALTOCO 5 MG DOSE	DIAZEPAM NASAL SPRAY 5 MG/0.1 ML	72100030000920	Brand
VALTOCO 10 MG DOSE	DIAZEPAM NASAL SPRAY 10 MG/0.1 ML	72100030000930	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

VALTOCO 15 MG DOSE	DIAZEPAM NASAL SPRAY THER PACK 2 X 7.5 MG/0.1ML (15 MG DOSE)	7210003000C440	Brand
VALTOCO 20 MG DOSE	DIAZEPAM NASAL SPRAY THER PACK 2 X 10 MG/0.1ML (20 MG DOSE)	7210003000C450	Brand
LIBERVANT	DIAZEPAM BUCCAL FILM 5 MG	72100030008210	Brand
LIBERVANT	DIAZEPAM BUCCAL FILM 7.5 MG	72100030008215	Brand
LIBERVANT	DIAZEPAM BUCCAL FILM 10 MG	72100030008220	Brand
LIBERVANT	DIAZEPAM BUCCAL FILM 12.5 MG	72100030008225	Brand
LIBERVANT	DIAZEPAM BUCCAL FILM 15 MG	72100030008230	Brand

**Approval Criteria**

1 - Diagnosis of epilepsy

**AND**

2 - Requested medication is being prescribed for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern

Product Name: Libervant, Nayzilam, Valtoco			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NAYZILAM	MIDAZOLAM NASAL SPRAY SOLN 5 MG/0.1 ML	72100060002010	Brand
VALTOCO 5 MG DOSE	DIAZEPAM NASAL SPRAY 5 MG/0.1 ML	72100030000920	Brand
VALTOCO 10 MG DOSE	DIAZEPAM NASAL SPRAY 10 MG/0.1 ML	72100030000930	Brand
VALTOCO 15 MG DOSE	DIAZEPAM NASAL SPRAY THER PACK 2 X 7.5 MG/0.1ML (15 MG DOSE)	7210003000C440	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

VALTOCO 20 MG DOSE	DIAZEPAM NASAL SPRAY THER PACK 2 X 10 MG/0.1ML (20 MG DOSE)	7210003000C450	Brand
LIBERVANT	DIAZEPAM BUCCAL FILM 5 MG	72100030008210	Brand
LIBERVANT	DIAZEPAM BUCCAL FILM 7.5 MG	72100030008215	Brand
LIBERVANT	DIAZEPAM BUCCAL FILM 10 MG	72100030008220	Brand
LIBERVANT	DIAZEPAM BUCCAL FILM 12.5 MG	72100030008225	Brand
LIBERVANT	DIAZEPAM BUCCAL FILM 15 MG	72100030008230	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**Product Name: Nayzilam, Valtoco**

Diagnosis	Requests Exceeding Quantity Limit
Approval Length	12 month(s)
Guideline Type	Quantity Limit

Product Name	Generic Name	GPI	Brand/Generic
NAYZILAM	MIDAZOLAM NASAL SPRAY SOLN 5 MG/0.1 ML	72100060002010	Brand
VALTOCO 5 MG DOSE	DIAZEPAM NASAL SPRAY 5 MG/0.1 ML	72100030000920	Brand
VALTOCO 10 MG DOSE	DIAZEPAM NASAL SPRAY 10 MG/0.1 ML	72100030000930	Brand
VALTOCO 15 MG DOSE	DIAZEPAM NASAL SPRAY THER PACK 2 X 7.5 MG/0.1ML (15 MG DOSE)	7210003000C440	Brand
VALTOCO 20 MG DOSE	DIAZEPAM NASAL SPRAY THER PACK 2 X 10 MG/0.1ML (20 MG DOSE)	7210003000C450	Brand

**Approval Criteria**

1 - Physician has provided rationale for needing to exceed the quantity limit of 2 boxes per 30 days

**AND**

**2** - The requested dose is within the FDA (Food and Drug Administration) maximum dose per day

## 2 . Revision History

Date	Notes
6/11/2024	Added Libervant as a target to the guideline. Updated gl name, product name lists, and GPI tables accordingly. No changes to criteria.

Lidoderm (lidocaine) 5% patches



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140762
<b>Guideline Name</b>	Lidoderm (lidocaine) 5% patches
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Brand Lidoderm patch, generic lidocaine 5% patch			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LIDOCAINE	LIDOCAINE PATCH 5%	90850060005930	Generic
LIDODERM	LIDOCAINE PATCH 5%	90850060005930	Brand
LIDOCAINE PATCH 5%	LIDOCAINE PATCH 5%	90850060005930	Generic
<b>Approval Criteria</b>			

**1** - One of the following:

**1.1** The requested drug must be used for a Food and Drug Administration (FDA)-approved indication

**OR**

**1.2** The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- Food and Drug Administration (FDA) approved indications and limits
- Published practice guidelines and treatment protocols
- Comparative data evaluating the efficacy, type and frequency of side effects and potential drug interactions among alternative products as well as the risks, benefits and potential member outcomes
- Drug Facts and Comparisons
- American Hospital Formulary Service Drug Information
- United States Pharmacopeia - Drug Information
- DRUGDEX Information System
- UpToDate
- MicroMedex
- Peer-reviewed medical literature, including randomized clinical trials, outcomes, research data and pharmacoeconomic studies
- Other drug reference resources

## 2 . Revision History

Date	Notes
12/12/2022	New guideline



Likmez



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-145687
<b>Guideline Name</b>	Likmez
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Likmez			
Approval Length	3 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LIKMEZ	METRONIDAZOLE SUSP 500 MG/5ML	16000035001850	Brand
<p><b>Approval Criteria</b></p> <p>1 - One of the following diagnoses:</p> <p>1.1 Trichomoniasis caused by Trichomonas vaginalis</p>			

**OR**

**1.2** Acute intestinal amebiasis (amoebic dysentery) and amebic liver abscess

**OR**

**1.3** Treatment of one the following serious infections caused by susceptible anaerobic bacteria:

- Intra-abdominal infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Parabacteroides distasonis, Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species
- Skin and skin structure infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species
- Gynecologic infections, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species
- Bacterial septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species
- Bone and joint infections, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group
- Central nervous system (CNS) infections, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group
- Lower respiratory tract infections, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group
- Endocarditis caused by Bacteroides species including the B. fragilis group

**AND**

**2** - One of the following:

**2.1** Patient has a history of failure, contraindication, or intolerance to metronidazole tablets as evidenced by submission of medical records or claims history

**OR**

**2.2** Patient has a swallowing disorder and cannot swallow solid oral dosage forms

## 2 . Revision History

Date	Notes
4/12/2024	New

Livdelzi (seladelpar)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-159587
<b>Guideline Name</b>	Livdelzi (seladelpar)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Livdelzi			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LIVDELZI	SELADELPAR LYSINE CAP 10 MG	52780070500120	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of primary biliary cholangitis (PBC) (also known as primary biliary cirrhosis)

**AND**

**2** - Submission of medical records (e.g., chart notes) or paid claims documenting ONE of the following:

**2.1** BOTH of the following:

**2.1.1** Patient has failed to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal (ULN) after at least 12 consecutive months of treatment with ursodeoxycholic acid (UDCA) (e.g., Urso, Urso Forte, ursodiol)

**AND**

**2.1.2** Used in combination with ursodeoxycholic acid (UDCA)

**OR**

**2.2** History of contraindication or intolerance to ursodeoxycholic acid (UDCA)

**AND**

**3** - Requested drug will NOT be used in combination with Ocaliva (obeticholic acid) or Iqirvo (elafibranor)

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Hepatologist
- Gastroenterologist

Product Name: Livdelzi

Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LIVDELZI	SELADELPAR LYSINE CAP 10 MG	52780070500120	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy (e.g., ALP level less than 1.67 times ULN, total bilirubin less than or equal to ULN, ALP decrease greater than or equal to 15% from baseline)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Requested drug will NOT be used in combination with Ocaliva (obeticholic acid) or Iqirvo (elafibranor)</p>			

## 2 . Revision History

Date	Notes
11/7/2024	New program.

Livmarli (maralixibat)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157258
<b>Guideline Name</b>	Livmarli (maralixibat)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Livmarli			
Diagnosis	Alagille Syndrome (ALGS)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LIVMARLI	MARALIXIBAT CHLORIDE ORAL SOLN 9.5 MG/ML	52350050102020	Brand
LIVMARLI	MARALIXIBAT CHLORIDE ORAL SOLN 19 MG/ML	52350050102040	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming BOTH of the following:

**1.1** Diagnosis of Alagille syndrome (ALGS)

**AND**

**1.2** Molecular genetic testing confirms mutations in the JAG1 or NOTCH2 gene

**AND**

**2** - Documentation of ONE of the following:

- Total serum bile acid > 3x the upper limit of normal (ULN)
- Conjugated bilirubin > 1 mg/dL (milligrams/deciliter)
- Fat soluble vitamin deficiency otherwise unexplainable
- Gammaglutamyl transpeptidase (GGT) > 3x ULN

**AND**

**3** - Patient is experiencing moderate to severe cholestatic pruritus

**AND**

**4** - Patient has had an inadequate response to at least TWO of the following treatments used for the relief of pruritus:

- Ursodeoxycholic acid (e.g., Ursodiol)
- Antihistamines (e.g., diphenhydramine, hydroxyzine)
- Rifampin
- Bile acid sequestrants (e.g., Questran, Colestid, Welchol)

**AND**

**5** - Patient is 3 months of age or older



**AND**

**6** - Prescribed by or in consultation with a hepatologist

Product Name: Livmarli			
Diagnosis	Progressive Familial Intrahepatic Cholestasis (PFIC)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LIVMARLI	MARALIXIBAT CHLORIDE ORAL SOLN 9.5 MG/ML	52350050102020	Brand
LIVMARLI	MARALIXIBAT CHLORIDE ORAL SOLN 19 MG/ML	52350050102040	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming BOTH of the following:

**1.1** Diagnosis of progressive familial intrahepatic cholestasis (PFIC)

**AND**

**1.2** Molecular genetic testing confirms mutations in the ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, or MYO5B gene

**AND**

**2** - Patient is experiencing BOTH of the following:

- Moderate to severe pruritus
- Patient has a serum bile acid concentration above the upper limit of the normal reference for the reporting laboratory

**AND**

**3** - Patient is 12 months of age or older

**AND**

**4** - Patient has had an inadequate response to at least TWO of the following treatments used for the relief of pruritus:

- Ursodeoxycholic acid (e.g., Ursodiol)
- Antihistamines (e.g., diphenhydramine, hydroxyzine)
- Rifampin
- Bile acid sequestrants (e.g., Questran, Colestid, Welchol)

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Hepatologist
- Gastroenterologist

Product Name: Livmarli			
Diagnosis	Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LIVMARLI	MARALIXIBAT CHLORIDE ORAL SOLN 9.5 MG/ML	52350050102020	Brand
LIVMARLI	MARALIXIBAT CHLORIDE ORAL SOLN 19 MG/ML	52350050102040	Brand
<b>Approval Criteria</b>			

1 - Documentation of positive clinical response to therapy (e.g., reduced bile acids, reduced pruritus severity score)

## 2 . Revision History

Date	Notes
10/9/2024	Added new GPI for Livmarli 19 mg/mL strength and updated age criterion in initial auth section for PFIC.

Livtency



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140947
<b>Guideline Name</b>	Livtency
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Livtency			
Diagnosis	CMV infection/disease		
Approval Length	8 Week(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LIVTENCITY	MARIBAVIR TAB 200 MG	12200050000320	Brand
<b>Approval Criteria</b>			

**1** - Diagnosis of cytomegalovirus (CMV) infection/disease as confirmed by one of the following methods:

- quantitative polymerase chain reaction (qPCR)
- CMV pp65 antigenemia

**AND**

**2** - Patient is a recipient of one of the following:

- Hematopoietic stem cell transplant
- Solid organ transplant

**AND**

**3** - Trial and failure of a minimum 2 weeks duration, contraindication, or intolerance to one of the following therapies at an appropriately indicated dose:

- Intravenous (IV) ganciclovir
- Oral valganciclovir
- IV foscarnet
- IV cidofovir

**AND**

**4** - Patient is 12 years of age or older

**AND**

**5** - Patient weighs greater than or equal to 35kg

**AND**

**6** - Prescribed by or in consultation with a provider who specializes in one of the following areas:

- Transplant

- Infectious Disease

## 2 . Revision History

Date	Notes
10/28/2022	Removed references and end note, no changes to clinical criteria.

Lodoco (colchicine)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140826
<b>Guideline Name</b>	Lodoco (colchicine)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2023
-----------------	-----------

### 1 . Criteria

Product Name: Lodoco			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LODOCO	COLCHICINE (CARDIOVASCULAR) TAB 0.5 MG	40220030000320	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of cardiovascular disease (CV)			

<b>AND</b>
<b>2</b> - Used for the secondary prevention of CV disease
<b>AND</b>
<b>3</b> - Patient is on guideline therapy management for multiple risk factors (e.g., dyslipidemia, hypertension, hyperglycemia) associated with CV disease
<b>AND</b>
<b>4</b> - Submission of medical records (e.g., chart notes) or paid claims documenting trial and failure or intolerance to colchicine 0.6 mg tablets

<b>Product Name: Lodoco</b>			
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LODOCO	COLCHICINE (CARDIOVASCULAR) TAB 0.5 MG	40220030000320	Brand
<b>Approval Criteria</b>			
1 - Patient demonstrates positive clinical response to therapy(e.g., reduced risk of cardiovascular death, myocardial infarction, ischemia-driven coronary revascularization)			

## 2 . Revision History

Date	Notes
11/7/2023	New GL





Long-Acting Opioid Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157530
<b>Guideline Name</b>	Long-Acting Opioid Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: generic morphine sulfate ER tabs, Brand MS Contin, morphine sulfate ER caps, morphine sulfate beads caps ER, fentanyl patches, generic hydrocodone ER tabs, Brand Hysingla ER, oxymorphone ER, Nucynta ER, generic oxycodone ER, Brand Oxycontin, Xtampza ER, Brand Conzip, generic tramadol ER biphasic release, generic tramadol ER, generic methadone, Brand Methadose, hydromorphone ER, hydrocodone ER caps			
Diagnosis	PA REQUIRED for use of MAT and other Opioids		
Guideline Type	DUR		
Product Name	Generic Name	GPI	Brand/Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MS CONTIN	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Brand
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Brand
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 10 MG	65100055107010	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 20 MG	65100055107020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 30 MG	65100055107030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 50 MG	65100055107040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 60 MG	65100055107045	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 80 MG	65100055107050	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 100 MG	65100055107060	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 30 MG	65100055207020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 45 MG	65100055207025	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 60 MG	65100055207030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 75 MG	65100055207035	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 90 MG	65100055207040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 120 MG	65100055207050	Generic
FENTANYL	FENTANYL TD PATCH 72HR 12 MCG/HR	65100025008610	Generic
FENTANYL	FENTANYL TD PATCH 72HR 25 MCG/HR	65100025008620	Generic
FENTANYL	FENTANYL TD PATCH 72HR 50 MCG/HR	65100025008630	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FENTANYL	FENTANYL TD PATCH 72HR 75 MCG/HR	65100025008640	Generic
FENTANYL	FENTANYL TD PATCH 72HR 100 MCG/HR	65100025008650	Generic
FENTANYL	FENTANYL TD PATCH 72HR 37.5 MCG/HR	65100025008626	Generic
FENTANYL	FENTANYL TD PATCH 72HR 62.5 MCG/HR	65100025008635	Generic
FENTANYL	FENTANYL TD PATCH 72HR 87.5 MCG/HR	65100025008645	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Brand
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 5 MG	65100080107405	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 7.5 MG	65100080107407	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 10 MG	65100080107410	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 15 MG	65100080107415	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 20 MG	65100080107420	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 30 MG	65100080107430	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 40 MG	65100080107440	Generic
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 50 MG	65100091107420	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 100 MG	65100091107430	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 150 MG	65100091107440	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 200 MG	65100091107450	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 250 MG	65100091107460	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 15 MG	6510007510A715	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 30 MG	6510007510A730	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 60 MG	6510007510A760	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 9 MG	6510007500A310	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 13.5 MG	6510007500A315	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 18 MG	6510007500A320	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 27 MG	6510007500A330	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 36 MG	6510007500A340	Brand
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 100 MG	65100095107560	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 200 MG	65100095107570	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 300 MG	65100095107580	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HYDROCHLORIDE INTENSOL	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HCL	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HCL	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

METHADONE HCL	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HCL	METHADONE HCL TAB 10 MG	65100050100310	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 10 MG	65100050100310	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 32 MG	65100035107556	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 10 MG	65100030106910	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 15 MG	65100030106915	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 20 MG	65100030106920	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 30 MG	65100030106930	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 40 MG	65100030106940	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 50 MG	65100030106950	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Brand
METHADOSE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
METHADOSE SUGAR-FREE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Brand

OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Brand
<p><b>Approval Criteria</b></p> <p>1 - Provider attests to notify the prescriber of the MAT (medication assisted treatment) therapy and the prescriber of the MAT therapy approves the concurrent opioid therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - The days supply does not exceed 14 days for a surgical procedure</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - The days supply does not exceed 5 days for all other requests</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - There has not been a previous approval in the last 6 months</p>			
Notes	Approval Length: 14 Days for surgical procedure, 5 Days for all other requests		

Product Name: generic morphine sulfate ER tabs, fentanyl patches 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hr, Xtampza, generic tramadol ER tabs (non-biphasic release)			
Diagnosis	Cancer related pain/Hospice care/end-of-life care*		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Generic
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Generic
FENTANYL	FENTANYL TD PATCH 72HR 12 MCG/HR	65100025008610	Generic
FENTANYL	FENTANYL TD PATCH 72HR 25 MCG/HR	65100025008620	Generic
FENTANYL	FENTANYL TD PATCH 72HR 50 MCG/HR	65100025008630	Generic
FENTANYL	FENTANYL TD PATCH 72HR 75 MCG/HR	65100025008640	Generic
FENTANYL	FENTANYL TD PATCH 72HR 100 MCG/HR	65100025008650	Generic
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 9 MG	6510007500A310	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 13.5 MG	6510007500A315	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 18 MG	6510007500A320	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 27 MG	6510007500A330	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 36 MG	6510007500A340	Brand
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic

**Approval Criteria**

1 - ONE of the following:

<p><b>1.1 Patient is being treated for cancer</b></p> <p style="text-align: center;"><b>OR</b></p> <p><b>1.2 Patient is receiving hospice or end-of-life care</b></p>	
Notes	<p>*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 30 day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p>

<p>Product Name: Brand MS Contin, morphine sulfate ER caps, morphine sulfate beads caps ER, fentanyl patches 37.5mcg/hr, 62.5mcg/hr, and 87.5mcg/hr, generic hydrocodone ER tabs, Brand Hysingla ER, oxymorphone ER, Nucynta ER, generic oxycodone ER, Brand Oxycotin, generic methadone, Brand Methadose, hydromorphone ER, generic hydrocodone ER caps</p>			
Diagnosis	Cancer related pain/Hospice care/end-of-life care*		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MS CONTIN	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Brand
MS CONTIN	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Brand
MS CONTIN	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Brand
MS CONTIN	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Brand
MS CONTIN	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 10 MG	65100055107010	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 20 MG	65100055107020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 30 MG	65100055107030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 50 MG	65100055107040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 60 MG	65100055107045	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 80 MG	65100055107050	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 100 MG	65100055107060	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 30 MG	65100055207020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 45 MG	65100055207025	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 60 MG	65100055207030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 75 MG	65100055207035	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 90 MG	65100055207040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 120 MG	65100055207050	Generic
FENTANYL	FENTANYL TD PATCH 72HR 37.5 MCG/HR	65100025008626	Generic
FENTANYL	FENTANYL TD PATCH 72HR 62.5 MCG/HR	65100025008635	Generic
FENTANYL	FENTANYL TD PATCH 72HR 87.5 MCG/HR	65100025008645	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Brand
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 5 MG	65100080107405	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 7.5 MG	65100080107407	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 10 MG	65100080107410	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 15 MG	65100080107415	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 20 MG	65100080107420	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 30 MG	65100080107430	Generic
OXYMORPHONE HYDROCHLORIDEER	OXYMORPHONE HCL TAB ER 12HR 40 MG	65100080107440	Generic
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 50 MG	65100091107420	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 100 MG	65100091107430	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 150 MG	65100091107440	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 200 MG	65100091107450	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 250 MG	65100091107460	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 15 MG	6510007510A715	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 30 MG	6510007510A730	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 60 MG	6510007510A760	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HYDROCHLORIDE INTENSOL	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HCL	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HCL	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HCL	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HCL	METHADONE HCL TAB 10 MG	65100050100310	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 10 MG	65100050100310	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 32 MG	65100035107556	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 10 MG	65100030106910	Generic

HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 15 MG	65100030106915	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 20 MG	65100030106920	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 30 MG	65100030106930	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 40 MG	65100030106940	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 50 MG	65100030106950	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Brand
METHADOSE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
METHADOSE SUGAR-FREE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 Patient is being treated for cancer

**OR**

1.2 Patient is receiving hospice or end-of-life care

**AND**

2 - BOTH of the following:

2.1 ONE of the following:

2.1.1 The patient has a history of failure, contraindication, or intolerance to a trial of at least THREE of the following (Document drugs and date of trials):\*

- morphine sulfate controlled release tablets (specifically generic MS Contin)
- preferred fentanyl transdermal patches (12 mcg, 25 mcg, 50 mcg, 75 mcg, 100 mcg)\*\*
- Butrans (buprenorphine)
- Xtampza ER (oxycodone extended-release)
- tramadol extended release tablets (non-biphasic release tablets)

**OR**

**2.1.2** Patient is established on pain therapy with the requested medication for cancer, hospice care, or end-of-life care pain, and the medication is not a new regimen for treatment of cancer, hospice care, or end-of-life care pain (Document date regimen was started)

**AND**

**2.2** Prescriber attests to the following: the information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested

Notes	<p>*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>*If the request is for a non-preferred product and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.</p> <p>**Fentanyl transdermal 37.5mcg/hr, 62.5mcg/hr, and 87.5mcg/hr are non-preferred.</p>
-------	--

Product Name: Brand Conzip, generic tramadol ER biphasic release caps, generic tramadol ER biphasic release tabs	
Diagnosis	Cancer related pain/Hospice care/end-of-life care*
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 100 MG	65100095107560	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 200 MG	65100095107570	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 300 MG	65100095107580	Generic

**Approval Criteria**

**1 - ONE** of the following:

**1.1** Patient is being treated for cancer

**OR**

**1.2** Patient is receiving hospice or end-of-life care

**AND**

**2 - BOTH** of the following:

**2.1 ONE** of the following:

**2.1.1** The patient has a history of failure, contraindication or intolerance to a trial of **BOTH** of the following (Document drugs and date of trials):\*

- tramadol immediate release (IR)



- tramadol extended release tablets (non-biphasic release tablets)

**OR**

**2.1.2** Patient is established on pain therapy with the requested medication for cancer, hospice care, or end-of-life care pain, and the medication is not a new regimen for treatment of cancer, hospice care, or end-of-life care pain (Document date regimen was started)

**AND**

**2.2** Prescriber attests to the following: the information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested

Notes	<p>*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.</p>
-------	--

Product Name: generic morphine sulfate ER tabs, fentanyl patches 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hr, Xtampza, generic tramadol ER tabs (non-biphasic release)			
Diagnosis	Non-cancer pain/Non-hospice care/Non-end-of-life care pain*		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Generic
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Generic
FENTANYL	FENTANYL TD PATCH 72HR 12 MCG/HR	65100025008610	Generic
FENTANYL	FENTANYL TD PATCH 72HR 25 MCG/HR	65100025008620	Generic
FENTANYL	FENTANYL TD PATCH 72HR 50 MCG/HR	65100025008630	Generic
FENTANYL	FENTANYL TD PATCH 72HR 75 MCG/HR	65100025008640	Generic
FENTANYL	FENTANYL TD PATCH 72HR 100 MCG/HR	65100025008650	Generic
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 9 MG	6510007500A310	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 13.5 MG	6510007500A315	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 18 MG	6510007500A320	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 27 MG	6510007500A330	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 36 MG	6510007500A340	Brand
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic

**Approval Criteria**

1 - Prescriber attests to ALL of the following:

- The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested
- Treatment goals are defined, including estimated duration of treatment
- Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention
- Patient has been screened for substance abuse/opioid dependence
- If used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression
- Pain is moderate to severe and expected to persist for an extended period of time
- Pain is chronic
- Pain is not postoperative (unless the patient is already receiving chronic opioid therapy prior to surgery, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time)
- Pain management is required around the clock with a long-acting opioid

**AND**

**2** - ONE of the following:

**2.1** Prior to the start of therapy with the long-acting opioid, the patient has failed an adequate (minimum of 2 week) trial of a short-acting opioid within the last 30 days [Document drug(s) and date of trial]\*

**OR**

**2.2** The patient is already receiving chronic opioid therapy prior to surgery for postoperative pain

**OR**

**2.3** Postoperative pain is expected to be moderate to severe and persist for an extended period of time

**AND**

**3** - If the request for neuropathic pain (examples of neuropathic pain include neuralgias, neuropathies, fibromyalgia), **BOTH** of the following:

**3.1** Unless it is contraindicated, the patient has not exhibited an adequate response to 8 weeks of treatment with gabapentin titrated to a therapeutic dose (Document date of trial)\*

**AND**

**3.2** Unless it is contraindicated, the patient has not exhibited an adequate response to at least 6 weeks of treatment with a tricyclic antidepressant titrated to the maximum tolerated dose (Document drug and date of trial)\*

Notes	<p>*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.</p> <p>**Fentanyl transdermal 37.5mcg/hr, 62.5mcg/hr, and 87.5 mcg/hr are non-preferred.</p>
-------	---

Product Name: Brand MS Contin, morphine sulfate ER caps, morphine sulfate beads caps ER, fentanyl patches 37.5mcg/hr, 62.5mcg/hr, and 87.5mcg/hr, generic hydrocodone ER tabs, Brand Hysingla ER, oxymorphone ER, Nucynta ER, generic oxycodone ER, Brand Oxycontin, generic methadone, Brand Methadose, hydromorphone ER, generic hydrocodone ER caps

Diagnosis	Non-cancer pain/Non-hospice care/Non-end-of-life care pain*
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
MS CONTIN	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Brand
MS CONTIN	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Brand
MS CONTIN	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Brand
MS CONTIN	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Brand
MS CONTIN	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 10 MG	65100055107010	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 20 MG	65100055107020	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 30 MG	65100055107030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 50 MG	65100055107040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 60 MG	65100055107045	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 80 MG	65100055107050	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 100 MG	65100055107060	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 30 MG	65100055207020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 45 MG	65100055207025	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 60 MG	65100055207030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 75 MG	65100055207035	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 90 MG	65100055207040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 120 MG	65100055207050	Generic
FENTANYL	FENTANYL TD PATCH 72HR 37.5 MCG/HR	65100025008626	Generic
FENTANYL	FENTANYL TD PATCH 72HR 62.5 MCG/HR	65100025008635	Generic
FENTANYL	FENTANYL TD PATCH 72HR 87.5 MCG/HR	65100025008645	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Brand
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 5 MG	65100080107405	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 7.5 MG	65100080107407	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 10 MG	65100080107410	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 15 MG	65100080107415	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 20 MG	65100080107420	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 30 MG	65100080107430	Generic
OXYMORPHONE HYDROCHLORIDEER	OXYMORPHONE HCL TAB ER 12HR 40 MG	65100080107440	Generic
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 50 MG	65100091107420	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 100 MG	65100091107430	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 150 MG	65100091107440	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 200 MG	65100091107450	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 250 MG	65100091107460	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 15 MG	6510007510A715	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 30 MG	6510007510A730	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 60 MG	6510007510A760	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HYDROCHLORIDE INTENSOL	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HCL	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HCL	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HCL	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HCL	METHADONE HCL TAB 10 MG	65100050100310	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 10 MG	65100050100310	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 32 MG	65100035107556	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 10 MG	65100030106910	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 15 MG	65100030106915	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 20 MG	65100030106920	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 30 MG	65100030106930	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 40 MG	65100030106940	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 50 MG	65100030106950	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Brand
METHADOSE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
METHADOSE SUGAR-FREE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Brand

**Approval Criteria**

1 - Prescriber attests to ALL of the following:

- The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested
- Treatment goals are defined, including estimated duration of treatment
- Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention
- Patient has been screened for substance abuse/opioid dependence
- If used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the



prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression

- Pain is moderate to severe and expected to persist for an extended period of time
- Pain is not postoperative (unless the patient is already receiving chronic opioid therapy prior to surgery, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time)
- Pain management is required around the clock with a long-acting opioid

**AND**

**2** - ONE of the following:

**2.1** Prior to the start of therapy with the long-acting opioid, the patient has failed an adequate (minimum of 2 week) trial of a short-acting opioid within the last 30 days [Document drug(s) and date of trial]\*

**OR**

**2.2** The patient is already receiving chronic opioid therapy prior to surgery for postoperative pain

**OR**

**2.3** Postoperative pain is expected to be moderate to severe and persist for an extended period of time

**AND**

**3** - The patient has a history of failure, contraindication, or intolerance to at least THREE of the following (Document drugs and date of trials):\*

- morphine sulfate controlled release tablets (specifically generic MS Contin)
- preferred fentanyl transdermal (12 mcg, 25 mcg, 50 mcg, 75 mcg, 100 mcg)\*\*
- Butrans (buprenorphine)
- Xtampza ER (oxycodone extended-release)
- tramadol extended release tablets (non-biphasic release tablets)

**AND**

**4** - If the request for neuropathic pain (examples of neuropathic pain include neuralgias, neuropathies, fibromyalgia), BOTH of the following:

**4.1** Unless it is contraindicated, the patient has not exhibited an adequate response to 8 weeks of treatment with gabapentin titrated to a therapeutic dose (Document date of trial)\*

**AND**

**4.2** Unless it is contraindicated, the patient has not exhibited an adequate response to at least 6 weeks of treatment with a tricyclic antidepressant titrated to the maximum tolerated dose (Document drug and date of trial)\*

Notes	<p>*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>*If the request is for a non-preferred product and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.</p> <p>**Fentanyl transdermal 37.5mcg/hr, 62.5mcg/hr, and 87.5 mcg/hr are non-preferred.</p>
-------	---

Product Name: Brand Conzip, generic tramadol ER biphasic release caps, generic tramadol ER biphasic release tabs			
Diagnosis	Non-cancer pain/Non-hospice care/Non-end-of-life care pain*		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic

CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 100 MG	65100095107560	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 200 MG	65100095107570	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 300 MG	65100095107580	Generic

**Approval Criteria**

1 - Prescriber attests to ALL of the following:

- The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested
- Treatment goals are defined, including estimated duration of treatment
- Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention
- Patient has been screened for substance abuse/opioid dependence
- If used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression
- Pain is moderate to severe and expected to persist for an extended period of time
- Pain is chronic
- Pain is not postoperative (unless the patient is already receiving chronic opioid therapy prior to surgery, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time)
- Pain management is required around the clock with a long-acting opioid

**AND**

2 - ONE of the following:

**2.1** Prior to the start of therapy with the long-acting opioid, the patient has failed an adequate (minimum of 2 week) trial of a short-acting opioid within the last 30 days [Document drug(s) and date of trial]\*

**OR**

**2.2** The patient is already receiving chronic opioid therapy prior to surgery for postoperative pain

**OR**

**2.3** Postoperative pain is expected to be moderate to severe and persist for an extended period of time

**AND**

**3** - If the request for neuropathic pain (examples of neuropathic pain include neuralgias, neuropathies, fibromyalgia), BOTH of the following:

**3.1** Unless it is contraindicated, the patient has not exhibited an adequate response to 8 weeks of treatment with gabapentin titrated to a therapeutic dose (Document date of trial)\*

**AND**

**3.2** Unless it is contraindicated, the patient has not exhibited an adequate response to at least 6 weeks of treatment with a tricyclic antidepressant titrated to the maximum tolerated dose (Document drug and date of trial)\*

**AND**

**4** - The patient has a history of failure, contraindication, or intolerance to BOTH of the following (Document drugs and date of trials):\*

- tramadol immediate release (IR)\*\*
- tramadol extended release tablets (non-biphasic release tablets)\*\*

Notes	*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested q
-------	---

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	<p>quantity for transition to an alternative treatment.</p> <p>*If the request is for tramadol extended release capsules or tramadol extended release biphasic release tablets and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.</p> <p>**Drug may require prior authorization.</p>
--	--

Product Name: generic morphine sulfate ER tabs, fentanyl patches 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hr, Xtampza, generic tramadol ER tabs (non-biphasic release)

Diagnosis	Non-cancer pain/Non-hospice care/Non-end-of-life care pain*
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Generic
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Generic
FENTANYL	FENTANYL TD PATCH 72HR 12 MCG/HR	65100025008610	Generic
FENTANYL	FENTANYL TD PATCH 72HR 25 MCG/HR	65100025008620	Generic
FENTANYL	FENTANYL TD PATCH 72HR 50 MCG/HR	65100025008630	Generic
FENTANYL	FENTANYL TD PATCH 72HR 75 MCG/HR	65100025008640	Generic
FENTANYL	FENTANYL TD PATCH 72HR 100 MCG/HR	65100025008650	Generic
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 9 MG	6510007500A310	Brand

XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 13.5 MG	6510007500A315	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 18 MG	6510007500A320	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 27 MG	6510007500A330	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 36 MG	6510007500A340	Brand
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic

**Approval Criteria**

1 - Patient demonstrates meaningful improvement in pain and function (Document improvement in function or pain score improvement)

**AND**

2 - Identify rationale for not tapering and discontinuing opioid (Document rationale)

**AND**

3 - Prescriber attests to ALL of the following:

- The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested
- Treatment goals are defined, including estimated duration of treatment

<ul style="list-style-type: none"> <li>• Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention</li> <li>• Patient has been screened for substance abuse/opioid dependence</li> <li>• If used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression</li> <li>• Pain is moderate to severe and expected to persist for an extended period of time</li> <li>• Pain is chronic</li> <li>• Pain is not postoperative (unless the patient is already receiving chronic opioid therapy prior to surgery, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time)</li> <li>• Pain management is required around the clock with a long-acting opioid</li> </ul>	
Notes	<p>*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>*If the request is for a non-preferred product and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.</p> <p>**Fentanyl transdermal 37.5mcg/hr, 62.5mcg/hr, and 87.5mcg/hr are non-preferred.</p>

Product Name: Brand MS Contin, morphine sulfate ER caps, morphine sulfate beads caps ER, fentanyl patches 37.5mcg/hr, 62.5mcg/hr, and 87.5mcg/hr, generic hydrocodone ER tabs, Brand Hysingla ER, oxymorphone ER, Nucynta ER, generic oxycodone ER, Brand Oxycontin, generic methadone, Brand Methadose, hydromorphone ER, generic hydrocodone ER caps			
Diagnosis	Non-cancer pain/Non-hospice care/Non-end-of-life care pain*		
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MS CONTIN	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Brand
MS CONTIN	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Brand
MS CONTIN	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MS CONTIN	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Brand
MS CONTIN	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 10 MG	65100055107010	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 20 MG	65100055107020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 30 MG	65100055107030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 50 MG	65100055107040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 60 MG	65100055107045	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 80 MG	65100055107050	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 100 MG	65100055107060	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 30 MG	65100055207020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 45 MG	65100055207025	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 60 MG	65100055207030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 75 MG	65100055207035	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 90 MG	65100055207040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 120 MG	65100055207050	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Brand
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 5 MG	65100080107405	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 7.5 MG	65100080107407	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 10 MG	65100080107410	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 15 MG	65100080107415	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 20 MG	65100080107420	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 30 MG	65100080107430	Generic
OXYMORPHONE HYDROCHLORIDEER	OXYMORPHONE HCL TAB ER 12HR 40 MG	65100080107440	Generic
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 50 MG	65100091107420	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 100 MG	65100091107430	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 150 MG	65100091107440	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 200 MG	65100091107450	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 250 MG	65100091107460	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 15 MG	6510007510A715	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 30 MG	6510007510A730	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 60 MG	6510007510A760	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HYDROCHLORIDE INTENSOL	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HCL	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HCL	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HCL	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HCL	METHADONE HCL TAB 10 MG	65100050100310	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 10 MG	65100050100310	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 32 MG	65100035107556	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 10 MG	65100030106910	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 15 MG	65100030106915	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 20 MG	65100030106920	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 30 MG	65100030106930	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 40 MG	65100030106940	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 50 MG	65100030106950	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Brand
METHADOSE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
METHADOSE SUGAR-FREE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
FENTANYL	FENTANYL TD PATCH 72HR 37.5 MCG/HR	65100025008626	Generic
FENTANYL	FENTANYL TD PATCH 72HR 62.5 MCG/HR	65100025008635	Generic
FENTANYL	FENTANYL TD PATCH 72HR 87.5 MCG/HR	65100025008645	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Brand

**Approval Criteria**

1 - Patient demonstrates meaningful improvement in pain and function (Document improvement in function or pain score improvement)

**AND**

**2** - Identify rationale for not tapering and discontinuing opioid (Document rationale)

**AND**

**3** - Prescriber attests to ALL of the following:

- The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested
- Treatment goals are defined, including estimated duration of treatment
- Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention
- Patient has been screened for substance abuse/opioid dependence
- If used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression
- Pain is moderate to severe and expected to persist for an extended period of time
- Pain is chronic
- Pain is not postoperative (unless the patient is already receiving chronic opioid therapy prior to surgery, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time)
- Pain management is required around the clock with a long-acting opioid

Notes

\*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.

\*If the request is for a non-preferred product and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.

\*\*Fentanyl transdermal 37.5mcg/hr, 62.5mcg/hr, and 87.5mcg/hr are non-preferred.

Product Name: Brand Conzip, generic tramadol ER biphasic release caps, generic tramadol ER biphasic release tabs			
Diagnosis	Non-cancer pain/Non-hospice care/Non-end-of-life care pain*		
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 100 MG	65100095107560	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 200 MG	65100095107570	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 300 MG	65100095107580	Generic
<p><b>Approval Criteria</b></p> <p>1 - Patient demonstrates meaningful improvement in pain and function (Document improvement in function or pain score improvement)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Identify rationale for not tapering and discontinuing opioid (Document rationale)</p> <p style="text-align: center;"><b>AND</b></p>			

**3 - Prescriber attests to ALL of the following:**

- The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested
- Treatment goals are defined, including estimated duration of treatment
- Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention
- Patient has been screened for substance abuse/opioid dependence
- If used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression
- Pain is moderate to severe and expected to persist for an extended period of time
- Pain is chronic
- Pain is not postoperative (unless the patient is already receiving chronic opioid therapy prior to surgery, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time)
- Pain management is required around the clock with a long-acting opioid

**Notes**

\*If the patient is currently taking the requested long-acting opioid for at least 30 days and does not meet the medical necessity authorization criteria requirements for treatment with an opioid, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.

\*If the request is for tramadol extended release capsules or tramadol extended release biphasic release tablets and the patient is currently taking the requested long-acting opioid for at least 30 days and has met the medical necessity authorization criteria requirements for treatment with an opioid, but has not tried the preferred alternatives a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested drug/strength combination up to the requested quantity for transition to an alternative treatment.

Product Name: generic morphine sulfate ER tabs, Brand MS Contin, morphine sulfate ER caps, morphine sulfate beads caps ER, fentanyl patches, generic hydrocodone ER tabs, Brand Hysingla ER, oxymorphone ER, Nucynta ER, generic oxycodone ER, Brand Oxycontin, Xtampza ER, Brand Conzip, generic tramadol ER biphasic release, generic tramadol ER, generic methadone, Brand Methadose, hydromorphone ER, hydrocodone ER caps

Guideline Type		Quantity Limit	
Product Name	Generic Name	GPI	Brand/Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MS CONTIN	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Brand
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Brand
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 10 MG	65100055107010	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 20 MG	65100055107020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 30 MG	65100055107030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 50 MG	65100055107040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 60 MG	65100055107045	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 80 MG	65100055107050	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 100 MG	65100055107060	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 30 MG	65100055207020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 45 MG	65100055207025	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 60 MG	65100055207030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 75 MG	65100055207035	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 90 MG	65100055207040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 120 MG	65100055207050	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FENTANYL	FENTANYL TD PATCH 72HR 12 MCG/HR	65100025008610	Generic
FENTANYL	FENTANYL TD PATCH 72HR 25 MCG/HR	65100025008620	Generic
FENTANYL	FENTANYL TD PATCH 72HR 50 MCG/HR	65100025008630	Generic
FENTANYL	FENTANYL TD PATCH 72HR 75 MCG/HR	65100025008640	Generic
FENTANYL	FENTANYL TD PATCH 72HR 100 MCG/HR	65100025008650	Generic
FENTANYL	FENTANYL TD PATCH 72HR 37.5 MCG/HR	65100025008626	Generic
FENTANYL	FENTANYL TD PATCH 72HR 62.5 MCG/HR	65100025008635	Generic
FENTANYL	FENTANYL TD PATCH 72HR 87.5 MCG/HR	65100025008645	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Brand
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 5 MG	65100080107405	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 7.5 MG	65100080107407	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 10 MG	65100080107410	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 15 MG	65100080107415	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 20 MG	65100080107420	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 30 MG	65100080107430	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 40 MG	65100080107440	Generic
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 50 MG	65100091107420	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 100 MG	65100091107430	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 150 MG	65100091107440	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 200 MG	65100091107450	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 250 MG	65100091107460	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 15 MG	6510007510A715	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 30 MG	6510007510A730	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 60 MG	6510007510A760	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 9 MG	6510007500A310	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 13.5 MG	6510007500A315	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 18 MG	6510007500A320	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 27 MG	6510007500A330	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 36 MG	6510007500A340	Brand
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 100 MG	65100095107560	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 200 MG	65100095107570	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 300 MG	65100095107580	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HYDROCHLORIDE INTENSOL	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

METHADONE HCL	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HCL	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HCL	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HCL	METHADONE HCL TAB 10 MG	65100050100310	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 10 MG	65100050100310	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 32 MG	65100035107556	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 10 MG	65100030106910	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 15 MG	65100030106915	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 20 MG	65100030106920	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 30 MG	65100030106930	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 40 MG	65100030106940	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 50 MG	65100030106950	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Brand
METHADOSE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand

METHADOSE SUGAR-FREE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Brand

**Approval Criteria**

1 - The requested dose cannot be achieved by moving to a higher strength of the product

**AND**

2 - The requested dose is within the Food and Drug Administration (FDA) maximum dose per day, where an FDA maximum dose per day exists (see Table 1 in the Background section)

Notes	Authorization will be issued for: <ul style="list-style-type: none"> <li>• Cancer pain/hospice/end-of-life related pain: 12 months</li> <li>• All Tramadol ER requests: 6 months</li> <li>• Non-cancer pain/non-hospice/non-end-of-life related pain: 6 months</li> </ul>
-------	---

Product Name: generic morphine sulfate ER tabs, Brand MS Contin, morphine sulfate ER caps, morphine sulfate beads caps ER, fentanyl patches, generic hydrocodone ER tabs, Brand Hysingla ER, oxymorphone ER, Nucynta ER, generic oxycodone ER, Brand Oxycontin, Xtampza ER, Brand Conzip, generic tramadol ER biphasic release, generic tramadol ER, generic methadone, Brand Methadose, hydromorphone ER, hydrocodone ER caps

Diagnosis	Doses Exceeding the Cumulative MME of 90 mg - Cancer/Hospice/End-of-Life/Palliative Care/Skilled Nursing Facility/Traumatic Injury Related Pain*
Approval Length	12 month(s)
Guideline Type	Morphine Milligram Equivalent (MME) MME 90.00 exceeded; PA REQUIRED; Dosage Above MEDD Limit

Product Name	Generic Name	GPI	Brand/Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MS CONTIN	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Brand
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Brand
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 10 MG	65100055107010	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 20 MG	65100055107020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 30 MG	65100055107030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 50 MG	65100055107040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 60 MG	65100055107045	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 80 MG	65100055107050	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 100 MG	65100055107060	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 30 MG	65100055207020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 45 MG	65100055207025	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 60 MG	65100055207030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 75 MG	65100055207035	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 90 MG	65100055207040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 120 MG	65100055207050	Generic
FENTANYL	FENTANYL TD PATCH 72HR 12 MCG/HR	65100025008610	Generic
FENTANYL	FENTANYL TD PATCH 72HR 25 MCG/HR	65100025008620	Generic
FENTANYL	FENTANYL TD PATCH 72HR 50 MCG/HR	65100025008630	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FENTANYL	FENTANYL TD PATCH 72HR 75 MCG/HR	65100025008640	Generic
FENTANYL	FENTANYL TD PATCH 72HR 100 MCG/HR	65100025008650	Generic
FENTANYL	FENTANYL TD PATCH 72HR 37.5 MCG/HR	65100025008626	Generic
FENTANYL	FENTANYL TD PATCH 72HR 62.5 MCG/HR	65100025008635	Generic
FENTANYL	FENTANYL TD PATCH 72HR 87.5 MCG/HR	65100025008645	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Brand
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 5 MG	65100080107405	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 7.5 MG	65100080107407	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 10 MG	65100080107410	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 15 MG	65100080107415	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 20 MG	65100080107420	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 30 MG	65100080107430	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 40 MG	65100080107440	Generic
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 50 MG	65100091107420	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 100 MG	65100091107430	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 150 MG	65100091107440	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 200 MG	65100091107450	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 250 MG	65100091107460	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 15 MG	6510007510A715	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 30 MG	6510007510A730	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 60 MG	6510007510A760	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 9 MG	6510007500A310	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 13.5 MG	6510007500A315	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 18 MG	6510007500A320	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE- DETERRENT 27 MG	6510007500A330	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE- DETERRENT 36 MG	6510007500A340	Brand
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 100 MG	65100095107560	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 200 MG	65100095107570	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 300 MG	65100095107580	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HYDROCHLORIDE INTENSOL	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HCL	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HCL	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

METHADONE HCL	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HCL	METHADONE HCL TAB 10 MG	65100050100310	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 10 MG	65100050100310	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 32 MG	65100035107556	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 10 MG	65100030106910	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 15 MG	65100030106915	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 20 MG	65100030106920	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 30 MG	65100030106930	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 40 MG	65100030106940	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 50 MG	65100030106950	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Brand
METHADOSE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
METHADOSE SUGAR-FREE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Brand

OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Brand
<p><b>Approval Criteria</b></p> <p>1 - Doses exceeding the cumulative morphine milligram equivalent (MME) of 90 milligrams will be approved up to the requested amount for ALL opioid products if the patient has one of the following conditions:</p> <ul style="list-style-type: none"> <li>• Active oncology diagnosis</li> <li>• Hospice care</li> <li>• End-of-life care (other than hospice)</li> <li>• Palliative care</li> <li>• Skilled nursing facility care</li> <li>• Traumatic injury, including burns and excluding post-surgical procedure</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Provider attests patient has been prescribed naloxone (may also be verified via paid pharmacy claims)</p>			
Notes	*Authorization will be issued for 12 months for one of the above conditions. The authorization should be entered for an MME of 9999 so as to prevent future disruptions in therapy if the patient's dose is increased.		

Product Name: generic morphine sulfate ER tabs, Brand MS Contin, morphine sulfate ER caps, morphine sulfate beads caps ER, fentanyl patches, generic hydrocodone ER tabs, Brand Hysingla ER, oxycodone ER, Nucynta ER, generic oxycodone ER, Brand Oxycotin, Xtampza ER, Brand Conzip, generic tramadol ER biphasic release, generic tramadol ER, generic methadone, Brand Methadose, hydromorphone ER, hydrocodone ER caps			
Diagnosis	Doses Exceeding the Cumulative MME of 90 mg - Non-cancer/non-hospice/non-end-of-life/non-palliative care/non-skilled nursing facility/non-traumatic injury related pain*		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Morphine Milligram Equivalent (MME) MME 90.00 exceeded; PA REQUIRED; Dosage Above MEDD Limit		
Product Name	Generic Name	GPI	Brand/Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MS CONTIN	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Brand
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Brand
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 10 MG	65100055107010	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 20 MG	65100055107020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 30 MG	65100055107030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 50 MG	65100055107040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 60 MG	65100055107045	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 80 MG	65100055107050	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 100 MG	65100055107060	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 30 MG	65100055207020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 45 MG	65100055207025	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 60 MG	65100055207030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 75 MG	65100055207035	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 90 MG	65100055207040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 120 MG	65100055207050	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FENTANYL	FENTANYL TD PATCH 72HR 12 MCG/HR	65100025008610	Generic
FENTANYL	FENTANYL TD PATCH 72HR 25 MCG/HR	65100025008620	Generic
FENTANYL	FENTANYL TD PATCH 72HR 50 MCG/HR	65100025008630	Generic
FENTANYL	FENTANYL TD PATCH 72HR 75 MCG/HR	65100025008640	Generic
FENTANYL	FENTANYL TD PATCH 72HR 100 MCG/HR	65100025008650	Generic
FENTANYL	FENTANYL TD PATCH 72HR 37.5 MCG/HR	65100025008626	Generic
FENTANYL	FENTANYL TD PATCH 72HR 62.5 MCG/HR	65100025008635	Generic
FENTANYL	FENTANYL TD PATCH 72HR 87.5 MCG/HR	65100025008645	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Brand
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 5 MG	65100080107405	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 7.5 MG	65100080107407	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 10 MG	65100080107410	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 15 MG	65100080107415	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 20 MG	65100080107420	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 30 MG	65100080107430	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 40 MG	65100080107440	Generic
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 50 MG	65100091107420	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 100 MG	65100091107430	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 150 MG	65100091107440	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 200 MG	65100091107450	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 250 MG	65100091107460	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 15 MG	6510007510A715	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 30 MG	6510007510A730	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 60 MG	6510007510A760	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 9 MG	6510007500A310	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 13.5 MG	6510007500A315	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 18 MG	6510007500A320	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 27 MG	6510007500A330	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 36 MG	6510007500A340	Brand
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 100 MG	65100095107560	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 200 MG	65100095107570	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 300 MG	65100095107580	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HYDROCHLORIDE INTENSOL	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

METHADONE HCL	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HCL	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HCL	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HCL	METHADONE HCL TAB 10 MG	65100050100310	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 10 MG	65100050100310	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 32 MG	65100035107556	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 10 MG	65100030106910	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 15 MG	65100030106915	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 20 MG	65100030106920	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 30 MG	65100030106930	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 40 MG	65100030106940	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 50 MG	65100030106950	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Brand
METHADOSE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand

METHADOSE SUGAR-FREE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Brand

**Approval Criteria**

1 - Prescriber attests to ALL of the following:

- The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested
- Treatment goals are defined, including estimated duration of treatment
- Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention
- Patient has been screened for substance abuse/opioid dependence
- if used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression

**AND**

2 - BOTH of the following:

**2.1** Patient has tried and failed non-opioid pain medication (document drug name and date of trial)

**AND**

**2.2** Opioid medication doses of less than 90 morphine milligram equivalent (MME) have been tried and did not adequately control pain (document drug regimen or MME and dates of therapy)

**AND**



**3 - Provider attests patient has been prescribed naloxone (may also be verified via paid pharmacy claims)**

Notes	<p>*If the patient has been established on the requested MME dose for at least 30 days and does not meet the medical necessity authorization criteria requirements, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested MME dose.</p> <p>**Authorization will be issued for 6 months for non-cancer/non-hospice/non-end-of-life/non-palliative care/non-skilled nursing facility/non-traumatic injury related pain up to the current requested MME plus 90 MME.</p>
-------	---

Product Name: generic morphine sulfate ER tabs, Brand MS Contin, morphine sulfate ER caps, morphine sulfate beads caps ER, fentanyl patches, generic hydrocodone ER tabs, Brand Hysingla ER, oxycodone ER, Nucynta ER, generic oxycodone ER, Brand Oxycontin, Xtampza ER, Brand Conzip, generic tramadol ER biphasic release, generic tramadol ER, generic methadone, Brand Methadose, hydromorphone ER, hydrocodone ER caps

Diagnosis	Doses Exceeding the Cumulative MME of 90 mg - Non-cancer/non-hospice/non-end-of-life/non-palliative care/non-skilled nursing facility/non-traumatic injury related pain*
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Morphine Milligram Equivalent (MME)** MME 90.00 exceeded; PA REQUIRED; Dosage Above MEDD Limit

Product Name	Generic Name	GPI	Brand/Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 15 MG	65100055100415	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 30 MG	65100055100432	Brand
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 60 MG	65100055100445	Brand
MORPHINE SULFATE CR	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MS CONTIN	MORPHINE SULFATE TAB ER 100 MG	65100055100460	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Generic
MS CONTIN	MORPHINE SULFATE TAB ER 200 MG	65100055100480	Brand
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 10 MG	65100055107010	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 20 MG	65100055107020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 30 MG	65100055107030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 50 MG	65100055107040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 60 MG	65100055107045	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 80 MG	65100055107050	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE CAP ER 24HR 100 MG	65100055107060	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 30 MG	65100055207020	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 45 MG	65100055207025	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 60 MG	65100055207030	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 75 MG	65100055207035	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 90 MG	65100055207040	Generic
MORPHINE SULFATE ER	MORPHINE SULFATE BEADS CAP ER 24HR 120 MG	65100055207050	Generic
FENTANYL	FENTANYL TD PATCH 72HR 12 MCG/HR	65100025008610	Generic
FENTANYL	FENTANYL TD PATCH 72HR 25 MCG/HR	65100025008620	Generic
FENTANYL	FENTANYL TD PATCH 72HR 50 MCG/HR	65100025008630	Generic
FENTANYL	FENTANYL TD PATCH 72HR 75 MCG/HR	65100025008640	Generic
FENTANYL	FENTANYL TD PATCH 72HR 100 MCG/HR	65100025008650	Generic
FENTANYL	FENTANYL TD PATCH 72HR 37.5 MCG/HR	65100025008626	Generic
FENTANYL	FENTANYL TD PATCH 72HR 62.5 MCG/HR	65100025008635	Generic
FENTANYL	FENTANYL TD PATCH 72HR 87.5 MCG/HR	65100025008645	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 20 MG	6510003010A810	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 30 MG	6510003010A820	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 40 MG	6510003010A830	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 60 MG	6510003010A840	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 80 MG	6510003010A850	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 100 MG	6510003010A860	Brand
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Generic
HYSINGLA ER	HYDROCODONE BITARTRATE TAB ER 24HR DETER 120 MG	6510003010A870	Brand
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 5 MG	65100080107405	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 7.5 MG	65100080107407	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 10 MG	65100080107410	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 15 MG	65100080107415	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 20 MG	65100080107420	Generic
OXYMORPHONE HYDROCHLORIDE ER	OXYMORPHONE HCL TAB ER 12HR 30 MG	65100080107430	Generic
OXYMORPHONE HYDROCHLORIDEER	OXYMORPHONE HCL TAB ER 12HR 40 MG	65100080107440	Generic
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 50 MG	65100091107420	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 100 MG	65100091107430	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 150 MG	65100091107440	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 200 MG	65100091107450	Brand
NUCYNTA ER	TAPENTADOL HCL TAB ER 12HR 250 MG	65100091107460	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 15 MG	6510007510A715	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 30 MG	6510007510A730	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 60 MG	6510007510A760	Brand
OXYCODONE HCL ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
OXYCODONE HYDROCHLORIDE ER	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Generic
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 9 MG	6510007500A310	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 13.5 MG	6510007500A315	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 18 MG	6510007500A320	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 27 MG	6510007500A330	Brand
XTAMPZA ER	OXYCODONE CAP ER 12HR ABUSE-DETERRENT 36 MG	6510007500A340	Brand
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 100 MG	65100095107070	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 200 MG	65100095107080	Generic
CONZIP	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL CAP ER 24HR BIPHASIC RELEASE 300 MG	65100095107090	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 100 MG	65100095107520	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 200 MG	65100095107530	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HYDROCHLORIDE ER	TRAMADOL HCL TAB ER 24HR 300 MG	65100095107540	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 100 MG	65100095107560	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 200 MG	65100095107570	Generic
TRAMADOL HCL ER	TRAMADOL HCL TAB ER 24HR BIPHASIC RELEASE 300 MG	65100095107580	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HYDROCHLORIDE INTENSOL	METHADONE HCL CONC 10 MG/ML	65100050101310	Generic
METHADONE HCL	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 5 MG/5ML	65100050102010	Generic
METHADONE HCL	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL SOLN 10 MG/5ML	65100050102015	Generic
METHADONE HCL	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 5 MG	65100050100305	Generic
METHADONE HCL	METHADONE HCL TAB 10 MG	65100050100310	Generic
METHADONE HYDROCHLORIDE	METHADONE HCL TAB 10 MG	65100050100310	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 8 MG	65100035107521	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 12 MG	65100035107531	Generic
HYDROMORPHONE HCL ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 16 MG	65100035107541	Generic
HYDROMORPHONE HYDROCHLORIDE ER	HYDROMORPHONE HCL TAB ER 24HR 32 MG	65100035107556	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 10 MG	65100030106910	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 15 MG	65100030106915	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 20 MG	65100030106920	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 30 MG	65100030106930	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 40 MG	65100030106940	Generic
HYDROCODONE BITARTRATE ER	HYDROCODONE BITARTRATE CAP ER 12HR 50 MG	65100030106950	Generic
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 80 MG	6510007510A780	Brand
METHADOSE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
METHADOSE SUGAR-FREE	METHADONE HCL CONC 10 MG/ML	65100050101310	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 10 MG	6510007510A710	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 20 MG	6510007510A720	Brand
OXYCONTIN	OXYCODONE HCL TAB ER 12HR DETER 40 MG	6510007510A740	Brand

**Approval Criteria**

1 - Prescriber attests to ALL of the following:

- The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested
- Treatment goals are defined, including estimated duration of treatment
- Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention
- Patient has been screened for substance abuse/opioid dependence
- if used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression

**AND**

2 - Identify rationale for not tapering and discontinuing opioid (Document rationale)

**AND**

3 - Patient demonstrates meaningful improvement in pain and function (Document improvement in function or pain score improvement)

**AND**

4 - Provider attests patient has been prescribed naloxone (may also be verified via paid pharmacy claims)

Notes	<p>*If the patient has been established on the requested MME dose for at least 30 days and does not meet the medical necessity authorization criteria requirements, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested MME dose.</p> <p>**Authorization will be issued for 6 months for non-cancer/non-hospice/non-end-of-life/non-palliative care/non-skilled nursing facility/non-traumatic injury related pain up to the current requested MME plus 90 MME.</p>
-------	---

## 2 . Background

<b>Benefit/Coverage/Program Information</b>		
<b>Table 1. CDC Recommended Morphine Milligram Equivalents per Day*</b>		
<b>Active Ingredient</b>	<b>FDA Label Max Daily Doses</b>	<b>90 MME Equivalent (mg/day) (non treatment naïve)</b>
Morphine	None	90mg
Morphine and naltrexone	None	90mg
Hydromorphone	None	22.5mg
Fentanyl transdermal, mcg/hr	None	37.5 mcg/hr
Hydrocodone	None	90mg
Methadone	None	Conversion factor is variable based upon dose
Tapentadol	500mg ER products	225mg
Oxymorphone	None	30mg
Oxycodone	Xtampza Only =288mg	60mg
Tramadol	300mg ER products	900mg

\*Doses are not considered equianalgesic and table does not represent a dose conversion chart.

Max MME is the maximum dose per day based on morphine milligram equivalents allowed without consultation or prescription by a pain specialist. Max MME is based upon the CDC guidelines and adjusted for currently available product strengths. Fentanyl is dosed in mcg/hr rather than mg/day.

### 3 . Revision History

Date	Notes
------	-------



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

10/16/2024	In QL section, updated approval duration for tramadol ER products from 12 months to 6 months. Cleaned up GPI tables, where applicable.
------------	--

Lonhala and Yupelri



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140778
<b>Guideline Name</b>	Lonhala and Yupelri
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	3/19/2023
-----------------	-----------

### 1 . Criteria

Product Name: Lonhala Magnair, Yupelri			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LONHALA MAGNAIR REFILL KIT	GLYCOPYRROLATE INHAL SOLUTION 25 MCG/ML	44100020102030	Brand
LONHALA MAGNAIR STARTER KIT	GLYCOPYRROLATE INHAL SOLUTION 25 MCG/ML	44100020102030	Brand

YUPELRI	REVEFENACIN INHALATION SOLUTION 175 MCG/3ML	44100075002020	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p style="padding-left: 20px;"><b>2.1</b> History of failure, contraindication, or intolerance to Spiriva Handihaler (tiotropium)</p> <p style="text-align: center;"><b>OR</b></p> <p style="padding-left: 20px;"><b>2.2</b> BOTH of the following:</p> <p style="padding-left: 40px;"><b>2.2.1</b> Patient is unable to use a metered-dose, dry powder, or slow mist inhaler (e.g., Spiriva Handihaler) to control his/her COPD due to ONE of the following:</p> <p style="padding-left: 60px;"><b>2.2.1.1</b> Cognitive or physical impairment limiting coordination of handheld devices (e.g., cognitive decline, arthritis in the hands) (Document impairment)</p> <p style="text-align: center;"><b>OR</b></p> <p style="padding-left: 60px;"><b>2.2.1.2</b> Patient is unable to generate adequate inspiratory force [e.g., peak inspiratory flow rate (PIFR) resistance is less than 60 liters per minute]</p> <p style="text-align: center;"><b>AND</b></p> <p style="padding-left: 40px;"><b>2.2.2</b> History of failure, contraindication, or intolerance to ipratropium nebulized solution (generic Atrovent)</p>			

Product Name: Lonhala Magnair, Yupelri	
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
LONHALA MAGNAIR REFILL KIT	GLYCOPYRROLATE INHAL SOLUTION 25 MCG/ML	44100020102030	Brand
LONHALA MAGNAIR STARTER KIT	GLYCOPYRROLATE INHAL SOLUTION 25 MCG/ML	44100020102030	Brand
YUPELRI	REVEFENACIN INHALATION SOLUTION 175 MCG/3ML	44100075002020	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

## 2 . Revision History

Date	Notes
2/9/2023	Removed TD criteria section.

Lucemyra (lofexidine)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157266
<b>Guideline Name</b>	Lucemyra (lofexidine)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Brand Lucemyra, generic lofexidine			
Approval Length	14 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUCEMYRA	LOFEXIDINE HCL TAB 0.18 MG (BASE EQUIVALENT)	62805045100315	Brand
LOFEXIDINE HYDROCHLORIDE	LOFEXIDINE HCL TAB 0.18 MG (BASE EQUIVALENT)	62805045100315	Generic
<b>Approval Criteria</b>			
1 - For symptoms of abrupt opioid withdrawal			

**AND**

**2** - Opioids have been discontinued

**AND**

**3** - History of failure, contraindication, or intolerance to clonidine as verified by recent clonidine claims history in the past 180 days

**AND**

**4** - Prescriber must verify patient has been screened for hepatic and renal impairment and that dosing is appropriate for the patient's degree of hepatic and renal function

**AND**

**5** - Prescriber must verify patient's vital signs have been monitored and that the patient is capable of and has been instructed on self-monitoring for hypotension, orthostasis, bradycardia, and associated symptoms

**AND**

**6** - Patient does NOT have severe coronary insufficiency, a recent myocardial infarction, cerebrovascular disease, chronic renal failure, or marked bradycardia

**AND**

**7** - Patient does NOT have congenital long QT syndrome

**AND**

**8** - If the request is for Brand Lucemyra, history of failure or intolerance to generic lofexidine

## 2 . Revision History

Date	Notes
10/9/2024	Updated guideline name. Added generic lofexidine as a target. Updated product name list and GPI table accordingly. Removed inpatient setting bypass. For Brand Lucemyra, added step through generic lofexidine. Minor cosmetic updates.

Lumizyme -Arizona



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140652
<b>Guideline Name</b>	Lumizyme -Arizona
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	
P&T Approval Date:	
P&T Revision Date:	

### 1 . Criteria

Product Name: Lumizyme			
Diagnosis	Pompe disease		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUMIZYME	ALGLUCOSIDASE ALFA FOR IV SOLN 50 MG	30907715002120	Brand



**Approval Criteria**

1 - Diagnosis of Pompe disease (acid alpha-glucosidase [GAA] deficiency)

**2 . Revision History**

Date	Notes
4/27/2020	Removed Myozyme from title

Lupkynis (voclosporin)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157422
<b>Guideline Name</b>	Lupkynis (voclosporin)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Lupkynis			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUPKYNIS	VOCLOSPORIN CAP 7.9 MG	9940208000120	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of active lupus nephritis			

**AND**

**2** - Provider attests to ONE of the following:

- Diagnosis is biopsy proven
- Biopsy is contraindicated in the patient

**AND**

**3** - Prescribed in combination with a background immunosuppressive therapy regimen (e.g., mycophenolate mofetil and corticosteroids)

**AND**

**4** - Patient is NOT receiving Lupkynis in combination with either of the following:

- Cyclophosphamide
- Benlysta (belimumab)

**AND**

**5** - Prescribed by ONE of the following:

- Nephrologist
- Rheumatologist

Product Name: Lupkynis			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUPKYNIS	VOCLOSPORIN CAP 7.9 MG	99402080000120	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to Lupkynis therapy

**AND**

**2** - Prescribed in combination with a background immunosuppressive therapy regimen (e.g., mycophenolate mofetil and corticosteroids)

**AND**

**3** - Patient is NOT receiving Lupkynis in combination with either of the following:

- Cyclophosphamide
- Benlysta (belimumab)

**AND**

**4** - Prescribed by ONE of the following:

- Nephrologist
- Rheumatologist

**AND**

**5** - ONE of the following:

**5.1** Patient has been on Lupkynis therapy for less than 12 months

**OR**

**5.2** BOTH of the following:

**5.2.1** Patient has completed 12 or more months of Lupkynis therapy

**AND**

**5.2.2** The provider attests that the benefit of continuation of therapy exceeds the risk in light of the patient's treatment response and risk of worsening nephrotoxicity

## 2 . Revision History

Date	Notes
10/14/2024	Replaced CORE criteria with FFS/state criteria.

Luxturna



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-141005
<b>Guideline Name</b>	Luxturna
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Luxturna			
Approval Length	45 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LUXTURNA	VORETIGENE NEPARVOVEC-RZYL 50000000000000 VG/ML INTRAOC SUSP	86370070601810	Brand
<b>Approval Criteria</b>			
1 - Patient is greater than 12 months of age			

**AND**

**2** - Diagnosis of a confirmed biallelic RPE65 mutation-associated retinal dystrophy [e.g., Leber's congenital amaurosis (LCA), retinitis pigmentosa (RP), early onset severe retinal dystrophy (EOSRD), etc.]

**AND**

**3** - Genetic testing documenting biallelic mutations of the RPE65 gene

**AND**

**4** - Sufficient viable retinal cells as determined by optical coherence tomography (OCT) confirming an area of retina within the posterior pole of greater than 100 micrometers thickness

**AND**

**5** - Prescribed and administered by ophthalmologist or retinal surgeon with experience providing sub-retinal injections

**AND**

**6** - Patient has not previously received Luxturna treatment in the intended eye

**AND**

**7** - Must not exceed more than 1 treatment per lifetime per eye

Notes	Authorization will be issued for no more than 1 treatment per lifetime per eye and for no longer than 45 days from approval.
-------	--

## 2 . Revision History

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
10/30/2023	Updated guideline name, updated approval length, added once per lifetime criteria and note.



Lyrica



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140672
<b>Guideline Name</b>	Lyrica
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Brand Lyrica			
Diagnosis	Seizure Disorder		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LYRICA	PREGABALIN CAP 25 MG	72600057000110	Brand
LYRICA	PREGABALIN CAP 50 MG	72600057000115	Brand
LYRICA	PREGABALIN CAP 75 MG	72600057000120	Brand
LYRICA	PREGABALIN CAP 100 MG	72600057000125	Brand
LYRICA	PREGABALIN CAP 150 MG	72600057000135	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LYRICA	PREGABALIN CAP 200 MG	72600057000145	Brand
LYRICA	PREGABALIN CAP 225 MG	72600057000150	Brand
LYRICA	PREGABALIN CAP 300 MG	72600057000160	Brand
LYRICA	PREGABALIN SOLN 20 MG/ML	72600057002020	Brand

**Approval Criteria**

1 - Diagnosis of seizure disorder

**AND**

2 - History of failure, contraindication, or intolerance to generic pregabalin immediate-release capsules or generic pregabalin solution

Product Name: Brand Lyrica			
Diagnosis	Neuropathic Pain Associated with Spinal Cord Injury		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LYRICA	PREGABALIN CAP 25 MG	72600057000110	Brand
LYRICA	PREGABALIN CAP 50 MG	72600057000115	Brand
LYRICA	PREGABALIN CAP 75 MG	72600057000120	Brand
LYRICA	PREGABALIN CAP 100 MG	72600057000125	Brand
LYRICA	PREGABALIN CAP 150 MG	72600057000135	Brand
LYRICA	PREGABALIN CAP 200 MG	72600057000145	Brand
LYRICA	PREGABALIN CAP 225 MG	72600057000150	Brand
LYRICA	PREGABALIN CAP 300 MG	72600057000160	Brand
LYRICA	PREGABALIN SOLN 20 MG/ML	72600057002020	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of neuropathic pain associated with spinal cord injury

**AND**

2 - One of the following:

- History of failure to generic pregabalin immediate-release capsules or solution at a minimum dose of 300mg daily for 4 weeks
- Contraindication or intolerance to generic pregabalin immediate-release capsules or solution

Product Name: Brand Lyrica

Diagnosis	Fibromyalgia
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
LYRICA	PREGABALIN CAP 25 MG	72600057000110	Brand
LYRICA	PREGABALIN CAP 50 MG	72600057000115	Brand
LYRICA	PREGABALIN CAP 75 MG	72600057000120	Brand
LYRICA	PREGABALIN CAP 100 MG	72600057000125	Brand
LYRICA	PREGABALIN CAP 150 MG	72600057000135	Brand
LYRICA	PREGABALIN CAP 200 MG	72600057000145	Brand
LYRICA	PREGABALIN CAP 225 MG	72600057000150	Brand
LYRICA	PREGABALIN CAP 300 MG	72600057000160	Brand
LYRICA	PREGABALIN SOLN 20 MG/ML	72600057002020	Brand

**Approval Criteria**

1 - Diagnosis of fibromyalgia

**AND**

**2 - One of the following:**

- History of failure to generic pregabalin immediate-release capsules or solution at a minimum dose of 300mg daily for 4 weeks
- Contraindication or intolerance to generic pregabalin immediate-release capsules or solution

Product Name: Brand Lyrica			
Diagnosis	Diabetic peripheral neuropathy (DPN)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LYRICA	PREGABALIN CAP 25 MG	72600057000110	Brand
LYRICA	PREGABALIN CAP 50 MG	72600057000115	Brand
LYRICA	PREGABALIN CAP 75 MG	72600057000120	Brand
LYRICA	PREGABALIN CAP 100 MG	72600057000125	Brand
LYRICA	PREGABALIN CAP 150 MG	72600057000135	Brand
LYRICA	PREGABALIN CAP 200 MG	72600057000145	Brand
LYRICA	PREGABALIN CAP 225 MG	72600057000150	Brand
LYRICA	PREGABALIN CAP 300 MG	72600057000160	Brand
LYRICA	PREGABALIN SOLN 20 MG/ML	72600057002020	Brand

**Approval Criteria**

**1 - Diagnosis of diabetic peripheral neuropathy (DPN)**

**AND**

**2 - One of the following:**

- History of failure to generic pregabalin immediate-release capsules or solution at a minimum dose of 300mg daily for 4 weeks

- Contraindication or intolerance to generic pregabalin immediate-release capsules or solution

**Product Name: Brand Lyrica**

Diagnosis	Post herpetic neuralgia (PHN)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
LYRICA	PREGABALIN CAP 25 MG	72600057000110	Brand
LYRICA	PREGABALIN CAP 50 MG	72600057000115	Brand
LYRICA	PREGABALIN CAP 75 MG	72600057000120	Brand
LYRICA	PREGABALIN CAP 100 MG	72600057000125	Brand
LYRICA	PREGABALIN CAP 150 MG	72600057000135	Brand
LYRICA	PREGABALIN CAP 200 MG	72600057000145	Brand
LYRICA	PREGABALIN CAP 225 MG	72600057000150	Brand
LYRICA	PREGABALIN CAP 300 MG	72600057000160	Brand
LYRICA	PREGABALIN SOLN 20 MG/ML	72600057002020	Brand

**Approval Criteria**

1 - Diagnosis of post herpetic neuralgia (PHN)

**AND**

2 - One of the following:

- History of failure to generic pregabalin immediate-release capsules or solution at a minimum dose of 300mg daily for 4 weeks
- Contraindication or intolerance to generic pregabalin immediate-release capsules or solution

Product Name: Lyrica CR	
Diagnosis	Diabetic peripheral neuropathy (DPN)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
LYRICA CR	PREGABALIN TAB ER 24HR 82.5 MG	62540060007520	Brand
LYRICA CR	PREGABALIN TAB ER 24HR 165 MG	62540060007530	Brand
LYRICA CR	PREGABALIN TAB ER 24HR 330 MG	62540060007540	Brand

**Approval Criteria**

1 - Diagnosis of diabetic peripheral neuropathy (DPN)

**AND**

2 - History of failure, contraindication, or intolerance to gabapentin (generic Neurontin) at a minimum dose of 1800 milligrams daily for 4 weeks

**AND**

3 - History of failure, contraindication, or intolerance to treatment with ONE of the following:

- Tricyclic antidepressant at the maximum tolerated dose for 6 to 8 weeks, or intolerance to a tricyclic antidepressant
- Serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressant (i.e. duloxetine, venlafaxine)

**AND**

4 - History of failure, contraindication, or intolerance to generic pregabalin immediate-release capsules or generic pregabalin solution

Product Name: Lyrica CR	
Diagnosis	Post herpetic neuralgia (PHN)
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
LYRICA CR	PREGABALIN TAB ER 24HR 82.5 MG	62540060007520	Brand
LYRICA CR	PREGABALIN TAB ER 24HR 165 MG	62540060007530	Brand
LYRICA CR	PREGABALIN TAB ER 24HR 330 MG	62540060007540	Brand

**Approval Criteria**

1 - Diagnosis of post herpetic neuralgia (PHN)

**AND**

2 - History of failure, contraindication, or intolerance to gabapentin (generic Neurontin) at a minimum dose of 1800 milligrams daily for 4 weeks

**AND**

3 - History of failure, contraindication, or intolerance to a tricyclic antidepressant at the maximum tolerated dose for 6 to 8 weeks

**AND**

4 - History of failure, contraindication, or intolerance to generic pregabalin immediate-release capsules or generic pregabalin solution

**2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22



Lysteda



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140641
<b>Guideline Name</b>	Lysteda
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

## 1 . Criteria

Product Name: Brand Lysteda, generic tranexamic acid			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LYSTEDA	TRANEXAMIC ACID TAB 650 MG	84100040000320	Brand
TRANEXAMIC ACID	TRANEXAMIC ACID TAB 650 MG	84100040000320	Generic
<b>Approval Criteria</b>			

1 - Diagnosis of cyclic heavy menstrual bleeding

## 2 . Revision History

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Lyvispah (baclofen granules), Ozobax-Ozobax DS (baclofen oral solution)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-143614
<b>Guideline Name</b>	Lyvispah (baclofen granules), Ozobax-Ozobax DS (baclofen oral solution)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/17/2024
-----------------	-----------

## 1 . Criteria

Product Name: Lyvispah, Ozobax, Ozobax DS, Baclofen oral solution			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LYVISPAH	BACLOFEN GRANULES PACKET 5 MG	75100010003010	Brand
LYVISPAH	BACLOFEN GRANULES PACKET 10 MG	75100010003020	Brand
LYVISPAH	BACLOFEN GRANULES PACKET 20 MG	75100010003030	Brand
OZOBAX	BACLOFEN ORAL SOLN 5 MG/5ML	75100010002070	Generic
OZOBAX DS	BACLOFEN ORAL SOLN 10 MG/5ML	75100010002075	Generic

BACLOFEN	BACLOFEN ORAL SOLN 5 MG/5ML	75100010002070	Brand
BACLOFEN	BACLOFEN ORAL SOLN 10 MG/5ML	75100010002075	Generic

**Approval Criteria**

1 - Trial and failure, or intolerance to baclofen tablets

**OR**

2 - Patient is unable to swallow oral tablets

**2 . Revision History**

Date	Notes
2/27/2024	Addition of Baclofen solution

Makena



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140949
<b>Guideline Name</b>	Makena
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Brand Makena*, generic hydroxyprogesterone caproate*			
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
HYDROXYPROGESTERONE CAPROATE	HYDROXYPROGESTERONE CAPROATE IM IN OIL 250 MG/ML	26000010101710	Generic
MAKENA	HYDROXYPROGESTERONE CAPROATE IM IN OIL 250 MG/ML	26000010101710	Brand
MAKENA	HYDROXYPROGESTERONE CAPROATE SOLN AUTO-INJECTOR 275 MG/1.1ML	2600001010D520	Brand
<b>Approval Criteria</b>			

1 - Current singleton pregnancy

**AND**

2 - History of a prior spontaneous preterm birth of a singleton pregnancy

**AND**

3 - Treatment is initiated between 16 weeks, 0 days of gestation and 20 weeks, 6 days of gestation

**AND**

4 - Administration is to continue weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first

**AND**

5 - If the request is for generic hydroxyprogesterone caproate, the patient has a history of failure, contraindication or intolerance to Brand Makena

Notes	*Approval duration is up to 21 weeks; approval duration should take in to account gestation week when Makena will be started and only authorized up to week 37.
-------	---

## 2 . Revision History

Date	Notes
11/7/2022	Updated gestational days for drug initiation to align w PI

Marinol, Syndros



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140676
<b>Guideline Name</b>	Marinol, Syndros
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Marinol, Syndros			
Diagnosis	Chemotherapy-induced nausea and vomiting		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYNDROS	DRONABINOL SOLN 5 MG/ML	50300030002020	Brand
MARINOL	DRONABINOL CAP 2.5 MG	50300030000110	Brand
<b>Approval Criteria</b>			

1 - Patient is receiving cancer chemotherapy

**AND**

2 - ONE of the following:

2.1 History of failure, contraindication, or intolerance to formulary generic dronabinol

**OR**

2.2 Patient is unable to swallow capsules

**AND**

3 - History of failure, contraindication, or intolerance to a 5HT-3 (5-hydroxytryptamine) receptor antagonist [eg, Anzemet (dolasetron), Kytril (granisetron), or Zofran (ondansetron)]

**AND**

4 - History of failure, contraindication, or intolerance to ONE of the following:

- Ativan (lorazepam)
- Compazine (prochlorperazine)
- Decadron (dexamethasone)
- Haldol (haloperidol)
- Phenergan (promethazine)
- Reglan (metoclopramide)
- Zyprexa (olanzapine)

Product Name: Generic Dronabinol			
Diagnosis	Chemotherapy-induced nausea and vomiting		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic



DRONABINOL	DRONABINOL CAP 2.5 MG	50300030000110	Generic
DRONABINOL	DRONABINOL CAP 5 MG	50300030000115	Generic
DRONABINOL	DRONABINOL CAP 10 MG	50300030000120	Generic

**Approval Criteria**

1 - Patient is receiving cancer chemotherapy

**AND**

2 - History of failure, contraindication, or intolerance to a 5HT-3 (5-hydroxytryptamine) receptor antagonist [eg, Anzemet (dolasetron), Kytril (granisetron), or Zofran (ondansetron)]

**AND**

3 - History of failure, contraindication, or intolerance to ONE of the following:

- Ativan (lorazepam)
- Compazine (prochlorperazine)
- Decadron (dexamethasone)
- Haldol (haloperidol)
- Phenergan (promethazine)
- Reglan (metoclopramide)
- Zyprexa (olanzapine)

Product Name: Brand Marinol, Syndros			
Diagnosis	Anorexia in Patients with AIDS		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYNDROS	DRONABINOL SOLN 5 MG/ML	503000300002020	Brand
MARINOL	DRONABINOL CAP 2.5 MG	50300030000110	Brand

**Approval Criteria**

1 - Diagnosis of anorexia with weight loss in patients with AIDS (acquired immunodeficiency syndrome)

**AND**

2 - Patient is on antiretroviral therapy

**AND**

3 - ONE of the following:

3.1 Patient is 65 years of age or greater

**OR**

3.2 BOTH of the following:

- Patient is less than 65 years of age
- History of failure, contraindication, or intolerance to Megace (megestrol)

**AND**

4 - ONE of the following:

4.1 History of failure, contraindication, or intolerance to formulary generic dronabinol

**OR**

4.2 Patient is unable to swallow capsules

Product Name: Generic dronabinol	
Diagnosis	Anorexia in Patients with AIDS

Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DRONABINOL	DRONABINOL CAP 2.5 MG	50300030000110	Generic
DRONABINOL	DRONABINOL CAP 5 MG	50300030000115	Generic
DRONABINOL	DRONABINOL CAP 10 MG	50300030000120	Generic

**Approval Criteria**

1 - Diagnosis of anorexia with weight loss in patients with AIDS (acquired immunodeficiency syndrome)

**AND**

2 - Patient is on antiretroviral therapy

**AND**

3 - ONE of the following:

3.1 Patient is 65 years of age or greater

**OR**

3.2 BOTH of the following:

- Patient is less than 65 years of age
- History of failure, contraindication, or intolerance to Megace (megestrol)

**2 . Revision History**

Date	Notes
------	-------

8/4/2022	C&S to match AZM as of 10.1.22
----------	--------------------------------

Mepron



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140689
<b>Guideline Name</b>	Mepron
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Mepron, generic atovaquone			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ATOVAQUONE	ATOVAQUONE SUSP 750 MG/5ML	16400020001820	Generic
MEPRON	ATOVAQUONE SUSP 750 MG/5ML	16400020001820	Brand
<b>Approval Criteria</b>			
1 - ONE of the following:			

**1.1 BOTH of the following:**

**1.1.1** The patient has a diagnosis (e.g. human immunodeficiency virus [HIV]) warranting Pneumocystis jirovecii pneumonia (PCP) infection prophylaxis

**AND**

**1.1.2** The patient has a documented intolerance or contraindication to trimethoprim-sulfamethoxazole (TMP-SMX) and dapsone

**OR**

**1.2 BOTH of the following:**

**1.2.1** The patient has a diagnosis of mild to moderate pneumonia caused by *P. jirovecii*

**AND**

**1.2.2** The patient has a documented intolerance, contraindication, or history of treatment failure to TMP-SMX

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Metformin Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140741
<b>Guideline Name</b>	Metformin Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: generic metformin 625 mg immediate-release tablets			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
METFORMIN HYDROCHLORIDE	METFORMIN HCL TAB 625 MG	27250050000330	Generic
<b>Approval Criteria</b>			
1 - History of greater than or equal to 12 week trial of preferred metformin immediate-release products			

Product Name: generic metformin extended-release (generic for Fortamet and generic for Glumetza)			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
METFORMIN HCL ER (OSM)	METFORMIN HCL TAB ER 24HR OSMOTIC 500 MG	27250050007560	Generic
METFORMIN HCL ER (OSM)	METFORMIN HCL TAB ER 24HR OSMOTIC 1000 MG	27250050007570	Generic
METFORMIN HCL ER (MOD)	METFORMIN HCL TAB ER 24HR MODIFIED RELEASE 500 MG	27250050007580	Generic
METFORMIN HCL ER (MOD)	METFORMIN HCL TAB ER 24HR MODIFIED RELEASE 1000 MG	27250050007590	Generic

**Approval Criteria**

1 - ALL of the following:

1.1 History of greater than or equal to 12 week trial of metformin extended-release (generic Glucophage XR)

**AND**

1.2 ONE of the following:

1.2.1 Submission of medical records (e.g. chart notes, laboratory values) documenting an inadequate response to metformin extended-release (generic Glucophage XR), in diabetic patients, as evidenced by the hemoglobin A1c level being above the patient's goal

**OR**

1.2.2 Submission of medical records (e.g. chart notes, laboratory values) documenting an intolerance to metformin extended-release (generic Glucophage XR) which is unable to be resolved with attempts to minimize the adverse effects where appropriate (e.g. dose reduction)



**AND**

**1.3** History of greater than or equal to 12 week trial of metformin immediate-release

**AND**

**1.4** One of the following:

**1.4.1** Submission of medical records (e.g. chart notes, laboratory values) documenting an inadequate response to metformin immediate-release, in diabetic patients, as evidenced by the hemoglobin A1c level being above the patient's goal

**OR**

**1.4.2** Submission of medical records (e.g. chart notes, laboratory values) documenting an intolerance to metformin immediate-release which is unable to be resolved with attempts to minimize the adverse effects where appropriate (e.g. dose reduction)

Product Name: Brand Glumetza, Brand Fortamet			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FORTAMET	METFORMIN HCL TAB ER 24HR OSMOTIC 500 MG	27250050007560	Brand
FORTAMET	METFORMIN HCL TAB ER 24HR OSMOTIC 1000 MG	27250050007570	Brand
GLUMETZA	METFORMIN HCL TAB ER 24HR MODIFIED RELEASE 500 MG	27250050007580	Brand
GLUMETZA	METFORMIN HCL TAB ER 24HR MODIFIED RELEASE 1000 MG	27250050007590	Brand
<b>Approval Criteria</b>			
1 - ALL of the following:			

**1.1** History of greater than or equal to 12 week trial of metformin extended-release (generic Glucophage XR)

**AND**

**1.2** ONE of the following:

**1.2.1** Submission of medical records (e.g. chart notes, laboratory values) documenting an inadequate response to metformin extended-release (generic Glucophage XR), in diabetic patients, as evidenced by the hemoglobin A1c level being above the patient's goal

**OR**

**1.2.2** Submission of medical records (e.g. chart notes, laboratory values) documenting an intolerance to metformin extended-release (generic Glucophage XR) which is unable to be resolved with attempts to minimize the adverse effects where appropriate (e.g. dose reduction)

**AND**

**1.3** History of greater than or equal to 12 week trial of metformin extended-release (generic Fortamet)

**AND**

**1.4** One of the following:

**1.4.1** Submission of medical records (e.g. chart notes, laboratory values) documenting an inadequate response to metformin extended-release (generic Fortamet), in diabetic patients, as evidenced by the hemoglobin A1c level being above the patient's goal

**OR**

**1.4.2** Submission of medical records (e.g. chart notes, laboratory values) documenting an intolerance to metformin extended-release (generic Fortamet) which is unable to be resolved with attempts to minimize the adverse effects where appropriate (e.g. dose reduction)

**AND**

**1.5** History of greater than or equal to 12 week trial of metformin immediate-release

**AND**

**1.6** One of the following:

**1.6.1** Submission of medical records (e.g. chart notes, laboratory values) documenting an inadequate response to metformin immediate-release, in diabetic patients, as evidenced by the hemoglobin A1c level being above the patient's goal

**OR**

**1.6.2** Submission of medical records (e.g. chart notes, laboratory values) documenting an intolerance to metformin immediate-release which is unable to be resolved with attempts to minimize the adverse effects where appropriate (e.g. dose reduction)

**AND**

**1.7** Submission of article(s) published in the peer-reviewed medical literature showing that the requested drug is likely to be more efficacious to this patient than metformin extended-release (generic Glucophage XR)

Migranal



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140817
<b>Guideline Name</b>	Migranal
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2023
-----------------	-----------

### 1 . Criteria

Product Name: Brand Migranal, generic dihydroergotamine mesylate			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DIHYDROERGOTAMINE MESYLATE	DIHYDROERGOTAMINE MESYLATE NASAL SPRAY 4 MG/ML	67000030102060	Generic
MIGRANAL	DIHYDROERGOTAMINE MESYLATE NASAL SPRAY 4 MG/ML	67000030102060	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of migraine headaches with or without aura			

**AND**

**2** - History of failure, contraindication, or intolerance to TWO preferred 5-HT<sub>1</sub> (5-hydroxytryptamine-1) receptor agonist (triptan) alternatives [e.g., Imitrex (sumatriptan), Maxalt or Maxalt-MLT (rizatriptan)]

## 2 . Revision History

Date	Notes
9/26/2023	Removed QL section, cleaned up criteria.

Monurol



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140675
<b>Guideline Name</b>	Monurol
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Monurol			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MONUROL	FOSFOMYCIN TROMETHAMINE POWD PACK 3 GM (BASE EQUIVALENT)	16800015203020	Brand
FOSFOMYCIN TROMETHAMINE	FOSFOMYCIN TROMETHAMINE POWD PACK 3 GM (BASE EQUIVALENT)	16800015203020	Generic
<b>Approval Criteria</b>			

**1** - The provider has submitted labs showing the culture and sensitivity is positive for Monural and negative to Ciprofloxacin or Nitrofurantoin

**OR**

**2** - Trial and failure, contraindication, or intolerance to ONE of the following:

- Ciprofloxacin
- Nitrofurantoin

## **2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Mozobil



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140850
<b>Guideline Name</b>	Mozobil
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Mozobil			
Approval Length	4 Days*		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MOZOBIL	PLERIXAFOR SUBCUTANEOUS INJ 24 MG/1.2ML (20 MG/ML)	82502060002020	Brand
<b>Approval Criteria</b>			
1 - ONE of the following:			



- Patients with non-Hodgkin’s lymphoma (NHL) who will be undergoing autologous hematopoietic stem cell (HSC) transplantation
- Patients with multiple myeloma (MM) who will be undergoing autologous HSC transplantation

**AND**

**2** - Used in combination with granulocyte-colony stimulating factor (G-CSF) [e.g., Zarxio (filgrastim)]

**AND**

**3** - Prescribed by, or in consultation with, a hematologist/oncologist

Notes	*Authorization will be issued for 1 course of therapy (up to four days of therapy).
-------	---

## 2 . Revision History

Date	Notes
3/31/2020	Bulk copy C&S New York SP to C&S Arizona SP for 5/1 effective

MS Agents



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160368
<b>Guideline Name</b>	MS Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Brand Gilenya, Brand Copaxone, Glatopa, Avonex, Rebif, Betaseron, Extavia, generic glatiramer, Vumerity, Bafiertam, Kesimpta, Brand Tecfidera, Plegridy, Brand Aubagio, generic teriflunomide, Mayzent, Tascenso ODT, generic fingolimod, generic dimethyl fumarate, Brand Ampyra, generic dalfampridine, Mavenclad, Ponvory			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GILENYA	FINGOLIMOD HCL CAP 0.25 MG (BASE EQUIV)	62407025100110	Brand
GILENYA	FINGOLIMOD HCL CAP 0.5 MG (BASE EQUIV)	62407025100120	Brand
COPAXONE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 20 MG/ML	6240003010E520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GLATOPA	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 40 MG/ML	6240003010E540	Generic
AVONEX PEN	INTERFERON BETA-1A IM AUTO-INJECTOR KIT 30 MCG/0.5ML	6240306045F530	Brand
AVONEX	INTERFERON BETA-1A IM PREFILLED SYRINGE KIT 30 MCG/0.5ML	6240306045F830	Brand
REBIF REBIDOSE	INTERFERON BETA-1A SOLN AUTO-INJ 22 MCG/0.5ML	6240306045D520	Brand
REBIF REBIDOSE	INTERFERON BETA-1A SOLN AUTO-INJ 44 MCG/0.5ML	6240306045D540	Brand
REBIF REBIDOSE TITRATION PACK	INTERFERON BETA-1A AUTO-INJ 6X8.8 MCG/0.2ML & 6X22 MCG/0.5ML	6240306045D560	Brand
REBIF	INTERFERON BETA-1A SOLN PREF SYR 22 MCG/0.5ML	6240306045E520	Brand
REBIF	INTERFERON BETA-1A SOLN PREF SYR 44 MCG/0.5ML	6240306045E540	Brand
REBIF TITRATION PACK	INTERFERON BETA-1A PREF SYR 6X8.8 MCG/0.2ML & 6X22 MCG/0.5ML	6240306045E560	Brand
BETASERON	INTERFERON BETA-1B FOR INJ KIT 0.3 MG	62403060506420	Brand
EXTAVIA	INTERFERON BETA-1B FOR INJ KIT 0.3 MG	62403060506420	Brand
GLATIRAMER ACETATE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 20 MG/ML	6240003010E520	Generic
GLATOPA	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 20 MG/ML	6240003010E520	Generic
GLATIRAMER ACETATE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 40 MG/ML	6240003010E540	Generic
COPAXONE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 40 MG/ML	6240003010E540	Brand
VUMERITY	DIROXIMEL FUMARATE CAPSULE DELAYED RELEASE 231 MG	62405530006540	Brand
BAFIERTAM	MONOMETHYL FUMARATE CAPSULE DELAYED RELEASE 95 MG	62405550006520	Brand
KESIMPTA	OFATUMUMAB SOLN AUTO-INJECTOR 20 MG/0.4ML	6240506500D520	Brand
TECFIDERA	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 120 MG	62405525006520	Brand
TECFIDERA	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 240 MG	62405525006540	Brand
PLEGRIDY	PEGINTERFERON BETA-1A SOLN PREFILLED SYRINGE 125 MCG/0.5ML	6240307530E520	Brand
PLEGRIDY	PEGINTERFERON BETA-1A IM SOLN PREFILLED SYR 125 MCG/0.5ML	6240307530E521	Brand
PLEGRIDY STARTER PACK	PEGINTERFERON BETA-1A SOLN PREF SYR 63 & 94 MCG/0.5ML PACK	6240307530E550	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AUBAGIO	TERIFLUNOMIDE TAB 7 MG	62404070000320	Brand
AUBAGIO	TERIFLUNOMIDE TAB 14 MG	62404070000330	Brand
MAYZENT STARTER PACK	SIPONIMOD FUMARATE TAB 0.25 MG (7) STARTER PACK	6240707020B710	Brand
MAYZENT STARTER PACK	SIPONIMOD FUMARATE TAB 0.25 MG (12) STARTER PACK	6240707020B720	Brand
MAYZENT	SIPONIMOD FUMARATE TAB 0.25 MG (BASE EQUIV)	62407070200320	Brand
MAYZENT	SIPONIMOD FUMARATE TAB 1 MG (BASE EQUIV)	62407070200330	Brand
MAYZENT	SIPONIMOD FUMARATE TAB 2 MG (BASE EQUIV)	62407070200340	Brand
TASCENSO ODT	FINGOLIMOD LAURYL SULFATE TABLET DISINTEGRATING 0.25 MG	62407025207220	Brand
TASCENSO ODT	FINGOLIMOD LAURYL SULFATE TABLET DISINTEGRATING 0.5 MG	62407025207230	Brand
DIMETHYL FUMARATE	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 120 MG	62405525006520	Generic
DIMETHYL FUMARATE	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 240 MG	62405525006540	Generic
TERIFLUNOMIDE	TERIFLUNOMIDE TAB 7 MG	62404070000320	Generic
TERIFLUNOMIDE	TERIFLUNOMIDE TAB 14 MG	62404070000330	Generic
DALFAMPRIDINE ER	DALFAMPRIDINE TAB ER 12HR 10 MG	62406030007420	Generic
AMPYRA	DALFAMPRIDINE TAB ER 12HR 10 MG	62406030007420	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (4 TABS)	6240101500B718	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (5 TABS)	6240101500B722	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (6 TABS)	6240101500B726	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (7 TABS)	6240101500B732	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (8 TABS)	6240101500B736	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (9 TABS)	6240101500B740	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (10 TABS)	6240101500B744	Brand
DIMETHYL FUMARATE STARTERPACK	DIMETHYL FUMARATE CAPSULE DR STARTER PACK 120 MG & 240 MG	6240552500B320	Generic
TECFIDERA STARTER PACK	DIMETHYL FUMARATE CAPSULE DR STARTER PACK 120 MG & 240 MG	6240552500B320	Brand

PONVORY 14-DAY STARTER PACK	PONESIMOD TAB STARTER PACK 2,3,4,5,6,7,8,9 &10 MG	6240706000B720	Brand
PONVORY	PONESIMOD TAB 20 MG	62407060000320	Brand
FINGOLIMOD HYDROCHLORIDE	FINGOLIMOD HCL CAP 0.5 MG (BASE EQUIV)	62407025100120	Generic
PLEGRIDY	PEGINTERFERON BETA-1A SOLN AUTO-INJECTOR 125 MCG/0.5ML	6240307530D520	Brand
PLEGRIDY STARTER PACK	PEGINTERFERON BETA-1A SOLN AUTO-INJ 63 & 94 MCG/0.5ML PACK	6240307530D550	Brand

**Approval Criteria**

1 - Diagnosis of multiple sclerosis (MS)

**AND**

2 - If the request is non-preferred\*\*, ONE of the following:

**2.1** Patient has a history of failure, contraindication, or intolerance to a trial of at least TWO preferred<sup>^</sup> alternatives (Verified via paid claims or submission of medical records)

**OR**

**2.2** Patient is currently established on requested medication as documented by claims history or medical records (document drug, date, and duration of therapy)

Notes	<p>**PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC</a> CCP</p> <p>*Preferred drugs may require PA.</p> <p><sup>^</sup>Preferred drugs include medical benefit drugs Ocrevus/Ocrevus Zuno and Tysabri.</p>
-------	---

Product Name: Brand Gilenya, Brand Copaxone, Glatopa, Avonex, Rebif, Betaseron, Extavia, generic glatiramer, Vumerity, Bafiertam, Kesimpta, Brand Tecfidera, Plegridy, Brand Aubagio, generic teriflunomide, Mayzent, Tascenso ODT, generic fingolimod, generic dimethyl fumarate, Brand Ampyra, generic dalfampridine, Mavenclad, Ponvory	
Approval Length	12 month(s)
Therapy Stage	Reauthorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
GILENYA	FINGOLIMOD HCL CAP 0.25 MG (BASE EQUIV)	62407025100110	Brand
GILENYA	FINGOLIMOD HCL CAP 0.5 MG (BASE EQUIV)	62407025100120	Brand
COPAXONE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 20 MG/ML	6240003010E520	Brand
GLATOPA	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 40 MG/ML	6240003010E540	Generic
AVONEX PEN	INTERFERON BETA-1A IM AUTO-INJECTOR KIT 30 MCG/0.5ML	6240306045F530	Brand
AVONEX	INTERFERON BETA-1A IM PREFILLED SYRINGE KIT 30 MCG/0.5ML	6240306045F830	Brand
REBIF REBIDOSE	INTERFERON BETA-1A SOLN AUTO-INJ 22 MCG/0.5ML	6240306045D520	Brand
REBIF REBIDOSE	INTERFERON BETA-1A SOLN AUTO-INJ 44 MCG/0.5ML	6240306045D540	Brand
REBIF REBIDOSE TITRATION PACK	INTERFERON BETA-1A AUTO-INJ 6X8.8 MCG/0.2ML & 6X22 MCG/0.5ML	6240306045D560	Brand
REBIF	INTERFERON BETA-1A SOLN PREF SYR 22 MCG/0.5ML	6240306045E520	Brand
REBIF	INTERFERON BETA-1A SOLN PREF SYR 44 MCG/0.5ML	6240306045E540	Brand
REBIF TITRATION PACK	INTERFERON BETA-1A PREF SYR 6X8.8 MCG/0.2ML & 6X22 MCG/0.5ML	6240306045E560	Brand
BETASERON	INTERFERON BETA-1B FOR INJ KIT 0.3 MG	62403060506420	Brand
EXTAVIA	INTERFERON BETA-1B FOR INJ KIT 0.3 MG	62403060506420	Brand
GLATIRAMER ACETATE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 20 MG/ML	6240003010E520	Generic
GLATOPA	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 20 MG/ML	6240003010E520	Generic
GLATIRAMER ACETATE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 40 MG/ML	6240003010E540	Generic
COPAXONE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 40 MG/ML	6240003010E540	Brand
VUMERITY	DIROXIMEL FUMARATE CAPSULE DELAYED RELEASE 231 MG	62405530006540	Brand
BAFIERTAM	MONOMETHYL FUMARATE CAPSULE DELAYED RELEASE 95 MG	62405550006520	Brand
KESIMPTA	OFATUMUMAB SOLN AUTO-INJECTOR 20 MG/0.4ML	6240506500D520	Brand
TECFIDERA	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 120 MG	62405525006520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TECFIDERA	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 240 MG	62405525006540	Brand
PLEGRIDY	PEGINTERFERON BETA-1A SOLN PREFILLED SYRINGE 125 MCG/0.5ML	6240307530E520	Brand
PLEGRIDY	PEGINTERFERON BETA-1A IM SOLN PREFILLED SYR 125 MCG/0.5ML	6240307530E521	Brand
PLEGRIDY STARTER PACK	PEGINTERFERON BETA-1A SOLN PREF SYR 63 & 94 MCG/0.5ML PACK	6240307530E550	Brand
AUBAGIO	TERIFLUNOMIDE TAB 7 MG	62404070000320	Brand
AUBAGIO	TERIFLUNOMIDE TAB 14 MG	62404070000330	Brand
MAYZENT STARTER PACK	SIPONIMOD FUMARATE TAB 0.25 MG (7) STARTER PACK	6240707020B710	Brand
MAYZENT STARTER PACK	SIPONIMOD FUMARATE TAB 0.25 MG (12) STARTER PACK	6240707020B720	Brand
MAYZENT	SIPONIMOD FUMARATE TAB 0.25 MG (BASE EQUIV)	62407070200320	Brand
MAYZENT	SIPONIMOD FUMARATE TAB 1 MG (BASE EQUIV)	62407070200330	Brand
MAYZENT	SIPONIMOD FUMARATE TAB 2 MG (BASE EQUIV)	62407070200340	Brand
TASCENSO ODT	FINGOLIMOD LAURYL SULFATE TABLET DISINTEGRATING 0.25 MG	62407025207220	Brand
TASCENSO ODT	FINGOLIMOD LAURYL SULFATE TABLET DISINTEGRATING 0.5 MG	62407025207230	Brand
DIMETHYL FUMARATE	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 120 MG	62405525006520	Generic
DIMETHYL FUMARATE	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 240 MG	62405525006540	Generic
TERIFLUNOMIDE	TERIFLUNOMIDE TAB 7 MG	62404070000320	Generic
TERIFLUNOMIDE	TERIFLUNOMIDE TAB 14 MG	62404070000330	Generic
DALFAMPRIDINE ER	DALFAMPRIDINE TAB ER 12HR 10 MG	62406030007420	Generic
AMPYRA	DALFAMPRIDINE TAB ER 12HR 10 MG	62406030007420	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (4 TABS)	6240101500B718	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (5 TABS)	6240101500B722	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (6 TABS)	6240101500B726	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (7 TABS)	6240101500B732	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (8 TABS)	6240101500B736	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (9 TABS)	6240101500B740	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (10 TABS)	6240101500B744	Brand
DIMETHYL FUMARATE STARTERPACK	DIMETHYL FUMARATE CAPSULE DR STARTER PACK 120 MG & 240 MG	6240552500B320	Generic
TECFIDERA STARTER PACK	DIMETHYL FUMARATE CAPSULE DR STARTER PACK 120 MG & 240 MG	6240552500B320	Brand
PONVORY 14-DAY STARTER PACK	PONESIMOD TAB STARTER PACK 2,3,4,5,6,7,8,9 &10 MG	6240706000B720	Brand
PONVORY	PONESIMOD TAB 20 MG	62407060000320	Brand
FINGOLIMOD HYDROCHLORIDE	FINGOLIMOD HCL CAP 0.5 MG (BASE EQUIV)	62407025100120	Generic
PLEGRIDY	PEGINTERFERON BETA-1A SOLN AUTO-INJECTOR 125 MCG/0.5ML	6240307530D520	Brand
PLEGRIDY STARTER PACK	PEGINTERFERON BETA-1A SOLN AUTO-INJ 63 & 94 MCG/0.5ML PACK	6240307530D550	Brand

**Approval Criteria**

1 - Patient demonstrates positive clinical response to therapy (e.g., stability in radiologic disease activity, clinical relapses, disease progression)

**2 . Revision History**

Date	Notes
11/8/2024	Updated notes in initial auth section. Minor update to GPI tables. No changes to clinical criteria.



Multaq



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140642
<b>Guideline Name</b>	Multaq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Multaq			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MULTAQ	DRONEDARONE HCL TAB 400 MG (BASE EQUIVALENT)	35400028100320	Brand
<b>Approval Criteria</b>			
1 - ONE of the following:			

**1.1** All of the following:

**1.1.1** Diagnosis of ONE of the following:

- Paroxysmal Atrial Fibrillation (AF)
- Persistent AF defined as AF less than 6 months duration

**AND**

**1.1.2** ONE of the following:

- Patient is in sinus rhythm
- Patient is planned to undergo cardioversion to sinus rhythm

**AND**

**1.1.3** Patient does not have New York Heart Association (NYHA) Class IV heart failure

**AND**

**1.1.4** Patient does not have symptomatic heart failure with recent decompensation requiring hospitalization

**OR**

**1.2** For continuation of current therapy

## 2 . Revision History

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Myalept



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140898
<b>Guideline Name</b>	Myalept
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Myalept			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYALEPT	METRELEPTIN FOR SUBCUTANEOUS INJ 11.3 MG	30906050002120	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of ONE of the following:			

- Congenital generalized lipodystrophy associated with leptin deficiency
- Acquired generalized lipodystrophy associated with leptin deficiency

**AND**

**2** - Used as an adjunct to diet modification

**AND**

**3** - Prescribed by an endocrinologist

**AND**

**4** - Documentation demonstrates that patient has at least ONE of the following:

**4.1** Diabetes mellitus or insulin resistance with persistent hyperglycemia ( hemoglobin A1C greater than 7.0%) despite BOTH of the following:

- Dietary intervention
- Optimized insulin therapy at maximum tolerated doses

**OR**

**4.2** Persistent hypertriglyceridemia (triglycerides greater than 250 milligrams per deciliter) despite BOTH of the following:

- Dietary intervention
- Optimized therapy with at least two triglyceride-lowering agents from different classes (e.g., fibrates, statins) at maximum tolerated doses

Product Name: Myalept	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
MYALEPT	METRELEPTIN FOR SUBCUTANEOUS INJ 11.3 MG	30906050002120	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Myalept therapy

**AND**

2 - Used as an adjunct to diet modification

**AND**

3 - Prescribed by an endocrinologist

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Myfembree, Oriahnn



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140770
<b>Guideline Name</b>	Myfembree, Oriahnn
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Oriahnn, Myfembree			
Diagnosis	Heavy Menstrual Bleeding Associated With Uterine Leiomyomas (Fibroids)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYFEMBREE	RELUGOLIX-ESTRADIOL-NORETHINDRONE ACETATE TAB 40-1-0.5 MG	24993503800320	Brand
ORIAHNN	ELAGOLIX-ESTRAD-NORETH 300-1-0.5MG & ELAGOLIX 300MG CAP PACK	2499350340B220	Brand

**Approval Criteria**

1 - Diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

**AND**

2 - Patient is premenopausal

**AND**

3 - One of the following:

**3.1** History of inadequate control of bleeding following a trial of at least 3 months, or history of intolerance or contraindication to one of the following:

- Combination (estrogen/progestin) contraceptive
- Progestins
- Tranexamic acid

**OR**

**3.2** Patient has had a previous interventional therapy to reduce bleeding

**AND**

4 - Treatment duration of therapy has not exceeded a total of 24 months

Product Name: Oriahnn, Myfembree	
Diagnosis	Heavy Menstrual Bleeding Associated With Uterine Leiomyomas (Fibroids)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
MYFEMBREE	RELUGOLIX-ESTRADIOL-NORETHINDRONE ACETATE TAB 40-1-0.5 MG	24993503800320	Brand
ORIAHNN	ELAGOLIX-ESTRAD-NORETH 300-1-0.5MG & ELAGOLIX 300MG CAP PACK	2499350340B220	Brand

**Approval Criteria**

1 - Patient has improvement in bleeding associated with uterine leiomyomas (fibroids) (e.g., significant/sustained reduction in menstrual blood loss per cycle, improved quality of life, etc.)

**AND**

2 - Treatment duration of therapy has not exceeded a total of 24 months

Product Name: Myfembree			
Diagnosis	Pain Associated With Endometriosis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYFEMBREE	RELUGOLIX-ESTRADIOL-NORETHINDRONE ACETATE TAB 40-1-0.5 MG	24993503800320	Brand

**Approval Criteria**

1 - Diagnosis of moderate to severe pain associated with endometriosis

**AND**

2 - Patient is premenopausal



**AND**

**3** - One of the following:

**3.1** History of inadequate pain control response following a trial of 30 days, or history of intolerance or contraindication to one of the following:

- Danazol
- Combination (estrogen/progestin) contraceptive
- Progestins

**OR**

**3.2** Patient has had surgical ablation to prevent recurrence

**AND**

**4** - Treatment duration of Myfembree has not exceeded a total of 24 months

Product Name: Myfembree			
Diagnosis	Pain Associated With Endometriosis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYFEMBREE	RELUGOLIX-ESTRADIOL-NORETHINDRONE ACETATE TAB 40-1-0.5 MG	24993503800320	Brand

**Approval Criteria**

**1** - Patient has improvement in pain associated with endometriosis (e.g., improvement in dysmenorrhea and nonmenstrual pelvic pain)

**AND**

**2** - Treatment duration of Myfembree has not exceeded a total of 24 months

## **2 . Revision History**

Date	Notes
2/9/2023	Moved guideline to standard formulary. Added Oriahnn. Added criteria for Myfembree - for Endometriosis pain.

Mytesi



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140643
<b>Guideline Name</b>	Mytesi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Mytesi			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYTESI	CROFELEMER TAB DELAYED RELEASE 125 MG	47250025000620	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) associated diarrhea</p>			

## 2 . Revision History

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Nadolol



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140731
<b>Guideline Name</b>	Nadolol
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: generic nadolol			
Diagnosis	PA required for patients 18 years of age or older		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NADOLOL	NADOLOL TAB 20 MG	33100010000303	Generic
NADOLOL	NADOLOL TAB 40 MG	33100010000305	Generic
NADOLOL	NADOLOL TAB 80 MG	33100010000310	Generic

**Approval Criteria**

1 - History of failure, contraindication, or intolerance to 3 of the following:

- atenolol
- atenolol/chlorthalidone
- bisoprolol fumarate
- bisoprolol/hydrochlorothiazide
- carvedilol
- labetalol HCl
- metoprolol succinate
- metoprolol tartrate
- metoprolol/hydrochlorothiazide
- propranolol HCl
- propranolol/hydrochlorothiazide
- sotalol HCl

**2 . Revision History**

Date	Notes
8/10/2022	C&S to match AZM 10.1.22

Namzarin



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140728
<b>Guideline Name</b>	Namzarin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Namzarin			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NAMZARIC	MEMANTINE HCL-DONEPEZIL HCL CAP ER 24HR 14-10 MG	62059902507030	Brand
NAMZARIC	MEMANTINE HCL-DONEPEZIL HCL CAP ER 24HR 28-10 MG	62059902507050	Brand
NAMZARIC	MEMANTINE HCL-DONEPEZIL HCL CAP ER 24HR 7-10 MG	62059902507020	Brand
NAMZARIC	MEMANTINE HCL-DONEPEZIL HCL CAP ER 24HR 21-10 MG	62059902507040	Brand

NAMZARIC	MEMANTINE-DONEPEZIL CAP ER 24HR 7 & 14 & 21 & 28-10 MG PACK	6205990250B630	Brand
<p><b>Approval Criteria</b></p> <p>1 - BOTH of the following:</p> <p>1.1 History of BOTH of the following:</p> <p>1.1.1 Memantine (generic Namenda)</p> <p style="text-align: center;"><b>AND</b></p> <p>1.1.2 Donepezil (generic Aricept)</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Patient is stabilized on 10mg of donepezil once daily</p>			

**2 . Revision History**

Date	Notes
8/5/2022	C&S to match AZM 10.1.22



Natpara



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140851
<b>Guideline Name</b>	Natpara
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Natpara			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NATPARA	PARATHYROID HORMONE (RECOMBINANT) FOR INJ CARTRIDGE 25 MCG	3004405510E110	Brand
NATPARA	PARATHYROID HORMONE (RECOMBINANT) FOR INJ CARTRIDGE 50 MCG	3004405510E120	Brand
NATPARA	PARATHYROID HORMONE (RECOMBINANT) FOR INJ CARTRIDGE 75 MCG	3004405510E130	Brand

NATPARA	PARATHYROID HORMONE (RECOMBINANT) FOR INJ CARTRIDGE 100 MCG	3004405510E140	Brand
---------	--	----------------	-------

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of hypocalcemia resulting from chronic hypoparathyroidism

**AND**

1.2 25-hydroxy vitamin D level is above the lower limit of the normal laboratory reference range

**AND**

1.3 Patient is currently on active vitamin D (calcitriol) therapy

**AND**

1.4 Total serum calcium level (albumin corrected) is above 7.5 milligrams per deciliter

**AND**

2 - ONE of the following:

2.1 Patient is currently on calcium supplementation of 1-2 grams per day of elemental calcium in divided doses

**OR**

2.2 Patient has a contraindication to calcium supplementation

**AND**

**3** - Prescribed by ONE of the following:

- Endocrinologist
- Nephrologist

Product Name: Natpara

Approval Length | 12 month(s)

Therapy Stage | Reauthorization

Guideline Type | Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NATPARA	PARATHYROID HORMONE (RECOMBINANT) FOR INJ CARTRIDGE 25 MCG	3004405510E110	Brand
NATPARA	PARATHYROID HORMONE (RECOMBINANT) FOR INJ CARTRIDGE 50 MCG	3004405510E120	Brand
NATPARA	PARATHYROID HORMONE (RECOMBINANT) FOR INJ CARTRIDGE 75 MCG	3004405510E130	Brand
NATPARA	PARATHYROID HORMONE (RECOMBINANT) FOR INJ CARTRIDGE 100 MCG	3004405510E140	Brand

**Approval Criteria**

**1** - Total serum calcium level (albumin corrected) within the lower half of the normal range (approximately 8 to 9 milligrams per deciliter)

**AND**

**2** - Patient continues to take concomitant calcium supplementation that is sufficient to meet daily requirements

**AND**

**3** - Prescribed by ONE of the following:

- Endocrinologist

- Nephrologist

## 2 . Revision History

Date	Notes
3/31/2020	Bulk copy C&S New York SP to C&S Arizona SP for 5/1 effective

Nexiclon XR (clonidine ER)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140801
<b>Guideline Name</b>	Nexiclon XR (clonidine ER)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	7/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Nexiclon XR, Brand Clonidine ER 24HR 0.17 mg tabs			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NEXICLON XR	CLONIDINE HCL TAB ER 24HR 0.17 MG (BASE EQUIVALENT)	36201010007510	Generic
CLONIDINE ER	CLONIDINE HCL TAB ER 24HR 0.17 MG (BASE EQUIVALENT)	36201010007510	Generic
<b>Approval Criteria</b>			

1 - Requested medication is being used for treatment of hypertension

**AND**

2 - Trial and failure, contraindication, or intolerance to ONE of the following (verified via paid pharmacy claims or submitted chart notes):

- generic clonidine oral tablet
- generic clonidine topical patch

## 2 . Revision History

Date	Notes
6/7/2023	Added brand clonidine ER 24Hr GPI and product name, updated criteria.

Nexletol (bempedoic acid) and Nexlizet (bempedoic acid-ezetimibe)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-148465
<b>Guideline Name</b>	Nexletol (bempedoic acid) and Nexlizet (bempedoic acid-ezetimibe)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Nexletol, Nexlizet			
Diagnosis	Heterozygous familial hypercholesterolemia (HeFH) or primary hyperlipidemia		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NEXLETOL	BEMPEDOIC ACID TAB 180 MG	39380020000320	Brand
NEXLIZET	BEMPEDOIC ACID-EZETIMIBE TAB 180-10 MG	39991002200320	Brand

**Approval Criteria**

**1** - ONE of the following diagnoses:

- Heterozygous familial hypercholesterolemia (HeFH)
- Primary Hyperlipidemia

**AND**

**2** - ONE of the following:

- Patient has been receiving at least 12 consecutive weeks of highest tolerable dose of statin therapy
- Patient is statin intolerant as evidenced by an inability to tolerate at least two statins, with at least one started at the lowest starting daily dose, due to intolerable symptoms or clinically significant biomarker changes of liver function or muscle function (e.g., creatine kinase)
- Patient has an FDA (Food and Drug Administration) labeled contraindication to all statins

**AND**

**3** - ONE of the following LDL-C (low-density lipoprotein cholesterol) values while on maximally tolerated statin therapy within the last 120 days:

- LDL-C greater than or equal to 55 mg/dL (milligrams/deciliter) with ASCVD (atherosclerotic cardiovascular disease)
- LDL-C greater than or equal to 100 mg/dL without ASCVD

**AND**

**4** - ONE of the following:

**4.1** For Nexletol, ONE of the following:

- Patient has been receiving at least 12 consecutive weeks of generic ezetimibe therapy as adjunct to maximally tolerated statin therapy
- Patient has a history of contraindication or intolerance to ezetimibe



**OR**

**4.2** For Nexlizet, patient has been receiving at least 12 consecutive weeks of generic ezetimibe therapy as adjunct to maximally tolerated statin therapy

Product Name: Nexletol, Nexlizet

Diagnosis	Heterozygous familial hypercholesterolemia (HeFH) or primary hyperlipidemia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NEXLETOL	BEMPEDOIC ACID TAB 180 MG	39380020000320	Brand
NEXLIZET	BEMPEDOIC ACID-EZETIMIBE TAB 180-10 MG	39991002200320	Brand

**Approval Criteria**

**1** - Patient demonstrates positive clinical response to therapy as evidenced by a reduction in LDL-C (low-density lipoprotein cholesterol) levels from baseline while on therapy

**AND**

**2** - ONE of the following:

- Patient continues to receive other lipid-lowering therapy (e.g., statins, ezetimibe) at the maximally tolerated dose
- Patient has a documented inability to take other lipid-lowering therapy (e.g., statins, ezetimibe)

Product Name: Nexletol, Nexlizet

Diagnosis	Established cardiovascular disease (CVD) or high risk for a CVD event but without established CVD
Approval Length	12 month(s)

Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NEXLETOL	BEMPEDOIC ACID TAB 180 MG	39380020000320	Brand
NEXLIZET	BEMPEDOIC ACID-EZETIMIBE TAB 180-10 MG	39991002200320	Brand

**Approval Criteria**

1 - ONE of the following diagnoses:

- Established cardiovascular disease (CVD) (e.g., coronary artery disease, symptomatic peripheral arterial disease, cerebrovascular atherosclerotic disease)
- A high risk for a CVD event but without established CVD [e.g., diabetes mellitus (type 1 or type 2) in females over 65 years of age or males over 60 years of age]

**AND**

2 - ONE of the following:

- Patient is statin intolerant as evidenced by an inability to tolerate at least two statins, with at least one started at the lowest starting daily dose, due to intolerable symptoms or clinically significant biomarker changes of liver function or muscle function (e.g., creatine kinase)
- Patient has an FDA (Food and Drug Administration) labeled contraindication to all statins

**AND**

3 - ONE of the following LDL-C (low-density lipoprotein cholesterol) values within the last 120 days:

- LDL-C greater than or equal to 55 mg/dL (milligrams/deciliter) with ASCVD (atherosclerotic cardiovascular disease)
- LDL-C greater than or equal to 100 mg/dL without ASCVD

**AND**

**4 - ONE of the following:**

**4.1** For Nexletol, ONE of the following:

- Patient has been receiving at least 12 consecutive weeks of generic ezetimibe therapy
- Patient has a history of contraindication or intolerance to ezetimibe

**OR**

**4.2** For Nexlizet, patient has been receiving at least 12 consecutive weeks of generic ezetimibe therapy

Product Name: Nexletol, Nexlizet			
Diagnosis	Established cardiovascular disease (CVD) or high risk for a CVD event but without established CVD		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NEXLETOL	BEMPEDOIC ACID TAB 180 MG	39380020000320	Brand
NEXLIZET	BEMPEDOIC ACID-EZETIMIBE TAB 180-10 MG	39991002200320	Brand
<b>Approval Criteria</b>			
1 - Patient demonstrates positive clinical response to therapy			

## 2 . Revision History

Date	Notes
6/14/2024	Updated criteria due to indication updates in prescribing information. Added criteria for the new FDA approved indication.

Nityr



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140899
<b>Guideline Name</b>	Nityr
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Nityr			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NITYR	NITISINONE TAB 2 MG	30904045000310	Brand
NITYR	NITISINONE TAB 5 MG	30904045000320	Brand
NITYR	NITISINONE TAB 10 MG	30904045000330	Brand

**Approval Criteria**

1 - Diagnosis of hereditary tyrosinemia type 1

**AND**

2 - Prescriber provides a reason or special circumstance the patient cannot use Orfadin (nitisinone) capsules or suspension

Product Name: Nityr			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NITYR	NITISINONE TAB 2 MG	30904045000310	Brand
NITYR	NITISINONE TAB 5 MG	30904045000320	Brand
NITYR	NITISINONE TAB 10 MG	30904045000330	Brand
<b>Approval Criteria</b>			
1 - Patient shows evidence of positive clinical response (e.g. decrease in urinary/plasma succinylacetone and alpha-1-microglobulin levels) while on Nityr therapy			

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Nocdurna



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140663
<b>Guideline Name</b>	Nocdurna
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Nocdurna			
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NOCDURNA	DESMOPRESSIN ACETATE SUBLINGUAL TAB 27.7 MCG	30201010100710	Brand
NOCDURNA	DESMOPRESSIN ACETATE SUBLINGUAL TAB 55.3 MCG	30201010100715	Brand

**Approval Criteria**

**1** - Diagnosis of nocturia due to nocturnal polyuria (as defined by nighttime urine production that exceeds one-third of the 24-hour urine production)

**AND**

**2** - Patient wakes at least twice per night on a reoccurring basis to void

**AND**

**3** - Documented serum sodium level is currently within normal limits of the normal laboratory reference range and has been within normal limits over the previous six months

**AND**

**4** - The patient has been evaluated for other medical causes and has either not responded to, tolerated, or has a contraindication to treatments for identifiable medical causes [e.g., overactive bladder, benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), elevated post-void residual urine, and heart failure]

**AND**

**5** - Prescriber attests that the risks have been assessed and benefits outweigh the risks

Product Name: Nocdurna			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NOCDURNA	DESMOPRESSIN ACETATE SUBLINGUAL TAB 27.7 MCG	30201010100710	Brand
NOCDURNA	DESMOPRESSIN ACETATE SUBLINGUAL TAB 55.3 MCG	30201010100715	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**AND**

2 - Patient has routine monitoring for serum sodium levels

**AND**

3 - Prescriber attests that the risks of hyponatremia have been assessed and benefits outweigh the risks

**2 . Revision History**

Date	Notes
3/1/2021	Noctiva removed from the guideline



Non-Preferred Drugs



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140781
<b>Guideline Name</b>	Non-Preferred Drugs
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	3/3/2023
-----------------	----------

### 1 . Criteria

Product Name: Non-Preferred Drugs			
Approval Length	12 months*		
Guideline Type	Administrative		
Product Name	Generic Name	GPI	Brand/Generic
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 ONE of the following**:</p> <p>1.1.1 If there are at least three preferred alternatives, history of trial per patient's pharmacy</p>			

claims resulting in a therapeutic failure, contraindication, or intolerance to at least THREE preferred alternatives [Prior trials of formulary/preferred drug list (PDL) alternatives must sufficiently demonstrate that the formulary/PDL alternatives are either ineffective or inappropriate at the time of the request]

**OR**

**1.1.2** If there are fewer than three preferred alternatives, the patient must have a history of trial per patient's pharmacy claims resulting in a therapeutic failure, contraindication, or intolerance to ALL of the preferred products (Prior trials of formulary/PDL alternatives must sufficiently demonstrate that the formulary/PDL alternatives are either ineffective or inappropriate at the time of the request)

**OR**

**1.1.3** There are no preferred formulary alternatives for the requested drug

**AND**

**1.2** If the request is for a multi-source brand medication (i.e., MSC O), ONE of the following:

**1.2.1** BOTH of the following:

**1.2.1.1** The brand is being requested because of an adverse reaction, allergy, or sensitivity to the generic and the prescriber must attest to submitting the FDA (Food and Drug Administration) MedWatch Form for allergic reactions to the medications

**AND**

**1.2.1.2** If there are generic product(s), the patient has tried at least three (if available)

**OR**

**1.2.2** ONE of the following:

- The brand is being requested due to a therapeutic failure with the generic (please provide reason for therapeutic failure)
- The brand is being requested because transition to the generic could result in destabilization of the patient (rationale must be provided)

- Special clinical circumstances exist that preclude the use of the generic equivalent of the multi-source brand medication for the patient (rationale must be provided)

**AND**

**1.3** ONE of the following:

**1.3.1** The requested drug must be used for an FDA-approved indication

**OR**

**1.3.2** The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- The requested drug must be used for an FDA-approved indication
- FDA approved indications and limits
- Published practice guidelines and treatment protocols
- Comparative data evaluating the efficacy, type and frequency of side effects and potential drug interactions among alternative products as well as the risks, benefits, and potential patient outcomes
- Drug Facts and Comparisons
- American Hospital Formulary Service Drug Information
- United States Pharmacopeia - Drug Information
- DRUGDEX Information System
- UpToDate
- MicroMedex
- Peer-reviewed medical literature, including randomized clinical trials, outcomes, research data, and pharmaco-economic studies
- Other drug reference resources

**AND**

**1.4** The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plan's program\*\*\*

**OR**

**2** - If the requested medication is a behavioral health medication, ONE of the following:

<ul style="list-style-type: none"> <li>The patient has been receiving treatment with the requested non-preferred behavioral health medication and is new to the plan (enrollment effective date within the past 90 days)</li> <li>The patient is currently receiving treatment with the requested non-preferred behavioral health medication in the hospital and must continue upon discharge</li> </ul>	
Notes	<p>*Anti-infectives: Approve for the requested time frame, or if duration is not specified approve the request for 30 days.</p> <p>*Controlled Substances shall be approved for the requested time. If there is not a requested time period and it is not clear in the directions, approve for one time only.</p> <p>*Other medications: Approved for the requested time frame, or if duration is not specified, approve for 12 months.</p> <p>**PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CCP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CCP</a></p> <p>***Medications used solely for anti-obesity/weight loss, cosmetic (e.g., alopecia, actinic keratosis, vitiligo), erectile dysfunction, or sexual dysfunction purposes are NOT medically accepted indications and are NOT recognized as a covered benefit. Erectile dysfunction drugs (Cialis/Tadalafil) are covered for clinical diagnoses other than ED.</p>

## 2 . Revision History

Date	Notes
3/3/2023	Removed Non-Preferred Generics (MSC Y) note per PAM and PA team request.

Non-Preferred Prenatal Vitamins



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140705
<b>Guideline Name</b>	Non-Preferred Prenatal Vitamins
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Non-Preferred Prenatal Vitamins			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
JENLIVA PRENATAL/POSTNATAL	*PRENATAL MULTIVITAMINS & MINERALS W/ IRON & FA CAP 1 MG***	7851200000115	Brand
MYNATAL	*PRENATAL MULTIVITAMINS & MINERALS W/ IRON & FA CAP 1 MG***	7851200000115	Brand
KPN PRENATAL	*PRENATAL MULTIVITAMINS & MINERALS W/IRON & FA TAB 0.1 MG***	78512000000303	Generic
PRE-NATAL FORMULA	*PRENATAL MULTIVITAMINS & MINERALS W/IRON & FA TAB 0.8 MG***	78512000000315	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRENATAL	*PRENATAL MULTIVITAMINS & MINERALS W/IRON & FA TAB 0.8 MG***	78512000000315	Generic
PRENATAL AND IRON	*PRENATAL MULTIVITAMINS & MINERALS W/IRON & FA TAB 0.8 MG***	78512000000315	Generic
PRENATAL FORTE	*PRENATAL MULTIVITAMINS & MINERALS W/IRON & FA TAB 0.8 MG***	78512000000315	Generic
PRENATVITE RX	*PRENATAL MULTIVITAMINS & MINERALS W/IRON & FA TAB 0.8 MG***	78512000000315	Brand
PRENATVITE COMPLETE	*PRENATAL MULTIVITAMINS & MINERALS W/ IRON & FA TAB 1 MG***	78512000000320	Brand
PRENATVITE PLUS	*PRENATAL MULTIVITAMINS & MINERALS W/ IRON & FA TAB 1 MG***	78512000000320	Brand
NEONATAL FE	*PRENATAL VITAMIN W/ IRON-FOLIC ACID TAB 90-1 MG***	78512003000330	Brand
VITAFOL GUMMIES	*PRENAT VIT W/ FE PHOS-FA-OMEGA CHEW TAB 3.33-0.333-34.8 MG*	78512005000520	Brand
ENBRACE HR	*PRENATAL VIT W/ FE GLY CYS-FA-OMEGA 3 FATTY ACIDS CAP***	78512007000120	Brand
PNV TABS 29-1	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***	78512010000330	Generic
PRENATABS RX	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***	78512010000330	Brand
PRENATAL PLUS IRON	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***	78512010000330	Generic
THRIVITE RX	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***	78512010000330	Brand
KOSHER PRENATAL PLUS IRON	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 30-1 MG***	78512010000331	Generic
OB COMPLETE	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 50-1.25 MG***	78512010000352	Brand
ONE A DAY WOMENS PRENATAL1	*PRENATAL VIT W/ FE CARBONYL-FA-OMEGA 3 CAP 28-0.8-235 MG***	78512011000130	Brand
PRENATE ELITE	*PRENATAL W/ FE ASP GLY-L METHYLFOL-FA TAB 20-0.6-0.4 MG***	78512012200330	Brand
OB COMPLETE/DHA	*PRENAT W/ IRON CBN-FE ASP GLYC-FA-OMEGA CAP 30-10-1-200 MG*	78512013000140	Brand
OB COMPLETE PREMIER	*PRENATAL VIT W/ FE CBN-FE ASP GLYC-FA TAB 30-20-1 MG***	78512014000350	Brand
PERRY PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA CAP 13.5-0.4 MG***	78512015000108	Brand
PRENARA	*PRENATAL VIT W/ FE FUMARATE-FA CAP 15-1 MG***	78512015000111	Brand
PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 6.75-0.2 MG***	78512015000303	Generic
PRENATAL COMPLETE	*PRENATAL VIT W/ FE FUMARATE-FA TAB 14-0.4 MG***	78512015000306	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

O-CAL PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 15-1 MG***	78512015000312	Brand
CVS PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-0.8 MG***	78512015000322	Generic
MULTI PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-0.8 MG***	78512015000322	Generic
NEONATAL VITAMIN	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-0.8 MG***	78512015000322	Brand
ONE VITE WOMENS PRENATAL VITAMIN	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-0.8 MG***	78512015000322	Brand
PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-0.8 MG***	78512015000322	Generic
PRENATAL LOW IRON	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-0.8 MG***	78512015000322	Generic
PRENATAL ONE DAILY	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-0.8 MG***	78512015000322	Generic
PRENATAL VITAMIN	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-0.8 MG***	78512015000322	Generic
RIGHT STEP PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-0.8 MG***	78512015000322	Brand
M-NATAL PLUS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Brand
NEONATAL COMPLETE	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Brand
NEONATAL PLUS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Brand
NIVA-PLUS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Brand
ONE VITE WOMENS PRENATAL VITAMIN PLUS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Brand
PNV PRENATAL PLUS MULTIVITAMIN	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Generic
PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Generic
PRENATAL PLUS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Generic
PRENATAL PLUS/IRON	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Generic
PRENATAL VITAMINS PLUS LOW IRON	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Generic
PRENATAL/FOLIC ACID	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Generic
PRENATRIX	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PRENATRYL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Brand
PREPLUS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Generic
THERANATAL CORE NUTRITION	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Brand
TRICARE	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Brand
VITATHELY/GINGER	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Brand
WESTAB PLUS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***	78512015000324	Brand
CLASSIC PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
EQL PRENATAL FORMULA	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
GNP PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
HM PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
KP PRENATAL MULTIVITAMINS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
PRENATAL MULTIVITAMIN	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
PRENATAL VITAMIN & MINERAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
PRENATAL VITAMIN/IRON	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
PRENATAL VITAMINS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
PX PRENATAL MULTIVITAMINS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
QC PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
RA PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
RA PRENATAL FORMULA/FOLICACID	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
SM PRENATAL VITAMINS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-0.8 MG***	78512015000328	Generic
TRINATE	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-1 MG***	78512015000329	Brand
CO-NATAL FA	*PRENATAL VIT W/ FE FUMARATE-FA TAB 29-1 MG***	78512015000332	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NEONATAL COMPLETE	*PRENATAL VIT W/ FE FUMARATE-FA TAB 29-1 MG***	78512015000332	Brand
PRENATABS FA	*PRENATAL VIT W/ FE FUMARATE-FA TAB 29-1 MG***	78512015000332	Brand
PRETAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 29-1 MG***	78512015000332	Brand
VINATE ONE	*PRENATAL VIT W/ FE FUMARATE-FA TAB 60-1 MG***	78512015000360	Brand
MYNATAL PLUS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 65-1 MG***	78512015000366	Brand
MYNATAL-Z	*PRENATAL VIT W/ FE FUMARATE-FA TAB 65-1 MG***	78512015000366	Brand
VITAFOL-OB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 65-1 MG***	78512015000366	Brand
NATALVIT	*PRENATAL VIT W/ FE FUMARATE-FA TAB 75-1 MG***	78512015000385	Brand
PRENATAL 19	*PRENATAL VIT W/ FE FUMARATE-FA CHEW TAB 29-1 MG***	78512015000530	Generic
SE-NATAL 19	*PRENATAL VIT W/ FE FUMARATE-FA CHEW TAB 29-1 MG***	78512015000530	Brand
PRENATAL MULTI +DHA	*PRENATAL VIT W/ FE FUM-FA-OMEGA 3 CAP 27-0.8-228 MG***	78512018000109	Generic
PRENATAL FORMULA	*PRENATAL VIT W/ FE FUM-FA-OMEGA 3 CAP 28-0.8-235 MG***	78512018000115	Generic
C-NATE DHA	*PRENATAL VIT W/ FE FUM-FA-OMEGA 3 CAP 28-1-200 MG***	78512018000116	Brand
RELNATE DHA	*PRENATAL VIT W/ FE FUM-FA-OMEGA 3 CAP 28-1-200 MG***	78512018000116	Brand
VIRT-NATE DHA	*PRENATAL VIT W/ FE FUM-FA-OMEGA 3 CAP 28-1-200 MG***	78512018000116	Generic
VIVA DHA	*PRENATAL VIT W/ FE FUM-FA-OMEGA 3 CAP 28-1-200 MG***	78512018000116	Brand
VP-PNV-DHA	*PRENATAL VIT W/ FE FUM-FA-OMEGA 3 CAP 28-1-215.8 MG***	78512018000117	Generic
ONE A DAY WOMENS PRENATAL/DHA	*PRENAT W/ FE FUM-FA TAB 28-0.8 MG & OMEGA 3 CAP 223 MG PAK*	78512018006315	Brand
HM ONE DAILY PRENATAL COMBO	*PRENAT W/ FE FUM-FA TAB 28-0.8 MG & OMEGA 3 CAP 440 MG PAK*	78512018006325	Generic
ONE-A-DAY WOMENS PRENATAL	*PRENAT W/ FE FUM-FA TAB 28-0.8 MG & OMEGA 3 CAP 440 MG PAK*	78512018006325	Brand
SM ONE DAILY PRENATAL	*PRENAT W/ FE FUM-FA TAB 28-0.8 MG & OMEGA 3 CAP 440 MG PAK*	78512018006325	Generic
TRINAZ	*PRENATAL VIT W/ FE GLUCONATE-FA TAB 12-1 MG***	78512020000318	Brand
AZESCO	*PRENATAL VIT W/ FE GLUCONATE-FA TAB 13-1 MG***	78512020000320	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZALVIT	*PRENATAL VIT W/ FE GLUCONATE-FA TAB 13-1 MG***	78512020000320	Brand
PRENATAL/OMEGA-3/FOLIC ACID/IRON	*PRENATAL VIT W/ FE FUM-FA-FISH OIL CAP 28-0.8-530 MG***	78512021000130	Generic
YOUR LIFE MULTI PRENATAL	*PRENATAL VIT W/ FE FUM-FA-FISH OIL CAP 28-0.8-530 MG***	78512021000130	Brand
PNV-SELECT	*PRENATAL VIT W/ FE FUM-METHYLFOLATE-FA TAB 27-0.6-0.4 MG***	78512022000320	Generic
CLINICAL NUTRIENTS PRENATAL FORMULA	*PRENATAL VIT W/ FE SUCCINATE-FA TAB 7.5-0.2 MG***	78512024000310	Brand
SELECT-OB	*PRENATAL VIT W/ FE POLYSAC CMLPX-FA CHEW TAB 29-1 MG***	78512030000530	Brand
SELECT-OB	*PRENAT W/ FEPOLYCMPLX-METHYLFOL-FA CHEW TAB 29-0.6-0.4 MG**	78512032000530	Brand
PNV TABS 20-1	*PRENAT VIT W/FE BISGLYC CHELATE-FA TAB 20-1MG (1.7MG DFE)**	78512046000315	Brand
PREGENNA	*PRENAT VIT W/FE BISGLYC CHELATE-FA TAB 20-1MG (1.7MG DFE)**	78512046000315	Brand
ATABEX OB	*PRENATAL VIT W/ FE BISGLYCINATE CHELATE-FA TAB 29-1 MG***	78512046000330	Brand
VINATE II	*PRENATAL VIT W/ FE BISGLYCINATE CHELATE-FA TAB 29-1 MG***	78512046000330	Brand
NATACHEW	*PRENATAL VIT W/ FE FUM-FE BISGLYCIN-FA CHEW TAB 28-1 MG***	78512047000525	Brand
PRENATAL-U	*PRENATAL W/O A VIT W/ FE FUMARATE-FA CAP 106.5-1 MG***	78512050000162	Brand
PRENATAL FORMULA A-FREE	*PRENATAL W/O A VIT W/ FE FUMARATE-FA TAB 9-0.267 MG***	78512050000310	Generic
AZESCHEW PRENATAL/POSTNATAL	*PRENATAL W/O A VIT W/ FE FUM-FA TAB CHEW 13-1 MG***	78512050000510	Brand
VINATE CARE	*PRENATAL W/O A VIT W/ FE FUM-FA TAB CHEW 40-1 MG***	78512050000540	Brand
VITAFOL-NANO	*PRENATAL W/O A W/ FEFUM-L METHYLFOL-FA TAB 18-0.6-0.4 MG***	78512050200320	Brand
CITRANATAL RX	*PRENATAL W/O A W/ FE CARBONYL-FE GLUC-DSS-FA TAB 27-1MG***	78512051000327	Brand
ATABEX PRENATAL	*PRENATAL W/O A VIT W/ FE CARBONYL-FA CHEW TAB 18-0.8 MG***	78512052000520	Brand
PROVIDA OB	*PRENATAL W/O A W/FE FUM-FE POLY-FA CAP 20-20-1.25 MG***	78512058000120	Brand
CONCEPT OB	*PRENATAL W/O A W/FE FUM-FE POLY-FA CAP 130-92.4-1 MG***	78512058000150	Brand
PNV-OMEGA	*PRENAT W/O A W/ FE FUMARATE-METHYLFOLATE-FA-OMEGA 3 CAP***	78512062000130	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

VIRT-PN PLUS	*PRENAT W/O A W/ FE FUMARATE-METHYLFOLATE-FA-OMEGA 3 CAP***	78512062000130	Generic
OBSTETRIX EC	*PRENATAL VIT W/ DSS-IRON CARBONYL-FA TAB 29-1 MG***	78512065000330	Brand
OBTREX	*PRENATAL VIT W/ DSS-IRON CARBONYL-FA TAB 29-1 MG***	78512065000330	Brand
INATAL GT	*PRENATAL VIT W/ DSS-IRON CARBONYL-FA TAB 90-1 MG***	78512065000375	Brand
ATABEX EC	*PRENATAL VIT W/ DSS-IRON CARBONYL-FA TAB DR 29-1 MG***	78512065000630	Brand
NESTABS	*PRENATAL VIT W/O VIT A W/ FE BISGLYCINATE-FA TAB 32-1 MG***	78512066000340	Brand
NESTABS DHA	*PRENAT W/O A W/ FE BISGLYC-FA TAB 32-1 MG & OMEGA CAP PACK*	78512067006340	Brand
PRENATAL 19	*PRENATAL VIT W/ DSS-FE FUMARATE-FA TAB 29-1 MG***	78512070000330	Generic
SE-NATAL 19	*PRENATAL VIT W/ DSS-FE FUMARATE-FA TAB 29-1 MG***	78512070000330	Brand
CITRANATAL B-CALM	*PRENAT W/O A W/FECBN-FEGLU-FA TAB 20-1 MG & VIT B6 TAB PAK*	78512071006320	Brand
OB COMPLETE ONE	*PRENATAL W/O A W/FECBN-FE ASP GLYC-FA-FISH CAP 50-1-476 MG*	78512072000135	Brand
OB COMPLETE PETITE	*PRENAT W/O A W/FECBN-FEASPGLYC-FA-OMEGA CAP 35-5-1-200 MG**	78512073000140	Brand
NEEVO DHA	*PRENAT W/O A W/FEFUM-METHYLFOL-OMEGAS CAP 27-1.13 MG***	78512076000130	Brand
VINATE DHA RF	*PRENAT W/O A W/FEFUM-METHYLFOL-OMEGAS CAP 27-1.13 MG***	78512076000130	Brand
PRENA1 PEARL	*PRENAT W/OA W/FEFUM-NA FERED-FA-DHA CAP ER 30-1.4-200 MG***	78512079000230	Brand
VITAPEARL	*PRENAT W/OA W/FEFUM-NA FERED-FA-DHA CAP ER 30-1.4-200 MG***	78512079000230	Brand
PRIMACARE	*PRENAT W/O A W/FEASP-METHLF-FA-OMEG CAP 30-0.75-0.25-470MG*	78512081000150	Brand
UPSPRING PRENATAL COMPLETE	*PRENAT-FE BISGLYC-METHYLF-FISH OIL CAP 9-0.267-191.67 MG***	78512082000120	Brand
CITRANATAL BLOOM	*PRENATAL VIT W/ DSS-FE CBN-FE GLUC-FA TAB 90-1 MG***	78512083000330	Brand
CONCEPT DHA	*PRENATAL W/FE FUM-FE POLY -FA-OMEGA 3 CAP 53.5-38-1 MG***	78512091000135	Brand
VIRT-C DHA	*PRENATAL W/FE FUM-FE POLY -FA-OMEGA 3 CAP 53.5-38-1 MG***	78512091000135	Generic
OBSTETRIX DHA	*PRENAT W/FECBN-FA-DSS TAB 29-1 MG & OMEGA 3 CAP 387 MG PAK*	78512093006330	Brand
TRICARE PRENATAL DHA ONE	*PRENATAL W/FE FUMARATE-FA-DSS-FISH OIL CAP 27-1-500 MG***	78512094000127	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DUET DHA BALANCED	*PRENAT W/FE POLY-NA FERED-FA TAB 25-1 & OMEGA CAP 267 MG***	78512097006316	Brand
DUET DHA 400	*PRENAT W/FE POLY-NA FERED-FA TAB 25-1 & OMEGA CAP 400 MG***	78512097006318	Brand
THERANATAL ONE	*PRENATAL W/O VIT A W/ FE FUMARATE-FA-DHA CAP 27-1-300 MG***	78516013000120	Brand
STUART ONE	*PRENATAL MV & MIN W/FE CARBONYL-FA-DHA CAP 27-0.8-200 MG**	78516015000130	Brand
PREGEN DHA	*PRENATAL MV & MIN W/FE CARBONYL-FA-DHA CAP 28-1-35 MG**	78516015000132	Brand
BRAINSTRONG PRENATAL	*PRENAT W/FE CARBONYL-FA TAB 33-0.8 MG & DHA CAP 350 MG PAK*	78516015006330	Brand
PRENATAL MULTI + DHA	*PRENATAL MV & MIN W/FE FUM-FA-DHA CAP 27-0.8-200 MG***	78516020000125	Generic
CVS PRENATAL MULTI+DHA	*PRENATAL MV & MIN W/FE FUM-FA-DHA CAP 27-0.8-250 MG***	78516020000130	Generic
PRENATAL MULTI + DHA	*PRENATAL MV & MIN W/FE FUM-FA-DHA CAP 27-0.8-250 MG***	78516020000130	Generic
PRENATAL MULTIVITAMIN PLUS DHA	*PRENATAL MV & MIN W/FE FUM-FA-DHA CAP 27-0.8-250 MG***	78516020000130	Generic
CENTRUM SPECIALIST PRENATAL	*PRENATAL W/FE FUM-FA TAB 27-0.8 MG & DHA CAP 200 MG PACK *	78516020006312	Brand
SIMILAC PRENATAL EARLY SHIELD	*PRENATAL W/FE FUM-FA TAB 27-0.8 MG & DHA CAP 200 MG PACK *	78516020006312	Brand
THERANATAL COMPLETE	*PRENATAL W/FE FUM-FA TAB 27-1 MG & VIT-DHA CAP 300 MG PAK *	78516020006317	Brand
CVS WOMENS PRENATAL+DHA	*PRENATAL W/FE FUM-FA TAB 28-0.975 MG & DHA CAP 200 MG PACK*	78516020006318	Generic
PRENATAL MULTIVITAMIN PLUS DHA	*PRENATAL W/FE FUM-FA TAB 28-0.975 MG & DHA CAP 200 MG PACK*	78516020006318	Generic
PRENATAL+DHA	*PRENATAL W/FE FUM-FA TAB 28-0.975 MG & DHA CAP 200 MG PACK*	78516020006318	Generic
ENFAMIL EXPECTA	*PRENATAL W/FE FUM-FA TAB 28-0.8 MG & DHA CAP 200 MG PACK*	78516020006319	Brand
PRENATAL MULTIVITAMIN + DHA	*PRENATAL W/FE FUM-FA TAB 28-0.8 MG & DHA CAP 200 MG PACK*	78516020006319	Brand
NEONATAL/DHA	*PRENATAL MV W/FE FUM-FA TAB 29-1 MG & DHA CAP 200 MG PACK *	78516020006323	Brand
VITAFOL-OB+DHA	*PRENATAL MV W/FE FUM-FA TAB 65-1 MG & DHA CAP 250 MG PACK *	78516020006330	Brand
CADEAU DHA	*PRENAT W/FE FUM-METHYLFOL-FA-DHA CAP 29-0.4-0.8-375 MG***	78516022000135	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TRISTART DHA	*PRENAT W/O A W/FECBN-METHYLF-FA-DHA CAP 31-0.6-0.4-200 MG**	78516023000140	Brand
WESTGEL DHA	*PRENAT W/O A W/FECBN-METHYLF-FA-DHA CAP 31-0.6-0.4-200 MG**	78516023000140	Brand
TRISTART ONE	*PRENAT W/O A W/FECBN-METHYLF-FA-DHA CAP 35-1-215 MG***	78516023000150	Brand
TRISTART FREE	*PRENAT W/O A W/DHA & FECBN-METHYLF-FA CAP 33-1 MG***	78516023000170	Brand
PNV-DHA	*PRENAT W/O A W/FEFUM-METHFOL-FA-DHA CAP 27-0.6-0.4-300 MG**	78516024000125	Generic
VIRT-PN DHA	*PRENAT W/O A W/FEFUM-METHFOL-FA-DHA CAP 27-0.6-0.4-300 MG**	78516024000125	Generic
PRENATE RESTORE	*PRENAT W/O A W/FEFUM-METHFOL-FA-DHA CAP 27-0.6-0.4-400 MG**	78516024000127	Brand
PRENATE ENHANCE	*PRENAT W/O A W/FEFUM-METHFOL-FA-DHA CAP 28-0.6-0.4-400 MG**	78516024000137	Brand
VITAMEDMD ONE RX/QUATREFOLIC	*PRENAT W/O A W/FEFUM-METHFOL-FA-DHA CAP 30-0.6-0.4-200 MG**	78516024000140	Brand
PRENATE PIXIE	*PRENAT W/O A W/FEASPG-METHFOL-FA-DHA CAP 10-0.6-0.4-200 MG*	78516025000115	Brand
PRENATE DHA	*PRENAT W/O A W/FEASPG-METHFOL-FA-DHA CAP 18-0.6-0.4-300 MG*	78516025000125	Brand
PRENATE ESSENTIAL	*PRENAT W/O A W/FEASPG-METHFOL-FA-DHA CAP 18-0.6-0.4-300 MG*	78516025000125	Brand
VITAFOL-ONE	*PRENATAL MV W/ FE POLYSAC CMLPX-FA-DHA CAP 29-1-200 MG***	78516032000130	Brand
SELECT-OB+DHA	*PRENATAL MV W/FE POLY-FA CHW 29-1 MG & DHA CAP 250 MG PAK *	78516032006325	Brand
PRENATAL VITAMINS AND MINERALS/DHA	*PRENATAL MV & MIN W/FE SULF-FA-DHA CAP 27-0.8-200 MG***	78516033000120	Generic
ULTRA PRENATAL + DHA	*PRENATAL MV & MIN W/FE SULF-FA-DHA CAP 27-0.8-200 MG***	78516033000120	Brand
PRENAISSANCE PLUS	*PRENATAL W/O A W/FE CBN-DSS-FA-DHA CAP 28-1-250 MG***	78516035000130	Brand
PNV-DHA+DOCUSATE	*PRENATAL W/O VIT A W/ FE FUM-DSS-FA-DHA CAP 27-1.25-300 MG*	78516037000138	Generic
TARON-PREX	*PRENATAL W/O VIT A W/ FE FUM-DSS-FA-DHA CAP 30-1.2-265 MG**	78516037000140	Brand
PRENAISSANCE	*PRENATAL W/O VIT A W/ FE FUM-DSS-FA-DHA CAP 29-1.25-325 MG*	78516037000170	Brand
CITRANATAL DHA	*PRENAT W/O A W/FECBN-FEGL-DSS-FA TAB & DHA CAP 250 MG PACK*	78516040006327	Brand
CITRANATAL ASSURE	*PRENAT W/O A W/FECBN-FEGL-DSS-FA TAB & DHA CAP 300 MG PACK*	78516040006340	Brand
CITRANATAL BLOOM DHA	*PRENAT W/O A W/FECBN-FEGL-DSS-FA TAB 90 &DHA CAP 300MG PAK*	78516040006370	Brand

CITRANATAL 90 DHA	*PRENAT W/O A W/FECBN-FEGL-DSS-FA TAB 90 &DHA CAP 300MG PAK*	78516040006370	Brand
CITRANATAL ESSENCE	*PRENAT W/O A W/FECBN-FEGL-FA TAB 35-1 & DHA CAP 300 MG PAK*	7851604100B120	Brand
PRENATE MINI	*PRENAT W/OA W/FECB-FEASP-METH-FA-DHA CAP 18-0.6-0.4-350 MG*	78516042000125	Brand
CITRANATAL HARMONY	*PRENAT W/O A W/FE FUM-FE CBN-DSS-FA-DHA CAP 27-1-260 MG***	78516047000130	Brand
CITRANATAL MEDLEY	*PRENAT W/O A W/FE FUM-FE CBN-FA-DHA CAP 27-1-200 MG***	78516048000120	Brand
VITAFOL ULTRA	*PRENAT W/FE POLY-METHYLFOL-FA-DHA CAP 29-0.6-0.4-200 MG***	78516058000130	Brand
VITAFOL FE+	*PRENAT W/FE POLY-METHYLFOL-FA-DHA CAP 90-0.6-0.4-200 MG***	78516058000145	Brand
OBSTETRIX ONE	*PRENAT W/O A W/FECBN-BISG-METHYLF-DSS-DHA CAP 38-1-225 MG**	78516060000145	Brand
NESTABS ONE	*PRENAT W/O A W/FECBN-BISG-METHYLF-DHA CAP 38-1-225 MG**	78516061000145	Brand
PRENA 1 TRUE	*PRENAT W/O A W/FE CHEL-FA TAB 30-1.4 MG & DHA CAP 300MG PK*	78516069006340	Brand

**Approval Criteria**

1 - History of failure, contraindication, or intolerance to ALL of the following preferred products:\*

Notes	*Please refer to the background table for the alternatives
-------	--

**2 . Background**

Benefit/Coverage/Program Information			
<b>Preferred Products:</b>			
GPI-14	Product ID	Product Label	GPI-14 Description
785120000003 15	7331710500 9	PRENATVITE TA B RX	*PRENATAL MULTIVITAMINS & MINERALS W/IRON & FA TAB 0.8 MG***

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

785120100003 30	6954302679 0	PNV TABS TAB 29-1MG	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***
785120100003 30	6025801930 9	PRENATABS RX TAB	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***
785120100003 30	4293707051 0	PRENATAL+FE T AB 29-1MG	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***
785120100003 30	4293707051 6	PRENATAL+FE T AB 29-1MG	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***
785120100003 30	4293707051 8	PRENATAL+FE T AB 29-1MG	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***
785120100003 30	5865701339 0	THRIVITE RX TAB 29-1MG	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***
785120100003 30	7118600192 4	VIL-RX TAB 29-1MG	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***
785120100003 30	1381105169 0	VOL-TAB RX TAB	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 29-1 MG***
785120100003 52	1381100271 0	ELITE-OB TAB	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 50-1.25 MG***
785120100003 52	6802500101 0	OB COMPLETE TAB	*PRENATAL VIT W/ IRON CARBONYL-FA TAB 50-1.25 MG***
785120150003 24	5865701700 1	M-NATAL PLUS TAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	1283008000 1	M-VIT TAB 27- 1MG	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	7089802200 1	NEONATAL TAB COMPLTE	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	7089801150 1	NEONATAL PLS TAB 27-1MG	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	7583400500 1	NIVA-PLUS TAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	0081393160 1	O-CAL FA TAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

785120150003 24	7139962460 9	ONE VITE TAB 1MG PLUS	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	3932801061 0	PRENATAL TAB 27-1MG	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	3932801065 0	PRENATAL TAB 27-1MG	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	6304401500 1	PRENATAL VIT TAB LOW IRON	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	6304401500 5	PRENATAL VIT TAB LOW IRON	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	6954302581 0	PREPLUS TAB 27-1MG	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	6954302585 0	PREPLUS TAB 27-1MG	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	6711201010 0	TRICARE TAB PRENATAL	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	1713908003 0	VITATHELY TAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	1381105191 0	VOL-PLUS TAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	1381105195 0	VOL-PLUS TAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 24	6936702670 1	WESTAB PLUS TAB 27- 1MG	*PRENATAL VIT W/ FE FUMARATE-FA TAB 27-1 MG***
785120150003 29	6025801920 1	TRINATE TAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-1 MG***
785120150003 29	1381105141 0	VOL-NATE TAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 28-1 MG***
785120150003 32	1026722700 1	CO-NATAL FA TAB 29-1MG	*PRENATAL VIT W/ FE FUMARATE-FA TAB 29-1 MG***
785120150003 32	7331782860 1	NEONATAL TAB COMPLETE	*PRENATAL VIT W/ FE FUMARATE-FA TAB 29-1 MG***



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

785120150003 32	6954302591 0	PRETAB TAB 29-1MG	*PRENATAL VIT W/ FE FUMARATE-FA TAB 29-1 MG***
785120150003 60	1381100071 0	TRINATAL RX TAB 1	*PRENATAL VIT W/ FE FUMARATE-FA TAB 60-1 MG***
785120150003 60	5199105660 1	VINATE ONE TAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 60-1 MG***
785120150003 66	5860708112 0	MYNATAL PLUS TAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 65-1 MG***
785120150003 66	5860701056 5	MYNATAL-Z TAB	*PRENATAL VIT W/ FE FUMARATE-FA TAB 65-1 MG***
785120150003 66	0064200791 2	VITAFOL-OB TAB 65-1MG	*PRENATAL VIT W/ FE FUMARATE-FA TAB 65-1 MG***
785120150005 30	1381100149 0	COMPLETENATE CHW	*PRENATAL VIT W/ FE FUMARATE-FA CHEW TAB 29-1 MG***
785120150005 30	4293707071 0	PRENATAL 19 CHW 29-1MG	*PRENATAL VIT W/ FE FUMARATE-FA CHEW TAB 29-1 MG***
785120150005 30	4293707071 6	PRENATAL 19 CHW 29-1MG	*PRENATAL VIT W/ FE FUMARATE-FA CHEW TAB 29-1 MG***
785120150005 30	4293707071 8	PRENATAL 19 CHW 29-1MG	*PRENATAL VIT W/ FE FUMARATE-FA CHEW TAB 29-1 MG***
785120150005 30	6025801970 1	PRENATAL 19 CHW TAB	*PRENATAL VIT W/ FE FUMARATE-FA CHEW TAB 29-1 MG***
785120150005 30	1392501170 1	SE-NATAL 19 CHW	*PRENATAL VIT W/ FE FUMARATE-FA CHEW TAB 29-1 MG***
785120160001 30	1381100493 0	ULTIMATECARE CAP ONE	*PRENATAL VIT W/ FE CBN-FE ASP GLYC-FA-OMEGA 3 CAP 27- 1MG***

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

7851201800011 6	2335901053 0	C-NATE DHA CAP 28-1- 200	*PRENATAL VIT W/ FE FUM-FA- OMEGA 3 CAP 28-1-200 MG***
7851201800011 6	2335902003 0	RELNATE DHA CAP	*PRENATAL VIT W/ FE FUM-FA- OMEGA 3 CAP 28-1-200 MG***
7851201800011 6	6954303703 0	VIRT-NATE CAP DHA	*PRENATAL VIT W/ FE FUM-FA- OMEGA 3 CAP 28-1-200 MG***
7851201800011 6	6466100803 0	VIVA DHA CAP	*PRENATAL VIT W/ FE FUM-FA- OMEGA 3 CAP 28-1-200 MG***
785120220003 20	6954302419 0	VIRT-PN TAB	*PRENATAL VIT W/ FE FUM- METHYLFOLATE-FA TAB 27-0.6- 0.4 MG***
785120460003 30	5549501250 1	ATABEX OB TAB 29-1MG	*PRENATAL VIT W/ FE BISGLYCINATE CHELATE-FA TAB 29-1 MG***
785120460003 30	5199101780 1	VINATE II TAB	*PRENATAL VIT W/ FE BISGLYCINATE CHELATE-FA TAB 29-1 MG***
785120510003 27	0017808589 0	CITRANATAL TA B RX	*PRENATAL W/O A W/ FE CARBONYL-FE GLUC-DSS-FA TAB 27-1MG***
785120580001 50	5274706203 0	CONCEPT OB CAP	*PRENATAL W/O A W/FE FUM-FE POLY-FA CAP 130-92.4-1 MG***
785120580001 50	1381105353 0	FOLIVANE- OB CAP	*PRENATAL W/O A W/FE FUM-FE POLY-FA CAP 130-92.4-1 MG***
785120600003 25	5199101550 1	VINATE M TAB	*PRENATAL VIT W/ SEL-FE FUMARATE-FA TAB 27-1 MG***
785120700003 30	4293707061 0	PRENATAL 19 TAB 29-1MG	*PRENATAL VIT W/ DSS-FE FUMARATE-FA TAB 29-1 MG***
785120700003 30	4293707061 6	PRENATAL 19 TAB 29-1MG	*PRENATAL VIT W/ DSS-FE FUMARATE-FA TAB 29-1 MG***
785120700003 30	4293707061 8	PRENATAL 19 TAB 29-1MG	*PRENATAL VIT W/ DSS-FE FUMARATE-FA TAB 29-1 MG***

785120700003 30	1392501160 1	SE-NATAL 19 TAB	*PRENATAL VIT W/ DSS-FE FUMARATE-FA TAB 29-1 MG***
785120910001 35	5274706213 0	CONCEPT DHA CAP	*PRENATAL W/FE FUM-FE POLY - FA-OMEGA 3 CAP 53.5-38-1 MG***
785120910001 35	5865701213 0	DOTHELLE DHA CAP	*PRENATAL W/FE FUM-FE POLY - FA-OMEGA 3 CAP 53.5-38-1 MG***
785120910001 35	1381105363 0	TARON-C DHA CAP	*PRENATAL W/FE FUM-FE POLY - FA-OMEGA 3 CAP 53.5-38-1 MG***
785120910001 35	7643903313 0	VIRT-C DHA CAP	*PRENATAL W/FE FUM-FE POLY - FA-OMEGA 3 CAP 53.5-38-1 MG***
785160200063 30	0064200763 0	VITAFOL-OB PAK +DHA	*PRENATAL MV W/FE FUM-FA TAB 65-1 MG & DHA CAP 250 MG PACK *
785160320001 30	0064200703 0	VITAFOL- ONE CAP	*PRENATAL MV W/ FE POLYSAC CMPLX-FA-DHA CAP 29-1-200 MG***
785160320063 25	0064200753 0	SELECT- OB+ PAK DHA	*PRENATAL MV W/FE POLY-FA CHW 29-1 MG & DHA CAP 250 MG PAK *

### 3 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Northera



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140900
<b>Guideline Name</b>	Northera
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Northera			
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NORTHERA	DROXIDOPA CAP 100 MG	38700030000130	Brand
NORTHERA	DROXIDOPA CAP 200 MG	38700030000140	Brand
NORTHERA	DROXIDOPA CAP 300 MG	38700030000150	Brand

**Approval Criteria**

**1** - Diagnosis of symptomatic neurogenic orthostatic hypotension (nOH) as defined by ONE of the following when an upright position is assumed or when using a head-up tilt-table testing at an angle of at least 60 degrees:

- At least a 20 millimeters of mercury (mm Hg) fall in systolic pressure
- At least a 10 mm Hg fall in diastolic pressure

**AND**

**2** - nOH caused by ONE of the following:

- Primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, and pure autonomic failure)
- Dopamine beta-hydroxylase deficiency
- Non-diabetic autonomic neuropathy

**AND**

**3** - Diagnostic evaluation has excluded other causes associated with orthostatic hypotension (e.g., congestive heart failure, fluid restriction, malignancy)

**AND**

**4** - The patient has tried at least TWO of the following non-pharmacologic interventions:

- Discontinuation of drugs which can cause orthostatic hypotension [e.g., diuretics, antihypertensive medications (primarily sympathetic blockers), anti-anginal drugs (nitrates), alpha-adrenergic antagonists, and antidepressants]
- Raising the head of the bed 10 to 20 degrees
- Compression garments to the lower extremities or abdomen
- Physical maneuvers to improve venous return (e.g., regular modest-intensity exercise)
- Increased salt and water intake, if appropriate
- Avoiding precipitating factors (e.g., overexertion in hot weather, arising too quickly from supine to sitting or standing)

**AND**

**5** - No previous diagnosis of supine hypertension

**AND**

**6** - Prescribed by, or in consultation with, ONE of the following specialists:

- Cardiologist
- Neurologist
- Nephrologist

**AND**

**7** - History of failure (after a trial of at least 30 days), contraindication or intolerance to BOTH of the following medications:

- Florinef (fludrocortisone)
- ProAmatine (midodrine)

Product Name: Northera			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NORTHERA	DROXIDOPA CAP 100 MG	38700030000130	Brand
NORTHERA	DROXIDOPA CAP 200 MG	38700030000140	Brand
NORTHERA	DROXIDOPA CAP 300 MG	38700030000150	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Northera therapy			
<b>AND</b>			

**2** - Physiological countermeasures for neurogenic orthostatic hypotension (nOH) continue to be employed

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Nourianz



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140644
<b>Guideline Name</b>	Nourianz
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Nourianz			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NOURIANZ	ISTRADEFYLLINE TAB 20 MG	73401025000320	Brand
NOURIANZ	ISTRADEFYLLINE TAB 40 MG	73401025000340	Brand
<b>Approval Criteria</b>			



1 - Diagnosis of Parkinson's disease

**AND**

2 - Used as adjunctive treatment to levodopa/carbidopa in patients experiencing "off" episodes

**AND**

3 - History of failure, contraindication, or intolerance to TWO anti-Parkinson's disease therapies from the following adjunctive pharmacotherapy classes (trial must be from two different classes):

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)

Product Name: Nourianz			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NOURIANZ	ISTRADEFYLLINE TAB 20 MG	73401025000320	Brand
NOURIANZ	ISTRADEFYLLINE TAB 40 MG	73401025000340	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Nourianz therapy

**AND**

2 - Patient will continue to receive treatment with a carbidopa/levodopa-containing medication

## 2 . Revision History

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Nucala (mepolizumab)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-144082
<b>Guideline Name</b>	Nucala (mepolizumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	4/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Nucala			
Diagnosis	Severe Asthma		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML	4460405500D530	Brand
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE 100 MG/ML	4460405500E530	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of severe asthma

**AND**

**2** - Asthma is an eosinophilic phenotype as defined by **ONE** of the following:

- Baseline (pre-treatment) peripheral blood eosinophil level is greater than or equal to 150 cells/microliter
- Peripheral blood eosinophil levels were greater than or equal to 300 cells/microliter within the past 12 months

**AND**

**3** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting **ONE** of the following:

**3.1** Patient has had at least two or more asthma exacerbations requiring systemic corticosteroids (e.g., prednisone) within the past 12 months

**OR**

**3.2** Prior asthma-related hospitalization within the past 12 months

**AND**

**4** - Patient is currently being treated with **ONE** of the following unless there is a contraindication or intolerance to these medications (verified via paid pharmacy claims):

**4.1** Both of the following:

- High-dose inhaled corticosteroid (ICS) (e.g., greater than 500 mcg fluticasone propionate equivalent/day)
- Additional asthma controller medication (e.g., leukotriene receptor antagonist [e.g., montelukast], long-acting beta-2 agonist [LABA] [e.g., salmeterol], tiotropium)

**OR**

**4.2** One maximally-dosed combination ICS/LABA product (e.g., Advair [fluticasone propionate/salmeterol], Symbicort [budesonide/formoterol], Breo Ellipta [fluticasone/vilanterol])

**AND**

**5** - Age greater than or equal to 6 years

**AND**

**6** - Prescribed by or in consultation with **ONE** of the following:

- Pulmonologist
- Allergist/Immunologist

Product Name: Nucala			
Diagnosis	Severe Asthma		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML	4460405500D530	Brand
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE 100 MG/ML	4460405500E530	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy (e.g., reduction in exacerbations, improvement in forced expiratory volume in 1 second [FEV1], decreased use of rescue medications)

**AND**

**2** - Patient continues to be treated with an inhaled corticosteroid (ICS) (e.g., fluticasone, budesonide) with or without additional asthma controller medication (e.g., leukotriene receptor antagonist [e.g., montelukast], long-acting beta-2 agonist [LABA] [e.g., salmeterol], tiotropium) unless there is a contraindication or intolerance to these medications (verified via paid pharmacy claims)

**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Pulmonologist
- Allergist/Immunologist

**Product Name: Nucala**

Diagnosis	Chronic rhinosinusitis with nasal polyps (CRSwNP)
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML	4460405500D530	Brand
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE 100 MG/ML	4460405500E530	Brand

**Approval Criteria**

**1** - Patient is 18 years of age or older

**AND**

**2** - Submission of documentation (e.g., chart notes) confirming ONE of the following:

**2.1 ALL of the following:**

**2.1.1** Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) defined by ALL of the following:

**2.1.1.1** TWO or more of the following symptoms for greater than or equal to 12 weeks duration:

- Mucopurulent discharge
- Nasal obstruction and congestion
- Decreased or absent sense of smell
- Facial pressure or pain

**AND**

**2.1.1.2** ONE of the following:

- Evidence of inflammation on paranasal sinus examination or computed tomography (CT)
- Evidence of purulence coming from paranasal sinuses or ostiomeatal complex

**AND**

**2.1.1.3** The presence of nasal polyps

**AND**

**2.1.2** ONE of the following:

- Patient has required prior sino-nasal surgery
- Patient has required systemic corticosteroids in the previous 2 years

**AND**

**2.1.3** Patient has been unable to obtain symptom relief after trial of ALL of the following agents/classes of agents:

- Nasal saline irrigations
- Intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone, etc.)

- Antileukotriene agents (e.g., montelukast, zafirlukast, zileuton)

**OR**

**2.2** ALL of the following:

**2.2.1** Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP)

**AND**

**2.2.2** Patient is currently on Nucala therapy

**AND**

**3** - Patient will receive Nucala as add-on maintenance therapy in combination with intranasal corticosteroids

**AND**

**4** - Patient is NOT receiving Nucala in combination with another biologic medication [e.g., Xolair (omalizumab), Dupixent (dupilumab)]

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Otolaryngologist
- Allergist
- Pulmonologist

Product Name: Nucala	
Diagnosis	Chronic rhinosinusitis with nasal polyps (CRSwNP)
Approval Length	12 month(s)
Therapy Stage	Reauthorization



Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML	4460405500D530	Brand
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE 100 MG/ML	4460405500E530	Brand

**Approval Criteria**

1 - Submission of documentation (e.g., chart notes) confirming positive clinical response to Nucala therapy

**AND**

2 - Patient will continue to receive Nucala as add-on maintenance therapy in combination with intranasal corticosteroids

**AND**

3 - Patient is NOT receiving Nucala in combination with another biologic medication [e.g., Xolair (omalizumab), Dupixent (dupilumab)]

**AND**

4 - Prescribed by or in consultation with ONE of the following:

- Otolaryngologist
- Allergist
- Pulmonologist

Product Name: Nucala	
Diagnosis	Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML	4460405500D530	Brand
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE 100 MG/ML	4460405500E530	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA)

**AND**

2 - Patient's disease has relapsed or is refractory to standard of care therapy (i.e., corticosteroid treatment with or without immunosuppressive therapy)

**AND**

3 - Patient is currently receiving corticosteroid therapy (e.g., prednisolone, prednisone)

**AND**

4 - Prescribed by or in consultation with ONE of the following:

- Pulmonologist
- Rheumatologist
- Allergist/Immunologist

Product Name: Nucala	
Diagnosis	Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML	4460405500D530	Brand
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE 100 MG/ML	4460405500E530	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy (e.g., increase in remission time)

**Product Name: Nucala**

Diagnosis	Hypereosinophilic Syndrome (HES)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML	4460405500D530	Brand
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE 100 MG/ML	4460405500E530	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of hypereosinophilic syndrome (HES)

**AND**

2 - Patient has been diagnosed for at least 6 months

**AND**

**3** - Verification that other non-hematologic secondary causes have been ruled out (e.g., drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy)

**AND**

**4** - Patient is Fip1-like1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFR $\alpha$ )-negative

**AND**

**5** - Patient has uncontrolled HES defined as BOTH of the following:

- History of 2 or more flares within the past 12 months
- Pre-treatment blood eosinophil count greater than or equal to 1000 cells/microliter

**AND**

**6** - Trial and failure, contraindication, or intolerance to ONE of the following:

- Corticosteroid therapy (e.g., prednisone)
- Cytotoxic/immunosuppressive therapy (e.g., hydroxyurea, cyclosporine, imatinib)

**AND**

**7** - Prescribed by or in consultation with ONE of the following:

- Allergist/Immunologist
- Hematologist

Product Name: Nucala	
Diagnosis	Hypereosinophilic Syndrome (HES)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML	4460405500D530	Brand
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE 100 MG/ML	4460405500E530	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy (e.g., reduction in flares, decreased blood eosinophil count, reduction in corticosteroid dose)

**2 . Background**

**Clinical Practice Guidelines**

The Global Initiative for Asthma Global Strategy for Asthma Management and Prevention: Table 1. Low, medium and high daily doses of inhaled corticosteroids in adolescents and adults 12 years and older

Inhaled corticosteroid	Total Daily ICS Dose (mcg)		
	Low	Medium	High
Beclometasone dipropionate (pMDI, standard particle, HFA)	200-500	> 500-1000	> 1000
Beclometasone dipropionate (pMDI, extrafine particle*, HFA)	100-200	> 200-400	> 400
Budesonide (DPI)	200-400	> 400-800	> 800
Ciclesonide (pMDI, extrafine particle*, HFA)	80-160	> 160-320	> 320
Fluticasone furoate (DPI)	100		200
Fluticasone propionate (DPI)	100-250	> 250-500	> 500

Fluticasone propionate (pMDI, standard particle, HFA)	100-250	> 250-500	> 500
Mometasone furoate (DPI)	200		400
Mometasone furoate (pMDI, standard particle, HFA)	200-400		> 400
<p>DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; ICS: inhaled corticosteroid; N/A: not applicable; pMDI: pressurized metered dose inhaler (non-chlorofluorocarbon formulations); ICS by pMDI should be preferably used with a spacer *See product information.</p> <p><b><i>This is not a table of equivalence</i></b>, but instead, suggested total daily doses for the 'low', 'medium' and 'high' dose ICS options for adults/adolescents, based on available studies and product information. Data on comparative potency are not readily available and therefore this table does NOT imply potency equivalence. Doses may be country -specific depending on local availability, regulatory labelling and clinical guidelines.</p> <p>For new preparations, including generic ICS, the manufacturer's information should be reviewed carefully; products containing the same molecule may not be clinically equivalent.</p>			

### 3 . Revision History

Date	Notes
3/11/2024	Updated criteria for CRSwNP. Removed GPIs 44604055002120 and 4460405500E520 due to being medical benefit. Minor cosmetic updates throughout guideline.

Nuedexta



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140645
<b>Guideline Name</b>	Nuedexta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Nuedexta			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NUDEXTA	DEXTROMETHORPHAN HBR-QUINIDINE SULFATE CAP 20-10 MG	62609902300120	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of pseudobulbar affect (PBA)			

## 2 . Revision History

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1



Nuplazid



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140646
<b>Guideline Name</b>	Nuplazid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Nuplazid			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NUPLAZID	PIMAVANSERIN TARTRATE CAP 34 MG (BASE EQUIVALENT)	59400028200120	Brand
NUPLAZID	PIMAVANSERIN TARTRATE TAB 10 MG (BASE EQUIVALENT)	59400028200310	Brand

**Approval Criteria**

1 - Diagnosis of Parkinson's disease

**AND**

2 - Patient is currently experiencing hallucinations and delusions associated with Parkinson's disease psychosis (i.e., hallucination and delusion symptoms started after Parkinson's disease diagnosis)

Product Name: Nuplazid			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NUPLAZID	PIMAVANSERIN TARTRATE CAP 34 MG (BASE EQUIVALENT)	59400028200120	Brand
NUPLAZID	PIMAVANSERIN TARTRATE TAB 10 MG (BASE EQUIVALENT)	59400028200310	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Nuplazid therapy			

**2 . Revision History**

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Nuzyra



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140701
<b>Guideline Name</b>	Nuzyra
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Nuzyra			
Diagnosis	Community-Acquired Bacterial Pneumonia		
Approval Length	14 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NUZYRA	OMADACYCLINE TOSYLATE TAB 150 MG (BASE EQUIVALENT)	04200050200320	Brand
<b>Approval Criteria</b>			

**1 - ONE of the following:**

**1.1** For continuation of therapy upon hospital discharge

**OR**

**1.2** As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

**1.3** ALL of the following:

**1.3.1** Diagnosis of community-acquired bacterial pneumonia (CABP)

**AND**

**1.3.2** Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Nuzyra

**AND**

**1.3.3** History of failure, contraindication, or intolerance to THREE of the following antibiotics or antibiotic regimens:

- Amoxicillin
- A macrolide
- Doxycycline
- A fluoroquinolone
- Combination therapy with amoxicillin/clavulanate or cephalosporin AND a macrolide or doxycycline

Product Name: Nuzyra	
Diagnosis	Acute Bacterial Skin and Skin Structure Infections
Approval Length	14 Day(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
NUZYRA	OMADACYCLINE TOSYLATE TAB 150 MG (BASE EQUIVALENT)	04200050200320	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 For continuation of therapy upon hospital discharge

**OR**

1.2 As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

1.3 ALL of the following:

1.3.1 ONE of the following diagnoses:

1.3.1.1 BOTH of the following:

- Acute bacterial skin and skin structure infections
- Infection caused by methicillin-resistant Staphylococcus aureus (MRSA) documented by culture and sensitivity report

**OR**

1.3.1.2 BOTH of the following:

- Empirical treatment of patients with acute bacterial skin and skin structure infections
- Presence of MRSA infection is likely

**AND**

1.3.2 History of failure, contraindication, or intolerance to linezolid (generic Zyvox)

**AND**

**1.3.3** History of failure, contraindication, or intolerance to ONE of the following antibiotics:

- Sulfamethoxazole-trimethoprim (SMZ-TMP)
- A tetracycline
- Clindamycin

**OR**

**1.4** ALL of the following:

**1.4.1** Diagnosis of acute bacterial skin and skin structure infections

**AND**

**1.4.2** Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Nuzyra

**AND**

**1.4.3** History of failure, contraindication, or intolerance to THREE of the following antibiotics:

- A penicillin
- A cephalosporin
- A tetracycline
- Sulfamethoxazole-trimethoprim (SMZ-TMP)
- Clindamycin

Product Name: Nuzyra			
Diagnosis		Off-Label Uses*	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic

NUZYRA	OMADACYCLINE TOSYLATE TAB 150 MG (BASE EQUIVALENT)	04200050200320	Brand
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 For continuation of therapy upon hospital discharge</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2 As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication</p> <p style="text-align: center;"><b>OR</b></p> <p>1.3 The medication is being prescribed by or in consultation with an infectious disease specialist.</p>			
Notes	*Note: Authorization duration based on provider treatment durations, not to exceed 6 months.		

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

OAB - Overactive Bladder Agents



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-148785
<b>Guideline Name</b>	OAB - Overactive Bladder Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

## 1 . Criteria

Product Name: darifenacin ER, Brand Ditropan XL, flavoxate, Gelnique, Gemtesa, Brand Myrbetriq tab, generic mirabegron ER tab, Myrbetriq granules, oxybutynin chloride sol, Oxytrol (Rx), trospium, trospium ER, Brand Vesicare, generic solifenacin, Vesicare LS, generic oxybutynin 2.5mg IR tablet			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DARIFENACIN HYDROBROMIDE ER	DARIFENACIN HYDROBROMIDE TAB ER 24HR 7.5 MG (BASE EQUIV)	54100010207520	Generic
DARIFENACIN HYDROBROMIDE ER	DARIFENACIN HYDROBROMIDE TAB ER 24HR 15 MG (BASE EQUIV)	54100010207530	Generic
DITROPAN XL	OXYBUTYNIN CHLORIDE TAB ER 24HR 5 MG	54100045207520	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DITROPAN XL	OXYBUTYNIN CHLORIDE TAB ER 24HR 10 MG	54100045207530	Brand
FLAVOXATE HCL	FLAVOXATE HCL TAB 100 MG	54400025100310	Generic
GELNIQUE	OXYBUTYNIN CHLORIDE TD GEL 10%	54100045204030	Brand
GEMTESA	VIBEGRON TAB 75 MG	54200080000320	Brand
MYRBETRIQ	MIRABEGRON GRANULES FOR ORAL EXTENDED RELEASE SUSP 8 MG/ML	5420005000G220	Brand
MYRBETRIQ	MIRABEGRON TAB ER 24 HR 25 MG	54200050007520	Brand
MYRBETRIQ	MIRABEGRON TAB ER 24 HR 50 MG	54200050007530	Brand
OXYTROL	OXYBUTYNIN TD PATCH TWICE WEEKLY 3.9 MG/24HR	54100045008720	Brand
TROSPIUM CHLORIDE	TROSPIUM CHLORIDE TAB 20 MG	54100065200320	Generic
TROSPIUM CHLORIDE ER	TROSPIUM CHLORIDE CAP ER 24HR 60 MG	54100065207020	Generic
VESICARE	SOLIFENACIN SUCCINATE TAB 5 MG	54100055200320	Brand
SOLIFENACIN SUCCINATE	SOLIFENACIN SUCCINATE TAB 5 MG	54100055200320	Generic
VESICARE	SOLIFENACIN SUCCINATE TAB 10 MG	54100055200330	Brand
SOLIFENACIN SUCCINATE	SOLIFENACIN SUCCINATE TAB 10 MG	54100055200330	Generic
VESICARE LS	SOLIFENACIN SUCCINATE SUSP 5 MG/5ML (1 MG/ML)	54100055201820	Brand
OXYBUTYNIN CHLORIDE	OXYBUTYNIN CHLORIDE SOLUTION 5 MG/5ML	54100045202010	Generic
OXYBUTYNIN CHLORIDE	OXYBUTYNIN CHLORIDE TAB 2.5 MG	54100045200310	Generic
MIRABEGRON ER	MIRABEGRON TAB ER 24 HR 25 MG	54200050007520	Generic
MIRABEGRON ER	MIRABEGRON TAB ER 24 HR 50 MG	54200050007530	Generic

**Approval Criteria**

**1** - The patient has a history of failure, contraindication, or intolerance to a trial of THREE preferred products:

- oxybutynin (generic Ditropan) 5 mg tablet
- oxybutynin ER (generic Ditropan XL)
- Brand Detrol
- Brand Detrol LA

- Brand Toviaz

**AND**

**2** - For oxybutynin solution requests ONLY, patient must have intolerance to oxybutynin syrup

## 2 . Revision History

Date	Notes
6/24/2024	Added generic mirabegron ER as target to the guideline. Removed B rand Enablex as a target (obsolete). Updated product name list and GPI table accordingly. Minor verbiage update in criterion 2 with no changes to clinical intent.

Ocaliva



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140901
<b>Guideline Name</b>	Ocaliva
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Ocaliva			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OCALIVA	OBETICHOLIC ACID TAB 5 MG	52750060000320	Brand
OCALIVA	OBETICHOLIC ACID TAB 10 MG	52750060000330	Brand
<b>Approval Criteria</b>			

**1 - Diagnosis of primary biliary cholangitis (aka primary biliary cirrhosis)**

**AND**

**2 - ONE of the following:**

**2.1 BOTH of the following:**

**2.1.1** Patient has failed to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal after at least 12 consecutive months of treatment with ursodeoxycholic acid(e.g., Urso, ursodiol)

**AND**

**2.1.2** Used in combination with ursodeoxycholic acid (e.g., Urso, ursodiol)

**OR**

**2.2** History of contraindication or intolerance to ursodeoxycholic acid (e.g., Urso, ursodiol)

**AND**

**3 - Prescribed by ONE of the following:**

- Hepatologist
- Gastroenterologist

Product Name: Ocaliva			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OCALIVA	OBETICHOLIC ACID TAB 5 MG	52750060000320	Brand

OCALIVA	OBETICHOLIC ACID TAB 10 MG	52750060000330	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., laboratory values) documenting a reduction in alkaline phosphatase (ALP) level from pre-treatment baseline (i.e., prior to Ocaliva therapy) while on Ocaliva therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by ONE of the following:</p> <ul style="list-style-type: none"> <li>• Hepatologist</li> <li>• Gastroenterologist</li> </ul>			

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Octreotide Products



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140960
<b>Guideline Name</b>	Octreotide Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Brand Sandostatin, generic octreotide, octreotide			
Diagnosis	Acromegaly		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Generic

SANDOSTATIN	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 50 MCG/ML	3017007010E505	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 100 MCG/ML	3017007010E510	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 500 MCG/ML	3017007010E520	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 200 MCG/ML (0.2 MG/ML)	30170070102015	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 1000 MCG/ML (1 MG/ML)	30170070102030	Generic

**Approval Criteria**

1 - Diagnosis of acromegaly

**AND**

2 - ONE of the following:

2.1 Inadequate response to ONE of the following:

- Surgery
- Pituitary irradiation

**OR**

2.2 Not a candidate for surgical resection or pituitary irradiation

**AND**

3 - Trial and failure, contraindication, or intolerance to a dopamine agonist (e.g., bromocriptine or cabergoline) at maximally tolerated doses

**AND**

**4** - If the request is for Brand Sandostatin, trial and failure, or intolerance to generic octreotide

Product Name: Mycapssa			
Diagnosis	Acromegaly		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYCAPSSA	OCTREOTIDE ACETATE CAP DELAYED RELEASE 20 MG	30170070106520	Brand

**Approval Criteria**

**1** - Diagnosis of acromegaly

**AND**

**2** - ONE of the following:

**2.1** Inadequate response to ONE of the following:

- Surgery
- Pituitary irradiation

**OR**

**2.2** Not a candidate for surgical resection or pituitary irradiation

**AND**



**3 - Patient has responded to and tolerated treatment with generic octreotide or lanreotide**

**Product Name: Brand Sandostatin, generic octreotide, octreotide, Mycapssa**

Diagnosis	Acromegaly
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 50 MCG/ML	3017007010E505	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 100 MCG/ML	3017007010E510	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 500 MCG/ML	3017007010E520	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 200 MCG/ML (0.2 MG/ML)	30170070102015	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 1000 MCG/ML (1 MG/ML)	30170070102030	Generic
MYCAPSSA	OCTREOTIDE ACETATE CAP DELAYED RELEASE 20 MG	30170070106520	Brand

**Approval Criteria**

**1 - Documentation of positive clinical response to therapy [e.g., reduction or normalization of IGF-1/GH (insulin-like growth factor-1/growth hormone) level for same age and sex, reduction in tumor size]**

Product Name: Brand Sandostatin, generic octreotide, octreotide	
Diagnosis	Carcinoid Tumors, for Symptomatic Treatment of Diarrhea or Flushing
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 50 MCG/ML	3017007010E505	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 100 MCG/ML	3017007010E510	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 500 MCG/ML	3017007010E520	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 200 MCG/ML (0.2 MG/ML)	30170070102015	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 1000 MCG/ML (1 MG/ML)	30170070102030	Generic

**Approval Criteria**

1 - Diagnosis of metastatic carcinoid tumor requiring symptomatic treatment of severe diarrhea or flushing episodes

**AND**

2 - If the request is for Brand Sandostatin, trial and failure, or intolerance to generic octreotide

Product Name: Brand Sandostatin, generic octreotide, octreotide	
Diagnosis	Carcinoid Tumors, for Symptomatic Treatment of Diarrhea or Flushing
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 50 MCG/ML	3017007010E505	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 100 MCG/ML	3017007010E510	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 500 MCG/ML	3017007010E520	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 200 MCG/ML (0.2 MG/ML)	30170070102015	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 1000 MCG/ML (1 MG/ML)	30170070102030	Generic

**Approval Criteria**

1 - Documentation of an improvement in the number of diarrhea or flushing episodes

Product Name: Brand Sandostatin, generic octreotide, octreotide	
Diagnosis	Vasoactive Intestinal Peptide Tumors, for Symptomatic Treatment of Diarrhea
Approval Length	12 month(s)

Therapy Stage		Initial Authorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 50 MCG/ML	3017007010E505	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 100 MCG/ML	3017007010E510	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 500 MCG/ML	3017007010E520	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 200 MCG/ML (0.2 MG/ML)	30170070102015	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 1000 MCG/ML (1 MG/ML)	30170070102030	Generic

**Approval Criteria**

**1** - Diagnosis of vasoactive intestinal peptide tumor requiring treatment of profuse watery diarrhea

**AND**

**2** - If the request is for Brand Sandostatin, trial and failure, or intolerance to generic octreotide

Product Name: Brand Sandostatin, generic octreotide, octreotide	
Diagnosis	Vasoactive Intestinal Peptide Tumors, for Symptomatic Treatment of Diarrhea

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 50 MCG/ML (0.05 MG/ML)	30170070102005	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 100 MCG/ML (0.1 MG/ML)	30170070102010	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Generic
SANDOSTATIN	OCTREOTIDE ACETATE INJ 500 MCG/ML (0.5 MG/ML)	30170070102020	Brand
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 50 MCG/ML	3017007010E505	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 100 MCG/ML	3017007010E510	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE SUBCUTANEOUS SOLN PREF SYR 500 MCG/ML	3017007010E520	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 200 MCG/ML (0.2 MG/ML)	30170070102015	Generic
OCTREOTIDE ACETATE	OCTREOTIDE ACETATE INJ 1000 MCG/ML (1 MG/ML)	30170070102030	Generic

**Approval Criteria**

1 - Documentation of an improvement in the number of diarrhea episodes

**2 . Revision History**

Date	Notes
2/7/2023	Updated product name lists, spelled out acronym, and updated T/F c riteria.

Ohtuvayre (ensifentrine)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157290
<b>Guideline Name</b>	Ohtuvayre (ensifentrine)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Ohtuvayre			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OHTUVAYRE	ENSIFENTRINE INHALATION SUSP 3 MG/2.5ML	44430020001820	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of chronic obstructive pulmonary disease (COPD)			

**AND**

**2** - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- Post-bronchodilator FEV1 % predicted greater than or equal to 30% and less than 80%
- Post-bronchodilator forced expiratory volume (FEV1) / forced vital capacity (FVC) ratio less than 0.7

**AND**

**3** - ONE of the following:

**3.1** BOTH of the following:

**3.1.1** Patient is on a stabilized dose and receiving concomitant therapy with ONE of the following (document name):

- A long-acting beta-agonist [LABA (e.g., Serevent Diskus)]
- A long-acting antimuscarinic agent [LAMA (e.g., Spiriva Respimat/HandiHaler)]
- A LABA/LAMA (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat)
- An ICS/LABA/LAMA (i.e., Breztri Aerosphere, Trelegy Ellipta)

**AND**

**3.1.2** ONE of the following:

**3.1.2.1** ALL of the following:

- FEV1 less than 50% of predicted
- History of chronic bronchitis
- History of failure, contraindication, or intolerance to a selective phosphodiesterase 4 (PDE4) inhibitor [i.e., roflumilast (Daliresp)]

**OR**

**3.1.2.2** FEV1 is less than 80% of predicted but greater than or equal to 50% of predicted

**OR**

**3.2 BOTH** of the following:

**3.2.1** Patient has a failure, contraindication, or intolerance to ALL of the following (document name and date tried):

- A long-acting beta-agonist [LABA (e.g., Serevent Diskus)]
- A long-acting antimuscarinic agent [LAMA (e.g., Spiriva Respimat/HandiHaler)]
- A LABA/LAMA (e.g., Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat)
- An ICS/LABA/LAMA (i.e., Breztri Aerosphere, Trelegy Ellipta)

**AND**

**3.2.2 ONE** of the following:

**3.2.2.1 ALL** of the following:

- FEV1 less than 50% of predicted
- History of chronic bronchitis
- History of failure, contraindication, or intolerance to a selective phosphodiesterase 4 (PDE4) inhibitor [i.e., roflumilast (Daliresp)]

**OR**

**3.2.2.2** FEV1 is less than 80% of predicted but greater than or equal to 50% of predicted

**OR**

**3.3 ALL** of the following:

**3.3.1** Patient is unable to use a metered-dose, dry powder, or slow mist inhaler (e.g. Spiriva Respimat) to control their COPD due to ONE of the following:

- Cognitive or physical impairment limiting coordination of handheld devices (e.g., cognitive decline, arthritis in the hands) (Document impairment)
- Patient is unable to generate adequate inspiratory force (e.g., peak inspiratory flow rate [PIFR] resistance is < 60 L/min)



**AND**

**3.3.2** Patient requires the use of BOTH of the following (document date):

- A nebulized LABA [i.e., arformoterol (generic Brovana), formoterol (generic Perforomist)]
- A nebulized long-acting antimuscarinic agent [LAMA (i.e.,Yupelri)]

**AND**

**3.3.3** ONE of the following:

**3.3.3.1** ALL of the following:

- FEV1 less than 50% of predicted
- History of chronic bronchitis
- History of failure, contraindication, or intolerance to a selective phosphodiesterase 4 (PDE4) inhibitors [i.e., roflumilast (Daliresp)]

**OR**

**3.3.3.2** FEV1 is less than 80% of predicted but greater than or equal to 50% of predicted

**AND**

**4** - Patient experiences dyspnea during everyday activities (e.g., short of breath when walking up a slight hill)

**AND**

**5** - Prescribed by or in consultation with a pulmonologist

Product Name: Ohtuvayre	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
OHTUVAYRE	ENSIFENTRINE INHALATION SUSP 3 MG/2.5ML	44430020001820	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Ohtuvayre therapy demonstrated by BOTH of the following:

- Improved COPD symptoms (e.g., dyspnea)
- Improved FEV1

**2 . Revision History**

Date	Notes
10/11/2024	New program.

Ojjaara (mometotinib)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-141017
<b>Guideline Name</b>	Ojjaara (mometotinib)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Ojjaara			
Diagnosis	Myelofibrosis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OJJAARA	MOMELOTINIB DIHYDROCHLORIDE TAB 100 MG	21537540300320	Brand
OJJAARA	MOMELOTINIB DIHYDROCHLORIDE TAB 150 MG	21537540300330	Brand
OJJAARA	MOMELOTINIB DIHYDROCHLORIDE TAB 200 MG	21537540300340	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting all of the following:

1.1 Diagnosis of one of the following:

- Primary myelofibrosis
- Post-polycythemia vera myelofibrosis
- Post-essential thrombocythemia myelofibrosis

**AND**

1.2 Disease is intermediate or high risk

**AND**

1.3 Patient has anemia

Product Name: Ojjaara			
Diagnosis	Myelofibrosis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OJJAARA	MOMELOTINIB DIHYDROCHLORIDE TAB 100 MG	21537540300320	Brand
OJJAARA	MOMELOTINIB DIHYDROCHLORIDE TAB 150 MG	21537540300330	Brand
OJJAARA	MOMELOTINIB DIHYDROCHLORIDE TAB 200 MG	21537540300340	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy (e.g., symptom improvement, spleen volume reduction)

## 2 . Revision History

Date	Notes
12/6/2023	New guideline

Olumiant



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140971
<b>Guideline Name</b>	Olumiant
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Olumiant 1mg and 2mg			
Diagnosis	Rheumatoid Arthritis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OLUMIANT	BARICITINIB TAB 1 MG	66603010000310	Brand
OLUMIANT	BARICITINIB TAB 2 MG	66603010000320	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming diagnosis of moderately to severely active rheumatoid arthritis

**AND**

**2** - Prescribed by or in consultation with a rheumatologist

**AND**

**3** - Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to ONE nonbiologic disease-modifying antirheumatic drug (DMARD) (e.g., methotrexate, leflunomide, sulfasalazine)

**AND**

**4** - ONE of the following:

**4.1** All of the following:

**4.1.1** Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to TWO of the following, or attestation demonstrating a trial may be inappropriate\*

- Humira (adalimumab)
- Enbrel (etanercept)
- Xeljanz (tofacitinib)

**AND**

**4.1.2** Paid claims or submission of medical records (e.g., chart notes) confirming trial and failure, contraindication, or intolerance to Orencia (abatacept)

**OR**

**4.2** Paid claims or submission of medical records (e.g., chart notes) confirming continuation of prior Olumiant therapy

**AND**

**5** - Not used in combination with other Janus kinase (JAK) inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)\*\*

Notes	*Includes attestation that a total of two TNF inhibitors have already been tried in the past, and the patient should not be made to try a third TNF inhibitor. **Olumiant may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).
-------	---

**Product Name: Olumiant 1mg and 2 mg**

Diagnosis	Rheumatoid Arthritis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
OLUMIANT	BARICITINIB TAB 1 MG	66603010000310	Brand
OLUMIANT	BARICITINIB TAB 2 MG	66603010000320	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to Olumiant therapy

**AND**

**2** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)\*\*

Notes	**Olumiant may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).
-------	--

**Product Name: Olumiant**



Diagnosis	Coronavirus disease 2019 (COVID-19)		
Approval Length	14 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OLUMIANT	BARICITINIB TAB 1 MG	66603010000310	Brand
OLUMIANT	BARICITINIB TAB 2 MG	66603010000320	Brand
OLUMIANT	BARICITINIB TAB 4 MG	66603010000340	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of COVID-19</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is hospitalized*</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient requires one of the following:</p> <ul style="list-style-type: none"> <li>• Supplemental oxygen</li> <li>• Non-invasive mechanical ventilation</li> <li>• Invasive mechanical ventilation</li> <li>• Extracorporeal membrane oxygenation (ECMO)</li> </ul>			
Notes	*Olumiant is only FDA approved when used for COVID 19 patients in an inpatient setting		

## 2 . Revision History

Date	Notes
5/2/2023	Updated Rheumatoid Arthritis section to remove 4mg strength per FF S clarification



Omnipod 5



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-147309
<b>Guideline Name</b>	Omnipod 5
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Omnipod 5			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OMNIPOD 5 G6 PODS (GEN 5)	*INSULIN INFUSION DISPOSABLE PUMP RESERVOIR***	97201030506300	Brand
OMNIPOD 5 G6 INTRO KIT (GEN 5)	*INSULIN INFUSION DISPOSABLE PUMP KIT***	97201030506400	Brand

OMNIPOD 5 G7 PODS (GEN 5)	*INSULIN INFUSION DISPOSABLE PUMP RESERVOIR***	97201030506300	Brand
OMNIPOD 5 G7 INTRO KIT (GEN 5)	*INSULIN INFUSION DISPOSABLE PUMP KIT***	97201030506400	Brand

**Approval Criteria**

1 - Diagnosis of diabetes

**AND**

2 - ALL of the following:

2.1 Patient has done ONE of the following for at least 8 weeks:

- Regularly tests blood glucose at least 4 times/day
- Utilizes a continuous glucose monitor (CGM)

**AND**

2.2 Patient has completed a diabetes management program

**AND**

2.3 Patient injects insulin at least 3 times/day

**AND**

3 - ONE of the following:

- Unexplained, nocturnal, or severe hypoglycemia
- Hypoglycemia unawareness
- Dawn phenomenon blood glucose greater than 200 mg/dL (milligrams/deciliter)
- Wide and unpredictable (erratic) swings in blood glucose levels
- Glycemic targets within individualized range but lifestyle requires increased flexibility of insulin pump use

- HbA1C greater than 7% or outside individualized targets

**AND**

**4 - BOTH** of the following:

**4.1** Patient or caregiver is motivated to assume responsibility for self-care and insulin management

**AND**

**4.2** Patient or caregiver demonstrates knowledge of importance of nutrition including carbohydrate counting and meal planning

**AND**

**5 -** Prescriber attests that there is a reason or special circumstance the patient cannot use external insulin pumps obtained on the medical benefit

Notes	If patient meets criteria, approve using NDC List OMNIPOD5
-------	--

Product Name: Omnipod 5			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OMNIPOD 5 G6 PODS (GEN 5)	*INSULIN INFUSION DISPOSABLE PUMP RESERVOIR***	97201030506300	Brand
OMNIPOD 5 G6 INTRO KIT (GEN 5)	*INSULIN INFUSION DISPOSABLE PUMP KIT***	97201030506400	Brand
OMNIPOD 5 G7 PODS (GEN 5)	*INSULIN INFUSION DISPOSABLE PUMP RESERVOIR***	97201030506300	Brand
OMNIPOD 5 G7	*INSULIN INFUSION DISPOSABLE PUMP KIT***	97201030506400	Brand

INTRO KIT (GEN 5)			
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response			
Notes	If patient meets criteria, approve using NDC List OMNIPOD5		

Product Name: Omnipod 5 G6 or G7 pods			
Approval Length	12 month(s)		
Guideline Type	Quantity Limit		
Product Name	Generic Name	GPI	Brand/Generic
OMNIPOD 5 G6 PODS (GEN 5)	*INSULIN INFUSION DISPOSABLE PUMP RESERVOIR***	97201030506300	Brand
OMNIPOD 5 G7 PODS (GEN 5)	*INSULIN INFUSION DISPOSABLE PUMP RESERVOIR***	97201030506300	Brand
<b>Approval Criteria</b>			
1 - Physician confirmation that the patient requires a greater quantity			
Notes	Authorization for quantity limit overrides should be entered at the NDC level for the requested Omnipod 5 G6 or G7 pods, for the requested quantity.		

## 2 . Revision History

Date	Notes
5/13/2024	Added Omnipod 5 G7 products.

OmvoH (mirikizumab-mrkz)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-149994
<b>Guideline Name</b>	OmvoH (mirikizumab-mrkz)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/1/2024
-----------------	----------

## 1 . Criteria

Product Name: OmvoH SC			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OMVOH	MIRIKIZUMAB-MRKZ SUBCUTANEOUS SOLN AUTO-INJECTOR 100 MG/ML	5250405040D520	Brand
OMVOH	MIRIKIZUMAB-MRKZ SUBCUTANEOUS SOL PREFILL SYRINGE 100 MG/ML	5250405040E520	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming a diagnosis of moderately to severely active ulcerative colitis

**AND**

2 - Will be used as a maintenance dose following the intravenous induction doses

**AND**

3 - Prescribed by or in consultation with a gastroenterologist

Product Name: Omvoh SC			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OMVOH	MIRIKIZUMAB-MRKZ SUBCUTANEOUS SOLN AUTO-INJECTOR 100 MG/ML	5250405040D520	Brand
OMVOH	MIRIKIZUMAB-MRKZ SUBCUTANEOUS SOL PREFILL SYRINGE 100 MG/ML	5250405040E520	Brand

**Approval Criteria**

1 - Patient demonstrates positive clinical response to therapy as evidenced by at least one of the following:

- Improvement in intestinal inflammation (e.g., mucosal healing, improvement of lab values [platelet counts, erythrocyte sedimentation rate, C-reactive protein level]) from baseline
- Reversal of high fecal output state

**2 . Revision History**



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
7/18/2024	Update to guideline name. Added new Omvoh SC prefilled syringe formulation as a target. No changes to criteria.

Onureg



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140860
<b>Guideline Name</b>	Onureg
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Onureg			
Diagnosis	Acute Myeloid Leukemia		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ONUREG	AZACITIDINE TAB 200 MG	21300003000320	Brand
ONUREG	AZACITIDINE TAB 300 MG	21300003000330	Brand

<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Acute Myeloid Leukemia</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Patient is not able to complete intensive curative therapy (e.g., transplant-ineligible)</p>
--

Product Name: Onureg			
Diagnosis	Acute Myeloid Leukemia		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ONUREG	AZACITIDINE TAB 200 MG	21300003000320	Brand
ONUREG	AZACITIDINE TAB 300 MG	21300003000330	Brand
<p><b>Approval Criteria</b></p> <p>1 - Patient does not show evidence of progressive disease while on Onureg therapy</p>			

Product Name: Onureg	
Diagnosis	NCCN Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ONUREG	AZACITIDINE TAB 200 MG	21300003000320	Brand
ONUREG	AZACITIDINE TAB 300 MG	21300003000330	Brand

**Approval Criteria**

1 - The use of Onureg is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium

**Product Name: Onureg**

Diagnosis	NCCN Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ONUREG	AZACITIDINE TAB 200 MG	21300003000320	Brand
ONUREG	AZACITIDINE TAB 300 MG	21300003000330	Brand

**Approval Criteria**

1 - There is documentation of positive clinical response to Onureg therapy

**2 . Revision History**

Date	Notes
1/21/2021	Copy of NY gl-79800 New Implementations

Opfolda



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-143582
<b>Guideline Name</b>	Opfolda
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/17/2024
-----------------	-----------

## 1 . Criteria

Product Name: Opfolda			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OPFOLDA	MIGLUSTAT (GAA DEFICIENCY) CAP 65 MG	30907760000120	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes) documenting all of the following:			

**1.1** Diagnosis of late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency)

**AND**

**1.2** Disease is confirmed by one of the following:

- Absence or deficiency (less than 40% of the lab specific normal mean) of GAA enzyme activity in lymphocytes, fibroblasts, or muscle tissues as confirmed by an enzymatic assay
- Molecular genetic testing confirms mutations in the GAA gene

**AND**

**1.3** Presence of clinical signs and symptoms of the disease (e.g., respiratory distress, skeletal muscle weakness, etc.)

**AND**

**1.4** Medication is used in combination with Pombiliti (cipaglucosidase alfa-atga)

**AND**

**1.5** Patient's weight is greater than or equal to 40 kg

**AND**

**2** - Opfolda is not substituted with other miglustat products (i.e., Zavesca, Yargesa)

Product Name: Opfolda	
Approval Length	24 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
OPFOLDA	MIGLUSTAT (GAA DEFICIENCY) CAP 65 MG	30907760000120	Brand

**Approval Criteria**

1 - Patient demonstrates positive clinical response to therapy (e.g., improvement in FVC, improvement in 6-minute walk distance [6MWD])

**AND**

2 - Medication is used in combination with Pombiliti (cipaglucosidase alfa-atga)

**AND**

3 - Opfolda is not substituted with other miglustat products (i.e., Zavesca, Yargesa)

**2 . Revision History**

Date	Notes
2/26/2024	New

Ophthalmic Antihistamine



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140759
<b>Guideline Name</b>	Ophthalmic Antihistamine
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2023
-----------------	----------

### 1 . Criteria

Product Name: azelastine ophth soln			
Approval Length	12 month(s)		
Guideline Type	Step Therapy		
Product Name	Generic Name	GPI	Brand/Generic
AZELASTINE HCL	AZELASTINE HCL OPHTH SOLN 0.05%	86802006102020	Generic
AZELASTINE HYDROCHLORIDE	AZELASTINE HCL OPHTH SOLN 0.05%	86802006102020	Generic
<b>Approval Criteria</b>			



**1** - Failure to Pataday OTC (over-the-counter), as confirmed by claims history or submission of medical records

**OR**

**2** - History of contraindication or intolerance to Pataday OTC (please specify contraindication or intolerance)

Product Name: olopatadine ophth soln (Rx formulation)

Approval Length | 12 month(s)

Guideline Type | Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
OLOPATADINE HYDROCHLORIDE	OLOPATADINE HCL OPHTH SOLN 0.1% (BASE EQUIVALENT)	86802065102020	Generic
OLOPATADINE HCL	OLOPATADINE HCL OPHTH SOLN 0.1% (BASE EQUIVALENT)	86802065102020	Generic
OLOPATADINE HYDROCHLORIDE	OLOPATADINE HCL OPHTH SOLN 0.2% (BASE EQUIVALENT)	86802065102030	Generic

**Approval Criteria**

**1** - ONE of the following:

**1.1** Failure to Pataday OTC (over-the-counter), as confirmed by claims history or submission of medical records

**OR**

**1.2** History of contraindication or intolerance to Pataday OTC (please specify contraindication or intolerance)

**AND**

**2** - ONE of the following:

**2.1** Failure to ONE of the following, as confirmed by claims history or submission of medical records:

- Azelastine ophthalmic solution
- Ketotifen
- Cromolyn

**OR**

**2.2** History of contraindication or intolerance to ALL of the following (please specify contraindication or intolerance):

- Azelastine ophthalmic solution
- Ketotifen
- Cromolyn

Opzelura (ruxolitinib)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-160510
<b>Guideline Name</b>	Opzelura (ruxolitinib)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Opzelura			
Diagnosis	Atopic Dermatitis		
Approval Length	12 Week(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OPZELURA	RUXOLITINIB PHOSPHATE CREAM 1.5%	90272060503720	Brand
<b>Approval Criteria</b>			

**1** - Diagnosis of mild to moderate atopic dermatitis

**AND**

**2** - ONE of the following:

- Greater than or equal to 3% body surface area (BSA) involvement
- Involvement of sensitive body areas (e.g., face, hands, feet, scalp, groin)

**AND**

**3** - Patient is 12 years of age or older

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Dermatologist
- Allergist/Immunologist

**AND**

**5** - Trial and failure of a minimum 30-day supply of non-pharmacologic topical therapies (e.g., moisturizers)

**AND**

**6** - Trial and failure of a minimum 30-day supply (14-day supply for topical corticosteroids), contraindication, or intolerance to at least TWO of the following:

- Medium or higher potency topical corticosteroid
- Elidel (pimecrolimus) cream\*
- Tacrolimus ointment
- Eucrisa (crisaborole) ointment\*

**AND**

**7** - Patient is NOT receiving Opzelura in combination with a potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

**8** - Opzelura will only be used for short-term and/or non-continuous chronic treatment

Notes	*Product may require step therapy.
-------	------------------------------------

Product Name: Opzelura			
Diagnosis	Atopic Dermatitis		
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OPZELURA	RUXOLITINIB PHOSPHATE CREAM 1.5%	90272060503720	Brand

**Approval Criteria**

**1** - Documentation of a positive clinical response to therapy as evidenced by at least ONE of the following:

- Reduction in body surface area involvement from baseline
- Reduction in pruritus severity from baseline
- Improvement in quality of life from baseline

**AND**

**2** - Patient is NOT receiving Opzelura in combination with a potent immunosuppressant (e.g., azathioprine or cyclosporine)

**AND**

**3** - Opzelura will only be used for short-term and/or non-continuous chronic treatment

Product Name: Opzelura			
Diagnosis	Nonsegmental Vitiligo		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OPZELURA	RUXOLITINIB PHOSPHATE CREAM 1.5%	90272060503720	Brand

**Approval Criteria**

**1** - Request for coverage for diagnosis of nonsegmental vitiligo is excluded and is to be denied as a benefit exclusion

**2 . Background**

Clinical Practice Guidelines			
Table 1. Relative potencies of topical corticosteroids			
Class	Drug	Dosage Form	Strength (%)
Very high potency	Augmented betamethasone dipropionate	Ointment, gel	0.05
	Clobetasol propionate	Cream, foam, ointment	0.05
	Diflorasone diacetate	Ointment	0.05
	Halobetasol propionate	Cream, ointment	0.05
	Amcinonide	Cream, lotion, ointment	0.1

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

High Potency	Augmented betamethasone dipropionate	Cream, lotion	0.05
	Betamethasone dipropionate	Cream, foam, ointment, solution	0.05
	Desoximetasone	Cream, ointment	0.25
	Desoximetasone	Gel	0.05
	Diflorasone diacetate	Cream	0.05
	Fluocinonide	Cream, gel, ointment, solution	0.05
	Halcinonide	Cream, ointment	0.1
	Mometasone furoate	Ointment	0.1
	Triamcinolone acetonide	Cream, ointment	0.5
Medium potency	Betamethasone valerate	Cream, foam, lotion, ointment	0.1
	Clocortolone pivalate	Cream	0.1
	Desoximetasone	Cream	0.05
	Fluocinolone acetonide	Cream, ointment	0.025
	Flurandrenolide	Cream, ointment, lotion	0.05
	Fluticasone propionate	Cream	0.05
	Fluticasone propionate	Ointment	0.005
	Mometasone furoate	Cream, lotion	0.1
Triamcinolone acetonide	Cream, ointment, lotion	0.1	
Lower- medium potency	Hydrocortisone butyrate	Cream, ointment, solution	0.1
	Hydrocortisone probutate	Cream	0.1
	Hydrocortisone valerate	Cream, ointment	0.2
	Prednicarbate	Cream	0.1
Low potency	Alclometasone dipropionate	Cream, ointment	0.05
	Desonide	Cream, gel, foam, ointment	0.05

	Fluocinolone acetonide	Cream, solution	0.01
Lowest potency	Dexamethasone	Cream	0.1
	Hydrocortisone	Cream, lotion, ointment, solution	0.25, 0.5, 1
	Hydrocortisone acetate	Cream, ointment	0.5-1

### 3 . Revision History

Date	Notes
11/12/2024	Update to guideline name. For AD (initial auth), updated notes section. Added section to indicate nonsegmental vitiligo is a benefit exclusion. Minor cosmetic updates.



Oral Oncology Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-159373
<b>Guideline Name</b>	Oral Oncology Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Akeega, Alecensa, Alunbrig, Augtyro, Ayvakit, Balversa, Bosulif, Braftovi, Brukinsa, Cabometyx, Calquence, Caprelsa, Cometriq, Copiktra, Cotellic, Daurismo, Erivedge, Erleada, etoposide capsules, Fruzaqla, Gavreto, Gilotrif, Hycamtin capsules, Ibrance, Iclusig, Idhifa, Imbruvica, Inlyta, Inrebic, Brand Iressa, generic gefitinib, Iwifin, Jakafi, Jaypirca, Jylamvo, Kisqali, Kisqali-Femara Co-pack, Koselugo, Krazati, Lazcluze, Lenvima, Lonsurf, Lorbrina, Lumakras, Lynparza, Lytgobi, Mekinist, Mektovi, Nerlynx, Brand Nexavar, generic sorafenib, Ninlaro, Nubeqa, Odomzo, Ogsiveo, Ojemda, Orserdu, Pemazyre, Piqray, Pomalyst, Qinlock, Retevmo, Rezlidhia, Rozlytrek, Rubraca, Rydapt, Scemblix, Brand Sprycel, generic dasatinib, Stivarga, Tavegyl, Tavegyl, Tafinlar, Tagrisso, Talzena, Brand Tarceva, generic erlotinib, Tassigna, Tazverik, Brand Temodar capsules, generic temozolomide capsules, Tepmetko, Tibsovo, Truqap, Tukysa, Turalio, Brand Tykerb, generic lapatinib, Vanflyta, Venclexta, Verzenio, Vitrakvi, Vizimpro, Voranigo, Votrient, Welireg, Xalkori, Xatmep, Brand Xeloda, generic capecitabine, Xospata, Xpovio, Xtandi, Yonsa, Zejula, Zelboraf, Zolinza, Zydelig, Zykadia, Brand Zytiga, generic abiraterone	
Diagnosis	Cancer Indications
Approval Length	12 month(s)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
NINLARO	IXAZOMIB CITRATE CAP 2.3 MG (BASE EQUIVALENT)	21536045100120	Brand
NINLARO	IXAZOMIB CITRATE CAP 3 MG (BASE EQUIVALENT)	21536045100130	Brand
NINLARO	IXAZOMIB CITRATE CAP 4 MG (BASE EQUIVALENT)	21536045100140	Brand
TIBSOVO	IVOSIDENIB TAB 250 MG	21534940000320	Brand
RUBRACA	RUCAPARIB CAMSYLATE TAB 200 MG (BASE EQUIVALENT)	21535570200320	Brand
RUBRACA	RUCAPARIB CAMSYLATE TAB 250 MG (BASE EQUIVALENT)	21535570200325	Brand
RUBRACA	RUCAPARIB CAMSYLATE TAB 300 MG (BASE EQUIVALENT)	21535570200330	Brand
ZEJULA	NIRAPARIB TOSYLATE CAP 100 MG (BASE EQUIVALENT)	21535550200120	Brand
MEKINIST	TRAMETINIB DIMETHYL SULFOXIDE TAB 0.5 MG (BASE EQUIVALENT)	21533570100310	Brand
MEKINIST	TRAMETINIB DIMETHYL SULFOXIDE TAB 2 MG (BASE EQUIVALENT)	21533570100330	Brand
TAFINLAR	DABRAFENIB MESYLATE CAP 50 MG (BASE EQUIVALENT)	21532025100120	Brand
TAFINLAR	DABRAFENIB MESYLATE CAP 75 MG (BASE EQUIVALENT)	21532025100130	Brand
CALQUENCE	ACALABRUTINIB CAP 100 MG	21532103000120	Brand
CALQUENCE	ACALABRUTINIB MALEATE TAB 100 MG	21532103500320	Brand
NUBEQA	DAROLUTAMIDE TAB 300 MG	21402425000320	Brand
RETEVMO	SELPERCATINIB CAP 40 MG	21535779000120	Brand
RETEVMO	SELPERCATINIB CAP 80 MG	21535779000140	Brand
GAVRETO	PRALSETINIB CAP 100 MG	21535750000120	Brand
TALZENNA	TALAZOPARIB TOSYLATE CAP 0.25 MG (BASE EQUIVALENT)	21535580400110	Brand
TALZENNA	TALAZOPARIB TOSYLATE CAP 0.5 MG (BASE EQUIVALENT)	21535580400114	Brand
TALZENNA	TALAZOPARIB TOSYLATE CAP 0.75 MG (BASE EQUIVALENT)	21535580400118	Brand
TALZENNA	TALAZOPARIB TOSYLATE CAP 1 MG (BASE EQUIVALENT)	21535580400120	Brand
LYNPARZA	OLAPARIB TAB 100 MG	21535560000330	Brand
LYNPARZA	OLAPARIB TAB 150 MG	21535560000340	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

IDHIFA	ENASIDENIB MESYLATE TAB 50 MG (BASE EQUIVALENT)	21535030200320	Brand
IDHIFA	ENASIDENIB MESYLATE TAB 100 MG (BASE EQUIVALENT)	21535030200340	Brand
VITRAKVI	LAROTRECTINIB SULFATE CAP 25 MG (BASE EQUIVALENT)	21533835200120	Brand
VITRAKVI	LAROTRECTINIB SULFATE CAP 100 MG (BASE EQUIVALENT)	21533835200150	Brand
VITRAKVI	LAROTRECTINIB SULFATE ORAL SOLN 20 MG/ML (BASE EQUIVALENT)	21533835202020	Brand
ROZLYTREK	ENTRECTINIB CAP 100 MG	21533820000120	Brand
ROZLYTREK	ENTRECTINIB CAP 200 MG	21533820000130	Brand
TEPMETKO	TEPOTINIB HCL TAB 225 MG	21533773100320	Brand
TABRECTA	CAPMATINIB HCL TAB 150 MG	21533716200320	Brand
TABRECTA	CAPMATINIB HCL TAB 200 MG	21533716200330	Brand
KOSELUGO	SELUMETINIB SULFATE CAP 10 MG	21533565500110	Brand
KOSELUGO	SELUMETINIB SULFATE CAP 25 MG	21533565500125	Brand
COTELLIC	COBIMETINIB FUMARATE TAB 20 MG (BASE EQUIVALENT)	21533530200320	Brand
MEKTOVI	BINIMETINIB TAB 15 MG	21533520000320	Brand
ALUNBRIG	BRIGATINIB TAB INITIATION THERAPY PACK 90 MG & 180 MG	2153051000B720	Brand
ALUNBRIG	BRIGATINIB TAB 30 MG	21530510000330	Brand
ALUNBRIG	BRIGATINIB TAB 90 MG	21530510000350	Brand
ALUNBRIG	BRIGATINIB TAB 180 MG	21530510000365	Brand
AYVAKIT	AVAPRITINIB TAB 25 MG	21490009000310	Brand
AYVAKIT	AVAPRITINIB TAB 50 MG	21490009000315	Brand
AYVAKIT	AVAPRITINIB TAB 100 MG	21490009000320	Brand
AYVAKIT	AVAPRITINIB TAB 200 MG	21490009000330	Brand
AYVAKIT	AVAPRITINIB TAB 300 MG	21490009000340	Brand
BALVERSA	ERDAFITINIB TAB 3 MG	21532225000320	Brand
BALVERSA	ERDAFITINIB TAB 4 MG	21532225000325	Brand
BALVERSA	ERDAFITINIB TAB 5 MG	21532225000330	Brand
BOSULIF	BOSUTINIB TAB 100 MG	21531812000320	Brand
BOSULIF	BOSUTINIB TAB 400 MG	21531812000327	Brand
BOSULIF	BOSUTINIB TAB 500 MG	21531812000340	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BRAFTOVI	ENCORAFENIB CAP 75 MG	21532040000130	Brand
BRUKINSA	ZANUBRUTINIB CAP 80 MG	21532195000120	Brand
CABOMETYX	CABOZANTINIB S-MALATE TAB 20 MG (BASE EQUIVALENT)	21533010100320	Brand
CABOMETYX	CABOZANTINIB S-MALATE TAB 40 MG (BASE EQUIVALENT)	21533010100330	Brand
CABOMETYX	CABOZANTINIB S-MALATE TAB 60 MG (BASE EQUIVALENT)	21533010100340	Brand
COMETRIQ	CABOZANTINIB S-MALATE CAP 3 X 20 MG (60 MG DOSE) KIT	21533010106460	Brand
COMETRIQ	CABOZANTINIB S-MAL CAP 1 X 80 MG & 1 X 20 MG (100 DOSE) KIT	21533010106470	Brand
COMETRIQ	CABOZANTINIB S-MAL CAP 1 X 80 MG & 3 X 20 MG (140 DOSE) KIT	21533010106480	Brand
COPIKTRA	DUVELISIB CAP 15 MG	21538030000120	Brand
COPIKTRA	DUVELISIB CAP 25 MG	21538030000130	Brand
DAURISMO	GLASDEGIB MALEATE TAB 25 MG (BASE EQUIVALENT)	21370030300320	Brand
DAURISMO	GLASDEGIB MALEATE TAB 100 MG (BASE EQUIVALENT)	21370030300335	Brand
ERLEADA	APALUTAMIDE TAB 60 MG	21402410000320	Brand
GILOTRIF	AFATINIB DIMALEATE TAB 20 MG (BASE EQUIVALENT)	21360006100320	Brand
GILOTRIF	AFATINIB DIMALEATE TAB 30 MG (BASE EQUIVALENT)	21360006100330	Brand
GILOTRIF	AFATINIB DIMALEATE TAB 40 MG (BASE EQUIVALENT)	21360006100340	Brand
HYCAMTIN	TOPOTECAN HCL CAP 0.25 MG (BASE EQUIV)	21550080100120	Brand
HYCAMTIN	TOPOTECAN HCL CAP 1 MG (BASE EQUIV)	21550080100140	Brand
IBRANCE	PALBOCICLIB CAP 75 MG	21531060000120	Brand
IBRANCE	PALBOCICLIB CAP 100 MG	21531060000130	Brand
IBRANCE	PALBOCICLIB CAP 125 MG	21531060000140	Brand
IBRANCE	PALBOCICLIB TAB 75 MG	21531060000320	Brand
IBRANCE	PALBOCICLIB TAB 100 MG	21531060000330	Brand
IBRANCE	PALBOCICLIB TAB 125 MG	21531060000340	Brand
ICLUSIG	PONATINIB HCL TAB 10 MG (BASE EQUIV)	21531875100315	Brand
ICLUSIG	PONATINIB HCL TAB 15 MG (BASE EQUIV)	21531875100320	Brand
ICLUSIG	PONATINIB HCL TAB 30 MG (BASE EQUIV)	21531875100330	Brand
ICLUSIG	PONATINIB HCL TAB 45 MG (BASE EQUIV)	21531875100340	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

INREBIC	FEDRATINIB HCL CAP 100 MG	21537520200120	Brand
KISQALI	RIBOCICLIB SUCCINATE TAB PACK 200 MG DAILY DOSE	2153107050B720	Brand
KISQALI	RIBOCICLIB SUCCINATE TAB PACK 400 MG DAILY DOSE (200 MG TAB)	2153107050B740	Brand
KISQALI	RIBOCICLIB SUCCINATE TAB PACK 600 MG DAILY DOSE (200 MG TAB)	2153107050B760	Brand
KISQALI FEMARA 200 DOSE	RIBOCICLIB 200 MG DOSE (200 MG TAB) & LETROZOLE 2.5 MG TBPk	2199000260B730	Brand
KISQALI FEMARA 400 DOSE	RIBOCICLIB 400 MG DOSE (200 MG TAB) & LETROZOLE 2.5 MG TBPk	2199000260B740	Brand
KISQALI FEMARA 600 DOSE	RIBOCICLIB 600 MG DOSE (200 MG TAB) & LETROZOLE 2.5 MG TBPk	2199000260B760	Brand
LENVIMA 4 MG DAILY DOSE	LENVATINIB CAP THERAPY PACK 4 MG (4 MG DAILY DOSE)	2133505420B210	Brand
LENVIMA 8 MG DAILY DOSE	LENVATINIB CAP THERAPY PACK 2 X 4 MG (8 MG DAILY DOSE)	2133505420B215	Brand
LENVIMA 10 MG DAILY DOSE	LENVATINIB CAP THERAPY PACK 10 MG (10 MG DAILY DOSE)	2133505420B220	Brand
LENVIMA 12MG DAILY DOSE	LENVATINIB CAP THERAPY PACK 3 X 4 MG (12 MG DAILY DOSE)	2133505420B223	Brand
LENVIMA 20 MG DAILY DOSE	LENVATINIB CAP THERAPY PACK 2 X 10 MG (20 MG DAILY DOSE)	2133505420B230	Brand
LENVIMA 14 MG DAILY DOSE	LENVATINIB CAP THERAPY PACK 10 & 4 MG (14 MG DAILY DOSE)	2133505420B240	Brand
LENVIMA 18 MG DAILY DOSE	LENVATINIB CAP THER PACK 10 MG & 2 X 4 MG (18 MG DAILY DOSE)	2133505420B244	Brand
LENVIMA 24 MG DAILY DOSE	LENVATINIB CAP THER PACK 2 X 10 MG & 4 MG (24 MG DAILY DOSE)	2133505420B250	Brand
LONSURF	TRIFLURIDINE-TIPIRACIL TAB 15-6.14 MG	21990002750320	Brand
LONSURF	TRIFLURIDINE-TIPIRACIL TAB 20-8.19 MG	21990002750330	Brand
LORBRENA	LORLATINIB TAB 25 MG	21530556000320	Brand
LORBRENA	LORLATINIB TAB 100 MG	21530556000330	Brand
NERLYNX	NERATINIB MALEATE TAB 40 MG (BASE EQUIVALENT)	21533035100320	Brand
ODOMZO	SONIDEGIB PHOSPHATE CAP 200 MG (BASE EQUIVALENT)	21370060200120	Brand
PEMAZYRE	PEMIGATINIB TAB 4.5 MG	21532260000320	Brand
PEMAZYRE	PEMIGATINIB TAB 9 MG	21532260000330	Brand
PEMAZYRE	PEMIGATINIB TAB 13.5 MG	21532260000340	Brand
PIQRAY 200MG DAILY DOSE	ALPELISIB TAB THERAPY PACK 200 MG DAILY DOSE	2153801000B720	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PIQRAY 250MG DAILY DOSE	ALPELISIB TAB PACK 250 MG DAILY DOSE (200 MG & 50 MG TABS)	2153801000B725	Brand
PIQRAY 300MG DAILY DOSE	ALPELISIB TAB PACK 300 MG DAILY DOSE (2X150 MG TAB)	2153801000B730	Brand
POMALYST	POMALIDOMIDE CAP 1 MG	21450080000110	Brand
POMALYST	POMALIDOMIDE CAP 2 MG	21450080000115	Brand
POMALYST	POMALIDOMIDE CAP 3 MG	21450080000120	Brand
POMALYST	POMALIDOMIDE CAP 4 MG	21450080000125	Brand
QINLOCK	RIPRETINIB TAB 50 MG	21533053000320	Brand
RYDAPT	MIDOSTAURIN CAP 25 MG	21533030000130	Brand
STIVARGA	REGORAFENIB TAB 40 MG	21533050000320	Brand
TAGRISSE	OSIMERTINIB MESYLATE TAB 40 MG (BASE EQUIVALENT)	21360068200320	Brand
TAGRISSE	OSIMERTINIB MESYLATE TAB 80 MG (BASE EQUIVALENT)	21360068200330	Brand
TAZVERIK	TAZEMETOSTAT HBR TAB 200 MG	21533675200320	Brand
TUKYSA	TUCATINIB TAB 50 MG	21170080000320	Brand
TUKYSA	TUCATINIB TAB 150 MG	21170080000340	Brand
TURALIO	PEXIDARTINIB HCL CAP 200 MG (BASE EQUIVALENT)	21533045010120	Brand
VENCLEXTA STARTING PACK	VENETOCLAX TAB THERAPY STARTER PACK 10 & 50 & 100 MG	2147008000B720	Brand
VENCLEXTA	VENETOCLAX TAB 10 MG	21470080000320	Brand
VENCLEXTA	VENETOCLAX TAB 50 MG	21470080000340	Brand
VENCLEXTA	VENETOCLAX TAB 100 MG	21470080000360	Brand
VERZENIO	ABEMACICLIB TAB 50 MG	21531010000305	Brand
VERZENIO	ABEMACICLIB TAB 100 MG	21531010000310	Brand
VERZENIO	ABEMACICLIB TAB 150 MG	21531010000315	Brand
VERZENIO	ABEMACICLIB TAB 200 MG	21531010000320	Brand
VIZIMPRO	DACOMITINIB TAB 15 MG	21360019000320	Brand
VIZIMPRO	DACOMITINIB TAB 30 MG	21360019000330	Brand
VIZIMPRO	DACOMITINIB TAB 45 MG	21360019000340	Brand
XOSPATA	GILTERITINIB FUMARATE TABLET 40 MG (BASE EQUIVALENT)	21533020200320	Brand
XPOVIO 80 MG TWICE WEEKLY	SELINEXOR TAB THERAPY PACK 20 MG (80 MG TWICE WEEKLY)	2156006000B720	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XPOVIO 60 MG TWICE WEEKLY	SELINEXOR TAB THERAPY PACK 20 MG (60 MG TWICE WEEKLY)	2156006000B755	Brand
XPOVIO	SELINEXOR TAB THERAPY PACK 40 MG (40 MG ONCE WEEKLY)	2156006000B760	Brand
XPOVIO	SELINEXOR TAB THERAPY PACK 40 MG (40 MG TWICE WEEKLY)	2156006000B765	Brand
XPOVIO	SELINEXOR TAB THERAPY PACK 40 MG (80 MG ONCE WEEKLY)	2156006000B770	Brand
XPOVIO	SELINEXOR TAB THERAPY PACK 50 MG (100 MG ONCE WEEKLY)	2156006000B775	Brand
XPOVIO	SELINEXOR TAB THERAPY PACK 60 MG (60 MG ONCE WEEKLY)	2156006000B780	Brand
XTANDI	ENZALUTAMIDE CAP 40 MG	21402430000120	Brand
XTANDI	ENZALUTAMIDE TAB 40 MG	21402430000320	Brand
XTANDI	ENZALUTAMIDE TAB 80 MG	21402430000340	Brand
ZYDELIG	IDELALISIB TAB 100 MG	21538040000320	Brand
ZYDELIG	IDELALISIB TAB 150 MG	21538040000330	Brand
ZYKADIA	CERITINIB TAB 150 MG	21530514000330	Brand
ABIRATERONE ACETATE	ABIRATERONE ACETATE TAB 250 MG	21406010200320	Generic
ZYTIGA	ABIRATERONE ACETATE TAB 250 MG	21406010200320	Brand
ABIRATERONE ACETATE	ABIRATERONE ACETATE TAB 500 MG	21406010200330	Generic
ZYTIGA	ABIRATERONE ACETATE TAB 500 MG	21406010200330	Brand
ALECENSA	ALECTINIB HCL CAP 150 MG (BASE EQUIVALENT)	21530507100120	Brand
CAPRELSA	VANDETANIB TAB 100 MG	21533085000320	Brand
CAPRELSA	VANDETANIB TAB 300 MG	21533085000340	Brand
ERIVEDGE	VISMODEGIB CAP 150 MG	21370070000120	Brand
ERLOTINIB HYDROCHLORIDE	ERLOTINIB HCL TAB 25 MG (BASE EQUIVALENT)	21360025100320	Generic
TARCEVA	ERLOTINIB HCL TAB 25 MG (BASE EQUIVALENT)	21360025100320	Brand
ERLOTINIB HYDROCHLORIDE	ERLOTINIB HCL TAB 100 MG (BASE EQUIVALENT)	21360025100330	Generic
TARCEVA	ERLOTINIB HCL TAB 100 MG (BASE EQUIVALENT)	21360025100330	Brand
ERLOTINIB HYDROCHLORIDE	ERLOTINIB HCL TAB 150 MG (BASE EQUIVALENT)	21360025100360	Generic
TARCEVA	ERLOTINIB HCL TAB 150 MG (BASE EQUIVALENT)	21360025100360	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ETOPOSIDE	ETOPOSIDE CAP 50 MG	21500010000120	Generic
IMBRUVICA	IBRUTINIB CAP 70 MG	21532133000110	Brand
IMBRUVICA	IBRUTINIB CAP 140 MG	21532133000120	Brand
IMBRUVICA	IBRUTINIB TAB 140 MG	21532133000320	Brand
IMBRUVICA	IBRUTINIB TAB 280 MG	21532133000330	Brand
IMBRUVICA	IBRUTINIB TAB 420 MG	21532133000340	Brand
IMBRUVICA	IBRUTINIB TAB 560 MG	21532133000350	Brand
IMBRUVICA	IBRUTINIB ORAL SUSP 70 MG/ML	21532133001820	Brand
INLYTA	AXITINIB TAB 1 MG	21335013000320	Brand
INLYTA	AXITINIB TAB 5 MG	21335013000340	Brand
IRESSA	GEFITINIB TAB 250 MG	21360030000320	Brand
JAKAFI	RUXOLITINIB PHOSPHATE TAB 5 MG (BASE EQUIVALENT)	21537560200310	Brand
JAKAFI	RUXOLITINIB PHOSPHATE TAB 10 MG (BASE EQUIVALENT)	21537560200320	Brand
JAKAFI	RUXOLITINIB PHOSPHATE TAB 15 MG (BASE EQUIVALENT)	21537560200325	Brand
JAKAFI	RUXOLITINIB PHOSPHATE TAB 20 MG (BASE EQUIVALENT)	21537560200330	Brand
JAKAFI	RUXOLITINIB PHOSPHATE TAB 25 MG (BASE EQUIVALENT)	21537560200335	Brand
LAPATINIB DITOSYLATE	LAPATINIB DITOSYLATE TAB 250 MG (BASE EQUIV)	21533026100320	Generic
TYKERB	LAPATINIB DITOSYLATE TAB 250 MG (BASE EQUIV)	21533026100320	Brand
NEXAVAR	SORAFENIB TOSYLATE TAB 200 MG (BASE EQUIVALENT)	21533060400320	Brand
SORAFENIB	SORAFENIB TOSYLATE TAB 200 MG (BASE EQUIVALENT)	21533060400320	Generic
SORAFENIB TOSYLATE	SORAFENIB TOSYLATE TAB 200 MG (BASE EQUIVALENT)	21533060400320	Generic
SPRYCEL	DASATINIB TAB 20 MG	21531820000320	Brand
SPRYCEL	DASATINIB TAB 50 MG	21531820000340	Brand
SPRYCEL	DASATINIB TAB 70 MG	21531820000350	Brand
SPRYCEL	DASATINIB TAB 80 MG	21531820000354	Brand
SPRYCEL	DASATINIB TAB 100 MG	21531820000360	Brand
SPRYCEL	DASATINIB TAB 140 MG	21531820000380	Brand
TASIGNA	NILOTINIB HCL CAP 50 MG (BASE EQUIVALENT)	21531860200110	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TASIGNA	NILOTINIB HCL CAP 150 MG (BASE EQUIVALENT)	21531860200115	Brand
TASIGNA	NILOTINIB HCL CAP 200 MG (BASE EQUIVALENT)	21531860200125	Brand
VOTRIENT	PAZOPANIB HCL TAB 200 MG (BASE EQUIV)	21533042100320	Brand
XALKORI	CRIZOTINIB CAP 200 MG	21530517000120	Brand
XALKORI	CRIZOTINIB CAP 250 MG	21530517000125	Brand
ZELBORAF	VEMURAFENIB TAB 240 MG	21532080000320	Brand
ZOLINZA	VORINOSTAT CAP 100 MG	21531575000120	Brand
LYTGOBI	FUTIBATINIB TAB THERAPY PACK 4 MG (12 MG DAILY DOSE)	2153222800B720	Brand
LYTGOBI	FUTIBATINIB TAB THERAPY PACK 4 MG (16 MG DAILY DOSE)	2153222800B725	Brand
LYTGOBI	FUTIBATINIB TAB THERAPY PACK 4 MG (20 MG DAILY DOSE)	2153222800B730	Brand
KRAZATI	ADAGRASIB TAB 200 MG	21532410000320	Brand
TURALIO	PEXIDARTINIB HCL CAP 125 MG (BASE EQUIVALENT)	21533045010110	Brand
CAPECITABINE	CAPECITABINE TAB 150 MG	21300005000320	Generic
XELODA	CAPECITABINE TAB 150 MG	21300005000320	Brand
CAPECITABINE	CAPECITABINE TAB 500 MG	21300005000350	Generic
XELODA	CAPECITABINE TAB 500 MG	21300005000350	Brand
REZLIDHIA	OLUTASIDENIB CAP 150 MG	21534960000120	Brand
JAYPIRCA	PIRTOBRUTINIB TAB 50 MG	21532165000320	Brand
JAYPIRCA	PIRTOBRUTINIB TAB 100 MG	21532165000330	Brand
ORSERDU	ELACESTRANT HYDROCHLORIDE TAB 86 MG	21403720100320	Brand
ORSERDU	ELACESTRANT HYDROCHLORIDE TAB 345 MG	21403720100340	Brand
ERLEADA	APALUTAMIDE TAB 240 MG	21402410000360	Brand
LUMAKRAS	SOTORASIB TAB 120 MG	21532480000320	Brand
LUMAKRAS	SOTORASIB TAB 320 MG	21532480000340	Brand
YONSA	ABIRATERONE ACETATE MICRONIZED TAB 125 MG	21406010250310	Brand
GEFITINIB	GEFITINIB TAB 250 MG	21360030000320	Generic
ZEJULA	NIRAPARIB TOSYLATE TAB 100 MG (BASE EQUIVALENT)	21535550200320	Brand
ZEJULA	NIRAPARIB TOSYLATE TAB 200 MG (BASE EQUIVALENT)	21535550200330	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZEJULA	NIRAPARIB TOSYLATE TAB 300 MG (BASE EQUIVALENT)	21535550200340	Brand
TALZENNA	TALAZOPARIB TOSYLATE CAP 0.1 MG (BASE EQUIVALENT)	21535580400105	Brand
TALZENNA	TALAZOPARIB TOSYLATE CAP 0.35 MG (BASE EQUIVALENT)	21535580400112	Brand
TAFINLAR	DABRAFENIB MESYLATE TAB FOR ORAL SUSP 10 MG (BASE EQUIV)	21532025107320	Brand
MEKINIST	TRAMETINIB DIMETHYL SULFOXIDE FOR SOLN 0.05 MG/ML (BASE EQ)	21533570102120	Brand
TABLOID	THIOGUANINE TAB 40 MG	21300060000305	Brand
VANFLYTA	QUIZARTINIB DIHYDROCHLORIDE TAB 17.7 MG	21533047100320	Brand
VANFLYTA	QUIZARTINIB DIHYDROCHLORIDE TAB 26.5 MG	21533047100325	Brand
AKEEGA	NIRAPARIB TOSYLATE-ABIRATERONE ACETATE TAB 50-500 MG	21409902120320	Brand
AKEEGA	NIRAPARIB TOSYLATE-ABIRATERONE ACETATE TAB 100-500 MG	21409902120330	Brand
TEMOZOLOMIDE	TEMOZOLOMIDE CAP 5 MG	21104070000110	Generic
TEMOZOLOMIDE	TEMOZOLOMIDE CAP 20 MG	21104070000120	Generic
TEMOZOLOMIDE	TEMOZOLOMIDE CAP 100 MG	21104070000140	Generic
TEMOZOLOMIDE	TEMOZOLOMIDE CAP 140 MG	21104070000143	Generic
TEMOZOLOMIDE	TEMOZOLOMIDE CAP 180 MG	21104070000147	Generic
TEMOZOLOMIDE	TEMOZOLOMIDE CAP 250 MG	21104070000150	Generic
TEMODAR	TEMOZOLOMIDE CAP 250 MG	21104070000150	Brand
ROZLYTREK	ENTRECTINIB PELLETT PACK 50 MG	21533820003020	Brand
AUGTYRO	REPOTRECTINIB CAP 40 MG	21533865000120	Brand
FRUZAQLA	FRUQUINTINIB CAP 1 MG	21335035000120	Brand
FRUZAQLA	FRUQUINTINIB CAP 5 MG	21335035000140	Brand
JYLAMVO	METHOTREXATE ORAL SOLN 2 MG/ML	21300050002075	Brand
OGSIVEO	NIROGACESTAT HYDROBROMIDE TAB 50 MG	21532350200320	Brand
TRUQAP	CAPIVASERTIB TAB 160 MG	21530320000320	Brand
TRUQAP	CAPIVASERTIB TAB 200 MG	21530320000325	Brand
XATMEP	METHOTREXATE ORAL SOLN 2.5 MG/ML	21300050002080	Brand
XALKORI	CRIZOTINIB CAP SPRINKLE 20 MG	21530517006820	Brand
XALKORI	CRIZOTINIB CAP SPRINKLE 50 MG	21530517006830	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XALKORI	CRIZOTINIB CAP SPRINKLE 150 MG	21530517006850	Brand
BOSULIF	BOSUTINIB CAP 50 MG	21531812000120	Brand
BOSULIF	BOSUTINIB CAP 100 MG	21531812000130	Brand
IWILFIN	EFLORNITHINE HCL TAB 192 MG	21757220300320	Brand
WELIREG	BELZUTIFAN TAB 40 MG	21421020000320	Brand
OGSIVEO	NIROGACESTAT HYDROBROMIDE TAB 100 MG	21532350200330	Brand
OGSIVEO	NIROGACESTAT HYDROBROMIDE TAB 150 MG	21532350200340	Brand
OJEMDA	TOVORAFENIB TAB 100 MG	21532075000320	Brand
OJEMDA	TOVORAFENIB FOR ORAL SUSP 25 MG/ML	21532075001920	Brand
SCSEMBLIX	ASCIMINIB HCL TAB 20 MG	21531806100320	Brand
SCSEMBLIX	ASCIMINIB HCL TAB 40 MG	21531806100340	Brand
SCSEMBLIX	ASCIMINIB HCL TAB 100 MG	21531806100380	Brand
RETEVMO	SELPERCATINIB TAB 40 MG	21535779000320	Brand
RETEVMO	SELPERCATINIB TAB 80 MG	21535779000330	Brand
RETEVMO	SELPERCATINIB TAB 120 MG	21535779000340	Brand
RETEVMO	SELPERCATINIB TAB 160 MG	21535779000350	Brand
VORANIGO	VORASIDENIB TAB 10 MG	21535180000320	Brand
VORANIGO	VORASIDENIB TAB 40 MG	21535180000340	Brand
LAZCLUZE	LAZERTINIB MESYLATE TAB 80 MG	21360048300320	Brand
LAZCLUZE	LAZERTINIB MESYLATE TAB 240 MG	21360048300340	Brand
DASATINIB	DASATINIB TAB 20 MG	21531820000320	Generic
DASATINIB	DASATINIB TAB 50 MG	21531820000340	Generic
DASATINIB	DASATINIB TAB 70 MG	21531820000350	Generic
DASATINIB	DASATINIB TAB 80 MG	21531820000354	Generic
DASATINIB	DASATINIB TAB 100 MG	21531820000360	Generic
DASATINIB	DASATINIB TAB 140 MG	21531820000380	Generic
TRUQAP	CAPIVASERTIB TAB THERAPY PACK 160 MG	2153032000B720	Brand
TRUQAP	CAPIVASERTIB TAB THERAPY PACK 200 MG	2153032000B725	Brand

**Approval Criteria**

1 - The drug is being used as indicated by National Comprehensive Cancer Network (NCCN) guidelines with a Category of Evidence and Consensus of 1, 2A, or 2B

Product Name: Brand Gleevec, generic imatinib, Brand Revlimid, generic lenalidomide

Diagnosis	Cancer Indications
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
LENALIDOMIDE	LENALIDOMIDE CAPS 2.5 MG	99394050000110	Generic
REVLIMID	LENALIDOMIDE CAPS 2.5 MG	99394050000110	Brand
LENALIDOMIDE	LENALIDOMIDE CAP 5 MG	99394050000120	Generic
REVLIMID	LENALIDOMIDE CAP 5 MG	99394050000120	Brand
LENALIDOMIDE	LENALIDOMIDE CAP 10 MG	99394050000130	Generic
REVLIMID	LENALIDOMIDE CAP 10 MG	99394050000130	Brand
LENALIDOMIDE	LENALIDOMIDE CAP 15 MG	99394050000140	Generic
REVLIMID	LENALIDOMIDE CAP 15 MG	99394050000140	Brand
LENALIDOMIDE	LENALIDOMIDE CAP 20 MG	99394050000145	Generic
REVLIMID	LENALIDOMIDE CAP 20 MG	99394050000145	Brand
LENALIDOMIDE	LENALIDOMIDE CAP 25 MG	99394050000150	Generic
REVLIMID	LENALIDOMIDE CAP 25 MG	99394050000150	Brand
IMATINIB MESYLATE	IMATINIB MESYLATE TAB 100 MG (BASE EQUIVALENT)	21531835100320	Generic
GLEEVEC	IMATINIB MESYLATE TAB 100 MG (BASE EQUIVALENT)	21531835100320	Brand
IMATINIB MESYLATE	IMATINIB MESYLATE TAB 400 MG (BASE EQUIVALENT)	21531835100340	Generic
GLEEVEC	IMATINIB MESYLATE TAB 400 MG (BASE EQUIVALENT)	21531835100340	Brand

**Approval Criteria**

1 - The drug is being used as indicated by National Comprehensive Cancer Network (NCCN) guidelines with a Category of Evidence and Consensus of 1, 2A, or 2B

**AND**

**2** - If the request is for the non-preferred Brand (Brand Gleevec or Brand Revlimid), patient must have tried and failed the preferred generic counterpart (generic imatinib or generic lenalidomide)

## 2 . Revision History

Date	Notes
11/6/2024	Added new GPIs for Truqap therapy packs. No changes to criteria.

Orencia (abatacept)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-141021
<b>Guideline Name</b>	Orencia (abatacept)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	1/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Orencia Clickject, Orencia prefilled syringe			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORENCIA CLICKJECT	ABATACEPT SUBCUTANEOUS SOLN AUTO-INJECTOR 125 MG/ML	6640001000D520	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.4ML	6640001000E510	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 87.5 MG/0.7ML	6640001000E515	Brand

ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 125 MG/ML	6640001000E520	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderately to severely active rheumatoid arthritis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with a rheumatologist</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Trial and failure, contraindication, or intolerance to ONE nonbiologic disease-modifying antirheumatic drug (DMARD) [e.g., methotrexate (Rheumatrex/Trexall), Arava (leflunomide), Azulfidine (sulfasalazine)]</p>			

Product Name: Orenzia Clickject, Orenzia prefilled syringe			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORENCIA CLICKJECT	ABATACEPT SUBCUTANEOUS SOLN AUTO-INJECTOR 125 MG/ML	6640001000D520	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.4ML	6640001000E510	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 87.5 MG/0.7ML	6640001000E515	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 125 MG/ML	6640001000E520	Brand
<p><b>Approval Criteria</b></p>			

1 - Documentation of positive clinical response to therapy

Product Name: Orenzia Clickject, Orenzia prefilled syringe

Diagnosis Polyarticular Juvenile Idiopathic Arthritis (PJIA)

Approval Length 12 month(s)

Therapy Stage Initial Authorization

Guideline Type Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ORENCIA CLICKJECT	ABATACEPT SUBCUTANEOUS SOLN AUTO-INJECTOR 125 MG/ML	6640001000D520	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.4ML	6640001000E510	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 87.5 MG/0.7ML	6640001000E515	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 125 MG/ML	6640001000E520	Brand

**Approval Criteria**

1 - Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis

**AND**

2 - Prescribed by or in consultation with a rheumatologist

**AND**

3 - Trial and failure, contraindication, or intolerance to ONE of the following nonbiologic disease modifying anti-rheumatic drugs (DMARDs):

- leflunomide (Arava)
- methotrexate (Rheumatrex/Trexall)



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: Orenzia Clickject, Orenzia prefilled syringe			
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (PJIA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORENCIA CLICKJECT	ABATACEPT SUBCUTANEOUS SOLN AUTO-INJECTOR 125 MG/ML	6640001000D520	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.4ML	6640001000E510	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 87.5 MG/0.7ML	6640001000E515	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 125 MG/ML	6640001000E520	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy			

Product Name: Orenzia Clickject, Orenzia prefilled syringe			
Diagnosis	Psoriatic Arthritis (PsA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORENCIA CLICKJECT	ABATACEPT SUBCUTANEOUS SOLN AUTO-INJECTOR 125 MG/ML	6640001000D520	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.4ML	6640001000E510	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 87.5 MG/0.7ML	6640001000E515	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 125 MG/ML	6640001000E520	Brand

**Approval Criteria**

1 - Diagnosis of active psoriatic arthritis (PsA)

**AND**

2 - Patient is 2 years of age or older

**AND**

3 - Prescribed by or in consultation with one of the following:

- Dermatologist
- Rheumatologist

**Product Name: Orenzia Clickject, Orenzia prefilled syringe**

Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ORENCIA CLICKJECT	ABATACEPT SUBCUTANEOUS SOLN AUTO-INJECTOR 125 MG/ML	6640001000D520	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.4ML	6640001000E510	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 87.5 MG/0.7ML	6640001000E515	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 125 MG/ML	6640001000E520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

## 2 . Revision History

Date	Notes
12/7/2023	Added age criterion to PsA indication.

Orfadin (nitisinone)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140993
<b>Guideline Name</b>	Orfadin (nitisinone)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	9/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Brand Orfadin, generic nitisinone			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NITISINONE	NITISINONE CAP 2 MG	30904045000110	Generic
ORFADIN	NITISINONE CAP 2 MG	30904045000110	Brand
NITISINONE	NITISINONE CAP 5 MG	30904045000120	Generic
ORFADIN	NITISINONE CAP 5 MG	30904045000120	Brand
NITISINONE	NITISINONE CAP 10 MG	30904045000130	Generic
ORFADIN	NITISINONE CAP 10 MG	30904045000130	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NITISINONE	NITISINONE CAP 20 MG	30904045000140	Generic
ORFADIN	NITISINONE CAP 20 MG	30904045000140	Brand
ORFADIN	NITISINONE SUSP 4 MG/ML	30904045001820	Brand

**Approval Criteria**

1 - Diagnosis of hereditary tyrosinemia type 1

**2 . Revision History**

Date	Notes
8/8/2023	Updated guideline name and GPIs

Orgovyx



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140862
<b>Guideline Name</b>	Orgovyx
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Orgovyx			
Diagnosis	Prostate Cancer		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORGOVYX	RELUGOLIX TAB 120 MG	21405570000320	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of advanced prostate cancer

**AND**

2 - Patient is a candidate for at least one year of continuous androgen-deprivation therapy

**AND**

3 - ONE of the following:

- Evidence of biochemical [PSA (prostate-specific antigen)] or clinical relapse after local primary intervention with curative intent
- Newly diagnosed hormone-sensitive metastatic disease
- Advanced localized disease unlikely to be cured by local primary intervention with curative intent

**AND**

4 - Patient has been without any major adverse cardiovascular events within 6 months before initiation (e.g., myocardial infarction, stroke)

Product Name: Orgovyx			
Diagnosis	Prostate Cancer		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORGOVYX	RELUGOLIX TAB 120 MG	21405570000320	Brand

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on therapy

Product Name: Orgovyx			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORGOVYX	RELUGOLIX TAB 120 MG	21405570000320	Brand
<b>Approval Criteria</b>			
1 - Use is supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium			

Product Name: Orgovyx			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORGOVYX	RELUGOLIX TAB 120 MG	21405570000320	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Orgovyx therapy			

## 2 . Revision History

Date	Notes
3/1/2021	New guideline



Orilissa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140726
<b>Guideline Name</b>	Orilissa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Orilissa 150 mg			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORILISSA	ELAGOLIX SODIUM TAB 150 MG (BASE EQUIV)	30090030100320	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of moderate to severe pain associated with endometriosis			

**AND**

**2** - Patient is premenopausal

**AND**

**3** - History of trial and failure (e.g., inadequate pain relief), contraindication or intolerance after a three month trial of TWO analgesics (e.g., ibuprofen, meloxicam, naproxen)

**AND**

**4** - History of trial and failure, contraindication, or intolerance after a three month trial to ONE of the following:

- Hormonal contraceptives
- Progestins [e.g., norethindrone (generic Aygestin)]

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Obstetrics/Gynecologist (OB/GYN)
- Reproductive endocrinologist

Product Name: Orilissa 150 mg			
Approval Length	6 months*		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORILISSA	ELAGOLIX SODIUM TAB 150 MG (BASE EQUIV)	30090030100320	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**AND**

2 - Impact to bone mineral density has been considered

**AND**

3 - Treatment duration has not exceeded a total of 24 months\*\*

Notes	<p>*NOTE: Authorization for Orilissa 150 mg will be issued for 6 months up to a maximum of 24 months.                  **NOTE: Orilissa 150 mg once daily is indicated for a maximum of 24 months.</p>
-------	--

Product Name: Orilissa 200 mg			
Approval Length	6 months*		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORILISSA	ELAGOLIX SODIUM TAB 200 MG (BASE EQUIV)	30090030100330	Brand

**Approval Criteria**

1 - Diagnosis of moderate to severe pain associated with endometriosis

**AND**

2 - Patient is premenopausal

**AND**

**3** - History of trial and failure (e.g., inadequate pain relief), contraindication or intolerance after a three month trial of TWO analgesics (e.g., ibuprofen, meloxicam, naproxen)

**AND**

**4** - History of trial and failure, contraindication, or intolerance after a three month trial to ONE of the following:

- Hormonal contraceptives
- Progestins [e.g., norethindrone (generic Aygestin)]

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Obstetrics/Gynecologist (OB/GYN)
- Reproductive endocrinologist

Notes	*NOTE: Orilissa 200 mg twice daily is indicated for a maximum of 6 months.
-------	--

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Orkambi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140950
<b>Guideline Name</b>	Orkambi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Orkambi			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORKAMBI	LUMACAFITOR-IVACAFITOR GRANULES PACKET 100-125 MG	45309902303010	Brand
ORKAMBI	LUMACAFITOR-IVACAFITOR GRANULES PACKET 150-188 MG	45309902303020	Brand
ORKAMBI	LUMACAFITOR-IVACAFITOR TAB 100-125 MG	45309902300310	Brand
ORKAMBI	LUMACAFITOR-IVACAFITOR TAB 200-125 MG	45309902300320	Brand

ORKAMBI	LUMACAFITOR-IVACAFITOR GRANULES PACKET 75-94 MG	45309902303005	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of cystic fibrosis (CF)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Submission of laboratory results confirming that patient is homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - The patient is 1 year of age or older</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - Prescribed by, or in consultation with, a specialist affiliated with a CF care center</p>			

Product Name: Orkambi			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORKAMBI	LUMACAFITOR-IVACAFITOR GRANULES PACKET 100-125 MG	45309902303010	Brand
ORKAMBI	LUMACAFITOR-IVACAFITOR GRANULES PACKET 150-188 MG	45309902303020	Brand
ORKAMBI	LUMACAFITOR-IVACAFITOR TAB 100-125 MG	45309902300310	Brand
ORKAMBI	LUMACAFITOR-IVACAFITOR TAB 200-125 MG	45309902300320	Brand
ORKAMBI	LUMACAFITOR-IVACAFITOR GRANULES PACKET 75-94 MG	45309902303005	Brand

**Approval Criteria**

**1** - Provider attests that the patient has achieved a clinically meaningful response while on Orkambi therapy to ONE of the following:

- Lung function as demonstrated by percent predicted expiratory volume in 1 second (ppFEV1)
- Body mass index (BMI)
- Pulmonary exacerbations
- Quality of life as demonstrated by Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score

**AND**

**2** - Prescribed by, or in consultation with, a specialist affiliated with a cystic fibrosis (CF) care center

**2 . Revision History**

Date	Notes
11/7/2022	Updated age requirement, added new GPI

Osphena



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140630
<b>Guideline Name</b>	Osphena
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Osphena			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OSPHENA	OSPEMIFENE TAB 60 MG	30053050000330	Brand
<b>Approval Criteria</b>			



1 - Treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy (VVA), due to menopause\*

**AND**

2 - History of failure, contraindication, or intolerance to BOTH of the following:

- Estradiol vaginal cream
- Estradiol vaginal tablet

Notes	*Treatment of dyspareunia is a benefit exclusion.
-------	---

Product Name: Osphe<sup>na</sup>

Approval Length	12 month(s)
-----------------	-------------

Therapy Stage	Reauthorization
---------------	-----------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
OSPHENA	OSPEMIFENE TAB 60 MG	30053050000330	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**2 . Revision History**

Date	Notes
3/16/2020	New program

Otezla (apremilast)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155089
<b>Guideline Name</b>	Otezla (apremilast)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Otezla			
Diagnosis	Psoriatic Arthritis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OTEZLA	APREMILAST TAB 30 MG	66700015000330	Brand
OTEZLA	APREMILAST TAB STARTER THERAPY PACK 10 MG & 20 MG & 30 MG	6670001500B720	Brand
OTEZLA	APREMILAST TAB STARTER THERAPY PACK 4 X 10 MG & 51 X 20 MG	6670001500B710	Brand

OTEZLA	APREMILAST TAB 20 MG	66700015000320	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of active psoriatic arthritis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)*</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Rheumatologist</li> <li>• Dermatologist</li> </ul>			
Notes		*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.	

Product Name: Otezla			
Diagnosis	Behcet's Disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OTEZLA	APREMILAST TAB 30 MG	66700015000330	Brand
OTEZLA	APREMILAST TAB STARTER THERAPY PACK 10 MG & 20 MG & 30 MG	6670001500B720	Brand
OTEZLA	APREMILAST TAB STARTER THERAPY PACK 4 X 10 MG & 51 X 20 MG	6670001500B710	Brand
OTEZLA	APREMILAST TAB 20 MG	66700015000320	Brand

**Approval Criteria**

1 - Diagnosis of Behcet's Disease

**AND**

2 - Patient has active oral ulcers

**AND**

3 - History of failure, contraindication, or intolerance to one non-biologic (e.g., corticosteroids, colchicine) within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

4 - Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.
-------	---

Product Name: Otezla			
Diagnosis	Psoriatic Arthritis, Behcet's Disease		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OTEZLA	APREMILAST TAB 30 MG	66700015000330	Brand
OTEZLA	APREMILAST TAB STARTER THERAPY PACK 10 MG & 20 MG & 30 MG	6670001500B720	Brand

OTEZLA	APREMILAST TAB STARTER THERAPY PACK 4 X 10 MG & 51 X 20 MG	6670001500B710	Brand
OTEZLA	APREMILAST TAB 20 MG	66700015000320	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Otezla therapy

**AND**

2 - Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Product Name: Otezla	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
OTEZLA	APREMILAST TAB 30 MG	66700015000330	Brand
OTEZLA	APREMILAST TAB STARTER THERAPY PACK 10 MG & 20 MG & 30 MG	6670001500B720	Brand
OTEZLA	APREMILAST TAB STARTER THERAPY PACK 4 X 10 MG & 51 X 20 MG	6670001500B710	Brand
OTEZLA	APREMILAST TAB 20 MG	66700015000320	Brand

**Approval Criteria**

1 - Diagnosis of plaque psoriasis

**AND**

**2** - BOTH of the following:

- Patient is 6 years of age or older
- Patient weighs at least 20 kg (kilograms)

**AND**

**3** - BOTH of the following:

**3.1** History of failure to ONE of the following topical therapies, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial):\*

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**3.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

**4** - Prescribed by or in consultation with a dermatologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.
-------	---

Product Name: Otezla	
Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)

Therapy Stage		Reauthorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
OTEZLA	APREMILAST TAB 30 MG	66700015000330	Brand
OTEZLA	APREMILAST TAB STARTER THERAPY PACK 10 MG & 20 MG & 30 MG	6670001500B720	Brand
OTEZLA	APREMILAST TAB STARTER THERAPY PACK 4 X 10 MG & 51 X 20 MG	6670001500B710	Brand
OTEZLA	APREMILAST TAB 20 MG	66700015000320	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Otezla therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with a dermatologist</p>			

## 2 . Revision History

Date	Notes
9/17/2024	Updated guideline name. Added new GPIs for Otezla. No changes to criteria.

Oxervate



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140852
<b>Guideline Name</b>	Oxervate
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Oxervate			
Diagnosis	Neurotrophic keratitis		
Approval Length	8 Week(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OXERVATE	CENEGERMIN-BKBJ OPHTH SOLN 0.002% (20 MCG/ML)	86770020202020	Brand
<b>Approval Criteria</b>			



**1** - Diagnosis of Stage 2 or 3 neurotrophic keratitis

**AND**

**2** - History of failure to at least one OTC ocular artificial tear product (e.g., Systane® Ultra, Akwa® Tears, Refresh Optive®, Soothe® XP)

**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Ophthalmologist
- Optometrist

## 2 . Revision History

Date	Notes
3/31/2020	Bulk copy C&S New York SP to C&S Arizona SP for 5/1 effective

Palforzia [Peanut (Arachis hypogaea)]



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157262
<b>Guideline Name</b>	Palforzia [Peanut (Arachis hypogaea)]
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Palforzia			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PALFORZIA INITIAL DOSE ESCALATION	PEANUT POWDER-DNFP STARTER PACK 0.5 & 1 & 1.5 & 3 & 6 MG	2010004020H510	Brand
PALFORZIA LEVEL 1	PEANUT POWDER-DNFP CAP SPRINKLE PACK 3 X 1 MG (3 MG DOSE)	2010004020H525	Brand
PALFORZIA LEVEL 2	PEANUT POWDER-DNFP CAP SPRINKLE PACK 6 X 1 MG (6 MG DOSE)	2010004020H530	Brand

PALFORZIA LEVEL 3	PEANUT POWDER-DNFP PACK 2 X 1 MG & 10 MG (12 MG DOSE)	2010004020H535	Brand
PALFORZIA LEVEL 4	PEANUT POWDER-DNFP CAP SPRINKLE PACK 20 MG (20 MG DOSE)	2010004020H540	Brand
PALFORZIA LEVEL 5	PEANUT POWDER-DNFP CAP SPRINKLE PACK 2 X 20 MG (40 MG DOSE)	2010004020H545	Brand
PALFORZIA LEVEL 6	PEANUT POWDER-DNFP CAP SPRINKLE PACK 4 X 20 MG (80 MG DOSE)	2010004020H550	Brand
PALFORZIA LEVEL 7	PEANUT POWDER-DNFP PACK 20 MG & 100 MG (120 MG DOSE)	2010004020H555	Brand
PALFORZIA LEVEL 8	PEANUT POWDER-DNFP PACK 3 X 20 MG & 100 MG (160 MG DOSE)	2010004020H560	Brand
PALFORZIA LEVEL 9	PEANUT POWDER-DNFP PACK 2 X 100 MG (200 MG DOSE)	2010004020H565	Brand
PALFORZIA LEVEL 10	PEANUT POWDER-DNFP PACK 2 X 20 MG & 2 X 100 MG (240 MG DOSE)	2010004020H570	Brand
PALFORZIA LEVEL 11 (TITRATION)	PEANUT ALLERGEN POWDER-DNFP TITRATION PACKET 300 MG	20100040203030	Brand
PALFORZIA LEVEL 11 (MAINTENANCE)	PEANUT ALLERGEN POWDER-DNFP MAINTENANCE PACKET 300 MG	20100040203050	Brand

**Approval Criteria**

1 - Diagnosis and clinical history of peanut allergy as documented by BOTH of the following:

1.1 A serum peanut-specific IgE level of greater than or equal to 0.35 kUA/L (kilo units of allergen per liter)

**AND**

1.2 A mean wheal diameter that is at least 3mm (millimeters) larger than the negative control on skin-prick testing for peanut

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

- Patient is 1 to 17 years of age

- Patient is in the initial dose escalation phase of therapy

**OR**

**2.2 BOTH of the following:**

- Patient is 1 year of age or older
- Patient is in the up-dosing or maintenance phase of therapy

**AND**

**3 - Used in conjunction with a peanut-avoidant diet**

**AND**

**4 - Patient does not have one of the following:**

- History of eosinophilic esophagitis (EoE) or eosinophilic gastrointestinal disease
- History of severe or life-threatening episode(s) of anaphylaxis or anaphylactic shock within the past 2 months
- Severe or poorly controlled asthma

**AND**

**5 - Prescribed by or in consultation with an allergist or immunologist**

**AND**

**6 - Prescriber is certified/enrolled in the Palforzia REMS (Risk Evaluation and Mitigation Strategy) Program**

Product Name: Palforzia	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
PALFORZIA INITIAL DOSE ESCALATION	PEANUT POWDER-DNFP STARTER PACK 0.5 & 1 & 1.5 & 3 & 6 MG	2010004020H510	Brand
PALFORZIA LEVEL 1	PEANUT POWDER-DNFP CAP SPRINKLE PACK 3 X 1 MG (3 MG DOSE)	2010004020H525	Brand
PALFORZIA LEVEL 2	PEANUT POWDER-DNFP CAP SPRINKLE PACK 6 X 1 MG (6 MG DOSE)	2010004020H530	Brand
PALFORZIA LEVEL 3	PEANUT POWDER-DNFP PACK 2 X 1 MG & 10 MG (12 MG DOSE)	2010004020H535	Brand
PALFORZIA LEVEL 4	PEANUT POWDER-DNFP CAP SPRINKLE PACK 20 MG (20 MG DOSE)	2010004020H540	Brand
PALFORZIA LEVEL 5	PEANUT POWDER-DNFP CAP SPRINKLE PACK 2 X 20 MG (40 MG DOSE)	2010004020H545	Brand
PALFORZIA LEVEL 6	PEANUT POWDER-DNFP CAP SPRINKLE PACK 4 X 20 MG (80 MG DOSE)	2010004020H550	Brand
PALFORZIA LEVEL 7	PEANUT POWDER-DNFP PACK 20 MG & 100 MG (120 MG DOSE)	2010004020H555	Brand
PALFORZIA LEVEL 8	PEANUT POWDER-DNFP PACK 3 X 20 MG & 100 MG (160 MG DOSE)	2010004020H560	Brand
PALFORZIA LEVEL 9	PEANUT POWDER-DNFP PACK 2 X 100 MG (200 MG DOSE)	2010004020H565	Brand
PALFORZIA LEVEL 10	PEANUT POWDER-DNFP PACK 2 X 20 MG & 2 X 100 MG (240 MG DOSE)	2010004020H570	Brand
PALFORZIA LEVEL 11 (TITRATION)	PEANUT ALLERGEN POWDER-DNFP TITRATION PACKET 300 MG	20100040203030	Brand
PALFORZIA LEVEL 11 (MAINTENANCE)	PEANUT ALLERGEN POWDER-DNFP MAINTENANCE PACKET 300 MG	20100040203050	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Palforzia therapy

**AND**

2 - Used in conjunction with a peanut-avoidant diet

**AND**

**3** - Prescribed by or in consultation with an allergist or immunologist

**AND**

**4** - Prescriber is certified/enrolled in the Palforzia REMS (Risk Evaluation and Mitigation Strategy) Program

## 2 . Revision History

Date	Notes
10/9/2024	Updated guideline name. Updated age criterion, where applicable.

Palynziq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140902
<b>Guideline Name</b>	Palynziq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Palynziq			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PALYNZIQ	PEGVALIASE-PQPZ SUBCUTANEOUS SOLN PREF SYRINGE 2.5 MG/0.5ML	3090855040E510	Brand
PALYNZIQ	PEGVALIASE-PQPZ SUBCUTANEOUS SOLN PREF SYRINGE 10 MG/0.5ML	3090855040E520	Brand
PALYNZIQ	PEGVALIASE-PQPZ SUBCUTANEOUS SOLN PREF SYRINGE 20 MG/ML	3090855040E530	Brand

**Approval Criteria**

1 - Diagnosis of phenylketonuria (PKU)

**AND**

2 - Patient is actively on a phenylalanine-restricted diet

**AND**

3 - Physician attestation that the patient will not be receiving Palynziq in combination with Kuvan (sapropterin dihydrochloride)

**AND**

4 - Submission of medical records (e.g. chart notes, laboratory values) documenting that the patient has a blood phenylalanine concentration greater than 600 micromoles per liter

Product Name: Palynziq			
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PALYNZIQ	PEGVALIASE-PQPZ SUBCUTANEOUS SOLN PREF SYRINGE 2.5 MG/0.5ML	3090855040E510	Brand
PALYNZIQ	PEGVALIASE-PQPZ SUBCUTANEOUS SOLN PREF SYRINGE 10 MG/0.5ML	3090855040E520	Brand
PALYNZIQ	PEGVALIASE-PQPZ SUBCUTANEOUS SOLN PREF SYRINGE 20 MG/ML	3090855040E530	Brand
<b>Approval Criteria</b>			



**1** - Patient is actively on a phenylalanine-restricted diet

**AND**

**2** - ONE of the following:

**2.1** Submission of medical records (e.g. chart notes, laboratory values) documenting that the patient has a blood phenylalanine concentration less than 600 micromoles per liter

**OR**

**2.2** Submission of medical records (e.g. chart notes, laboratory values) documenting that the patient has achieved a 20% reduction in blood phenylalanine concentration from pre-treatment baseline

**OR**

**2.3** BOTH of the following:

**2.3.1** Patient is in initial titration/maintenance phase of dosing regimen (week 1-33)

**AND**

**2.3.2** Patient will receive maximum labeled dosage of 40 milligrams (mg) once daily if response has not been obtained after 24 weeks of 20 mg once daily maintenance dosing

**AND**

**3** - Submission of medical records (e.g. chart notes, laboratory values) documenting that the patient is not receiving Palynziq in combination with Kuvan (sapropterin dihydrochloride) [Prescription claim history that does not show any concomitant Kuvan claim within 60 days of reauthorization request may be used as documentation]

## **2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Panretin



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140695
<b>Guideline Name</b>	Panretin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Panretin			
Diagnosis	AIDS-related Kaposi's Sarcoma (KS)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PANRETIN	ALITRETINOIN GEL 0.1%	90376015004020	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of acquired immunodeficiency syndrome (AIDS)-related Kaposi's Sarcoma (KS)			

**AND**

**2** - Patient is not receiving systemic anti-KS treatment

Product Name: Panretin			
Diagnosis	NCCN Recommended Regimen		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PANRETIN	ALITRETINOIN GEL 0.1%	90376015004020	Brand
<b>Approval Criteria</b>			
1 - Panretin will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.			

Product Name: Panretin			
Diagnosis	NCCN Recommended Regimen		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PANRETIN	ALITRETINOIN GEL 0.1%	90376015004020	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Panretin therapy			

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Pediculicides



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140732
<b>Guideline Name</b>	Pediculicides
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Natroba, generic spinosad, Sklice			
Diagnosis	Head lice		
Approval Length	30 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SPINOSAD	SPINOSAD SUSP 0.9%	90900048001820	Generic
NATROBA	SPINOSAD SUSP 0.9%	90900048001820	Brand
SKLICE	IVERMECTIN LOTION 0.5%	90900017004120	Brand

**Approval Criteria**

1 - Diagnosis of topical treatment of head lice infestations

**AND**

2 - For Brand Natroba requests ONLY: Trial and failure to generic spinosad suspension (verified via paid pharmacy claims or submission of medical records/chart notes)

**2 . Revision History**

Date	Notes
8/10/2022	C&S to match AZM 10.1.22

Phexxi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-150820
<b>Guideline Name</b>	Phexxi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Phexxi			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PHEXXI	LACTIC ACID-CITRIC ACID-POTASSIUM BITARTRATE GEL 1.8-1-0.4%	55329903404020	Brand
<b>Approval Criteria</b>			
1 - Used for the prevention of pregnancy			



**AND**

**2 - ONE of the following:**

**2.1** Failure to ALL of the following methods of contraception as confirmed by claims history or submission of medical records:

- Injection (e.g., Depo-Provera)
- Oral Contraceptive [e.g., norethindrone (generic Micronor), Yaz]
- Transdermal Patch (e.g., Twirla, Xulane)
- Vaginal Contraceptive Ring (e.g., Annovera, NuvaRing)
- Diaphragm
- Cervical Cap (e.g., FemCap)
- Female Condom

**OR**

**2.2** History of intolerance or contraindication to ALL of the following methods of contraception (please document intolerance or contraindication):

- Injection (e.g., Depo-Provera)
- Oral Contraceptive [e.g., norethindrone (generic Micronor), Yaz]
- Transdermal Patch (e.g., Twirla, Xulane)
- Vaginal Contraceptive Ring (e.g., Annovera, NuvaRing)
- Diaphragm
- Cervical Cap (e.g., FemCap)
- Female Condom

**AND**

**3 - ONE of the following:**

**3.1** Failure to nonoxynol-9 based spermicide as confirmed by claims history or submission of medical records

**OR**

**3.2** History of intolerance or contraindication to nonoxynol-9 based spermicide (please document intolerance or contraindication)

**AND**

**4** - Provider attests they have counseled the patient regarding higher rate of pregnancy prevention with the use of other methods of contraception (e.g., injection, oral contraception, transdermal patch, vaginal ring) compared to Phexxi

## 2 . Revision History

Date	Notes
8/1/2024	Minor update in criterion 2.1 to remove "other" verbiage. No changes to clinical intent.

Pombiliti



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-143526
<b>Guideline Name</b>	Pombiliti
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	3/17/2024
-----------------	-----------

### 1 . Criteria

Product Name: Pombiliti			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
POMBILITI	CIPAGLUCOSIDASE ALFA-ATGA FOR IV SOLN 105 MG	30907730052120	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) documenting all of the following:

**1.1** Diagnosis of late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency)

**AND**

**1.2** Disease is confirmed by one of the following:

- Absence or deficiency (less than 40% of the lab specific normal mean) of GAA enzyme activity in lymphocytes, fibroblasts, or muscle tissues as confirmed by an enzymatic assay
- Molecular genetic testing confirms mutations in the GAA gene

**AND**

**1.3** Presence of clinical signs and symptoms of the disease (e.g., respiratory distress, skeletal muscle weakness, etc.)

**AND**

**1.4** Medication is used in combination with Opfolda (miglustat)

**AND**

**1.5** Patient's weight is greater than or equal to 40 kg

**AND**

**2** - Pombiliti will not to be used in combination with other miglustat products (i.e., Zavesca, Yargesa)

Product Name: Pombiliti	
Approval Length	24 month(s)
Therapy Stage	Reauthorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
POMBILITI	CIPAGLUCOSIDASE ALFA-ATGA FOR IV SOLN 105 MG	30907730052120	Brand
<p><b>Approval Criteria</b></p> <p>1 - Patient demonstrates positive clinical response to therapy (e.g., improvement in FVC, improvement in 6-minute walk distance [6MWD])</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Medication is used in combination with Opfolda (miglustat)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Pombiliti will not to be used in combination with other miglustat products (i.e., Zavesca, Yargesa)</p>			

## 2 . Revision History

Date	Notes
2/26/2024	New

Pradaxa Pellet Packs



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140822
<b>Guideline Name</b>	Pradaxa Pellet Packs
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2023
-----------------	-----------

### 1 . Criteria

Product Name: Pradaxa Pellet Packs			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PRADAXA	DABIGATRAN ETEXILATE MESYLATE PELLETT PACK 20 MG	83337030203020	Brand
PRADAXA	DABIGATRAN ETEXILATE MESYLATE PELLETT PACK 30 MG	83337030203025	Brand
PRADAXA	DABIGATRAN ETEXILATE MESYLATE PELLETT PACK 40 MG	83337030203030	Brand
PRADAXA	DABIGATRAN ETEXILATE MESYLATE PELLETT PACK 50 MG	83337030203035	Brand

PRADAXA	DABIGATRAN ETEXILATE MESYLATE PELLETT PACK 110 MG	83337030203040	Brand
PRADAXA	DABIGATRAN ETEXILATE MESYLATE PELLETT PACK 150 MG	83337030203045	Brand

**Approval Criteria**

1 - Patient is 8 years of age or younger

**OR**

2 - ALL of the following:

2.1 Patient is between 9 and 12 years of age

**AND**

2.2 Requested medication is being used for ONE of the following diagnoses:

- Treatment of venous thromboembolic events (VTE) in patients who have been treated with a parenteral anticoagulant for at least 5 days
- To reduce the risk of recurrence of VTE in patients who have been previously treated

**AND**

2.3 ONE of the following:

- Trial and failure, contraindication, or intolerance to Brand Pradaxa capsules (verified via paid pharmacy claims or submitted chart notes)
- Patient is unable to swallow oral tablets/capsules

**2 . Revision History**

Date	Notes
10/3/2023	New





Praluent



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140811
<b>Guideline Name</b>	Praluent
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2023
-----------------	-----------

## 1 . Criteria

Product Name: Praluent			
Diagnosis	Primary Hyperlipidemia [Including Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD), and Secondary Prevention of Cardiovascular Events in Patients with ASCVD]		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PRALUENT	ALIROCUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 75 MG/ML	3935001000D520	Brand

PRALUENT	ALIROCUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML	3935001000D530	Brand
----------	--	----------------	-------

**Approval Criteria**

1 - Diagnosis of ONE of the following:

1.1 Heterozygous familial hypercholesterolemia (HeFH) as confirmed by ONE of the following\*:

1.1.1 BOTH of the following:

1.1.1.1 Pre-treatment low density lipoprotein cholesterol (LDL-C) of ONE of the following:

- Greater than 190 milligrams per deciliter (mg/dL)
- Greater than 155 mg/dL if less than 16 years of age

**AND**

1.1.1.2 ONE of the following:

- Family history of myocardial infarction in first-degree relative less than 60 years of age
- Family history of myocardial infarction in second-degree relative less than 50 years of age
- Family history of LDL-C greater than 190 mg/dL in first- or second-degree relative
- Family history of heterozygous or homozygous familial hypercholesterolemia in first- or second-degree relative
- Family history of tendinous xanthomata and/or arcus cornealis in first- or second degree relative

**OR**

1.1.2 BOTH of the following:

1.1.2.1 Pre-treatment LDL-C of ONE of the following:

- Greater than 190 mg/dL
- Greater than 155 mg/dL if less than 16 years of age

**AND**

**1.1.2.2** Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following:

- Functional mutation in LDL (low density lipoprotein), apoB (apolipoprotein B), or PCSK9 (proprotein convertase subtilisin/kexin type 9) gene\*
- Tendinous xanthomata
- Arcus cornealis before age 45

**OR**

**1.2** Atherosclerotic cardiovascular disease (ASCVD) as confirmed by ONE of the following:

- Acute coronary syndromes
- History of myocardial infarction
- Stable or unstable angina
- Coronary or other arterial revascularization
- Stroke
- Transient ischemic attack
- Peripheral arterial disease presumed to be of atherosclerotic origin

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following [prescription claims history may be used in conjunction as documentation of medication use, dose, and duration]:

**2.1** Patient has been receiving at least 12 consecutive weeks of high-intensity statin therapy [i.e. atorvastatin 40-80 milligrams (mg), rosuvastatin 20-40mg] and will continue to receive high intensity statin at maximally tolerated dose

**OR**

**2.2** BOTH of the following:

**2.2.1** Patient is unable to tolerate high-intensity statin as evidenced by one of the following intolerable and persistent (i.e. more than 2 weeks) symptoms:

- Myalgia (muscle symptoms without creatine kinase [CK] elevations)
- Myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN])

**AND**

**2.2.2 ONE of the following:**

**2.2.2.1** Patient has been receiving at least 12 consecutive weeks of moderate-intensity statin [i.e. atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin greater than or equal to 20 mg, pravastatin greater than or equal to 40 mg, lovastatin 40 mg, Lescol XL (fluvastatin XL) 80 mg, fluvastatin 40 mg twice daily or Livalo (pitavastatin) greater than or equal to 2 mg] and will continue to receive a moderate-intensity statin at maximally tolerated dose

**OR**

**2.2.2.2** Patient has been receiving at least 12 consecutive weeks of low-intensity statin [i.e. simvastatin 10 mg, pravastatin 10-20 mg, lovastatin 20 mg, fluvastatin 20-40 mg, or Livalo (pitavastatin) 1 mg] therapy and will continue to receive a low-intensity statin at maximally tolerated dose

**OR**

**2.3** Patient is unable to tolerate low or moderate-, and high-intensity statins as evidenced by ONE of the following:

**2.3.1** ONE of the following intolerable and persistent (i.e. more than 2 weeks) symptoms for low or moderate-, and high-intensity statins:

- Myalgia (muscle symptoms without CK elevations)
- Myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN])

**OR**

**2.3.2** Patient has a labeled contraindication to all statins as documented in medical records

**OR**

**2.3.3** Patient has experienced rhabdomyolysis or muscle symptoms with statin treatment with CK elevations greater than 10 times ULN

**AND**

**3** - ONE of the following:

**3.1** Submission of medical records (e.g., laboratory values) documenting ONE of the following LDL-C values while on maximally tolerated lipid lowering therapy for a minimum of at least 12 weeks within the last 120 days:

- LDL-C greater than or equal to 100 mg/dL with ASCVD
- LDL-C greater than or equal to 130 mg/dL without ASCVD

**OR**

**3.2** BOTH of the following:

**3.2.1** Submission of medical records (e.g., laboratory values) documenting ONE of the following LDL-C values while on maximally tolerated lipid lowering therapy for a minimum of at least 12 weeks within the last 120 days:

- LDL-C between 55 mg/dL and 99 mg/dL with ASCVD
- LDL-C between 100 mg/dL and 129 mg/dL without ASCVD

**AND**

**3.2.2** Submission of medical records (e.g., laboratory values) documenting ONE of the following [prescription claims history may be used in conjunction as documentation of medication use, dose, and duration]:

**3.2.2.1** Patient has been receiving at least 12 consecutive weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy

**OR**

**3.2.2.2** Patient has a history of contraindication or intolerance to ezetimibe

**AND**

**4** - Used as an adjunct to a low-fat diet and exercise

**AND**

**5** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**6** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (e.g., Repatha (evolcumab))

Notes	*Note: Results of prior genetic testing can be submitted as confirmation of diagnosis of HeFH.
-------	--

**Product Name: Praluent**

Diagnosis	Primary Hyperlipidemia [Including Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD), and Secondary Prevention of Cardiovascular Events in Patients with ASCVD]
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
PRALUENT	ALIROCUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 75 MG/ML	3935001000D520	Brand
PRALUENT	ALIROCUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML	3935001000D530	Brand

**Approval Criteria**

**1** - Patient continues to receive statin at maximally tolerated dose (unless patient has documented inability to take statins)

**AND**

**2** - Patient is continuing a low-fat diet and exercise regimen

**AND**

**3** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**4** - Submission of medical records (e.g. chart notes, laboratory values) documenting low density lipoprotein cholesterol (LDL-C) reduction while on Praluent therapy

**AND**

**5** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (e.g., Repatha (evolocumab))

Product Name: Praluent			
Diagnosis	Homozygous Familial Hypercholesterolemia		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PRALUENT	ALIROCUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 75 MG/ML	3935001000D520	Brand
PRALUENT	ALIROCUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML	3935001000D530	Brand

**Approval Criteria**

**1** - Diagnosis of homozygous familial hypercholesterolemia (HoFH) as confirmed by submission of medical records (e.g., chart notes, laboratory values) documenting BOTH of the following:\*

**1.1** ONE of the following:

- Pre-treatment LDL-C (low-density lipoprotein cholesterol) greater than 500 mg/dL (milligrams per deciliter)
- Treated LDL-C greater than 300 mg/dL

**AND**

**1.2** ONE of the following:

- Xanthoma before 10 years of age
- Evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents

**AND**

**2** - Used as an adjunct to a low-fat diet and exercise

**AND**

**3** - Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, LDL [low-density lipoprotein] apheresis)

**AND**

**4** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist



**AND**

**5** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (e.g., Repatha (evolocumab))

Notes	*Results of prior genetic testing can be submitted as confirmation of diagnosis of HoFH.
-------	--

Product Name: Praluent			
Diagnosis	Homozygous Familial Hypercholesterolemia		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PRALUENT	ALIROCUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 75 MG/ML	3935001000D520	Brand
PRALUENT	ALIROCUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML	3935001000D530	Brand

**Approval Criteria**

**1** - Patient continues to receive other lipid-lowering therapy (e.g., statin, LDL apheresis)

**AND**

**2** - Patient is continuing a low-fat diet and exercise regimen

**AND**

**3** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**4** - Submission of medical records (e.g. chart notes, laboratory values) documenting low density lipoprotein cholesterol (LDL-C) reduction while on Praluent therapy

**AND**

**5** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (e.g., Repatha (evolocumab))

## 2 . Revision History

Date	Notes
9/11/2023	Updated SP to standard formulary. Update to account for 2022 ACC recommendations of a lower LDL threshold of 55mg/dl for patients with ASCVD at very high risk.

Preferred Drugs



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140727
<b>Guideline Name</b>	Preferred Drugs
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Diagnosis	Prior Authorization Administrative Guideline for Preferred Drugs Without Drug-Specific Criteria		
Approval Length	12 month(s)		
Guideline Type	Administrative		
Product Name	Generic Name	GPI	Brand/Generic
Preferred			
Drug Specific			
No PA			
<b>Approval Criteria</b>			

**1** - ALL of the following:

**1.1** ONE of the following:

**1.1.1** The requested drug must be used for a Food and Drug Administration (FDA)-approved indication

**OR**

**1.1.2** The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology

**AND**

**1.2** The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plans' program

**AND**

**1.3** If the patient is less than FDA minimum age, the prescriber attests they are aware of FDA labeling and feels the treatment with the requested product is medically necessary. (Document rationale for use)

Notes	Medications used solely for anti-obesity/weight loss, cosmetic (e.g., alopecia, actinic keratosis, vitiligo), erectile dysfunction, and sexual dysfunction purposes are NOT medically accepted indications and are NOT recognized as a covered benefit. Erectile dysfunction drugs (Cialis/Tadalafil) are covered for clinical diagnoses other than ED.
-------	---

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22



Preferred Non-Solid Dosage Forms



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140783
<b>Guideline Name</b>	Preferred Non-Solid Dosage Forms
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	4/16/2023
-----------------	-----------

### 1 . Criteria

Diagnosis	Requests for Non-Solid Dosage Forms		
Approval Length	12 month(s)		
Guideline Type	Administrative		
Product Name	Generic Name	GPI	Brand/Generic
Non-solid dosage forms			
Non solid dosage forms			
Solid oral dosage forms			

**Approval Criteria**

**1** - ONE of the following:

**1.1** Requested drug must be used for an FDA (Food and Drug Administration)-approved indication

**OR**

**1.2** The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopeia-National Formulary (USP-NF)

**AND**

**2** - The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plans' program

**AND**

**3** - ONE of the following:

**3.1** BOTH of the following:

**3.1.1** The patient is able to swallow a solid dosage form

**AND**

**3.1.2** ONE of the following:

**3.1.2.1** History of failure, contraindication, or intolerance to at least THREE preferred\* solid oral dosage forms (Prior trials of formulary/PDL (preferred drug list) alternatives must sufficiently demonstrate that the formulary/PDL alternatives are either ineffective or inappropriate at the time of the request. NOTE: In instances where there are fewer than three preferred alternatives, the patient must have a history of failure, contraindication, or intolerance to ALL of the preferred products.)

**OR**

**3.1.2.2** There are no preferred formulary alternatives for the requested drug

**OR**

**3.2** Patient is unable to swallow a solid dosage form

**OR**

**3.3** Patient utilizes a feeding tube for medication administration

**OR**

**3.4** Request is for a nebulized formulation of an inhaled medication for a patient who has an inability to effectively utilize an agent in an inhaler formulation due to neuromuscular or cognitive disability, or other evidence of lack of response to the inhaled formulation supported by clinical documentation

Notes

\*PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP>



Pretomanid



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140653
<b>Guideline Name</b>	Pretomanid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Pretomanid			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PRETOMANID	PRETOMANID TAB 200 MG	09000063000320	Generic
<p><b>Approval Criteria</b></p> <p>1 - One of the following:</p> <p>1.1 Diagnosis of pulmonary extensively drug resistant (XDR) tuberculosis (TB)</p>			

**OR**

**1.2** Treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB)

**AND**

**2** - Pretomanid will be used in combination with bedaquiline and linezolid

## 2 . Revision History

Date	Notes
5/12/2020	New program

Prevymis



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140987
<b>Guideline Name</b>	Prevymis
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Prevymis			
Diagnosis	CMV Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients		
Approval Length	6 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PREVMIS	LETERMOVIR TAB 240 MG	12200045000320	Brand
PREVMIS	LETERMOVIR TAB 480 MG	12200045000340	Brand

**Approval Criteria**

1 - Patient is a recipient of an allogeneic hematopoietic stem cell transplant

**AND**

2 - Patient is cytomegalovirus (CMV) seropositive (R+)

**AND**

3 - Provider attests that Prevyomis will be initiated between Day 0 and Day 28 post-transplantation (before or after engraftment) and is being prescribed as prophylaxis and not treatment of CMV infection

Product Name: Prevyomis			
Diagnosis	CMV Prophylaxis in Kidney Transplant Recipients		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PREVYMIS	LETERMOVIR TAB 240 MG	12200045000320	Brand
PREVYMIS	LETERMOVIR TAB 480 MG	12200045000340	Brand

**Approval Criteria**

1 - Patient is a recipient of a kidney transplant

**AND**

2 - Patient is cytomegalovirus (CMV) seronegative [Donor CMV seropositive/Recipient CMV seronegative (D+/R-)]

**AND**

**3** - Provider attests that Prevymsis will be initiated between Day 0 and Day 7 post-transplantation; and is being prescribed as prophylaxis and not treatment of CMV infection

## 2 . Revision History

Date	Notes
7/10/2023	Updated indications and added new criteria section for kidney transplant, cleaned up criteria.

Primary Hyperoxaluria (PH1) Agents [Oxlumo (lumasiran), Rivfloza (nedosiran)]



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-145524
<b>Guideline Name</b>	Primary Hyperoxaluria (PH1) Agents [Oxlumo (lumasiran), Rivfloza (nedosiran)]
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Oxlumo			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OXLUMO	LUMASIRAN SODIUM SUBCUTANEOUS SOLN 94.5 MG/0.5ML	56626040202020	Brand
<b>Approval Criteria</b>			

**1 - Diagnosis of primary hyperoxaluria type 1 (PH1)**

**AND**

**2 - Submission of medical records (e.g., chart notes) documenting diagnosis has been confirmed by BOTH of the following:**

**2.1 ONE of the following:**

- Elevated urinary oxalate excretion
- Elevated plasma oxalate concentration
- Spot urinary oxalate to creatinine molar ratio greater than normal for age

**AND**

**2.2 ONE of the following:**

- Genetic testing demonstrating a mutation in the alanine:glyoxylate aminotransferase (AGXT) gene
- Liver biopsy demonstrating absence or reduced alanine:glyoxylate aminotransferase (AGT) activity

**AND**

**3 - Patient has NOT received a liver transplant**

**AND**

**4 - Prescribed by or in consultation with ONE of the following:**

- Hepatologist
- Nephrologist
- Urologist
- Geneticist
- Specialist with expertise in the treatment of PH1

Product Name: Rivfloza

Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RIVFLOZA	NEDOSIRAN SODIUM SUBCUTANEOUS SOLN PREF SYR 128 MG/0.8ML	5662605060E520	Brand
RIVFLOZA	NEDOSIRAN SODIUM SUBCUTANEOUS SOLN PREF SYR 160 MG/ML	5662605060E530	Brand
RIVFLOZA	NEDOSIRAN SODIUM SUBCUTANEOUS SOLN 80 MG/0.5ML	56626050602020	Brand

**Approval Criteria**

1 - Diagnosis of primary hyperoxaluria type 1 (PH1)

**AND**

2 - Submission of medical records (e.g., chart notes) documenting diagnosis has been confirmed by BOTH of the following:

2.1 ONE of the following:

- Elevated urinary oxalate excretion
- Elevated plasma oxalate concentration
- Spot urinary oxalate to creatinine molar ratio greater than normal for age

**AND**

2.2 ONE of the following:

- Genetic testing demonstrating a mutation in the alanine:glyoxylate aminotransferase (AGXT) gene
- Liver biopsy demonstrating absence or reduced alanine:glyoxylate aminotransferase (AGT) activity

**AND**



**3** - Patient is 9 years of age or older

**AND**

**4** - Patient has preserved kidney function [e.g., estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m<sup>2</sup>]

**AND**

**5** - Patient has NOT received a liver transplant

**AND**

**6** - Prescribed by or in consultation with ONE of the following:

- Hepatologist
- Nephrologist
- Urologist
- Geneticist
- Specialist with expertise in the treatment of PH1

Product Name: Oxlumo, Rivfloza			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
OXLUMO	LUMASIRAN SODIUM SUBCUTANEOUS SOLN 94.5 MG/0.5ML	56626040202020	Brand
RIVFLOZA	NEDOSIRAN SODIUM SUBCUTANEOUS SOLN PREF SYR 128 MG/0.8ML	5662605060E520	Brand
RIVFLOZA	NEDOSIRAN SODIUM SUBCUTANEOUS SOLN PREF SYR 160 MG/ML	5662605060E530	Brand
RIVFLOZA	NEDOSIRAN SODIUM SUBCUTANEOUS SOLN 80 MG/0.5ML	56626050602020	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming positive clinical response to therapy (e.g., decreased urinary oxalate excretion, decreased plasma oxalate concentration)

**AND**

2 - Patient has NOT received a liver transplant

**AND**

3 - Prescribed by or in consultation with ONE of the following:

- Hepatologist
- Nephrologist
- Urologist
- Geneticist
- Specialist with expertise in the treatment of PH1

**2 . Revision History**

Date	Notes
4/8/2024	Added criteria for new target drug Rivfloza. Updated GPI table and product name list accordingly. Updated guideline name.

Procysbi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140934
<b>Guideline Name</b>	Procysbi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Procysbi			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PROCYSBI	CYSTEAMINE BITARTRATE DELAYED RELEASE GRANULES PACKET 75 MG	56400030103020	Brand
PROCYSBI	CYSTEAMINE BITARTRATE DELAYED RELEASE GRANULES PACKET 300 MG	56400030103040	Brand
PROCYSBI	CYSTEAMINE BITARTRATE CAP DELAYED RELEASE 25 MG (BASE EQUIV)	56400030106520	Brand

PROCYSBI	CYSTEAMINE BITARTRATE CAP DELAYED RELEASE 75 MG (BASE EQUIV)	56400030106530	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of nephropathic cystinosis</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is 1 year of age or older</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - History of failure or intolerance to Cystagon (immediate-release cysteamine bitartrate)*</p>			
Notes		*Frequency of dosing and/or lack of compliance to dosing regimens is not generally considered an indication of medical necessity.	

Product Name: Procysbi			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PROCYSBI	CYSTEAMINE BITARTRATE DELAYED RELEASE GRANULES PACKET 75 MG	56400030103020	Brand
PROCYSBI	CYSTEAMINE BITARTRATE DELAYED RELEASE GRANULES PACKET 300 MG	56400030103040	Brand
PROCYSBI	CYSTEAMINE BITARTRATE CAP DELAYED RELEASE 25 MG (BASE EQUIV)	56400030106520	Brand
PROCYSBI	CYSTEAMINE BITARTRATE CAP DELAYED RELEASE 75 MG (BASE EQUIV)	56400030106530	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Procysbi therapy</p>			

## 2 . Revision History

Date	Notes
8/10/2022	C&S to match AZM 10.1.22

Progesterone - Non-Oral



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140647
<b>Guideline Name</b>	Progesterone - Non-Oral
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Crinone, Endometrin			
Approval Length	6 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CRINONE	PROGESTERONE VAGINAL GEL 4%	55370060004010	Brand
CRINONE	PROGESTERONE VAGINAL GEL 8%	55370060004020	Brand
ENDOMETRIN	PROGESTERONE VAGINAL INSERT 100 MG	55370060009910	Brand
<b>Approval Criteria</b>			

1 - Treatment is for non-infertility use (e.g., secondary amenorrhea, reduce the risk of recurrent spontaneous preterm birth)

## 2 . Revision History

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Progesterone - Oral



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-161395
<b>Guideline Name</b>	Progesterone - Oral
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name: Brand Prometrium, generic progesterone caps			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PROGESTERONE	PROGESTERONE CAP 100 MG	26000040000120	Generic
PROMETRIUM	PROGESTERONE CAP 100 MG	26000040000120	Brand
PROGESTERONE	PROGESTERONE CAP 200 MG	26000040000140	Generic
PROMETRIUM	PROGESTERONE CAP 200 MG	26000040000140	Brand
<b>Approval Criteria</b>			



**1 - Diagnosis of ONE of the following:**

- Amenorrhea
- Endometrial hyperplasia or prevention of endometrial hyperplasia
- Abnormal uterine or vaginal bleeding
- History of preterm birth
- Prevention of preterm delivery for current pregnancy

**2 . Revision History**

Date	Notes
11/27/2024	Updated product name list

Provigil, Nuvigil



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140691
<b>Guideline Name</b>	Provigil, Nuvigil
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Provigil, generic modafinil, Brand Nuvigil, generic armodafinil			
Diagnosis	Narcolepsy, Obstructive Sleep Apnea, Shift Work Disorder, Idiopathic Hypersomnia (off label)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MODAFINIL	MODAFINIL TAB 100 MG	61400024000310	Generic
PROVIGIL	MODAFINIL TAB 100 MG	61400024000310	Brand
MODAFINIL	MODAFINIL TAB 200 MG	61400024000320	Generic
PROVIGIL	MODAFINIL TAB 200 MG	61400024000320	Brand

ARMODAFINIL	ARMODAFINIL TAB 50 MG	61400010000310	Generic
NUVIGIL	ARMODAFINIL TAB 50 MG	61400010000310	Brand
ARMODAFINIL	ARMODAFINIL TAB 150 MG	61400010000330	Generic
NUVIGIL	ARMODAFINIL TAB 150 MG	61400010000330	Brand
ARMODAFINIL	ARMODAFINIL TAB 200 MG	61400010000335	Generic
NUVIGIL	ARMODAFINIL TAB 200 MG	61400010000335	Brand
ARMODAFINIL	ARMODAFINIL TAB 250 MG	61400010000340	Generic
NUVIGIL	ARMODAFINIL TAB 250 MG	61400010000340	Brand

**Approval Criteria**

1 - ONE of the following diagnoses:

- Narcolepsy
- Excessive sleepiness due to obstructive sleep apnea
- Excessive sleepiness due to shift work disorder (circadian rhythm sleep disorder, shift work type)
- Idiopathic hypersomnia

**AND**

2 - If the request is for modafinil, the patient has a history of failure, contraindication, or intolerance to armodafinil

Product Name: Brand Provigil, generic modafinil, Brand Nuvigil, generic armodafinil			
Diagnosis	Fatigue due to Multiple Sclerosis (off-label)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MODAFINIL	MODAFINIL TAB 100 MG	61400024000310	Generic
PROVIGIL	MODAFINIL TAB 100 MG	61400024000310	Brand
MODAFINIL	MODAFINIL TAB 200 MG	61400024000320	Generic
PROVIGIL	MODAFINIL TAB 200 MG	61400024000320	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ARMODAFINIL	ARMODAFINIL TAB 50 MG	61400010000310	Generic
NUVIGIL	ARMODAFINIL TAB 50 MG	61400010000310	Brand
ARMODAFINIL	ARMODAFINIL TAB 150 MG	61400010000330	Generic
NUVIGIL	ARMODAFINIL TAB 150 MG	61400010000330	Brand
ARMODAFINIL	ARMODAFINIL TAB 200 MG	61400010000335	Generic
NUVIGIL	ARMODAFINIL TAB 200 MG	61400010000335	Brand
ARMODAFINIL	ARMODAFINIL TAB 250 MG	61400010000340	Generic
NUVIGIL	ARMODAFINIL TAB 250 MG	61400010000340	Brand

**Approval Criteria**

1 - Diagnosis of multiple sclerosis (MS)

**AND**

2 - Patient is experiencing fatigue

**AND**

3 - If the request is for modafinil, the patient has a history of failure, contraindication, or intolerance to armodafinil

Product Name: Brand Provigil, generic modafinil, Brand Nuvigil, generic armodafinil			
Diagnosis	Adjunctive Therapy for the Treatment of Major Depressive Disorder or Bipolar Depression (off-label)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MODAFINIL	MODAFINIL TAB 100 MG	61400024000310	Generic
PROVIGIL	MODAFINIL TAB 100 MG	61400024000310	Brand

MODAFINIL	MODAFINIL TAB 200 MG	61400024000320	Generic
PROVIGIL	MODAFINIL TAB 200 MG	61400024000320	Brand
ARMODAFINIL	ARMODAFINIL TAB 50 MG	61400010000310	Generic
NUVIGIL	ARMODAFINIL TAB 50 MG	61400010000310	Brand
ARMODAFINIL	ARMODAFINIL TAB 150 MG	61400010000330	Generic
NUVIGIL	ARMODAFINIL TAB 150 MG	61400010000330	Brand
ARMODAFINIL	ARMODAFINIL TAB 200 MG	61400010000335	Generic
NUVIGIL	ARMODAFINIL TAB 200 MG	61400010000335	Brand
ARMODAFINIL	ARMODAFINIL TAB 250 MG	61400010000340	Generic
NUVIGIL	ARMODAFINIL TAB 250 MG	61400010000340	Brand

**Approval Criteria**

**1** - Treatment-resistant depression, defined as BOTH of the following:

**1.1** Diagnosis of ONE of the following:

- Major depressive disorder (MDD)
- Bipolar depression

**AND**

**1.2** History of failure, contraindication, or intolerance to at least TWO antidepressants from different classes (e.g., SSRIs [selective serotonin reuptake inhibitors], SNRIs [serotonin-norepinephine reuptake inhibitors], bupropion)

**AND**

**2** - Used as adjunctive therapy

**AND**

**3** - If the request is for modafinil, the patient has a history of failure, contraindication, or intolerance to armodafinil

Product Name: Brand Provigil, generic modafinil, Brand Nuvigil, generic armodafinil	
Diagnosis	Adjunctive Therapy for the Treatment of Major Depressive Disorder or Bipolar Depression (off-label)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
MODAFINIL	MODAFINIL TAB 100 MG	61400024000310	Generic
PROVIGIL	MODAFINIL TAB 100 MG	61400024000310	Brand
MODAFINIL	MODAFINIL TAB 200 MG	61400024000320	Generic
PROVIGIL	MODAFINIL TAB 200 MG	61400024000320	Brand
ARMODAFINIL	ARMODAFINIL TAB 50 MG	61400010000310	Generic
NUVIGIL	ARMODAFINIL TAB 50 MG	61400010000310	Brand
ARMODAFINIL	ARMODAFINIL TAB 150 MG	61400010000330	Generic
NUVIGIL	ARMODAFINIL TAB 150 MG	61400010000330	Brand
ARMODAFINIL	ARMODAFINIL TAB 200 MG	61400010000335	Generic
NUVIGIL	ARMODAFINIL TAB 200 MG	61400010000335	Brand
ARMODAFINIL	ARMODAFINIL TAB 250 MG	61400010000340	Generic
NUVIGIL	ARMODAFINIL TAB 250 MG	61400010000340	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**AND**

2 - Used as adjunctive therapy

**AND**

3 - If the request is for modafinil, the patient has a history of failure, contraindication, or intolerance to armodafinil

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Pulmonary Arterial Hypertension (PAH) Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-156246
<b>Guideline Name</b>	Pulmonary Arterial Hypertension (PAH) Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Brand Adcirca, generic ambrisentan, generic bosentan, generic sildenafil 20 mg tabs, generic sildenafil susp, Brand Revatio susp, Adempas, generic Alyq, generic tadalafil 20 mg (PAH), Brand Letairis, Liqrev, Opsumit, Opsynvi, Orenitram Titration, Orenitram, Brand Revatio tabs, Tadliq, Brand Tracleer, Tracleer oral susp, Tyvaso, Tyvaso DPI, Upravi Titration, Upravi tabs, Ventavis			
Diagnosis	Pulmonary Arterial Hypertension		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ADCIRCA	TADALAFIL TAB 20 MG (PAH)	40143080000320	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AMBRISANTAN	AMBRISANTAN TAB 5 MG	40160007000310	Generic
AMBRISANTAN	AMBRISANTAN TAB 10 MG	40160007000320	Generic
BOSENTAN	BOSENTAN TAB 62.5 MG	40160015000320	Generic
BOSENTAN	BOSENTAN TAB 125 MG	40160015000330	Generic
SILDENAFIL CITRATE	SILDENAFIL CITRATE TAB 20 MG	40143060100320	Generic
SILDENAFIL CITRATE	SILDENAFIL CITRATE FOR SUSPENSION 10 MG/ML	40143060101920	Generic
REVATIO	SILDENAFIL CITRATE FOR SUSPENSION 10 MG/ML	40143060101920	Brand
ADEMPAS	RIOCIGUAT TAB 0.5 MG	40134050000310	Brand
ADEMPAS	RIOCIGUAT TAB 1 MG	40134050000320	Brand
ADEMPAS	RIOCIGUAT TAB 1.5 MG	40134050000330	Brand
ADEMPAS	RIOCIGUAT TAB 2 MG	40134050000340	Brand
ADEMPAS	RIOCIGUAT TAB 2.5 MG	40134050000350	Brand
ALYQ	TADALAFIL TAB 20 MG (PAH)	40143080000320	Generic
TADALAFIL	TADALAFIL TAB 20 MG (PAH)	40143080000320	Generic
LETAIRIS	AMBRISANTAN TAB 5 MG	40160007000310	Brand
LETAIRIS	AMBRISANTAN TAB 10 MG	40160007000320	Brand
OPSUMIT	MACITENTAN TAB 10 MG	40160050000320	Brand
ORENITRAM TITRATION KIT MONTH 1	TREPROSTINIL TAB ER TITR PK (MO1) 126 X0.125MG & 42 X0.25MG	4017008005C110	Brand
ORENITRAM TITRATION KIT MONTH 2	TREPROSTINIL TAB ER TITR PK (MO2) 126 X0.125MG & 210 X0.25MG	4017008005C120	Brand
ORENITRAM TITRATION KIT MONTH 3	TREPROSTINIL TAB ER TITR PK(MO3)126X0.125MG&42X0.25MG&84X1MG	4017008005C130	Brand
ORENITRAM	TREPROSTINIL DIOLAMINE TAB ER 0.125 MG (BASE EQUIV)	40170080050410	Brand
ORENITRAM	TREPROSTINIL DIOLAMINE TAB ER 0.25 MG (BASE EQUIV)	40170080050415	Brand
ORENITRAM	TREPROSTINIL DIOLAMINE TAB ER 1 MG (BASE EQUIV)	40170080050420	Brand
ORENITRAM	TREPROSTINIL DIOLAMINE TAB ER 2.5 MG (BASE EQUIV)	40170080050425	Brand
ORENITRAM	TREPROSTINIL DIOLAMINE TAB ER 5 MG (BASE EQUIV)	40170080050435	Brand
REVATIO	SILDENAFIL CITRATE TAB 20 MG	40143060100320	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TADLIQ	TADALAFIL ORAL SUSP 20 MG/5ML (PAH)	40143080001820	Brand
TRACLEER	BOSENTAN TAB 62.5 MG	40160015000320	Brand
TRACLEER	BOSENTAN TAB 125 MG	40160015000330	Brand
TRACLEER	BOSENTAN TAB FOR ORAL SUSP 32 MG	40160015007320	Brand
TYVASO REFILL	TREPROSTINIL INHALATION SOLUTION 0.6 MG/ML	40170080002020	Brand
TYVASO STARTER	TREPROSTINIL INHALATION SOLUTION 0.6 MG/ML	40170080002020	Brand
TYVASO	TREPROSTINIL INHALATION SOLUTION 0.6 MG/ML	40170080002020	Brand
TYVASO DPI MAINTENANCE KIT	TREPROSTINIL INH POWDER 16 MCG/CARTRIDGE	40170080002920	Brand
TYVASO DPI MAINTENANCE KIT	TREPROSTINIL INH POWDER 32 MCG/CARTRIDGE	40170080002930	Brand
TYVASO DPI MAINTENANCE KIT	TREPROSTINIL INH POWDER 48 MCG/CARTRIDGE	40170080002940	Brand
TYVASO DPI MAINTENANCE KIT	TREPROSTINIL INH POWDER 64 MCG/CARTRIDGE	40170080002950	Brand
TYVASO DPI MAINTENANCE KIT	TREPROSTINIL INH POWDER 112 X 32MCG & 112 X 48MCG	40170080002960	Brand
TYVASO DPI TITRATION KIT	TREPROSTINIL INH POWDER 112 X 16MCG & 84 X 32MCG	40170080002970	Brand
TYVASO DPI TITRATION KIT	TREPROSTINIL INH POWD 112 X 16MCG & 112 X 32MCG & 28 X 48MCG	40170080002980	Brand
UPTRAVI TITRATION PACK	SELEXIPAG TAB THERAPY PACK 200 MCG (140) & 800 MCG (60)	4012007000B720	Brand
UPTRAVI	SELEXIPAG TAB 200 MCG	40120070000310	Brand
UPTRAVI	SELEXIPAG TAB 400 MCG	40120070000315	Brand
UPTRAVI	SELEXIPAG TAB 600 MCG	40120070000320	Brand
UPTRAVI	SELEXIPAG TAB 800 MCG	40120070000325	Brand
UPTRAVI	SELEXIPAG TAB 1000 MCG	40120070000330	Brand
UPTRAVI	SELEXIPAG TAB 1200 MCG	40120070000335	Brand
UPTRAVI	SELEXIPAG TAB 1400 MCG	40120070000340	Brand
UPTRAVI	SELEXIPAG TAB 1600 MCG	40120070000345	Brand
VENTAVIS	ILOPROST INHALATION SOLUTION 10 MCG/ML	40170060002020	Brand

VENTAVIS	ILOPROST INHALATION SOLUTION 20 MCG/ML	40170060002040	Brand
LIQREV	SILDENAFIL CITRATE ORAL SUSP 10 MG/ML	40143060101825	Brand
OPSYNVI	MACITENTAN-TADALAFIL TAB 10-20 MG	40995502500310	Brand
OPSYNVI	MACITENTAN-TADALAFIL TAB 10-40 MG	40995502500320	Brand

**Approval Criteria**

1 - Diagnosis of pulmonary arterial hypertension

**AND**

2 - Pulmonary arterial hypertension is symptomatic

**AND**

3 - ONE of the following:

3.1 Diagnosis of pulmonary arterial hypertension was confirmed by right heart catheterization

**OR**

3.2 Patient is currently on any therapy for the diagnosis of pulmonary arterial hypertension

**AND**

4 - Prescribed by or in consultation with ONE of the following:

- Pulmonologist
- Cardiologist

**AND**

5 - If the request is non-preferred\*, patient has a history of failure, contraindication, or

intolerance to at least THREE preferred\* alternatives (NOTE: In instances where there are fewer than three preferred alternatives, the patient must have a history of failure, contraindication, or intolerance to ALL of the preferred products)

**AND**

**6** - If the request is for Brand Adcirca, patient must have tried and failed generic tadalafil 20 mg (PAH) or Alyq

**AND**

**7** - If the request is for Brand Revatio suspension, ALL of the following:

- Patient is between 12 and 17 years of age
- Trial and failure or intolerance to oral tablet formulation
- Trial and failure or intolerance to generic sildenafil suspension

**AND**

**8** - If the request is for Opsynvi, patient must have tried and failed BOTH of the following as separate products:

- generic tadalafil 20 mg (PAH)
- Opsumit^

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a> ^Drug may require PA.
-------	---

Product Name: Brand Adcirca, generic ambrisentan, generic bosentan, generic sildenafil 20 mg tabs, generic sildenafil susp, Brand Revatio susp, Adempas, generic Alyq, generic tadalafil 20 mg (PAH), Brand Letairis, Liqrev, Opsumit, Opsynvi, Orenitram Titration, Orenitram, Brand Revatio tabs, Tadliq, Brand Tracleer, Tracleer oral susp, Tyvaso, Tyvaso DPI, Upravi Titration, Upravi tabs, Ventavis	
Diagnosis	Pulmonary Arterial Hypertension
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name	Generic Name	GPI	Brand/Generic
ADCIRCA	TADALAFIL TAB 20 MG (PAH)	40143080000320	Brand
AMBRISENTAN	AMBRISENTAN TAB 5 MG	40160007000310	Generic
AMBRISENTAN	AMBRISENTAN TAB 10 MG	40160007000320	Generic
BOSENTAN	BOSENTAN TAB 62.5 MG	40160015000320	Generic
BOSENTAN	BOSENTAN TAB 125 MG	40160015000330	Generic
SILDENAFIL CITRATE	SILDENAFIL CITRATE TAB 20 MG	40143060100320	Generic
SILDENAFIL CITRATE	SILDENAFIL CITRATE FOR SUSPENSION 10 MG/ML	40143060101920	Generic
REVATIO	SILDENAFIL CITRATE FOR SUSPENSION 10 MG/ML	40143060101920	Brand
ADEMPAS	RIOCIGUAT TAB 0.5 MG	40134050000310	Brand
ADEMPAS	RIOCIGUAT TAB 1 MG	40134050000320	Brand
ADEMPAS	RIOCIGUAT TAB 1.5 MG	40134050000330	Brand
ADEMPAS	RIOCIGUAT TAB 2 MG	40134050000340	Brand
ADEMPAS	RIOCIGUAT TAB 2.5 MG	40134050000350	Brand
ALYQ	TADALAFIL TAB 20 MG (PAH)	40143080000320	Generic
TADALAFIL	TADALAFIL TAB 20 MG (PAH)	40143080000320	Generic
LETAIRIS	AMBRISENTAN TAB 5 MG	40160007000310	Brand
LETAIRIS	AMBRISENTAN TAB 10 MG	40160007000320	Brand
OPSUMIT	MACITENTAN TAB 10 MG	40160050000320	Brand
ORENITRAM TITRATION KIT MONTH 1	TREPROSTINIL TAB ER TITR PK (MO1) 126 X0.125MG & 42 X0.25MG	4017008005C110	Brand
ORENITRAM TITRATION KIT MONTH 2	TREPROSTINIL TAB ER TITR PK (MO2) 126 X0.125MG & 210 X0.25MG	4017008005C120	Brand
ORENITRAM TITRATION KIT MONTH 3	TREPROSTINIL TAB ER TITR PK(MO3)126X0.125MG&42X0.25MG&84X1MG	4017008005C130	Brand
ORENITRAM	TREPROSTINIL DIOLAMINE TAB ER 0.125 MG (BASE EQUIV)	40170080050410	Brand
ORENITRAM	TREPROSTINIL DIOLAMINE TAB ER 0.25 MG (BASE EQUIV)	40170080050415	Brand
ORENITRAM	TREPROSTINIL DIOLAMINE TAB ER 1 MG (BASE EQUIV)	40170080050420	Brand
ORENITRAM	TREPROSTINIL DIOLAMINE TAB ER 2.5 MG (BASE EQUIV)	40170080050425	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ORENITRAM	TREPROSTINIL DIOLAMINE TAB ER 5 MG (BASE EQUIV)	40170080050435	Brand
REVATIO	SILDENAFIL CITRATE TAB 20 MG	40143060100320	Brand
TADLIQ	TADALAFIL ORAL SUSP 20 MG/5ML (PAH)	40143080001820	Brand
TRACLEER	BOSENTAN TAB 62.5 MG	40160015000320	Brand
TRACLEER	BOSENTAN TAB 125 MG	40160015000330	Brand
TRACLEER	BOSENTAN TAB FOR ORAL SUSP 32 MG	40160015007320	Brand
TYVASO REFILL	TREPROSTINIL INHALATION SOLUTION 0.6 MG/ML	40170080002020	Brand
TYVASO STARTER	TREPROSTINIL INHALATION SOLUTION 0.6 MG/ML	40170080002020	Brand
TYVASO	TREPROSTINIL INHALATION SOLUTION 0.6 MG/ML	40170080002020	Brand
TYVASO DPI MAINTENANCE KIT	TREPROSTINIL INH POWDER 16 MCG/CARTRIDGE	40170080002920	Brand
TYVASO DPI MAINTENANCE KIT	TREPROSTINIL INH POWDER 32 MCG/CARTRIDGE	40170080002930	Brand
TYVASO DPI MAINTENANCE KIT	TREPROSTINIL INH POWDER 48 MCG/CARTRIDGE	40170080002940	Brand
TYVASO DPI MAINTENANCE KIT	TREPROSTINIL INH POWDER 64 MCG/CARTRIDGE	40170080002950	Brand
TYVASO DPI MAINTENANCE KIT	TREPROSTINIL INH POWDER 112 X 32MCG & 112 X 48MCG	40170080002960	Brand
TYVASO DPI TITRATION KIT	TREPROSTINIL INH POWDER 112 X 16MCG & 84 X 32MCG	40170080002970	Brand
TYVASO DPI TITRATION KIT	TREPROSTINIL INH POWD 112 X 16MCG & 112 X 32MCG & 28 X 48MCG	40170080002980	Brand
UPTRAVI TITRATION PACK	SELEXIPAG TAB THERAPY PACK 200 MCG (140) & 800 MCG (60)	4012007000B720	Brand
UPTRAVI	SELEXIPAG TAB 200 MCG	40120070000310	Brand
UPTRAVI	SELEXIPAG TAB 400 MCG	40120070000315	Brand
UPTRAVI	SELEXIPAG TAB 600 MCG	40120070000320	Brand
UPTRAVI	SELEXIPAG TAB 800 MCG	40120070000325	Brand
UPTRAVI	SELEXIPAG TAB 1000 MCG	40120070000330	Brand
UPTRAVI	SELEXIPAG TAB 1200 MCG	40120070000335	Brand
UPTRAVI	SELEXIPAG TAB 1400 MCG	40120070000340	Brand

UPTRAVI	SELEXIPAG TAB 1600 MCG	40120070000345	Brand
VENTAVIS	ILOPROST INHALATION SOLUTION 10 MCG/ML	40170060002020	Brand
VENTAVIS	ILOPROST INHALATION SOLUTION 20 MCG/ML	40170060002040	Brand
LIQREV	SILDENAFIL CITRATE ORAL SUSP 10 MG/ML	40143060101825	Brand
OPSYNVI	MACITENTAN-TADALAFIL TAB 10-20 MG	40995502500310	Brand
OPSYNVI	MACITENTAN-TADALAFIL TAB 10-40 MG	40995502500320	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

Product Name: Adempas			
Diagnosis	Chronic Thromboembolic Pulmonary Hypertension (CTEPH)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ADEMPAS	RIOCIGUAT TAB 0.5 MG	40134050000310	Brand
ADEMPAS	RIOCIGUAT TAB 1 MG	40134050000320	Brand
ADEMPAS	RIOCIGUAT TAB 1.5 MG	40134050000330	Brand
ADEMPAS	RIOCIGUAT TAB 2 MG	40134050000340	Brand
ADEMPAS	RIOCIGUAT TAB 2.5 MG	40134050000350	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 BOTH of the following:

1.1.1 Diagnosis of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH)

<p><b>AND</b></p> <p><b>1.1.2</b> CTEPH is symptomatic</p> <p><b>OR</b></p> <p><b>1.2</b> Patient is currently on any therapy for the diagnosis of CTEPH</p> <p><b>AND</b></p> <p><b>2</b> - Prescribed by or in consultation with <b>ONE</b> of the following:</p> <ul style="list-style-type: none"> <li>• Pulmonologist</li> <li>• Cardiologist</li> </ul>
---

<b>Product Name: Adempas</b>			
Diagnosis	Chronic Thromboembolic Pulmonary Hypertension (CTEPH)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ADEMPAS	RIOCIGUAT TAB 0.5 MG	40134050000310	Brand
ADEMPAS	RIOCIGUAT TAB 1 MG	40134050000320	Brand
ADEMPAS	RIOCIGUAT TAB 1.5 MG	40134050000330	Brand
ADEMPAS	RIOCIGUAT TAB 2 MG	40134050000340	Brand
ADEMPAS	RIOCIGUAT TAB 2.5 MG	40134050000350	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy			



Product Name: Winrevaair	
Diagnosis	Pulmonary Arterial Hypertension
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
WINREVAIR	SOTATERCEPT-CSRK FOR SUBCUTANEOUS SOLN KIT 45 MG	40110070206420	Brand
WINREVAIR	SOTATERCEPT-CSRK FOR SUBCUTANEOUS SOLN KIT 60 MG	40110070206425	Brand
WINREVAIR	SOTATERCEPT-CSRK FOR SUBCUTANEOUS SOLN KIT 2 X 45 MG	40110070206430	Brand
WINREVAIR	SOTATERCEPT-CSRK FOR SUBCUTANEOUS SOLN KIT 2 X 60 MG	40110070206435	Brand

**Approval Criteria**

1 - Diagnosis of pulmonary arterial hypertension

**AND**

2 - Pulmonary arterial hypertension is symptomatic

**AND**

3 - Patient is currently on at least TWO therapies indicated for the treatment of pulmonary arterial hypertension from the following different mechanisms of action, unless there is a contraindication or intolerance:

- Endothelin receptor antagonists (i.e., Bosentan, ambrisentan or macitentan)
- Phosphodiesterase 5 inhibitors (i.e., Tadalafil or sildenafil)

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Pulmonologist
- Cardiologist

Product Name: Winrevair			
Diagnosis	Pulmonary Arterial Hypertension		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
WINREVAIR	SOTATERCEPT-CSRK FOR SUBCUTANEOUS SOLN KIT 45 MG	40110070206420	Brand
WINREVAIR	SOTATERCEPT-CSRK FOR SUBCUTANEOUS SOLN KIT 60 MG	40110070206425	Brand
WINREVAIR	SOTATERCEPT-CSRK FOR SUBCUTANEOUS SOLN KIT 2 X 45 MG	40110070206430	Brand
WINREVAIR	SOTATERCEPT-CSRK FOR SUBCUTANEOUS SOLN KIT 2 X 60 MG	40110070206435	Brand
<b>Approval Criteria</b>			
1 - Patient demonstrates positive clinical response to therapy			

## 2 . Revision History

Date	Notes
9/25/2024	Added criteria for Winrevair. Updated embedded step for Brand Revatio to require step through generic sildenafil suspension instead of Liqrev.

Pulmozyme



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140864
<b>Guideline Name</b>	Pulmozyme
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Pulmozyme			
Diagnosis	Cystic Fibrosis		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PULMOZYME	DORNASE ALFA INHAL SOLN 1 MG/ML	45304020002010	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of Cystic Fibrosis			

## 2 . Revision History

Date	Notes
3/8/2021	Added product name list.

Pyrukynd (mitapivat)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140892
<b>Guideline Name</b>	Pyrukynd (mitapivat)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Pyrukynd			
Diagnosis	Hemolytic Anemia		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PYRUKYND TAPER PACK	MITAPIVAT SULFATE TAB THERAPY PACK 5 MG	8587005070B710	Brand
PYRUKYND TAPER PACK	MITAPIVAT SULFATE TAB THERAPY PACK 7 X 20 MG & 7 X 5 MG	8587005070B720	Brand

PYRUKYND TAPER PACK	MITAPIVAT SULFATE TAB THERAPY PACK 7 X 50 MG & 7 X 20 MG	8587005070B735	Brand
PYRUKYND	MITAPIVAT SULFATE TAB 5 MG	85870050700310	Brand
PYRUKYND	MITAPIVAT SULFATE TAB 20 MG	85870050700325	Brand
PYRUKYND	MITAPIVAT SULFATE TAB 50 MG	85870050700340	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ALL of the following:

**1.1** Diagnosis of hemolytic anemia confirmed by the presence of chronic hemolysis (e.g., increased indirect bilirubin, elevated lactated dehydrogenase [LDH], decreased haptoglobin, increased reticulocyte count)

**AND**

**1.2** Diagnosis of pyruvate kinase deficiency confirmed by molecular testing of ALL the following mutations on the PKLR gene:

- Presence of at least 2 variant alleles in the pyruvate kinase liver and red blood cell (PKLR) gene, of which at least 1 was a missense variant
- Patients is not homozygous for the c.1436G>A (p.R479H) variant
- Patient does not have 2 non-missense variants (without the presence of another missense variant) in the PKLR gene

**AND**

**1.3** Hemoglobin is less than or equal to 10g/dL

**AND**

**1.4** Patient has symptomatic anemia or is transfusion dependent

**AND**

**1.5** Exclusion of other causes of hemolytic anemias (e. g., infections, toxins, drugs)

**AND**

**2** - Prescribed by or in consultation with a hematologist

Product Name: Pyrukynd			
Diagnosis	Hemolytic Anemia		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
PYRUKYND TAPER PACK	MITAPIVAT SULFATE TAB THERAPY PACK 5 MG	8587005070B710	Brand
PYRUKYND TAPER PACK	MITAPIVAT SULFATE TAB THERAPY PACK 7 X 20 MG & 7 X 5 MG	8587005070B720	Brand
PYRUKYND TAPER PACK	MITAPIVAT SULFATE TAB THERAPY PACK 7 X 50 MG & 7 X 20 MG	8587005070B735	Brand
PYRUKYND	MITAPIVAT SULFATE TAB 5 MG	85870050700310	Brand
PYRUKYND	MITAPIVAT SULFATE TAB 20 MG	85870050700325	Brand
PYRUKYND	MITAPIVAT SULFATE TAB 50 MG	85870050700340	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy [e.g., hemoglobin greater than or equal to 1.5g/dL from baseline, reduction in transfusions of greater than or equal to 33% in the number of red blood cell units transfused during the fixed dose period compared with the patient's historical transfusion burden, improvement in markers of hemolysis from baseline (e.g., bilirubin, lactated dehydrogenase [LDH], haptoglobin, reticulocyte count)]

**AND**

<b>2 - Prescribed by or in consultation with a hematologist</b>	
Notes	If the member does not meet the medical necessity reauthorization criteria requirements, a denial should be issued and a 1-month authorization should be issued one time for Pyrukynd gradual therapy discontinuation.

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22



Qbrexza



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140795
<b>Guideline Name</b>	Qbrexza
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Qbrexza			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
QBREXZA	GLYCOPYRRONIUM TOSYLATE PAD 2.4% (BASE EQUIVALENT)	90970030204320	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of primary axillary hyperhidrosis			

**AND**

**2** - ONE of the following:

**2.1** Failure to Xerac-AC as confirmed by claims history or submission of medical records

**OR**

**2.2** History of contraindication or intolerance to Xerac-AC (please specify contraindication or intolerance)

## **2 . Revision History**

Date	Notes
5/16/2023	New

Qlosi, Vuity



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-143421
<b>Guideline Name</b>	Qlosi, Vuity
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	4/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Vuity			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VUITY	PILOCARPINE HCL OPHTH SOLN 1.25%	86501030102017	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of presbyopia			

**AND**

**2** - Patient is between the ages of 40 to 55

**AND**

**3** - Patient is unable to use corrective lenses (e.g., glasses, contacts) (document medical rationale why patient is unable to use corrective lenses)

**AND**

**4** - Prescribed by ONE of the following:

- Optometrist
- Ophthalmologist

Product Name: Vuity			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VUITY	PILOCARPINE HCL OPHTH SOLN 1.25%	86501030102017	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy

**AND**

**2** - Age less than 55

**AND**

**3** - Prescribed by ONE of the following:

- Optometrist
- Ophthalmologist

Product Name: Qlosi			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
Qlosi			

**Approval Criteria**

**1** - Diagnosis of presbyopia

**AND**

**2** - Patient is between the ages of 45 to 64

**AND**

**3** - Patient is unable to use corrective lenses (e.g., glasses, contacts) (document medical rationale why patient is unable to use corrective lenses)

**AND**

**4** - Prescribed by ONE of the following:

- Optometrist

- Ophthalmologist

Product Name: Qlosi			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
Qlosi			

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**AND**

2 - Age less than 64

**AND**

3 - Prescribed by ONE of the following:

- Optometrist
- Ophthalmologist

**2 . Revision History**

Date	Notes
2/22/2024	Added criteria for Qlosi (GPI currently unavailable). Name change from Vuity.

Qutenza (capsaicin)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140808
<b>Guideline Name</b>	Qutenza (capsaicin)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	9/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Qutenza			
Diagnosis	Neuropathic pain associated with postherpetic neuralgia (PHN)		
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
QUTENZA	CAPSAICIN PATCH 8% & CLEANSING GEL KIT	90850025306420	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) confirming diagnosis of neuropathic pain associated with postherpetic neuralgia (PHN)

**AND**

**2** - Submission of medical records (e.g., chart notes, paid claims history) documenting trial and failure, contraindication, or intolerance to ALL of the following:

- gabapentin
- pregabalin
- minimum 60-day trial of a tricyclic antidepressant (e.g., amitriptyline, nortriptyline, desipramine)
- generic lidocaine 5% patch
- topical capsaicin cream

Product Name: Qutenza			
Diagnosis	Neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet		
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
QUTENZA	CAPSAICIN PATCH 8% & CLEANSING GEL KIT	90850025306420	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming diagnosis of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet

**AND**

**2** - Submission of medical records (e.g., chart notes, paid claims history) documenting trial and failure, contraindication, or intolerance to ALL of the following:

- gabapentin



- pregabalin
- minimum 60-day trial of a tricyclic antidepressant (e.g., amitriptyline, nortriptyline, desipramine)
- generic lidocaine 5% patch
- topical capsaicin cream
- duloxetine

Product Name: Qutenza			
Diagnosis	Neuropathic pain associated with PHN, Neuropathic pain associated with DPN of the feet		
Approval Length	3 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
QUTENZA	CAPSAICIN PATCH 8% & CLEANSING GEL KIT	90850025306420	Brand

**Approval Criteria**

1 - It has been at least 3 months since the last application/administration

**AND**

2 - Patient experienced pain relief with a prior course of therapy

**AND**

3 - Patient is experiencing a return of neuropathic pain

**2 . Revision History**

Date	Notes
8/9/2023	New guideline



Radicava (edaravone)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140940
<b>Guideline Name</b>	Radicava (edaravone)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Radicava ORS			
Diagnosis	Amyotrophic Lateral Sclerosis (ALS)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RADICAVA ORS STARTER KIT	EDARAVONE ORAL SUSP 105 MG/5ML	74509030001820	Brand
RADICAVA ORS	EDARAVONE ORAL SUSP 105 MG/5ML	74509030001820	Brand

**Approval Criteria**

1 - Submission of documentation (e.g., chart notes) confirming diagnosis of “definite” or “probable” amyotrophic lateral sclerosis (ALS) per the revised EL Escorial and Airlie House diagnostic criteria

**AND**

2 - Prescribed by or in consultation with a neurologist with expertise in the diagnosis of ALS

**AND**

3 - Patient has scores greater than or equal to 2 in all items of the ALS Functional Rating Scale-Revised (ALSFRRS-R) criteria at the start of treatment

**AND**

4 - Patient has a percent forced vital capacity (%FVC) greater than or equal to 80% at the start of treatment

Product Name: Radicava ORS			
Diagnosis	Amyotrophic Lateral Sclerosis (ALS)		
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RADICAVA ORS STARTER KIT	EDARAVONE ORAL SUSP 105 MG/5ML	74509030001820	Brand
RADICAVA ORS	EDARAVONE ORAL SUSP 105 MG/5ML	74509030001820	Brand

**Approval Criteria**

1 - Submission of documentation (e.g., chart notes) confirming positive clinical response to therapy (e.g., slowing in the decline of functional abilities)

**AND**

2 - Patient is not dependent on invasive ventilation or tracheostomy

**2 . Revision History**

Date	Notes
10/21/2022	Removed the Radicava-solution (Medical benefit)

Ranolazine products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140748
<b>Guideline Name</b>	Ranolazine products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Ranexa, generic ranolazine			
Approval Length	12 month(s)		
Guideline Type	Step Therapy		
Product Name	Generic Name	GPI	Brand/Generic
RANEXA	RANOLAZINE TAB ER 12HR 500 MG	32200040007420	Brand
RANOLAZINE ER	RANOLAZINE TAB ER 12HR 500 MG	32200040007420	Generic
RANEXA	RANOLAZINE TAB ER 12HR 1000 MG	32200040007430	Brand
RANOLAZINE ER	RANOLAZINE TAB ER 12HR 1000 MG	32200040007430	Generic

**Approval Criteria**

1 - History of ONE of the following standard anti-angina treatments:

1.1 One beta-blocker [e.g. Lopressor (metoprolol), Inderal (propranolol)]

**OR**

1.2 One calcium channel blocker [e.g. Procardia XL (nifedipine ER), Cardizem LA/Cardizem CD (diltiazemER)]

**OR**

1.3 One long acting nitrate therapy [e.g. Imdur (isosorbide mononitrate), Isordil (isosorbide dinitrate), Nitro-Time/Nitro-Dur/Nitro-Bid (nitroglycerin ER)]

**AND**

2 - For Brand Ranexa requests ONLY: Trial and failure to generic ranolazine (verified via paid pharmacy claims or submission of medical records/chart notes)

Product Name: Aspruzyo Sprinkle			
Approval Length	12 month(s)		
Guideline Type	Step Therapy		
Product Name	Generic Name	GPI	Brand/Generic
ASPRUZYO SPRINKLE	RANOLAZINE ER GRANULES PACKET 500 MG	32200040003020	Brand
ASPRUZYO SPRINKLE	RANOLAZINE ER GRANULES PACKET 1000 MG	32200040003040	Brand
<b>Approval Criteria</b>			
1 - History of ONE of the following standard anti-angina treatments:			

**1.1** One beta-blocker [e.g. Lopressor (metoprolol), Inderal (propranolol)]

**OR**

**1.2** One calcium channel blocker [e.g. Procardia XL (nifedipine ER), Cardizem LA/Cardizem CD (diltiazemER)]

**OR**

**1.3** One long acting nitrate therapy [e.g. Imdur (isosorbide mononitrate), Isordil (isosorbide dinitrate), Nitro-Time/Nitro-Dur/Nitro-Bid (nitroglycerin ER)]

**AND**

**2** - One of the following:

**2.1** Trial and failure to generic ranolazine (verified via paid pharmacy claims or submission of medical records/chart notes)

**OR**

**2.2** One of the following:

- Patient is 8 years of age or younger
- Patient is unable to swallow the oral tablet (solid formulation) due to swallowing difficulties

## 2 . Revision History

Date	Notes
10/26/2022	Added Aspruzyo Sprinkle as target. Updated guideline name to Ranolazine Products



Rayos



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140702
<b>Guideline Name</b>	Rayos
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Rayos			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RAYOS	PREDNISONONE TAB DELAYED RELEASE 1 MG	22100045000610	Brand
RAYOS	PREDNISONONE TAB DELAYED RELEASE 2 MG	22100045000620	Brand
RAYOS	PREDNISONONE TAB DELAYED RELEASE 5 MG	22100045000630	Brand
<b>Approval Criteria</b>			

**1 - ONE of the following:**

**1.1** The requested drug must be used for a Food and Drug Administration (FDA)-approved indication

**OR**

**1.2** The use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

**2 -** The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plan's program\*

**AND**

**3 -** Submission of medical records (e.g. chart notes, laboratory values) or claims history documenting an intolerance to generic prednisone tablets which is unable to be resolved with attempts to minimize the adverse effects where appropriate

**AND**

**4 -** History of failure, contraindication, or intolerance to TWO the following:

- Dexamethasone tablet, oral solution
- Hydrocortisone tablet
- Methylprednisolone tablet
- Prednisolone tablet, oral solution

Notes

\*Note: Medications used solely for anti-obesity/weight loss, cosmetic (e.g., alopecia, actinic keratosis, vitiligo), erectile dysfunction, and sexual dysfunction purposes are NOT medically accepted indications and

	are NOT recognized as a covered benefit. Erectile dysfunction drugs (Cialis/Tadalafil) are covered for clinical diagnoses other than ED.
--	--

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Recorlev (levoketoconazole)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140883
<b>Guideline Name</b>	Recorlev (levoketoconazole)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Recorlev			
Diagnosis	Cushing's Disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RECORLEV	LEVOKETOCONAZOLE TAB 150 MG	30022040000320	Brand
<b>Approval Criteria</b>			

1 - Both of the following:

1.1 Diagnosis of Cushing's disease

**AND**

1.2 ONE of the following:

- Patient is not a candidate for pituitary surgery
- Pituitary surgery has not been curative

Product Name: Recorlev			
Diagnosis	Cushing's Disease		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RECORLEV	LEVOKETOCONAZOLE TAB 150 MG	30022040000320	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive response to therapy			

Product Name: Recorlev			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RECORLEV	LEVOKETOCONAZOLE TAB 150 MG	30022040000320	Brand

**Approval Criteria**

1 - Recorlev will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.

Product Name: Recorlev			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RECORLEV	LEVOKETOCONAZOLE TAB 150 MG	30022040000320	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy			

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Rectiv



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140648
<b>Guideline Name</b>	Rectiv
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Rectiv			
Diagnosis	Pain Associated with Chronic Anal Fissures		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RECTIV	NITROGLYCERIN OINT 0.4%	89254060004220	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of moderate to severe pain associated with chronic anal fissures			

## 2 . Revision History

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1



Regranex



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140670
<b>Guideline Name</b>	Regranex
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Regranex			
Approval Length	6 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REGRANEX	BECAPLERMIN GEL 0.01%	90945020004020	Brand
<b>Approval Criteria</b>			
1 - Patient has a lower extremity diabetic neuropathic ulcer			

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Relyvrio (sodium phenylbutyrate and taurursodiol)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140963
<b>Guideline Name</b>	Relyvrio (sodium phenylbutyrate and taurursodiol)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	3/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Relyvrio			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RELYVRIO	SODIUM PHENYLBUTYRATE-TAURURSODIOL POWD PACK 3-1 GM	74509902703020	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) documenting diagnosis of amyotrophic lateral sclerosis (ALS)

**AND**

**2** - Diagnosis of ALS is further supported by neurogenic changes in electromyography (EMG)

**AND**

**3** - Patient has had ALS symptoms for less than or equal to 18 months

**AND**

**4** - Patient has a percent (%) forced vital capacity (FVC) or slow vital capacity (SVC) greater than or equal to 60% at the start of treatment

**AND**

**5** - Patient does not require permanent noninvasive ventilation or invasive ventilation

**AND**

**6** - Prescribed by or in consultation with a neurologist with expertise in the diagnosis of ALS

Product Name: Relyvrio			
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RELYVRIO	SODIUM PHENYLBUTYRATE-TAURURSODIOL POWD PACK 3-1 GM	74509902703020	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting slowed disease progression from baseline

**AND**

2 - Prescribed by or in consultation with a neurologist with expertise in the diagnosis of ALS

**2 . Revision History**

Date	Notes
2/8/2023	New guideline

Repatha



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140814
<b>Guideline Name</b>	Repatha
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2023
-----------------	-----------

## 1 . Criteria

Product Name: Repatha			
Diagnosis	Heterozygous familial hypercholesterolemia (HeFH), Atherosclerotic cardiovascular disease (ASCVD)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REPATHA	EVOLOCUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 140 MG/ML	3935002000E520	Brand
REPATHA PUSHTRONEX SYSTEM	EVOLOCUMAB SUBCUTANEOUS SOLN CARTRIDGE/INFUSOR 420 MG/3.5ML	3935002000E230	Brand

REPATHA SURECLICK	EVOLOCUMAB SUBCUTANEOUS SOLN AUTO- INJECTOR 140 MG/ML	3935002000D520	Brand
----------------------	--	----------------	-------

**Approval Criteria**

1 - ONE of the following diagnoses:

1.1 Heterozygous familial hypercholesterolemia (HeFH) as confirmed by ONE of the following\*:

1.1.1 BOTH of the following:

1.1.1.1 Pre-treatment LDL-C (low-density lipoprotein cholesterol) greater than 190 milligrams per deciliter (mg/dL) (greater than 155 mg/dL if less than 16 years of age)

**AND**

1.1.1.2 ONE of the following:

- Family history of myocardial infarction in first degree relative less than 60 years of age
- Family history of myocardial infarction in second degree relative less than 50 years of age
- Family history of LDL-C greater than 190 mg/dL in first or second degree relative
- Family history of heterozygous or homozygous familial hypercholesterolemia in first or second degree relative
- Family history of tendinous xanthomata and or arcus cornealis in first or second degree relative

**OR**

1.1.2 BOTH of the following:

1.1.2.1 Pre-treatment LDL-C greater than 190 mg/dL (greater than 155 mg/dL if less than 16 years of age)

**AND**

1.1.2.2 Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following:

- Functional mutation in LDL (low-density lipoprotein), apoB (Apolipoprotein B), or PCSK9 (Proprotein convertase subtilisin/kexin type 9) gene\*
- Tendinous xanthomata
- Arcus cornealis before age 45

**OR**

**1.2** Atherosclerotic cardiovascular disease (ASCVD) as confirmed by ONE of the following:

- Acute coronary syndromes
- History of myocardial infarction
- Stable or unstable angina
- Coronary or other arterial revascularization
- Stroke
- Transient ischemic attack
- Peripheral arterial disease presumed to be of atherosclerotic origin

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following (prescription claims history may be used in conjunction as documentation of medication use, dose, and duration):

**2.1** Patient has been receiving at least 12 consecutive weeks of high-intensity statin therapy (i.e. atorvastatin 40-80 mg, rosuvastatin 20-40 mg) and will continue to receive high-intensity statin at maximally tolerated dose

**OR**

**2.2** BOTH of the following:

**2.2.1** Patient is unable to tolerate high-intensity statin as evidenced by ONE of the following intolerable and persistent (i.e. more than 2 weeks) symptoms:

- Myalgia (muscle symptoms without CK elevations)
- Myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN])

**AND**



**2.2.2 ONE of the following:**

**2.2.2.1** Patient has been receiving at least 12 consecutive weeks of moderate-intensity statin [i.e. atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin greater than or equal to 20 mg, pravastatin greater than or equal to 40 mg, lovastatin 40 mg, Lescol XL (fluvastatin XL) 80 mg, fluvastatin 40 mg twice daily or Livalo (pitavastatin) greater than or equal to 2 mg] and will continue to receive a moderate-intensity statin at maximally tolerated dose

**OR**

**2.2.2.2** Patient has been receiving at least 12 consecutive weeks of low-intensity statin [i.e. simvastatin 10 mg, pravastatin 10-20 mg, lovastatin 20 mg, fluvastatin 20-40 mg, or Livalo (pitavastatin) 1 mg] therapy and will continue to receive a low-intensity statin at maximally tolerated dose

**OR**

**2.3** Patient is unable to tolerate low or moderate, and high intensity statins as evidenced by ONE of the following:

**2.3.1** ONE of the following intolerable and persistent (i.e. more than 2 weeks) symptoms for low or moderate, and high intensity statins:

- Myalgia (muscle symptoms without CK elevations)
- Myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN])

**OR**

**2.3.2** Patient has a labeled contraindication to all statins as documented in medical records

**OR**

**2.3.3** Patient has experienced rhabdomyolysis or muscle symptoms with statin treatment with CK elevations greater than 10 times ULN

**AND**

**3 - ONE of the following:**

**3.1** Submission of medical records (e.g., laboratory values) documenting ONE of the following LDL-C values while on maximally tolerated lipid lowering therapy for a minimum of at least 12 weeks within the last 120 days:

- LDL-C greater than or equal to 100 mg/dL with ASCVD
- LDL-C greater than or equal to 130 mg/dL without ASCVD

**OR**

**3.2 BOTH of the following:**

**3.2.1** Submission of medical records (e.g., laboratory values) documenting ONE of the following LDL-C values while on maximally tolerated lipid lowering therapy for a minimum of at least 12 weeks within the last 120 days:

- LDL-C between 55 mg/dL and 99 mg/dL with ASCVD
- LDL-C between 100 mg/dL and 129 mg/dL without ASCVD

**AND**

**3.2.2** Submission of medical records (e.g., chart notes, laboratory values) documenting ONE of the following [prescription claims history may be used in conjunction as documentation of medication use, dose, and duration]:

- Patient has been receiving at least 12 consecutive weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy
- Patient has a history of contraindication or intolerance to ezetimibe

**AND**

**4 - Used as an adjunct to a low-fat diet and exercise**

**AND**

**5 - Prescribed by ONE of the following:**

- Cardiologist
- Endocrinologist

<ul style="list-style-type: none"> <li>Lipid specialist</li> </ul>	
<b>AND</b>	
<b>6</b> - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (e.g., Praluent (alirocumab))	
Notes	*Results of prior genetic testing can be submitted as confirmation of diagnosis of HeFH .

Product Name: Repatha	
Diagnosis	Heterozygous familial hypercholesterolemia (HeFH), Atherosclerotic cardiovascular disease (ASCVD)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
REPATHA	EVOLOCUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 140 MG/ML	3935002000E520	Brand
REPATHA PUSHTRONEX SYSTEM	EVOLOCUMAB SUBCUTANEOUS SOLN CARTRIDGE/INFUSOR 420 MG/3.5ML	3935002000E230	Brand
REPATHA SURECLICK	EVOLOCUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 140 MG/ML	3935002000D520	Brand

**Approval Criteria**

**1** - Patient continues to receive statin at maximally tolerated dose (unless patient has documented inability to take statins)

**AND**

**2** - Patient is continuing a low-fat diet and exercise regimen

**AND**

**3** - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**4** - Submission of medical records (e.g. chart notes, laboratory values) documenting LDL-C (low-density lipoprotein cholesterol) reduction while on Repatha therapy

**AND**

**5** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (e.g., Praluent (alirocumab))

**Product Name: Repatha**

Diagnosis	Homozygous Familial Hypercholesterolemia (HoFH)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
REPATHA	EVOLOCUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 140 MG/ML	3935002000E520	Brand
REPATHA PUSHTRONEX SYSTEM	EVOLOCUMAB SUBCUTANEOUS SOLN CARTRIDGE/INFUSOR 420 MG/3.5ML	3935002000E230	Brand
REPATHA SURECLICK	EVOLOCUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 140 MG/ML	3935002000D520	Brand

**Approval Criteria**

**1** - Diagnosis of homozygous familial hypercholesterolemia (HoFH) as confirmed by submission of medical records (e.g., chart notes, laboratory values) documenting BOTH of the following:\*

**1.1 ONE of the following:**

- Pre-treatment LDL-C (low-density lipoprotein cholesterol) greater than 500 mg/dL (milligrams per deciliter)
- Treated LDL-C greater than 300 mg/dL

**AND**

**1.2 ONE of the following:**

- Xanthoma before 10 years of age
- Evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents

**AND**

**2 - Used as an adjunct to a low-fat diet and exercise**

**AND**

**3 - Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, LDL [low-density lipoprotein] apheresis)**

**AND**

**4 - Prescribed by ONE of the following:**

- Cardiologist
- Endocrinologist
- Lipid specialist

**AND**

**5 - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (e.g., Praluent (alirocumab))**

Notes

\*Results of prior genetic testing can be submitted as confirmation of diagnosis of HoFH.

Product Name: Repatha	
Diagnosis	Homozygous Familial Hypercholesterolemia
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
REPATHA	EVOLOCUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 140 MG/ML	3935002000E520	Brand
REPATHA PUSHTRONEX SYSTEM	EVOLOCUMAB SUBCUTANEOUS SOLN CARTRIDGE/INFUSOR 420 MG/3.5ML	3935002000E230	Brand
REPATHA SURECLICK	EVOLOCUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 140 MG/ML	3935002000D520	Brand

**Approval Criteria**

1 - Patient is continuing a low-fat diet and exercise regimen

**AND**

2 - Patient continues to receive other lipid-lowering therapy (e.g., statin, LDL apheresis)

**AND**

3 - Submission of medical records (e.g. chart notes, laboratory values) documenting LDL-C (low-density lipoprotein cholesterol) reduction while on Repatha therapy

**AND**

4 - Prescribed by ONE of the following:

- Cardiologist
- Endocrinologist
- Lipid Specialist

**AND**

**5** - Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (e.g., Praluent (alirocumab))

## 2 . Revision History

Date	Notes
9/11/2023	Updated SP to standard formulary. Update to account for 2022 ACC recommendations of a lower LDL threshold of 55mg/dl for patients with ASCVD at very high risk.

Respiratory Syncytial Virus (RSV) Vaccines



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-152633
<b>Guideline Name</b>	Respiratory Syncytial Virus (RSV) Vaccines
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Abrysvo, Arexvy, mResvia			
Approval Length	14 days (1 injection per 2 years)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ABRYSVO	RSV PRE-FUSION F A&B VAC RECOMB FOR IM SOLN 120 MCG/0.5ML	17100072202120	Brand
AREXVY	RSVPREF3 VACCINE RECOMB ADJUVANTED FOR IM SUSP 120 MCG/0.5ML	17100072101920	Brand
MRESVIA	RSV MRNA PRE-F VACCINE IM SUSP PREF SYR 50 MCG/0.5ML	1710007205E620	Brand



**Approval Criteria**

**1** - Vaccine is being used for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV)

**AND**

**2** - Patient has NOT received an RSV vaccine (i.e., Abrysvo, Arexvy, mResvia) in the previous 2 years

**AND**

**3** - ONE of the following:

**3.1** ONE of the following:

- If the request is for Abrysvo: Age greater than or equal to 60 years
- If the request is for Arexvy: Age greater than or equal to 50 years
- If the request is for mResvia: Age greater than or equal to 60 years

**OR**

**3.2** If the request is for Abrysvo, BOTH of the following:

**3.2.1** Will be used for active immunization of pregnant individuals at 32 through 36 weeks gestational age

**AND**

**3.2.2** Will also be used for the prevention of severe LRTD caused by RSV in infants from birth through 6 months of age

**AND**

**4** - If the request is for mResvia, trial and failure, intolerance, or contraindication to ONE of the following:

- Abrysvo

- Arexvy

## 2 . Revision History

Date	Notes
8/27/2024	New program.

Revcovi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140857
<b>Guideline Name</b>	Revcovi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/14/2020
-----------------	-----------

### 1 . Criteria

Product Name: Revcovi			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REVCОВI	ELAPEGADEMASE-LVLR IM SOLN 2.4 MG/1.5ML (1.6 MG/ML)	30902030202020	Brand
<b>Approval Criteria</b>			

**1 - Diagnosis of severe combined immunodeficiency disease (SCID)**

**AND**

**2 - Deficiency of adenosine deaminase is confirmed by one of the following:**

- Deficiency or absence of adenosine deaminase (ADA) in plasma, lysed erythrocytes, fibroblasts (cultured from amniotic fluid), or chorionic villus
- Increase in deoxyadenosine triphosphate (dATP) levels in erythrocyte lysates compared to laboratory standard
- Decrease in ATP (Adenosine triphosphate) concentration in erythrocytes
- Molecular genetic confirmation of mutations in both alleles of the ADA1 gene
- Positive screening by T cell receptor excision circles (TRECs)

**AND**

**3 - One of the following:**

- Patient is not a suitable candidate for hematopoietic cell transplantation (HCT)
- Patient has failed HCT
- Patient is awaiting HCT

**AND**

**4 - Dosing is in accordance with the United States Food and Drug Administration approved labeling**

Product Name: Revcovi			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REVCОВI	ELAPEGADEMASE-LVLR IM SOLN 2.4 MG/1.5ML (1.6 MG/ML)	309020302020	Brand

**Approval Criteria**

1 - Patient has previously received treatment with Revcovi (elapegademase) therapy

**AND**

2 - Patient has experienced a positive clinical response to therapy (e.g., normalization of plasma ADA activity, erythrocyte dATP levels, improvement of disease symptoms, etc.)

**AND**

3 - Dosing is in accordance with the United States Food and Drug Administration approved labeling

**2 . Revision History**

Date	Notes
7/14/2020	2020 Implementation

Reyvow



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140711
<b>Guideline Name</b>	Reyvow
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Reyvow			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REYVOW	LASMIDITAN SUCCINATE TAB 50 MG	67406540600310	Brand
REYVOW	LASMIDITAN SUCCINATE TAB 100 MG	67406540600320	Brand
<b>Approval Criteria</b>			

**1** - Diagnosis of moderate to severe migraine headaches with or without aura

**AND**

**2** - Used for acute treatment of migraine

**AND**

**3** - Patient is 18 years of age or older

**AND**

**4** - Documentation of a one month trial resulting in therapeutic failure, contraindication, or intolerance to **THREE** of the following:

- naratriptan tablets
- rizatriptan tablets/ODT (oral disintegrating tablets)
- sumatriptan tablets/auto injection/cartridge or Imitrex nasal spray (Brand only)
- zolmitriptan tablets/ODT

**AND**

**5** - Prescribed by or in consultation with one of the following specialists with expertise in the acute treatment of migraine:

- Neurologist
- Pain Specialist
- Headache Specialist\*

**AND**

**6** - Prescriber attests to **ALL** of the following:

- Patient has been informed the use of Reyvow may result in significant CNS impairment, and may impact the patient's ability to drive or operate machinery for 8 hours after each dose
- If used concurrently with a benzodiazepine or other drugs that could potentially cause central nervous system (CNS) depression, the prescriber has acknowledged that they

have completed an assessment of increased risk for sedation and other cognitive and/or neuropsychiatric adverse events

- The information provided is true and accurate to the best of their knowledge and they understand that OptumRx may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided

**AND**

**7** - Both of the following:

**7.1** One of the following

**7.1.1** The patient must have a history of therapeutic failure, contraindication, or intolerance to **THREE** of the following:

- Amitriptyline (Elavil)\*\*
- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*\*
- Divalproex sodium [Depakote/Depakote ER (extended-release)]\*\*
- Topiramate (Topamax)\*\*
- VENLAFAXINE [EFFEXOR/EFFEXOR XR (EXTENDED-RELEASE)]\*\*

**OR**

**7.1.2** The patient must be currently treated with one of the following prophylactic therapies unless there is a contraindication or intolerance to **ALL**:

- Amitriptyline (Elavil)\*\*
- A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\*\*
- Divalproex sodium [Depakote/Depakote ER (extended-release)]\*\*
- Topiramate (Topamax)\*\*
- Venlafaxine [Effexor/Effexor XR (extended-release)]\*\*

**AND**

**7.2** Both of the Following

**7.2.1** History of a therapeutic failure after 3 month trial, contraindication, or intolerance to two of the following biologic calcitonin gene-related peptide receptor (CGRP) antagonists for preventive treatment of migraine

- Ajovy (fremanezumab)
- Emgality (galcanezumab)



<ul style="list-style-type: none"> <li>Aimovig (erenumab)</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>7.2.2</b> History of a therapeutic failure, contraindication, or intolerance to Ubrelyv</p>	
Notes	*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS) **Drugs may require PA

Product Name: Reyvow			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REYVOW	LASMIDITAN SUCCINATE TAB 50 MG	67406540600310	Brand
REYVOW	LASMIDITAN SUCCINATE TAB 100 MG	67406540600320	Brand
<p><b>Approval Criteria</b></p> <p><b>1</b> - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Prescribed by or in consultation with one of the following specialists with expertise in the acute treatment of migraine:</p> <ul style="list-style-type: none"> <li>Neurologist</li> <li>Pain Specialist</li> <li>Headache Specialist*</li> </ul>			
Notes	*Headache specialists are physicians certified by the United Council f or Neurologic Subspecialties (UCNS)		

## 2 . Revision History

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Rezdiffra (resmetirom)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-155257
<b>Guideline Name</b>	Rezdiffra (resmetirom)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Rezdiffra			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REZDIFFRA	RESMETIROM 60 MG TAB	52601060000320	Brand
REZDIFFRA	RESMETIROM 80 MG TAB	52601060000330	Brand
REZDIFFRA	RESMETIROM 100 MG TAB	52601060000340	Brand

**Approval Criteria**

**1** - Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH)

**AND**

**2** - Patient does NOT have cirrhosis (e.g., decompensated cirrhosis)

**AND**

**3** - Submission of medical records (e.g., chart notes) confirming diagnosis has been confirmed by ONE of the following:

- FibroScan-aspartate aminotransferase (FAST)
- MRI-aspartate aminotransferase (MAST)
- Liver biopsy

**AND**

**4** - Submission of medical records (e.g., chart notes) confirming disease is fibrosis stage F2 or F3 as confirmed by ONE of the following:

- FibroScan
- Fibrosis-4 index (FIB-4)
- Magnetic Resonance Elastography (MRE)

**AND**

**5** - Presence of greater than or equal to 3 metabolic risk factors (e.g., Type 2 diabetes, hypertension, obesity)

**AND**

**6** - Submission of medical records (e.g., chart notes) confirming drug is used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community based program)

**AND**

**7** - Prescribed by or in consultation with ONE of the following:

- Gastroenterologist
- Hepatologist

Product Name: Rezdiffra			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REZDIFFRA	RESMETIROM 60 MG TAB	52601060000320	Brand
REZDIFFRA	RESMETIROM 80 MG TAB	52601060000330	Brand
REZDIFFRA	RESMETIROM 100 MG TAB	52601060000340	Brand

**Approval Criteria**

**1** - Patient demonstrates positive response to therapy (e.g., NASH resolution, fibrosis stage improvement, etc.)

**AND**

**2** - Submission of medical records (e.g., chart notes) confirming drug will continue to be used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community based program)

**AND**

**3** - Submission of medical records (e.g., chart notes) confirming patient has NOT progressed to cirrhosis

## 2 . Revision History

Date	Notes
9/18/2024	Replaced CORE criteria with FFS/state criteria.

Rezurock (belumosudil)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140885
<b>Guideline Name</b>	Rezurock (belumosudil)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Rezurock			
Diagnosis	Chronic graft-versus-host disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REZUROCK	BELUMOSUDIL MESYLATE TAB 200 MG	99407510500320	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of chronic graft-versus-host disease

**AND**

2 - Trial and failure of two or more lines of systemic therapy (e.g., corticosteroids, mycophenolate, etc.)

**AND**

3 - Prescribed by or in consultation with one of the following:

- Hematologist
- Oncologist
- Physician experienced in the management of transplant patients

Product Name: Rezero			
Diagnosis	Chronic graft-versus-host disease		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
REZERO	BELUMOSUDIL MESYLATE TAB 200 MG	99407510500320	Brand
<b>Approval Criteria</b>			
1 - Patient does not show evidence of progressive disease while on therapy			

Product Name: Rezero	
Diagnosis	Chronic graft-versus-host disease - Twice daily (BID) Therapy
Approval Length	12 month(s)
Guideline Type	Quantity Limit



Product Name	Generic Name	GPI	Brand/Generic
REZUROCK	BELUMOSUDIL MESYLATE TAB 200 MG	99407510500320	Brand

**Approval Criteria**

1 - Patient is using medication concomitantly with one of the following:

- Strong CYP3A inducer (e.g., carbamazepine, phenobarbital, phenytoin, rifampin)
- Proton pump inhibitor (e.g., omeprazole, pantoprazole, lansoprazole)

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Rhofade



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140692
<b>Guideline Name</b>	Rhofade
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Rhofade			
Diagnosis	Persistent erythema associated with rosacea		
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RHOFADE	OXYMETAZOLINE HCL CREAM 1%	90060050103720	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of persistent erythema associated with rosacea

**AND**

2 - ONE of the following:

2.1 History of a 30 day or longer trial and failure of one of the following:

- metronidazole cream, gel, or lotion
- azelaic acid gel

**OR**

2.2 Contraindication or intolerance to both of the following:

- metronidazole cream, gel, or lotion
- azelaic acid gel

Product Name: Rhofade			
Diagnosis	Persistent erythema associated with rosacea		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RHOFADE	OXYMETAZOLINE HCL CREAM 1%	90060050103720	Brand

**Approval Criteria**

1 - Documentation of a positive clinical response to Rhofade therapy

**2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Rinvoq (upadacitinib)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-158131
<b>Guideline Name</b>	Rinvoq (upadacitinib)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Rinvoq			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming a diagnosis of moderately to severely active rheumatoid arthritis

**AND**

2 - Prescribed by or in consultation with a rheumatologist

**AND**

3 - Submission of medical records (e.g., chart notes) or paid claims documenting BOTH of the following:\*\*

**3.1** History of failure to a 3 month trial of ONE non-biologic disease modifying anti-rheumatic drug (DMARD) (e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) at maximally indicated doses within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced\*

**AND**

**3.2** History of failure, contraindication, or intolerance to ALL of the following:\*\*\*

- A preferred adalimumab biosimilar or Enbrel (etanercept)
- infliximab
- Orencia (abatacept)
- Xeljanz oral tablet (tofacitinib)

**AND**

4 - Not used in combination with other Janus kinase (JAK) inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)\*

Notes	<p>*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).</p> <p>**PA may be required. PDL link: <a href="https://www.uhcprovider.com/en/health">https://www.uhcprovider.com/en/health</a></p>
-------	---

	<p>th-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCP</p> <p>***Patients requesting initial authorization who were established on therapy via the receipt of a manufacturer supplied sample at no cost in the prescriber's office or any form of assistance from manufacturer sponsored programs shall be required to meet initial authorization criteria as if patient were new to therapy.</p>
--	---

<b>Product Name: Rinvoq</b>			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand
<p><b>Approval Criteria</b></p> <p><b>1</b> - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)*</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Prescribed by or in consultation with a rheumatologist</p>			
Notes	*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).		

Product Name: Rinvoq, Rinvoq LQ	
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand
RINVOQ LQ	UPADACITINIB ORAL SOLN 1 MG/ML	66603072002020	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming a diagnosis of active polyarticular juvenile idiopathic arthritis (PJIA)

**AND**

2 - Prescribed by or in consultation with a rheumatologist

**AND**

3 - Submission of medical records (e.g., chart notes) or paid claims documenting BOTH of the following:\*\*

3.1 History of failure, contraindication, or intolerance to ALL of the following:\*\*\*

- A preferred adalimumab biosimilar or Enbrel (etanercept)
- Orencia (abatacept)
- Xeljanz (tofacitinib) oral tablet

**AND**



**3.2** Minimum duration of a 6-week trial and failure, contraindication, or intolerance to ONE of the following conventional therapies at maximally tolerated doses:\*

- methotrexate
- leflunomide

**AND**

**4** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)\*

Notes	<p>*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).</p> <p>**PA may be required. PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCP</a></p> <p>***Patients requesting initial authorization who were established on therapy via the receipt of a manufacturer supplied sample at no cost in the prescriber's office or any form of assistance from manufacturer sponsored programs shall be required to meet initial authorization criteria as if patient were new to therapy.</p>
-------	--

Product Name: Rinvoq, Rinvoq LQ			
Diagnosis	Polyarticular Juvenile Idiopathic Arthritis (PJIA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand
RINVOQ LQ	UPADACITINIB ORAL SOLN 1 MG/ML	66603072002020	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy

**AND**

2 - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)\*

**AND**

3 - Prescribed by or in consultation with a rheumatologist

Notes	*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).
-------	---

**Product Name: Rinvoq, Rinvoq LQ**

Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand
RINVOQ LQ	UPADACITINIB ORAL SOLN 1 MG/ML	66603072002020	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming a diagnosis of active psoriatic arthritis

**AND**

**2** - Prescribed by or in consultation with ONE of the following:

- Dermatologist
- Rheumatologist

**AND**

**3** - Submission of medical records (e.g., chart notes) or paid claims documenting BOTH of the following:\*\*

**3.1** History of failure, contraindication, or intolerance to ALL of the following:\*\*\*

- A preferred adalimumab biosimilar or Enbrel (etanercept)
- infliximab
- Orencia (abatacept)
- Otezla (apremilast)
- Xeljanz (tofacitinib) oral tablet

**AND**

**3.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced\*

**AND**

**4** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)\*

Notes

\*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).

\*\*PA may be required. PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCP>

\*\*\*Patients requesting initial authorization who were established on th

	erapy via the receipt of a manufacturer supplied sample at no cost in the prescriber's office or any form of assistance from manufacturer sponsored programs shall be required to meet initial authorization criteria as if patient were new to therapy.
--	--

Product Name: Rinvoq, Rinvoq LQ	
Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand
RINVOQ LQ	UPADACITINIB ORAL SOLN 1 MG/ML	66603072002020	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy

**AND**

**2** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)\*

**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Dermatologist
- Rheumatologist

Notes	*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).
-------	---

Product Name: Rinvoq	
Diagnosis	Non-radiographic Axial Spondyloarthritis (nr-AxSpA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming a diagnosis of active non-radiographic axial spondyloarthritis

**AND**

2 - Patient has objective signs of inflammation [e.g., C-reactive protein (CRP) levels above the upper limit of normal and/or sacroiliitis on magnetic resonance imaging (MRI), indicative of inflammatory disease, but without definitive radiographic evidence of structural damage on sacroiliac joints]

**AND**

3 - Prescribed by or in consultation with a rheumatologist

**AND**

4 - Minimum duration of one month trial and failure, contraindication, or intolerance to TWO different NSAIDs (e.g., ibuprofen, naproxen) at maximally tolerated doses

**AND**

**5** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)\*

Notes	*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).
-------	---

Product Name: Rinvoq			
Diagnosis	Non-radiographic Axial Spondyloarthritis (nr-AxSpA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy as evidenced by improvement from baseline for at least ONE of the following:

- Disease activity (e.g., pain, fatigue, inflammation, stiffness)
- Lab values (erythrocyte sedimentation rate, C-reactive protein level)
- Function
- Axial status (e.g., lumbar spine motion, chest expansion)
- Total active (swollen and tender) joint count

**AND**

**2** - Prescribed by or in consultation with a rheumatologist

**AND**

**3** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)\*

Notes	*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).
-------	---

Product Name: Rinvoq			
Diagnosis	Ankylosing Spondylitis (AS)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of active ankylosing spondylitis

**AND**

**2** - Prescribed by or in consultation with a rheumatologist

**AND**

**3** - Submission of medical records (e.g., chart notes) or paid claims documenting BOTH of the following:\*\*

**3.1** Trial and failure, contraindication, or intolerance to TWO nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen)

**AND**

**3.2** History of failure, contraindication, or intolerance to ALL of the following:\*\*\*

- A preferred adalimumab biosimilar or Enbrel (etanercept)
- infliximab
- Xeljanz (tofacitinib) oral tablet

**AND**

**4** - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)\*

Notes	<p>*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).</p> <p>**PA may be required. PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCP</a></p> <p>***Patients requesting initial authorization who were established on therapy via the receipt of a manufacturer supplied sample at no cost in the prescriber's office or any form of assistance from manufacturer sponsored programs shall be required to meet initial authorization criteria as if patient were new to therapy.</p>
-------	--

Product Name: Rinvoq			
Diagnosis	Ankylosing Spondylitis (AS)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand



RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand
<p><b>Approval Criteria</b></p> <p><b>1</b> - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p><b>2</b> - Not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (e.g., azathioprine or cyclosporine)*</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3</b> - Prescribed by or in consultation with a rheumatologist</p>			
Notes	*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).		

Product Name: Rinvoq			
Diagnosis	Atopic Dermatitis (AD)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand
<p><b>Approval Criteria</b></p>			

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of moderate to severe atopic dermatitis

**AND**

**2** - Patient is 12 years of age or older

**AND**

**3** - Submission of medical records (e.g., chart notes) documenting ONE of the following:

- Involvement of at least 10% body surface area (BSA)
- SCORing Atopic Dermatitis (SCORAD) index value of at least 25

**AND**

**4** - Prescribed by or in consultation with ONE of the following:

- Dermatologist
- Allergist/Immunologist

**AND**

**5** - Submission of medical records (e.g., chart notes) or paid claims documenting ALL of the following:\*\*

**5.1** History of failure, contraindication, or intolerance to BOTH of the following topical therapies.\*\*\*

- One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]
- Eucrisa (crisaborole)

**AND**

**5.2** Trial and failure of a minimum 12-week supply of Dupixent (dupilumab)\*\*\*

**AND**

**5.3** Trial and failure of a minimum 12-week supply of Adbry (tralokinumab-ldrm)\*\*\*

**AND**

**6** - Not used in combination with other JAK inhibitors, biologic immunomodulators (e.g., Dupixent, Adbry), or other immunosuppressants (e.g., azathioprine, cyclosporine)\*

Notes

\*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).

\*\*PA may be required. PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCPA>

\*\*\*Patients requesting initial authorization who were established on therapy via the receipt of a manufacturer supplied sample at no cost in the prescriber's office or any form of assistance from manufacturer sponsored programs shall be required to meet initial authorization criteria as if patient were new to therapy.

<b>Product Name: Rinvoq</b>			
Diagnosis	Atopic Dermatitis (AD)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy as evidenced by at least ONE of the following:

- Reduction in body surface area involvement from baseline
- Reduction in SCORing Atopic Dermatitis (SCORAD) index value from baseline

**AND**

**2** - Prescribed by or in consultation with ONE of the following:

- Dermatologist
- Allergist/Immunologist

**AND**

**3** - Not used in combination with other JAK inhibitors, biologic immunomodulators (e.g., Dupixent, Adbry), or other immunosuppressants (e.g., azathioprine, cyclosporine)\*

Notes	*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).
-------	---

<b>Product Name: Rinvoq</b>			
Diagnosis	Ulcerative Colitis (UC)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of moderately to severely active ulcerative colitis

**AND**

**2** - Prescribed by or in consultation with a gastroenterologist

**AND**

**3** - Submission of medical records (e.g., chart notes) or paid claims documenting BOTH of the following:\*\*

**3.1** Trial and failure, contraindication, or intolerance to ONE of the following conventional therapies:

- 6-mercaptopurine
- Aminosalicylate (e.g., mesalamine, olsalazine, sulfasalazine)
- Azathioprine
- Corticosteroids (e.g., prednisone)

**AND**

**3.2** History of failure, contraindication, or intolerance to ALL of the following:\*\*\*

- A preferred adalimumab biosimilar
- infliximab
- Xeljanz oral tablet (tofacitinib)

**AND**

**4** - Not used in combination with other JAK inhibitors, biological therapies for UC, or with potent immunosuppressants (e.g., azathioprine, cyclosporine)\*

Notes	<p>*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).</p> <p>**PA may be required. PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCP</a></p>
-------	---

	<p>***Patients requesting initial authorization who were established on therapy via the receipt of a manufacturer supplied sample at no cost in the prescriber's office or any form of assistance from manufacturer sponsored programs shall be required to meet initial authorization criteria as if patient were new to therapy.</p>
--	--

Product Name: Rinvoq	
Diagnosis	Ulcerative Colitis (UC)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy

**AND**

2 - Prescribed by or in consultation with a gastroenterologist

**AND**

3 - Not used in combination with other JAK inhibitors, biological therapies for UC, or with potent immunosuppressants (e.g., azathioprine, cyclosporine)\*

Notes	<p>*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).</p>
-------	--

Product Name: Rinvoq	
Diagnosis	Crohn's Disease (CD)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) confirming a diagnosis of moderately to severely active Crohn's disease (CD)

**AND**

2 - Prescribed by or in consultation with a gastroenterologist

**AND**

3 - Submission of medical records (e.g., chart notes) or paid claims documenting BOTH of the following:\*\*

3.1 Trial and failure, contraindication, or intolerance to ONE of the following conventional therapies:

- 6-mercaptopurine
- Azathioprine
- Methotrexate
- Corticosteroids (e.g., prednisone)

**AND**

3.2 History of failure, contraindication, or intolerance to ALL of the following:\*\*\*

- Cimzia (certolizumab)
- A preferred adalimumab biosimilar
- infliximab

**AND**

**4** - Not used in combination with other JAK inhibitors, biological therapies for CD, or with potent immunosuppressants (e.g., azathioprine, cyclosporine)\*

Notes	<p>*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).</p> <p>**PA may be required. PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHCCP</a></p> <p>***Patients requesting initial authorization who were established on therapy via the receipt of a manufacturer supplied sample at no cost in the prescriber's office or any form of assistance from manufacturer sponsored programs shall be required to meet initial authorization criteria as if patient were new to therapy.</p>
-------	--

Product Name: Rinvoq	
Diagnosis	Crohn's Disease (CD)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy as evidenced by at least ONE of the following:



- Improvement in intestinal inflammation (e.g., mucosal healing, improvement of lab values [platelet counts, erythrocyte sedimentation rate, C-reactive protein level]) from baseline
- Reversal of high fecal output state

**AND**

**2** - Prescribed by or in consultation with a gastroenterologist

**AND**

**3** - Not used in combination with other JAK inhibitors, biological therapies for CD, or with potent immunosuppressants (e.g., azathioprine, cyclosporine)\*

Notes

\*Rinvoq may be used with concomitant methotrexate, topical or inhaled corticosteroids, and/or low stable dosages of oral corticosteroids (equivalent to 10 mg or less of prednisone daily).

## 2 . Background

<b>Clinical Practice Guidelines</b>			
<b>Table 1. Relative potencies of topical corticosteroids</b>			
<b>Class</b>	<b>Drug</b>	<b>Dosage Form</b>	<b>Strength (%)</b>
Very high potency	Augmented betamethasone dipropionate	Ointment, gel	0.05
	Clobetasol propionate	Cream, foam, ointment	0.05
	Diflorasone diacetate	Ointment	0.05
	Halobetasol propionate	Cream, ointment	0.05
	Amcinonide	Cream, lotion, ointment	0.1

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

High Potency	Augmented betamethasone dipropionate	Cream, lotion	0.05
	Betamethasone dipropionate	Cream, foam, ointment, solution	0.05
	Desoximetasone	Cream, ointment	0.25
	Desoximetasone	Gel	0.05
	Diflorasone diacetate	Cream	0.05
	Fluocinonide	Cream, gel, ointment, solution	0.05
	Halcinonide	Cream, ointment	0.1
	Mometasone furoate	Ointment	0.1
	Triamcinolone acetonide	Cream, ointment	0.5
Medium potency	Betamethasone valerate	Cream, foam, lotion, ointment	0.1
	Clocortolone pivalate	Cream	0.1
	Desoximetasone	Cream	0.05
	Fluocinolone acetonide	Cream, ointment	0.025
	Flurandrenolide	Cream, ointment, lotion	0.05
	Fluticasone propionate	Cream	0.05
	Fluticasone propionate	Ointment	0.005
	Mometasone furoate	Cream, lotion	0.1
Triamcinolone acetonide	Cream, ointment, lotion	0.1	
Lower- medium potency	Hydrocortisone butyrate	Cream, ointment, solution	0.1
	Hydrocortisone probutate	Cream	0.1
	Hydrocortisone valerate	Cream, ointment	0.2
	Prednicarbate	Cream	0.1
Low potency	Alclometasone dipropionate	Cream, ointment	0.05
	Desonide	Cream, gel, foam, ointment	0.05

	Fluocinolone acetonide	Cream, solution	0.01
Lowest potency	Dexamethasone	Cream	0.1
	Hydrocortisone	Cream, lotion, ointment, solution	0.25, 0.5, 1
	Hydrocortisone acetate	Cream, ointment	0.5-1

### 3 . Revision History

Date	Notes
10/29/2024	Added submission of medical records requirement for all diagnosis checks. Updated existing submission of medical records verbiage throughout guideline. Updated notes sections for nr-AxSpA indication. Updated embedded steps to replace Humira with a preferred adalimumab biosimilar, where applicable. Linked notes to criteria, where applicable.

Ryaltris



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140754
<b>Guideline Name</b>	Ryaltris
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Ryaltris			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RYALTRIS	OLOPATADINE HCL-MOMETASONE FUROATE NASAL SUSP 665-25 MCG/ACT	42995502601820	Brand
<b>Approval Criteria</b>			
1 - Trial and failure to BOTH of the following as separate agents:			

- generic mometasone nasal spray
- azelastine or olopatadine nasal spray

## 2 . Revision History

Date	Notes
11/7/2022	New guideline following FFS.

Samsca



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140869
<b>Guideline Name</b>	Samsca
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	9/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Brand Samsca, generic tolvaptan			
Approval Length	30 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SAMSCA	TOLVAPTAN TAB 15 MG	30454060000320	Generic
TOLVAPTAN	TOLVAPTAN TAB 15 MG	30454060000320	Generic
TOLVAPTAN	TOLVAPTAN TAB 30 MG	30454060000330	Generic
SAMSCA	TOLVAPTAN TAB 30 MG	30454060000330	Brand

**Approval Criteria**

**1** - One of the following:

- Diagnosis of clinically significant euvolemic hyponatremia
- Diagnosis of clinically significant hypervolemic hyponatremia

**AND**

**2** - Patient has not responded to fluid restriction

**AND**

**3** - Treatment has been initiated or re-initiated in a hospital setting prior to discharge

Sedative Hypnotics



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140843
<b>Guideline Name</b>	Sedative Hypnotics
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	2/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Ambien, Brand Ambien CR, zolpidem SL, Edluar, Zolpimist, Belsomra, estazolam, Brand Lunesta, flurazepam, triazolam, Brand Halcion, Brand Restoril, generic temazepam 7.5 mg and 22.5 mg, generic ramelteon, Brand Rozerem, generic doxepin, Brand Silenor, zaleplon, Quviviq, Dayvigo			
Diagnosis	Non-Preferred		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AMBIEN	ZOLPIDEM TARTRATE TAB 5 MG	60204080100310	Brand
AMBIEN	ZOLPIDEM TARTRATE TAB 10 MG	60204080100315	Brand
AMBIEN CR	ZOLPIDEM TARTRATE TAB ER 6.25 MG	60204080100410	Brand
AMBIEN CR	ZOLPIDEM TARTRATE TAB ER 12.5 MG	60204080100420	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE SL TAB 1.75 MG	60204080100708	Generic
ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE SL TAB 3.5 MG	60204080100715	Generic
EDLUAR	ZOLPIDEM TARTRATE SL TAB 5 MG	60204080100720	Brand
EDLUAR	ZOLPIDEM TARTRATE SL TAB 10 MG	60204080100730	Brand
ZOLPIMIST	ZOLPIDEM TARTRATE ORAL SPRAY 5 MG/ACT	60204080102020	Brand
BELSOMRA	SUVOREXANT TAB 5 MG	60500070000305	Brand
BELSOMRA	SUVOREXANT TAB 10 MG	60500070000310	Brand
BELSOMRA	SUVOREXANT TAB 15 MG	60500070000315	Brand
BELSOMRA	SUVOREXANT TAB 20 MG	60500070000320	Brand
ESTAZOLAM	ESTAZOLAM TAB 1 MG	60201005000310	Generic
ESTAZOLAM	ESTAZOLAM TAB 2 MG	60201005000320	Generic
LUNESTA	ESZOPICLONE TAB 1 MG	60204035000320	Brand
LUNESTA	ESZOPICLONE TAB 2 MG	60204035000330	Brand
LUNESTA	ESZOPICLONE TAB 3 MG	60204035000340	Brand
FLURAZEPAM HCL	FLURAZEPAM HCL CAP 15 MG	60201010100105	Generic
FLURAZEPAM HCL	FLURAZEPAM HCL CAP 30 MG	60201010100110	Generic
TRIAZOLAM	TRIAZOLAM TAB 0.125 MG	60201040000305	Generic
HALCION	TRIAZOLAM TAB 0.25 MG	60201040000310	Brand
TRIAZOLAM	TRIAZOLAM TAB 0.25 MG	60201040000310	Generic
RESTORIL	TEMAZEPAM CAP 7.5 MG	60201030000103	Brand
TEMAZEPAM	TEMAZEPAM CAP 7.5 MG	60201030000103	Generic
RESTORIL	TEMAZEPAM CAP 15 MG	60201030000105	Brand
RESTORIL	TEMAZEPAM CAP 22.5 MG	60201030000108	Brand
TEMAZEPAM	TEMAZEPAM CAP 22.5 MG	60201030000108	Generic
RESTORIL	TEMAZEPAM CAP 30 MG	60201030000110	Brand
RAMELTEON	RAMELTEON TAB 8 MG	60250060000320	Generic
ROZEREM	RAMELTEON TAB 8 MG	60250060000320	Brand
DOXEPIN HYDROCHLORIDE	DOXEPIN HCL (SLEEP) TAB 3 MG (BASE EQUIV)	60400030100320	Generic
SILENOR	DOXEPIN HCL (SLEEP) TAB 3 MG (BASE EQUIV)	60400030100320	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DOXEPIN HYDROCHLORIDE	DOXEPIN HCL (SLEEP) TAB 6 MG (BASE EQUIV)	60400030100330	Generic
SILENOR	DOXEPIN HCL (SLEEP) TAB 6 MG (BASE EQUIV)	60400030100330	Brand
ZALEPLON	ZALEPLON CAP 5 MG	60204070000120	Generic
ZALEPLON	ZALEPLON CAP 10 MG	60204070000130	Generic
QUVIVIQ	DARIDOREXANT HCL TAB 25 MG	60500020100320	Brand
QUVIVIQ	DARIDOREXANT HCL TAB 50 MG	60500020100340	Brand
DAYVIGO	LEMBOREXANT TAB 5 MG	60500040000320	Brand
DAYVIGO	LEMBOREXANT TAB 10 MG	60500040000340	Brand

**Approval Criteria**

**1** - History of failure, contraindication, or intolerance to a trial of at least two of the following preferred agents:

- Eszopiclone (Generic Lunesta)
- Zolpidem/Zolpidem ER (Generic Ambien/Ambien CR)
- Temazepam 15/30 mg (milligram) capsules (Generic Restoril)

**AND**

**2** - For generic ramelteon requests ONLY, patient must have tried and failed Brand Rozerem

Product Name: Brand Ambien, generic zolpidem, Brand Ambien CR, generic zolpidem ER, zolpidem SL, Edluar, Zolpimist, Belsomra, estazolam, generic eszopiclone, Brand Lunesta, flurazepam, triazolam, Brand Halcion, Brand Restoril, generic temazepam, generic ramelteon, Brand Rozerem, generic doxepin, Brand Silenor, zaleplon, Quviviq, Dayvigo

Diagnosis	Greater than 1 hypnotic in 30 days
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
AMBIEN	ZOLPIDEM TARTRATE TAB 5 MG	60204080100310	Brand
ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE TAB 5 MG	60204080100310	Generic
AMBIEN	ZOLPIDEM TARTRATE TAB 10 MG	60204080100315	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE TAB 10 MG	60204080100315	Generic
AMBIEN CR	ZOLPIDEM TARTRATE TAB ER 6.25 MG	60204080100410	Brand
ZOLPIDEM TARTRATE ER	ZOLPIDEM TARTRATE TAB ER 6.25 MG	60204080100410	Generic
AMBIEN CR	ZOLPIDEM TARTRATE TAB ER 12.5 MG	60204080100420	Brand
ZOLPIDEM TARTRATE ER	ZOLPIDEM TARTRATE TAB ER 12.5 MG	60204080100420	Generic
ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE SL TAB 1.75 MG	60204080100708	Generic
ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE SL TAB 3.5 MG	60204080100715	Generic
EDLUAR	ZOLPIDEM TARTRATE SL TAB 5 MG	60204080100720	Brand
EDLUAR	ZOLPIDEM TARTRATE SL TAB 10 MG	60204080100730	Brand
ZOLPIMIST	ZOLPIDEM TARTRATE ORAL SPRAY 5 MG/ACT	60204080102020	Brand
BELSOMRA	SUVOREXANT TAB 5 MG	60500070000305	Brand
BELSOMRA	SUVOREXANT TAB 10 MG	60500070000310	Brand
BELSOMRA	SUVOREXANT TAB 15 MG	60500070000315	Brand
BELSOMRA	SUVOREXANT TAB 20 MG	60500070000320	Brand
ESTAZOLAM	ESTAZOLAM TAB 1 MG	60201005000310	Generic
ESTAZOLAM	ESTAZOLAM TAB 2 MG	60201005000320	Generic
ESZOPICLONE	ESZOPICLONE TAB 1 MG	60204035000320	Generic
LUNESTA	ESZOPICLONE TAB 1 MG	60204035000320	Brand
ESZOPICLONE	ESZOPICLONE TAB 2 MG	60204035000330	Generic
LUNESTA	ESZOPICLONE TAB 2 MG	60204035000330	Brand
ESZOPICLONE	ESZOPICLONE TAB 3 MG	60204035000340	Generic
LUNESTA	ESZOPICLONE TAB 3 MG	60204035000340	Brand
FLURAZEPAM HCL	FLURAZEPAM HCL CAP 15 MG	60201010100105	Generic
FLURAZEPAM HCL	FLURAZEPAM HCL CAP 30 MG	60201010100110	Generic
TRIAZOLAM	TRIAZOLAM TAB 0.125 MG	60201040000305	Generic
HALCION	TRIAZOLAM TAB 0.25 MG	60201040000310	Brand
TRIAZOLAM	TRIAZOLAM TAB 0.25 MG	60201040000310	Generic
RESTORIL	TEMAZEPAM CAP 7.5 MG	60201030000103	Brand
TEMAZEPAM	TEMAZEPAM CAP 7.5 MG	60201030000103	Generic

RESTORIL	TEMAZEPAM CAP 15 MG	60201030000105	Brand
TEMAZEPAM	TEMAZEPAM CAP 15 MG	60201030000105	Generic
RESTORIL	TEMAZEPAM CAP 22.5 MG	60201030000108	Brand
TEMAZEPAM	TEMAZEPAM CAP 22.5 MG	60201030000108	Generic
RESTORIL	TEMAZEPAM CAP 30 MG	60201030000110	Brand
TEMAZEPAM	TEMAZEPAM CAP 30 MG	60201030000110	Generic
RAMELTEON	RAMELTEON TAB 8 MG	60250060000320	Generic
ROZEREM	RAMELTEON TAB 8 MG	60250060000320	Brand
DOXEPIN HYDROCHLORIDE	DOXEPIN HCL (SLEEP) TAB 3 MG (BASE EQUIV)	60400030100320	Generic
SILENOR	DOXEPIN HCL (SLEEP) TAB 3 MG (BASE EQUIV)	60400030100320	Brand
DOXEPIN HYDROCHLORIDE	DOXEPIN HCL (SLEEP) TAB 6 MG (BASE EQUIV)	60400030100330	Generic
SILENOR	DOXEPIN HCL (SLEEP) TAB 6 MG (BASE EQUIV)	60400030100330	Brand
ZALEPLON	ZALEPLON CAP 5 MG	60204070000120	Generic
ZALEPLON	ZALEPLON CAP 10 MG	60204070000130	Generic
QUVIVIQ	DARIDOREXANT HCL TAB 25 MG	60500020100320	Brand
QUVIVIQ	DARIDOREXANT HCL TAB 50 MG	60500020100340	Brand
DAYVIGO	LEMBOREXANT TAB 5 MG	60500040000320	Brand
DAYVIGO	LEMBOREXANT TAB 10 MG	60500040000340	Brand

**Approval Criteria**

1 - The requested medication is being used to adjust the dose of the drug

**OR**

2 - The requested medication will be used in place of the previously prescribed drug, and not in addition to it

**OR**

**3** - The requested medication dosage form will be used in place of the previously prescribed medication dosage form, and not in addition to it

**OR**

**4** - The physician attests they are aware of the multiple sedative hypnotics prescribed to the patient and feels treatment with both medications is medically necessary (Document rationale for use)

Product Name: Brand Ambien, generic zolpidem, Brand Ambien CR, generic zolpidem ER, zolpidem SL, Edluar, Zolpimist, Belsomra, estazolam, generic eszopiclone, Brand Lunesta, flurazepam, triazolam, Brand Halcion, Brand Restoril, generic temazepam, generic ramelteon, Brand Rozerem, generic doxepin, Brand Silenor, zaleplon, Quviviq, Dayvigo

Diagnosis	Requests for Patients less than 6 years of age
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
AMBIEN	ZOLPIDEM TARTRATE TAB 5 MG	60204080100310	Brand
ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE TAB 5 MG	60204080100310	Generic
AMBIEN	ZOLPIDEM TARTRATE TAB 10 MG	60204080100315	Brand
ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE TAB 10 MG	60204080100315	Generic
AMBIEN CR	ZOLPIDEM TARTRATE TAB ER 6.25 MG	60204080100410	Brand
ZOLPIDEM TARTRATE ER	ZOLPIDEM TARTRATE TAB ER 6.25 MG	60204080100410	Generic
AMBIEN CR	ZOLPIDEM TARTRATE TAB ER 12.5 MG	60204080100420	Brand
ZOLPIDEM TARTRATE ER	ZOLPIDEM TARTRATE TAB ER 12.5 MG	60204080100420	Generic
ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE SL TAB 1.75 MG	60204080100708	Generic
ZOLPIDEM TARTRATE	ZOLPIDEM TARTRATE SL TAB 3.5 MG	60204080100715	Generic
EDLUAR	ZOLPIDEM TARTRATE SL TAB 5 MG	60204080100720	Brand
EDLUAR	ZOLPIDEM TARTRATE SL TAB 10 MG	60204080100730	Brand
ZOLPIMIST	ZOLPIDEM TARTRATE ORAL SPRAY 5 MG/ACT	60204080102020	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BELSOMRA	SUVOREXANT TAB 5 MG	60500070000305	Brand
BELSOMRA	SUVOREXANT TAB 10 MG	60500070000310	Brand
BELSOMRA	SUVOREXANT TAB 15 MG	60500070000315	Brand
BELSOMRA	SUVOREXANT TAB 20 MG	60500070000320	Brand
ESTAZOLAM	ESTAZOLAM TAB 1 MG	60201005000310	Generic
ESTAZOLAM	ESTAZOLAM TAB 2 MG	60201005000320	Generic
ESZOPICLONE	ESZOPICLONE TAB 1 MG	60204035000320	Generic
LUNESTA	ESZOPICLONE TAB 1 MG	60204035000320	Brand
ESZOPICLONE	ESZOPICLONE TAB 2 MG	60204035000330	Generic
LUNESTA	ESZOPICLONE TAB 2 MG	60204035000330	Brand
ESZOPICLONE	ESZOPICLONE TAB 3 MG	60204035000340	Generic
LUNESTA	ESZOPICLONE TAB 3 MG	60204035000340	Brand
FLURAZEPAM HCL	FLURAZEPAM HCL CAP 15 MG	60201010100105	Generic
FLURAZEPAM HCL	FLURAZEPAM HCL CAP 30 MG	60201010100110	Generic
TRIAZOLAM	TRIAZOLAM TAB 0.125 MG	60201040000305	Generic
HALCION	TRIAZOLAM TAB 0.25 MG	60201040000310	Brand
TRIAZOLAM	TRIAZOLAM TAB 0.25 MG	60201040000310	Generic
RESTORIL	TEMAZEPAM CAP 7.5 MG	60201030000103	Brand
TEMAZEPAM	TEMAZEPAM CAP 7.5 MG	60201030000103	Generic
RESTORIL	TEMAZEPAM CAP 15 MG	60201030000105	Brand
TEMAZEPAM	TEMAZEPAM CAP 15 MG	60201030000105	Generic
RESTORIL	TEMAZEPAM CAP 22.5 MG	60201030000108	Brand
TEMAZEPAM	TEMAZEPAM CAP 22.5 MG	60201030000108	Generic
RESTORIL	TEMAZEPAM CAP 30 MG	60201030000110	Brand
TEMAZEPAM	TEMAZEPAM CAP 30 MG	60201030000110	Generic
RAMELTEON	RAMELTEON TAB 8 MG	60250060000320	Generic
ROZEREM	RAMELTEON TAB 8 MG	60250060000320	Brand
DOXEPIN HYDROCHLORIDE	DOXEPIN HCL (SLEEP) TAB 3 MG (BASE EQUIV)	60400030100320	Generic
SILENOR	DOXEPIN HCL (SLEEP) TAB 3 MG (BASE EQUIV)	60400030100320	Brand
DOXEPIN HYDROCHLORIDE	DOXEPIN HCL (SLEEP) TAB 6 MG (BASE EQUIV)	60400030100330	Generic

SILENOR	DOXEPIN HCL (SLEEP) TAB 6 MG (BASE EQUIV)	60400030100330	Brand
ZALEPLON	ZALEPLON CAP 5 MG	60204070000120	Generic
ZALEPLON	ZALEPLON CAP 10 MG	60204070000130	Generic
QUVIVIQ	DARIDOREXANT HCL TAB 25 MG	60500020100320	Brand
QUVIVIQ	DARIDOREXANT HCL TAB 50 MG	60500020100340	Brand
DAYVIGO	LEMBOREXANT TAB 5 MG	60500040000320	Brand
DAYVIGO	LEMBOREXANT TAB 10 MG	60500040000340	Brand

**Approval Criteria**

1 - The patient is unresponsive to other treatment modalities, unless contraindicated (i.e., other medications or behavioral modification attempted)

**AND**

2 - The physician attests that the requested medication is medically necessary (Document rationale for use)

**2 . Revision History**

Date	Notes
1/22/2024	Removed generic zolpidem ER as a target from non-preferred section and added as a prerequisite option with zolpidem IR formulation; Removed asterisk (*) in criteria that doesn't have an associated note.

Sensipar



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-158117
<b>Guideline Name</b>	Sensipar
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Brand Sensipar, generic cinacalcet			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CINACALCET HYDROCHLORIDE	CINACALCET HCL TAB 30 MG (BASE EQUIV)	30905225100320	Generic
SENSIPAR	CINACALCET HCL TAB 30 MG (BASE EQUIV)	30905225100320	Brand
CINACALCET HYDROCHLORIDE	CINACALCET HCL TAB 60 MG (BASE EQUIV)	30905225100330	Generic
SENSIPAR	CINACALCET HCL TAB 60 MG (BASE EQUIV)	30905225100330	Brand



CINACALCET HYDROCHLORIDE	CINACALCET HCL TAB 90 MG (BASE EQUIV)	30905225100340	Generic
SENSIPAR	CINACALCET HCL TAB 90 MG (BASE EQUIV)	30905225100340	Brand

**Approval Criteria**

1 - Prescribed by or in consultation with an oncologist, endocrinologist, or nephrologist

**AND**

2 - ONE of the following:

2.1 Diagnosis of hypercalcemia with parathyroid carcinoma

**OR**

2.2 ALL of the following:

2.2.1 Diagnosis of primary hyperparathyroidism (HPT)

**AND**

2.2.2 Severe hypercalcemia [serum calcium level greater than 12.5 mg/dL (milligrams/deciliter)] due to primary HPT

**AND**

2.2.3 Patient is unable to undergo parathyroidectomy

**OR**

2.3 ALL of the following:

2.3.1 Diagnosis of secondary hyperparathyroidism with chronic kidney disease

**AND**

**2.3.2** Patient is on dialysis

**AND**

**2.3.3** BOTH of the following:

**2.3.3.1** ONE of the following:

- Patient has therapeutic failure to ONE phosphate binder (e.g., PhosLo, Fosrenol, Renvela, Renagel, etc.) confirmed by claims history or submitted medical records
- Patient has intolerance or contraindication to ONE phosphate binders (e.g., PhosLo, Fosrenol, Renvela, Renagel, etc.) (please specify intolerance or contraindication)

**AND**

**2.3.3.2** ONE of the following:

- Patient has therapeutic failure to ONE vitamin D analog (e.g., calcitriol, Hectorol, Zemplar, etc.) confirmed by claims history or submitted medical records
- Patient has intolerance or contraindication to ONE vitamin D analogs (e.g., calcitriol, Hectorol, Zemplar, etc.) (please specify intolerance or contraindication)

Product Name: Brand Sensipar, generic cinacalcet			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CINACALCET HYDROCHLORIDE	CINACALCET HCL TAB 30 MG (BASE EQUIV)	30905225100320	Generic
SENSIPAR	CINACALCET HCL TAB 30 MG (BASE EQUIV)	30905225100320	Brand
CINACALCET HYDROCHLORIDE	CINACALCET HCL TAB 60 MG (BASE EQUIV)	30905225100330	Generic
SENSIPAR	CINACALCET HCL TAB 60 MG (BASE EQUIV)	30905225100330	Brand

CINACALCET HYDROCHLORIDE	CINACALCET HCL TAB 90 MG (BASE EQUIV)	30905225100340	Generic
SENSIPAR	CINACALCET HCL TAB 90 MG (BASE EQUIV)	30905225100340	Brand

**Approval Criteria**

1 - Patient has experienced a reduction in serum calcium from baseline

## 2 . Revision History

Date	Notes
10/28/2024	Minor updates throughout guideline with no changes to clinical intent.

Serevent Diskus



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140779
<b>Guideline Name</b>	Serevent Diskus
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/19/2023
-----------------	-----------

## 1 . Criteria

Product Name: Serevent Diskus			
Diagnosis	Asthma		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SEREVENT DISKUS	SALMETEROL XINAFOATE AER POW BA 50 MCG/DOSE (BASE EQUIV)	44201058108020	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of asthma

**AND**

2 - Patient is 4 years of age or older

**AND**

3 - Patient is also receiving treatment with an inhaled corticosteroid

Product Name: Serevent Diskus

Diagnosis	Exercise-Induced Bronchospasm
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SEREVENT DISKUS	SALMETEROL XINAFOATE AER POW BA 50 MCG/DOSE (BASE EQUIV)	44201058108020	Brand

**Approval Criteria**

1 - Diagnosis of exercise-induced bronchospasm (EIB)

**AND**

2 - Being used for prevention

**AND**

3 - Patient is 4 years of age or older

Product Name: Serevent Diskus

Diagnosis	Bronchospasm associated with chronic obstructive pulmonary disease (COPD)		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SEREVENT DISKUS	SALMETEROL XINAFOATE AER POW BA 50 MCG/DOSE (BASE EQUIV)	44201058108020	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of bronchospasm associated with chronic obstructive pulmonary disease (COPD)</p>			

## 2 . Revision History

Date	Notes
2/9/2023	Removed TD criteria section.

SGLT-2 Inhibitors



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-151893
<b>Guideline Name</b>	SGLT-2 Inhibitors
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	9/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Farxiga, generic dapagliflozin			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
FARXIGA	DAPAGLIFLOZIN PROPANEDIOL TAB 5 MG (BASE EQUIVALENT)	27700040200310	Brand
FARXIGA	DAPAGLIFLOZIN PROPANEDIOL TAB 10 MG (BASE EQUIVALENT)	27700040200320	Brand
DAPAGLIFLOZIN PROPANEDIOL	DAPAGLIFLOZIN PROPANEDIOL TAB 5 MG (BASE EQUIVALENT)	27700040200310	Generic
DAPAGLIFLOZIN PROPANEDIOL	DAPAGLIFLOZIN PROPANEDIOL TAB 10 MG (BASE EQUIVALENT)	27700040200320	Generic

**Approval Criteria**

1 - ONE of the following:

1.1 ALL of the following:

- Patient is 10 years of age or older
- Diagnosis of type 2 diabetes mellitus
- History of failure to metformin at a minimum dose of 1500mg daily for 90 days, or contraindication or intolerance to metformin

**OR**

1.2 ONE of the following:

- Diagnosis of chronic kidney disease (CKD)
- Diagnosis of heart failure (NYHA class II-IV) with reduced ejection fraction
- Diagnosis of heart failure (NYHA class II-IV) with preserved ejection fraction

**AND**

2 - If the request is for generic dapagliflozin, history of failure, intolerance, or contraindication to Brand Farxiga

Product Name: Jardiance

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
JARDIANCE	EMPAGLIFLOZIN TAB 10 MG	27700050000310	Brand
JARDIANCE	EMPAGLIFLOZIN TAB 25 MG	27700050000320	Brand

**Approval Criteria**

1 - ALL of the following:



- Patient is 10 years of age or older
- Diagnosis of type 2 diabetes mellitus
- History of failure to metformin at a minimum dose of 1500 mg daily for 90 days, or contraindication or intolerance to metformin

**OR**

**2 - BOTH** of the following:

- Requested medication is being used to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease
- History of failure to metformin at a minimum dose of 1500mg daily for 90 days, or contraindication or intolerance to metformin.

**OR**

**3 - Requested medication is being used for ONE** of the following:

- To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure
- To reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.

<b>Product Name: Invokana</b>			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
INVOKANA	CANAGLIFLOZIN TAB 100 MG	27700020000320	Brand
INVOKANA	CANAGLIFLOZIN TAB 300 MG	27700020000330	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of type 2 diabetes mellitus			

**AND**

**2** - History of failure to metformin at a minimum dose of 1500 mg daily for 90 days, or contraindication or intolerance to metformin

Product Name: Invokamet, Invokamet XR, Segluromet, Steglatro, Synjardy, Synjardy XR, Trijardy XR			
Approval Length		12 month(s)	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
INVOKAMET	CANAGLIFLOZIN-METFORMIN HCL TAB 50-500 MG	27996002200320	Brand
INVOKAMET	CANAGLIFLOZIN-METFORMIN HCL TAB 50-1000 MG	27996002200330	Brand
INVOKAMET	CANAGLIFLOZIN-METFORMIN HCL TAB 150-500 MG	27996002200340	Brand
INVOKAMET	CANAGLIFLOZIN-METFORMIN HCL TAB 150-1000 MG	27996002200350	Brand
INVOKAMET XR	CANAGLIFLOZIN-METFORMIN HCL TAB ER 24HR 50-500 MG	27996002207520	Brand
INVOKAMET XR	CANAGLIFLOZIN-METFORMIN HCL TAB ER 24HR 50-1000 MG	27996002207530	Brand
INVOKAMET XR	CANAGLIFLOZIN-METFORMIN HCL TAB ER 24HR 150-500 MG	27996002207540	Brand
INVOKAMET XR	CANAGLIFLOZIN-METFORMIN HCL TAB ER 24HR 150-1000 MG	27996002207550	Brand
SEGLUROMET	ERTUGLIFLOZIN-METFORMIN HCL TAB 2.5-500 MG	27996002450310	Brand
SEGLUROMET	ERTUGLIFLOZIN-METFORMIN HCL TAB 2.5-1000 MG	27996002450320	Brand
SEGLUROMET	ERTUGLIFLOZIN-METFORMIN HCL TAB 7.5-500 MG	27996002450330	Brand
SEGLUROMET	ERTUGLIFLOZIN-METFORMIN HCL TAB 7.5-1000 MG	27996002450340	Brand
STEGLATRO	ERTUGLIFLOZIN L-PYROGLUTAMIC ACID TAB 5 MG (BASE EQUIV)	27700055200320	Brand
STEGLATRO	ERTUGLIFLOZIN L-PYROGLUTAMIC ACID TAB 15 MG (BASE EQUIV)	27700055200340	Brand

SYNJARDY XR	EMPAGLIFLOZIN-METFORMIN HCL TAB ER 24HR 5-1000 MG	27996002407530	Brand
SYNJARDY XR	EMPAGLIFLOZIN-METFORMIN HCL TAB ER 24HR 10-1000 MG	27996002407540	Brand
SYNJARDY XR	EMPAGLIFLOZIN-METFORMIN HCL TAB ER 24HR 12.5-1000 MG	27996002407550	Brand
SYNJARDY XR	EMPAGLIFLOZIN-METFORMIN HCL TAB ER 24HR 25-1000 MG	27996002407560	Brand
TRIJARDY XR	EMPAGLIFLOZIN-LINAGLIPTIN-METFORMIN TAB ER 24HR 5-2.5-1000MG	27996703407510	Brand
TRIJARDY XR	EMPAGLIFLOZIN-LINAGLIPTIN-METFORMIN TAB ER 24HR 10-5-1000 MG	27996703407520	Brand
TRIJARDY XR	EMPAGLIFLOZIN-LINAGLIP-METFORMIN TAB ER 24HR 12.5-2.5-1000MG	27996703407530	Brand
TRIJARDY XR	EMPAGLIFLOZIN-LINAGLIPTIN-METFORMIN TAB ER 24HR 25-5-1000 MG	27996703407540	Brand
SYNJARDY	EMPAGLIFLOZIN-METFORMIN HCL TAB 5-500 MG	27996002400310	Brand
SYNJARDY	EMPAGLIFLOZIN-METFORMIN HCL TAB 5-1000 MG	27996002400315	Brand
SYNJARDY	EMPAGLIFLOZIN-METFORMIN HCL TAB 12.5-500 MG	27996002400320	Brand
SYNJARDY	EMPAGLIFLOZIN-METFORMIN HCL TAB 12.5-1000 MG	27996002400325	Brand

**Approval Criteria**

1 - Diagnosis of type 2 diabetes mellitus

**AND**

2 - History of failure to metformin at a minimum dose of 1500 mg daily for 90 days, or contraindication or intolerance to metformin

**AND**

3 - History of failure, intolerance, or contraindication to ALL of the following:

- Farxiga
- Jardiance

- Invokana

**AND**

**4** - If the request is for Synjardy, patient is 10 years of age or older

Product Name: Brand Xigduo XR, generic dapagliflozin-metformin

Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
XIGDUO XR	DAPAGLIFLOZIN PROP-METFORMIN HCL TAB ER 24HR 2.5-1000 MG	27996002307507	Brand
XIGDUO XR	DAPAGLIFLOZIN PROP-METFORMIN HCL TAB ER 24HR 5-500 MG	27996002307510	Brand
XIGDUO XR	DAPAGLIFLOZIN PROP-METFORMIN HCL TAB ER 24HR 5-1000 MG	27996002307515	Brand
XIGDUO XR	DAPAGLIFLOZIN PROP-METFORMIN HCL TAB ER 24HR 10-500 MG	27996002307520	Brand
XIGDUO XR	DAPAGLIFLOZIN PROP-METFORMIN HCL TAB ER 24HR 10-1000 MG	27996002307525	Brand
DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HYDROCHLORIDE	DAPAGLIFLOZIN PROP-METFORMIN HCL TAB ER 24HR 5-1000 MG	27996002307515	Generic
DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HYDROCHLORIDE	DAPAGLIFLOZIN PROP-METFORMIN HCL TAB ER 24HR 10-1000 MG	27996002307525	Generic

**Approval Criteria**

**1** - ONE of the following:

**1.1** ALL of the following:

- Patient is 10 years of age or older
- Diagnosis of type 2 diabetes mellitus

- History of failure to metformin at a minimum dose of 1500mg daily for 90 days, or contraindication or intolerance to metformin

**OR**

**1.2 ONE** of the following:

- Diagnosis of chronic kidney disease (CKD)
- Diagnosis of heart failure (NYHA class II-IV) with reduced ejection fraction

**AND**

**2** - If the request is for generic dapagliflozin-metformin, history of failure, intolerance, or contraindication to brand Xigduo XR

Product Name: Brand Bexagliflozin, Brenzavvy, Glyxambi, Qtern, Steglujan

Approval Length	12 month(s)
-----------------	-------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
GLYXAMBI	EMPAGLIFLOZIN-LINAGLIPTIN TAB 10-5 MG	27996502300320	Brand
GLYXAMBI	EMPAGLIFLOZIN-LINAGLIPTIN TAB 25-5 MG	27996502300330	Brand
QTERN	DAPAGLIFLOZIN-SAXAGLIPTIN TAB 5-5 MG	27996502200320	Brand
QTERN	DAPAGLIFLOZIN-SAXAGLIPTIN TAB 10-5 MG	27996502200330	Brand
STEGLUJAN	ERTUGLIFLOZIN-SITAGLIPTIN TAB 5-100 MG	27996502350320	Brand
STEGLUJAN	ERTUGLIFLOZIN-SITAGLIPTIN TAB 15-100 MG	27996502350330	Brand
BRENZAVVY	BEXAGLIFLOZIN TAB 20 MG	27700010000320	Generic
BEXAGLIFLOZIN	BEXAGLIFLOZIN TAB 20 MG	27700010000320	Generic

**Approval Criteria**

**1** - Diagnosis of type 2 diabetes mellitus

**AND**

**2** - History of failure to metformin at a minimum dose of 1500 mg daily for 90 days, or contraindication or intolerance to metformin

**AND**

**3** - History of failure, intolerance, or contraindication to ALL of the following:

- Janumet or Janumet XR
- Januvia
- Jentadueto or Jentadueto XR
- Kombiglyze XR
- Onglyza
- Tradjenta
- Trijardy XR
- Farxiga
- Jardiance
- Invokana

Product Name: Inpefa			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
INPEFA	SOTAGLIFLOZIN TAB 200 MG	40750010000320	Brand
INPEFA	SOTAGLIFLOZIN TAB 400 MG	40750010000340	Brand

**Approval Criteria**

**1** - Requested medication is being used to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with ONE of the following:

- Heart failure
- Type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors

**AND**

2 - History of failure, intolerance, or contraindication to Farxiga

## 2 . Revision History

Date	Notes
8/16/2024	Added Brand Bexagliflozin as a target to the guideline. Updated GPI table and product name list accordingly.

Shingrix (zoster vaccine recombinant, adjuvanted)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140755
<b>Guideline Name</b>	Shingrix (zoster vaccine recombinant, adjuvanted)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Shingrix			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SHINGRIX	ZOSTER VAC RECOMBINANT ADJUVANTED FOR IM INJ 50 MCG/0.5ML	17100095401920	Brand
<b>Approval Criteria</b>			
1 - Vaccine is being used for prevention of herpes zoster (shingles)			



**AND**

**2** - BOTH of the following:

**2.1** Patient is between 18 to 49 years of age\*

**AND**

**2.2** Patient is or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

Notes	*Prior authorization is not required for patients 50 years of age and older.
-------	--

## 2 . Revision History

Date	Notes
11/7/2022	New guideline following FFS.

Short-Acting Opioid Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-160630
<b>Guideline Name</b>	Short-Acting Opioid Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: butorphanol nasal soln, codeine sulfate, acetaminophen/codeine soln/tabs, generic butalbital/acetaminophen/caffeine/codeine, Brand Fioricet/codeine, Ascomp/codeine, butalbital/aspirin/caffeine/codeine, morphine sulfate oral soln/supp/tabs, hydrocodone/acetaminophen soln, Lortab, hydrocodone/acetaminophen tabs, Brand Xodol, hydrocodone/ibuprofen, Brand Dilaudid liqd/tabs, generic hydromorphone liqd/supp/tabs, oxycodone caps/conc/soln/tabs, Oxaydo, Brand Roxicodone, Nalocet, oxycodone/acetaminophen tabs/soln, Endocet, Brand Percocet, Prolate tabs/soln, oxymorphone, generic tramadol tabs, Brand Ultram, Synapryn Fusepaq, generic tramadol/acetaminophen, Brand Ultracet, Nucynta, meperidine tabs/oral soln, levorphanol tabs, generic acetaminophen/caffeine/dihydrocodeine, Brand Trezix, belladonna/opium supp, opium tinc, Apadaz, benzhydrocodone/acetaminophen, pentazocine/naloxone, Qdolo, tramadol soln, Seglentis, Roxybond, oxycodone abuse deterrent tabs, carisoprodol-aspirin-codeine	
Diagnosis	PA REQUIRED for use of MAT and other Opioids
Guideline Type	DUR

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name	Generic Name	GPI	Brand/Gener ic
BUTORPHANOL TARTRATE	BUTORPHANOL TARTRATE NASAL SOLN 10 MG/ML	6520002010205 0	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 15 MG	6510002020030 5	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 30 MG	6510002020031 0	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 60 MG	6510002020031 5	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE SOLN 120-12 MG/5ML	6599100205202 0	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	6599100205031 0	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	6599100205031 0	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE #3	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/COD EINE	BUTALBITAL- ACETAMINOPHEN- CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Generic
FIORICET/CODEINE	BUTALBITAL- ACETAMINOPHEN- CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-325-40-30 MG	6599100410011 5	Generic
ASCOMP/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	6599100430011 5	Generic
BUTALBITAL/ASPIRIN/CAFFEINE/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	6599100430011 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 10 MG/5ML	6510005510206 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 20 MG/5ML	6510005510207 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 100 MG/5ML (20 MG/ML)	6510005510209 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 5 MG	6510005510520 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 10 MG	6510005510521 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 20 MG	6510005510521 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 30 MG	6510005510522 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 15 MG	6510005510031 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 30 MG	6510005510031 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN SOLN 7.5-325 MG/15ML	6599170210201 5	Generic
LORTAB	HYDROCODONE-ACETAMINOPHEN SOLN 10-300 MG/15ML	6599170210202 4	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 10-325 MG	6599170210030 5	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Generic
XODOL	HYDROCODONE- ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-300 MG	6599170210032 2	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 5-325 MG	6599170210035 6	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 10-300 MG	6599170210037 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 5- 200 MG	6599170250031 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 7.5-200 MG	6599170250032 0	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 10-200 MG	6599170250033 0	Generic
DILAUDID	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HCL	HYDROMORPHONE HCL SUPPOS 3 MG	6510003510520 5	Generic
DILAUDID	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Generic
DILAUDID	HYDROMORPHONE HCL TAB 4 MG	6510003510032 0	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Generic
DILAUDID	HYDROMORPHONE HCL TAB 8 MG	65100035100330	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 8 MG	65100035100330	Generic
OXYCODONE HCL	OXYCODONE HCL CAP 5 MG	65100075100110	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CAP 5 MG	65100075100110	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CONC 100 MG/5ML (20 MG/ML)	65100075101320	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL SOLN 5 MG/5ML	65100075102005	Generic
OXAYDO	OXYCODONE HCL TAB 5 MG	65100075100310	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 5 MG	65100075100310	Generic
OXAYDO	OXYCODONE HCL TAB 7.5 MG	65100075100315	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 10 MG	65100075100320	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 15 MG	65100075100325	Generic
ROXICODONE	OXYCODONE HCL TAB 15 MG	65100075100325	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 20 MG	65100075100330	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 30 MG	65100075100340	Generic
ROXICODONE	OXYCODONE HCL TAB 30 MG	65100075100340	Brand
NALOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	65990002200303	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	65990002200303	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	65990002200305	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Brand
OXYCODONE AND ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Brand
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 5 MG	6510008010030 5	Generic
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 10 MG	6510008010031 0	Generic
TRAMADOL HCL	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
ULTRAM	TRAMADOL HCL TAB 50 MG	6510009510032 0	Brand
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 100 MG	6510009510034 0	Generic
SYNAPRYN FUSEPAQ	*TRAMADOL HCL FOR ORAL SUSP 10 MG/ML (COMPOUND KIT)***	6510009510192 0	Brand
TRAMADOL HYDROCHLORIDE/ACETAMINOPHEN	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Generic
ULTRACET	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 50 MG	6510009110032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 75 MG	6510009110033 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 100 MG	6510009110034 0	Brand
MEPERIDINE HCL	MEPERIDINE HCL TAB 50 MG	6510004510030 5	Generic
MEPERIDINE HCL	MEPERIDINE HCL ORAL SOLN 50 MG/5ML	6510004510206 0	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 2 MG	6510004010030 5	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 3 MG	6510004010031 0	Generic
ACETAMINOPHEN/CAFFEINE/DIHYDROCODEIN E	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TREZIX	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Brand
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-30 MG	4910990215521 0	Generic
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-60 MG	4910990215522 0	Generic
OPIUM	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
OPIUM TINCTURE	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
PENTAZOCINE/NALOXONE HCL	PENTAZOCINE W/ NALOXONE HCL TAB 50-0.5 MG	6520004030031 0	Generic
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 5-325 MG/5ML	6599000220200 5	Brand
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PROLATE	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
QDOLO	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic
SEGLENTIS	CELECOXIB- TRAMADOL HCL TAB 56-44 MG	6599500210032 0	Brand
CARISOPRODOL-ASPIRIN-CODEINE	CARISOPRODOL W/ ASPIRIN & CODEINE TAB 200- 325-16 MG	7599000310031 0	Generic
APAP-CAFF-DIHYDROCODEINE	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE TAB 325-30-16 MG	6599130305032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 25 MG	6510009510031 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 10 MG	6510007510A53 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic

**Approval Criteria**

**1** - Provider attests to notify the prescriber of the MAT (medication-assisted treatment) therapy and the prescriber of the MAT therapy approves the concurrent opioid therapy

**AND**

**2** - The days supply does not exceed 14 days for a surgical procedure

**AND**

**3** - The days supply does not exceed 5 days for all other requests

**AND**

**4** - There has not been a previous approval in the last 6 months

Notes	Approval Length: 14 Days for surgical procedure, 5 Days for all other requests
-------	--

Product Name: butorphanol nasal soln, codeine sulfate, Brand Fioricet/codeine, Lortab, Brand Xodol, Brand Dilaudid liqd/tabs, Oxaydo, Brand Roxicodone, Nalocet, Endocet, Brand Percocet, Prolate tabs, oxymorphone, Brand Ultram, generic tramadol 25mg tablets, Synapryn Fusepaq, generic tramadol/acetaminophen, Brand Ultracet, Nucynta, levorphanol tabs, generic acetaminophen/caffeine/dihydrocodeine, Brand Trezix, belladonna/opium supp, opium tinc, Apadaz, benzhydrocodone/acetaminophen, pentazocine/naloxone, Prolate soln, Qdolo, Seglentis, Roxybond, oxycodone abuse deterrent tabs, carisoprodol-aspirin-codeine

Diagnosis	Non-Preferred
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generi c
BUTORPHANOL TARTRATE	BUTORPHANOL TARTRATE NASAL SOLN 10 MG/ML	65200020102050	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 15 MG	65100020200305	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 30 MG	65100020200310	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CODEINE SULFATE	CODEINE SULFATE TAB 60 MG	65100020200315	Generic
FIORICET/CODEINE	BUTALBITAL- ACETAMINOPHEN- CAFF W/ COD CAP 50-300-40-30 MG	65991004100113	Brand
LORTAB	HYDROCODONE- ACETAMINOPHEN SOLN 10-300 MG/15ML	65991702102024	Brand
XODOL	HYDROCODONE- ACETAMINOPHEN TAB 5-300 MG	65991702100309	Brand
DILAUDID	HYDROMORPHONE HCL LIQD 1 MG/ML	65100035100920	Brand
DILAUDID	HYDROMORPHONE HCL TAB 2 MG	65100035100310	Brand
DILAUDID	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Brand
DILAUDID	HYDROMORPHONE HCL TAB 8 MG	65100035100330	Brand
OXAYDO	OXYCODONE HCL TAB 5 MG	65100075100310	Brand
OXAYDO	OXYCODONE HCL TAB 7.5 MG	65100075100315	Brand
ROXICODONE	OXYCODONE HCL TAB 15 MG	65100075100325	Brand
ROXICODONE	OXYCODONE HCL TAB 30 MG	65100075100340	Brand
NALOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	65990002200303	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	65990002200305	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	65990002200305	Brand
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	65990002200308	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	65990002200310	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	65990002200310	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	65990002200325	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	65990002200327	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	65990002200327	Brand
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	65990002200333	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	65990002200335	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	65990002200335	Brand
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 5 MG	65100080100305	Generic
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 10 MG	65100080100310	Generic
ULTRAM	TRAMADOL HCL TAB 50 MG	65100095100320	Brand
SYNAPRYN FUSEPAQ	*TRAMADOL HCL FOR ORAL SUSP 10 MG/ML (COMPOUND KIT)***	65100095101920	Brand
TRAMADOL HYDROCHLORIDE/ACETAMINOPHEN	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	65995002200320	Generic
ULTRACET	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	65995002200320	Brand
NUCYNTA	TAPENTADOL HCL TAB 50 MG	65100091100320	Brand
NUCYNTA	TAPENTADOL HCL TAB 75 MG	65100091100330	Brand
NUCYNTA	TAPENTADOL HCL TAB 100 MG	65100091100340	Brand
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 2 MG	65100040100305	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 3 MG	65100040100310	Generic
ACETAMINOPHEN/CAFFEINE/DIHYDROCODEI NE	ACETAMINOPHEN- CAFFEINE-	65991303050115	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	DIHYDROCODEINE CAP 320.5-30-16 MG		
TREZIX	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	65991303050115	Brand
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-30 MG	49109902155210	Generic
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-60 MG	49109902155220	Generic
OPIUM	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	47100030201505	Generic
OPIUM TINCTURE	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	47100030201505	Generic
APADAZ	BENZHYDROCODON E HCL- ACETAMINOPHEN TAB 4.08-325 MG	65990002020310	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODON E HCL- ACETAMINOPHEN TAB 4.08-325 MG	65990002020310	Brand
APADAZ	BENZHYDROCODON E HCL- ACETAMINOPHEN TAB 6.12-325 MG	65990002020320	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODON E HCL- ACETAMINOPHEN TAB 6.12-325 MG	65990002020320	Brand
APADAZ	BENZHYDROCODON E HCL- ACETAMINOPHEN TAB 8.16-325 MG	65990002020330	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODON E HCL- ACETAMINOPHEN TAB 8.16-325 MG	65990002020330	Brand
PENTAZOCINE/NALOXONE HCL	PENTAZOCINE W/ NALOXONE HCL TAB 50-0.5 MG	65200040300310	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	65990002202020	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

QDOLO	TRAMADOL HCL ORAL SOLN 5 MG/ML	65100095102005	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL ORAL SOLN 5 MG/ML	65100095102005	Generic
SEGLENTIS	CELECOXIB- TRAMADOL HCL TAB 56-44 MG	65995002100320	Brand
CARISOPRODOL-ASPIRIN-CODEINE	CARISOPRODOL W/ ASPIRIN & CODEINE TAB 200-325-16 MG	75990003100310	Generic
APAP-CAFF-DIHYDROCODEINE	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE TAB 325-30-16 MG	65991303050320	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 25 MG	65100095100310	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A530	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A530	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 10 MG	6510007510A535	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A540	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A540	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A560	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A560	Generic

**Approval Criteria**

1 - If the request is for a non-preferred\* medication, the patient must have a history of failure, contraindication, or intolerance to a trial of at least FIVE of the following preferred short-acting opioids:

- hydromorphone (generic Dilaudid)

<ul style="list-style-type: none"> <li>• meperidine</li> <li>• morphine sulfate</li> <li>• oxycodone (generic Roxicodone)</li> <li>• tramadol (generic Ultram)</li> <li>• oxycodone w/acetaminophen (generic Percocet)</li> <li>• oxycodone-ibuprofen</li> <li>• acetaminophen w/codeine</li> <li>• butalbital-acetaminophen-caffeine w/codeine (Generic Fioricet)</li> <li>• butalbital-aspirin-caffeine w/cod (generic Fiorinal)</li> <li>• hydrocodone-acetaminophen (generic Norco)</li> <li>• hydrocodone-ibuprofen</li> </ul>	
Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>

<p>Product Name: butorphanol nasal soln, codeine sulfate, acetaminophen/codeine soln/tabs, generic butalbital/acetaminophen/caffeine/codeine, Brand Fioricet/codeine, Ascomp/codeine, butalbital/aspirin/caffeine/codeine, morphine sulfate oral soln/supp/tabs, hydrocodone/acetaminophen soln, Lortab, hydrocodone/acetaminophen tabs, Brand Xodol, hydrocodone/ibuprofen, Brand Dilaudid liqd/tabs, generic hydromorphone liqd/supp/tabs, oxycodone caps/conc/soln/tabs, Oxaydo, Brand Roxicodone, Nalocet, oxycodone/acetaminophen tabs/soln, Endocet, Brand Percocet, Prolate tabs/soln, oxymorphone, generic tramadol tabs, Brand Ultram, Synapryn Fusepaq, generic tramadol/acetaminophen, Brand Ultracet, Nucynta, meperidine tabs/oral soln, levorphanol tabs, generic acetaminophen/caffeine/dihydrocodeine, Brand Trezix, belladonna/opium supp, opium tinc, Apadaz, benzhydrocodone/acetaminophen, pentazocine/naloxone, Qdolo, tramadol soln, Seglentis, Roxybond, oxycodone abuse deterrent tabs, carisoprodol-aspirin-codeine</p>			
Diagnosis	PA Required for > 2 Short Acting Opioids		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BUTORPHANOL TARTRATE	BUTORPHANOL TARTRATE NASAL SOLN 10 MG/ML	6520002010205 0	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 15 MG	6510002020030 5	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 30 MG	6510002020031 0	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 60 MG	6510002020031 5	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE SOLN 120-12 MG/5ML	65991002052020	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	65991002050310	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	65991002050310	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
ACETAMINOPHEN/CODEINE #3	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	65991002050320	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	65991002050320	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	65991002050320	Generic
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-300-40-30 MG	65991004100113	Generic
FIORICET/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-300-40-30 MG	65991004100113	Brand
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-325-40-30 MG	65991004100115	Generic
ASCOMP/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	65991004300115	Generic
BUTALBITAL/ASPIRIN/CAFFEINE/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	65991004300115	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 10 MG/5ML	6510005510206 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 20 MG/5ML	6510005510207 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 100 MG/5ML (20 MG/ML)	6510005510209 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 5 MG	6510005510520 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 10 MG	6510005510521 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 20 MG	6510005510521 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 30 MG	6510005510522 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 15 MG	6510005510031 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 30 MG	6510005510031 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN SOLN 7.5-325 MG/15ML	6599170210201 5	Generic
LORTAB	HYDROCODONE-ACETAMINOPHEN SOLN 10-300 MG/15ML	6599170210202 4	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 10-325 MG	6599170210030 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Generic
XODOL	HYDROCODONE-ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 7.5-300 MG	6599170210032 2	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 5-325 MG	6599170210035 6	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 10-300 MG	6599170210037 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 5- 200 MG	6599170250031 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 7.5-200 MG	6599170250032 0	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 10-200 MG	6599170250033 0	Generic
DILAUDID	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HCL	HYDROMORPHONE HCL SUPPOS 3 MG	6510003510520 5	Generic
DILAUDID	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Generic
DILAUDID	HYDROMORPHONE HCL TAB 4 MG	6510003510032 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 4 MG	6510003510032 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 4 MG	6510003510032 0	Generic
DILAUDID	HYDROMORPHONE HCL TAB 8 MG	6510003510033 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 8 MG	6510003510033 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYCODONE HCL	OXYCODONE HCL CAP 5 MG	6510007510011 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CAP 5 MG	6510007510011 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CONC 100 MG/5ML (20 MG/ML)	6510007510132 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL SOLN 5 MG/5ML	6510007510200 5	Generic
OXAYDO	OXYCODONE HCL TAB 5 MG	6510007510031 0	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 5 MG	6510007510031 0	Generic
OXAYDO	OXYCODONE HCL TAB 7.5 MG	6510007510031 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 10 MG	6510007510032 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 15 MG	6510007510032 5	Generic
ROXICODONE	OXYCODONE HCL TAB 15 MG	6510007510032 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 20 MG	6510007510033 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 30 MG	6510007510034 0	Generic
ROXICODONE	OXYCODONE HCL TAB 30 MG	6510007510034 0	Brand
NALOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	6599000220030 3	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	6599000220030 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Brand
OXYCODONE AND ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Brand
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 5 MG	6510008010030 5	Generic
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 10 MG	6510008010031 0	Generic
TRAMADOL HCL	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
ULTRAM	TRAMADOL HCL TAB 50 MG	6510009510032 0	Brand
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 100 MG	6510009510034 0	Generic
SYNAPRYN FUSEPAQ	*TRAMADOL HCL FOR ORAL SUSP 10 MG/ML (COMPOUND KIT)***	6510009510192 0	Brand
TRAMADOL HYDROCHLORIDE/ACETAMINOPHEN	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Generic
ULTRACET	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 50 MG	6510009110032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 75 MG	6510009110033 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 100 MG	6510009110034 0	Brand
MEPERIDINE HCL	MEPERIDINE HCL TAB 50 MG	6510004510030 5	Generic
MEPERIDINE HCL	MEPERIDINE HCL ORAL SOLN 50 MG/5ML	6510004510206 0	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 2 MG	6510004010030 5	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 3 MG	6510004010031 0	Generic
ACETAMINOPHEN/CAFFEINE/DIHYDROCODEIN E	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Generic
TREZIX	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Brand
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-30 MG	4910990215521 0	Generic
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS &	4910990215522 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	OPIUM SUPPOS 16.2-60 MG		
OPIUM	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
OPIUM TINCTURE	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
PENTAZOCINE/NALOXONE HCL	PENTAZOCINE W/ NALOXONE HCL TAB 50-0.5 MG	6520004030031 0	Generic
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 5-325 MG/5ML	6599000220200 5	Brand
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
QDOLO	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TRAMADOL HYDROCHLORIDE	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic
SEGLENTIS	CELECOXIB- TRAMADOL HCL TAB 56-44 MG	6599500210032 0	Brand
CARISOPRODOL-ASPIRIN-CODEINE	CARISOPRODOL W/ ASPIRIN & CODEINE TAB 200- 325-16 MG	7599000310031 0	Generic
APAP-CAFF-DIHYDROCODEINE	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE TAB 325-30-16 MG	6599130305032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 25 MG	6510009510031 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 10 MG	6510007510A53 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic

**Approval Criteria**

1 - One of the following:

1.1 The requested medication is being used to adjust the dose of the drug

**OR**



**1.2** The requested medication will be used in place of the previously prescribed drug, and not in addition to it

**OR**

**1.3** The requested medication dosage form will be used in place of the previously prescribed medication dosage form, and not in addition to it

**OR**

**1.4** The physician attests they are aware of the multiple short-acting opioids prescribed to the patient and feels treatment with all medications is medically necessary (Document rationale for use)

Notes	Authorization will be issued for the requested duration, not to exceed 12 months.
-------	---

Product Name: butorphanol nasal soln, codeine sulfate, acetaminophen/codeine soln/tabs, generic butalbital/acetaminophen/caffeine/codeine, Brand Fioricet/codeine, Ascomp/codeine, butalbital/aspirin/caffeine/codeine, morphine sulfate oral soln/supp/tabs, hydrocodone/acetaminophen soln, Lortab, hydrocodone/acetaminophen tabs, Brand Xodol, hydrocodone/ibuprofen, Brand Dilaudid liqd/tabs, generic hydromorphone liqd/supp/tabs, oxycodone caps/conc/soln/tabs, Oxaydo, Brand Roxicodone, Nalocet, oxycodone/acetaminophen tabs/soln, Endocet, Brand Percocet, Prolate tabs/soln, oxymorphone, generic tramadol tabs, Brand Ultram, Synapryn Fusepaq, generic tramadol/acetaminophen, Brand Ultracet, Nucynta, meperidine tabs/oral soln, levorphanol tabs, generic acetaminophen/caffeine/dihydrocodeine, Brand Trezix, belladonna/opium supp, opium tinc, Apadaz, benzhydrocodone/acetaminophen, pentazocine/naloxone, Qdolo, tramadol soln, Seglentis, Roxybond, oxycodone abuse deterrent tabs, carisoprodol-aspirin-codeine

Approval Length	12 month(s)
Guideline Type	Quantity Limit

Product Name	Generic Name	GPI	Brand/Gener ic
BUTORPHANOL TARTRATE	BUTORPHANOL TARTRATE NASAL SOLN 10 MG/ML	6520002010205 0	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 15 MG	6510002020030 5	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 30 MG	6510002020031 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CODEINE SULFATE	CODEINE SULFATE TAB 60 MG	6510002020031 5	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE SOLN 120-12 MG/5ML	6599100205202 0	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	6599100205031 0	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	6599100205031 0	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE #3	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/COD EINE	BUTALBITAL- ACETAMINOPHEN- CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Generic
FIORICET/CODEINE	BUTALBITAL- ACETAMINOPHEN- CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Brand
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/COD EINE	BUTALBITAL- ACETAMINOPHEN- CAFF W/ COD CAP 50-325-40-30 MG	6599100410011 5	Generic
ASCOMP/CODEINE	BUTALBITAL- ASPIRIN-CAFF W/ CODEINE CAP 50- 325-40-30 MG	6599100430011 5	Generic
BUTALBITAL/ASPIRIN/CAFFEINE/CODEINE	BUTALBITAL- ASPIRIN-CAFF W/	6599100430011 5	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	CODEINE CAP 50-325-40-30 MG		
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 10 MG/5ML	65100055102065	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 20 MG/5ML	65100055102070	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 100 MG/5ML (20 MG/ML)	65100055102090	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 5 MG	65100055105205	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 10 MG	65100055105210	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 20 MG	65100055105215	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 30 MG	65100055105220	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 15 MG	65100055100310	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 30 MG	65100055100315	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN SOLN 7.5-325 MG/15ML	65991702102015	Generic
LORTAB	HYDROCODONE-ACETAMINOPHEN SOLN 10-300 MG/15ML	65991702102024	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 10-325 MG	65991702100305	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 5-300 MG	65991702100309	Generic
XODOL	HYDROCODONE-ACETAMINOPHEN TAB 5-300 MG	65991702100309	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 7.5-300 MG	65991702100322	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 5-325 MG	6599170210035 6	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 10-300 MG	6599170210037 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 5- 200 MG	6599170250031 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 7.5-200 MG	6599170250032 0	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 10-200 MG	6599170250033 0	Generic
DILAUDID	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HCL	HYDROMORPHONE HCL SUPPOS 3 MG	6510003510520 5	Generic
DILAUDID	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Generic
DILAUDID	HYDROMORPHONE HCL TAB 4 MG	6510003510032 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 4 MG	6510003510032 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 4 MG	6510003510032 0	Generic
DILAUDID	HYDROMORPHONE HCL TAB 8 MG	6510003510033 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 8 MG	6510003510033 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYCODONE HCL	OXYCODONE HCL CAP 5 MG	6510007510011 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CAP 5 MG	6510007510011 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CONC 100 MG/5ML (20 MG/ML)	6510007510132 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL SOLN 5 MG/5ML	6510007510200 5	Generic
OXAYDO	OXYCODONE HCL TAB 5 MG	6510007510031 0	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 5 MG	6510007510031 0	Generic
OXAYDO	OXYCODONE HCL TAB 7.5 MG	6510007510031 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 10 MG	6510007510032 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 15 MG	6510007510032 5	Generic
ROXICODONE	OXYCODONE HCL TAB 15 MG	6510007510032 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 20 MG	6510007510033 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 30 MG	6510007510034 0	Generic
ROXICODONE	OXYCODONE HCL TAB 30 MG	6510007510034 0	Brand
NALOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	6599000220030 3	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	6599000220030 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Brand
OXYCODONE AND ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Brand
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 5 MG	6510008010030 5	Generic
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 10 MG	6510008010031 0	Generic
TRAMADOL HCL	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
ULTRAM	TRAMADOL HCL TAB 50 MG	6510009510032 0	Brand
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 100 MG	6510009510034 0	Generic
SYNAPRYN FUSEPAQ	*TRAMADOL HCL FOR ORAL SUSP 10 MG/ML (COMPOUND KIT)***	6510009510192 0	Brand
TRAMADOL HYDROCHLORIDE/ACETAMINOPHEN	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Generic
ULTRACET	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 50 MG	6510009110032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 75 MG	6510009110033 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 100 MG	6510009110034 0	Brand
MEPERIDINE HCL	MEPERIDINE HCL TAB 50 MG	6510004510030 5	Generic
MEPERIDINE HCL	MEPERIDINE HCL ORAL SOLN 50 MG/5ML	6510004510206 0	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 2 MG	6510004010030 5	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 3 MG	6510004010031 0	Generic
ACETAMINOPHEN/CAFFEINE/DIHYDROCODEIN E	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Generic
TREZIX	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Brand
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-30 MG	4910990215521 0	Generic
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS &	4910990215522 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	OPIUM SUPPOS 16.2-60 MG		
OPIUM	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
OPIUM TINCTURE	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
PENTAZOCINE/NALOXONE HCL	PENTAZOCINE W/ NALOXONE HCL TAB 50-0.5 MG	6520004030031 0	Generic
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 5-325 MG/5ML	6599000220200 5	Brand
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
QDOLO	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TRAMADOL HYDROCHLORIDE	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic
SEGLENTIS	CELECOXIB- TRAMADOL HCL TAB 56-44 MG	6599500210032 0	Brand
CARISOPRODOL-ASPIRIN-CODEINE	CARISOPRODOL W/ ASPIRIN & CODEINE TAB 200- 325-16 MG	7599000310031 0	Generic
APAP-CAFF-DIHYDROCODEINE	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE TAB 325-30-16 MG	6599130305032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 25 MG	6510009510031 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 10 MG	6510007510A53 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic

**Approval Criteria**

1 - The requested dose cannot be achieved by moving to a higher strength of the product

**AND**

2 - The requested dose is within FDA (Food and Drug Administration) approved maximum

dose per day, where an FDA maximum dose per day exists (See Table 1 in background section)

Product Name: butorphanol nasal soln, codeine sulfate, acetaminophen/codeine soln/tabs, generic butalbital/acetaminophen/caffeine/codeine, Brand Fioricet/codeine, Ascomp/codeine, butalbital/aspirin/caffeine/codeine, morphine sulfate oral soln/supp/tabs, hydrocodone/acetaminophen soln, Lortab, hydrocodone/acetaminophen tabs, Brand Xodol, hydrocodone/ibuprofen, Brand Dilaudid liqd/tabs, generic hydromorphone liqd/supp/tabs, oxycodone caps/conc/soln/tabs, Oxaydo, Brand Roxicodone, Nalocet, oxycodone/acetaminophen tabs/soln, Endocet, Brand Percocet, Prolate tabs/soln, oxymorphone, generic tramadol tabs, Brand Ultram, Synapryn Fusepaq, generic tramadol/acetaminophen, Brand Ultracet, Nucynta, meperidine tabs/oral soln, levorphanol tabs, generic acetaminophen/caffeine/dihydrocodeine, Brand Trezix, belladonna/opium supp, opium tinc, Apadaz, benzhydrocodone/acetaminophen, pentazocine/naloxone, Qdolo, tramadol soln, Seglentis, Roxybond, oxycodone abuse deterrent tabs, carisoprodol-aspirin-codeine

Diagnosis	Greater than 5 day supply requests for patients 18 years of age and older
-----------	---

Guideline Type	Quantity Limit
----------------	----------------

Product Name	Generic Name	GPI	Brand/Generic
BUTORPHANOL TARTRATE	BUTORPHANOL TARTRATE NASAL SOLN 10 MG/ML	65200020102050	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 15 MG	65100020200305	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 30 MG	65100020200310	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 60 MG	65100020200315	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE SOLN 120-12 MG/5ML	65991002052020	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	65991002050310	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	65991002050310	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
ACETAMINOPHEN/CODEINE #3	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Generic
FIORICET/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Brand
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-325-40-30 MG	6599100410011 5	Generic
ASCOMP/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	6599100430011 5	Generic
BUTALBITAL/ASPIRIN/CAFFEINE/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	6599100430011 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 10 MG/5ML	6510005510206 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 20 MG/5ML	6510005510207 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 100 MG/5ML (20 MG/ML)	6510005510209 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 5 MG	6510005510520 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 10 MG	6510005510521 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 20 MG	6510005510521 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 30 MG	6510005510522 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 15 MG	6510005510031 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 30 MG	6510005510031 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN SOLN 7.5-325 MG/15ML	6599170210201 5	Generic
LORTAB	HYDROCODONE-ACETAMINOPHEN SOLN 10-300 MG/15ML	6599170210202 4	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 10-325 MG	6599170210030 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Generic
XODOL	HYDROCODONE-ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 7.5-300 MG	6599170210032 2	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 5-325 MG	6599170210035 6	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 10-300 MG	6599170210037 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE-IBUPROFEN TAB 5-200 MG	6599170250031 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE-IBUPROFEN TAB 7.5-200 MG	6599170250032 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 10-200 MG	6599170250033 0	Generic
DILAUDID	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HCL	HYDROMORPHONE HCL SUPPOS 3 MG	6510003510520 5	Generic
DILAUDID	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Generic
DILAUDID	HYDROMORPHONE HCL TAB 4 MG	6510003510032 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 4 MG	6510003510032 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 4 MG	6510003510032 0	Generic
DILAUDID	HYDROMORPHONE HCL TAB 8 MG	6510003510033 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 8 MG	6510003510033 0	Generic
OXYCODONE HCL	OXYCODONE HCL CAP 5 MG	6510007510011 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CAP 5 MG	6510007510011 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CONC 100 MG/5ML (20 MG/ML)	6510007510132 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL SOLN 5 MG/5ML	6510007510200 5	Generic
OXAYDO	OXYCODONE HCL TAB 5 MG	6510007510031 0	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 5 MG	6510007510031 0	Generic
OXAYDO	OXYCODONE HCL TAB 7.5 MG	6510007510031 5	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 10 MG	6510007510032 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 15 MG	6510007510032 5	Generic
ROXICODONE	OXYCODONE HCL TAB 15 MG	6510007510032 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 20 MG	6510007510033 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 30 MG	6510007510034 0	Generic
ROXICODONE	OXYCODONE HCL TAB 30 MG	6510007510034 0	Brand
NALOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	6599000220030 3	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	6599000220030 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Brand
OXYCODONE AND ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Brand
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 5 MG	6510008010030 5	Generic
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 10 MG	6510008010031 0	Generic
TRAMADOL HCL	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
ULTRAM	TRAMADOL HCL TAB 50 MG	6510009510032 0	Brand
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 100 MG	6510009510034 0	Generic
SYNAPRYN FUSEPAQ	*TRAMADOL HCL FOR ORAL SUSP 10 MG/ML (COMPOUND KIT)***	6510009510192 0	Brand
TRAMADOL HYDROCHLORIDE/ACETAMINOPHEN	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Generic
ULTRACET	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 50 MG	6510009110032 0	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NUCYNTA	TAPENTADOL HCL TAB 75 MG	6510009110033 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 100 MG	6510009110034 0	Brand
MEPERIDINE HCL	MEPERIDINE HCL TAB 50 MG	6510004510030 5	Generic
MEPERIDINE HCL	MEPERIDINE HCL ORAL SOLN 50 MG/5ML	6510004510206 0	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 2 MG	6510004010030 5	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 3 MG	6510004010031 0	Generic
ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Generic
TREZIX	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Brand
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-30 MG	4910990215521 0	Generic
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-60 MG	4910990215522 0	Generic
OPIUM	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
OPIUM TINCTURE	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL-ACETAMINOPHEN TAB 6.12-325 MG	65990002020320	Brand
APADAZ	BENZHYDROCODONE HCL-ACETAMINOPHEN TAB 8.16-325 MG	65990002020330	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL-ACETAMINOPHEN TAB 8.16-325 MG	65990002020330	Brand
PENTAZOCINE/NALOXONE HCL	PENTAZOCINE W/ NALOXONE HCL TAB 50-0.5 MG	65200040300310	Generic
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 5-325 MG/5ML	65990002202005	Brand
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	65990002202020	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	65990002202020	Generic
QDOLO	TRAMADOL HCL ORAL SOLN 5 MG/ML	65100095102005	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL ORAL SOLN 5 MG/ML	65100095102005	Generic
SEGLENTIS	CELECOXIB-TRAMADOL HCL TAB 56-44 MG	65995002100320	Brand
CARISOPRODOL-ASPIRIN-CODEINE	CARISOPRODOL W/ ASPIRIN & CODEINE TAB 200-325-16 MG	75990003100310	Generic
APAP-CAFF-DIHYDROCODEINE	ACETAMINOPHEN-CAFFEINE-DIHYDROCODEINE TAB 325-30-16 MG	65991303050320	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 25 MG	65100095100310	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A530	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A530	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 10 MG	6510007510A53 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic

**Approval Criteria**

1 - ONE of the following conditions or care instances:

- Active oncology diagnosis
- Hospice care
- End-of-life care (other than hospice)
- Palliative care
- Skilled nursing facility care
- Traumatic injury, excluding post-surgical procedures
- Chronic conditions for which the provider has received PA (prior authorization) approval
- Post-surgical procedures

**Notes**

Approvals are for 6 months for all of the listed conditions with the exception of post-surgical procedures which can be approved for a 14 day supply. Adults may obtain additional fills without PA if the refill is requested within 60 days from the initial fill.

Product Name: butorphanol nasal soln, codeine sulfate, acetaminophen/codeine soln/tabs, generic butalbital/acetaminophen/caffeine/codeine, Brand Fioricet/codeine, Ascomp/codeine, butalbital/aspirin/caffeine/codeine, morphine sulfate oral soln/supp/tabs, hydrocodone/acetaminophen soln, Lortab, hydrocodone/acetaminophen tabs, Brand Xodol, hydrocodone/ibuprofen, Brand Dilaudid liqd/tabs, generic hydromorphone liqd/supp/tabs, oxycodone caps/conc/soln/tabs, Oxaydo, Brand Roxicodone, Nalocet, oxycodone/acetaminophen tabs/soln, Endocet, Brand Percocet, Prolate tabs/soln, oxymorphone, generic tramadol tabs, Brand Ultram, Synapryn Fusepaq, generic tramadol/acetaminophen, Brand Ultracet, Nucynta, meperidine tabs/oral soln, levorphanol tabs, generic acetaminophen/caffeine/dihydrocodeine, Brand Trezix, belladonna/opium supp, opium tinc, Apadaz, benzhydrocodone/acetaminophen, pentazocine/naloxone, Qdolo,

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

tramadol soln, Seglentis, Roxybond, oxycodone abuse deterrent tabs, carisoprodol-aspirin-codeine			
Diagnosis	Greater than 5 day supply requests for patients under 18 years of age		
Guideline Type	Quantity Limit		
Product Name	Generic Name	GPI	Brand/Generic
BUTORPHANOL TARTRATE	BUTORPHANOL TARTRATE NASAL SOLN 10 MG/ML	65200020102050	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 15 MG	65100020200305	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 30 MG	65100020200310	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 60 MG	65100020200315	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE SOLN 120-12 MG/5ML	65991002052020	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	65991002050310	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	65991002050310	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
ACETAMINOPHEN/CODEINE #3	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	65991002050320	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	65991002050320	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	65991002050320	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Generic
FIORICET/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Brand
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-325-40-30 MG	6599100410011 5	Generic
ASCOMP/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	6599100430011 5	Generic
BUTALBITAL/ASPIRIN/CAFFEINE/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	6599100430011 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 10 MG/5ML	6510005510206 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 20 MG/5ML	6510005510207 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 100 MG/5ML (20 MG/ML)	6510005510209 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 5 MG	6510005510520 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 10 MG	6510005510521 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 20 MG	6510005510521 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 30 MG	6510005510522 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 15 MG	6510005510031 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 30 MG	6510005510031 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN	6599170210201 5	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	SOLN 7.5-325 MG/15ML		
LORTAB	HYDROCODONE- ACETAMINOPHEN SOLN 10-300 MG/15ML	6599170210202 4	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 10-325 MG	6599170210030 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Generic
XODOL	HYDROCODONE- ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-300 MG	6599170210032 2	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 5-325 MG	6599170210035 6	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 10-300 MG	6599170210037 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 5- 200 MG	6599170250031 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 7.5-200 MG	6599170250032 0	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 10-200 MG	6599170250033 0	Generic
DILAUDID	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HCL	HYDROMORPHONE HCL SUPPOS 3 MG	6510003510520 5	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DILAUDID	HYDROMORPHONE HCL TAB 2 MG	65100035100310	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 2 MG	65100035100310	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 2 MG	65100035100310	Generic
DILAUDID	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Generic
DILAUDID	HYDROMORPHONE HCL TAB 8 MG	65100035100330	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 8 MG	65100035100330	Generic
OXYCODONE HCL	OXYCODONE HCL CAP 5 MG	65100075100110	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CAP 5 MG	65100075100110	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CONC 100 MG/5ML (20 MG/ML)	65100075101320	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL SOLN 5 MG/5ML	65100075102005	Generic
OXAYDO	OXYCODONE HCL TAB 5 MG	65100075100310	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 5 MG	65100075100310	Generic
OXAYDO	OXYCODONE HCL TAB 7.5 MG	65100075100315	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 10 MG	65100075100320	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 15 MG	65100075100325	Generic
ROXICODONE	OXYCODONE HCL TAB 15 MG	65100075100325	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 20 MG	65100075100330	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 30 MG	65100075100340	Generic
ROXICODONE	OXYCODONE HCL TAB 30 MG	65100075100340	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NALOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	6599000220030 3	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	6599000220030 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Brand
OXYCODONE AND ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Brand
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 5 MG	6510008010030 5	Generic
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 10 MG	6510008010031 0	Generic
TRAMADOL HCL	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
ULTRAM	TRAMADOL HCL TAB 50 MG	6510009510032 0	Brand
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 100 MG	6510009510034 0	Generic
SYNAPRYN FUSEPAQ	*TRAMADOL HCL FOR ORAL SUSP 10 MG/ML (COMPOUND KIT)***	6510009510192 0	Brand
TRAMADOL HYDROCHLORIDE/ACETAMINOPHEN	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Generic
ULTRACET	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 50 MG	6510009110032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 75 MG	6510009110033 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 100 MG	6510009110034 0	Brand
MEPERIDINE HCL	MEPERIDINE HCL TAB 50 MG	6510004510030 5	Generic
MEPERIDINE HCL	MEPERIDINE HCL ORAL SOLN 50 MG/5ML	6510004510206 0	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 2 MG	65100040100305	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 3 MG	65100040100310	Generic
ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE	ACETAMINOPHEN-CAFFEINE-DIHYDROCODEINE CAP 320.5-30-16 MG	65991303050115	Generic
TREZIX	ACETAMINOPHEN-CAFFEINE-DIHYDROCODEINE CAP 320.5-30-16 MG	65991303050115	Brand
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-30 MG	49109902155210	Generic
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-60 MG	49109902155220	Generic
OPIUM	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	47100030201505	Generic
OPIUM TINCTURE	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	47100030201505	Generic
APADAZ	BENZHYDROCODONE HCL-ACETAMINOPHEN TAB 4.08-325 MG	65990002020310	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL-ACETAMINOPHEN TAB 4.08-325 MG	65990002020310	Brand
APADAZ	BENZHYDROCODONE HCL-ACETAMINOPHEN TAB 6.12-325 MG	65990002020320	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL-ACETAMINOPHEN TAB 6.12-325 MG	65990002020320	Brand
APADAZ	BENZHYDROCODONE HCL-ACETAMINOPHEN TAB 8.16-325 MG	65990002020330	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL-ACETAMINOPHEN TAB 8.16-325 MG	65990002020330	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PENTAZOCINE/NALOXONE HCL	PENTAZOCINE W/ NALOXONE HCL TAB 50-0.5 MG	6520004030031 0	Generic
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 5-325 MG/5ML	6599000220200 5	Brand
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
QDOLO	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic
SEGLENTIS	CELECOXIB- TRAMADOL HCL TAB 56-44 MG	6599500210032 0	Brand
CARISOPRODOL-ASPIRIN-CODEINE	CARISOPRODOL W/ ASPIRIN & CODEINE TAB 200- 325-16 MG	7599000310031 0	Generic
APAP-CAFF-DIHYDROCODEINE	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE TAB 325-30-16 MG	6599130305032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 25 MG	6510009510031 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 10 MG	6510007510A53 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic

OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic

**Approval Criteria**

1 - ONE of the following conditions or care instances:

- Active oncology diagnosis
- Hospice care
- End-of-life care (other than hospice)
- Palliative care
- Children on opioid wean at time of hospital discharge
- Skilled nursing facility care
- Traumatic injury, excluding post-surgical procedures
- Chronic conditions for which the provider has received PA (prior authorization) approval
- Post-surgical procedures

Notes	Approvals are for 6 months for all of the listed conditions with the exception of post-surgical procedures which can be approved for a 14 day supply. Children and adolescents may obtain additional fills without P A for 5 days supply unless the submitted PA supports a longer duration for use.
-------	--

Product Name: butorphanol nasal soln, codeine sulfate, acetaminophen/codeine soln/tabs, generic butalbital/acetaminophen/caffeine/codeine, Brand Fioricet/codeine, Ascomp/codeine, butalbital/aspirin/caffeine/codeine, morphine sulfate oral soln/supp/tabs, hydrocodone/acetaminophen soln, Lortab, hydrocodone/acetaminophen tabs, Brand Xodol, hydrocodone/ibuprofen, Brand Dilaudid liqd/tabs, generic hydromorphone liqd/supp/tabs, oxycodone caps/conc/soln/tabs, Oxaydo, Brand Roxicodone, Nalocet, oxycodone/acetaminophen tabs/soln, Endocet, Brand Percocet, Prolate tabs/soln, oxymorphone, generic tramadol tabs, Brand Ultram, Synapryn Fusepaq, generic tramadol/acetaminophen, Brand Ultracet, Nucynta, meperidine tabs/oral soln, levorphanol tabs, generic acetaminophen/caffeine/dihydrocodeine, Brand Trezix, belladonna/opium supp, opium tinc, Apadaz, benzhydrocodone/acetaminophen, pentazocine/naloxone, Qdolo, tramadol soln, Seglentis, Roxybond, oxycodone abuse deterrent tabs, carisoprodol-aspirin-codeine	
Diagnosis	Cancer/Hospice/End of Life/Palliative Care/Skilled Nursing Facility/Traumatic Injury Related Pain Exceeding the 90 MME Cumulative Threshold*
Approval Length	12 month(s)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Guideline Type	Morphine Milligram Equivalents (MME) Reviews* (MME 90.00 exceeded; PA REQUIRED; Dosage Above MEDD Limit)		
Product Name	Generic Name	GPI	Brand/Generic
BUTORPHANOL TARTRATE	BUTORPHANOL TARTRATE NASAL SOLN 10 MG/ML	65200020102050	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 15 MG	65100020200305	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 30 MG	65100020200310	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 60 MG	65100020200315	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE SOLN 120-12 MG/5ML	65991002052020	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	65991002050310	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	65991002050310	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
ACETAMINOPHEN/CODEINE #3	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	65991002050315	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	65991002050320	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	65991002050320	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	65991002050320	Generic
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-300-40-30 MG	65991004100113	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FIORICET/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Brand
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-325-40-30 MG	6599100410011 5	Generic
ASCOMP/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	6599100430011 5	Generic
BUTALBITAL/ASPIRIN/CAFFEINE/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	6599100430011 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 10 MG/5ML	6510005510206 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 20 MG/5ML	6510005510207 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 100 MG/5ML (20 MG/ML)	6510005510209 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 5 MG	6510005510520 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 10 MG	6510005510521 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 20 MG	6510005510521 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 30 MG	6510005510522 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 15 MG	6510005510031 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 30 MG	6510005510031 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN SOLN 7.5-325 MG/15ML	6599170210201 5	Generic
LORTAB	HYDROCODONE-ACETAMINOPHEN	6599170210202 4	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	SOLN 10-300 MG/15ML		
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 10-325 MG	6599170210030 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Generic
XODOL	HYDROCODONE- ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-300 MG	6599170210032 2	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 5-325 MG	6599170210035 6	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 10-300 MG	6599170210037 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 5- 200 MG	6599170250031 5	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 7.5-200 MG	6599170250032 0	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE- IBUPROFEN TAB 10-200 MG	6599170250033 0	Generic
DILAUDID	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL LIQD 1 MG/ML	6510003510092 0	Generic
HYDROMORPHONE HCL	HYDROMORPHONE HCL SUPPOS 3 MG	6510003510520 5	Generic
DILAUDID	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 2 MG	6510003510031 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 2 MG	65100035100310	Generic
DILAUDID	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Generic
DILAUDID	HYDROMORPHONE HCL TAB 8 MG	65100035100330	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 8 MG	65100035100330	Generic
OXYCODONE HCL	OXYCODONE HCL CAP 5 MG	65100075100110	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CAP 5 MG	65100075100110	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CONC 100 MG/5ML (20 MG/ML)	65100075101320	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL SOLN 5 MG/5ML	65100075102005	Generic
OXAYDO	OXYCODONE HCL TAB 5 MG	65100075100310	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 5 MG	65100075100310	Generic
OXAYDO	OXYCODONE HCL TAB 7.5 MG	65100075100315	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 10 MG	65100075100320	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 15 MG	65100075100325	Generic
ROXICODONE	OXYCODONE HCL TAB 15 MG	65100075100325	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 20 MG	65100075100330	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 30 MG	65100075100340	Generic
ROXICODONE	OXYCODONE HCL TAB 30 MG	65100075100340	Brand
NALOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	65990002200303	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	6599000220030 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Brand
OXYCODONE AND ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Brand
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 5 MG	6510008010030 5	Generic
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 10 MG	6510008010031 0	Generic
TRAMADOL HCL	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
ULTRAM	TRAMADOL HCL TAB 50 MG	6510009510032 0	Brand
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 100 MG	6510009510034 0	Generic
SYNAPRYN FUSEPAQ	*TRAMADOL HCL FOR ORAL SUSP 10 MG/ML (COMPOUND KIT)***	6510009510192 0	Brand
TRAMADOL HYDROCHLORIDE/ACETAMINOPHEN	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Generic
ULTRACET	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 50 MG	6510009110032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 75 MG	6510009110033 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 100 MG	6510009110034 0	Brand
MEPERIDINE HCL	MEPERIDINE HCL TAB 50 MG	6510004510030 5	Generic
MEPERIDINE HCL	MEPERIDINE HCL ORAL SOLN 50 MG/5ML	6510004510206 0	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 2 MG	6510004010030 5	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 3 MG	6510004010031 0	Generic
ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Generic
TREZIX	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Brand
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-30 MG	4910990215521 0	Generic
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-60 MG	4910990215522 0	Generic
OPIUM	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
OPIUM TINCTURE	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
PENTAZOCINE/NALOXONE HCL	PENTAZOCINE W/ NALOXONE HCL TAB 50-0.5 MG	6520004030031 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 5-325 MG/5ML	6599000220200 5	Brand
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
QDOLO	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic
SEGLENTIS	CELECOXIB- TRAMADOL HCL TAB 56-44 MG	6599500210032 0	Brand
CARISOPRODOL-ASPIRIN-CODEINE	CARISOPRODOL W/ ASPIRIN & CODEINE TAB 200- 325-16 MG	7599000310031 0	Generic
APAP-CAFF-DIHYDROCODEINE	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE TAB 325-30-16 MG	6599130305032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 25 MG	6510009510031 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 10 MG	6510007510A53 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic

ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following conditions:</p> <ul style="list-style-type: none"> <li>• Active oncology diagnosis</li> <li>• Hospice</li> <li>• End-of-life care (other than hospice)</li> <li>• Palliative care</li> <li>• Skilled nursing facility care</li> <li>• Traumatic injury, including burns and excluding post-surgical procedures</li> </ul>			
Notes	*The authorization should be entered for an MME of 9999 so as to prevent future disruptions in therapy if the patient's dose is increased.		

<p>Product Name: butorphanol nasal soln, codeine sulfate, acetaminophen/codeine soln/tabs, generic butalbital/acetaminophen/caffeine/codeine, Brand Fioricet/codeine, Ascomp/codeine, butalbital/aspirin/caffeine/codeine, morphine sulfate oral soln/supp/tabs, hydrocodone/acetaminophen soln, Lortab, hydrocodone/acetaminophen tabs, Brand Xodol, hydrocodone/ibuprofen, Brand Dilaudid liqd/tabs, generic hydromorphone liqd/supp/tabs, oxycodone caps/conc/soln/tabs, Oxaydo, Brand Roxicodone, Nalocet, oxycodone/acetaminophen tabs/soln, Endocet, Brand Percocet, Prolate tabs/soln, oxymorphone, generic tramadol tabs, Brand Ultram, Synapryn Fusepaq, generic tramadol/acetaminophen, Brand Ultracet, Nucynta, meperidine tabs/oral soln, levorphanol tabs, generic acetaminophen/caffeine/dihydrocodeine, Brand Trezix, belladonna/opium supp, opium tinc, Apadaz, benzhydrocodone/acetaminophen, pentazocine/naloxone, Qdolo, tramadol soln, Seglentis, Roxybond, oxycodone abuse deterrent tabs, carisoprodol-aspirin-codeine</p>			
Diagnosis	Non-cancer/non-hospice/non-end of life/non-palliative care/non-skilled nursing facility/non-traumatic injury related pain Exceeding the 90 MME Cumulative Threshold*		
Therapy Stage	Initial Authorization		
Guideline Type	Morphine Milligram Equivalents (MME) Reviews** (MME 90.00 exceeded; PA REQUIRED; Dosage Above MEDD Limit)		
Product Name	Generic Name	GPI	Brand/Generic
BUTORPHANOL TARTRATE	BUTORPHANOL TARTRATE NASAL SOLN 10 MG/ML	6520002010205 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CODEINE SULFATE	CODEINE SULFATE TAB 15 MG	6510002020030 5	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 30 MG	6510002020031 0	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 60 MG	6510002020031 5	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE SOLN 120-12 MG/5ML	6599100205202 0	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	6599100205031 0	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	6599100205031 0	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE #3	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL- ACETAMINOPHEN- CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Generic
FIORICET/CODEINE	BUTALBITAL- ACETAMINOPHEN- CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Brand
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL- ACETAMINOPHEN- CAFF W/ COD CAP 50-325-40-30 MG	6599100410011 5	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ASCOMP/CODEINE	BUTALBITAL- ASPIRIN-CAFF W/ CODEINE CAP 50- 325-40-30 MG	6599100430011 5	Generic
BUTALBITAL/ASPIRIN/CAFFEINE/CODEINE	BUTALBITAL- ASPIRIN-CAFF W/ CODEINE CAP 50- 325-40-30 MG	6599100430011 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 10 MG/5ML	6510005510206 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 20 MG/5ML	6510005510207 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 100 MG/5ML (20 MG/ML)	6510005510209 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 5 MG	6510005510520 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 10 MG	6510005510521 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 20 MG	6510005510521 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 30 MG	6510005510522 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 15 MG	6510005510031 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 30 MG	6510005510031 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN SOLN 7.5-325 MG/15ML	6599170210201 5	Generic
LORTAB	HYDROCODONE- ACETAMINOPHEN SOLN 10-300 MG/15ML	6599170210202 4	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 10-325 MG	6599170210030 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE- ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

XODOL	HYDROCODONE-ACETAMINOPHEN TAB 5-300 MG	65991702100309	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 7.5-300 MG	65991702100322	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 5-325 MG	65991702100356	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 7.5-325 MG	65991702100358	Generic
HYDROCODONE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 7.5-325 MG	65991702100358	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 10-300 MG	65991702100375	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE-IBUPROFEN TAB 5-200 MG	65991702500315	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE-IBUPROFEN TAB 7.5-200 MG	65991702500320	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE-IBUPROFEN TAB 10-200 MG	65991702500330	Generic
DILAUDID	HYDROMORPHONE HCL LIQD 1 MG/ML	65100035100920	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL LIQD 1 MG/ML	65100035100920	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL LIQD 1 MG/ML	65100035100920	Generic
HYDROMORPHONE HCL	HYDROMORPHONE HCL SUPPOS 3 MG	65100035105205	Generic
DILAUDID	HYDROMORPHONE HCL TAB 2 MG	65100035100310	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 2 MG	65100035100310	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 2 MG	65100035100310	Generic
DILAUDID	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Generic
DILAUDID	HYDROMORPHONE HCL TAB 8 MG	65100035100330	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 8 MG	65100035100330	Generic
OXYCODONE HCL	OXYCODONE HCL CAP 5 MG	65100075100110	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CAP 5 MG	65100075100110	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CONC 100 MG/5ML (20 MG/ML)	65100075101320	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL SOLN 5 MG/5ML	65100075102005	Generic
OXAYDO	OXYCODONE HCL TAB 5 MG	65100075100310	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 5 MG	65100075100310	Generic
OXAYDO	OXYCODONE HCL TAB 7.5 MG	65100075100315	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 10 MG	65100075100320	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 15 MG	65100075100325	Generic
ROXICODONE	OXYCODONE HCL TAB 15 MG	65100075100325	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 20 MG	65100075100330	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 30 MG	65100075100340	Generic
ROXICODONE	OXYCODONE HCL TAB 30 MG	65100075100340	Brand
NALOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	65990002200303	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	65990002200303	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	65990002200305	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Brand
OXYCODONE AND ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Brand
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 5 MG	6510008010030 5	Generic
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 10 MG	6510008010031 0	Generic
TRAMADOL HCL	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
ULTRAM	TRAMADOL HCL TAB 50 MG	6510009510032 0	Brand
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 100 MG	6510009510034 0	Generic
SYNAPRYN FUSEPAQ	*TRAMADOL HCL FOR ORAL SUSP 10 MG/ML (COMPOUND KIT)***	6510009510192 0	Brand
TRAMADOL HYDROCHLORIDE/ACETAMINOPHEN	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Generic
ULTRACET	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 50 MG	6510009110032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 75 MG	6510009110033 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 100 MG	6510009110034 0	Brand
MEPERIDINE HCL	MEPERIDINE HCL TAB 50 MG	6510004510030 5	Generic
MEPERIDINE HCL	MEPERIDINE HCL ORAL SOLN 50 MG/5ML	6510004510206 0	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 2 MG	6510004010030 5	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 3 MG	6510004010031 0	Generic
ACETAMINOPHEN/CAFFEINE/DIHYDROCODEIN E	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TREZIX	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Brand
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-30 MG	4910990215521 0	Generic
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-60 MG	4910990215522 0	Generic
OPIUM	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
OPIUM TINCTURE	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
PENTAZOCINE/NALOXONE HCL	PENTAZOCINE W/ NALOXONE HCL TAB 50-0.5 MG	6520004030031 0	Generic
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 5-325 MG/5ML	6599000220200 5	Brand
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PROLATE	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
QDOLO	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic
SEGLENTIS	CELECOXIB- TRAMADOL HCL TAB 56-44 MG	6599500210032 0	Brand
CARISOPRODOL-ASPIRIN-CODEINE	CARISOPRODOL W/ ASPIRIN & CODEINE TAB 200- 325-16 MG	7599000310031 0	Generic
APAP-CAFF-DIHYDROCODEINE	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE TAB 325-30-16 MG	6599130305032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 25 MG	6510009510031 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 10 MG	6510007510A53 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic

**Approval Criteria**

1 - Prescriber attests to ALL of the following:

**1.1** The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested

**AND**

**1.2** Treatment goals are defined, including estimated duration of treatment

**AND**

**1.3** Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention

**AND**

**1.4** Patient has been screened for substance abuse/opioid dependence

**AND**

**1.5** If used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression

**AND**

**2 - BOTH** of the following:

- Patient has tried and failed non-opioid pain medication (document drug name and date of trial)
- Opioid medication doses of less than 90 morphine milligram equivalent (MME) have been tried and did not adequately control pain (document drug regimen or MME and dates of therapy)\*\*

Notes

\*Authorization will be issued for 6 months for non-cancer/non-hospice/non-end-of-life/non-palliative care/non-skilled nursing facility/non-traumatic injury related pain related pain up to the current requested MME

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	<p>plus 90 MME.                  **If the member has been established on the requested MME dose for at least 30 days and does not meet the medical necessity authorization criteria requirements, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested MME dose.</p>
--	---

Product Name: butorphanol nasal soln, codeine sulfate, acetaminophen/codeine soln/tabs, generic butalbital/acetaminophen/caffeine/codeine, Brand Fioricet/codeine, Ascomp/codeine, butalbital/aspirin/caffeine/codeine, morphine sulfate oral soln/supp/tabs, hydrocodone/acetaminophen soln, Lortab, hydrocodone/acetaminophen tabs, Brand Xodol, hydrocodone/ibuprofen, Brand Dilaudid liqd/tabs, generic hydromorphone liqd/supp/tabs, oxycodone caps/conc/soln/tabs, Oxaydo, Brand Roxicodone, Nalocet, oxycodone/acetaminophen tabs/soln, Endocet, Brand Percocet, Prolate tabs/soln, oxymorphone, generic tramadol tabs, Brand Ultram, Synapryn Fusepaq, generic tramadol/acetaminophen, Brand Ultracet, Nucynta, meperidine tabs/oral soln, levorphanol tabs, generic acetaminophen/caffeine/dihydrocodeine, Brand Trezix, belladonna/opium supp, opium tinc, Apadaz, benzhydrocodone/acetaminophen, pentazocine/naloxone, Qdolo, tramadol soln, Seglentis, Roxybond, oxycodone abuse deterrent tabs, carisoprodol-aspirin-codeine

Diagnosis	Non-cancer/non-hospice/non-end of life/non-palliative care/non-skilled nursing facility/non-traumatic injury related pain Exceeding the 90 MME Cumulative Threshold*
Therapy Stage	Reauthorization
Guideline Type	Morphine Milligram Equivalents (MME) Reviews** (MME 90.00 exceeded; PA REQUIRED; Dosage Above MEDD Limit)

Product Name	Generic Name	GPI	Brand/Generic
BUTORPHANOL TARTRATE	BUTORPHANOL TARTRATE NASAL SOLN 10 MG/ML	65200020102050	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 15 MG	65100020200305	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 30 MG	65100020200310	Generic
CODEINE SULFATE	CODEINE SULFATE TAB 60 MG	65100020200315	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE SOLN 120-12 MG/5ML	65991002052020	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	65991002050310	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-15 MG	6599100205031 0	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE #3	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-30 MG	6599100205031 5	Generic
ACETAMINOPHEN/CODEINE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
ACETAMINOPHEN/CODEINE PHOSPHATE	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
CODEINE/ACETAMINOPHEN	ACETAMINOPHEN W/ CODEINE TAB 300-60 MG	6599100205032 0	Generic
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Generic
FIORICET/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-300-40-30 MG	6599100410011 3	Brand
BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE	BUTALBITAL-ACETAMINOPHEN-CAFF W/ COD CAP 50-325-40-30 MG	6599100410011 5	Generic
ASCOMP/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	6599100430011 5	Generic
BUTALBITAL/ASPIRIN/CAFFEINE/CODEINE	BUTALBITAL-ASPIRIN-CAFF W/ CODEINE CAP 50-325-40-30 MG	6599100430011 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 10 MG/5ML	6510005510206 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 20 MG/5ML	6510005510207 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MORPHINE SULFATE	MORPHINE SULFATE ORAL SOLN 100 MG/5ML (20 MG/ML)	6510005510209 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 5 MG	6510005510520 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 10 MG	6510005510521 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 20 MG	6510005510521 5	Generic
MORPHINE SULFATE	MORPHINE SULFATE SUPPOS 30 MG	6510005510522 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 15 MG	6510005510031 0	Generic
MORPHINE SULFATE	MORPHINE SULFATE TAB 30 MG	6510005510031 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN SOLN 7.5-325 MG/15ML	6599170210201 5	Generic
LORTAB	HYDROCODONE-ACETAMINOPHEN SOLN 10-300 MG/15ML	6599170210202 4	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 10-325 MG	6599170210030 5	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Generic
XODOL	HYDROCODONE-ACETAMINOPHEN TAB 5-300 MG	6599170210030 9	Brand
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 7.5-300 MG	6599170210032 2	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 5-325 MG	6599170210035 6	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 7.5-325 MG	6599170210035 8	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYDROCODONE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 7.5-325 MG	65991702100358	Generic
HYDROCODONE BITARTRATE/ACETAMINOPHEN	HYDROCODONE-ACETAMINOPHEN TAB 10-300 MG	65991702100375	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE-IBUPROFEN TAB 5-200 MG	65991702500315	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE-IBUPROFEN TAB 7.5-200 MG	65991702500320	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE-IBUPROFEN TAB 10-200 MG	65991702500330	Generic
DILAUDID	HYDROMORPHONE HCL LIQD 1 MG/ML	65100035100920	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL LIQD 1 MG/ML	65100035100920	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL LIQD 1 MG/ML	65100035100920	Generic
HYDROMORPHONE HCL	HYDROMORPHONE HCL SUPPOS 3 MG	65100035105205	Generic
DILAUDID	HYDROMORPHONE HCL TAB 2 MG	65100035100310	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 2 MG	65100035100310	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 2 MG	65100035100310	Generic
DILAUDID	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Generic
HYDROMORPHONE HYDROCHLORIDE	HYDROMORPHONE HCL TAB 4 MG	65100035100320	Generic
DILAUDID	HYDROMORPHONE HCL TAB 8 MG	65100035100330	Brand
HYDROMORPHONE HCL	HYDROMORPHONE HCL TAB 8 MG	65100035100330	Generic
OXYCODONE HCL	OXYCODONE HCL CAP 5 MG	65100075100110	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CAP 5 MG	65100075100110	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OXYCODONE HYDROCHLORIDE	OXYCODONE HCL CONC 100 MG/5ML (20 MG/ML)	6510007510132 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL SOLN 5 MG/5ML	6510007510200 5	Generic
OXAYDO	OXYCODONE HCL TAB 5 MG	6510007510031 0	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 5 MG	6510007510031 0	Generic
OXAYDO	OXYCODONE HCL TAB 7.5 MG	6510007510031 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 10 MG	6510007510032 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 15 MG	6510007510032 5	Generic
ROXICODONE	OXYCODONE HCL TAB 15 MG	6510007510032 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 20 MG	6510007510033 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB 30 MG	6510007510034 0	Generic
ROXICODONE	OXYCODONE HCL TAB 30 MG	6510007510034 0	Brand
NALOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	6599000220030 3	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-300 MG	6599000220030 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 2.5-325 MG	6599000220030 5	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 5-300 MG	6599000220030 8	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 5-325 MG	6599000220031 0	Brand
OXYCODONE AND ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-300 MG	6599000220032 5	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 7.5-325 MG	6599000220032 7	Brand
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN TAB 10-300 MG	6599000220033 3	Generic
ENDOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
OXYCODONE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Generic
PERCOCET	OXYCODONE W/ ACETAMINOPHEN TAB 10-325 MG	6599000220033 5	Brand
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 5 MG	6510008010030 5	Generic
OXYMORPHONE HYDROCHLORIDE	OXYMORPHONE HCL TAB 10 MG	6510008010031 0	Generic
TRAMADOL HCL	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 50 MG	6510009510032 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ULTRAM	TRAMADOL HCL TAB 50 MG	6510009510032 0	Brand
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 100 MG	6510009510034 0	Generic
SYNAPRYN FUSEPAQ	*TRAMADOL HCL FOR ORAL SUSP 10 MG/ML (COMPOUND KIT)***	6510009510192 0	Brand
TRAMADOL HYDROCHLORIDE/ACETAMINOPHEN	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Generic
ULTRACET	TRAMADOL- ACETAMINOPHEN TAB 37.5-325 MG	6599500220032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 50 MG	6510009110032 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 75 MG	6510009110033 0	Brand
NUCYNTA	TAPENTADOL HCL TAB 100 MG	6510009110034 0	Brand
MEPERIDINE HCL	MEPERIDINE HCL TAB 50 MG	6510004510030 5	Generic
MEPERIDINE HCL	MEPERIDINE HCL ORAL SOLN 50 MG/5ML	6510004510206 0	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 2 MG	6510004010030 5	Generic
LEVORPHANOL TARTRATE	LEVORPHANOL TARTRATE TAB 3 MG	6510004010031 0	Generic
ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Generic
TREZIX	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE CAP 320.5-30-16 MG	6599130305011 5	Brand
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-30 MG	4910990215521 0	Generic
BELLADONNA/OPIUM	BELLADONNA ALKALOIDS & OPIUM SUPPOS 16.2-60 MG	4910990215522 0	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OPIUM	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
OPIUM TINCTURE	OPIUM TINCTURE 1% (10 MG/ML) (MORPHINE EQUIV)	4710003020150 5	Generic
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 4.08-325 MG	6599000202031 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 6.12-325 MG	6599000202032 0	Brand
APADAZ	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
BENZHYDROCODONE/ACETAMINOPHEN	BENZHYDROCODONE HCL- ACETAMINOPHEN TAB 8.16-325 MG	6599000202033 0	Brand
PENTAZOCINE/NALOXONE HCL	PENTAZOCINE W/ NALOXONE HCL TAB 50-0.5 MG	6520004030031 0	Generic
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 5-325 MG/5ML	6599000220200 5	Brand
OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
PROLATE	OXYCODONE W/ ACETAMINOPHEN SOLN 10-300 MG/5ML	6599000220202 0	Generic
QDOLO	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL ORAL SOLN 5 MG/ML	6510009510200 5	Generic

SEGLENTIS	CELECOXIB- TRAMADOL HCL TAB 56-44 MG	6599500210032 0	Brand
CARISOPRODOL-ASPIRIN-CODEINE	CARISOPRODOL W/ ASPIRIN & CODEINE TAB 200- 325-16 MG	7599000310031 0	Generic
APAP-CAFF-DIHYDROCODEINE	ACETAMINOPHEN- CAFFEINE- DIHYDROCODEINE TAB 325-30-16 MG	6599130305032 0	Generic
TRAMADOL HYDROCHLORIDE	TRAMADOL HCL TAB 25 MG	6510009510031 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 5 MG	6510007510A53 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 10 MG	6510007510A53 5	Brand
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 15 MG	6510007510A54 0	Generic
OXYCODONE HYDROCHLORIDE	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic
ROXYBOND	OXYCODONE HCL TAB ABUSE DETER 30 MG	6510007510A56 0	Generic

**Approval Criteria**

1 - Prescriber attests to ALL of the following:

1.1 The information provided is true and accurate to the best of their knowledge and they understand that a routine audit may be performed and the medical information necessary to verify the accuracy of the information provided may be requested

**AND**

**1.2** Treatment goals are defined, including estimated duration of treatment

**AND**

**1.3** Treatment plan includes the use of a non-opioid analgesic and/or non-pharmacologic intervention

**AND**

**1.4** Patient has been screened for substance abuse/opioid dependence

**AND**

**1.5** If used in patients with medical comorbidities or if used concurrently with a benzodiazepine or other drugs that could potentially cause drug-drug interactions, the prescriber has acknowledged that they have completed an assessment of increased risk for respiratory depression

**AND**

**2** - Identify rationale for not tapering and discontinuing opioid (Document rationale)

**AND**

**3** - Patient demonstrates meaningful improvement in pain and function (Document improvement in function or pain score improvement)\*\*

Notes

\*Authorization will be issued for 6 months for non-cancer/non-hospice/non-end-of-life/non-palliative care/non-skilled nursing facility/non-traumatic injury related pain related pain up to the current requested MME plus 90 MME.

\*\*If the member has been established on the requested MME dose for at least 30 days and does not meet the medical necessity authorization criteria requirements, a denial should be issued and a maximum 30-day authorization may be authorized one time for the requested MME dose.

## 2 . Background

Benefit/Coverage/Program Information		
Table 1. CDC Recommended Opioid Maximum Morphine Milligram Equivalents per Day*		
Active Ingredient	FDA Label Max Daily Doses	90 MME Equivalent (mg/day) (non treatment naïve)
Morphine	None	90mg
Hydromorphone	None	22.5mg
Hydrocodone	None	90mg
Tapentadol	600mg IR products	225mg
Oxymorphone	None	30mg
Oxycodone	None	60mg
Codeine	360mg	600mg
Pentazocine	None	243mg
Tramadol	400mg IR products	900mg
Meperidine	600mg	900mg
Butorphanol	None	12.86mg
Opium	4 suppositories/day Deodorized tincture: 24mg/day Camphorated tincture: 16mg/day	90mg
Benzhydrocodone**	None	73.77mg
Levorphanol	None	8.18mg
Acetaminophen	4000 mg	N/A

\*Doses are not considered equianalgesic and table does not represent a dose conversion chart.



\*\*Morphine Milligram Equivalent is derived from the package insert.

### 3 . Revision History

Date	Notes
11/13/2024	Added GPIs for Roxycodone abuse deterrent tabs. Updated product name lists and GPI tables accordingly.

Signifor



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140853
<b>Guideline Name</b>	Signifor
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Signifor			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SIGNIFOR	PASIREOTIDE DIASPARTATE INJ 0.3 MG/ML (BASE EQUIV)	30170075202020	Brand
SIGNIFOR	PASIREOTIDE DIASPARTATE INJ 0.6 MG/ML (BASE EQUIV)	30170075202030	Brand
SIGNIFOR	PASIREOTIDE DIASPARTATE INJ 0.9 MG/ML (BASE EQUIV)	30170075202040	Brand

**Approval Criteria**

1 - Both of the following:

1.1 Diagnosis of endogenous Cushing’s disease (i.e., hypercortisolism is not a result of chronic administration of high dose glucocorticoids)

**AND**

1.2 One of the following:

- Pituitary surgery has not been curative for the patient
- Patient is not a candidate for pituitary surgery

Product Name: Signifor			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SIGNIFOR	PASIREOTIDE DIASPARTATE INJ 0.3 MG/ML (BASE EQUIV)	30170075202020	Brand
SIGNIFOR	PASIREOTIDE DIASPARTATE INJ 0.6 MG/ML (BASE EQUIV)	30170075202030	Brand
SIGNIFOR	PASIREOTIDE DIASPARTATE INJ 0.9 MG/ML (BASE EQUIV)	30170075202040	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Signifor therapy			

**2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
3/31/2020	Bulk copy C&S New York SP to C&S Arizona SP for 5/1 effective

Siliq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140914
<b>Guideline Name</b>	Siliq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Siliq			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SILIQ	BRODALUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 210 MG/1.5ML	9025052000E520	Brand
<b>Approval Criteria</b>			

**1** - One of the following:

**1.1** Submission of medical records (e.g., chart notes, laboratory values, prescription claims history) documenting ALL of the following:

**1.1.1** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**1.1.2** Greater than or equal to 3 percent body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**1.1.3** Both of the following:

**1.1.3.1** History of failure to ONE of the following topical therapies, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**1.1.3.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

**1.1.4** History of failure, contraindication, or intolerance to ALL of the following preferred biologic products (document drug, date, and duration of trial)\*:

- Humira (adalimumab)
- Enbrel (etanercept)

- Otezla (apremilast)

**AND**

**1.1.5** Patient is not receiving Siliq in combination with ONE of the following:

- Biologic Disease-modifying anti-rheumatic drugs (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.1.6** Prescribed by or in consultation with a dermatologist

**OR**

**1.2** All of the following:

**1.2.1** Patient is currently on Siliq therapy as documented by claims history or medical records (document drug, date, and duration of therapy)

**AND**

**1.2.2** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**1.2.3** Patient is not receiving Siliq in combination with ONE of the following:

- Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

<b>1.2.4</b> Prescribed by or in consultation with a dermatologist	
Notes	Claims history may be used in conjunction as documentation of drug, date, and duration of trial

Product Name: Siliq			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SILIQ	BRODALUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 210 MG/1.5ML	9025052000E520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Siliq therapy

**AND**

2 - Patient is not receiving Siliq in combination with one of the following:

- Biologic Disease-modifying anti-rheumatic drugs (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a dermatologist

**2 . Revision History**



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Simponi (golimumab)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-144461
<b>Guideline Name</b>	Simponi (golimumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	4/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Simponi			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 50 MG/0.5ML	6627004000D520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 100 MG/ML	6627004000D540	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.5ML	6627004000E520	Brand

SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/ML	6627004000E540	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:</p> <p>1.1 Diagnosis of moderately to severely active rheumatoid arthritis (RA)</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 ONE of the following:</p> <p>1.2.1 Patient is receiving concurrent therapy with methotrexate (e.g., Rheumatrex, Trexall)</p> <p style="text-align: center;"><b>OR</b></p> <p>1.2.2 History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document date and duration of trial)*</p> <p style="text-align: center;"><b>AND</b></p> <p>1.3 History of failure, contraindication, or intolerance to ALL of the following:</p> <ul style="list-style-type: none"> <li>• Enbrel (etanercept) or Humira (adalimumab)</li> <li>• Infliximab (Janssen manufacturer)</li> <li>• Orenzia (abatacept)</li> <li>• Xeljanz (tofacitinib) oral tablet</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>1.4 Prescribed by or in consultation with a rheumatologist</p>			
Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial		

Product Name: Simponi	
Diagnosis	Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 50 MG/0.5ML	6627004000D520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 100 MG/ML	6627004000D540	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.5ML	6627004000E520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/ML	6627004000E540	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:

1.1 Diagnosis of active ankylosing spondylitis

**AND**

1.2 History of failure to TWO NSAIDs (non-steroidal anti-inflammatory drugs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trials)\*

**AND**

1.3 History of failure, contraindication, or intolerance to ALL of the following:

- Enbrel (etanercept) or Humira (adalimumab)
- Infliximab (Janssen manufacturer)
- Xeljanz (tofacitinib) oral tablet

**AND**

**1.4** Prescribed by or in consultation with a rheumatologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial
-------	--

**Product Name: Simponi**

Diagnosis	Rheumatoid Arthritis, Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 50 MG/0.5ML	6627004000D520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 100 MG/ML	6627004000D540	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.5ML	6627004000E520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/ML	6627004000E540	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) demonstrating positive clinical response to therapy

**AND**

**2** - Prescribed by or in consultation with a rheumatologist

**Product Name: Simponi**

Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s)

Therapy Stage		Initial Authorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 50 MG/0.5ML	6627004000D520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 100 MG/ML	6627004000D540	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.5ML	6627004000E520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/ML	6627004000E540	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:

1.1 Diagnosis of active psoriatic arthritis

**AND**

1.2 History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document date and duration of trial)\*

**AND**

1.3 History of failure, contraindication, or intolerance to ALL of the following:

- Enbrel (etanercept) or Humira (adalimumab)
- Infliximab (Janssen manufacturer)
- Orencia (abatacept)
- Otezla (apremilast)
- Xeljanz (tofacitinib) oral tablet

**AND**

1.4 Prescribed by or in consultation with ONE of the following:

<ul style="list-style-type: none"> <li>• Rheumatologist</li> <li>• Dermatologist</li> </ul>	
Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trials

Product Name: Simponi			
Diagnosis	Psoriatic Arthritis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 50 MG/0.5ML	6627004000D520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 100 MG/ML	6627004000D540	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.5ML	6627004000E520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/ML	6627004000E540	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) demonstrating positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Rheumatologist</li> <li>• Dermatologist</li> </ul>			

Product Name: Simponi
-----------------------

Diagnosis	Ulcerative Colitis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 50 MG/0.5ML	6627004000D520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 100 MG/ML	6627004000D540	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.5ML	6627004000E520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/ML	6627004000E540	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:

1.1 Diagnosis of moderately to severely active ulcerative colitis

**AND**

1.2 ONE of the following:

1.2.1 Patient is corticosteroid dependent (i.e., an inability to successfully taper corticosteroids without a return of the symptoms of UC)

**OR**

1.2.2 History of failure to ONE of the following conventional therapies at maximally indicated doses within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*:

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- 6-mercaptopurine (Purinethol)
- Azathioprine (Imuran)
- Aminosalicylates (e.g., mesalamine, sulfasalazine)



**AND**

**1.3** History of failure, contraindication, or intolerance to ALL of the following (document drug, date, and duration of trial):

- Humira (adalimumab)
- Infliximab (Janssen manufacturer)
- Xeljanz (tofacitinib) oral tablet

**AND**

**1.4** Prescribed by or in consultation with a gastroenterologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trials
-------	---

**Product Name: Simponi**

Diagnosis	Ulcerative Colitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 50 MG/0.5ML	6627004000D520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 100 MG/ML	6627004000D540	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.5ML	6627004000E520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/ML	6627004000E540	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) demonstrating positive clinical response to therapy

**AND**

**2** - Prescribed by or in consultation with a gastroenterologist

## **2 . Revision History**

Date	Notes
3/15/2024	Updated guideline name and updated criteria (both initial and reauth sections) for all indications.

Sivextro



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140724
<b>Guideline Name</b>	Sivextro
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Sivextro			
Diagnosis	Skin and Skin Structure Infections		
Approval Length	6 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SIVEXTRO	TEDIZOLID PHOSPHATE TAB 200 MG	16230070200320	Brand
<b>Approval Criteria</b>			
1 - ONE of the following:			

**1.1** For continuation of therapy upon hospital discharge

**OR**

**1.2** As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication.

**OR**

**1.3** ALL of the following:

**1.3.1** Diagnosis of acute bacterial skin and skin structure infection (including diabetic foot infections)

**AND**

**1.3.2** ONE of the following diagnoses:

**1.3.2.1** BOTH of the following:

- Acute bacterial skin and skin structure infections
- Infection caused by methicillin-resistant *Staphylococcus aureus* (MRSA) documented by culture and sensitivity report

**OR**

**1.3.2.2** BOTH of the following:

- Empirical treatment of patients with acute bacterial skin and skin structure infections
- Presence of MRSA infection is likely

**AND**

**1.3.3** History of failure, contraindication, or intolerance to linezolid (generic Zyvox)

**AND**

**1.3.4** History of failure, contraindication, or intolerance to ONE of the following antibiotics:

- Sulfamethoxazole-trimethoprim (SMX-TMP)
- A tetracycline
- Clindamycin

**OR**

**1.4** ALL of the following:

**1.4.1** Diagnosis of acute bacterial skin and skin structure infection(including diabetic foot infections)

**AND**

**1.4.2** Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Sivextro

**AND**

**1.4.3** History of failure, contraindication, or intolerance to linezolid (generic Zyvox)

**AND**

**1.4.4** History of failure, contraindication, or intolerance to TWO of the following antibiotics:

- Dicloxacillin
- A cephalosporin
- A tetracycline
- Amoxicillin/clavulanate
- Clindamycin
- Sulfamethoxazole-trimethoprim (SMX-TMP)
- A fluoroquinolone

Product Name: Sivextro	
Diagnosis	Off-Label Uses

Approval Length	60 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SIVEXTRO	TEDIZOLID PHOSPHATE TAB 200 MG	16230070200320	Brand

**Approval Criteria**

1 - One of the following:

1.1 For continuation of therapy upon hospital discharge

**OR**

1.2 As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

1.3 BOTH of the following:

1.3.1 The medication is being prescribed by or in consultation with an infectious disease specialist

**AND**

1.3.2 History of failure, contraindication, or intolerance to linezolid (generic Zyvox), if culture and susceptibility confirm susceptibility.

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Skyclarys



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-145462
<b>Guideline Name</b>	Skyclarys
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Skyclarys			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SKYCLARYS	OMAVELOXOLONE CAP 50 MG	74135060000120	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:			

- Diagnosis of Friedreich's ataxia
- Confirmed presence of a mutation in the frataxin (FXN) gene

**AND**

**2** - Prescribed by or in consultation with ONE of the following:

- Neurologist
- Neurogeneticist
- Psychiatrist (Physical Medicine and Rehabilitation Specialist)

Product Name: Skyclarys			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SKYCLARYS	OMAVELOXOLONE CAP 50 MG	74135060000120	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy (e.g., slowed disease progression, improvement in or stabilization of speech or swallowing, upper/lower limb coordination, upright stability)

**AND**

**2** - Prescribed by or in consultation with ONE of the following:

- Neurologist
- Neurogeneticist
- Psychiatrist (Physical Medicine and Rehabilitation Specialist)



## 2 . Revision History

Date	Notes
4/5/2024	Updated criteria to remove mFARS scoring. Addition of specialist for re-auth.

Skyrizi (risankizumab-rzaa)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155752
<b>Guideline Name</b>	Skyrizi (risankizumab-rzaa)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Skyrizi SC 150 mg			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SKYRIZI PEN	RISANKIZUMAB-RZAA SOLN AUTO-INJECTOR 150 MG/ML	9025057070D520	Brand
SKYRIZI	RISANKIZUMAB-RZAA SOLN PREFILLED SYRINGE 150 MG/ML	9025057070E540	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory values) documenting ALL of the following:

**1.1** Diagnosis of moderate to severe plaque psoriasis

**AND**

**1.2** Greater than or equal to 3 percent body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**1.3** BOTH of the following:

**1.3.1** History of failure to ONE of the following topical therapies, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial):\*

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**1.3.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document date and duration of trial)\*

**AND**

**1.4** History of failure, contraindication, or intolerance to ALL of the following (document drug, date, and duration of trial):\*

- Enbrel (etanercept) or a preferred^ adalimumab biosimilar
- infliximab
- Otezla (apremilast)

**AND**

**2** - Prescribed by or in consultation with a dermatologist

Notes	<p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.</p> <p>^PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC%20CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP</a></p> <p>**If patient meets criteria above, please approve at GPI-14**</p>
-------	---

**Product Name: Skyrizi SC 150 mg**

Diagnosis	Plaque Psoriasis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SKYRIZI PEN	RISANKIZUMAB-RZAA SOLN AUTO-INJECTOR 150 MG/ML	9025057070D520	Brand
SKYRIZI	RISANKIZUMAB-RZAA SOLN PREFILLED SYRINGE 150 MG/ML	9025057070E540	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to Skyrizi therapy

**AND**

**2** - Prescribed by or in consultation with a dermatologist

Notes	**If patient meets criteria above, please approve at GPI-14**
-------	---

Product Name: Skyrizi SC 150 mg			
Diagnosis	Psoriatic Arthritis (PsA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SKYRIZI PEN	RISANKIZUMAB-RZAA SOLN AUTO-INJECTOR 150 MG/ML	9025057070D520	Brand
SKYRIZI	RISANKIZUMAB-RZAA SOLN PREFILLED SYRINGE 150 MG/ML	9025057070E540	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, laboratory values) documenting ALL of the following:

1.1 Diagnosis of active psoriatic arthritis (PsA)

**AND**

1.2 History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document date and duration of trial)\*

**AND**

1.3 History of failure, contraindication, or intolerance to ALL of the following (document drug, date, and duration of trial):\*

- Enbrel (etanercept) or a preferred^ adalimumab biosimilar
- infliximab
- Orencia (abatacept)
- Otezla (apremilast)
- Xeljanz (tofacitinib) oral tablet

**AND**

**2** - Prescribed by or in consultation with ONE of the following:

- Dermatologist
- Rheumatologist

Notes

\*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.

^PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP>

\*\*If patient meets criteria above, please approve at GPI-14\*\*

Product Name: Skyrizi SC 150 mg

Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SKYRIZI PEN	RISANKIZUMAB-RZAA SOLN AUTO-INJECTOR 150 MG/ML	9025057070D520	Brand
SKYRIZI	RISANKIZUMAB-RZAA SOLN PREFILLED SYRINGE 150 MG/ML	9025057070E540	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to Skyrizi therapy

**AND**

**2** - Prescribed by or in consultation with ONE of the following:

<ul style="list-style-type: none"> <li>• Dermatologist</li> <li>• Rheumatologist</li> </ul>	
Notes	**If patient meets criteria above, please approve at GPI-14**

Product Name: Skyrizi SC 180 mg, 360 mg			
Diagnosis	Crohn's Disease (CD)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SKYRIZI	RISANKIZUMAB-RZAA SUBCUTANEOUS SOLN CARTRIDGE 180 MG/1.2ML	5250406070E210	Brand
SKYRIZI	RISANKIZUMAB-RZAA SUBCUTANEOUS SOLN CARTRIDGE 360 MG/2.4ML	5250406070E220	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, laboratory values) documenting ALL of the following:

1.1 Diagnosis of moderately to severely active Crohn's disease (CD)

**AND**

1.2 History of failure, contraindication, or intolerance to ONE of the following conventional therapies (document drug, date, and duration of trial):\*

- 6-mercaptopurine
- Azathioprine
- Methotrexate
- Corticosteroid (e.g., prednisone)

**AND**

**1.3** History of failure, contraindication, or intolerance to ALL of the following (document drug, date, and duration of trial):\*

- Cimzia (certolizumab)
- A preferred^ adalimumab biosimilar
- infliximab

**AND**

**2** - Will be used as a maintenance dose following the intravenous induction doses

**AND**

**3** - Prescribed by or in consultation with a gastroenterologist

Notes	<p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.</p> <p>^PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>**If patient meets criteria above, please approve at GPI-14**</p>
-------	---

Product Name: Skyrizi SC 180 mg, 360 mg			
Diagnosis	Ulcerative Colitis (UC)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SKYRIZI	RISANKIZUMAB-RZAA SUBCUTANEOUS SOLN CARTRIDGE 180 MG/1.2ML	5250406070E210	Brand
SKYRIZI	RISANKIZUMAB-RZAA SUBCUTANEOUS SOLN CARTRIDGE 360 MG/2.4ML	5250406070E220	Brand
<b>Approval Criteria</b>			



**1** - Submission of medical records (e.g., chart notes, laboratory values), or verification of paid claims, documenting ALL of the following:

**1.1** Diagnosis of moderately to severely active ulcerative colitis (UC)

**AND**

**1.2** History of failure, contraindication, or intolerance to ONE of the following conventional therapies:

- 6-mercaptopurine
- Azathioprine
- Corticosteroid (e.g., prednisone)
- Aminosalicylate (e.g., mesalamine, olsalazine, sulfasalazine)

**AND**

**1.3** History of failure, contraindication, or intolerance to ALL of the following:

- A preferred^ adalimumab biosimilar
- infliximab
- Xeljanz (tofacitinib) oral tablet

**AND**

**2** - Will be used as a maintenance dose following the intravenous induction doses

**AND**

**3** - Prescribed by or in consultation with a gastroenterologist

Notes

^PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP>

\*\*If patient meets criteria above, please approve at GPI-14\*\*

Product Name: Skyrizi SC 180 mg, 360 mg

Diagnosis	Crohn's Disease (CD), Ulcerative Colitis (UC)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SKYRIZI	RISANKIZUMAB-RZAA SUBCUTANEOUS SOLN CARTRIDGE 180 MG/1.2ML	5250406070E210	Brand
SKYRIZI	RISANKIZUMAB-RZAA SUBCUTANEOUS SOLN CARTRIDGE 360 MG/2.4ML	5250406070E220	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy as evidenced by at least ONE of the following:</p> <ul style="list-style-type: none"> <li>Improvement in intestinal inflammation (e.g., mucosal healing, improvement of lab values [platelet counts, erythrocyte sedimentation rate, C-reactive protein level]) from baseline</li> <li>Reversal of high fecal output state</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with a gastroenterologist</p>			
Notes	**If patient meets criteria above, please approve at GPI-14**		

## 2 . Revision History

Date	Notes
9/24/2024	Added new criteria for UC indication. Updated embedded steps and notes section throughout guideline. Minor cosmetic updates.

Sodium Oxybate Products (Lumryz, Xyrem, Xywav)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140980
<b>Guideline Name</b>	Sodium Oxybate Products (Lumryz, Xyrem, Xywav)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	7/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Lumryz, Xyrem, sodium oxybate, Xywav			
Diagnosis	Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SODIUM OXYBATE	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYREM	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYWAV	CALCIUM, MAG, POTASSIUM, & SOD OXYBATES ORAL SOLN 500 MG/ML	62459904202020	Brand

LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 4.5 GM	62450060203020	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 6 GM	62450060203025	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 7.5 GM	62450060203030	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 9 GM	62450060203035	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g. chart notes, laboratory values) documenting a diagnosis of narcolepsy with cataplexy (i.e., Narcolepsy Type 1) with BOTH of the following:

**1.1** The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months

**AND**

**1.2** A mean sleep latency of less than or equal to 8 minutes and two or more sleep onset rapid eye movement (REM) periods (SOREMPs) on a Multiple Sleep Latency Test (MSLT) performed according to standard techniques following a normal overnight polysomnogram. A SOREMP (within 15 minutes of sleep onset) on the preceding nocturnal polysomnogram may replace one of the SOREMPs on the MSLT

**AND**

**2** - Physician attestation to BOTH of the following:

**2.1** Patient has experienced cataplexy defined as more than one episode of sudden loss of muscle tone with retained consciousness

**AND**

**2.2** Other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications, or other sleep disorders)

**AND**

**3 - Prescribed by ONE of the following:**

- Neurologist
- Psychiatrist
- Sleep Medicine Specialist

Product Name: Lumryz, Xyrem, sodium oxybate, Xywav			
Diagnosis	Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SODIUM OXYBATE	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYREM	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYWAV	CALCIUM, MAG, POTASSIUM, & SOD OXYBATES ORAL SOLN 500 MG/ML	62459904202020	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 4.5 GM	62450060203020	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 6 GM	62450060203025	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 7.5 GM	62450060203030	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 9 GM	62450060203035	Brand

**Approval Criteria**

**1 - Submission of medical records (e.g., chart notes) documenting a reduction in frequency of cataplexy attacks associated with therapy**

**OR**

**2 - Documentation demonstrating reduction in symptoms of excessive daytime sleepiness associated with therapy**

Product Name: Lumryz, Xyrem, sodium oxybate, Xywav	
Diagnosis	Narcolepsy without Cataplexy (i.e., Narcolepsy Type 2)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SODIUM OXYBATE	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYREM	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYWAV	CALCIUM, MAG, POTASSIUM, & SOD OXYBATES ORAL SOLN 500 MG/ML	62459904202020	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 4.5 GM	62450060203020	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 6 GM	62450060203025	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 7.5 GM	62450060203030	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 9 GM	62450060203035	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g. chart notes, lab values) documenting a diagnosis of narcolepsy without cataplexy (i.e., Narcolepsy Type 2) with BOTH of the following:

**1.1** The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months

**AND**

**1.2** A mean sleep latency of less than or equal to 8 minutes and two or more sleep onset rapid eye movement (REM) periods (SOREMPs) are found on a Multiple Sleep Latency Test (MSLT) performed according to standard techniques following a normal overnight polysomnogram. A SOREMP (within 15 minutes of sleep onset) on the preceding nocturnal polysomnogram may replace one of the SOREMPs on the MSLT

**AND**

**2** - Physician attestation to BOTH of the following:

**2.1** Cataplexy is absent

**AND**

**2.2** Other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications or their withdrawal, sleep phase disorder, or other sleep disorders)

**AND**

**3** - History of failure, contraindication, or intolerance of ALL of the following (MUST be verified via paid pharmacy claims or submission of medical records):

**3.1** ONE of the following:

- Amphetamine based stimulant (e.g., amphetamine, dextroamphetamine)
- Methylphenidate based stimulant

**AND**

**3.2** Armodafanil (Nuvigil)

**AND**

**3.3** Sunosi (solriamfetol)

**AND**

**4** - Prescribed by ONE of the following:

- Neurologist
- Psychiatrist
- Sleep Medicine Specialist

Product Name: Lumryz, Xyrem, sodium oxybate, Xywav

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Diagnosis	Narcolepsy without Cataplexy (i.e., Narcolepsy Type 2)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SODIUM OXYBATE	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYREM	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYWAV	CALCIUM, MAG, POTASSIUM, & SOD OXYBATES ORAL SOLN 500 MG/ML	62459904202020	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 4.5 GM	62450060203020	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 6 GM	62450060203025	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 7.5 GM	62450060203030	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 9 GM	62450060203035	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting reduction in symptoms of excessive daytime sleepiness associated with therapy

Product Name: Xywav	
Diagnosis	Idiopathic Hypersomnia (IH)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SODIUM OXYBATE	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYREM	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYWAV	CALCIUM, MAG, POTASSIUM, & SOD OXYBATES ORAL SOLN 500 MG/ML	62459904202020	Brand



LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 4.5 GM	62450060203020	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 6 GM	62450060203025	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 7.5 GM	62450060203030	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 9 GM	62450060203035	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting a diagnosis of idiopathic hypersomnia (IH) confirmed by ALL of the following:

**1.1** Patient has experienced daily periods of irrepressible need for sleep or daytime lapses into sleep (i.e., excessive daytime sleepiness) for at least 3 months

**AND**

**1.2** A multiple sleep latency test (MSLT) documents fewer than two sleep-onset rapid eye movement periods (SOREMPs), or no SOREMPs if the REM sleep latency on the preceding polysomnogram was less than or equal to 15 minutes

**AND**

**1.3** The presence of at least ONE of the following:

- MSLT shows a mean sleep latency of less than or equal to 8 minutes
- Total 24-hour sleep time is greater than or equal to 660 minutes (typically 12 to 14 hours) on 24-hour polysomnography or by wrist actigraphy in association with a sleep log

**AND**

**2** - Physician attestation to BOTH of the following:

**2.1** Cataplexy is absent

**AND**

**2.2** Other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications or their withdrawal, sleep phase disorder, or other sleep disorders)

**AND**

**3** - Prescribed by or in consultation with one of the following:

- Neurologist
- Psychiatrist
- Sleep Medicine Specialist

**AND**

**4** - History of failure, contraindication, or intolerance of ALL of the following (MUST be verified via paid pharmacy claims or submission of medical records):

- An amphetamine or methylphenidate based stimulant
- Modafinil
- Amodafinil

Product Name: Xywav			
Diagnosis	Idiopathic Hypersomnia (IH)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SODIUM OXYBATE	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYREM	SODIUM OXYBATE ORAL SOLUTION 500 MG/ML	62450060202020	Generic
XYWAV	CALCIUM, MAG, POTASSIUM, & SOD OXYBATES ORAL SOLN 500 MG/ML	62459904202020	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 4.5 GM	62450060203020	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 6 GM	62450060203025	Brand

LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 7.5 GM	62450060203030	Brand
LUMRYZ	SODIUM OXYBATE PACK FOR ORAL ER SUSP 9 GM	62450060203035	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting reduction in symptoms of excessive daytime sleepiness associated with therapy

**2 . Revision History**

Date	Notes
6/8/2023	New program for sodium oxybate products. Replaces Xyrem, Xywav.

Sofdra (sofpironium)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-157307
<b>Guideline Name</b>	Sofdra (sofpironium)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Sofdra			
Diagnosis	Primary Axillary Hyperhidrosis		
Approval Length	6 Week(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOFDRA	SOFPIRONIUM BROMIDE GEL 12.45%	90970083204020	Brand
<b>Approval Criteria</b>			

**1** - Diagnosis of primary axillary hyperhidrosis

**AND**

**2** - Patient has experienced symptoms of disease for a duration of at least 6 months

**AND**

**3** - Patient is 9 years of age or older

**AND**

**4** - Provider attests other causes of axillary hyperhidrosis have been ruled out (e.g., menopause, medications)

**AND**

**5** - Disease frequently interferes with daily activities (e.g., lower productivity at work, lower psychosocial wellbeing)

**AND**

**6** - Trial and failure (minimum 6 weeks supply), contraindication, or intolerance to a topical prescription strength drying agent [e.g., Drysol, Xerac AC (aluminum chloride hexahydrate)]

**AND**

**7** - Prescribed by or in consultation with a dermatologist

Product Name: Sofdra	
Diagnosis	Primary Axillary Hyperhidrosis
Approval Length	6 month(s)
Therapy Stage	Reauthorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
SOFDRA	SOPPIRONIUM BROMIDE GEL 12.45%	90970083204020	Brand
<p><b>Approval Criteria</b></p> <p>1 - Patient demonstrates positive clinical response to therapy (e.g., improvement in productivity, improvement in psychosocial wellbeing)</p>			

## 2 . Revision History

Date	Notes
10/10/2024	New program.

Sohonos (palovarotene)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-141019
<b>Guideline Name</b>	Sohonos (palovarotene)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	1/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Sohonos			
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOHONOS	PALOVAROTENE CAP 1 MG	75886060000120	Brand
SOHONOS	PALOVAROTENE CAP 1.5 MG	75886060000125	Brand
SOHONOS	PALOVAROTENE CAP 2.5 MG	75886060000130	Brand
SOHONOS	PALOVAROTENE CAP 5 MG	75886060000135	Brand
SOHONOS	PALOVAROTENE CAP 10 MG	75886060000140	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting ALL of the following:

**1.1** Diagnosis of Fibrodysplasia Ossificans Progressiva (FOP)

**AND**

**1.2** Molecular genetic testing confirms mutation in the ACVR1 gene

**AND**

**1.3** One of the following:

**1.3.1** Both of the following:

- Patient is female
- Patient is 8 years of age or older

**OR**

**1.3.2** Both of the following:

- Patient is male
- Patient is 10 years of age or older

**AND**

**2** - Prescribed by or in consultation with one of the following:

- Geneticist
- Orthopedic physician
- Rheumatologist
- Endocrinologist



Product Name: Sohonos			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOHONOS	PALOVAROTENE CAP 1 MG	75886060000120	Brand
SOHONOS	PALOVAROTENE CAP 1.5 MG	75886060000125	Brand
SOHONOS	PALOVAROTENE CAP 2.5 MG	75886060000130	Brand
SOHONOS	PALOVAROTENE CAP 5 MG	75886060000135	Brand
SOHONOS	PALOVAROTENE CAP 10 MG	75886060000140	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting that patient demonstrates positive clinical response to therapy (e.g., reduction of volume in new abnormal bone growth)</p>			

## 2 . Revision History

Date	Notes
12/6/2023	New guideline

Soliris



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140991
<b>Guideline Name</b>	Soliris
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Soliris			
Diagnosis	Atypical hemolytic uremic syndrome (aHUS)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOLIRIS	ECULIZUMAB IV SOLN 300 MG/30ML (10 MG/ML) (FOR INFUSION)	85805050002020	Brand
<b>Approval Criteria</b>			

**1** - Documentation supporting the diagnosis of atypical hemolytic uremic syndrome (aHUS) by ruling out BOTH of the following:

- Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS)\*
- Thrombotic thrombocytopenia purpura (TTP) (e.g., rule out ADAMTS13 deficiency)

**AND**

**2** - Laboratory results, signs, and/or symptoms attributed to aHUS (e.g., thrombocytopenia, microangiopathic hemolysis, thrombotic microangiopathy, acute renal failure, etc.)

**AND**

**3** - Patient is treatment naïve with Soliris

**AND**

**4** - Soliris is dosed according to the Food and Drug Administration (FDA) labeled dosing for aHUS

**AND**

**5** - Prescribed by, or in consultation with, a hematologist or nephrologist

Product Name: Soliris			
Diagnosis	Atypical hemolytic uremic syndrome (aHUS)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOLIRIS	ECULIZUMAB IV SOLN 300 MG/30ML (10 MG/ML) (FOR INFUSION)	85805050002020	Brand

**Approval Criteria**

1 - Patient has previously been treated with Soliris

**AND**

2 - Documentation demonstrating a positive clinical response from baseline (e.g., reduction of plasma exchanges, reduction of dialysis, increased platelet count, reduction of hemolysis)

**AND**

3 - Soliris is dosed according to the United States Food and Drug Administration (FDA) labeled dosing for atypical hemolytic uremic syndrome (aHUS)

**AND**

4 - Prescribed by, or in consultation with, a hematologist or nephrologist

Product Name: Soliris			
Diagnosis	Paroxysmal nocturnal hemoglobinuria (PNH)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOLIRIS	ECULIZUMAB IV SOLN 300 MG/30ML (10 MG/ML) (FOR INFUSION)	85805050002020	Brand

**Approval Criteria**

1 - Documentation supporting the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) that includes BOTH of the following:

- Flow cytometry analysis confirming presence of PNH clones
- Laboratory results, signs, and/or symptoms attributed to PNH (e.g., abdominal pain, anemia, dyspnea, extreme fatigue, smooth muscle dystonia, unexplained/unusual thrombosis, hemolysis/hemoglobinuria, kidney disease, pulmonary hypertension, etc.)

**AND**

**2** - Patient is treatment naïve with Soliris

**AND**

**3** - Soliris is dosed according to the United States Food and Drug Administration (FDA) labeled dosing for PNH

**AND**

**4** - Prescribed by, or in consultation with, ONE of the following:

- Hematologist
- Oncologist

Product Name: Soliris			
Diagnosis	Paroxysmal nocturnal hemoglobinuria (PNH)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOLIRIS	ECULIZUMAB IV SOLN 300 MG/30ML (10 MG/ML) (FOR INFUSION)	85805050002020	Brand
<b>Approval Criteria</b>			
<b>1</b> - Patient has previously been treated with Soliris			

**AND**

**2** - Documentation demonstrating a positive clinical response from baseline (e.g., increased or stabilization of hemoglobin levels, reduction in transfusions, improvement in hemolysis, decrease in lactate dehydrogenase [LDH], increased reticulocyte count, etc.)

**AND**

**3** - Soliris is dosed according to the United States Food and Drug Administration (FDA) labeled dosing for paroxysmal nocturnal hemoglobinuria (PNH)

**AND**

**4** - Prescribed by, or in consultation with, ONE of the following:

- Hematologist
- Oncologist

Product Name: Soliris			
Diagnosis	Generalized myasthenia gravis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOLIRIS	ECULIZUMAB IV SOLN 300 MG/30ML (10 MG/ML) (FOR INFUSION)	85805050002020	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory values, etc.) to support the diagnosis of generalized myasthenia gravis (gMG) confirming ALL of the following:

**1.1** Patient has not failed a previous course of Soliris therapy

**AND**

**1.2** Positive serologic test for anti-acetylcholine receptor (AChR) antibodies

**AND**

**1.3** ONE of the following:

- History of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation
- History of positive anticholinesterase test, e.g., edrophonium chloride test
- Patient has demonstrated improvement in myasthenia gravis (MG) signs on oral cholinesterase inhibitors, as assessed by the treating neurologist

**AND**

**1.4** Patient has a Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of class II, III, or IV at initiation of therapy

**AND**

**1.5** Patient has a Myasthenia Gravis-specific Activities of Daily Living scale (MG-ADL) total score greater than or equal to 6 at initiation of therapy

**AND**

**2** - BOTH of the following:

**2.1** History of failure of at least TWO immunosuppressive agents over the course of at least 12 months [e.g., azathioprine, methotrexate, cyclosporine, mycophenolate, etc.]

**AND**

**2.2** Patient has required TWO or more courses of plasmapheresis/plasma exchanges and/or intravenous immune globulin for at least the previous 12 months without symptom control

**AND**

**3** - Patient is currently on a stable therapeutic dose (at least 3 to 6 months) of immunosuppressive therapy

**AND**

**4** - Soliris is initiated and titrated according to the United States Food and Drug Administration (FDA) labeled dosing for gMG: up to a maximum of 1200 milligrams every 2 weeks

**AND**

**5** - Prescribed by, or in consultation, with a neurologist

Product Name: Soliris			
Diagnosis	Generalized myasthenia gravis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOLIRIS	ECULIZUMAB IV SOLN 300 MG/30ML (10 MG/ML) (FOR INFUSION)	85805050002020	Brand

**Approval Criteria**

**1** - Patient has previously been treated with Soliris

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory tests) to demonstrate a positive clinical response from baseline as demonstrated by ALL of the following:



- Improvement and/or maintenance of at least a 3 point improvement (reduction in score) in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score from pre-treatment baseline
- Reduction in signs and symptoms of myasthenia gravis
- Maintenance, reduction, or discontinuation of dose(s) of baseline immunosuppressive therapy (IST) prior to starting Soliris (Note: Add on, dose escalation of IST, or additional rescue therapy from baseline to treat myasthenia gravis or exacerbation of symptoms while on Soliris therapy will be considered as treatment failure)

**AND**

**3** - Soliris is dosed according to the United States Food and Drug Administration (FDA) labeled dosing for generalized myasthenia gravis (gMG): up to a maximum of 1200 milligrams every 2 weeks

**AND**

**4** - Prescribed by, or in consultation, with a neurologist

Product Name: Soliris			
Diagnosis	Neuromyelitis optica spectrum disorder (NMOSD)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOLIRIS	ECULIZUMAB IV SOLN 300 MG/30ML (10 MG/ML) (FOR INFUSION)	85805050002020	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory values, etc.) to support the diagnosis of neuromyelitis optica spectrum disorder (NMOSD) confirming ALL of the following:

**1.1** Past medical history of ONE of the following:

- Optic neuritis

- Acute myelitis
- Area postrema syndrome: Episode of otherwise unexplained hiccups or nausea and vomiting
- Acute brainstem syndrome
- Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
- Symptomatic cerebral syndrome with NMOSD-typical brain lesions

**AND**

**1.2** Positive serologic test for anti-aquaporin-4 immunoglobulin G (AQP4-IgG)/NMO-IgG antibodies

**AND**

**1.3** Diagnosis of multiple sclerosis or other diagnoses have been ruled out

**AND**

**2** - Patient has not failed a previous course of Soliris therapy

**AND**

**3** - History of failure of, contraindication, or intolerance to rituximab (Rituxan, Ruxience, Truxima) therapy

**AND**

**4** - One of the following:

**4.1** History of at least two relapses during the previous 12 months prior to initiating Soliris

**OR**

**4.2** History of at least three relapses during the previous 24 months, at least one relapse occurring within the past 12 months prior to initiating Soliris

**AND**

**5** - Soliris is initiated and titrated according to the U.S. FDA labeled dosing for NMOSD, up to a maximum of 1200 mg every 2 weeks

**AND**

**6** - Prescribed by, or in consultation with, a neurologist

**AND**

**7** - Patient is NOT receiving Soliris in combination with one of the following:

- Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya (fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]
- Anti-IL6 (interleukin 6) therapy [e.g., Actemra (tocilizumab)]

Product Name: Soliris			
Diagnosis	Neuromyelitis optica spectrum disorder (NMOSD)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOLIRIS	ECULIZUMAB IV SOLN 300 MG/30ML (10 MG/ML) (FOR INFUSION)	85805050002020	Brand

**Approval Criteria**

**1** - Patient has previously been treated with Soliris

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory tests) to demonstrate a positive clinical response from baseline as demonstrated by BOTH of the following:

**2.1** Reduction in the number and/or severity of relapses or signs and symptoms of neuromyelitis optica spectrum disorder (NMOSD)

**AND**

**2.2** Maintenance, reduction, or discontinuation of dose(s) of any baseline immunosuppressive therapy (IST) prior to starting Soliris. (Note: Add on, dose escalation of IST, or additional rescue therapy from baseline to treat NMOSD or exacerbation of symptoms while on Soliris therapy will be considered as treatment failure)

**AND**

**3** - Soliris is dosed according to the U.S. FDA (Food and Drug Administration) labeled dosing for NMOSD: up to a maximum of 1200 mg every 2 weeks

**AND**

**4** - Prescribed by, or in consultation with, a neurologist

**AND**

**5** - Patient is not receiving Soliris in combination with one of the following:

- Disease modifying therapies for the treatment of multiple sclerosis [e.g., Gilenya (fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.]
- Anti-IL6 (interleukin 6) therapy [e.g., Actemra (tocilizumab)]

## 2 . Revision History

Date	Notes
7/25/2023	Updated GPI

Somavert



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140854
<b>Guideline Name</b>	Somavert
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Somavert			
Diagnosis	Acromegaly		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOMAVERT	PEGVISOMANT FOR INJ 15 MG (AS PROTEIN)	30180060002130	Brand
SOMAVERT	PEGVISOMANT FOR INJ 20 MG (AS PROTEIN)	30180060002140	Brand
SOMAVERT	PEGVISOMANT FOR INJ 25 MG (AS PROTEIN)	30180060002150	Brand

SOMAVERT	PEGVISOMANT FOR INJ 30 MG (AS PROTEIN)	30180060002160	Brand
SOMAVERT	PEGVISOMANT FOR INJ 10 MG (AS PROTEIN)	30180060002120	Brand

**Approval Criteria**

1 - All of the following:

1.1 Diagnosis of acromegaly by ONE of the following:

- Serum GH (growth hormone) level greater than 1 ng/mL (nanograms per milliliter) after a 2 hour oral glucose tolerance test (OGTT) at time of diagnosis
- Elevated serum IGF-1 (Insulin-like growth factor-1) levels (above the age and gender adjusted normal range as provided by the physician's lab) at time of diagnosis

**AND**

1.2 One of the following:

1.2.1 Inadequate response to one of the following:

- Surgery
- Radiation therapy
- Dopamine agonist (e.g., bromocriptine, cabergoline) therapy

**OR**

1.2.2 Not a candidate for all of the following:

- Surgery
- Radiation therapy
- Dopamine agonist (e.g., bromocriptine, cabergoline) therapy

**AND**

1.3 Inadequate response, intolerance, or contraindication to one of the following somatostatin analogs:

- Sandostatin (octreotide) or Sandostatin LAR

- Somatuline Depot (lanreotide)
- OR**
- 2** - Patient is currently on Somavert therapy for acromegaly

Product Name: Somavert			
Diagnosis	Acromegaly		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOMAVERT	PEGVISOMANT FOR INJ 15 MG (AS PROTEIN)	30180060002130	Brand
SOMAVERT	PEGVISOMANT FOR INJ 20 MG (AS PROTEIN)	30180060002140	Brand
SOMAVERT	PEGVISOMANT FOR INJ 25 MG (AS PROTEIN)	30180060002150	Brand
SOMAVERT	PEGVISOMANT FOR INJ 30 MG (AS PROTEIN)	30180060002160	Brand
SOMAVERT	PEGVISOMANT FOR INJ 10 MG (AS PROTEIN)	30180060002120	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Somavert therapy			

## 2 . Revision History

Date	Notes
3/31/2020	Bulk copy C&S New York SP to C&S Arizona SP for 5/1 effective

Soriatane



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140693
<b>Guideline Name</b>	Soriatane
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Soriatane, Generic acitretin			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACITRETIN	ACITRETIN CAP 10 MG	90250510000110	Generic
SORIATANE	ACITRETIN CAP 10 MG	90250510000110	Brand
ACITRETIN	ACITRETIN CAP 17.5 MG	90250510000115	Generic
ACITRETIN	ACITRETIN CAP 25 MG	90250510000125	Generic
SORIATANE	ACITRETIN CAP 25 MG	90250510000125	Brand



**Approval Criteria**

1 - Diagnosis of severe psoriasis

**AND**

2 - Prescribed or recommended by a dermatologist

**AND**

3 - One of the following:

**3.1** Patient is unresponsive to other therapies (e.g., topical corticosteroids, topical vitamin D analogs, tazarotene, methotrexate)

**OR**

**3.2** Other therapies are contraindicated based on the patient's clinical condition

**AND**

4 - One of the following:

- Greater than or equal to 10% body surface area involvement
- Palmoplantar, facial, or genital involvement
- Severe scalp psoriasis

Product Name: Brand Soriatane, Generic acitretin	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ACITRETIN	ACITRETIN CAP 10 MG	90250510000110	Generic
SORIATANE	ACITRETIN CAP 10 MG	90250510000110	Brand
ACITRETIN	ACITRETIN CAP 17.5 MG	90250510000115	Generic
ACITRETIN	ACITRETIN CAP 25 MG	90250510000125	Generic
SORIATANE	ACITRETIN CAP 25 MG	90250510000125	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Soriatane therapy

**AND**

2 - Prescribed or recommended by a dermatologist

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Sotyktu (deucravacitinib)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140961
<b>Guideline Name</b>	Sotyktu (deucravacitinib)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Sotyktu			
Diagnosis	Plaque Psoriasis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOTYKTU	DEUCRAVACITINIB TAB 6 MG	90250524000320	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) confirming diagnosis of moderate to severe plaque psoriasis

**AND**

**2** - Submission of medical records (e.g., chart notes) confirming ONE of the following:

- At least 3% body surface area (BSA) involvement
- Severe scalp psoriasis
- Palmoplantar (i.e., palms, soles), facial, or genital involvement

**AND**

**3** - Minimum duration of a 4-week trial and failure, contraindication, or intolerance to ONE of the following topical therapies:

- corticosteroids (e.g., betamethasone, clobetasol)
- vitamin D analogs (e.g., calcitriol, calcipotriene)
- tazarotene
- calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- anthralin
- coal tar

**AND**

**4** - Prescribed by or in consultation with a dermatologist

**AND**

**5** - BOTH of the following (verified via submission of records or paid pharmacy claims):

**5.1** Trial and failure, contraindication, or intolerance to ONE of the following:

- Enbrel (etanercept)
- Humira (adalimumab)

**AND**

**5.2** Trial and failure, contraindication, or intolerance to Otezla (apremilast)

**AND**

**6** - Not used in combination with other potent immunosuppressants (e.g., azathioprine, cyclosporine)

Product Name: Sotyktu			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SOTYKTU	DEUCRAVACITINIB TAB 6 MG	90250524000320	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming positive clinical response to therapy as evidenced by ONE of the following:

- Reduction of the body surface area (BSA) involvement from baseline
- Improvement in symptoms (e.g., pruritus, inflammation) from baseline

**AND**

**2** - Not used in combination with other potent immunosuppressants (e.g., azathioprine, cyclosporine)

**2 . Revision History**

Date	Notes
2/7/2023	Updated T/F criteria to Otezla.



Spevigo (spesolimab-sbzo)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-148368
<b>Guideline Name</b>	Spevigo (spesolimab-sbzo)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Spevigo SC			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SPEVIGO	SPESOLIMAB-SBZO SUBCUTANEOUS SOLN PREF SYR 150 MG/ML	9025057770E530	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) confirming diagnosis of generalized pustular psoriasis (GPP) as defined by BOTH of the following:

- Primary, sterile, macroscopically visible pustules on non-acral skin (excluding cases where pustulation is restricted to psoriatic plaques)
- Disease is relapsing (> 1 episode) or persistent (> 3 months)

**AND**

**2** - Subcutaneous formulation will NOT be used to treat GPP flare

**AND**

**3** - BOTH of the following:

- Patient is 12 years of age or older
- Patient weighs at least 40 kg (kilograms)

**AND**

**4** - Prescribed by or in consultation with a dermatologist

Product Name: Spevigo SC			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SPEVIGO	SPESOLIMAB-SBZO SUBCUTANEOUS SOLN PREF SYR 150 MG/ML	9025057770E530	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy (e.g., reduction in number of flares)



## 2 . Revision History

Date	Notes
6/10/2024	New program.

Spinraza



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140922
<b>Guideline Name</b>	Spinraza
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Spinraza			
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SPINRAZA	NUSINERSEN INTRATHECAL SOLN 12 MG/5ML (2.4 MG/ML)	74701050002020	Brand
<b>Approval Criteria</b>			

**1** - Diagnosis of spinal muscular atrophy (SMA) type I, II, or III made by, or in consultation with, a neurologist with expertise in the diagnosis of SMA

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) confirming both of the following:

**2.1** The mutation or deletion of genes in chromosome 5q resulting in one of the following:

- Homozygous gene deletion or mutation (e.g., homozygous deletion of exon 7 at locus 5q13)
- Compound heterozygous mutation (e.g., deletion of SMN1 exon 7 [allele 1] and mutation of SMN1 [allele 2])

**AND**

**2.2** Patient has at least 2 copies of SMN2

**AND**

**3** - Patient is not dependent on invasive ventilation or tracheostomy

**AND**

**4** - Patient is not dependent on use of non-invasive ventilation beyond use for naps and nighttime sleep

**AND**

**5** - Submission of medical records (e.g., chart notes, laboratory values) or claims history of the baseline exam of one of the following exams (based on patient age and motor ability) to establish baseline motor ability:

- Hammersmith Infant Neurological Exam Part 2 (HINE-2) (infant to early childhood)
- Hammersmith Functional Motor Scale Expanded (HFMSSE)
- Upper Limb Module (ULM) Test (Non ambulatory)

- Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)

**AND**

**6** - Prescribed by, or in consultation with, a neurologist with expertise in the treatment of SMA

**AND**

**7** - One of the following:

**7.1** Patient has not previously received gene replacement therapy for the treatment of SMA

**OR**

**7.2** One of the following:

**7.2.1** Both of the following:

**7.2.1.1** Patient recently received gene replacement therapy within the previous 6 months

**AND**

**7.2.1.2** Patient has experienced a declination in clinical status since receipt of gene replacement therapy

**OR**

**7.2.2** Both of the following:

**7.2.2.1** Patient has previously received gene replacement therapy

**AND**

**7.2.2.2** Patient has experienced a declination in clinical status that represents a potential abatement of gene therapy efficacy

**AND**

**8** - Spinraza is to be administered intrathecally by, or under the direction of, healthcare professionals experienced in performing lumbar punctures

**AND**

**9** - Spinraza dosing for SMA is within accordance with the United States Food and Drug Administration approved labeling: maximum dosing of 12 milligrams for each loading dose

Product Name: Spinraza			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SPINRAZA	NUSINERSEN INTRATHECAL SOLN 12 MG/5ML (2.4 MG/ML)	74701050002020	Brand

**Approval Criteria**

**1** - Diagnosis of spinal muscular atrophy (SMA) type I, II, or III made by, or in consultation with, a neurologist with expertise in the diagnosis of SMA

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) or claims history confirming both of the following:

**2.1** The mutation or deletion of genes in chromosome 5q resulting in one of the following:

- Homozygous gene deletion or mutation (e.g., homozygous deletion of exon 7 at locus 5q13)

- Compound heterozygous mutation (e.g., deletion of SMN1 exon 7 [allele 1] and mutation of SMN1 [allele 2])

**AND**

**2.2** Patient has at least 2 copies of SMN2

**AND**

**3** - Patient is not dependent on invasive ventilation or tracheostomy

**AND**

**4** - Patient is not dependent on use of non-invasive ventilation beyond use for naps and nighttime sleep

**AND**

**5** - One of the following:

**5.1** Patient has not previously received gene replacement therapy for the treatment of SMA

**OR**

**5.2** Both of the following:

**5.2.1** Patient has previously received gene replacement therapy

**AND**

**5.2.2** Patient has experienced a declination in clinical status that represented a potential failure or abatement of gene therapy efficacy

**AND**

**6** - Submission of medical records (e.g., chart notes, laboratory values) or claims history with the most recent results (less than 1 month prior to request) documenting a positive clinical response from pretreatment baseline status to Spinraza therapy as demonstrated by one of the following exams:

**6.1** Both of the following for Hammersmith Infant Neurological Exam Part 2 (HINE-2) milestones:

**6.1.1** One of the following:

- Improvement or maintenance of previous improvement of at least 2 point (or maximal score) increase in ability to kick
- Improvement or maintenance of previous improvement of at least 1 point increase in any other HINE-2 milestone (e.g., head control, rolling, sitting, crawling, etc.), excluding voluntary grasp

**AND**

**6.1.2** One of the following:

- The patient exhibited improvement or maintenance of previous improvement in more HINE motor milestones than worsening, from pretreatment baseline (net positive improvement)
- Achieved and maintained any new motor milestones when they would otherwise be unexpected to do so (e.g., sit unassisted, stand, walk)

**OR**

**6.2** One of the following for Hammersmith Functional Motor Scale Expanded (HFMSE):

- Improvement or maintenance of previous improvement of at least a 3 point increase in score from pretreatment baseline
- Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so

**OR**

**6.3** One of the following for Upper Limb Module (ULM):

- Improvement or maintenance of previous improvement of at least a 2 point increase in score from pretreatment baseline

- Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so

**OR**

**6.4** One of the following for Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND):

**6.4.1** Improvement or maintenance of previous improvement of at least a 4 point increase in score from pretreatment baseline

**OR**

**6.4.2** Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so

**OR**

**6.4.3** Both of the following:

- Patient was prescribed Spinraza due to clinical declination after receipt of gene therapy
- Patients clinical status has stabilized after receipt of Spinraza therapy

**AND**

**7** - Prescribed by, or in consultation with, a neurologist with expertise in the treatment of SMA

**AND**

**8** - Spinraza is to be administered intrathecally by, or under the direction of, healthcare professionals experienced in performing lumbar punctures

**AND**

**9** - Spinraza dosing for SMA is within accordance with the United States Food and Drug



Administration approved labeling: maximum dosing of 12 milligrams every 4 months, starting 4 months after the last loading dose

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Spravato, ketamine



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-160543
<b>Guideline Name</b>	Spravato, ketamine
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Spravato, ketamine			
Diagnosis	Major Depressive Disorder (Treatment-Resistant)		
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SPRAVATO (56 MG DOSE)	ESKETAMINE HCL NASAL SOLN 28 MG/DEVICE X 2 (56 MG DOSE PACK)	5811002010C520	Brand
SPRAVATO (84 MG DOSE)	ESKETAMINE HCL NASAL SOLN 28 MG/DEVICE X 3 (84 MG DOSE PACK)	5811002010C530	Brand
KETAMINE HYDROCHLORIDE	KETAMINE HCL SOLN PREF SYR 50 MG/ML	7040002010E520	Brand

KETAMINE HYDROCHLORIDE	KETAMINE HCL SOLN PREF SYR 100 MG/2ML	7040002010E540	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 20 MG/2ML-0.9% (10MG/ML)	7040002011E525	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 50 MG/5ML-0.9% (10MG/ML)	7040002011E530	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 100 MG/10ML-0.9% (10MG/ML)	7040002011E535	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL IV SOLN 500 MG/100ML-0.8%	70400020112040	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL IV SOLN 1000 MG/100ML-0.65%	70400020112050	Brand

**Approval Criteria**

**1** - Patient has a confirmed diagnosis of major depressive disorder as defined by the DSM-V (Diagnostic and Statistical Manual of Mental Disorders) criteria and is treatment resistant

**AND**

**2** - Patient is 18 years of age or older

**AND**

**3** - Requested medication is prescribed by, or in consultation with, a psychiatric provider

**AND**

**4** - ONE of the following:

**4.1** Patient does not have an active substance use disorder (SUD)

**OR**

**4.2 BOTH of the following:**

- Patient has an active substance use disorder
- Patient is currently receiving treatment

**AND**

**5 - ONE of the following:**

**5.1** Patient has experienced an inadequate response during the current depressive episode with BOTH of the following therapies:

**5.1.1** TWO antidepressants from at least TWO different classes [must include one of each AHCCCS (Arizona Health Care Cost Containment System) preferred agents: SSRI (selective serotonin reuptake inhibitor), SNRI (serotonin-norepinephrine reuptake inhibitor), or bupropion] having different mechanisms of action at the maximally tolerated labeled dose, each used for at least 4-6 weeks

**AND**

**5.1.2** At least TWO augmentation therapies below for at least 4 weeks:

- SSRI or SNRI, and a second-generation antipsychotic used concomitantly (aripiprazole, quetiapine, risperidone, olanzapine)
- SSRI or SNRI, and lithium used concomitantly
- SSRI or SNRI, and liothyronine (T3) used concomitantly
- SSRI or SNRI, and mirtazapine
- SSRI and bupropion and buspirone

**OR**

**5.2** Patient has active suicidal ideation and urgent symptom control is necessary

**AND**

**6 -** Requested medication is used in combination with an oral antidepressant (e.g., duloxetine, escitalopram, sertraline, venlafaxine)

**AND**

**7** - Requested medication is administered under the direct supervision of a healthcare provider

**AND**

**8** - Provider is certified in the Spravato REMS (risk evaluation and mitigation strategy) program (Applies to Spravato requests ONLY)

**AND**

**9** - Patient must be monitored by a health care provider for at least 2 hours after administration

Product Name: Spravato, ketamine			
Diagnosis	Major Depressive Disorder (Treatment-Resistant)		
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SPRAVATO (56 MG DOSE)	ESKETAMINE HCL NASAL SOLN 28 MG/DEVICE X 2 (56 MG DOSE PACK)	5811002010C520	Brand
SPRAVATO (84 MG DOSE)	ESKETAMINE HCL NASAL SOLN 28 MG/DEVICE X 3 (84 MG DOSE PACK)	5811002010C530	Brand
KETAMINE HYDROCHLORIDE	KETAMINE HCL SOLN PREF SYR 50 MG/ML	7040002010E520	Brand
KETAMINE HYDROCHLORIDE	KETAMINE HCL SOLN PREF SYR 100 MG/2ML	7040002010E540	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 20 MG/2ML-0.9% (10MG/ML)	7040002011E525	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 50 MG/5ML-0.9% (10MG/ML)	7040002011E530	Brand

KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 100 MG/10ML-0.9% (10MG/ML)	7040002011E535	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL IV SOLN 500 MG/100ML-0.8%	70400020112040	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL IV SOLN 1000 MG/100ML-0.65%	70400020112050	Brand

**Approval Criteria**

1 - Provider attests that the patient has documented improvement or sustained improvement in depressive symptoms from baseline

**AND**

2 - Patient use of requested medication is in combination with an oral antidepressant

**AND**

3 - Patient administers requested medication under the direct supervision of a healthcare provider

**AND**

4 - Provider is certified in the Spravato REMS (risk evaluation and mitigation strategy) program (applies to Spravato requests ONLY)

**AND**

5 - Patient must continue to be monitored by a health care provider for at least 2 hours after administration

Product Name: Spravato, ketamine	
Diagnosis	Requests for Patients less than 6 years of age

Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SPRAVATO (56 MG DOSE)	ESKETAMINE HCL NASAL SOLN 28 MG/DEVICE X 2 (56 MG DOSE PACK)	5811002010C520	Brand
SPRAVATO (84 MG DOSE)	ESKETAMINE HCL NASAL SOLN 28 MG/DEVICE X 3 (84 MG DOSE PACK)	5811002010C530	Brand
KETAMINE HYDROCHLORIDE	KETAMINE HCL SOLN PREF SYR 50 MG/ML	7040002010E520	Brand
KETAMINE HYDROCHLORIDE	KETAMINE HCL SOLN PREF SYR 100 MG/2ML	7040002010E540	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 20 MG/2ML-0.9% (10MG/ML)	7040002011E525	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 50 MG/5ML-0.9% (10MG/ML)	7040002011E530	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 100 MG/10ML-0.9% (10MG/ML)	7040002011E535	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL IV SOLN 500 MG/100ML-0.8%	70400020112040	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL IV SOLN 1000 MG/100ML-0.65%	70400020112050	Brand

**Approval Criteria**

1 - The patient is unresponsive to other treatment modalities, unless contraindicated (i.e., other medications or behavioral modification attempted)

**AND**

2 - The physician attests that the requested medication is medically necessary. (Document rationale for use)

Product Name: Spravato, ketamine	
Diagnosis	Depressive symptoms in an adult with major depressive disorder (MDD) with acute suicidal ideation or behavior

Approval Length	1 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SPRAVATO (56 MG DOSE)	ESKETAMINE HCL NASAL SOLN 28 MG/DEVICE X 2 (56 MG DOSE PACK)	5811002010C520	Brand
SPRAVATO (84 MG DOSE)	ESKETAMINE HCL NASAL SOLN 28 MG/DEVICE X 3 (84 MG DOSE PACK)	5811002010C530	Brand
KETAMINE HYDROCHLORIDE	KETAMINE HCL SOLN PREF SYR 50 MG/ML	7040002010E520	Brand
KETAMINE HYDROCHLORIDE	KETAMINE HCL SOLN PREF SYR 100 MG/2ML	7040002010E540	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 20 MG/2ML-0.9% (10MG/ML)	7040002011E525	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 50 MG/5ML-0.9% (10MG/ML)	7040002011E530	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL SOLN PREF SY 100 MG/10ML-0.9% (10MG/ML)	7040002011E535	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL IV SOLN 500 MG/100ML-0.8%	70400020112040	Brand
KETAMINE HYDROCHLORIDE/SODIUM CHLORIDE	KETAMINE HCL-NACL IV SOLN 1000 MG/100ML-0.65%	70400020112050	Brand

**Approval Criteria**

**1** - Diagnosis of major depressive disorder according to the current Diagnostic and Statistical Manual of Mental Disorders (DSM) (i.e., DSM-5) criteria

**AND**

**2** - Patient is experiencing an acute suicidal ideation or behavior

**AND**

**3** - Patient is receiving newly initiated or optimized oral antidepressant



**AND**

**4** - Provider and/or the provider's healthcare setting is certified in the Spravato REMS (Risk Evaluation and Mitigation Strategy) program (applies to Spravato requests ONLY)

## **2 . Revision History**

Date	Notes
11/13/2024	Added new GPIs for ketamine inj; Minor cosmetic updates.

Stelara



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140945
<b>Guideline Name</b>	Stelara
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Stelara (all subcutaneous strengths)			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
STELARA	USTEKINUMAB INJ 45 MG/0.5ML	90250585002020	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 45 MG/0.5ML	9025058500E520	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 90 MG/ML	9025058500E540	Brand

**Approval Criteria**

1 - ONE of the following:

**1.1** Submission of medical records (e.g., chart notes, laboratory values, prescription claims history) documenting ALL of the following:

**1.1.1** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**1.1.2** Greater than or equal to 3 percent body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**1.1.3** History of failure to ONE of the following topical therapies, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**1.1.4** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

**1.1.5** History of failure, contraindication, or intolerance to ALL of the following preferred biologic products (document drug, date, and duration of trial)\*:

- Humira (adalimumab)
- Enbrel (etanercept)
- Otezla (apremilast)

**AND**

**1.1.6** Patient is NOT receiving Stelara in combination with ONE of the following:

- Biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.1.7** ONE of the following:

**1.1.7.1** Requested medication is Stelara 45 mg (milligrams) per 0.5 mL (milliliter)

**OR**

**1.1.7.2** BOTH of the following:

- Requested medication is Stelara 90 mg per 1 mL
- Patient's weight is greater than 100 kg (kilograms) (220 pounds)

**AND**

**1.1.8** Prescribed by or in consultation with a dermatologist

**OR**

**1.2** All of the following:

**1.2.1** Patient is currently on Stelara therapy as documented by claims history or medical records (document drug, date, and duration of therapy)

**AND**

**1.2.2** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**1.2.3** Patient is NOT receiving Stelara in combination with ONE of the following:

- Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.2.4** Prescribed by or in consultation with a dermatologist

**AND**

**2** - Patient is 6 years of age or older

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial
-------	--

Product Name: Stelara (all subcutaneous strengths)			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
STELARA	USTEKINUMAB INJ 45 MG/0.5ML	90250585002020	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 45 MG/0.5ML	9025058500E520	Brand

STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 90 MG/ML	9025058500E540	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Stelara therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is NOT receiving Stelara in combination with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]</li> <li>• Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]</li> <li>• Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Prescribed by or in consultation with a dermatologist</p>			

Product Name: Stelara (all subcutaneous strengths)			
Diagnosis	Psoriatic Arthritis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
STELARA	USTEKINUMAB INJ 45 MG/0.5ML	90250585002020	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 45 MG/0.5ML	9025058500E520	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 90 MG/ML	9025058500E540	Brand
<p><b>Approval Criteria</b></p>			

**1** - ONE of the following:

**1.1** ALL of the following:

**1.1.1** ONE of the following

**1.1.1.1** BOTH of the following:

- Requested medication is Stelara 45 mg (milligrams) per 0.5 mL (milliliter)
- Diagnosis of active psoriatic arthritis

**OR**

**1.1.1.2** ALL of the following:

- Diagnosis of active psoriatic arthritis
- Diagnosis of co-existent moderate to severe plaque psoriasis

**AND**

**1.1.2** Patient is NOT receiving Stelara in combination with ONE of the following:

- Biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.1.3** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*

**AND**

**1.1.4** History of failure, contraindication, or intolerance to three of the following:

- Humira (adalimumab)
- Enbrel (etanercept)
- Otezla (apremilast)

- Xeljanz (tofacitinib)

**AND**

**1.1.5** Prescribed by or in consultation with one of the following:

- Rheumatologist
- Dermatologist

**OR**

**1.2** All of the following:

**1.2.1** Patient is currently on Stelara therapy as documented by claims history or medical records (document drug, date, and duration of therapy)

**AND**

**1.2.2** Diagnosis of active psoriatic arthritis

**AND**

**1.2.3** Patient is NOT receiving Stelara in combination with ONE of the following:

- Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.2.4** Prescribed by or in consultation with one of the following:

- Rheumatologist
- Dermatologist



<b>AND</b>	
<b>2 - Patient is 6 years of age or older</b>	
Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial

<b>Product Name: Stelara (all subcutaneous strengths)</b>			
Diagnosis	Psoriatic Arthritis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
STELARA	USTEKINUMAB INJ 45 MG/0.5ML	90250585002020	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 45 MG/0.5ML	9025058500E520	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 90 MG/ML	9025058500E540	Brand

**Approval Criteria**

**1 - Documentation of positive clinical response to Stelara therapy**

**AND**

**2 - Patient is NOT receiving Stelara in combination with ONE of the following:**

- Biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**3 - Prescribed by or in consultation with one of the following:**

- Rheumatologist
- Dermatologist

Product Name: Stelara (all subcutaneous strengths)			
Diagnosis	Crohn's Disease		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
STELARA	USTEKINUMAB INJ 45 MG/0.5ML	90250585002020	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 45 MG/0.5ML	9025058500E520	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 90 MG/ML	9025058500E540	Brand

**Approval Criteria**

1 - Diagnosis of moderately to severely active Crohn's disease

**AND**

2 - One of the following:

2.1 Both of the following

2.1.1 History of failure to one of the following conventional therapies at maximally indicated doses within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*:

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- 6-mercaptopurine (Purinethol)
- Azathioprine (Imuran)
- Methotrexate (Rheumatrex, Trexall)

**AND**

**2.1.2** History of failure, contraindication or intolerance to Humira (adalimumab)

**OR**

**2.2** Patient is currently on Stelara therapy as documented by claims history or medical records (document drug, date, and duration of therapy)

**AND**

**3** - Patient is NOT receiving Stelara in combination with ONE of the following:

- Biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
- Janus Kinase Inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**4** - Prescribed by or in consultation with a gastroenterologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial
-------	--

Product Name: Stelara (all subcutaneous strengths)			
Diagnosis	Ulcerative Colitis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
STELARA	USTEKINUMAB INJ 45 MG/0.5ML	90250585002020	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 45 MG/0.5ML	9025058500E520	Brand

STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 90 MG/ML	9025058500E540	Brand
---------	---	----------------	-------

**Approval Criteria**

1 - Diagnosis of moderately to severely active ulcerative colitis

**AND**

2 - One of the following:

2.1 Both of the following

2.1.1 History of failure to one of the following conventional therapies at maximally indicated doses within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*:

- Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)
- 6-mercaptopurine (Purinethol)
- Azathioprine (Imuran)
- Aminosalicylates (e.g., mesalamine, sulfasalazine)

**AND**

2.1.2 History of failure, contraindication or intolerance to Humira (adalimumab)

**OR**

2.2 Patient is currently on Stelara therapy as documented by claims history or medical records (document drug, date, and duration of therapy)

**AND**

3 - Patient is NOT receiving Stelara in combination with ONE of the following:

- Biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
- Janus Kinase Inhibitor [e.g., Xeljanz (tofacitinib)]

<ul style="list-style-type: none"> <li>Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Prescribed by or in consultation with a gastroenterologist</p>	
Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trial

Product Name: Stelara (all subcutaneous strengths)	
Diagnosis	Crohn's Disease, Ulcerative Colitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
STELARA	USTEKINUMAB INJ 45 MG/0.5ML	90250585002020	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 45 MG/0.5ML	9025058500E520	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 90 MG/ML	9025058500E540	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to Stelara therapy

**AND**

**2** - Patient is NOT receiving Stelara in combination with ONE of the following:

- Biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
- Janus Kinase Inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**3** - Prescribed by or in consultation with a gastroenterologist

## 2 . Revision History

Date	Notes
10/25/2022	Added age criterion for PsA and PsO. Added all SC formulations for Chron's.

Strensiq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140903
<b>Guideline Name</b>	Strensiq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Strensiq			
Diagnosis	perinatal/infantile or juvenile-onset hypophosphatasia (HPP)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
STRENSIQ	ASFOTASE ALFA SUBCUTANEOUS INJ 18 MG/0.45ML	30905610002020	Brand
STRENSIQ	ASFOTASE ALFA SUBCUTANEOUS INJ 28 MG/0.7ML	30905610002030	Brand
STRENSIQ	ASFOTASE ALFA SUBCUTANEOUS INJ 40 MG/ML	30905610002040	Brand
STRENSIQ	ASFOTASE ALFA SUBCUTANEOUS INJ 80 MG/0.8ML	30905610002050	Brand

## Approval Criteria

1 - All of the following:

1.1 Diagnosis of perinatal/infantile or juvenile-onset hypophosphatasia based on all of the following:

1.1.1 One of the following:

- Onset of clinical signs and symptoms of hypophosphatasia prior to age 18 years (e.g., respiratory insufficiency, vitamin B6 responsive seizures, hypotonia, failure to thrive, delayed walking, waddling gait, dental abnormalities, low trauma fractures)
- Radiographic evidence supporting the diagnosis of hypophosphatasia at the age of onset prior to age 18 years (e.g., craniosynostosis, infantile rickets, non-traumatic fractures)

**AND**

1.1.2 One of the following:

1.1.2.1 Both of the following:

- Patient has low level activity of serum alkaline phosphatase (ALP) evidenced by an ALP level below the age-adjusted normal range
- Patient has an elevated level of tissue non-specific alkaline phosphatase (TNSALP) substrate (e.g. serum pyridoxal 5'-phosphate [PLP] level, serum or urine phosphoethanolamine [PEA] level, urinary inorganic pyrophosphate [PPI level])

**OR**

1.1.2.2 Confirmation of tissue-nonspecific alkaline phosphatase (TNSALP) gene mutation by ALPL genomic DNA testing\*

**AND**

1.2 Prescribed by one of the following:

- Endocrinologist
- A specialist experienced in the treatment of metabolic bone disorders



**AND**

**1.3** One of the following:

**1.3.1** Both of the following:

- Diagnosis of perinatal/infantile-onset hypophosphatasia
- Coverage will be provided up to a maximum supply limit of 9 mg/kg/week

**OR**

**1.3.2** Both of the following:

- Diagnosis of juvenile-onset hypophosphatasia
- Coverage will be provided up to a maximum supply limit of 6 mg/kg/week

**AND**

**1.4** One of the following:

**1.4.1** Patient is prescribed Strensiq 18 mg/0.45 mL, Strensiq 28 mg/0.7 mL, or Strensiq 40 mg/mL vials

**OR**

**1.4.2** Both of the following:

- Patient is prescribed Strensiq 80 mg/0.8 mL vial
- Patient's weight is greater than or equal to 40 kg

**AND**

**1.5** Prescriber attests to the following: the information provided is true and accurate to the best of their knowledge and they understand that UnitedHealthcare may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided

Notes

\*Results of prior genetic testing can be submitted as confirmation of diagnosis of HPP, however please note that the provider should confirm

	coverage status of any new genetic testing under the patient's United Healthcare plan prior to ordering
--	---

<b>Product Name: Strensiq</b>	
Diagnosis	perinatal/infantile or juvenile-onset hypophosphatasia (HPP)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
STRENSIQ	ASFOTASE ALFA SUBCUTANEOUS INJ 18 MG/0.45ML	30905610002020	Brand
STRENSIQ	ASFOTASE ALFA SUBCUTANEOUS INJ 28 MG/0.7ML	30905610002030	Brand
STRENSIQ	ASFOTASE ALFA SUBCUTANEOUS INJ 40 MG/ML	30905610002040	Brand
STRENSIQ	ASFOTASE ALFA SUBCUTANEOUS INJ 80 MG/0.8ML	30905610002050	Brand

**Approval Criteria**

1 - All of the following:

1.1 Clinically relevant decrease from baseline in tissue non-specific alkaline phosphatase (TNSALP) substrate (e.g. serum pyridoxal 5'-phosphate [PLP] level, serum or urine phosphoethanolamine [PEA] level, urinary inorganic pyrophosphate [PPi level])

**AND**

1.2 Prescribed by one of the following:

- Endocrinologist
- A specialist experienced in the treatment of metabolic bone diseases

**AND**

1.3 One of the following:

1.3.1 Both of the following:

- Diagnosis of perinatal/infantile-onset hypophosphatasia
- Coverage will be provided up to a maximum supply limit of 9 mg/kg/week

**OR**

**1.3.2** Both of the following:

- Diagnosis of juvenile-onset hypophosphatasia
- Coverage will be provided up to a maximum supply limit of 6 mg/kg/week

**AND**

**1.4** One of the following:

**1.4.1** Patient is prescribed Strensiq 18 mg/0.45 mL, Strensiq 28 mg/0.7 mL, or Strensiq 40 mg/mL vials

**OR**

**1.4.2** Both of the following

- Patient is prescribed Strensiq 80 mg/0.8 mL vials
- Patient's weight is greater than or equal to 40 kg

**AND**

**1.5** Prescriber attests to the following: the information provided is true and accurate to the best of their knowledge and they understand that UnitedHealthcare may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Sublingual Immunotherapy (SLIT)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140785
<b>Guideline Name</b>	Sublingual Immunotherapy (SLIT)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	4/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Grastek, Oralair, Ragwitek, Odactra			
Diagnosis	Patients 21 years of age and older		
Approval Length	N/A - All requests for patients 21 years of age and older should be DENIED as benefit exclusion		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
GRASTEK	TIMOTHY GRASS POLLEN ALLERGEN EXT SL TAB 2800 BAU	20100048000740	Brand
ORALAIR CHILDREN/ADOLESCENTS STARTER PACK	*GRASS MIXED POLLEN EXT SL TAB 100 IR (INDEX OF REACTIVITY)*	20109905200720	Brand
ORALAIR	*GRASS MIXED POLLEN EXT SL TAB 300 IR (INDEX OF REACTIVITY)*	20109905200730	Brand

ORALAIR ADULT STARTER PACK	*GRASS MIXED POLLEN EXT SL TAB 300 IR (INDEX OF REACTIVITY)*	20109905200730	Brand
RAGWITEK	SHORT RAGWEED POLLEN ALLERGEN EXTRACT SL TAB 12 AMB A 1-U	20100060200720	Brand
ODACTRA	*DUST MITE MIXED EXT SL TAB 12 SQ-HDM***	20109902220740	Brand

**Approval Criteria**

1 - Requests for patients 21 years of age and older are not covered

Notes	Approval Length: N/A - All requests for patients 21 years of age and older should be denied as a benefit exclusion.
-------	---

**Product Name: Grastek**

Diagnosis	Grass pollen-induced allergic rhinitis for patients under 21 years of age
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
GRASTEK	TIMOTHY GRASS POLLEN ALLERGEN EXT SL TAB 2800 BAU	20100048000740	Brand

**Approval Criteria**

1 - Diagnosis of moderate to severe grass pollen-induced allergic rhinitis

**AND**

2 - Diagnosis confirmed by ONE of the following:

- Positive skin test to Timothy grass or cross-reactive grass pollens (e.g., Sweet Vernal, Orchard/Cocksfoot, Perennial Rye, Kentucky blue/June grass, Meadow Fescue, or Redtop)

- In vitro testing for pollen-specific IgE (immunoglobulin E) antibodies for Timothy grass or cross-reactive grass pollens (e.g., Sweet Vernal, Orchard/Cocksfoot, Perennial Rye, Kentucky blue/June grass, Meadow Fescue, or Redtop)

**AND**

**3** - Treatment is started or will be started at least 12 weeks before the beginning of the grass pollen season

**AND**

**4** - History of failure, contraindication, or intolerance to TWO of the following:

- Oral antihistamine [e.g., cetirizine (Zyrtec)]
- Intranasal antihistamine [e.g., azelastine (Astelin)]
- Intranasal corticosteroid [e.g., fluticasone (Flonase)]
- Leukotriene inhibitor [e.g., montelukast (Singulair)]

**AND**

**5** - Not received in combination with similar cross-reactive grass pollen immunotherapy (e.g., Oralair)

**AND**

**6** - Patient does not have unstable and/or uncontrolled asthma

**AND**

**7** - Prescribed by or in consultation with a specialist in allergy and immunology

Product Name: Grastek	
Diagnosis	Grass pollen-induced allergic rhinitis for patients under 21 years of age
Approval Length	12 month(s)
Therapy Stage	Reauthorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
GRASTEK	TIMOTHY GRASS POLLEN ALLERGEN EXT SL TAB 2800 BAU	20100048000740	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Grastek therapy			

Product Name: Oralair			
Diagnosis	Grass pollen-induced allergic rhinitis for patients under 21 years of age		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORALAIR CHILDREN/ADOLESCENTS STARTER PACK	*GRASS MIXED POLLEN EXT SL TAB 100 IR (INDEX OF REACTIVITY)*	20109905200720	Brand
ORALAIR	*GRASS MIXED POLLEN EXT SL TAB 300 IR (INDEX OF REACTIVITY)*	20109905200730	Brand
ORALAIR ADULT STARTER PACK	*GRASS MIXED POLLEN EXT SL TAB 300 IR (INDEX OF REACTIVITY)*	20109905200730	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of moderate to severe grass pollen-induced allergic rhinitis			
<b>AND</b>			
2 - Diagnosis confirmed by ONE of the following:			
<ul style="list-style-type: none"> <li>Positive skin test to any of the five grass species contained in Oralair [(i.e., Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue grass mixed pollens) or cross-reactive grass pollens (e.g., Cocksfoot, Meadow Fescue, or Redtop)]</li> </ul>			

- In vitro testing for pollen-specific IgE antibodies for any of the five grass species contained in Oralair [(i.e., Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue grass mixed pollens) or cross-reactive grass pollens (e.g., Cocksfoot, Meadow Fescue, or Redtop)]

**AND**

**3** - Treatment is started or will be started at least 4 months before the beginning of the grass pollen season

**AND**

**4** - History of failure, contraindication, or intolerance to TWO of the following:

- Oral antihistamine [e.g., cetirizine (Zyrtec)]
- Intranasal antihistamine [e.g., azelastine (Astelin)]
- Intranasal corticosteroid [e.g., fluticasone (Flonase)]
- Leukotriene inhibitor [e.g., montelukast (Singulair)]

**AND**

**5** - Not received in combination with similar cross-reactive grass pollen immunotherapy (e.g., Grastek)

**AND**

**6** - Patient does not have unstable and/or uncontrolled asthma

**AND**

**7** - Prescribed by or in consultation with a specialist in allergy and immunology

Product Name: Oralair	
Diagnosis	Grass pollen-induced allergic rhinitis for patients under 21 years of age
Approval Length	12 month(s)



Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ORALAIR CHILDREN/ADOLESCENTS STARTER PACK	*GRASS MIXED POLLEN EXT SL TAB 100 IR (INDEX OF REACTIVITY)*	20109905200720	Brand
ORALAIR	*GRASS MIXED POLLEN EXT SL TAB 300 IR (INDEX OF REACTIVITY)*	20109905200730	Brand
ORALAIR ADULT STARTER PACK	*GRASS MIXED POLLEN EXT SL TAB 300 IR (INDEX OF REACTIVITY)*	20109905200730	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Oralair therapy			

Product Name: Ragwitek			
Diagnosis	Short ragweed pollen-induced allergic rhinitis for patients under 21 years of age		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RAGWITEK	SHORT RAGWEED POLLEN ALLERGEN EXTRACT SL TAB 12 AMB A 1-U	20100060200720	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of moderate to severe short ragweed pollen-induced allergic rhinitis			
<b>AND</b>			
2 - Diagnosis confirmed by ONE of the following:			
<ul style="list-style-type: none"> <li>Positive skin test to short ragweed pollen</li> </ul>			

- In vitro testing for pollen-specific IgE antibodies for short ragweed pollen

**AND**

**3** - Treatment is started or will be started at least 12 weeks before the beginning of the short ragweed pollen season

**AND**

**4** - History of failure, contraindication, or intolerance to TWO of the following:

- Oral antihistamine [e.g., cetirizine (Zyrtec)]
- Intranasal antihistamine [e.g., azelastine (Astelin)]
- Intranasal corticosteroid [e.g., fluticasone (Flonase)]
- Leukotriene inhibitor [e.g., montelukast (Singulair)]

**AND**

**5** - Patient does not have unstable and/or uncontrolled asthma

**AND**

**6** - Prescribed by or in consultation with a specialist in allergy and immunology

Product Name: Ragwitek			
Diagnosis	Short ragweed pollen-induced allergic rhinitis for patients under 21 years of age		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RAGWITEK	SHORT RAGWEED POLLEN ALLERGEN EXTRACT SL TAB 12 AMB A 1-U	20100060200720	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Ragwitek therapy

Product Name: Odactra			
Diagnosis	House dust mite (HDM)-induced allergic rhinitis for patients under 21 years of age		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ODACTRA	*DUST MITE MIXED EXT SL TAB 12 SQ-HDM***	20109902220740	Brand

**Approval Criteria**

1 - Diagnosis of house dust mite (HDM)-induced allergic rhinitis

**AND**

2 - Diagnosis confirmed by ONE of the following:

- Positive skin test to licensed house dust mite allergen extracts
- In vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites

**AND**

3 - History of failure, contraindication, or intolerance to TWO of the following:

- Oral antihistamine [e.g., cetirizine (Zyrtec)]
- Intranasal antihistamine [e.g., azelastine (Astelin)]
- Intranasal corticosteroid [e.g., fluticasone (Flonase)]

<ul style="list-style-type: none"> <li>Leukotriene inhibitor [e.g., montelukast (Singulair)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>4</b> - Patient does not have unstable and/or uncontrolled asthma</p> <p style="text-align: center;"><b>AND</b></p> <p><b>5</b> - Prescribed by or in consultation with a specialist in allergy and immunology</p> <p style="text-align: center;"><b>AND</b></p> <p><b>6</b> - Patient is at least 12 years of age and not greater than 20 years of age</p>
---

Product Name: Odactra			
Diagnosis	House dust mite (HDM)-induced allergic rhinitis for patients under 21 years of age		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ODACTRA	*DUST MITE MIXED EXT SL TAB 12 SQ-HDM***	20109902220740	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Odactra therapy			
<b>AND</b>			
2 - Patient is at least 12 years of age and not greater than 20 years of age			

## 2 . Revision History

Date	Notes
3/14/2023	Added age criteria for Odactra, cleaned up GPI list for Oralair, updated indications to include age restriction, cleaned up criteria.

Sublocade, Brixadi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-162608
<b>Guideline Name</b>	Sublocade, Brixadi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Brixadi, Sublocade			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BRIXADI	BUPRENORPHINE EXTENDED RELEASE SOLN PREF SYR 64 MG/0.18ML	6520001000E515	Brand
BRIXADI	BUPRENORPHINE EXTENDED RELEASE SOLN PREF SYR 96 MG/0.27ML	6520001000E518	Brand
BRIXADI	BUPRENORPHINE EXTENDED RELEASE SOLN PREF SYR 128 MG/0.36ML	6520001000E523	Brand

BRIXADI	BUPRENORPHINE EXT REL SOLN PEF SYR (WEEKLY) 8 MG/0.16ML	6520001000E560	Brand
BRIXADI	BUPRENORPHINE EXT REL SOLN PEF SYR (WEEKLY) 16 MG/0.32ML	6520001000E565	Brand
BRIXADI	BUPRENORPHINE EXT REL SOLN PEF SYR (WEEKLY) 24 MG/0.48ML	6520001000E570	Brand
BRIXADI	BUPRENORPHINE EXT REL SOLN PEF SYR (WEEKLY) 32 MG/0.64ML	6520001000E575	Brand
SUBLOCADE	BUPRENORPHINE EXTENDED RELEASE SOLN PEF SYR 100 MG/0.5ML	6520001000E520	Brand
SUBLOCADE	BUPRENORPHINE EXTENDED RELEASE SOLN PEF SYR 300 MG/1.5ML	6520001000E530	Brand

**Approval Criteria**

1 - ALL of the following:

1.1 Patient has severe Opioid Use Disorder (OUD) as defined by the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) OUD Diagnostic Tool and has a demonstrated history of non-adherence to oral medications

**AND**

1.2 Patient is currently maintained on 8mg to 24mg per day dose of oral, sublingual, or transmucosal buprenorphine product equivalent prior to initiation of Brixadi or Sublocade

**AND**

1.3 Patient will not receive supplemental oral, sublingual, or transmucosal buprenorphine for greater than 6 weeks after initiation of Brixadi or Sublocade

**AND**

1.4 Patient is receiving psychosocial interventions as part of a comprehensive medication assisted treatment (MAT) program

**AND**

**1.5** Prescriber checks the Arizona State Board of Pharmacy Controlled Substance Prescription Monitoring Program (CSPMP) database prior to each monthly injection of Brixadi or Sublocade

**AND**

**1.6** Dosing of Brixadi or Sublocade is in accordance with the U. S. Food and Drug Administration approved labeling

**OR**

**2** - Brixadi or Sublocade is being requested due to circumstances other than non-adherence to oral medications. Document circumstance(s).

Product Name: Brixadi, Sublocade			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BRIXADI	BUPRENORPHINE EXTENDED RELEASE SOLN PEF SYR 64 MG/0.18ML	6520001000E515	Brand
BRIXADI	BUPRENORPHINE EXTENDED RELEASE SOLN PEF SYR 96 MG/0.27ML	6520001000E518	Brand
BRIXADI	BUPRENORPHINE EXTENDED RELEASE SOLN PEF SYR 128 MG/0.36ML	6520001000E523	Brand
BRIXADI	BUPRENORPHINE EXT REL SOLN PEF SYR (WEEKLY) 8 MG/0.16ML	6520001000E560	Brand
BRIXADI	BUPRENORPHINE EXT REL SOLN PEF SYR (WEEKLY) 16 MG/0.32ML	6520001000E565	Brand
BRIXADI	BUPRENORPHINE EXT REL SOLN PEF SYR (WEEKLY) 24 MG/0.48ML	6520001000E570	Brand
BRIXADI	BUPRENORPHINE EXT REL SOLN PEF SYR (WEEKLY) 32 MG/0.64ML	6520001000E575	Brand
SUBLOCADE	BUPRENORPHINE EXTENDED RELEASE SOLN PEF SYR 100 MG/0.5ML	6520001000E520	Brand
SUBLOCADE	BUPRENORPHINE EXTENDED RELEASE SOLN PEF SYR 300 MG/1.5ML	6520001000E530	Brand



**Approval Criteria**

**1** - Physician documentation that the patient has experienced a positive clinical response to Brixadi or Sublocade therapy, as defined by the provider

**AND**

**2** - ONE of the following:

**2.1** ALL of the following:

**2.1.1** Patient will not receive supplemental oral, sublingual, or transmucosal buprenorphine for greater than 6 weeks after Brixadi or Sublocade therapy initiation

**AND**

**2.1.2** Patient is receiving psychosocial interventions as part of a comprehensive medication assisted treatment (MAT) program

**AND**

**2.1.3** Prescriber checks the Arizona State Board of Pharmacy Controlled Substance Prescription Monitoring Program (CSPMP) database prior to each monthly injection of Brixadi or Sublocade

**AND**

**2.1.4** Dosing of Brixadi or Sublocade is in accordance with the U. S. Food and Drug Administration approved labeling

**OR**

**2.2** Brixadi or Sublocade is being requested due to circumstances other than non-adherence to oral medications. Document circumstance(s).

## 2 . Revision History

Date	Notes
12/31/2024	Update to guideline name. Added Sublocade back as a target. Updated criteria, product name lists, and GPI tables.

Suboxone



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140749
<b>Guideline Name</b>	Suboxone
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Generic buprenorphine-naloxone film, Zubsolv *			
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZUBSOLV	BUPRENORPHINE HCL- NALOXONE HCL SL TAB 0.7-0.18 MG (BASE EQ)	65200010200710	Brand
ZUBSOLV	BUPRENORPHINE HCL- NALOXONE HCL SL TAB 1.4-0.36 MG (BASE EQ)	65200010200715	Brand
ZUBSOLV	BUPRENORPHINE HCL- NALOXONE HCL SL TAB 2.9-0.71 MG (BASE EQ)	65200010200725	Brand

ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 5.7-1.4 MG (BASE EQ)	65200010200732	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 8.6-2.1 MG (BASE EQ)	65200010200745	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 11.4-2.9 MG (BASE EQ)	65200010200760	Brand
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 2-0.5 MG (BASE EQUIV)	65200010208220	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 4-1 MG (BASE EQUIV)	65200010208230	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 8-2 MG (BASE EQUIV)	65200010208240	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 12-3 MG (BASE EQUIV)	65200010208250	Generic

**Approval Criteria**

1 - The patient has a Diagnostic and Statistical Manual, Fifth Edition, Text Revision, (DSM-V-TR) diagnosis of opioid use disorder

**AND**

2 - The patient must have a reason or special circumstance that they cannot use the preferred products \*\*

- brand Suboxone Film
- buprenorphine (generic Subutex)
- buprenorphine HCl/naloxone Tab (Generic Suboxone Tab)
- naloxone
- naltrexone
- Narcan (naloxone)
- Sublocade (buprenorphine)
- Vivitrol (naltrexone microspheres)

Notes

\*Up to 24 mg per day of Suboxone, or equivalent dosing of an alternative medication, will be authorized for the initial period

\*\*PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/ariz>

	<a href="https://www.uhcare.com/health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC">ona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC</a> CCP
--	---

**Product Name: Generic buprenorphine-naloxone film, Zubsolv \***

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 0.7-0.18 MG (BASE EQ)	65200010200710	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 1.4-0.36 MG (BASE EQ)	65200010200715	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 2.9-0.71 MG (BASE EQ)	65200010200725	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 5.7-1.4 MG (BASE EQ)	65200010200732	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 8.6-2.1 MG (BASE EQ)	65200010200745	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 11.4-2.9 MG (BASE EQ)	65200010200760	Brand
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 2-0.5 MG (BASE EQUIV)	65200010208220	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 4-1 MG (BASE EQUIV)	65200010208230	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 8-2 MG (BASE EQUIV)	65200010208240	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 12-3 MG (BASE EQUIV)	65200010208250	Generic

**Approval Criteria**

1 - The patient has been prescribed a buprenorphine product for the purpose of opioid use disorder maintenance therapy

**AND**

**2** - The patient must have a reason or special circumstance that they cannot use the preferred products\*\*

**AND**

**3** - Patient must have tried Suboxone film or buprenorphine-naloxone ODT tablets

Notes	<p>*Up to 16 mg per day of Suboxone, or equivalent dosing of an alternative medication, will be authorized for the reauthorization period                  **PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC</a></p>
-------	--

Product Name: Brand suboxone, generic buprenorphine-naloxone film, buprenorphine/naloxone sublingual tablet, Zubsolv *			
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Quantity Limit		
Product Name	Generic Name	GPI	Brand/Generic
SUBOXONE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 2-0.5 MG (BASE EQUIV)	65200010208220	Brand
SUBOXONE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 8-2 MG (BASE EQUIV)	65200010208240	Brand
SUBOXONE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 4-1 MG (BASE EQUIV)	65200010208230	Brand
SUBOXONE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 12-3 MG (BASE EQUIV)	65200010208250	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 0.7-0.18 MG (BASE EQ)	65200010200710	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 1.4-0.36 MG (BASE EQ)	65200010200715	Brand

ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 2.9-0.71 MG (BASE EQ)	65200010200725	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 5.7-1.4 MG (BASE EQ)	65200010200732	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 8.6-2.1 MG (BASE EQ)	65200010200745	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 11.4-2.9 MG (BASE EQ)	65200010200760	Brand
BUPRENORPHINE HCL/NALOXONE HCL	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 2-0.5 MG (BASE EQUIV)	65200010200720	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 2-0.5 MG (BASE EQUIV)	65200010200720	Generic
BUPRENORPHINE HCL/NALOXONE HCL	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 8-2 MG (BASE EQUIV)	65200010200740	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 8-2 MG (BASE EQUIV)	65200010200740	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 2-0.5 MG (BASE EQUIV)	65200010208220	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 4-1 MG (BASE EQUIV)	65200010208230	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 8-2 MG (BASE EQUIV)	65200010208240	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 12-3 MG (BASE EQUIV)	65200010208250	Generic

**Approval Criteria**

1 - Physician has provided rationale for needing to exceed the buprenorphine daily limit

**AND**

2 - The requested dosage cannot be achieved using the plan accepted quantity limit of a different dose or formulation

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Notes	* This criteria applies to requests exceeding 24 mg of buprenorphine or equivalent
-------	--

Product Name: Brand suboxone, generic buprenorphine-naloxone film, buprenorphine/naloxone sublingual tablet, Zubsolv *			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Quantity Limit		
Product Name	Generic Name	GPI	Brand/Generic
SUBOXONE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 2-0.5 MG (BASE EQUIV)	65200010208220	Brand
SUBOXONE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 8-2 MG (BASE EQUIV)	65200010208240	Brand
SUBOXONE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 4-1 MG (BASE EQUIV)	65200010208230	Brand
SUBOXONE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 12-3 MG (BASE EQUIV)	65200010208250	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 0.7-0.18 MG (BASE EQ)	65200010200710	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 1.4-0.36 MG (BASE EQ)	65200010200715	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 2.9-0.71 MG (BASE EQ)	65200010200725	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 5.7-1.4 MG (BASE EQ)	65200010200732	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 8.6-2.1 MG (BASE EQ)	65200010200745	Brand
ZUBSOLV	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 11.4-2.9 MG (BASE EQ)	65200010200760	Brand
BUPRENORPHINE HCL/NALOXONE HCL	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 2-0.5 MG (BASE EQUIV)	65200010200720	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 2-0.5 MG (BASE EQUIV)	65200010200720	Generic



BUPRENORPHINE HCL/NALOXONE HCL	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 8-2 MG (BASE EQUIV)	65200010200740	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL TAB 8-2 MG (BASE EQUIV)	65200010200740	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 2-0.5 MG (BASE EQUIV)	65200010208220	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 4-1 MG (BASE EQUIV)	65200010208230	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 8-2 MG (BASE EQUIV)	65200010208240	Generic
BUPRENORPHINE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE	BUPRENORPHINE HCL-NALOXONE HCL SL FILM 12-3 MG (BASE EQUIV)	65200010208250	Generic

**Approval Criteria**

1 - Physician has provided rationale for needing to exceed the buprenorphine daily limit

**AND**

2 - The requested dosage cannot be achieved using the plan accepted quantity limit of a different dose or formulation

Notes	*This criteria applies to requests exceeding 16 mg of buprenorphine or equivalent
-------	---

**2 . Revision History**

Date	Notes
10/28/2022	Updated GL name and GPIs to be complete. Updated NP criteria to add generic buprenorphine-naloxone film. Updated PDL links.

Sucraid



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-145460
<b>Guideline Name</b>	Sucraid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Sucraid			
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUCRAID	SACROSIDASE SOLN 8500 UNIT/ML	51200060002030	Brand
<b>Approval Criteria</b>			

**1** - Diagnosis of congenital sucrase-isomaltase deficiency (CSID) as confirmed by one of the following:

**1.1** Duodenal biopsy showing low sucrose activity and normal amounts of other disaccharides

**OR**

**1.2** All of the following:

- Stool pH less than 6
- Negative lactose breath test
- Increase in breath hydrogen greater than 10 ppm (parts per million) when challenged with sucrose after fasting

**AND**

**2** - Prescribed by or in consultation with a gastroenterologist or rare disease specialist

**AND**

**3** - Will be used with a sucrose-free, low starch diet

**AND**

**4** - Provider attests that the requested medication will be obtained under compassionate use

Product Name: Sucraid			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUCRAID	SACROSIDASE SOLN 8500 UNIT/ML	51200060002030	Brand

**Approval Criteria**

1 - Prescribed by or in consultation with a gastroenterologist or rare disease specialist

**AND**

2 - Will be used with a sucrose-free, low starch diet

**AND**

3 - Provider attests that the patient has achieved a clinically meaningful response while on Sucraid therapy, defined as at least a 50 percent reduction in all of the following:

- Symptoms of abdominal pain, cramps, bloating, gas, vomiting
- Number of stools per day
- Watery, loose stool consistency
- Number of symptomatic days

**AND**

4 - Provider attests that the requested medication will be obtained under compassionate use

**2 . Revision History**

Date	Notes
4/5/2024	Added criterion that the drug will be obtained under compassionate use

Sunlenca



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140784
<b>Guideline Name</b>	Sunlenca
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	4/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Sunlenca			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUNLENCA	LENACAPAVIR SODIUM TAB THERAPY PACK 4 X 300 MG	1210155520B720	Brand
SUNLENCA	LENACAPAVIR SODIUM TAB THERAPY PACK 5 X 300 MG	1210155520B725	Brand
<b>Approval Criteria</b>			

**1** - One of the following:

**1.1** Submission of medical records (e.g., chart notes) documenting all of the following:

**1.1.1** Diagnosis of HIV-1 infection

**AND**

**1.1.2** Both of the following:

**1.1.2.1** Patient is heavily treatment-experienced with multidrug resistance as confirmed by a resistance assay

**AND**

**1.1.2.2** Patient is failing their current antiretroviral regimen due to ONE of the following:

- Resistance
- Intolerance
- Safety considerations

**AND**

**1.1.3** Patient is currently taking, or will be prescribed, an active and optimized background antiretroviral therapy regimen

**AND**

**1.1.4** Prescribed by or in consultation with a clinician with HIV expertise

**OR**

**1.2** For continuation of prior therapy

## **2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
3/9/2023	New

Sunosi



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140703
<b>Guideline Name</b>	Sunosi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Sunosi			
Diagnosis	Narcolepsy		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUNOSI	SOLRIAMFETOL HCL TAB 75 MG (BASE EQUIV)	61370070200320	Brand
SUNOSI	SOLRIAMFETOL HCL TAB 150 MG (BASE EQUIV)	61370070200340	Brand



**Approval Criteria**

**1** - Submission of medical records (e.g. chart notes, lab values) documenting a diagnosis of narcolepsy with BOTH of the following:

**1.1** The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months.

**OR**

**1.2** A mean sleep latency of less than or equal to 8 minutes and two or more sleep onset rapid eye movement (REM) periods (SOREMPs) are found on a multiple sleep latency test (MSLT) performed according to standard techniques following a normal overnight polysomnogram. A SOREMP (within 15 minutes of sleep onset) on the preceding nocturnal polysomnogram may replace one of the SOREMPs on the MSLT.

**AND**

**2** - Physician attestation to the following:

- Other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications or their withdrawal, sleep phase disorder, or other sleep disorders)

**AND**

**3** - History of failure, contraindication, or intolerance to BOTH of the following:

**3.1** ONE of the following:

- Amphetamine based stimulant (e.g., amphetamine, dextroamphetamine)
- Methylphenidate based stimulant

**AND**

**3.2** Armodafinil

**AND**

**4 - Prescribed by one of the following:**

- Neurologist
- Psychiatrist
- Sleep Medicine Specialist

Product Name: Sunosi			
Diagnosis	Narcolepsy		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUNOSI	SOLRIAMFETOL HCL TAB 75 MG (BASE EQUIV)	61370070200320	Brand
SUNOSI	SOLRIAMFETOL HCL TAB 150 MG (BASE EQUIV)	61370070200340	Brand
<b>Approval Criteria</b>			
1 - Reduction in symptoms of excessive daytime sleepiness associated with Sunosi therapy			

Product Name: Sunosi			
Diagnosis	Obstructive Sleep Apnea		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUNOSI	SOLRIAMFETOL HCL TAB 75 MG (BASE EQUIV)	61370070200320	Brand
SUNOSI	SOLRIAMFETOL HCL TAB 150 MG (BASE EQUIV)	61370070200340	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g. chart notes, lab values) documenting a diagnosis of obstructive sleep apnea with ONE of the following:

**1.1** Fifteen or more obstructive respiratory events per hour of sleep confirmed by a sleep study

**OR**

**1.2** BOTH of the following:

**1.2.1** Five or more obstructive respiratory events per hour of sleep confirmed by a sleep study

**AND**

**1.2.2** ONE or more of the following sign/symptoms are present:

- Daytime sleepiness
- Nonrestorative sleep
- Fatigue
- Insomnia
- Waking up with breath holding, gasping, or choking
- Habitual snoring noted by bed partner or other observer
- Observed apnea

**AND**

**2** - BOTH of the following:

**2.1** Standard treatments for the underlying airway obstruction (e.g., continuous positive airway pressure [CPAP], bi-level positive airway pressure [BiPAP]) have been used for one month or longer

**AND**

**2.2** Patient is fully compliant with ongoing treatment(s) for the underlying airway obstruction

**AND**

**3** - History of failure, contraindication, or intolerance to armodafinil

**AND**

**4** - Prescribed by one of the following:

- Neurologist
- Psychiatrist
- Sleep Medicine Specialist

Product Name: Sunosi			
Diagnosis	Obstructive Sleep Apnea		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUNOSI	SOLRIAMFETOL HCL TAB 75 MG (BASE EQUIV)	61370070200320	Brand
SUNOSI	SOLRIAMFETOL HCL TAB 150 MG (BASE EQUIV)	61370070200340	Brand

**Approval Criteria**

**1** - Reduction in symptoms of excessive daytime sleepiness associated with Sunosi therapy

**AND**

**2** - Patient continues to be fully compliant with ongoing treatment(s) for the underlying airway obstruction (e.g. continuous positive airway pressure [CPAP], bi-level positive airway pressure [BiPAP])

**2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Sutent



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140925
<b>Guideline Name</b>	Sutent
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Sutent			
Diagnosis	Gastrointestinal Stromal Tumor (GIST)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUTENT	SUNITINIB MALATE CAP 12.5 MG (BASE EQUIVALENT)	21533070300120	Brand
SUTENT	SUNITINIB MALATE CAP 37.5 MG (BASE EQUIVALENT)	21533070300135	Brand
SUTENT	SUNITINIB MALATE CAP 50 MG (BASE EQUIVALENT)	21533070300140	Brand

SUTENT	SUNITINIB MALATE CAP 25 MG (BASE EQUIVALENT)	21533070300130	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of gastrointestinal stromal tumor (GIST)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - History of failure, contraindication, or intolerance to Gleevec (imatinib)</p>			

Product Name: Sutent			
Diagnosis	Renal Cell Carcinoma (RCC)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUTENT	SUNITINIB MALATE CAP 12.5 MG (BASE EQUIVALENT)	21533070300120	Brand
SUTENT	SUNITINIB MALATE CAP 25 MG (BASE EQUIVALENT)	21533070300130	Brand
SUTENT	SUNITINIB MALATE CAP 37.5 MG (BASE EQUIVALENT)	21533070300135	Brand
SUTENT	SUNITINIB MALATE CAP 50 MG (BASE EQUIVALENT)	21533070300140	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of renal cell carcinoma (RCC)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>    <b>2.1</b> Disease has relapsed</p>			

<p><b>OR</b></p> <p><b>2.2</b> Diagnosis of Stage IV disease</p> <p><b>OR</b></p> <p><b>2.3</b> BOTH of the following:</p> <p><b>2.3.1</b> Used in adjuvant setting</p> <p><b>AND</b></p> <p><b>2.3.2</b> Patient has a high risk of recurrence following nephrectomy</p>
---

<b>Product Name: Sutent</b>			
Diagnosis	Islet Cell Tumor / Progressive Pancreatic Neuroendocrine Tumors (pNET)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUTENT	SUNITINIB MALATE CAP 12.5 MG (BASE EQUIVALENT)	21533070300120	Brand
SUTENT	SUNITINIB MALATE CAP 25 MG (BASE EQUIVALENT)	21533070300130	Brand
SUTENT	SUNITINIB MALATE CAP 37.5 MG (BASE EQUIVALENT)	21533070300135	Brand
SUTENT	SUNITINIB MALATE CAP 50 MG (BASE EQUIVALENT)	21533070300140	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of islet cell tumor / progressive pancreatic neuroendocrine tumors (pNET)			



**AND**

**2** - Disease is ONE of the following:

- Unresectable, locally advanced
- Metastatic

Product Name: Sutent			
Diagnosis	Soft Tissue Sarcoma		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUTENT	SUNITINIB MALATE CAP 12.5 MG (BASE EQUIVALENT)	21533070300120	Brand
SUTENT	SUNITINIB MALATE CAP 25 MG (BASE EQUIVALENT)	21533070300130	Brand
SUTENT	SUNITINIB MALATE CAP 37.5 MG (BASE EQUIVALENT)	21533070300135	Brand
SUTENT	SUNITINIB MALATE CAP 50 MG (BASE EQUIVALENT)	21533070300140	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of ONE of the following:			
<ul style="list-style-type: none"> <li>• Alveolar soft part sarcoma (ASPS)</li> <li>• Angiosarcoma</li> <li>• Solitary fibrous tumor / hemangiopericytoma</li> </ul>			

Product Name: Sutent	
Diagnosis	Thyroid Carcinoma
Approval Length	12 month(s)
Therapy Stage	Initial Authorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
SUTENT	SUNITINIB MALATE CAP 12.5 MG (BASE EQUIVALENT)	21533070300120	Brand
SUTENT	SUNITINIB MALATE CAP 25 MG (BASE EQUIVALENT)	21533070300130	Brand
SUTENT	SUNITINIB MALATE CAP 37.5 MG (BASE EQUIVALENT)	21533070300135	Brand
SUTENT	SUNITINIB MALATE CAP 50 MG (BASE EQUIVALENT)	21533070300140	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 ALL of the following:

1.1.1 Diagnosis of ONE of the following:

- Follicular carcinoma
- Hürthle cell carcinoma
- Papillary carcinoma

**AND**

1.1.2 ONE of the following:

- Unresectable locoregional recurrent disease
- Persistent disease
- Metastatic disease

**AND**

1.1.3 ONE of the following:

- Patient has symptomatic disease
- Patient has progressive disease

**AND**

**1.1.4** Disease is refractory to radioactive iodine treatment

**OR**

**1.2** ALL of the following:

**1.2.1** Diagnosis of medullary thyroid carcinoma

**AND**

**1.2.2** ONE of the following:

- Patient has progressive disease
- Patient has symptomatic metastatic disease

**AND**

**1.2.3** History of failure, contraindication, or intolerance to ONE of the following:

- Caprelsa (vandetanib)
- Cometriq (cabozantinib)

Product Name: Sutent			
Diagnosis	Chordoma		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUTENT	SUNITINIB MALATE CAP 12.5 MG (BASE EQUIVALENT)	21533070300120	Brand
SUTENT	SUNITINIB MALATE CAP 25 MG (BASE EQUIVALENT)	21533070300130	Brand
SUTENT	SUNITINIB MALATE CAP 37.5 MG (BASE EQUIVALENT)	21533070300135	Brand
SUTENT	SUNITINIB MALATE CAP 50 MG (BASE EQUIVALENT)	21533070300140	Brand

**Approval Criteria**

1 - Diagnosis of recurrent chordoma

Product Name: Sutent			
Diagnosis	Central Nervous System Cancer		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUTENT	SUNITINIB MALATE CAP 12.5 MG (BASE EQUIVALENT)	21533070300120	Brand
SUTENT	SUNITINIB MALATE CAP 25 MG (BASE EQUIVALENT)	21533070300130	Brand
SUTENT	SUNITINIB MALATE CAP 37.5 MG (BASE EQUIVALENT)	21533070300135	Brand
SUTENT	SUNITINIB MALATE CAP 50 MG (BASE EQUIVALENT)	21533070300140	Brand

**Approval Criteria**

1 - Diagnosis of surgically inaccessible meningiomas

**AND**

2 - ONE of the following:

- Disease is recurrent
- Disease is progressive

**AND**

3 - Further radiation is not possible

Product Name: Sutent			
Diagnosis	Thymic Carcinoma		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUTENT	SUNITINIB MALATE CAP 12.5 MG (BASE EQUIVALENT)	21533070300120	Brand
SUTENT	SUNITINIB MALATE CAP 25 MG (BASE EQUIVALENT)	21533070300130	Brand
SUTENT	SUNITINIB MALATE CAP 37.5 MG (BASE EQUIVALENT)	21533070300135	Brand
SUTENT	SUNITINIB MALATE CAP 50 MG (BASE EQUIVALENT)	21533070300140	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of thymic carcinoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used as second-line following a failure, contraindication, or intolerance to a first-line chemotherapy regimen (e.g., carboplatin/paclitaxel)</p>			

Product Name: Sutent			
Diagnosis	Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Islet Cell Tumor / Progressive Pancreatic Neuroendocrine Tumors (pNET), Soft Tissue Sarcoma, Thyroid Carcinoma, Chordoma, Central Nervous System Cancer, Thymic Carcinoma		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SUTENT	SUNITINIB MALATE CAP 12.5 MG (BASE EQUIVALENT)	21533070300120	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SUTENT	SUNITINIB MALATE CAP 25 MG (BASE EQUIVALENT)	21533070300130	Brand
SUTENT	SUNITINIB MALATE CAP 37.5 MG (BASE EQUIVALENT)	21533070300135	Brand
SUTENT	SUNITINIB MALATE CAP 50 MG (BASE EQUIVALENT)	21533070300140	Brand

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Sutent therapy

Product Name: Sutent

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SUTENT	SUNITINIB MALATE CAP 12.5 MG (BASE EQUIVALENT)	21533070300120	Brand
SUTENT	SUNITINIB MALATE CAP 25 MG (BASE EQUIVALENT)	21533070300130	Brand
SUTENT	SUNITINIB MALATE CAP 37.5 MG (BASE EQUIVALENT)	21533070300135	Brand
SUTENT	SUNITINIB MALATE CAP 50 MG (BASE EQUIVALENT)	21533070300140	Brand

**Approval Criteria**

1 - Sutent will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.

Product Name: Sutent

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SUTENT	SUNITINIB MALATE CAP 12.5 MG (BASE EQUIVALENT)	21533070300120	Brand
SUTENT	SUNITINIB MALATE CAP 25 MG (BASE EQUIVALENT)	21533070300130	Brand
SUTENT	SUNITINIB MALATE CAP 37.5 MG (BASE EQUIVALENT)	21533070300135	Brand
SUTENT	SUNITINIB MALATE CAP 50 MG (BASE EQUIVALENT)	21533070300140	Brand

**Approval Criteria**

- 1 - Documentation of positive clinical response to Sutent therapy

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Symdeko



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140905
<b>Guideline Name</b>	Symdeko
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Symdeko			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYMDEKO	TEZACAFTOR-IVACAFTOR 100-150 MG & IVACAFTOR 150 MG TAB TBPB	4530990280B720	Brand
SYMDEKO	TEZACAFTOR-IVACAFTOR 50-75 MG & IVACAFTOR 75 MG TAB TBPB	4530990280B710	Brand



**Approval Criteria**

1 - Diagnosis of cystic fibrosis (CF)

**AND**

2 - Submission of laboratory result documenting ONE of the following:

2.1 The patient is homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene

**OR**

2.2 The patient has at least ONE mutation in the CFTR gene that is responsive to Symdeko (See Table in Background Section)

**AND**

3 - The patient is greater than or equal to 6 years of age

**AND**

4 - Prescribed by or in consultation with a specialist affiliated with a CF care center

Product Name: Symdeko			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYMDEKO	TEZACAFTOR-IVACAFTOR 100-150 MG & IVACAFTOR 150 MG TAB TBPB	4530990280B720	Brand
SYMDEKO	TEZACAFTOR-IVACAFTOR 50-75 MG & IVACAFTOR 75 MG TAB TBPB	4530990280B710	Brand

**Approval Criteria**

1 - Provider attests that the patient has achieved a clinically meaningful response while on Symdeko therapy to ONE of the following:

- Lung function as demonstrated by percent predicted expiratory volume in 1 second (ppFEV1)
- Body mass index (BMI)
- Pulmonary exacerbations
- Quality of life as demonstrated by Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score

**AND**

2 - Prescribed by, or in consultation with, a specialist affiliated with a cystic fibrosis (CF) care center

**2 . Background**

Benefit/Coverage/Program Information					
<b>Table 1 CFTR Gene Mutations</b>					
A1067T	D1270N	F1052V	R1070W	S945L	3272-26A→G
A455E	D579G	F1074L	R117C	S977F	3849+10kbC→T
D110E	E193K	K1060T	R347H		711+3A→G
D110H	E56K	L206W	R352Q		2789+5G→A
D1152H	E831X	P67L	R74W		

**3 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Symlin



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140649
<b>Guideline Name</b>	Symlin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2020
-----------------	----------

## 1 . Criteria

Product Name: Symlin			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYMLINPEN 120	PRAMLINTIDE ACETATE PEN-INJ 2700 MCG/2.7ML (1000 MCG/ML)	2715005010D240	Brand
SYMLINPEN 60	PRAMLINTIDE ACETATE PEN-INJ 1500 MCG/1.5ML (1000 MCG/ML)	2715005010D220	Brand
<b>Approval Criteria</b>			

1 - Patient must have ONE of the following diagnoses:

- Type 1 diabetes
- Type 2 diabetes

**AND**

2 - Concurrent use of insulin therapy

## 2 . Revision History

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Synagis



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140953
<b>Guideline Name</b>	Synagis
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	1/1/2023
-----------------	----------

### Note:

PA is not required for children under 2 years of age

## 1 . Criteria

Product Name: Synagis*			
Diagnosis	Prematurity		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYNAGIS	PALIVIZUMAB IM SOLN 50 MG/0.5ML	19502060002015	Brand
SYNAGIS	PALIVIZUMAB IM SOLN 100 MG/ML	19502060002020	Brand

**Approval Criteria**

1 - BOTH of the following:

1.1 Patient is an infant born before 29 weeks, 0 days gestation

**AND**

1.2 Patient is less than 12 months of age at the start of RSV “season”

**AND**

2 - Administered during RSV season\*\*

**AND**

3 - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose

**AND**

4 - Monthly dose of Synagis does not exceed 5 doses per single RSV “season”\*\*\*

**AND**

5 - The patient does not meet ONE of the following situations

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]

<ul style="list-style-type: none"> <li>• Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)</li> <li>• Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab</li> <li>• Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children</li> <li>• Synagis prophylaxis for prevention of nosocomial disease</li> <li>• Treatment of symptomatic RSV disease</li> </ul>	
Notes	<p>*NOTE: Approval for up to 5 doses per single RSV “season”</p> <p>** Information regarding RSV season may be found at:</p> <ul style="list-style-type: none"> <li>• Centers for Disease and Prevention (CDC) surveillance reports (<a href="http://www.cdc.gov/surveillance/nrevss/rsv/index.html">http://www.cdc.gov/surveillance/nrevss/rsv/index.html</a>)</li> <li>• <a href="http://uhc-cs-10.uhc.com/sites/cspm/CSSP/Pages/Synagis.aspx">http://uhc-cs-10.uhc.com/sites/cspm/CSSP/Pages/Synagis.aspx</a></li> </ul> <p>***NOTE: Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the hospital, this dose will be considered the first dose of the maximum 5 dose series for the season. And any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV “season,” fewer than 5 monthly doses may be needed.</p>

Product Name: Synagis*			
Diagnosis	Chronic Lung Disease (CLD)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYNAGIS	PALIVIZUMAB IM SOLN 50 MG/0.5ML	19502060002015	Brand
SYNAGIS	PALIVIZUMAB IM SOLN 100 MG/ML	19502060002020	Brand
<p><b>Approval Criteria</b></p> <p>1 - ONE of the following:</p> <p>1.1 ALL of the following for patients age 0 to less than 12 months:</p> <p>1.1.1 The patient is a preterm infant defined as gestational age less than 32 weeks, 0 days</p>			

**AND**

**1.1.2** Patient has developed chronic lung disease (CLD) of prematurity

**AND**

**1.1.3** There was a requirement for greater than 21% oxygen for at least the first 28 days after birth

**OR**

**1.2** ALL of the following for patients age greater than or equal to 12 months to less than 24 months:

**1.2.1** The patient was born at less than 32 weeks, 0 days gestation

**AND**

**1.2.2** The patient required at least 28 days of oxygen after birth

**AND**

**1.2.3** The patient continues to require supplemental oxygen, diuretics, or chronic systemic corticosteroid therapy within 6 months of the start of the second RSV "season"

**AND**

**2** - Administered during RSV season\*\*

**AND**

**3** - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose



**AND**

**4** - Monthly dose of Synagis does not exceed 5 doses per single RSV “season”\*\*\*

**AND**

**5** - The patient does not meet ONE of the following situations

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]
- Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)
- Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab
- Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children
- Synagis prophylaxis for prevention of nosocomial disease
- Treatment of symptomatic RSV disease

Notes	<p>*NOTE: Approval for up to 5 doses per single RSV “season”</p> <p>** Information regarding RSV season may be found at:</p> <ul style="list-style-type: none"> <li>• Centers for Disease and Prevention (CDC) surveillance reports (<a href="http://www.cdc.gov/surveillance/nrevss/rsv/index.html">http://www.cdc.gov/surveillance/nrevss/rsv/index.html</a>)</li> <li>• <a href="http://uhc-cs-10.uhc.com/sites/cspm/CSSP/Pages/Synagis.aspx">http://uhc-cs-10.uhc.com/sites/cspm/CSSP/Pages/Synagis.aspx</a></li> </ul> <p>***NOTE: Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the hospital, this dose will be considered the first dose of the maximum 5 dose series for the season. And any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV “season,” fewer than 5 monthly doses may be needed.</p>
-------	--

Product Name: Synagis*			
Diagnosis	Congenital Heart Disease (CHD)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYNAGIS	PALIVIZUMAB IM SOLN 50 MG/0.5ML	19502060002015	Brand
SYNAGIS	PALIVIZUMAB IM SOLN 100 MG/ML	19502060002020	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 ONE of the following for patients age 0 to less than 12 months:

1.1.1 Patient has hemodynamically significant congenital heart disease (CHD) including ONE of the following:

- Acyanotic heart disease and receiving medication to control congestive heart failure and will require cardiac surgical procedures
- Moderate to severe pulmonary hypertension
- Documentation that decisions regarding prophylaxis for infants with cyanotic heart defects were made in consultation with a pediatric cardiologist

**OR**

1.1.2 The patient is undergoing cardiac transplantation during the RSV “season”

**OR**

1.2 BOTH of the following:

1.2.1 The patient is greater than or equal to 12 months to less than 24 months of age:

**AND**

1.2.2 ONE of the following:

- After cardiac bypass

- At the conclusion of extracorporeal membrane oxygenation
- The patient is undergoing cardiac transplantation during the RSV “season”

**AND**

**2** - Administered during RSV season\*\*

**AND**

**3** - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose

**AND**

**4** - Monthly dose of Synagis does not exceed 5 doses per single RSV “season”\*\*\*

**AND**

**5** - The patient does not meet ONE of the following situations

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]
- Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)
- Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab
- Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children
- Synagis prophylaxis for prevention of nosocomial disease
- Treatment of symptomatic RSV disease

Notes	<p>*NOTE: Approval for up to 5 doses per single RSV “season”</p> <p>** Information regarding RSV season may be found at:</p> <ul style="list-style-type: none"> <li>Centers for Disease and Prevention (CDC) surveillance reports (<a href="http://www.cdc.gov/surveillance/nrevss/rsv/index.html">http://www.cdc.gov/surveillance/nrevss/rsv/index.html</a>)</li> <li><a href="http://uhc-cs-10.uhc.com/sites/cspm/CSSP/Pages/Synagis.aspx">http://uhc-cs-10.uhc.com/sites/cspm/CSSP/Pages/Synagis.aspx</a></li> </ul> <p>***NOTE: Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the hospital, this dose will be considered the first dose of the maximum 5 dose series for the season. And any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV “season,” fewer than 5 monthly doses may be needed.</p>
-------	--

Product Name: Synagis*			
Diagnosis	Congenital abnormalities of the airway or neuromuscular disease		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
SYNAGIS	PALIVIZUMAB IM SOLN 50 MG/0.5ML	19502060002015	Brand
SYNAGIS	PALIVIZUMAB IM SOLN 100 MG/ML	19502060002020	Brand
<p><b>Approval Criteria</b></p> <p>1 - ALL of the following:</p> <p>1.1 Patient is age 0 to less than 12 months</p> <p style="text-align: center;"><b>AND</b></p> <p>1.2 Patient has ONE of the following:</p> <ul style="list-style-type: none"> <li>Neuromuscular disease</li> <li>A congenital anomaly that impairs the ability to clear secretions from the lower airway because of ineffective cough</li> </ul> <p style="text-align: center;"><b>AND</b></p>			

2 - Administered during RSV season\*\*

**AND**

3 - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose

**AND**

4 - Monthly dose of Synagis does not exceed 5 doses per single RSV “season”\*\*\*

**AND**

5 - The patient does not meet ONE of the following situations

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]
- Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)
- Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab
- Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children
- Synagis prophylaxis for prevention of nosocomial disease
- Treatment of symptomatic RSV disease

Notes

\*NOTE: Approval for up to 5 doses per single RSV “season”  
 \*\* Information regarding RSV season may be found at:  
 • Centers for Disease and Prevention (CDC) surveillance reports (<http://www.cdc.gov/surveillance/nrevss/rsv/index.html>)  
 • <http://uhc-cs-10.uhc.com/sites/cspm/CSSP/Pages/Synagis.aspx>  
 \*\*\*NOTE: Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the

	hospital, this dose will be considered the first dose of the maximum 5 dose series for the season. And any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV “season,” fewer than 5 monthly doses may be needed.
--	---

**Product Name: Synagis\***

Diagnosis	Immunocompromised children less than 24 months of age
-----------	---

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
SYNAGIS	PALIVIZUMAB IM SOLN 50 MG/0.5ML	19502060002015	Brand
SYNAGIS	PALIVIZUMAB IM SOLN 100 MG/ML	19502060002020	Brand

**Approval Criteria**

1 - BOTH of the following:

1.1 Patient is less than 24 months of age

**AND**

1.2 The patient is immunocompromised (e.g. receiving cancer chemotherapy, undergoing hematopoietic stem cell transplantation, or solid organ transplantation)

**AND**

2 - Administered during RSV season\*\*

**AND**

3 - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose

**AND**

4 - Monthly dose of Synagis does not exceed 5 doses per single RSV “season”\*\*\*

**AND**

5 - The patient does not meet ONE of the following situations

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]
- Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)
- Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab
- Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children
- Synagis prophylaxis for prevention of nosocomial disease
- Treatment of symptomatic RSV disease

Notes

\*NOTE: Approval for up to 5 doses per single RSV “season”  
 \*\* Information regarding RSV season may be found at:  
 • Centers for Disease and Prevention (CDC) surveillance reports (<http://www.cdc.gov/surveillance/nrevss/rsv/index.html>)  
 • <http://uhc-cs-10.uhc.com/sites/cspm/CSSP/Pages/Synagis.aspx>  
 \*\*\*NOTE: Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the hospital, this dose will be considered the first dose of the maximum 5 dose series for the season. And any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV “season,” fewer than 5 monthly doses may be needed.

Product Name: Synagis\*

Diagnosis Cystic fibrosis (CF)

Guideline Type Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
SYNAGIS	PALIVIZUMAB IM SOLN 50 MG/0.5ML	19502060002015	Brand
SYNAGIS	PALIVIZUMAB IM SOLN 100 MG/ML	19502060002020	Brand

**Approval Criteria**

**1 - ONE of the following:**

**1.1 BOTH of the following for patients age 0 to less than 12 months:**

**1.1.1 Patient has cystic fibrosis**

**AND**

**1.1.2 Patient has clinical evidence of at least ONE of the following:**

- Chronic lung disease (CLD)
- Nutritional compromise
- Failure to thrive defined as weight for length less than the 10th percentile on a pediatric growth chart

**OR**

**1.2 BOTH of the following:**

**1.2.1 Patient is greater than or equal to 12 months to less than 24 months of age**

**AND**

**1.2.2 Patient has manifestations of severe lung disease including ONE of the following:**

- Previous hospitalization for pulmonary exacerbation in the first year of life
- Abnormalities on chest radiography or chest computed tomography that persists when stable
- Weight for length less than the 10th percentile on a pediatric growth chart



**AND**

**2 - Administered during RSV season\*\***

**AND**

**3 - Monthly dose of Synagis does not exceed 15 milligram per kilogram per dose**

**AND**

**4 - Monthly dose of Synagis does not exceed 5 doses per single RSV "season"\*\*\***

**AND**

**5 - The patient does not meet ONE of the following situations**

- Infants and children with hemodynamically insignificant heart disease (e.g., secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)
- Infants with congenital heart disease and cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with cardiomyopathy sufficiently mild that they do not require pharmacotherapy
- Routine use of prophylaxis in children with Down syndrome [unless qualifying heart disease, CLD, airway clearance issues (the inability to clear secretions from the upper airway because of ineffective cough), or prematurity (less than 29 weeks, 0 days gestation) is present]
- Routine use of prophylaxis in children with cystic fibrosis (unless indications noted in proven indications above are present)
- Administration of monthly Synagis prophylaxis after an infant or child has experienced a breakthrough RSV hospitalization during the current season if child had met criteria for palivizumab
- Prophylaxis for primary asthma prevention or to reduce subsequent episodes of wheezing in infants and children
- Synagis prophylaxis for prevention of nosocomial disease
- Treatment of symptomatic RSV disease

Notes

\*NOTE: Approval for up to 5 doses per single RSV "season"

\*\* Information regarding RSV season may be found at:

• Centers for Disease and Prevention (CDC) surveillance reports (<http://www.cdc.gov/surveillance/nrevss/rsv/index.html>)

• <http://uhc-cs-10.uhc.com/sites/cspm/CSSP/Pages/Synagis.aspx>

	<p>***NOTE: Infants in a neonatal intensive care unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge. If the first dose is administered in the hospital, this dose will be considered the first dose of the maximum 5 dose series for the season. And any subsequent doses received in the hospital setting, are also considered as part of the maximum 5 dose series. For infants born during the RSV “season,” fewer than 5 monthly doses may be needed.</p>
--	--

## 2 . Background

Benefit/Coverage/Program Information
<p><b>Additional Information</b></p> <p>In most of North America, peak RSV activity typically occurs between November and March, usually beginning in November or December, peaking in January or February, and ending by the end of March or sometime in April. Communities in the southern United States, particularly some communities in the state of Florida, tend to experience the earliest onset of RSV. Data from the Centers for Disease Control and Prevention (CDC) have identified variations in the onset and offset of the RSV “season” in the state of Florida that could affect the timing of Synagis administration. <sup>10</sup></p> <ul style="list-style-type: none"> <li>• Despite varied onsets, the RSV “season” is of the same duration (5 months) in the different regions of Florida.</li> <li>• On the basis of the epidemiology of RSV in Alaska, particularly in remote regions where the burden of RSV disease is significantly greater than the general US population, the selection of Alaska Native infants eligible for prophylaxis may differ from the remainder of the United States. Clinicians may wish to use RSV surveillance data generated by the state of Alaska to assist in determining onset and end of the RSV season for qualifying infants.</li> <li>• Limited information is available concerning the burden of RSV disease among Native American populations. However, special consideration may be prudent for Navajo and White Mountain Apache infants in the first year of life.</li> </ul> <p>For analysis of National Respiratory and Enteric Virus Surveillance System (NREVSS) reports in the CDC Morbidity and Mortality Weekly Report, season onset is defined as the first of 2 consecutive weeks during which the mean percentage of specimens testing positive for RSV antigen is <math>\geq 10\%</math> and RSV “season” offset is defined as the last of 2 consecutive weeks during which the mean percentage of positive specimens is <math>\geq 10\%</math>. Use of specimens</p>

to determine the start of the RSV “season” requires that the number of specimens tested be statistically significant.

### 3 . Revision History

Date	Notes
12/8/2022	Added guideline note for PA is not required if patient is under 2 years of age.

Systane, Refresh, Gonak, Genteal, Tears Naturale



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140708
<b>Guideline Name</b>	Systane, Refresh, Gonak, Genteal, Tears Naturale
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: brand Systane, brand Refresh, brand Gonak, brand Genteal, Tears Naturale			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
CARBOXYMETHYLCELLULOSE SODIUM	CARBOXYMETHYLCELLULOSE SODIUM OPHTH SOLN 0.5%	86200010102020	Generic
EQ RESTORE TEARS	CARBOXYMETHYLCELLULOSE SODIUM OPHTH SOLN 0.5%	86200010102020	Generic
EYE DROPS	CARBOXYMETHYLCELLULOSE SODIUM OPHTH SOLN 0.5%	86200010102020	Generic
LUBRICANT EYE DROPS	CARBOXYMETHYLCELLULOSE SODIUM OPHTH SOLN 0.5%	86200010102020	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

RA LUBRICANT EYE DROPS	CARBOXYMETHYLCELLULOSE SODIUM OPHTH SOLN 0.5%	86200010102020	Generic
REFRESH TEARS	CARBOXYMETHYLCELLULOSE SODIUM OPHTH SOLN 0.5%	86200010102020	Brand
ULTRA FRESH	CARBOXYMETHYLCELLULOSE SODIUM OPHTH SOLN 0.5%	86200010102020	Generic
BIOLLE TEARS	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH SOLN 0.5%	86200010102021	Brand
EQ RESTORE PLUS LUBRICANTEYE DROPS	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH SOLN 0.5%	86200010102021	Generic
GNP LUBRICATING PLUS EYE DROPS	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH SOLN 0.5%	86200010102021	Generic
GOODSENSE LUBRICATING PLUS EYE DROPS	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH SOLN 0.5%	86200010102021	Generic
HM LUBRICATING PLUS	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH SOLN 0.5%	86200010102021	Generic
LUBRICANT EYE DROPS	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH SOLN 0.5%	86200010102021	Generic
LUBRICATING PLUS EYE DROPS	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH SOLN 0.5%	86200010102021	Generic
REFRESH PLUS	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH SOLN 0.5%	86200010102021	Brand
RETAINÉ CMC	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH SOLN 0.5%	86200010102021	Brand
SM LUBRICATING PLUS	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH SOLN 0.5%	86200010102021	Generic
REFRESH LIQUIGEL	CARBOXYMETHYLCELLULOSE SODIUM OPHTH GEL 1%	86200010104030	Brand
BIOLLE GEL TEARS	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH GEL 1%	86200010104031	Brand
REFRESH CELLUVISC	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH GEL 1%	86200010104031	Brand
THERATEARS	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH GEL 1%	86200010104031	Brand
THERATEARS LIQUID GEL NIGHTTIME DRY EYE THERAPY	CARBOXYMETHYLCELLULOSE SODIUM (PF) OPHTH GEL 1%	86200010104031	Brand
GENTEAL SEVERE	HYPROMELLOSE OPHTH GEL 0.3%	86200025004020	Brand
GENTEAL SEVERE TEARS	HYPROMELLOSE OPHTH GEL 0.3%	86200025004020	Brand
SYSTANE OVERNIGHT THERAPY LUBRICANT EYE	HYPROMELLOSE OPHTH GEL 0.3%	86200025004020	Brand
VISTA GEL	HYPROMELLOSE OPHTH GEL 0.3%	86200025004020	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LUBRICANT EYE DROPS	PROPYLENE GLYCOL OPHTH SOLN 0.6%	86200060002015	Generic
RA LUBRICANT EYE DROPS	PROPYLENE GLYCOL OPHTH SOLN 0.6%	86200060002015	Generic
SYSTANE COMPLETE	PROPYLENE GLYCOL OPHTH SOLN 0.6%	86200060002015	Brand
VISTA MEIBO TEARS	PROPYLENE GLYCOL OPHTH SOLN 0.6%	86200060002015	Brand
GENTEAL TEARS LIQUID DROPS MODERATE	*ARTIFICIAL TEAR OPHTH SOLUTION***	86201000002000	Brand
JUST TEARS EYE DROPS	*ARTIFICIAL TEAR OPHTH SOLUTION***	86201000002000	Generic
SM ARTIFICIAL TEARS	*ARTIFICIAL TEAR OPHTH SOLUTION***	86201000002000	Generic
SOOTHE HYDRATION	*ARTIFICIAL TEAR OPHTH SOLUTION***	86201000002000	Brand
SOOTHE XP	*ARTIFICIAL TEAR OPHTH SOLUTION***	86201000002000	Generic
SOOTHE XP	*ARTIFICIAL TEAR OPHTH SOLUTION***	86201000002000	Brand
SOOTHE XP/XTRA PROTECTION	*ARTIFICIAL TEAR OPHTH SOLUTION***	86201000002000	Brand
SYSTANE CONTACTS SOOTHING DROPS	*ARTIFICIAL TEAR OPHTH SOLUTION***	86201000002000	Brand
TEARS AGAIN ADVANCED EYELID SPRAY	*ARTIFICIAL TEAR OPHTH SOLUTION***	86201000002000	Brand
LUBRICANT EYE DROPS/DUAL-ACTION	CARBOXYMETHYLCELLULOSE-GLYCERIN OPHTH SOLN 0.5-0.9%	86209902122010	Generic
LUBRICATING EYE DROPS	CARBOXYMETHYLCELLULOSE-GLYCERIN OPHTH SOLN 0.5-0.9%	86209902122010	Generic
REFRESH OPTIVE	CARBOXYMETHYLCELLULOSE-GLYCERIN OPHTH SOLN 0.5-0.9%	86209902122010	Brand
REFRESH RELIEVA	CARBOXYMETHYLCELLULOSE-GLYCERIN OPHTH SOLN 0.5-0.9%	86209902122010	Brand
REFRESH OPTIVE PRESERVATIVE FREE	CARBOXYMETHYLCELLULOSE-GLYCERIN (PF) OPHTH SOLN 0.5-0.9%	86209902122012	Brand
REFRESH RELIEVA PF	CARBOXYMETHYLCELLULOSE-GLYCERIN (PF) OPHTH SOLN 0.5-0.9%	86209902122012	Brand
REFRESH RELIEVA PF	CARBOXYMETHYLCELLULOSE-GLYCERIN (PF) OPHTH SOLN 0.5-1%	86209902122015	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

REFRESH OPTIVE	CARBOXYMETHYLCELLULOSE-GLYCERIN OPHTH GEL 1-0.9%	86209902124020	Brand
ARTIFICIAL TEARS	DEXTRAN 70-HYPROMELLOSE OPHTH SOLN 0.1-0.3%	86209902242020	Generic
GENTEAL TEARS MILD	DEXTRAN 70-HYPROMELLOSE OPHTH SOLN 0.1-0.3%	86209902242020	Brand
LUBRICATING TEARS EYE DROPS	DEXTRAN 70-HYPROMELLOSE OPHTH SOLN 0.1-0.3%	86209902242020	Generic
NATURAL BALANCE TEARS	DEXTRAN 70-HYPROMELLOSE OPHTH SOLN 0.1-0.3%	86209902242020	Generic
TEARS PURE	DEXTRAN 70-HYPROMELLOSE OPHTH SOLN 0.1-0.3%	86209902242020	Generic
ARTIFICIAL TEARS	DEXTRAN 70-HYPROMELLOSE (PF) OPHTH SOLN 0.1-0.3%	86209902242025	Generic
BION TEARS	DEXTRAN 70-HYPROMELLOSE (PF) OPHTH SOLN 0.1-0.3%	86209902242025	Brand
GENTEAL TEARS MODERATE PF	DEXTRAN 70-HYPROMELLOSE (PF) OPHTH SOLN 0.1-0.3%	86209902242025	Brand
GENTEAL TEARS MODERATE PF	DEXTRAN 70-HYPROMELLOSE (PF) OPHTH SOLN 0.1-0.3%	86209902242025	Brand
EQ LUBRICANT EYE DROPS HIGH PERFORMANCE	POLYETHYLENE GLYCOL-PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Generic
GNP EYE DROPS LONG LASTING	POLYETHYLENE GLYCOL-PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Generic
GOODSENSE ULTRA LUBRICANT EYE DROPS	POLYETHYLENE GLYCOL-PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Generic
HM LUBRICATING TEARS	POLYETHYLENE GLYCOL-PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Generic
LUBRICANT EYE DROPS	POLYETHYLENE GLYCOL-PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Generic
LUBRICATING EYE DROPS	POLYETHYLENE GLYCOL-PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Generic
RA LUBRICANT EYE DROPS	POLYETHYLENE GLYCOL-PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Generic
SM LUBRICANT EYE DROPS	POLYETHYLENE GLYCOL-PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Generic
SM LUBRICATING TEARS	POLYETHYLENE GLYCOL-PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SYSTANE	POLYETHYLENE GLYCOL- PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Brand
SYSTANE ULTRA	POLYETHYLENE GLYCOL- PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Brand
ULTRA LUBRICATING EYE DROPS	POLYETHYLENE GLYCOL- PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Generic
VISTA TEARS	POLYETHYLENE GLYCOL- PROPYLENE GLYCOL OPHTH SOLN 0.4-0.3%	86209902482020	Brand
GOODSENSE LUBRICANT EYE DROPS	POLYETHYLENE GLYCOL- PROPYLENE GLYCOL PF OP SOLN 0.4-0.3%	86209902482022	Generic
SYSTANE HYDRATION PF	POLYETHYLENE GLYCOL- PROPYLENE GLYCOL PF OP SOLN 0.4-0.3%	86209902482022	Brand
SYSTANE PRESERVATIVE FREE	POLYETHYLENE GLYCOL- PROPYLENE GLYCOL PF OP SOLN 0.4-0.3%	86209902482022	Brand
SYSTANE ULTRA PRESERVATIVE FREE	POLYETHYLENE GLYCOL- PROPYLENE GLYCOL PF OP SOLN 0.4-0.3%	86209902482022	Brand
ALTALUBE	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic
ARTIFICIAL EYE	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic
ARTIFICIAL TEARS	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic
EQ RESTORE PM	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic
EYE LUBRICANT	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic
FOR STY RELIEF	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic
GENTEAL TEARS NIGHT-TIME	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Brand
HYPOTEARAS	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Brand
LUBRICANT EYE	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic
LUBRICANT EYE FAST ACTING	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic
LUBRICANT EYE NIGHTTIME	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic
LUBRICANT EYE PM	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LUBRICANT PM	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic
PURALUBE	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Brand
REFRESH LACRI-LUBE	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Brand
REFRESH P.M.	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Brand
RETAINÉ PM	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Brand
SOOTHE NIGHTTIME DRY EYE THERAPY	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Brand
STYE	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Generic
SYSTANE NIGHTTIME	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Brand
TEARS AGAIN	*WHITE PETROLATUM-MINERAL OIL OPHTH OINTMENT***	86209902904220	Brand
REFRESH DIGITAL	CARBOXYMETHYLCELL-GLYCERIN-POLYSORB 80 OPHTH SOLN 0.5-1-0.5%	86209903202020	Brand
REFRESH OPTIVE ADVANCED	CARBOXYMETHYLCELL-GLYCERIN-POLYSORB 80 OPHTH SOLN 0.5-1-0.5%	86209903202020	Brand
REFRESH DIGITAL PF	CARBOXYMETHYLCELL-GLYC-POLYSORB 80 (PF) OPHTH SOL 0.5-1-0.5%	86209903202022	Brand
REFRESH OPTIVE ADVANCED SENSITIVE	CARBOXYMETHYLCELL-GLYC-POLYSORB 80 (PF) OPHTH SOL 0.5-1-0.5%	86209903202022	Brand
REFRESH OPTIVE MEGA-3	CARBOXYMETHYLCELL-GLYC-POLYSORB 80 (PF) OPHTH SOL 0.5-1-0.5%	86209903202022	Brand

**Approval Criteria**

1 - History of failure, contraindication, or intolerance to ALL of the following:

- Generic equivalents for drops, ointments and gel formulations for Systane, Refresh, Gonak, Genteal, Tears Naturale, and Generic equivalent to the requested brand product
- sodium chloride ophthalmic ointment

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Talicia and Mycobutin



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140669
<b>Guideline Name</b>	Talicia and Mycobutin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Mycobutin			
Diagnosis	Mycobacterium Avium Complex Prophylaxis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYCOBUTIN	RIFABUTIN CAP 150 MG	09000075000120	Brand
TALICIA	AMOXICILLIN-RIFABUTIN-OMEPRAZOLE CAP DR 250-12.5-10 MG	49993003406520	Brand

**Approval Criteria**

1 - Diagnosis of Mycobacterium Avium Complex Prophylaxis

**AND**

2 - Prescribed by or in consultation with an HIV or infectious disease specialist

**AND**

3 - Member has failed azithromycin or clarithromycin or is intolerant to the medication due to significant adverse effects or both are contraindicated

**AND**

4 - If request is for brand Mycobutin and the member is allergic to the generic formulation, the prescriber must submit the FDA MedWatch form

**AND**

5 - The requested dosage does not exceed 450 mg per day

Product Name: Mycobutin			
Diagnosis	Mycobacterium Avium Complex Prophylaxis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYCOBUTIN	RIFABUTIN CAP 150 MG	09000075000120	Brand
TALICIA	AMOXICILLIN-RIFABUTIN-OMEPRAZOLE CAP DR 250-12.5-10 MG	49993003406520	Brand

**Approval Criteria**

1 - Member is responding positively to therapy

Product Name: Mycobutin			
Diagnosis	Mycobacterium Avium Complex Prophylaxis		
Approval Length	12 month(s)		
Guideline Type	Quantity Limit		
Product Name	Generic Name	GPI	Brand/Generic
MYCOBUTIN	RIFABUTIN CAP 150 MG	09000075000120	Brand
TALICIA	AMOXICILLIN-RIFABUTIN-OMEPRAZOLE CAP DR 250-12.5-10 MG	49993003406520	Brand

**Approval Criteria**

1 - For doses that exceed 450mg, the use of this drug is supported by information from ONE of the following appropriate compendia of current literature:

- Food and Drug Administration (FDA) approved indications and limits
- Published practice guidelines and treatment protocols
- Comparative data evaluating the efficacy, type and frequency of side effects and potential drug interactions among alternative products as well as the risks, benefits and potential member outcomes
- Drug Facts and Comparisons
- American Hospital Formulary Service Drug Information
- United States Pharmacopeia – Drug Information
- DRUGDEX Information System
- UpToDate
- MicroMedex
- Peer-reviewed medical literature, including randomized clinical trials, outcomes, research data and pharmaco-economic studies
- Other drug reference resources

Product Name: Mycobutin	
Diagnosis	Helicobacter pylori Infection (off-label)

Approval Length	14 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYCOBUTIN	RIFABUTIN CAP 150 MG	09000075000120	Brand
TALICIA	AMOXICILLIN-RIFABUTIN-OMEPRAZOLE CAP DR 250-12.5-10 MG	49993003406520	Brand
RIFABUTIN	RIFABUTIN CAP 150 MG	09000075000120	Generic
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of H. pylori infection</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed in combination with amoxicillin and a proton pump inhibitor</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - If request is for brand Mycobutin, inability to use generic rifabutin (e.g., contraindications to excipients in rifabutin)</p>			

Product Name: Talicia			
Diagnosis	Helicobacter pylori Infection		
Approval Length	14 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TALICIA	AMOXICILLIN-RIFABUTIN-OMEPRAZOLE CAP DR 250-12.5-10 MG	49993003406520	Brand
<p><b>Approval Criteria</b></p>			

1 - Diagnosis of H. pylori infection

**AND**

2 - The medication is prescribed by or in consultation with a gastroenterologist or infectious disease specialist

**AND**

3 - One of the following:

**3.1** Member has tried 3 first-line treatment regimens listed in the table in background section (One of which must be Rifabutin triple therapy)

**OR**

**3.2** Both of the following:

**3.2.1** Culture and sensitivity report indicate resistance or lack of susceptibility of H. pylori to all first-line treatment regimens except Rifabutin triple therapy

**AND**

**3.2.2** Member must have tried and failed Rifabutin triple therapy

Product Name: Mycobutin			
Diagnosis	Tuberculosis (off-label)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYCOBUTIN	RIFABUTIN CAP 150 MG	09000075000120	Brand
TALICIA	AMOXICILLIN-RIFABUTIN-OMEPRAZOLE CAP DR 250-12.5-10 MG	49993003406520	Brand

RIFABUTIN	RIFABUTIN CAP 150 MG	09000075000120	Generic
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of tuberculosis infection</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with an HIV or infectious disease specialist</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Current treatment with protease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV infection</p> <p style="text-align: center;"><b>AND</b></p> <p>4 - If the request is for brand Mycobutin, inability to use generic rifabutin (e.g., contraindications to excipients in rifabutin).</p>			

Product Name: Mycobutin			
Diagnosis	Tuberculosis (off-label)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
MYCOBUTIN	RIFABUTIN CAP 150 MG	09000075000120	Brand
TALICIA	AMOXICILLIN-RIFABUTIN-OMEPRAZOLE CAP DR 250-12.5-10 MG	49993003406520	Brand
RIFABUTIN	RIFABUTIN CAP 150 MG	09000075000120	Generic



**Approval Criteria**

1 - Member is responding positively to therapy

**2 . Background**

Benefit/Coverage/Program Information		
Dosing Table		
Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Azithromycin	<b>MAC:</b> 1,200 mg PO once weekly or 600 mg PO twice weekly	500 mg/day
Clarithromycin	<b>MAC:</b> 500 mg PO BID	1.5 g/day
clarithromycin triple regimen	<b><i>H. pylori</i> infection:</b> 14 days: PPI (standard or double dose) BID; Clarithromycin 500 mg; Amoxicillin 1,000 mg or metronidazole 500 mg TID (if penicillin allergy)	See dosing regimen
bismuth quadruple regimen	<b><i>H. pylori</i> infection:</b> 10-14 days: PPI (standard dose) BID; bismuth subcitrate (120-300 mg) or subsalicylate (300 mg) QID; tetracycline 500 mg QID; metronidazole 250 mg QID or 500 mg TID-QID	See dosing regimen
concomitant regimen	<b><i>H. pylori</i> infection:</b> 10-14 days: PPI (standard dose) BID; Clarithromycin 500 mg; Amoxicillin 1,000 mg;	See dosing regimen

	Metronidazole or tinidazole 500 mg	
sequential regimen	<b>H. pylori infection:</b> 5-7 days of BID PPI (standard dose) + amoxicillin 1,000 mg; followed by 5-7 days of BID PPI, clarithromycin 500 mg + metronidazole/tinidazole	See dosing regimen
hybrid regimen	<b>H. pylori infection:</b> 7 days of BID PPI (standard dose) + amoxicillin 1,000 mg; followed by 7 days of BID PPI, amoxicillin +  clarithromycin 500 mg + metronidazole/tinidazole	See dosing regimen
levofloxacin triple regimen	<b>H. pylori infection:</b> 10-14 days:  PPI (standard dose) BID; levofloxacin 500 mg QD; amoxicillin 1,000 mg BID	See dosing regimen
levofloxacin sequential regimen	<b>H. pylori infection:</b>	See dosing regimen
	5-7 days of BID PPI (standard dose) + amoxicillin 1,000 mg; followed by 5-7 days of BID PPI, amoxicillin +  metronidazole/tinidazole + QD levofloxacin 500 mg	
rifabutin triple	<b>H. pylori infection:</b> 10 days of BID PPI (standard dose) + amoxicillin 1,000 mg BID + rifabutin 300 mg QD	See dosing regimen

### 3 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Taltz (ixekizumab)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-155737
<b>Guideline Name</b>	Taltz (ixekizumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Taltz			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 80 MG/ML	9025055400D520	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 20 MG/0.25ML	9025055400E510	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 40 MG/0.5ML	9025055400E515	Brand

TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 80 MG/ML	9025055400E520	Brand
-------	---	----------------	-------

**Approval Criteria**

1 - ONE of the following:

**1.1** Submission of medical records (e.g., chart notes, laboratory values) documenting ALL of the following:

**1.1.1** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**1.1.2** Greater than or equal to 3 percent body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**1.1.3** BOTH of the following:

**1.1.3.1** History of failure to ONE of the following topical therapies, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial):\*

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**1.1.3.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document date, and duration of trial)\*

**AND**

**1.1.4** History of failure, contraindication, or intolerance to ALL of the following preferred biologic products (document drug, date, and duration of trial):\*

- A preferred^ adalimumab biosimilar
- Enbrel (etanercept)
- Otezla (apremilast)

**AND**

**1.1.5** Patient is not receiving Taltz in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drugs (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orenzia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.1.6** Prescribed by or in consultation with a dermatologist

**OR**

**1.2** ALL of the following:

**1.2.1** Patient is currently on Taltz therapy as documented by claims history or medical records (document date, and duration of therapy)

**AND**

**1.2.2** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**1.2.3** Patient is not receiving Taltz in combination with ANY of the following:

- Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orenzia (abatacept)]

- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.2.4 Prescribed by or in consultation with a dermatologist**

Notes	<p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trials.</p> <p>^PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP</a></p>
-------	---

Product Name: Taltz			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 80 MG/ML	9025055400D520	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 20 MG/0.25ML	9025055400E510	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 40 MG/0.5ML	9025055400E515	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 80 MG/ML	9025055400E520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Taltz therapy

**AND**

2 - Patient is not receiving Taltz in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drugs (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orenzia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**3** - Prescribed by or in consultation with a dermatologist

**Product Name: Taltz**

Diagnosis	Psoriatic Arthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 80 MG/ML	9025055400D520	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 20 MG/0.25ML	9025055400E510	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 40 MG/0.5ML	9025055400E515	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 80 MG/ML	9025055400E520	Brand

**Approval Criteria**

**1** - ONE of the following:

**1.1** Submission of medical records (e.g., chart notes, laboratory values) documenting ALL of the following:

**1.1.1** Diagnosis of active psoriatic arthritis

**AND**

**1.1.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document date, and duration of trial)\*

**AND**

**1.1.3** History of failure, contraindication, or intolerance to ALL of the following preferred biologic products (document drug, date, and duration of trial):\*

- A preferred^ adalimumab biosimilar or Enbrel (etanercept)
- infliximab
- Orenzia (abatacept)
- Otezla (apremilast)
- Xeljanz (tofacitinib) oral tablet

**AND**

**1.1.4** Patient is not receiving Taltz in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drugs (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orenzia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.1.5** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**OR**

**1.2** ALL of the following:

**1.2.1** Patient is currently on Taltz therapy as documented by claims history or medical records (document date, and duration of therapy)



**AND**

**1.2.2** Diagnosis of active psoriatic arthritis

**AND**

**1.2.3** Patient is not receiving Taltz in combination with ANY of the following:

- Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.2.4** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Notes	<p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trials.</p> <p>^PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p>
-------	---

Product Name: Taltz			
Diagnosis	Psoriatic Arthritis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 80 MG/ML	9025055400D520	Brand

TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 20 MG/0.25ML	9025055400E510	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 40 MG/0.5ML	9025055400E515	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 80 MG/ML	9025055400E520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Taltz therapy

**AND**

2 - Patient is not receiving Taltz in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drugs (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Product Name: Taltz			
Diagnosis	Ankylosing Spondylitis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 80 MG/ML	9025055400D520	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 20 MG/0.25ML	9025055400E510	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 40 MG/0.5ML	9025055400E515	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 80 MG/ML	9025055400E520	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 Submission of medical records (e.g., chart notes, laboratory values) documenting ALL of the following:

1.1.1 Diagnosis of active ankylosing spondylitis

**AND**

1.1.2 History of failure to TWO nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trials)\*

**AND**

1.1.3 History of failure, contraindication, or intolerance to ALL of the following (document drug, date, and duration of trial):

- A preferred^ adalimumab biosimilar or Enbrel (etanercept)
- infliximab
- Xeljanz (tofacitinib) oral tablet

**AND**

1.1.4 Patient is not receiving Taltz in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drugs (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.1.5** Prescribed by or in consultation with a rheumatologist

**OR**

**1.2** ALL of the following:

**1.2.1** Patient is currently on Taltz therapy as documented by claims history or medical records (document date, and duration of therapy)

**AND**

**1.2.2** Diagnosis of active ankylosing spondylitis

**AND**

**1.2.3** Patient is not receiving Taltz in combination with ANY of the following:

- Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.2.4** Prescribed by or in consultation with a rheumatologist

Notes

\*Claims history may be used in conjunction as documentation of drug, date, and duration of trials.

^PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizo>

	na-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP
--	--

<b>Product Name: Taltz</b>	
Diagnosis	Ankylosing Spondylitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 80 MG/ML	9025055400D520	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 20 MG/0.25ML	9025055400E510	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 40 MG/0.5ML	9025055400E515	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 80 MG/ML	9025055400E520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Taltz therapy

**AND**

2 - Patient is not receiving Taltz in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drugs (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a rheumatologist

Product Name: Taltz	
Diagnosis	Non-radiographic axial spondyloarthritis
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 80 MG/ML	9025055400D520	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 20 MG/0.25ML	9025055400E510	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 40 MG/0.5ML	9025055400E515	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 80 MG/ML	9025055400E520	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 Submission of medical records (e.g., chart notes, laboratory values) documenting ALL of the following:

1.1.1 Diagnosis of active non-radiographic axial spondyloarthritis

**AND**

1.1.2 History of failure to TWO nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen) at maximally indicated doses, each used for at least 4 weeks, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trials)\*

**AND**

1.1.3 Patient is not receiving Taltz in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drugs (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]

- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.1.4** Prescribed by or in consultation with a rheumatologist

**OR**

**1.2** ALL of the following:

**1.2.1** Patient is currently on Taltz therapy as documented by claims history or medical records (document date, and duration of therapy)

**AND**

**1.2.2** Diagnosis of active non-radiographic axial spondyloarthritis

**AND**

**1.2.3** Patient is not receiving Taltz in combination with ANY of the following:

- Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

**1.2.4** Prescribed by or in consultation with a rheumatologist

Notes	*Claims history may be used in conjunction as documentation of drug, date, and duration of trials.
-------	--

Product Name: Taltz	
Diagnosis	Non-radiographic axial spondyloarthritis
Approval Length	12 month(s)

Therapy Stage		Reauthorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 80 MG/ML	9025055400D520	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 20 MG/0.25ML	9025055400E510	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 40 MG/0.5ML	9025055400E515	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 80 MG/ML	9025055400E520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Taltz therapy

**AND**

2 - Patient is not receiving Taltz in combination with ANY of the following:

- Biologic disease-modifying anti-rheumatic drugs (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

**AND**

3 - Prescribed by or in consultation with a rheumatologist

**2 . Revision History**

Date	Notes
------	-------



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

9/23/2024	Update to guideline name. Added new GPs for Taltz and updated criteria/embedded steps throughout guideline. Updated notes section to add PDL link, where applicable.
-----------	--

Targretin



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140926
<b>Guideline Name</b>	Targretin
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Targretin caps, generic bexarotene caps, Targretin gel			
Diagnosis	Cutaneous T-Cell Lymphoma		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BEXAROTENE	BEXAROTENE CAP 75 MG	21708220000120	Generic
TARGRETIN	BEXAROTENE CAP 75 MG	21708220000120	Brand
TARGRETIN	BEXAROTENE GEL 1%	90376220004020	Brand

**Approval Criteria**

1 - Diagnosis of cutaneous T-cell lymphoma (CTCL)

**AND**

2 - History of failure, contraindication, or intolerance to at least one prior therapy (including skin-directed therapies [e.g., corticosteroids (clobetasol, diflorasone, halobetasol, augmented betamethasone dipropionate), phototherapy, or systemic therapies [e.g. Interferons])

Product Name: Brand Targretin caps, generic bexarotene caps, Targretin gel			
Diagnosis	Cutaneous T-Cell Lymphoma		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BEXAROTENE	BEXAROTENE CAP 75 MG	21708220000120	Generic
TARGRETIN	BEXAROTENE CAP 75 MG	21708220000120	Brand
TARGRETIN	BEXAROTENE GEL 1%	90376220004020	Brand
<b>Approval Criteria</b>			
1 - Patient has not had disease progression while on therapy			

Product Name: Brand Targretin caps, generic bexarotene caps, Targretin gel	
Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
BEXAROTENE	BEXAROTENE CAP 75 MG	21708220000120	Generic
TARGRETIN	BEXAROTENE CAP 75 MG	21708220000120	Brand
TARGRETIN	BEXAROTENE GEL 1%	90376220004020	Brand

**Approval Criteria**

1 - Targretin will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.

Product Name: Brand Targretin caps, generic bexarotene caps, Targretin gel			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BEXAROTENE	BEXAROTENE CAP 75 MG	21708220000120	Generic
TARGRETIN	BEXAROTENE CAP 75 MG	21708220000120	Brand
TARGRETIN	BEXAROTENE GEL 1%	90376220004020	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Targretin therapy			

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Tarpeyo (budesonide)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140750
<b>Guideline Name</b>	Tarpeyo (budesonide)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Tarpeyo			
Approval Length	9 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TARPEYO	BUDESONIDE DELAYED RELEASE CAP 4 MG	22100012006520	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of primary immunoglobulin A nephropathy (IgAN) as confirmed by a kidney biopsy</p>			

**AND**

**2** - Patient is at risk of rapid disease progression [e.g., generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g (gram), or by other criteria such as clinical risk scoring using the International IgAN Prediction Tool]

**AND**

**3** - Used to reduce proteinuria

**AND**

**4** - Estimated glomerular filtration rate (eGFR) greater than or equal to 35 mL/min/1.73 m<sup>2</sup> (milliliters/minute/1.73 square meters)

**AND**

**5** - One of the following:

**5.1** Patient has been on a minimum 90-day trial of a maximally tolerated dose and will continue to receive therapy with one of the following:

- An angiotensin-converting enzyme (ACE) inhibitor (e.g., benazepril, lisinopril)
- An angiotensin II receptor blocker (ARB) (e.g., losartan, valsartan)

**OR**

**5.2** Patient has a contraindication or intolerance to both ACE inhibitors and ARBs

**AND**

**6** - Trial and failure, contraindication, or intolerance to another glucocorticoid (e.g., methylprednisolone, prednisone)

**AND**

**7** - Prescribed by or in consultation with a nephrologist

## **2 . Revision History**

Date	Notes
10/28/2022	Removed references and updated abbreviations, no clinical criteria changes.

Tasmar



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140792
<b>Guideline Name</b>	Tasmar
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2023
-----------------	----------

### 1 . Criteria

Product Name: generic tolcapone, Brand Tasmar			
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TOLCAPONE	TOLCAPONE TAB 100 MG	73152070000320	Generic
TASMAR	TOLCAPONE TAB 100 MG	73152070000320	Brand
<b>Approval Criteria</b>			



**1** - Diagnosis of Parkinson's disease

**AND**

**2** - Patient is currently on a stable dose of a carbidopa/levodopa-containing medication and will continue receiving treatment with a carbidopa/levodopa-containing medication while on therapy

**AND**

**3** - ONE of the following:

**3.1** Failure to TWO of the following anti-Parkinson's disease adjunctive pharmacotherapy classes (trial must be from TWO different classes) as confirmed by claims history or submission of medical records:

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., selegiline)

**OR**

**3.2** History of intolerance or contraindication to ALL of the following anti-Parkinson's disease adjunctive pharmacotherapy classes (please specify intolerance or contraindication):

- Dopamine agonists (e.g., pramipexole, ropinirole)
- Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
- Monoamine oxidase (MAO) B inhibitors (e.g., selegiline)

**AND**

**4** - Patient has received baseline liver function tests to rule out the presence of underlying liver disease

**AND**

**5** - Prescribed by or in consultation with a neurologist or specialist in the treatment of Parkinson's disease

**AND**

**6** - Prescriber attests they have had complete discussion with the patient about the risks and benefits of Tasmar (tolcapone) use, including the risk of liver failure

Product Name: generic tolcapone, Brand Tasmar			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TOLCAPONE	TOLCAPONE TAB 100 MG	73152070000320	Generic
TASMAR	TOLCAPONE TAB 100 MG	73152070000320	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to Tasmar (tolcapone) therapy

**AND**

**2** - Patient will continue to receive treatment with a carbidopa/levodopa-containing medication

**AND**

**3** - Patient has received periodic evaluation of liver function tests to rule out liver failure associated with Tasmar (tolcapone) use

Tavneos



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140964
<b>Guideline Name</b>	Tavneos
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	4/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Tavneos			
Diagnosis	ANCA (Anti-Neutrophil Cytoplasmic Autoantibody)-Associated Vasculitis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TAVNEOS	AVACOPAN CAP 10 MG	85805510000120	Brand

**Approval Criteria**

**1** - Diagnosis of severe active ANCA (anti-neutrophil cytoplasmic autoantibody)-associated vasculitis

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values, etc.) documenting the disease is ONE of the following types:

**2.1** Granulomatosis with polyangiitis (GPA)

**OR**

**2.2** Microscopic polyangiitis (MPA)

**AND**

**3** - Patient is being treated with an initial immunosuppressive regimen to induce remission (i.e., rituximab, cyclophosphamide)

**AND**

**4** - Tavneos is being prescribed as adjunctive treatment in combination with standard therapy (e.g., prednisone, azathioprine, mycophenolate, methotrexate, rituximab, cyclophosphamide)

**AND**

**5** - Prescribed by ONE of the following:

- Rheumatologist
- Nephrologist
- Pulmonologist
- Vascular Medicine Specialist

Product Name: Tavneos

Diagnosis	ANCA (Anti-Neutrophil Cytoplasmic Autoantibody)-Associated Vasculitis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TAVNEOS	AVACOPAN CAP 10 MG	85805510000120	Brand

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Tavneos therapy

**AND**

2 - Tavneos is being prescribed as adjunctive treatment in combination with standard therapy (e.g., prednisone, azathioprine, mycophenolate, methotrexate, rituximab, cyclophosphamide)

**AND**

3 - Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Nephrologist
- Pulmonologist
- Vascular Medicine Specialist

Tecelra (afamitresgene autoleucel)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-159332
<b>Guideline Name</b>	Tecelra (afamitresgene autoleucel)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Tecelra			
Approval Length	1 Time Authorization in Lifetime		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TECELRA	AFAMITRESGENE AUTOLEUCEL IV SUSP 10,000,000,000 CELLS	21651006101820	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes) confirming ALL of the following:			

**1.1** Diagnosis of synovial sarcoma

**AND**

**1.2** Disease is ONE of the following:

- Unresectable
- Metastatic

**AND**

**1.3** BOTH of the following:

**1.3.1** Patient is HLA-A\*02:01P, HLA-A\*02:02P, HLA-A\*02:03P, or HLA-A\*02:06P positive

**AND**

**1.3.2** Patient does NOT have HLA-A\*02:05P in either allele

**AND**

**1.4** Presence of MAGE-A4 antigen as detected by a U.S. Food and Drug Administration (FDA)-approved test or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA)

**AND**

**2** - Submission of medical records (e.g., chart notes) or paid claims confirming patient has received prior therapy with ONE of the following:

- An anthracycline (e.g., doxorubicin)
- Ifosfamide

**AND**

**3** - Patient is 16 years of age or older

**AND**

**4** - Submission of medical records (e.g., chart notes) or paid claims confirming patient has never received Tecelra treatment in their lifetime

## **2 . Revision History**

Date	Notes
11/5/2024	New program.



Tegsedi



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140859
<b>Guideline Name</b>	Tegsedi
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	2/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Tegsedi			
Diagnosis	Hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TEGSEDI	INOTERSEN SOD SUBCUTANEOUS PREF SYR 284 MG/1.5ML (BASE EQ)	6270104010E520	Brand

**Approval Criteria**

**1** - BOTH of the following:

- Diagnosis of Hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy
- Documentation that the patient has a pathogenic transthyretin (TTR) mutation (e.g., V30M)

**AND**

**2** - Prescribed by or in consultation with a neurologist

**AND**

**3** - Documentation of ONE of the following:

- Patient has a baseline polyneuropathy disability (PND) score less than or equal to IIIb
- Patient has a baseline familial amyloidotic polyneuropathy (FAP) Stage 1 or 2
- Patient has a baseline neuropathy impairment (NIS) score greater than or equal to 10 and less than or equal to 130

**AND**

**4** - Patient has not had a liver transplant

**AND**

**5** - Presence of clinical signs and symptoms of the disease (e.g., peripheral sensorimotor polyneuropathy, autonomic neuropathy, motor disability, etc.)

**AND**

**6** - Patient is not receiving Tegsedi in combination with ONE of the following:

- Oligonucleotide agents [e.g., Onpattro (patisiran)]
- Tafamidis (e.g., Vyndaqel, Vyndamax)

Product Name: Tegsedi			
Diagnosis	Hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TEGSEDI	INOTERSEN SOD SUBCUTANEOUS PREF SYR 284 MG/1.5ML (BASE EQ)	6270104010E520	Brand

**Approval Criteria**

1 - Patient has previously received treatment with Tegsedi

**AND**

2 - Prescribed by or in consultation with a neurologist

**AND**

3 - Documentation of ONE of the following:

- Patient continues to have a polyneuropathy disability (PND) score less than or equal to IIIb
- Patient continues to have a familial amyloidotic polyneuropathy (FAP) Stage 1 or 2
- Patient continues to have a neuropathy impairment (NIS) score greater than or equal to 10 and less than or equal to 130

**AND**

4 - Documentation that the patient has experienced a positive clinical response to Tegsedi therapy (e.g., improved neurologic impairment, motor function, quality of life, slowing of disease progression, etc.)

**AND**

**5** - Patient is not receiving Tegsedi in combination with ONE of the following:

- Oligonucleotide agents [e.g., Onpattro (patisiran)]
- Tafamidis (e.g., Vyndaqel, Vyndamax)

## 2 . Revision History

Date	Notes
12/17/2020	Added examples of tafamidis products but no change to clinical intent.

Test Strips



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140802
<b>Guideline Name</b>	Test Strips
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	8/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Non-preferred Test Strips			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ACCU-CHEK AVIVA PLUS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ACCU-CHEK GUIDE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ACCU-CHEK SMARTVIEW STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ACCUTREND GLUCOSE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADVANCE INTUITION TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ADVANCE MICRO-DRAW TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ADVOCATE REDI-CODE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ADVOCATE REDI-CODE+ TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ADVOCATE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
AGAMATRIX AMP NO CODE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
AGAMATRIX JAZZ TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
AGAMATRIX KEYNOTE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
AGAMATRIX PRESTO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE II	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE II CHECK STRIP	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE II TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE PLATINUM TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE PRISM MULTI TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE PRO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE 3 TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE 4 TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
BIOSCANNER GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BLOOD GLUCOSE TEST STRIPS PREMIUM	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CAREONE BLOOD GLUCOSE TEST STRIPS/PREMIUM	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CAREONE BLOOD GLUCOSE TEST STRIPS/VALUE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CARESENS N BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CARETOUCH BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHEK AUTO-CODE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHEK AUTO-CODE VOICE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHEK TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHOICE AUTO-CODE PRO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHOICE MICRO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHOICE NO CODING TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHOICE TALK NO CODING TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CONTOUR BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CONTOUR NEXT BLOOD GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
COOL BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CVS ADVANCED GLUCOSE METER TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
D-CARE BLOOD GLUCOSE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

DIATHRIVE BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
DIATRUE PLUS BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
DUO-CARE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY PLUS II BLOOD GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY STEP TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY TALK BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY TOUCH GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY TOUCH HEALTHPRO GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY TRAK BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASYGLUCO	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASYMAX TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASYMAX 15 TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASYPRO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASYPRO PLUS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ELEMENT COMPACT TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ELEMENT TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EMBRACE BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EMBRACE EVO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EMBRACE PRO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EMBRACE TALK BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EQ BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EVOLUTION AUTOCODE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FIFTY50 GLUCOSE TEST STRIP 2.0	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA D15G BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA D20 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA D40/G31 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA GD20 TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA GD50 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA GTEL BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA G20 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA G30/PREMIUM V10 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA TN'G/TN'G VOICE BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA V10 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FORA V12 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA V20 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA V30A BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORACARE GD40	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORACARE PREMIUM V10 TESTSTRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORACARE TEST N GO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORTISCARE BLOOD GLUCOSE TEST STRIP	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FREESTYLE INSULINX BLOOD GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FREESTYLE INSULINX BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FREESTYLE LITE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FREESTYLE PRECISION NEO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FREESTYLE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GENULTIMATE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GE100 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GHT TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCO PERFECT 3 TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCARD EXPRESSION BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCARD SHINE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GLUCOCARD VITAL TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCARD X-SENSOR	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCARD 01 SENSOR PLUS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCARD 01 SENSOR PLUS TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCOM TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCONAVII BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOSE METER TEST STRIPS ADVANCED	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GNP EASY TOUCH GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GOODSENSE PREMIUM BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
HW EMBRACE PRO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
HW EMBRACE TALK BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
IGLUCOSE BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
IN TOUCH BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
INFINITY BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
INFINITY VOICE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
KROGER BLOOD GLUCOSE TESTSTRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
KROGER PREMIUM BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LIBERTY NEXT GENERATION BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
LIBERTY TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MEIJER BLOOD GLUCOSE TESTSTRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MEIJER ESSENTIAL BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MEIJER PREMIUM BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MEIJER TRUETEST BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MEIJER TRUETRACK BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MICRODOT TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MM EASY TOUCH GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MYGLUCOHEALTH BLOOD GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
NEUTEK 2TEK TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
NOVA MAX GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ONE DROP BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
OPTIUMEZ TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PHARMACIST CHOICE AUTOCODE BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PHARMACIST CHOICE NO CODING BLOOD	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GLUCOSE TEST STRIPS			
POCKETCHEM EZ BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PRECISION XTRA BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PREMIUM BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PRO VOICE V8/V9 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PRODIGY NO CODING BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PTS PANELS GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
QUICKTEK TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
QUINTET AC BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
QUINTET BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
REFUAH PLUS BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RELION CONFIRM/MICRO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RELION PREMIER BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RELION PRIME BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RELION ULTIMA BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
REXALL BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RIGHTEST GS100 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

RIGHTEST GS300 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RIGHTEST GS550 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
SMART SENSE PREMIUM BLOODGLUCOSE STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
SMART SENSE VALUE BLOOD GLUCOSE STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
SMARTEST BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
SOLUS V2 AUDIBLE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
SUPREME TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TGT BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TGT BLOOD GLUCOSE TEST STRIPS PREMIUM	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUE FOCUS SELF MONITORING BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUE METRIX BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUE METRIX SELF MONITORING BLOOD GLUCOSE STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUETEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUETRACK BLOOD GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUETRACK TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
UNISTRIP1 GENERIC	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BLULINK GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CVS GLUCOSE METER TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
DIATHRIVE+ BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY TRAK II BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA TN'G ADVANCE PRO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA 6 CONNECT	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GOJJI BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GOJJI BLOOD GLUCOSE TEST STRIPS/GOJJI STERILE LANCETS 30G	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
KROGER HEALTHPRO GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MICRODOT XTRA TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RELION TRUE METRIX BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUE METRIX PRO GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
VERASENS BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
VIVAGUARD INO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY TALK PLUS II BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

FORTISCARE G1 BLOOD GLUCOSE TEST STRIP	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GNP TRUE METRIX SELF MONITORING BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GNP TRUETRACK BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GNP TRUETRACK SMART SYSTEM	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RIGHTTEST GS333 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
BLOOD GLUCOSE TEST STRIPS333	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ON CALL EXPRESS BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ONETOUCH VERIO IN VITRO MEDI-CAL	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PIP BLOOD GLUCOSE TEST STRIP	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 Failure of both of the following confirmed by claims history or submitted medical records:

- OneTouch Ultra Test Strips
- OneTouch Verio Test Strips

**OR**

1.2 History of intolerance or contraindication to both of the following (please specify intolerance or contraindication):

- OneTouch Ultra Test Strips



- OneTouch Verio Test Strips

**OR**

**2** - Patient is on an insulin pump

**Product Name: All Test Strips**

Approval Length | 12 month(s)

Guideline Type | Quantity Limit

Product Name	Generic Name	GPI	Brand/Generic
ACCU-CHEK AVIVA PLUS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ACCU-CHEK GUIDE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ACCU-CHEK SMARTVIEW STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ACCUTREND GLUCOSE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ADVANCE INTUITION TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ADVANCE MICRO-DRAW TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ADVOCATE REDI-CODE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ADVOCATE REDI-CODE+ TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ADVOCATE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
AGAMATRIX AMP NO CODE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
AGAMATRIX JAZZ TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
AGAMATRIX KEYNOTE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
AGAMATRIX PRESTO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ASSURE II	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE II CHECK STRIP	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE II TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE PLATINUM TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE PRISM MULTI TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE PRO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE 3 TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ASSURE 4 TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
BIOSCANNER GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
BLOOD GLUCOSE TEST STRIPS PREMIUM	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CAREONE BLOOD GLUCOSE TEST STRIPS/PREMIUM	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CAREONE BLOOD GLUCOSE TEST STRIPS/VALUE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CARESENS N BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CARETOUCH BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHEK AUTO-CODE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHEK AUTO-CODE VOICE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHEK TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CLEVER CHOICE AUTO-CODE PRO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHOICE MICRO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHOICE NO CODING TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CLEVER CHOICE TALK NO CODING TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CONTOUR BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CONTOUR NEXT BLOOD GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
COOL BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CVS ADVANCED GLUCOSE METER TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
D-CARE BLOOD GLUCOSE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
DIATHRIVE BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
DIATRUE PLUS BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
DUO-CARE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY PLUS II BLOOD GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY STEP TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY TALK BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY TOUCH GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY TOUCH HEALTHPRO GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

EASY TRAK BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASYGLUCO	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASYMAX TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASYMAX 15 TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASYPRO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASYPRO PLUS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ELEMENT COMPACT TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ELEMENT TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EMBRACE BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EMBRACE EVO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EMBRACE PRO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EMBRACE TALK BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EQ BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EVOLUTION AUTOCODE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FIFTY50 GLUCOSE TEST STRIP 2.0	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA D15G BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA D20 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FORA D40/G31 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA GD20 TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA GD50 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA GTEL BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA G20 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA G30/PREMIUM V10 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA TN'G/TN'G VOICE BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA V10 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA V12 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA V20 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA V30A BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORACARE GD40	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORACARE PREMIUM V10 TESTSTRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORACARE TEST N GO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORTISCARE BLOOD GLUCOSE TEST STRIP	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FREESTYLE INSULINX BLOOD GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FREESTYLE INSULINX BLOOD	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GLUCOSE TEST STRIPS			
FREESTYLE LITE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FREESTYLE PRECISION NEO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FREESTYLE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GENULTIMATE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GE100 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GHT TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCO PERFECT 3 TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCARD EXPRESSION BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCARD SHINE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCARD VITAL TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCARD X-SENSOR	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCARD 01 SENSOR PLUS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCARD 01 SENSOR PLUS TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOCOM TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCONAVII BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GLUCOSE METER TEST STRIPS ADVANCED	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GNP EASY TOUCH GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GOODSENSE PREMIUM BLOOD	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GLUCOSE TEST STRIPS			
HW EMBRACE PRO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
HW EMBRACE TALK BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
IGLUCOSE BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
IN TOUCH BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
INFINITY BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
INFINITY VOICE	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
KROGER BLOOD GLUCOSE TESTSTRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
KROGER PREMIUM BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
LIBERTY NEXT GENERATION BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
LIBERTY TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MEIJER BLOOD GLUCOSE TESTSTRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MEIJER ESSENTIAL BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MEIJER PREMIUM BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MEIJER TRUETEST BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MEIJER TRUETRACK	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BLOOD GLUCOSE TEST STRIPS			
MICRODOT TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MM EASY TOUCH GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MYGLUCOHEALTH BLOOD GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
NEUTEK 2TEK TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
NOVA MAX GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ONE DROP BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ONETOUCH VERIO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
OPTIUMEZ TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PHARMACIST CHOICE AUTOCODE BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PHARMACIST CHOICE NO CODING BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
POCKETCHEM EZ BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PRECISION XTRA BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PREMIUM BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PRO VOICE V8/V9 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PRODIGY NO CODING BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PTS PANELS GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
QUICKTEK TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
QUINTET AC BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
QUINTET BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
REFUAH PLUS BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RELION CONFIRM/MICRO TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RELION PREMIER BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RELION PRIME BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RELION ULTIMA BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
REXALL BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RIGHTEST GS100 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RIGHTEST GS300 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RIGHTEST GS550 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
SMART SENSE PREMIUM BLOODGLUCOSE STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
SMART SENSE VALUE BLOOD GLUCOSE STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
SMARTEST BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
SOLUS V2 AUDIBLE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SUPREME TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TGT BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TGT BLOOD GLUCOSE TEST STRIPS PREMIUM	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUE FOCUS SELF MONITORING BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUE METRIX BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUE METRIX SELF MONITORING BLOOD GLUCOSE STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUETEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUETRACK BLOOD GLUCOSE TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUETRACK TEST	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
UNISTRIP1 GENERIC	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
BLULINK GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
CVS GLUCOSE METER TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
DIATHRIVE+ BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY TRAK II BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA TN'G ADVANCE PRO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORA 6 CONNECT	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GOJJI BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GOJJI BLOOD GLUCOSE TEST STRIPS/GOJJI STERILE LANCETS 30G	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
KROGER HEALTHPRO GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
MICRODOT XTRA TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ONETOUCH ULTRA	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RELION TRUE METRIX BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
TRUE METRIX PRO GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
VERASENS BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
VIVAGUARD INO BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
EASY TALK PLUS II BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
FORTISCARE G1 BLOOD GLUCOSE TEST STRIP	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GNP TRUE METRIX SELF MONITORING BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GNP TRUETRACK BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
GNP TRUETRACK SMART SYSTEM	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
RIGHTEST GS333 BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

BLOOD GLUCOSE TEST STRIPS333	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ON CALL EXPRESS BLOOD GLUCOSE TEST STRIPS	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
ONETOUCH VERIO IN VITRO MEDI-CAL	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand
PIP BLOOD GLUCOSE TEST STRIP	GLUCOSE BLOOD TEST STRIP	94100030006100	Brand

**Approval Criteria**

1 - If the patient is insulin dependent or pregnant, the physician must confirm the patient requires a greater quantity because of more frequent blood glucose testing (e.g., patients on intravenous insulin infusions)

**OR**

2 - If the patient is not insulin dependent nor pregnant, ONE the following:

2.1 The patient is experiencing or is prone to hypoglycemia or hyperglycemia and requires additional testing to achieve glycemic control

**OR**

2.2 The patient's physician is adjusting medications and the patient requires additional blood glucose testing during this time

**OR**

2.3 The patient's physician is adjusting MNT (medical nutrition therapy) and the patient requires additional blood glucose testing during this time

**OR**

**2.4** The patient requires additional testing due to fluctuations in blood glucose due to physical activity/exercise

**OR**

**2.5** Other circumstances where prescribing physician confirms that the patient requires a greater quantity because of more frequent blood glucose testing (clinical review required by UnitedHealthcare reviewing pharmacist and/or medical director)

Notes

The quantity limit for insulin-dependent and pregnant patients is 6 test strips/day. The quantity limit for non-insulin dependent and non-pregnant patients is 2 test strips/day.

## 2 . Revision History

Date	Notes
6/27/2023	Added new GPIs to market since last update. No changes to clinical criteria.

Testosterone



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-160634
<b>Guideline Name</b>	Testosterone
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Brand Androgel, generic testosterone gel 1% and 1.62%, Brand Testim, Brand Vogelxo, testosterone enanthate, Androderm, testosterone soln, testosterone cypionate, Tlando, Jatenzo, Kyzatrex, Undecatrex			
Diagnosis	Hypogonadism		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TESTOSTERONE	TESTOSTERONE TD GEL 25 MG/2.5GM (1%)	23100030004025	Generic
ANDROGEL	TESTOSTERONE TD GEL 25 MG/2.5GM (1%)	23100030004025	Brand
TESTIM	TESTOSTERONE TD GEL 50 MG/5GM (1%)	23100030004030	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TESTOSTERONE	TESTOSTERONE TD GEL 50 MG/5GM (1%)	23100030004030	Generic
VOGELXO	TESTOSTERONE TD GEL 50 MG/5GM (1%)	23100030004030	Brand
TESTOSTERONE	TESTOSTERONE TD GEL 20.25 MG/1.25GM (1.62%)	23100030004044	Generic
TESTOSTERONE	TESTOSTERONE TD GEL 40.5 MG/2.5GM (1.62%)	23100030004047	Generic
TESTOSTERONE	TESTOSTERONE TD GEL 20.25 MG/ACT (1.62%)	23100030004050	Generic
TESTOSTERONE PUMP	TESTOSTERONE TD GEL 20.25 MG/ACT (1.62%)	23100030004050	Generic
ANDROGEL PUMP	TESTOSTERONE TD GEL 20.25 MG/ACT (1.62%)	23100030004050	Brand
TESTOSTERONE ENANTHATE	TESTOSTERONE ENANTHATE IM INJ IN OIL 200 MG/ML	23100030202010	Generic
ANDRODERM	TESTOSTERONE TD PATCH 24HR 2 MG/24HR	23100030008503	Brand
ANDRODERM	TESTOSTERONE TD PATCH 24HR 4 MG/24HR	23100030008510	Brand
TESTOSTERONE	TESTOSTERONE TD SOLN 30 MG/ACT	23100030002020	Generic
TESTOSTERONE TOPICAL SOLUTION	TESTOSTERONE TD SOLN 30 MG/ACT	23100030002020	Generic
TESTOSTERONE CYPIONATE	TESTOSTERONE CYPIONATE IM INJ IN OIL 100 MG/ML	23100030102010	Generic
TESTOSTERONE CYPIONATE	TESTOSTERONE CYPIONATE IM INJ IN OIL 200 MG/ML	23100030102015	Generic
TESTOSTERONE CYPIONATE	TESTOSTERONE CYP IM OR SUBCUTANEOUS INJ IN OIL 200 MG/ML	23100030102070	Brand
TESTOSTERONE PUMP	TESTOSTERONE TD GEL 12.5 MG/ACT (1%)	23100030004040	Generic
VOGELXO PUMP	TESTOSTERONE TD GEL 12.5 MG/ACT (1%)	23100030004040	Brand
TLANDO	TESTOSTERONE UNDECANOATE CAP 112.5 MG	23100030800125	Brand
JATENZO	TESTOSTERONE UNDECANOATE CAP 158 MG	23100030800130	Brand
JATENZO	TESTOSTERONE UNDECANOATE CAP 198 MG	23100030800135	Brand
JATENZO	TESTOSTERONE UNDECANOATE CAP 237 MG	23100030800140	Brand
KYZATREX	TESTOSTERONE UNDECANOATE CAP 100 MG	23100030800124	Brand
KYZATREX	TESTOSTERONE UNDECANOATE CAP 150 MG	23100030800128	Brand
KYZATREX	TESTOSTERONE UNDECANOATE CAP 200 MG	23100030800136	Brand
UNDECATREX	TESTOSTERONE UNDECANOATE CAP 200 MG	23100030800136	Generic

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting **ONE** of the following:

**1.1** TWO pre-treatment serum total testosterone levels less than 300 ng/dL (nanograms/deciliter) [less than 10.4 nmol/L (nanomoles/liter)] or less than the reference range for the lab, taken at separate times (document lab value and date for both levels)

**OR**

**1.2** BOTH of the following:

**1.2.1** Patient has a condition that may cause altered sex-hormone binding globulin (SHBG) [e.g., thyroid disorder, HIV (human immunodeficiency virus) disease, liver disorder, diabetes, obesity]

**AND**

**1.2.2** ONE pre-treatment calculated free or bioavailable testosterone level less than 50 pg/mL (picograms/milliliter) (less than 5 ng/dL or less than 0.17 nmol/L) or less than the reference range for the lab (This may require treatment to be temporarily held. Document lab value and date)

**OR**

**1.3** Patient has a history of **ONE** of the following:

- Bilateral orchiectomy
- Panhypopituitarism
- A genetic disorder known to cause hypogonadism (e.g., congenital anorchia, Klinefelter's syndrome)

**AND**

**2** - Patient is **NOT** taking any of the following growth hormones, unless diagnosed with panhypopituitarism:



- Genotropin
- Humatrope
- Norditropin FlexPro
- Nutropin AQ
- Omnitrope
- Saizen

**AND**

**3** - Patient is NOT taking with an aromatase inhibitor [e.g., Arimidex (anastrozole), Femara (letrozole), or Aromasin (exemestane)]

**AND**

**4** - Patient was male at birth

**AND**

**5** - Diagnosis of hypogonadism

**AND**

**6** - ONE of the following:

- Significant reduction in weight (less than 90 percent ideal body weight) [e.g., AIDS (acquired immunodeficiency syndrome) wasting syndrome]
- Osteopenia
- Osteoporosis
- Decreased bone density
- Decreased libido
- Organic cause of testosterone deficiency (e.g., injury, tumor, infection, or genetic defects)

**AND**

**7** - If the request is for Jatenzo, Kyzatrex, Tlando, or Undecatrex, patient must have tried and failed ONE preferred\* testosterone gel product (verified via paid pharmacy claims or submission of medical records)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Brand Androgel, generic testosterone gel 1% and 1.62%, Brand Testim, Brand Vogelxo, testosterone enanthate, Androderm, testosterone soln, testosterone cypionate, Tlando, Jatenzo, Kyzatrex, Undecatrex			
Diagnosis	Gender Dysphoria		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TESTOSTERONE	TESTOSTERONE TD GEL 25 MG/2.5GM (1%)	23100030004025	Generic
ANDROGEL	TESTOSTERONE TD GEL 25 MG/2.5GM (1%)	23100030004025	Brand
TESTIM	TESTOSTERONE TD GEL 50 MG/5GM (1%)	23100030004030	Brand
TESTOSTERONE	TESTOSTERONE TD GEL 50 MG/5GM (1%)	23100030004030	Generic
VOGELXO	TESTOSTERONE TD GEL 50 MG/5GM (1%)	23100030004030	Brand
TESTOSTERONE	TESTOSTERONE TD GEL 20.25 MG/1.25GM (1.62%)	23100030004044	Generic
TESTOSTERONE	TESTOSTERONE TD GEL 40.5 MG/2.5GM (1.62%)	23100030004047	Generic
TESTOSTERONE	TESTOSTERONE TD GEL 20.25 MG/ACT (1.62%)	23100030004050	Generic
TESTOSTERONE PUMP	TESTOSTERONE TD GEL 20.25 MG/ACT (1.62%)	23100030004050	Generic
ANDROGEL PUMP	TESTOSTERONE TD GEL 20.25 MG/ACT (1.62%)	23100030004050	Brand
TESTOSTERONE ENANTHATE	TESTOSTERONE ENANTHATE IM INJ IN OIL 200 MG/ML	23100030202010	Generic
ANDRODERM	TESTOSTERONE TD PATCH 24HR 2 MG/24HR	23100030008503	Brand
ANDRODERM	TESTOSTERONE TD PATCH 24HR 4 MG/24HR	23100030008510	Brand
TESTOSTERONE	TESTOSTERONE TD SOLN 30 MG/ACT	23100030002020	Generic
TESTOSTERONE TOPICAL SOLUTION	TESTOSTERONE TD SOLN 30 MG/ACT	23100030002020	Generic
TESTOSTERONE CYPIONATE	TESTOSTERONE CYPIONATE IM INJ IN OIL 100 MG/ML	23100030102010	Generic
TESTOSTERONE CYPIONATE	TESTOSTERONE CYPIONATE IM INJ IN OIL 200 MG/ML	23100030102015	Generic

TESTOSTERONE CYPIONATE	TESTOSTERONE CYP IM OR SUBCUTANEOUS INJ IN OIL 200 MG/ML	23100030102070	Brand
TESTOSTERONE PUMP	TESTOSTERONE TD GEL 12.5 MG/ACT (1%)	23100030004040	Generic
VOGELXO PUMP	TESTOSTERONE TD GEL 12.5 MG/ACT (1%)	23100030004040	Brand
TLANDO	TESTOSTERONE UNDECANOATE CAP 112.5 MG	23100030800125	Brand
JATENZO	TESTOSTERONE UNDECANOATE CAP 158 MG	23100030800130	Brand
JATENZO	TESTOSTERONE UNDECANOATE CAP 198 MG	23100030800135	Brand
JATENZO	TESTOSTERONE UNDECANOATE CAP 237 MG	23100030800140	Brand
KYZATREX	TESTOSTERONE UNDECANOATE CAP 100 MG	23100030800124	Brand
KYZATREX	TESTOSTERONE UNDECANOATE CAP 150 MG	23100030800128	Brand
KYZATREX	TESTOSTERONE UNDECANOATE CAP 200 MG	23100030800136	Brand
UNDECATREX	TESTOSTERONE UNDECANOATE CAP 200 MG	23100030800136	Generic

**Approval Criteria**

**1** - Patient is using hormones to change physical characteristics

**AND**

**2** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of gender dysphoria, as defined by the current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM)

**AND**

**3** - Patient is NOT taking any of the following growth hormones, unless diagnosed with panhypopituitarism:

- Genotropin
- Humatrope
- Norditropin FlexPro
- Nutropin AQ
- Omnitrope
- Saizen

**AND**

**4** - Patient is NOT taking with an aromatase inhibitor [e.g., Arimidex (anastrozole), Femara (letrozole), Aromasin (exemestane)]

**AND**

**5** - If the request is for Jatenzo, Kyzatrex, Tlando, or Undecatrex, patient must have tried and failed ONE preferred\* testosterone gel product (verified via paid pharmacy claims or submission of medical records)

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Brand Androgel, generic testosterone gel 1% and 1.62%, Brand Testim, Brand Vogelxo, testosterone enanthate, Androderm, testosterone soln, testosterone cypionate, Tlando, Jatenzo, Kyzatrex, Undecatrex

Diagnosis	Hypogonadism, Gender Dysphoria
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TESTOSTERONE	TESTOSTERONE TD GEL 25 MG/2.5GM (1%)	23100030004025	Generic
ANDROGEL	TESTOSTERONE TD GEL 25 MG/2.5GM (1%)	23100030004025	Brand
TESTIM	TESTOSTERONE TD GEL 50 MG/5GM (1%)	23100030004030	Brand
TESTOSTERONE	TESTOSTERONE TD GEL 50 MG/5GM (1%)	23100030004030	Generic
VOGELXO	TESTOSTERONE TD GEL 50 MG/5GM (1%)	23100030004030	Brand
TESTOSTERONE	TESTOSTERONE TD GEL 20.25 MG/1.25GM (1.62%)	23100030004044	Generic
TESTOSTERONE	TESTOSTERONE TD GEL 40.5 MG/2.5GM (1.62%)	23100030004047	Generic
TESTOSTERONE	TESTOSTERONE TD GEL 20.25 MG/ACT (1.62%)	23100030004050	Generic
TESTOSTERONE PUMP	TESTOSTERONE TD GEL 20.25 MG/ACT (1.62%)	23100030004050	Generic
ANDROGEL PUMP	TESTOSTERONE TD GEL 20.25 MG/ACT (1.62%)	23100030004050	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TESTOSTERONE ENANTHATE	TESTOSTERONE ENANTHATE IM INJ IN OIL 200 MG/ML	23100030202010	Generic
ANDRODERM	TESTOSTERONE TD PATCH 24HR 2 MG/24HR	23100030008503	Brand
ANDRODERM	TESTOSTERONE TD PATCH 24HR 4 MG/24HR	23100030008510	Brand
TESTOSTERONE	TESTOSTERONE TD SOLN 30 MG/ACT	23100030002020	Generic
TESTOSTERONE TOPICAL SOLUTION	TESTOSTERONE TD SOLN 30 MG/ACT	23100030002020	Generic
TESTOSTERONE CYPIONATE	TESTOSTERONE CYPIONATE IM INJ IN OIL 100 MG/ML	23100030102010	Generic
TESTOSTERONE CYPIONATE	TESTOSTERONE CYPIONATE IM INJ IN OIL 200 MG/ML	23100030102015	Generic
TESTOSTERONE CYPIONATE	TESTOSTERONE CYP IM OR SUBCUTANEOUS INJ IN OIL 200 MG/ML	23100030102070	Brand
TESTOSTERONE PUMP	TESTOSTERONE TD GEL 12.5 MG/ACT (1%)	23100030004040	Generic
VOGELXO PUMP	TESTOSTERONE TD GEL 12.5 MG/ACT (1%)	23100030004040	Brand
TLANDO	TESTOSTERONE UNDECANOATE CAP 112.5 MG	23100030800125	Brand
JATENZO	TESTOSTERONE UNDECANOATE CAP 158 MG	23100030800130	Brand
JATENZO	TESTOSTERONE UNDECANOATE CAP 198 MG	23100030800135	Brand
JATENZO	TESTOSTERONE UNDECANOATE CAP 237 MG	23100030800140	Brand
KYZATREX	TESTOSTERONE UNDECANOATE CAP 100 MG	23100030800124	Brand
KYZATREX	TESTOSTERONE UNDECANOATE CAP 150 MG	23100030800128	Brand
KYZATREX	TESTOSTERONE UNDECANOATE CAP 200 MG	23100030800136	Brand
UNDECATREX	TESTOSTERONE UNDECANOATE CAP 200 MG	23100030800136	Generic

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting ONE of the following:

**1.1** Follow-up total serum testosterone level drawn within the past 12 months is within or below the normal male limits of the reporting lab (document value and date)

**OR**

**1.2** Follow-up total serum testosterone level drawn within the past 12 months is outside of

upper male limits of normal for the reporting lab and the dose is adjusted (document value and date)

**OR**

**1.3 BOTH of the following:**

**1.3.1** Patient has a condition that may cause altered sex-hormone binding globulin (SHBG) [e.g., thyroid disorder, HIV (human immunodeficiency virus) disease, liver disorder, diabetes, obesity]

**AND**

**1.3.2 ONE of the following:**

**1.3.2.1** Follow-up calculated free or bioavailable testosterone level drawn within the past 12 months is within or below the normal male limits of the reporting lab (document lab value and date)

**OR**

**1.3.2.2** Follow-up calculated free or bioavailable testosterone level drawn within the past 12 months is outside of upper male limits of normal for the reporting lab and the dose is adjusted (document value and date)

**AND**

**2 - Patient is NOT taking any of the following growth hormones, unless diagnosed with panhypopituitarism:**

- Genotropin
- Humatrope
- Norditropin FlexPro
- Nutropin AQ
- Omnitrope
- Saizen

**AND**

**3** - Patient is NOT taking with an aromatase inhibitor [e.g., Arimidex (anastrozole), Femara (letrozole), Aromasin (exemestane)]

**AND**

**4** - If the request is for Jatenzo, Kyzatrex, Tlando, or Undecatrex, patient must have tried and failed ONE preferred\* testosterone gel product (verified via paid pharmacy claims or submission of medical records)

Notes

\*PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP>

## 2 . Revision History

Date	Notes
11/18/2024	Removed obsolete Brand Androgel GPIs. Added Undecatrex as a target. Updated product name lists and GPI tables accordingly. Updated criteria throughout guideline.

Thalomid



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140927
<b>Guideline Name</b>	Thalomid
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Thalomid			
Diagnosis	Multiple Myeloma		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand



**Approval Criteria**

1 - Diagnosis of multiple myeloma

**Product Name: Thalomid**

Diagnosis	Multiple Myeloma
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Thalomid therapy

**Product Name: Thalomid**

Diagnosis	Erythema Nodosum Leprosum (ENL)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand

THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of moderate to severe erythema nodosum leprosum (ENL)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - ONE of the following:</p> <p>    <b>2.1</b> Used for acute treatment</p> <p style="text-align: center;"><b>OR</b></p> <p>    <b>2.2</b> Used as maintenance therapy for prevention &amp; suppression of cutaneous manifestations of ENL recurrence</p>			

Product Name: Thalomid			
Diagnosis	Erythema Nodosum Leprosum (ENL)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to Thalomid therapy</p>			

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name: Thalomid			
Diagnosis	Aphthous Stomatitis or Ulcer		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of severe, recurrent aphthous stomatitis or ulcer			

Product Name: Thalomid			
Diagnosis	Aphthous Stomatitis or Ulcer		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Thalomid therapy			

Product Name: Thalomid			
Diagnosis	Pyoderma Gangrenosum		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of pyoderma gangrenosum</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Used as third line treatment</p>			

Product Name: Thalomid			
Diagnosis	Pyoderma Gangrenosum		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Thalomid therapy

**Product Name: Thalomid**

Diagnosis	Cutaneous Manifestations Systemic Lupus Erythematosus (SLE)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand

**Approval Criteria**

1 - Diagnosis of cutaneous manifestations of systemic lupus erythematosus (SLE)

**Product Name: Thalomid**

Diagnosis	Cutaneous Manifestations Systemic Lupus Erythematosus (SLE)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand

THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Thalomid therapy			

Product Name: Thalomid			
Diagnosis	B-Cell Lymphomas		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of Castleman's Disease (CD)			
<b>AND</b>			
2 - NOT used as first line therapy			

Product Name: Thalomid	
Diagnosis	B-Cell Lymphomas
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Thalomid therapy

Product Name: Thalomid	
Diagnosis	Myelofibrosis-Associated Anemia
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

  

Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand

**Approval Criteria**

1 - Diagnosis of primary myelofibrosis

**AND**

2 - One of the following:

2.1 Both of the following:

**2.1.1** Serum erythropoietin levels less than 500 mU/mL

**AND**

**2.1.2** History of failure, contraindication, or intolerance to erythropoietins [e.g., Procrit (epoetin alfa)]

**OR**

**2.2** Serum erythropoietin levels greater than or equal to 500 mU/mL

Product Name: Thalomid			
Diagnosis	Myelofibrosis-Associated Anemia		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand
<b>Approval Criteria</b>			
1 - Documentation that member has evidence of symptom improvement or reduction in spleen-liver volume while on Thalomid			

Product Name: Thalomid	
Diagnosis	Acquired Immunodeficiency Syndrome (AIDS)- Related Kaposi Sarcoma
Approval Length	12 month(s)



Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of Acquired Immunodeficiency Syndrome (AIDS)- Related Kaposi Sarcoma</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient is currently being treated with antiretroviral therapy (ART)</p> <p style="text-align: center;"><b>AND</b></p> <p>3 - Not used as first line therapy</p>			

Product Name: Thalomid			
Diagnosis	AIDS- Related Kaposi Sarcoma		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand

**Approval Criteria**

1 - Patient does not show evidence of progressive disease while on Thalomid therapy

**Product Name: Thalomid**

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand
THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand

**Approval Criteria**

1 - Thalomid will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.

**Product Name: Thalomid**

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
THALOMID	THALIDOMIDE CAP 50 MG	99392070000120	Brand
THALOMID	THALIDOMIDE CAP 100 MG	99392070000130	Brand

THALOMID	THALIDOMIDE CAP 150 MG	99392070000135	Brand
THALOMID	THALIDOMIDE CAP 200 MG	99392070000140	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Thalomid therapy

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Therapeutic Duplication (Subtype A)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-162198
<b>Guideline Name</b>	Therapeutic Duplication (Subtype A)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	1/1/2025
-----------------	----------

## 1 . Criteria

Product Name: Generic arformoterol nebulizer solution, Brand Brovana nebulizer, generic formoterol nebulizer solution, Brand Perforomist nebulizer, Striverdi Respimat, Serevent Diskus, Incruse Ellipta, Brand Spiriva Handihaler, generic tiotropium, Spiriva Respimat, Tudorza Pressair, generic ipratropium inhalation solution, Atrovent HFA, Anoro Ellipta, Stiolto Respimat, Bevespi Aerosphere, Duaklir Pressair, Breztri Aerosphere, Glyxambi, Steglujan, Qtern, Trijardy XR, Brand Pulmicort suspension, generic budesonide suspension, Victoza, Adlyxin, Trulicity, Bydureon BCise, Byetta, Ozempic, Rybelsus, Januvia, Janumet, Janumet XR, Brand Onglyza, generic saxagliptin, Brand Kombiglyze XR, generic saxagliptin/metformin ER, Tradjenta, Jentadueto, Jentadueto XR, Nesina, alogliptin, Kazano, alogliptin/metformin, Oseni, alogliptin/pioglitazone, Mounjaro, Xultophy, Soliqua, Invokana, brand Farxiga, generic dapagliflozin, Jardiance, Invokamet, Invokamet XR, brand Xigduo XR, generic dapagliflozin/metformin ER, Synjardy, Synjardy XR, Steglatro, Segluromet, Zituvio, Brand Flovent HFA, Fluticasone propionate HFA, Flovent Diskus, Brand Fluticasone propionate Diskus, Brand Pulmicort Flexhaler, Airsupra, Alvesco, ArmonAir Digihaler, Asmanex Twisthaler, Asmanex HFA, Arnuity Ellipta, Qvar RediHaler, Lonhala Magnair, Trelegy Ellipta, Brand Advair Diskus, generic fluticasone propionate/salmeterol diskus (generic Advair Diskus), generic Wixela Inhub (generic Advair Diskus), AirDuo Resplick,

fluticasone/salmeterol (authorized generic of AirDuo), Brand Advair HFA, Brand Fluticasone/salmeterol HFA, Brand Symbicort, generic budesonide/formoterol, Breyna, AirDuo Digihaler, Dulera, Breo Ellipta, Brand fluticasone/vilanterol Ellipta, Basaglar Tempo pen, Basaglar Kwikpen, Insulin Glargine Solostar, Lantus Solostar, Toujeo Solostar, Toujeo Max Solostar, Semglee Pen Injector, Insulin Glargine-YFGN pen, Lantus vial, Insulin Glargine vial, Semglee vial, Insulin Glargine-YFGN vial, Levemir vial, Levemir Flextouch, Levemir Flexpen, Tresiba vial, Insulin Degludec vial, Tresiba Flextouch, Insulin Degludec Flextouch, Rezvoglar, Baclofen tabs, generic baclofen suspension, Brand Fleqsuvy, Brand Ozobax DS, brand Ozobax, Brand Baclofen solution, brand Lioresal intrathecal, generic baclofen intrathecal, brand Gablofen intrathecal, baclofen intrathecal solution, Lyvispah, generic carisoprodol tab, brand Soma, brand Vanadom tab, generic chlorzoxazone, brand Lorzone, generic cyclobenzaprine, brand Fexmid, generic cyclobenzaprine ER, brand Amrix, metaxalone, methocarbamol, orphenadrine CR/ER, generic tizanidine caps/tabs, brand Zanaflex caps/tabs, brand Dantrium, generic dantrolene, brand Norgesic, generic orphenadrine/aspirin/caffeine, norgesic forte, orphengesic forte, Brand Neurontin caps/tabs/soln, generic gabapentin caps/tabs/soln, gabapentin tinytabs, brand Lyrica caps/soln, generic pregabalin caps/soln, brand Gralise, brand Lyrica CR, generic pregabalin ER, Horizant, Zorvolex, brand Zipsor, generic diclofenac caps, brand Lofena, generic diclofenac tabs, diclofenac DR/ER, brand Cambia, generic diclofenac packet (migraine), etodolac cap, brand Lodine, generic etodolac tab, etodolac ER, brand Nalfon caps/tabs, generic fenoprofen caps/tabs, flurbiprofen, ibuprofen caps/tabs/chewable (includes All Manufactures), Brand Advil, ibuprofen suspension (40 mg/ml & 100 mg/5ml), indomethacin caps, indomethacin ER/SR caps, indocin susp, indocin suppository, indomethacin suppository, ketoprofen cap, ketoprofen ER cap, ketorolac tabs, meclizolone cap, mefenamic acid, meloxicam cap/tab, brand Relafen DS, generic nabumetone, generic naproxen tab/susp/caps (includes All Manufactures), brand naprosyn tab/susp, brand Aleve, brand Anaprox DS, brand EC-Naprosyn, generic naproxen DR, generic EC-naproxen, brand Naprelan, generic naproxen CR/ER, Brand Daypro, generic oxaprozin, brand Feldene, generic piroxicam, sulindac, tolmetin, brand Celebrex, generic celecoxib, Elyxyb, brand Arthrotec, generic diclofenac sodium/misoprostol, brand Duexis, generic ibuprofen/famotidine, brand Vimovo, generic naproxen/esomeprazole, brand Advil PM, generic ibuprofen/diphenhydramine, brand Aleve PM, generic naproxen/diphenhydramine, hydrocodone/ibuprofen, brand Treximet, generic sumatriptan/naproxen, Motrin Dual Action/Tylenol, Advil Dual Action/acetaminophen, acetaminophen/ibuprofen, Naproxen/capsaicin cream (Naprotin), Inpefa, Saxenda, Wegovy, Brand Brenzavvy, Brand Bexagliflozin, Zepbound, Coxanto, Zituvimet, Sitagliptin/metformin, Brand Tanlor, Dolobid, generic diflunisal, Zituvimet XR, Tresni

Diagnosis	DUR: Therapeutic Duplication
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ARFORMOTEROL TARTRATE	ARFORMOTEROL TARTRATE SOLN NEBU 15 MCG/2ML (BASE EQUIV)	44201012102520	Generic
BROVANA	ARFORMOTEROL TARTRATE SOLN NEBU 15 MCG/2ML (BASE EQUIV)	44201012102520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FORMOTEROL FUMARATE	FORMOTEROL FUMARATE SOLN NEBU 20 MCG/2ML	44201027102520	Generic
PERFOROMIST	FORMOTEROL FUMARATE SOLN NEBU 20 MCG/2ML	44201027102520	Brand
STRIVERDI RESPIMAT	OLODATEROL HCL INHAL AEROSOL SOLN 2.5 MCG/ACT (BASE EQUIV)	44201052203410	Brand
SPIRIVA HANDIHALER	TIOTROPIUM BROMIDE MONOHYDRATE INHAL CAP 18 MCG (BASE EQUIV)	44100080100120	Brand
SPIRIVA RESPIMAT	TIOTROPIUM BROMIDE MONOHYDRATE INHAL AEROSOL 1.25 MCG/ACT	44100080103410	Brand
SPIRIVA RESPIMAT	TIOTROPIUM BROMIDE MONOHYDRATE INHAL AEROSOL 2.5 MCG/ACT	44100080103420	Brand
TUDORZA PRESSAIR	ACLIDINIUM BROMIDE AEROSOL POWD BREATH ACTIVATED 400 MCG/ACT	44100007108020	Brand
IPRATROPIUM BROMIDE	IPRATROPIUM BROMIDE INHAL SOLN 0.02%	44100030102020	Generic
ATROVENT HFA	IPRATROPIUM BROMIDE HFA INHAL AEROSOL 17 MCG/ACT	44100030123420	Brand
STIOLTO RESPIMAT	TIOTROPIUM BR-OLODATEROL INHAL AERO SOLN 2.5-2.5 MCG/ACT	44209902923420	Brand
BEVESPI AEROSPHERE	GLYCOPYRROLATE-FORMOTEROL FUMARATE AEROSOL 9-4.8 MCG/ACT	44209902543220	Brand
DUAKLIR PRESSAIR	ACLIDINIUM BR-FORMOTEROL FUM AERO POW BR ACT 400-12 MCG/ACT	44209902268030	Brand
GLYXAMBI	EMPAGLIFLOZIN-LINAGLIPTIN TAB 10-5 MG	27996502300320	Brand
GLYXAMBI	EMPAGLIFLOZIN-LINAGLIPTIN TAB 25-5 MG	27996502300330	Brand
STEGLUJAN	ERTUGLIFLOZIN-SITAGLIPTIN TAB 5-100 MG	27996502350320	Brand
STEGLUJAN	ERTUGLIFLOZIN-SITAGLIPTIN TAB 15-100 MG	27996502350330	Brand
QTERN	DAPAGLIFLOZIN-SAXAGLIPTIN TAB 5-5 MG	27996502200320	Brand
QTERN	DAPAGLIFLOZIN-SAXAGLIPTIN TAB 10-5 MG	27996502200330	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TRIJARDY XR	EMPAGLIFLOZIN-LINAGLIPTIN-METFORMIN TAB ER 24HR 5-2.5-1000MG	27996703407510	Brand
TRIJARDY XR	EMPAGLIFLOZIN-LINAGLIPTIN-METFORMIN TAB ER 24HR 10-5-1000 MG	27996703407520	Brand
TRIJARDY XR	EMPAGLIFLOZIN-LINAGLIP-METFORMIN TAB ER 24HR 12.5-2.5-1000MG	27996703407530	Brand
TRIJARDY XR	EMPAGLIFLOZIN-LINAGLIPTIN-METFORMIN TAB ER 24HR 25-5-1000 MG	27996703407540	Brand
BREZTRI AEROSPHERE	BUDESONIDE-GLYCOPYRROLATE-FORMOTEROL AERS 160-9-4.8 MCG/ACT	44209903303220	Brand
PULMICORT	BUDESONIDE INHALATION SUSP 0.25 MG/2ML	44400015001830	Brand
BUDESONIDE	BUDESONIDE INHALATION SUSP 0.25 MG/2ML	44400015001830	Generic
PULMICORT	BUDESONIDE INHALATION SUSP 0.5 MG/2ML	44400015001840	Brand
BUDESONIDE	BUDESONIDE INHALATION SUSP 0.5 MG/2ML	44400015001840	Generic
PULMICORT	BUDESONIDE INHALATION SUSP 1 MG/2ML	44400015001850	Brand
BUDESONIDE	BUDESONIDE INHALATION SUSP 1 MG/2ML	44400015001850	Generic
ADLYXIN	LIXISENATIDE SOLN PEN-INJECTOR 20 MCG/0.2ML (100 MCG/ML)	2717005600D230	Brand
VICTOZA	LIRAGLUTIDE SOLN PEN-INJECTOR 18 MG/3ML (6 MG/ML)	2717005000D220	Brand
TRULICITY	DULAGLUTIDE SOLN PEN-INJECTOR 0.75 MG/0.5ML	2717001500D520	Brand
TRULICITY	DULAGLUTIDE SOLN PEN-INJECTOR 1.5 MG/0.5ML	2717001500D530	Brand
TRULICITY	DULAGLUTIDE SOLN PEN-INJECTOR 3 MG/0.5ML	2717001500D540	Brand
TRULICITY	DULAGLUTIDE SOLN PEN-INJECTOR 4.5 MG/0.5ML	2717001500D550	Brand
BYDUREON BCISE	EXENATIDE EXTENDED RELEASE SUSP AUTO-INJECTOR 2 MG/0.85ML	2717002000D420	Brand
BYETTA	EXENATIDE SOLN PEN-INJECTOR 5 MCG/0.02ML	2717002000D220	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

BYETTA	EXENATIDE SOLN PEN-INJECTOR 10 MCG/0.04ML	2717002000D240	Brand
OZEMPIC	SEMAGLUTIDE SOLN PEN-INJ 0.25 OR 0.5 MG/DOSE (2 MG/1.5ML)	2717007000D210	Brand
OZEMPIC	SEMAGLUTIDE SOLN PEN-INJ 0.25 OR 0.5 MG/DOSE (2 MG/3ML)	2717007000D221	Brand
OZEMPIC	SEMAGLUTIDE SOLN PEN-INJ 1 MG/DOSE (4 MG/3ML)	2717007000D222	Brand
OZEMPIC	SEMAGLUTIDE SOLN PEN-INJ 2 MG/DOSE (8 MG/3ML)	2717007000D225	Brand
RYBELSUS	SEMAGLUTIDE TAB 3 MG	27170070000310	Brand
RYBELSUS	SEMAGLUTIDE TAB 7 MG	27170070000320	Brand
RYBELSUS	SEMAGLUTIDE TAB 14 MG	27170070000330	Brand
JANUVIA	SITAGLIPTIN PHOSPHATE TAB 25 MG (BASE EQUIV)	27550070100320	Brand
JANUVIA	SITAGLIPTIN PHOSPHATE TAB 50 MG (BASE EQUIV)	27550070100330	Brand
JANUVIA	SITAGLIPTIN PHOSPHATE TAB 100 MG (BASE EQUIV)	27550070100340	Brand
JANUMET	SITAGLIPTIN-METFORMIN HCL TAB 50-500 MG	27992502700320	Brand
JANUMET	SITAGLIPTIN-METFORMIN HCL TAB 50-1000 MG	27992502700340	Brand
JANUMET XR	SITAGLIPTIN-METFORMIN HCL TAB ER 24HR 50-500 MG	27992502707520	Brand
JANUMET XR	SITAGLIPTIN-METFORMIN HCL TAB ER 24HR 50-1000 MG	27992502707530	Brand
JANUMET XR	SITAGLIPTIN-METFORMIN HCL TAB ER 24HR 100-1000 MG	27992502707540	Brand
ONGLYZA	SAXAGLIPTIN HCL TAB 2.5 MG (BASE EQUIV)	27550065100320	Brand
ONGLYZA	SAXAGLIPTIN HCL TAB 5 MG (BASE EQUIV)	27550065100330	Brand
KOMBIGLYZE XR	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 2.5-1000 MG	27992502607520	Brand
KOMBIGLYZE XR	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 5-500 MG	27992502607530	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

KOMBIGLYZE XR	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 5-1000 MG	27992502607540	Brand
TRADJENTA	LINAGLIPTIN TAB 5 MG	27550050000320	Brand
JENTADUETO	LINAGLIPTIN-METFORMIN HCL TAB 2.5-500 MG	27992502400320	Brand
JENTADUETO	LINAGLIPTIN-METFORMIN HCL TAB 2.5-850 MG	27992502400330	Brand
JENTADUETO	LINAGLIPTIN-METFORMIN HCL TAB 2.5-1000 MG	27992502400340	Brand
JENTADUETO XR	LINAGLIPTIN-METFORMIN HCL TAB ER 24HR 2.5-1000 MG	27992502407520	Brand
JENTADUETO XR	LINAGLIPTIN-METFORMIN HCL TAB ER 24HR 5-1000 MG	27992502407530	Brand
ALOGLIPTIN	ALOGLIPTIN BENZOATE TAB 6.25 MG (BASE EQUIV)	27550010100310	Generic
NESINA	ALOGLIPTIN BENZOATE TAB 6.25 MG (BASE EQUIV)	27550010100310	Generic
ALOGLIPTIN	ALOGLIPTIN BENZOATE TAB 12.5 MG (BASE EQUIV)	27550010100320	Generic
NESINA	ALOGLIPTIN BENZOATE TAB 12.5 MG (BASE EQUIV)	27550010100320	Generic
ALOGLIPTIN	ALOGLIPTIN BENZOATE TAB 25 MG (BASE EQUIV)	27550010100330	Generic
NESINA	ALOGLIPTIN BENZOATE TAB 25 MG (BASE EQUIV)	27550010100330	Generic
ALOGLIPTIN/METFORMIN HCL	ALOGLIPTIN-METFORMIN HCL TAB 12.5-500 MG	27992502100320	Generic
KAZANO	ALOGLIPTIN-METFORMIN HCL TAB 12.5-500 MG	27992502100320	Generic
ALOGLIPTIN/METFORMIN HYDROCHLORIDE	ALOGLIPTIN-METFORMIN HCL TAB 12.5-1000 MG	27992502100330	Generic
KAZANO	ALOGLIPTIN-METFORMIN HCL TAB 12.5-1000 MG	27992502100330	Generic
OSENI	ALOGLIPTIN-PIOGLITAZONE TAB 12.5-15 MG	27994002100320	Brand
ALOGLIPTIN/PIOGLITAZONE	ALOGLIPTIN-PIOGLITAZONE TAB 12.5-30 MG	27994002100325	Generic
OSENI	ALOGLIPTIN-PIOGLITAZONE TAB 12.5-30 MG	27994002100325	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ALOGLIPTIN/PIOGLITAZONE	ALOGLIPTIN-PIOGLITAZONE TAB 12.5-45 MG	27994002100330	Generic
OSENI	ALOGLIPTIN-PIOGLITAZONE TAB 12.5-45 MG	27994002100330	Generic
ALOGLIPTIN/PIOGLITAZONE	ALOGLIPTIN-PIOGLITAZONE TAB 25-15 MG	27994002100340	Generic
OSENI	ALOGLIPTIN-PIOGLITAZONE TAB 25-15 MG	27994002100340	Generic
ALOGLIPTIN/PIOGLITAZONE	ALOGLIPTIN-PIOGLITAZONE TAB 25-30 MG	27994002100345	Generic
OSENI	ALOGLIPTIN-PIOGLITAZONE TAB 25-30 MG	27994002100345	Generic
ALOGLIPTIN/PIOGLITAZONE	ALOGLIPTIN-PIOGLITAZONE TAB 25-45 MG	27994002100350	Generic
OSENI	ALOGLIPTIN-PIOGLITAZONE TAB 25-45 MG	27994002100350	Generic
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 2.5 MG/0.5ML	2717308000D510	Brand
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 5 MG/0.5ML	2717308000D515	Brand
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 7.5 MG/0.5ML	2717308000D520	Brand
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 10 MG/0.5ML	2717308000D525	Brand
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 12.5 MG/0.5ML	2717308000D530	Brand
MOUNJARO	TIRZEPATIDE SOLN PEN-INJECTOR 15 MG/0.5ML	2717308000D535	Brand
XULTOPHY 100/3.6	INSULIN DEGLUDEC-LIRAGLUTIDE SOL PEN-INJ 100-3.6 UNIT-MG/ML	2799100225D220	Brand
SOLIQUA 100/33	INSULIN GLARGINE-LIXISENATIDE SOL PEN-INJ 100-33 UNIT-MCG/ML	2799100235D220	Brand
INVOKANA	CANAGLIFLOZIN TAB 100 MG	27700020000320	Brand
INVOKANA	CANAGLIFLOZIN TAB 300 MG	27700020000330	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FARXIGA	DAPAGLIFLOZIN PROPANEDIOL TAB 5 MG (BASE EQUIVALENT)	27700040200310	Brand
FARXIGA	DAPAGLIFLOZIN PROPANEDIOL TAB 10 MG (BASE EQUIVALENT)	27700040200320	Brand
JARDIANCE	EMPAGLIFLOZIN TAB 10 MG	27700050000310	Brand
JARDIANCE	EMPAGLIFLOZIN TAB 25 MG	27700050000320	Brand
INVOKAMET	CANAGLIFLOZIN- METFORMIN HCL TAB 50- 500 MG	27996002200320	Brand
INVOKAMET	CANAGLIFLOZIN- METFORMIN HCL TAB 50- 1000 MG	27996002200330	Brand
INVOKAMET	CANAGLIFLOZIN- METFORMIN HCL TAB 150- 500 MG	27996002200340	Brand
INVOKAMET	CANAGLIFLOZIN- METFORMIN HCL TAB 150- 1000 MG	27996002200350	Brand
INVOKAMET XR	CANAGLIFLOZIN- METFORMIN HCL TAB ER 24HR 50-500 MG	27996002207520	Brand
INVOKAMET XR	CANAGLIFLOZIN- METFORMIN HCL TAB ER 24HR 50-1000 MG	27996002207530	Brand
INVOKAMET XR	CANAGLIFLOZIN- METFORMIN HCL TAB ER 24HR 150-500 MG	27996002207540	Brand
INVOKAMET XR	CANAGLIFLOZIN- METFORMIN HCL TAB ER 24HR 150-1000 MG	27996002207550	Brand
SYNJARDY	EMPAGLIFLOZIN- METFORMIN HCL TAB 5- 500 MG	27996002400310	Brand
SYNJARDY	EMPAGLIFLOZIN- METFORMIN HCL TAB 5- 1000 MG	27996002400315	Brand
SYNJARDY	EMPAGLIFLOZIN- METFORMIN HCL TAB 12.5- 500 MG	27996002400320	Brand
SYNJARDY	EMPAGLIFLOZIN- METFORMIN HCL TAB 12.5- 1000 MG	27996002400325	Brand
SYNJARDY XR	EMPAGLIFLOZIN- METFORMIN HCL TAB ER 24HR 5-1000 MG	27996002407530	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SYNJARDY XR	EMPAGLIFLOZIN-METFORMIN HCL TAB ER 24HR 10-1000 MG	27996002407540	Brand
SYNJARDY XR	EMPAGLIFLOZIN-METFORMIN HCL TAB ER 24HR 12.5-1000 MG	27996002407550	Brand
SYNJARDY XR	EMPAGLIFLOZIN-METFORMIN HCL TAB ER 24HR 25-1000 MG	27996002407560	Brand
STEGLATRO	ERTUGLIFLOZIN L-PYROGLUTAMIC ACID TAB 5 MG (BASE EQUIV)	27700055200320	Brand
STEGLATRO	ERTUGLIFLOZIN L-PYROGLUTAMIC ACID TAB 15 MG (BASE EQUIV)	27700055200340	Brand
SEGLUOMET	ERTUGLIFLOZIN-METFORMIN HCL TAB 2.5-500 MG	27996002450310	Brand
SEGLUOMET	ERTUGLIFLOZIN-METFORMIN HCL TAB 2.5-1000 MG	27996002450320	Brand
SEGLUOMET	ERTUGLIFLOZIN-METFORMIN HCL TAB 7.5-500 MG	27996002450330	Brand
SEGLUOMET	ERTUGLIFLOZIN-METFORMIN HCL TAB 7.5-1000 MG	27996002450340	Brand
FLOVENT HFA	FLUTICASONE PROPIONATE HFA INHAL AERO 44 MCG/ACT (50/VALVE)	44400033223220	Generic
FLOVENT HFA	FLUTICASONE PROPIONATE HFA INHAL AER 110 MCG/ACT (125/VALVE)	44400033223230	Generic
FLOVENT HFA	FLUTICASONE PROPIONATE HFA INHAL AER 220 MCG/ACT (250/VALVE)	44400033223240	Generic
FLOVENT DISKUS	FLUTICASONE PROPIONATE AER POW BA 50 MCG/ACT	44400033208010	Brand
FLOVENT DISKUS	FLUTICASONE PROPIONATE AER POW BA 100 MCG/ACT	44400033208020	Brand
FLOVENT DISKUS	FLUTICASONE PROPIONATE AER POW BA 250 MCG/ACT	44400033208030	Brand
ALVESCO	CICLESONIDE INHAL AEROSOL 80 MCG/ACT	44400017003420	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ALVESCO	CICLESONIDE INHAL AEROSOL 160 MCG/ACT	44400017003440	Brand
ARMONAIR DIGIHALER	FLUTICASONE PROPIONATE AER POW BA 55 MCG/ACT WITH SENSOR	44400033218020	Brand
ARMONAIR DIGIHALER	FLUTICASONE PROPIONATE AER POW BA 113 MCG/ACT WITH SENSOR	44400033218030	Brand
ARMONAIR DIGIHALER	FLUTICASONE PROPIONATE AER POW BA 232 MCG/ACT WITH SENSOR	44400033218040	Brand
ASMANEX HFA	MOMETASONE FUROATE INHAL AEROSOL SUSPENSION 50 MCG/ACT	44400036203210	Brand
ASMANEX HFA	MOMETASONE FUROATE INHAL AEROSOL SUSPENSION 100 MCG/ACT	44400036203220	Brand
ASMANEX HFA	MOMETASONE FUROATE INHAL AEROSOL SUSPENSION 200 MCG/ACT	44400036203230	Brand
ASMANEX TWISTHALER 30 METERED DOSES	MOMETASONE FUROATE INHAL POWD 110 MCG/ACT (BREATH ACTIVATED)	44400036208010	Brand
ASMANEX TWISTHALER 120 METERED DOSES	MOMETASONE FUROATE INHAL POWD 220 MCG/ACT (BREATH ACTIVATED)	44400036208020	Brand
ASMANEX TWISTHALER 14 METERED DOSES	MOMETASONE FUROATE INHAL POWD 220 MCG/ACT (BREATH ACTIVATED)	44400036208020	Brand
ASMANEX TWISTHALER 30 METERED DOSES	MOMETASONE FUROATE INHAL POWD 220 MCG/ACT (BREATH ACTIVATED)	44400036208020	Brand
ASMANEX TWISTHALER 60 METERED DOSES	MOMETASONE FUROATE INHAL POWD 220 MCG/ACT (BREATH ACTIVATED)	44400036208020	Brand
ARNUITY ELLIPTA	FLUTICASONE FUROATE AEROSOL POWDER BREATH ACTIV 50 MCG/ACT	44400033108010	Brand
ARNUITY ELLIPTA	FLUTICASONE FUROATE AEROSOL POWDER BREATH ACTIV 100 MCG/ACT	44400033108020	Brand
ARNUITY ELLIPTA	FLUTICASONE FUROATE AEROSOL POWDER	44400033108030	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	BREATH ACTIV 200 MCG/ACT		
QVAR REDIHALER	BECLOMETHASONE DIPROP HFA BREATH ACT INH AER 40 MCG/ACT	44400010128120	Brand
QVAR REDIHALER	BECLOMETHASONE DIPROP HFA BREATH ACT INH AER 80 MCG/ACT	44400010128140	Brand
LONHALA MAGNAIR REFILL KIT	GLYCOPYRROLATE INHAL SOLUTION 25 MCG/ML	44100020102030	Brand
LONHALA MAGNAIR STARTER KIT	GLYCOPYRROLATE INHAL SOLUTION 25 MCG/ML	44100020102030	Brand
TRELEGY ELLIPTA	FLUTICASONE-UMECLIDINIUM-VILANTEROL AEPB 100-62.5-25 MCG/ACT	44209903408020	Brand
TRELEGY ELLIPTA	FLUTICASONE-UMECLIDINIUM-VILANTEROL AEPB 200-62.5-25 MCG/ACT	44209903408040	Brand
AIRDUO RESPICLICK 55/14	FLUTICASONE-SALMETEROL AER POWDER BA 55-14 MCG/ACT	44209902708010	Generic
FLUTICASONE PROPIONATE/SALMETEROL	FLUTICASONE-SALMETEROL AER POWDER BA 55-14 MCG/ACT	44209902708010	Generic
AIRDUO RESPICLICK 113/14	FLUTICASONE-SALMETEROL AER POWDER BA 113-14 MCG/ACT	44209902708015	Generic
FLUTICASONE PROPIONATE/SALMETEROL	FLUTICASONE-SALMETEROL AER POWDER BA 113-14 MCG/ACT	44209902708015	Generic
ADVAIR DISKUS	FLUTICASONE-SALMETEROL AER POWDER BA 100-50 MCG/ACT	44209902708020	Brand
FLUTICASONE PROPIONATE/SALMETEROL	FLUTICASONE-SALMETEROL AER POWDER BA 100-50 MCG/ACT	44209902708020	Generic
FLUTICASONE PROPIONATE/SALMETEROL DISKUS	FLUTICASONE-SALMETEROL AER POWDER BA 100-50 MCG/ACT	44209902708020	Generic
WIXELA INHUB	FLUTICASONE-SALMETEROL AER	44209902708020	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	POWDER BA 100-50 MCG/ACT		
AIRDUO RESPICLICK 232/14	FLUTICASONE- SALMETEROL AER POWDER BA 232-14 MCG/ACT	44209902708025	Generic
FLUTICASONE PROPIONATE/SALMETEROL	FLUTICASONE- SALMETEROL AER POWDER BA 232-14 MCG/ACT	44209902708025	Generic
ADVAIR DISKUS	FLUTICASONE- SALMETEROL AER POWDER BA 250-50 MCG/ACT	44209902708030	Brand
FLUTICASONE PROPIONATE/SALMETEROL	FLUTICASONE- SALMETEROL AER POWDER BA 250-50 MCG/ACT	44209902708030	Generic
FLUTICASONE PROPIONATE/SALMETEROL DISKUS	FLUTICASONE- SALMETEROL AER POWDER BA 250-50 MCG/ACT	44209902708030	Generic
WIXELA INHUB	FLUTICASONE- SALMETEROL AER POWDER BA 250-50 MCG/ACT	44209902708030	Generic
ADVAIR DISKUS	FLUTICASONE- SALMETEROL AER POWDER BA 500-50 MCG/ACT	44209902708040	Brand
FLUTICASONE PROPIONATE/SALMETEROL	FLUTICASONE- SALMETEROL AER POWDER BA 500-50 MCG/ACT	44209902708040	Generic
FLUTICASONE PROPIONATE/SALMETEROL DISKUS	FLUTICASONE- SALMETEROL AER POWDER BA 500-50 MCG/ACT	44209902708040	Generic
WIXELA INHUB	FLUTICASONE- SALMETEROL AER POWDER BA 500-50 MCG/ACT	44209902708040	Generic
BUDESONIDE/FORMOTEROL FUMARATE DIHYDRATE	BUDESONIDE- FORMOTEROL FUMARATE DIHYD AEROSOL 80-4.5 MCG/ACT	44209902413220	Generic
BUDESONIDE/FORMOTEROL FUMARATE DIHYDRATE	BUDESONIDE- FORMOTEROL FUMARATE DIHYD AEROSOL 160-4.5 MCG/ACT	44209902413240	Generic
AIRDUO DIGIHALER 55/14	FLUTICASONE- SALMETEROL AER	44209902718020	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

	POWDER BA 55-14 MCG/ACT W/ SENSOR		
AIRDUO DIGIHALER 113/14	FLUTICASONE- SALMETEROL AER POWDER BA 113-14 MCG/ACT W/SENSOR	44209902718030	Brand
AIRDUO DIGIHALER 232/14	FLUTICASONE- SALMETEROL AER POWDER BA 232-14 MCG/ACT W/SENSOR	44209902718040	Brand
DULERA	MOMETASONE FUROATE- FORMOTEROL FUMARATE AEROSOL 50-5 MCG/ACT	44209902903210	Brand
DULERA	MOMETASONE FUROATE- FORMOTEROL FUMARATE AEROSOL 100-5 MCG/ACT	44209902903220	Brand
DULERA	MOMETASONE FUROATE- FORMOTEROL FUMARATE AEROSOL 200-5 MCG/ACT	44209902903240	Brand
BREO ELLIPTA	FLUTICASONE FUROATE- VILANTEROL AERO POWD BA 100-25 MCG/ACT	44209902758020	Generic
FLUTICASONE FUROATE/VILANTEROL ELLIPTA	FLUTICASONE FUROATE- VILANTEROL AERO POWD BA 100-25 MCG/ACT	44209902758020	Generic
BREO ELLIPTA	FLUTICASONE FUROATE- VILANTEROL AERO POWD BA 200-25 MCG/ACT	44209902758030	Generic
FLUTICASONE FUROATE/VILANTEROL ELLIPTA	FLUTICASONE FUROATE- VILANTEROL AERO POWD BA 200-25 MCG/ACT	44209902758030	Generic
BASAGLAR TEMPO PEN	INSULIN GLARGINE PEN- INJ WITH TRANSMITTER PORT 100 UNIT/ML	2710400300D222	Brand
BASAGLAR KWIKPEN	INSULIN GLARGINE SOLN PEN-INJECTOR 100 UNIT/ML	2710400300D220	Brand
INSULIN GLARGINE SOLOSTAR	INSULIN GLARGINE SOLN PEN-INJECTOR 100 UNIT/ML	2710400300D220	Brand
LANTUS SOLOSTAR	INSULIN GLARGINE SOLN PEN-INJECTOR 100 UNIT/ML	2710400300D220	Brand
TOUJEO SOLOSTAR	INSULIN GLARGINE SOLN PEN-INJECTOR 300 UNIT/ML (1 UNIT DIAL)	2710400300D233	Brand
TOUJEO MAX SOLOSTAR	INSULIN GLARGINE SOLN PEN-INJECTOR 300 UNIT/ML (2 UNIT DIAL)	2710400300D236	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

INSULIN GLARGINE	INSULIN GLARGINE-YFGN SOLN PEN-INJECTOR 100 UNIT/ML	2710400390D220	Brand
SEMGLEE	INSULIN GLARGINE-YFGN SOLN PEN-INJECTOR 100 UNIT/ML	2710400390D220	Brand
INSULIN GLARGINE	INSULIN GLARGINE INJ 100 UNIT/ML	27104003002020	Brand
LANTUS	INSULIN GLARGINE INJ 100 UNIT/ML	27104003002020	Brand
SEMGLEE	INSULIN GLARGINE INJ 100 UNIT/ML	27104003002020	Brand
SEMGLEE	INSULIN GLARGINE-YFGN INJ 100 UNIT/ML	27104003902020	Brand
LEVEMIR	INSULIN DETEMIR INJ 100 UNIT/ML	27104006002020	Brand
LEVEMIR FLEXPEN	INSULIN DETEMIR SOLN PEN-INJECTOR 100 UNIT/ML	2710400600D220	Brand
LEVEMIR FLEXTOUCH	INSULIN DETEMIR SOLN PEN-INJECTOR 100 UNIT/ML	2710400600D220	Brand
INSULIN DEGLUDEC	INSULIN DEGLUDEC INJ 100 UNIT/ML	27104007002020	Brand
TRESIBA	INSULIN DEGLUDEC INJ 100 UNIT/ML	27104007002020	Brand
INSULIN DEGLUDEC FLEXTOUCH	INSULIN DEGLUDEC SOLN PEN-INJECTOR 100 UNIT/ML	2710400700D210	Brand
TRESIBA FLEXTOUCH	INSULIN DEGLUDEC SOLN PEN-INJECTOR 100 UNIT/ML	2710400700D210	Brand
INSULIN DEGLUDEC FLEXTOUCH	INSULIN DEGLUDEC SOLN PEN-INJECTOR 200 UNIT/ML	2710400700D220	Brand
TRESIBA FLEXTOUCH	INSULIN DEGLUDEC SOLN PEN-INJECTOR 200 UNIT/ML	2710400700D220	Brand
REZVOGLAR KWIKPEN	INSULIN GLARGINE-AGLR SOLN PEN-INJECTOR 100 UNIT/ML	2710400305D220	Brand
BACLOFEN	BACLOFEN TAB 5 MG	75100010000303	Generic
BACLOFEN	BACLOFEN TAB 10 MG	75100010000305	Generic
BACLOFEN	BACLOFEN TAB 20 MG	75100010000310	Generic
BACLOFEN	BACLOFEN SUSP 25 MG/5ML	75100010001825	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LIORESAL INTRATHECAL	BACLOFEN INTRATHECAL INJ 0.05 MG/ML (50 MCG/ML)	75100010002020	Brand
BACLOFEN	BACLOFEN INTRATHECAL INJ 10 MG/20ML (500 MCG/ML)	75100010002034	Generic
GABLOFEN	BACLOFEN INTRATHECAL INJ 10 MG/20ML (500 MCG/ML)	75100010002034	Brand
LIORESAL INTRATHECAL	BACLOFEN INTRATHECAL INJ 10 MG/20ML (500 MCG/ML)	75100010002034	Brand
BACLOFEN	BACLOFEN INTRATHECAL INJ 20 MG/20ML (1000 MCG/ML)	75100010002039	Generic
GABLOFEN	BACLOFEN INTRATHECAL INJ 20 MG/20ML (1000 MCG/ML)	75100010002039	Brand
LIORESAL INTRATHECAL	BACLOFEN INTRATHECAL INJ 10 MG/5ML (2000 MCG/ML)	75100010002046	Brand
BACLOFEN	BACLOFEN INTRATHECAL INJ 40 MG/20ML (2000 MCG/ML)	75100010002050	Generic
GABLOFEN	BACLOFEN INTRATHECAL INJ 40 MG/20ML (2000 MCG/ML)	75100010002050	Brand
LIORESAL INTRATHECAL	BACLOFEN INTRATHECAL INJ 40 MG/20ML (2000 MCG/ML)	75100010002050	Brand
BACLOFEN	BACLOFEN ORAL SOLN 5 MG/5ML	75100010002070	Generic
OZOBAX	BACLOFEN ORAL SOLN 5 MG/5ML	75100010002070	Generic
LYVISPAH	BACLOFEN GRANULES PACKET 5 MG	75100010003010	Brand
LYVISPAH	BACLOFEN GRANULES PACKET 10 MG	75100010003020	Brand
LYVISPAH	BACLOFEN GRANULES PACKET 20 MG	75100010003030	Brand
CARISOPRODOL	CARISOPRODOL TAB 250 MG	75100020000304	Generic
SOMA	CARISOPRODOL TAB 250 MG	75100020000304	Brand
CARISOPRODOL	CARISOPRODOL TAB 350 MG	75100020000305	Generic
SOMA	CARISOPRODOL TAB 350 MG	75100020000305	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

VANADOM	CARISOPRODOL TAB 350 MG	75100020000305	Brand
CHLORZOXAZONE	CHLORZOXAZONE TAB 250 MG	75100040000305	Generic
CHLORZOXAZONE	CHLORZOXAZONE TAB 375 MG	75100040000307	Generic
LORZONE	CHLORZOXAZONE TAB 375 MG	75100040000307	Brand
CHLORZOXAZONE	CHLORZOXAZONE TAB 500 MG	75100040000310	Generic
CHLORZOXAZONE	CHLORZOXAZONE TAB 750 MG	75100040000320	Generic
LORZONE	CHLORZOXAZONE TAB 750 MG	75100040000320	Brand
CYCLOBENZAPRINE HYDROCHLORIDE	CYCLOBENZAPRINE HCL TAB 5 MG	75100050100303	Generic
CYCLOBENZAPRINE HYDROCHLORIDE	CYCLOBENZAPRINE HCL TAB 7.5 MG	75100050100304	Generic
FEXMID	CYCLOBENZAPRINE HCL TAB 7.5 MG	75100050100304	Brand
CYCLOBENZAPRINE HYDROCHLORIDE	CYCLOBENZAPRINE HCL TAB 10 MG	75100050100305	Generic
AMRIX	CYCLOBENZAPRINE HCL CAP ER 24HR 15 MG	75100050107015	Brand
CYCLOBENZAPRINE HYDROCHLORIDE ER	CYCLOBENZAPRINE HCL CAP ER 24HR 15 MG	75100050107015	Generic
AMRIX	CYCLOBENZAPRINE HCL CAP ER 24HR 30 MG	75100050107030	Brand
CYCLOBENZAPRINE HYDROCHLORIDE ER	CYCLOBENZAPRINE HCL CAP ER 24HR 30 MG	75100050107030	Generic
METAXALONE	METAXALONE TAB 400 MG	75100060000310	Generic
METAXALONE	METAXALONE TAB 800 MG	75100060000320	Generic
METHOCARBAMOL	METHOCARBAMOL TAB 500 MG	75100070000305	Generic
METHOCARBAMOL	METHOCARBAMOL TAB 750 MG	75100070000310	Generic
METHOCARBAMOL	METHOCARBAMOL TAB 1000 MG	75100070000320	Generic
ORPHENADRINE CITRATE CR	ORPHENADRINE CITRATE TAB ER 12HR 100 MG	75100080107410	Generic
ORPHENADRINE CITRATE ER	ORPHENADRINE CITRATE TAB ER 12HR 100 MG	75100080107410	Generic
TIZANIDINE HCL	TIZANIDINE HCL CAP 2 MG (BASE EQUIVALENT)	75100090100110	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZANAFLEX	TIZANIDINE HCL CAP 2 MG (BASE EQUIVALENT)	75100090100110	Brand
TIZANIDINE HCL	TIZANIDINE HCL CAP 4 MG (BASE EQUIVALENT)	75100090100120	Generic
ZANAFLEX	TIZANIDINE HCL CAP 4 MG (BASE EQUIVALENT)	75100090100120	Brand
TIZANIDINE HCL	TIZANIDINE HCL CAP 6 MG (BASE EQUIVALENT)	75100090100130	Generic
ZANAFLEX	TIZANIDINE HCL CAP 6 MG (BASE EQUIVALENT)	75100090100130	Brand
TIZANIDINE HCL	TIZANIDINE HCL TAB 2 MG (BASE EQUIVALENT)	75100090100310	Generic
TIZANIDINE HYDROCHLORIDE	TIZANIDINE HCL TAB 4 MG (BASE EQUIVALENT)	75100090100320	Generic
ZANAFLEX	TIZANIDINE HCL TAB 4 MG (BASE EQUIVALENT)	75100090100320	Brand
DANTRIUM	DANTROLENE SODIUM CAP 25 MG	75200010100105	Brand
DANTROLENE SODIUM	DANTROLENE SODIUM CAP 25 MG	75200010100105	Generic
DANTROLENE SODIUM	DANTROLENE SODIUM CAP 50 MG	75200010100110	Generic
DANTROLENE SODIUM	DANTROLENE SODIUM CAP 100 MG	75200010100115	Generic
NORGESIC	ORPHENADRINE W/ ASPIRIN & CAFFEINE TAB 25-385-30 MG	75990003200310	Brand
ORPHENADRINE/ASPIRIN/CAFFEINE	ORPHENADRINE W/ ASPIRIN & CAFFEINE TAB 25-385-30 MG	75990003200310	Generic
NORGESIC FORTE	ORPHENADRINE W/ ASPIRIN & CAFFEINE TAB 50-770-60 MG	75990003200320	Generic
ORPHENGESIC FORTE	ORPHENADRINE W/ ASPIRIN & CAFFEINE TAB 50-770-60 MG	75990003200320	Generic
GABAPENTIN	GABAPENTIN CAP 100 MG	72600030000110	Generic
NEURONTIN	GABAPENTIN CAP 100 MG	72600030000110	Brand
GABAPENTIN	GABAPENTIN CAP 300 MG	72600030000130	Generic
NEURONTIN	GABAPENTIN CAP 300 MG	72600030000130	Brand
GABAPENTIN	GABAPENTIN CAP 400 MG	72600030000140	Generic
NEURONTIN	GABAPENTIN CAP 400 MG	72600030000140	Brand
GABAPENTIN TINYTABS	GABAPENTIN TAB 25 MG	72600030000303	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GABAPENTIN TINYTABS	GABAPENTIN TAB 50 MG	72600030000305	Brand
GABAPENTIN	GABAPENTIN TAB 600 MG	72600030000330	Generic
NEURONTIN	GABAPENTIN TAB 600 MG	72600030000330	Brand
GABAPENTIN	GABAPENTIN TAB 800 MG	72600030000340	Generic
NEURONTIN	GABAPENTIN TAB 800 MG	72600030000340	Brand
GABAPENTIN	GABAPENTIN ORAL SOLN 250 MG/5ML	72600030002020	Generic
NEURONTIN	GABAPENTIN ORAL SOLN 250 MG/5ML	72600030002020	Brand
LYRICA	PREGABALIN CAP 25 MG	72600057000110	Brand
PREGABALIN	PREGABALIN CAP 25 MG	72600057000110	Generic
LYRICA	PREGABALIN CAP 50 MG	72600057000115	Brand
PREGABALIN	PREGABALIN CAP 50 MG	72600057000115	Generic
LYRICA	PREGABALIN CAP 75 MG	72600057000120	Brand
PREGABALIN	PREGABALIN CAP 75 MG	72600057000120	Generic
LYRICA	PREGABALIN CAP 100 MG	72600057000125	Brand
PREGABALIN	PREGABALIN CAP 100 MG	72600057000125	Generic
LYRICA	PREGABALIN CAP 150 MG	72600057000135	Brand
PREGABALIN	PREGABALIN CAP 150 MG	72600057000135	Generic
LYRICA	PREGABALIN CAP 200 MG	72600057000145	Brand
PREGABALIN	PREGABALIN CAP 200 MG	72600057000145	Generic
LYRICA	PREGABALIN CAP 225 MG	72600057000150	Brand
PREGABALIN	PREGABALIN CAP 225 MG	72600057000150	Generic
LYRICA	PREGABALIN CAP 300 MG	72600057000160	Brand
PREGABALIN	PREGABALIN CAP 300 MG	72600057000160	Generic
LYRICA	PREGABALIN SOLN 20 MG/ML	72600057002020	Brand
PREGABALIN	PREGABALIN SOLN 20 MG/ML	72600057002020	Generic
GRALISE	GABAPENTIN (ONCE- DAILY) TAB 300 MG	62540030000320	Brand
GRALISE	GABAPENTIN (ONCE- DAILY) TAB 450 MG	62540030000325	Brand
GRALISE	GABAPENTIN (ONCE- DAILY) TAB 600 MG	62540030000330	Brand
GRALISE	GABAPENTIN (ONCE- DAILY) TAB 750 MG	62540030000345	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GRALISE	GABAPENTIN (ONCE-DAILY) TAB 900 MG	62540030000360	Brand
GRALISE	GABAPENTIN (ONCE-DAILY) TAB PACK 300 MG (9) & 600 MG (24)	62540030006330	Brand
LYRICA CR	PREGABALIN TAB ER 24HR 82.5 MG	62540060007520	Brand
PREGABALIN ER	PREGABALIN TAB ER 24HR 82.5 MG	62540060007520	Generic
LYRICA CR	PREGABALIN TAB ER 24HR 165 MG	62540060007530	Brand
PREGABALIN ER	PREGABALIN TAB ER 24HR 165 MG	62540060007530	Generic
LYRICA CR	PREGABALIN TAB ER 24HR 330 MG	62540060007540	Brand
PREGABALIN ER	PREGABALIN TAB ER 24HR 330 MG	62540060007540	Generic
HORIZANT	GABAPENTIN ENACARBIL TAB ER 300 MG	62560030200420	Brand
HORIZANT	GABAPENTIN ENACARBIL TAB ER 600 MG	62560030200430	Brand
ZORVOLEX	DICLOFENAC CAP 18 MG	66100007000120	Brand
ZORVOLEX	DICLOFENAC CAP 35 MG	66100007000130	Brand
DICLOFENAC POTASSIUM	DICLOFENAC POTASSIUM TAB 25 MG	66100007100320	Generic
LOFENA	DICLOFENAC POTASSIUM TAB 25 MG	66100007100320	Brand
DICLOFENAC POTASSIUM	DICLOFENAC POTASSIUM TAB 50 MG	66100007100330	Generic
DICLOFENAC POTASSIUM	DICLOFENAC POTASSIUM CAP 25 MG	66100007100120	Generic
ZIPSOR	DICLOFENAC POTASSIUM CAP 25 MG	66100007100120	Brand
DICLOFENAC SODIUM DR	DICLOFENAC SODIUM TAB DELAYED RELEASE 25 MG	66100007200610	Generic
DICLOFENAC SODIUM DR	DICLOFENAC SODIUM TAB DELAYED RELEASE 50 MG	66100007200620	Generic
DICLOFENAC SODIUM DR	DICLOFENAC SODIUM TAB DELAYED RELEASE 75 MG	66100007200630	Generic
DICLOFENAC SODIUM ER	DICLOFENAC SODIUM TAB ER 24HR 100 MG	66100007207530	Generic
CAMBIA	DICLOFENAC POTASSIUM (MIGRAINE) PACKET 50 MG	67600040103020	Brand
DICLOFENAC POTASSIUM	DICLOFENAC POTASSIUM (MIGRAINE) PACKET 50 MG	67600040103020	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ETODOLAC	ETODOLAC CAP 200 MG	66100008000120	Generic
ETODOLAC	ETODOLAC CAP 300 MG	66100008000130	Generic
ETODOLAC	ETODOLAC TAB 400 MG	66100008000310	Generic
LODINE	ETODOLAC TAB 400 MG	66100008000310	Brand
ETODOLAC	ETODOLAC TAB 500 MG	66100008000320	Generic
ETODOLAC ER	ETODOLAC TAB ER 24HR 400 MG	66100008007520	Generic
ETODOLAC ER	ETODOLAC TAB ER 24HR 500 MG	66100008007530	Generic
ETODOLAC ER	ETODOLAC TAB ER 24HR 600 MG	66100008007540	Generic
FENOPROFEN CALCIUM	FENOPROFEN CALCIUM CAP 200 MG	66100010100105	Generic
FENOPROFEN CALCIUM	FENOPROFEN CALCIUM CAP 400 MG	66100010100120	Generic
NALFON	FENOPROFEN CALCIUM CAP 400 MG	66100010100120	Brand
FENOPROFEN CALCIUM	FENOPROFEN CALCIUM TAB 600 MG	66100010100305	Generic
NALFON	FENOPROFEN CALCIUM TAB 600 MG	66100010100305	Brand
FLURBIPROFEN	FLURBIPROFEN TAB 50 MG	66100012000310	Generic
FLURBIPROFEN	FLURBIPROFEN TAB 100 MG	66100012000315	Generic
IBUPROFEN	IBUPROFEN CAP 200 MG	66100020000105	Generic
IBUPROFEN	IBUPROFEN TAB 200 MG	66100020000305	Generic
IBUPROFEN	IBUPROFEN CHEW TAB 100 MG	66100020000520	Generic
IBUPROFEN INFANTS	IBUPROFEN SUSP 40 MG/ML	66100020001810	Generic
CHILDRENS IBUPROFEN	IBUPROFEN SUSP 100 MG/5ML	66100020001820	Generic
INDOMETHACIN	INDOMETHACIN CAP 25 MG	66100030000105	Generic
INDOMETHACIN	INDOMETHACIN CAP 50 MG	66100030000110	Generic
INDOMETHACIN ER	INDOMETHACIN CAP ER 75 MG	66100030000205	Generic
INDOMETHACIN SR	INDOMETHACIN CAP ER 75 MG	66100030000205	Generic
INDOCIN	INDOMETHACIN SUSP 25 MG/5ML	66100030001805	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

INDOCIN	INDOMETHACIN SUPPOS 50 MG	66100030005205	Brand
INDOMETHACIN	INDOMETHACIN SUPPOS 100 MG	66100030005210	Brand
KETOPROFEN	KETOPROFEN CAP 25 MG	66100035000103	Generic
KETOPROFEN	KETOPROFEN CAP 50 MG	66100035000105	Generic
KETOPROFEN ER	KETOPROFEN CAP ER 24HR 200 MG	66100035007030	Generic
KETOROLAC TROMETHAMINE	KETOROLAC TROMETHAMINE TAB 10 MG	66100037100320	Generic
MECLOFENAMATE SODIUM	MECLOFENAMATE SODIUM CAP 50 MG	66100040100105	Generic
MECLOFENAMATE SODIUM	MECLOFENAMATE SODIUM CAP 100 MG	66100040100110	Generic
MEFENAMIC ACID	MEFENAMIC ACID CAP 250 MG	66100050000105	Generic
MELOXICAM	MELOXICAM CAP 5 MG	66100052000115	Generic
MELOXICAM	MELOXICAM CAP 10 MG	66100052000125	Generic
MELOXICAM	MELOXICAM TAB 7.5 MG	66100052000320	Generic
MELOXICAM	MELOXICAM TAB 15 MG	66100052000330	Generic
NABUMETONE	NABUMETONE TAB 500 MG	66100055000320	Generic
NABUMETONE	NABUMETONE TAB 750 MG	66100055000330	Generic
RELAFEN DS	NABUMETONE TAB 1000 MG	66100055000340	Brand
NAPROXEN	NAPROXEN TAB 250 MG	66100060000305	Generic
NAPROXEN	NAPROXEN TAB 375 MG	66100060000310	Generic
NAPROSYN	NAPROXEN TAB 500 MG	66100060000315	Brand
NAPROXEN	NAPROXEN TAB 500 MG	66100060000315	Generic
EC-NAPROSYN	NAPROXEN TAB EC 375 MG	66100060000610	Brand
EC-NAPROXEN	NAPROXEN TAB EC 375 MG	66100060000610	Generic
NAPROXEN	NAPROXEN TAB EC 375 MG	66100060000610	Generic
EC-NAPROSYN	NAPROXEN TAB EC 500 MG	66100060000615	Brand
EC-NAPROXEN	NAPROXEN TAB EC 500 MG	66100060000615	Generic
NAPROXEN	NAPROXEN TAB EC 500 MG	66100060000615	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

NAPROSYN	NAPROXEN SUSP 125 MG/5ML	66100060001805	Brand
NAPROXEN	NAPROXEN SUSP 125 MG/5ML	66100060001805	Generic
NAPROXEN SODIUM	NAPROXEN SODIUM CAP 220 MG	66100060100127	Generic
NAPROXEN	NAPROXEN SODIUM TAB 220 MG	66100060100303	Generic
NAPRELAN	NAPROXEN SODIUM TAB ER 24HR 375 MG (BASE EQUIV)	66100060107520	Brand
NAPROXEN SODIUM CR	NAPROXEN SODIUM TAB ER 24HR 375 MG (BASE EQUIV)	66100060107520	Generic
NAPROXEN SODIUM ER	NAPROXEN SODIUM TAB ER 24HR 375 MG (BASE EQUIV)	66100060107520	Generic
NAPRELAN	NAPROXEN SODIUM TAB ER 24HR 500 MG (BASE EQUIV)	66100060107540	Brand
NAPROXEN SODIUM ER	NAPROXEN SODIUM TAB ER 24HR 500 MG (BASE EQUIV)	66100060107540	Generic
NAPRELAN	NAPROXEN SODIUM TAB ER 24HR 750 MG (BASE EQUIV)	66100060107550	Brand
NAPROXEN SODIUM	NAPROXEN SODIUM TAB ER 24HR 750 MG (BASE EQUIV)	66100060107550	Generic
DAYPRO	OXAPROZIN TAB 600 MG	66100065000320	Brand
OXAPROZIN	OXAPROZIN TAB 600 MG	66100065000320	Generic
FELDENE	PIROXICAM CAP 10 MG	66100070000105	Brand
PIROXICAM	PIROXICAM CAP 10 MG	66100070000105	Generic
FELDENE	PIROXICAM CAP 20 MG	66100070000110	Brand
PIROXICAM	PIROXICAM CAP 20 MG	66100070000110	Generic
SULINDAC	SULINDAC TAB 150 MG	66100080000305	Generic
SULINDAC	SULINDAC TAB 200 MG	66100080000310	Generic
TOLMETIN SODIUM	TOLMETIN SODIUM TAB 600 MG	66100090100320	Generic
CELEBREX	CELECOXIB CAP 50 MG	66100525000110	Brand
CELECOXIB	CELECOXIB CAP 50 MG	66100525000110	Generic
CELEBREX	CELECOXIB CAP 100 MG	66100525000120	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CELECOXIB	CELECOXIB CAP 100 MG	66100525000120	Generic
CELEBREX	CELECOXIB CAP 200 MG	66100525000130	Brand
CELECOXIB	CELECOXIB CAP 200 MG	66100525000130	Generic
CELEBREX	CELECOXIB CAP 400 MG	66100525000140	Brand
CELECOXIB	CELECOXIB CAP 400 MG	66100525000140	Generic
ELYXYB	CELECOXIB ORAL SOLN 120 MG/4.8ML (25 MG/ML)	67604030002020	Brand
ARTHROTEC 50	DICLOFENAC W/ MISOPROSTOL TAB DELAYED RELEASE 50-0.2 MG	66109902200620	Brand
DICLOFENAC SODIUM/MISOPROSTOL	DICLOFENAC W/ MISOPROSTOL TAB DELAYED RELEASE 50-0.2 MG	66109902200620	Generic
ARTHROTEC 75	DICLOFENAC W/ MISOPROSTOL TAB DELAYED RELEASE 75-0.2 MG	66109902200630	Brand
DICLOFENAC SODIUM/MISOPROSTOL	DICLOFENAC W/ MISOPROSTOL TAB DELAYED RELEASE 75-0.2 MG	66109902200630	Generic
DUEXIS	IBUPROFEN-FAMOTIDINE TAB 800-26.6 MG	66109902320340	Brand
IBUPROFEN/FAMOTIDINE	IBUPROFEN-FAMOTIDINE TAB 800-26.6 MG	66109902320340	Generic
NAPROXEN/ESOMEPRAZOLE MAGNESIUM	NAPROXEN- ESOMEPRAZOLE MAGNESIUM TAB DR 375- 20 MG	66109902440620	Generic
VIMOVO	NAPROXEN- ESOMEPRAZOLE MAGNESIUM TAB DR 375- 20 MG	66109902440620	Brand
NAPROXEN/ESOMEPRAZOLE MAGNESIUM	NAPROXEN- ESOMEPRAZOLE MAGNESIUM TAB DR 500- 20 MG	66109902440640	Generic
VIMOVO	NAPROXEN- ESOMEPRAZOLE MAGNESIUM TAB DR 500- 20 MG	66109902440640	Brand
QC IBUPROFEN/DIPHENHYDRAMINE	IBUPROFEN- DIPHENHYDRAMINE HCL CAP 200-25 MG	60309902420120	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ALEVE PM	NAPROXEN SODIUM-DIPHENHYDRAMINE HCL TAB 220-25 MG	60309902600320	Brand
RA NAPROXEN SODIUM PM	NAPROXEN SODIUM-DIPHENHYDRAMINE HCL TAB 220-25 MG	60309902600320	Generic
ADVIL PM	IBUPROFEN-DIPHENHYDRAMINE HCL CAP 200-25 MG	60309902420120	Brand
HYDROCODONE/IBUPROFEN	HYDROCODONE-IBUPROFEN TAB 5-200 MG	65991702500315	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE-IBUPROFEN TAB 7.5-200 MG	65991702500320	Generic
HYDROCODONE/IBUPROFEN	HYDROCODONE-IBUPROFEN TAB 10-200 MG	65991702500330	Generic
SUMATRIPTAN/NAPROXEN SODIUM	SUMATRIPTAN-NAPROXEN SODIUM TAB 85-500 MG	67992002600320	Generic
TREXIMET	SUMATRIPTAN-NAPROXEN SODIUM TAB 85-500 MG	67992002600320	Brand
ADVIL DUAL ACTION /ACETAMINOPHEN	IBUPROFEN-ACETAMINOPHEN TAB 125-250 MG	66109902300305	Brand
MOTRIN DUAL ACTION/TYLENOL	IBUPROFEN-ACETAMINOPHEN TAB 125-250 MG	66109902300305	Brand
NAPROTIN	NAPROXEN TAB 500 MG & CAPSAICIN CREAM 0.025% KIT	66109902476420	Brand
IBUPROFEN	IBUPROFEN TAB 400 MG	66100020000320	Generic
IBUPROFEN	IBUPROFEN TAB 600 MG	66100020000330	Generic
IBUPROFEN	IBUPROFEN TAB 800 MG	66100020000340	Generic
ALEVE	NAPROXEN SODIUM CAP 220 MG	66100060100127	Brand
ALEVE	NAPROXEN SODIUM TAB 220 MG	66100060100303	Brand
INPEFA	SOTAGLIFLOZIN TAB 200 MG	40750010000320	Brand
SAXENDA	LIRAGLUTIDE (WEIGHT MNGMT) SOLN PEN-INJ 18 MG/3ML (6 MG/ML)	6125205000D220	Brand
WEGOVY	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 0.25 MG/0.5ML	6125207000D520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

WEGOVY	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 0.5 MG/0.5ML	6125207000D525	Brand
WEGOVY	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 1 MG/0.5ML	6125207000D530	Brand
WEGOVY	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 1.7 MG/0.75ML	6125207000D535	Brand
WEGOVY	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 2.4 MG/0.75ML	6125207000D540	Brand
TOLMETIN SODIUM	TOLMETIN SODIUM CAP 400 MG	66100090100105	Generic
BREO ELLIPTA	FLUTICASONE FUROATE-VILANTEROL AERO POWD BA 50-25 MCG/ACT	44209902758010	Brand
AIRSUPRA	ALBUTEROL-BUDESONIDE INHALATION AEROSOL 90-80 MCG/ACT	44209902783220	Brand
FLUTICASONE PROPIONATE/SALMETEROL HFA	FLUTICASONE-SALMETEROL INHAL AEROSOL 45-21 MCG/ACT	44209902703250	Generic
ADVAIR HFA	FLUTICASONE-SALMETEROL INHAL AEROSOL 45-21 MCG/ACT	44209902703250	Generic
FLUTICASONE PROPIONATE/SALMETEROL HFA	FLUTICASONE-SALMETEROL INHAL AEROSOL 115-21 MCG/ACT	44209902703260	Generic
ADVAIR HFA	FLUTICASONE-SALMETEROL INHAL AEROSOL 115-21 MCG/ACT	44209902703260	Generic
FLUTICASONE PROPIONATE/SALMETEROL HFA	FLUTICASONE-SALMETEROL INHAL AEROSOL 230-21 MCG/ACT	44209902703270	Generic
ADVAIR HFA	FLUTICASONE-SALMETEROL INHAL AEROSOL 230-21 MCG/ACT	44209902703270	Generic
FLEQSUVY	BACLOFEN SUSP 25 MG/5ML	75100010001825	Brand
PULMICORT FLEXHALER	BUDESONIDE INHAL AERO POWD 90 MCG/ACT (BREATH ACTIVATED)	44400015008009	Generic
PULMICORT FLEXHALER	BUDESONIDE INHAL AERO POWD 180 MCG/ACT (BREATH ACTIVATED)	44400015008018	Generic
BREYNA	BUDESONIDE-FORMOTEROL FUMARATE DIHYD AEROSOL 80-4.5 MCG/ACT	44209902413220	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SYMBICORT	BUDESONIDE- FORMOTEROL FUMARATE DIHYD AEROSOL 80-4.5 MCG/ACT	44209902413220	Brand
BREYNA	BUDESONIDE- FORMOTEROL FUMARATE DIHYD AEROSOL 160-4.5 MCG/ACT	44209902413240	Generic
SYMBICORT	BUDESONIDE- FORMOTEROL FUMARATE DIHYD AEROSOL 160-4.5 MCG/ACT	44209902413240	Brand
ANORO ELLIPTA	UMECLIDINIUM- VILANTEROL AERO POWD BA 62.5-25 MCG/ACT	44209902958020	Brand
INCRUSE ELLIPTA	UMECLIDINIUM BR AERO POWD BREATH ACT 62.5 MCG/ACT (BASE EQ)	44100090208030	Brand
SEREVENT DISKUS	SALMETEROL XINAFOATE AER POW BA 50 MCG/ACT (BASE EQUIV)	44201058108020	Brand
XIGDUO XR	DAPAGLIFLOZIN PROP- METFORMIN HCL TAB ER 24HR 2.5-1000 MG	27996002307507	Brand
XIGDUO XR	DAPAGLIFLOZIN PROP- METFORMIN HCL TAB ER 24HR 5-500 MG	27996002307510	Brand
XIGDUO XR	DAPAGLIFLOZIN PROP- METFORMIN HCL TAB ER 24HR 5-1000 MG	27996002307515	Brand
XIGDUO XR	DAPAGLIFLOZIN PROP- METFORMIN HCL TAB ER 24HR 10-500 MG	27996002307520	Brand
XIGDUO XR	DAPAGLIFLOZIN PROP- METFORMIN HCL TAB ER 24HR 10-1000 MG	27996002307525	Brand
INSULIN GLARGINE-YFGN	INSULIN GLARGINE-YFGN INJ 100 UNIT/ML	27104003902020	Brand
INDOMETHACIN	INDOMETHACIN SUPPOS 50 MG	66100030005205	Generic
SAXAGLIPTIN HYDROCHLORIDE/METFORMIN HYDROCHLORIDE ER	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 2.5-1000 MG	27992502607520	Generic
SAXAGLIPTIN HYDROCHLORIDE/METFORMIN HYDROCHLORIDE ER	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 5-500 MG	27992502607530	Generic
SAXAGLIPTIN HYDROCHLORIDE/METFORMIN HYDROCHLORIDE ER	SAXAGLIPTIN-METFORMIN HCL TAB ER 24HR 5-1000 MG	27992502607540	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

SAXAGLIPTIN HYDROCHLORIDE	SAXAGLIPTIN HCL TAB 2.5 MG (BASE EQUIV)	27550065100320	Generic
SAXAGLIPTIN HYDROCHLORIDE	SAXAGLIPTIN HCL TAB 5 MG (BASE EQUIV)	27550065100330	Generic
TIOTROPIUM BROMIDE	TIOTROPIUM BROMIDE MONOHYDRATE INHAL CAP 18 MCG (BASE EQUIV)	44100080100120	Generic
INPEFA	SOTAGLIFLOZIN TAB 400 MG	40750010000340	Brand
BACLOFEN	BACLOFEN ORAL SOLN 10 MG/5ML	75100010002075	Generic
OZOBAX DS	BACLOFEN ORAL SOLN 10 MG/5ML	75100010002075	Generic
BEXAGLIFLOZIN	BEXAGLIFLOZIN TAB 20 MG	27700010000320	Generic
BRENZAVVY	BEXAGLIFLOZIN TAB 20 MG	27700010000320	Generic
FLUTICASONE PROPIONATE DISKUS	FLUTICASONE PROPIONATE AER POW BA 50 MCG/ACT	44400033208010	Brand
FLUTICASONE PROPIONATE DISKUS	FLUTICASONE PROPIONATE AER POW BA 100 MCG/ACT	44400033208020	Brand
FLUTICASONE PROPIONATE DISKUS	FLUTICASONE PROPIONATE AER POW BA 250 MCG/ACT	44400033208030	Brand
FLUTICASONE PROPIONATE HFA	FLUTICASONE PROPIONATE HFA INHAL AERO 44 MCG/ACT (50/VALVE)	44400033223220	Brand
FLUTICASONE PROPIONATE HFA	FLUTICASONE PROPIONATE HFA INHAL AER 110 MCG/ACT (125/VALVE)	44400033223230	Brand
FLUTICASONE PROPIONATE HFA	FLUTICASONE PROPIONATE HFA INHAL AER 220 MCG/ACT (250/VALVE)	44400033223240	Brand
NAPROXEN DR	NAPROXEN TAB EC 500 MG	66100060000615	Generic
ACETAMINOPHEN/IBUPROFEN	IBUPROFEN-ACETAMINOPHEN TAB 125-250 MG	66109902300305	Generic
ADVIL JUNIOR STRENGTH	IBUPROFEN TAB 100 MG	66100020000303	Brand
ZEPBOUND	TIRZEPATIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 2.5 MG/0.5ML	6125258000D520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZEPBOUND	TIRZEPATIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 5 MG/0.5ML	6125258000D525	Brand
ZEPBOUND	TIRZEPATIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 7.5 MG/0.5ML	6125258000D530	Brand
ZEPBOUND	TIRZEPATIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 10 MG/0.5ML	6125258000D535	Brand
ZEPBOUND	TIRZEPATIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 12.5 MG/0.5ML	6125258000D540	Brand
ZEPBOUND	TIRZEPATIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 15 MG/0.5ML	6125258000D545	Brand
COXANTO	OXAPROZIN CAP 300 MG	66100065000120	Brand
OXAPROZIN	OXAPROZIN CAP 300 MG	66100065000120	Generic
DAPAGLIFLOZIN PROPANEDIOL	DAPAGLIFLOZIN PROPANEDIOL TAB 5 MG (BASE EQUIVALENT)	27700040200310	Generic
DAPAGLIFLOZIN PROPANEDIOL	DAPAGLIFLOZIN PROPANEDIOL TAB 10 MG (BASE EQUIVALENT)	27700040200320	Generic
DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HYDROCHLORIDE	DAPAGLIFLOZIN PROP-METFORMIN HCL TAB ER 24HR 5-1000 MG	27996002307515	Generic
DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HYDROCHLORIDE	DAPAGLIFLOZIN PROP-METFORMIN HCL TAB ER 24HR 10-1000 MG	27996002307525	Generic
ZITUVIO	SITAGLIPTIN TAB 25 MG	27550070000320	Brand
ZITUVIO	SITAGLIPTIN TAB 50 MG	27550070000330	Brand
ZITUVIO	SITAGLIPTIN TAB 100 MG	27550070000340	Brand
BACLOFEN	BACLOFEN TAB 15 MG	75100010000308	Generic
SITAGLIPTIN/METFORMIN HYDROCHLORIDE	SITAGLIPTIN FREE BASE-METFORMIN HCL TAB 50-500 MG	27992502690320	Brand
SITAGLIPTIN/METFORMIN HYDROCHLORIDE	SITAGLIPTIN FREE BASE-METFORMIN HCL TAB 50-1000 MG	27992502690330	Brand
TANLOR	METHOCARBAMOL TAB 1000 MG	75100070000320	Brand
DOLOBID	DIFLUNISAL TAB 250 MG	64100050000305	Brand
DIFLUNISAL	DIFLUNISAL TAB 500 MG	64100050000310	Generic

ZITUVIMET XR	SITAGLIPTIN FREE BASE-METFORMIN HCL TAB ER 24HR 50-500 MG	27992502697520	Brand
ZITUVIMET XR	SITAGLIPTIN FREE BASE-METFORMIN HCL TAB ER 24HR 50-1000 MG	27992502697530	Brand
ZITUVIMET XR	SITAGLIPTIN FREE BASE-METFORMIN HCL TAB ER 24HR 100-1000 MG	27992502697540	Brand
ZITUVIMET	SITAGLIPTIN FREE BASE-METFORMIN HCL TAB 50-500 MG	27992502690320	Brand
ZITUVIMET	SITAGLIPTIN FREE BASE-METFORMIN HCL TAB 50-1000 MG	27992502690330	Brand
TRESNI	DICLOFENAC SODIUM SUPPOS 100 MG	66100007205220	Brand

**Approval Criteria**

1 - The requested medication will be used exclusively, and the previously prescribed medication will be discontinued

**OR**

2 - All of the following:

2.1 The requested medication combination is supported by information from ONE of the following appropriate compendia of current literature:

- American Hospital Formulary Service Drug Information
- National Comprehensive Cancer Network Drugs and Biologics Compendium
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**AND**

2.2 The drug combination is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plan's program



**AND**

**2.3** The provider attests that they are aware that the patient is using duplicate therapy

**AND**

**2.4** Special clinical circumstances exist that necessitate the need for duplicate therapy (document special circumstances)

**AND**

**2.5** Provider attests that the necessity for continued concomitant therapy and safety will be periodically assessed

## 2 . Revision History

Date	Notes
12/17/2024	Added Dolobid, generic diflunisal, Zituvimet, Zituvimet XR, Tresni.

Therapeutic Duplication (Subtype B)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-162158
<b>Guideline Name</b>	Therapeutic Duplication (Subtype B)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2025
-----------------	----------

### 1 . Criteria

Product Name: (All formulations/packaging, except for Entyvio) Entyvio Pen, Stelara, Cimzia, Abrilada, Humira, Amjevita, Idacio, Hulio, Cyltezo, Yusimry, Yuflyma, Hadlima, Hyrimoz, adalimumab (adalimumab-AATY, adalimumab-RYVK, adalimumab-ADBM, adalimumab-AACF, adalimumab-ADAZ, adalimumab-FKJP), Simponi, Enbrel, Actemra, Cosentyx, Ilaris, Kineret, Kevzara, Taltz, Tremfya, Orencia, Xeljanz, Xeljanz XR, Xeljanz Solution, Siliq, Otezla, Olumiant, Ilumya, Skyrizi, Rinvoq, Sotyktu, Cibinqo, Adbry, Dupixent, brand Copaxone, generic glatiramer acetate, generic glatopa, Mavenclad, Rebif, Avonex, Betaseron, Extavia, brand Aubagio, generic teriflunomide, Plegridy, Lemtrada, Tysabri, Ocrevus, Ocrevus Zunovo, brand Tecfidera, generic dimethyl fumarate, Vumerity, brand Gilenya, generic fingolimod, Tascenso ODT, Zeposia, Mayzent, Bafiertam, Kesimpta, Ponvory, Xolair, Fasenna, Nucala, Cinqair, Tezspire, Velsipity, Bimzelx, Omvoh, Zymfentra, Simlandi, Spevigo, Tyenne, Rinvoq LQ, Nemluvio, Ebglyss	
Diagnosis	DUR: Therapeutic Duplication
Approval Length	12 month(s)
Guideline Type	Prior Authorization

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Product Name	Generic Name	GPI	Brand/Generic
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 45 MG/0.5ML	9025058500E520	Brand
STELARA	USTEKINUMAB SOLN PREFILLED SYRINGE 90 MG/ML	9025058500E540	Brand
STELARA	USTEKINUMAB INJ 45 MG/0.5ML	90250585002020	Brand
CIMZIA	CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG	52505020106420	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.8ML	6627001500F520	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 40 MG/0.4ML	6627001500F530	Brand
HUMIRA PEN	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-CD/UC/HS STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PEDIATRIC UC STARTER PACK	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML	6627001500F540	Brand
HUMIRA PEN-PS/UV STARTER	ADALIMUMAB PEN-INJECTOR KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F550	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 10 MG/0.1ML	6627001500F804	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001500F809	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001500F820	Brand
HUMIRA	ADALIMUMAB PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001500F830	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML	6627001500F840	Brand
HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB PREFILLED SYRINGE KIT 80 MG/0.8ML & 40 MG/0.4ML	6627001500F880	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001510D520	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 10 MG/0.2ML	6627001510E505	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.4ML	6627001510E510	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001510E520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 50 MG/0.5ML	6627004000D520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 100 MG/ML	6627004000D540	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.5ML	6627004000E520	Brand
SIMPONI	GOLIMUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/ML	6627004000E540	Brand
ENBREL SURECLICK	ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML	6629003000D530	Brand
ENBREL MINI	ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML	6629003000E230	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML	6629003000E525	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML	6629003000E530	Brand
ENBREL	ETANERCEPT SUBCUTANEOUS INJ 25 MG/0.5ML	66290030002015	Brand
ACTEMRA ACTPEN	TOCILIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 162 MG/0.9ML	6650007000D520	Brand
ACTEMRA	TOCILIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 162 MG/0.9ML	6650007000E520	Brand
ACTEMRA	TOCILIZUMAB IV INJ 80 MG/4ML	66500070002030	Brand
ACTEMRA	TOCILIZUMAB IV INJ 200 MG/10ML	66500070002035	Brand
ACTEMRA	TOCILIZUMAB IV INJ 400 MG/20ML	66500070002040	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	9025057500D520	Brand
COSENTYX SENSOREADY PEN	SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE)	9025057500D530	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	9025057500E510	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	9025057500E520	Brand
COSENTYX	SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE)	9025057500E530	Brand
ILARIS	CANAKINUMAB SUBCUTANEOUS INJ 150 MG/ML	66460020002015	Brand
KINERET	ANAKINRA SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	6626001000E520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/1.14ML	6650006000D520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/1.14ML	6650006000D530	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/1.14ML	6650006000E520	Brand
KEVZARA	SARILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	6650006000E530	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 80 MG/ML	9025055400D520	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 80 MG/ML	9025055400E520	Brand
TREMFYA	GUSELKUMAB SOLN PEN-INJECTOR 100 MG/ML	9025054200D520	Brand
TREMFYA	GUSELKUMAB SOLN PREFILLED SYRINGE 100 MG/ML	9025054200E520	Brand
ORENCIA CLICKJECT	ABATACEPT SUBCUTANEOUS SOLN AUTO-INJECTOR 125 MG/ML	6640001000D520	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/0.4ML	6640001000E510	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 87.5 MG/0.7ML	6640001000E515	Brand
ORENCIA	ABATACEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 125 MG/ML	6640001000E520	Brand
ORENCIA	ABATACEPT FOR IV SOLN 250 MG	66400010002120	Brand
XELJANZ	TOFACITINIB CITRATE TAB 5 MG (BASE EQUIVALENT)	66603065100320	Brand
XELJANZ	TOFACITINIB CITRATE TAB 10 MG (BASE EQUIVALENT)	66603065100330	Brand
XELJANZ	TOFACITINIB CITRATE ORAL SOLN 1 MG/ML (BASE EQUIVALENT)	66603065102020	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 11 MG (BASE EQUIVALENT)	66603065107530	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 22 MG (BASE EQUIVALENT)	66603065107550	Brand
SILIQ	BRODALUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 210 MG/1.5ML	9025052000E520	Brand
OTEZLA	APREMILAST TAB STARTER THERAPY PACK 10 MG & 20 MG & 30 MG	6670001500B720	Brand
OTEZLA	APREMILAST TAB 30 MG	66700015000330	Brand
OLUMIANT	BARICITINIB TAB 1 MG	66603010000310	Brand
OLUMIANT	BARICITINIB TAB 2 MG	66603010000320	Brand
OLUMIANT	BARICITINIB TAB 4 MG	66603010000340	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ILUMYA	TILDRAKIZUMAB-ASMN SUBCUTANEOUS SOLN PREF SYRINGE 100 MG/ML	9025058010E520	Brand
SKYRIZI	RISANKIZUMAB-RZAA SUBCUTANEOUS SOLN CARTRIDGE 180 MG/1.2ML	5250406070E210	Brand
SKYRIZI	RISANKIZUMAB-RZAA SUBCUTANEOUS SOLN CARTRIDGE 360 MG/2.4ML	5250406070E220	Brand
SKYRIZI	RISANKIZUMAB-RZAA IV SOLN 600 MG/10ML (60 MG/ML)	52504060702020	Brand
SKYRIZI PEN	RISANKIZUMAB-RZAA SOLN AUTO-INJECTOR 150 MG/ML	9025057070D520	Brand
SKYRIZI	RISANKIZUMAB-RZAA SOLN PREFILLED SYRINGE 150 MG/ML	9025057070E540	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 15 MG	66603072007520	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 30 MG	66603072007530	Brand
RINVOQ	UPADACITINIB TAB ER 24HR 45 MG	66603072007540	Brand
SOTYKTU	DEUCRAVACITINIB TAB 6 MG	90250524000320	Brand
CIBINQO	ABROCITINIB TAB 50 MG	90272005000320	Brand
CIBINQO	ABROCITINIB TAB 100 MG	90272005000325	Brand
CIBINQO	ABROCITINIB TAB 200 MG	90272005000330	Brand
ADBRY	TRALOKINUMAB-LDRM SUBCUTANEOUS SOLN PREFILLED SYR 150 MG/ML	9027308045E520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML	9027302000D515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 300 MG/2ML	9027302000D520	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 100 MG/0.67ML	9027302000E510	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML	9027302000E515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	9027302000E520	Brand
STELARA	USTEKINUMAB IV SOLN 130 MG/26ML (5 MG/ML) (FOR IV INFUSION)	52504070002020	Brand
COPAXONE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 20 MG/ML	6240003010E520	Brand
GLATIRAMER ACETATE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 20 MG/ML	6240003010E520	Generic
GLATOPA	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 20 MG/ML	6240003010E520	Generic
COPAXONE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 40 MG/ML	6240003010E540	Brand
GLATIRAMER ACETATE	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 40 MG/ML	6240003010E540	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

GLATOPA	GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 40 MG/ML	6240003010E540	Generic
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (4 TABS)	6240101500B718	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (5 TABS)	6240101500B722	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (6 TABS)	6240101500B726	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (7 TABS)	6240101500B732	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (8 TABS)	6240101500B736	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (9 TABS)	6240101500B740	Brand
MAVENCLAD	CLADRIBINE TAB THERAPY PACK 10 MG (10 TABS)	6240101500B744	Brand
REBIF REBIDOSE	INTERFERON BETA-1A SOLN AUTO-INJ 22 MCG/0.5ML	6240306045D520	Brand
REBIF REBIDOSE	INTERFERON BETA-1A SOLN AUTO-INJ 44 MCG/0.5ML	6240306045D540	Brand
REBIF REBIDOSE TITRATION PACK	INTERFERON BETA-1A AUTO-INJ 6X8.8 MCG/0.2ML & 6X22 MCG/0.5ML	6240306045D560	Brand
REBIF	INTERFERON BETA-1A SOLN PREF SYR 22 MCG/0.5ML	6240306045E520	Brand
REBIF	INTERFERON BETA-1A SOLN PREF SYR 44 MCG/0.5ML	6240306045E540	Brand
REBIF TITRATION PACK	INTERFERON BETA-1A PREF SYR 6X8.8 MCG/0.2ML & 6X22 MCG/0.5ML	6240306045E560	Brand
AVONEX PEN	INTERFERON BETA-1A IM AUTO-INJECTOR KIT 30 MCG/0.5ML	6240306045F530	Brand
AVONEX	INTERFERON BETA-1A IM PREFILLED SYRINGE KIT 30 MCG/0.5ML	6240306045F830	Brand
BETASERON	INTERFERON BETA-1B FOR INJ KIT 0.3 MG	62403060506420	Brand
EXTAVIA	INTERFERON BETA-1B FOR INJ KIT 0.3 MG	62403060506420	Brand
PLEGRIDY	PEGINTERFERON BETA-1A SOLN PEN-INJECTOR 125 MCG/0.5ML	6240307530D520	Brand
PLEGRIDY STARTER PACK	PEGINTERFERON BETA-1A SOLN PEN-INJ 63 & 94 MCG/0.5ML PACK	6240307530D550	Brand
PLEGRIDY	PEGINTERFERON BETA-1A SOLN PREFILLED SYRINGE 125 MCG/0.5ML	6240307530E520	Brand
PLEGRIDY	PEGINTERFERON BETA-1A IM SOLN PREFILLED SYR 125 MCG/0.5ML	6240307530E521	Brand
PLEGRIDY STARTER PACK	PEGINTERFERON BETA-1A SOLN PREF SYR 63 & 94 MCG/0.5ML PACK	6240307530E550	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

AUBAGIO	TERIFLUNOMIDE TAB 7 MG	62404070000320	Brand
TERIFLUNOMIDE	TERIFLUNOMIDE TAB 7 MG	62404070000320	Generic
AUBAGIO	TERIFLUNOMIDE TAB 14 MG	62404070000330	Brand
TERIFLUNOMIDE	TERIFLUNOMIDE TAB 14 MG	62404070000330	Generic
LEMTRADA	ALEMTUZUMAB IV INJ 12 MG/1.2ML (10 MG/ML)	62405010002020	Brand
TYSABRI	NATALIZUMAB FOR IV INJ CONC 300 MG/15ML	62405050001320	Brand
OCREVUS	OCRELIZUMAB SOLN FOR IV INFUSION 300 MG/10ML	62405060002020	Brand
VUMERITY	DIROXIMEL FUMARATE CAPSULE DELAYED RELEASE 231 MG	62405530006540	Brand
GILENYA	FINGOLIMOD HCL CAP 0.25 MG (BASE EQUIV)	62407025100110	Brand
FINGOLIMOD	FINGOLIMOD HCL CAP 0.5 MG (BASE EQUIV)	62407025100120	Generic
GILENYA	FINGOLIMOD HCL CAP 0.5 MG (BASE EQUIV)	62407025100120	Brand
TASCENSO ODT	FINGOLIMOD LAURYL SULFATE TABLET DISINTEGRATING 0.25 MG	62407025207220	Brand
TASCENSO ODT	FINGOLIMOD LAURYL SULFATE TABLET DISINTEGRATING 0.5 MG	62407025207230	Brand
ZEPOSIA	OZANIMOD HCL CAP 0.92 MG	62407050200120	Brand
MAYZENT	SIPONIMOD FUMARATE TAB 0.25 MG (BASE EQUIV)	62407070200320	Brand
MAYZENT	SIPONIMOD FUMARATE TAB 1 MG (BASE EQUIV)	62407070200330	Brand
MAYZENT	SIPONIMOD FUMARATE TAB 2 MG (BASE EQUIV)	62407070200340	Brand
MAYZENT STARTER PACK	SIPONIMOD FUMARATE TAB 0.25 MG (7) STARTER PACK	6240707020B710	Brand
MAYZENT STARTER PACK	SIPONIMOD FUMARATE TAB 0.25 MG (12) STARTER PACK	6240707020B720	Brand
BAFIERTAM	MONOMETHYL FUMARATE CAPSULE DELAYED RELEASE 95 MG	62405550006520	Brand
KESIMPTA	OFATUMUMAB SOLN AUTO-INJECTOR 20 MG/0.4ML	6240506500D520	Brand
DIMETHYL FUMARATE	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 120 MG	62405525006520	Generic
TECFIDERA	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 120 MG	62405525006520	Brand
DIMETHYL FUMARATE	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 240 MG	62405525006540	Generic



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

TECFIDERA	DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 240 MG	62405525006540	Brand
PONVORY	PONESIMOD TAB 20 MG	62407060000320	Brand
PONVORY 14-DAY STARTER PACK	PONESIMOD TAB STARTER PACK 2,3,4,5,6,7,8,9 &10 MG	6240706000B720	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	4460306000E510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	4460306000E520	Brand
XOLAIR	OMALIZUMAB FOR INJ 150 MG	44603060002120	Brand
FASENRA PEN	BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 30 MG/ML	4460402000D520	Brand
FASENRA	BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 30 MG/ML	4460402000E520	Brand
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML	4460405500D530	Brand
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE 40 MG/0.4ML	4460405500E520	Brand
NUCALA	MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE 100 MG/ML	4460405500E530	Brand
NUCALA	MEPOLIZUMAB FOR INJ 100 MG	44604055002120	Brand
CINQAIR	RESLIZUMAB IV INFUSION SOLN 100 MG/10ML (10 MG/ML)	44604460002020	Brand
TEZSPIRE	TEZEPELUMAB-EKKO SUBCUTANEOUS SOLN PREF SYR 210 MG/1.91ML	4460807525E520	Brand
TEZSPIRE	TEZEPELUMAB-EKKO SUBCUTANEOUS SOLN AUTO-INJ 210 MG/1.91ML	4460807525D520	Brand
ZEPOSIA 7-DAY STARTER PACK	OZANIMOD CAP PACK 4 X 0.23 MG & 3 X 0.46 MG	6240705020B210	Brand
ZEPOSIA STARTER KIT	OZANIMOD CAP PACK 4 X 0.23 MG & 3 X 0.46 MG & 21 X 0.92 MG	6240705020B215	Brand
ZEPOSIA STARTER KIT	OZANIMOD CAP PACK 4 X 0.23 MG & 3 X 0.46 MG & 30 X 0.92 MG	6240705020B220	Brand
IDACIO	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR CROHNS DISEASE	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001535F810	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
HULIO	ADALIMUMAB-FKJP AUTO-INJECTOR KIT 40 MG/0.8ML	6627001535F520	Brand
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
HULIO	ADALIMUMAB-FKJP PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001535F820	Brand
CYLTEZO	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
CYLTEZO	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
CYLTEZO	ADALIMUMAB-ADBIM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
CYLTEZO STARTER PACKAGE FOR PSORIASIS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBIM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
YUSIMRY	ADALIMUMAB-AQVH SOLN PEN-INJECTOR 40 MG/0.8ML	6627001509D520	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001520D510	Brand
HADLIMA PUSHTOUCH	ADALIMUMAB-BWWD SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001520D520	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001520E510	Brand
HADLIMA	ADALIMUMAB-BWWD SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001520E520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001504D515	Brand
HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

HYRIMOZ PLAQUE PSORIASIS STARTER PACK	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML & 40 MG/0.4ML	6627001504D560	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 10 MG/0.1ML	6627001504E508	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001504E513	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001504E515	Brand
HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 80 MG/0.8ML	6627001504E540	Brand
HYRIMOZ PEDIATRIC CROHN'S DISEASE STARTER PACK	ADALIMUMAB-ADAZ SOLN PREFILLED SYR 80 MG/0.8ML & 40 MG/0.4ML	6627001504E560	Brand
YUFLYMA 2-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 1-PEN KIT	ADALIMUMAB-AATY AUTO-INJECTOR KIT 40 MG/0.4ML	6627001503F530	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001503F830	Brand
DIMETHYL FUMARATE STARTERPACK	DIMETHYL FUMARATE CAPSULE DR STARTER PACK 120 MG & 240 MG	6240552500B320	Generic
TECFIDERA STARTER PACK	DIMETHYL FUMARATE CAPSULE DR STARTER PACK 120 MG & 240 MG	6240552500B320	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 40 MG/0.8ML	6627001504D520	Brand
HYRIMOZ	ADALIMUMAB-ADAZ SOLN PREFILLED SYRINGE 40 MG/0.8ML	6627001504E520	Brand
ENTYVIO	VEDOLIZUMAB SOLN PEN-INJECTOR 108 MG/0.68ML	5250308000D520	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001507F810	Brand
ABRILADA	ADALIMUMAB-AFZB PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001507F820	Brand
VELSIPITY	ETRASIMOD ARGININE TAB 2 MG	52504525100350	Brand
BIMZELX	BIMEKIZUMAB-BKZX SUBCUTANEOUS SOLN AUTO-INJECTOR 160 MG/ML	9025051800D520	Brand
BIMZELX	BIMEKIZUMAB-BKZX SUBCUTANEOUS SOLN PREFILLED SYR 160 MG/ML	9025051800E520	Brand
OMVOH	MIRIKIZUMAB-MRKZ SUBCUTANEOUS SOLN AUTO-INJECTOR 100 MG/ML	5250405040D520	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

OMVOH	MIRIKIZUMAB-MRKZ IV SOLN 300 MG/15ML (20 MG/ML)	52504050402030	Brand
COSENTYX UNOREADY	SECUKINUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9025057500D550	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM CROHNS/UC/HS STARTER	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM PSORIASIS/UVEITIS STARTER	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.8ML	6627001505F520	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 10 MG/0.2ML	6627001505F805	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 20 MG/0.4ML	6627001505F810	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001505F820	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 20 MG/0.2ML	6627001510E508	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN PREFILLED SYRINGE 40 MG/0.4ML	6627001510E517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 40 MG/0.4ML	6627001510D517	Brand
AMJEVITA	ADALIMUMAB-ATTO SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001510D537	Brand
YUFLYMA	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
YUFLYMA CD/UC/HS STARTER	ADALIMUMAB-AATY AUTO-INJECTOR KIT 80 MG/0.8ML	6627001503F560	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 75 MG/0.5ML	4460306000D510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	4460306000D520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	4460306000D530	Brand
ABRILADA 1-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
ABRILADA 2-PEN KIT	ADALIMUMAB-AFZB AUTO-INJECTOR KIT 40 MG/0.8ML	6627001507F520	Brand
HYRIMOZ SENSOREADY PENS	ADALIMUMAB-ADAZ SOLN AUTO-INJECTOR 80 MG/0.8ML	6627001504D540	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ADALIMUMAB-AACF (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 PEN)	ADALIMUMAB-AACF AUTO-INJECTOR KIT 40 MG/0.8ML	6627001502F540	Brand
IDACIO (2 SYRINGE)	ADALIMUMAB-AACF PREFILLED SYRINGE KIT 40 MG/0.8ML	6627001502F840	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	4460306000E530	Brand
ZYMFENTRA 2-SYRINGE	INFLIXIMAB-DYYB SOLN PREFILLED SYRINGE KIT 120 MG/ML	5250504020F830	Brand
ZYMFENTRA 1-PEN	INFLIXIMAB-DYYB SOLN AUTO-INJECTOR KIT 120 MG/ML	5250504020F530	Brand
ZYMFENTRA 2-PEN	INFLIXIMAB-DYYB SOLN AUTO-INJECTOR KIT 120 MG/ML	5250504020F530	Brand
ADALIMUMAB-AATY 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
YUFLYMA 2-SYRINGE KIT	ADALIMUMAB-AATY PREFILLED SYRINGE KIT 20 MG/0.2ML	6627001503F820	Brand
ADALIMUMAB-RYVK (2 PEN)	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 1-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SIMLANDI 2-PEN KIT	ADALIMUMAB-RYVK AUTO-INJECTOR KIT 40 MG/0.4ML	6627001540F520	Brand
SPEVIGO	SPESOLIMAB-SBZO SUBCUTANEOUS SOLN PREF SYR 150 MG/ML	9025057770E530	Brand
TYENNE	TOCILIZUMAB-AAZG IV INJ 80 MG/4ML	66500070172030	Brand
TYENNE	TOCILIZUMAB-AAZG IV INJ 200 MG/10ML	66500070172035	Brand
TYENNE	TOCILIZUMAB-AAZG IV INJ 400 MG/20ML	66500070172040	Brand
ADALIMUMAB-ADBM	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBM STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS	ADALIMUMAB-ADBM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

CYLTEZO STARTER PACKAGE FOR PSORIASIS/UVEITIS	ADALIMUMAB-ADBAM AUTO-INJECTOR KIT 40 MG/0.4ML	6627001505F515	Brand
ADALIMUMAB-ADBAM	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
CYLTEZO	ADALIMUMAB-ADBAM PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001505F815	Brand
OMVOH	MIRIKIZUMAB-MRKZ SUBCUTANEOUS SOLN PREFILL SYRINGE 100 MG/ML	5250405040E520	Brand
FASENRA	BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 10 MG/0.5ML	4460402000E515	Brand
RINVOQ LQ	UPADACITINIB ORAL SOLN 1 MG/ML	66603072002020	Brand
TYENNE	TOCILIZUMAB-AAZG SUBCUTANEOUS SOLN AUTO-INJ 162 MG/0.9ML	6650007017D520	Brand
TYENNE	TOCILIZUMAB-AAZG SUBCUTANEOUS SOLN PREF SYR 162 MG/0.9ML	6650007017E520	Brand
ADBRY	TRALOKINUMAB-LDRM SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9027308045D530	Brand
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK PREFILLED SYRINGE KIT 40 MG/0.4ML	6627001540F820	Brand
OTEZLA	APREMILAST TAB 20 MG	66700015000320	Brand
OTEZLA	APREMILAST TAB STARTER THERAPY PACK 4 X 10 MG & 51 X 20 MG	6670001500B710	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 20 MG/0.25ML	9025055400E510	Brand
TALTZ	IXEKIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 40 MG/0.5ML	9025055400E515	Brand
NEMLUVIO	NEMOLIZUMAB-ILTO FOR SUBCUTANEOUS AUTO-INJECTOR 30 MG	9079355510D420	Brand
EBGLYSS	LEBRIKIZUMAB-LBKZ SUBCUTANEOUS SOLN AUTO-INJECT 250 MG/2ML	9027304010D520	Brand
EBGLYSS	LEBRIKIZUMAB-LBKZ SOLUTION PREFILLED SYRINGE 250 MG/2ML	9027304010E520	Brand
TREMFYA	GUSELKUMAB SOLN AUTO-INJECTOR 100 MG/ML	9025054200D520	Brand
TREMFYA	GUSELKUMAB SOLN AUTO-INJECTOR 200 MG/2ML	9025054200D540	Brand
TREMFYA	GUSELKUMAB SOLN PREFILLED SYRINGE 200 MG/2ML	9025054200E540	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 200 MG/1.14ML	9027302000D515	Brand
DUPIXENT	DUPILUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	9027302000D520	Brand
OCREVUS ZUNOVO	OCRELIZUMAB-HYALURONIDASE-OCSQ INJ 920-23000 MG-UNIT/23ML	62409902602040	Brand

**Approval Criteria**

1 - The requested medication will be used exclusively, and the previously prescribed medication will be discontinued

**2 . Revision History**

Date	Notes
12/17/2024	Updated drug list/GPIs.

Thrombopoiesis Stimulating Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-147130
<b>Guideline Name</b>	Thrombopoiesis Stimulating Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Nplate, Promacta tablet			
Diagnosis	Chronic Immune Thrombocytopenia (ITP)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NPLATE	ROMIPLOSTIM FOR INJ 125 MCG	82405060002110	Brand
NPLATE	ROMIPLOSTIM FOR INJ 250 MCG	82405060002120	Brand
NPLATE	ROMIPLOSTIM FOR INJ 500 MCG	82405060002130	Brand



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

PROMACTA	ELTROMBOPAG OLAMINE TAB 12.5 MG (BASE EQUIV)	82405030100310	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 25 MG (BASE EQUIV)	82405030100320	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 50 MG (BASE EQUIV)	82405030100330	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 75 MG (BASE EQUIV)	82405030100340	Brand

**Approval Criteria**

1 - Diagnosis of chronic immune thrombocytopenia (ITP)

**AND**

2 - History of failure, contraindication, or intolerance to ONE of the following:

- Corticosteroids
- Immunoglobulins
- Splenectomy

Product Name: Alvaiz, Doptelet, Promacta powder pack/oral suspension, Tavalisse			
Diagnosis	Chronic Immune Thrombocytopenia (ITP)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DOPTELET	AVATROMBOPAG MALEATE TAB 20 MG (BASE EQUIV)	82405010200320	Brand
PROMACTA	ELTROMBOPAG OLAMINE POWDER PACK FOR SUSP 25 MG (BASE EQUIV)	82405030103020	Brand
PROMACTA	ELTROMBOPAG OLAMINE POWDER PACK FOR SUSP 12.5 MG (BASE EQ)	82405030103030	Brand
TAVALISSE	FOSTAMATINIB DISODIUM TAB 100 MG (BASE EQUIVALENT)	85756040100310	Brand
TAVALISSE	FOSTAMATINIB DISODIUM TAB 150 MG (BASE EQUIVALENT)	85756040100320	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 9 MG (BASE EQUIV)	82405030050310	Brand

ALVAIZ	ELTROMBOPAG CHOLINE TAB 18 MG (BASE EQUIV)	82405030050320	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 36 MG (BASE EQUIV)	82405030050330	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 54 MG (BASE EQUIV)	82405030050340	Brand

**Approval Criteria**

1 - Diagnosis of chronic immune thrombocytopenia (ITP)

**AND**

2 - ONE of the following:

2.1 BOTH of the following:

2.1.1 History of failure, contraindication, or intolerance to ONE of the following:

- Corticosteroids
- Immunoglobulins
- Splenectomy

**AND**

2.1.2 History of failure, contraindication, or intolerance to BOTH of the following preferred alternatives\*:

- Promacta Tablet (eltrombopag)\*
- Nplate (romiplostim)\*

**OR**

2.2 Patient is currently stable on requested non-preferred medication

Notes	*Drugs may require PA
-------	-----------------------

Product Name: Alvaiz, Doptelet, Nplate, Promacta tablets, Promacta powder pack/oral suspension, Tavalisse	
Diagnosis	Chronic Immune (idiopathic) thrombocytopenia (ITP)

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
DOPTELET	AVATROMBOPAG MALEATE TAB 20 MG (BASE EQUIV)	82405010200320	Brand
NPLATE	ROMIPLOSTIM FOR INJ 125 MCG	82405060002110	Brand
NPLATE	ROMIPLOSTIM FOR INJ 250 MCG	82405060002120	Brand
NPLATE	ROMIPLOSTIM FOR INJ 500 MCG	82405060002130	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 12.5 MG (BASE EQUIV)	82405030100310	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 25 MG (BASE EQUIV)	82405030100320	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 50 MG (BASE EQUIV)	82405030100330	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 75 MG (BASE EQUIV)	82405030100340	Brand
PROMACTA	ELTROMBOPAG OLAMINE POWDER PACK FOR SUSP 25 MG (BASE EQUIV)	82405030103020	Brand
PROMACTA	ELTROMBOPAG OLAMINE POWDER PACK FOR SUSP 12.5 MG (BASE EQ)	82405030103030	Brand
TAVALISSE	FOSTAMATINIB DISODIUM TAB 100 MG (BASE EQUIVALENT)	85756040100310	Brand
TAVALISSE	FOSTAMATINIB DISODIUM TAB 150 MG (BASE EQUIVALENT)	85756040100320	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 9 MG (BASE EQUIV)	82405030050310	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 18 MG (BASE EQUIV)	82405030050320	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 36 MG (BASE EQUIV)	82405030050330	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 54 MG (BASE EQUIV)	82405030050340	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

Product Name: Alvaiz, Promacta tablets, Promacta powder pack/oral suspension	
Diagnosis	Severe Aplastic Anemia
Approval Length	6 month(s)
Therapy Stage	Initial Authorization

Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
PROMACTA	ELTROMBOPAG OLAMINE TAB 12.5 MG (BASE EQUIV)	82405030100310	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 25 MG (BASE EQUIV)	82405030100320	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 50 MG (BASE EQUIV)	82405030100330	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 75 MG (BASE EQUIV)	82405030100340	Brand
PROMACTA	ELTROMBOPAG OLAMINE POWDER PACK FOR SUSP 25 MG (BASE EQUIV)	82405030103020	Brand
PROMACTA	ELTROMBOPAG OLAMINE POWDER PACK FOR SUSP 12.5 MG (BASE EQ)	82405030103030	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 9 MG (BASE EQUIV)	82405030050310	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 18 MG (BASE EQUIV)	82405030050320	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 36 MG (BASE EQUIV)	82405030050330	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 54 MG (BASE EQUIV)	82405030050340	Brand

**Approval Criteria**

1 - Diagnosis of severe aplastic anemia

**AND**

2 - ONE of the following:

**2.1** Used in combination with standard immunosuppressive therapy [e.g., Atgam (antithymocyte globulin equine), Thymoglobulin (antithymocyte globulin rabbit), cyclosporine]

**OR**

**2.2** History of failure, contraindication, or intolerance to at least one course of immunosuppressive therapy [e.g., Atgam (antithymocyte globulin equine), Thymoglobulin (antithymocyte globulin rabbit), cyclosporine]

**AND**

**3** - For Alvaiz and Promacta powder pack/oral suspension requests ONLY: clinical rationale for use instead of preferred Promacta tablet

Product Name: Alvaiz, Promacta tablets, Promacta powder pack/oral suspension

Diagnosis	Severe Aplastic Anemia
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
PROMACTA	ELTROMBOPAG OLAMINE TAB 12.5 MG (BASE EQUIV)	82405030100310	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 25 MG (BASE EQUIV)	82405030100320	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 50 MG (BASE EQUIV)	82405030100330	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 75 MG (BASE EQUIV)	82405030100340	Brand
PROMACTA	ELTROMBOPAG OLAMINE POWDER PACK FOR SUSP 25 MG (BASE EQUIV)	82405030103020	Brand
PROMACTA	ELTROMBOPAG OLAMINE POWDER PACK FOR SUSP 12.5 MG (BASE EQ)	82405030103030	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 9 MG (BASE EQUIV)	82405030050310	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 18 MG (BASE EQUIV)	82405030050320	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 36 MG (BASE EQUIV)	82405030050330	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 54 MG (BASE EQUIV)	82405030050340	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy

Product Name: Alvaiz, Promacta tablet

Diagnosis	Chronic Hepatitis C-associated Thrombocytopenia
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
PROMACTA	ELTROMBOPAG OLAMINE TAB 12.5 MG (BASE EQUIV)	82405030100310	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 25 MG (BASE EQUIV)	82405030100320	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 50 MG (BASE EQUIV)	82405030100330	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 75 MG (BASE EQUIV)	82405030100340	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 9 MG (BASE EQUIV)	82405030050310	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 18 MG (BASE EQUIV)	82405030050320	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 36 MG (BASE EQUIV)	82405030050330	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 54 MG (BASE EQUIV)	82405030050340	Brand

**Approval Criteria**

**1 -** Diagnosis of chronic Hepatitis C-associated thrombocytopenia

**AND**

**2 -** ONE of the following:

- Planning to initiate and maintain interferon-based treatment
- Currently receiving interferon-based treatment

**AND**

**3 -** For Alvaiz requests ONLY: History of failure, contraindication, or intolerance to Promacta tablet

Product Name: Alvaiz, Promacta tablet	
Diagnosis	Chronic Hepatitis C-associated Thrombocytopenia
Approval Length	6 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
PROMACTA	ELTROMBOPAG OLAMINE TAB 12.5 MG (BASE EQUIV)	82405030100310	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 25 MG (BASE EQUIV)	82405030100320	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 50 MG (BASE EQUIV)	82405030100330	Brand
PROMACTA	ELTROMBOPAG OLAMINE TAB 75 MG (BASE EQUIV)	82405030100340	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 9 MG (BASE EQUIV)	82405030050310	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 18 MG (BASE EQUIV)	82405030050320	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 36 MG (BASE EQUIV)	82405030050330	Brand
ALVAIZ	ELTROMBOPAG CHOLINE TAB 54 MG (BASE EQUIV)	82405030050340	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**AND**

2 - Patient is currently on antiviral interferon therapy for treatment of chronic Hepatitis C

Product Name: Doptelet, Mulpleta			
Diagnosis	Thrombocytopenia		
Approval Length	1 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DOPTELET	AVATROMBOPAG MALEATE TAB 20 MG (BASE EQUIV)	82405010200320	Brand
MULPLETA	LUSUTROMBOPAG TAB 3 MG	82405045000320	Brand

**Approval Criteria**

1 - Diagnosis of thrombocytopenia

<b>AND</b>	
<b>2</b> - Patient has chronic liver disease	
<b>AND</b>	
<b>3</b> - Patient is scheduled to undergo a procedure	
<b>AND</b>	
<b>4</b> - History of failure, contraindication, or intolerance to BOTH of the following preferred alternatives*:	
<ul style="list-style-type: none"> <li>• Promacta Tablets (eltrombopag)*</li> <li>• Nplate (romiplostim)*</li> </ul>	
<b>Notes</b>	*Drugs may require PA

<b>Product Name: Nplate</b>			
<b>Diagnosis</b>	Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]		
<b>Approval Length</b>	6 month(s)		
<b>Guideline Type</b>	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
NPLATE	ROMIPLOSTIM FOR INJ 125 MCG	82405060002110	Brand
NPLATE	ROMIPLOSTIM FOR INJ 250 MCG	82405060002120	Brand
NPLATE	ROMIPLOSTIM FOR INJ 500 MCG	82405060002130	Brand
<b>Approval Criteria</b>			
<b>1</b> - Diagnosis of Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]			



**AND**

**2** - Patient is receiving myelosuppressive doses of radiation

## **2 . Revision History**

Date	Notes
5/7/2024	Added Alvaiz as a target to the guideline and updated criteria; Cosmetic/formatting updates.

Tobramycin Inhalation



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140865
<b>Guideline Name</b>	Tobramycin Inhalation
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Brand Bethkis, Kitabis			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
KITABIS PAK	TOBRAMYCIN NEBU SOLN 300 MG/5ML	07000070002520	Brand
BETHKIS	TOBRAMYCIN NEBU SOLN 300 MG/4ML	07000070002530	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of cystic fibrosis (CF)

Product Name: Brand TOBI Nebulizer Solution, generic tobramycin solution for inhalation, TOBI Podhaler

Approval Length 12 month(s)

Therapy Stage Initial Authorization

Guideline Type Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TOBI PODHALER	TOBRAMYCIN INHAL CAP 28 MG	07000070000120	Brand
TOBI	TOBRAMYCIN NEBU SOLN 300 MG/5ML	07000070002520	Brand
TOBRAMYCIN	TOBRAMYCIN NEBU SOLN 300 MG/5ML	07000070002520	Generic
TOBRAMYCIN	TOBRAMYCIN NEBU SOLN 300 MG/4ML	07000070002530	Generic

**Approval Criteria**

1 - Diagnosis of cystic fibrosis (CF)

**AND**

2 - Lung infection with positive culture demonstrating Pseudomonas aeruginosa infection

**AND**

3 - History of failure, intolerance, or contraindication to BOTH of the following

- Brand Bethkis
- Kitabis

Product Name: Brand TOBI Nebulizer Solution, generic tobramycin solution for inhalation, TOBI Podhaler

Approval Length 12 month(s)

Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TOBI PODHALER	TOBRAMYCIN INHAL CAP 28 MG	07000070000120	Brand
TOBI	TOBRAMYCIN NEBU SOLN 300 MG/5ML	07000070002520	Brand
TOBRAMYCIN	TOBRAMYCIN NEBU SOLN 300 MG/5ML	07000070002520	Generic
TOBRAMYCIN	TOBRAMYCIN NEBU SOLN 300 MG/4ML	07000070002530	Generic
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy			

## 2 . Revision History

Date	Notes
3/10/2021	Added generic Bethkis. Updated product name listing of first criteria box to specify brand Bethkis and updated NP language to specify T/F must be brand Bethkis.

Topical Capsaicin Products



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140833
<b>Guideline Name</b>	Topical Capsaicin Products
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Diclareal			
Approval Length	3 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DICLAREAL	DICLOFENAC SOD SOLN 2% & CAPSAICIN CREAM 0.025% THER PACK	9021990225B132	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes) confirming diagnosis of osteoarthritis of the knees			

**AND**

**2** - Submission of medical records (e.g., chart notes, paid claims history) documenting history of failure to ALL of the following:

- diclofenac 1% topical gel
- diclofenac 2% topical solution
- topical capsaicin cream/patch

Product Name: Trubrex			
Approval Length	3 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TRUBREXA	LIDOCAINE-CAPSAICIN PATCH 4.75-0.025%	90859902995930	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming requested medication is being used for the treatment of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, etc.

**AND**

**2** - Submission of medical records (e.g., chart notes, paid claims history) documenting trial and failure, contraindication, or intolerance to ALL of the following:

- diclofenac 1% topical gel
- topical capsaicin cream/patch
- topical lidocaine patch

**2 . Revision History**

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Date	Notes
12/7/2023	New guideline

Topical NSAIDs



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140719
<b>Guideline Name</b>	Topical NSAIDs
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Flector Patch, generic diclofenac epolamine 1.3% patch			
Approval Length	2 Week(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DICLOFENAC EPOLAMINE	DICLOFENAC EPOLAMINE PATCH 1.3%	90210030205920	Generic
FLECTOR	DICLOFENAC EPOLAMINE PATCH 1.3%	90210030205920	Generic
<b>Approval Criteria</b>			



**1 - Diagnosis of acute pain due to minor strains, sprains, or contusions**

**AND**

**2 - ONE of the following:**

**2.1** The patient did not receive adequate pain relief when treated with at least three preferred non-steroidal anti-inflammatory drugs (NSAIDs) (An inadequate response to treatment is defined as pain and/or inflammatory symptoms not resolved after 14 days of therapy)

- Diclofenac DR (Generic Voltaren)
- Diclofenac ER (Generic Voltaren ER)
- Etodolac (Generic Lodine)
- Etodolac ER (Generic Lodine ER)
- Fenoprofen (Generic Nalfon)
- Flurbiprofen (Generic Ansaid)
- Ibuprofen
- Indomethacin (Generic Indocin)
- Ketorolac (Generic Toradol)
- Mefenamic (Generic Ponstel)
- Meloxicam (Generic Mobic)
- Nabumetone (Generic Relafen)
- Nabumetone DS (Generic Relafen DS)
- Naproxen (Generic Anaprox)
- Naproxen DR (Generic Anaprox DR)
- Naproxen EC (Generic Anaprox EC)
- Oxaprozin (Generic Daypro)
- Piroxicam (Generic Feldene)
- Sulindac (Generic Clinoril)

**OR**

**2.2** The patient has one of the following risk factors for NSAID-induced adverse GI (gastrointestinal) events:

- Patient is greater than or equal to 65 years of age
- Prior history of peptic, gastric, or duodenal ulcer
- History of NSAID-related ulcer
- History of clinically significant GI (gastrointestinal) bleeding
- Untreated or active H. Pylori gastritis
- Concurrent use of oral corticosteroids (e.g. prednisone, prednisolone, dexamethasone)
- Concurrent use of anticoagulants (e.g. warfarin, heparin)

- Concurrent use of antiplatelets (e.g. aspirin including low-dose, clopidogrel)

Product Name: Pennsaid 2%, diclofenac sodium soln 1.5%

Approval Length | 12 month(s)

Guideline Type | Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
PENNSAID	DICLOFENAC SODIUM SOLN 2%	90210030302030	Brand
DICLOFENAC SODIUM	DICLOFENAC SODIUM SOLN 1.5%	90210030302025	Generic

**Approval Criteria**

1 - Patient has a diagnosis of pain due to osteoarthritis of the knee(s)

**AND**

2 - ONE of the following:

**2.1** The patient did not receive adequate pain relief when treated with at least three preferred non-steroidal anti-inflammatory drugs (NSAIDs) (An inadequate response to treatment is defined as pain and/or inflammatory symptoms not resolved after 14 days of therapy)

- Diclofenac DR (Generic Voltaren)
- Diclofenac ER (Generic Voltaren ER)
- Etodolac (Generic Lodine)
- Etodolac ER (Generic Lodine ER)
- Fenoprofen (Generic Nalfon)
- Flurbiprofen (Generic Ansaid)
- Ibuprofen
- Indomethacin (Generic Indocin)
- Ketorolac (Generic Toradol)
- Mefenamic (Generic Ponstel)
- Meloxicam (Generic Mobic)
- Nabumetone (Generic Relafen)
- Nabumetone DS (Generic Relafen DS)
- Naproxen (Generic Anaprox)
- Naproxen DR (Generic Anaprox DR)
- Naproxen EC (Generic Anaprox EC)
- Oxaprozin (Generic Daypro)

- Piroxicam (Generic Feldene)
- Sulindac (Generic Clinoril)

**OR**

**2.2** The patient has one of the following risk factors for NSAID-induced adverse GI (gastrointestinal) events:

- Patient is greater than or equal to 65 years of age
- Prior history of peptic, gastric, or duodenal ulcer
- History of NSAID-related ulcer
- History of clinically significant GI bleeding
- Untreated or active H. Pylori gastritis
- Concurrent use of oral corticosteroids (e.g. prednisone, prednisolone, dexamethasone)
- Concurrent use of anticoagulants (e.g. warfarin, heparin)
- Concurrent use of antiplatelets (e.g. aspirin including low-dose, clopidogrel)

**AND**

**3** - Patient has a history of failure, intolerance, or contraindication to diclofenac topical gel 1% (Rx formulation), or Voltaren OTC (over the counter)

Product Name: generic diclofenac topical gel 1% (Rx formulation), Voltaren OTC			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
DICLOFENAC SODIUM	DICLOFENAC SODIUM GEL 1%	90210030304020	Generic
VOLTAREN	DICLOFENAC SODIUM GEL 1%	90210030304020	Brand
<b>Approval Criteria</b>			
1 - The patient has a diagnosis of pain due to osteoarthritis of joints amenable to topical treatment, including but not limited to the hands, knees, ankles, elbows, feet, and wrists			

**AND**

**2** - ONE of the following:

**2.1** The patient did not receive adequate pain relief when treated with at least three preferred non-steroidal anti-inflammatory drugs (NSAIDs) (An inadequate response to treatment is defined as pain and/or inflammatory symptoms not resolved after 14 days of therapy)

- Diclofenac DR (Generic Voltaren)
- Diclofenac ER (Generic Voltaren ER)
- Etodolac (Generic Lodine)
- Etodolac ER (Generic Lodine ER)
- Fenoprofen (Generic Nalfon)
- Flurbiprofen (Generic Ansaid)
- Ibuprofen
- Indomethacin (Generic Indocin)
- Ketorolac (Generic Toradol)
- Mefenamic (Generic Ponstel)
- Meloxicam (Generic Mobic)
- Nabumetone (Generic Relafen)
- Nabumetone DS (Generic Relafen DS)
- Naproxen (Generic Anaprox)
- Naproxen DR (Generic Anaprox DR)
- Naproxen EC (Generic Anaprox EC)
- Oxaprozin (Generic Daypro)
- Piroxicam (Generic Feldene)
- Sulindac (Generic Clinoril)

**OR**

**2.2** The patient has one of the following risk factors for NSAID-induced adverse GI (gastrointestinal) events:

- Patient is greater than or equal to 65 years of age
- Prior history of peptic, gastric, or duodenal ulcer
- History of NSAID-related ulcer
- History of clinically significant GI bleeding
- Untreated or active H. Pylori gastritis
- Concurrent use of oral corticosteroids (e.g. prednisone, prednisolone, dexamethasone)
- Concurrent use of anticoagulants (e.g. warfarin, heparin)
- Concurrent use of antiplatelets (e.g. aspirin including low-dose, clopidogrel)

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Tremfya (guselkumab)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-160380
<b>Guideline Name</b>	Tremfya (guselkumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	12/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Tremfya SC 100 mg			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TREMFYA	GUSELKUMAB SOLN AUTO-INJECTOR 100 MG/ML	9025054200D520	Brand
TREMFYA	GUSELKUMAB SOLN PREFILLED SYRINGE 100 MG/ML	9025054200E520	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory values) documenting ALL of the following:

**1.1** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**1.2** Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis

**AND**

**1.3** BOTH of the following:

**1.3.1** History of failure to ONE of the following topical therapies, unless contraindicated or clinically significant adverse effects are experienced (document drug, date, and duration of trial)\*:

- Corticosteroids (e.g., betamethasone, clobetasol, desonide)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**1.3.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document date and duration of trial)\*

**AND**

**1.4** History of failure, contraindication, or intolerance to ALL of the following preferred biologic products (document drug, date, and duration of trial)\*:

- A preferred^ adalimumab biosimilar
- Enbrel (etanercept)
- Otezla (apremilast)

**AND**

**1.5** Patient is not receiving Tremfya in combination with ANY of the following:

- Biologic disease modifying antirheumatic drug (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**1.6** Prescribed by or in consultation with a dermatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Tremfya therapy as documented by claims history or medical records (document date and duration of therapy)

**AND**

**2.2** Diagnosis of chronic moderate to severe plaque psoriasis

**AND**

**2.3** Patient is not receiving Tremfya in combination with ANY of the following:

- Biologic disease modifying antirheumatic drug (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]



<ul style="list-style-type: none"> <li>Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2.4 Prescribed by or in consultation with a dermatologist</b></p>	
Notes	<p>*Claims history may be used in conjunction as documentation of drug, date, and duration of trial.</p> <p>^PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>If patient meets criteria above, please approve at GPI-14.</p>

Product Name: Tremfya SC 100 mg			
Diagnosis	Plaque Psoriasis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TREMFYA	GUSELKUMAB SOLN AUTO-INJECTOR 100 MG/ML	9025054200D520	Brand
TREMFYA	GUSELKUMAB SOLN PREFILLED SYRINGE 100 MG/ML	9025054200E520	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Tremfya therapy

**AND**

2 - Patient is not receiving Tremfya in combination with ANY of the following:

- Biologic disease modifying antirheumatic drug (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]

- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**3** - Prescribed by or in consultation with a dermatologist

Notes	If patient meets criteria above, please approve at GPI-14.
-------	--

Product Name: Tremfya SC 100 mg

Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TREMFYA	GUSELKUMAB SOLN AUTO-INJECTOR 100 MG/ML	9025054200D520	Brand
TREMFYA	GUSELKUMAB SOLN PREFILLED SYRINGE 100 MG/ML	9025054200E520	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory values) documenting ALL of the following:

**1.1** Diagnosis of active psoriatic arthritis

**AND**

**1.2** History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document date and duration of trial)

**AND**

**1.3** History of failure, contraindication, or intolerance to ALL of the following preferred biologic products (document drug, date, and duration of trial):

- A preferred^ adalimumab biosimilar or Enbrel (etanercept)
- infliximab
- Orenzia (abatacept)
- Otezla (apremilast)
- Xeljanz (tofacitinib) oral tablet

**AND**

**1.4** Patient is not receiving Tremfya in combination with ANY of the following:

- Biologic disease modifying antirheumatic drug (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orenzia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**1.5** Prescribed by, or in consultation with, ONE of the following:

- Rheumatologist
- Dermatologist

**OR**

**2** - ALL of the following:

**2.1** Patient is currently on Tremfya therapy as documented by claims history or medical records (document date and duration of therapy)

**AND**

**2.2** Diagnosis of active psoriatic arthritis

**AND**

**2.3** Patient is not receiving Tremfya in combination with ANY of the following:

- Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**2.4** Prescribed by, or in consultation with, ONE of the following:

- Rheumatologist
- Dermatologist

Notes	<p>^PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a></p> <p>If patient meets criteria above, please approve at GPI-14.</p>
-------	---

Product Name: Tremfya SC 100 mg			
Diagnosis	Psoriatic Arthritis (PsA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TREMFYA	GUSELKUMAB SOLN AUTO-INJECTOR 100 MG/ML	9025054200D520	Brand
TREMFYA	GUSELKUMAB SOLN PREFILLED SYRINGE 100 MG/ML	9025054200E520	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to Tremfya therapy

**AND**

**2** - Patient is not receiving Tremfya in combination with ANY of the following:

- Biologic disease modifying antirheumatic drug (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

**AND**

**3** - Prescribed by, or in consultation with, ONE of the following:

- Rheumatologist
- Dermatologist

Notes

If patient meets criteria above, please approve at GPI-14.

**Product Name: Tremfya SC**

Diagnosis | Ulcerative Colitis (UC)

Approval Length | 12 month(s)

Therapy Stage | Initial Authorization

Guideline Type | Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TREMFYA	GUSELKUMAB SOLN AUTO-INJECTOR 100 MG/ML	9025054200D520	Brand
TREMFYA	GUSELKUMAB SOLN PREFILLED SYRINGE 100 MG/ML	9025054200E520	Brand
TREMFYA	GUSELKUMAB SOLN AUTO-INJECTOR 200 MG/2ML	9025054200D540	Brand
TREMFYA	GUSELKUMAB SOLN PREFILLED SYRINGE 200 MG/2ML	9025054200E540	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of moderately to severely active ulcerative colitis

**AND**

2 - Will be used as a maintenance dose following the intravenous induction doses

**AND**

3 - Prescribed by or in consultation with a gastroenterologist

**AND**

4 - Patient is not receiving Tremfya in combination with ANY of the following:

- Biologic disease modifying antirheumatic drug (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

Product Name: Tremfya SC			
Diagnosis	Ulcerative Colitis (UC)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TREMFYA	GUSELKUMAB SOLN AUTO-INJECTOR 100 MG/ML	9025054200D520	Brand
TREMFYA	GUSELKUMAB SOLN PREFILLED SYRINGE 100 MG/ML	9025054200E520	Brand
TREMFYA	GUSELKUMAB SOLN AUTO-INJECTOR 200 MG/2ML	9025054200D540	Brand
TREMFYA	GUSELKUMAB SOLN PREFILLED SYRINGE 200 MG/2ML	9025054200E540	Brand
<b>Approval Criteria</b>			
1 - Patient demonstrates positive clinical response to therapy as evidenced by at least ONE of the following:			

- Improvement in intestinal inflammation (e.g., mucosal healing, improvement of lab values [platelet counts, erythrocyte sedimentation rate, C-reactive protein level]) from baseline
- Reversal of high fecal output state

**AND**

**2** - Prescribed by or in consultation with a gastroenterologist

**AND**

**3** - Patient is not receiving Tremfya in combination with ANY of the following:

- Biologic disease modifying antirheumatic drug (DMARD) [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
- Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

## 2 . Revision History

Date	Notes
11/8/2024	Updated GL name. Added new criteria for UC. Updated criteria and notes section for PsA and PsO. Updated product name lists and GPI tables accordingly.

Tretinoin Capsules



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140696
<b>Guideline Name</b>	Tretinoin Capsules
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Tretinoin capsules			
Diagnosis	Acute Promyelocytic Leukemia (APL)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TRETINOIN	TRETINOIN CAP 10 MG	21708080000110	Generic
<b>Approval Criteria</b>			



1 - Diagnosis of acute promyelocytic leukemia

Product Name: Tretinoin capsules

Diagnosis	Acute Promyelocytic Leukemia (APL)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TRETINOIN	TRETINOIN CAP 10 MG	21708080000110	Generic

**Approval Criteria**

1 - Documentation of positive clinical response to tretinoin capsules

Product Name: Tretinoin capsules

Diagnosis	NCCN Recommended Regimens
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TRETINOIN	TRETINOIN CAP 10 MG	21708080000110	Generic

**Approval Criteria**

1 - Tretinoin capsules will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.

Product Name: Tretinoin capsules

Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TRETINOIN	TRETINOIN CAP 10 MG	21708080000110	Generic
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to tretinoin capsules</p>			

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Tretinoin Topical



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140723
<b>Guideline Name</b>	Tretinoin Topical
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Retin-A cream and gel*			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
RETIN-A	TRETINOIN CREAM 0.025%	90050030003703	Brand
RETIN-A	TRETINOIN CREAM 0.05%	90050030003705	Brand
RETIN-A	TRETINOIN CREAM 0.1%	90050030003710	Brand
RETIN-A	TRETINOIN GEL 0.01%	90050030004005	Brand
RETIN-A	TRETINOIN GEL 0.025%	90050030004010	Brand

**Approval Criteria**

1 - One of the following:

1.1 Patient is 26 years of age or less

**OR**

1.2 Both of the following:

- Patient is greater than 26 years of age
- Diagnosis of acne vulgaris

**AND**

2 - The patient must have a history of therapeutic failure, contraindication, or intolerance to ALL of the following:

- benzoyl peroxide
- topical clindamycin
- topical erythromycin

Notes	*Only Brand Covered
-------	---------------------

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Trikafta (elexacaftor/tezacaftor/ivacaftor)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140982
<b>Guideline Name</b>	Trikafta (elexacaftor/tezacaftor/ivacaftor)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	7/1/2023
-----------------	----------

## 1 . Criteria

Product Name: Trikafta (80-40-60 mg) granules packet, Trikafta (100-50-75 mg) granules packet			
Diagnosis	Cystic Fibrosis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TRIKAFTA	ELEXACAF-TEZACAF-IVACAF 80-40-60 MG& IVACAF 59.5MG THPK GRAN	4530990340B120	Brand
TRIKAFTA	ELEXACAF-TEZACAF-IVACAF 100-50-75 MG& IVACAF 75MG THPK GRAN	4530990340B140	Brand

**Approval Criteria**

1 - Diagnosis of cystic fibrosis (CF)

**AND**

2 - Submission of laboratory results documenting that the patient has at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data

**AND**

3 - Patient is between 2 and 6 years of age

**AND**

4 - Prescribed by, or in consultation with, a specialist affiliated with a CF care center

Product Name: Trikafta (50-25-37.5 mg) tablet pack, Trikafta (100-50-75 mg) tablet pack

Diagnosis	Cystic Fibrosis
Approval Length	6 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TRIKAFTA	ELEXACAF-TEZACAF-IVACAF 50-25-37.5 MG & IVACAFTOR 75 MG TBPB	4530990340B720	Brand
TRIKAFTA	ELEXACAF-TEZACAF-IVACAF 100-50-75 MG & IVACAFTOR 150 MG TBPB	4530990340B740	Brand

**Approval Criteria**

1 - Diagnosis of cystic fibrosis (CF)

**AND**

**2** - Submission of laboratory results documenting that the patient has at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data

**AND**

**3** - The patient is 6 years of age or older

**AND**

**4** - Prescribed by, or in consultation with, a specialist affiliated with a CF care center

**Product Name: Trikafta granules packets, Trikafta tablet packs**

Diagnosis	Cystic Fibrosis
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
TRIKAFTA	ELEXACAF-TEZACAF-IVACAF 80-40-60 MG& IVACAF 59.5MG THPK GRAN	4530990340B120	Brand
TRIKAFTA	ELEXACAF-TEZACAF-IVACAF 100-50-75 MG& IVACAF 75MG THPK GRAN	4530990340B140	Brand
TRIKAFTA	ELEXACAF-TEZACAF-IVACAF 50-25-37.5 MG & IVACAFTOR 75 MG TBPk	4530990340B720	Brand
TRIKAFTA	ELEXACAF-TEZACAF-IVACAF 100-50-75 MG &IVACAFTOR 150 MG TBPk	4530990340B740	Brand

**Approval Criteria**

**1** - Provider attests that the patient has achieved a clinically meaningful response while on Trikafta therapy to ONE of the following:

- Lung function as demonstrated by percent predicted expiratory volume in 1 second (ppFEV1)
- Body mass index (BMI)
- Pulmonary exacerbations
- Quality of life as demonstrated by Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score

**AND**

**2** - Prescribed by, or in consultation with, a specialist affiliated with a cystic fibrosis (CF) care center

## 2 . Revision History

Date	Notes
6/8/2023	Added criteria for granule packets. Updated GL name



Triptans



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-148523
<b>Guideline Name</b>	Triptans
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Brand Amerge, Brand Imitrex tablets, Brand Imitrex injection, generic sumatriptan 6mg PFS, generic almotriptan, Brand Maxalt, Brand Maxalt MLT, Onzetra Xsail, Brand Relpax, generic eletriptan, Brand Treximet, generic sumatriptan-naproxen, Zembrace, Brand Zomig, Brand Frova, generic frovatriptan, Tosymra			
Diagnosis	Non-preferred products		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
AMERGE	NARATRIPTAN HCL TAB 1 MG (BASE EQUIV)	67406050100310	Brand
AMERGE	NARATRIPTAN HCL TAB 2.5 MG (BASE EQUIV)	67406050100320	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

IMITREX	SUMATRIPTAN SUCCINATE TAB 25 MG	67406070100305	Brand
IMITREX	SUMATRIPTAN SUCCINATE TAB 50 MG	67406070100310	Brand
IMITREX	SUMATRIPTAN SUCCINATE TAB 100 MG	67406070100320	Brand
IMITREX	SUMATRIPTAN SUCCINATE INJ 6 MG/0.5ML	67406070102010	Brand
IMITREX STATDOSE REFILL	SUMATRIPTAN SUCCINATE SOLUTION CARTRIDGE 4 MG/0.5ML	6740607010E210	Brand
IMITREX STATDOSE REFILL	SUMATRIPTAN SUCCINATE SOLUTION CARTRIDGE 6 MG/0.5ML	6740607010E220	Brand
IMITREX STATDOSE SYSTEM	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 4 MG/0.5ML	6740607010D510	Brand
SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE SOLUTION PREFILLED SYRINGE 6 MG/0.5ML	6740607010E520	Generic
ALMOTRIPTAN MALATE	ALMOTRIPTAN MALATE TAB 6.25 MG	67406010100320	Generic
ALMOTRIPTAN MALATE	ALMOTRIPTAN MALATE TAB 12.5 MG	67406010100330	Generic
MAXALT	RIZATRIPTAN BENZOATE TAB 10 MG (BASE EQUIVALENT)	67406060100320	Brand
MAXALT-MLT	RIZATRIPTAN BENZOATE ORAL DISINTEGRATING TAB 10 MG (BASE EQ)	67406060107230	Brand
ONZETRA XSAIL	SUMATRIPTAN SUCCINATE EXHALER POWDER 11 MG/NOSEPIECE	6740607010G420	Brand
ELETRIPTAN HYDROBROMIDE	ELETRIPTAN HYDROBROMIDE TAB 20 MG (BASE EQUIVALENT)	67406025100320	Generic
RELPAK	ELETRIPTAN HYDROBROMIDE TAB 20 MG (BASE EQUIVALENT)	67406025100320	Brand
ELETRIPTAN HYDROBROMIDE	ELETRIPTAN HYDROBROMIDE TAB 40 MG (BASE EQUIVALENT)	67406025100340	Generic
RELPAK	ELETRIPTAN HYDROBROMIDE TAB 40 MG (BASE EQUIVALENT)	67406025100340	Brand
ZEMBRACE SYMTOUCH	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 3 MG/0.5ML	6740607010D505	Brand
ZOMIG	ZOLMITRIPTAN TAB 2.5 MG	67406080000320	Brand
ZOMIG	ZOLMITRIPTAN TAB 5 MG	67406080000330	Brand
FROVA	FROVATRIPTAN SUCCINATE TAB 2.5 MG (BASE EQUIVALENT)	67406030100320	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

FROVATRIPTAN SUCCINATE	FROVATRIPTAN SUCCINATE TAB 2.5 MG (BASE EQUIVALENT)	67406030100320	Generic
TOSYMRA	SUMATRIPTAN NASAL SPRAY 10 MG/ACT	67406070002020	Brand
MAXALT-MLT	RIZATRIPTAN BENZOATE ORAL DISINTEGRATING TAB 5 MG (BASE EQ)	67406060107220	Brand
TREXIMET	SUMATRIPTAN-NAPROXEN SODIUM TAB 85-500 MG	67992002600320	Brand
IMITREX STATDOSE SYSTEM	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 6 MG/0.5ML	6740607010D520	Brand
SUMATRIPTAN/NAPROXEN SODIUM	SUMATRIPTAN-NAPROXEN SODIUM TAB 85-500 MG	67992002600320	Generic
ALMOTRIPTAN	ALMOTRIPTAN MALATE TAB 6.25 MG	67406010100320	Generic
ALMOTRIPTAN	ALMOTRIPTAN MALATE TAB 12.5 MG	67406010100330	Generic

**Approval Criteria**

1 - Diagnosis of migraine headaches with or without aura

**AND**

2 - Patient has a history of failure, contraindication, or intolerance to a trial of at least three preferred products (document drugs, duration, and date of trials)\*

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Brand Imitrex (inj, cartridge, auto-injector and PFS), generic sumatriptan (inj, cartridge, auto-injector and PFS)\*

Diagnosis	Migraine Headaches with or without Aura
Approval Length	12 month(s)
Guideline Type	Quantity Limits

Product Name	Generic Name	GPI	Brand/Generic
IMITREX	SUMATRIPTAN SUCCINATE INJ 6 MG/0.5ML	67406070102010	Brand

SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE INJ 6 MG/0.5ML	67406070102010	Generic
IMITREX STATDOSE REFILL	SUMATRIPTAN SUCCINATE SOLUTION CARTRIDGE 4 MG/0.5ML	6740607010E210	Brand
SUMATRIPTAN SUCCINATE REFILL	SUMATRIPTAN SUCCINATE SOLUTION CARTRIDGE 4 MG/0.5ML	6740607010E210	Generic
IMITREX STATDOSE REFILL	SUMATRIPTAN SUCCINATE SOLUTION CARTRIDGE 6 MG/0.5ML	6740607010E220	Brand
SUMATRIPTAN SUCCINATE REFILL	SUMATRIPTAN SUCCINATE SOLUTION CARTRIDGE 6 MG/0.5ML	6740607010E220	Generic
IMITREX STATDOSE SYSTEM	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 4 MG/0.5ML	6740607010D510	Brand
SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 4 MG/0.5ML	6740607010D510	Generic
IMITREX STATDOSE SYSTEM	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 6 MG/0.5ML	6740607010D520	Brand
SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 6 MG/0.5ML	6740607010D520	Generic
SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE SOLUTION PREFILLED SYRINGE 6 MG/0.5ML	6740607010E520	Generic

**Approval Criteria**

1 - Diagnosis of migraine headaches with or without aura

**AND**

2 - Prescribed by or in consultation with one of the following:

- Neurologist
- Pain management specialist

**AND**

3 - Patient is currently receiving prophylactic therapy with at least ONE of the following:

**3.1 Amitriptyline (Elavil)**

**OR**

**3.2 One of the following beta-blockers:**

- atenolol
- metoprolol
- nadolol\*\*
- propranolol
- timolol\*\*

**OR**

**3.3 Divalproex sodium (Depakote/Depakote ER)**

**OR**

**3.4 OnabotulinumtoxinA (Botox) \*\*\***

**OR**

**3.5 Topiramate (Topamax)**

**OR**

**3.6 Venlafaxine (Effexor/Effexor XR)**

**OR**

**3.7 Calcitonin gene-related peptide (CGRP) receptor antagonists [e.g., Aimovig (erenumab), Emgality (galcanezumab)]**

**AND**

**4** - One of the following:

**4.1** Higher dose or quantity is supported in the dosage and administration section of the manufacturer’s prescribing information

**OR**

**4.2** Higher dose or quantity is supported by one of the following compendia:

- American Hospital Formulary Service Drug Information
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**OR**

**4.3** Physician provides evidence from published biomedical literature to support safety and additional efficacy at doses/quantities greater than those approved by the Food and Drug Administration (FDA) for the diagnosis indicated

**AND**

**5** - Physician acknowledges that the potential benefit outweighs the risk associated with the higher dose or quantity

Notes	<p>* See “Quantity Limits” table in background section for quantity limits</p> <p>** Nadolol and timolol are non-preferred and should not be included in denial to provider</p> <p>*** OnabotulinumtoxinA (Botox) is a medical benefit, should not be included in denial to provider</p>
-------	--

Product Name: Brand Imitrex (inj, cartridge, auto-injector and PFS), generic sumatriptan (inj, cartridge, auto-injector and PFS)*	
Diagnosis	Cluster Headaches
Approval Length	12 month(s)

Guideline Type		Quantity Limit	
Product Name	Generic Name	GPI	Brand/Generic
IMITREX	SUMATRIPTAN SUCCINATE INJ 6 MG/0.5ML	67406070102010	Brand
SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE INJ 6 MG/0.5ML	67406070102010	Generic
IMITREX STATDOSE REFILL	SUMATRIPTAN SUCCINATE SOLUTION CARTRIDGE 4 MG/0.5ML	6740607010E210	Brand
SUMATRIPTAN SUCCINATE REFILL	SUMATRIPTAN SUCCINATE SOLUTION CARTRIDGE 4 MG/0.5ML	6740607010E210	Generic
IMITREX STATDOSE REFILL	SUMATRIPTAN SUCCINATE SOLUTION CARTRIDGE 6 MG/0.5ML	6740607010E220	Brand
SUMATRIPTAN SUCCINATE REFILL	SUMATRIPTAN SUCCINATE SOLUTION CARTRIDGE 6 MG/0.5ML	6740607010E220	Generic
IMITREX STATDOSE SYSTEM	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 4 MG/0.5ML	6740607010D510	Brand
SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 4 MG/0.5ML	6740607010D510	Generic
IMITREX STATDOSE SYSTEM	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 6 MG/0.5ML	6740607010D520	Brand
SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 6 MG/0.5ML	6740607010D520	Generic
SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE SOLUTION PREFILLED SYRINGE 6 MG/0.5ML	6740607010E520	Generic

**Approval Criteria**

1 - Diagnosis of cluster headaches

**AND**

2 - Prescribed by or in consultation with one of the following:

- Neurologist
- Pain management specialist

**AND**

**3** - Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least three months.

**AND**

**4** - One of the following:

**4.1** Higher dose or quantity is supported in the dosage and administration section of the manufacturer's prescribing information

**OR**

**4.2** Higher dose or quantity is supported by one of the following compendia:

- American Hospital Formulary Service Drug Information
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**OR**

**4.3** Physician provides evidence from published biomedical literature to support safety and additional efficacy at doses/quantities greater than those approved by the Food and Drug Administration (FDA) for the diagnosis indicated

**AND**

**5** - Physician acknowledges that the potential benefit outweighs the risk associated with the higher dose or quantity

Notes

\* See "Quantity Limits" table in background section for quantity limits

Product Name: Brand Amerge, generic naratriptan, Brand Frova, generic frovatriptan, Brand Imitrex tablets and nasal spray, generic sumatriptan tablets and nasal spray, generic almotriptan, Brand Maxalt and Maxalt MLT, generic rizatriptan and rizatriptan MLT, Onzetra Xsail, Brand Relpax, generic eletriptan, Brand Treximet, generic sumatriptan-naproxen,



UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

Zembrace Sym Touch, Brand Zomig, generic zolmitriptan and zolmitriptan ZMT, Brand Zomig nasal spray, generic zolmitriptan nasal spray, Tosymra *			
Approval Length	12 month(s)		
Guideline Type	Quantity Limit		
Product Name	Generic Name	GPI	Brand/Generic
AMERGE	NARATRIPTAN HCL TAB 1 MG (BASE EQUIV)	67406050100310	Brand
NARATRIPTAN HCL	NARATRIPTAN HCL TAB 1 MG (BASE EQUIV)	67406050100310	Generic
AMERGE	NARATRIPTAN HCL TAB 2.5 MG (BASE EQUIV)	67406050100320	Brand
NARATRIPTAN HCL	NARATRIPTAN HCL TAB 2.5 MG (BASE EQUIV)	67406050100320	Generic
IMITREX	SUMATRIPTAN NASAL SPRAY 5 MG/ACT	67406070002010	Brand
SUMATRIPTAN	SUMATRIPTAN NASAL SPRAY 5 MG/ACT	67406070002010	Generic
IMITREX	SUMATRIPTAN NASAL SPRAY 20 MG/ACT	67406070002040	Brand
SUMATRIPTAN	SUMATRIPTAN NASAL SPRAY 20 MG/ACT	67406070002040	Generic
IMITREX	SUMATRIPTAN SUCCINATE TAB 25 MG	67406070100305	Brand
SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE TAB 25 MG	67406070100305	Generic
IMITREX	SUMATRIPTAN SUCCINATE TAB 50 MG	67406070100310	Brand
SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE TAB 50 MG	67406070100310	Generic
IMITREX	SUMATRIPTAN SUCCINATE TAB 100 MG	67406070100320	Brand
SUMATRIPTAN SUCCINATE	SUMATRIPTAN SUCCINATE TAB 100 MG	67406070100320	Generic
ALMOTRIPTAN MALATE	ALMOTRIPTAN MALATE TAB 6.25 MG	67406010100320	Generic
ALMOTRIPTAN MALATE	ALMOTRIPTAN MALATE TAB 12.5 MG	67406010100330	Generic
RIZATRIPTAN BENZOATE	RIZATRIPTAN BENZOATE TAB 5 MG (BASE EQUIVALENT)	67406060100310	Generic
MAXALT	RIZATRIPTAN BENZOATE TAB 10 MG (BASE EQUIVALENT)	67406060100320	Brand
RIZATRIPTAN BENZOATE	RIZATRIPTAN BENZOATE TAB 10 MG (BASE EQUIVALENT)	67406060100320	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

MAXALT-MLT	RIZATRIPTAN BENZOATE ORAL DISINTEGRATING TAB 10 MG (BASE EQ)	67406060107230	Brand
ONZETRA XSAIL	SUMATRIPTAN SUCCINATE EXHALER POWDER 11 MG/NOSEPIECE	6740607010G420	Brand
ELETRIPTAN HYDROBROMIDE	ELETRIPTAN HYDROBROMIDE TAB 20 MG (BASE EQUIVALENT)	67406025100320	Generic
RELPAK	ELETRIPTAN HYDROBROMIDE TAB 20 MG (BASE EQUIVALENT)	67406025100320	Brand
ELETRIPTAN HYDROBROMIDE	ELETRIPTAN HYDROBROMIDE TAB 40 MG (BASE EQUIVALENT)	67406025100340	Generic
RELPAK	ELETRIPTAN HYDROBROMIDE TAB 40 MG (BASE EQUIVALENT)	67406025100340	Brand
TREXIMET	SUMATRIPTAN-NAPROXEN SODIUM TAB 85-500 MG	67992002600320	Brand
ZEMBRACE SYMTOUCH	SUMATRIPTAN SUCCINATE SOLUTION AUTO-INJECTOR 3 MG/0.5ML	6740607010D505	Brand
ZOMIG	ZOLMITRIPTAN NASAL SPRAY 2.5 MG/SPRAY UNIT	67406080002010	Brand
ZOMIG	ZOLMITRIPTAN NASAL SPRAY 5 MG/SPRAY UNIT	67406080002020	Brand
ZOLMITRIPTAN	ZOLMITRIPTAN TAB 2.5 MG	67406080000320	Generic
ZOMIG	ZOLMITRIPTAN TAB 2.5 MG	67406080000320	Brand
ZOLMITRIPTAN	ZOLMITRIPTAN TAB 5 MG	67406080000330	Generic
ZOMIG	ZOLMITRIPTAN TAB 5 MG	67406080000330	Brand
FROVA	FROVATRIPTAN SUCCINATE TAB 2.5 MG (BASE EQUIVALENT)	67406030100320	Brand
FROVATRIPTAN SUCCINATE	FROVATRIPTAN SUCCINATE TAB 2.5 MG (BASE EQUIVALENT)	67406030100320	Generic
ZOLMITRIPTAN	ZOLMITRIPTAN NASAL SPRAY 2.5 MG/SPRAY UNIT	67406080002010	Generic
ZOLMITRIPTAN	ZOLMITRIPTAN NASAL SPRAY 5 MG/SPRAY UNIT	67406080002020	Generic
TOSYMRA	SUMATRIPTAN NASAL SPRAY 10MG/ACT	67406070000202	Brand
SUMATRIPTAN/NAPROXEN SODIUM	SUMATRIPTAN-NAPROXEN SODIUM TAB 85-500 MG	67992002600320	Generic
ALMOTRIPTAN	ALMOTRIPTAN MALATE TAB 6.25 MG	67406010100320	Generic
ALMOTRIPTAN	ALMOTRIPTAN MALATE TAB 12.5 MG	67406010100330	Generic
ZOLMITRIPTAN ODT	ZOLMITRIPTAN ORALLY DISINTEGRATING TAB 2.5 MG	67406080007220	Generic

ZOLMITRIPTAN ODT	ZOLMITRIPTAN ORALLY DISINTEGRATING TAB 5 MG	67406080007230	Generic
RIZATRIPTAN BENZOATE ODT	RIZATRIPTAN BENZOATE ORAL DISINTEGRATING TAB 5 MG (BASE EQ)	67406060107220	Generic
RIZATRIPTAN BENZOATE ODT	RIZATRIPTAN BENZOATE ORAL DISINTEGRATING TAB 10 MG (BASE EQ)	67406060107230	Generic

**Approval Criteria**

1 - Diagnosis of migraine headaches with or without aura

**AND**

2 - Prescribed by or in consultation with one of the following:

- Neurologist
- Pain management specialist

**AND**

3 - Patient is currently receiving prophylactic therapy with at least ONE of the following:

3.1 Amitriptyline (Elavil)

**OR**

3.2 One of the following beta-blockers:

- atenolol
- metoprolol
- nadolol\*\*
- propranolol
- timolol\*\*

**OR**

**3.3** Divalproex sodium (Depakote/Depakote ER)

**OR**

**3.4** OnabotulinumtoxinA (Botox) \*\*\*

**OR**

**3.5** Topiramate (Topamax)

**OR**

**3.6** Venlafaxine (Effexor/Effexor XR)

**OR**

**3.7** Calcitonin gene-related peptide (CGRP) receptor antagonists [e.g., Aimovig (erenumab), Emgality (galcanezumab)]

**AND**

**4** - One of the following:

**4.1** Higher dose or quantity is supported in the dosage and administration section of the manufacturer's prescribing information

**OR**

**4.2** Higher dose or quantity is supported by one of the following compendia:

- American Hospital Formulary Service Drug Information
- Thomson Micromedex DrugDex
- Clinical pharmacology
- United States Pharmacopoeia-National Formulary (USP-NF)

**OR**

**4.3** Physician provides evidence from published biomedical literature to support safety and additional efficacy at doses/quantities greater than those approved by the FDA (Food and Drug Administration) for the diagnosis indicated

**AND**

**5** - Physician acknowledges that the potential benefit outweighs the risk associated with the higher dose or quantity

Notes

\* See "Quantity Limits" table in background section for quantity limits  
 \*\* Nadolol and timolol are non-preferred and should not be included in denial to provider  
 \*\*\* OnabotulinumtoxinA (Botox) is a medical benefit, should not be included in denial to provider

Product Name: generic zolmitriptan nasal spray

Approval Length | 12 month(s)

Guideline Type | Step Therapy

Product Name	Generic Name	GPI	Brand/Generic
ZOLMITRIPTAN	ZOLMITRIPTAN NASAL SPRAY 2.5 MG/SPRAY UNIT	67406080002010	Generic
ZOLMITRIPTAN	ZOLMITRIPTAN NASAL SPRAY 5 MG/SPRAY UNIT	67406080002020	Generic

**Approval Criteria**

**1** - Patient has a history of failure, contraindication, or intolerance to a trial of Brand Zomig Nasal Spray

**2 . Background**

**Benefit/Coverage/Program Information**

**Quantity Limits**

**Quantity Limits**

<b>Drug Name</b>	<b>Strength</b>	<b>Quantity Limit</b>
Brand Amerge generic naratriptan	1mg, 2.5mg	9 tabs/month
Brand Frova Generic frovatriptan	2.5mg	9 tabs/month
Brand Imitrex tablets generic sumatriptan tablets	25mg, 50mg, 100mg	9 tabs/month
Brand Maxalt Generic rizatriptan	5mg, 10mg	9 tabs/month
Brand Maxalt MLT Generic rizatriptan ODT	5mg, 10mg	9 tabs/month
Generic almotriptan	6.25mg, 12.5mg	6 tabs/month
Relpax Generic eletriptan	20mg, 40mg	6 tabs/month
Brand Zomig Generic zolmitriptan	2.5mg, 5mg	6 tabs/month
Generic zolmitriptan ODT	2.5mg, 5mg	6 tabs/month
Brand Imitrex Nasal Spray Generic sumatriptan nasal spray	5mg, 20mg	6 spray devices/month
Zomig Nasal Spray	2.5mg, 5mg	6 spray devices/month

Treximet Generic sumatriptan/naproxen	85mg/500 mg, 10mg/60mg	9 tabs/month
Onzetra Xsail	11mg	1 box (8 units)/month
Zembrace SymTouch	3mg	1 box (4 units)/month
Brand Imitrex Generic Sumatriptan Autoinjector/Cartridge Refills	4mg/0.5mL 6mg/0.5mL	8 autoinjectors or cartridge refills/month (4 boxes/month)
Brand Imitrex Generic Sumatriptan Vials	6mg/0.5mL	10 vials/month (2 boxes/month)
Generic Sumatriptan Pre-filled Syringe	6mg/0.5mL	8 prefilled syringes (4 boxes/month)
Tosymra nasal spray	10mg	6 units per month

### 3 . Revision History

Date	Notes
6/13/2024	Removed ST for Brand Zomig nasal spray and generic zolmitriptan nasal spray now only requires trial of Brand Zomig nasal spray; Removed Brand Zomig ZMT(obsolete), where applicable; Updated product name lists and GPI tables; Minor cosmetic updates.

Tryvio (aprocitentan)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157435
<b>Guideline Name</b>	Tryvio (aprocitentan)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Tryvio			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TRYVIO	APROCITENTAN TAB 12.5 MG	36180010000320	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of hypertension			



**AND**

**2** - Submission of medical records (e.g., chart notes) or verification of paid claims confirming patient has not achieved target blood pressure (e.g., systolic blood pressure [SBP] less than 130 mmHg) after treatment with ALL of the following antihypertensive medications from different classes for an adequate duration (minimum 4 weeks each) at a maximally tolerated dose:

**2.1** ONE of the following:

- Angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril)
- Angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan)

**AND**

**2.2** Diuretic (e.g., hydrochlorothiazide, chlorthalidone)

**AND**

**2.3** Calcium channel blocker (e.g., amlodipine, nifedipine)

**AND**

**2.4** Mineralocorticoid receptor antagonist (MRA) (e.g., eplerenone, spironolactone)

**AND**

**3** - Provider attests other causes of hypertension have been excluded (e.g., secondary causes [e.g., primary hyperaldosteronism], white coat effect, medication nonadherence)

**AND**

**4** - Used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community based program)

**AND**

**5** - Requested drug will be used in combination with at least 3 antihypertensive medications from different classes

**AND**

**6** - Prescribed by or in consultation with a specialist experienced in the treatment of resistant hypertension (e.g., cardiologist, nephrologist)

Product Name: Tryvio			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TRYVIO	APROCITENTAN TAB 12.5 MG	36180010000320	Brand

**Approval Criteria**

**1** - Patient demonstrates positive clinical response to therapy (e.g., systolic blood pressure [SBP] less than 130 mmHg)

**AND**

**2** - Patient continues to use Tryvio in combination with at least 3 antihypertensive medications from different classes and is adherent to therapy

**AND**

**3** - Requested drug will continue to be used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community based program)

**AND**

**4** - Submission of medical records (e.g., chart notes) or verification of paid claims confirming patient has been previously treated with ALL of the following antihypertensive medications from different classes for an adequate duration (minimum 4 weeks each) at a maximally tolerated dose:

**4.1** ONE of the following:

- Angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril)
- Angiotensin II receptor blocker (ARB) (e.g., candesartan, valsartan)

**AND**

**4.2** Diuretic (e.g., hydrochlorothiazide, chlorthalidone)

**AND**

**4.3** Calcium channel blocker (e.g., amlodipine, nifedipine)

**AND**

**4.4** Mineralocorticoid receptor antagonist (MRA) (e.g., eplerenone, spironolactone)

## 2 . Revision History

Date	Notes
10/14/2024	Replaced CORE criteria with FFS/state criteria.

Twynéo (tretinoin-benzoyl peroxide 0.1-3% cream)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140674
<b>Guideline Name</b>	Twynéo (tretinoin-benzoyl peroxide 0.1-3% cream)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Twynéo			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TWYNEO	TRETINOIN-BENZOYL PEROXIDE CREAM 0.1-3%	90059902853720	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting both of the following:</p>			

**1.1 Both of the following:**

- Patient is 9 years of age or older
- Diagnosis of acne vulgaris

**AND**

**1.2 The patient must have a history of therapeutic failure, contraindication, or intolerance to ALL of the following (verified via paid pharmacy claims or submission of medical records):**

- benzoyl peroxide
- topical clindamycin
- topical erythromycin
- topical tretinoin (Brand Retin-A)

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Uloric



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140650
<b>Guideline Name</b>	Uloric
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Brand Uloric, generic febuxostat			
Approval Length	12 month(s)		
Guideline Type	Step Therapy		
Product Name	Generic Name	GPI	Brand/Generic
FEBUXOSTAT	FEBUXOSTAT TAB 40 MG	68000030000320	Generic
ULORIC	FEBUXOSTAT TAB 40 MG	68000030000320	Brand
FEBUXOSTAT	FEBUXOSTAT TAB 80 MG	68000030000330	Generic
ULORIC	FEBUXOSTAT TAB 80 MG	68000030000330	Brand

**Approval Criteria**

1 - History of failure, contraindication or intolerance to allopurinol (generic Zyloprim)

**2 . Revision History**

Date	Notes
3/31/2020	Bulk Copy C&S New York to C&S Arizona for effective date of 5/1

Ultomiris (ravulizumab-cwvz)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-148352
<b>Guideline Name</b>	Ultomiris (ravulizumab-cwvz)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Ultomiris			
Diagnosis	Paroxysmal Nocturnal Hemoglobinuria (PNH)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 300 MG/3ML (100 MG/ML)	85805080202045	Brand
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 1100 MG/11ML (100 MG/ML)	85805080202060	Brand



**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH)

**AND**

2 - Patient is one month of age or older

**AND**

3 - Prescribed by or in consultation with a hematologist/oncologist

Product Name: Ultomiris			
Diagnosis	Paroxysmal Nocturnal Hemoglobinuria (PNH)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 300 MG/3ML (100 MG/ML)	85805080202045	Brand
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 1100 MG/11ML (100 MG/ML)	85805080202060	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response (e.g., hemoglobin stabilization, decrease in the number of red blood cell transfusions) to therapy			

Product Name: Ultomiris	
Diagnosis	Atypical Hemolytic Uremic Syndrome (aHUS)

Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 300 MG/3ML (100 MG/ML)	85805080202045	Brand
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 1100 MG/11ML (100 MG/ML)	85805080202060	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting a diagnosis of atypical hemolytic uremic syndrome (aHUS)

**AND**

2 - Patient is one month of age or older

**AND**

3 - Prescribed by or in consultation with ONE of the following:

- Hematologist
- Nephrologist

Product Name: Ultomiris			
Diagnosis	Atypical Hemolytic Uremic Syndrome (aHUS)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic

ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 300 MG/3ML (100 MG/ML)	85805080202045	Brand
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 1100 MG/11ML (100 MG/ML)	85805080202060	Brand

**Approval Criteria**

1 - Documentation of positive clinical response (e.g., hemoglobin stabilization, decrease in the number of red blood cell transfusions) to therapy

Product Name: Ultomiris			
Diagnosis	Generalized Myasthenia Gravis (gMG)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 300 MG/3ML (100 MG/ML)	85805080202045	Brand
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 1100 MG/11ML (100 MG/ML)	85805080202060	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:

- Diagnosis of generalized myasthenia gravis (gMG)
- Patient is anti-acetylcholine receptor (AChR) antibody positive

**AND**

2 - Submission of medical records (e.g., chart notes) or paid claims documenting ONE of the following:

**2.1** Trial and failure, contraindication, or intolerance to TWO preferred immunosuppressive therapies (e.g., glucocorticoids, azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, tacrolimus)

**OR**

**2.2** BOTH of the following:

**2.2.1** Trial and failure, contraindication, or intolerance to ONE preferred immunosuppressive therapy (e.g., glucocorticoids, azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, tacrolimus)

**AND**

**2.2.2** Trial and failure, contraindication, or intolerance to ONE of the following:

- Chronic plasmapheresis or plasma exchange (PE)
- Intravenous immunoglobulin (IVIG)

**AND**

**3** - Prescribed by or in consultation with a neurologist

Product Name: Ultomiris			
Diagnosis	Generalized Myasthenia Gravis (gMG)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 300 MG/3ML (100 MG/ML)	85805080202045	Brand
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 1100 MG/11ML (100 MG/ML)	85805080202060	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy			

Product Name: Ultomiris			
Diagnosis	Neuromyelitis Optica Spectrum Disorder (NMOSD)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 300 MG/3ML (100 MG/ML)	85805080202045	Brand
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 1100 MG/11ML (100 MG/ML)	85805080202060	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting BOTH of the following:</p> <ul style="list-style-type: none"> <li>• Diagnosis of neuromyelitis optica spectrum disorder (NMOSD)</li> <li>• Patient is anti-aquaporin-4 (AQP4) antibody positive</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with ONE of the following:</p> <ul style="list-style-type: none"> <li>• Neurologist</li> <li>• Ophthalmologist</li> </ul>			

Product Name: Ultomiris			
Diagnosis	Neuromyelitis Optica Spectrum Disorder (NMOSD)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 300 MG/3ML (100 MG/ML)	85805080202045	Brand

ULTOMIRIS	RAVULIZUMAB-CWVZ IV SOLN 1100 MG/11ML (100 MG/ML)	85805080202060	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p>			

## 2 . Revision History

Date	Notes
6/10/2024	Added criteria for new indication of NMOSD and added submission of records/paid claims where applicable to all initial authorization criteria.

Upneeq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140659
<b>Guideline Name</b>	Upneeq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/1/2021
-----------------	----------

## 1 . Criteria

Product Name: Upneeq			
Diagnosis	Acquired Blepharoptosis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
UPNEEQ	OXYMETAZOLINE HCL OPHTH SOLN 0.1%	86802236102020	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of acquired blepharoptosis

**AND**

2 - Patient has a functional impairment related to the position of the eyelid

**AND**

3 - ONE of the following:

3.1 Marginal reflex distance-1 (MRD-1) is less than or equal to 2 millimeters (mm) in primary gaze

**OR**

3.2 Marginal reflex distance-1 (MRD-1) is less than or equal to 2 mm in down gaze

**OR**

3.3 Superior visual field loss of at least 12 degrees or 24 percent

**AND**

4 - Other treatable causes of blepharoptosis have been ruled out (e.g., recent botulinum toxin injections, myasthenia gravis)

Product Name: Upneeq			
Diagnosis	Acquired Blepharoptosis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic



UPNEEQ	OXYMETAZOLINE HCL OPHTH SOLN 0.1%	86802236102020	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of a positive clinical response to therapy</p>			

## 2 . Revision History

Date	Notes
1/26/2021	Copy of NY-79983 New Program

Urea Cycle Disorder Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140994
<b>Guideline Name</b>	Urea Cycle Disorder Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	9/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Brand Buphenyl, generic sodium phenylbutyrate, Pheburane			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BUPHENYL	SODIUM PHENYL BUTYRATE TAB 500 MG	30908060000320	Brand
BUPHENYL	SODIUM PHENYL BUTYRATE ORAL POWDER 3 GM/TEASPOONFUL	30908060002950	Brand
SODIUM PHENYL BUTYRATE	SODIUM PHENYL BUTYRATE TAB 500 MG	30908060000320	Generic
SODIUM PHENYL BUTYRATE	SODIUM PHENYL BUTYRATE ORAL POWDER 3 GM/TEASPOONFUL	30908060002950	Generic

PHEBURANE	SODIUM PHENYLBUTYRATE ORAL PELLETS 483 MG/GM	30908060008920	Brand
<p><b>Approval Criteria</b></p> <p><b>1 - BOTH of the following:</b></p> <p><b>1.1</b> Diagnosis of urea cycle disorder (UCD)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>1.2 ONE</b> of the following deficiencies:</p> <ul style="list-style-type: none"><li>• carbamylphosphate synthetase (CPS)</li><li>• ornithine transcarbamylase (OTC)</li><li>• argininosuccinic acid synthetase (AS)</li></ul> <p style="text-align: center;"><b>AND</b></p> <p><b>2 -</b> Molecular genetic testing confirms mutations in the CPS1, OTC, or ASS1 gene</p> <p style="text-align: center;"><b>AND</b></p> <p><b>3 -</b> If the request is for Brand Buphenyl or Pheburane, trial and failure, or intolerance to generic sodium phenylbutyrate</p> <p style="text-align: center;"><b>AND</b></p> <p><b>4 -</b> Used as an adjunct with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements)</p> <p style="text-align: center;"><b>AND</b></p> <p><b>5 -</b> Prescribed by or in consultation with a specialist focused on the treatment of metabolic disorders</p>			

Product Name: Olpruva, Ravicti	
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
RAVICTI	GLYCEROL PHENYLBUTYRATE LIQUID 1.1 GM/ML	30908030000920	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 2 GM THERAPY PACK	3090806000B120	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 3 GM THERAPY PACK	3090806000B130	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 4 GM THERAPY PACK	3090806000B140	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 5 GM THERAPY PACK	3090806000B150	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 6 GM THERAPY PACK	3090806000B160	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 6.67 GM THERAPY PACK	3090806000B170	Brand

**Approval Criteria**

1 - BOTH of the following:

1.1 Diagnosis of urea cycle disorder (UCD)

**AND**

1.2 ONE of the following deficiencies:

- carbamylphosphate synthetase (CPS)
- ornithine transcarbamylase (OTC)
- argininosuccinic acid synthetase (AS)

**AND**

2 - Molecular genetic testing confirms mutations in the CPS1, OTC, or ASS1 gene

**AND**

**3** - Inadequate response to ONE of the following:

- Dietary protein restriction
- Amino acid supplementation

**AND**

**4** - Trial and failure, contraindication, or intolerance to generic sodium phenylbutyrate

**AND**

**5** - Used as an adjunct with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements)

**AND**

**6** - Prescribed by or in consultation with a specialist focused on the treatment of metabolic disorders

Product Name: Brand Buphenyl, generic sodium phenylbutyrate, Olpruva, Pheburane, Ravicti			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
BUPHENYL	SODIUM PHENYLBUTYRATE TAB 500 MG	30908060000320	Brand
BUPHENYL	SODIUM PHENYLBUTYRATE ORAL POWDER 3 GM/TEASPOONFUL	30908060002950	Brand
SODIUM PHENYLBUTYRATE	SODIUM PHENYLBUTYRATE TAB 500 MG	30908060000320	Generic
SODIUM PHENYLBUTYRATE	SODIUM PHENYLBUTYRATE ORAL POWDER 3 GM/TEASPOONFUL	30908060002950	Generic

PHEBURANE	SODIUM PHENYLBUTYRATE ORAL PELLETS 483 MG/GM	30908060008920	Brand
RAVICTI	GLYCEROL PHENYLBUTYRATE LIQUID 1.1 GM/ML	30908030000920	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 2 GM THERAPY PACK	3090806000B120	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 3 GM THERAPY PACK	3090806000B130	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 4 GM THERAPY PACK	3090806000B140	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 5 GM THERAPY PACK	3090806000B150	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 6 GM THERAPY PACK	3090806000B160	Brand
OLPRUVA	SODIUM PHENYLBUTYRATE PACKET FOR SUSP 6.67 GM THERAPY PACK	3090806000B170	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy (e.g., plasma ammonia and amino acid levels within normal limits)

**AND**

**2** - Used as an adjunct with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements)

**2 . Revision History**

Date	Notes
8/8/2023	Added Olpruva

Vafseo (vadadustat)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157239
<b>Guideline Name</b>	Vafseo (vadadustat)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Vafseo			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VAFSEO	VADADUSTAT TAB 150 MG	82402580000320	Brand
VAFSEO	VADADUSTAT TAB 300 MG	82402580000330	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) or paid claims confirming ALL of the following:

**1.1** Diagnosis of chronic kidney disease (CKD)

**AND**

**1.2** Patient has been on dialysis for at least 3 months

**AND**

**1.3** Adequate iron stores confirmed by BOTH of the following:

- Patient's ferritin level is greater than 100 mcg/L (micrograms per liter)
- Patient's transferrin saturation (TSAT) is greater than 20%

**AND**

**1.4** Hemoglobin level is less than 11 g/dL (grams per deciliter)

**AND**

**1.5** Trial and failure, contraindication, or intolerance to ONE of the following preferred erythropoietin stimulating agents (ESA):

- Epogen (epoetin alfa)
- Retacrit (epoetin alfa-epbx)

**AND**

**2** - Prescribed by or in consultation with ONE of the following:

- Hematologist
- Nephrologist



**AND**

**3** - Patient is NOT on concurrent treatment with an erythropoietin stimulating agent [ESA] (e.g., Aranesp, Epogen, Procrit)

Product Name: Vafseo

Approval Length | 12 month(s)

Therapy Stage | Reauthorization

Guideline Type | Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
VAFSEO	VADADUSTAT TAB 150 MG	82402580000320	Brand
VAFSEO	VADADUSTAT TAB 300 MG	82402580000330	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) or paid claims confirming ALL of the following:

**1.1** Patient demonstrates positive clinical response to therapy (e.g., increase in hemoglobin)

**AND**

**1.2** Hemoglobin level does NOT exceed 11 g/dL (grams per deciliter)

**AND**

**1.3** Adequate iron stores confirmed by BOTH of the following:

- Patient's ferritin level is greater than 100 mcg/L (micrograms per liter)
- Patient's transferrin saturation (TSAT) is greater than 20%

**AND**

**1.4** Trial and failure, contraindication, or intolerance to ONE of the following preferred erythropoietin stimulating agents (ESA):

- Epogen (epoetin alfa)
- Retacrit (epoetin alfa-epbx)

**AND**

**2** - Patient is NOT on concurrent treatment with an erythropoietin stimulating agent [ESA] (e.g., Aranesp, Epogen, Procrit)

## 2 . Revision History

Date	Notes
10/9/2024	New program.

Valchlor



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140912
<b>Guideline Name</b>	Valchlor
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Valchlor			
Diagnosis	Primary Cutaneous Lymphomas		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VALCHLOR	MECHLORETHAMINE HCL GEL 0.016% (BASE EQUIVALENT)	90371050204030	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of ONE of the following:

- Chronic or smoldering T-cell leukemia-lymphoma
- Primary cutaneous marginal zone or follicle center B-cell lymphoma
- Lymphomatoid papulosis (LyP) with extensive lesions
- Mycosis fungoides (MF)-Sezary syndrome (SS)

Product Name: Valchlor			
Diagnosis	Primary Cutaneous Lymphomas		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VALCHLOR	MECHLORETHAMINE HCL GEL 0.016% (BASE EQUIVALENT)	90371050204030	Brand
<b>Approval Criteria</b>			
1 - Patient does not show evidence of progressive disease while on Valchlor			

Product Name: Valchlor			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VALCHLOR	MECHLORETHAMINE HCL GEL 0.016% (BASE EQUIVALENT)	90371050204030	Brand
<b>Approval Criteria</b>			

1 - Valchlor will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B.

Product Name: Valchlor			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VALCHLOR	MECHLORETHAMINE HCL GEL 0.016% (BASE EQUIVALENT)	90371050204030	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Valchlor therapy			

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Valsartan oral solution



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140742
<b>Guideline Name</b>	Valsartan oral solution
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Valsartan oral solution			
Diagnosis	Patients 7 years of age or older		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VALSARTAN	VALSARTAN ORAL SOLN 4 MG/ML	36150080002025	Brand
<b>Approval Criteria</b>			
1 - Patient is 7 years of age or older			

**AND**

**2** - Patient cannot take solid dosage forms due to swallowing issues

## **2 . Revision History**

Date	Notes
10/21/2022	New guideline

Vecamyl



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140855
<b>Guideline Name</b>	Vecamyl
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Vecamyl			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
<b>Product Name</b>	<b>Generic Name</b>	<b>GPI</b>	<b>Brand/Generic</b>
VECAMYL	MECAMYLAMINE HCL TAB 2.5 MG	36600020100310	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of moderately severe to severe essential hypertension			



**OR**

**2** - Diagnosis of uncomplicated malignant hypertension

Product Name: Vecamyl			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VECAMYL	MECAMYLAMINE HCL TAB 2.5 MG	36600020100310	Brand
<b>Approval Criteria</b>			
1 - Documentation of a positive clinical response to Vecamyl therapy			

## 2 . Revision History

Date	Notes
3/31/2020	Bulk copy C&S New York SP to C&S Arizona SP for 5/1 effective

Velphoro (sucroferric oxyhydroxide), Auryxia (ferric citrate)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151794
<b>Guideline Name</b>	Velphoro (sucroferric oxyhydroxide), Auryxia (ferric citrate)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Velphoro, Auryxia			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VELPHORO	SUCROFERRIC OXYHYDROXIDE CHEW TAB 500 MG	52800080100520	Brand
AURYXIA	FERRIC CITRATE TAB 1 GM (210 MG FERRIC IRON)	52800030100320	Brand
<b>Approval Criteria</b>			
1 - ONE of the following:			

- Diagnosis of hyperphosphatemia
- Diagnosis of End Stage Renal Disease

**AND**

**2** - ONE of the following:

**2.1** If the request is for Velphoro, patient is 9 years of age or older

**OR**

**2.2** If the request is for Auryxia, patient is 18 years of age or older

**AND**

**3** - Adherence to and trial and failure to ONE of the following at maximum dosages (MUST be verified via paid pharmacy claims or submission of medical records):

- Sevelamer Carbonate at the maximum dosage – 800mg/15 per day
- Sevelamer Powder Packets at maximum dosage – 2.4gm packet 4 per day

Notes	<p>1. Approval will not be granted for requests based on potential side effects, i.e., constipation</p> <p>2. Approval will not be granted for submitted prior authorizations based on pill burden. Velphoro and Sevelamer are both taken 3 times a day.</p>
-------	--

## 2 . Revision History

Date	Notes
8/15/2024	Added age requirement to criteria. Minor cosmetic updates/spelling correction.

Velsipity



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-143589
<b>Guideline Name</b>	Velsipity
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/17/2024
-----------------	-----------

### 1 . Criteria

Product Name: Velsipity			
Diagnosis	Ulcerative Colitis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VELSIPITY	ETRASIMOD ARGININE TAB 2 MG	52504525100350	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) confirming a diagnosis of moderately to severely active ulcerative colitis

**AND**

**2** - One of the following:

- Greater than 6 stools per day
- Frequent blood in the stools
- Frequent urgency
- Presence of ulcers
- Abnormal lab values (e.g., hemoglobin, ESR, CRP)
- Dependent on, or refractory to, corticosteroids

**AND**

**3** - Paid claims or submission of medical records (e.g., chart notes) confirming a trial and failure, contraindication, or intolerance to one of the following conventional therapies:

- 6-mercaptopurine
- Aminosalicylate (e.g., mesalamine, olsalazine, sulfasalazine)
- Azathioprine
- Corticosteroids (e.g., prednisone)

**AND**

**4** - One of the following:

**4.1** Paid claims or submission of medical records (e.g., chart notes) confirming history of failure, contraindication, or intolerance to ALL of the following\*\*\* (document drug, date, and duration of trial):

- Humira (adalimumab)
- Infliximab
- Xeljanz oral tablet (tofacitinib)

**OR**

**4.2** Paid claims or submission of medical records (e.g., chart notes) confirming continuation of prior therapy, defined as no more than a 45-day gap in therapy

**AND**

**5** - Prescribed by or in consultation with a gastroenterologist

Product Name: Velsipity			
Diagnosis	Ulcerative Colitis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VELSIPITY	ETRASIMOD ARGININE TAB 2 MG	52504525100350	Brand

**Approval Criteria**

**1** - Patient demonstrates positive clinical response to therapy as evidenced by at least one of the following:

**1.1** Improvement in intestinal inflammation (e.g., mucosal healing, improvement of lab values [platelet counts, erythrocyte sedimentation rate, C-reactive protein level]) from baseline

**OR**

**1.2** Reversal of high fecal output state

**2 . Revision History**

Date	Notes
2/26/2024	New

Veltassa



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-157252
<b>Guideline Name</b>	Veltassa
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	11/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Veltassa			
Diagnosis	Non-Life Threatening Hyperkalemia		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VELTASSA	PATIROMER SORBITEX CALCIUM FOR SUSP PACKET 8.4 GM (BASE EQ)	99450060203020	Brand
VELTASSA	PATIROMER SORBITEX CALCIUM FOR SUSP PACKET 16.8 GM (BASE EQ)	99450060203030	Brand
VELTASSA	PATIROMER SORBITEX CALCIUM FOR SUSP PACKET 25.2 GM (BASE EQ)	99450060203040	Brand

VELTASSA	PATIROMER SORBITEX CALCIUM FOR SUSP PACKET 1 GM (BASE EQ)	99450060203005	Brand
----------	--	----------------	-------

**Approval Criteria**

1 - Diagnosis of non-life threatening hyperkalemia

**AND**

2 - Patient is 12 years of age or older

**AND**

3 - Where clinically appropriate, medications known to cause hyperkalemia (e.g. angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, aldosterone antagonist, non-steroidal anti-inflammatory drugs [NSAIDs]) have been discontinued or reduced to the lowest effective dose

**AND**

4 - Where clinically appropriate, loop or thiazide diuretic therapy for potassium removal has failed

**AND**

5 - Patient follows a low potassium diet (less than or equal to 3 grams per day)

**AND**

6 - History of failure, intolerance, or contraindication to Lokelma

Product Name: Veltassa	
Diagnosis	Non-Life Threatening Hyperkalemia
Approval Length	12 month(s)



Therapy Stage		Reauthorization	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
VELTASSA	PATIROMER SORBITEX CALCIUM FOR SUSP PACKET 8.4 GM (BASE EQ)	99450060203020	Brand
VELTASSA	PATIROMER SORBITEX CALCIUM FOR SUSP PACKET 16.8 GM (BASE EQ)	99450060203030	Brand
VELTASSA	PATIROMER SORBITEX CALCIUM FOR SUSP PACKET 25.2 GM (BASE EQ)	99450060203040	Brand
VELTASSA	PATIROMER SORBITEX CALCIUM FOR SUSP PACKET 1 GM (BASE EQ)	99450060203005	Brand

**Approval Criteria**

1 - Patient has a positive clinical response to Veltassa therapy

**AND**

2 - Patient continues to require treatment for hyperkalemia

**AND**

3 - Where clinically appropriate, medications known to cause hyperkalemia (e.g. angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, aldosterone antagonist, non-steroidal anti-inflammatory drugs [NSAIDs])) have been discontinued or reduced to the lowest effective dose

**2 . Revision History**

Date	Notes
10/9/2024	Added new GPI for Veltassa 1 gm strength and added age criterion i n initial auth section.

Vemlidy



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147124
<b>Guideline Name</b>	Vemlidy
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	6/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Vemlidy			
Diagnosis	Treatment-Naïve Chronic Hepatitis B Infection		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VEMLIDY	TENOFOVIR ALAFENAMIDE FUMARATE TAB 25 MG	12352083200320	Brand
<b>Approval Criteria</b>			
1 - Patient has a contraindication to entecavir therapy			

**AND**

**2 - BOTH** of the following:

- Patient is 6 years of age or older
- Patient weighs at least 25 kg (kilograms)

Product Name: Vemlidy			
Diagnosis	Treatment-Experienced Chronic Hepatitis B Infection		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VEMLIDY	TENOFOVIR ALAFENAMIDE FUMARATE TAB 25 MG	12352083200320	Brand
<b>Approval Criteria</b>			
<b>1 - ALL</b> of the following:			
1.1 Patient is currently on Viread therapy			
<b>AND</b>			
1.2 <b>ONE</b> of the following:			
<ul style="list-style-type: none"> <li>• Patient has a creatinine clearance less than 60 mL (milliliters) per minute</li> <li>• Patient has a diagnosis of osteoporosis</li> </ul>			
<b>AND</b>			
1.3 <b>BOTH</b> of the following:			
<ul style="list-style-type: none"> <li>• Patient is 6 years of age or older</li> </ul>			

- Patient weighs at least 25 kg (kilograms)

**OR**

**2** - Patient is currently on Vemlidy therapy

## 2 . Revision History

Date	Notes
5/7/2024	Updated age criterion and added weight requirement due to expanded indication.

Veozah (fezolinetant)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140809
<b>Guideline Name</b>	Veozah (fezolinetant)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	9/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Veozah			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VEOZAH	FEZOLINETANT TAB 45 MG	30606030000320	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of moderate to severe vasomotor symptoms due to menopause			

**AND**

**2** - Submission of medical records (e.g., chart notes, paid claims history) documenting trial and failure, contraindication, or intolerance to BOTH of the following (document drug, date, and duration of trial):

- Menopausal hormone therapy (e.g., Premarin, Bijuva, Estrogel, etc.)
- Non-hormonal therapy (e.g., paroxetine mesylate, venlafaxine, clonidine, etc.)

Product Name: VeozaH			
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VEOZAH	FEZOLINETANT TAB 45 MG	30606030000320	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy (e.g., decrease in frequency and severity of vasomotor symptoms from baseline, etc.)			

**2 . Revision History**

Date	Notes
8/10/2023	New guideline

Verkazia (cyclosporine ophthalmic emulsion 0.1%)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140673
<b>Guideline Name</b>	Verkazia (cyclosporine ophthalmic emulsion 0.1%)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Verkazia			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VERKAZIA	CYCLOSPORINE (OPHTH) EMULSION 0.1%	86720020001630	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting all of the following:

**1.1** Diagnosis of moderate to severe vernal keratoconjunctivitis confirmed by the presence of clinical signs and symptoms (e.g., itching, photophobia, giant papillae at the upper tarsal conjunctiva or at the limbus, thick mucus discharge, conjunctival hyperaemia)

**AND**

**1.2** Trial and failure, contraindication, or intolerance to one of the following (verified via pharmacy paid claims or submission of medical records):

- Topical ophthalmic “dual-acting” mast cell stabilizer and antihistamine (e.g., olopatadine, azelastine)
- Topical ophthalmic mast cell stabilizers (e.g., cromolyn)

**AND**

**1.3** Trial and failure, contraindication, or intolerance, for short term use (up to 2 to 3 weeks), of topical ophthalmic corticosteroids (e.g., dexamethasone, prednisolone, fluorometholone) ((verified via pharmacy paid claims or submission of medical records)

**AND**

**2** - Prescribed by or in consultation with **ONE** of the following:

- Ophthalmologist
- Optometrist

Product Name: Verkazia			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VERKAZIA	CYCLOSPORINE (OPHTH) EMULSION 0.1%	86720020001630	Brand



**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy as evidenced by an improvement in clinical signs and symptoms (e.g., itching, photophobia, papillary hypertrophy, mucus discharge, conjunctival hyperaemia)

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Verquvo



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-145898
<b>Guideline Name</b>	Verquvo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Verquvo			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VERQUVO	VERICIGUAT TAB 2.5 MG	40900085000321	Brand
VERQUVO	VERICIGUAT TAB 5 MG	40900085000330	Brand
VERQUVO	VERICIGUAT TAB 10 MG	40900085000340	Brand

**Approval Criteria**

**1** - Diagnosis of heart failure

**AND**

**2** - Ejection fraction is less than 45 percent

**AND**

**3** - Heart failure is classified as ONE of the following:

- New York Heart Association Class II
- New York Heart Association Class III
- New York Heart Association Class IV

**AND**

**4** - ONE of the following:

**4.1** Hospitalization for heart failure within the past six months

**OR**

**4.2** Outpatient IV (intravenous) diuretics for heart failure within the past three months

**AND**

**5** - ONE of the following:

**5.1** Patient is on a stabilized dose and receiving concomitant therapy with a maximally tolerated beta-blocker (e.g., bisoprolol, carvedilol, metoprolol) confirmed by claims history or submission of medical records

**OR**

**5.2** Patient has a contraindication or intolerance to beta-blocker therapy (please specify intolerance or contraindication)

**AND**

**6** - ONE of the following:

**6.1** Patient is on a stabilized dose and receiving concomitant therapy with one of the following confirmed by claims history or submission of medical records:

- Angiotensin converting enzyme (ACE) inhibitor (e.g., captopril, enalapril)
- Angiotensin II receptor blocker (ARB) (e.g., losartan)
- Angiotensin receptor-neprilysin inhibitor (ARNI) (e.g., Entresto)

**OR**

**6.2** Patient has an allergy, contraindication, or intolerance to ACE inhibitors, ARBs, and ARNIs (please specify intolerance or contraindication)

**AND**

**7** - ONE of the following:

**7.1** Patient is on a stabilized dose and receiving concomitant therapy with a maximally tolerated aldosterone antagonist (e.g., spironolactone) confirmed by claims history or submission of medical records

**OR**

**7.2** Patient has a contraindication or intolerance to aldosterone antagonist therapy (please specify intolerance or contraindication)

**AND**

**8** - ONE of the following:

**8.1** Patient is on a stabilized dose and receiving concomitant therapy with a sodium-glucose

cotransporter 2 (SGLT2) inhibitor indicated for heart failure (e.g., Farxiga) confirmed by claims history or submission of medical records

**OR**

**8.2** Patient has a contraindication or intolerance to SGLT2 inhibitor therapy (please specify intolerance or contraindication)

**AND**

**9** - Verquvo is prescribed by or in consultation with a cardiologist

Product Name: Verquvo			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VERQUVO	VERICIGUAT TAB 2.5 MG	40900085000321	Brand
VERQUVO	VERICIGUAT TAB 5 MG	40900085000330	Brand
VERQUVO	VERICIGUAT TAB 10 MG	40900085000340	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy			

## 2 . Revision History

Date	Notes
4/18/2024	Copy Core

Vijoice (alpelisib)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-149995
<b>Guideline Name</b>	Vijoice (alpelisib)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	8/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Vijoice tablets, Vijoice granules			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VIJOICE	ALPELISIB (PROS) TAB THERAPY PACK 50 MG DAILY DOSE	9948601000B720	Brand
VIJOICE	ALPELISIB (PROS) TAB THERAPY PACK 125 MG DAILY DOSE	9948601000B730	Brand
VIJOICE	ALPELISIB (PROS) PAK 250 MG DAILY DOSE (200 MG & 50 MG TABS)	9948601000B740	Brand
VIJOICE	ALPELISIB (PROS) ORAL GRANULES PACKET 50 MG	99486010003020	Brand

**Approval Criteria**

1 - Diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS)

**AND**

2 - Submission of documentation of mutation in the PIK3CA gene

**AND**

3 - Patient is 2 years of age or older

**AND**

4 - Submission of documentation of severe clinical manifestations (e.g., Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/skeletal and spinal [CLOVES], Facial Infiltrating Lipomatosis [FIL], Klippel-Trenaunay Syndrome [KTS], Megalencephaly-Capillary Malformation Polymicrogyria [MCAP])

**AND**

5 - Prescribed by or in consultation with a physician who specializes in the treatment of PROS

Product Name: Vioice tablets, Vioice granules			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VIJOICE	ALPELISIB (PROS) TAB THERAPY PACK 50 MG DAILY DOSE	9948601000B720	Brand
VIJOICE	ALPELISIB (PROS) TAB THERAPY PACK 125 MG DAILY DOSE	9948601000B730	Brand

VIJOICE	ALPELISIB (PROS) PAK 250 MG DAILY DOSE (200 MG & 50 MG TABS)	9948601000B740	Brand
VIJOICE	ALPELISIB (PROS) ORAL GRANULES PACKET 50 MG	99486010003020	Brand

**Approval Criteria**

1 - Submission of documentation of positive clinical response to therapy (e.g., radiological response defined as a  $\geq 20\%$  reduction from baseline in the sum of target lesion volume)

**AND**

2 - Prescribed by or in consultation with a physician who specializes in the treatment of PROS

## 2 . Revision History

Date	Notes
7/18/2024	Added new Vijoice granule formulation as a target. Updated product name list and GPI table accordingly. No changes to criteria.



Viltepso



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-148987
<b>Guideline Name</b>	Viltepso
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Viltepso			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VILTEPSO	VILTOLARSEN IV SOLN 250 MG/5ML (50 MG/ML)	74600080002020	Brand
<b>Approval Criteria</b>			

**1** - Diagnosis of Duchenne muscular dystrophy (DMD) by, or in consultation with, a neurologist with expertise in the diagnosis of DMD

**AND**

**2** - Submission of medical records (e.g., chart notes, laboratory values) confirming the mutation of the DMD gene is amenable to exon 53 skipping

**AND**

**3** - ONE of the following:

**3.1** Submission of medical records (e.g., chart notes, laboratory values) confirming that the patient has a 6-Minute Walk Test (6MWT) greater than or equal to 300 meters while walking independently (e.g., without side-by-side assist, cane, walker, wheelchair, etc.) prior to beginning Viltepso therapy

**OR**

**3.2** BOTH of the following:

**3.2.1** Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)

**AND**

**3.2.2** ONE of the following:

**3.2.2.1** Patient has achieved a score of greater than 17 on the North Star Ambulatory Assessment (NSAA)

**OR**

**3.2.2.2** Patient has achieved a time to rise from the floor (Gower's test) of less than 7 seconds

**AND**

**4** - Prescribed by, or in consultation with, a neurologist with expertise in the treatment of DMD

**AND**

**5** - Dosing is in accordance with the United States Food and Drug Administration approved labeling

**AND**

**6** - Not used concomitantly with other exon skipping therapies for DMD

Product Name: Viltepso			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VILTEPSO	VILTOLARSEN IV SOLN 250 MG/5ML (50 MG/ML)	74600080002020	Brand

**Approval Criteria**

**1** - Patient has previously received Viltepso

**AND**

**2** - Prescribed by, or in consultation with, a neurologist with expertise in the treatment of DMD (Duchenne muscular dystrophy)

**AND**

**3** - Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)

**AND**

**4** - Dosing is in accordance with the United States Food and Drug Administration approved labeling

**AND**

**5** - Not used concomitantly with other exon skipping therapies for DMD

## 2 . Revision History

Date	Notes
6/26/2024	Updated guideline name. Updated initial authorization length to 12 months. Updated "6-Minute Walk Time" verbiage with "6-Minute Walk Test". Update to reauth criteria section.

Vivjoa (oteseconazole)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140743
<b>Guideline Name</b>	Vivjoa (oteseconazole)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Vivjoa			
Approval Length	4 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VIVJOA	OTESECONAZOLE CAP THERAPY PACK 150 MG (12 WEEKS)	1140805000B220	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of recurrent vulvovaginal candidiasis (RVVC)			

**AND**

**2** - Patient is NOT of reproductive potential

**AND**

**3** - Diagnosis of RVVC confirmed by one of the following:

- Positive potassium hydroxide (KOH) preparation
- Vaginal fungal culture

**AND**

**4** - Patient has experienced 3 or more symptomatic episodes of vulvovaginal candidiasis (VVC) within the past 12 months

**AND**

**5** - Trial and failure, contraindication, or intolerance to both of the following:

- One intravaginal product (e.g., clotrimazole, miconazole, tioconazole, terconazole, boric acid)
- Oral fluconazole

## 2 . Revision History

Date	Notes
10/21/2022	New guideline

Vonjo (pacritinib)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140891
<b>Guideline Name</b>	Vonjo (pacritinib)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Vonjo			
Diagnosis	Myelofibrosis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VONJO	PACRITINIB CITRATE CAP 100 MG	21537550100120	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ALL of the following:

**1.1** Diagnosis of ONE of the following:

- Primary myelofibrosis
- Post-polycythemia vera myelofibrosis
- Post-essential thrombocythemia myelofibrosis

**AND**

**1.2** Disease is intermediate or high risk

**AND**

**1.3** Pre-treatment platelet count below  $50 \times 10^9$  L

**AND**

**2** - Prescribed by or in consultation with ONE of the following:

- Hematologist
- Oncologist

Product Name: Vonjo			
Diagnosis	Myelofibrosis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VONJO	PACRITINIB CITRATE CAP 100 MG	21537550100120	Brand



**Approval Criteria**

1 - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy (e.g., symptom improvement, spleen volume reduction)

Product Name: Vonjo			
Diagnosis	NCCN Recommended Regimens		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VONJO	PACRITINIB CITRATE CAP 100 MG	21537550100120	Brand
<b>Approval Criteria</b>			
1 - This drug will be approved for uses supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of Evidence and Consensus of 1, 2A, or 2B			

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Vonoprazan Containing Agents



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-157272
<b>Guideline Name</b>	Vonoprazan Containing Agents
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	11/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Voquezna Dual Pak, Voquezna Triple Pak			
Diagnosis	Helicobacter pylori (H. pylori) Infection		
Approval Length	1 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VOQUEZNA DUAL PAK	AMOXICILLIN CAP 500 MG & VONOPRAZAN TAB 20 MG THERAPY PACK	4999320220B120	Brand
VOQUEZNA TRIPLE PAK	AMOXICILLIN CAP & CLARITHROMYCIN TAB & VONOPRAZAN TAB PACK	4999320320B120	Brand

**Approval Criteria**

1 - Diagnosis of Helicobacter pylori infection

**AND**

2 - Trial and failure, contraindication, or intolerance to BOTH of the following first line treatment regimens:

- Clarithromycin based therapy (e.g., clarithromycin based triple therapy, clarithromycin based concomitant therapy)
- Bismuth quadruple therapy (e.g., bismuth and metronidazole and tetracycline and proton pump inhibitor [PPI])

Product Name: Voquezna 20 mg tablet			
Diagnosis	Helicobacter pylori (H. pylori) Infection		
Approval Length	1 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VOQUEZNA	VONOPRAZAN FUMARATE TAB 20 MG	49275087100340	Brand

**Approval Criteria**

1 - Diagnosis of Helicobacter pylori infection

**AND**

2 - ONE of the following:

- Used in combination with amoxicillin and clarithromycin for the treatment of H. pylori infection
- Used in combination with amoxicillin for the treatment of H. pylori infection

**AND**

**3** - Trial and failure, contraindication, or intolerance to BOTH of the following first line treatment regimens:

- Clarithromycin based therapy (e.g., clarithromycin based triple therapy, clarithromycin based concomitant therapy)
- Bismuth quadruple therapy (e.g., bismuth and metronidazole and tetracycline and proton pump inhibitor [PPI])

Product Name: Voquezna 20 mg tablet

Diagnosis	Healing and Relief of Heartburn associated with Erosive Esophagitis
Approval Length	8 Week(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
VOQUEZNA	VONOPRAZAN FUMARATE TAB 20 MG	49275087100340	Brand

**Approval Criteria**

**1** - Diagnosis of erosive esophagitis

**AND**

**2** - Used for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis

**AND**

**3** - Trial (of a minimum 8-week supply) and inadequate response (within the last 365 days), contraindication, or intolerance to TWO of the following generic proton pump inhibitors (PPI's):

- omeprazole
- esomeprazole
- pantoprazole

- lansoprazole
- rabeprazole
- dexlansoprazole

Product Name: Voquezna 10 mg tablet

Diagnosis	Maintenance of Healing and Relief of Heartburn associated with Erosive Esophagitis
-----------	--

Approval Length	6 month(s)
-----------------	------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
VOQUEZNA	VONOPRAZAN FUMARATE TAB 10 MG	49275087100320	Brand

**Approval Criteria**

1 - Used to maintain healing and relief of heartburn associated with erosive esophagitis

**AND**

2 - Trial (of a minimum 8-week supply) and inadequate response (within the last 365 days), contraindication, or intolerance to TWO of the following generic proton pump inhibitors (PPI's):

- omeprazole
- esomeprazole
- pantoprazole
- lansoprazole
- rabeprazole
- dexlansoprazole

Product Name: Voquezna 10 mg tablet\*

Diagnosis	Relief of Heartburn associated with Non-Erosive Gastroesophageal Reflux Disease
-----------	---

Approval Length	1 month(s)
-----------------	------------

Guideline Type	Prior Authorization
----------------	---------------------

Product Name	Generic Name	GPI	Brand/Generic
VOQUEZNA	VONOPRAZAN FUMARATE TAB 10 MG	49275087100320	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of non-erosive gastroesophageal reflux disease</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - BOTH of the following:</p> <ul style="list-style-type: none"> <li>• Patient has history of heartburn for at least 6 months</li> <li>• Heartburn symptoms are present for at least 4 days during any consecutive 7-day period</li> </ul> <p style="text-align: center;"><b>AND</b></p> <p>3 - Trial (of a minimum 8-week supply) and inadequate response (within the last 365 days), contraindication, or intolerance to TWO of the following generic proton pump inhibitors (PPI's):</p> <ul style="list-style-type: none"> <li>• omeprazole</li> <li>• esomeprazole</li> <li>• pantoprazole</li> <li>• lansoprazole</li> <li>• rabeprazole</li> <li>• dexlansoprazole</li> </ul>			
Notes	*Voquezna 20 mg tablets are not FDA approved for non-erosive gastr oesophageal reflux disease.		

## 2 . Revision History

Date	Notes
10/9/2024	Added new criteria for relief of heartburn associated with non-erosive GERD for Voquezna 10 mg tabs. Specified which strengths of Voqu

	ezna apply to which indication. Updated product name lists and GPI tables accordingly.
--	--

Voxzogo (vosoritide)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-141023
<b>Guideline Name</b>	Voxzogo (vosoritide)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Voxzogo			
Diagnosis	Achondroplasia		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VOXZOGO	VOSORITIDE FOR SUBCUTANEOUS INJ 0.4 MG	30950080002120	Brand
VOXZOGO	VOSORITIDE FOR SUBCUTANEOUS INJ 0.56 MG	30950080002130	Brand
VOXZOGO	VOSORITIDE FOR SUBCUTANEOUS INJ 1.2 MG	30950080002140	Brand



**Approval Criteria**

**1** - Patient has open epiphyses

**AND**

**2** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting diagnosis of achondroplasia as confirmed by one of the following:

**2.1** Both of the following:

**2.1.1** Patient has clinical manifestations characteristic of achondroplasia (e.g., macrocephaly, frontal bossing, midface retrusion, disproportionate short stature with rhizomelic shortening of the arms and the legs, brachydactyly, trident configuration of the hands, thoracolumbar kyphosis, and accentuated lumbar lordosis)

**AND**

**2.1.2** Patient has radiographic findings characteristic of achondroplasia (e.g., large calvaria and narrowing of the foramen magnum region, undertubulated, shortened long bones with metaphyseal abnormalities, narrowing of the interpedicular distance of the caudal spine, square ilia and horizontal acetabula, small sacrosiatic notches, proximal scooping of the femoral metaphyses, and short and narrow chest)

**OR**

**2.2** Molecular genetic testing confirmed c.1138G > A or c.1138G > C variant (i.e., p.Gly380Arg mutation) in the fibroblast growth factor receptor-3 (FGFR3) gene

**AND**

**3** - Patient did not have limb-lengthening surgery in the previous 18 months and does not plan on having limb-lengthening surgery while on Voxzogo therapy

**AND**

**4** - Prescribed by or in consultation with one of the following:

- Clinical geneticist
- Endocrinologist
- A physician who has specialized expertise in the management of achondroplasia

Notes

Requests for Idiopathic Short Stature (ISS) should not be approved. Deny as a benefit exclusion.

Product Name: Voxzogo			
Diagnosis	Achondroplasia		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VOXZOGO	VOSORITIDE FOR SUBCUTANEOUS INJ 0.4 MG	30950080002120	Brand
VOXZOGO	VOSORITIDE FOR SUBCUTANEOUS INJ 0.56 MG	30950080002130	Brand
VOXZOGO	VOSORITIDE FOR SUBCUTANEOUS INJ 1.2 MG	30950080002140	Brand

**Approval Criteria**

**1** - Patient continues to have open epiphyses

**AND**

**2** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting positive clinical response to therapy as evidenced by one of the following:

- Improvement in annualized growth velocity (AGV) compared to baseline
- Improvement in height Z-score compared to baseline

**AND**

**3** - Prescribed by or in consultation with one of the following:

<ul style="list-style-type: none"> <li>• Clinical geneticist</li> <li>• Endocrinologist</li> <li>• A physician who has specialized expertise in the management of achondroplasia</li> </ul>	
Notes	Requests for Idiopathic Short Stature (ISS) should not be approved. Deny as a benefit exclusion.

## 2 . Revision History

Date	Notes
12/7/2023	Removed age criterion for Achondroplasia, removed ISS criteria section, added notes.

Vtama (tapinarof)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140745
<b>Guideline Name</b>	Vtama (tapinarof)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Vtama			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VTAMA	TAPINAROF CREAM 1%	90250075003720	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes, lab work, imaging, paid claims history) documenting a diagnosis of plaque psoriasis

**AND**

**2** - Submission of medical records (e.g., chart notes, lab work, imaging, paid claims history) documenting a minimum duration of a 4 week trial and failure, contraindication, or intolerance to TWO of the following topical therapies:

- Corticosteroids (e.g., betamethasone, clobetasol)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**3** - Prescribed by or in consultation with a dermatologist

Product Name: Vtama			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VTAMA	TAPINAROF CREAM 1%	90250075003720	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, lab work, imaging, paid claims history) documenting positive clinical response to therapy as evidenced by one of the following:

- Reduction in the body surface area (BSA) involvement from baseline
- Improvement in symptoms (e.g., pruritus, inflammation) from baseline

## 2 . Revision History

Date	Notes
10/21/2022	New guideline

Vyjuvek (beremagene geperpavec-svdt)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-144883
<b>Guideline Name</b>	Vyjuvek (beremagene geperpavec-svdt)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	4/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Vyjuvek			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VYJUVEK	BEREMAGENE GEPERPAVEC-SVDT GEL 5,000,000,000 PFU/2.5ML	90944520204020	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) documenting a diagnosis of dystrophic epidermolysis bullosa (DEB)

**AND**

**2** - Submission of medical records (e.g., chart notes) confirming patient has mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene

**AND**

**3** - Medication is being used for the treatment of wounds

**AND**

**4** - Patient is 6 months of age or older

**AND**

**5** - Medication will be applied by a healthcare professional

**AND**

**6** - Submission of medical records (e.g., chart notes) confirming wound(s) being treated meet ALL of the following criteria:

- Adequate granulation tissue
- Excellent vascularization
- No evidence of active wound infection in the wound being treated
- No evidence or history of squamous cell carcinoma in the wound being treated

**AND**

**7** - Prescribed by or in consultation with a dermatologist



Product Name: Vyjuvek			
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VYJUVEK	BEREMAGENE GEPERPAVEC-SVDT GEL 5,000,000,000 PFU/2.5ML	90944520204020	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting positive clinical response (e.g., decrease in wound size, increase in granulation tissue, complete wound closure)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Wound(s) being treated meet ALL of the following criteria:</p> <ul style="list-style-type: none"> <li>• Adequate granulation tissue</li> <li>• Excellent vascularization</li> <li>• No evidence of active wound infection in the wound being treated</li> <li>• No evidence or history of squamous cell carcinoma in the wound being treated</li> </ul>			

## 2 . Revision History

Date	Notes
3/26/2024	New program.

Vyndaqel and Vyndamax



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140932
<b>Guideline Name</b>	Vyndaqel and Vyndamax
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Vyndaqel, Vyndamax			
Diagnosis	Transthyretin (ATTR)-mediated amyloidosis with cardiomyopathy (ATTR-CM)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VYND AQEL	TAFAMIDIS MEGLUMINE (CARDIAC) CAP 20 MG	40550080200120	Brand
VYNDAMAX	TAFAMIDIS CAP 61 MG	40550080000120	Brand

**Approval Criteria**

**1** - Diagnosis of transthyretin (ATTR)-mediated amyloidosis with cardiomyopathy (ATTR-CM)

**AND**

**2** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting ONE of the following:

**2.1** Documentation that the patient has a pathogenic transthyretin (TTR) mutation (e.g., V30M)

**OR**

**2.2** Cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of ATTR amyloid deposits

**OR**

**2.3** Submission of medical records (e.g., chart notes, lab work, imaging) documenting ALL of the following

**2.3.1** Echocardiogram or cardiac magnetic resonance imaging suggestive of amyloidosis

**AND**

**2.3.2** Radionuclide imaging (99mTc-DPD, 99mTc-PYP, or 99m Tc-HMDP) showing grade 2 or 3 cardiac uptake\*

**AND**

**2.3.3** Absence of monoclonal protein identified in serum, urine immunofixation (IFE), serum free light chain (sFLC) assay

**AND**

**3** - Prescribed by, or in consultation, with a cardiologist

**AND**

**4** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting presence of clinical signs and symptoms of cardiomyopathy (e.g., heart failure, dyspnea, edema, hepatomegaly, ascites, angina, etc.)

**AND**

**5** - Submission of medical records (e.g., chart notes, lab work, imaging) documenting BOTH of the following:

**5.1** ONE of the following:

**5.1.1** Patient has New York Heart Association (NYHA) Functional Class I or II heart failure

**OR**

**5.1.2** BOTH of the following:

**5.1.2.1** Patient has New York Heart Association (NYHA) Functional Class III heart failure

**AND**

**5.1.2.2** Patient's cardiopulmonary functional status allows patient to ambulate 100 meters or greater in six minutes or less

**AND**

**5.2** Patient has an N-terminal pro-B-type natriuretic peptide (NT-proBNP) level greater than or equal to 600 picograms/milliliter

**AND**

**6** - One of the following:

**6.1** Paid claims or submission of medical records (e.g., chart notes) verifying patient is not receiving Vyndaqel or Vyndamax in combination with either of the following:

- Onpattro (patisiran)
- Tegsedi ( inotersen)

**OR**

**6.2** If the patient is receiving Vyndaqel/Vyndamax in combination with Onpattro (patisiran) or Tegsedi (inotersen), the physician attests that he/she will coordinate care with other specialist(s) involved in the patient’s amyloidosis treatment plan to determine optimal long term monotherapy\*\* treatment regimen

Notes	NOTE: *May require prior authorization and notification ** Referring to monotherapy with Vyndaqel/Vyndamax, Onpattro, or T egseidi
-------	---

**Product Name: Vyndaqel, Vyndamax**

Diagnosis	Transthyretin (ATTR)-mediated amyloidosis with cardiomyopathy (ATTR-CM)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
VYND AQEL	TAFAMIDIS MEGLUMINE (CARDIAC) CAP 20 MG	40550080200120	Brand
VYNDAMAX	TAFAMIDIS CAP 61 MG	40550080000120	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting that the patient has experienced a positive clinical response to Vyndaqel or Vyndamax (e.g., improved symptoms, quality of life, slowing of disease progression, decreased hospitalizations, etc.)

**AND**

**2** - Prescribed by or in consultation with a cardiologist

**AND**

**3** - Submission of medical records (e.g., chart notes) documenting that patient continues to have New York Heart Association (NYHA) Functional Class I, II, or III heart failure

**AND**

**4** - Paid claims or submission of medical records (e.g., chart notes) verifying patient is not receiving Vyndaqel or Vyndamax in combination with either of the following:

- Onpattro (patisiran)
- Tegsedi (inotersen)

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Vyondys 53



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-147021
<b>Guideline Name</b>	Vyondys 53
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	6/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Vyondys 53			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VYONDYS 53	GOLODIRSEN IV SOLN 100 MG/2ML (50 MG/ML)	74600042002020	Brand
<b>Approval Criteria</b>			

**1 - Diagnosis of Duchenne muscular dystrophy (DMD)**

**AND**

**2 - Diagnosis of DMD by, or in consultation with, a neurologist with expertise in the diagnosis of DMD**

**AND**

**3 - Submission of medical records (e.g., chart notes, laboratory values) confirming the mutation of the DMD gene is amenable to exon 53 skipping**

**AND**

**4 - One of the following**

**4.1** Submission of medical records (e.g., chart notes, laboratory values) confirming that the patient has a 6-Minute Walk Test (6MWT) greater than or equal to 300 meters while walking independently (e.g., without side-by-side assist, cane, walker, wheelchair, etc.) prior to beginning Vyondys 53 therapy

**OR**

**4.2** Both of the following:

**4.2.1** Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)

**AND**

**4.2.2** One of the following:

- Patient has achieved a score of greater than 17 on the North Star Ambulatory Assessment (NSAA)
- Patient has achieved a time to rise from the floor (Gower's test) of less than 7 seconds



**AND**

**5** - Vyondys 53 is prescribed by, or in consultation with, a neurologist with expertise in the treatment of DMD

**AND**

**6** - Dosing is in accordance with the United States Food and Drug Administration approved labeling

**AND**

**7** - Vyondys 53 is not used concomitantly with other exon skipping therapies for DMD

Product Name: Vyondys 53			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
VYONDYS 53	GOLODIRSEN IV SOLN 100 MG/2ML (50 MG/ML)	74600042002020	Brand

**Approval Criteria**

**1** - Prescribed by, or in consultation with, a neurologist with expertise in the treatment of Duchenne muscular dystrophy (DMD)

**AND**

**2** - Submission of medical records (e.g., chart notes) confirming that the patient is ambulatory without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair, etc.)

**AND**

**3** - Vyondys 53 dosing for DMD is in accordance with the United States Food and Drug Administration approved labeling

**AND**

**4** - Vyondys 53 is not used concomitantly with other exon skipping therapies for DMD

## 2 . Revision History

Date	Notes
5/3/2024	Updated Initial authorization length to 12 months and changed "6-Minute Walk Time" to "6-Minute Walk Test". Added prescriber, dosing and concomitant criteria to initial. Removed serial monitoring of renal function from reauth criteria.

Wainua (eplontersen)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-145433
<b>Guideline Name</b>	Wainua (eplontersen)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	5/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Wainua			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
WAINUA	EPLONTERSEN SODIUM SUBCUTANEOUS SOLN AUTO-INJ 45 MG/0.8ML	6270102510D520	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) documenting a diagnosis of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with polyneuropathy

**AND**

**2** - Submission of medical records (e.g., chart notes) confirming patient has a transthyretin (TTR) mutation (e.g., V30M)

**AND**

**3** - Submission of medical records (e.g., chart notes) confirming ONE of the following:

- Patient has a baseline familial amyloidotic polyneuropathy (FAP) stage of 1 or 2
- Patient has a baseline neuropathy impairment score (NIS) greater than or equal to 10 and less than or equal to 130
- Patient has a baseline Karnofsky Performance Status score greater than 50%

**AND**

**4** - Presence of clinical signs and symptoms of the disease (e.g., neuropathy, quality of life)

**AND**

**5** - Patient has NOT had a liver transplant

**AND**

**6** - Prescribed by or in consultation with a neurologist

Product Name: Wainua	
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
WAINUA	EPLONTERSEN SODIUM SUBCUTANEOUS SOLN AUTO-INJ 45 MG/0.8ML	6270102510D520	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart note) documenting a positive clinical response to therapy as evidenced by an improvement in clinical signs and symptoms from baseline (e.g., neuropathy, quality of life, lower serum TTR level)

**AND**

2 - Submission of medical records (e.g., chart notes) confirming ONE of the following:

- Patient continues to have a familial amyloidotic polyneuropathy (FAP) stage of 1 or 2
- Patient continues to have a neuropathy impairment score (NIS) greater than or equal to 10 and less than or equal to 130
- Patient continues to have a Karnofsky Performance Status score greater than 50%

**AND**

3 - Patient has NOT had a liver transplant

**2 . Revision History**

Date	Notes
4/5/2024	New program.

Wakix (pitolisant)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-155143
<b>Guideline Name</b>	Wakix (pitolisant)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2024
-----------------	-----------

### 1 . Criteria

Product Name: Wakix			
Diagnosis	Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
WAKIX	PITOLISANT HCL TAB 4.45 MG (BASE EQUIVALENT)	61450070100318	Brand
WAKIX	PITOLISANT HCL TAB 17.8 MG (BASE EQUIVALENT)	61450070100338	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g. chart notes) documenting ALL of the following:

**1.1** Diagnosis of narcolepsy as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible)

**AND**

**1.2** Symptoms of cataplexy are present

**AND**

**1.3** Symptoms of excessive daytime sleepiness (e.g., irrepresible need to sleep or daytime lapses into sleep) are present

**AND**

**2** - Physician attestation to the following: Other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications or their withdrawal, sleep phase disorder, or other sleep disorders)

**AND**

**3** - Prescribed by ONE of the following:

- Neurologist
- Psychiatrist
- Sleep Medicine Specialist

Product Name: Wakix	
Diagnosis	Narcolepsy without Cataplexy (i.e., Narcolepsy Type 2)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
WAKIX	PITOLISANT HCL TAB 4.45 MG (BASE EQUIVALENT)	61450070100318	Brand
WAKIX	PITOLISANT HCL TAB 17.8 MG (BASE EQUIVALENT)	61450070100338	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g. chart notes) documenting ALL of the following:

**1.1** Diagnosis of narcolepsy as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible)

**AND**

**1.2** Symptoms of cataplexy are absent

**AND**

**1.3** Symptoms of excessive daytime sleepiness (e.g., irrepressible need to sleep or daytime lapses into sleep) are present

**AND**

**2** - Physician attestation to the following: Other causes of sleepiness have been ruled out or treated (including but not limited to obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of substances or medications or their withdrawal, sleep phase disorder, or other sleep disorders)

**AND**

**3** - Patient is 6 years of age or older

**AND**



**4** - Paid claims or submission of medical records (e.g., chart notes) confirming BOTH of the following:

**4.1** Trial and failure, contraindication (e.g., age), or intolerance to BOTH of the following:

- armodafinil or modafinil
- Sunosi (solriamfetol)

**AND**

**4.2** Trial and failure, contraindication, or intolerance to an amphetamine (e.g., amphetamine, dextroamphetamine) or methylphenidate based stimulant UNLESS patient is not a candidate

**AND**

**5** - Prescribed by ONE of the following:

- Neurologist
- Psychiatrist
- Sleep Medicine Specialist

Product Name: Wakix			
Diagnosis	Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1), Narcolepsy without Cataplexy (i.e., Narcolepsy Type 2)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
WAKIX	PITOLISANT HCL TAB 4.45 MG (BASE EQUIVALENT)	61450070100318	Brand
WAKIX	PITOLISANT HCL TAB 17.8 MG (BASE EQUIVALENT)	61450070100338	Brand
<b>Approval Criteria</b>			

1 - Patient has a reduction in symptoms of excessive daytime sleepiness associated with therapy

## 2 . Revision History

Date	Notes
9/17/2024	Update to guideline name and criteria.

Wegovy (semaglutide)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155326
<b>Guideline Name</b>	Wegovy (semaglutide)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Wegovy			
Diagnosis	Reduction of risk of major adverse cardiovascular events		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
WEGOYV	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 0.25 MG/0.5ML	6125207000D520	Brand
WEGOYV	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 0.5 MG/0.5ML	6125207000D525	Brand
WEGOYV	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 1 MG/0.5ML	6125207000D530	Brand

WEGOVY	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 1.7 MG/0.75ML	6125207000D535	Brand
WEGOVY	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 2.4 MG/0.75ML	6125207000D540	Brand

**Approval Criteria**

1 - Treatment is being requested to reduce the risk of major adverse cardiovascular events

**AND**

2 - Patient is 45 years of age or older

**AND**

3 - Submission of medical records (e.g., chart notes) documenting ALL the following:

3.1 BMI (body mass index) greater than or equal to 30 kg/m<sup>2</sup> (kilograms per square meter)

**AND**

3.2 Established cardiovascular disease as evidenced by ONE of the following:

3.2.1 Prior myocardial infarction (MI)

**OR**

3.2.2 ONE of the following diagnoses/diagnosis codes:

- I25.2 Old myocardial infarction
- I46.2 Cardiac arrest due to underlying cardiac condition
- I46.8 Cardiac arrest due to other underlying condition
- I46.9 Cardiac arrest, cause unspecified
- Z95.0 Presence of cardiac pacemaker
- Z95.1 Presence of aortocoronary bypass graft
- Z95.2 Presence of prosthetic heart valve
- Z95.3 Presence of xenogenic heart valve
- Z95.4 Presence of other heart-valve replacement

- Z95.5 Presence of coronary angioplasty implant and graft

**AND**

**4** - Used in combination with a reduced calorie diet and increased physical activity

**AND**

**5** - For patients with a history of myocardial infarction, submission of medical records (e.g., chart notes) or paid claims documenting ONE of the following:

**5.1** Patient is on therapy from each of the following classes (as confirmed by claims history or submission of medical records):

- Cholesterol lowering medication (e.g., statin, PCSK9i)
- Beta blocker (i.e., carvedilol, metoprolol, or bisoprolol)
- Angiotensin-converting enzyme inhibitor (ACE-I)/angiotensin II receptor blocker (ARB)/angiotensin II receptor blocker neprilysin inhibitor (ARNI)
- Antiplatelet (e.g., aspirin, clopidogrel)

**OR**

**5.2** Patient has a history of intolerance or contraindication to ALL of the following therapeutic classes (please specify intolerance or contraindication):

- Cholesterol lowering medication (e.g., statin, PCSK9i)
- Beta blocker (i.e., carvedilol, metoprolol, or bisoprolol)
- Angiotensin-converting enzyme inhibitor (ACE-I)/angiotensin II receptor blocker (ARB)/angiotensin II receptor blocker neprilysin inhibitor (ARNI)
- Antiplatelet (e.g., aspirin, clopidogrel)

**AND**

**6** - Patient does NOT have diagnosis of diabetes or HgA1c greater than or equal to 6.5%

**AND**

**7** - Patient does NOT have New York Heart Association class IV heart failure

**AND**

**8** - Patient does NOT have end-stage renal disease

Product Name: Wegovy			
Diagnosis	Reduction of risk of major adverse cardiovascular events		
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
WEGOVI	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 0.25 MG/0.5ML	6125207000D520	Brand
WEGOVI	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 0.5 MG/0.5ML	6125207000D525	Brand
WEGOVI	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 1 MG/0.5ML	6125207000D530	Brand
WEGOVI	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 1.7 MG/0.75ML	6125207000D535	Brand
WEGOVI	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 2.4 MG/0.75ML	6125207000D540	Brand

**Approval Criteria**

**1** - BMI (body mass index) greater than or equal to 30 kg/m<sup>2</sup> (kilograms per square meter)

**AND**

**2** - Used in combination with a reduced calorie diet and increased physical activity

**AND**

**3** - Patient does NOT have diagnosis of diabetes or HgA1c greater than or equal to 6.5%

<p><b>AND</b></p> <p><b>4</b> - Patient does NOT have New York Heart Association class IV heart failure</p> <p><b>AND</b></p> <p><b>5</b> - Patient does NOT have end-stage renal disease</p>
---

<b>Product Name: Wegovy</b>			
Diagnosis	Weight Loss		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
WEGOVI	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 0.25 MG/0.5ML	6125207000D520	Brand
WEGOVI	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 0.5 MG/0.5ML	6125207000D525	Brand
WEGOVI	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 1 MG/0.5ML	6125207000D530	Brand
WEGOVI	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 1.7 MG/0.75ML	6125207000D535	Brand
WEGOVI	SEMAGLUTIDE (WEIGHT MNGMT) SOLN AUTO-INJECTOR 2.4 MG/0.75ML	6125207000D540	Brand
<p><b>Approval Criteria</b></p> <p><b>1</b> - Wegovy when used solely for the treatment of weight loss is excluded and is to be denied as a benefit exclusion</p>			

## 2 . Revision History

Date	Notes
9/19/2024	New program.





Xdemvy (lotilaner)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140834
<b>Guideline Name</b>	Xdemvy (lotilaner)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	1/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Xdemvy			
Approval Length	2 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XDEMZY	LOTILANER OPHTH SOLN 0.25%	86106050002020	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:</p> <p>1.1 Diagnosis of Demodex blepharitis</p>			

**AND**

**1.2** Patient exhibits one of the following signs of Demodex infestation:

- Collarettes
- Eyelid margin erythema
- Eyelash anomalies (e.g., eyelash misdirection)

**AND**

**1.3** Patient is experiencing symptoms or architectural changes associated with Demodex infestation (e.g., burning, tearing, itching, foreign body sensation, eyelashes missing, eyelashes growing inward)

**AND**

**1.4** Trial and inadequate response to tea tree-oil shampoo or eyelid scrub

**AND**

**2** - Prescribed by or in consultation with one of the following:

- Ophthalmologist
- Optometrist

## 2 . Revision History

Date	Notes
12/7/2023	New guideline

Xeljanz, Xeljanz XR (tofacitinib)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155762
<b>Guideline Name</b>	Xeljanz, Xeljanz XR (tofacitinib)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Xeljanz tablets, Xeljanz XR tablets			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XELJANZ	TOFACITINIB CITRATE TAB 5 MG (BASE EQUIVALENT)	66603065100320	Brand
XELJANZ	TOFACITINIB CITRATE TAB 10 MG (BASE EQUIVALENT)	66603065100330	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 11 MG (BASE EQUIVALENT)	66603065107530	Brand

XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 22 MG (BASE EQUIVALENT)	66603065107550	Brand
------------	---	----------------	-------

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of moderately to severely active rheumatoid arthritis (RA)

**AND**

1.2 Submission of medical records (e.g., chart notes) or paid claims documenting history of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced

**AND**

1.3 If the request is for Xeljanz XR, submission of medical records (e.g., chart notes) or paid claims documenting history of failure, contraindication, or intolerance to ALL of the following:

- A preferred\* adalimumab biosimilar
- Enbrel (etanercept)
- Xeljanz (tofacitinib) immediate-release tablets
- Orencia (abatacept)

**AND**

1.4 Prescribed by or in consultation with a rheumatologist

**OR**

2 - ALL of the following:

2.1 Submission of medical records (e.g., chart notes) or paid claims documenting patient is currently on the requested therapy

<b>AND</b>	
<b>2.2</b> Diagnosis of moderately to severely active RA	
<b>AND</b>	
<b>2.3</b> Prescribed by or in consultation with a rheumatologist	
Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>

Product Name: Xeljanz tablets, Xeljanz XR tablets			
Diagnosis	Rheumatoid Arthritis (RA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XELJANZ	TOFACITINIB CITRATE TAB 5 MG (BASE EQUIVALENT)	66603065100320	Brand
XELJANZ	TOFACITINIB CITRATE TAB 10 MG (BASE EQUIVALENT)	66603065100330	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 11 MG (BASE EQUIVALENT)	66603065107530	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 22 MG (BASE EQUIVALENT)	66603065107550	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy			
<b>AND</b>			
2 - Prescribed by or in consultation with a rheumatologist			

Product Name: Xeljanz tablets, Xeljanz XR tablets	
Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
XELJANZ	TOFACITINIB CITRATE TAB 5 MG (BASE EQUIVALENT)	66603065100320	Brand
XELJANZ	TOFACITINIB CITRATE TAB 10 MG (BASE EQUIVALENT)	66603065100330	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 11 MG (BASE EQUIVALENT)	66603065107530	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 22 MG (BASE EQUIVALENT)	66603065107550	Brand

**Approval Criteria**

1 - ALL of the following:

1.1 Diagnosis of active psoriatic arthritis

**AND**

1.2 Submission of medical records (e.g., chart notes) or paid claims documenting history of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced

**AND**

1.3 If the request is for Xeljanz XR, submission of medical records (e.g., chart notes) or paid claims documenting history of failure, contraindication, or intolerance to ALL of the following:

- A preferred\* adalimumab biosimilar
- Enbrel (etanercept)
- Otezla (apremilast)
- Xeljanz (tofacitinib) immediate-release

- Orencia (abatacept)

**AND**

**1.4** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

**OR**

**2** - ALL of the following:

**2.1** Submission of medical records (e.g., chart notes) or paid claims documenting patient is currently on the requested therapy

**AND**

**2.2** Diagnosis of active psoriatic arthritis

**AND**

**2.3** Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

Product Name: Xeljanz tablets, Xeljanz XR tablets	
Diagnosis	Psoriatic Arthritis (PsA)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
XELJANZ	TOFACITINIB CITRATE TAB 5 MG (BASE EQUIVALENT)	66603065100320	Brand
XELJANZ	TOFACITINIB CITRATE TAB 10 MG (BASE EQUIVALENT)	66603065100330	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 11 MG (BASE EQUIVALENT)	66603065107530	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 22 MG (BASE EQUIVALENT)	66603065107550	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

**AND**

2 - Prescribed by or in consultation with ONE of the following:

- Rheumatologist
- Dermatologist

Product Name: Xeljanz tablets, Xeljanz XR tablets			
Diagnosis	Ulcerative Colitis (UC)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XELJANZ	TOFACITINIB CITRATE TAB 5 MG (BASE EQUIVALENT)	66603065100320	Brand
XELJANZ	TOFACITINIB CITRATE TAB 10 MG (BASE EQUIVALENT)	66603065100330	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 11 MG (BASE EQUIVALENT)	66603065107530	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 22 MG (BASE EQUIVALENT)	66603065107550	Brand



**Approval Criteria**

**1** - ALL of the following:

**1.1** Diagnosis of moderately to severely active ulcerative colitis (UC)

**AND**

**1.2** Submission of medical records (e.g., chart notes) or paid claims documenting history of failure to ONE of the following conventional therapies at maximally indicated doses within the last 3 months, unless contraindicated or clinically significant adverse effects are experienced:

- Corticosteroids (e.g., prednisone, methylprednisone, budesonide)
- 6-mercaptopurine (Purinethol)
- Azathioprine (Imuran)
- Aminosalicylates (e.g., mesalamine, sulfasalazine)

**AND**

**1.3** If the request is for Xeljanz XR, submission of medical records (e.g., chart notes) or paid claims documenting history of failure, contraindication, or intolerance to Xeljanz (tofacitinib) immediate release tablets

**AND**

**1.4** Prescribed by or in consultation with a gastroenterologist

**OR**

**2** - ALL of the following:

**2.1** Submission of medical records (e.g., chart notes) or paid claims documenting patient is currently on the requested therapy

**AND**

**2.2** Diagnosis of moderately to severely active UC

**AND**

**2.3** Prescribed by or in consultation with a gastroenterologist

Product Name: Xeljanz tablets, Xeljanz XR tablets			
Diagnosis	Ulcerative Colitis (UC)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XELJANZ	TOFACITINIB CITRATE TAB 5 MG (BASE EQUIVALENT)	66603065100320	Brand
XELJANZ	TOFACITINIB CITRATE TAB 10 MG (BASE EQUIVALENT)	66603065100330	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 11 MG (BASE EQUIVALENT)	66603065107530	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 22 MG (BASE EQUIVALENT)	66603065107550	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to therapy			
<b>AND</b>			
2 - Prescribed by or in consultation with a gastroenterologist			

Product Name: Xeljanz tablets, Xeljanz XR tablets	
Diagnosis	Ankylosing Spondylitis (AS)
Approval Length	12 month(s)

Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XELJANZ	TOFACITINIB CITRATE TAB 5 MG (BASE EQUIVALENT)	66603065100320	Brand
XELJANZ	TOFACITINIB CITRATE TAB 10 MG (BASE EQUIVALENT)	66603065100330	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 11 MG (BASE EQUIVALENT)	66603065107530	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 22 MG (BASE EQUIVALENT)	66603065107550	Brand

**Approval Criteria**

1 - Diagnosis of active ankylosing spondylitis

**AND**

2 - Prescribed by or in consultation with a rheumatologist

**AND**

3 - ONE of the following:

3.1 BOTH of the following:

3.1.1 Trial and failure, contraindication, or intolerance to TWO nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen)

**AND**

3.1.2 If the request is for Xeljanz XR, submission of medical records (e.g., chart notes) or paid claims documenting history of failure, contraindication, or intolerance to ALL of the following:

- A preferred\* adalimumab biosimilar
- Enbrel (etanercept)

<ul style="list-style-type: none"> <li>Xeljanz (tofacitinib) immediate-release tablets</li> </ul> <p style="text-align: center;"><b>OR</b></p> <p><b>3.2</b> Submission of medical records (e.g., chart notes) or paid claims documenting patient is currently on the requested therapy</p>	
Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>

Product Name: Xeljanz tablets, Xeljanz XR tablets			
Diagnosis	Ankylosing Spondylitis (AS)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XELJANZ	TOFACITINIB CITRATE TAB 5 MG (BASE EQUIVALENT)	66603065100320	Brand
XELJANZ	TOFACITINIB CITRATE TAB 10 MG (BASE EQUIVALENT)	66603065100330	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 11 MG (BASE EQUIVALENT)	66603065107530	Brand
XELJANZ XR	TOFACITINIB CITRATE TAB ER 24HR 22 MG (BASE EQUIVALENT)	66603065107550	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with a rheumatologist</p>			

Product Name: Xeljanz tablets and oral solution
---

Diagnosis	Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)
Approval Length	12 month(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
XELJANZ	TOFACITINIB CITRATE TAB 5 MG (BASE EQUIVALENT)	66603065100320	Brand
XELJANZ	TOFACITINIB CITRATE TAB 10 MG (BASE EQUIVALENT)	66603065100330	Brand
XELJANZ	TOFACITINIB CITRATE ORAL SOLN 1 MG/ML (BASE EQUIVALENT)	66603065102020	Brand

**Approval Criteria**

1 - Diagnosis of active polyarticular course juvenile idiopathic arthritis

**AND**

2 - Prescribed by or in consultation with a rheumatologist

**AND**

3 - ONE of the following:

3.1 BOTH of the following:

3.1.1 Submission of medical records (e.g., chart notes) or paid claims documenting trial and failure, contraindication, or intolerance to ONE of the following nonbiologic DMARDs:

- leflunomide
- methotrexate

**AND**

3.1.2 If the request is for Xeljanz oral solution, submission of medical records (e.g., chart notes) or paid claims documenting history of failure, contraindication, or intolerance to ALL of the following:

- A preferred\* adalimumab biosimilar
- Enbrel (etanercept)
- Xeljanz (tofacitinib) immediate-release tablets
- Orenzia (abatacept)

**OR**

**3.2** Submission of medical records (e.g., chart notes) or paid claims documenting patient is currently on the requested therapy

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC%20CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC CP</a>
-------	--

Product Name: Xeljanz tablets and oral solution			
Diagnosis	Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XELJANZ	TOFACITINIB CITRATE TAB 5 MG (BASE EQUIVALENT)	66603065100320	Brand
XELJANZ	TOFACITINIB CITRATE TAB 10 MG (BASE EQUIVALENT)	66603065100330	Brand
XELJANZ	TOFACITINIB CITRATE ORAL SOLN 1 MG/ML (BASE EQUIVALENT)	66603065102020	Brand

**Approval Criteria**

**1** - Documentation of positive clinical response to therapy

**AND**

**2** - Prescribed by or in consultation with a rheumatologist

## 2 . Revision History

Date	Notes
9/25/2024	Update to guideline name. Updated submission of medical records verbiage, updated embedded steps, and updated notes section throughout guideline. Updated polyarticular juvenile idiopathic arthritis diagnosis to specify "course". Cosmetic updates.

Xenazine



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140906
<b>Guideline Name</b>	Xenazine
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Brand Xenazine, generic tetrabenazine			
Diagnosis	Chorea associated with Huntington’s Disease		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TETRABENAZINE	TETRABENAZINE TAB 12.5 MG	62380070000310	Generic
XENAZINE	TETRABENAZINE TAB 12.5 MG	62380070000310	Brand
TETRABENAZINE	TETRABENAZINE TAB 25 MG	62380070000320	Generic
XENAZINE	TETRABENAZINE TAB 25 MG	62380070000320	Brand



**Approval Criteria**

1 - Diagnosis of chorea in patients with Huntington's disease

Product Name: Brand Xenazine, generic tetrabenazine			
Diagnosis	Tardive Dyskinesia (Off Label)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TETRABENAZINE	TETRABENAZINE TAB 12.5 MG	62380070000310	Generic
XENAZINE	TETRABENAZINE TAB 12.5 MG	62380070000310	Brand
TETRABENAZINE	TETRABENAZINE TAB 25 MG	62380070000320	Generic
XENAZINE	TETRABENAZINE TAB 25 MG	62380070000320	Brand

**Approval Criteria**

1 - Diagnosis of tardive dyskinesia

**AND**

2 - One of the following:

**2.1** Patient has persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication

**OR**

**2.2** Patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication

**AND**

**3** - Prescribed by or in consultation with one of the following:

- Neurologist
- Psychiatrist

Product Name: Brand Xenazine, generic tetrabenazine			
Diagnosis	Tardive Dyskinesia (Off Label)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TETRABENAZINE	TETRABENAZINE TAB 12.5 MG	62380070000310	Generic
XENAZINE	TETRABENAZINE TAB 12.5 MG	62380070000310	Brand
TETRABENAZINE	TETRABENAZINE TAB 25 MG	62380070000320	Generic
XENAZINE	TETRABENAZINE TAB 25 MG	62380070000320	Brand
<b>Approval Criteria</b>			
<b>1</b> - Documentation of positive clinical response to therapy			

Product Name: Brand Xenazine, generic tetrabenazine			
Diagnosis	Tourette's syndrome (off-label)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TETRABENAZINE	TETRABENAZINE TAB 12.5 MG	62380070000310	Generic
XENAZINE	TETRABENAZINE TAB 12.5 MG	62380070000310	Brand

TETRABENAZINE	TETRABENAZINE TAB 25 MG	62380070000320	Generic
XENAZINE	TETRABENAZINE TAB 25 MG	62380070000320	Brand

**Approval Criteria**

1 - Patient has tics associated with Tourette's syndrome

**AND**

2 - History of failure, contraindication, or intolerance to Haldol (haloperidol)

**AND**

3 - Prescribed by or in consultation with one of the following:

- Neurologist
- Psychiatrist

Product Name: Brand Xenazine, generic tetrabenazine			
Diagnosis	Tourette's syndrome (off-label)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
TETRABENAZINE	TETRABENAZINE TAB 12.5 MG	62380070000310	Generic
XENAZINE	TETRABENAZINE TAB 12.5 MG	62380070000310	Brand
TETRABENAZINE	TETRABENAZINE TAB 25 MG	62380070000320	Generic
XENAZINE	TETRABENAZINE TAB 25 MG	62380070000320	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to therapy

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Xenleta



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140706
<b>Guideline Name</b>	Xenleta
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Xenleta			
Diagnosis	Community-acquired bacterial pneumonia		
Approval Length	7 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XENLETA	LEFAMULIN ACETATE TAB 600 MG	16240040100320	Brand
<b>Approval Criteria</b>			
1 - One of the following:			

**1.1** For continuation of therapy upon hospital discharge

**OR**

**1.2** As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

**1.3** All of the following:

**1.3.1** Diagnosis of community-acquired bacterial pneumonia (CABP)

**AND**

**1.3.2** Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Xenleta

**AND**

**1.3.3** History of failure, contraindication, or intolerance to three of the following antibiotics:

- Amoxicillin
- A macrolide
- Doxycycline
- A fluoroquinolone
- Combination therapy with amoxicillin/clavulanate or cephalosporin AND a macrolide or doxycycline

Product Name: Xenleta*			
Diagnosis		Off-Label Uses	
Guideline Type		Prior Authorization	
Product Name	Generic Name	GPI	Brand/Generic
XENLETA	LEFAMULIN ACETATE TAB 600 MG	16240040100320	Brand

**Approval Criteria**

1 - One of the following:

1.1 For continuation of therapy upon hospital discharge

**OR**

1.2 As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

1.3 The medication is being prescribed by or in consultation with an infectious disease specialist

Notes	*Approval Duration: Based on provider recommended treatment durations, not to exceed 6 months
-------	---

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Xermelo



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140907
<b>Guideline Name</b>	Xermelo
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Xermelo			
Diagnosis	Carcinoid Syndrome Diarrhea		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XERMELO	TELOTRISTAT ETIPRATE TAB 250 MG (TELOTRISTAT ETHYL EQUIV)	52570075100330	Brand
<b>Approval Criteria</b>			



**1 - Diagnosis of carcinoid syndrome diarrhea**

**AND**

**2 - Diarrhea is inadequately controlled with somatostatin analog therapy (e.g., octreotide, Sandostatin LAR, Somatuline Depot)**

**AND**

**3 - Used in combination with somatostatin analog therapy (e.g., octreotide, Sandostatin LAR, Somatuline Depot)**

Product Name: Xermelo			
Diagnosis	Carcinoid Syndrome Diarrhea		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XERMELO	TELOTRISTAT ETIPRATE TAB 250 MG (TELOTRISTAT ETHYL EQUIV)	52570075100330	Brand
<b>Approval Criteria</b>			
1 - Documentation of positive clinical response to Xermelo			

## 2 . Revision History

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Xhance (fluticasone nasal spray)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-148425
<b>Guideline Name</b>	Xhance (fluticasone nasal spray)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	7/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Xhance			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XHANCE	FLUTICASONE PROPIONATE NASAL EXHALER SUSP 93 MCG/ACT	4220003230G720	Brand
<b>Approval Criteria</b>			
1 - Diagnosis of ONE of the following:			

- Chronic rhinosinusitis with nasal polyps (CRSwNP)
- Chronic rhinosinusitis without nasal polyps (CRSsNP)

**AND**

**2** - History of failure to generic fluticasone nasal spray

## **2 . Revision History**

Date	Notes
6/11/2024	New program.

Xolair (omalizumab)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-147108
<b>Guideline Name</b>	Xolair (omalizumab)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	6/1/2024
-----------------	----------

### 1 . Criteria

Product Name: Xolair			
Diagnosis	Allergic Asthma		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XOLAIR	OMALIZUMAB FOR INJ 150 MG	44603060002120	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	4460306000E510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	4460306000E520	Brand

XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 75 MG/0.5ML	4460306000D510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	4460306000D520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	4460306000D530	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	4460306000E530	Brand

**Approval Criteria**

1 - Submission of documentation (e.g., chart notes) confirming diagnosis of moderate to severe persistent allergic asthma

**AND**

2 - Submission of documentation (e.g., chart notes, lab values) confirming a positive skin test or in vitro reactivity to a perennial aeroallergen

**AND**

3 - ONE of the following:

3.1 BOTH of the following:

- Patient is 12 years of age or older
- Submission of documentation (e.g., chart notes, lab values) confirming pre-treatment serum immunoglobulin (Ig)E level between 30 to 700 IU/mL

**OR**

3.2 BOTH of the following:

- Patient is 6 years to less than 12 years of age
- Submission of documentation (e.g. chart notes, lab values) confirming pre-treatment serum immunoglobulin (Ig)E level between 30 to 1300 IU/mL

**AND**

**4** - Paid claims or submission of documentation (e.g., chart notes) confirming patient is currently being treated with ONE of the following, unless there is a contraindication or intolerance to these medications:

**4.1** BOTH of the following:

- High-dose inhaled corticosteroid (ICS) (e.g., greater than 500 mcg fluticasone propionate equivalent/day)
- Additional asthma controller medication (e.g., leukotriene receptor antagonist [e.g., montelukast], long-acting beta-2 agonist [LABA] [e.g., salmeterol ], tiotropium)

**OR**

**4.2** One maximally-dosed combination ICS/LABA product (e.g., Advair [fluticasone propionate/salmeterol], Symbicort [budesonide/formoterol], Breo Ellipta [fluticasone/vilanterol])

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Pulmonologist
- Allergist/immunologist

Product Name: Xolair			
Diagnosis	Allergic Asthma		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XOLAIR	OMALIZUMAB FOR INJ 150 MG	44603060002120	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	4460306000E510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	4460306000E520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 75 MG/0.5ML	4460306000D510	Brand

XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	4460306000D520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	4460306000D530	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	4460306000E530	Brand

**Approval Criteria**

**1** - Submission of documentation (e.g., chart notes) confirming a positive clinical response to therapy (e.g., reduction in exacerbations, improvement in forced expiratory volume in 1 second [FEV1], decreased use of rescue medications)

**AND**

**2** - Paid claims or submission of documentation (e.g., chart notes) confirming patient continues to be treated with an inhaled corticosteroid (ICS) (e.g., fluticasone, budesonide) with or without additional asthma controller medication (e.g., leukotriene receptor antagonist [e.g., montelukast], long-acting beta-2 agonist [LABA] [e.g., salmeterol], tiotropium) unless there is a contraindication or intolerance to these medications

**AND**

**3** - Prescribed by or in consultation with **ONE** of the following:

- Pulmonologist
- Allergist/immunologist

Product Name: Xolair			
Diagnosis	Chronic Spontaneous Urticaria (CSU)		
Approval Length	3 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XOLAIR	OMALIZUMAB FOR INJ 150 MG	44603060002120	Brand

XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	4460306000E510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	4460306000E520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 75 MG/0.5ML	4460306000D510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	4460306000D520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	4460306000D530	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	4460306000E530	Brand

**Approval Criteria**

**1** - Submission of documentation (e.g., chart notes) confirming diagnosis of chronic spontaneous urticaria

**AND**

**2** - Persistent symptoms (itching and hives) for at least 4 consecutive weeks despite titrating to an optimal dose with a second generation H1 antihistamine (e.g., cetirizine, fexofenadine), unless there is a contraindication or intolerance to H1 antihistamines

**AND**

**3** - Paid claims or submission of documentation (e.g., chart notes) confirming concurrent use with an H1 antihistamine, unless there is a contraindication or intolerance to H1 antihistamines

**AND**

**4** - Paid claims or submission of documentation (e.g., chart notes) confirming patient has tried and had an inadequate response or intolerance to at least TWO of the following additional therapies:

- Doxepin
- H1 antihistamine
- H2 antagonist (e.g., famotidine, cimetidine)
- Hydroxyzine



- Leukotriene receptor antagonist (e.g., montelukast)

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Allergist/immunologist
- Dermatologist

Product Name: Xolair			
Diagnosis	Chronic Spontaneous Urticaria (CSU)		
Approval Length	6 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XOLAIR	OMALIZUMAB FOR INJ 150 MG	44603060002120	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	4460306000E510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	4460306000E520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 75 MG/0.5ML	4460306000D510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	4460306000D520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	4460306000D530	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	4460306000E530	Brand

**Approval Criteria**

**1** - Patient's disease status has been re-evaluated since the last authorization to confirm the patient's condition warrants continued treatment

**AND**

**2** - Submission of documentation (e.g., chart notes) confirming patient has experienced at least ONE of the following:

- Reduction in itching severity from baseline
- Reduction in the number of hives from baseline

Product Name: Xolair			
Diagnosis	Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XOLAIR	OMALIZUMAB FOR INJ 150 MG	44603060002120	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	4460306000E510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	4460306000E520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 75 MG/0.5ML	4460306000D510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	4460306000D520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	4460306000D530	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	4460306000E530	Brand

**Approval Criteria**

**1** - Patient is 18 years of age or older

**AND**

**2** - Submission of documentation (e.g., chart notes) confirming ONE of the following:

**2.1** ALL of the following:

**2.1.1** Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) defined by ALL of the following:

**2.1.1.1** TWO or more of the following symptoms for greater than or equal to 12 weeks duration:

- Mucopurulent discharge
- Nasal obstruction and congestion
- Decreased or absent sense of smell
- Facial pressure or pain

**AND**

**2.1.1.2** ONE of the following:

- Evidence of inflammation on paranasal sinus examination or computed tomography (CT)
- Evidence of purulence coming from paranasal sinuses or ostiomeatal complex

**AND**

**2.1.1.3** The presence of nasal polyps

**AND**

**2.1.2** ONE of the following:

- Patient has required prior sino-nasal surgery
- Patient has required systemic corticosteroids in the previous 2 years

**AND**

**2.1.3** Patient has been unable to obtain symptom relief after trial of ALL of the following agents/classes of agents:

- Nasal saline irrigations
- Intranasal corticosteroids (e.g. fluticasone, mometasone, triamcinolone, etc.)
- Antileukotriene agents (e.g. montelukast, zafirlukast, zileuton)

**OR**

**2.2** BOTH of the following:

**2.2.1** Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP)

**AND**

**2.2.2** Patient is currently on Xolair therapy

**AND**

**3** - Patient will receive Xolair as add-on maintenance therapy in combination with intranasal corticosteroids

**AND**

**4** - Patient is NOT receiving Xolair in combination with another biologic medication (e.g., Dupixent [dupilumab], Nucala [mepolizumab])

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Otolaryngologist
- Allergist
- Pulmonologist

Product Name: Xolair	
Diagnosis	Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
XOLAIR	OMALIZUMAB FOR INJ 150 MG	44603060002120	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	4460306000E510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	4460306000E520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 75 MG/0.5ML	4460306000D510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	4460306000D520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	4460306000D530	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	4460306000E530	Brand

**Approval Criteria**

1 - Submission of documentation (e.g., chart notes, lab values) confirming a positive clinical response to Xolair therapy

**AND**

2 - Patient will continue to receive Xolair as add-on maintenance therapy in combination with intranasal corticosteroids

**AND**

3 - Patient is NOT receiving Xolair in combination with another biologic medication (e.g., Dupixent [dupilumab], Nucala [mepolizumab])

**AND**

4 - Prescribed by or in consultation with ONE of the following:

- Otolaryngologist
- Allergist
- Pulmonologist

Product Name: Xolair	
Diagnosis	IgE-Mediated Food Allergy
Approval Length	20 Week(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
XOLAIR	OMALIZUMAB FOR INJ 150 MG	44603060002120	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	4460306000E510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	4460306000E520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 75 MG/0.5ML	4460306000D510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	4460306000D520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	4460306000D530	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	4460306000E530	Brand

**Approval Criteria**

1 - ONE of the following:

1.1 Submission of documentation (e.g., chart notes, lab values) confirming BOTH of the following:

1.1.1 Diagnosis of IgE Mediated Food Allergy as evidenced by ONE of the following:

- Positive skin prick test (defined as greater than or equal to 4 millimeters wheal greater than saline control) to food
- Positive food specific IgE (greater than or equal to 6 kUA/L)
- Positive oral food challenge, defined as experiencing dose-limiting symptoms at a single dose of less than or equal to 300 mg of food protein

**AND**

**1.1.2 Clinical history of IgE Mediated Food Allergy**

**OR**

**1.2** Submission of documentation (e.g., chart notes, lab values) confirming patient has a history of severe allergic response, including anaphylaxis, following exposure to one or more foods

**AND**

**2** - Patient is 1 year of age or older

**AND**

**3** - Used in conjunction with food allergen avoidance

**AND**

**4** - Submission of documentation (e.g., chart notes, lab values) confirming BOTH of the following:

- Baseline (pre-Xolair treatment) serum total IgE level is greater than or equal to 30 IU/mL and less than or equal to 1850 IU/mL
- Dosing is according to serum total IgE levels and body weight

**AND**

**5** - Prescribed by or in consultation with ONE of the following:

- Allergist
- Immunologist

Product Name: Xolair

Diagnosis

IgE-Mediated Food Allergy

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
XOLAIR	OMALIZUMAB FOR INJ 150 MG	44603060002120	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML	4460306000E510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 150 MG/ML	4460306000E520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 75 MG/0.5ML	4460306000D510	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 150 MG/ML	4460306000D520	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 300 MG/2ML	4460306000D530	Brand
XOLAIR	OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML	4460306000E530	Brand

**Approval Criteria**

**1** - Submission of documentation (e.g., chart notes, lab values) confirming a positive clinical response to therapy (e.g., reduction of type 1 allergic reactions, including anaphylaxis, following accidental exposure to one or more foods)

**AND**

**2** - Used in conjunction with food allergen avoidance

**AND**

**3** - Submission of documentation (e.g., chart notes, lab values) confirming that dosing will continue to be based on body weight and pretreatment total IgE serum levels (Note: Dose should only be adjusted during therapy due to significant changes in patient body weight)

**AND**



4 - Prescribed by or in consultation with ONE of the following:

- Allergist
- Immunologist

## 2 . Background

### Clinical Practice Guidelines

**The Global Initiative for Asthma Global Strategy for Asthma Management and Prevention: Table 1. Low, medium and high daily doses of inhaled corticosteroids in adolescents and adults 12 years and older.**

Inhaled corticosteroid	Total Daily ICS Dose (mcg)		
	Low	Medium	High
Beclometasone dipropionate (pMDI, standard particle, HFA)	200-500	> 500-1000	> 1000
Beclometasone dipropionate (DPI or pMDI, extrafine particle*, HFA)	100-200	> 200-400	> 400
Budesonide (DPI, or pMDI, standard particle, HFA)	200-400	> 400-800	> 800
Ciclesonide (pMDI, extrafine particle*, HFA)	80-160	> 160-320	> 320
Fluticasone furoate (DPI)	100		200
Fluticasone propionate (DPI)	100-250	> 250-500	> 500
Fluticasone propionate (pMDI, standard particle, HFA)	100-250	> 250-500	> 500
Mometasone furoate (DPI)	Depends on DPI device – see product information		
Mometasone furoate (pMDI, standard particle, HFA)	200-400		> 400

DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; ICS: inhaled corticosteroid; N/A: not applicable; pMDI: pressurized metered dose inhaler (non-chlorofluorocarbon formulations); ICS by pMDI should be preferably used with a spacer \*See product information.

***This is not a table of equivalence***, but instead, suggested total daily doses for the 'low', 'medium' and 'high' dose ICS options for adults/adolescents, based on available studies and product information. Data on comparative potency are not readily available and therefore this table does NOT imply potency equivalence. Doses may be country -specific depending on local availability, regulatory labelling and clinical guidelines.

For new preparations, including generic ICS, the manufacturer's information should be reviewed carefully; products containing the same molecule may not be clinically equivalent.

### 3 . Revision History

Date	Notes
5/16/2024	Updated criteria and GPI table.

Xolremdi (mavorixafor)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-151359
<b>Guideline Name</b>	Xolremdi (mavorixafor)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	9/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Xolremdi			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XOLREMDI	MAVORIXAFOR CAP 100 MG	82502046000120	Brand
<b>Approval Criteria</b>			
1 - Submission of medical records (e.g., chart notes) documenting ALL of the following:			

**1.1** Diagnosis of WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome

**AND**

**1.2** Patient has genotype confirmed variant of CXCR4 as detected by an FDA (Food and Drug Administration)-approved test or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA)

**AND**

**1.3** Patient has an absolute neutrophil count (ANC) less than or equal to 500 cells/ $\mu$ L

**AND**

**2** - Patient is 12 years of age or older

**AND**

**3** - Prescribed by or in consultation with ONE of the following:

- Immunologist
- Hematologist
- Geneticist
- Allergist

Product Name: Xolremdi			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XOLREMDI	MAVORIXAFOR CAP 100 MG	82502046000120	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy (e.g., improvement in ANC, reduction in infections)

**2 . Revision History**

Date	Notes
8/12/2024	New program.

Xopenex Respules



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140660
<b>Guideline Name</b>	Xopenex Respules
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/1/2021
-----------------	----------

## 1 . Criteria

Product Name: Brand Xopenex inhalation soln, generic levalbuterol inhalation soln			
Approval Length	12 month(s)		
Guideline Type	Step Therapy		
Product Name	Generic Name	GPI	Brand/Generic
LEVALBUTEROL HCL	LEVALBUTEROL HCL SOLN NEBU 0.31 MG/3ML (BASE EQUIV)	44201045102510	Generic
LEVALBUTEROL HYDROCHLORIDE	LEVALBUTEROL HCL SOLN NEBU 0.31 MG/3ML (BASE EQUIV)	44201045102510	Generic
XOPENEX	LEVALBUTEROL HCL SOLN NEBU 0.31 MG/3ML (BASE EQUIV)	44201045102510	Brand
LEVALBUTEROL HCL	LEVALBUTEROL HCL SOLN NEBU 0.63 MG/3ML (BASE EQUIV)	44201045102520	Generic

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

LEVALBUTEROL HYDROCHLORIDE	LEVALBUTEROL HCL SOLN NEBU 0.63 MG/3ML (BASE EQUIV)	44201045102520	Generic
XOPENEX	LEVALBUTEROL HCL SOLN NEBU 0.63 MG/3ML (BASE EQUIV)	44201045102520	Brand
LEVALBUTEROL HCL	LEVALBUTEROL HCL SOLN NEBU 1.25 MG/3ML (BASE EQUIV)	44201045102530	Generic
LEVALBUTEROL HYDROCHLORIDE	LEVALBUTEROL HCL SOLN NEBU 1.25 MG/3ML (BASE EQUIV)	44201045102530	Generic
XOPENEX	LEVALBUTEROL HCL SOLN NEBU 1.25 MG/3ML (BASE EQUIV)	44201045102530	Brand
LEVALBUTEROL	LEVALBUTEROL HCL SOLN NEBU CONC 1.25 MG/0.5ML (BASE EQUIV)	44201045102560	Generic
XOPENEX CONCENTRATE	LEVALBUTEROL HCL SOLN NEBU CONC 1.25 MG/0.5ML (BASE EQUIV)	44201045102560	Brand

**Approval Criteria**

1 - The patient has a history of failure, contraindication, or intolerance to treatment with albuterol inhalation solution

**2 . Revision History**

Date	Notes
1/26/2021	Copy NY to AZ and fix guideline name for PA CHIP

Xphozah (tenapanor)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-143587
<b>Guideline Name</b>	Xphozah (tenapanor)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	3/17/2024
-----------------	-----------

## 1 . Criteria

Product Name: Xphozah			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XPHOZAH	TENAPANOR HCL TAB 20 MG	30903260600325	Brand
XPHOZAH	TENAPANOR HCL TAB 30 MG	30903260600330	Brand
<b>Approval Criteria</b>			



**1 - Diagnosis of hyperphosphatemia in chronic kidney disease**

**AND**

**2 - Patient is on dialysis**

**AND**

**3 - Submission of medical records (e.g., chart notes) or paid claims confirming trial and inadequate response (minimum 30-day supply), contraindication, or intolerance to ALL of the following:**

- calcium carbonate
- calcium acetate
- sevelamer carbonate

**Product Name: Xphozah**

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
XPHOZAH	TENAPANOR HCL TAB 20 MG	30903260600325	Brand
XPHOZAH	TENAPANOR HCL TAB 30 MG	30903260600330	Brand

**Approval Criteria**

**1 - Patient demonstrates positive clinical response to therapy**

**AND**

**2 - Trial and inadequate response (minimum 30-day supply), contraindication, or intolerance to ALL of the following:**

- calcium carbonate
- calcium acetate
- sevelamer carbonate

## 2 . Revision History

Date	Notes
2/26/2024	New program.

Xuriden



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140856
<b>Guideline Name</b>	Xuriden
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	5/1/2020
-----------------	----------

### 1 . Criteria

Product Name: Xuriden			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
XURIDEN	URIDINE TRIACETATE ORAL GRANULES PACKET 2 GM	30903875203020	Brand
<b>Approval Criteria</b>			

1 - Diagnosis of a hereditary orotic aciduria

Product Name: Xuriden

Approval Length 12 month(s)

Therapy Stage Reauthorization

Guideline Type Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
XURIDEN	URIDINE TRIACETATE ORAL GRANULES PACKET 2 GM	30903875203020	Brand

**Approval Criteria**

1 - Documentation of positive clinical response to Xuriden therapy

**2 . Revision History**

Date	Notes
3/31/2020	Bulk copy C&S New York SP to C&S Arizona SP for 5/1 effective

Zeposia (ozanimod)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-144201
<b>Guideline Name</b>	Zeposia (ozanimod)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	4/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Zeposia			
Diagnosis	Multiple Sclerosis		
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZEPOSIA 7-DAY STARTER PACK	OZANIMOD CAP PACK 4 X 0.23 MG & 3 X 0.46 MG	6240705020B210	Brand
ZEPOSIA	OZANIMOD HCL CAP 0.92 MG	62407050200120	Brand

ZEPOSIA STARTER KIT	OZANIMOD CAP PACK 4 X 0.23 MG & 3 X 0.46 MG & 21 X 0.92 MG	6240705020B215	Brand
<p><b>Approval Criteria</b></p> <p>1 - Diagnosis of multiple sclerosis (MS)</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Patient has a history of failure, contraindication, or intolerance to a trial of at least TWO of the preferred* alternatives (Verified via pharmacy paid claims or submission of medical records):</p> <ul style="list-style-type: none"> <li>• Avonex</li> <li>• Brand Copaxone</li> <li>• generic dalfampridine</li> <li>• generic dimethyl fumarate</li> <li>• generic fingolimod</li> <li>• Kesimpta</li> <li>• Ocrevus^</li> <li>• Rebif</li> <li>• generic teriflunomide</li> <li>• Tysabri^</li> </ul>			
Notes		*Preferred alternatives may require PA. ^This is a medical benefit.	

Product Name: Zeposia			
Diagnosis	Multiple Sclerosis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZEPOSIA 7-DAY STARTER PACK	OZANIMOD CAP PACK 4 X 0.23 MG & 3 X 0.46 MG	6240705020B210	Brand

ZEPOSIA	OZANIMOD HCL CAP 0.92 MG	62407050200120	Brand
ZEPOSIA STARTER KIT	OZANIMOD CAP PACK 4 X 0.23 MG & 3 X 0.46 MG & 21 X 0.92 MG	6240705020B215	Brand

**Approval Criteria**

1 - Patient demonstrates positive clinical response to therapy (e.g., stability in radiologic disease activity, clinical relapses, disease progression)

**Product Name: Zeposia**

Diagnosis	Ulcerative Colitis
Approval Length	12 Week(s)
Therapy Stage	Initial Authorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ZEPOSIA 7-DAY STARTER PACK	OZANIMOD CAP PACK 4 X 0.23 MG & 3 X 0.46 MG	6240705020B210	Brand
ZEPOSIA	OZANIMOD HCL CAP 0.92 MG	62407050200120	Brand
ZEPOSIA STARTER KIT	OZANIMOD CAP PACK 4 X 0.23 MG & 3 X 0.46 MG & 21 X 0.92 MG	6240705020B215	Brand

**Approval Criteria**

1 - Diagnosis of moderately to severely active ulcerative colitis

**AND**

2 - Prescribed by or in consultation with a gastroenterologist

**AND**

**3** - Submission of medical records (e.g., chart notes, lab work, imaging, paid claims history) documenting BOTH of the following\*:

**3.1** Trial and failure, contraindication, or intolerance to ONE of the following conventional therapies (document drug, date, and duration of trial):

- 6-mercaptopurine
- Aminosalicylate (e.g., mesalamine, olsalazine, sulfasalazine)
- Azathioprine
- Corticosteroids (e.g., prednisone)

**AND**

**3.2** History of failure, contraindication, or intolerance to ALL of the following\*\* (document drug, date, and duration of trial):

- Humira (adalimumab)
- infliximab
- Xeljanz oral tablet (tofacitinib)

Notes	<p>*PA may be required</p> <p>**Patients requesting initial authorization who were established on the therapy via the receipt of a manufacturer supplied sample at no cost in the prescriber's office or any form of assistance from manufacturer sponsored programs shall be required to meet initial authorization criteria as if patient were new to therapy.</p>
-------	--

Product Name: Zeposia			
Diagnosis	Ulcerative Colitis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZEPOSIA 7-DAY STARTER PACK	OZANIMOD CAP PACK 4 X 0.23 MG & 3 X 0.46 MG	6240705020B210	Brand
ZEPOSIA	OZANIMOD HCL CAP 0.92 MG	62407050200120	Brand



ZEPOSIA STARTER KIT	OZANIMOD CAP PACK 4 X 0.23 MG & 3 X 0.46 MG & 21 X 0.92 MG	6240705020B215	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy</p> <p style="text-align: center;"><b>AND</b></p> <p>2 - Prescribed by or in consultation with a gastroenterologist</p>			

## 2 . Revision History

Date	Notes
3/11/2024	For MS and UC indications, updated preferred agent prerequisites in initial auth sections. For MS, updated reauth criterion. Updated notes section where applicable. Updated GPI table.

Zilbrysq



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-144702
<b>Guideline Name</b>	Zilbrysq
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	4/1/2024
-----------------	----------

## 1 . Criteria

Product Name: Zilbrysq			
Approval Length	12 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZILBRYSQ	ZILUCOPLAN SODIUM SUBCUTANEOUS SOLN PREF SYR 16.6 MG/0.416ML	8580509520E520	Brand
ZILBRYSQ	ZILUCOPLAN SODIUM SUBCUTANEOUS SOLN PREF SYR 23 MG/0.574ML	8580509520E530	Brand
ZILBRYSQ	ZILUCOPLAN SODIUM SUBCUTANEOUS SOLN PREF SYR 32.4 MG/0.81ML	8580509520E540	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming ALL of the following:

**1.1** Diagnosis of generalized myasthenia gravis (gMG)

**AND**

**1.2** Positive serologic test for anti-AChR antibodies

**AND**

**1.3** Patient has a Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of class II, III, or IV at initiation of therapy

**AND**

**1.4** Patient has a Myasthenia Gravis Activities of Daily Living scale (MG-ADL) total score greater than or equal to 6 at initiation of therapy

**AND**

**2** - ONE of the following:

**2.1** History of failure of at least two immunosuppressive agents over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.) as confirmed by claims history or submission of medical records

**OR**

**2.2** Patient has a history of failure of at least one immunosuppressive therapy (as confirmed by claims history or submission of medical records) and has required four or more courses of plasmapheresis/ plasma exchanges and/or intravenous immune globulin over the course of at least 12 months without symptom control

**OR**

**2.3** Contraindication or intolerance to at least two immunosuppressive agents (please specify contraindication or intolerance)

**AND**

**3** - Patient is not receiving Zilbrysq in combination with another complement inhibitor (e.g., Soliris, Ultomiris) or a neonatal Fc receptor blocker (e.g., Rystiggo, Vyvgart, Vyvgart Hytrulo)

**AND**

**4** - Prescribed by, or in consultation with, a neurologist

Product Name: Zilbrysq

Approval Length	12 month(s)
Therapy Stage	Reauthorization
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ZILBRYSQ	ZILUCOPLAN SODIUM SUBCUTANEOUS SOLN PREF SYR 16.6 MG/0.416ML	8580509520E520	Brand
ZILBRYSQ	ZILUCOPLAN SODIUM SUBCUTANEOUS SOLN PREF SYR 23 MG/0.574ML	8580509520E530	Brand
ZILBRYSQ	ZILUCOPLAN SODIUM SUBCUTANEOUS SOLN PREF SYR 32.4 MG/0.81ML	8580509520E540	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes, laboratory tests) to demonstrate a positive clinical response from baseline as demonstrated by at least ALL of the following:

**1.1** Improvement and/or maintenance of at least a 2-point improvement (reduction in score) in the MG-ADL score from pre-treatment baseline

**AND**

**1.2** Reduction in signs and symptoms of myasthenia gravis

**AND**

**1.3** Maintenance, reduction, or discontinuation of dose(s) of baseline immunosuppressive therapy (IST) prior to starting Zilbrysq\*

**AND**

**2** - Patient is not receiving Zilbrysq in combination with another complement inhibitor (e.g., Soliris, Ultomiris) or a neonatal Fc receptor blocker (e.g., Rystiggo, Vyvgart, Vyvgart Hytrulo)

**AND**

**3** - Prescribed by, or in consultation with, a neurologist

Notes	*Add on, dose escalation of IST, or additional rescue therapy from baseline to treat myasthenia gravis or exacerbation of symptoms while on Zilbrysq therapy will be considered as treatment failure
-------	--

## 2 . Revision History

Date	Notes
3/20/2024	New

Zimhi (naloxone)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140747
<b>Guideline Name</b>	Zimhi (naloxone)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Zimhi			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZIMHI	NALOXONE HCL SOLN PREFILLED SYRINGE 5 MG/0.5ML	9340002010E560	Brand
<b>Approval Criteria</b>			
1 - History of failure or intolerance to preferred* naloxone products (e.g., Brand Narcan nasal spray, Kloxxado, preferred naloxone injections)			

Notes	*PDL link: <a href="https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP">https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP</a>
-------	--

## 2 . Revision History

Date	Notes
10/24/2022	New guideline

Zokinvy



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140867
<b>Guideline Name</b>	Zokinvy
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	6/1/2021
-----------------	----------

### 1 . Criteria

Product Name: Zokinvy			
Diagnosis	Hutchinson-Gilford Progeria Syndrome		
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZOKINVY	LONAFARNIB CAP 50 MG	99463045000120	Brand
ZOKINVY	LONAFARNIB CAP 75 MG	99463045000130	Brand
<b>Approval Criteria</b>			



**1 - Diagnosis of Hutchinson-Gilford Progeria Syndrome**

**Product Name: Zokinvy**

Diagnosis	Progeroid Laminopathies
Approval Length	12 month(s)
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
ZOKINVY	LONAFARNIB CAP 50 MG	99463045000120	Brand
ZOKINVY	LONAFARNIB CAP 75 MG	99463045000130	Brand

**Approval Criteria**

**1 - Diagnosis of processing deficient Progeroid Laminopathies**

**AND**

**2 - Documentation of ONE of the following:**

- Heterozygous LMNA mutation with progerin-like protein accumulation
- Homozygous or compound heterozygous ZMPSTE24 mutations

Zolgensma (onasemnogene abeparvovec-xioi)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140974
<b>Guideline Name</b>	Zolgensma (onasemnogene abeparvovec-xioi)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	6/1/2023
-----------------	----------

### 1 . Criteria

Product Name: Zolgensma			
Approval Length	1 Time Authorization in Lifetime		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZOLGENSMA 2.6-3.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X8.3 ML SUSP KIT	74704050106410	Brand
ZOLGENSMA 3.1-3.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 1X8.3 ML SUSP KIT	74704050106412	Brand
ZOLGENSMA 3.6-4.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 2X8.3 ML SUSP KIT	74704050106414	Brand
ZOLGENSMA 4.1-4.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 3X8.3 ML SUSP KIT	74704050106416	Brand

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

ZOLGENSMA 4.6-5.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 2X8.3 ML SUSP KIT	74704050106418	Brand
ZOLGENSMA 5.1-5.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 3X8.3 ML SUSP KIT	74704050106420	Brand
ZOLGENSMA 5.6-6.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 4X8.3 ML SUSP KIT	74704050106422	Brand
ZOLGENSMA 6.1-6.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 3X8.3 ML SUSP KIT	74704050106424	Brand
ZOLGENSMA 6.6-7.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 4X8.3 ML SUSP KIT	74704050106426	Brand
ZOLGENSMA 7.1-7.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 5X8.3 ML SUSP KIT	74704050106428	Brand
ZOLGENSMA 7.6-8.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 4X8.3 ML SUSP KIT	74704050106430	Brand
ZOLGENSMA 8.1-8.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 5X8.3 ML SUSP KIT	74704050106432	Brand
ZOLGENSMA 8.6-9.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 6X8.3 ML SUSP KIT	74704050106434	Brand
ZOLGENSMA 9.1-9.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 5X8.3 ML SUSP KIT	74704050106436	Brand
ZOLGENSMA 9.6-10.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 6X8.3 ML SUSP KIT	74704050106438	Brand
ZOLGENSMA 10.1-10.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 7X8.3 ML SUSP KIT	74704050106440	Brand
ZOLGENSMA 10.6-11.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 6X8.3 ML SUSP KIT	74704050106442	Brand
ZOLGENSMA 11.1-11.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 7X8.3 ML SUSP KIT	74704050106444	Brand
ZOLGENSMA 11.6-12.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 8X8.3 ML SUSP KIT	74704050106446	Brand
ZOLGENSMA 12.1-12.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 7X8.3 ML SUSP KIT	74704050106448	Brand
ZOLGENSMA 12.6-13.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 8X8.3 ML SUSP KIT	74704050106450	Brand
ZOLGENSMA 13.1-13.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 9X8.3 ML SUSP KIT	74704050106452	Brand
ZOLGENSMA 13.6-14.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 8X8.3 ML SUSP KIT	74704050106454	Brand
ZOLGENSMA 14.1-14.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 9X8.3 ML SUSP KIT	74704050106456	Brand
ZOLGENSMA 14.6-15.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 10X8.3 ML SUSP KIT	74704050106458	Brand
ZOLGENSMA 15.1-15.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 9X8.3 ML SUSP KIT	74704050106460	Brand
ZOLGENSMA 15.6-16.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 10X8.3 ML SUSP KIT	74704050106462	Brand

ZOLGENSMA 16.1-16.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 11X8.3 ML SUSP KIT	74704050106464	Brand
ZOLGENSMA 16.6-17.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 10X8.3 ML SUSP KIT	74704050106466	Brand
ZOLGENSMA 17.1-17.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 11X8.3 ML SUSP KIT	74704050106468	Brand
ZOLGENSMA 17.6-18.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 12X8.3 ML SUSP KIT	74704050106470	Brand
ZOLGENSMA 18.1-18.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 11X8.3 ML SUSP KIT	74704050106472	Brand
ZOLGENSMA 18.6-19.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 12X8.3 ML SUSP KIT	74704050106474	Brand
ZOLGENSMA 19.1-19.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 13X8.3 ML SUSP KIT	74704050106476	Brand
ZOLGENSMA 19.6-20.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 2X5.5 ML & 12X8.3 ML SUSP KIT	74704050106478	Brand
ZOLGENSMA 20.1-20.5 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 1X5.5 ML & 13X8.3 ML SUSP KIT	74704050106480	Brand
ZOLGENSMA 20.6-21.0 KG	ONASEMNOGENE ABEPARVOVEC-XIOI 14X8.3 ML SUSP KIT	74704050106482	Brand

**Approval Criteria**

**1** - The mutation or deletion of genes in chromosome 5q resulting in ONE of the following:

**1.1** Homozygous gene deletion or mutation of SMN1 gene (e.g., homozygous deletion of exon 7 at locus 5q13)

**OR**

**1.2** Compound heterozygous mutation of SMN1 gene [e.g., deletion of Survival of Motor Neuron 1 (SMN1) exon 7 (allele 1) and mutation of SMN1 (allele 2)]

**AND**

**2** - ONE of the following:

**2.1** BOTH of the following:

**2.1.1** Diagnosis of diagnosis of SMA Type 0, I, or Type II spinal muscular atrophy (SMA) confirmed by a neurologist with expertise in the treatment of SMA

**AND**

**2.1.2** Patient is less than or equal to 2 years of age

**OR**

**2.2** BOTH of the following:

**2.2.1** Diagnosis of SMA based on the results of SMA newborn screening

**AND**

**2.2.2** Patient has 3 copies or less of Survival of Motor Neuron 2 (SMN 2)

**AND**

**3** - Patient is NOT dependent on either of the following:

- Invasive ventilation or tracheostomy
- Use of invasive ventilation beyond use of naps and nighttime sleep

**AND**

**4** - Submission of medical records (e.g., chart notes, laboratory values) documenting patient's anti-AAV9 antibody titers are less than or equal to 1:50

**AND**

**5** - Patient is NOT to receive concomitant SMN modifying therapy (e.g., Spinraza)

**AND**

**6** - Prescribed by a neurologist with expertise in the diagnosis of SMA

**AND**

**7** - Patient has never received Zolgensma treatment in their lifetime

## **2 . Revision History**

Date	Notes
5/4/2023	Updated GPI's, cleaned up criteria, removed endnotes and references.

Zontivity



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140655
<b>Guideline Name</b>	Zontivity
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	12/1/2020
-----------------	-----------

## 1 . Criteria

Product Name: Zontivity			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZONTIVITY	VORAPAXAR SULFATE TAB 2.08 MG (BASE EQUIVALENT)	85155780300320	Brand
<b>Approval Criteria</b>			
1 - ONE of the following:			

- History of myocardial infarction (MI)
- Peripheral arterial disease (PAD)

**AND**

**2** - Patient does not have a history of ONE of the following:

- Stroke
- Transient ischemic attack (TIA)
- Intracranial hemorrhage (ICH)

**AND**

**3** - Patient does not have active pathological bleeding



Zortress



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140694
<b>Guideline Name</b>	Zortress
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Zortress			
Approval Length	12 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZORTRESS	EVEROLIMUS TAB 0.25 MG	99404035000320	Brand
ZORTRESS	EVEROLIMUS TAB 0.5 MG	99404035000325	Brand
ZORTRESS	EVEROLIMUS TAB 0.75 MG	99404035000330	Brand
ZORTRESS	EVEROLIMUS TAB 1 MG	99404035000335	Brand

**Approval Criteria**

1 - Kidney transplant rejection prophylaxis in patients at low-moderate immunologic risk

**OR**

2 - Liver transplant rejection prophylaxis

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22

Zoryve (roflumilast)



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-155021
<b>Guideline Name</b>	Zoryve (roflumilast)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2024
-----------------	-----------

## 1 . Criteria

Product Name: Zoryve 0.3% cream			
Diagnosis	Plaque Psoriasis (PsO)		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZORYVE	ROFLUMILAST CREAM 0.3%	90250045003720	Brand
<b>Approval Criteria</b>			

**1** - Submission of medical records (e.g., chart notes) documenting a diagnosis of plaque psoriasis

**AND**

**2** - Patient is 6 years of age or older

**AND**

**3** - Submission of medical records (e.g., chart notes) or paid claims history documenting a minimum duration of a 4 week trial and failure, contraindication, or intolerance to TWO of the following topical therapies (trial must be from two different classes):

- Corticosteroids (e.g., betamethasone, clobetasol)
- Vitamin D analogs (e.g., calcitriol, calcipotriene)
- Tazarotene
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- Anthralin
- Coal tar

**AND**

**4** - Prescribed by or in consultation with a dermatologist

Product Name: Zoryve 0.3% cream			
Diagnosis	Plaque Psoriasis (PsO)		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZORYVE	ROFLUMILAST CREAM 0.3%	90250045003720	Brand
<b>Approval Criteria</b>			

1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy as evidenced by ONE of the following:

- Reduction in the body surface area (BSA) involvement from baseline
- Improvement in symptoms (e.g., pruritus, inflammation) from baseline

Product Name: Zoryve 0.15% cream			
Diagnosis	Atopic Dermatitis		
Approval Length	6 month(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZORYVE	ROFLUMILAST CREAM 0.15%	90230060003720	Brand

**Approval Criteria**

1 - Submission of medical records (e.g., chart notes) documenting a diagnosis of mild to moderate atopic dermatitis

**AND**

2 - Patient is 6 years of age or older

**AND**

3 - Submission of medical records (e.g., chart notes) or paid claims history documenting trial and failure of a minimum 30-day supply (14-day supply for topical corticosteroids), contraindication, or intolerance to BOTH of the following:

- ONE topical corticosteroid [e.g., mometasone furoate, fluocinolone acetonide (generic Synalar), fluocinonide]
- ONE topical calcineurin inhibitor [e.g., pimecrolimus (generic Elidel), tacrolimus (generic Protopic)]

**AND**

**4** - Prescribed by or in consultation with a dermatologist

Product Name: Zoryve foam			
Diagnosis	Seborrheic Dermatitis		
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZORYVE	ROFLUMILAST FOAM 0.3%	90300045003920	Brand

**Approval Criteria**

**1** - Submission of medical records (e.g., chart notes) documenting a diagnosis of seborrheic dermatitis

**AND**

**2** - Patient is 9 years of age or older

**AND**

**3** - Submission of medical records (e.g., chart notes) or paid claims history documenting a minimum duration of a 4 week trial and failure, contraindication, or intolerance to TWO of the following topical therapies (trial must be from two different classes):

- Corticosteroids (e.g., betamethasone, clobetasol)
- Antifungals (e.g., ciclopirox, ketoconazole)
- Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)

**AND**

4 - Prescribed by or in consultation with a dermatologist

Product Name: Zoryve foam			
Diagnosis	Seborrheic Dermatitis		
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZORYVE	ROFLUMILAST FOAM 0.3%	90300045003920	Brand
<p><b>Approval Criteria</b></p> <p>1 - Submission of medical records (e.g., chart notes) documenting positive clinical response to therapy as evidenced by improvement from baseline for ONE of the following:</p> <ul style="list-style-type: none"> <li>• Scaling</li> <li>• Erythema</li> <li>• Pruritis</li> <li>• Body surface area (BSA) involvement</li> </ul>			

## 2 . Revision History

Date	Notes
9/16/2024	Added criteria for new Zoryve cream 0.15% indicated for AD; Specified Zoryve "0.3%" cream in product name list for PsO criteria.

Ztalmy (ganaxolone)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-140938
<b>Guideline Name</b>	Ztalmy (ganaxolone)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

**Guideline Note:**

Effective Date:	12/1/2022
-----------------	-----------

### 1 . Criteria

Product Name: Ztalmy			
Approval Length	6 month(s)		
Therapy Stage	Initial Authorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZTALMY	GANAXOLONE SUSP 50 MG/ML	72600033001820	Brand
<b>Approval Criteria</b>			



**1** - Submission of documentation (e.g., chart notes) confirming diagnosis of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)

**AND**

**2** - Patient has a mutation in the CDKL5 gene

**AND**

**3** - Patient is 2 years of age or older

**AND**

**4** - Patient is experiencing motor seizures (e.g., bilateral tonic, generalized tonic-clonic, bilateral clonic, atonic, focal, or bilateral tonic-clonic)

**AND**

**5** - One of the following:

**5.1** Trial and failure, contraindication, or intolerance to two preferred\* anticonvulsants (e.g., valproic acid, levetiracetam, lamotrigine)

**OR**

**5.2** For continuation of prior therapy

**AND**

**6** - Prescribed by or in consultation with a neurologist

Notes

\*PDL link: <https://www.uhcprovider.com/en/health-plans-by-state/arizona-health-plans/az-comm-plan-home/az-cp-pharmacy.html?rfid=UHC-CP>

Product Name: Ztalmly			
Approval Length	12 month(s)		
Therapy Stage	Reauthorization		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZTALMY	GANAXOLONE SUSP 50 MG/ML	72600033001820	Brand
<p><b>Approval Criteria</b></p> <p>1 - Documentation of positive clinical response to therapy as evidenced by a reduction in the frequency of seizures from baseline</p>			

## 2 . Revision History

Date	Notes
10/24/2022	New guideline

Zurzuvae (zuranolone)



### Prior Authorization Guideline

<b>Guideline ID</b>	GL-143585
<b>Guideline Name</b>	Zurzuvae (zuranolone)
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

#### Guideline Note:

Effective Date:	3/17/2024
-----------------	-----------

### 1 . Criteria

Product Name: Zurzuvae			
Approval Length	14 Day(s)		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
ZURZUVAE	ZURANOLONE CAP 20 MG	58060090000120	Brand
ZURZUVAE	ZURANOLONE CAP 25 MG	58060090000125	Brand
ZURZUVAE	ZURANOLONE CAP 30 MG	58060090000130	Brand
<b>Approval Criteria</b>			

**1** - One of the following:

**1.1** Diagnosis of severe postpartum depression (PPD)

**OR**

**1.2** Both of the following:

**1.2.1** Diagnosis of mild to moderate postpartum depression (PPD)

**AND**

**1.2.2** Trial and failure, contraindication or intolerance to at least one oral SSRI or SNRI (e.g., escitalopram, duloxetine)

**AND**

**2** - Patient is 18 years of age or older

**AND**

**3** - Onset of symptoms in the third trimester or within 4 weeks of delivery

**AND**

**4** - Prescriber attests that the patient has been counseled and has agreed to adhere to the following: Will follow instructions to not drive or operate machinery until at least 12 hours after taking each dose of Zurzuvae for the duration of the 14-day treatment course and that patients are informed that they may not be able to assess their own driving competence or the degree of driving impairment caused by Zurzuvae

## 2 . Revision History

Date	Notes
------	-------

UnitedHealthcare Community Plan of Arizona - Clinical Pharmacy Guidelines

2/26/2024	New program.
-----------	--------------

Zyvox



## Prior Authorization Guideline

<b>Guideline ID</b>	GL-140720
<b>Guideline Name</b>	Zyvox
<b>Formulary</b>	<ul style="list-style-type: none"> <li>Medicaid - Community &amp; State Arizona</li> </ul>

### Guideline Note:

Effective Date:	10/1/2022
-----------------	-----------

## 1 . Criteria

Product Name: Brand Zyvox*, generic linezolid*			
Diagnosis	Labeled Uses		
Guideline Type	Prior Authorization		
Product Name	Generic Name	GPI	Brand/Generic
LINEZOLID	LINEZOLID TAB 600 MG	16230040000330	Generic
ZYVOX	LINEZOLID TAB 600 MG	16230040000330	Brand
LINEZOLID	LINEZOLID FOR SUSP 100 MG/5ML	16230040001920	Generic
ZYVOX	LINEZOLID FOR SUSP 100 MG/5ML	16230040001920	Brand

**Approval Criteria**

1 - One of the following:

1.1 For continuation of therapy upon hospital discharge

**OR**

1.2 As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

1.3 BOTH of the following:

1.3.1 ONE of the following diagnoses:

- Nosocomial pneumonia
- Community-acquired pneumonia
- Skin and skin structure infections (complicated and uncomplicated)

**AND**

1.3.2 Infection caused by an organism that is confirmed to be or likely to be susceptible to treatment with Zyvox

**OR**

1.4 Invasive infection caused by or likely to be caused by vancomycin-resistant Enterococcus faecium (VRE)

Notes	*Approval Duration: For vancomycin-resistant Enterococcus faecium, authorization will be issued for 28 days. For osteomyelitis, authorization will be issued for the requested duration, not to exceed 6 weeks. All other approvals will be issued for 14 days.
-------	---

Product Name: Brand Zyvox*, generic linezolid*	
Diagnosis	Off label Uses
Guideline Type	Prior Authorization

Product Name	Generic Name	GPI	Brand/Generic
LINEZOLID	LINEZOLID TAB 600 MG	16230040000330	Generic
ZYVOX	LINEZOLID TAB 600 MG	16230040000330	Brand
LINEZOLID	LINEZOLID FOR SUSP 100 MG/5ML	16230040001920	Generic
ZYVOX	LINEZOLID FOR SUSP 100 MG/5ML	16230040001920	Brand

**Approval Criteria**

1 - For continuation of therapy upon hospital discharge

**OR**

2 - As continuation of therapy when transitioning from intravenous antibiotics that are shown to be sensitive to the cultured organism for the requested indication

**OR**

3 - The medication is being prescribed by or in consultation with an Infectious Disease specialist

Notes	*Approval Duration: Based on provider recommended treatment durations, not to exceed 6 months.
-------	--

**2 . Revision History**

Date	Notes
8/4/2022	C&S to match AZM as of 10.1.22